PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Luque, A; Gomez, M; Puzon, W; Takada, Y; SanchezMadrid, F; Cabanas, C				Luque, A; Gomez, M; Puzon, W; Takada, Y; SanchezMadrid, F; Cabanas, C			Activated conformations of very late activation integrins detected by a group of antibodies (HUTS) specific for a novel regulatory region (355-425) of the common beta 1 chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; INTERCELLULAR-ADHESION MOLECULE-1; PLATELET GPIIB-IIIA; CELL-ADHESION; MONOCLONAL-ANTIBODY; PHORBOL ESTER; LEUKOCYTE INTEGRINS; BINDING-SITE; T-CELLS; LIGAND	The very late activation antigens (VLA) or beta 1 integrins mediate cell attachment to different extracellular matrix proteins and intercellular adhesions. The ligand binding activity of these adhesion receptors is not constitutive and can be regulated by temperature, presence of extracellular divalent cations, stimulatory monoclonal antibodies (mAbs), and cellular activation. We have generated three novel mAbs, HUTS-4, HUTS-7, and HUTS-21, recognizing specific epitopes on the common beta 1 subunit (CD29) of VLA integrins whose expression correlates with the ligand binding activity of these heterodimeric glycoproteins. This correlation has been demonstrated for several integrin heterodimers in different cell systems using a variety of extracellular and intracellular stimuli for integrin activation. Thus, the presence of micromolar concentrations of extracellular Mn2+, preincubation with the activating anti-beta 1 mAb TS2/16, and cell treatment with phorbol esters or calcium ionophores, induced the expression of the HUTS beta 1 epitopes on T lymphoblasts. Using a panel of human-mouse beta 1 chimeric molecules, we have mapped these epitopes to the 355-425 sequence of the beta 1 polypeptide. This segment represents therefore a novel regulatory region of beta 1 that is exposed upon integrin activation. Interestingly, binding of HUTS mAbs to partially activated VLA integrins results in maximal activation of these adhesion receptors and enhancement of cell adhesion to beta 1 integrin ligands collagen, laminin, and fibronectin.	UNIV COMPLUTENSE MADRID, FAC MED, DEPT BIOQUIM & BIOL MOLEC, E-28040 MADRID, SPAIN; UAM, HOSP PRINCESA, SERV IMMUNOL, E-28006 MADRID, SPAIN; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Complutense University of Madrid; Autonomous University of Madrid; Hospital de La Princesa; Scripps Research Institute			Luque, Alfonso/C-5846-2018; Sanchez-Madrid, Francisco/M-7889-2016; CABAÑAS, CARLOS/J-4595-2012	Sanchez-Madrid, Francisco/0000-0001-5303-0762; CABAÑAS, CARLOS/0000-0002-8767-060X; takada, yoshikazu/0000-0001-5481-9589	NIGMS NIH HHS [GM 47157, GM 49899] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049899, R01GM047157] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; ARROYO AG, 1994, J CELL BIOL, V126, P1277, DOI 10.1083/jcb.126.5.1277; ARROYO AG, 1993, J BIOL CHEM, V268, P9863; ARROYO AG, 1995, EUR J IMMUNOL, V25, P1720, DOI 10.1002/eji.1830250635; BEDNARCZYK JL, 1994, J BIOL CHEM, V269, P8348; CABANAS C, 1993, P NATL ACAD SCI USA, V90, P5838, DOI 10.1073/pnas.90.12.5838; CABANAS C, 1988, HYBRIDOMA, V7, P167, DOI 10.1089/hyb.1988.7.167; CAMPANERO MR, 1994, J CELL BIOL, V127, P867, DOI 10.1083/jcb.127.3.867; CAMPANERO MR, 1992, EUR J IMMUNOL, V22, P3111, DOI 10.1002/eji.1830221213; CAMPANERO MR, 1990, J CELL BIOL, V110, P2157, DOI 10.1083/jcb.110.6.2157; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DRANSFIELD I, 1992, J CELL BIOL, V116, P1527, DOI 10.1083/jcb.116.6.1527; DRANSFIELD I, 1990, IMMUNOL REV, V114, P29, DOI 10.1111/j.1600-065X.1990.tb00560.x; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GIANCOTTI FG, 1994, BBA-REV CANCER, V1198, P47, DOI 10.1016/0304-419X(94)90005-1; GRZESIAK JJ, 1992, J CELL BIOL, V117, P1109, DOI 10.1083/jcb.117.5.1109; HARTFIELD PJ, 1993, BIOCHEM BIOPH RES CO, V196, P1183, DOI 10.1006/bbrc.1993.2376; HEMLER ME, 1990, CELL DIFFER DEV, V32, P229, DOI 10.1016/0922-3371(90)90035-U; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KEIZER GD, 1988, J IMMUNOL, V140, P1393; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P18525; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; KOVACH NL, 1992, J CELL BIOL, V116, P499, DOI 10.1083/jcb.116.2.499; Kuhn K, 1994, Trends Cell Biol, V4, P256, DOI 10.1016/0962-8924(94)90124-4; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; LUQUE A, 1994, FEBS LETT, V346, P278, DOI 10.1016/0014-5793(94)00490-0; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MELERO I, 1993, EUR J IMMUNOL, V23, P1859, DOI 10.1002/eji.1830230819; MIYAKE K, 1994, INT IMMUNOL, V6, P1221, DOI 10.1093/intimm/6.8.1221; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PICKER LJ, 1993, EUR J IMMUNOL, V23, P2751, DOI 10.1002/eji.1830231105; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; Sanchez-Madrid F, 1992, Semin Cell Biol, V3, P199; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; VANKOOYK Y, 1993, CELL ADHES COMMUN, V1, P21, DOI 10.3109/15419069309095679; VANKOOYK Y, 1994, J CELL BIOL, V124, P1061, DOI 10.1083/jcb.124.6.1061; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; ZIMMERMAN GA, 1992, IMMUNOL TODAY, V13, P93, DOI 10.1016/0167-5699(92)90149-2	57	268	280	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11067	11075		10.1074/jbc.271.19.11067	http://dx.doi.org/10.1074/jbc.271.19.11067			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626649	hybrid			2022-12-25	WOS:A1996UJ94400009
J	Larsson, O; Deeney, JT; Branstrom, R; Berggren, PO; Corkey, BE				Larsson, O; Deeney, JT; Branstrom, R; Berggren, PO; Corkey, BE			Activation of the ATP-sensitive K+ channel by long chain acyl-CoA - A role in modulation of pancreatic beta-cell glucose sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN-SECRETION; FATTY-ACIDS; COENZYME-A; POTASSIUM CHANNELS; MALONYL-COA; METABOLISM; RAT; INHIBITION; ISLETS; ESTERS	Long term exposure to elevated levels of long chain free fatty acids decreases glucose-induced insulin secretion from pancreatic islets and clonal pancreatic beta-cells. The mechanism for this loss of glucose sensitivity is at present not known, In this study, we evaluated the possibility that increases in long chain acyl-CoA esters (LC-CoA), the metabolically active form of free fatty acids, might mediate the loss of glucose sensitivity, We observed that cellular levels of LC-CoA increased more than 100% in response to overnight incubation with 0.5 mM palmitic acid complexed to albumin, In the same studies, the total CoA pool increased by about 40%. Patch-clamp studies demonstrated that saturated and unsaturated LC-CoA, but not malonyl-CoA or free CoASH, induced a rapid and slowly reversible opening of ATP-sensitive K+ channels, The effect was concentration-dependent between 10 nn and 1 mu M. These findings indicate that the ATP-regulated K+ channel is a sensitive target for LC-CoA and suggest that high levels of LC-CoA, which accumulate in response to hyperglycemia or prolonged exposure to free fatty acids, may prevent channel closure and contribute to the development of beta-cell glucose insensitivity.	BOSTON UNIV, MED CTR,SCH MED,EVANS DEPT MED,DIABET & METAB UNIT, BOSTON, MA 02118 USA; BOSTON UNIV, MED CTR, DEPT BIOCHEM, BOSTON, MA 02118 USA; KAROLINSKA INST, ROLF LUFT CTR DIABET RES, DEPT MOLEC MED, S-17176 STOCKHOLM, SWEDEN	Boston University; Boston University; Karolinska Institutet			Corkey, Barbara/E-7712-2015	Corkey, Barbara/0000-0002-5467-1630; Deeney, Jude/0000-0003-0988-9419; Branstrom, Robert/0000-0001-6245-7223; Berggren, Per-Olof/0000-0001-8991-413X	NIDDK NIH HHS [DK46200, DK35914] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK035914, R37DK035914, R01DK035914, P30DK046200] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARKHAMMAR P, 1987, J BIOL CHEM, V262, P5448; ASHCROFT FM, 1990, BIOCHEM SOC T, V18, P109, DOI 10.1042/bst0180109; ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; BERNE C, 1975, BIOCHEM J, V152, P667, DOI 10.1042/bj1520667; BERNE C, 1975, BIOCHEM J, V152, P661, DOI 10.1042/bj1520661; BOKVIST K, 1991, P ROY SOC B-BIOL SCI, V243, P139, DOI 10.1098/rspb.1991.0022; CAPITO K, 1992, ACTA DIABETOL, V28, P193, DOI 10.1007/BF00778997; CORKEY BE, 1988, METHOD ENZYMOL, V166, P55; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; CORKEY BE, 1990, PROG CLIN BIOL RES, V321, P217; DEENEY JT, 1992, J BIOL CHEM, V267, P19840; ELKS ML, 1993, ENDOCRINOLOGY, V133, P208, DOI 10.1210/en.133.1.208; Foster D W, 1982, Ciba Found Symp, V87, P120, DOI 10.1002/9780470720691.ch7; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOPKINS WF, 1992, J MEMBRANE BIOL, V129, P287; HUANG WH, 1989, J BIOL CHEM, V264, P2605; HUANG WH, 1986, BIOCHEM INT, V12, P521; KAKAR SS, 1987, J BIOL CHEM, V262, P42; KAKEI M, 1986, FEBS LETT, V208, P63, DOI 10.1016/0014-5793(86)81533-2; KATIYAR SS, 1991, BIOCHEM BIOPH RES CO, V175, P1104, DOI 10.1016/0006-291X(91)91679-7; LARSSON O, 1993, J PHYSIOL-LONDON, V463, P349, DOI 10.1113/jphysiol.1993.sp019598; MULLER M, 1992, BIOCHEMISTRY-US, V31, P4656; PETROU S, 1995, PROSTAG LEUKOTR ESS, V52, P173, DOI 10.1016/0952-3278(95)90018-7; POWELL GL, 1985, FED PROC, V44, P81; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; SAKO Y, 1990, ENDOCRINOLOGY, V127, P1580, DOI 10.1210/endo-127-4-1580; TIPPETT PS, 1982, J BIOL CHEM, V257, P2839; TIPPETT PS, 1982, J BIOL CHEM, V257, P2846; TSUURA Y, 1993, DIABETES, V42, P1446, DOI 10.2337/diabetes.42.10.1446; VARA E, 1986, METABOLISM, V35, P266, DOI 10.1016/0026-0495(86)90212-X; Williamson J R, 1979, Methods Enzymol, V55, P200; WOLDEGIORGIS G, 1982, J BIOL CHEM, V257, P4783; ZHOU YP, 1994, J CLIN INVEST, V93, P870, DOI 10.1172/JCI117042	33	138	144	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10623	10626		10.1074/jbc.271.18.10623	http://dx.doi.org/10.1074/jbc.271.18.10623			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631866				2022-12-25	WOS:A1996UJ34200034
J	LeRoy, C; Leduque, P; Dubois, PM; Saez, JM; Langlois, D				LeRoy, C; Leduque, P; Dubois, PM; Saez, JM; Langlois, D			Repression of transforming growth factor beta 1 protein by antisense oligonucleotide-induced increase of adrenal cell differentiated functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVINE ADRENOCORTICAL-CELLS; ANGIOTENSIN-II; GENE-EXPRESSION; RECEPTOR; OLIGODEOXYNUCLEOTIDES; INHIBITION; SEQUENCE; CLONING; INSULIN; FACTOR-BETA-1	Transforming growth factor beta 1 (TGF beta 1) is a potent inhibitor of several differentiated functions in bovine adrenal fasciculata cells (BAC). In addition, these cells express and secrete this factor. To determine whether this peptide plays an autocrine role in BAC, cells were transfected with 10 mu M unmodified sense (SON) or antisense (AON) oligonucleotide complementary to the translation initiation region of the TGF beta 1 mRNA in an attempt to inhibit TGF beta 1 protein synthesis. We investigated first, the cellular uptake, the stability, and the intracellular distribution of P-32-labeled TGF beta 1 AON and SON; and second, the effects of both oligonucleotides on BAC specific functions. We have demonstrated that in BAC, the TGF beta 1 AON uptake reached a plateau after 8 h of transfection (16% of the radioactivity added) and remained fairly constant for at least 24 h. In contrast, the uptake of TGF beta 1 SON reached a plateau after 2 h of transfection (8% of the radioactivity added), remained stable for only 3 h, and then declined. After 8 h of transfection, followed by 44 h of culture without oligonucleotides, the intracellular level of TGF beta 1 AON was still high with about 8% of the radioactivity added, whereas that of TGF beta 1 SON represented only 1.2%. Moreover, AON was present in the cytoplasmic and nuclear fractions, and it was hybridized in both compartments. However, TGF beta 1 SON was present mainly in the cytoplasmic fraction where it was not hybridized. Neither TGF beta 1 AON nor SON modified TGF beta 1 mRNA levels; however, TGF beta 1 AON, but not SON, caused the disappearance of TGF beta 1 immunoreactivity inside the cells. Finally, the steroidogenic responsiveness of BAC transfected with TGF beta 1 AON increased about 2-fold, and this was associated with a 2-fold increase of the mRNA levels of both cytochrome P450 17 alpha-hydroxylase and 3 beta-hydroxysteroid dehydrogenase. Neither TGF beta 1 SON nor a scrambled oligonucleotide containing the same number of G nucleotides as TGF beta 1 AON had any effect on these parameters Thus, these studies demonstrate that TGF beta 1 has an autocrine inhibitory effect on BAC differentiated functions, an effect that can be overcome by TGF beta 1 AON.	HOP DEBROUSSE,INSERM,INRA,U418,F-69322 LYON 05,FRANCE; FAC MED LYON SUD,HISTOL LAB,F-69600 OULLINS,FRANCE	CHU Lyon; INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm)			Le Roy, Christine/N-3718-2017	Le Roy, Christine/0000-0003-3538-6487				AGRAWAL S, 1990, P NATL ACAD SCI USA, V87, P1401, DOI 10.1073/pnas.87.4.1401; Akhtar S, 1992, Trends Cell Biol, V2, P139, DOI 10.1016/0962-8924(92)90100-2; AVALLET O, 1994, ENDOCRINOLOGY, V134, P2079, DOI 10.1210/en.134.5.2079; BAERTSCHI AJ, 1994, MOL CELL ENDOCRINOL, V101, P15; BELTINGER C, 1995, J CLIN INVEST, V95, P1814, DOI 10.1172/JCI117860; BOIZIAU C, 1992, P NATL ACAD SCI USA, V89, P768, DOI 10.1073/pnas.89.2.768; BURT DW, 1992, DNA CELL BIOL, V11, P497, DOI 10.1089/dna.1992.11.497; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCHET C, 1988, J BIOL CHEM, V263, P5707; CROOKE RM, 1991, ANTI-CANCER DRUG DES, V6, P609; CUMIN F, 1993, EUR J BIOCHEM, V212, P347, DOI 10.1111/j.1432-1033.1993.tb17668.x; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FEIGE JJ, 1991, ENDOCR RES, V17, P267, DOI 10.1080/07435809109027201; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; FRANZEN P, 1995, BIOCHEM BIOPH RES CO, V207, P682, DOI 10.1006/bbrc.1995.1241; GAO WY, 1993, MOL PHARMACOL, V43, P45; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HELENE C, 1994, M S-MED SCI, V10, P253, DOI 10.4267/10608/2604; HOTTA M, 1986, P NATL ACAD SCI USA, V83, P7795, DOI 10.1073/pnas.83.20.7795; ITOH H, 1993, J CLIN INVEST, V91, P2268, DOI 10.1172/JCI116454; JAROSZEWSKI JW, 1991, ADV DRUG DELIVER REV, V6, P235, DOI 10.1016/0169-409X(91)90019-9; KHANNA A, 1994, BIOCHEM BIOPH RES CO, V204, P1061, DOI 10.1006/bbrc.1994.2570; LANGLOIS D, 1990, ENDOCRINOLOGY, V126, P1867, DOI 10.1210/endo-126-4-1867; LANGLOIS D, 1994, ENDOCRINOLOGY, V135, P480, DOI 10.1210/en.135.1.480; LANGLOIS D, 1992, COLLOQ INSE, V222, P61; LEONETTI JP, 1993, PROG NUCLEIC ACID RE, V44, P143, DOI 10.1016/S0079-6603(08)60219-6; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MOATSSTAATS BM, 1993, MOL ENDOCRINOL, V7, P171, DOI 10.1210/me.7.2.171; MORISSON RS, 1991, J BIOL CHEM, V266, P15917; NAVILLE D, 1991, MOL CELL ENDOCRINOL, V75, P257, DOI 10.1016/0303-7207(91)90168-R; OUALI R, 1992, J STEROID BIOCHEM, V43, P271, DOI 10.1016/0960-0760(92)90161-B; PERRIN A, 1990, ENDOCRINOLOGY, V128, P357; RAINEY WE, 1990, ENDOCRINOLOGY, V127, P1910, DOI 10.1210/endo-127-4-1910; RAINEY WE, 1988, MOL CELL ENDOCRINOL, V60, P189, DOI 10.1016/0303-7207(88)90178-5; RAINEY WE, 1991, ENDOCR RES, V17, P281, DOI 10.1080/07435809109027202; RAINEY WE, 1989, J BIOL CHEM, V264, P21474; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; TEMSAMANI J, 1994, ANTISENSE RES DEV, V4, P35, DOI 10.1089/ard.1994.4.35; THE VL, 1989, MOL ENDOCRINOL, V3, P1310, DOI 10.1210/mend-3-8-1310; WANG DH, 1995, J BIOL CHEM, V270, P14154, DOI 10.1074/jbc.270.23.14154; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WOOLF TM, 1990, NUCLEIC ACIDS RES, V18, P1763, DOI 10.1093/nar/18.7.1763; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAKUBOV LA, 1989, P NATL ACAD SCI USA, V86, P6454, DOI 10.1073/pnas.86.17.6454; ZUBER MX, 1986, J BIOL CHEM, V261, P2475	51	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					11027	11033		10.1074/jbc.271.18.11027	http://dx.doi.org/10.1074/jbc.271.18.11027			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631925	hybrid			2022-12-25	WOS:A1996UJ34200093
J	Lussier, M; Sdicu, AM; Camirand, A; Bussey, H				Lussier, M; Sdicu, AM; Camirand, A; Bussey, H			Functional characterization of the YUR1, KTR1, and KTR2 genes as members of the yeast KRE2/MNT1 mannosyltransferase gene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; O-GLYCOSYLATION; GLYCOPROTEIN-BIOSYNTHESIS; LINKED OLIGOSACCHARIDES; MEMBRANE-PROTEIN; OUTER CHAIN; ENCODES; LOCALIZATION; COMPARTMENT; PATHWAY	Eukaryotic glycan structures are progressively elaborated in the secretory pathway. Following the addition of a core N-linked carbohydrate in the endoplasmic reticulum, glycoproteins move to the Golgi complex where the elongation of O-linked sugar chains and processing of complex N-linked oligosaccharide structures take place. In order to better define how such post-translational modifications occur, we have been studying a yeast gene family in which at least one member, KRE2/MNT1, is involved in protein glycosylation. The family currently contains five other members: YUR1, KTR1, RTR2, KTR3 and KTR4 (Mallet, L., Bussereau, F., and Jacquet, M. (1994) Yeast 10, 819-831). All encode putative type II membrane proteins with a short cytoplasmic N terminus, a membrane-spanning region, and a highly conserved catalytic lumenal domain. Kre2p/Mnt1p is a alpha 1,2-mannosyltransferase involved in O- and N-linked glycosylation (Hausler, A., Ballou, L., Ballou, C. E., and Bobbins, P. W. (1992) Proc. Natl. Acad. Sci. U.S. A. 89, 6846-6850); however, the role of the other proteins has not yet been established. We have carried out a functional analysis of Ktr1p, Ktr2p, and Yur1p. By in vitro assays, Ktr1p, Ktr2p, and Yur1p have been shown to be mannosyltransferases but, in vivo, do not appear to be involved in O-glycosylation. Examination of the electrophoretic mobility of the N-linked modified protein invertase in null mutant strains indicates that Ktr1p, Ktr2p, and Yur1p are involved in N-linked glycosylation, possibly as redundant enzymes. As found with Kre2p (Hill, K., Boone, C., Goebl, M., Puccia, R., Sdicu, A.-M., and Bussey, H. (1992) Genetics 130, 273-283), Ktr1p, Ktr2p, and Yur1p also seem to be implicated in the glycosylation of cell wall mannoproteins, since yeast cells containing different gene disruptions become K1 killer toxin-resistant. Immunofluorescence microscopy reveals that like Kre2p; Ktr1p, Ktr2p and Yur1p are localized in the Golgi complex.	MCGILL UNIV, DEPT BIOL, MONTREAL, PQ H3A 1B1, CANADA	McGill University								BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BOONE C, 1990, J CELL BIOL, V110, P1833, DOI 10.1083/jcb.110.5.1833; BROWN JL, 1993, MOL CELL BIOL, V13, P6346, DOI 10.1128/MCB.13.10.6346; BROWN JL, 1994, MOL GENETICS YEAST P, P217; BUSSEY H, 1991, MOL MICROBIOL, V5, P2339, DOI 10.1111/j.1365-2958.1991.tb02079.x; CHAPMAN RE, 1994, EMBO J, V13, P4896, DOI 10.1002/j.1460-2075.1994.tb06817.x; COOPER A, 1989, MOL CELL BIOL, V9, P2706, DOI 10.1128/MCB.9.6.2706; COOPER A, 1992, J CELL BIOL, V119, P1459, DOI 10.1083/jcb.119.6.1459; ELHAMMER A, 1984, J CELL BIOL, V99, P327, DOI 10.1083/jcb.99.1.327; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GRAHAM TR, 1994, J CELL BIOL, V127, P667, DOI 10.1083/jcb.127.3.667; HASELBECK A, 1983, FEBS LETT, V158, P335, DOI 10.1016/0014-5793(83)80608-5; HAUSLER A, 1992, GLYCOBIOLOGY, V2, P77, DOI 10.1093/glycob/2.1.77; HAUSLER A, 1992, P NATL ACAD SCI USA, V89, P6846, DOI 10.1073/pnas.89.15.6846; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HILL K, 1992, GENETICS, V130, P273; HUFFAKER TC, 1982, J BIOL CHEM, V257, P3203; IKMMERVOLL T, 1995, YEAST, V11, P1345; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KELLEHER DJ, 1994, J BIOL CHEM, V269, P12908; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; KNAUER R, 1994, FEBS LETT, V344, P83, DOI 10.1016/0014-5793(94)00356-4; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LEHLE L, 1995, GLYCOPROTEINS, P1; LEIDICH SD, 1994, J BIOL CHEM, V269, P10193; LEIDICH SD, 1995, J BIOL CHEM, V270, P13029, DOI 10.1074/jbc.270.22.13029; LEWIS MS, 1991, J BIOL CHEM, V266, P8255; LOCKER JK, 1992, J BIOL CHEM, V267, P14094; LU CF, 1995, J CELL BIOL, V128, P333, DOI 10.1083/jcb.128.3.333; LUSSIER M, 1993, YEAST, V9, P1057, DOI 10.1002/yea.320091004; LUSSIER M, 1995, J BIOL CHEM, V270, P2770, DOI 10.1074/jbc.270.6.2770; LUSSIER M, 1995, J CELL BIOL, V131, P913, DOI 10.1083/jcb.131.4.913; MALLET L, 1994, YEAST, V10, P819, DOI 10.1002/yea.320100612; MONTIJN RC, 1994, J BIOL CHEM, V269, P19338; NAKANISHISHINDO Y, 1993, J BIOL CHEM, V268, P26338; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; ORLEAN P, 1991, METHOD ENZYMOL, V194, P682; RAYMOND CK, 1990, J CELL BIOL, V111, P877, DOI 10.1083/jcb.111.3.877; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; ROBERTS CJ, 1992, J CELL BIOL, V119, P69, DOI 10.1083/jcb.119.1.69; ROTH J, 1984, J CELL BIOL, V98, P399, DOI 10.1083/jcb.98.2.399; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; ROUSSEL P, 1988, BIOCHIMIE, V70, P1471, DOI 10.1016/0300-9084(88)90284-2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPER JH, 1992, CURR OPIN STRUC BIOL, V2, P701; SIPOS G, 1995, J BIOL CHEM, V270, P19709, DOI 10.1074/jbc.270.34.19709; STAGLJAR I, 1994, P NATL ACAD SCI USA, V91, P5977, DOI 10.1073/pnas.91.13.5977; STRAHLBOLSINGER S, 1993, P NATL ACAD SCI USA, V90, P8164, DOI 10.1073/pnas.90.17.8164; TANNER W, 1987, BIOCHIM BIOPHYS ACTA, V906, P81, DOI 10.1016/0304-4157(87)90006-2; YIP CL, 1994, P NATL ACAD SCI USA, V91, P2723, DOI 10.1073/pnas.91.7.2723; ZIEGLER FD, 1988, J BIOL CHEM, V263, P6986	54	50	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					11001	11008		10.1074/jbc.271.18.11001	http://dx.doi.org/10.1074/jbc.271.18.11001			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631921	hybrid			2022-12-25	WOS:A1996UJ34200089
J	Wilson, AL; Erdman, RA; Maltese, WA				Wilson, AL; Erdman, RA; Maltese, WA			Association of Rab1B with GDP-dissociation inhibitor (GDI) is required for recycling but not initial membrane targeting of the Rab protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; GERANYLGERANYL TRANSFERASE; SMG P25A; EXCHANGE PROTEIN; EFFECTOR DOMAIN; CDNA CLONING; COMPONENT-A; TRANSPORT; ENZYME; IDENTIFICATION	We have identified a Rab1B effector-domain mutant (D44N) that, when geranylgeranylated by Rab:geranylgeranyltransferase (GGTase II) in cell-free systems or intact cells, fails to form detectable complexes with GDP . dissociation inhibitors (GDIs). GDI-Rab complexes were collected on anti-FLAG affinity beads after incubating recombinant geranylgeranylated Rab1B with FLAG epitope-tagged GDI in vitro, or transiently coexpressing Myc-tagged Rab1B with FLAG-GDI-alpha or FLAG-GDI-2 in human embryonal kidney 293 cells. [H-3]Mevalonate labeling and immunoprecipitation studies confirmed that the inability of Myc-Rab1B(D44N) to associate with GDI in vivo was not due to failure of the mutant to undergo geranylgeranylation. Immunofluorescence localization and immunoblot analysis of subcellular fractions indicated that expressed Myc-Rab1B(D44N) efficiently delivered to intracellular membranes in 293 cells. This was confirmed when the fate of the prenylated pool of Rab1B(D44N) in 293 cells was traced by labeling the geranylgeranyl groups attached to the nascent protein with [H-3]mevalonate. However, in contrast to the prenylated Rab1B(WT), which was distributed in both the membrane and soluble fractions, the prenylated Rab1B(D44N) was completely absent from the cytosol. Overexpression of Myc-Rab1B(D44N) did not impair ER --> Golgi glycoprotein trafficking in 293 cells, which was assessed by monitoring the Golgi-dependent processing of coexpressed beta-amyloid precursor protein. The current findings suggest that nascent prenylated Rab1B can be delivered to intracellular membranes in intact cells without forming a stable complex with GDI, but that recycling of prenylated Rab1B to the cytosolic compartment is absolutely dependent on GDI interaction.	GEISINGER MED CLIN,WEIS CTR RES,DANVILLE,PA 17822	Geisinger Medical Center					NATIONAL CANCER INSTITUTE [R01CA034569] Funding Source: NIH RePORTER; NCI NIH HHS [CA34569] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BACHNER D, 1995, HUM MOL GENET, V4, P701, DOI 10.1093/hmg/4.4.701; BECKER J, 1991, EMBO J, V10, P785, DOI 10.1002/j.1460-2075.1991.tb08010.x; BERANGER F, 1994, J BIOL CHEM, V269, P13637; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; BURSTEIN ES, 1992, P NATL ACAD SCI USA, V89, P1154, DOI 10.1073/pnas.89.4.1154; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; CHAVRIER P, 1992, GENE, V112, P261, DOI 10.1016/0378-1119(92)90387-5; CREMERS FPM, 1994, J BIOL CHEM, V269, P2111; DIRACSVEJSTRUP AB, 1994, J BIOL CHEM, V269, P15427; DUGAN JM, 1995, J BIOL CHEM, V270, P10982, DOI 10.1074/jbc.270.18.10982; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; Higuchi R., 1989, PCR TECHNOLOGY, P61; HORIUCHI H, 1995, J BIOL CHEM, V270, P11257, DOI 10.1074/jbc.270.19.11257; HUBER LA, 1993, J CELL BIOL, V123, P47, DOI 10.1083/jcb.123.1.47; JANOUEIXLEROSEY I, 1995, J BIOL CHEM, V270, P14801, DOI 10.1074/jbc.270.24.14801; KHOSRAVIFAR R, 1992, J BIOL CHEM, V267, P24363; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI GP, 1993, J BIOL CHEM, V268, P24475; MALTESE WA, 1990, J BIOL CHEM, V265, P17883; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MUSHA T, 1992, J BIOL CHEM, V267, P9821; NISHIMURA N, 1994, J BIOL CHEM, V269, P14191; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PETER F, 1994, J CELL BIOL, V126, P1393, DOI 10.1083/jcb.126.6.1393; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; SANFORD JC, 1995, J BIOL CHEM, V270, P26904, DOI 10.1074/jbc.270.45.26904; SANFORD JC, 1995, MOL BIOL CELL, V6, P71, DOI 10.1091/mbc.6.1.71; SANFORD JC, 1993, J BIOL CHEM, V268, P23773; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SHISHEVA A, 1994, J BIOL CHEM, V269, P23865; SHISHEVA A, 1994, MOL CELL BIOL, V14, P3459, DOI 10.1128/MCB.14.5.3459; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; STEELEMORTIMER O, 1993, FEBS LETT, V329, P313, DOI 10.1016/0014-5793(93)80244-O; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VIELH E, 1989, NUCLEIC ACIDS RES, V17, P1770, DOI 10.1093/nar/17.4.1770; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WILSON AL, 1993, J BIOL CHEM, V268, P14561; WILSON AL, 1994, METHOD ENZYMOL, V250, P79; YANG CZ, 1994, J BIOL CHEM, V269, P31891; ZAHNER JE, 1993, MOL CELL BIOL, V13, P217, DOI 10.1128/MCB.13.1.217	58	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10932	10940		10.1074/jbc.271.18.10932	http://dx.doi.org/10.1074/jbc.271.18.10932			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631911	hybrid			2022-12-25	WOS:A1996UJ34200079
J	Bandaru, B; Gopal, J; Bhagwat, AS				Bandaru, B; Gopal, J; Bhagwat, AS			Overproduction of DNA cytosine methyltransferases causes methylation and C->T mutations at non-canonical sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; RESTRICTION-MODIFICATION SYSTEM; DEOXYRIBONUCLEIC-ACID; MISMATCH-REPAIR; INDUCED DEAMINATION; MODIFICATION ENZYME; 5-METHYLCYTOSINE; ENDONUCLEASE; GENE; RECOGNITION	Multicopy clones of Escherichia coli cytosine methyltransferases Dcm and EcoRII methylase (M. EcoRII) cause similar to 50-fold increase in C --> T mutations at their canonical site of methylation, 5'-CmeCAGG (meC is 5-methylcytosine). These plasmids also cause transition mutations at the second cytosine in the sequences CCGGG at similar to 10-fold lower frequency. Similarly, M. HpaII was found to cause a significant increase in C --> T mutations at a CCAG site, in addition to causing mutations at its canonical site of methylation, CCGG. Using a plasmid that substantially overproduces M. EcoRII, in vivo methylation at CCSGG (S is C or G) and other noncanonical sites could be detected using a gel electrophoretic assay. There is a direct correlation between the level of M. EcoRII activity in cells, the extent of methylation at non-canonical sites and frequency of mutations at these same sites. Overproduction of M. EcoRII in cells also causes degradation of DNA and induction of the SOS response. In vitro, M. EcoRII methylates an oligonucleotide duplex containing a CCGGG site at a slow rate, suggesting that overproduction of the enzyme is essential for significant amounts of such methylation to occur. Together these results show that cytosine methyltransferases occasionally methylate cellular DNA at non-canonical sites and suggest that in E. coli, methylation-specific restriction systems and sequence specificity of the DNA mismatch correction systems may have evolved to accommodate this fact. These results also suggest that mutational effects of cytosine methyltransferases may be much broader than previously imagined.	WAYNE STATE UNIV,DEPT CHEM,DETROIT,MI 48202	Wayne State University			Bhagwat, Ashok/AAU-4186-2021; Bhagwat, Ashok/ABA-3861-2020	Bhagwat, Ashok/0000-0003-1188-0579; 	NHGRI NIH HHS [HG 00004] Funding Source: Medline; NIGMS NIH HHS [GM 45860] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANDARU B, 1995, J BACTERIOL, V177, P2950, DOI 10.1128/jb.177.10.2950-2952.1995; BANNISTE.D, 1968, BIOCHEM BIOPH RES CO, V30, P735, DOI 10.1016/0006-291X(68)90575-5; BHAGWAT AS, 1986, J BACTERIOL, V166, P751, DOI 10.1128/jb.166.3.751-755.1986; BHAGWAT AS, 1990, J BIOL CHEM, V265, P767; BHAGWAT AS, 1981, MOL GEN GENET, V182, P505, DOI 10.1007/BF00293943; BIGGER CH, 1973, NATURE-NEW BIOL, V244, P7, DOI 10.1038/newbio244007a0; BOYER HW, 1973, NATURE-NEW BIOL, V244, P40, DOI 10.1038/newbio244040a0; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; BUTKUS V, 1987, NUCLEIC ACIDS RES, V15, P7091, DOI 10.1093/nar/15.17.7091; CLARK SJ, 1995, NAT GENET, V10, P20, DOI 10.1038/ng0595-20; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; COULONDRE C, 1978, NATURE, V274, P775, DOI 10.1038/274775a0; DAVIS R, 1993, APPL ENVIRON MICROB, V59, P777, DOI 10.1128/AEM.59.3.777-785.1993; DOBRITSA AP, 1980, GENE, V10, P105, DOI 10.1016/0378-1119(80)90128-6; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; FRIEDMAN S, 1993, J BACTERIOL, V175, P6293, DOI 10.1128/JB.175.19.6293-6298.1993; GLASNER W, 1995, J MOL BIOL, V245, P1; GLASNER W, 1992, STRUCTURAL TOOLS ANA, P65; GOPAL J, 1994, NUCLEIC ACIDS RES, V22, P4482, DOI 10.1093/nar/22.21.4482; GOPAL J, 1995, NUCLEIC ACIDS RES, V23, P29, DOI 10.1093/nar/23.1.29; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HEITMAN J, 1991, GENE, V103, P1, DOI 10.1016/0378-1119(91)90383-M; HEITMAN J, 1987, J BACTERIOL, V169, P3243, DOI 10.1128/jb.169.7.3243-3250.1987; HENNECKE F, 1991, NATURE, V353, P776, DOI 10.1038/353776a0; JONES M, 1987, CELL, V50, P621, DOI 10.1016/0092-8674(87)90035-3; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; KARYAGINA AS, 1990, GENE, V87, P113, DOI 10.1016/0378-1119(90)90501-H; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; KELLEHER JE, 1991, J BACTERIOL, V173, P5220, DOI 10.1128/jb.173.16.5220-5223.1991; KLIMASAUSKAS S, 1995, NUCLEIC ACIDS RES, V23, P1388, DOI 10.1093/nar/23.8.1388; KRETZ PL, 1991, J BACTERIOL, V173, P4707, DOI 10.1128/jb.173.15.4707-4716.1991; KULAKAUSKAS S, 1994, GENE, V142, P9, DOI 10.1016/0378-1119(94)90348-4; LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487; LIEB M, 1991, GENETICS, V128, P23; LIEB M, 1987, J BACTERIOL, V169, P5241, DOI 10.1128/jb.169.11.5241-5246.1987; LIEB M, 1986, GENETICS, V114, P1041; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; MANN MB, 1977, NUCLEIC ACIDS RES, V4, P4211, DOI 10.1093/nar/4.12.4211; MARINUS MG, 1973, J BACTERIOL, V114, P1143, DOI 10.1128/JB.114.3.1143-1150.1973; MAY MS, 1975, J BACTERIOL, V122, P129, DOI 10.1128/JB.122.1.129-138.1975; Miller JH., 1992, SHORT COURSE BACTERI, P72; NELSON M, 1984, NUCLEIC ACIDS RES, V12, P5165, DOI 10.1093/nar/12.13.5165; RALEIGH EA, 1992, MOL MICROBIOL, V6, P1079, DOI 10.1111/j.1365-2958.1992.tb01546.x; RALEIGH EA, 1986, P NATL ACAD SCI USA, V83, P9070, DOI 10.1073/pnas.83.23.9070; REICH NO, 1992, J BIOL CHEM, V267, P15802; RINGQUIST S, 1992, P NATL ACAD SCI USA, V89, P4539, DOI 10.1073/pnas.89.10.4539; SCHLAGMAN S, 1976, J BACTERIOL, V126, P990, DOI 10.1128/JB.126.2.990-996.1976; SHEN JC, 1992, NUCLEIC ACIDS RES, V20, P5119, DOI 10.1093/nar/20.19.5119; SHEN JC, 1992, CELL, V71, P1; SMITH DW, 1992, NUCLEIC ACIDS RES, V20, P6091, DOI 10.1093/nar/20.22.6091; SOM S, 1993, EMBO J, V12, P4297, DOI 10.1002/j.1460-2075.1993.tb06114.x; SOM S, 1994, NUCLEIC ACIDS RES, V22, P5347, DOI 10.1093/nar/22.24.5347; SOM S, 1987, NUCLEIC ACIDS RES, V15, P313, DOI 10.1093/nar/15.1.313; SUTHERLAND E, 1992, J MOL BIOL, V225, P327, DOI 10.1016/0022-2836(92)90925-A; TAYLOR JD, 1990, BIOCHEMISTRY-US, V29, P10727, DOI 10.1021/bi00500a003; VAIRAPANDI M, 1993, NUCLEIC ACIDS RES, V21, P5323, DOI 10.1093/nar/21.23.5323; WALDER RY, 1983, J BIOL CHEM, V258, P1235; WANG RYH, 1982, BIOCHIM BIOPHYS ACTA, V697, P371, DOI 10.1016/0167-4781(82)90101-4; WOODBURY CP, 1980, J BIOL CHEM, V255, P1526; WYSZYNSKI M, 1994, P NATL ACAD SCI USA, V91, P1574, DOI 10.1073/pnas.91.4.1574; WYSZYNSKI MW, 1992, NUCLEIC ACIDS RES, V20, P319, DOI 10.1093/nar/20.2.319; YANG AS, 1995, NUCLEIC ACIDS RES, V23, P1380, DOI 10.1093/nar/23.8.1380; YEBRA MJ, 1995, BIOCHEMISTRY-US, V34, P14752, DOI 10.1021/bi00045a016; YOSHIMORI R, 1972, J BACTERIOL, V112, P1275, DOI 10.1128/JB.112.3.1275-1279.1972; ZELL R, 1987, EMBO J, V6, P1809, DOI 10.1002/j.1460-2075.1987.tb02435.x	65	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7851	7859		10.1074/jbc.271.13.7851	http://dx.doi.org/10.1074/jbc.271.13.7851			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631830	hybrid			2022-12-25	WOS:A1996UC77400098
J	Singer, WD; Brown, HA; Jiang, XJ; Sternweis, PC				Singer, WD; Brown, HA; Jiang, XJ; Sternweis, PC			Regulation of phospholipase D by protein kinase C is synergistic with ADP-ribosylation factor and independent of protein kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; PURIFICATION; PHOSPHATASE; ACTIVATION; CLEAVAGE; ASSAY	Phospholipase D (PLD) which was partially purified from membranes of porcine brain could be stimulated by multiple cytosolic components; these included ADP-ribosylation factor (Arf) and RhoA, which required guanine nucleotides for activity, and an unidentified factor which activated the enzyme in a nucleotide-independent manner (Singer, W. D., Brown, H. A., Bokoch, G. M., and Sternweis, P. C. (1995) J. Biol. Chem. 270, 14944-14950). Here, we report purification of the latter factor, its identification as the alpha isoform of protein kinase C (PKC alpha), and characterization of its regulation of PLD activity. Stimulation of PLD by purified PKC alpha or recombinant PKC alpha (rPKC alpha) occurred in the absence of any nucleotide and required activators such as Ca2+ or phorbol ester. This action was synergistic with stimulation of PLD evoked by either Arf or RhoA. Dephosphorylation of rPKC alpha with protein phosphatase 1 or 2A resulted in a loss of its kinase activity, but had little effect on its ability to stimulate PLD either alone or in conjunction with Arf. Staurosporine inhibited the kinase activity of PKC alpha without affecting activation of PLD. Finally, gel filtration of PKC alpha that had been cleaved with trypsin demonstrated that stimulatory activity for PLD coeluted with the regulatory domain of the enzyme. These data indicate that PKC may regulate signaling events through direct molecular interaction with downstream effectors as well as through its well characterized catalytic modification of proteins by phosphorylation.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIGMS NIH HHS [GM31954, GM15817] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015817, R01GM031954] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BILLAH MM, 1993, CURR OPIN IMMUNOL, V5, P114; BOURGOIN S, 1995, J BIOL CHEM, V270, P3172, DOI 10.1074/jbc.270.7.3172; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONRICODE KM, 1994, FEBS LETT, V342, P149, DOI 10.1016/0014-5793(94)80490-7; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; EXTON JH, 1990, J BIOL CHEM, V265, P1; FUJISE A, 1994, J BIOL CHEM, V269, P31642; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Heller M, 1978, Adv Lipid Res, V16, P267; HOULE MG, 1995, J BIOL CHEM, V270, P22795, DOI 10.1074/jbc.270.39.22795; KAHN RA, 1992, FASEB J, V6, P2512, DOI 10.1096/fasebj.6.8.1592203; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBETH JD, 1995, J BIOL CHEM, V270, P2431, DOI 10.1074/jbc.270.6.2431; LEE MH, 1986, J BIOL CHEM, V261, P4867; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LISCOVITCH M, 1994, SIGNAL ACTIVATED PHO, P31; LOPEZ I, 1995, J BIOL CHEM, V270, P19465, DOI 10.1074/jbc.270.33.19465; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MARTIN A, 1991, METHOD ENZYMOL, V197, P553; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MOCHLYROSEN D, 1995, BIOCHEM SOC T, V23, P596, DOI 10.1042/bst0230596; NAKADATE T, 1988, BIOCHEM PHARMACOL, V37, P1541, DOI 10.1016/0006-2952(88)90016-0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OHGUCHI K, 1995, BIOCHEM BIOPH RES CO, V211, P306, DOI 10.1006/bbrc.1995.1811; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; SAITO M, 1975, ARCH BIOCHEM BIOPHYS, V169, P318, DOI 10.1016/0003-9861(75)90346-X; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1994, J BIOL CHEM, V269, P19796; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z	42	227	230	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4504	4510						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626805				2022-12-25	WOS:A1996TW96000083
J	Blocker, A; Severin, FF; Habermann, A; Hyman, AA; Griffiths, G; Burkhardt, JK				Blocker, A; Severin, FF; Habermann, A; Hyman, AA; Griffiths, G; Burkhardt, JK			Microtubule-associated protein-dependent binding of phagosomes to microtubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANOUS ORGANELLES INVIVO; ENDOCYTIC CARRIER VESICLES; CYTOPLASMIC DYNEIN; CULTURED-CELLS; MONOCLONAL-ANTIBODIES; ENDOPLASMIC-RETICULUM; LYSOSOMAL MOVEMENTS; TUBULAR LYSOSOMES; FUSION INVITRO; GOLGI ELEMENTS	In macrophages, phagosome movement is microtubule-dependent. Microtubules are a prerequisite for phagosome maturation because they facilitate interact-ions between phagosomes and organelles of the endocytic pathway. We have established an in vitro assay that measures the binding of purified phagosomes to microtubules. This binding depends on the presence of membrane proteins, most likely integral to the surface of phagosomes, and on macrophage cytosol. The cytosolic binding factor can interact with microtubules prior to the addition of phagosomes to the assay, suggesting that it is a microtubule-associated protein (MAP). Consistent with this, depletion of MAPs from the cytosol by microtubule affinity removes all binding activity. Microtubule motor proteins show no binding activity, whereas a crude MAP preparation is sufficient to support binding and to restore full binding activity to MAP-depleted cytosol. We show that the activating MAP factor is a heat-sensitive protein(s) that migrates at around 150 kDa by gel filtration.	EUROPEAN MOLEC BIOL LAB,CELL BIOL PROGRAMME,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Hyman, Anthony A/B-3917-2017; Severin, Fedor/AAD-5444-2019; Blocker, Ariel/Q-6617-2016; Hyman, Tony/F-1923-2011	Hyman, Anthony A/0000-0003-3664-154X; Habermann, Anja/0000-0003-3686-9050; Severin, Fedor/0000-0001-6703-1256				ACHLER C, 1989, J CELL BIOL, V109, P179, DOI 10.1083/jcb.109.1.179; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BURKHARDT JK, 1993, J CELL SCI, V104, P151; BURKHARDT JK, 1995, IN PRESS ELECTROPHOR; DESJARDINS M, 1994, J BIOL CHEM, V269, P32194; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; FEIGUIN F, 1994, J CELL BIOL, V127, P1021, DOI 10.1083/jcb.127.4.1021; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HART PD, 1983, J EXP MED, V158, P477, DOI 10.1084/jem.158.2.477; HART PD, 1987, J EXP MED, V166, P933, DOI 10.1084/jem.166.4.933; HERZOG W, 1978, EUR J BIOCHEM, V92, P1, DOI 10.1111/j.1432-1033.1978.tb12716.x; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; HIROKAWA N, 1991, J CELL BIOL, V114, P295, DOI 10.1083/jcb.114.2.295; HIROKAWA N, 1990, J CELL BIOL, V111, P1027, DOI 10.1083/jcb.111.3.1027; HO WC, 1989, EUR J CELL BIOL, V48, P250; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; HOWARD J, 1993, METHOD CELL BIOL, V39, P105, DOI 10.1016/S0091-679X(08)60164-8; INGOLD AL, 1988, J CELL BIOL, V107, P2657, DOI 10.1083/jcb.107.6.2657; JAHRAUS A, 1994, J CELL SCI, V107, P145; KELLY RB, 1990, CELL, V61, P5, DOI 10.1016/0092-8674(90)90206-T; KIM H, 1979, J CELL BIOL, V80, P266, DOI 10.1083/jcb.80.2.266; KNAPP PE, 1990, J CELL SCI, V95, P433; KORNFELD S, 1989, ANN REV CELL BIOL, V98, P139; KREIS TE, 1989, EUR J CELL BIOL, V49, P128; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KUZNETSOV SA, 1978, FEBS LETT, V95, P339, DOI 10.1016/0014-5793(78)81025-4; LACEY ML, 1992, J BIOL CHEM, V267, P4793; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFONT F, 1994, NATURE, V372, P801; LEOPOLD PL, 1992, CELL MOTIL CYTOSKEL, V23, P19, DOI 10.1002/cm.970230104; LIN SXH, 1992, J CELL SCI, V101, P125; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MIZUNO M, 1994, J CELL SCI, V107, P1321; MORIN PJ, 1993, BIOCHIM BIOPHYS ACTA, V1146, P275, DOI 10.1016/0005-2736(93)90366-8; MULLER WA, 1980, J CELL BIOL, V86, P292, DOI 10.1083/jcb.86.1.292; NEIGHBORS BW, 1988, J CELL BIOL, V106, P1193, DOI 10.1083/jcb.106.4.1193; Olmsted J. B., 1993, P115; PARTON RG, 1991, J CELL BIOL, V113, P261, DOI 10.1083/jcb.113.2.261; PARYSEK LM, 1984, J CELL BIOL, V99, P1309, DOI 10.1083/jcb.99.4.1309; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; PITT A, 1992, METHOD ENZYMOL, V219, P21; PITT A, 1992, J BIOL CHEM, V267, P126; RICKARD JE, 1991, J BIOL CHEM, V266, P17597; RICKARD JE, 1990, J CELL BIOL, V110, P1623, DOI 10.1083/jcb.110.5.1623; Sandoval I. V., 1984, J CELL BIOL, V99, P113; SCHEEL J, 1991, J BIOL CHEM, V266, P18141; SCHEEL J, 1990, J CELL SCI, V96, P711; SCHROER TA, 1988, J CELL BIOL, V107, P1785, DOI 10.1083/jcb.107.5.1785; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SEVERIN FF, 1991, FEBS LETT, V282, P65, DOI 10.1016/0014-5793(91)80445-9; Silverstein SC, 1989, FUNDAMENTAL IMMUNOLO, P703; SORGER PK, 1994, J CELL BIOL, V127, P995, DOI 10.1083/jcb.127.4.995; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; STOSSEL TP, 1971, J CLIN INVEST, V50, P1745, DOI 10.1172/JCI106664; SWANSON J, 1987, P NATL ACAD SCI USA, V84, P1921, DOI 10.1073/pnas.84.7.1921; TERASAKI M, 1986, J CELL BIOL, V103, P1557, DOI 10.1083/jcb.103.4.1557; TERASAKI M, 1984, CELL, V38, P101, DOI 10.1016/0092-8674(84)90530-0; TOYOHARA A, 1989, J CELL SCI, V94, P143; URRUTIA R, 1993, METHOD CELL BIOL, V39, P253, DOI 10.1016/S0091-679X(08)60175-2; VAISBERG EA, 1993, J CELL BIOL, V123, P849, DOI 10.1083/jcb.123.4.849; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; VANDERSLUIJS P, 1990, J CELL SCI, V95, P545; VAUX DJT, 1988, NATURE, V336, P36, DOI 10.1038/336036a0; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; Walden Paul D., 1993, P111; WEHLAND J, 1983, J CELL BIOL, V97, P1476, DOI 10.1083/jcb.97.5.1476; WETZEL MG, 1969, J CELL BIOL, V43, P90, DOI 10.1083/jcb.43.1.90; YOUNG MR, 1990, EXP CELL RES, V190, P283, DOI 10.1016/0014-4827(90)90198-J; YU H, 1992, J BIOL CHEM, V267, P20457	77	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3803	3811						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631997				2022-12-25	WOS:A1996TV72400071
J	Tsai, JC; Jain, M; Hsieh, CM; Lee, WS; Yoshizumi, M; Patterson, C; Perrella, MA; Cooke, C; Wang, H; Haber, E; Schlegel, R; Lee, ME				Tsai, JC; Jain, M; Hsieh, CM; Lee, WS; Yoshizumi, M; Patterson, C; Perrella, MA; Cooke, C; Wang, H; Haber, E; Schlegel, R; Lee, ME			Induction of apoptosis by pyrrolidinedithiocarbamate and N-acetylcysteine in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; PHEOCHROMOCYTOMA CELLS; METAL-IONS; VITAMIN-C; KAPPA-B; DEATH; PROTOONCOGENE; TRANSCRIPTION; EXPRESSION; ACTIVATION	Pyrrolidinedithiocarbamate (PDTC) and N-acetylcysteine (NAG) have been used as antioxidants to prevent apoptosis in lymphocytes, neurons, and vascular endothelial cells, We report here that PDTC and NAC induce apoptosis in rat and human smooth muscle cells, In rat aortic smooth muscle cells, PDTC induced cell shrinkage, chromatin condensation, and DNA strand breaks consistent with apoptosis. In addition, overexpression of Bcl-2 suppressed vascular smooth muscle cell death caused by PDTC and NAG. The viability of rat aortic smooth muscle cells decreased within 3 h of treatment with PDTC and was reduced to 30% at 12 h. The effect of PDTC and NAC on smooth muscle cells was not species specific because PDTC and NAC both caused dose-dependent reductions in viability in rat and human aortic smooth muscle cells. In contrast, neither PDTC nor NAC reduced viability in human aortic endothelial cells. The use of antioxidants to induce apoptosis in vascular smooth muscle cells may help prevent their proliferation in arteriosclerotic lesions.	HARVARD UNIV,SCH PUBL HLTH,CARDIOVASC BIOL LAB,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT MOLEC & CELLULAR TOXICOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV PULM,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115; JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL,BALTIMORE,MD 21205	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Johns Hopkins University					NATIONAL CANCER INSTITUTE [R01CA049749] Funding Source: NIH RePORTER; NCI NIH HHS [CA49749] Funding Source: Medline; NIGMS NIH HHS [GM53249] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELLO PA, 1994, ARCH SURG-CHICAGO, V129, P134; ARINAGA M, 1994, SCIENCE, V263, P754; BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; COHEN JJ, 1994, J LAB CLIN MED, V124, P761; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GERSCHENSON LE, 1992, FASEB J, V6, P2450, DOI 10.1096/fasebj.6.7.1563596; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; JASJSEN YMW, 1993, LAB INVEST, V69, P261; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LIN KT, 1995, J BIOL CHEM, V270, P16487, DOI 10.1074/jbc.270.28.16487; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MORSE NR, 1995, PROTOPLASMA, V184, P184; NELSON SK, 1994, FREE RADICAL BIO MED, V16, P195, DOI 10.1016/0891-5849(94)90143-0; OLIVIER R, 1992, INT C AIDS, V8, P65; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OMAR BA, 1990, FREE RADICAL BIO MED, V9, P465, DOI 10.1016/0891-5849(90)90123-Z; OMAR BA, 1990, FREE RADICAL BIO MED, V9, P473, DOI 10.1016/0891-5849(90)90124-2; RAFF MC, 1994, SCIENCE, V264, P668, DOI 10.1126/science.8171317; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RETSKY KL, 1993, J BIOL CHEM, V268, P1304; ROEDERER M, 1993, PHARMACOLOGY, V46, P121, DOI 10.1159/000139037; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROTHSTEIN JD, 1994, P NATL ACAD SCI USA, V91, P4155, DOI 10.1073/pnas.91.10.4155; Sambrook J, 1989, MOL CLONING LABORATO; SAMUNI A, 1983, EUR J BIOCHEM, V137, P119, DOI 10.1111/j.1432-1033.1983.tb07804.x; SANDSTROM PA, 1994, J LEUKOCYTE BIOL, V55, P221, DOI 10.1002/jlb.55.2.221; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHIMIZU S, 1995, NATURE, V374, P81; STEINMAN HM, 1995, J BIOL CHEM, V270, P3487; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WHITE E, 1993, GENE DEV, V7, P2277, DOI 10.1101/gad.7.12a.2277; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2	50	203	208	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3667	3670						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631978				2022-12-25	WOS:A1996TV72400052
J	Willmott, N; Sethi, JK; Walseth, TF; Lee, HC; White, AM; Galione, A				Willmott, N; Sethi, JK; Walseth, TF; Lee, HC; White, AM; Galione, A			Nitric oxide-induced mobilization of intracellular calcium via the cyclic ADP-ribose signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGGS; INDUCED CA2+ RELEASE; INOSITOL TRISPHOSPHATE; RYANODINE RECEPTOR; CGMP; ACTIVATION; CHANNEL; CELLS; FERTILIZATION; MECHANISMS	Cyclic adenosine diphosphate ribose (cADPR) is a potent endogenous calcium-mobilizing agent synthesized from beta-NAD(+) by ADP-ribosyl cyclases in sea urchin eggs and in several mammalian cells (Galione, A, and White, A (1994) Trends Cell Biol, 4, 431-436), Pharmacological studies suggest that cADPR is an endogenous modulator of Ca2+-induced Ca2+ release mediated by ryanodine-sensitive Ca2+ release channels, An unresolved question is whether cADPR can act as a Ca2+-mobilizing intracellular messenger, We show that exogenous application of nitric oxide (NO) mobilizes Ca2+ from intracellular stores in intact sea urchin eggs and that it releases Ca2+ and elevates cADPR levels in egg homogenates, 8-Amino-cADPR, a selective competitive antagonist of cADPR-mediated Ca2+ release, and nicotinamide, an inhibitor of ADP-ribosyl cyclase, inhibit the Ca2+-mobilizing actions of NO, while, heparin, a competitive antagonist of the inositol 1,4,5-trisphosphate receptor, did not affect NO-induced Ca2+ release, Since the Ca2+-mobilizing effects of NO can be mimicked by cGRIP, are inhibited by the cGMP-dependent-protein kinase inhibitor, R(p)-8-pCPT-cGMPS, and in egg homogenates show a requirement for the guanylyl cyclase substrate, GTP, we suggest a novel action of NO in mobilizing intracellular calcium from microsomal stores via a signaling pathway involving cGMP and cADPR, These results suggest that cADPR has the capacity to act as a Ca2+-mobilizing intracellular messenger.	UNIV OXFORD,DEPT PHARMACOL,OXFORD OX1 3QT,ENGLAND; UNIV MINNESOTA,DEPT PHARMACOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT PHYSIOL,MINNEAPOLIS,MN 55455	University of Oxford; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Walseth, Timothy F/F-9518-2010; Lee, Hon Cheung/C-4329-2009; Sethi, Jaswinder K./B-1413-2008	Walseth, Timothy F/0000-0003-2558-7859; Sethi, Jaswinder K./0000-0003-4157-0475; Galione, Antony/0000-0002-4132-7646	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLEN GJ, 1995, SCIENCE, V268, P735, DOI 10.1126/science.7732384; AYABE T, 1995, DEVELOPMENT, V121, P2233; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY IB, 1993, MOL BIOL CELL, V4, P347, DOI 10.1091/mbc.4.3.347; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P17917, DOI 10.1074/jbc.270.30.17917; BUCK WR, 1992, EXP CELL RES, V202, P59, DOI 10.1016/0014-4827(92)90404-V; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; DONNELLY LE, 1994, BIOCHEM PHARMACOL, V48, P1669, DOI 10.1016/0006-2952(94)90450-2; DOSHI M, 1985, EXP EYE RES, V41, P61, DOI 10.1016/0014-4835(85)90094-6; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Galione Antony, 1994, Trends in Cell Biology, V4, P431, DOI 10.1016/0962-8924(94)90104-X; GROMADA J, 1995, FEBS LETT, V360, P303, DOI 10.1016/0014-5793(95)00131-R; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; IGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485, DOI 10.1016/0006-2952(91)90618-F; KOHDA K, 1995, J NEUROPHYSIOL, V74, P2184, DOI 10.1152/jn.1995.74.5.2184; KONG SK, 1994, BIOCHEM BIOPH RES CO, V199, P234, DOI 10.1006/bbrc.1994.1219; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; LEE HC, 1994, NEWS PHYSIOL SCI, V9, P134; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCPHERSON SM, 1992, J CELL BIOL, V116, P1111, DOI 10.1083/jcb.116.5.1111; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; MILLER GL, 1959, ANAL CHEM, V31, P964, DOI 10.1021/ac60149a611; MONCADA S, 1991, PHARMACOL REV, V43, P109; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; PUBLICOVER NG, 1993, P NATL ACAD SCI USA, V90, P2087, DOI 10.1073/pnas.90.5.2087; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; VINCENT SR, 1994, PROG NEUROBIOL, V42, P129, DOI 10.1016/0301-0082(94)90023-X; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WALSETH TF, 1993, J BIOL CHEM, V268, P26686; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; WHALLEY T, 1992, MOL BIOL CELL, V3, P373, DOI 10.1091/mbc.3.3.373; WHITE AM, 1993, FEBS LETT, V318, P259, DOI 10.1016/0014-5793(93)80524-X; WILLMOTT NJ, 1995, FEBS LETT, V371, P99, DOI 10.1016/0014-5793(95)00848-4; XU X, 1994, J BIOL CHEM, V269, P12645; YUE CP, 1995, DEVELOPMENT, V121, P2645	51	195	203	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3699	3705						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631983				2022-12-25	WOS:A1996TV72400057
J	Helftenbein, G; Krusekopf, K; Just, U; Cross, M; Ostertag, W; Niemann, H; Tamura, T				Helftenbein, G; Krusekopf, K; Just, U; Cross, M; Ostertag, W; Niemann, H; Tamura, T			Transcriptional regulation of the c-fms proto-oncogene mediated by granulocyte macrophage colony-stimulating factor (GM-CSF) in murine cell lines	ONCOGENE			English	Article						transreceptor control; c-fms proto-oncogene; M-CSF receptor; GM-CSF mediated signal transduction	RECEPTOR GENE FAMILY; FACTOR-I RECEPTOR; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; MESSENGER-RNA; BETA-SUBUNIT; EXPRESSION; INTERLEUKIN-3; CLONING	Differentiation of blood cells is paralleled by a timely ordered expression of cytokine receptor genes. We show here that the expression of the c-fms gene which encodes the lineage-specific receptor for macrophage colony-stimulating factor (M-CSF or CSF-1) is directly linked to ligand-mediated activation of the receptor for the granulocyte/macrophage colony-stimulating factor (GMCSF). In interleukin-3 (IL-3) dependent multipotent progenitor cells, FDC-Pmix GMV#2 cells, GM-CSF treatment results in the rapid formation of full-length c-fms transcripts. Surprisingly, this upregulation of c-fms transcripts is also observed in mouse NIH3T3 fibroblasts stably transfected with genes coding for the alpha- and beta-subunits of the GM-CSF receptor. These results indicate a direct control by the GM-CSF receptor that takes place regardless of cell differentiation. Furthermore, a 2.1 kb genomic fragment containing the c-fins proximal promoter directs GM-CSF-inducible expression of a reporter gene, suggesting a regulation of c-fms gene expression on the transcriptional level.	UNIV GIESSEN, INST VIROL, D-35392 GIESSEN, GERMANY; UNIV HAMBURG, HEINRICH PETTE INST EXPTL VIROL & IMMUNOL, D-20251 HAMBURG, GERMANY; CHRISTIE HOSP NATL HLTH SERV TRUST, PATERSON INST CANC RES, CANC RES CAMPAIGN DEPT EXPTL HAEMATOL, MANCHESTER M20 8BX, LANCS, ENGLAND; BUNDESFORSCH ANSTALT VIRUSKRANKHEITEN TIERE, D-72076 TUBINGEN, GERMANY	Justus Liebig University Giessen; Heinrich Pette Institute; University of Hamburg; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research			Just, Ursula/E-6992-2010	Cross, Michael/0000-0002-8815-7621				ADUNYAH SE, 1991, J BIOL CHEM, V266, P5670; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; EDER M, 1993, EMBO J, V12, P1647, DOI 10.1002/j.1460-2075.1993.tb05810.x; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; JUST U, 1993, GROWTH FACTORS, V9, P291, DOI 10.3109/08977199308991589; JUST U, 1991, CELL, V64, P1163, DOI 10.1016/0092-8674(91)90271-Y; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P378, DOI 10.1016/0968-0004(92)90004-S; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NIENHUIS AW, 1985, CELL, V42, P421, DOI 10.1016/0092-8674(85)90099-6; OKUDA K, 1992, BLOOD, V79, P2880; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; REDDY MA, 1992, MOL ENDOCRINOL, V6, P1051, DOI 10.1210/me.6.7.1051; REDDY MA, 1994, J EXP MED, V180, P2309, DOI 10.1084/jem.180.6.2309; ROBERTS WM, 1992, BLOOD, V79, P586; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHATZMUNDING M, 1992, EUR J BIOCHEM, V204, P705, DOI 10.1111/j.1432-1033.1992.tb16685.x; SHERR CJ, 1990, BLOOD, V75, P1; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; TAMURA T, 1986, MOL CELL BIOL, V6, P4745, DOI 10.1128/MCB.6.12.4745; WATANABE S, 1993, MOL CELL BIOL, V13, P1440, DOI 10.1128/MCB.13.3.1440; WEBER B, 1989, MOL CELL BIOL, V9, P769, DOI 10.1128/MCB.9.2.769; WOOLFORD J, 1985, MOL CELL BIOL, V5, P3458, DOI 10.1128/MCB.5.12.3458; YUE X, 1993, MOL CELL BIOL, V13, P3191, DOI 10.1128/MCB.13.6.3191; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	35	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	1996	12	4					931	935						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632916				2022-12-25	WOS:A1996TW68600025
J	Han, JS; Chung, JK; Kang, HS; Donaldson, J; Bae, YS; Rhee, SG				Han, JS; Chung, JK; Kang, HS; Donaldson, J; Bae, YS; Rhee, SG			Multiple forms of phospholipase D inhibitor from rat brain cytosol - Purification and characterization of heat-labile form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLCHOLINE HYDROLYSIS; PLASMA-MEMBRANES; G-PROTEIN; PHOSPHORYLATION; IDENTIFICATION; NEUTROPHILS; ACTIVATION; RECEPTOR; CELLS	Rat brain cytosol contains proteins that markedly inhibit the activity of partially purified brain membrane phospholipase D (PLD) stimulated by ADP-ribosylation factor (Arf) and phosphatidylinositol 4,5-bisphosphate (PIP2). Sequential chromatography of the brain cytosol yielded four inhibitor fractions, which exhibited different kinetics to heat treatment at 70 degrees C. Purification of the most heat-labile inhibitor to homogeneity yielded two preparations, which displayed apparent molecular masses of 150 kDa and 135 kDa, respectively, on SDS-polyacrylamide gels. Tryptic digests of the 150- and 135-kDa proteins yielded similar elution profiles on a C-18 reverse-phase column, suggesting that the 135-kDa form is a truncated form of the 150-kDa form. Sequences of two tryptic peptides were determined. A data base search revealed no proteins with these sequences. The purified 150-kDa inhibitor negated the PLD activity stimulated by Arf, RhoA, or Cdc42. The concentration required for half-maximal inhibition was 0.4 nM. Concentration dependence on the 150-kDa inhibitor was not affected by changes in the concentrations of Arf, PIP2, or phosphatidylcholine used in the assays, suggesting that the inhibition is not due to competition with the activators or substrate for PLD. The purified inhibitor did not affect the PIP2-hydrolyzing activity of a phospholipase C isozyme that was measured with substrate vesicles of lipid composition identical with that used for the PLD assay. Thus, the mechanism of inhibition appears to be a specific allosteric modification of PLD rather than disruption of substrate vesicles.	NHLBI,LAB CELL SIGNALLING,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Han, Joong-Soo/P-2072-2015	Han, Joong-Soo/0000-0002-0875-6158				AHMED A, 1994, AM J PHYSIOL, V266, pC206, DOI 10.1152/ajpcell.1994.266.1.C206; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOURGOIN S, 1995, J BIOL CHEM, V270, P3172, DOI 10.1074/jbc.270.7.3172; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CHALIFA V, 1990, J BIOL CHEM, V265, P17512; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONRICODE KM, 1994, FEBS LETT, V342, P149, DOI 10.1016/0014-5793(94)80490-7; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; GENY B, 1995, EUR J BIOCHEM, V231, P31, DOI 10.1111/j.1432-1033.1995.tb20666.x; GUSTAVSSON L, 1994, J BIOL CHEM, V269, P849; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; HONG JX, 1994, J BIOL CHEM, V269, P9743; HUANG CF, 1992, J BIOL CHEM, V267, P16859; INOUE H, 1995, BIOCHEM BIOPH RES CO, V210, P542, DOI 10.1006/bbrc.1995.1694; KANFER JN, 1994, FEBS LETT, V337, P251, DOI 10.1016/0014-5793(94)80202-5; KISS Z, 1994, BIOCHEM J, V300, P751, DOI 10.1042/bj3000751; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LEE YH, 1994, J BIOL CHEM, V269, P26842; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MARTIN TW, 1989, J BIOL CHEM, V264, P8847; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MOEHREN G, 1994, J BIOL CHEM, V269, P838; MOHN H, 1992, J BIOL CHEM, V267, P11131; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SIDDIQUI RA, 1992, J BIOL CHEM, V267, P5755; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; UINGS IJ, 1992, BIOCHEM J, V281, P597, DOI 10.1042/bj2810597	34	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11163	11169		10.1074/jbc.271.19.11163	http://dx.doi.org/10.1074/jbc.271.19.11163			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626662	hybrid			2022-12-25	WOS:A1996UJ94400022
J	Karzai, AW; McMacken, R				Karzai, AW; McMacken, R			A bipartite signaling mechanism involved in DnaJ-mediated activation of the Escherichia coli DnaK protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; BACTERIOPHAGE-LAMBDA; NUCLEOPROTEIN STRUCTURES; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONES; BINDING-SPECIFICITY; REPLICATION ORIGIN; PEPTIDE-BINDING; GRPE; INITIATION	The DnaK and DnaJ heat shock proteins function as the primary Hsp70 and Hsp40 homologues, respectively, of Escherichia coli. Intensive studies of various Hsp70 and DnaJ-like proteins over the past decade have led to the suggestion that interactions between specific pairs of these two types of proteins permit them to serve as molecular chaperones in a diverse array of protein metabolic events, including protein folding, protein trafficking, and assembly and disassembly of multisubunit protein complexes. To further our understanding of the nature of Hsp70-DnaJ interactions, we have sought to define the minimal sequence elements of DnaJ required for stimulation of the intrinsic ATPase activity of DnaK. As judged by proteolysis sensitivity, DnaJ is composed of three separate regions, a 9-kDa NH2-terminal domain, a 30-kDa COOH-terminal domain, and a protease-sensitive glycine- and phenylalanine-rich (G/F-rich) segment of 30 amino acids that serves as a flexible linker between the two domains. The stable 9-kDa proteolytic fragment was identified as the highly conserved J-region found in all DnaJ homologues. Using this structural information as a guide, we constructed, expressed, purified, and characterized several mutant DnaJ proteins that contained either NH2-terminal or C00H-terminal deletions. At variance with current models of DnaJ action, DnaJ1-75, a polypeptide containing an intact J-region, mas found to be incapable of stimulating ATP hydrolysis by DnaK protein. We found, instead, that two sequence elements of DnaJ, the J-region and the G/F-rich linker segment, are each required for activation of DnaJ-mediated ATP hydrolysis and for minimal DnaJ function in the initiation of bacteriophage lambda DNA replication. Further analysis indicated that maximal activation of ATP hydrolysis by DnaK requires two independent but simultaneous protein-protein interactions: (i) interaction of DnaK with the J-region of DnaJ and (ii) binding of a peptide or polypeptide to the polypeptide-binding site associated with the COOH-terminal domain of DnaK. This dual signaling process required for activation of DnaK function has mechanistic implications for those protein metabolic events, such as polypeptide translocation into the endoplasmic reticulum in eukaryotic cells, that are dependent on interactions between Hsp70-like and DnaJ-like proteins.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOCHEM,BALTIMORE,MD 21205	Johns Hopkins University					NIEHS NIH HHS [ES-03819] Funding Source: Medline; NIGMS NIH HHS [GM36526, GM32253] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES003819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032253, R01GM036526] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALFANO C, 1989, J BIOL CHEM, V264, P10709; ALFANO C, 1989, J BIOL CHEM, V264, P10699; BAKER TA, 1992, ANNU REV GENET, V26, P447; BARDWELL JCA, 1984, P NATL ACAD SCI-BIOL, V81, P848, DOI 10.1073/pnas.81.3.848; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993; CRAIG EA, 1994, CELL, V78, P365, DOI 10.1016/0092-8674(94)90416-2; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; CYR DM, 1994, J BIOL CHEM, V269, P9798; DESHAIES RJ, 1988, NATURE, V332, P80; DODSON M, 1989, J BIOL CHEM, V264, P10719; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; Georgopoulos C., 1971, BACTERIOPHAGE LAMBDA, P553; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAGEROV A, 1994, J MOL BIOL, V241, P133, DOI 10.1006/jmbi.1994.1482; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; GROSS CA, 1990, STRESS PROTEINS BIOL, P167; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HILL RB, 1995, BIOCHEMISTRY-US, V34, P5587, DOI 10.1021/bi00016a033; JORDAN R, 1995, J BIOL CHEM, V270, P4563, DOI 10.1074/jbc.270.9.4563; KANG PJ, 1990, J BACTERIOL, V172, P2055, DOI 10.1128/jb.172.4.2055-2064.1990; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1995, P NATL ACAD SCI USA, V92, P6224, DOI 10.1073/pnas.92.14.6224; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MENSAWILMOT K, 1989, J BIOL CHEM, V264, P2853; MILMAN G, 1987, METHOD ENZYMOL, V153, P482; MOTOHASHI K, 1994, J BIOL CHEM, V269, P27074; NEIDHARDT FC, 1987, ESCHERICHIA COLI SAL, P1334; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ROUVIEREYANIV J, 1979, FEBS LETT, V106, P297, DOI 10.1016/0014-5793(79)80518-9; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SAITO H, 1977, J MOL BIOL, V113, P1, DOI 10.1016/0022-2836(77)90038-9; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLENSTEDT G, 1995, J BIOL CHEM, V129, P949; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SEIDMORE MA, 1993, MOL BIOL CELL, V4, P1145; SHI WY, 1992, J BACTERIOL, V174, P6256, DOI 10.1128/JB.174.19.6256-6263.1992; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; STRAUS D, 1990, GENE DEV, V4, P2202, DOI 10.1101/gad.4.12a.2202; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; TILLY K, 1983, CELL, V34, P641, DOI 10.1016/0092-8674(83)90396-3; WALL D, 1994, J BIOL CHEM, V269, P5446; WALL D, 1995, J BIOL CHEM, V270, P2139, DOI 10.1074/jbc.270.5.2139; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19307, DOI 10.1074/jbc.270.33.19307; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; YOCHEM J, 1978, MOL GEN GENET, V164, P9, DOI 10.1007/BF00267593; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	71	196	198	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11236	11246		10.1074/jbc.271.19.11236	http://dx.doi.org/10.1074/jbc.271.19.11236			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626673	hybrid			2022-12-25	WOS:A1996UJ94400033
J	Gong, JH; Uguccioni, M; Dewald, B; Baggiolini, M; ClarkLewis, I				Gong, JH; Uguccioni, M; Dewald, B; Baggiolini, M; ClarkLewis, I			RANTES and MCP-3 antagonists bind multiple chemokine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; MOLECULAR-CLONING; FUNCTIONAL EXPRESSION; CDNA; IDENTIFICATION; INTERLEUKIN-8; CYTOKINES; FAMILY; CELLS	Antagonists of multiple chemokines could be more effective than inhibitors of specific chemokines for controlling cell migration and inflammation. To attempt to identify such antagonists we characterized a number of truncated analogs of regulated on activation normal T cell expressed protein (RANTES), monocyte chemoattractant protein (MCP)-3, and MCP-1. On the basis of their ability to compete for binding of their parent chemokines, three analogs were selected for cross-reactivity studies: RANTES (9-68), MCP-3 (10-76), and MCP-1 (9-76), These analogs bound to THP-1 monocytic cells with dissociation constants that were within 4-6-fold of their native counterparts, but they did not promote detectable chemotaxis of THP-1 cells or enzyme release from purified human monocytes, The RANTES (9-68) analog competed for the binding and inhibited the activities of all three chemokines. In contrast, native RANTES was specific for RANTES binding sites, However, truncation of either MCP-1 or MCP-3 did not change their respective binding specificity, MCP-3 and MCP-S (10-76) competed for binding of all three labeled chemokines. MCP-1 (9-76) competed strongly for binding of labeled MCP-1, but only weakly for the other two labeled ligands and inhibited the activities induced by MCP-1 and MCP-3 but not RANTES. Although RANTES (9-68) and MCP-3 (10-76) inhibited all three chemokines, the RANTES analog was significantly more potent for RANTES induced activity, The results indicate that NH2-terminal residues partly determine the receptor specificity of RANTES, and deletions within this region permit binding to multiple chemokine receptors, The findings suggest the feasibility of design of high affinity multi-specific CC chemokine antagonists.	UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER,BC V6T 1Z3,CANADA; UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOLEC BIOL,VANCOUVER,BC V6T 1Z3,CANADA; UNIV BERN,THEODOR KOCHER INST,CH-3000 BERN,SWITZERLAND	University of British Columbia; University of British Columbia; University of Bern				Uguccioni, Mariagrazia/0000-0002-9570-7011	NIGMS NIH HHS [R01 GM-50969-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050969] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; BENBARUCH A, 1995, J BIOL CHEM, V270, P22123, DOI 10.1074/jbc.270.38.22123; CALVO JC, 1983, BIOCHEM J, V212, P259, DOI 10.1042/bj2120259; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CLARKLEWIS I, 1994, J BIOL CHEM, V269, P16075; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; CLARKLEWIS I, 1991, BIOCHEMISTRY-US, V30, P3128, DOI 10.1021/bi00226a021; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; COLOTTA F, 1984, J IMMUNOL, V132, P936; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; FRANCI C, 1995, J IMMUNOL, V154, P6511; FURIE MB, 1995, AM J PATHOL, V146, P1287; FURUTANI Y, 1989, BIOCHEM BIOPH RES CO, V159, P249, DOI 10.1016/0006-291X(89)92430-3; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; KELVIN DJ, 1993, J LEUKOCYTE BIOL, V54, P604, DOI 10.1002/jlb.54.6.604; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NOMURA H, 1993, INT IMMUNOL, V5, P1239, DOI 10.1093/intimm/5.10.1239; OPDENAKKER G, 1993, BIOCHEM BIOPH RES CO, V191, P535, DOI 10.1006/bbrc.1993.1251; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; SOZZANI S, 1993, J IMMUNOL, V150, P1544; UGUCCIONI M, 1995, EUR J IMMUNOL, V25, P64, DOI 10.1002/eji.1830250113; VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59; VANRIPER G, 1993, J EXP MED, V177, P851, DOI 10.1084/jem.177.3.851; WANG JM, 1993, J EXP MED, V177, P699, DOI 10.1084/jem.177.3.699; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3; ZHANG YJ, 1994, J BIOL CHEM, V269, P15918	34	143	186	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10521	10527		10.1074/jbc.271.18.10521	http://dx.doi.org/10.1074/jbc.271.18.10521			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631850	hybrid			2022-12-25	WOS:A1996UJ34200018
J	Nag, B; Arimilli, S; Mukku, PV; Astafieva, I				Nag, B; Arimilli, S; Mukku, PV; Astafieva, I			Functionally active recombinant alpha and beta chain-peptide complexes of human major histocompatibility class II molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECOGNITION; ANTIGENIC PEPTIDES; LIPID-MEMBRANES; BINDING; STIMULATION; INDUCTION; CLONES; PH	Major histocompatibility (MHC) class II molecules are cell surface heterodimeric (alpha beta) glycoproteins that display processed antigens to T cell receptors (TCRs) of CD4-positive T cells. The present study describes that individual recombinant alpha and beta chains of human MHC class II molecules lacking the transmembrane region (alpha-Tm and beta-Tm) are capable of binding antigenic peptide and that these complexes of chain-peptide are recognized by TCRs to induce antigen-specific apoptosis in restricted T cells. The alpha-Tm and the beta-Tm of human HLA-DR2 (DRB5*0101) were cloned, expressed in Escherichia coli, and purified in large scale by conventional chromatographic methods. The in vitro binding of an immunodominant epitope from the myelin basic protein (MBP-(83-102)Y-83) to purified DR2 alpha-Tm and DR2 beta-Tm was demonstrated with biotinylated and fluoresceinated MBP-(83-102)Y-83 peptide. The specificity of the MBP-(83-102)Y-83 peptide binding to both DR2 alpha-Tm and DR2 beta-Tm was demonstrated in a competitive peptide binding assay. When exposed to a transformed T cell clone (SS8T) restricted to DR2(DRB5*0101) and MBP-(84-102) peptide, complexes of DR2 alpha-Tm and DR2 beta-Tm with MBP-(83-102)Y-83 peptide were able to specifically recognize TCRs as measured by the increase in gamma-interferon (gamma-IFN) cytokine. Such recognition of TCRs by soluble alpha-MBP-(83-102)Y-83 and beta-MBP-(83-102)Y-83 complexes led to the induction of antigen-specific apoptosis in SS8T cells as measured by double fluorescence flow cytometry and electron microscop. These results provide the first evidence that soluble complexes of antigenic peptide and individual chains of human MHC class II molecules lacking the transmembrane region can recognize TCRs and induce antigen-specific apoptosis in T cells. Since activated CD4-positive T cells are involved in pathogenesis of various autoimmune diseases, the apoptosis triggered by individual soluble chain-peptide complexes has significant potential for eliminating autoreactive T cells.			Nag, B (corresponding author), ANERGEN INC,REDWOOD CITY,CA 94063, USA.							ARIMILLI S, 1995, J BIOL CHEM, V270, P971, DOI 10.1074/jbc.270.2.971; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BUSS S, 1986, P NATL ACAD SCI USA, V83, P3968; DALTON TA, 1992, AM J MED, V92, P183, DOI 10.1016/0002-9343(92)90110-W; DORNMAIR K, 1989, COLD SPRING HARB SYM, V54, P409; GERMAIN RN, 1993, NATURE, V363, P725, DOI 10.1038/363725a0; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GOLDING H, 1985, NATURE, V317, P425, DOI 10.1038/317425a0; GORCZYCA W, 1993, LEUKEMIA, V7, P659; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; LANZAVECCHIA A, 1988, NATURE, V334, P530, DOI 10.1038/334530a0; MCCLUSKEY J, 1988, J IMMUNOL, V140, P2081; MUKKU PV, 1995, MOL IMMUNOL, V32, P555, DOI 10.1016/0161-5890(95)00030-I; NAG B, 1993, J IMMUNOL, V150, P1358; NAG B, 1992, J IMMUNOL, V148, P2040; NAG B, 1994, J BIOL CHEM, V269, P10061; NAG B, 1994, MOL IMMUNOL, V31, P1161, DOI 10.1016/0161-5890(94)90030-2; NAG B, 1992, J IMMUNOL, V148, P369; NAG B, 1993, P NATL ACAD SCI USA, V87, P352; PASSMORE D, 1992, J IMMUNOL METHODS, V155, P193, DOI 10.1016/0022-1759(92)90285-2; PICHLER WJ, 1994, IMMUNOL TODAY, V15, P312, DOI 10.1016/0167-5699(94)90078-7; QUILL H, 1987, J IMMUNOL, V138, P3704; ROTHENHAUSLER B, 1990, P NATL ACAD SCI USA, V87, P352, DOI 10.1073/pnas.87.1.352; SETTE A, 1992, J IMMUNOL, V148, P844; SHARMA SD, 1991, P NATL ACAD SCI USA, V88, P11465, DOI 10.1073/pnas.88.24.11465; Spack EG, 1995, J AUTOIMMUN, V8, P787, DOI 10.1016/S0896-8411(95)80018-2; STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; VALLI A, 1993, J CLIN INVEST, V91, P616, DOI 10.1172/JCI116242; WATTS TH, 1986, P NATL ACAD SCI USA, V83, P9660, DOI 10.1073/pnas.83.24.9660; WEBER F, 1993, P NATL ACAD SCI USA, V90, P11049, DOI 10.1073/pnas.90.23.11049; WITT SN, 1991, P NATL ACAD SCI USA, V88, P8164, DOI 10.1073/pnas.88.18.8164; WUCHERPFENNIG KW, 1994, J EXP MED, V179, P279, DOI 10.1084/jem.179.1.279	34	18	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10413	10418		10.1074/jbc.271.17.10413	http://dx.doi.org/10.1074/jbc.271.17.10413			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626615	hybrid			2022-12-25	WOS:A1996UG25700087
J	Klatt, P; Pfeiffer, S; List, BM; Lehner, D; Glatter, O; Bachinger, HP; Werner, ER; Schmidt, K; Mayer, B				Klatt, P; Pfeiffer, S; List, BM; Lehner, D; Glatter, O; Bachinger, HP; Werner, ER; Schmidt, K; Mayer, B			Characterization of heme-deficient neuronal nitric-oxide synthase reveals a role for heme in subunit dimerization and binding of the amino acid substrate and tetrahydrobiopterin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN; PURIFICATION; CALMODULIN; REDUCTASE; FLAVIN; CYTOCHROME-P-450; BACTERIOPHAGE-T4; INTERMEDIATE; ENZYME; CELLS	Neuronal nitric-oxide (NO) synthase contains FAD, FMN, heme, and tetrahydrobiopterin as prosthetic groups and represents a multifunctional oxidoreductase catalyzing oxidation of L-arginine to L-citrulline and NO, reduction of molecular oxygen to superoxide, and electron transfer to cytochromes. To investigate how binding of the prosthetic heme moiety is related to enzyme activities, cofactor, and L-arginine binding, as well as to secondary and quaternary protein structure, we have purified and characterized heme-deficient neuronal NO synthase. The heme-deficient enzyme, which had preserved its cytochrome c reductase activity, contained FAD and FMN, but virtually no tetrahydrobiopterin, and exhibited only marginal NO synthase activity. By means of gel filtration and static light scattering, we demonstrate that the heme-deficient enzyme is a monomer and provide evidence that heme is the sole prosthetic group controlling the quaternary structure of neuronal NO synthase. CD spectroscopy showed that most of the structural elements found in the dimeric holoenzyme were conserved in heme-deficient monomeric NO synthase. However, in spite of being properly folded, the heme-deficient enzyme did bind neither tetrahydrobiopterin nor the substrate analog N-G-nitro-L-arginine. Our results demonstrate that the prosthetic heme group of neuronal NO synthase is requisite for dimerization of enzyme subunits and for the binding of amino acid substrate and tetrahydrobiopterin.	KARL FRANZENS UNIV GRAZ, INST PHARMAKOL & TOXIKOL, A-8010 GRAZ, AUSTRIA; KARL FRANZENS UNIV GRAZ, INST PHYS CHEM, A-8010 GRAZ, AUSTRIA; OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA; SHRINERS HOSP CRIPPLED CHILDREN, RES DEPT, PORTLAND, OR 97201 USA; UNIV INNSBRUCK, INST MED CHEM & BIOCHEM, A-6020 INNSBRUCK, AUSTRIA	University of Graz; University of Graz; Oregon Health & Science University; University of Innsbruck			Mayer, Bernd/B-9391-2008	Werner, Ernst R./0000-0003-1948-3391; Mayer, Bernd/0000-0002-2921-3494				ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRUNNER F, 1991, BRIT J PHARMACOL, V102, P373, DOI 10.1111/j.1476-5381.1991.tb12181.x; Chu B, 1991, LASER LIGHT SCATTERI; COMPTON LA, 1987, J BIOL CHEM, V262, P13039; COMPTON LA, 1992, EUR J BIOCHEM, V206, P927, DOI 10.1111/j.1432-1033.1992.tb17002.x; DEGTYARENKO KN, 1993, FEBS LETT, V332, P1, DOI 10.1016/0014-5793(93)80470-F; DELEVIE R, 1986, J CHEM EDUC, V63, P10, DOI 10.1021/ed063p10; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; HARTENECK C, 1994, BIOCHEM J, V304, P683, DOI 10.1042/bj3040683; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; Huglin M. B., 1972, LIGHT SCATTERING POL; KLATT P, 1994, J BIOL CHEM, V269, P1674; KLATT P, 1994, J BIOL CHEM, V269, P13861; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; KLATT P, 1993, J BIOL CHEM, V268, P14781; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; KLATT P, 1992, J BIOL CHEM, V267, P11374; KLATT P, 1996, IN PRESS METHODS ENZ; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MAYER B, 1994, NEUROPHARMACOLOGY, V33, P1253, DOI 10.1016/0028-3908(94)90024-8; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MAYER B, 1995, IN PRESS METHODS ENZ; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NISHIMURA JS, 1995, BIOCHEM BIOPH RES CO, V210, P288, DOI 10.1006/bbrc.1995.1659; PINNIX IB, 1994, ARCH BIOCHEM BIOPHYS, V312, P447, DOI 10.1006/abbi.1994.1331; POU S, 1992, J BIOL CHEM, V267, P24173; RENAUD JP, 1993, BIOCHEM BIOPH RES CO, V192, P53, DOI 10.1006/bbrc.1993.1380; RICHARDS MK, 1994, BIOCHEMISTRY-US, V33, P14743; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SHETA EA, 1994, J BIOL CHEM, V269, P15147; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; WANG JL, 1993, J BIOL CHEM, V268, P22255; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020; WERNER ER, 1994, BIOCHEM J, V304, P189, DOI 10.1042/bj3040189	52	166	166	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7336	7342		10.1074/jbc.271.13.7336	http://dx.doi.org/10.1074/jbc.271.13.7336			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631754	hybrid			2022-12-25	WOS:A1996UC77400022
J	deCarvalho, MGS; McCormack, AL; Olson, E; Ghomashchi, F; Gelb, MH; Yates, JR; Leslie, CC				deCarvalho, MGS; McCormack, AL; Olson, E; Ghomashchi, F; Gelb, MH; Yates, JR; Leslie, CC			Identification of phosphorylation sites of human 85-kDa cytosolic phospholipase A(2) expressed in insect cells and present in human monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONOYL-HYDROLYZING PHOSPHOLIPASE-A2; PRODUCT-CONTAINING VESICLES; PROTEIN-KINASE-C; MOBILIZING PHOSPHOLIPASE-A2; MACROPHAGES; ACTIVATION; ACID; LIPOPOLYSACCHARIDE; MEMBRANE; LINE	The phosphorylation sites on the human, 85-kDa cytosolic phospholipase A(2) (cPLA(2)) were identified using recombinant cPLA, expressed in Spodoptera frugiperda (Sf9) cells, Analysis by high performance liquid chromatography of tryptic digests of P-32-labeled recombinant cPLA(2) showed four major peaks of radiolabeled phosphopeptides. The phosphorylated residues were identified as Ser-437, Ser-454, Ser-505, and Ser-727 using mass spectrometry and automated Edman sequencing, Sf9 cells infected with recombinant virus expressing cPLA(2) exhibited a time-dependent release of arachidonic acid in response to the calcium ionophore A23187 or the protein phosphatase inhibitor okadaic acid, which was not observed in Sf9 cells infected with wild-type virus, Stimulation of Sf9 cells with A23187 and okadaic acid also increased the level of phosphorylation of cPLA(2). Okadaic acid, but not A23187, induced a gel shift of cPLA(2) and increased the level of phosphorylation of Ser-727 by 4.5-fold, whereas the level of phosphorylation of the other sites increased by 60% or less in response to both agonists, To determine whether the same sites on cPLA(2) were phosphorylated in mammalian cells, human monocytes were studied, Okadaic acid stimulation of monocytes induced a gel shift of cPLA(2), increased the release of arachidonic acid, and increased the level of phosphorylation of cPLA(2) on serine residues, Comparison of two-dimensional peptide maps of tryptic digests of P-32-labeled recombinant cPLA(2) and human monocyte cPLA(2) demonstrated that the same peptides on cPLA(2) were phosphorylated in mammalian cells as in insect cells. These results show that the Sf9-baculovirus expression system is useful for investigation of the phosphorylation sites on cPLA(2). The results also suggest that phosphorylation of the cPLA(2) by protein kinases other than mitogen-activated protein kinase may he important for the regulation of arachidonic acid release.	NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, DIV BASIC SCI, DENVER, CO 80206 USA; UNIV COLORADO, SCH MED, DEPT PATHOL, DENVER, CO 80262 USA; UNIV WASHINGTON, DEPT MOLEC BIOTECHNOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT CHEM & BIOCHEM, SEATTLE, WA 98195 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				gelb, michael/0000-0001-7000-5219	NHLBI NIH HHS [HL34303, HL50040, P01 HL034303] Funding Source: Medline; NIGMS NIH HHS [GM562] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050040, P01HL034303] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDULLAH K, 1995, BBA-GEN SUBJECTS, V1244, P157, DOI 10.1016/0304-4165(94)00218-M; BECKER GW, 1994, BIO-TECHNOL, V12, P69, DOI 10.1038/nbt0194-69; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CURRIE GJ, 1993, J AM SOC MASS SPECTR, V4, P955, DOI 10.1016/1044-0305(93)80022-Q; DECARVALHO MS, 1993, ARCH BIOCHEM BIOPHYS, V306, P534, DOI 10.1006/abbi.1993.1549; DIEZ E, 1992, J BIOL CHEM, V267, P18342; DOERFLER ME, 1994, J CLIN INVEST, V93, P1583, DOI 10.1172/JCI117138; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GRONICH J, 1994, J CLIN INVEST, V93, P1224, DOI 10.1172/JCI117076; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; HANEL AM, 1993, BIOCHEMISTRY-US, V32, P5949, DOI 10.1021/bi00074a005; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNEDY RT, 1989, ANAL CHEM, V61, P1128, DOI 10.1021/ac00185a016; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOZMA SC, 1993, J BIOL CHEM, V268, P7134; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; KRAMER RM, 1995, J BIOL CHEM, V270, P14816, DOI 10.1074/jbc.270.24.14816; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LESLIE CC, 1986, BIOCHEM J, V236, P251, DOI 10.1042/bj2360251; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; QIU ZH, 1993, J BIOL CHEM, V268, P24506; QIU ZH, 1994, J BIOL CHEM, V269, P19480; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; SVENSSON U, 1993, EUR J BIOCHEM, V213, P81, DOI 10.1111/j.1432-1033.1993.tb17736.x; VIK TA, 1990, P NATL ACAD SCI USA, V87, P2685, DOI 10.1073/pnas.87.7.2685; WATERMAN WH, 1995, BIOCHEM BIOPH RES CO, V209, P271, DOI 10.1006/bbrc.1995.1499; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WIJKANDER J, 1992, BIOCHEM BIOPH RES CO, V184, P118, DOI 10.1016/0006-291X(92)91166-N; WIJKANDER J, 1992, FEBS LETT, V311, P299, DOI 10.1016/0014-5793(92)81124-5; XU XX, 1994, J BIOL CHEM, V269, P31693; YATES JR, 1995, ANAL CHEM, V67, P3202, DOI 10.1021/ac00114a016; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020; YATES JR, 1994, CELL BIOL LABORATORY, P380	44	152	152	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6987	6997		10.1074/jbc.271.12.6987	http://dx.doi.org/10.1074/jbc.271.12.6987			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636128	hybrid			2022-12-25	WOS:A1996UB15700063
J	Fox, JEB; Shattil, SJ; KinloughRathbone, RL; Richardson, M; Packham, MA; Sanan, DA				Fox, JEB; Shattil, SJ; KinloughRathbone, RL; Richardson, M; Packham, MA; Sanan, DA			The platelet cytoskeleton stabilizes the interaction between alpha(IIb)beta(3) and its ligand and induces selective movements of ligand-occupied integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; SUSPENSION-ACTIVATED PLATELETS; OPEN CANALICULAR SYSTEM; MEMBRANE SKELETON; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; ACTIN-FILAMENTS; COLLOIDAL GOLD; GPIIB-IIIA; DEPENDENT PHOSPHORYLATION	Previously, we showed that a subpopulation of the major platelet integrin, alpha(IIb)beta(3), co-sediments from detergent lysates with talin and other membrane skeleton proteins. Once alpha(IIb)beta(3) has bound adhesive ligand in a platelet aggregate, the detergent-insoluble alpha(IIb)beta(3) redistributes (along with the detergent-insoluble membrane skeleton proteins and a variety of signaling molecules) to a fraction that contains cytoplasmic actin filaments. Concomitantly, certain signaling molecules are activated, The present study shows that, in intact platelets, alpha(IIb)beta(3) forms clusters when occupied by ligand and is selectively moved into the open canalicular system; alpha(IIb)beta(3) that has not bound ligand remains diffusely distributed at the periphery of the cell. When cytoplasmic actin filaments are depolymerized by cytochalasins, the ability of alpha(IIb)beta(3) to bind ligand is decreased, and the movement of ligand-occupied alpha(IIb)beta(3) is prevented. Together with the previous findings, these results suggest that (i) membrane skeleton-associated alpha(IIb)beta(3) is selectively induced to bind ligand in activated platelets, (ii) ligand-induced transmembrane signaling causes an altered association of membrane skeleton-associated alpha(IIb)beta(3) with the cytoplasmic component of the cytoskeleton, (iii) ligand-induced cytoskeletal reorganizations stabilize the interaction between ligand and integrin, and (iv) ligand-occupancy triggers cytoskeletal reorganizations that result in selective movements of occupied ligand.	CHILDRENS HOSP,OAKLAND RES INST,OAKLAND,CA 94609; UNIV PENN,DEPT MED,DIV HEMATOL ONCOL,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PATHOL & LAB MED,DIV HEMATOL ONCOL,PHILADELPHIA,PA 19104; MCMASTER UNIV,HAMILTON,ON,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON,CANADA; QUEENS UNIV,KINGSTON,ON,CANADA; GLADSTONE INST,SAN FRANCISCO,CA 94141	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; University of Pennsylvania; University of Pennsylvania; McMaster University; University of Toronto; Queens University - Canada; University of California System; University of California San Francisco; The J David Gladstone Institutes	Fox, JEB (corresponding author), CLEVELAND CLIN FDN,JOSEPH J JACOBS CTR THROMBOSIS & VASC BIOL FF20,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030657, P01HL040387, R23HL030657, R01HL030657] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40387, HL-49888, HL30657] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS C, 1994, J BIOL CHEM, V269, P18781; ALBRECHT RM, 1989, AM J ANAT, V185, P149, DOI 10.1002/aja.1001850208; ALBRECHT RM, 1994, PROC ANN MEET MSA, P1016; ALBRECHT RM, 1990, FIBRINOGEN, V4, P87; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CASELLA JF, 1981, NATURE, V293, P302, DOI 10.1038/293302a0; DANSCHER G, 1983, J HISTOCHEM CYTOCHEM, V31, P1394, DOI 10.1177/31.12.6631001; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; EARNEST JP, 1995, J BIOL CHEM, V270, P27259, DOI 10.1074/jbc.270.45.27259; EPPELL SJ, 1995, BIOPHYS J, V68, P671, DOI 10.1016/S0006-3495(95)80228-6; ESCOLAR G, 1989, BLOOD, V74, P1983; ESCOLAR G, 1994, MICROSC RES TECHNIQ, V28, P308, DOI 10.1002/jemt.1070280407; ESCOLAR G, 1991, BLOOD CELLS, V17, P467; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FOX JEB, 1987, BLOOD, V69, P537; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1993, THROMB HAEMOSTASIS, V70, P884; FOX JEB, 1989, J BIOL CHEM, V264, P9520; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FOX JEB, 1981, NATURE, V292, P650, DOI 10.1038/292650a0; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; HARTWIG JH, 1991, J CELL BIOL, V112, P407, DOI 10.1083/jcb.112.3.407; HEMLER ME, 1990, IMMUNOL REV, V114, P45, DOI 10.1111/j.1600-065X.1990.tb00561.x; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; KOUNS WC, 1992, J BIOL CHEM, V267, P18844; KOUNS WC, 1991, J BIOL CHEM, V266, P13891; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LOFTUS JC, 1984, J CELL BIOL, V99, P822, DOI 10.1083/jcb.99.3.822; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MARGUERIE GA, 1983, ANN NY ACAD SCI, V408, P556, DOI 10.1111/j.1749-6632.1983.tb23272.x; MARUYAMA K, 1980, BIOCHIM BIOPHYS ACTA, V626, P494; OLIVER JA, 1987, SCANNING MICROSCOPY, V1, P745; OLORUNDARE OE, 1993, EUR J CELL BIOL, V60, P131; OLURANDARE OE, 1992, BLOOD, V79, P99; PEERSCHKE EI, 1980, THROMB HAEMOSTASIS, V43, P58; PEERSCHKE EIB, 1985, AM J PHYSIOL, V248, pC466, DOI 10.1152/ajpcell.1985.248.5.C466; PEERSCHKE EIB, 1985, SEMIN HEMATOL, V22, P241; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; PHILLIPS DR, 1988, BLOOD, V71, P831; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SIMMONS SR, 1993, P 51 ANN M MICR SOC, P230; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SUZUKI H, 1988, BLOOD, V71, P1310; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VEDDER NB, 1988, J CLIN INVEST, V81, P676, DOI 10.1172/JCI113372; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WHITE JG, 1990, BRIT J HAEMATOL, V76, P108, DOI 10.1111/j.1365-2141.1990.tb07844.x; WHITE JG, 1990, BLOOD CELLS, V16, P43; WHITE JG, 1990, EUR J CELL BIOL, V52, P341; WHITE JG, 1990, ARTERIOSCLEROSIS, V10, P738, DOI 10.1161/01.ATV.10.5.738; ZHANG J, 1992, J BIOL CHEM, V267, P4686	60	72	73	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7004	7011		10.1074/jbc.271.12.7004	http://dx.doi.org/10.1074/jbc.271.12.7004			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636130	hybrid			2022-12-25	WOS:A1996UB15700065
J	Kobayashi, K; Oka, K; Forte, T; Ishida, B; Teng, BB; IshimuraOka, K; Nakamuta, M; Chan, L				Kobayashi, K; Oka, K; Forte, T; Ishida, B; Teng, BB; IshimuraOka, K; Nakamuta, M; Chan, L			Reversal of hypercholesterolemia in low density lipoprotein receptor knockout mice by adenovirus-mediated gene transfer of the very low density lipoprotein receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LDL-RECEPTOR; PROTEIN; RNA; METABOLISM; CLEARANCE; TYPE-5	We have used the technique of adenovirus-mediated gene transfer to study the in vivo function of the very low density lipoprotein receptor (VLDLR) in low density lipoprotein receptor (VLDLR) knockout mice. We generated a replication-defective adenovirus (AdmVLDLR) containing mouse VLDLR cDNA driven by a cytomegalovirus promoter, Transduction of cultured Hepa (mouse hepatoma) cells and LDLR-deficient CHO-IdIA7 cells in vitro by the virus led to high-level expression of immunoreactive VLDLR proteins with molecular sizes of 143 kDa and 161 kDa, Digestion of the cell extract with the enzymes neuraminidase, N-glycanase, and O-glycanase resulted in the stepwise lowering of the apparent size of the 161-kDa species toward the 143-kDa species. LDLR (-/-) mice fed a 0.2% cholesterol diet were treated with a single intravenous injection of 3 x 10(9) plaque-forming units of AdmVLDLR, Control LDLR (-/-) mice received either phosphate-buffered saline or AdLacZ, a similar adenovirus containing the LacZ cDNA instead of mVLDLR cDNA. Comparison of the plasma lipids in the 3 groups of mice indicates that in the AdmVLDL animals, total cholesterol is reduced by similar to 50% at days 4 and 9 and returned toward control values on day 21. in these animals, there was also a similar to 30% reduction in plasma apolipoprotein (apo) E accompanied by a 90% fall in apoB-100 on day 4 of treatment, By FPLC analysis, the major reduction in plasma cholesterol in the AdmVLDL animals was accounted for by a marked reduction in the intermediate density lipoprotein/low density lipoprotein (IDL/LDL) fraction. Plasma VLDL, IDL/LDL, and HDL were isolated from the three groups of animals by ultracentrifugal flotation, In the AdmVLDLR animals, there was substantial loss (similar to 65%) of protein and cholesterol mainly in the IDL/LDL fraction on days 4 and 9, Nondenaturing gradient gel electrophoresis indicates a preferential loss of the IDL peak although the LDL peak was also reduced, When I-125-IDL was administered intravenously into animals on day 4, the AdmVLDLR animals cleared the I-125-IDL at a rate 5-10 times higher than the AdLacZ animals. We conclude that adenovirus-mediated transfer of the	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; USDA ARS,CHILDRENS NUTR RES CTR,HOUSTON,TX 77030; UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV LIFE SCI,BERKELEY,CA 94720; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; United States Department of Agriculture (USDA); United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Baylor College of Medicine			Kobayashi, Kunihisa/V-9554-2019	Kobayashi, Kunihisa/0000-0002-7741-846X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016512, P01HL018574, R01HL016512] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-16512, HL-18574] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE TG, 1988, BIOCOMMUNIQUE, V4, P4; DIAS VC, 1988, CLIN CHEM, V34, P2322; FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453; GAFVELS ME, 1994, ENDOCRINOLOGY, V135, P387, DOI 10.1210/en.135.1.387; GAFVELS ME, 1993, SOMAT CELL MOLEC GEN, V19, P557, DOI 10.1007/BF01233382; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HEEGAARD CW, 1995, J BIOL CHEM, V270, P20855, DOI 10.1074/jbc.270.35.20855; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; ISHIDA BY, 1992, J LIPID RES, V33, P1073; JOKINEN EV, 1994, J BIOL CHEM, V269, P26411; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; KRIEGER M, 1981, J MOL BIOL, V150, P167, DOI 10.1016/0022-2836(81)90447-2; KROCZEK RA, 1989, NUCLEIC ACIDS RES, V17, P9497, DOI 10.1093/nar/17.22.9497; LI J, 1995, J CLIN INVEST, V95, P768, DOI 10.1172/JCI117725; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; OKA K, 1994, EUR J BIOCHEM, V224, P975, DOI 10.1111/j.1432-1033.1994.00975.x; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SAKAI J, 1994, J BIOL CHEM, V269, P2173; SHIMANO H, 1992, J CLIN INVEST, V90, P2084, DOI 10.1172/JCI116091; SIMONSEN ACW, 1994, FEBS LETT, V354, P279, DOI 10.1016/0014-5793(94)01138-9; SUZUKI J, 1995, BIOCHEM BIOPH RES CO, V206, P835, DOI 10.1006/bbrc.1995.1119; TAKAHASHI S, 1995, J BIOL CHEM, V270, P15747, DOI 10.1074/jbc.270.26.15747; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; TENG BB, 1994, J BIOL CHEM, V269, P29395; WEBB JC, 1994, HUM MOL GENET, V3, P531, DOI 10.1093/hmg/3.4.531; YAMAMOTO T, 1993, TRENDS CARDIOVAS MED, V3, P144, DOI 10.1016/1050-1738(93)90015-X; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	34	106	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6852	6860		10.1074/jbc.271.12.6852	http://dx.doi.org/10.1074/jbc.271.12.6852			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636110	hybrid			2022-12-25	WOS:A1996UB15700045
J	Nehrke, K; Hagen, FK; Tabak, LA				Nehrke, K; Hagen, FK; Tabak, LA			Charge distribution of flanking amino acids influences O-glycan acquisition in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; UDP-GALNAC; GLYCOSYLATION SITES; GLYCOPROTEINS; SPECIFICITY; SEQUENCES; PROTEINS; INVITRO; GOLGI; CELLS	The elements that regulate O-glycosylation are poorly understood, We have developed a novel in vivo system to analyze the role of flanking sequence on the modification of a single well characterized O-glycosylation site derived from human von Willebrand factor (PHMAQVTVGPGL), A secreted chimeric reporter protein, containing the human von Willebrand factor sequence, an antibody recognition epitope, and a heart muscle kinase site, was engineered and expressed in COS7 and MCF-7 cells, Glycosylated and non-glycosylated forms of the immunoprecipitated reporter were resolved electrophoretically and their relative amounts quantitated, Using mutational analysis we find that the glycosylation apparatus of COS7 cells can accommodate a broad range of changes in the flanking sequence without compromising glycosylation, but that the distribution of charged amino acids flanking the O-glycosylation site can have a profound influence on glycosylation with position -1 relative to the glycosylation site being particularly sensitive, A combination of acidic residues at positions -1 and +3 almost completely eliminates glycosylation of the reporter in both COS7 and MCF-7 cells. The overall density of charged amino acids is less important since substitution of acidic residues at position -2, +1, and +2 had no effect in the level of glycosylation observed.	UNIV ROCHESTER, SCH MED & DENT, DEPT DENT RES, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester				Nehrke, Keith/0000-0001-9697-726X	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE008108, R01DE008108, T32DE007202] Funding Source: NIH RePORTER; NIDCR NIH HHS [T32 DE-07202, DE-08108] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		CHOU KC, 1995, PROTEINS, V21, P118, DOI 10.1002/prot.340210205; DOWBENKO D, 1993, J BIOL CHEM, V268, P4525; DRICKAMER K, 1983, J BIOL CHEM, V258, P2357; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; GOOLEY AA, 1994, GLYCOBIOLOGY, V4, P413, DOI 10.1093/glycob/4.4.413; HAGEN FK, 1995, GLYCOCONJUGATE J, V12, P901, DOI 10.1007/BF00731252; HAGEN FK, 1993, J BIOL CHEM, V268, P18960; HENLE KJ, 1990, J CELL SCI, V95, P555; KINLOCH RA, 1995, P NATL ACAD SCI USA, V92, P263, DOI 10.1073/pnas.92.1.263; NISHIMORI I, 1994, J BIOL CHEM, V269, P16123; OCONNELL B, 1991, BIOCHEM BIOPH RES CO, V180, P1024, DOI 10.1016/S0006-291X(05)81168-4; OCONNELL BC, 1992, J BIOL CHEM, V267, P25010; OCONNELL BC, 1993, J DENT RES, V72, P1554, DOI 10.1177/00220345930720120401; PISANO A, 1993, GLYCOBIOLOGY, V3, P429, DOI 10.1093/glycob/3.5.429; PISANO A, 1994, GLYCOBIOLOGY, V4, P837, DOI 10.1093/glycob/4.6.837; Sambrook J, 1989, MOL CLONING LABORATO; SASTRY MVK, 1986, J BIOL CHEM, V261, P1726; SAWADA T, 1994, INT J CANCER, V57, P901, DOI 10.1002/ijc.2910570621; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SORENSEN T, 1995, J BIOL CHEM, V270, P24166, DOI 10.1074/jbc.270.41.24166; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; TABAK LA, 1995, ANNU REV PHYSIOL, V57, P547, DOI 10.1146/annurev.ph.57.030195.002555; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WANG WC, 1991, J BIOL CHEM, V266, P23185; WANG Y, 1993, J BIOL CHEM, V268, P22979; WANG YC, 1992, J BIOL CHEM, V267, P2728; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; WRAGG S, 1995, J BIOL CHEM, V270, P16947, DOI 10.1074/jbc.270.28.16947; YEO KT, 1985, J BIOL CHEM, V260, P7896	29	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7061	7065		10.1074/jbc.271.12.7061	http://dx.doi.org/10.1074/jbc.271.12.7061			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636138	hybrid			2022-12-25	WOS:A1996UB15700073
J	Telen, MJ; Udani, M; Washington, MK; Levesque, MC; Lloyd, E; Rao, N				Telen, MJ; Udani, M; Washington, MK; Levesque, MC; Lloyd, E; Rao, N			A blood group-related polymorphism of CD44 abolishes a hyaluronan binding consensus sequence without preventing hyaluronan binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE HOMING RECEPTOR; HUMAN-ERYTHROCYTE ANTIGENS; CELL-SURFACE GLYCOPROTEINS; IN(LU) GENE; MONOCLONAL-ANTIBODIES; EXTRACELLULAR DOMAIN; SPLICE VARIANTS; INB ANTIGEN; EXPRESSION; MOLECULE	CD44 is a widely expressed integral membrane protein that acts as a receptor for hyaluronan (HA) and is proposed to be important to cell-extracellular matrix interaction. The Indian (In) blood group antigens reside on CD44, and most individuals express the In-b antigen. Homozygosity for the In-a allele occurs as a rare event and is associated with production of alloantibody to the common In-b antigen after transfusion or pregnancy. The present study demonstrates that a single point mutation (G(252) --> C) causes an Arg(46) --> Pro substitution, which is responsible for the In-b/In-a polymorphism. Additional mutations were found in In(a+b-) cDNA but were not necessary to the antigenic phenotype as determined in site-directed mutagenesis studies, In studies using CD44 chimeric constructs, Arg(46) has previously been shown to be crucial for maintenance of HA-binding ability to a CD44 peptide. However, the present study demonstrates that the Arg(46) --> Pro substitution does not reduce HA binding to the intact CD44 protein, which contains two proposed extracellular HA-binding motifs. Down-regulation of HA binding to In(a+b-) CD44 by anti-CD44 monoclonal antibody (mAb) ligands, however, was weakened, although all mAbs tested bound In(a+b-) and In(a-b+) CD44 equally well. Competitive inhibition studies using human anti-In-b also showed that some mAbs that inhibit HA binding to CD44 may do so by interacting with a domain separate from, but affecting the structure of, the In-b epitope.	DUKE UNIV, MED CTR, DEPT PATHOL, DURHAM, NC 27710 USA	Duke University	Telen, MJ (corresponding author), DUKE UNIV, MED CTR, DEPT MED, 2615 DUMC, DURHAM, NC 27710 USA.			Telen, Marilyn/0000-0003-3809-1780	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033572] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL33572] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BRUCE LJ, 1995, BLOOD, V85, P541; CARTER WG, 1982, J BIOL CHEM, V257, P3249; CARTER WG, 1988, J BIOL CHEM, V263, P4193; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOW FL, 1985, BLOOD, V66, P940; DEBELDER AN, 1975, CARBOHYD RES, V44, P251, DOI 10.1016/S0008-6215(00)84168-3; DENNING SM, 1990, J IMMUNOL, V144, P7; DENNING SM, 1995, LEUCOCYTE TYPING, V5, P1713; DOUGHERTY GJ, 1994, J BIOL CHEM, V269, P9074; FERGUSON DJ, 1988, TRANSFUSION, V28, P479, DOI 10.1046/j.1537-2995.1988.28588337342.x; GEE B, 1995, BLOOD S, V86, P137; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GROVER J, 1994, BIOCHEM J, V300, P317, DOI 10.1042/bj3000317; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HERRLICH P, 1993, IMMUNOL TODAY, V14, P395, DOI 10.1016/0167-5699(93)90141-7; HOFMANN M, 1991, CANCER RES, V51, P5292; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; HUGHES EN, 1981, J BIOL CHEM, V256, P7023; HUGHES EN, 1983, J BIOL CHEM, V258, P1014; JACKSON DG, 1992, J BIOL CHEM, V267, P4732; JACOBSON K, 1984, J CELL BIOL, V99, P1613, DOI 10.1083/jcb.99.5.1613; JALKANEN S, 1988, J IMMUNOL, V141, P1615; JALKANEN ST, 1986, EUR J IMMUNOL, V16, P1195, DOI 10.1002/eji.1830161003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIO HX, J IMMUNOL, V155, P3938; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LIAO HX, 1993, J IMMUNOL, V151, P6490; LIAO HX, 1995, LEUCOCYTE TYPING, V5, P1735; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; PICKER LJ, 1989, J IMMUNOL, V142, P2046; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SPRING FA, 1988, IMMUNOLOGY, V64, P37; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; TELEN MJ, 1990, VOX SANG, V58, P118, DOI 10.1111/j.1423-0410.1990.tb02073.x; TELEN MJ, 1983, J CLIN INVEST, V71, P1878, DOI 10.1172/JCI110943; TELEN MJ, 1987, VOX SANG, V52, P236, DOI 10.1111/j.1423-0410.1987.tb03035.x; TELEN MJ, 1995, BLOOD, V85, P299; TELEN MJ, 1984, BLOOD, V64, P599; TELEN MJ, 1992, PROTEIN BLOOD GROUP, P70; TELEN MJ, 1995, LEUCOCYTE TYPING, V5, P1730; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERFAILLIE CM, 1994, BLOOD, V84, P1802; YANG BH, 1994, EMBO J, V13, P286, DOI 10.1002/j.1460-2075.1994.tb06261.x; ZHENG Z, 1995, J CELL BIOL, V130, P485, DOI 10.1083/jcb.130.2.485	47	30	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7147	7153		10.1074/jbc.271.12.7147	http://dx.doi.org/10.1074/jbc.271.12.7147			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636151	hybrid			2022-12-25	WOS:A1996UB15700086
J	Weber, E; Jilling, T; Kirk, KL				Weber, E; Jilling, T; Kirk, KL			Distinct functional properties of Rab3A and Rab3B in PC12 neuroendocrine cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; TARGET PROTEIN; ACTIVATING PROTEIN; ENDOCYTIC PATHWAY; SYNAPTIC VESICLES; SMG P25A; RABPHILIN-3A; ASSOCIATION; SENSITIVITY; EXOCYTOSIS	Rab3A and Rab3B are highly homologous monomeric GTPases that are putative regulators of exocytosis in those tissues in which they are expressed, We have characterized and directly compared the targeting and functional properties of these isoforms in PC12 neuroendocrine cells. Rab3A and Rab3B both targeted to norepinephrine (NE)-containing large dense core vesicles (LDCVs) when stably expressed in PC12 cells, as determined by immunofluorescence and membrane fractionation. Both Rab3 isoforms also bound to recombinant rabphilin-3A in a GTP-dependent manner. The membrane association of rabphilin-3A was modestly enhanced in Rab3B-expressing PC12 cells relative to Rab3A-overexpressing cells, In addition, overexpression of Rab3A modestly inhibited Ca2+-evoked NE release, whereas Rab3B and a GTP binding mutant (Rab3B N135I) markedly stimulated the efficiency of [H-3]NE secretion by PC12 cells (i.e. secretion normalized to total cell radioactivity). Expression of Rab3B and Rab3B N135I increased not only the efficiency of NE secretion but also the accumulation of [H-3]NE into LDCVs (i.e. the secretory cargo available for secretion). Neither of these effects was attributable to changes in the numbers of LDCVs nor the docking of LDCVs at the plasma membrane. Our results indicate that Rab3A and Rab3B have similar membrane targeting properties and are capable of interacting with the same putative downstream effector; i.e. rabphilin-3A. However, these isoforms are functionally distinct monomeric GTPases with Rab3B stimulating a late step in Ca2+-evoked secretion when expressed in PC12 cells.	UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,GREGORY FLEMING JAMES CYST FIBROSIS RES CTR,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham				Jilling, Tamas/0000-0002-6200-3851	NIDDK NIH HHS [DK50830] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050830] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI S, 1990, J BIOL CHEM, V265, P13007; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BRONDYK WH, 1993, J BIOL CHEM, V268, P9410; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHUNG SH, 1995, J BIOL CHEM, V270, P16714, DOI 10.1074/jbc.270.28.16714; DARCHEN F, 1995, J CELL SCI, V108, P1639; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; GREENE LA, 1987, METHOD ENZYMOL, V147, P207; GROGER RK, 1989, GENE, V81, P285, DOI 10.1016/0378-1119(89)90189-3; HAWLEY-NELSON P, 1993, FOCUS MADISON, V15, P73; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; IMAZUMI K, 1994, BIOCHEM BIOPH RES CO, V205, P1409, DOI 10.1006/bbrc.1994.2822; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KISHIDA S, 1993, J BIOL CHEM, V268, P22259; KONGSAMUT S, 1986, P NATL ACAD SCI USA, V83, P2243, DOI 10.1073/pnas.83.7.2243; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; LIU YJ, 1994, J CELL BIOL, V127, P1419, DOI 10.1083/jcb.127.5.1419; LLEDO PM, 1993, NATURE, V364, P540, DOI 10.1038/364540a0; MACARA IG, 1994, TRENDS ENDOCRIN MET, V5, P267, DOI 10.1016/1043-2760(94)P3201-H; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; ROSA P, 1985, J CELL BIOL, V101, P1999, DOI 10.1083/jcb.101.5.1999; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SANFORD JC, 1993, J BIOL CHEM, V268, P23773; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; SMITH DB, 1991, CURRENT PROTOCOLS MO, V2; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; STENMARK H, 1994, EMBO J, V13, P575, DOI 10.1002/j.1460-2075.1994.tb06295.x; STETTLER O, 1995, EUR J NEUROSCI, V7, P702, DOI 10.1111/j.1460-9568.1995.tb00674.x; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; VONMOLLARD GF, 1994, J BIOL CHEM, V269, P10971; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WEBER E, 1994, J CELL BIOL, V125, P583, DOI 10.1083/jcb.125.3.583; WEI NM, 1995, AM J PHYSIOL-ENDOC M, V268, pE145, DOI 10.1152/ajpendo.1995.268.1.E145; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	45	75	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6963	6971		10.1074/jbc.271.12.6963	http://dx.doi.org/10.1074/jbc.271.12.6963			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636125	hybrid			2022-12-25	WOS:A1996UB15700060
J	Muda, M; Boschert, U; Dickinson, R; Martinou, JC; Martinou, I; Camps, M; Schlegel, W; Arkinstall, S				Muda, M; Boschert, U; Dickinson, R; Martinou, JC; Martinou, I; Camps, M; Schlegel, W; Arkinstall, S			MKP-3, a novel cytosolic protein-tyrosine phosphatase that exemplifies a new class of mitogen-activated protein kinase phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; DUAL-SPECIFICITY PHOSPHATASE; GROWTH-FACTOR; MAP KINASE; EXPRESSION; SEQUENCE; P21(RAS); ENCODES; 3CH134; CL100	MKP-1 (also known as CL100, 3CH134, Erp, and hVH-1) exemplifies a class of dual-specificity phosphatase able to reverse the activation of mitogen-activated protein (MAP) kinase family members by dephosphorylating critical tyrosine and threonine residues. We now report the cloning of MKP-3, a novel protein phosphatase that also suppresses MAP kinase activation state. The deduced amino acid sequence of MKP-3 is 36% identical to MKP-1 and contains the characteristic extended active-site sequence motif VXVHCXXGXSRSXTXXXAYLM (where X is any amino acid) as well as two N-terminal CH2 domains displaying homology to the cell cycle regulator Cdc25 phosphatase. When expressed in COS-7 cells, MKP-3 blocks both the phosphorylation and enzymatic activation of ERK2 by mitogens. Northern analysis reveals a single mRNA species of 2.7 kilobases with an expression pattern distinct from other dual-specificity phosphatases. MKP-3 is expressed in lung, heart, brain, and kidney, but not significantly in skeletal muscle or testis. In situ hybridization studies of MKP-3 in brain reveal enrichment within the CA1, CA3, and CA4 layers of the hippocampus. Metrazole-stimulated seizure activity triggers rapid (<1 h) but transient up-regulation of MKP-3 mRNA in the cortex, piriform cortex, and some amygdala nuclei. Metrazole stimulated similar regional up-regulation of MKP-1, although this was additionally induced within the thalamus. MKP-3 mRNA also undergoes powerful induction in PC12 cells after 3 h of nerve growth factor treatment. This response appears specific insofar as epidermal growth factor and dibutyryl cyclic AMP fail to induce significant MKP-3 expression. Subcellular localization of epitope-tagged MKP-3 in sympathetic neurons reveals expression in the cytosol with exclusion from the nucleus. Together, these observations indicate that MKP-3 is a novel dual-specificity phosphatase that displays a distinct tissue distribution, subcellular localization, and regulated expression, suggesting a unique function in controlling MAP kinase family members. Identification of a second partial cDNA clone (MKP-X) encoding the C-terminal 280 amino acids of an additional phosphatase that is 76% identical to MKP-3 suggests the existence of a distinct structurally homologous subfamily of MAP kinase phosphatases.	GLAXO INST MOL BIOL,CH-1228 PLAN LES OUATES,GENEVA,SWITZERLAND; UNIV GENEVA,DEPT MED,FDN RECH MED,CH-1211 GENEVA 4,SWITZERLAND	GlaxoSmithKline; University of Geneva				martinou, Jean-claude/0000-0002-9847-2051; Camps, Montserrat/0000-0002-9849-8657				ALESSI DR, 1993, ONCOGENE, V8, P2015; ARKINSTALL S, 1995, MOL CELL BIOL, V15, P1431; Ausubel F.M., 1994, CURRENT PROTOCOLS MO, V1; BERETTA L, 1995, EUR J BIOCHEM, V227, P388, DOI 10.1111/j.1432-1033.1995.tb20401.x; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; DUFF JL, 1995, J BIOL CHEM, V270, P7161, DOI 10.1074/jbc.270.13.7161; FUKUDA M, 1995, ONCOGENE, V11, P239; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GUAN KL, 1991, J BIOL CHEM, V266, P17026; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; KWAK SP, 1994, J BIOL CHEM, V269, P3596; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; SAFFEN DW, 1988, P NATL ACAD SCI USA, V85, P7795, DOI 10.1073/pnas.85.20.7795; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WISDEN W, 1991, MOL NEUROBIOLOGY PRA, P205; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	61	315	321	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4319	4326						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626780				2022-12-25	WOS:A1996TW96000058
J	Davis, EC; Mecham, RP				Davis, EC; Mecham, RP			Selective degradation of accumulated secretory proteins in the endoplasmic reticulum - A possible clearance pathway for abnormal tropoelastin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPRAVALVULAR AORTIC-STENOSIS; BREFELDIN-A; CYSTEINE PROTEASE; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; INTRACELLULAR-TRANSPORT; ORGANELLE STRUCTURE; ELASTIN RECEPTOR; MEMBRANE-PROTEIN; APOLIPOPROTEIN-B; GOLGI PROTEINS	The specific pathway of tropoelastin secretion was investigated in fetal calf ligamentum nuchae (FCL) cells using brefeldin A (BFA) to disrupt the secretory pathway, Electron microscopic studies of BFA-treated FCL cells showed ultrastructural changes consistent with the reported effects of BFA on intracellular organelles. When FCL cells were labeled with [H-3]leucine in the presence of BFA, radiolabeled tropoelastin was not secreted, nor was there an intracellular accumulation of the protein, In contrast, fibronectin accumulated within the cells in the presence of BFA. Northern analysis of mRNA levels in FCL cells showed that the message for tropoelastin was unaffected by BFA treatment, Pulse chase experiments conducted in the presence of BFA demonstrated that the tropoelastin retained within the cells was rapidly degraded, Ammonium chloride, nocodazole, and cycloheximide had no effect on the degradation of tropoelastin, indicating that the degradation did not involve the endosome/lysosome pathway, movement via microtubules, or a short-lived protein, respectively. Incubation of FCL cells with BFA in the presence of N-acetyl-Leu-Leu-norleucinal, however, allowed tropoelastin to steadily accumulate in the cells, Cells pulsed in the presence of BFA alone showed that tropoelastin initially accumulates within the cells for approximately 1 h prior to being degraded, thus indicating that a critical threshold of tropoelastin must be reached before degradation can occur, Results from this study provide evidence for selective degradation of a soluble secreted protein by a cysteine protease following retention of the protein in the endoplasmic reticulum.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,DIV RESP & CRIT CARE,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL)	Davis, EC (corresponding author), WASHINGTON UNIV,SCH MED,DEPT PHYSIOL & CELL BIOL,BOX 8228,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.		Davis, Elaine/F-3449-2012		NHLBI NIH HHS [HL-53325, HL-41926] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL053325, R01HL041926, R01HL053325] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELI K, 1994, J BIOL CHEM, V269, P9166; ALCALDE J, 1992, J CELL BIOL, V116, P69, DOI 10.1083/jcb.116.1.69; AMITAY R, 1992, J BIOL CHEM, V267, P20694; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUN KT, 1990, J BIOL CHEM, V265, P22004; COTNER T, 1995, J BIOL CHEM, V270, P2379, DOI 10.1074/jbc.270.5.2379; COX BA, 1974, J BIOL CHEM, V249, P997; CURRAN ME, 1993, CELL, V73, P159, DOI 10.1016/0092-8674(93)90168-P; DAGAGORDINI D, 1987, HISTOCHEM J, V19, P623, DOI 10.1007/BF01676168; DAMIANO V, 1984, COLLAGEN REL RES, V4, P153; DAVID V, 1993, J BIOL CHEM, V268, P9585; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; EWART AK, 1993, P NATL ACAD SCI USA, V90, P3226, DOI 10.1073/pnas.90.8.3226; FRANC S, 1984, J HISTOCHEM CYTOCHEM, V32, P251, DOI 10.1177/32.2.6198356; FRISCH SM, 1985, MOL CELL BIOL, V5, P253, DOI 10.1128/MCB.5.1.253; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GROSSO L, 1988, BIOCHEM BIOPH RES CO, V151, P822; HINEK A, 1988, SCIENCE, V239, P1539, DOI 10.1126/science.2832941; HIWASA T, 1990, CARCINOGENESIS, V11, P75, DOI 10.1093/carcin/11.1.75; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; INOUE S, 1992, J BIOL CHEM, V267, P9080; INOUE S, 1991, J BIOL CHEM, V266, P13311; JAIN N, 1994, BIOCHEM J, V304, P61, DOI 10.1042/bj3040061; JAIN N, 1994, ARCH BIOCHEM BIOPHYS, V314, P23, DOI 10.1006/abbi.1994.1407; KARR SR, 1981, J BIOL CHEM, V256, P5946; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KUUSELA P, 1984, INFECT IMMUN, V45, P433, DOI 10.1128/IAI.45.2.433-436.1984; LECUREUX LW, 1994, J CELL SCI, V107, P2635; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MAGNER JA, 1988, ENDOCRINOLOGY, V122, P912, DOI 10.1210/endo-122-3-912; Mecham R. P., 1994, EXTRACELLULAR MATRIX, P281; MECHAM RP, 1987, METHOD ENZYMOL, V144, P232; MECHAM RP, 1989, J BIOL CHEM, V264, P16652; MECHAM RP, 1989, BIOCHEMISTRY-US, V28, P3716, DOI 10.1021/bi00435a014; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; OTSU M, 1995, J BIOL CHEM, V270, P14958, DOI 10.1074/jbc.270.25.14958; PARKS WC, 1988, J BIOL CHEM, V263, P4416; PARKS WC, 1992, MATRIX, V12, P156, DOI 10.1016/S0934-8832(11)80057-0; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; ROY S, 1992, J BIOL CHEM, V267, P23151; SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517; SATO R, 1990, J BIOL CHEM, V265, P11880; SAUNDERS NA, 1984, BIOCHEM J, V221, P333; THYBERG J, 1979, HISTOCHEM J, V11, P1, DOI 10.1007/BF01041263; URADE R, 1992, J BIOL CHEM, V267, P15152; URADE R, 1992, FEBS LETT, V312, P83, DOI 10.1016/0014-5793(92)81415-I; URADE R, 1993, J BIOL CHEM, V268, P22004; WILEMAN T, 1991, CELL REGUL, V2, P753, DOI 10.1091/mbc.2.9.753; WRENN DS, 1986, BIOCHEMISTRY-US, V25, P5172, DOI 10.1021/bi00366a028	57	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3787	3794						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631995				2022-12-25	WOS:A1996TV72400069
J	Bonapace, IM; Addeo, R; Altucci, L; Cicatiello, L; Bifulco, M; Laezza, C; Salzano, S; Sica, V; Bresciani, F; Weisz, A				Bonapace, IM; Addeo, R; Altucci, L; Cicatiello, L; Bifulco, M; Laezza, C; Salzano, S; Sica, V; Bresciani, F; Weisz, A			17 beta-Estradiol overcomes a G1 block induced by HMG-CoA reductase inhibitors and fosters cell cycle progression without inducing ERK-1 and -2 MAP kinases activation	ONCOGENE			English	Article						estrogen; cell cycle; mevalonate; HMG-CoA reductase; c-fos; ras	HUMAN-BREAST-CANCER; ESTROGEN RESPONSE ELEMENT; C-FOS PROTOONCOGENE; GROWTH-INHIBITION; RECEPTOR; IDENTIFICATION; LOVASTATIN; SERUM; GENE; LINE	HMG-CoA reductase inhibitors, such as Lovastatin and Simvastatin, cause cell cycle arrest by interfering with the mitogenic activity of mitogens present in culture media. Cells are induced to pause in G(1) and can readily resume growth upon removal of the enzymatic block. Estrogens, acting via their nuclear receptor, are mitogens for different normal and transformed cell types, where they foster cell cycle progression and cell division. In estrogen-responsive MCF-7 human breast cancer cells, but not in non responsive cells, 17 beta-estradiol (E(2)) induces cells arrested with Lovastatin or Simvastatin to proliferate in the presence of inhibitor, without restoring HMG-CoA reductase activity or affecting the protein prenylation pattern. Mitogenic stimulation of G(1)-arrested MCF-7 cells with E(2) includes primary transcriptional activation of c-fos, accompanied by transient binding in vivo of the estrogen receptor and/or other factors to the ERE and the estrogen-responsive DNA region of this proto-oncogene, as detected by dimethylsulphate genomic footprinting analysis. Mitogenic stimulation of growth-arrested MCF-7 cells by E(2) occurs, under these conditions, without evident activation of ERK-1 and -2 kinases, and thus independently from the mitogen-responsive signal transduction pathways that converge on these enzymes.	UNIV NAPLES 2, FAC MED & CHIRURG, IST PATOL GEN & ONCOL, I-80138 NAPLES, ITALY; UNIV NAPLES FEDERICO II, CNR, CEOS, NAPLES, ITALY; UNIV REGGIO CALABRIA, DIPARTIMENTO MED SPERIMENTALE & CLIN, CATANZARO, ITALY; UNIV NAPLES FEDERICO II, DIPARTIMENTO BIOL & PATOL CELLULARE & MOL L CALIF, NAPLES, ITALY	Universita della Campania Vanvitelli; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita Mediterranea di Reggio Calabria; University of Naples Federico II			Altucci, Lucia/S-8031-2019; laez, chi/AAW-4437-2020; Weisz, Alessandro/A-1317-2014	Weisz, Alessandro/0000-0003-0455-2083; Bifulco, Maurizio/0000-0002-1771-4531; altucci, lucia/0000-0002-7312-5387; BONAPACE, IAN MARC/0000-0001-6580-8893				ABBONDANZA C, 1993, STEROIDS, V58, P4, DOI 10.1016/0039-128X(93)90011-B; AMBROSINO C, 1993, MOL ENDOCRINOL, V7, P1472, DOI 10.1210/me.7.11.1472; ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; BARBU V, 1990, ONCOGENE, V5, P1077; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRIAND P, 1986, ANTICANCER RES, V6, P85; BRUNNER N, 1989, CANCER RES, V49, P1515; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; CICATIELLO L, 1993, RECEPTOR, V3, P17; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DAVIDSON NE, 1989, ONCOGENESIS, V1, P89; DECLUE JE, 1991, CANCER RES, V51, P712; DEY A, 1991, DNA CELL BIOL, V10, P537, DOI 10.1089/dna.1991.10.537; DOYLE A, 1994, CELL TISSUE CULTURE; DUBIK D, 1992, ONCOGENE, V7, P1587; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GRIECO D, 1990, J BIOL CHEM, V265, P19343; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HU AW, 1994, MOL CELL BIOL, V14, P8202; HYDER SM, 1992, J BIOL CHEM, V267, P18047; IACOBELLI S, 1984, J STEROID BIOCHEM, V20, P747, DOI 10.1016/0022-4731(84)90079-7; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; JAKOBISIAK M, 1991, P NATL ACAD SCI USA, V88, P3628, DOI 10.1073/pnas.88.9.3628; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KNOWLER JT, 1985, ESSAYS BIOCHEM, V20, P1; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LARSSON O, 1989, CANCER RES, V49, P5605; LIPPMAN M, 1976, CANCER RES, V36, P4595; MARSHALL E, 1994, SCIENCE, V264, P1524, DOI 10.1126/science.8202702; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MATSUDA S, 1993, P NATL ACAD SCI USA, V90, P10803, DOI 10.1073/pnas.90.22.10803; Maxam A M, 1980, Methods Enzymol, V65, P499; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; MULLER R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P151, DOI 10.1016/0304-419X(93)90003-U; NEMERE I, 1993, RECEPTOR, V3, P277; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OGASAWARA M, 1988, IN VITRO CELL DEV B, V24, P911; PERILLO B, 1995, J BIOL CHEM, V270, P15237, DOI 10.1074/jbc.270.25.15231; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; RICHARDFOY H, 1994, NATURE, V370, P417, DOI 10.1038/370417a0; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SCHULZ S, 1992, CANCER RES, V52, P1372; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEILERTUYNS A, 1981, J MOL BIOL, V151, P607, DOI 10.1016/0022-2836(81)90426-5; SHAFIE SM, 1980, SCIENCE, V209, P701, DOI 10.1126/science.6994231; SOULE HD, 1990, CANCER RES, V50, P6075; TAIT L, 1990, CANCER RES, V50, P6087; TAMANOI F, 1993, TRENDS BIOCHEM SCI, V18, P349, DOI 10.1016/0968-0004(93)90072-U; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; VANDERBURG B, 1989, MOL CELL ENDOCRINOL, V64, P223, DOI 10.1016/0303-7207(89)90149-4; VINCENT TS, 1991, BIOCHEM BIOPH RES CO, V180, P1284, DOI 10.1016/S0006-291X(05)81334-8; WEIGEL RJ, 1993, CANCER RES, V53, P3472; WEISS W, 1991, INDAGAT MATH NEW SER, V2, P115, DOI 10.1016/0019-3577(91)90047-B; WEISZ A, 1993, CRIT REV ONCOGENESIS, V4, P361; WEISZ A, 1990, MOL ENDOCRINOL, V4, P1041, DOI 10.1210/mend-4-7-1041; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; WEISZ A, 1988, MOL ENDOCRINOL, V2, P816, DOI 10.1210/mend-2-9-816; WEJDE J, 1993, J CELL PHYSIOL, V155, P539, DOI 10.1002/jcp.1041550312	65	54	55	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	1996	12	4					753	763						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632897				2022-12-25	WOS:A1996TW68600006
J	Flaman, JM; Waridel, F; Estreicher, A; Vannier, A; Limacher, JM; Gilbert, D; Iggo, R; Frebourg, T				Flaman, JM; Waridel, F; Estreicher, A; Vannier, A; Limacher, JM; Gilbert, D; Iggo, R; Frebourg, T			The human tumour suppressor gene p53 is alternatively spliced in normal cells	ONCOGENE			English	Article						p53; alternative splicing; transcription	WILD-TYPE P53; LYMPHOBLASTIC-LEUKEMIA; TRANSCRIPTION; PROTEIN; MUTATIONS; GROWTH; DNA; APOPTOSIS; ANTIGEN; YEAST	Alternative splicing affecting the p53 carboxy-terminus has previously been described in mouse but not in normal human cells. We report here the detection in normal human lymphocytes of an alternatively spliced form of human p53 mRNA containing an additional 133 bp exon derived from intron 9. This splice variant encodes a truncated protein of 341 amino-acids including 10 new amino-acids derived from the novel exon. The truncated protein, which lacks part of the p53 tetramerization domain, fails to bind DNA in vitro and has transcriptional defect in vivo in both yeast and mammalian cells. Quantitative RT-PCR experiments suggests that the alternatively spliced form is only present in significant amounts in quiescent cells. Considering the numerous functions ascribed to the carboxy-terminus of the p53 protein, this splice variant may have important implications for the biological role of p53 in normal cells.	CHU ROUEN,LAB GENET MOL,F-76031 ROUEN,FRANCE; SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND; CHU VAUDOIS,SERV ORL,CH-1011 LAUSANNE,SWITZERLAND; CHU ROUEN,LAB IMMUN PATHOL CLIN & EXPT,F-76031 ROUEN,FRANCE; HOP UNIV,F-67091 STRASBOURG,FRANCE	CHU de Rouen; Swiss Institute Experimental Cancer Research; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); CHU de Rouen; CHU Strasbourg			Frebourg, Thierry/AAK-8390-2020; Flaman, Jean-Michel/K-8415-2018; Iggo, Richard/G-3546-2014	Flaman, Jean-Michel/0000-0003-3544-0199; Estreicher, Anne/0000-0001-6828-2508				ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CALABRETTA B, 1986, CANCER RES, V46, P5738; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOW VTK, 1993, CANCER LETT, V73, P141, DOI 10.1016/0304-3835(93)90256-9; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FELIX CA, 1992, J CLIN INVEST, V89, P640, DOI 10.1172/JCI115630; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FLAMAN JM, 1994, NUCLEIC ACIDS RES, V22, P3259, DOI 10.1093/nar/22.15.3259; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; HAN KA, 1992, NUCLEIC ACIDS RES, V20, P1979, DOI 10.1093/nar/20.8.1979; HARLOW E, 1988, ANTIBODIES LABORATOR; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; MATLASHEWSKI G, 1987, ONCOGENE RES, V1, P77; MIYASHITA T, 1995, CELL, V80, P293; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P8974, DOI 10.1073/pnas.91.19.8974; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; TARUNINA M, 1993, ONCOGENE, V8, P3165; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	47	90	97	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					813	818						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632903				2022-12-25	WOS:A1996TW68600012
J	Ohta, Y; Haire, RN; Amemiya, CT; Litman, RT; Trager, T; Riess, O; Litman, GW				Ohta, Y; Haire, RN; Amemiya, CT; Litman, RT; Trager, T; Riess, O; Litman, GW			Human Txk: Genomic organization, structure and contiguous physical linkage with the Tec gene	ONCOGENE			English	Article						protein tyrosine kinase; gene linkage; Tec gene family; P1 artificial chromosome; DNA sequencing	X-LINKED AGAMMAGLOBULINEMIA; PROTEIN-TYROSINE KINASE; EXPRESSION; SEQUENCE	Txk is a Tec-family tyrosine kinase expressed in mouse and human T lymphocytes. Among the Tec kinases, Txk is unique in that its amino terminal region does not include a pleckstrin homology domain or other known extended functional region. Txk is encoded at human chromosome 4p12 and at a recognized region of conserved synteny on mouse chromosome 5. The genomic organization of Txk consists of 15 exons with strong exon-intron organizational homology to Btk, the only other Tee-family kinase for which the genomic structure is fully known. The human Tec gene also maps to 4p12 and, based on limited studies reported here, possesses organizational homology with Btk and Txk. We have sequenced a continuous region of DNA that contains 3' Tec and 5' Txk exons separated by only a similar to 1.5 kb intergenic region containing the putative promoter region of Txk. The close physical linkage of these Tee-family tyrosine kinases, which are expressed in different hematopoetic cell lineages, suggests their potential for coordinate cis-regulation.	UNIV S FLORIDA,ALL CHILDRENS HOSP,DEPT PEDIAT,ST PETERSBURG,FL 33701; BOSTON UNIV,CTR HUMAN GENET,BOSTON,MA 02118; RUHR UNIV BOCHUM,DEPT HUMAN MOLEC GENET,W-4470 BOCHUM,GERMANY	State University System of Florida; University of South Florida; Boston University; Ruhr University Bochum								BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CONLEY ME, 1994, HUM MOL GENET, V3, P1751, DOI 10.1093/hmg/3.10.1751; DHALLAN RS, 1992, J NEUROSCI, V12, P3248, DOI 10.1523/JNEUROSCI.12-08-03248.1992; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GIBSON S, 1993, BLOOD, V82, P1561; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; HAGEMANN TL, 1994, HUM MOL GENET, V3, P1743, DOI 10.1093/hmg/3.10.1743; HAIRE RN, 1995, MAMM GENOME, V6, P476, DOI 10.1007/BF00360659; HAIRE RN, 1994, HUM MOL GENET, V3, P897, DOI 10.1093/hmg/3.6.897; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HU Q, 1995, J BIOL CHEM, V270, P1928, DOI 10.1074/jbc.270.4.1928; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; LEE ST, 1993, ONCOGENE, V8, P3403; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1993, ONCOGENE, V8, P417; MAZZARELLA R, 1995, GENOMICS, V26, P629, DOI 10.1016/0888-7543(95)80190-W; Nadeau J H, 1991, Mamm Genome, V1 Spec No, pS461, DOI 10.1007/BF00656504; NAGLE DL, 1995, HUM MOL GENET, V4, P2073, DOI 10.1093/hmg/4.11.2073; OELTJEN JC, 1995, MAMM GENOME, V6, P334, DOI 10.1007/BF00364796; OHTA Y, 1994, P NATL ACAD SCI USA, V91, P9062, DOI 10.1073/pnas.91.19.9062; OLSEN AS, 1993, BIOTECHNIQUES, V14, P116; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; RIESS O, 1994, CYTOGENET CELL GENET, V65, P238, DOI 10.1159/000133638; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; SATO K, 1994, LEUKEMIA, V8, P1663; SIDERAS P, 1994, J IMMUNOL, V153, P5607; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SOMMERS CL, 1995, ONCOGENE, V11, P245; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P266	33	17	20	2	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					937	942						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632917				2022-12-25	WOS:A1996TW68600026
J	Sun, QH; DeLisser, HM; Zukowski, MM; Paddock, C; Albelda, SM; Newman, PJ				Sun, QH; DeLisser, HM; Zukowski, MM; Paddock, C; Albelda, SM; Newman, PJ			Individually distinct Ig homology domains in PECAM-1 regulate hemophilic binding and modulate receptor affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; PLATELET GLYCOPROTEIN-IIIA; HUMAN-ENDOTHELIAL CELLS; MONOCLONAL-ANTIBODY; CD31; FIBRINOGEN; INTEGRINS; PROTEIN; LEUKOCYTES; ACTIVATION	PECAM-1 (CD31) is a 130-kDa member of the immunoglobulin (Ig) gene superfamily that is constitutively expressed at high concentration at endothelial cell intercellular junctions and at moderate density on the surface of circulating leukocytes and platelets, Recent in vitro and in vivo studies have shown that PECAM-1 plays a central, role in mediating the extravasation of leukocytes from the vessel wall in response to inflammatory mediators. To study the binding characteristics of PECAM-1, phospholipid vesicles were prepared and examined by flow cytometry and immunofluorescence microscopy for their ability to associate with each other and with cells. Proteoliposomes containing high concentrations of PECAM-1 interacted homophilically with each other, forming large self-aggregates. PECAM-1 proteoliposomes, as well as soluble bivalent PECAM-1 in the form of a PECAM-1/IgG immunoadhesin, associated homophilically with cells expressing human, but not murine, PECAM-1. This binding could be completely inhibited by monoclonal antibody Fab fragments specific for Ig homology Domain 1 or Domains 1 + 2. Binding studies using cells expressing human PECAM-1 deletion mutants and murine/human chimeras confirmed that both Ig Domains 1 and 2 were both necessary and sufficient for homophilic binding. In contrast, engagement of membrane-proximal Domain 6 with monoclonal antibody Fab fragments had the opposite effect and augmented the binding of PECAM-1 proteoliposomes to cells. Thus, PECAM-1, like certain integrins, appears to be capable of antibody-induced conformational changes that alter affinity for its ligand. Similar changes induced by physiologic stimuli could be important in regulating the function of PECAM-1 in vascular cells.	BLOOD CTR SE WISCONSIN INC, BLOOD RES INST, MILWAUKEE, WI 53233 USA; UNIV PENN, MED CTR, DEPT MED, PHILADELPHIA, PA 19104 USA; AMGEN BOULDER INC, BOULDER, CO 80301 USA; MED COLL WISCONSIN, DEPT PHARMACOL, MILWAUKEE, WI 53226 USA; MED COLL WISCONSIN, DEPT CELLULAR BIOL, MILWAUKEE, WI 53226 USA	Versiti Blood Center of Wisconsin; University of Pennsylvania; Medical College of Wisconsin; Medical College of Wisconsin			DeLisser, Horace/AFM-1942-2022		NHLBI NIH HHS [HL-43611, HL-40926, HL-03382] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K14HL003382, R01HL043611, R01HL040926] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1991, J CELL BIOL, V114, P1059, DOI 10.1083/jcb.114.5.1059; ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; AYALON O, 1994, J CELL BIOL, V126, P247, DOI 10.1083/jcb.126.1.247; BALDWIN HS, 1994, DEVELOPMENT, V120, P2539; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BERMAN ME, 1995, J IMMUNOL, V154, P299; BOGEN S, 1994, J EXP MED, V179, P1059, DOI 10.1084/jem.179.3.1059; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; DELISSER HM, 1994, IMMUNOL TODAY, V15, P490, DOI 10.1016/0167-5699(94)90195-3; DELISSER HM, 1994, J CELL BIOL, V124, P195, DOI 10.1083/jcb.124.1.195; DELISSER HM, 1993, J BIOL CHEM, V268, P16037; DU XP, 1993, J BIOL CHEM, V268, P23087; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FAWCETT J, 1995, J CELL BIOL, V128, P1229, DOI 10.1083/jcb.128.6.1229; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; HAWIGER J, 1982, P NATL ACAD SCI-BIOL, V79, P2068, DOI 10.1073/pnas.79.6.2068; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; KIRSCHBAUM NE, 1994, BLOOD, V84, P4028, DOI 10.1182/blood.V84.12.4028.bloodjournal84124028; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; KOUNS WC, 1991, BLOOD, V78, P3215; KOUNS WC, 1992, J BIOL CHEM, V267, P18844; LAMPUGNANI MG, 1991, J CELL BIOL, V112, P479, DOI 10.1083/jcb.112.3.479; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LIAO F, 1995, J EXP MED, V182, P1337, DOI 10.1084/jem.182.5.1337; MARTIN S, 1993, J VIROL, V67, P3561, DOI 10.1128/JVI.67.6.3561-3568.1993; MULLER WA, 1992, J EXP MED, V175, P1401, DOI 10.1084/jem.175.5.1401; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; MULLER WA, 1989, J EXP MED, V170, P399, DOI 10.1084/jem.170.2.399; NEWMAN PJ, 1992, J CELL BIOL, V119, P239, DOI 10.1083/jcb.119.1.239; NEWMAN PJ, 1994, ANN NY ACAD SCI, V714, P165, DOI 10.1111/j.1749-6632.1994.tb12041.x; NEWMAN PJ, 1985, BLOOD, V65, P227; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; OSBORN L, 1994, J CELL BIOL, V124, P601, DOI 10.1083/jcb.124.4.601; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; OTOOLE TE, 1991, SCIENCE, V254, P345; PIALI L, 1993, EUR J IMMUNOL, V23, P2464, DOI 10.1002/eji.1830231013; PIALI L, 1994, ADV EXP MED BIOL, V355, P147; PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451; RENZ ME, 1994, J CELL BIOL, V125, P1395, DOI 10.1083/jcb.125.6.1395; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STOCKINGER H, 1990, J IMMUNOL, V145, P3889; TANAKA Y, 1992, J EXP MED, V176, P245, DOI 10.1084/jem.176.1.245; THIAGARAJAN P, 1985, J CLIN INVEST, V75, P896, DOI 10.1172/JCI111789; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; VONDERHEIDE RH, 1994, J CELL BIOL, V125, P215, DOI 10.1083/jcb.125.1.215; YAN HC, 1995, J BIOL CHEM, V270, P23672, DOI 10.1074/jbc.270.40.23672; YAN HC, 1995, CELL ADHES COMMUN, V3, P45, DOI 10.3109/15419069509081277; ZEHNDER JL, 1992, J BIOL CHEM, V267, P5243	50	149	155	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11090	11098		10.1074/jbc.271.19.11090	http://dx.doi.org/10.1074/jbc.271.19.11090			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626652	hybrid			2022-12-25	WOS:A1996UJ94400012
J	Aragones, J; LopezRodriquez, C; Corbi, A; delArco, PG; LopezCabrera, M; deLandazuri, MO; Redondo, JM				Aragones, J; LopezRodriquez, C; Corbi, A; delArco, PG; LopezCabrera, M; deLandazuri, MO; Redondo, JM			Dithiocarbamates trigger differentiation and induction of CD11c gene through AP-1 in the myeloid lineage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR KAPPA-B; ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; C-JUN GENE; HUMAN-IMMUNODEFICIENCY-VIRUS; U937 CELLS; REGULATED EXPRESSION; TRANSCRIPTION FACTOR; OXIDATIVE STRESS	It has recently been shown that the alteration of the cell-redox status affects the transcription factor expression and activity. Dithiocarbamates (DTCs) are potent antioxidant agents that can switch the expression of genes dependent on the activation of the transcription factors AP-1 and NF kappa B. In this study, we show that these agents triggered the expression of genes involved in myeloid differentiation of the promonocytic U-937 cell line. DTCs promoted differentiation-associated changes that included the surface up-regulation of pa-integrins (CD11a-c/CD18), cell growth arrest concomitant with transferrin receptor (CD71) down modulation, induction of the nonspecific esterase enzyme, and a rapid drop in the mRNA levels of c-myc. A further analysis, focused on the molecular mechanisms leading 60 the activation of CD11c expression, revealed that the pyrrolidine derivative of DTC (PDTC) increased CD11c mRNA levels and augmented its gene promoter activity. Transfection experiments with reporter constructs harboring different promoter regions of CD11c gene, indicated the presence of a functional DTC-responsive region located between positions -160 and +40 of the promoter. Gel retardation assays revealed that the PDTC-induced DNA-protein complexes were restricted to members of the Fos and Jun families that bound to an AP-1 site located at position -60 from the transcription start site. A role for this site was confirmed by in vitro mutagenesis experiments that indicated the functional importance of this site for the CD11c gene transcriptional activation in response to PDTC. The effect of DTCs on myeloid cell differentiation supports a possible role for these agents in the therapy of some bone marrow-derived malignancies.	UNIV AUTONOMA MADRID, FAC CIENCIAS, CSIC, CTR BIOL MOLEC, E-28049 MADRID, SPAIN; HOSP PRINCESA, SERV IMMUNOL, MADRID, SPAIN; HOSP PRINCESA, SERV BIOL MOL, MADRID, SPAIN; CSIC, INST LOPEZ NEYRA, GRANADA, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Hospital de La Princesa; Hospital de La Princesa; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)			Lopez-Rodriguez, C/G-4482-2014; Corbi, Angel/B-7194-2011; Corbí, Angel L./ABC-8146-2020; Cabrera, Manuel López/AAA-5463-2019; Redondo, Juan Miguel/H-6351-2015; Gomez-del Arco, Pablo/L-2728-2013	Lopez-Rodriguez, C/0000-0002-2311-2406; Corbi, Angel/0000-0003-1980-5733; Corbí, Angel L./0000-0003-1980-5733; Redondo, Juan Miguel/0000-0001-5779-9122; Gomez-del Arco, Pablo/0000-0001-6748-7157; Lopez Cabrera, Manuel/0000-0002-0976-9719; Aragones Lopez, Julian/0000-0002-0193-4679				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BELLON T, 1994, EUR J IMMUNOL, V24, P41, DOI 10.1002/eji.1830240107; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CABANAS C, 1990, EUR J BIOCHEM, V191, P599, DOI 10.1111/j.1432-1033.1990.tb19163.x; CABANAS C, 1989, EUR J IMMUNOL, V19, P1373, DOI 10.1002/eji.1830190804; CHEN ZX, 1991, BLOOD, V78, P1413; COLLINS SJ, 1987, BLOOD, V70, P1233; CORBI AL, 1987, EMBO J, V6, P4023, DOI 10.1002/j.1460-2075.1987.tb02746.x; COTTER TG, 1994, IMMUNOL REV, V142, P93, DOI 10.1111/j.1600-065X.1994.tb00884.x; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; DELVA L, 1993, BLOOD, V82, P2175; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DOOD TC, 1983, P NATL ACAD SCI USA, V80, P7538; DUSTIN ML, 1986, J IMMUNOL, V137, P245; FERREIRA OC, 1991, EXP CELL RES, V193, P20, DOI 10.1016/0014-4827(91)90533-Z; GUERRERO JAL, 1989, IMMUNOLOGY, V66, P252; HASS R, 1989, EUR J CELL BIOL, V48, P282; HOGG N, 1986, EUR J IMMUNOL, V16, P240, DOI 10.1002/eji.1830160306; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KEIZER GD, 1988, J IMMUNOL, V140, P1393; LANG JM, 1985, LANCET, V2, P1066; LI Y, 1992, J BIOL CHEM, V267, P15097; LOPEZCABRERA M, 1993, J BIOL CHEM, V268, P1187; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MILLER LJ, 1986, J IMMUNOL, V137, P2891; MINTA JO, 1985, AM J PATHOL, V119, P111; MUNOZ E, 1992, EUR J IMMUNOL, V22, P2101, DOI 10.1002/eji.1830220821; NUEDA A, 1995, CELL IMMUNOL, V164, P163, DOI 10.1006/cimm.1995.1157; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PEREZ C, 1994, CELL GROWTH DIFFER, V5, P949; POSTIGO AA, 1991, J EXP MED, V174, P1313, DOI 10.1084/jem.174.6.1313; PULIDO R, 1991, J BIOL CHEM, V266, P10241; RALPH P, 1983, BLOOD, V62, P1169; REDONDO JM, 1991, MOL CELL BIOL, V11, P5671, DOI 10.1128/MCB.11.11.5671; RIUS C, 1990, EXP CELL RES, V188, P129, DOI 10.1016/0014-4827(90)90287-K; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHUTZE S, 1988, J IMMUNOL, V140, P3000; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; SUNDERMAN FW, 1967, AM J MED SCI, V254, P24, DOI 10.1097/00000441-196707000-00003; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997	51	42	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10924	10931		10.1074/jbc.271.18.10924	http://dx.doi.org/10.1074/jbc.271.18.10924			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631910				2022-12-25	WOS:A1996UJ34200078
J	Illenberger, S; Drewes, G; Trinczek, B; Biernat, J; Meyer, HE; Olmsted, JB; Mandelkow, EM; Mandelkow, E				Illenberger, S; Drewes, G; Trinczek, B; Biernat, J; Meyer, HE; Olmsted, JB; Mandelkow, EM; Mandelkow, E			Phosphorylation of microtubule-associated proteins MAP2 and MAP4 by the protein kinase p110(mark) - Phosphorylation sites and regulation of microtubule dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMER-LIKE STATE; TAU-PROTEIN; DEPENDENT KINASE; DOMAIN-STRUCTURE; BINDING DOMAINS; NERVOUS-SYSTEM; TUBULIN; BRAIN; DISEASE; IDENTIFICATION	The phosphorylation of microtubule-associated proteins (MAPs) is thought to be a key factor in the regulation of microtubule stability. We have shown recently that a novel protein kinase, termed p110 microtubule-affinity regulating kinase (''MARK''), phosphorylates microtubule-associated protein tau at the KXGS motifs in the region of internal repeats and causes the detach ment of tau from microtubules (Drewes, G., Trinczek, B., Illenberger, S., Biernat, J., Schmitt-Ulms, G., Meyer, H. E., Mandelkow, E.-M., and Mandelkow, E. (1995) J. Biol. Chem, 270, 7679-7688). Here we show that p110(mark) phosphorylates analogous KXGS sites in the microtubule binding domains of the neuronal MAP2 and the ubiquitous MAP4. Phosphorylation in vitro leads to the dissociation of MAP2 and MAP4 from microtubules and to a pronounced increase in dynamic instability, Thus the phosphorylation of the repeated motifs in the micro tubule binding domains of MAPs by p110(mark) might provide a mechanism for the regulation of microtubule dynamics in cells.	MAX PLANCK UNIT STRUCT MOLEC BIOL, D-22603 HAMBURG, GERMANY; RUHR UNIV BOCHUM, INST PHYSIOL CHEM, D-44780 BOCHUM, GERMANY; UNIV ROCHESTER, DEPT BIOL, ROCHESTER, NY 14627 USA	Max Planck Society; Ruhr University Bochum; University of Rochester				Drewes, Gerard/0000-0003-0575-6766				AINSZTEIN AM, 1994, J BIOL CHEM, V269, P28465; AIZAWA H, 1991, J BIOL CHEM, V266, P9841; AIZAWA H, 1990, J BIOL CHEM, V265, P13849; AIZAWA H, 1989, J BIOL CHEM, V264, P5885; BAUMANN K, 1993, FEBS LETT, V336, P417, DOI 10.1016/0014-5793(93)80849-P; BERLING B, 1994, EUR J CELL BIOL, V64, P120; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRANDT R, 1994, J BIOL CHEM, V269, P11776; BRUGG B, 1991, J CELL BIOL, V114, P735, DOI 10.1083/jcb.114.4.735; BULINSKI JC, 1980, J CELL BIOL, V87, P802, DOI 10.1083/jcb.87.3.802; BURNS RG, 1984, EUR J BIOCHEM, V141, P609, DOI 10.1111/j.1432-1033.1984.tb08236.x; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; CHAPIN SJ, 1994, CELL MOTIL CYTOSKEL, V27, P133, DOI 10.1002/cm.970270205; CHAPIN SJ, 1995, BIOCHEMISTRY-US, V34, P2289, DOI 10.1021/bi00007a025; CHAPIN SJ, 1991, J CELL SCI, V98, P27; CHAPIN SJ, 1992, CELL MOTIL CYTOSKEL, V23, P236, DOI 10.1002/cm.970230403; CHEN J, 1992, NATURE, V360, P674, DOI 10.1038/360674a0; CORREAS I, 1992, J BIOL CHEM, V267, P15721; COUCHIE D, 1992, P NATL ACAD SCI USA, V89, P4378, DOI 10.1073/pnas.89.10.4378; DHAMODHARAN R, 1995, J CELL SCI, V108, P1679; DINSMORE JH, 1991, CELL, V64, P817, DOI 10.1016/0092-8674(91)90510-6; DOLL T, 1993, J CELL SCI, V106, P633; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; DREWES G, 1995, J BIOL CHEM, V270, P7679, DOI 10.1074/jbc.270.13.7679; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; ENNULAT DJ, 1989, J BIOL CHEM, V264, P5327; FARUKI S, 1994, CELL MOTIL CYTOSKEL, V28, P108, DOI 10.1002/cm.970280203; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GUSTKE N, 1992, FEBS LETT, V307, P199, DOI 10.1016/0014-5793(92)80767-B; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; HALPAIN S, 1990, NEURON, V5, P237, DOI 10.1016/0896-6273(90)90161-8; HIMMLER A, 1989, MOL CELL BIOL, V9, P1381, DOI 10.1128/MCB.9.4.1381; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; JAKES R, 1991, EMBO J, V10, P2725, DOI 10.1002/j.1460-2075.1991.tb07820.x; JOLY JC, 1990, BIOCHEMISTRY-US, V29, P8916, DOI 10.1021/bi00490a006; KINDLER S, 1990, J BIOL CHEM, V265, P19679; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; LEE G, 1992, J CELL SCI, V102, P227; LEHRICH RW, 1994, J BIOL CHEM, V269, P32446; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; LICHTENBERGKRAAG B, 1992, P NATL ACAD SCI USA, V89, P5384, DOI 10.1073/pnas.89.12.5384; LIEUVIN A, 1994, J CELL BIOL, V124, P985, DOI 10.1083/jcb.124.6.985; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; LITTAUER UZ, 1986, P NATL ACAD SCI USA, V83, P7162, DOI 10.1073/pnas.83.19.7162; MANDELKOW E, 1995, CURR OPIN CELL BIOL, V7, P72, DOI 10.1016/0955-0674(95)80047-6; MANDELKOW EM, 1993, TRENDS BIOCHEM SCI, V18, P480, DOI 10.1016/0968-0004(93)90011-B; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MEYER HE, 1993, FASEB J, V7, P776, DOI 10.1096/fasebj.7.9.7687226; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MORI A, 1991, BIOCHEMISTRY-US, V30, P9341, DOI 10.1021/bi00102a029; MURPHY DB, 1975, P NATL ACAD SCI USA, V72, P2696, DOI 10.1073/pnas.72.7.2696; OBAR RA, 1989, NEURON, V3, P639, DOI 10.1016/0896-6273(89)90274-2; Olmsted JB, 1991, CURR OPIN CELL BIOL, V3, P52, DOI 10.1016/0955-0674(91)90165-U; OLSON KR, 1995, J CELL BIOL, V130, P639, DOI 10.1083/jcb.130.3.639; OOKATA K, 1995, J CELL BIOL, V128, P849, DOI 10.1083/jcb.128.5.849; PANDA D, 1995, BIOCHEMISTRY-US, V34, P11117, DOI 10.1021/bi00035a017; PARYSEK LM, 1984, J CELL BIOL, V99, P1309, DOI 10.1083/jcb.99.4.1309; PREUSS U, 1995, MOL BIOL CELL, V6, P1397, DOI 10.1091/mbc.6.10.1397; PRYER NK, 1992, J CELL SCI, V103, P965; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; RIEDERER B, 1985, P NATL ACAD SCI USA, V82, P6006, DOI 10.1073/pnas.82.17.6006; SCHOENFELD TA, 1994, INT REV CYTOL, V151, P67, DOI 10.1016/S0074-7696(08)62631-5; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; SHIINA N, 1992, EMBO J, V11, P3977, DOI 10.1002/j.1460-2075.1992.tb05491.x; SLOBODA RD, 1975, P NATL ACAD SCI USA, V72, P177, DOI 10.1073/pnas.72.1.177; SONG JS, 1995, J PROTEIN CHEM, V14, P95, DOI 10.1007/BF01888367; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THEURKAUF WE, 1983, J BIOL CHEM, V258, P7883; TRINCZEK B, 1995, MOL BIOL CELL, V6, P1887, DOI 10.1091/mbc.6.12.1887; TRINCZEK B, 1993, MOL BIOL CELL, V4, P323, DOI 10.1091/mbc.4.3.323; TROJANOWSKI JQ, 1994, AM J PATHOL, V144, P449; TSUYAMA S, 1986, J BIOL CHEM, V261, P4110; UMEYAMA T, 1993, J CELL BIOL, V120, P451, DOI 10.1083/jcb.120.2.451; VALLEE R, 1980, P NATL ACAD SCI-BIOL, V77, P3206, DOI 10.1073/pnas.77.6.3206; VANDRE DD, 1991, J CELL SCI, V98, P577; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; WATANABE A, 1993, J BIOL CHEM, V268, P25712; WEST RR, 1991, J BIOL CHEM, V266, P21886; WILLE H, 1992, J STRUCT BIOL, V108, P49, DOI 10.1016/1047-8477(92)90006-V	89	154	157	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10834	10843		10.1074/jbc.271.18.10834	http://dx.doi.org/10.1074/jbc.271.18.10834			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631898	hybrid			2022-12-25	WOS:A1996UJ34200066
J	Proweller, A; Butler, JS				Proweller, A; Butler, JS			Ribosomal association of poly(A)-binding protein in poly(A)-deficient Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; POLY(A) BINDING-PROTEIN; MESSENGER-RNA; POSSIBLE INVOLVEMENT; XENOPUS-LAEVIS; INITIATION; YEAST; GENE; IDENTIFICATION; TRANSLATION	Poly(A) binding protein, the most abundant eukaryotic mRNP protein, is known primarily for its association with polyadenylate tails of mRNA. In the yeast, Saccharomyces cerevisiae, this protein (Pabp) was found to be essential for viability and has been implicated in models featuring roles in mRNA stability and as an enhancer of translation initiation. Although the mechanism of action is unknown, it is thought to require an activity to bind poly(A) tails and an additional capacity for an interaction with 60 S ribosomal subunits, perhaps via ribosomal protein L46 (RpI46), We have found that a significant amount of Pabp in wild-type cells is not associated with polyribosome complexes. The remaining majority, which is found in these complexes, maintains its association even in yeast cells deficient in polyadenylated mRNA and/or RpI46, These observations suggest that Pabp may not require interaction with poly(A) tails during translation, Further treatment of polyribosome lysates with agents known to differentially disrupt components of polyribosomes indicated that Pabp may require contact with some RNA component of the polyribosome, which could be either non-poly(A)-rich sequences of the translated mRNA or possibly a component of the ribosome. These findings suggest that Pabp may possess the ability to bind to ribosomes independently of its interaction with poly(A), We discuss these conclusions with respect to current models suggesting a multifunctional binding capacity of Pabp.	UNIV ROCHESTER, SCH MED & DENT, DEPT MICROBIOL & IMMUNOL, ROCHESTER, NY 14642 USA	University of Rochester					NIAID NIH HHS [5-T32-AI070362] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM07356] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007356] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM SA, 1986, J VIROL, V57, P614, DOI 10.1128/JVI.57.2.614-622.1986; ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; BAER BW, 1983, J CELL BIOL, V96, P717, DOI 10.1083/jcb.96.3.717; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BLOBEL G, 1973, P NATL ACAD SCI USA, V70, P924, DOI 10.1073/pnas.70.3.924; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1991, MOL CELL BIOL, V11, P3419, DOI 10.1128/MCB.11.7.3419; CAPONIGRO G, 1995, GENE DEV, V9, P2421, DOI 10.1101/gad.9.19.2421; DE SA MFG, 1988, EUR J BIOCHEM, V176, P521; DRAWBRIDGE J, 1990, MOL CELL BIOL, V10, P3994, DOI 10.1128/MCB.10.8.3994; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; GORLACH M, 1994, EXP CELL RES, V211, P400, DOI 10.1006/excr.1994.1104; JACOBSON A, 1983, NUCLEIC ACIDS RES, V11, P6353, DOI 10.1093/nar/11.18.6353; Jacobson A., 1995, TRANSLATIONAL CONTRO, P451; LEMAY G, 1986, ARCH BIOCHEM BIOPHYS, V249, P191, DOI 10.1016/0003-9861(86)90574-6; LUTZ CS, 1994, GENE DEV, V8, P576, DOI 10.1101/gad.8.5.576; MARTIN TE, 1973, EXP CELL RES, V80, P496, DOI 10.1016/0014-4827(73)90333-9; MORITZ M, 1991, MOL CELL BIOL, V11, P5681, DOI 10.1128/MCB.11.11.5681; MORITZ M, 1990, J CELL BIOL, V111, P2261, DOI 10.1083/jcb.111.6.2261; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; NETO OPD, 1995, NUCLEIC ACIDS RES, V23, P2198, DOI 10.1093/nar/23.12.2198; NIETFELD W, 1990, EMBO J, V9, P3699, DOI 10.1002/j.1460-2075.1990.tb07582.x; PATEL D, 1992, MOL CELL BIOL, V12, P3297, DOI 10.1128/MCB.12.7.3297; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; PROWELLER A, 1994, GENE DEV, V8, P2629, DOI 10.1101/gad.8.21.2629; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SACHS AB, 1987, MOL CELL BIOL, V7, P3268, DOI 10.1128/MCB.7.9.3268; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SETYONO B, 1981, CELL, V24, P775, DOI 10.1016/0092-8674(81)90103-3; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TARUN ZS, 1995, GENE DEV, V9, P2997; ZELUS BD, 1989, MOL CELL BIOL, V9, P2756, DOI 10.1128/MCB.9.6.2756	33	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10859	10865		10.1074/jbc.271.18.10859	http://dx.doi.org/10.1074/jbc.271.18.10859			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631901	hybrid			2022-12-25	WOS:A1996UJ34200069
J	Przywara, DA; Guo, X; Angelilli, ML; Wakade, TD; Wakade, AR				Przywara, DA; Guo, X; Angelilli, ML; Wakade, TD; Wakade, AR			A non-cholinergic transmitter, pituitary adenylate cyclase-activating polypeptide, utilizes a novel mechanism to evoke catecholamine secretion in rat adrenal chromaffin cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; HYPOTHALAMIC PEPTIDE; TYROSINE-HYDROXYLASE; MEDULLA; VIP; NEUROTRANSMITTER; PHOSPHORYLATION; EXOCYTOSIS; OUTGROWTH; NEURONS	Pituitary adenylate cyclase-activating polypeptide (PACAP) is the most potent non-cholinergic neurotransmitter to stimulate catecholamine secretion from rat chromaffin cells; however, the mechanism of action is not clear, We used amperometric detection of exocytosis and indo-1 monitoring of [Ca2+](i) to identify PACAP actions in cultured chromaffin cells, PACAP (100 nM) required external Ca2+ to evoke secretion, However, unlike nicotine and KCl which caused immediate and relatively brief secretion, PACAP had a latency of 6.8 +/- 0.96 s to the first secretory response and secretion continued for up to 2 min, PACAP elevation of [Ca2+](i) showed similar latency and often remained above base line for several minutes following a brief exposure, ZnCl2 (100 ECM) selectively inhibited PACAP-stimulated secretion and [Ca2+](i) with little effect on nicotine-evoked responses, Nifedipine (10 mu M) had little effect on PACAP-evoked secretion but inhibited nicotine-evoked secretion by more than 80%, while omega-conotoxin (100 nM) failed to affect either agonist, PACAP-stimulated cAMP levels required 5 s to significantly increase, consistent with the latency of exocytotic and Ca2+ responses. Forskolin (10 mu M) caused responses similar to PACAP. PACAP-evoked exocytosis was blocked by the protein kinase A inhibitor adenosine 3',5'-cyclic monophosphorothioate R(p)-diastereomer (R(p)-cAMPS). These data show that PACAP stimulates exocytosis by a mechanism distinctly different from cholinergic transmitters that appears to involve cAMP-mediated Ca2+ influx, Differences in receptor coupling mechanisms and pharmacology of Ca2+ entry stimulated by cholinergic and peptidergic agonists support the idea that the peptidergic system maintains catecholamine secretion under conditions where the cholinergic system desensitizes or otherwise fails.	WAYNE STATE UNIV,SCH MED,DEPT PEDIAT,DETROIT,MI 48201	Wayne State University	Przywara, DA (corresponding author), WAYNE STATE UNIV,SCH MED,DEPT PHARMACOL,540 E CANFIELD AVE,DETROIT,MI 48201, USA.							ARIMURA A, 1991, P NATL ACAD SCI USA, V81, P6388; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; CHOWDHURY PS, 1994, NEUROSCIENCE, V59, P1, DOI 10.1016/0306-4522(94)90092-2; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; EDWARDS AV, 1994, AM J PHYSIOL, V266, pE870, DOI 10.1152/ajpendo.1994.266.6.E870; GOTTSCHALL PE, 1990, ENDOCRINOLOGY, V127, P272, DOI 10.1210/endo-127-1-272; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUO X, 1994, J PHYSIOL-LONDON, V475, P539, DOI 10.1113/jphysiol.1994.sp020092; GUO X, 1996, IN PRESS J NEUROCHEM; HAYCOCK JW, 1992, J NEUROCHEM, V58, P57, DOI 10.1111/j.1471-4159.1992.tb09276.x; HILLE B, 1992, IONIC CHANNELS EXCIT, P177; HOKFELT T, 1981, ACTA PHYSIOL SCAND, V113, P575, DOI 10.1111/j.1748-1716.1981.tb06944.x; HOLZWARTH MA, 1984, J AUTONOM NERV SYST, V11, P283; HONG Y, 1993, NEUROSCIENCE, V57, P1121, DOI 10.1016/0306-4522(93)90054-J; ISOBE K, 1993, ENDOCRINOLOGY, V132, P1757, DOI 10.1210/en.132.4.1757; KOVES K, 1990, ENDOCRINOLOGY, V127, P264; LESZCZYSZYN DJ, 1990, J BIOL CHEM, V265, P14736; LILLIEN LE, 1985, NATURE, V317, P623; MALHOTRA RK, 1989, J NEUROSCI, V9, P4150; MARLEY PD, 1995, BRIT J PHARMACOL, V114, P1687, DOI 10.1111/j.1476-5381.1995.tb14958.x; MAUBERT E, 1990, NEUROSCI LETT, V113, P121, DOI 10.1016/0304-3940(90)90290-P; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; OOMORI Y, 1994, CELL TISSUE RES, V275, P201, DOI 10.1007/BF00319418; PRZYWARA DA, 1991, J PHYSIOL-LONDON, V437, P201, DOI 10.1113/jphysiol.1991.sp018591; PRZYWARA DA, 1993, P NATL ACAD SCI USA, V90, P557, DOI 10.1073/pnas.90.2.557; SCHACTERLE GR, 1973, ANAL BIOCHEM, V51, P654, DOI 10.1016/0003-2697(73)90523-X; TABARIN A, 1994, NEUROENDOCRINOLOGY, V59, P113, DOI 10.1159/000126647; TISCHLER AS, 1982, CELL TISSUE RES, V255, P525; UNSICKER K, 1978, P NATL ACAD SCI USA, V75, P3498, DOI 10.1073/pnas.75.7.3498; WAKADE AR, 1992, REGUL PEPTIDES, V37, P331, DOI 10.1016/0167-0115(92)90643-9; WAKADE TD, 1991, J PHYSIOL-LONDON, V444, P349, DOI 10.1113/jphysiol.1991.sp018882; WATANABE T, 1992, BIOCHEM BIOPH RES CO, V182, P403, DOI 10.1016/S0006-291X(05)80159-7; WAYMIRE JC, 1991, J NEUROCHEM, V57, P1313, DOI 10.1111/j.1471-4159.1991.tb08296.x; WIGHTMAN RM, 1991, P NATL ACAD SCI USA, V88, P10074	34	80	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10545	10550		10.1074/jbc.271.18.10545	http://dx.doi.org/10.1074/jbc.271.18.10545			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631854	hybrid			2022-12-25	WOS:A1996UJ34200022
J	Wilkinson, MF; Earle, ML; Triggle, CR; Barnes, S				Wilkinson, MF; Earle, ML; Triggle, CR; Barnes, S			Interleukin-1 beta, tumor necrosis factor-alpha, and LPS enhance calcium channel current in isolated vascular smooth muscle cells of rat tail artery	FASEB JOURNAL			English	Article						cytokine; calcium channel; immunomodulation; endotoxin; patch clamp	NITRIC-OXIDE SYNTHASE; RECEPTOR ANTAGONIST; SEPTIC SHOCK; ENDOTOXIN-SHOCK; INFLAMMATION; SURVIVAL; THERAPY; RABBITS; DISEASE	Cytokines, such as interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha), are thought to be responsible for the compromised blood pressure regulation after systemic infection or other antigenic challenge. Because Ca homeostasis is critical for the maintenance of vascular tone, we hypothesized that cytokines may contribute to alterations in blood pressure by a mechanism involving the voltage-sensitive Ca channel in vascular smooth muscle (VSM) cells. Using nystatin-permeabilized patch techniques we examined the effects of IL-1 beta, TNF-alpha, and lipopolysaccharide (LPS) on the Ca channel of VSM cells isolated from rat tail artery. Both IL-1 beta (0.05-1 nM) and TNF-alpha (0.1-1 nM) increased, dose-dependently, the Ba2+ current carried in VSM Ca channels, whereas heat-denatured IL-1 beta was without significant effect on the channel. LPS (0.01-1.0 ng/ml) also increased the Ba2+ current with onset kinetics similar to the two cytokines. Prostaglandins were ruled out as an intermediary in VSM Ca channel modulation, as prostaglandin E(2) had no effect and indomethacin (1 mu M) failed to block TNF-alpha-induced Ca channel enhancement. The role of cyclic nucleotides in mediating TNF-alpha-induced changes in Ca channel activity was also assessed. Increasing intracellular cAMP via forskolin (1 mu M) did not affect the response to TNF-alpha, but pretreatment with the membrane-permeant analog of cGMP, dibutyryl cGMP (100 mu M), inhibited the response to TNF-alpha. These data demonstrate that IL-1 beta, TNF-alpha, and LPS have immediate effects on VSM cells via an interaction with the voltage-sensitive Ca channel, and these effects may be regulated by intracellular cGMP. Immunomodulation of Ca channels may represent an early signaling step in VSM cells mediating kinetically slower events, such as changes in gene transcription.	UNIV CALGARY,FAC MED,SMOOTH MUSCLE RES GRP,CALGARY,AB T2N 4N1,CANADA	University of Calgary	Wilkinson, MF (corresponding author), UNIV CALGARY,FAC MED,NEUROSCI RES GRP,3330 HOSP DR NW,CALGARY,AB T2N 4N1,CANADA.			Triggle, Christopher/0000-0001-5307-0537				ALEXANDER HR, 1992, SURGERY, V112, P188; BATAAILLARD A, 1994, AM J PHYSIOL, V3, pR1148; BEASLEY D, 1994, AM J PHYSIOL, V266, pR1197, DOI 10.1152/ajpregu.1994.266.4.R1197; BEASLEY D, 1994, J EXP MED, V179, P71, DOI 10.1084/jem.179.1.71; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BUSSE R, 1990, FEBS LETT, V275, P87, DOI 10.1016/0014-5793(90)81445-T; CANNON JG, 1990, J INFECT DIS, V161, P79, DOI 10.1093/infdis/161.1.79; CLINTON SK, 1991, AM J PATHOL, V138, P1005; DERIJK R, 1992, AM J PHYSIOL, V263, pE1092; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; FISCHER E, 1992, BLOOD, V79, P2196; FISCHER E, 1992, J CLIN INVEST, V89, P1551, DOI 10.1172/JCI115748; FRENCH JF, 1993, EUR J PHARMACOL, V233, P109, DOI 10.1016/0014-2999(93)90355-L; FRENCH JF, 1991, J PHARMACOL EXP THER, V259, P260; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; HINSHAW LB, 1990, CIRC SHOCK, V30, P279; LEE HC, 1986, CIRC SHOCK, V18, P193; Loppnow H, 1994, Prog Clin Biol Res, V388, P309; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MARKS TN, 1990, PFLUG ARCH EUR J PHY, V417, P433, DOI 10.1007/BF00370664; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MIYOSHI H, 1994, J MOL CELL CARDIOL, V26, P1487, DOI 10.1006/jmcc.1994.1167; MORIMOTO K, 1992, J PHYSIOL-LONDON, V448, P307, DOI 10.1113/jphysiol.1992.sp019043; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; OKUSAWA S, 1988, J CLIN INVEST, V81, P1162, DOI 10.1172/JCI113431; RUSSELL DA, 1995, J INFECT DIS, V171, P1528, DOI 10.1093/infdis/171.6.1528; SPINAS GA, 1991, J INFECT DIS, V163, P89, DOI 10.1093/infdis/163.1.89; STRIETER RM, 1993, CRIT CARE MED, V21, pS447, DOI 10.1097/00003246-199310001-00006; WAKABAYASHI GO, 1991, FASEB J, V5, P338, DOI 10.1096/fasebj.5.3.1825816; WANG R, 1989, AM J PHYSIOL, V256, pH1361, DOI 10.1152/ajpheart.1989.256.5.H1361; WARNER SJC, 1989, J IMMUNOL, V142, P100	32	46	46	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1996	10	7					785	791		10.1096/fasebj.10.7.8635696	http://dx.doi.org/10.1096/fasebj.10.7.8635696			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UN798	8635696				2022-12-25	WOS:A1996UN79800013
J	Binnerts, ME; vanKooyk, Y; Edwards, CP; Champe, M; Presta, L; Bodary, SC; Figdor, CG; Berman, PW				Binnerts, ME; vanKooyk, Y; Edwards, CP; Champe, M; Presta, L; Bodary, SC; Figdor, CG; Berman, PW			Antibodies that selectively inhibit leukocyte function-associated antigen 1 binding to intercellular adhesion molecule-3 recognize a unique epitope within the CD11a I domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; CR3-DEPENDENT ADHESION; COUNTER-RECEPTOR; LYMPHOCYTES-T; LFA-1; INTEGRIN; CLONING; LIGAND; ACTIVATION; EXPRESSION	Several studies indicate that the I domain located in the alpha chain (CD11a) of leukocyte function-associated antigen-1 (LFA-1; CD11a/CD18) plays an essential role in ligand recognition. me recently identified three distinct epitopes (IdeA, IdeB, and IdeC) within the CD11a I domain, recognized by antibodies that block binding of LFA-1 to intercellular adhesion molecules (ICAM) 1, 2, and 3. In the present study, we used a series of human/ murine CD11a I domain chimeras, to localize a fourth I domain epitope (IdeD), recognized by three independently derived anti-CD11a antibodies that selectively block the binding of LFA-1 to ICAM-3, but not to ICAM-1. The IdeD epitope depended on human CD11a residues Asp(182) and Ser(184) and was not present in CD11b or CD11c. Although mutation of Asp(182) and Ser(184) failed to abolish ICAM-3 adhesion of LFA-1 transfectants, alignment of these residues with the crystal structure of the CD11a I domain suggested that the IdeD epitope is located in close proximity to residues (Ile(126) and Asn(129)) recently implicated in the ICAM-3 binding site (1). Interestingly, the IdeB and IdeC epitopes appeared to be in close proximity of a divalent cation binding pocket within the CD11a I domain that regulates both ICAM-1 and ICAM-3 adhesion. Taken together, these data indicate that distinct regions of the CD11a I domain contain epitopes for antibodies that either selectively inhibit binding of LFA-1 to ICAM-3, or interfere with both ICAM-1 and ICAM-3 binding of LFA-1.	UNIV NIJMEGEN ST RADBOUD HOSP, DEPT TUMOR IMMUNOL, 6525 EX NIJMEGEN, NETHERLANDS; GENENTECH INC, DEPT IMMUNOL, San Francisco, CA 94080 USA	Radboud University Nijmegen; Roche Holding; Genentech			Figdor, Carl G/A-4232-2010	Figdor, Carl G/0000-0002-2366-9212				ACEVEDO A, 1993, AM J PATHOL, V143, P774; ANDREW D, 1993, EUR J IMMUNOL, V23, P2217, DOI 10.1002/eji.1830230925; ARROYO AG, 1994, J CELL BIOL, V126, P1277, DOI 10.1083/jcb.126.5.1277; BERGELSON JM, 1995, CURR BIOL, V5, P615, DOI 10.1016/S0960-9822(95)00124-2; BERMAN PW, 1993, J CELL BIOCHEM, V52, P183, DOI 10.1002/jcb.240520210; BINNERTS ME, 1994, EUR J IMMUNOL, V24, P2155, DOI 10.1002/eji.1830240933; CHAMPE M, 1995, J BIOL CHEM, V270, P1388, DOI 10.1074/jbc.270.3.1388; CORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; DEFOUGEROLLES AR, 1993, J EXP MED, V177, P1187, DOI 10.1084/jem.177.4.1187; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DIACOVO TG, 1994, J CLIN INVEST, V94, P1243, DOI 10.1172/JCI117442; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DUSTIN ML, 1986, J IMMUNOL, V137, P245; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EDWARDS CP, 1995, J BIOL CHEM, V270, P12635, DOI 10.1074/jbc.270.21.12635; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; FIGDOR CG, 1990, IMMUNOL TODAY, V11, P277, DOI 10.1016/0167-5699(90)90112-M; HILDRETH JEK, 1983, EUR J IMMUNOL, V13, P202, DOI 10.1002/eji.1830130305; HOLNESS CL, 1995, J BIOL CHEM, V270, P877, DOI 10.1074/jbc.270.2.877; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1995, J BIOL CHEM, V270, P12531, DOI 10.1074/jbc.270.21.12531; KANNER SB, 1993, P NATL ACAD SCI USA, V90, P7099, DOI 10.1073/pnas.90.15.7099; KEIZER GD, 1985, EUR J IMMUNOL, V15, P1142, DOI 10.1002/eji.1830151114; KERN A, 1994, J BIOL CHEM, V269, P22811; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LANDIS RC, 1994, J CELL BIOL, V126, P529, DOI 10.1083/jcb.126.2.529; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; LARSON RS, 1989, J CELL BIOL, V108, P703, DOI 10.1083/jcb.108.2.703; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MARTZ E, 1987, HUM IMMUNOL, V18, P3, DOI 10.1016/0198-8859(87)90110-8; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; NORTAMO P, 1991, EUR J IMMUNOL, V21, P2629, DOI 10.1002/eji.1830211049; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RANDI AM, 1994, J BIOL CHEM, V269, P12395; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; SADHU C, 1994, CELL ADHES COMMUN, V2, P429, DOI 10.3109/15419069409004453; SHAW SK, 1994, J BIOL CHEM, V269, P6016; SIMS MJ, 1993, J IMMUNOL, V151, P2296; SPITS H, 1983, HYBRIDOMA, V2, P423, DOI 10.1089/hyb.1983.2.423; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; TUFTY RM, 1975, SCIENCE, V187, P167, DOI 10.1126/science.1111094; vanKooyk Y, 1996, J EXP MED, V183, P1247, DOI 10.1084/jem.183.3.1247; VANKOOYK Y, 1994, J CELL BIOL, V124, P1061, DOI 10.1083/jcb.124.6.1061; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; VAZEUX R, 1992, NATURE, V360, P485, DOI 10.1038/360485a0; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	53	37	37	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9962	9968		10.1074/jbc.271.17.9962	http://dx.doi.org/10.1074/jbc.271.17.9962			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626634	Green Published, hybrid			2022-12-25	WOS:A1996UG25700018
J	Lee, HJ; Young, WJ; Shih, CCY; Chang, CS				Lee, HJ; Young, WJ; Shih, CCY; Chang, CS			Suppression of the human erythropoietin gene expression by the TR2 orphan receptor, a member of the steroid receptor superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; INSITU HYBRIDIZATION; HORMONE RECEPTORS; ENHANCER ELEMENT; RETINOIC ACID; CELL-LINES; PROTEIN; HYPOXIA; LOCALIZATION; ACTIVATION	A DNA response element, TR2RE-EPO (5'-TCTGACCTCTCGACCTAC-3') has been identified in the 3'-minimal hypoxia-inducible enhancer of the human erythropoietin gene for the TR2 orphan receptor, an androgen-repressed transcription factor and a member of the steroid/thyroid hormone receptor superfamily. Electrophoretic mobility shift assay showed a specific binding with high affinity (K-d = 0.14 nM) between the TR2 orphan receptor and the TR2RE-EPO. Our data further indicated that this specific binding is not due to the homo-dimerization of the TR2 orphan receptor. In addition, reporter gene expression using chloramphenicol acetyltransferase assay demonstrated that the TR2 orphan receptor may suppress the expression of the chloramphenicol acetyltransferase activities via the TR2RE-EPO in the hypoxic/normoxic human hepatoma HepG2 cells. Finally, our in situ hybridization data also indicated that the TR2 orphan receptor and the erythropoietin transcripts can be co-expressed in mouse kidney and liver. Together, our data suggest that the human erythropoietin gene could represent the first human target gene regulated directly by the human TR2 orphan receptor.	UNIV WISCONSIN, CTR COMPREHENS CANC, ENDOCRINOL REPROD PHYSIOL PROGRAM, MADISON, WI 53792 USA						NCI NIH HHS [CA55639] Funding Source: Medline; NIDDK NIH HHS [DK47258] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055639, R29CA055639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047258] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECK I, 1991, J BIOL CHEM, V266, P15563; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BURBACH JPH, 1994, J BIOL CHEM, V269, P15046; CHANG C, 1988, BIOCHEM BIOPH RES CO, V155, P971, DOI 10.1016/S0006-291X(88)80591-6; CHANG C, 1989, J STEROID BIOCHEM, V34, P391; CHANG C, 1989, BIOCHEM BIOPH RES CO, V165, P735, DOI 10.1016/S0006-291X(89)80028-2; Chang C, 1993, ENDOCR J, V1, P541; CHANG CS, 1989, ENDOCRINOLOGY, V125, P1097, DOI 10.1210/endo-125-2-1097; CHANG CS, 1992, P NATL ACAD SCI USA, V89, P5946, DOI 10.1073/pnas.89.13.5946; CHANG CS, 1994, P NATL ACAD SCI USA, V91, P6040, DOI 10.1073/pnas.91.13.6040; ESCHBACH JW, 1995, NEPHROL DIAL TRANSPL, V10, P96, DOI 10.1093/ndt/10.supp2.96; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GOLDBERG MA, 1987, P NATL ACAD SCI USA, V84, P7972, DOI 10.1073/pnas.84.22.7972; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HIROSE T, 1994, MOL ENDOCRINOL, V8, P1667, DOI 10.1210/me.8.12.1667; HO V, 1995, J BIOL CHEM, V270, P10084, DOI 10.1074/jbc.270.17.10084; IDETA R, 1995, ENDOCRINE, V3, P277, DOI 10.1007/BF03021406; JACOBS K, 1985, NATURE, V313, P806, DOI 10.1038/313806a0; JACOBSON LO, 1957, NATURE, V179, P633, DOI 10.1038/179633a0; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; JEPSON JH, 1967, ENDOCRINOLOGY, V80, P430, DOI 10.1210/endo-80-3-430; Kokontis J, 1991, Receptor, V1, P261; KOURY ST, 1988, BLOOD, V71, P524; KOURY ST, 1991, BLOOD, V77, P2497; KRANTZ SB, 1991, BLOOD, V77, P419; LAI PH, 1986, J BIOL CHEM, V261, P3116; LEE HJ, 1993, BIOCHEM BIOPH RES CO, V194, P97, DOI 10.1006/bbrc.1993.1790; LEE HJ, 1995, J BIOL CHEM, V270, P5434, DOI 10.1074/jbc.270.10.5434; LEE HJ, 1995, J BIOL CHEM, V270, P30129; LEE HJ, 1993, ENDOCR J, V1, P203; LEEHUANG S, 1993, GENE, V128, P227, DOI 10.1016/0378-1119(93)90567-M; LEEHUANG S, 1993, GENE, V137, P203; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; LIN TM, 1995, J BIOL CHEM, V270, P30121; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MASUDA S, 1994, J BIOL CHEM, V269, P19488; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; MOWSZOWICZ I, 1993, MOL ENDOCRINOL, V7, P861, DOI 10.1210/me.7.7.861; NAUGHTON BA, 1977, SCIENCE, V196, P301, DOI 10.1126/science.847471; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; OMALLEY BW, 1992, MOL ENDOCRINOL, V6, P1359, DOI 10.1210/me.6.9.1359; PAULO LG, 1974, BLOOD, V43, P39, DOI 10.1182/blood.V43.1.39.39; PAULSEN RE, 1992, J BIOL CHEM, V267, P16491; RIDLEY DM, 1994, J NATL MED ASSOC, V86, P129; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WIESENBERG I, 1995, NUCLEIC ACIDS RES, V23, P327, DOI 10.1093/nar/23.3.327; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; ZUCALI JR, 1977, BRIT J HAEMATOL, V35, P639, DOI 10.1111/j.1365-2141.1977.tb00627.x	60	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10405	10412		10.1074/jbc.271.17.10405	http://dx.doi.org/10.1074/jbc.271.17.10405			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626614	hybrid			2022-12-25	WOS:A1996UG25700086
J	Garwood, J; Kohiyama, M				Garwood, J; Kohiyama, M			Novel cytoplasmic hemimethylated oriC binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; REPLICATION ORIGIN; DNA-REPLICATION; DAM METHYLATION; SALMONELLA-TYPHIMURIUM; INITIATION; PROTEIN; MEMBRANE; COMPLEX; SITES	Using hemimethylated, fully methylated, and unmethylated oligonucleotide probes corresponding to part of the origin of Escherichia coli DNA replication, oriC (+81-136), we have characterized a novel hemimethylated DNA-specific protein binding activity. This activity appears to be located in the cytoplasm rather than in membrane fractions. It has been partially purified and, in DNase footprinting analysis, found to preferentially protect only a subset of the hemimethylated GATC sites present in the minimal oriC. These sites are found adjacent to the DnaA binding box, R1, and overlap the integration host factor binding site. The activity does not correspond to known hemimethylated binding proteins, although in the seqA deletion mutant, there is a 3-fold reduction of the activity. The stage of the cell cycle in synchronized PC2 cultures does not seem to significantly affect the relative levels of this binding activity. A possible role in sequestration of the newly replicated hemimethylated origin is discussed.	UNIV PARIS 07, INST JACQUES MONOD, BIOCHEM GENET GRP, F-75251 PARIS, FRANCE	UDICE-French Research Universities; Universite Paris Cite								AU KG, 1992, J BIOL CHEM, V267, P12142; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; CARL PL, 1970, MOL GEN GENET, V109, P107, DOI 10.1007/BF00269647; CHAKRABORTI A, 1992, J BACTERIOL, V174, P7202, DOI 10.1128/jb.174.22.7202-7206.1992; CROOKE E, 1993, J MOL BIOL, V233, P16, DOI 10.1006/jmbi.1993.1481; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; GAYAMA S, 1990, EMBO J, V9, P3761, DOI 10.1002/j.1460-2075.1990.tb07589.x; GILLE H, 1991, EMBO J, V10, P1579, DOI 10.1002/j.1460-2075.1991.tb07678.x; HANSEN FG, 1991, RES MICROBIOL, V142, P161, DOI 10.1016/0923-2508(91)90025-6; HANSEN FG, 1991, J BACTERIOL, V173, P5194, DOI 10.1128/jb.173.16.5194-5199.1991; HENDRICKSON WG, 1982, CELL, V30, P915, DOI 10.1016/0092-8674(82)90296-3; HERRICK J, 1994, EMBO J, V13, P4695, DOI 10.1002/j.1460-2075.1994.tb06793.x; HUPP TR, 1993, J BIOL CHEM, V268, P13128; HWANG DS, 1992, J BIOL CHEM, V267, P23083; ISHIDATE K, 1986, J BIOL CHEM, V261, P428; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; JOSELEAUPETIT D, 1975, BIOCHIM BIOPHYS ACTA, V406, P36, DOI 10.1016/0005-2736(75)90040-1; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; KUSANO T, 1984, J BACTERIOL, V158, P313, DOI 10.1128/JB.158.1.313-316.1984; LANDOULSI A, 1990, CELL, V63, P1053, DOI 10.1016/0092-8674(90)90508-C; LANDOULSI A, 1989, MOL GEN GENET, V216, P217, DOI 10.1007/BF00334359; LU M, 1994, CELL, V77, P413, DOI 10.1016/0092-8674(94)90156-2; MAHAFFY JM, 1989, J THEOR BIOL, V140, P453, DOI 10.1016/S0022-5193(89)80109-2; MARSH RC, 1978, MOL GEN GENET, V166, P299, DOI 10.1007/BF00267622; MESSER W, 1985, EMBO J, V4, P1327, DOI 10.1002/j.1460-2075.1985.tb03780.x; MESSER W, 1988, CELL, V54, P735, DOI 10.1016/S0092-8674(88)90911-7; MESSER W, 1995, ESCHERICHIA COLI SAL; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; NAGAI K, 1980, P NATL ACAD SCI-BIOL, V77, P262, DOI 10.1073/pnas.77.1.262; OGDEN GB, 1988, CELL, V54, P127, DOI 10.1016/0092-8674(88)90186-9; OKA A, 1980, MOL GEN GENET, V178, P9, DOI 10.1007/BF00267207; POLACZEK P, 1990, New Biologist, V2, P265; ROTH A, 1994, BIOCHIMIE, V76, P917, DOI 10.1016/0300-9084(94)90016-7; RUSSELL DW, 1987, CELL, V50, P1071, DOI 10.1016/0092-8674(87)90173-5; SAMITT CE, 1989, EMBO J, V8, P989, DOI 10.1002/j.1460-2075.1989.tb03462.x; SCHAECHTER M, 1990, AM SOC MICROBIOL, P313; SCHAEFER C, 1991, MOL GEN GENET, V226, P34, DOI 10.1007/BF00273584; SKARSTAD K, 1986, EMBO J, V5, P1711, DOI 10.1002/j.1460-2075.1986.tb04415.x; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; SKARSTAD K, 1990, EMBO J, V9, P2341, DOI 10.1002/j.1460-2075.1990.tb07406.x; SMITH DW, 1985, EMBO J, V4, P1319, DOI 10.1002/j.1460-2075.1985.tb03779.x; THEISEN PW, 1993, MOL MICROBIOL, V10, P575, DOI 10.1111/j.1365-2958.1993.tb00929.x; VONFREIESLEBEN U, 1994, MOL MICROBIOL, V14, P763; WOELKER B, 1993, NUCLEIC ACIDS RES, V21, P5025, DOI 10.1093/nar/21.22.5025; YOSHIKAWA H, 1991, MOL MICROBIOL, V5, P2589, DOI 10.1111/j.1365-2958.1991.tb01967.x; ZYSKIND JW, 1986, CELL, V46, P489, DOI 10.1016/0092-8674(86)90873-1	48	5	5	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7404	7411		10.1074/jbc.271.13.7404	http://dx.doi.org/10.1074/jbc.271.13.7404			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631765	hybrid			2022-12-25	WOS:A1996UC77400033
J	MartinMoutot, N; Charvin, N; Leveque, C; Sato, K; Nishiki, T; Kozaki, S; Takahashi, M; Seagar, M				MartinMoutot, N; Charvin, N; Leveque, C; Sato, K; Nishiki, T; Kozaki, S; Takahashi, M; Seagar, M			Interaction of SNARE complexes with P/Q-type calcium channels in rat cerebellar synaptosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUID GIANT SYNAPSE; CA2+ CHANNELS; SYNAPTOTAGMIN; DOCKING; FUSION	P- and Q-type calcium channels, which trigger rapid neurotransmitter release at many mammalian synapses, are blocked by omega-conotoxin MVIIC. I-125-omega Conotoxin MVIIC binding to rat cerebellar synaptosomes was not displaced by omega-conotogins GVIA or MVIIA (K-i > 1 mu M), which are selective for N-type calcium channels. Solubilized I-125-omega-conotoxin MMIC receptors were specifically recognized by antibodies directed against alpha(1)A calcium channel subunits, proteins known to constitute a pore with P/Q-like channel properties, Antibodies against syntaxin 1, SNAP 25, and VAMP 2 (synaptobrevin) each immunoprecipitated a similar fraction (20-40%) of omega-conotoxin MVIIC receptors. Immunoprecipitation was not additive, suggesting that heterotrimeric (SNARE) complexes containing these three proteins interact with P/Q-type calcium channels. Immobilized monoclonal anti-syntaxin antibodies retained ru,A calcium channel subunits of 220, 180 and 160 kDa monitored by immunoblotting with site directed antibodies. Synaptotagmin was detected in channel-associated complexes; but not synaptophysin, Rab 3A nor rat cysteine string protein, Trimeric SNARE complexes are implicated in calcium-dependent exocytosis, a process thought to be regulated by synaptotagmin. Our results indicate that these proteins interact with P/Q-type calcium channels, which may optimize their location within domains of calcium influx.	MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN; UNIV OSAKA PREFECTURE,DEPT VET SCI,OSAKA 593,JAPAN	Osaka Metropolitan University	MartinMoutot, N (corresponding author), FAC MED,INST JEAN ROCHE,INSERM,U374,SECT NORD,BLVD PIERRE DRAMARD,F-13916 MARSEILLE 20,FRANCE.		leveque, christian/GVU-3567-2022	leveque, christian/0000-0003-2583-2148				ADLER EM, 1991, J NEUROSCI, V11, P1496; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; BIRNBAUMER L, 1994, NEURON, V13, P505, DOI 10.1016/0896-6273(94)90021-3; ELFAR O, 1995, FEBS LETT, V361, P101, DOI 10.1016/0014-5793(95)00156-4; GRANTHAM CJ, 1994, NEUROPHARMACOLOGY, V33, P255, DOI 10.1016/0028-3908(94)90017-5; HILLYARD DR, 1992, NEURON, V9, P69, DOI 10.1016/0896-6273(92)90221-X; KRISTIPATI R, 1994, MOL CELL NEUROSCI, V5, P219, DOI 10.1006/mcne.1994.1026; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; LEVEQUE C, 1994, J BIOL CHEM, V269, P6306; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LITTLETON JT, 1995, TRENDS NEUROSCI, V18, P177; LLINAS R, 1981, BIOPHYS J, V33, P323, DOI 10.1016/S0006-3495(81)84899-0; MARTINMOUTOT N, 1995, FEBS LETT, V366, P21, DOI 10.1016/0014-5793(95)00467-N; MINTZ IM, 1995, NEURON, V15, P675, DOI 10.1016/0896-6273(95)90155-8; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; RANDALL A, 1995, J NEUROSCI, V15, P2995; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; TURNER TJ, 1995, NEUROPHARMACOLOGY, V34, P1469, DOI 10.1016/0028-3908(95)00133-Q; WESTENBROEK RE, 1995, J NEUROSCI, V15, P6403; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925	31	112	115	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6567	6570		10.1074/jbc.271.12.6567	http://dx.doi.org/10.1074/jbc.271.12.6567			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636067	hybrid			2022-12-25	WOS:A1996UB15700002
J	Nakahira, K; Shi, GY; Rhodes, KJ; Trimmer, JS				Nakahira, K; Shi, GY; Rhodes, KJ; Trimmer, JS			Selective interaction of voltage-gated K+ channel beta-subunits with alpha-subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; RAT-BRAIN; EXPRESSION; CLONING; CDNA	To begin to study the molecular bases that determine the selective interaction of the beta-subunits of voltage-gated K+ channels with alpha-subunits observed in situ, we have expressed these polypeptides in transfected mammalian cells. Analysis of the specificity of alpha/beta-subunit interaction indicates that both the Kv beta 1 and Kv beta 2 beta-subunits display robust and selective interaction with the five members of the Shaker-related (Kv1) alpha-subunit subfamily tested. The interaction of these beta-subunits with Kv1 alpha-subunits does not require the beta-subunit N-terminal domains. Thus, the previously observed failure of N-terminal mutants of Kv beta 1 to modulate inactivation kinetics of Kv1 family members is not simply due to a lack of subunit interaction. Interaction of these beta-subunits with members of two other subfamilies (Shab- and Shaw-related) could not be detected. Somewhat surprisingly, a member of the Shal-related subfamily was found to interact with beta-subunits; however, this interaction had biochemical characteristics distinct from the beta-subunit interaction with Kv1 family members. In an cases, Kv beta 1 and Kv beta 2 exhibited indistinguishable alpha-subunit selectivity. These studies point to a selective interaction between K+ channel alpha- and beta-subunits mediated through conserved domains in the respective subunits.	SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794; WYETH AYERST RES,CENT NERVOUS SYST DIV,PEARL RIVER,NY 10965	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Pfizer					NINDS NIH HHS [NS34383] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034383, R37NS034383] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALDWIN TJ, 1991, NEURON, V7, P471, DOI 10.1016/0896-6273(91)90299-F; CAI YC, 1993, J BIOL CHEM, V268, P23720; CHABALA LD, 1993, J GEN PHYSIOL, V102, P713, DOI 10.1085/jgp.102.4.713; CHANDY KG, 1995, LIGAND VOLTAGE GATED, P1; CHRISTIE MJ, 1989, SCIENCE, V244, P221, DOI 10.1126/science.2539643; ENGLAND SK, 1995, P NATL ACAD SCI USA, V92, P6309, DOI 10.1073/pnas.92.14.6309; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; LENZ S, 1994, SYNAPSE, V18, P55, DOI 10.1002/syn.890180108; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LUNEAU CJ, 1991, P NATL ACAD SCI USA, V88, P3932, DOI 10.1073/pnas.88.9.3932; MAJUMDER K, 1995, FEBS LETT, V361, P13, DOI 10.1016/0014-5793(95)00120-X; MCKINNON D, 1989, J BIOL CHEM, V264, P8230; MORALES MJ, 1995, J BIOL CHEM, V270, P6272, DOI 10.1074/jbc.270.11.6272; OETTGEN HC, 1986, NATURE, V320, P272, DOI 10.1038/320272a0; PAULMICHL M, 1991, P NATL ACAD SCI USA, V88, P7892, DOI 10.1073/pnas.88.17.7892; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RHODES KJ, 1995, J NEUROSCI, V15, P5360; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; SCOTT VES, 1994, BIOCHEMISTRY-US, V33, P1617, DOI 10.1021/bi00173a001; SHEN NV, 1993, NEURON, V11, P67; SHI GY, 1994, J BIOL CHEM, V269, P23204; STRONG M, 1993, MOL BIOL EVOL, V10, P221; SWANSON R, 1990, NEURON, V4, P929, DOI 10.1016/0896-6273(90)90146-7; TRIMMER JS, 1991, P NATL ACAD SCI USA, V88, P10764, DOI 10.1073/pnas.88.23.10764; XU J, 1995, J BIOL CHEM, V270, P24761, DOI 10.1074/jbc.270.42.24761	28	126	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7084	7089		10.1074/jbc.271.12.7084	http://dx.doi.org/10.1074/jbc.271.12.7084			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636142	hybrid			2022-12-25	WOS:A1996UB15700077
J	Riewald, M; Morgenstern, KA; Schleef, RR				Riewald, M; Morgenstern, KA; Schleef, RR			Identification and characterization of the cytoplasmic antiproteinase (CAP) in human platelets - Evidence for the interaction of CAP with endogenous platelet proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; PROTEASE NEXIN-I; CELL-LINE; MOLECULAR CHARACTERIZATION; BINDING-SITES; MESSENGER-RNA; THROMBIN; COMPLEXES; PURIFICATION; POLYPEPTIDES	To define the presence and potential role of platelet-associated protease inhibitors, we initiated a study designed to characterize the platelet components that are responsible for the formation of two SDS-stable complexes of approximately 58 and 70 kDa initially observed following the incubation of I-125-thrombin and human platelets. We demonstrate that thermal-mediated unfolding of the 58-kDa complex between I-125-thrombin and a nonsecreted platelet protein leads to an apparent molecular mass of 70 kDa. This platelet component is functionally and immunologically indistinguishable from the cytoplasmic antiproteinase (CAP), also known as placental thrombin inhibitor, a recently cloned member of the ovalbumin family of intracellular serpins (serine proteinase inhibitors), CAP-specific mRNA and antigen were detected in human platelets, suggesting that CAP synthesis occurs concurrent with platelet development. Utilizing quantitative immunoblotting, CAP antigen was estimated at 1.014 +/- 0.181 mu g/10(9) nonstimulated platelets. After platelet activation with the calcium ionophore A23187, CAP antigen was detected in released microparticles at approximately 0.195 +/- 0.031 mu g/10(9) platelets and a fraction of platelet CAP was proteolytically modified. We provide evidence that these lower molecular mass species arise by cleavage of CAP at or near the reactive site loop. Most importantly, molecular sieving chromatography indicates the presence of an approximately 68-kDa SDS-labile complex between cleaved CAP and a cellular component in A23187-stimulated platelets, suggesting a physiological target of this intracellular serpin and a potential role for this inhibitor in regulating proteolytic activity that may be formed during platelet activation.	Scripps Res Inst, DEPT VASC BIOL VB1, LA JOLLA, CA 92037 USA; UNIV NEW MEXICO, SCH MED, DEPT PATHOL, BLOOD SYST RES FDN LAB, ALBUQUERQUE, NM 87131 USA	Scripps Research Institute; University of New Mexico					NCRR NIH HHS [M01 RR00833] Funding Source: Medline; NHLBI NIH HHS [HL45954, HL49563] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045954, R01HL049563] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKER JB, 1986, SEMIN THROMB HEMOST, V12, P216, DOI 10.1055/s-2007-1003554; BELIN D, 1989, EMBO J, V8, P3287, DOI 10.1002/j.1460-2075.1989.tb08489.x; BENNETT WF, 1980, CELL, V22, P621, DOI 10.1016/0092-8674(80)90372-4; BONTHRON D, 1986, NUCLEIC ACIDS RES, V14, P7125, DOI 10.1093/nar/14.17.7125; BROWNE PC, 1988, ARCH BIOCHEM BIOPHYS, V265, P534, DOI 10.1016/0003-9861(88)90158-0; COUGHLIN P, 1993, P NATL ACAD SCI USA, V90, P9417, DOI 10.1073/pnas.90.20.9417; COUGHLIN PB, 1993, J BIOL CHEM, V268, P9541; EATON DL, 1983, J CELL PHYSIOL, V117, P175, DOI 10.1002/jcp.1041170207; FAY WP, 1992, NEW ENGL J MED, V327, P1729, DOI 10.1056/NEJM199212103272406; GAUSSEM P, 1993, J BIOL CHEM, V268, P12150; GEORGE JN, 1982, BLOOD, V60, P834; GREENBERG SM, 1988, BLOOD, V72, P1968; GRONKE RS, 1989, BLOOD, V73, P472; GRONKE RS, 1987, J BIOL CHEM, V262, P3030; HARFENIST EJ, 1982, BLOOD, V59, P952; HOWARD EW, 1986, J BIOL CHEM, V261, P684; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HUNT LT, 1980, BIOCHEM BIOPH RES CO, V95, P864, DOI 10.1016/0006-291X(80)90867-0; JANDROTPERRUS M, 1988, EUR J BIOCHEM, V174, P359, DOI 10.1111/j.1432-1033.1988.tb14106.x; JENSEN PH, 1994, BRIT J CANCER, V70, P834, DOI 10.1038/bjc.1994.407; KIRSCHNER RJ, 1980, J BIOL CHEM, V255, P5468; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KONKLE BA, 1993, ARTERIOSCLER THROMB, V13, P669, DOI 10.1161/01.ATV.13.5.669; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEREA KM, 1987, P NATL ACAD SCI USA, V84, P5620, DOI 10.1073/pnas.84.16.5620; LONG MW, 1990, J CLIN INVEST, V85, P1072, DOI 10.1172/JCI114538; MILLER JJ, 1988, BIOCHEM BIOPH RES CO, V151, P9, DOI 10.1016/0006-291X(88)90552-9; MORGENSTERN KA, 1993, J BIOL CHEM, V268, P21560; MORGENSTERN KA, 1994, BIOCHEMISTRY-US, V33, P3432, DOI 10.1021/bi00177a037; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; REMOLDODONNELL E, 1992, P NATL ACAD SCI USA, V89, P5635, DOI 10.1073/pnas.89.12.5635; REMOLDODONNELL E, 1993, FEBS LETT, V315, P105, DOI 10.1016/0014-5793(93)81143-N; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLEEF RR, 1988, J BIOL CHEM, V263, P5797; SCHNEIDER SS, 1995, P NATL ACAD SCI USA, V92, P3147, DOI 10.1073/pnas.92.8.3147; Shuman M A, 1981, Ann N Y Acad Sci, V370, P57, DOI 10.1111/j.1749-6632.1981.tb29721.x; SMITH DE, 1984, J CELL BIOL, V99, P20, DOI 10.1083/jcb.99.1.20; SUMINAMI Y, 1991, BIOCHEM BIOPH RES CO, V181, P51, DOI 10.1016/S0006-291X(05)81380-4; TESSMER U, 1989, ELECTROPHORESIS, V10, P277, DOI 10.1002/elps.1150100414; YE RD, 1987, J BIOL CHEM, V262, P3728; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	41	8	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7160	7167		10.1074/jbc.271.12.7160	http://dx.doi.org/10.1074/jbc.271.12.7160			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636153	hybrid			2022-12-25	WOS:A1996UB15700088
J	Toukdarian, AE; Helinski, DR; Perri, S				Toukdarian, AE; Helinski, DR; Perri, S			The plasmid RK2 initiation protein binds to the origin of replication as a monomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOST-RANGE PLASMID-RK2; GRAM-NEGATIVE BACTERIA; DNA-BINDING; TRFA GENE; SEQUENCE REQUIREMENTS; NUCLEOTIDE-SEQUENCE; REGION; MAINTENANCE; MUTATIONS; DOMAINS	The TrfA protein encoded by the broad host range bacterial plasmid RK2 specifically binds to eight direct repeats (iterons) present at the plasmid replication origin to initiate DNA replication. purified TrfA protein is largely in the form of a dimer, and using a dimerization test system that involves the fusion of the amino-terminal domain of the lambda cI repressor protein to TrfA, we show that the TrfA protein forms dimers in vivo., Because of the high stability of the dimer form of TrfA, the formation of heterodimers between the wild-type and different sized TrfA proteins requires in vivo de novo folding of the primary protein sequence or in vitro denaturation and renaturation. The results of gel mobility shift assays using in vitro or in vivo formed heterodimers indicated that the TrfA protein binds to the iteron DNA as a monomer. Furthermore, when the monomeric and dimeric forms of TrfA are separated by gel filtration chromatography, only the protein in the chromatographic position of the monomeric form demonstrated significant DNA binding activity. These results indicate that only the monomer form of the TrfA protein is active for binding to the iterons at the RK2 replication origin.	UNIV CALIF SAN DIEGO,CTR GENET MOLEC,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI007194] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-07194] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arber W., 1983, LAMBDA, P433; BACKMAN K, 1978, CELL, V13, P65, DOI 10.1016/0092-8674(78)90138-1; BAILONE A, 1980, NUCLEIC ACIDS RES, V8, P2147, DOI 10.1093/nar/8.10.2147; BATTAGLIA PA, 1994, BIOCHEM BIOPH RES CO, V201, P701, DOI 10.1006/bbrc.1994.1757; BRENNER M, 1991, P NATL ACAD SCI USA, V88, P405, DOI 10.1073/pnas.88.2.405; BUNKER CA, 1995, NUCLEIC ACIDS RES, V23, P269, DOI 10.1093/nar/23.2.269; CEREGHINO JL, 1994, PLASMID, V31, P89, DOI 10.1006/plas.1994.1009; CEREGHINO JL, 1993, J BIOL CHEM, V268, P24926; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DASGUPTA S, 1993, J MOL BIOL, V232, P23, DOI 10.1006/jmbi.1993.1367; DURLAND RH, 1990, J BACTERIOL, V172, P3859, DOI 10.1128/jb.172.7.3859-3867.1990; DURLAND RH, 1990, J BACTERIOL, V172, P3849, DOI 10.1128/jb.172.7.3849-3858.1990; DURLAND RH, 1987, PLASMID, V18, P164, DOI 10.1016/0147-619X(87)90044-8; FANG FC, 1991, J BACTERIOL, V173, P5861, DOI 10.1128/jb.173.18.5861-5868.1991; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; HARLOW E, 1988, ANTIBODIES LAB MANUA, P561; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HAUGAN K, 1995, PLASMID, V33, P27, DOI 10.1006/plas.1995.1004; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; ISHIAI M, 1994, P NATL ACAD SCI USA, V91, P3839, DOI 10.1073/pnas.91.9.3839; KHYSEANDERSON J, 1984, J BIOCHEM BIOPH METH, V10, P203; KITTELL BL, 1991, P NATL ACAD SCI USA, V88, P1389, DOI 10.1073/pnas.88.4.1389; KORNACKI JA, 1984, PLASMID, V11, P48, DOI 10.1016/0147-619X(84)90006-4; LARSEN MH, 1994, J BACTERIOL, V176, P5022, DOI 10.1128/jb.176.16.5022-5032.1994; LIN J, 1992, J BACTERIOL, V174, P4110, DOI 10.1128/jb.174.12.4110-4119.1992; MANEN D, 1994, MOL MICROBIOL, V11, P875, DOI 10.1111/j.1365-2958.1994.tb00366.x; MANEN D, 1992, P NATL ACAD SCI USA, V89, P8923, DOI 10.1073/pnas.89.19.8923; MARCHETTI A, 1995, J MOL BIOL, V248, P541, DOI 10.1006/jmbi.1995.0241; MASSON L, 1988, NUCLEIC ACIDS RES, V16, P413, DOI 10.1093/nar/16.2.413; PABO CO, 1979, P NATL ACAD SCI USA, V76, P1608, DOI 10.1073/pnas.76.4.1608; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PANSEGRAU W, 1994, J MOL BIOL, V239, P623, DOI 10.1006/jmbi.1994.1404; PERRI S, 1991, J BIOL CHEM, V266, P12536; PERRI S, 1993, J BIOL CHEM, V268, P3662; PINKNEY M, 1988, J MOL BIOL, V203, P927, DOI 10.1016/0022-2836(88)90118-0; ROBERTS RC, 1990, J BACTERIOL, V172, P6204, DOI 10.1128/jb.172.11.6204-6216.1990; SAUER RT, 1979, NATURE, V279, P396, DOI 10.1038/279396a0; SCHMIDHAUSER TJ, 1985, J BACTERIOL, V164, P446, DOI 10.1128/JB.164.1.446-455.1985; SHINGLER V, 1984, J MOL BIOL, V175, P229, DOI 10.1016/0022-2836(84)90346-2; SHINGLER V, 1989, BIOCHIM BIOPHYS ACTA, V1007, P301, DOI 10.1016/0167-4781(89)90152-8; SMITH CA, 1984, J MOL BIOL, V175, P251, DOI 10.1016/0022-2836(84)90347-4; STALKER DM, 1981, MOL GEN GENET, V181, P8, DOI 10.1007/BF00338997; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; SUGIURA S, 1990, J BIOCHEM-TOKYO, V107, P369, DOI 10.1093/oxfordjournals.jbchem.a123052; SWACK JA, 1987, J BACTERIOL, V169, P3737, DOI 10.1128/jb.169.8.3737-3742.1987; THOMAS CM, 1981, MOL GEN GENET, V181, P1, DOI 10.1007/BF00338996; THOMAS CM, 1980, J BACTERIOL, V141, P231; Thomas CM, 1989, PROMISCUOUS PLASMIDS, P1; VALLA S, 1991, PLASMID, V25, P131, DOI 10.1016/0147-619X(91)90025-R; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903	50	35	36	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7072	7078		10.1074/jbc.271.12.7072	http://dx.doi.org/10.1074/jbc.271.12.7072			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636140	hybrid			2022-12-25	WOS:A1996UB15700075
J	Mozzarelli, A; Bettati, S; Rivetti, C; Rossi, GL; Colotti, G; Chiancone, E				Mozzarelli, A; Bettati, S; Rivetti, C; Rossi, GL; Colotti, G; Chiancone, E			Cooperative oxygen binding to Scapharca inaequivalvis hemoglobin in the crystal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGANDED T-STATE; STRUCTURAL TRANSITIONS; TETRAMERIC HEMOGLOBINS; DIMERIC HEMOGLOBIN; SINGLE-CRYSTALS	Oxygen binding to homodimeric Scapharca inaequivalvis hemoglobin (HbI) crystals has been investigated by single-crystal polarized absorption microspectrophotometry. The saturation curve, characterized by a Hill coefficient n(H) = 1.45 and an oxygen pressure at half saturation p(50) = 4.8 torr, at 15 degrees C, shows that HbI in the crystalline state retains positive cooperativity in ligand binding. This finding will permit the correlation of the oxygen-linked conformational changes in the crystal with the expression of cooperativity. Polarized absorption spectra of deoxy-HbI, oxy-HbI, and oxidized HbI crystals indicate that oxygenation does not induce heme reorientation, whereas oxidation does. Lattice interactions prevent the dissociation of oxidized dimers that occurs in solution and stabilize an equilibrium distribution of pentacoordinate and hexacoordinate high spin species.	UNIV ROMA LA SAPIENZA,DIPARTIMENTO SCI BIOCHIM A ROSSI FANELLI,CTR STUDIO BIOL MOLEC,I-00185 ROME,ITALY	Sapienza University Rome	Mozzarelli, A (corresponding author), UNIV PARMA,IST SCI BIOCHIM,I-43100 PARMA,ITALY.		Mozzarelli, Andrea/C-3615-2014; Colotti, Gianni/D-2015-2010; Bettati, Stefano/V-9975-2018; Colotti, Gianni/AAG-4918-2019	Mozzarelli, Andrea/0000-0003-3762-0062; Colotti, Gianni/0000-0002-9913-0635; Bettati, Stefano/0000-0001-6787-0594; Rivetti, Claudio/0000-0003-3775-6779				AHMED SA, 1987, BIOCHEMISTRY-US, V260, P5492; ANSARI A, 1993, BIOPHYS J, V64, P852, DOI 10.1016/S0006-3495(93)81446-2; BERNI R, 1977, J MOL BIOL, V110, P405, DOI 10.1016/S0022-2836(77)80079-X; BRZOZOWSKI A, 1984, NATURE, V307, P74, DOI 10.1038/307074a0; CHIANCONE E, 1981, J MOL BIOL, V152, P577, DOI 10.1016/0022-2836(81)90270-9; CONDON PJ, 1994, J BIOL CHEM, V269, P25259; DVORAK JA, 1971, EXP CELL RES, V68, P144, DOI 10.1016/0014-4827(71)90596-9; Eaton W A, 1981, Methods Enzymol, V76, P175; GOUAUX JE, 1989, P NATL ACAD SCI USA, V86, P845, DOI 10.1073/pnas.86.3.845; HAUROWITZ F, 1938, Z PHYSL CHEM, V234, P266; HOFRICHTER J, 1976, ANNU REV BIOPHYS BIO, V5, P511, DOI 10.1146/annurev.bb.05.060176.002455; IKEDASAITO M, 1983, J MOL BIOL, V170, P1009, DOI 10.1016/S0022-2836(83)80200-9; IWATA S, 1994, NAT STRUCT BIOL, V1, P176, DOI 10.1038/nsb0394-176; KASVINSKY PJ, 1976, J BIOL CHEM, V251, P6852; KAVANAUGH JS, 1995, J MOL BIOL, V248, P136, DOI 10.1006/jmbi.1995.0207; KIRSTEN H, 1983, P NATL ACAD SCI-BIOL, V80, P1807, DOI 10.1073/pnas.80.7.1807; LIDDINGTON R, 1992, J MOL BIOL, V228, P551, DOI 10.1016/0022-2836(92)90842-8; LIDDINGTON R, 1988, NATURE, V331, P725, DOI 10.1038/331725a0; MAKINEN MW, 1977, ANNU REV BIOPHYS BIO, V6, P301, DOI 10.1146/annurev.bb.06.060177.001505; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MOZZARELLI A, 1982, J BIOL CHEM, V257, P6739; MOZZARELLI A, 1989, J BIOL CHEM, V264, P15774; MOZZARELLI A, 1991, NATURE, V351, P416, DOI 10.1038/351416a0; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PERUTZ MF, 1953, ACTA CRYSTALLOGR, V6, P859, DOI 10.1107/S0365110X53002507; RIVETTI C, 1993, BIOCHEMISTRY-US, V32, P2888, DOI 10.1021/bi00062a021; RIVETTI C, 1993, BIOCHEMISTRY-US, V32, P6411, DOI 10.1021/bi00076a014; ROSSI GL, 1992, PHILOS T R SOC A, V340, P191, DOI 10.1098/rsta.1992.0060; ROSSI GL, 1992, CURR OPIN STRUC BIOL, V2, P816; ROYER WE, 1985, NATURE, V316, P277, DOI 10.1038/316277a0; ROYER WE, 1994, J MOL BIOL, V235, P657, DOI 10.1006/jmbi.1994.1019; ROYER WE, 1989, J BIOL CHEM, V264, P21052; ROYER WE, 1990, SCIENCE, V249, P518, DOI 10.1126/science.2382132; RUPLEY JA, 1969, STRUCTURE STABILITY, P291; SPAGNUOLO C, 1994, J BIOL CHEM, V269, P20441; VAS M, 1979, J BIOL CHEM, V254, P8480	36	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3627	3632						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631972				2022-12-25	WOS:A1996TV72400046
J	Tobin, D; Nilsson, M; Toftgard, R				Tobin, D; Nilsson, M; Toftgard, R			Ras-independent activation of Rel-family transcription factors by UVB and TPA in cultured keratinocytes	ONCOGENE			English	Article						ultraviolet radiation; NF kappa B; transcription factor; keratinocyte; rasGTPase	NF-KAPPA-B; HUMAN IMMUNODEFICIENCY VIRUS; PROTEIN-KINASE-C; VL30 TRANSCRIPTION; INDUCED EXPRESSION; TYROSINE KINASES; GENE-EXPRESSION; REQUIRES RAF-1; PHORBOL ESTER; PHOSPHORYLATION	UV irradiation of mammalian cells results in the activation of transcription factors which mediate induction of early response genes designed to repair and minimise the damage sustained by the cell. Evidence from studies in HeLa cells suggest that UVC regulates NF-kappa B activity via tyrosine kinases and activation of Ras and Raf kinase. In this study we have used a previously characterized TPA-responsive element (VLTRE) that binds Rel/NF-kappa B proteins and a Ras-responsive element (B10 RRE) to analyse the signalling pathway in UVB-stimulated gene transcription in cultured keratinocytes, We demonstrate that the tumour promoters TPA and WB use different signalling intermediates to activate different sets of Rel/NF-kappa B proteins. UVB transactivation is independent of PKC activity but dependent on tyrosine kinase activity whereas TPA stimulation requires PKC but not tyrosine kinase activity. Furthermore, neither UVB- nor TPA-transactivation is mediated through p21 Ras but both stimuli are dependent on a functional Raf protein. A constitutively active Raf-1 kinase however, was unable to induce transactivation through VLTRE. Thus, Raf has an essential but permissive role in UVB activation of Rel proteins. These findings demonstrate that keratinocytes contain a novel Ras-independent pathway for induction of Rel mediated transcription.	KAROLINSKA INST,NOVUM,CTR NUTR & TOXICOL,S-14157 HUDDINGE,SWEDEN	Karolinska Institutet	Tobin, D (corresponding author), KAROLINSKA INST,NOVUM,DEPT BIOSCI,S-14157 HUDDINGE,SWEDEN.							BOHM S, 1993, J BIOL CHEM, V268, P3952; BOHM S, 1991, J BIOL CHEM, V266, P24834; BRUDER JT, 1993, NUCLEIC ACIDS RES, V21, P5229, DOI 10.1093/nar/21.22.5229; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUSCHER M, 1988, ONCOGENE, V3, P301; CRESPO P, 1994, J BIOL CHEM, V269, P21103; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EICHER DM, 1994, J IMMUNOL, V152, P2710; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FINCO TS, 1993, J BIOL CHEM, V268, P17676; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; ISLAM TC, 1993, J BIOL CHEM, V268, P3251; KRUTMANN J, 1990, J INVEST DERMATOL, V95, P127, DOI 10.1111/1523-1747.ep12477839; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI CCH, 1994, BIOCHEM J, V303, P499, DOI 10.1042/bj3030499; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARQUARDT B, 1994, ONCOGENE, V9, P3213; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MILLER CC, 1994, J BIOL CHEM, V269, P3529; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NABEL G, 1990, NATURE, V344, P178, DOI 10.1038/344178b0; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; NEUMANN M, 1992, ONCOGENE, V7, P2095; NILSSON M, 1994, J VIROL, V68, P276, DOI 10.1128/JVI.68.1.276-288.1994; NILSSON M, 1995, J BIOL CHEM, V270, P12210, DOI 10.1074/jbc.270.20.12210; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Sambrook J, 1989, MOL CLONING LABORATO; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SIMON MM, 1994, J INVEST DERMATOL, V102, P422, DOI 10.1111/1523-1747.ep12372194; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STRUHL K, 1990, CURRENT PROTOCOLS S, V11; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; 1992, IARC MONOGRPAHS EVAL, V55	50	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					785	793						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632900				2022-12-25	WOS:A1996TW68600009
J	Heath, RJ; Rock, CO				Heath, RJ; Rock, CO			Inhibition of beta-ketoacyl-acyl carrier protein synthase III (FabH) by acyl-acyl carrier protein in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; COENZYME-A; INVIVO	beta-Ketoacyl-acyl carrier protein (ACP) synthase III (the fabH gene product) condenses acetyl-CoA with malonyl-ACP to initiate fatty acid biosynthesis in the dissociated, type II fatty acid synthase systems typified by Escherichia coli. The accumulation of malonyl-acyl carrier protein (ACP) following the inhibition of a reconstituted fatty acid synthase system by acyl-ACP implicated synthase III (FabH) as a target for acyl-ACP regulation (Heath, R. J., and Rock, C. O. (1996) J. Biol. Chem. 271, 1833-1836); therefore, the FabH protein was purified and its biochemical and regulatory properties examined. FabH exhibited a K-m of 40 mu M for acetyl-CoA and 5 mu M for malonyl-ACP. FabH also accepted other acyl-CoAs as primers with the rank order of activity being acetyl-CoA approximate to propionyl-CoA much greater than butyryl-CoA. FabH utilized neither hexanoyl-CoA nor octanoyl-CoA. Acyl-ACPs suppressed FabH activity, and their potency increased with increasing acyl chain length between 12 and 20 carbon atoms. Nonesterified ACP was not an inhibitor. Acyl-ACP inhibition kinetics were mixed with respect to acetyl-CoA, but were competitive with malonyl-ACP, indicating that acyl-ACPs decrease FabH activity by binding to either the free enzyme or the acyl-enzyme intermediate. These data support the concept that the inhibition of chain initiation at the beta-ketoacyl-ACP synthase III step contributes to the attenuation of fatty acid biosynthesis by acyl-ACP.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, CTR HLTH SCI, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center				Heath, Richard/0000-0002-1795-1254	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034496, R37GM034496] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM34496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS AW, 1972, J BIOL CHEM, V247, P3190; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHO HS, 1995, J BIOL CHEM, V270, P4216, DOI 10.1074/jbc.270.9.4216; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; DAGNOLO G, 1975, J BIOL CHEM, V250, P5283; DORMANN P, 1995, ARCH BIOCHEM BIOPHYS, V316, P612, DOI 10.1006/abbi.1995.1081; HEATH RJ, 1994, J BIOL CHEM, V269, P26584; Heath RJ, 1996, J BIOL CHEM, V271, P1833, DOI 10.1074/jbc.271.4.1833; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; HEATH RJ, 1995, J BIOL CHEM, V270, P15531, DOI 10.1074/jbc.270.26.15531; INGRAM LO, 1977, J BACTERIOL, V131, P1023, DOI 10.1128/JB.131.3.1023-1025.1977; JACKOWSKI S, 1984, J BACTERIOL, V158, P115, DOI 10.1128/JB.158.1.115-120.1984; JACKOWSKI S, 1986, J BACTERIOL, V166, P866, DOI 10.1128/jb.166.3.866-871.1986; JACKOWSKI S, 1981, J BACTERIOL, V148, P926, DOI 10.1128/JB.148.3.926-932.1981; JACKOWSKI S, 1989, J BIOL CHEM, V264, P7624; JACKOWSKI S, 1987, J BIOL CHEM, V262, P7927; JACKOWSKI S, 1994, J BIOL CHEM, V269, P2921; JIANG P, 1994, J BACTERIOL, V176, P2814, DOI 10.1128/JB.176.10.2814-2821.1994; MAGNUSON K, 1995, J BACTERIOL, V177, P3593, DOI 10.1128/jb.177.12.3593-3595.1995; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; Miller J.H., 1972, EXPT MOL GENETICS; OHLROGGE J, 1995, ARCH BIOCHEM BIOPHYS, V317, P185, DOI 10.1006/abbi.1995.1152; PETTY KJ, 1994, CURRENT PROTOCOLS MO; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; ROCK CO, 1979, J BIOL CHEM, V254, P7123; ROCK CO, 1982, J BIOL CHEM, V257, P10759; SIGGAARDANDERSEN M, 1994, P NATL ACAD SCI USA, V91, P11027, DOI 10.1073/pnas.91.23.11027; TSAY JT, 1992, J BIOL CHEM, V267, P6807; VALLARI DS, 1988, J BACTERIOL, V170, P3961, DOI 10.1128/jb.170.9.3961-3966.1988; VALLARI DS, 1987, J BIOL CHEM, V262, P2468; VOELKER TA, 1994, J BACTERIOL, V176, P7320, DOI 10.1128/JB.176.23.7320-7327.1994	31	182	214	2	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10996	11000		10.1074/jbc.271.18.10996	http://dx.doi.org/10.1074/jbc.271.18.10996			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631920	hybrid			2022-12-25	WOS:A1996UJ34200088
J	Kolla, V; Lindner, DJ; Weihua, X; Borden, EC; Kalvakolanu, DV				Kolla, V; Lindner, DJ; Weihua, X; Borden, EC; Kalvakolanu, DV			Modulation of interferon (IFN)-inducible gene expression by retinoic acid - Up-regulation of STAT1 protein in IFN-unresponsive cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; FACTOR-ALPHA; GAMMA	Interferons (IFN) and retinoids failed to inhibit the growth of a number of breast tumor cell lines, However, a combination of these two biological response modifiers significantly suppressed the cell growth at pharmacologically achievable doses. The molecular basis for such enhancement was investigated in MCF-7, a breast tumor cell line resistant to growth inhibition by IFN-beta. Pretrentment of cells with retinoic acid (RA) for 16 h followed by IFN-beta, but not the converse, induced cytotoxic effects in the cells. Continuous presence of RA was not necessary, although it enhanced the degree of cell death when present. Further analyses revealed that IFN-beta failed to activate IFN-stimulated gene transcription. However, IFN-beta strongly up-regulated the gene expression in RA-pretreated cells. Both IFN-beta- and IFN-gamma-inducible gene expression were enhanced via a modulation of the transcriptional factor IFN-stimulated gene factors-3 and GAF binding to respective cognate regulatory elements. STAT1 was undetectable in these cells prior to RA treatment: RA increased the levels of this crucial regulator, thereby restoring IFN responses. Thus, BA augmentation of STAT1 may be an early step in the cooperative anti-tumor effects of IFN and RA.	UNIV MARYLAND,SCH MED,CTR CANC,DEPT MICROBIOL & IMMUNOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,CTR CANC,DEPT MED,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,CTR CANC,DEPT PHARMACOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,CTR CANC,PROGRAM ONCOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,CTR CANC,MOLEC & CELLULAR BIOL PROGRAM,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore			Lindner, Daniel/ABB-5440-2020; Xiao, Weihua/N-2775-2013	Xiao, Weihua/0000-0001-9102-6326				ACKRILL AM, 1991, NUCLEIC ACIDS RES, V19, P4387, DOI 10.1093/nar/19.16.4387; AUGRET M, 1981, VIROLOGY, V114, P585; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BANDYOPADHYAY SK, 1995, J BIOL CHEM, V270, P19624, DOI 10.1074/jbc.270.33.19624; BOLLAG W, 1994, J CELL BIOCHEM, V56, P427, DOI 10.1002/jcb.240560402; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FONTANA JA, 1992, CANCER RES, V52, P3938; FOSTER GR, 1991, P NATL ACAD SCI USA, V88, P2888, DOI 10.1073/pnas.88.7.2888; GOLDSTEIN D, 1986, CANCER RES, V46, P4315; Gudas Lorraine J., 1994, P443; GUTCH MJ, 1991, P NATL ACAD SCI USA, V88, P7913, DOI 10.1073/pnas.88.18.7913; HIGUCHI T, 1991, CANCER RES, V51, P3958; HONG WK, 1994, RETINOIDS BIOL CHEM; Kalvakolanu DV, 1996, CANCER INVEST, V14, P25, DOI 10.3109/07357909609018435; KALVAKOLANU DVR, 1991, P NATL ACAD SCI USA, V88, P7459, DOI 10.1073/pnas.88.17.7459; KANDA K, 1992, MOL CELL BIOL, V12, P4930, DOI 10.1128/MCB.12.11.4930; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; Katze Michael G., 1995, Trends in Microbiology, V3, P75, DOI 10.1016/S0966-842X(00)88880-0; LIPPMAN SM, 1983, EUR J CANC A S5, V29, pS9; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; Mangelsdorf David J., 1994, P319; MARTH C, 1987, INT J CANCER, V40, P840, DOI 10.1002/ijc.2910400623; MARTH C, 1986, J NATL CANCER I, V77, P1197; MATIKAINEN S, 1995, J INTERFERON CYTOKIN, V15, pS216; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PETRICOIN E, 1994, MOL CELL BIOL, V14, P1477, DOI 10.1128/MCB.14.2.1477; SEN GC, 1993, ADV VIRUS RES, V42, P57, DOI 10.1016/S0065-3527(08)60083-4; SILVERMAN RH, 1994, J INTERFERON RES, V14, P101, DOI 10.1089/jir.1994.14.101; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; WAKELING AE, 1989, J STEROID BIOCHEM, V34, P183, DOI 10.1016/0022-4731(89)90081-2; WONG LH, 1995, J INTERFERON CYTOKIN, V15, pS172; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	35	104	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10508	10514		10.1074/jbc.271.18.10508	http://dx.doi.org/10.1074/jbc.271.18.10508			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631848	hybrid			2022-12-25	WOS:A1996UJ34200016
J	Peist, H; SchneiderFresenius, C; Boos, W				Peist, H; SchneiderFresenius, C; Boos, W			The MalT-dependent and malZ-encoded maltodextrin glucosidase of Escherichia coli can be converted into a dextrinyltransferase by a single mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHARACTERIZATION; CLONING VEHICLES; STRUCTURAL GENE; ALPHA-AMYLASE; IDENTIFICATION; SYSTEM; DNA; REGULON; AMYLOMALTASE; CONSTRUCTION	malZ is a member of the mat regulon, It is controlled by MalT, the transcriptional activator of the maltose system, MalZ has been purified and identified as an enzyme hydrolyzing maltotriose and longer maltodextrins to glucose and maltose, MalZ is dispensable for growth on maltose or maltodextrins, Mutants lacking amylomaltase (encoded by malQ), the major maltose utilizing enzyme, cannot grow on maltose, maltotriose, or maltotetraose, despite the fact that they contain an effective transport system and MalZ, From such a mole mutant a pseudorevertant was isolated that was able to grow on maltose, The suppressor mutation was mapped in malZ, The mutant gene was cloned: It contained a Trp to Cys exchange at position 292 of the deduced protein sequence. Surprisingly, the purified mutant enzyme was still unable to hydrolyze maltose as was the wild type enzyme, while both were able to release glucose from maltodextrins. However, the mutant enzyme had gained the ability to transfer dextrinyl moieties to glucose, maltose, and other maltodextrins. Thus, it had gained an activity associated with amylomaltase, It was the MalZ292 associated transferase reaction that allowed the utilization of maltose, In addition, we discovered that mutant and wild type enzymes alike were highly active as gamma-cyclodextrinases.	UNIV KONSTANZ,DEPT BIOL,D-78434 CONSTANCE,GERMANY	University of Konstanz								ADHYA S, 1971, J BACTERIOL, V108, P621, DOI 10.1128/JB.108.2.621-626.1971; BELEV TN, 1991, PLASMID, V26, P147, DOI 10.1016/0147-619X(91)90056-3; BENDER H, 1994, CARBOHYD RES, V260, P119, DOI 10.1016/0008-6215(94)80026-X; BENDER H, 1994, CARBOHYD RES, V263, P123, DOI 10.1016/0008-6215(94)00145-6; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BOOS W, 1996, REGULATION GENE EXPR; BOOS W, 1996, IN PRESS ESCHERICHIA; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DECKER K, 1993, J BACTERIOL, V175, P5655, DOI 10.1128/JB.175.17.5655-5665.1993; DESSEIN A, 1974, EUR J BIOCHEM, V45, P363, DOI 10.1111/j.1432-1033.1974.tb03561.x; EHRMANN M, 1987, J BACTERIOL, V169, P3539, DOI 10.1128/jb.169.8.3539-3545.1987; FREUNDLIEB S, 1988, J BIOL CHEM, V263, P314; FREUNDLIEB S, 1986, J BIOL CHEM, V261, P2946; GAREN A, 1960, BIOCHIM BIOPHYS ACTA, V38, P470, DOI 10.1016/0006-3002(60)91282-8; HATFIELD D, 1969, J BACTERIOL, V98, P559, DOI 10.1128/JB.98.2.559-567.1969; HENGGEARONIS R, 1992, MOL MICROBIOL, V6, P1877, DOI 10.1111/j.1365-2958.1992.tb01360.x; HOFNUNG M, 1971, J MOL BIOL, V61, P681, DOI 10.1016/0022-2836(71)90072-6; HOFNUNG M, 1976, MOL GEN GENET, V145, P207, DOI 10.1007/BF00269595; LU M, 1994, J BACTERIOL, V176, P5847, DOI 10.1128/JB.176.18.5847-5851.1994; LUCHT JM, 1992, J BACTERIOL, V174, P1709, DOI 10.1128/jb.174.5.1709-1710.1992; Miller J.H., 1972, EXPT MOL GENETICS; PALM D, 1985, NATURE, V313, P500, DOI 10.1038/313500a0; PALMER TN, 1976, EUR J BIOCHEM, V69, P105, DOI 10.1111/j.1432-1033.1976.tb10863.x; PODKOVYROV SM, 1992, J BACTERIOL, V174, P5400, DOI 10.1128/JB.174.16.5400-5405.1992; PUGSLEY AP, 1988, MOL MICROBIOL, V2, P473, DOI 10.1111/j.1365-2958.1988.tb00053.x; RAIBAUD O, 1989, J MOL BIOL, V205, P471, DOI 10.1016/0022-2836(89)90218-0; RAIBAUD O, 1987, J BACTERIOL, V169, P3059, DOI 10.1128/jb.169.7.3059-3061.1987; REYES M, 1986, J BACTERIOL, V165, P918, DOI 10.1128/jb.165.3.918-922.1986; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER E, 1992, J BIOL CHEM, V267, P5148; SCHWARTZ M, 1967, EUR J BIOCHEM, V2, P132, DOI 10.1111/j.1432-1033.1967.tb00117.x; SCHWARTZ M, 1987, ESCHERICHIA COLI SAL, V2, P1482; Silhavy T.J., 1984, EXPT GENE FUSIONS; SINGER M, 1989, MICROBIOL REV, V53, P1; TAPIO S, 1991, J BIOL CHEM, V266, P19450; WEICHART D, 1993, MOL MICROBIOL, V10, P407, DOI 10.1111/j.1365-2958.1993.tb02672.x; WIESMEYER H, 1960, BIOCHIM BIOPHYS ACTA, V39, P427, DOI 10.1016/0006-3002(60)90195-5; ZHANG H, 1988, NUCLEIC ACIDS RES, V16, P1220, DOI 10.1093/nar/16.3.1220	42	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10681	10689		10.1074/jbc.271.18.10681	http://dx.doi.org/10.1074/jbc.271.18.10681			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631875	hybrid			2022-12-25	WOS:A1996UJ34200043
J	Straus, DB; Chan, AC; Patai, B; Weiss, A				Straus, DB; Chan, AC; Patai, B; Weiss, A			SH2 domain function is essential for the role of the Lck tyrosine kinase in T cell receptor signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; ZETA-CHAIN; PHOSPHOLIPASE C-GAMMA-1; THYMOCYTE DEVELOPMENT; MICE LACKING; P56LCK; ACTIVATION; PHOSPHORYLATION; ZAP-70; LINE	Tyrosine kinase activity is required for signal transduction through the T cell antigen receptor (TCR), The Src family tyrosine kinase Lck appears to play a key role in the initiation of TCR signaling events. We have investigated the role of the phosphotyrosine-binding Src homology-2 (SH2), domain of Lck in TCR signaling. Lck containing a mutation in the phosphotyrosine binding pocket of the SH2 domain was expressed in an Lck-deficient cell line, We found that, in contrast to wild-type Lck, the SH2 domain mutant was unable to restore even the earliest TCR-mediated signaling events, To investigate the role of the Lck SH2 domain, we examined the association of tyrosine phosphoproteins with Lck, The predominant associated phosphoprotein was the ZAP-70 tyrosine kinase, which has also been implicated in the initiation of TCR signaling, In addition, the zeta subunit of the T cell receptor was found to weakly associate with Lck. Further analysis indicated that the SH2 domain of Lck can directly recognize both ZAP-70 and zeta in immunoprecipitates from TCR-stimulated cells. Our findings demonstrate that the SH2 domain of Lck is essential for the initiation of signaling events following TCR stimulation probably as a result of-its ability to mediate an interaction between Lck and the ZAP-70 tyrosine kinase and/or the zeta subunit of the T cell receptor.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT MED, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco	Straus, DB (corresponding author), UNIV CHICAGO, DEPT MED, 5841 S MARYLAND AVE, MC6084, CHICAGO, IL 60637 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039553] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39553] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BU JY, 1995, P NATL ACAD SCI USA, V92, P5106, DOI 10.1073/pnas.92.11.5106; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DANIELIAN S, 1989, EUR J IMMUNOL, V19, P2183, DOI 10.1002/eji.1830191202; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; LUO KX, 1992, MOL CELL BIOL, V12, P4724, DOI 10.1128/MCB.12.10.4724; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; SALCEDO TW, 1993, J EXP MED, V177, P1475, DOI 10.1084/jem.177.5.1475; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SEFTON BM, 1994, CURR OPIN IMMUNOL, V6, P372, DOI 10.1016/0952-7915(94)90115-5; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; VEILLETTE A, 1992, ONCOGENE, V7, P971; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	48	91	91	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9976	9981		10.1074/jbc.271.17.9976	http://dx.doi.org/10.1074/jbc.271.17.9976			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626636	hybrid			2022-12-25	WOS:A1996UG25700020
J	Bird, GSJ; Putney, JW				Bird, GSJ; Putney, JW			Effect of inositol 1,3,4,5-tetrakisphosphate on inositol trisphosphate-activated Ca2+ signaling in mouse lacrimal acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER; ENTRY; CA-2+	In mouse lacrimal acinar cells, microinjection of the metabolically stable analog of inositol 1,4,5-trisphosphate, inositol 2,4,5-trisphosphate ((2,4,5)IP3), stimulated both intracellular Ca2+ mobilization and Ca2+ entry. Microinjection of inositol 1,3,4,5-tetrakisphosphate ((1,3,4,5)IP4), the inositol 1,4,5-trisphosphate-3-kinase product, was ineffective at mobilizing intracellular Ca2+ or activating Ca2+ entry. In lacrimal cells previously microinjected with submaximal levels of (2,4,5)IP3, the subsequent microinjection of low to moderate concentrations of (1,3,4,5)IP4 did not result in additional release of intracellular Ca2+, nor did it potentiate the Ca2+ entry phase attributable to (2,4,5)IP3. However, as previously demonstrated (Bird, G. S. J., Rossier, M. F., Hughes, A. R., Shears, S. B., Armstrong, D. L., and Putney, J. W., Jr. (1991) Nature 352, 162-165), additional injections of (2,4,5)IP3 induced further mobilization of intracellular Ca2+ and increased the elevated and sustained Ca2+ entry phase. Introduction of high concentrations of (1,3,4,5)IP4 appeared to inhibit or block the (2,4,5)IP3-induced Ca2+ entry phase. These results were consistent with the observed effect of (1,3,4,5)IP4 in permeabilized lacrimal cells, where (1,3,4,5)IP4 did not release cellular Ca-45(2+) but at high concentrations inhibited the ability of submaximal concentrations of (2,4,5)IP3 to release Ca-45(2+). Likewise, injection of a high concentration of (1,3,4,5)IP4 prior to injection of (2,4,5)IP3 blocked both release and influx of Ca2+. The inhibitory action of (1,3,4,5)IP4 on Ca2+ signaling observed in intact cells occurred at concentrations that might be obtained in agonist-stimulated cells. However, in permeabilized cells, (1,3,4,5)IP4 inhibited Ca2+ mobilization at concentrations exceeding those likely to occur in agonist-stimulated cells. These results suggest that physiologically relevant levels of (1,3,4,5)IP4, in the cell cytoplasm do not release Ca2+, nor do they potentiate inositol trisphosphate-induced Ca2+ entry across the plasma membrane. Rather, the possibility is raised that (1,3,4,5)IP4 or one of its metabolites could function as a negative feedback on Ca2+ mobilization by inhibiting inositol 1,4,5-trisphosphate-induced Ca2+ release.			Bird, GSJ (corresponding author), NIEHS, CELLULAR & MOLEC PHARMACOL LAB, CALCIUM REGULAT SECT, NIH, POB 12233, RES TRIANGLE PK, NC 27709 USA.		Bird, Gary/AAI-8186-2021; Putney, James W/F-7247-2019	Bird, Gary/0000-0003-1389-8748; Putney, James W/0000-0002-3379-4789				AGRANOFF BW, 1985, INOSITOL PHOSPHOINOS, pR21; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BIRD GS, 1992, J BIOL CHEM, V267, P18382; BURGESS GM, 1983, J BIOL CHEM, V258, P5336; CHANGYA L, 1989, FEBS LETT, V251, P43, DOI 10.1016/0014-5793(89)81425-5; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; HUGHES AR, 1989, J BIOL CHEM, V264, P9400; IRVINE RF, 1992, FASEB J, V6, P3085, DOI 10.1096/fasebj.6.12.1325932; IRVINE RF, 1991, NATURE, V352, P115, DOI 10.1038/352115a0; IRVINE RF, 1993, CURR BIOL, V3, P540, DOI 10.1016/0960-9822(93)90052-P; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LU CY, 1989, J MEMBRANE BIOL, V109, P85, DOI 10.1007/BF01870793; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PAROD RJ, 1980, AM J PHYSIOL, V239, pG99, DOI 10.1152/ajpgi.1980.239.2.G99; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Shears Stephen B., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P63; SMITH PM, 1992, BIOCHEM J, V283, P27, DOI 10.1042/bj2830027; TOESCU EC, 1994, PFLUG ARCH EUR J PHY, V427, P325, DOI 10.1007/BF00374541; WILCOX RA, 1993, MOL PHARMACOL, V44, P810; WILCOX RA, 1994, SIGNAL ACTIVATED PHO, P190	24	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6766	6770		10.1074/jbc.271.12.6766	http://dx.doi.org/10.1074/jbc.271.12.6766			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636098	hybrid			2022-12-25	WOS:A1996UB15700033
J	Dunphy, JT; Greentree, WK; Manahan, CL; Linder, ME				Dunphy, JT; Greentree, WK; Manahan, CL; Linder, ME			G-protein palmitoyltransferase activity is enriched in plasma membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; BETA-GAMMA; AMINO TERMINUS; PALMITOYLATION; RECEPTOR; AFFINITY	Heterotrimeric G proteins are covalently modified by lipids. Myristoylation of G-protein alpha subunits and prenylation of gamma subunits are stable modifications. In contrast, palmitoylation of a subunits is dynamic and thus has the potential for regulating protein function. Indeed, receptor activation of G(s) increases palmitate turnover on the alpha subunit, presumably by stimulating deacylation. The enzymes that catalyze reversible palmitoylation of G-protein alpha subunits have not been characterized. Here we report the identification of a palmitoyl-CoA:protein S-palmitoyltransferase activity that acylates G-protein alpha subunits in vitro. Palmitoyltransferase activity is membrane-associated and requires detergent for solubilization. The preferred G-protein substrate for the enzyme activity is the alpha subunit in the context of the heterotrimer. Both myristoylated and nonmyristoylated G-protein a subunits are recognized as substrates. The palmitoyltransferase activity demonstrates a modest preference for palmitoyl-Coa over other fatty acyl-CoA substrates. Palmitoyltransferase activity is high in plasma membrane and present at low or undetectable levels in Golgi, endoplasmic reticulum, and mitochondria of rat liver. The subcellular localization of this enzyme activity is consistent with a role for regulated cycles of acylation and deacylation accompanying activation of G-protein signal transduction pathways.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)			Linder, Maurine/AAU-9999-2021	Linder, Maurine/0000-0003-2202-9712	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007067] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32GM07067, GM50556] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aronson N N Jr, 1974, Methods Enzymol, V31, P90; BERTHIAUME L, 1994, J BIOL CHEM, V269, P6498; BERTHIAUME L, 1995, J BIOL CHEM, V270, P22399, DOI 10.1074/jbc.270.38.22399; BIZZOZERO OA, 1987, J BIOL CHEM, V262, P13550; BLANCO G, 1995, BIOCHEMISTRY-US, V34, P9897, DOI 10.1021/bi00031a011; BROWN RE, 1989, ANAL BIOCHEM, V180, P136, DOI 10.1016/0003-2697(89)90101-2; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; Fleischer S, 1974, Methods Enzymol, V31, P6; GUITIERREZ L, 1991, BIOCHIM BIOPHYS ACTA, V1078, P147; HALLAK H, 1994, J BIOL CHEM, V269, P4571; HALLAK H, 1994, J BIOL CHEM, V269, P7413; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; NAVON S, 1987, J BIOL CHEM, V262, P15476; NEER EJ, 1988, J BIOL CHEM, V263, P8996; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; OBRIEN PJ, 1987, J BIOL CHEM, V262, P5210; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PARENTI M, 1993, BIOCHEM J, V291, P349, DOI 10.1042/bj2910349; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; PENNINGTON R, 1961, BIOCHEM J, V80, P649, DOI 10.1042/bj0800649; ROBISHAW JD, 1986, J BIOL CHEM, V261, P9587; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESINGER MJ, 1993, LIPID MODIFICATIONS, P2; SCHMIDT MFG, 1989, BIOCHEM SOC T, V17, P625, DOI 10.1042/bst0170625; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; STERNWEIS PC, 1979, J BIOL CHEM, V254, P3333; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; TAYLOR DC, 1990, ANAL BIOCHEM, V184, P311, DOI 10.1016/0003-2697(90)90686-4; UEDA N, 1994, J BIOL CHEM, V269, P4388; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6	44	151	152	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7154	7159		10.1074/jbc.271.12.7154	http://dx.doi.org/10.1074/jbc.271.12.7154			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636152	hybrid			2022-12-25	WOS:A1996UB15700087
J	Wang, XY; Dumont, ME; Sherman, F				Wang, XY; Dumont, ME; Sherman, F			Sequence requirements for mitochondrial import of yeast cytochrome c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN APOCYTOCHROME-C; SACCHAROMYCES-CEREVISIAE; HEME LYASE; NEUROSPORA-CRASSA; MODEL MEMBRANES; ISO-1-CYTOCHROME-C; GENE; APOISO-1-CYTOCHROME-C; TRANSLOCATION; MUTAGENESIS	Apocytochrome c is synthesized in the cytoplasm, transported to the mitochondrial intermembrane space, and subsequently covalently attached to heme in a reaction catalyzed by the enzyme cytochrome c heme lyase. We have investigated the amino acid sequences in cytochrome c which are required for mitochondrial import, using a systematic: series of site-directed alterations of the CYC7-H3 gene which encodes iso-2-cytochrome c in the yeast Saccharomyces cerevisiae. Import of the altered apocytochromes c was assayed in yeast strains that overexpressed cytochrome c heme lyase. Under these conditions, there was efficient mitochondrial accumulation of forms of apocytochrome c which are incapable of having heme covalently attached. In fact, all apocytochromes c containing deletions located to the carboxyl-terminal side of His(27) efficiently accumulated in the mitochondria of strains overexpressing heme lyase, even though all but one of these deletion-containing proteins were incapable of heme attachment. A minimum length of polypeptide chain at the extreme amino terminus of cytochrome c, rather than any specific sequence element in this region, appears to be required for efficient mitochondrial import. Certain amino acid substitutions in the region extending from Gly(15) to Leu(18), at residue Phe(19) and at residue His(27), lead to reduced mitochondrial import of apocytochrome c, resulting from stalling of the altered apocytochrome c in partially imported states.	UNIV ROCHESTER, SCH MED & DENT, DEPT BIOCHEM, ROCHESTER, NY 14642 USA	University of Rochester					NIGMS NIH HHS [GM12702] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AULD DS, 1991, BIOCHEMISTRY-US, V30, P8684, DOI 10.1021/bi00099a028; BABUL J, 1972, BIOCHEMISTRY-US, V11, P1195, DOI 10.1021/bi00757a013; BAIM SB, 1985, MOL CELL BIOL, V5, P1839, DOI 10.1128/MCB.5.8.1839; DAS G, 1989, P NATL ACAD SCI USA, V86, P496, DOI 10.1073/pnas.86.2.496; DAUM G, 1982, J BIOL CHEM, V257, P3028; DOWNIE JA, 1977, J MOL BIOL, V113, P369, DOI 10.1016/0022-2836(77)90147-4; DUMONT MD, 1990, J BIOL CHEM, V265, P2733; DUMONT ME, 1991, MOL CELL BIOL, V11, P5487, DOI 10.1128/MCB.11.11.5487; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; DUMONT ME, 1993, MOL CELL BIOL, V13, P6442, DOI 10.1128/MCB.13.10.6442; DUMONT ME, 1988, J BIOL CHEM, V263, P15928; DUMONT ME, 1996, IN PRESS ADV MOL CEL, V43; FETROW JS, 1989, PROTEINS, V6, P372, DOI 10.1002/prot.340060404; FISHER WR, 1973, J BIOL CHEM, V248, P3188; HACHIYA N, 1994, EMBO J, V13, P5146, DOI 10.1002/j.1460-2075.1994.tb06844.x; HAKVOORT TBM, 1990, P NATL ACAD SCI USA, V87, P4996, DOI 10.1073/pnas.87.13.4996; HAMPSEY DM, 1988, FEBS LETT, V231, P275, DOI 10.1016/0014-5793(88)80834-2; Hannavy K, 1993, CURR OPIN CELL BIOL, V5, P694, DOI 10.1016/0955-0674(93)90142-D; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HENNIG B, 1981, EUR J BIOCHEM, V121, P203, DOI 10.1111/j.1432-1033.1981.tb06450.x; HICKEY DR, 1991, GENE, V105, P73, DOI 10.1016/0378-1119(91)90515-D; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JORDI W, 1989, BIOCHEMISTRY-US, V28, P8998, DOI 10.1021/bi00449a007; JORDI W, 1989, J BIOL CHEM, V264, P2292; KIEBLER M, 1993, J MEMBRANE BIOL, V135, P191; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Maniatis T, 1989, MOL CLONING; MATSUURA S, 1981, P NATL ACAD SCI-BIOL, V78, P4368, DOI 10.1073/pnas.78.7.4368; MATSUURA Y, 1982, J MOL BIOL, V156, P389, DOI 10.1016/0022-2836(82)90335-7; MAYER A, 1995, J BIOL CHEM, V270, P12390, DOI 10.1074/jbc.270.21.12390; MCKIMMBRESCHKIN JL, 1990, J IMMUNOL METHODS, V135, P277, DOI 10.1016/0022-1759(90)90282-Z; MCKNIGHT GL, 1981, CELL, V25, P409, DOI 10.1016/0092-8674(81)90059-3; MELNICK L, 1993, J MOL BIOL, V233, P372, DOI 10.1006/jmbi.1993.1518; MOORE GR, 1990, CYTOCHROMES C EVOLUT, P116; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; NARGANG FE, 1988, J BIOL CHEM, V263, P9388; NYE SH, 1990, MOL CELL BIOL, V10, P5763, DOI 10.1128/MCB.10.11.5763; NYE SH, 1990, MOL CELL BIOL, V10, P5753, DOI 10.1128/MCB.10.11.5753; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Scharf SJ, 1990, PCR PROTOCOLS GUIDE, P84; SHERMAN F, 1966, P NATL ACAD SCI USA, V55, P1498, DOI 10.1073/pnas.55.6.1498; SHERMAN F, 1965, J MOL BIOL, V13, P21, DOI 10.1016/S0022-2836(65)80077-8; SHERMAN F, 1975, GENETICS, V81, P51; SHERMAN F, 1974, GENETICS, V77, P255; SHERMAN F, 1973, BIOCH GENE EXPRESSIO, P56; SHERMAN F, 1987, METHODS YEAST GENETI; SPRINKLE JR, 1990, P NATL ACAD SCI USA, V87, P5729, DOI 10.1073/pnas.87.15.5729; STUART RA, 1987, EMBO J, V6, P2131, DOI 10.1002/j.1460-2075.1987.tb02480.x; STUART RA, 1990, BIOCHIMIE, V72, P115, DOI 10.1016/0300-9084(90)90136-5; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; VELOSO D, 1984, J BIOL CHEM, V259, P6067; ZHOU LX, 1988, BIOCHIM BIOPHYS ACTA, V942, P115	54	31	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6594	6604		10.1074/jbc.271.12.6594	http://dx.doi.org/10.1074/jbc.271.12.6594			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636074	hybrid			2022-12-25	WOS:A1996UB15700009
J	Morii, M; Hayata, Y; Mizoguchi, K; Takeguchi, N				Morii, M; Hayata, Y; Mizoguchi, K; Takeguchi, N			Oligomeric regulation of gastric H+,K+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATPASE ACTIVITY; H,K-ATPASE; BINDING; PHOSPHOENZYME; CONDUCTANCE; OMEPRAZOLE; INHIBITORS; SCH-28080; E3810; SITE	The H+,K+-ATPase of intact gastric vesicles has two K-m values for ATP hydrolysis, 7 and 80 mu M. Irradiation of vesicles with ultraviolet light in the presence of 1 mM ATP resulted in K+-ATPase activity that shows only the low affinity ATP binding, The irradiation stimulated or inhibited proton uptake rate compared with control vesicles at high or low ATP concentrations, respectively, The relation between proton uptake rate and K+-ATPase activity at different ATP concentrations was linear with irradiated vesicles and nonlinear with control vesicles. These results indicate that hydrolysis at the high affinity ATP binding site regulates the energy transport coupling in negative and positive manners at high and low ATP concentrations, respectively. The complete inhibition of K+-ATPase by a specific proton pump inhibitor E3810 (rabeprazole) (2-{[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl}-1H-benzimidazole sodium salt) occurred when E3810 bound to half of the alpha-subunit of H+,K+-ATPase in unirradiated vesicles at both 200 and 10 mu M ATP, whereas the complete inhibition of proton uptake occurred when E3810 bound to half or a quarter of the alpha-subunit at 200 or 10 mu M ATP, respectively, These results suggest that dimeric interaction between the alpha-subunits is necessary for the enzyme activity at all ATP concentrations and that dimeric or tetrameric interaction is necessary for proton transport at high or low ATP concentrations, respectively.			Morii, M (corresponding author), TOYAMA MED & PHARMACEUT UNIV,FAC PHARMACEUT SCI,2630 SUGITANI,TOYAMA 93001,JAPAN.							ADAM H, 1961, BIOCHEM Z, V335, P25; ASANO S, 1992, J BIOL CHEM, V267, P6590; ASKARI A, 1982, BIOCHEM BIOPH RES CO, V104, P1447, DOI 10.1016/0006-291X(82)91412-7; BLANCO G, 1994, P NATL ACAD SCI USA, V91, P8542, DOI 10.1073/pnas.91.18.8542; CHOW DC, 1992, AM J PHYSIOL, V263, pC39, DOI 10.1152/ajpcell.1992.263.1.C39; FALLER LD, 1991, BIOCHEMISTRY-US, V30, P3503, DOI 10.1021/bi00228a022; GANSER AL, 1973, BIOCHIM BIOPHYS ACTA, V307, P169, DOI 10.1016/0005-2736(73)90035-7; HEBERT H, 1992, FEBS LETT, V299, P159, DOI 10.1016/0014-5793(92)80237-B; HELMICHDEJONG ML, 1986, BIOCHIM BIOPHYS ACTA, V860, P641, DOI 10.1016/0005-2736(86)90564-X; KEELING DJ, 1988, BIOCHEM PHARMACOL, V37, P2231, DOI 10.1016/0006-2952(88)90586-2; KOSTER JC, 1995, J BIOL CHEM, V270, P14332, DOI 10.1074/jbc.270.24.14332; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORII M, 1993, J BIOL CHEM, V268, P21553; MORII M, 1990, BIOCHEM PHARMACOL, V39, P661, DOI 10.1016/0006-2952(90)90143-9; OLIVER IT, 1955, BIOCHEM J, V61, P116, DOI 10.1042/bj0610116; RABON E, 1986, J BIOL CHEM, V261, P1434; RABON EC, 1990, J BIOL CHEM, V265, P19594; SCHARSCHMIDT BF, 1979, J LAB CLIN MED, V93, P790; SHULL GE, 1986, J BIOL CHEM, V261, P6788; TAKEGUCHI N, 1983, J BIOL CHEM, V258, P3094; TAKEGUCHI N, 1986, J BIOL CHEM, V261, P2560; WALLMARK B, 1980, J BIOL CHEM, V255, P5313; WALLMARK B, 1979, J BIOL CHEM, V254, P1899; WALLMARK B, 1987, J BIOL CHEM, V262, P2077; WARD DG, 1993, P NATL ACAD SCI USA, V90, P5332, DOI 10.1073/pnas.90.11.5332; YODA A, 1970, BIOCHEM BIOPH RES CO, V40, P880, DOI 10.1016/0006-291X(70)90985-X; ZOLOTARJOVA N, 1995, J BIOL CHEM, V270, P3989, DOI 10.1074/jbc.270.8.3989	28	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4068	4072						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626741				2022-12-25	WOS:A1996TW96000019
J	Desrosiers, MG; Gately, LJ; Gambel, AM; Menick, DR				Desrosiers, MG; Gately, LJ; Gambel, AM; Menick, DR			Purification and characterization of the Ca2+-ATPase of Flavobacterium odoratum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLOCATING KDP-ATPASE; SARCOPLASMIC-RETICULUM; CALCIUM-TRANSPORT; MEMBRANE-VESICLES; STREPTOCOCCUS-FAECALIS; ESCHERICHIA-COLI; RECONSTITUTION; CA-2+-ATPASE; HYDROLYSIS; CALMODULIN	The P-type Ca2+-ATPase from Flavobacterium odoratum has been purified to homogeneity and characterized. Inside-out membrane vesicles were extracted with C(12)E(8), followed by ammonium sulfate fractionation, centrifugation through two successive 32-48% glycerol gradients, and DE52 ion exchange chromatography. The purified Ca2+-ATPase consists of a single polypeptide. It migrates electrophoretically with an apparent molecular mass of 60,000 Da, consistent with the phosphorylation pattern originally reported in membrane vesicles. This single polypeptide is functional and capable of calcium-dependent vanadate-sensitive ATP hydrolysis and of forward and reverse phosphorylation. Maximum hydrolysis activity occurs at pH 8.0, with a specific activity of similar to 75 mu mol of ATP hydrolyzed min(-1) mg(-1) protein. The purified Ca2+-ATPase has an apparent K-m for calcium of 1.5 mu M and for ATP of 90 mu M. Vanadate strongly inhibits the activity with an IC50 of 0.6 mu M. The prokaryotic Ca2+-ATPase is insensitive to the SR Ca2+-ATPase inhibitors fluorescein isothiocyanate, thapsigargin, and cyclopiazonic acid. It is rapidly phosphorylated by [gamma-P-32]ATP in a calcium-dependent vanadate-inhibited manner and can be phosphorylated by P-i in both the presence and absence of calcium.	MED UNIV S CAROLINA, DIV CARDIOL, DEPT MED, CHARLESTON, SC 29425 USA; MED UNIV S CAROLINA, DEPT BIOCHEM & MOLEC BIOL, CHARLESTON, SC 29425 USA; MED UNIV S CAROLINA, GAZES CARDIAC RES INST, CHARLESTON, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina					PHS HHS [R01 44202] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMBUDKAR SV, 1986, J BIOL CHEM, V261, P5596; BERKELMAN T, 1994, J BACTERIOL, V176, P4430, DOI 10.1128/jb.176.14.4430-4436.1994; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARONI P, 1981, J BIOL CHEM, V256, P3263; DEES SB, 1986, J CLIN MICROBIOL, V23, P267, DOI 10.1128/JCM.23.2.267-273.1986; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GAMBEL AM, 1992, J BIOL CHEM, V267, P15923; GAMBEL AM, 1993, J BIOL CHEM, V268, P20590; HOUNG HS, 1986, J BACTERIOL, V168, P1040, DOI 10.1128/jb.168.2.1040-1044.1986; HUGENTOBLER G, 1983, J BIOL CHEM, V258, P7611; KOBAYASHI H, 1978, J BIOL CHEM, V253, P2085; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOCKAU W, 1983, BIOCH BOPHYS ACTA, V773, P124; Lynn A.R., 1987, ION TRANSPORT PROKAR, P181; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MARTIN RB, 1979, Q REV BIOPHYS, V12, P181, DOI 10.1017/S0033583500002754; MENICK DR, 1992, ANN NY ACAD SCI, V671, P427, DOI 10.1111/j.1749-6632.1992.tb43819.x; MOLLER JV, 1980, J BIOL CHEM, V255, P1912; NELSON N, 1980, METHOD ENZYMOL, V69, P301; NIGGLI V, 1981, J BIOL CHEM, V256, P395; PANET R, 1971, J BIOL CHEM, V246, P7349; PICK U, 1980, BIOCHIM BIOPHYS ACTA, V626, P255, DOI 10.1016/0005-2795(80)90216-0; ROSEN BP, 1987, BIOCHIM BIOPHYS ACTA, V906, P101, DOI 10.1016/0304-4157(87)90007-4; ROSSI B, 1979, J BIOL CHEM, V254, P2302; SARKADI B, 1986, J BIOL CHEM, V261, P9552; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; SIEBERS A, 1988, EUR J BIOCHEM, V178, P131, DOI 10.1111/j.1432-1033.1988.tb14438.x; SIEBERS A, 1992, J BIOL CHEM, V267, P12717; SIEBERS A, 1988, METHOD ENZYMOL, V157, P668; Silhavy T.J., 1984, EXPT GENE FUSIONS; TRUMBLE WR, 1981, J BIOL CHEM, V256, P7101; VIANNA AL, 1975, BIOCHIM BIOPHYS ACTA, V410, P389, DOI 10.1016/0005-2744(75)90241-7; YU X, 1994, J BIOL CHEM, V269, P16656	34	17	18	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3945	3951						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632017				2022-12-25	WOS:A1996TV72400091
J	KonKozlowski, M; Pani, G; Pawson, T; Siminovitch, KA				KonKozlowski, M; Pani, G; Pawson, T; Siminovitch, KA			The tyrosine phosphatase PTP1C associates with Vav, Grb2, and mSos1 in hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTH-EATEN MICE; PROTOONCOGENE PRODUCT; SH2 DOMAIN; SACCHAROMYCES-CEREVISIAE; EXCHANGE FACTOR; PROTEIN; RECEPTOR; GENE; PHOSPHORYLATION; EXPRESSION	The association of the murine motheaten phenotype of severe hemopoietic dysregulation with loss of PTP1C tyrosine phosphatase activity indicates a critical role for this SH2 domain-containing phosphotyrosine phosphatase in the regulation of hemopoietic cell growth and differentiation. To explore the molecular basis for PTP1C effects on hematopoiesis, we have investigated the possibility that this enzyme interacts with the product of the Vav proto-oncogene, a putative guanine nucleotide exchange factor expressed exclusively in hemopoietic cells. Our data indicate that PTP1C physically associates with Vav in murine spleen cells and in EL4 T lymphoma and P815 mastocytoma cells, and that this interaction is increased following mitogenic stimulation and the induction of both PTP1C and Vav tyrosine phosphorylation. The results also reveal tyrosine phosphatase activity to be present in Vav immunoprecipitates from stimulated splenic and P815 cells and suggest that a major portion of total cellular PTP1C catalytic activity is associated with Vav. As Vav-associated tyrosine phosphatase activity was not detected in PTP1C deficient motheaten splenic cells, it appears that PTP1C accounts for most, if not all, Vav coprecipitable tyrosine phosphatase activity in normal cells. The data also demonstrate the capacity of the Vav SH2 domain alone to bind to PTP1C in activated P815 cells, but suggest a role for the two Vav SH3 domains in enhancing this interaction. In addition, the results reveal PTP1C association with two other molecules implicated in Ras activation, the Grb2 adaptor protein and mSos1, a GTP/GDP exchanger for Ras. PTP1C therefore has the capacity to bind and potentially modulate various signaling effecters involved in activation of Ras or Ras-related proteins, and, accordingly, regulation of Ras activation represents a possible mechanism whereby PTP1C influences hemopoietic cellular responses.	UNIV TORONTO, DEPT MED, TORONTO, ON, CANADA; UNIV TORONTO, DEPT IMMUNOL, TORONTO, ON, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO, ON, CANADA; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO, ON M5G 1X5, CANADA	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	KonKozlowski, M (corresponding author), DEPT HLTH & WELF, BUR DRUG RES, DIV LIFE SCI, TUNNEYS PASTURE, OTTAWA, ON K1A 0L2, CANADA.		Pawson, Tony J/E-4578-2013; Pani, Giovambattista/AAB-1446-2019; Siminovitch, Katherine/K-1475-2013	Pani, Giovambattista/0000-0001-7133-8728				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; BIGNON JS, 1994, CLIN IMMUNOL IMMUNOP, V73, P168, DOI 10.1006/clin.1994.1185; BOUCHARD P, 1994, J BIOL CHEM, V269, P19585; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GALLAND F, 1992, ONCOGENE, V7, P585; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, J IMMUNOL, V152, P2123; HARDER KW, 1994, BIOCHEM J, V298, P395, DOI 10.1042/bj2980395; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KIENER PA, 1993, J BIOL CHEM, V268, P24442; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; OKADA M, 1993, J BIOL CHEM, V268, P18070; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; UCHIDA T, 1993, J BIOL CHEM, V268, P11845; WULF GM, 1993, EMBO J, V12, P5065, DOI 10.1002/j.1460-2075.1993.tb06200.x; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	50	108	109	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3856	3862						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632004				2022-12-25	WOS:A1996TV72400078
J	Davis, BH; Chen, AP; Beno, DWA				Davis, BH; Chen, AP; Beno, DWA			Raf and mitogen-activated protein kinase regulate stellate cell collagen gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; RETINOIC ACID; PROMOTER	Hepatic stellate cells become activated into myofibroblast-like cells during the early stages of hepatic injury associated with fibrogenesis. The subsequent dysregulation of hepatic stellate cell collagen gene expression is a central pathogenetic step during the development of cirrhosis. The cytoplasmic Raf and mitogen-activated protein (MAPK) kinases were found to differentially regulate alpha I(I) collagen gene expression in activated stellate cells. This suggests an unappreciated branch point exists between Raf and MAPK. A MAPK-stimulatory signal was mapped to the most proximal NF-1 and Sp-1 binding domains of the 5'-untranslated region of the collagen gene. A Raf-inhibitory signal was mapped to a further upstream binding domain involving a novel 60-kDa DNA-binding protein (p60). The cell-specific expression and induction of p60 in stellate cells during the early stages of hepatic fibrogenesis in vivo suggest a central role for this pathway during liver injury and stellate cell activation.			Davis, BH (corresponding author), UNIV CHICAGO,MED CTR,DEPT MED,GASTROENTEROL SECT,MC 4076,5841 S MARYLAND AVE,CHICAGO,IL 60637, USA.				NIDDK NIH HHS [DK 42086, DK40223, DK 02022] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002022, P30DK042086, R29DK040223] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGARWAL S, 1995, ONCOGENE, V11, P427; ARMENDARIZBORUNDA J, 1994, BIOCHEM J, V304, P817, DOI 10.1042/bj3040817; ATFI A, 1995, P NATL ACAD SCI USA, V92, P1210; BENO DWA, 1995, AM J PHYSIOL-CELL PH, V268, pC604, DOI 10.1152/ajpcell.1995.268.3.C604; BENO DWA, 1995, J BIOL CHEM, V270, P3642, DOI 10.1074/jbc.270.8.3642; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRENNER DA, 1989, NUCLEIC ACIDS RES, V17, P6055, DOI 10.1093/nar/17.15.6055; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS BH, 1991, BIOCHEM J, V278, P43, DOI 10.1042/bj2780043; DAVIS BH, 1990, J CLIN INVEST, V86, P2062, DOI 10.1172/JCI114943; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; FRIEDMAN SL, 1994, J BIOL CHEM, V269, P10551; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOUGLUM K, 1995, J CLIN INVEST, V96, P2269, DOI 10.1172/JCI118282; HOWE PH, 1993, J BIOL CHEM, V268, P21448; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KATAI H, 1992, MOL CELL BIOCHEM, V118, P119; LASKIN DL, 1990, SEMIN LIVER DIS, V10, P293, DOI 10.1055/s-2008-1040485; LISKA DJ, 1994, J CELL BIOL, V125, P695, DOI 10.1083/jcb.125.3.695; PAVLIN D, 1992, J CELL BIOL, V116, P227, DOI 10.1083/jcb.116.1.227; RIPPE RA, 1995, HEPATOLOGY, V22, P241, DOI 10.1016/0270-9139(95)90378-X; RITZENTHALER JD, 1993, J BIOL CHEM, V268, P13625; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; SLACK JL, 1992, MOL CELL BIOL, V12, P4714, DOI 10.1128/MCB.12.10.4714; SLACK JL, 1991, MOL CELL BIOL, V11, P2066, DOI 10.1128/MCB.11.4.2066; WONG L, 1994, J CLIN INVEST, V94, P1563, DOI 10.1172/JCI117497; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	30	77	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11039	11042		10.1074/jbc.271.19.11039	http://dx.doi.org/10.1074/jbc.271.19.11039			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626642	hybrid			2022-12-25	WOS:A1996UJ94400002
J	Gilbert, GE; Arena, AA				Gilbert, GE; Arena, AA			Activation of the factor VIIIa-factor IXa enzyme complex of blood coagulation by membranes containing phosphatidyl-L-serine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-X; PHOSPHOLIPID-VESICLES; HUMAN-PLATELETS; FACTOR-VA; BINDING; PROTHROMBINASE	Factor IXa, a serine protease of blood coagulation, functions at least 100,000 times more efficiently when bound to factor VIIIa on a phospholipid membrane than when free in solution. We have utilized the catalytic activity of the factor VIIIa-factor IXa complex to report the effect of phospholipid membranes on binding of factor IXa to factor VIIIa and on enzymatic cleavage of the product. The apparent affinity of factor IXa for factor VIIIa was 10-fold lower in the absence of phospholipid membranes with a K-D of 46 nM versus 4.3 nM with phospholipid membranes. The K-m for activation of factor X by the factor VIIIa-factor IXa complex was 1700 nM in solution, 70-fold higher than the value of 28 nM when bound to membranes containing phosphatidyl-L-serine, phosphatidylethanolamine, and phosphatidylcholine at a ratio of 4:20:76. The largest effect of phosphatidyl-L-serine-containing membranes on the factor VIIIa-factor IXa complex was the accelerated rate of peptide bond cleavage, with the k(cat) increased by 1,500-fold from 0.022 to 33 min(-1). Membranes in which phosphatidyl-L-serine was replaced by phosphatidyl-D-serine, phosphatidic acid, or phosphatidylglycerol were at least 10-fold less effective for enhancing the k(cat). Thus, while membranes containing phosphatidyl-L-serine enhance condensation of the enzyme with its cofactor and substrate, their largest effect is activation of the assembled factor VIIIa-factor IXa enzyme complex.	BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02132; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02132	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Gilbert, GE (corresponding author), BROCKTON W ROXBURY VET AFFAIRS MED CTR,DEPT MED,1400 VFW PKWY,BOSTON,MA 02132, USA.				NHLBI NIH HHS [P01 HL42443I] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL042443] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEALS JM, 1986, BIOCHEM J, V236, P861, DOI 10.1042/bj2360861; BEVERS EM, 1983, BIOCHIM BIOPHYS ACTA, V736, P57, DOI 10.1016/0005-2736(83)90169-4; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; COMFURIUS P, 1990, J LIPID RES, V31, P1719; COMFURIUS P, 1977, BIOCHIM BIOPHYS ACTA, V488, P36, DOI 10.1016/0005-2760(77)90120-5; CURTIS JE, 1994, J BIOL CHEM, V269, P6246; DUFFY EJ, 1992, J BIOL CHEM, V267, P7821; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; GILBERT GE, 1993, BIOCHEMISTRY-US, V32, P9577, DOI 10.1021/bi00088a009; GILBERT GE, 1995, J BIOL CHEM, V270, P18500, DOI 10.1074/jbc.270.31.18500; GILBERT GE, 1992, J BIOL CHEM, V267, P15861; GILBERT GE, 1990, J BIOL CHEM, V265, P815; GILBERT GE, 1991, J BIOL CHEM, V266, P17261; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; KRISHNASWAMY S, 1994, BIOCHEMISTRY-US, V33, P7897, DOI 10.1021/bi00191a017; KUNG C, 1994, J BIOL CHEM, V269, P25838; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; MANN KG, 1990, BLOOD, V76, P1; MERTENS K, 1984, BIOCHEM J, V223, P599, DOI 10.1042/bj2230599; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4172, DOI 10.1021/bi00638a006; NESHEIM ME, 1988, J BIOL CHEM, V263, P16467; PRYZDIAL ELG, 1991, J BIOL CHEM, V266, P8969; RAWALASHEIKH R, 1990, BIOCHEMISTRY-US, V29, P2606, DOI 10.1021/bi00462a025; ROSING J, 1980, J BIOL CHEM, V255, P274; SANDBERG H, 1985, THROMB RES, V39, P63, DOI 10.1016/0049-3848(85)90122-7; SIMS PJ, 1986, BLOOD, V68, P556; SKOGEN WF, 1984, J BIOL CHEM, V259, P2306; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; WOLF P, 1967, BRIT J HAEMATOL, V13, P269, DOI 10.1111/j.1365-2141.1967.tb08741.x	31	80	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11120	11125		10.1074/jbc.271.19.11120	http://dx.doi.org/10.1074/jbc.271.19.11120			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626656	hybrid			2022-12-25	WOS:A1996UJ94400016
J	Mandriota, SJ; Menoud, PA; Pepper, MS				Mandriota, SJ; Menoud, PA; Pepper, MS			Transforming growth factor beta 1 down-regulates vascular endothelial growth factor receptor 2/flk-1 expression in vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; TYROSINE KINASE; ANGIOGENESIS; ACTIVATION; FACTOR-BETA-1; IDENTIFICATION; INHIBITION; PERICYTES; SEQUENCE; PLASMIN	Although the importance of the vascular endothelial growth factor (VEGF)/VEGF tyrosine kinase receptor (VEGFR) system in angiogenesis is well established, very little is known about the regulation of VEGFR expression in vascular endothelial cells. We have cloned partial cDNAs encoding bovine VEGFR-1 (flt) and -2 (flk-1) and used them to study VEGFR expression by bovine microvascular- and large vessel-derived endothelial cells. Both cell lines express flk-1, but not flt. Transforming growth factor beta 1 (TGF-beta 1) reduced the high affinity I-125-VEGF binding capacity of both cell types in a dose-dependent manner, with a 2.0-2.7-fold decrease at 1-10 ng/ml. Cross-linking experiments revealed a decrease in I-125-VEGF binding to a cell surface monomeric protein corresponding to Flk-1 on the basis of its affinity for VEGF, molecular mass (185-190 kDa), and apparent internalization after VEGF binding. Immunoprecipitation and Western blot experiments demonstrated a decrease in Flk-1 protein expression, and TGF-beta 1 reduced flk-1 mRNA levels in a dose-dependent manner. These results imply that TGF-beta 1 is a major regulator of the VEGF/Flk-1 signal transduction pathway in endothelial cells.	UNIV GENEVA,MED CTR,DEPT MORPHOL,CH-1211 GENEVA 4,SWITZERLAND; UNIV GENEVA,MED CTR,DIV ONCOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva; University of Geneva			Pepper, Michael S./M-6143-2014	Pepper, Michael S./0000-0001-6406-2380				AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; AUSPRUNK D, 1977, MICROVASC RES, V14, P52; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; Brogi E, 1996, J CLIN INVEST, V97, P469, DOI 10.1172/JCI118437; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FINNERTY H, 1993, ONCOGENE, V8, P2293; FLAUMENHAFT R, 1992, J CELL BIOL, V118, P901, DOI 10.1083/jcb.118.4.901; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FURIE MB, 1984, J CELL BIOL, V98, P1033, DOI 10.1083/jcb.98.3.1033; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; ISACCHI A, 1990, NUCLEIC ACIDS RES, V18, P1906, DOI 10.1093/nar/18.7.1906; Joukov V, 1996, EMBO J, V15, P290; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MACFARLANE DE, 1993, NATURE, V362, P186, DOI 10.1038/362186a0; MANDRIOTA SJ, 1995, J BIOL CHEM, V270, P9709, DOI 10.1074/jbc.270.17.9709; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Namiki A, 1995, J BIOL CHEM, V270, P31189, DOI 10.1074/jbc.270.52.31189; PAKU S, 1991, LAB INVEST, V65, P334; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PEPPER MS, 1992, AM J PHYSIOL, V262, pC1246, DOI 10.1152/ajpcell.1992.262.5.C1246; PEPPER MS, 1995, J CELL SCI, V108, P73; PEPPER MS, 1993, EXP CELL RES, V204, P356, DOI 10.1006/excr.1993.1043; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P902, DOI 10.1016/0006-291X(91)91276-I; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; PEPPER MS, 1996, IN PRESS CURR TOP MI, V2; PEPPER MS, 1996, IN PRESS ENZYME PROT; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; VASSALLI JD, 1984, J EXP MED, V159, P1653, DOI 10.1084/jem.159.6.1653; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; YAMANE A, 1994, ONCOGENE, V9, P2683	47	138	144	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11500	11505		10.1074/jbc.271.19.11500	http://dx.doi.org/10.1074/jbc.271.19.11500			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626709	hybrid			2022-12-25	WOS:A1996UJ94400069
J	Meyer, DF; Mabuchi, Y; Grabarek, Z				Meyer, DF; Mabuchi, Y; Grabarek, Z			The role of Phe-92 in the Ca2+-induced conformational transition in the C-terminal domain of calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT CHAIN KINASE; TROPONIN-C; ANGSTROM RESOLUTION; TRYPTIC FRAGMENTS; PEPTIDE COMPLEX; DISULFIDE BOND; PROTEIN; BINDING; PHOSPHODIESTERASE; PSEUDOSUBSTRATE	Recent studies have shown that substitution of Ala for one or more Phe residues in calmodulin (CaM) imparts a temperature-sensitive phenotype to yeast (Ohya, Y., and Botstein, D. (1994) Science 263, 963-966). The Phe residue immediately preceding the first Ca2+ ligand in site III of CaM (Phe-92) was found to be of particular importance because the mutation at this position alone was sufficient to induce this phenotype. In the present work we have studied the functional and structural consequences of the Phe-92 --> Ala mutation in human liver calmodulin. We found that the mutant (CaMF92A) is incapable of activating phosphodiesterase, and the maximal activation of calcineurin is reduced by 40% as compared with the wild type CaM. Impaired regulatory properties of CaMF92A are accompanied by an increase in affinity for Ca2+ at the C-terminal domain. To investigate the structural consequences of the F92A mutation, we constructed four recombinant C-terminal domain fragments (C-CaM) of calmodulin (residues 78-148): 1) wild type (C-CaMW); 2) Ala substituted for Phe-92 (C-CaMF92A); 3) cysteine residues introduced at position 85 and 112 to lock the domain with a disulfide bond in the Ca2+-free (closed) conformation (C-CaM85/112); and 4) mutations 2 and 3 combined (C-CaM85/112F92A). The Cys-containing mutants readily form intramolecular disulfide bonds regardless whether Phe or Ala is present at position 92. The F92A mutation causes a decrease in stability of the domain in the absence of Ca2+ as indicated by an 11.8 degrees C shift in the far UV circular dichroism thermal unfolding curve. This effect is reversed by the disulfide bond in the C-CaM85/112F92A mutant. The C-CaMW peptide shows a characteristic Ca2+-dependent increase in solvent-exposed hydrophobic surface which was monitored by an increase in the fluorescence of the hydrophobic probe 1,1'-bis(4-anilino)-naphthalene-5,5'-disulfonic acid. The fluorescence increase induced by C-CaMF92A is similar to 45% lower than that induced by C-CaMW suggesting that the F92A mutation causes a decrease in the accessibility of several hydrophobic side chains in the C-terminal domain of CaM in the presence of Ca2+. The Cys-85-Cys-112 disulfide bond causes a 10- or 5.9-fold decrease in Ca2+ affinity depending on whether Phe or Ala is present at position 92, respectively, suggesting that coupling between Ca2+ binding and the conformational transition is weaker in the absence of the phenyl ring at position 92. Our results indicate that Phe-92 makes an important contribution to the Ca2+-induced transition in the C-terminal domain of CaM. This is most likely the reason for the severely impaired regulatory properties of the CaM mutants having Ala substituted for Phe-92.	BOSTON BIOMED RES INST, MUSCLE RES GRP, BOSTON, MA 02114 USA	Boston Biomedical Research Institute				Grabarek, Zenon/0000-0002-3636-5701	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR041637] Funding Source: NIH RePORTER; NIAMS NIH HHS [P01AR-41637, AR-41156] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; Cohen P, 1988, CALMODULIN MOL ASPEC, V5; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; FINN BE, 1995, NAT STRUCT BIOL, V2, P777, DOI 10.1038/nsb0995-777; FORSEN S, 1990, ADV EXP MED BIOL, V269, P37; FOSTER CJ, 1990, ARCH BIOCHEM BIOPHYS, V280, P397, DOI 10.1016/0003-9861(90)90348-3; GRABAREK Z, 1990, NATURE, V345, P132, DOI 10.1038/345132a0; GRABAREK Z, 1995, BIOCHEMISTRY-US, V34, P11872, DOI 10.1021/bi00037a027; GUSEV NB, 1991, J BIOL CHEM, V266, P16622; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JOHNSON ML, 1992, METHOD ENZYMOL, V210, P1; KLEE CB, 1983, METHOD ENZYMOL, V102, P227; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MARTIN SR, 1985, EUR J BIOCHEM, V151, P543, DOI 10.1111/j.1432-1033.1985.tb09137.x; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEANS AR, 1988, RECENT PROG HORM RES, V44, P223; MORRIS EP, 1984, BIOCHEMISTRY-US, V23, P2214, DOI 10.1021/bi00305a018; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NEWTON DL, 1984, J BIOL CHEM, V259, P4419; OHYA Y, 1994, GENETICS, V138, P1041; OHYA Y, 1994, SCIENCE, V263, P963, DOI 10.1126/science.8310294; PEARSON RB, 1988, SCIENCE, V241, P970, DOI 10.1126/science.3406746; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; RAO ST, 1993, PROTEIN SCI, V2, P436; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHELLMAN JA, 1980, PROTEIN FOLDING, P331; SILLEN LG, 1964, SPECIAL PUBLICATION, V17; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; Tan RY, 1996, J BIOL CHEM, V271, P7479, DOI 10.1074/jbc.271.13.7479; TAYLOR DA, 1991, J BIOL CHEM, V266, P21375; WALLACE RW, 1983, METHOD ENZYMOL, V102, P39; WALSH M, 1977, J BIOL CHEM, V252, P7440; WAWRZYNCZAK EJ, 1984, BIOCHEM INT, V9, P177; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758	42	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11284	11290		10.1074/jbc.271.19.11284	http://dx.doi.org/10.1074/jbc.271.19.11284			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626680	hybrid			2022-12-25	WOS:A1996UJ94400040
J	CervantesLaurean, D; Jacobson, EL; Jacobson, MK				CervantesLaurean, D; Jacobson, EL; Jacobson, MK			Glycation and glycoxidation of histones by ADP-ribose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINK; PROTEIN; INVIVO; GLUCOSE; N-EPSILON-(CARBOXYMETHYL)LYSINE; IDENTIFICATION; GLYCOSYLATION; AUTOXIDATION; DEGRADATION; PENTOSIDINE	The reaction of long lived proteins with reducing sugars has been implicated in the pathophysiology of aging and age-related diseases, A likely intranuclear source of reducing sugar is ADP-ribose, which is generated following DNA damage from the turnover of ADP-ribose polymers, In this study, ADP-ribose has been shown to be a potent histone glycation and glycoxidation agent in vitro. Incubation of ADP ribose with histones H1, H2A, H2B, and H4 at pH 7.5 resulted in the formation of ketoamine glycation conjugates, Incubation of histone H1 with ADP-ribose also rapidly resulted in the formation of protein carboxymethyllysine residues, protein-protein cross-links, and highly fluorescent products with properties similar to the advanced glycosylation end product pentosidine. The formation of glycoxidation products was related to the degradation of ketoamine glycation conjugates by two different pathways, One pathway resulted in the formation of protein carboxymethyllysine residues and release of an ADP moiety containing a glyceric acid fragment, A second pathway resulted in the release of ADP, and it is postulated that this pathway is involved in the formation of histone-histone cross-links and fluorescent advanced glycosylation end products.	UNIV KENTUCKY, COLL PHARM, DIV MED CHEM & PHARMACEUT, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, LUCILLE P MARKEY CANC CTR, DEPT CLIN SCI, LEXINGTON, KY 40536 USA	University of Kentucky; University of Kentucky			YAMAMOTO, MASAHIRO/F-9094-2011	YAMAMOTO, MASAHIRO/0000-0003-3859-0125	NATIONAL CANCER INSTITUTE [R01CA043894] Funding Source: NIH RePORTER; NCI NIH HHS [CA43894] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED MU, 1986, J BIOL CHEM, V261, P4889; ALTHAUS FR, 1987, ADP RIBOSYLATION PRO; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BERNET D, 1994, BIOCHEM J, V299, P679, DOI 10.1042/bj2990679; Bernofsky C, 1980, Methods Enzymol, V66, P23; BOJANOVI.JJ, 1970, GERONTOLOGY, V16, P304, DOI 10.1159/000211792; BONNER WM, 1980, EUR J BIOCHEM, V109, P17, DOI 10.1111/j.1432-1033.1980.tb04762.x; Bucala R, 1992, Adv Pharmacol, V23, P1; BUCALA R, 1984, P NATL ACAD SCI-BIOL, V81, P105, DOI 10.1073/pnas.81.1.105; CERAMI A, 1986, TRENDS PHARMACOL SCI, V7, P271, DOI 10.1016/0165-6147(86)90350-0; CERAMI A, 1986, J CELL BIOCHEM, V30, P111, DOI 10.1002/jcb.240300203; CERVANTESLAUREAN D, 1993, BIOCHEMISTRY-US, V32, P1528, DOI 10.1021/bi00057a017; DEPETROCELLIS L, 1986, EUR J BIOCHEM, V156, P143; DUNN JA, 1991, BIOCHEMISTRY-US, V30, P1205, DOI 10.1021/bi00219a007; DUNN JA, 1990, BIOCHEMISTRY-US, V29, P10964, DOI 10.1021/bi00501a014; DYER DG, 1991, J BIOL CHEM, V266, P11654; DYRKS T, 1992, J BIOL CHEM, V267, P18210; FU MX, 1994, DIABETES, V43, P676, DOI 10.2337/diabetes.43.5.676; GERHARDINGER C, 1995, J BIOL CHEM, V270, P218, DOI 10.1074/jbc.270.1.218; GRANDHEE SK, 1991, J BIOL CHEM, V266, P11649; GUGLIUCCI A, 1995, BIOCHEM BIOPH RES CO, V212, P56, DOI 10.1006/bbrc.1995.1935; GUGLIUCCI A, 1994, BIOCHEM BIOPH RES CO, V203, P588, DOI 10.1006/bbrc.1994.2223; HARDING JJ, 1985, ADV PROTEIN CHEM, V37, P247, DOI 10.1016/S0065-3233(08)60066-2; HORIUCHI T, 1991, AGR BIOL CHEM TOKYO, V55, P333, DOI 10.1080/00021369.1991.10870584; JACOBSON EL, 1994, MOL CELL BIOCHEM, V138, P207, DOI 10.1007/BF00928463; JACOBSON MK, 1990, ADP RIBOSYLATING TOX, P479; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; KREIMEYER A, 1984, J BIOL CHEM, V259, P890; LEE HC, 1994, CELL SIGNAL, V6, P591, DOI 10.1016/0898-6568(94)90042-6; LIEBICH HM, 1993, BIOL MASS SPECTROM, V22, P121, DOI 10.1002/bms.1200220204; MIWA M, 1977, NUCLEIC ACIDS RES, V4, P3997, DOI 10.1093/nar/4.11.3997; MONNIER VM, 1990, J GERONTOL, V45, pB105, DOI 10.1093/geronj/45.4.B105; OKA J, 1984, J BIOL CHEM, V259, P986; PAPOULIS A, 1995, BIOCHEMISTRY-US, V34, P648, DOI 10.1021/bi00002a032; SELL DR, 1989, J BIOL CHEM, V264, P21597; SMITH MA, 1994, P NATL ACAD SCI USA, V91, P5710, DOI 10.1073/pnas.91.12.5710; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STADTMAN ER, 1990, BIOCHEMISTRY-US, V29, P6323, DOI 10.1021/bi00479a001; VITEK MP, 1994, P NATL ACAD SCI USA, V91, P4766, DOI 10.1073/pnas.91.11.4766; VLASSARA H, 1994, LAB INVEST, V70, P138; Williamson KC, 1990, ADP RIBOSYLATING TOX, P493; WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243; WONG M, 1983, P NATL ACAD SCI-BIOL, V80, P205, DOI 10.1073/pnas.80.1.205; YAMADA H, 1994, J BIOL CHEM, V269, P20275	44	117	123	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10461	10469		10.1074/jbc.271.18.10461	http://dx.doi.org/10.1074/jbc.271.18.10461			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631841	hybrid			2022-12-25	WOS:A1996UJ34200009
J	Chen, L; Sumbilla, C; Lewis, D; Zhong, LL; Strock, C; Kirtley, ME; Inesi, G				Chen, L; Sumbilla, C; Lewis, D; Zhong, LL; Strock, C; Kirtley, ME; Inesi, G			Short and long range functions of amino acids in the transmembrane region of the sarcoplasmic reticulum ATPase - A mutational study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT ATPASE; CA2+-ATPASE; DOMAIN; CELLS; PHOSPHORYLATION; CA-2+-ATPASE; CONSEQUENCES; EXPRESSION; MUSCLE; SITE	Mutational analysis of several amino acids in the transmembrane region of the sarcoplasmic reticulum ATPase was performed by expressing wild type ATPase and 32 site-directed mutants in COS-1 cells followed by functional characterization of the microsomal fraction, Four different phenotype characteristics were observed in the mutants: (a) functions similar to those sustained by the wild type ATPase; (b) Ca2+ transport inhibited to a greater extent than ATPase hydrolytic activity; (c) inhibition of transport and hydrolytic activity in the presence of high levels of phosphorylated enzyme intermediate; and (d) total inhibition of ATP utilization by the enzyme while retaining the ability to form phosphoenzyme by utilization of P-i, Analysis of experimental observations and molecular models revealed short and long range functions of several amino acids within the transmembrane region, Short range functions include: (a) direct involvement of five amino acids in Ca2+ binding within a channel formed by clustered transmembrane helices M4, M5, M6, and M8; (b) roles of several amino acids in structural stabilization of the helical cluster for optimal channel function; and (c) a specific role of Lys(297) in sealing the distal end of the channel, suggesting that the M4 helix rotates to allow vectorial flux of Ca2+ upon enzyme phosphorylation, Long range functions are related to the influence of several transmembrane amino acids on phosphorylation reactions with ATP or P-i, transmitted to the extramembranous region of the ATPase in the presence or in the absence of Ca2+.	UNIV MARYLAND, SCH MED, DEPT BIOCHEM & MOLEC BIOL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore					NHLBI NIH HHS [P01HL-27867] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL027867] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; ANDERSEN JP, 1994, FEBS LETT, V354, P93, DOI 10.1016/0014-5793(94)01100-1; ANDERSEN JP, 1992, J BIOL CHEM, V267, P19383; ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; AURORA R, 1994, SCIENCE, V264, P1126, DOI 10.1126/science.8178170; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DEMEIS L, 1991, J BIOL CHEM, V266, P5736; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLMES MA, 1982, J MOL BIOL, V160, P623, DOI 10.1016/0022-2836(82)90319-9; INESI G, 1990, PHYSIOL REV, V70, P749, DOI 10.1152/physrev.1990.70.3.749; INESI G, 1992, ADV ENZYMOL RAMB, V65, P185; INESI G, 1990, J MEMBRANE BIOL, V116, P1, DOI 10.1007/BF01871666; KARIN NJ, 1989, MOL CELL BIOL, V9, P1978, DOI 10.1128/MCB.9.5.1978; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; MASUDA H, 1973, BIOCHEMISTRY-US, V12, P4581, DOI 10.1021/bi00747a006; NAYAL M, 1994, P NATL ACAD SCI USA, V91, P817, DOI 10.1073/pnas.91.2.817; RICE WJ, 1994, BIOPHYS J, V66, pA121; RICE WJ, 1995, BIOPHYS J, V68, P315; SKERJANC IS, 1993, J BIOL CHEM, V268, P15944; SUMBILLA C, 1993, J BIOL CHEM, V268, P21185; SUMBILLA C, 1991, J BIOL CHEM, V266, P12682; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VILSEN B, 1992, FEBS LETT, V306, P247, DOI 10.1016/0014-5793(92)81010-J; WEBER K, 1969, J BIOL CHEM, V244, P4406; YU X, 1994, J BIOL CHEM, V269, P16656; ZHANG Z, 1995, J BIOL CHEM, V270, P16283	30	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10745	10752		10.1074/jbc.271.18.10745	http://dx.doi.org/10.1074/jbc.271.18.10745			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631884	hybrid			2022-12-25	WOS:A1996UJ34200052
J	Edelman, AM; Mitchelhill, KI; Selbert, MA; Anderson, KA; Hook, SS; Stapleton, D; Goldstein, EG; Means, AR; Kemp, BE				Edelman, AM; Mitchelhill, KI; Selbert, MA; Anderson, KA; Hook, SS; Stapleton, D; Goldstein, EG; Means, AR; Kemp, BE			Multiple Ca2+-calmodulin-dependent protein kinase kinases from rat brain - Purification, regulation by Ca2+-calmodulin, and partial amino acid sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN; PHOSPHORYLATION; IDENTIFICATION; EXPRESSION; GENE; IV; GR; AUTOPHOSPHORYLATION; SITE; IA	We have purified to near homogeneity from rat brain two Ca2+-calmodulin-dependent protein kinase I (CaM kinase I) activating kinases, termed here CaM kinase I kinase-alpha and CaM kinase I kinase-beta (CaMKIK alpha and CaMKIK beta, respectively). Both CaMKIK alpha and CaMKIK beta are also capable of activating CaM kinase IV, Activation of CaM kinase I and CaM kinase TV occurs via phosphorylation of an equivalent Thr residue within the ''activation loop'' region of both kinases, Thr-177 and Thr-196, respectively. The activities of CaMKIK alpha and CaMKIK beta are themselves strongly stimulated by the presence of Ca2+-CaM, and both appear to be capable of Ca2+-CaM-dependent autophosphorylation. Automated microsequence analysis of the purified enzymes established that CaMKIK alpha and -beta are the products of distinct genes, In addition to rat, homologous nucleic acids corresponding to these CaM kinase kinases are present in humans and the nematode, Caenorhabditis elegans. CaMKIK alpha and CaMKIK beta are thus representatives of a family of enzymes, which may function as key intermediaries in Ca2+-CaM-driven signal transduction cascades in a wide variety of eukaryotic organisms.	ST VINCENTS INST MED RES,FITZROY,VIC 3065,AUSTRALIA; DUKE UNIV,DEPT PHARMACOL,DURHAM,NC 27710	St. Vincent's Institute of Medical Research; Duke University	Edelman, AM (corresponding author), SUNY BUFFALO,DEPT PHARMACOL & TOXICOL,BUFFALO,NY 14214, USA.		Kemp, Bruce/G-9602-2019; Kemp, Bruce E/L-2633-2014	Kemp, Bruce/0000-0001-6735-5082; Kemp, Bruce E/0000-0001-6735-5082	NICHD NIH HHS [HD07503] Funding Source: Medline; NIGMS NIH HHS [GM33976] Funding Source: Medline; NINDS NIH HHS [NS24738] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033976] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024738, R29NS024738] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; DEREMER MF, 1992, J BIOL CHEM, V267, P13460; DEREMER MF, 1992, J BIOL CHEM, V267, P13466; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P15792; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HANKS SK, 1995, PROTEIN KINASE FACTS, P7; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; HAYGOOD MG, 1993, BIOTECHNIQUES, V15, P1084; ITO T, 1994, ARCH BIOCHEM BIOPHYS, V312, P278, DOI 10.1006/abbi.1994.1310; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; LEE JC, 1995, BIOCHEM BIOPH RES CO, V210, P631, DOI 10.1006/bbrc.1995.1705; LEE JSC, 1994, J BIOL CHEM, V269, P2158; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCDONALD OB, 1993, J BIOL CHEM, V268, P10054; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; MIYANO O, 1992, J BIOL CHEM, V267, P1198; MOCHIZUKI H, 1993, BIOCHEM BIOPH RES CO, V197, P1595, DOI 10.1006/bbrc.1993.2661; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; OKUNO S, 1994, J BIOCHEM, V116, P923, DOI 10.1093/oxfordjournals.jbchem.a124617; OKUNO S, 1995, J BIOCHEM-TOKYO, V117, P686, DOI 10.1093/oxfordjournals.jbchem.a124764; ORR JW, 1994, J BIOL CHEM, V269, P27715; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; SAKAGAMI H, 1992, MOL BRAIN RES, V16, P20, DOI 10.1016/0169-328X(92)90189-I; SAKAGAMI H, 1994, BRAIN RES, V666, P173, DOI 10.1016/0006-8993(94)90769-2; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; SUGITA R, 1994, BIOCHEM BIOPH RES CO, V203, P694, DOI 10.1006/bbrc.1994.2238; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	42	91	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10806	10810		10.1074/jbc.271.18.10806	http://dx.doi.org/10.1074/jbc.271.18.10806			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631893				2022-12-25	WOS:A1996UJ34200061
J	Greenfield, EM; Horowitz, MC; Lavish, SA				Greenfield, EM; Horowitz, MC; Lavish, SA			Stimulation by parathyroid hormone of interleukin-6 and leukemia inhibitory factor expression in osteoblasts is an immediate-early gene response induced by cAMP signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; PROTEIN-KINASE-C; MESSENGER-RNA DEGRADATION; BONE-RESORPTION; CYCLIC-AMP; OSTEOSARCOMA CELLS; CYTOSOLIC CALCIUM; FACTOR INDUCTION; PHOSPHOLIPASE-C; STROMAL CELLS	Parathyroid hormone and other agents that stimulate bone resorption function, at least in part, by inducing osteoblasts to secrete cytokines that stimulate osteoclast differentiation and activity. We previously demonstrated that parathyroid hormone induces expression by osteoblasts of interleukin-6 and leukemia inhibitory factor without affecting the 16 other cytokines that were examined. We also showed that stimulation of osteoclast activity by parathyroid hormone is dependent on activation of the cAMP signal transduction pathway and secretion of interleukin-6 by osteoblasts. In the current study, we demonstrate that the rapid and transient stimulation of interleukin-6 and leukemia inhibitory factor is inhibited by actinomycin D and superinduced by protein synthesis inhibitors, the classical characteristics of an immediate-early gene response. Moreover, activation of cAMP signal transduction by parathyroid hormone and parathyroid hormone-related protein is necessary and sufficient to induce both interleukin-6 and leukemia inhibitory factor. In addition, cAMP analogues as well as vasoactive intestinal peptide and iso; proterenol, two neuropeptides that stimulate bone resorption by activating cAMP signal transduction in osteoblasts, also induce interleukin-6 and leukemia inhibitory factor in these cells. Taken together with our previous results, this study suggests that interleukin-6 is crucial for stimulation of bone resorption not only by parathyroid hormone, but also by parathyroid hormone-related protein, vasoactive intestinal peptide, and beta-adrenergic agonists, like isoproterenol.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, INST PATHOL, CLEVELAND, OH 44106 USA; YALE UNIV, SCH MED, DEPT ORTHOPAED & REHABIL, NEW HAVEN, CT 06520 USA	Case Western Reserve University; Case Western Reserve University; Yale University	Greenfield, EM (corresponding author), CASE WESTERN RESERVE UNIV, SCH MED, DEPT ORTHOPED, 11100 EUCLID AVE, CLEVELAND, OH 44106 USA.				NIAMS NIH HHS [AR40073, AR40507, AR41674] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041674, R01AR040507, R29AR041674, R01AR040073] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABE E, 1988, J BONE MINER RES, V3, P635; ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ALLAN EH, 1990, J CELL PHYSIOL, V145, P110, DOI 10.1002/jcp.1041450116; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; BOS MP, 1992, BIOCHEM BIOPH RES CO, V184, P1317, DOI 10.1016/S0006-291X(05)80026-9; BOTELLA A, 1994, ENDOCRINOLOGY, V135, P2160, DOI 10.1210/en.135.5.2160; CHARD MD, 1991, ANN RHEUM DIS, V50, P727, DOI 10.1136/ard.50.10.727; DAVIDOVITCH Z, 1988, DENT CLIN N AM, V32, P411; DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; DERIGS HG, 1993, LEUKEMIA, V7, P630; DUNLAY R, 1990, AM J PHYSIOL, V258, pF223, DOI 10.1152/ajprenal.1990.258.2.F223; EXTON JH, 1985, AM J PHYSIOL, V248, pE633, DOI 10.1152/ajpendo.1985.248.6.E633; FEYEN JHM, 1989, J BONE MINER RES, V4, P633, DOI 10.1002/jbmr.5650040422; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; Foulkes, 1991, HORMONAL CONTROL REG, P257; FRANCHIMONT N, 1993, 4TH INT S OST, P249; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; FUJIMORI A, 1991, ENDOCRINOLOGY, V128, P3032, DOI 10.1210/endo-128-6-3032; FUJIMORI A, 1992, ENDOCRINOLOGY, V130, P29, DOI 10.1210/en.130.1.29; GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668; GREENFIELD EM, 1995, J CLIN INVEST, V96, P1238, DOI 10.1172/JCI118157; GREENFIELD EM, 1993, J BONE MINER RES, V8, P1163; GREENFIELD EM, 1996, IN PRESS BIOL MECH T; GREENFIELD EM, 1996, T ORTHOP RES SOC, V21, P337; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HERRMANNERLEE MPM, 1983, CALCIFIED TISSUE INT, V35, P70, DOI 10.1007/BF02405009; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOHMANN EL, 1983, ENDOCRINOLOGY, V112, P1233, DOI 10.1210/endo-112-4-1233; HOHMANN EL, 1986, SCIENCE, V232, P868, DOI 10.1126/science.3518059; HOROWITZ M, 1990, PROG LEUC B, V10, P471; HOROWITZ MC, 1993, SCIENCE, V260, P626, DOI 10.1126/science.8480174; HUGHES FJ, 1993, BONE MINER, V21, P21, DOI 10.1016/S0169-6009(08)80117-1; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ISHIMI Y, 1992, J CELL PHYSIOL, V152, P71, DOI 10.1002/jcp.1041520110; ISHIMI Y, 1990, J IMMUNOL, V145, P3297; KAJI H, 1992, BIOCHEM BIOPH RES CO, V182, P1356, DOI 10.1016/0006-291X(92)91882-Q; KOJIMA I, 1985, AM J PHYSIOL, V248, pE36, DOI 10.1152/ajpendo.1985.248.1.E36; KUMAGAI H, 1989, CALCIFIED TISSUE INT, V45, P251, DOI 10.1007/BF02556045; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LITTLEWOOD AJ, 1991, ENDOCRINOLOGY, V129, P1513, DOI 10.1210/endo-129-3-1513; LJUNGGREN O, 1993, BIOCHEM BIOPH RES CO, V193, P821, DOI 10.1006/bbrc.1993.1699; LOWIK CWGM, 1989, BIOCHEM BIOPH RES CO, V162, P1546, DOI 10.1016/0006-291X(89)90851-6; LUBBERT M, 1991, LEUKEMIA, V5, P361; MAGISTRETTI PJ, 1990, TRENDS PHARMACOL SCI, V11, P250, DOI 10.1016/0165-6147(90)90253-5; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MAIMONE D, 1993, J NEUROIMMUNOL, V47, P73, DOI 10.1016/0165-5728(93)90286-8; MAKINO R, 1990, Technique (Philadelphia), V2, P295; MALHOTRA RK, 1988, J BIOL CHEM, V263, P2123; MARTIN TJ, 1993, PHYSL PHARM BONE, P617; MARUSIC A, 1993, J BONE MINER RES, V8, P617; MERRILL JE, 1991, DEV NEUROSCI-BASEL, V13, P130, DOI 10.1159/000112150; MIYAUCHI A, 1990, J CELL BIOL, V111, P2543, DOI 10.1083/jcb.111.6.2543; MOORE RE, 1993, BONE MINER, V23, P301, DOI 10.1016/S0169-6009(08)80105-5; MURTHY KS, 1994, J BIOL CHEM, V269, P15977; NORRIS JG, 1993, J NEUROIMMUNOL, V45, P137; NORTHEMANN W, 1989, J BIOL CHEM, V264, P16072; PANDOL SJ, 1986, AM J PHYSIOL, V250, pG553, DOI 10.1152/ajpgi.1986.250.4.G553; PARTRIDGE NC, 1983, CANCER RES, V43, P4308; PEARMAN AT, 1994, J BONE MINER RES  S1, V9, P416; POLLOCK JH, 1996, IN PRESS J BONE MINE, V11; REID IR, 1990, ENDOCRINOLOGY, V126, P1416, DOI 10.1210/endo-126-3-1416; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; RITCHIE AJ, 1991, J IMMUNOL, V146, P3056; RODAN GA, 1981, CALCIFIED TISSUE INT, V33, P349, DOI 10.1007/BF02409454; RODAN SB, 1990, ENDOCRINOLOGY, V127, P1602, DOI 10.1210/endo-127-4-1602; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHECTERSON LC, 1991, MOL ENDOCRINOL, V5, P170, DOI 10.1210/mend-5-2-170; SEHGAL PB, 1987, P NATL ACAD SCI USA, V84, P3663, DOI 10.1073/pnas.84.11.3663; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SPANGELO BL, 1990, ENDOCRINOLOGY, V127, P403, DOI 10.1210/endo-127-1-403; STAHL J, 1990, J BIOL CHEM, V265, P8833; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; SUZUKI A, 1994, CELL SIGNAL, V6, P11, DOI 10.1016/0898-6568(94)90056-6; TANABE O, 1988, J IMMUNOL, V141, P3875; Vazquez D., 1979, INHIBITORS PROTEIN B; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; ZHANG YH, 1988, J BIOL CHEM, V263, P6177	80	111	113	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10984	10989		10.1074/jbc.271.18.10984	http://dx.doi.org/10.1074/jbc.271.18.10984			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631918	hybrid			2022-12-25	WOS:A1996UJ34200086
J	Higgs, HN; Glomset, JA				Higgs, HN; Glomset, JA			Purification and properties of a phosphatidic acid-preferring phospholipase A(1) from bovine testis - Examination of the molecular basis of its activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BICINCHONINIC ACID; BRAIN; MEMBRANES; BINDING; LIPIDS; HEART	We recently identified a cytosolic phospholipase A(1) activity in bovine brain and testis that preferentially hydrolyzes phosphatidic acid substrates. We also showed that the enzyme displays sigmoidal kinetics toward phosphatidic acid substrates in a Triton X-100 mixed micelle assay system (Higgs, H. N., and Glomset, J. A. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 9574-9578), In the present work we purified the bovine testis enzyme 14,000 fold and used a combination of size exclusion chromatography, labeling with the phospholipase A inhibitor, methyl arachidonyl fluorophosphonate, and SDS-polyacrylamide gel electrophoresis to provide evidence that it is a homotetramer of 110-kDa subunits. Studies of the molecular basis of the enzyme reaction in Triton micelles revealed that (a) a nonhydrolyzable sn-1-alkyl-2-oleoyl analogue of phosphatidic acid activated the enzyme 30-fold in a sigmoidal fashion (Hill coefficient 3.2, EC(50) 4 mol %) without substantially affecting its preference for specific diacyl phosphoglyceride substrates, (b) the activator promoted tight binding of the enzyme to micelles, and (c) the enzyme's activity toward unsaturated phosphatidic acid substrates was affected by the location and nature of the fatty acyl chain double bonds.	UNIV WASHINGTON, HOWARD HUGHES MED INST, DEPT BIOCHEM, SEATTLE, WA 98195 USA; UNIV WASHINGTON, REG PRIMATE RES CTR, SEATTLE, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				Higgs, Henry/0000-0002-2917-9644	NCRR NIH HHS [RR00166] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ACKERMANN EJ, 1995, BBA-LIPID LIPID MET, V1259, P125, DOI 10.1016/0005-2760(95)00143-Z; ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; BADIANI K, 1992, BIOCHEM J, V288, P965, DOI 10.1042/bj2880965; BAZZI MD, 1993, CELL SIGNAL, V5, P357, DOI 10.1016/0898-6568(93)90075-W; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROWN RE, 1989, ANAL BIOCHEM, V180, P136, DOI 10.1016/0003-2697(89)90101-2; CARMAN GM, 1980, J FOOD BIOCHEM, V4, P53, DOI 10.1111/j.1745-4514.1980.tb00877.x; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FOLCH J, 1957, J BIOL CHEM, V226, P497; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HIGGS HN, 1994, P NATL ACAD SCI USA, V91, P9574, DOI 10.1073/pnas.91.20.9574; HOSTETLER KY, 1986, BIOCHEMISTRY-US, V25, P6456, DOI 10.1021/bi00369a017; HUTERER SJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P204, DOI 10.1016/0005-2760(93)90163-4; INOUE M, 1984, J BIOL CHEM, V259, P5083; JAIN MK, 1991, METHOD ENZYMOL, V197, P112; KOYNOVA R, 1994, CHEM PHYS LIPIDS, V69, P1, DOI 10.1016/0009-3084(94)90024-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Marsh D., 1990, CRC HDB LIPID BILAYE; MARTELL AE, 1974, CRITICAL STABILITY C, V1, P139; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MOSIOR M, 1992, BIOCHEMISTRY-US, V31, P1767, DOI 10.1021/bi00121a026; NALBONE G, 1985, J LIPID RES, V26, P104; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4661, DOI 10.1021/bi00134a018; PETE MJ, 1994, J BIOL CHEM, V269, P19494; PETE MJ, 1995, BBA-LIPID LIPID MET, V1256, P367, DOI 10.1016/0005-2760(95)00047-G; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TATE MW, 1991, CHEM PHYS LIPIDS, V57, P147, DOI 10.1016/0009-3084(91)90073-K; UEDA H, 1993, J NEUROCHEM, V61, P1874, DOI 10.1111/j.1471-4159.1993.tb09829.x; UEDA H, 1993, BIOCHEM BIOPH RES CO, V195, P1272, DOI 10.1006/bbrc.1993.2181; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; Waite M, 1981, Methods Enzymol, V71 Pt C, P674	32	50	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10874	10883		10.1074/jbc.271.18.10874	http://dx.doi.org/10.1074/jbc.271.18.10874			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631903	hybrid			2022-12-25	WOS:A1996UJ34200071
J	Hu, E; Liang, P; Spiegelman, BM				Hu, E; Liang, P; Spiegelman, BM			AdipoQ is a novel adipose-specific gene dysregulated in obesity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PULMONARY SURFACTANT APOPROTEIN; RESPONSIVE GLUCOSE TRANSPORTER; MESSENGER-RNA CONTENT; TUMOR-NECROSIS-FACTOR; GROWTH FACTOR-I; 3T3-L1 CELLS; BINDING-PROTEIN; DIFFERENTIAL DISPLAY; ELECTRON-MICROSCOPY; CLASSICAL PATHWAY	Adipose differentiation is accompanied by changes in cellular morphology, a dramatic accumulation of intracellular lipid and activation of a specific program of gene expression, Using an mRNA differential display technique, we have isolated a novel adipose cDNA, termed adipoQ. The adipoQ cDNA encodes a polypeptide of 247 amino acids with a secretory signal sequence at the amino terminus, a collagenous region (Gly-X-Y repeats), and a globular domain. The globular domain of adipoQ shares significant homology with subunits of complement factor Clq, collagen alpha 1(X), and the brain-specific factor cerebellin, The expression of adipoQ is highly specific to adipose tissue in both mouse and rat, Expression of adipoQ is observed exclusively in mature fat cells as the stromal-vascular fraction of fat tissue does not contain adipoQ mRNA. In cultured 3T3-F442A and 3T3-L1 preadipocytes, hormone-induced differentiation dramatically increases the level of expression for adipoQ, Furthermore, the expression of adipoQ mRNA is significantly reduced in the adipose tissues from obese mice and humans. Whereas the biological function of this polypeptide is presently unknown, the tissue-specific expression of a putative secreted protein suggests that this factor may function as a novel signaling molecule for adipose tissue.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042539] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42539] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER M, 1985, J BIOL CHEM, V260, P1978; BALDO A, 1993, J CLIN INVEST, V92, P1543, DOI 10.1172/JCI116733; BEALE EG, 1992, BIOCHEM BIOPH RES CO, V189, P925, DOI 10.1016/0006-291X(92)92292-6; BOBAK DA, 1987, J IMMUNOL, V138, P1150; BRODSKYDOYLE B, 1976, BIOCHEM J, V159, P279, DOI 10.1042/bj1590279; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOY LN, 1992, J BIOL CHEM, V267, P12736; COOK KS, 1985, P NATL ACAD SCI USA, V82, P6480, DOI 10.1073/pnas.82.19.6480; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; CORNELIUS P, 1988, BIOCHEM J, V249, P765, DOI 10.1042/bj2490765; DOGLIO A, 1987, EMBO J, V6, P4011, DOI 10.1002/j.1460-2075.1987.tb02744.x; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; ELIMA K, 1993, BIOCHEM J, V289, P247, DOI 10.1042/bj2890247; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; ERDEI A, 1990, J IMMUNOL, V145, P1754; FEVE B, 1990, J BIOL CHEM, V265, P16343; FINEBERG AP, 1984, ANAL BIOCHEM, V137, P266; FLIER JS, 1987, SCIENCE, V237, P405, DOI 10.1126/science.3299706; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; GHEBREHIWET B, 1978, J IMMUNOL, V120, P27; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GREGOIRE F, 1990, BIOL CELL, V69, P215, DOI 10.1016/0248-4900(90)90348-7; GUEST SJ, 1990, J BIOL CHEM, V265, P5370; HABICHT GS, 1987, J IMMUNOL, V138, P2593; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; IKEDA K, 1987, J BIOL CHEM, V262, P7451; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KINOSHITA T, 1991, IMMUNOL TODAY, V12, P291, DOI 10.1016/0167-5699(91)90001-A; KNOBEL HR, 1975, EUR J IMMUNOL, V5, P78, DOI 10.1002/eji.1830050119; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1994, P NATL ACAD SCI USA, V91, P12515, DOI 10.1073/pnas.91.26.12515; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LIANG P, 1994, NUCLEIC ACIDS RES, V22, P5763, DOI 10.1093/nar/22.25.5763; LU J, 1990, J IMMUNOL, V144, P2287; MALHOTRA R, 1990, J EXP MED, V172, P955, DOI 10.1084/jem.172.3.955; MALHOTRA R, 1993, BIOCHEM J, V293, P15, DOI 10.1042/bj2930015; Maniatis T, 1989, DECONTAMINATION DILU; Martin H, 1990, EUR J IMMUNOL, V20, P1641, DOI 10.1002/eji.1830200804; MOUSTAID N, 1991, J BIOL CHEM, V266, P18550; OIKI S, 1988, J IMMUNOL, V141, P3177; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PETRY F, 1991, J IMMUNOL, V147, P3988; PETRY F, 1992, EUR J BIOCHEM, V209, P129, DOI 10.1111/j.1432-1033.1992.tb17269.x; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; REED BC, 1980, P NATL ACAD SCI-BIOL, V77, P285, DOI 10.1073/pnas.77.1.285; ROSEN BS, 1989, SCIENCE, V244, P1483, DOI 10.1126/science.2734615; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; SIM RB, 1991, IMMUNOL TODAY, V12, P307, DOI 10.1016/0167-5699(91)90004-D; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; SPIEGELMAN BM, 1993, CELL, V73, P625, DOI 10.1016/0092-8674(93)90243-J; SPIEGELMAN BM, 1993, J BIOL CHEM, V268, P6823; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; URADE Y, 1991, P NATL ACAD SCI USA, V88, P1069, DOI 10.1073/pnas.88.3.1069; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WHITE RT, 1985, NATURE, V317, P361, DOI 10.1038/317361a0; WISE LS, 1984, J BIOL CHEM, V259, P4827; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	68	1722	1834	4	67	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10697	10703		10.1074/jbc.271.18.10697	http://dx.doi.org/10.1074/jbc.271.18.10697			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631877	hybrid, Green Published			2022-12-25	WOS:A1996UJ34200045
J	Junghans, RP; Stone, AL; Lewis, MS				Junghans, RP; Stone, AL; Lewis, MS			Biophysical characterization of a recombinant soluble interleukin 2 receptor (Tac) - Evidence for a monomeric structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM; IL-2 RECEPTOR; PROTEIN; ANTIGEN; FORM; EXPRESSION; TARGET; SYSTEM; CELLS; CORE	The interleukin 2 receptor (IL2R) plays a prominent role in the biology of T cells, B cells, and NK cells during activation, Of the three chains described, the alpha-chain of the receptor (Tac; IL2R alpha; CD25) is the most subject to regulation and is shed from the surface of activated cells to generate a soluble form in serum and tissues, Conflicting results have been reported on the native structure of soluble Tac, suggesting variously a monomer, a dimer, or higher noncovalent forms, spawning different models for its mechanism of action, We similarly show a large M(r(app)) by HPLC sieving chromatography, suggesting a tetrameric form, However, stoichiometry-ordered size (SOS) analysis of antibody-antigen complexes indicated only a single epitope per Tac molecule, compatible with a monomeric form, This larger M(r(app)) also conflicted with prior in vivo data showing rapid filtration of soluble Tac through the renal glomerulus that was not expected of a larger complex, Using different solvents, denaturants, and columns in the chromatography suggested that the elevated M(r(app)) values were an artifact of solute column interactions, termed ''ionic exclusion,'' rather than reflecting larger native structures, Analytical ultracentrifugation using a new type of analysis specific to glycoproteins demonstrated monomeric masses under all salt conditions with no tendency to form dimers or higher aggregates, Finally, circular dichroism spectroscopy showed no salt-dependent changes to suggest conformational alterations that might correlate with mobility changes on high pressure liquid chromatography, We conclude therefore that Tac is monomeric under physiologic conditions, Assessments of higher molecular weight for the purified soluble protein by other methods may be explained by the highly acidic nature of the molecule, which hampers matrix penetration with chromatographic media and by the high carbohydrate content and low partial specific volumes that accelerate the molecule in sedimentation media relative to pure protein standards.	NICHHD,DEV & MOLEC IMMUN LAB,NIH,BETHESDA,MD 20892; NIH,NATL CTR RES RESOURCES,BIOMED ENGN & INSTRUMENTAT PROGRAM,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA	Junghans, RP (corresponding author), HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,BIOTHERAPEUT DEV LAB,DIV HEMATOL ONCOL,BOSTON,MA 02215, USA.							ATTRI AK, 1992, ANAL ULTRACENTRIFUGA, P138; BARTH HG, 1980, J CHROMATOGR SCI, V18, P409, DOI 10.1093/chromsci/18.9.409; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; DEPPER JM, 1984, J IMMUNOL, V133, P3054; DISCIPIO RG, 1982, BIOCHIM BIOPHYS ACTA, V709, P58, DOI 10.1016/0167-4838(82)90421-6; DOWER SK, 1990, J CLIN IMMUNOL, V10, P289, DOI 10.1007/BF00917473; FANSLOW WC, 1990, SCIENCE, V248, P739, DOI 10.1126/science.2139736; HAKIMI J, 1987, J BIOL CHEM, V262, P17336; JACQUES Y, 1990, J BIOL CHEM, V265, P20252; JUNGHANS RP, 1996, IN PRESS J EXP MED, V183; KATO K, 1987, BIOCHEMISTRY-US, V26, P5359, DOI 10.1021/bi00391a021; KNOTT GD, 1979, COMPUT PROG BIOMED, V10, P271, DOI 10.1016/0010-468X(79)90075-8; LAMBERT G, 1989, J BIOL CHEM, V264, P12730; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LEONARD WJ, 1983, P NATL ACAD SCI-BIOL, V80, P6957, DOI 10.1073/pnas.80.22.6957; LEONARD WJ, 1985, SCIENCE, V230, P633, DOI 10.1126/science.2996141; MANOUSSAKIS MN, 1989, CLIN IMMUNOL IMMUNOP, V50, P321, DOI 10.1016/0090-1229(89)90140-2; MIEDEL MC, 1989, J BIOL CHEM, V264, P21097; MIEDEL MC, 1988, BIOCHEM BIOPH RES CO, V154, P372, DOI 10.1016/0006-291X(88)90695-X; MIOSSEC P, 1990, ARTHRITIS RHEUM, V33, P1688, DOI 10.1002/art.1780331112; NELSON DL, 1986, ANN INTERN MED, V105, P560; PAULSON JC, 1990, PROTEINS FORM FUNCTI, P209; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; ROBB RJ, 1987, J IMMUNOL, V139, P855; RUSK CM, 1988, J IMMUNOL, V140, P2249; SARAGOVI H, 1987, J IMMUNOL, V139, P1918; SMITH KA, 1989, ANNU REV CELL BIOL, V5, P397; SMITH MH, 1968, HDB BIOCH, pC3; STONE AL, 1985, BIOCHEMISTRY-US, V24, P6666, DOI 10.1021/bi00344a055; SVEDBERG T, 1940, ULTRACENTRIFUGE, P35; SYMONS JA, 1988, J IMMUNOL, V141, P2612; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; WALDMANN TA, 1992, ANN INTERN MED, V116, P148, DOI 10.7326/0003-4819-116-2-148; WALDMANN TA, 1993, BLOOD, V82, P1701; WANO Y, 1984, J IMMUNOL, V132, P3005; WANO Y, 1985, MICROBIOL IMMUNOL, V29, P45; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15; YANG JT, 1986, METHOD ENZYMOL, V130, P208	39	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10453	10460		10.1074/jbc.271.18.10453	http://dx.doi.org/10.1074/jbc.271.18.10453			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631840	hybrid			2022-12-25	WOS:A1996UJ34200008
J	Keri, RA; Nilson, JH				Keri, RA; Nilson, JH			A steroidogenic factor-1 binding site is required for activity of the luteinizing hormone beta subunit promoter in gonadotropes of transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHORIONIC-GONADOTROPIN; GENE-EXPRESSION; EVOLUTION; PITUITARY; ENCODES; PROTEIN	Analysis of luteinizing hormone (LH) beta subunit promoters from a broad range of species including teleosts and humans revealed strict conservation of a sequence homologous to the steroidogenic factor-1 (SF-1) regulatory element of cytochrome P-450 steroid hydroxylase genes. Interaction between SF-1 and this putative response element in the bovine LH beta promoter was confirmed by electrophoretic mobility shift assays. Furthermore, cotransfection of alpha T3-1 cells with an expression vector encoding; SF-1 induced binding site-dependent transcription from the bovine LH beta promoter. Physiological significance of the LH beta SF-1 consensus sequence was established using transgenic mice containing either the wild type bovine promoter or a promoter with a site-specific mutation of this site. Mutation of the SF-1 binding site nearly eliminated promoter activity, and the mutant transgene remained inactive following induction of gonadotropin-releasing hormone accomplished by castrating male and female mice. Thus, increases of gonadotropin-releasing hormone within a physiological range did not compensate for the loss of the SF-1 binding site. Together, these findings indicate that the SF-1 binding site is a key regulator of LH beta promoter activity in vivo and implicate SF-1 as at least one of the transcription factors that acts through this site.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHARMACOL,CLEVELAND,OH 44106	Case Western Reserve University			Keri, Ruth/ABF-2209-2021	Keri, Ruth/0000-0002-1640-3088				ALBARRACIN CT, 1994, ENDOCRINOLOGY, V135, P2300, DOI 10.1210/en.135.6.2300; BARNHART KM, 1994, MOL ENDOCRINOL, V8, P878, DOI 10.1210/me.8.7.878; Conn P. Michael, 1994, P1815; FIDDES JC, 1984, RECENT PROG HORM RES, V40, P43; GHARIB SD, 1990, ENDOCR REV, V11, P177, DOI 10.1210/edrv-11-1-177; HECKERT LL, 1995, J BIOL CHEM, V270, P26497, DOI 10.1074/jbc.270.44.26497; HORN F, 1992, MOL CELL BIOL, V12, P2143, DOI 10.1128/MCB.12.5.2143; HSIEH KP, 1992, MOL ENDOCRINOL, V6, P1673, DOI 10.1210/me.6.10.1673; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; IKEDA Y, 1995, MOL ENDOCRINOL, V9, P478, DOI 10.1210/me.9.4.478; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; JAMESON L, 1984, J BIOL CHEM, V259, P5474; KERI RA, 1994, MOL ENDOCRINOL, V8, P1807, DOI 10.1210/me.8.12.1807; KUMAR TR, 1992, MOL ENDOCRINOL, V6, P81, DOI 10.1210/me.6.1.81; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; LUO XR, 1995, MOL ENDOCRINOL, V9, P1233, DOI 10.1210/me.9.9.1233; ROBERSON MS, 1995, MOL CELL BIOL, V15, P3531; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; SHERMAN GB, 1992, MOL ENDOCRINOL, V6, P951, DOI 10.1210/me.6.6.951; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; VIRGIN JB, 1985, J BIOL CHEM, V260, P7072; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597; XIONG F, 1994, MOL ENDOCRINOL, V8, P771, DOI 10.1210/me.8.6.771	25	141	143	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10782	10785		10.1074/jbc.271.18.10782	http://dx.doi.org/10.1074/jbc.271.18.10782			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631889	hybrid			2022-12-25	WOS:A1996UJ34200057
J	Ostermeier, M; DeSutter, K; Georgiou, G				Ostermeier, M; DeSutter, K; Georgiou, G			Eukaryotic protein disulfide isomerase complements Escherichia coli dsbA mutants and increases the yield of a heterologous secreted protein with disulfide bonds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; FORMATION INVIVO; BETA-LACTAMASE; KINETIC ROLE; IDENTIFICATION; CATALYSIS; PATHWAY; STATE; BPTI	Eukaryotic protein disulfide isomerase (PDI) is a 55-kDa enzyme with cysteine oxidoreductase, chaperone, and antichaperone activities that catalyze disulfide formation and rearrangement in the eukaryotic endoplasmic reticulum, In Gram-negative bacteria, the formation of disulfide bonds in the periplasm is mediated by DsbA, a strong cysteine oxidase but an inefficient catalyst of disulfide bond isomerization with no known chaperone activity, We show that rat PDI (rPDI) secreted in the periplasmic space of Escherichia coli can catalyze the formation of disulfide bonds and complement several of the phenotypes of dsbA mutants, The function of rPDI was dependent on the dsbB gene, suggesting that the reoxidation of this eukaryotic enzyme involves direct interactions with bacterial redox proteins, Co-expression of rPDI increased the yield of bovine pancreatic trypsin inhibitor (BPTI) severalfold, an effect that was enhanced when reduced glutathione was added to the growth medium, Whereas PDI is thought to function primarily as an isomerase in the eukaryotic endoplasmic reticulum, rPDI failed to decrease the accumulation of two-disulfide folding intermediates of BPTI and thus did not appear to appreciably catalyze the rate-limiting step in the oxidative folding pathway of BPTI. These results demonstrate that expression of eukaryotic foldases in E, coli can be exploited to better understand their function in vivo and also to increase the yield of biotechnologically valuable proteins.	UNIV TEXAS, DEPT CHEM ENGN, AUSTIN, TX 78712 USA; STATE UNIV GHENT, MOLEC BIOL LAB, B-9000 GHENT, BELGIUM	University of Texas System; University of Texas Austin; Ghent University			Ostermeier, Marc/A-2697-2010	Ostermeier, Marc/0000-0003-0900-3665	NIGMS NIH HHS [GM47520-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047520] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; CAI H, 1994, J BIOL CHEM, V269, P24550; CREIGHTON TE, 1980, J MOL BIOL, V142, P43, DOI 10.1016/0022-2836(80)90205-3; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1993, J MOL BIOL, V232, P1176, DOI 10.1006/jmbi.1993.1470; CREIGHTON TE, 1992, BIOESSAYS, V14, P195, DOI 10.1002/bies.950140310; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; DARBY NJ, 1994, BIOCHEMISTRY-US, V33, P7937, DOI 10.1021/bi00191a022; DESUTTER K, 1992, MOL MICROBIOL, V6, P2201; DESUTTER K, 1994, GENE, V141, P163, DOI 10.1016/0378-1119(94)90566-5; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GOLDENBERG DP, 1992, TRENDS BIOCHEM SCI, V17, P257, DOI 10.1016/0968-0004(92)90405-X; GOLDENBERG DP, 1988, BIOCHEMISTRY-US, V27, P2481, DOI 10.1021/bi00407a034; GUILHOT C, 1995, P NATL ACAD SCI USA, V92, P9895, DOI 10.1073/pnas.92.21.9895; HUMPHREYS DP, 1995, J BIOL CHEM, V270, P28210; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JANDER G, 1994, EMBO J, V13, P5121, DOI 10.1002/j.1460-2075.1994.tb06841.x; JOLY JC, 1994, BIOCHEMISTRY-US, V33, P4231, DOI 10.1021/bi00180a017; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KISHIGAMI S, 1995, FEBS LETT, V364, P55, DOI 10.1016/0014-5793(95)00354-C; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P619, DOI 10.1021/bi00217a005; LYLES MM, 1994, J BIOL CHEM, V269, P30946; MCGRATH ME, 1991, J BIOL CHEM, V266, P6620; MISSIAKAS D, 1993, P NATL ACAD SCI USA, V90, P7084, DOI 10.1073/pnas.90.15.7084; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; MISSIAKAS D, 1995, EMBO J, V14, P3415, DOI 10.1002/j.1460-2075.1995.tb07347.x; NEU HC, 1965, J BIOL CHEM, V240, P3685; OSTERMEIER M, 1994, J BIOL CHEM, V269, P21072; POLLITT S, 1983, J BACTERIOL, V153, P27, DOI 10.1128/JB.153.1.27-32.1983; PUIG A, 1994, J BIOL CHEM, V269, P7764; PUIG A, 1994, J BIOL CHEM, V269, P19128; SILHAVY T, 1983, EXPT GENE FUSIONS; VINCENT JP, 1972, BIOCHEMISTRY-US, V11, P2967, DOI 10.1021/bi00766a007; WALKER KW, 1994, J BIOL CHEM, V269, P28487; WEISSMAN JS, 1992, P NATL ACAD SCI USA, V89, P9900, DOI 10.1073/pnas.89.20.9900; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; WITTRUP KD, 1995, IN PRESS CURR OPIN B; WULFING C, 1994, MOL MICROBIOL, V12, P685, DOI 10.1111/j.1365-2958.1994.tb01056.x; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P5202, DOI 10.1021/bi00183a025; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	45	73	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10616	10622		10.1074/jbc.271.18.10616	http://dx.doi.org/10.1074/jbc.271.18.10616			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631865	hybrid			2022-12-25	WOS:A1996UJ34200033
J	Paradis, P; MacLellan, WR; Belaguli, NS; Schwartz, RJ; Schneider, MD				Paradis, P; MacLellan, WR; Belaguli, NS; Schwartz, RJ; Schneider, MD			Serum response factor mediates AP-1-dependent induction of the skeletal alpha-actin promoter in ventricular myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; INDUCED CARDIAC-HYPERTROPHY; TRANSFORMING GROWTH-FACTOR; PROTO-ONCOGENE FAMILY; C-FOS GENE; TRANSCRIPTIONAL ACTIVATION; MOLECULAR CHARACTERIZATION; PHYSICAL ASSOCIATION; EXPRESSION; JUN	''Fetal'' gene transcription, including activation of the skeletal alpha-actin (SkA) promoter, is provoked in cardiac myocytes by mechanical stress and trophic ligands. Induction of the promoter by transforming growth factor beta or norepinephrine requires serum response factor (SRF) and TEF-1; expression is inhibited by YY1. We and others postulated that immediate-early transcription factors might couple trophic signals to this fetal program. However, multiple Fos/Jun proteins exist, and the exact relationship between control by Fos/Jun versus SRF, TEF-1, and YY1 is unexplained. We therefore cotransfected ventricular myocytes with Fos, Jun, or JunB, and SkA reporter genes, SkA transcription was augmented by Jun, Fos/Jun, Fos/JunB, and Jun/JunB; Fos and JunB alone were neutral or inhibitory. Mutation of the SRF site, SRE1, impaired activation by Jun; YY1, TEF-1, and Sp1 sites were dispensable. SRE1 conferred Jun activation to a heterologous promoter, as did the c-fos SRE. Deletions of DNA binding, dimerization, or trans-activation domains of Jun and SRF abolished activation by Jun and synergy with SRF. Neither direct binding of Fos/Jun to SREs, nor physical interaction between Fos/Jun and SRF, was detected in mobility-shift assays. Thus, AP-1 factors activate a hypertrophy-associated gene via SRF, without detectable binding to the promoter or to SRF.	BAYLOR COLL MED,MOLEC CARDIOL UNIT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007706, P01HL049953, R01HL047567] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07706, P01 HL49953, R01 HL47567] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDELLATIF M, 1994, J BIOL CHEM, V269, P15423; AOYAGI T, 1993, J BIOL CHEM, V268, P27176; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BISHOPRIC NH, 1992, J BIOL CHEM, V267, P25535; BLACK FM, 1991, J CLIN INVEST, V88, P1581, DOI 10.1172/JCI115470; BODMER R, 1993, DEVELOPMENT, V118, P719; BRAND T, 1995, J BIOL CHEM, V270, P8274, DOI 10.1074/jbc.270.14.8274; BRAND T, 1993, J BIOL CHEM, V268, P11500; BRAND T, 1993, J MOL CELL CARDIOL, V25, P1325, DOI 10.1006/jmcc.1993.1145; BRAND T, 1992, CIRC RES, V71, P1351, DOI 10.1161/01.RES.71.6.1351; BROWN PH, 1993, ONCOGENE, V8, P877; CHEN CY, 1995, CIRCULATION, V92, P369; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; CURRAN T, 1987, ONCOGENE, V2, P79; FRANKLIN CC, 1995, BIOCHEM J, V305, P967, DOI 10.1042/bj3050967; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HEWETT TE, 1994, CIRC RES, V74, P740, DOI 10.1161/01.RES.74.4.740; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; IMBRA RJ, 1986, NATURE, V323, P555, DOI 10.1038/323555a0; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; JOHANSEN FE, 1995, BBA-REV CANCER, V1242, P1, DOI 10.1016/0304-419X(94)00014-S; JOLIET V, 1995, NATURE, V373, P632, DOI 10.1038/373632a0; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; KIM JH, 1994, J BIOL CHEM, V269, P13740; KIM SJ, 1989, J BIOL CHEM, V264, P7041; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KOVACICMILIVOJEVIC B, 1992, MOL CELL BIOL, V12, P292, DOI 10.1128/MCB.12.1.292; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LI L, 1990, J BIOL CHEM, V265, P1556; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MACLELLAN WR, 1993, CIRC RES, V73, P783, DOI 10.1161/01.RES.73.5.783; MCBRIDE K, 1993, MOL CELL BIOL, V13, P600, DOI 10.1128/MCB.13.1.600; NARANJO JR, 1991, NEURON, V6, P607, DOI 10.1016/0896-6273(91)90063-6; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ORNITZ DM, 1991, P NATL ACAD SCI USA, V88, P698, DOI 10.1073/pnas.88.3.698; PARKER TG, 1992, J BIOL CHEM, V267, P3343; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; Ransone Lynn J., 1993, Gene Expression, V3, P37; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; ROSENZWEIG A, 1991, CIRCULATION, V84, P1256, DOI 10.1161/01.CIR.84.3.1256; SADOSHIMA J, 1995, CIRC RES, V77, P1040, DOI 10.1161/01.RES.77.6.1040; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; TANAKA M, 1995, J AM COLL CARDIOL, V26, P85, DOI 10.1016/0735-1097(95)00145-P; TREISMAN R, 1995, NATURE, V376, P468, DOI 10.1038/376468a0; WADE EJ, 1992, J VIROL, V66, P2407, DOI 10.1128/JVI.66.4.2407-2417.1992; ZACHOW KR, 1992, J VIROL, V66, P1659; ZHU H, 1994, J BIOL CHEM, V269, P3489	58	87	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10827	10833		10.1074/jbc.271.18.10827	http://dx.doi.org/10.1074/jbc.271.18.10827			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631897	hybrid			2022-12-25	WOS:A1996UJ34200065
J	Ridky, TW; BizubBender, D; Cameron, CE; Weber, IT; Wlodawer, A; Copeland, T; Skalka, AM; Leis, J				Ridky, TW; BizubBender, D; Cameron, CE; Weber, IT; Wlodawer, A; Copeland, T; Skalka, AM; Leis, J			Programming the rous sarcoma virus protease to cleave new substrate sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								The Rous sarcoma virus protease displays a high degree of specificity and catalyzes the cleavage of only a limited number of amino acid sequences. This specificity is governed by interactions between side chains of eight substrate amino acids and eight corresponding subsite pockets within the homodimeric enzyme, We have examined these complex interactions in order to learn how to introduce changes into the retroviral protease (PR) that direct it to cleave new substrates. Mutant enzymes with altered substrate specificity and wild-type or greater catalytic rates have been constructed previously by substituting single key amino acids in each of the eight enzyme subsites with those residues found in structurally related positions of human immunodeficiency virus (HIV)-1 PR. These individual amino acid substitutions have now been combined into one enzyme, resulting in a highly active mutant Rous sarcoma virus (RSV) protease that displays many characteristics associated with the HIV-1 enzyme, The hybrid protease is capable of catalyzing the cleavage of a set of HIV-1 viral polyprotein substrates that are not recognized by the wild-type RSV enzyme. Additionally, the modified PR is inhibited completely by the HIV-1 PR-specific inhibitor KNI-272 at concentrations where wild-type RSV PR is unaffected, These results indicate that the major determinants that dictate RSV and HIV-1 PR substrate specificity have been identified, Since the viral protease is a homodimer, the rational design of enzymes with altered specificity also requires a thorough understanding of the importance of enzyme symmetry in substrate selection, We demonstrate here that the enzyme homodimer acts symmetrically in substrate selection with each enzyme subunit being capable of recognizing both halves of a peptide substrate equally.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; FOX CHASE CANC CTR,INST CANC RES,PHILADELPHIA,PA 19111; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107; NCI,FREDERICK CANC RES & DEV CTR,MACROMOL STRUCT LAB,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	Case Western Reserve University; Fox Chase Cancer Center; Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [CA52047, CA06937, CA58166] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052047, R01CA058166] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER F, 1987, J VIROL, V61, P534, DOI 10.1128/JVI.61.2.534-542.1987; BIZUB D, 1991, J BIOL CHEM, V266, P4951; CAMERON CE, 1994, J BIOL CHEM, V269, P11170; CAMERON CE, 1993, J BIOL CHEM, V268, P11711; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; FITZGERALD P, 1991, J BIOL CHEM, V265, P14209; GRINDE B, 1992, J BIOL CHEM, V267, P9481; GRINDE B, 1992, J BIOL CHEM, V267, P9491; GULNIK SV, 1995, BIOCHEMISTRY-US, V34, P9282, DOI 10.1021/bi00029a002; JASKOLSKI M, 1990, BIOCHEMISTRY-US, V29, P5889, DOI 10.1021/bi00477a002; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; RIDKY T, 1995, J BIOL CHEM, V270, P29621, DOI 10.1074/jbc.270.50.29621; Ridky TW, 1996, J BIOL CHEM, V271, P4709, DOI 10.1074/jbc.271.9.4709; SEDLACEK J, 1993, VIROLOGY, V192, P667, DOI 10.1006/viro.1993.1085; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279	15	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10538	10544		10.1074/jbc.271.18.10538	http://dx.doi.org/10.1074/jbc.271.18.10538			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631853	Green Submitted, hybrid			2022-12-25	WOS:A1996UJ34200021
J	Roll, B; Amons, R; deJong, WW				Roll, B; Amons, R; deJong, WW			Vitamin A(2) bound to cellular retinol-binding protein as ultraviolet filter in the eye lens of the gecko Lygodactylus picturatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VISUAL PIGMENTS; CRYSTALLINS; EXPRESSION; EVOLUTION; TISSUE	The yellow eye lenses of the diurnal gecko Lygodactylus picturatus contain, in addition to the usual crystallins, a monomeric protein with a molecular mass of 16 kDa., It comprises 6-8% of the total water-soluble lens proteins. We here identify it as a novel type of crystallin, most closely related with cellular retinol-binding protein I (CRBP I), Because of its tiny size, we designate it as L-crystallin. The typical endogenous ligand of CRBP is all-trans-retinol. In the gecko lens, however, the ligand of L-crystallin turns out to be 3-dehydroretinol (vitamin A(2)), which causes the yellow color of this lens, The L-crystallin . 3-dehydroretinol complex absorbs shortwave radiation, supposedly improving the optical quality of the dioptric apparatus and protecting the retina against ultraviolet damage, Whereas other crystallins have been recruited from stress proteins and metabolic enzymes, L-crystallin represents a completely new class of taxon-specific lens proteins, Also, its ligand 3-dehydroretinol represents a novel type of lens pigment.	LEIDEN UNIV,DEPT BIOCHEM MED,2300 RA LEIDEN,NETHERLANDS; UNIV NIJMEGEN,DEPT BIOCHEM,6500 HB NIJMEGEN,NETHERLANDS; UNIV AMSTERDAM,INST SYSTEMAT & POPULAT BIOL,1090 GT AMSTERDAM,NETHERLANDS	Leiden University; Leiden University - Excl LUMC; Radboud University Nijmegen; University of Amsterdam	Roll, B (corresponding author), RUHR UNIV BOCHUM,FAK BIOL,LEHRSTUHL TIERPHYSIOL,D-44780 BOCHUM,GERMANY.							BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BECKER RS, 1988, PHOTOCHEM PHOTOBIOL, V48, P369, DOI 10.1111/j.1751-1097.1988.tb02836.x; CHIOU SH, 1987, FEBS LETT, V221, P134, DOI 10.1016/0014-5793(87)80367-8; COLLIER R, 1987, DEGENERATIVE RETINAL, P571; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; DEJONG WW, 1994, PROG RETIN EYE RES, V13, P391, DOI 10.1016/1350-9462(94)90018-3; JAWORSKI CJ, 1994, INVEST OPHTH VIS SCI, V35, P1706; JIMENEZASENSIO J, 1995, BIOCHEM BIOPH RES CO, V209, P796, DOI 10.1006/bbrc.1995.1570; KUCHLING H, 1979, TASCHENBUCH PHYSIK; LI E, 1986, P NATL ACAD SCI USA, V83, P5779, DOI 10.1073/pnas.83.16.5779; MACDONALD PN, 1987, J BIOL CHEM, V262, P10550; NEWCOMER ME, 1995, FASEB J, V9, P229, DOI 10.1096/fasebj.9.2.7781925; ONG DE, 1978, J BIOL CHEM, V253, P828; PIATIGORSKY J, 1991, SCIENCE, V252, P1078, DOI 10.1126/science.252.5009.1078; PROVENCIO I, 1992, VISION RES, V32, P2201, DOI 10.1016/0042-6989(92)90084-V; RAJAN N, 1990, J LIPID RES, V31, P821; Roll B, 1995, BIOCHEM BIOPH RES CO, V217, P452, DOI 10.1006/bbrc.1995.2797; ROLL B, 1995, HERPETOL J, V5, P298; ROLL B, 1990, THESIS RUHR U BOCHUM; Roll Beate, 1994, Sauria, V16, P307; Saari J.C., 1990, Progress in Retinal Research, V9, P363, DOI 10.1016/0278-4327(90)90011-6; THORPE A, 1993, VISION RES, V33, P289, DOI 10.1016/0042-6989(93)90085-B; UNDERWOOD G, 1970, BIOLOGY REPTILIA, V2, P1; VEERKAMP JH, 1995, PROG LIPID RES, V34, P17, DOI 10.1016/0163-7827(94)00005-7; WALLS G. L, 1934, AM J OPHTHALMOL, V17, P892, DOI DOI 10.1016/S0002-9394(34)93309-2; WALLS GL, 1942, VERTEBRATE EYE ITS A, P622; Wistow G, 1995, MOL BIOL EVOLUTION C; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; YU NT, 1991, EXP EYE RES, V52, P475, DOI 10.1016/0014-4835(91)90045-G; ZIGLER JS, 1991, FASEB J, V5, P223, DOI 10.1096/fasebj.5.2.2004667; ZIGMAN S, 1988, EXP EYE RES, V47, P819, DOI 10.1016/0014-4835(88)90065-6	31	27	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10437	10440						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631836				2022-12-25	WOS:A1996UJ34200004
J	Steinberger, P; Kraft, D; Valenta, R				Steinberger, P; Kraft, D; Valenta, R			Construction of a combinatorial IgE library from an allergic patient - Isolation and characterization of human IgE Fabs with specificity for the major timothy grass pollen allergen, Phl p 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNOGLOBULIN-E; EPSILON-CHAIN CDNA; MONOCLONAL-ANTIBODIES; PRATENSE POLLEN; PHAGE SURFACES; BINDING-SITE; CLONING; GENE; PROTEIN; LINKAGE	To characterize human IgE antibodies with specificity for a major allergen at the molecular level, we have constructed an IgE combinatorial library from a grass pollen allergic patient. cDNAs coding for IgE heavy chain fragments and for light chains were reverse-transcribed and polymerase chain reaction-amplified from RNA of peripheral blood lymphocytes and randomly combined in plasmid pComb3H to yield a combinatorial library of 5 x 10(7) primary clones. IgE Fabs with specificity for Phl p 5, a major timothy grass pollen allergen, were isolated by panning. Sequence analysis showed that the 4 of the Fabs used the same heavy chain fragments which had combined with different kappa light chains. Soluble recombinant IgE Fabs were purified by affinity chromatography to Phl p 5 and, like natural IgE antibodies, cross-reacted with group 5 allergens from different grass species. The described approach should facilitate studies on the molecular interaction between IgE antibodies and allergens and encourages the consideration of specific IgE Fabs that are capable of interfering with allergen-IgE binding as potential therapeutic tools.	UNIV VIENNA,INST GEN & EXPTL PATHOL,AKH,A-1090 VIENNA,AUSTRIA	University of Vienna				Steinberger, Peter/0000-0001-6848-4097; Valenta, Rudolf/0000-0001-5944-3365				BARBAS CF, 1994, P NATL ACAD SCI USA, V91, P3809, DOI 10.1073/pnas.91.9.3809; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BENNICH H, 1973, FEBS LETT, V33, P49, DOI 10.1016/0014-5793(73)80156-5; BENNICH HH, 1968, IMMUNOLOGY, V15, P323; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; BUFE A, 1994, J ALLERGY CLIN IMMUN, V94, P173, DOI 10.1016/0091-6749(94)90037-X; DOLECEK C, 1993, FEBS LETT, V335, P299, DOI 10.1016/0014-5793(93)80406-K; FLANAGAN JG, 1982, EMBO J, V1, P655, DOI 10.1002/j.1460-2075.1982.tb01223.x; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; HELM B, 1988, NATURE, V331, P180, DOI 10.1038/331180a0; ISHIZAKA K, 1970, ANN ALLERGY, V28, P189; KABAT EA, 1987, SEQUENCES PROTEINS I, P674; KANG A S, 1991, Methods (Orlando), V2, P111, DOI 10.1016/S1046-2023(05)80211-7; KANG AS, 1991, P NATL ACAD SCI USA, V88, P4363, DOI 10.1073/pnas.88.10.4363; KOCHWA S, 1971, ANN NY ACAD SCI, V190, P49, DOI 10.1111/j.1749-6632.1971.tb13523.x; KUROKAWA T, 1983, NUCLEIC ACIDS RES, V11, P3077, DOI 10.1093/nar/11.10.3077; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; Leonard Davis G., 1986, BASIC METHODS MOL BI; MACKENZIE T, 1989, J EXP MED, V169, P407, DOI 10.1084/jem.169.2.407; MATTHIESEN F, 1993, MOLECULAR BIOLOGY AND IMMUNOLOGY OF ALLERGENS, P189; NISSIM A, 1992, MOL IMMUNOL, V29, P1065, DOI 10.1016/0161-5890(92)90038-Y; PERSSON MAA, 1991, P NATL ACAD SCI USA, V88, P2432, DOI 10.1073/pnas.88.6.2432; PRESTA L, 1994, J BIOL CHEM, V269, P26368; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENO M, 1983, NUCLEIC ACIDS RES, V11, P719, DOI 10.1093/nar/11.3.719; SILVANOVICH A, 1991, J BIOL CHEM, V266, P1204; SINGH MB, 1991, P NATL ACAD SCI USA, V88, P1384, DOI 10.1073/pnas.88.4.1384; STEINBERGER P, 1995, J ALLERGY CLIN IMMUN, V96, P209, DOI 10.1016/S0091-6749(95)70010-2; TERRY WD, 1970, J IMMUNOL, V105, P783; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1994, ALLERGY CLIN IMMUNOL, V6, P165; VANDERSTOEP N, 1993, J EXP MED, V177, P99, DOI 10.1084/jem.177.1.99; VANREE R, 1992, CLIN EXP ALLERGY, V22, P611; VRTALA S, 1993, J IMMUNOL, V151, P4773; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160, DOI 10.1159/000236567; VRTALA S, 1996, IN PRESS; WALDMANN TA, 1991, SCIENCE, V252, P1657, DOI 10.1126/science.2047874	38	70	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10967	10972		10.1074/jbc.271.18.10967	http://dx.doi.org/10.1074/jbc.271.18.10967			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631916	hybrid			2022-12-25	WOS:A1996UJ34200084
J	Conrad, KP; Benyo, DF; WesterhausenLarsen, A; Miles, TM				Conrad, KP; Benyo, DF; WesterhausenLarsen, A; Miles, TM			Expression of erythropoietin by the human placenta	FASEB JOURNAL			English	Article						syncytiotrophoblast; cytotrophoblast; JAR choriocarcinoma cells; hypoxia; pregnancy; preeclampsia	COLONY-STIMULATING FACTOR; CONSCIOUS RATS; INSITU HYBRIDIZATION; GENE-EXPRESSION; CELLS; MACROPHAGE; PREGNANCY; DIFFERENTIATION; HEMODYNAMICS; TROPHOBLAST	Circulating levels of maternal erythropoietin (EPO) rise during gestation due to increased biosynthesis of the hormone, Our objective was to investigate the human placenta as a potential extrarenal site of EPO production, Using two monoclonal antibodies recognizing different antigenic determinants, we identified immunoreactive EPO associated with villous cytotrophoblast, endovascular and intravascular cytotrophoblast, cytotrophoblast cell colunms, and syncytiotrophoblast of first and second-trimester placenta as well as syncytiotrophoblast and extravillous cytotrophoblast of normal third-trimester and preeclamptic placenta, In addition, cultured JAR (trophoblast-derived) choriocarcinoma cells, cytotrophoblasts isolated from term placenta, villous core cells, and possibly other nontrophoblast cells within the decidual basal plate expressed immunoreactive EPO, Using reverse transcription-polymerase chain reaction and EPO-specific primers, a 378 bp DNA product was amplified from placental tissues of various gestational ages, cytotrophoblasts isolated from term placenta, and JAR choriocarcinoma cells, The amplified product yielded restriction enzyme fragments of predicted sizes, On Southern analysis, hybridization was observed for two of these fragments in which the radiolabeled EPO cDNA probe did not overlap with the primer sequences, Finally, the JAR choriocarcinoma cells elaborated EPO into the culture medium as determined by enzyme-linked immunosorbant assay and expressed EPO mRNA as determined by Northern analysis, both of which were stimulated by hypoxia (15-20 torr), Taken together, these results suggest a new site of EPO expression: the trophoblast cell of the human placenta.	UNIV PITTSBURGH,DEPT OBSTET GYNECOL & REPROD SCI,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Conrad, KP (corresponding author), MAGEE WOMENS RES INST,204 CRAFT AVE,PITTSBURGH,PA 15213, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030325, K04HD001098] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD30325, K04 HD01098] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANAGNOSTOU A, 1990, P NATL ACAD SCI USA, V87, P5978, DOI 10.1073/pnas.87.15.5978; BACHMANN S, 1993, J HISTOCHEM CYTOCHEM, V41, P335, DOI 10.1177/41.3.8429197; BONDURANT MC, 1991, SEMIN HEMATOL, V28, P20; CARLINI RG, 1995, KIDNEY INT, V47, P740, DOI 10.1038/ki.1995.113; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CONRAD KP, 1984, KIDNEY INT, V26, P24, DOI 10.1038/ki.1984.129; CONRAD KP, 1992, UROL ANN, V6, P313; DELVALLE GO, 1993, AM J PHYSIOL, V265, pR399, DOI 10.1152/ajpregu.1993.265.2.R399; FRANDREY J, 1993, BLOOD, V81, P617; GARCIALLORET MI, 1994, EXP CELL RES, V214, P46, DOI 10.1006/excr.1994.1232; GILSON GJ, 1992, AM J PHYSIOL, V263, pH1911, DOI 10.1152/ajpheart.1992.263.6.H1911; GOUGH SR, 1995, AM J PHYSIOL-REG I, V268, pR1117, DOI 10.1152/ajpregu.1995.268.5.R1117; GUILBERT L, 1993, IMMUNOL CELL BIOL, V71, P49, DOI 10.1038/icb.1993.5; HERMINE O, 1991, BLOOD, V78, P2253; HUCH R, 1993, ANN MED, V25, P289; JELKMANN W, 1994, CLIN INVESTIGATOR, V72, pS3; KLIMAN HJ, 1986, ENDOCRINOLOGY, V118, P1567, DOI 10.1210/endo-118-4-1567; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; KOURY ST, 1993, MICROSC RES TECHNIQ, V25, P29, DOI 10.1002/jemt.1070250106; LONGO LD, 1983, AM J PHYSIOL, V245, pR720, DOI 10.1152/ajpregu.1983.245.5.R720; MASUDA S, 1994, J BIOL CHEM, V269, P19488; *NAT HIGH BLOOD PR, 1991, 913029 NIH; OHLS RK, 1994, PEDIATR RES, V35, P169, DOI 10.1203/00006450-199402000-00008; PEKONEN F, 1987, ACTA ENDOCRINOL-COP, V116, P561, DOI 10.1530/acta.0.1160561; PRITCHARD JA, 1960, AM J OBSTET GYNECOL, V79, P750, DOI 10.1016/0002-9378(60)90633-5; SAITO S, 1993, GROWTH FACTORS, V9, P11, DOI 10.3109/08977199308991578; SAITO S, 1991, BIOCHEM BIOPH RES CO, V178, P1099, DOI 10.1016/0006-291X(91)91005-W; SAWYER ST, 1989, BLOOD, V74, P103; SHIRAMIZU M, 1994, EXP CELL RES, V215, P249, DOI 10.1006/excr.1994.1340; UENO M, 1989, AM J PHYSIOL, V257, pC743, DOI 10.1152/ajpcell.1989.257.4.C743; VOGT C, 1989, EXP HEMATOL, V17, P391; WIDNESS JA, 1991, J DEV PHYSIOL, V15, P139; WOGNUM AW, 1990, EXP HEMATOL, V18, P228; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223; ZANJANI ED, 1974, J LAB CLIN MED, V83, P281; ZANJANI ED, 1977, J LAB CLIN MED, V89, P640	37	106	111	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1996	10	7					760	768		10.1096/fasebj.10.7.8635693	http://dx.doi.org/10.1096/fasebj.10.7.8635693			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UN798	8635693				2022-12-25	WOS:A1996UN79800010
J	Schonfelder, G; John, M; Hopp, H; Fuhr, N; vanderGiet, M; Paul, M				Schonfelder, G; John, M; Hopp, H; Fuhr, N; vanderGiet, M; Paul, M			Expression of inducible nitric oxide synthase in placenta of women with gestational diabetes	FASEB JOURNAL			English	Article						human placenta; RT-PCR	PROTEINS	Gestational diabetes is one of the most prevalent medical complications of pregnancy and causes increased fetal wastage, Investigation of placentas from diabetic mothers indicate chronic: disturbances in intervillous circulation, dilatation of capillaries, and a relatively immature villous structure, Abnormal levels of nitric oxide (NO) may contribute to maternal disorders such as the pathogenesis of diabetic: vascular complications, In the normal placenta NO is generated only by endothelial NOS, which apparently serves to regulate vascular tone in the fetoplacental circulation, In contrast, studies have reported the absence of inducible nitric oxide synthase (iNOS) in human placentas under normal conditions, The aim of our study was to investigate whether iNOS is expressed in placentas from patients with gestational diabetes, Reverse transcription-polymerase chain reaction and Western blot analysis demonstrated iNOS mRNA and protein expression in placental tissue only from patients with gestational diabetes, Immunohistochemistry localized iNOS staining to endothelial cells and trophoblasts, We conclude that iNOS can be expressed in human placenta, Its expression might play an important role in placental pathophysiology.	FREE UNIV BERLIN,KLINIKUM BENJAMIN FRANKLIN,DEPT CLIN PHARMACOL,D-12200 BERLIN,GERMANY; FREE UNIV BERLIN,KLINIKUM BENJAMIN FRANKLIN,DEPT GASTROENTEROL,D-12200 BERLIN,GERMANY; FREE UNIV BERLIN,KLINIKUM BENJAMIN FRANKLIN,DEPT OBSTET & GYNECOL,D-12200 BERLIN,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin			Paul, Martin/K-5425-2015	Schonfelder, Gilbert/0000-0001-6134-1990				ANKARCRONA M, 1994, EXP CELL RES, V213, P172, DOI 10.1006/excr.1994.1187; BACKE E, 1991, J CLIN PATHOL, V44, P936, DOI 10.1136/jcp.44.11.936; BARON AD, 1994, AM J PHYSIOL, V267, pE187, DOI 10.1152/ajpendo.1994.267.2.E187; BENIRSCHKE K, 1990, PATHOLOGY HUMAN PLAC, P475; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURSTEIN R, 1963, AM J OBSTET GYNECOL, V86, P66, DOI 10.1016/0002-9378(63)90077-2; BUTTERY LDK, 1994, PLACENTA, V15, P257, DOI 10.1016/0143-4004(94)90017-5; CETKOVICCVRLJE M, 1994, CYTOKINE, V6, P399, DOI 10.1016/1043-4666(94)90064-7; CONRAD KP, 1993, FASEB J, V7, P1269, DOI 10.1096/fasebj.7.13.7691671; CORBETT JA, 1995, J EXP MED, V181, P559, DOI 10.1084/jem.181.2.559; DIKRANIAN K, 1994, ACTA HISTOCHEM, V96, P145, DOI 10.1016/S0065-1281(11)80170-4; EIS ALW, 1995, PLACENTA, V16, P113, DOI 10.1016/0143-4004(95)90000-4; EMMRICH P, 1968, PATHOL MICROBIOL, V32, P285, DOI 10.1159/000162069; FOX H, 1969, OBSTET GYNECOL, V34, P792; GARVEY EP, 1994, ARCH BIOCHEM BIOPHYS, V311, P235, DOI 10.1006/abbi.1994.1232; HARTY JR, 1992, J CLIN ENDOCR METAB, V75, P947, DOI 10.1210/jc.75.3.947; Haust M D, 1981, Monogr Pathol, P201; HOLEBERG G, 1995, AM J OBSTET GYNECOL, V172, P71; HOPP H, 1995, GEBURTSH FRAUENHEILK, V55, P28, DOI 10.1055/s-2007-1022769; HU XL, 1992, J REPROD IMMUNOL, V22, P257, DOI 10.1016/0165-0378(92)90047-8; KOLB H, 1991, LIFE SCI, V49; KRISTOFFERSEN EK, 1994, APMIS, V102, P509, DOI 10.1111/j.1699-0463.1994.tb05198.x; KRONCKE KD, 1994, IMMUNOBIOLOGY, V19, P267; Kukor Z., 1994, Acta Physiologica Hungarica, V82, P313; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBRACH CL, 1994, J BIOL CHEM, V269, P17125; LINDSAY RM, 1995, DIABETES, V44, P365, DOI 10.2337/diabetes.44.3.365; LUKIC ML, 1991, BIOCHEM BIOPH RES CO, V178, P913, DOI 10.1016/0006-291X(91)90978-G; MOHR H, 1950, Zentralbl Gynakol, V72, P1530; MYATT L, 1993, PLACENTA, V14, P487, DOI 10.1016/S0143-4004(05)80202-4; MYATT L, 1993, PLACENTA, V14, P373, DOI 10.1016/S0143-4004(05)80459-X; MYATT L, 1991, AM J OBSTET GYNECOL, V164, P687, DOI 10.1016/S0002-9378(11)80047-5; Nagy G, 1993, Zentralbl Gynakol, V115, P450; REILING N, 1994, EUR J IMMUNOL, V24, P1941, DOI 10.1002/eji.1830240836; SHARMA K, 1995, BIOCHEM BIOPH RES CO, V207, P80, DOI 10.1006/bbrc.1995.1156; SPRINGALL DR, 1992, HISTOCHEMISTRY, V98, P259, DOI 10.1007/BF00271040; THOMSEN K, 1958, ACTA ENDOCRINOL-COP, V29, P602, DOI 10.1530/acta.0.0290602; VOGEL M, 1967, VIRCHOWS ARCH A, V343, P51, DOI 10.1007/BF00959345; 1979, DIABETES, V28, P1039	39	64	67	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1996	10	7					777	784		10.1096/fasebj.10.7.8635695	http://dx.doi.org/10.1096/fasebj.10.7.8635695			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UN798	8635695				2022-12-25	WOS:A1996UN79800012
J	Akha, AAS; Willmott, NJ; Brickley, K; Dolphin, AC; Galione, A; Hunt, SV				Akha, AAS; Willmott, NJ; Brickley, K; Dolphin, AC; Galione, A; Hunt, SV			Anti-Ig-induced calcium influx in rat B lymphocytes mediated by cGMP through a dihydropyridine-sensitive channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SMOOTH-MUSCLE CELLS; CYCLIC-GMP; INTRACELLULAR CA-2+; PLASMA-MEMBRANE; STIMULATION; ANTIIMMUNOGLOBULIN; ALPHA-1-SUBUNIT; IDENTIFICATION; THAPSIGARGIN	In contrast to excitable tissues where calcium channels are well characterized, the nature of the B lymphocyte calcium channel is unresolved. Here, we demonstrate by single cell analysis of freshly isolated rat B cells that the anti-immunoglobulin (Ig)-induced calcium influx takes place through a channel which shares pharmacologic and serologic properties with the L-type calcium channel found in excitable tissues, It is sensitive to the dihydropyridines nicardipine and Bay K 8644, to calciseptine, and to an anti-peptide antibody raised against the alpha(1) subunit of the L-type calcium channel, but is voltage-insensitive. Anti-alpha(1) and anti-alpha(2) antibodies stain B but not T lymphocytes, Application of a cGMP agonist, measurement of cGMP levels in anti-Ig-stimulated B cells, and examining the effect of a guanylyl cyclase inhibitor on the anti-Ig response show that cGMP mediates the influx, This possibly involves a cGMP-dependent protein kinase, The anti-Ig-induced response is not abolished by prior treatment of B cells with a high dose of thapsigargin. These findings undermine the widely held belief of a categorical divide between excitable and non-excitable tissue calcium channels, demonstrate the limitations of the capacitative calcium influx theory, and point to a distinction between the calcium response mechanisms utilized by B and T lymphocytes.	UNIV OXFORD,DEPT PHARMACOL,OXFORD OX1 3QT,ENGLAND; ROYAL FREE HOSP,SCH MED,DEPT PHARMACOL,LONDON NW3 2PF,ENGLAND	University of Oxford; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Akha, AAS (corresponding author), UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,S PARKS RD,OXFORD OX1 3RE,ENGLAND.		Galione, Antony/E-5884-2011; Dolphin, Annette C/F-7416-2010	Dolphin, Annette C/0000-0003-4626-4856; Galione, Antony/0000-0002-4132-7646				BAZIN H, 1978, J IMMUNOL, V121, P2077; BERROW NS, 1995, J PHYSIOL-LONDON, V482, P481, DOI 10.1113/jphysiol.1995.sp020534; BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; BRAUGHLER JM, 1979, J BIOL CHEM, V254, P2450; BRICKLEY K, 1995, FEBS LETT, V364, P129, DOI 10.1016/0014-5793(95)00371-F; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CAMPBELL V, 1995, J PHYSIOL-LONDON, V487P, pP130; CAMPBELL V, 1994, J PHYSIOL-LONDON, V480P, pP29; CATTERALL WA, 1994, CURR OPIN CELL BIOL, V6, P607, DOI 10.1016/0955-0674(94)90083-3; CLAPHAM DE, 1994, ANNU REV NEUROSCI, V17, P441; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; DEFRANCO AL, 1994, CURR OPIN IMMUNOL, V6, P364, DOI 10.1016/0952-7915(94)90114-7; DEWEILLE JR, 1991, P NATL ACAD SCI USA, V88, P2437, DOI 10.1073/pnas.88.6.2437; DOSHI M, 1985, EXP EYE RES, V41, P61, DOI 10.1016/0014-4835(85)90094-6; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; GALIONE A, 1993, NATURE, V365, P457; GELFAND EW, 1989, J EXP MED, V170, P315, DOI 10.1084/jem.170.1.315; HUI A, 1991, NEURON, V7, P35, DOI 10.1016/0896-6273(91)90072-8; HUNT SV, 1981, CELL TISSUE KINET, V14, P445, DOI 10.1111/j.1365-2184.1981.tb00551.x; HUNT SV, 1986, HDB EXPT IMMUNOLOGY; HUNT SV, 1987, LYMPHOCYTES PRACTICA, P1; KOKUBUN S, 1984, P NATL ACAD SCI-BIOL, V81, P4824, DOI 10.1073/pnas.81.15.4824; LABAER J, 1986, J IMMUNOL, V137, P1836; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA YS, 1995, J BIOL CHEM, V270, P483, DOI 10.1074/jbc.270.1.483; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MASON MJ, 1991, J BIOL CHEM, V266, P10872; MCCLESKEY EW, 1987, P NATL ACAD SCI USA, V84, P4327, DOI 10.1073/pnas.84.12.4327; MERINEY SD, 1994, NATURE, V369, P336, DOI 10.1038/369336a0; MILLER GL, 1959, ANAL CHEM, V31, P964, DOI 10.1021/ac60149a611; MORTON ME, 1988, J BIOL CHEM, V263, P613; ODONNELL ME, 1986, J BIOL CHEM, V261, P5461; OLKEN NM, 1993, BIOCHEMISTRY-US, V32, P9677, DOI 10.1021/bi00088a020; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; REUTER H, 1983, NATURE, V301, P569, DOI 10.1038/301569a0; SAKUMA I, 1988, P NATL ACAD SCI USA, V85, P8664, DOI 10.1073/pnas.85.22.8664; SARKADI B, 1991, J MEMBRANE BIOL, V123, P9, DOI 10.1007/BF01993958; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; VONDERHEIDE RH, 1990, EUR J IMMUNOL, V20, P79, DOI 10.1002/eji.1830200112; WOLFE L, 1989, J BIOL CHEM, V264, P7734; YAU KW, 1994, P NATL ACAD SCI USA, V91, P3481, DOI 10.1073/pnas.91.9.3481; ZIMMERMAN AL, 1995, CURR OPIN NEUROBIOL, V5, P296, DOI 10.1016/0959-4388(95)80041-7	46	61	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7297	7300		10.1074/jbc.271.13.7297	http://dx.doi.org/10.1074/jbc.271.13.7297			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631746	hybrid			2022-12-25	WOS:A1996UC77400014
J	Bang, OS; Ruscetti, FW; Lee, MH; Kim, SJ; BirchenallRoberts, MC				Bang, OS; Ruscetti, FW; Lee, MH; Kim, SJ; BirchenallRoberts, MC			Transforming growth factor-beta 1 modulates p107 function in myeloid cells - Correlation with cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR E2F; FACTOR-BETA; TGF-BETA; NEGATIVE REGULATION; CATALYTIC SUBUNIT; DEPENDENT KINASE; MAMMALIAN-CELLS; PROTEIN-KINASE; DNA-SYNTHESIS	Transforming growth factor-beta 1 (TGF-beta 1) is a potent inhibitor of hematopoietic cell growth. Here we report that TGF-beta 1 signals inhibition of IL-3-dependent 32D-123 murine myeloid cell growth by modulating the activities of cyclin E and cyclin-dependent kinase 2 (cdk2) proteins and their complex formation in the G(1) phase of the cell cycle. Whereas the cyclin E protein was hyperphosphorylated in TGF-beta 1-treated cells, TGF-beta 1 decreased both the phosphorylation of cdk2 and the kinase activity of the cyclin E-cdk2 complex. Decreased cyclin E-cdk2 kinase activity correlated with decreased phosphorylation of the retinoblastoma-related protein p107. In support of these observations, transient overexpression of p107 inhibited the proliferation of the myeloid cells, and expression of antisense oligo deoxynucleotides to p107 mRNA blocked TGF-beta 1 inhibition of myeloid cell growth. Furthermore, as reported previously, in 32D-123 TGF-beta 1-treated cells, c-Myc protein expression was decreased. TGF-beta 1 increased the binding of p107 to the transcription factor E2F, leading to decreased c-Myc protein levels, p107 inhibited E2F transactivation activity and was also found to bind the c-Myc protein, suggesting p107 negative regulation of c-Myc protein function. These studies demonstrate the modulation of p107 function by TGF-beta 1 and suggest a novel mechanism by which TGF-beta 1 blocks cell cycle progression in myeloid cells.	NCI,CHEMOPREVENT LAB,NIH,BETHESDA,MD 20892; HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP CANC CTR,MOLEC ONCOL LAB,BOSTON,MA 02129; NCI,BIOL CARCINOGENESIS & DEV PROGRAM,SAIC FREDERICK,NIH,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702; NCI,LAB LEUKOCYTE BIOL,DIV BASIC SCI,NIH,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702; NCI,DIV CANC TREATMENT,NIH,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard Medical School; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick								AYUSAWA D, 1983, J BIOL CHEM, V258, P2448; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; BIRCHENALLROBERTS MC, 1991, J BIOL CHEM, V266, P9617; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHAMBARD JC, 1988, J CELL PHYSIOL, V135, P101, DOI 10.1002/jcp.1041350114; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DIMITRIS K, 1995, EXP CELL RES, V217, P477; DON QP, 1994, J BIOL CHEM, V269, P1306; DOU QP, 1993, CANCER RES, V53, P1493; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; EBLEN ST, 1994, CELL GROWTH DIFFER, V5, P109; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FURUKAWA Y, 1992, J BIOL CHEM, V267, P17121; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; KELLER JR, 1988, J EXP MED, V168, P737, DOI 10.1084/jem.168.2.737; KITAGAWA M, 1992, ONCOGENE, V7, P1067; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; NEVINS JR, 1992, SCIENCE, V258, P424; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REDDY GPV, 1994, J CELL BIOCHEM, V54, P379, DOI 10.1002/jcb.240540404; RICHON VM, 1992, CELL GROWTH DIFFER, V3, P413; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROBERTS AB, 1990, TRANSFORMING GROWTH; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SMITH PJ, 1983, BIOCHIM BIOPHYS ACTA, V739, P17, DOI 10.1016/0167-4781(83)90039-8; SPORN MB, 1987, J CELL BIOL, V105, P1039, DOI 10.1083/jcb.105.3.1039; TSAI LH, 1993, ONCOGENE, V8, P1593; VILLAMORUZZI E, 1992, FEBS LETT, V304, P211, DOI 10.1016/0014-5793(92)80621-M; WARNER GL, 1992, CELL GROWTH DIFFER, V3, P175; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; YAMASHITA M, 1991, DEV GROWTH DIFFER, V33, P617; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	73	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7811	7819		10.1074/jbc.271.13.7811	http://dx.doi.org/10.1074/jbc.271.13.7811			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631825	hybrid			2022-12-25	WOS:A1996UC77400093
J	Diehl, AM; Johns, DC; Yang, SQ; Lin, HZ; Yin, M; Matelis, LA; Lawrence, JH				Diehl, AM; Johns, DC; Yang, SQ; Lin, HZ; Yin, M; Matelis, LA; Lawrence, JH			Adenovirus-mediated transfer of CCAAT/enhancer-binding protein-alpha identifies a dominant antiproliferative role for this isoform in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENRICHED TRANSCRIPTIONAL ACTIVATOR; 3 C/EBP ISOFORMS; ADULT-RAT HEPATOCYTES; ACUTE-PHASE RESPONSE; GENE-EXPRESSION; NUCLEAR-PROTEIN; 3T3-L1 PREADIPOCYTES; MESSENGER-RNA; ADIPOCYTE DIFFERENTIATION; REGENERATING LIVER	CCAAT/enhancer-binding protein (C/EBP) isoforms are thought to be important regulators of the hepatocyte phenotype, However, the specific physiological roles of different isoforms are poorly understood because hepatocytes express multiple C/EBPs, and various isoforms have overlapping functions, To identify the functions of C/EBP alpha in mature hepatocytes, replication-defective adenovirus vectors were used to efficiently and homogeneously overexpress the mouse C/EBP alpha gene in a SV40 virus conditionally transformed rat hepatocyte line that can be induced to express C/EBP beta and C/EBP delta but that has little endogenous C/EBP alpha expression, Hepatocytes were infected with a recombinant adenovirus vector carrying the cDNA for C/EBP alpha driven by Rous sarcoma virus promoter elements (AdCEBP alpha) or a similar vector carrying the Escherichia coli lacZ gene (Ad beta gal). Staining for beta-galactosidase demonstrated an infection efficiency of 100% at a multiplicity of infection of 25 plaque-forming units/cell and persistence of foreign gene expression for at least 9 days. Cultures infected with AdCEBP alpha had 50-fold higher levels of C/EBP alpha mRNA and protein than those infected with Ad beta gal, but similar expression of C/EBP beta, Infection with AdCEBP alpha inhibited proliferation in cells expressing little C/EBP beta, even when proliferation was driven by the SV40 transforming antigen, and also blunted mitogenic induction of the c-myc proto-oncogene in nontransformed cells with high levels of C/EBP beta, Although overexpression of C/EBP alpha consistently increased C/EBP alpha DNA binding activity, it was not sufficient for albumin expression, Infection with AdCEBP alpha only increased albumin mRNA levels in nontransformed cells that also expressed relatively high levels of C/EBP beta. Thus, in hepatocytes, C/EBP alpha has a dominant antiproliferative function, but must interact with other factors to regulate hepatocyte-specific gene expression.	JOHNS HOPKINS UNIV,DEPT PEDIAT,BALTIMORE,MD 21205	Johns Hopkins University	Diehl, AM (corresponding author), JOHNS HOPKINS UNIV,DEPT MED,ROSS 912,720 RUTLAND ST,BALTIMORE,MD 21205, USA.				NIAAA NIH HHS [R01 AA 09347, R01 AA 10154, K02 AA 00173] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [K02AA000173, R01AA009347, R01AA010154] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, J BIOL CHEM, V267, P5021; BETT AJ, 1993, J VIROL, V67, P5911, DOI 10.1128/JVI.67.10.5911-5921.1993; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BRASIER AR, 1990, EMBO J, V9, P3933, DOI 10.1002/j.1460-2075.1990.tb07614.x; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU JY, 1983, MOL CELL BIOL, V3, P1013, DOI 10.1128/MCB.3.6.1013; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIEHL AM, 1994, HEPATOLOGY, V19, P447; DIEHL AM, 1994, AM J PHYSIOL-GASTR L, V267, pG552, DOI 10.1152/ajpgi.1994.267.4.G552; DIEHL AM, 1995, HEPATOLOGY, V22, P252, DOI 10.1016/0270-9139(95)90379-8; DIEHL AM, 1992, J CLIN INVEST, V89, P1706, DOI 10.1172/JCI115771; FLODBY P, 1993, EXP CELL RES, V208, P248, DOI 10.1006/excr.1993.1244; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; HAYWARD SW, 1995, IN VITRO CELL DEV-AN, V31, P14; HERBST RS, 1989, P NATL ACAD SCI USA, V86, P1553, DOI 10.1073/pnas.86.5.1553; HERBST RS, 1991, NEW BIOL, V3, P289; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; ISSHIKI H, 1991, NEW BIOL, V3, P63; JARNAGIN WR, 1992, NUCLEIC ACIDS RES, V20, P4205, DOI 10.1093/nar/20.16.4205; JOHNS DC, 1995, J CLIN INVEST, V96, P1152, DOI 10.1172/JCI118103; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KUO CF, 1990, DEVELOPMENT, V109, P473; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEE LA, 1995, J CLIN INVEST, V95, P900, DOI 10.1172/JCI117741; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; LIU JK, 1988, GENE DEV, V2, P528, DOI 10.1101/gad.2.5.528; MACDOUGALD OA, 1994, J BIOL CHEM, V269, P19041; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MISCHOULON D, 1992, MOL CELL BIOL, V12, P2553, DOI 10.1128/MCB.12.6.2553; MOHN KL, 1991, MOL CELL BIOL, V11, P381, DOI 10.1128/MCB.11.1.381; MORELLO D, 1990, MOL CELL BIOL, V10, P3185, DOI 10.1128/MCB.10.6.3185; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; PASCO DS, 1989, DNA-J MOLEC CELL BIO, V8, P535, DOI 10.1089/dna.1.1989.8.535; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; RIPPE RA, 1990, MOL CELL BIOL, V10, P689, DOI 10.1128/MCB.10.2.689; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SAMUELSSON L, 1991, EMBO J, V10, P3787, DOI 10.1002/j.1460-2075.1991.tb04948.x; SCOTT LM, 1992, BLOOD, V80, P1725; SHALABY F, 1990, P NATL ACAD SCI USA, V87, P2652, DOI 10.1073/pnas.87.7.2652; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VASSEUR-COGNET M, 1993, P NATL ACAD SCI USA, V90, P7312, DOI 10.1073/pnas.90.15.7312; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; Wang N., 1994, Molecular Biology of the Cell, V5, p336A; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; ZARET KS, 1988, P NATL ACAD SCI USA, V85, P9076, DOI 10.1073/pnas.85.23.9076	61	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7343	7350		10.1074/jbc.271.13.7343	http://dx.doi.org/10.1074/jbc.271.13.7343			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631755	hybrid			2022-12-25	WOS:A1996UC77400023
J	Kojima, K; Yamamoto, K; Irimura, T; Osawa, T; Ogawa, H; Matsumoto, I				Kojima, K; Yamamoto, K; Irimura, T; Osawa, T; Ogawa, H; Matsumoto, I			Characterization of carbohydrate-binding protein p33/41 - Relation with annexin IV, molecular basis of the doublet forms (p33 and p41), and modulation for the carbohydrate binding activity phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTICOAGULANT PROTEIN; PHOSPHATIDYLSERINE EXPOSURE; LIPOCORTIN FAMILY; CALPACTIN FAMILY; CELL-ADHESION; BOVINE KIDNEY; CALCIUM; GLUCOCORTICOIDS; SEQUENCES; MEMBRANES	A protein, p33/41, expressed in bovine kidney and many other tissues was identified as a lectin which binds to sialoglycoproteins and glycosaminoglycans in a calcium-dependent manner. Partial amino acid sequences of p33/41 are highly homologous to those of a calcium/phospholipid-binding annexin protein, annexin IV (endonexin), p33/41 exhibited similar calcium-dependent phospholipid binding activity (Kojima, K., Ogawa, H., Seno, N., Yamamoto, K., Irimura, T., Osawa, T., and Matsumoto, I. (1992) J. Biol. Chem. 267, 20536-20539). To further characterize p33/41, we cloned the p33/41 cDNA and characterized the recombinant protein encoded by this cDNA. Oligonucleotide probes were synthesized based on partial amino acid sequences of p33/41 and used for screening. A p33/41 cDNA clone was isolated encoding a protein of 319 amino acids with a calculated molecular mass of 35,769 Da, The deduced amino acid sequence was identical to that of bovine annexin IV except for one amino acid substitution. The recombinant protein gave two 33-kDa (p33) and 41-kDa (p41) bands on SDS-polyacrylamide gel electrophoresis under non-reducing conditions, and only one 33-kDa band under reducing conditions, as did the native protein, Mass spectrometric analysis combined with site-directed mutagenesis of each of the four cysteine residues of the recombinant protein revealed that p41 is a dimer of p33 cross-linked at Cys-198 via a disulfide bond, The recombinant protein bound to columns of heparin and fetuin glycopeptides in a calcium dependent manner and to phospholipid vesicles composed of phosphatidylserine (PS)/phosphatidylcholine (PC), phosphatidylethanolamine (PE)/PC or phosphatidylinositol (PI)/PC, Furthermore, concurrent binding assays showed that the binding of the recombinant protein to phospholipid vesicles was not affected by heparin, whereas that to heparin was influenced by the phospholipid composition of the vesicles; the highest binding was observed with vesicles composed of PE/PC. These results suggest that p53/41 binds two types of ligands via different sites and that phospholipids modulate the carbohydrate binding activity of p33/41.	UNIV TOKYO,FAC PHARMACEUT SCI,DIV CANC BIOL & MOLEC IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo	Kojima, K (corresponding author), OCHANOMIZU UNIV,FAC SCI,DEPT CHEM,BUNKYO KU,2-1-1 OTSUKA,TOKYO 112,JAPAN.							ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BARONDES SH, 1981, ANNU REV BIOCHEM, V50, P207, DOI 10.1146/annurev.bi.50.070181.001231; BECKER T, 1990, EMBO J, V9, P4207, DOI 10.1002/j.1460-2075.1990.tb07868.x; BIANCHI R, 1992, FEBS LETT, V296, P158, DOI 10.1016/0014-5793(92)80369-R; BLACKWELL GJ, 1980, NATURE, V287, P147, DOI 10.1038/287147a0; BLACKWELL GJ, 1982, BRIT J PHARMACOL, V76, P185, DOI 10.1111/j.1476-5381.1982.tb09205.x; BRISSON A, 1991, J MOL BIOL, V220, P199, DOI 10.1016/0022-2836(91)90002-N; CHAN HC, 1994, J BIOL CHEM, V269, P32464; CHEN JM, 1993, J BIOMOL STRUCT DYN, V10, P1067, DOI 10.1080/07391102.1993.10508696; CHRISTMAS P, 1991, J BIOL CHEM, V266, P2499; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; CRUETZ CE, 1992, SCIENCE, V258, P924; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; FLAHERTY MJ, 1990, J LAB CLIN MED, V115, P174; GENGE BR, 1991, J BIOL CHEM, V266, P10678; GEOFFROY JS, 1989, J CELL BIOL, V109, P2463, DOI 10.1083/jcb.109.5.2463; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; GOULDING NJ, 1992, ARTHRITIS RHEUM, V35, P1395, DOI 10.1002/art.1780351126; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; HAMMAN HC, 1988, BIOCHEM BIOPH RES CO, V156, P660, DOI 10.1016/S0006-291X(88)80893-3; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; IKEDA K, 1987, J BIOL CHEM, V262, P7451; KANAMORI A, 1986, J CHROMATOGR, V363, P231, DOI 10.1016/S0021-9673(01)83742-0; KITAGAKIOGAWA H, 1990, BIOCHIM BIOPHYS ACTA, V1033, P49, DOI 10.1016/0304-4165(90)90193-Z; KOJIMA K, 1992, J CHROMATOGR, V597, P323, DOI 10.1016/0021-9673(92)80127-G; KOJIMA K, 1992, J BIOL CHEM, V267, P20536; KOJIMA K, 1994, FEBS LETT, V342, P313, DOI 10.1016/0014-5793(94)80523-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEARMONTH MP, 1992, BIOCHIM BIOPHYS ACTA, V1160, P76, DOI 10.1016/0167-4838(92)90040-K; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MATSUMOTO L, 1980, J BIOCHEM-TOKYO, V85, P1091; OTTO M, 1994, FEBS LETT, V356, P125, DOI 10.1016/0014-5793(94)01241-5; PFAFFLE M, 1988, EMBO J, V7, P2335, DOI 10.1002/j.1460-2075.1988.tb03077.x; RAO LVM, 1992, THROMB RES, V67, P517, DOI 10.1016/0049-3848(92)90013-Z; RAVANAT C, 1992, BIOCHEM J, V282, P7, DOI 10.1042/bj2820007; ROJAS E, 1990, J BIOL CHEM, V265, P21207; ROSS TS, 1990, SCIENCE, V248, P605, DOI 10.1126/science.2159184; TAIT JF, 1989, J BIOL CHEM, V264, P7944; TAIT JF, 1988, BIOCHEMISTRY-US, V27, P6268, DOI 10.1021/bi00417a011; THIAGARAJAN P, 1990, J BIOL CHEM, V265, P17420; TRESSLER RJ, 1993, J CELL BIOCHEM, V53, P265, DOI 10.1002/jcb.240530311; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; WRIGHT JF, 1994, BIOCHEM BIOPH RES CO, V198, P983, DOI 10.1006/bbrc.1994.1140; YEATMAN TJ, 1993, CLIN EXP METASTAS, V11, P37, DOI 10.1007/BF00880064	45	40	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7679	7685		10.1074/jbc.271.13.7679	http://dx.doi.org/10.1074/jbc.271.13.7679			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631806	hybrid			2022-12-25	WOS:A1996UC77400074
J	Leno, GH; Mills, AD; Philpott, A; Laskey, RA				Leno, GH; Mills, AD; Philpott, A; Laskey, RA			Hyperphosphorylation of nucleoplasmin facilitates Xenopus sperm decondensation at fertilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACIDIC PROTEIN; EGG CYTOPLASM; NUCLEI; OOCYTES; LAEVIS; PHOSPHORYLATION; REPLICATION; CHROMATIN; EXTRACTS	Previous studies showed that the nuclear phosphoprotein nucleoplasmin performs the first stage of chromatin decondensation of Xenopus sperm at fertilization. It binds and removes sperm basic proteins replacing them with histones. We now show that this activity depends upon the massive hyperphosphorylation of nucleoplasmin that occurs when oocytes mature into eggs. Egg extracts or purified hyperphosphorylated egg nucleoplasmin decondense sperm chromatin and re move sperm basic proteins much faster than oocyte extracts or hypophosphorylated oocyte nucleoplasmin. Furthermore, dephosphorylation of egg nucleoplasmin slows sperm decondensation and prevents basic protein removal from sperm chromatin. We conclude that hyperphosphorylation of nucleoplasmin is used to modulate the rapid changes in chromatin structure that accompany early development in Xenopus.	WELLCOME CANC RES CTR INST CANC & DEV BIOL,CAMBRIDGE CB2 1QR,ENGLAND; UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 1QR,ENGLAND	University of Cambridge	Leno, GH (corresponding author), UNIV MISSISSIPPI,MED CTR,DEPT BIOCHEM,2500 N STATE ST,JACKSON,MS 39216, USA.			Philpott, Anna/0000-0003-3789-2463	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARRY JM, 1972, EXP CELL RES, V71, P90, DOI 10.1016/0014-4827(72)90267-4; BURGLIN TR, 1987, GENE DEV, V1, P190; COTTEN M, 1986, BIOCHEMISTRY-US, V25, P5063, DOI 10.1021/bi00366a014; COX LS, 1990, J CELL SCI, V97, P177; DIMITROV S, 1994, J CELL BIOL, V126, P591, DOI 10.1083/jcb.126.3.591; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; KROHNE G, 1980, P NATL ACAD SCI-BIOL, V77, P1034, DOI 10.1073/pnas.77.2.1034; KROHNE G, 1980, EXP CELL RES, V129, P167, DOI 10.1016/0014-4827(80)90341-9; LASKEY RA, 1983, PHILOS T ROY SOC B, V302, P143, DOI 10.1098/rstb.1983.0047; LENO GH, 1993, JOHN INN S, P135; LOHKA MJ, 1983, EXP CELL RES, V148, P481, DOI 10.1016/0014-4827(83)90169-6; MANN M, 1982, J EXP ZOOL, V222, P173, DOI 10.1002/jez.1402220209; MILLS AD, 1980, J MOL BIOL, V139, P561, DOI 10.1016/0022-2836(80)90148-5; OHSUMI K, 1991, DEV BIOL, V147, P110, DOI 10.1016/S0012-1606(05)80011-9; PHILPOTT A, 1992, CELL, V69, P759, DOI 10.1016/0092-8674(92)90288-N; PHILPOTT A, 1991, CELL, V65, P569, DOI 10.1016/0092-8674(91)90089-H; RISLEY MS, 1981, DEV BIOL, V84, P79, DOI 10.1016/0012-1606(81)90372-9; SEALY L, 1986, BIOCHEMISTRY-US, V25, P3064, DOI 10.1021/bi00358a049; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1	19	78	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7253	7256		10.1074/jbc.271.13.7253	http://dx.doi.org/10.1074/jbc.271.13.7253			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631735	hybrid			2022-12-25	WOS:A1996UC77400003
J	Prepens, U; Just, I; vonEichelStreiber, C; Aktories, K				Prepens, U; Just, I; vonEichelStreiber, C; Aktories, K			Inhibition of Fc epsilon RI-mediated activation of rat basophilic leukemia cells by Clostridium difficile toxin B (monoglucosyltransferase)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; BOTULINUM ADP-RIBOSYLTRANSFERASE; RHO GENE-PRODUCT; MAST-CELLS; TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; HISTAMINE-SECRETION; PERTUSSIS TOXIN; RBL-2H3 CELLS	Treatment of rat basophilic leukemia (RBL) 2H3-hm1 cells with Clostridium difficile toxin B (2 ng/ml), which reportedly depolymerizes the actin cytoskeleton, blocked [H-3]serotonin release induced by 2,4-dinitrophenyl-bovine serum albumin, carbachol, mastoparan, and reduced ionophore A23187-stimulated degranulation by about 55-60%. In lysates of RBL cells, toxin B C-14-glucosylated two major and one minor protein, By using two-dimensional gel electrophoresis and immunoblotting, RhoA and Cdc42 were identified as protein substrates of toxin B. In contrast to toxin B, Clostridium botulinum transferase C3 that selectively inactivates RhoA by ADP-ribosylation did not inhibit degranulation up to a concentration of 150 mu g/ml. Antigen-stimulated tyrosine phosphorylation of a 110-kDa protein was inhibited by toxin B as well as by the phosphatidylinositol 3-kinase inhibitor wortmannin. Depolymerization of the microfilament cytoskeleton of RBL cells by C. botulinum C2 toxin or cytochalasin D resulted in an increased [H-3]serotonin release induced by antigen, carbachol, mastoparan, or by calcium ionophore A23187, but without affecting toxin B-induced inhibition of degranulation, The data indicate that toxin B inhibits activation of RBL cells by glucosylation of low molecular mass GTP-binding proteins of the Rho subfamily (most likely Cdc42) by a mechanism not involving the actin cytoskeleton.	UNIV FREIBURG, INST PHARMAKOL & TOXIKOL, D-79104 FREIBURG, GERMANY; UNIV MAINZ, INST MED MIKROBIOL & HYG, D-55101 MAINZ, GERMANY	University of Freiburg; Johannes Gutenberg University of Mainz			Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				AKTORIES K, 1995, METHOD ENZYMOL, V256, P184; AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; AKTORIES K, 1994, MOL CELL BIOCHEM, V138, P167, DOI 10.1007/BF00928459; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; AKTORIES K, 1989, J CELL BIOL, V109, P1385, DOI 10.1083/jcb.109.4.1385; AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P97; ALI H, 1989, J IMMUNOL, V143, P2626; ATKINSON TP, 1992, J IMMUNOL, V148, P2194; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BONGAERTS GPA, 1994, MICROB PATHOGENESIS, V17, P1, DOI 10.1006/mpat.1994.1047; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; DEANIN GG, 1991, BIOCHEM BIOPH RES CO, V179, P551, DOI 10.1016/0006-291X(91)91406-3; EISEMAN E, 1992, NATURE, V355, P78; GARCIAGIL M, 1986, J IMMUNOL, V136, P259; GOMPERTS BD, 1994, ANN NY ACAD SCI, V710, P217, DOI 10.1111/j.1749-6632.1994.tb26630.x; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; JUST I, 1995, J CLIN INVEST, V95, P1026, DOI 10.1172/JCI117747; JUST I, 1992, J BIOL CHEM, V267, P10274; JUST I, 1994, J BIOL CHEM, V269, P10706; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KAWAKAMI T, 1992, J IMMUNOL, V148, P3513; KOFFER A, 1990, J CELL BIOL, V111, P919, DOI 10.1083/jcb.111.3.919; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LILLIE THW, 1993, BIOCHEM J, V290, P389, DOI 10.1042/bj2900389; LIN PY, 1991, J IMMUNOL, V146, P1609; MAEYAMA K, 1988, J IMMUNOL, V140, P3919; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MINOGUCHI K, 1994, J BIOL CHEM, V269, P16902; NAKAMURA T, 1985, J BIOL CHEM, V260, P3584; NAKATANI Y, 1994, J IMMUNOL, V153, P796; NARASIMHAN V, 1990, BIOCHEM BIOPH RES CO, V171, P222, DOI 10.1016/0006-291X(90)91380-B; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NORMAN JC, 1994, J CELL BIOL, V126, P1005, DOI 10.1083/jcb.126.4.1005; OHISHI I, 1980, INFECT IMMUN, V30, P668; OTTLINGER ME, 1988, EXP CELL RES, V174, P215, DOI 10.1016/0014-4827(88)90156-5; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PRICE LS, 1995, CURR BIOL, V5, P68, DOI 10.1016/S0960-9822(95)00018-2; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAITO H, 1987, J IMMUNOL, V138, P3927; SEAGRAVE J, 1991, J CELL PHYSIOL, V148, P139, DOI 10.1002/jcp.1041480117; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHOSHAN MC, 1993, J CELL BIOCHEM, V52, P107, DOI 10.1002/jcb.240520114; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; VONEICHELSTREIBER C, 1987, MICROB PATHOGENESIS, V2, P307, DOI 10.1016/0882-4010(87)90073-8; WIEGERS W, 1991, EUR J CELL BIOL, V54, P237; YANO H, 1993, J BIOL CHEM, V268, P25846; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	58	72	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7324	7329		10.1074/jbc.271.13.7324	http://dx.doi.org/10.1074/jbc.271.13.7324			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631752	hybrid			2022-12-25	WOS:A1996UC77400020
J	Rankin, S; HooshmandRad, R; ClaessonWelsh, L; Rozengurt, E				Rankin, S; HooshmandRad, R; ClaessonWelsh, L; Rozengurt, E			Requirement for phosphatidylinositol 3'-kinase activity in platelet-derived growth factor-stimulated tyrosine phosphorylation of p125 focal adhesion kinase and paxillin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; PHOSPHOLIPASE-C-GAMMA; PDGF BETA-RECEPTOR; SIGNALING COMPLEX; SRC FAMILY; ASSOCIATION; BINDING; VASOPRESSIN; BOMBESIN; 3-KINASE	The role of phosphatidylinositol 3'-kinase (PI 3'-kinase) activity in platelet-derived growth factor (PDGF)-stimulated tyrosine phosphorylation of focal adhesion kinase (p125(FAK)) paxillin has been examined. The tyrosine phosphorylation of p125(FAK) and paxillin in response to PDGF was markedly inhibited by wortmannin in a dose-dependent manner. PDGF-stimulated PI 3'-kinase activity, membrane ruffle formation, and tyrosine phosphorylation of p125(FAK) and paxillin were all inhibited by the same low concentrations of wortmannin (>90% inhibition at 40 nM). In contrast, tyrosine phosphorylation of p125(FAK) and paxillin in response to bombesin, endothelin, and phorbol 12,13-dibutyrate was not inhibited by wortmannin in these cells. Furthermore, LY294002, an inhibitor of PI 3'-kinase structurally unrelated to wortmannin, also inhibited PDGF-stimulated p125(FAK) tyrosine phosphorylation. PDGF was shown to stimulate the tyrosine phosphorylation of p125(FAK) in porcine aortic endothelial (PAE) cells transfected with the wild type PDGF-beta receptors, but not in PAE cells transfected with PDGF-beta receptors in which the PI 3'-kinase binding sites (Tyr-740/751) were replaced by phenylalanine. PDGF-stimulated, PI 3'-kinase-dependent tyrosine phosphorylation of p125(FAK) was not inhibited by rapamycin, and thus it was dissociated from the activation of p70 S6 kinase, previously identified as a molecular downstream target of PI 3'-kinase. Thus, we have identified a PI 3'-kinase-dependent signal transduction pathway in the action of PDGF, which leads to the phosphorylation of p125(FAK) and paxillin.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; LUDWIG INST CANC RES,UPPSALA BRANCH,S-75124 UPPSALA,SWEDEN	Cancer Research UK; Ludwig Institute for Cancer Research								ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FERRARI S, 1994, CRIT REV BIOCHEM MOL, V29, P385, DOI 10.3109/10409239409083485; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LLIC D, 1995, NATURE, V377, P539; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NOBES CD, 1995, J CELL SCI, V108, P225; OKADA T, 1994, J BIOL CHEM, V269, P3563; POWIS G, 1994, CANCER RES, V54, P2419; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RANKIN S, 1994, J BIOL CHEM, V269, P704; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; ROZENGURT E, 1995, CANCER SURV, V24, P81; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, J CELL SCI, V107, P1583; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENG QP, 1995, MOL CELL BIOL, V15, P2333; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WENNSTROM S, 1994, ONCOGENE, V9, P651; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; YANO H, 1993, J BIOL CHEM, V268, P25846; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	67	95	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7829	7834		10.1074/jbc.271.13.7829	http://dx.doi.org/10.1074/jbc.271.13.7829			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631827	hybrid			2022-12-25	WOS:A1996UC77400095
J	Xiao, J; Messinger, Y; Jin, JZ; Myers, DE; Bolen, JB; Uckun, FM				Xiao, J; Messinger, Y; Jin, JZ; Myers, DE; Bolen, JB; Uckun, FM			Signal transduction through the beta 1 integrin family surface adhesion molecules VLA-4 and VLA-5 of human B-cell precursors activates CD19 receptor-associated protein-tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISCRETE DEVELOPMENTAL STAGES; LYMPHOBLASTIC-LEUKEMIA CELLS; BONE-MARROW FIBROBLASTS; STROMAL CELLS; ALPHA-4-BETA-1 INTEGRIN; PHOSPHORYLATION; FIBRONECTIN; VCAM-1; ENDOTHELIUM; STIMULATION	We demonstrate that the CD19 receptor associates with the beta 1 family integrin receptors on human B-cell precursors as well as mature B-lymphocytes, and engagement of the beta 1 family integrin receptors with monoclonal antibody homoconjugates leads to rapid activation of the CD19-associated protein-tyrosine kinases (PTK) and results in hyperphosphorylation of CD19 on tyrosine residues, Our findings prompt the hypothesis that homoconjugate-induced integrin clustering may effect the approximation and, by intermolecular cross-phosphorylation, activation of the CD19-associated PTK and subsequent tyrosine phosphorylation of the CD19 receptor, The ability of the beta 1 family integrin receptors to transmit a biochemical signal triggering the CD19-linked multifunctional PTK pathway provides a possible explanation for the pleiotropic biologic responses generated through adhesive VLA-4- and VLA-6-mediated contacts.	UNIV MINNESOTA,BIOTHERAPY PROGRAM,SIGNAL TRANSDUCT LAB,ROSEVILLE,MN 55113; UNIV MINNESOTA,CHILDRENS CANC GRP,LEUKEMIA BIOL REFERENCE LAB,ROSEVILLE,MN 55113; DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT CELL SIGNALING,PALO ALTO,CA 94304	University of Minnesota System; University of Minnesota System; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.				Uckun, Fatih M./0000-0001-9334-183X	NCI NIH HHS [R01-CA42633, R01-CA51425, R01-CA44114] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044114, R01CA051425, R01CA042633] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERNARDI P, 1987, J CELL BIOL, V105, P489, DOI 10.1083/jcb.105.1.489; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BRADSTOCK K, 1993, BLOOD, V82, P3437; BRADSTOCK KF, 1995, LEUKEMIA LYMPHOMA, V18, P1, DOI 10.3109/10428199509064917; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DITTEL BN, 1993, BLOOD, V81, P2272; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FARGNOLI J, 1995, J BIOL CHEM, V270, P26533, DOI 10.1074/jbc.270.44.26533; FREEDMAN AS, 1993, J IMMUNOL, V150, P1645; GARCIAPARDO A, 1990, J IMMUNOL, V144, P3361; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HOLZMANN B, 1989, EMBO J, V8, P1735, DOI 10.1002/j.1460-2075.1989.tb03566.x; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JUNEJA HS, 1992, EXP HEMATOL, V20, P1263; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; MAKRYNIKOLA V, 1993, LEUKEMIA, V7, P86; MANABE A, 1994, BLOOD, V83, P758; MIYAKE K, 1992, J CELL BIOL, V119, P653, DOI 10.1083/jcb.119.3.653; MIYAKE K, 1991, J EXP MED, V173, P599, DOI 10.1084/jem.173.3.599; MOULD AP, 1991, J BIOL CHEM, V266, P3579; MYERS DE, 1991, J IMMUNOL METHODS, V36, P221; MYERS DE, 1995, P NATL ACAD SCI USA, V92, P1; NOJIMA Y, 1992, J EXP MED, V175, P1045, DOI 10.1084/jem.175.4.1045; PAPAYANNOPOULOU T, 1993, P NATL ACAD SCI USA, V90, P9374, DOI 10.1073/pnas.90.20.9374; RICKERT RC, 1995, NATURE, V376, P352, DOI 10.1038/376352a0; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RYAN DH, 1991, J CLIN INVEST, V88, P995, DOI 10.1172/JCI115403; RYAN DH, 1992, J IMMUNOL, V149, P3759; SANCHEZMATEOS P, 1993, J IMMUNOL, V151, P3817; SIMMONS PJ, 1994, LEUKEMIA LYMPHOMA, V12, P353, DOI 10.3109/10428199409073776; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TAICHMAN DB, 1991, CELL REGUL, V2, P347, DOI 10.1091/mbc.2.5.347; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TANG JH, 1993, BLOOD, V82, P3415; TEDDER TE, 1994, IMMUNOL TODAY, V15, P437, DOI 10.1016/0167-5699(94)90274-7; UCKUN FM, 1995, SCIENCE, V267, P886, DOI 10.1126/science.7531365; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; UCKUN FM, 1991, J BIOL CHEM, V266, P17478; UCKUN FM, 1993, J BIOL CHEM, V268, P21172	44	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7659	7664		10.1074/jbc.271.13.7659	http://dx.doi.org/10.1074/jbc.271.13.7659			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631803				2022-12-25	WOS:A1996UC77400071
J	Cui, YH; Midkiff, MA; Wang, Q; Calvo, JM				Cui, YH; Midkiff, MA; Wang, Q; Calvo, JM			The leucine-responsive regulatory protein (Lrp) from Escherichia coli - Stoichiometry and minimal requirements for binding to DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBAL RESPONSE; SITES; TRANSCRIPTION; ILVIH	Lrp (Leucine-responsive regulatory protein) regulates the expression of a number of operons in Escherichia coli, A recent study of DNA sequences recognized by Lrp established the consensus as a 15-bp sequence, YAGHA-WATTWTDCTR (Y = C/T, H = ''not G,'' W = A/T, D = ''not C,'' R = A/G) (Cui, Y., Wang, Q,, Stormo, G, D,, and Calvo, J, M, (1995) J, Bacteriol, 177, 4872-4880). Here we report the stoichiometry of Lrp binding (an Lrp dimer binds to a single binding site) and studies that define the minimal length of DNA required for binding, A double-stranded 15 mer having a sequence that closely matches the consensus does not show measurable binding to Lrp, One or two base pairs of DNA flanking each end are not sufficient for binding, but constructs having 3-5 additional base pairs (21 mer) show relatively strong binding, Single-stranded flanking DNA also contributes to strong binding, The extent of the contribution to binding is dependent upon whether the single strand is on the left or right of the double stranded region and whether the polarity of the single-stranded DNA is 5' to 3' or 3' to 5'.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853	Cornell University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039496] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39496] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CALVO JM, 1994, MICROBIOL REV, V58, P466, DOI 10.1128/MMBR.58.3.466-490.1994; CHEN YF, 1992, P NATL ACAD SCI USA, V89, P5123, DOI 10.1073/pnas.89.11.5123; CUI YH, 1995, J BACTERIOL, V177, P4872, DOI 10.1128/jb.177.17.4872-4880.1995; FERRARIO M, 1995, J BACTERIOL, V177, P103, DOI 10.1128/jb.177.1.103-113.1995; GALLY DL, 1994, J BACTERIOL, V176, P5665, DOI 10.1128/JB.176.18.5665-5672.1994; GAZEAU M, 1994, J MOL BIOL, V241, P378, DOI 10.1006/jmbi.1994.1514; HAGER DA, 1980, ANAL BIOCHEM, V109, P87; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; LIN R, 1992, J BACTERIOL, V174, P2779, DOI 10.1128/JB.174.9.2779-2784.1992; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; LOHMAN TM, 1992, METHOD ENZYMOL, V212, P400; NEWMAN EB, 1992, CELL, V68, P617, DOI 10.1016/0092-8674(92)90135-Y; NOU XW, 1993, MOL MICROBIOL, V7, P545, DOI 10.1111/j.1365-2958.1993.tb01145.x; ORCHARD K, 1993, NUCLEIC ACIDS RES, V21, P3335, DOI 10.1093/nar/21.14.3335; PLATKO JV, 1993, J BACTERIOL, V175, P1110, DOI 10.1128/JB.175.4.1110-1117.1993; REX JH, 1991, J BACTERIOL, V173, P5944, DOI 10.1128/jb.173.19.5944-5953.1991; Sambrook J, 1989, MOL CLONING LAB MANU, V1-3; SVAREN J, 1987, NUCLEIC ACIDS RES, V15, P8739, DOI 10.1093/nar/15.21.8739; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WANG Q, 1993, J MOL BIOL, V229, P306, DOI 10.1006/jmbi.1993.1036; WANG Q, 1993, MOL MICROBIOL, V7, P883, DOI 10.1111/j.1365-2958.1993.tb01179.x; WANG Q, 1993, EMBO J, V12, P2495, DOI 10.1002/j.1460-2075.1993.tb05904.x; WILLINS DA, 1991, J BIOL CHEM, V266, P10768; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5	24	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6611	6617		10.1074/jbc.271.12.6611	http://dx.doi.org/10.1074/jbc.271.12.6611			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636076				2022-12-25	WOS:A1996UB15700011
J	Harding, PA; Wang, XZ; Okada, S; Chen, WY; Wan, W; Kopchick, JJ				Harding, PA; Wang, XZ; Okada, S; Chen, WY; Wan, W; Kopchick, JJ			Growth hormone (GH) and a GH antagonist promote GH receptor dimerization and internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; TRANSGENIC MICE; 3T3-F442A PREADIPOCYTES; EXTRACELLULAR DOMAIN; PROTEIN-KINASES; RAT ADIPOCYTES; INSULIN-LIKE; PHOSPHORYLATION; CELLS; EXPRESSION	It has previously been shown that a human growth hormone (hGH) analog, hGH-G120R, acts as a GH antagonist (Chen, W. Y., might, D. C., Wagner, T. E., and Kopchick, J, J. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 5061-5065; Chen, m. Y., White, M. E., Wagner, T. E., and Kopchick, J. J. (1991) Endocrinology 129, 1402-1408; Chen, W. Y., Chen, N-Y., Yun, J., Wang X. Z., Wagner, T. E., and Kopchick, J. J. (1994) J. Biol. Chem. 269, 15892-15897). In this study, we report the ability of hGH and hGH-G120R 60 be internalized by GH receptor expressing cells. Additionally, results of chemical cross-linking experiments revealed that both native hGH and hGH-G120R form complexes similar in size to that expected for hGH when bound to recombinant hGH-binding protein (bp). The molecular mass of the complex was determined to be approximately 280 kDa which is consistent with multiple receptors interacting with the ligand, The predominant radiolabeled band detected was a complex of approximately 140 kDa which probably represents one GH molecule bound to one GH receptor. The crosslinked complexes were not detected in the presence of excess unlabeled hGH or hGH-G120R and were not observed in cells which do not express detectable levels of GH receptors. Also, GH induced tyrosine phosphorylation of a complex of proteins of approximately 95 kDa in these cells whereas hGH-G120R did not. Thus, we have separated the hGH or hGH-G120R/GHR binding and internalization capabilities from the ability to stimulate tyrosine phosphorylation of intracellular proteins.	OHIO UNIV,EDISON BIOTECHNOL INST,PROGRAM MOLEC & CELLULAR BIOL,ATHENS,OH 45701; OHIO UNIV,DEPT BIOL SCI,ATHENS,OH 45701	University System of Ohio; Ohio University; University System of Ohio; Ohio University								ANDERSON NG, 1992, BIOCHEM J, V284, P649, DOI 10.1042/bj2840649; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BARRAZONE P, 1980, J CELL BIOL, V87, P360; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CARTERSU C, 1984, J BIOL CHEM, V259, P1099; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; CHEN WY, 1994, J BIOL CHEM, V269, P15892; CHEN WY, 1991, J BIOL CHEM, V266, P2252; CHEN WY, 1991, MOL ENDOCRINOL, V5, P1845, DOI 10.1210/mend-5-12-1845; CHEN WY, 1990, P NATL ACAD SCI USA, V87, P5061, DOI 10.1073/pnas.87.13.5061; CHEN WY, 1991, ENDOCRINOLOGY, V129, P1402, DOI 10.1210/endo-129-3-1402; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GOODMAN HM, 1986, HUMAN GROWTH HORMONE, P499; GORIN E, 1985, ENDOCRINOLOGY, V116, P1796, DOI 10.1210/endo-116-5-1796; GU TY, 1995, BIOTECHNOL BIOENG, V48, P520, DOI 10.1002/bit.260480515; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HARDING PA, 1994, MOL CELL ENDOCRINOL, V106, P171, DOI 10.1016/0303-7207(94)90200-3; HARDING PA, 1995, RECEPTOR, V5, P81; HIZUKA N, 1982, ENDOCRINOLOGY, V111, P1576, DOI 10.1210/endo-111-5-1576; HJALMARSON A, 1967, ACTA ENDOCRINOL-COP, V56, P347, DOI 10.1530/acta.0.0560347; ILONDO MM, 1994, ENDOCRINOLOGY, V134, P2397, DOI 10.1210/en.134.6.2397; KOSTYO JL, 1973, HORM METAB RES, V5, P167, DOI 10.1055/s-0028-1093965; KOSTYO JL, 1974, HDB PHYSIOLOGY     2, V4, P187; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MILMAN AE, 1950, ENDOCRINOLOGY, V47, P114, DOI 10.1210/endo-47-2-114; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MORIKAWA M, 1982, CELL, V29, P783, DOI 10.1016/0092-8674(82)90440-8; OKADA S, 1992, ENDOCRINOLOGY, V130, P2284, DOI 10.1210/en.130.4.2284; ROUPAS P, 1988, MOL CELL ENDOCRINOL, V57, P93, DOI 10.1016/0303-7207(88)90037-8; SILVA CM, 1993, ENDOCRINOLOGY, V132, P101, DOI 10.1210/en.132.1.101; STRED SE, 1990, ENDOCRINOLOGY, V127, P2506, DOI 10.1210/endo-127-5-2506; STRED SE, 1992, ENDOCRINOLOGY, V130, P1626, DOI 10.1210/en.130.3.1626; STUBBART JR, 1991, ENDOCRINOLOGY, V129, P1659, DOI 10.1210/endo-129-3-1659; SWISLOCKI NI, 1970, ENDOCRINOLOGY, V87, P900, DOI 10.1210/endo-87-5-900; THORELL JI, 1971, BIOCHIM BIOPHYS ACTA, V251, P363, DOI 10.1016/0005-2795(71)90123-1; TOLLET P, 1991, MOL ENDOCRINOL, V5, P1351; WANG X, 1993, P NATL ACAD SCI USA, V91, P1391; WANG XY, 1992, J BIOL CHEM, V267, P17390; WANG XY, 1993, J BIOL CHEM, V268, P3573; WANG XZ, 1995, J BIOL CHEM, V270, P6261, DOI 10.1074/jbc.270.11.6261; WANG XZ, 1993, MOL CELL ENDOCRINOL, V94, P89, DOI 10.1016/0303-7207(93)90055-O; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; XU BC, 1995, RECEPTOR, V5, P105; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	48	65	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6708	6712		10.1074/jbc.271.12.6708	http://dx.doi.org/10.1074/jbc.271.12.6708			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636090	hybrid			2022-12-25	WOS:A1996UB15700025
J	Li, CY; Gudas, LJ				Li, CY; Gudas, LJ			Murine laminin B1 gene regulation during the retinoic acid- and dibutyryl cyclic AMP-induced differentiation of embryonic F9 teratocarcinoma stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN MESSENGER-RNA; A-CHAIN; MULTIDOMAIN PROTEIN; MOUSE EMBRYOGENESIS; BASEMENT-MEMBRANES; RESPONSIVE ELEMENT; MOLECULAR-CLONING; ALBUMIN GENE; COLLAGEN-IV; B2 CHAIN	Retinoic acid (RA) and cyclic AMP analogs cause the differentiation of F9 embryonic teratocarcinoma stem cells into parietal endoderm, an epithelial cell of the early mouse embryo. Laminin B1 is induced in this differentiation process, but is not transcriptionally activated until 24-48 h after RA addition and is not maximally induced until approximately 72 h. Cyclic AMP analogs enhance this transcriptional activation. Although several DNase I hypersensitive sites (DHSS) were observed in the LAMB1 5'-flanking DNA, one of the sites, DHSS2, was detected only after 72 h of RA treatment. Transient transfections have demonstrated that the DHSS2 region functions as a 'late-acting RA-inducible enhancer,'' and motifs in this enhancer contain the homeobox protein-binding site TTATTAACA. Greater binding is observed at these sites by electrophoretic mobility shift assay when cells are cultured with RA and cyclic AMP analogs versus RA alone, and no binding is seen in extracts from RA-treated F9 RAR gamma(-/-) cells which lack RAR gamma mRNA and protein. Laminin B1 mRNA is not induced by RA in the RAR gamma(-/-) cells (Boylan, J. F., Lohnes, D., Taneja, R., Chambon, P., and Gudas, L. J. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 9601-9605). Our data show that these DNA regulatory elements contribute to the transcriptional activation of the LAMBI gene during the later stages of the differentiation process.	CORNELL UNIV, COLL MED, DEPT PHARMACOL, NEW YORK, NY 10021 USA	Cornell University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024319] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD24319] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; COOPER AR, 1983, DEV BIOL, V96, P467, DOI 10.1016/0012-1606(83)90183-5; DECURTIS I, 1993, DEVELOPMENT, V118, P377; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRAGO J, 1991, EXP CELL RES, V196, P246, DOI 10.1016/0014-4827(91)90258-V; DURKIN ME, 1986, DIFFERENTIATION, V32, P260, DOI 10.1111/j.1432-0436.1986.tb00582.x; DZIADEK M, 1985, DEV BIOL, V111, P372, DOI 10.1016/0012-1606(85)90491-9; EDELMAN GM, 1993, J BIOL CHEM, V268, P20683; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; EKBLOM M, 1990, CELL, V60, P337, DOI 10.1016/0092-8674(90)90748-4; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; ENGEL J, 1991, BIOCHEM SOC T, V19, P8339; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; FRENETTE GP, 1988, CANCER RES, V48, P5193; GERECKE DR, 1994, J BIOL CHEM, V269, P11073; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUDAS LJ, 1990, ANN NY ACAD SCI, V580, P245, DOI 10.1111/j.1749-6632.1990.tb17933.x; Gudas Lorraine J., 1994, P443; HAAPARANTA T, 1991, MATRIX, V11, P151, DOI 10.1016/S0934-8832(11)80153-8; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HIERCK BP, 1993, CELL ADHES COMMUN, V1, P33, DOI 10.3109/15419069309095680; HOGERVORST F, 1993, J BIOL CHEM, V268, P18427; HOSLER BA, 1989, MOL CELL BIOL, V9, P5623, DOI 10.1128/MCB.9.12.5623; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; JONES FS, 1993, P NATL ACAD SCI USA, V90, P6557, DOI 10.1073/pnas.90.14.6557; KALIONIS B, 1993, MECH DEVELOP, V43, P57, DOI 10.1016/0925-4773(93)90023-Q; KALLUNKI T, 1991, J BIOL CHEM, V266, P221; KLEIN G, 1990, DEVELOPMENT, V110, P823; KLEINMAN HK, 1987, DEV BIOL, V122, P373, DOI 10.1016/0012-1606(87)90302-2; KLEINMAN HK, 1993, VITAM HORM, V47, P161, DOI 10.1016/S0083-6729(08)60446-X; KROLL TG, 1994, J BIOL CHEM, V269, P9270; KURKINEN M, 1983, J BIOL CHEM, V258, P6543; LANGSTON AW, 1992, MECH DEVELOP, V38, P217, DOI 10.1016/0925-4773(92)90055-O; LANGSTON AW, 1994, CURR OPIN GENET DEV, V4, P550, DOI 10.1016/0959-437X(94)90071-A; LAROSA GJ, 1988, MOL CELL BIOL, V8, P3906, DOI 10.1128/MCB.8.9.3906; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARINKOVICH P, 1993, J CELL BIOL, V119, P695; Maxam A M, 1980, Methods Enzymol, V65, P499; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; NISSINEN M, 1991, BIOCHEM J, V276, P369, DOI 10.1042/bj2760369; OGAWA K, 1988, J BIOL CHEM, V263, P8384; OREAR JJ, 1992, J BIOL CHEM, V267, P20555; PAULSSON M, 1989, J BIOL CHEM, V264, P18726; PIKKARAINEN T, 1987, J BIOL CHEM, V262, P10454; PIKKARAINEN T, 1988, J BIOL CHEM, V263, P6751; Sambrook J., 2002, MOL CLONING LAB MANU; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SENIOR PV, 1988, DEVELOPMENT, V104, P431; SIMO P, 1991, DEVELOPMENT, V112, P477; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; TIMPL R, 1979, J BIOL CHEM, V254, P9933; VALARCHE I, 1993, DEVELOPMENT, V119, P881; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; VUOLTEENAHO R, 1990, J BIOL CHEM, V265, P15611; WANG SY, 1985, DEV BIOL, V107, P75, DOI 10.1016/0012-1606(85)90377-X; WANG SY, 1988, J CELL PHYSIOL, V136, P305, DOI 10.1002/jcp.1041360213; WANG SY, 1989, J BIOL CHEM, V264, P15556; WANG SY, 1983, P NATL ACAD SCI-BIOL, V80, P5880, DOI 10.1073/pnas.80.19.5880; XU H, 1994, P NATL ACAD SCI USA, V91, P5572, DOI 10.1073/pnas.91.12.5572	70	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6810	6818		10.1074/jbc.271.12.6810	http://dx.doi.org/10.1074/jbc.271.12.6810			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636104	hybrid			2022-12-25	WOS:A1996UB15700039
J	Nightingale, KP; Pruss, D; Wolffe, AP				Nightingale, KP; Pruss, D; Wolffe, AP			A single high affinity binding site for histone H1 in a nucleosome containing the Xenopus borealis 5 S ribosomal RNA gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II TRANSCRIPTION; DNA; CHROMATIN; H-1; ORGANIZATION; INVITRO; PROTEIN; NUCLEI; CORE; H5	We have reconstituted nucleosomes containing the Xenopus borealis 5 S rRNA gene, a single histone octamer, and 1 or 2 molecules of histone H1. We determine that the 1st molecule of histone H1 to associate with the 5 S nucleosome binds with high affinity (K-D similar to 2 nM), and the 2nd molecule of H1 binds with a reduced affinity (K-D similar to 10 nM). This latter binding is comparable with the association of histone H1 with naked DNA. Neither molecule of histone al alters the helical periodicity of DNA in the nucleosome as revealed by hydroxyl radical cleavage. We conclude that although multiple molecules of histone H1 can associate with nucleosomal DNA, there is only a single high affinity binding site for histone H1 within the 5 S nucleosome.	NICHHD,NIH,MOLEC EMBRYOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								BATES DL, 1981, NUCLEIC ACIDS RES, V9, P5883, DOI 10.1093/nar/9.22.5883; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; BOULIKAS T, 1980, P NATL ACAD SCI-BIOL, V77, P127, DOI 10.1073/pnas.77.1.127; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; CAMERINIOTERO RD, 1976, CELL, V8, P333, DOI 10.1016/0092-8674(76)90145-8; CARON F, 1981, J MOL BIOL, V146, P513, DOI 10.1016/0022-2836(81)90045-0; CHIPEV CC, 1992, MOL CELL BIOL, V12, P45, DOI 10.1128/MCB.12.1.45; CLARK DJ, 1986, J MOL BIOL, V187, P569, DOI 10.1016/0022-2836(86)90335-9; CROSTON GE, 1991, SCIENCE, V251, P643, DOI 10.1126/science.1899487; DIMITROV S, 1994, J CELL BIOL, V126, P591, DOI 10.1083/jcb.126.3.591; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; EISENBERG H, 1981, J MOL BIOL, V150, P537, DOI 10.1016/0022-2836(81)90379-X; GLOTOV BO, 1978, FEBS LETT, V91, P149, DOI 10.1016/0014-5793(78)80037-4; GOODWIN GH, 1977, BIOCHEM J, V167, P485, DOI 10.1042/bj1670485; HAYES JJ, 1994, P NATL ACAD SCI USA, V91, P7817, DOI 10.1073/pnas.91.16.7817; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HAYES JJ, 1993, P ANTL ACAD SCI US, V90, P615; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; KRYLOV D, 1993, P NATL ACAD SCI USA, V90, P5052, DOI 10.1073/pnas.90.11.5052; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; NELSON PP, 1979, J BIOL CHEM, V254, P1751; NIGHTINGALE K, 1995, J BIOL CHEM, V270, P4197, DOI 10.1074/jbc.270.9.4197; OLINS AL, 1977, MOL BIOL MAMMALIAN G, V1, P211; PRUSS D, 1993, BIOCHEMISTRY-US, V32, P6810, DOI 10.1021/bi00078a002; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; RODRIGUEZCAMPOS A, 1989, J MOL BIOL, V209, P135, DOI 10.1016/0022-2836(89)90177-0; SANDALTZOPOULOS R, 1994, EMBO J, V13, P373, DOI 10.1002/j.1460-2075.1994.tb06271.x; SHIMAMURA A, 1989, MOL CELL BIOL, V9, P5573, DOI 10.1128/MCB.9.12.5573; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; SINGER DS, 1976, NUCLEIC ACIDS RES, V3, P2531, DOI 10.1093/nar/3.10.2531; SMITH RC, 1988, GENE DEV, V2, P1284, DOI 10.1101/gad.2.10.1284; TATCHELL K, 1977, BIOCHEMISTRY-US, V16, P5295, DOI 10.1021/bi00643a021; THOMAS JO, 1992, NUCLEIC ACIDS RES, V20, P187, DOI 10.1093/nar/20.2.187; TODD RD, 1979, J BIOL CHEM, V254, P3074; URA K, 1994, J BIOL CHEM, V269, P27171; URA K, 1995, EMBO J, V14, P3752, DOI 10.1002/j.1460-2075.1995.tb00045.x; URBAN MK, 1980, CAN J BIOCHEM CELL B, V58, P726, DOI 10.1139/o80-102; van Holde K.E., 1988, CHROMATIN; VARGAWEISZ P, 1994, P NATL ACAD SCI USA, V91, P3525, DOI 10.1073/pnas.91.9.3525; WEINTRAUB H, 1978, NUCLEIC ACIDS RES, V5, P1178; WOLFFE AP, 1989, EMBO J, V8, P527, DOI 10.1002/j.1460-2075.1989.tb03407.x; WOLFFE AP, 1989, NUCLEIC ACIDS RES, V17, P767, DOI 10.1093/nar/17.2.767; WOLFFE AP, 1993, METH MOL G, V2, P314	47	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7090	7094		10.1074/jbc.271.12.7090	http://dx.doi.org/10.1074/jbc.271.12.7090			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636143	hybrid			2022-12-25	WOS:A1996UB15700078
J	Paz, K; Voliovitch, H; Hadari, YR; Roberts, CT; LeRoith, D; Zick, Y				Paz, K; Voliovitch, H; Hadari, YR; Roberts, CT; LeRoith, D; Zick, Y			Interaction between the insulin receptor and its downstream effectors - Use of individually expressed receptor domains for structure function analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; TYROSINE PHOSPHORYLATION; JUXTAMEMBRANE REGION; KINASE-ACTIVITY; INTACT-CELLS; BETA-SUBUNIT; PROTEINS; STIMULATE	A structural analysis has been carried out to determine which part of the intracellular domain of the insulin receptor (IR) beta subunit is involved in direct interaction with the receptor substrates IRS-1 and She. Toward this end, the juxtamembrane (JM) domain (amino acids 943-984) and the carboxyl-terminal (CT) region (amino acids 1245-1331) of IR were expressed in bacteria as (His)(6)-fusion peptides, and their interaction with IRS-1 and She was studied, We could demonstrate that the CT region of IR was sufficient to bind She, although significant, but much lower binding of She to the JM region could be detected as well. Furthermore, in vitro Tyr phosphorylation of the CT region potentiated its interactions with She 2-fold. In contrast, the JM region, but not the CT domain of the IR, was sufficient to mediate interactions between the IR and IRS-1. These interactions did not involve the pleckstrin homology (PH) region of IRS-1, since an IRS-I mutant, in which four ''blocks'' of the PH domain (pro(5)-pro(65)) were deleted, interacted with the JM region of IR with the same efficiency as native IRS-l, These results suggest that the IR interacts with its downstream effecters through distinct receptor regions, and that autophosphorylation of Tyr residues located at the CT domain of the IR can modulate these interactions.	WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL; NIH, DIABET BRANCH, BETHESDA, MD 20982 USA	Weizmann Institute of Science; National Institutes of Health (NIH) - USA			Zick, Yehiel/K-1479-2012; Roberts, Charles/K-6953-2017	Roberts, Charles/0000-0003-1756-5772				BACKER JM, 1990, J BIOL CHEM, V265, P16450; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FEENER EP, 1993, J BIOL CHEM, V268, P11256; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HEFFETZ D, 1992, BIOCHEM J, V288, P631, DOI 10.1042/bj2880631; KABURAGI Y, 1993, J BIOL CHEM, V268, P16610; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PANG L, 1994, J BIOL CHEM, V269, P10604; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SEGER R, 1994, J BIOL CHEM, V269, P25699; SEGER R, 1995, J BIOL CHEM, V270, P28325; SHEMER J, 1987, J BIOL CHEM, V262, P15476; STUMPO DJ, 1991, J BIOL CHEM, V266, P455; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TAVARE JM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P21, DOI 10.1016/0167-4889(93)90106-Y; TAVARE JM, 1988, BIOCHEM J, V253, P783, DOI 10.1042/bj2530783; THIES RS, 1989, J BIOL CHEM, V264, P12820; TORNQVIST HE, 1988, J BIOL CHEM, V263, P350; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WHITE MF, 1988, J BIOL CHEM, V263, P2969; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZICK Y, 1983, J BIOL CHEM, V258, P75	49	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6998	7003		10.1074/jbc.271.12.6998	http://dx.doi.org/10.1074/jbc.271.12.6998			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636129	hybrid			2022-12-25	WOS:A1996UB15700064
J	Schalinske, KL; Eisenstein, RS				Schalinske, KL; Eisenstein, RS			Phosphorylation and activation of both iron regulatory proteins 1 and 2 in HL-60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; TRANSFERRIN RECEPTOR EXPRESSION; MESSENGER-RNA TRANSLATION; RESPONSIVE ELEMENT; 5-AMINOLEVULINATE SYNTHASE; DISULFIDE EXCHANGE; REDOX REGULATION; FERRITIN; DIFFERENTIATION; INVITRO	Iron regulatory proteins (IRPs) are RNA-binding proteins that post-transcriptionally regulate synthesis of iron uptake (transferrin receptor) and storage (ferritin) proteins. Our previous work demonstrating that IRP1 is phosphorylated by protein kinase C supported the hypothesis that factors in addition to iron modulate IRP function. We have investigated changes in activity and expression of both IRP1 and IRP2 during phorbol 12-myristate 13 acetate (PMA)-induced differentiation of HL-60 cells. In contrast to IRP1, IRP2 was highly phosphorylated in untreated cells. PMA stimulated phosphorylation of IRP1 and IRP2 by at least 2-3-fold without affecting incorporation of [S-35]methionine into the proteins. IRP1 and IRP2 isolated from PMA-treated cells displayed different phosphopeptides. Phosphorylation of IRPs was associated with a 2-fold increase in high affinity RNA binding activity without altering K-D, and this was accompanied by a 50% increase in transferrin receptor mRNA abundance. PMA acted on a latent pool of binding activity that is present in a nonaconitase oxidized form and is largely composed of a stable but inactive species of IRP2. Desferal and hemin modulated iron-responsive element binding activity in HL-60 cells without affecting the phosphorylation state of IRP1. Hemin appeared to reduce the abundance of phosphorylated IRP2. Thus, multiple factors affect the function of both IRPs and indicate that extracellular agents may program changes in cellular iron metabolism by altering the phosphorylation state of these regulatory RNA-binding proteins.	UNIV WISCONSIN,DEPT NUTR SCI,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NIDDK NIH HHS [DK-47219] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK047219, R01DK047219] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS ML, 1989, BIOCHIM BIOPHYS ACTA, V1012, P243, DOI 10.1016/0167-4889(89)90104-3; ANDREESEN R, 1984, BLUT, V49, P195, DOI 10.1007/BF00319822; CAIRO G, 1994, J BIOL CHEM, V269, P6405; CAPPEL RE, 1988, J BIOL CHEM, V263, P12204; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHAN RYY, 1994, EUR J BIOCHEM, V220, P683, DOI 10.1111/j.1432-1033.1994.tb18669.x; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CHITAMBAR CR, 1983, J CLIN INVEST, V72, P1314, DOI 10.1172/JCI111087; CHOU CC, 1986, MOL CELL BIOL, V6, P566, DOI 10.1128/MCB.6.2.566; Chromczynski P, 1987, ANAL BIOCHEM, V162, P156; CLERCH LB, 1995, ARCH BIOCHEM BIOPHYS, V317, P267, DOI 10.1006/abbi.1995.1162; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; EISENSTEIN RS, 1993, J BIOL CHEM, V268, P27363; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; FAZZONE H, 1993, J CLIN INVEST, V92, P1278, DOI 10.1172/JCI116700; GOESSLING LS, 1992, SCIENCE, V256, P670, DOI 10.1126/science.1316633; GUO B, 1994, J BIOL CHEM, V269, P24252; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HENDERSON BR, 1995, J BIOL CHEM, V270, P20509, DOI 10.1074/jbc.270.35.20509; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; HO PTC, 1989, CANCER RES, V49, P1989; JABBAR SAB, 1994, LEUKEMIA RES, V18, P523, DOI 10.1016/0145-2126(94)90090-6; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; KIM HY, 1995, J BIOL CHEM, V270, P4983, DOI 10.1074/jbc.270.10.4983; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KUHN LC, 1992, J INORG BIOCHEM, V47, P183, DOI 10.1016/0162-0134(92)84064-T; KUMAGAI N, 1988, J IMMUNOL, V140, P37; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; MCBRIDE AA, 1992, P NATL ACAD SCI USA, V89, P7531, DOI 10.1073/pnas.89.16.7531; MELEFORS O, 1993, J BIOL CHEM, V268, P5974; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; PANTOPOULOS K, 1995, RNA, V1, P155; RONDON IJ, 1995, FEBS LETT, V359, P267, DOI 10.1016/0014-5793(95)00066-I; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; SANCHEZGARCIA I, 1993, J MOL BIOL, V231, P945, DOI 10.1006/jmbi.1993.1343; SNYDER GH, 1981, BIOCHEMISTRY-US, V20, P6509, DOI 10.1021/bi00526a001; TANG CK, 1992, J BIOL CHEM, V267, P24466; TEIXEIRA S, 1991, EUR J BIOCHEM, V202, P819, DOI 10.1111/j.1432-1033.1991.tb16438.x; TESTA U, 1989, J BIOL CHEM, V264, P13181; THEIL EC, 1994, BIOCHEM J, V304, P1; TUAZON PT, 1989, J BIOL CHEM, V264, P2773; WALDEN WE, 1988, P NATL ACAD SCI USA, V85, P9503, DOI 10.1073/pnas.85.24.9503; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x	51	116	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7168	7176		10.1074/jbc.271.12.7168	http://dx.doi.org/10.1074/jbc.271.12.7168			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636154	hybrid			2022-12-25	WOS:A1996UB15700089
J	Sun, XY; Ollagnier, S; Schmidt, PP; Atta, M; Mulliez, E; Lepape, L; Eliasson, R; Graslund, A; Fontecave, M; Reichard, P; Sjoberg, BM				Sun, XY; Ollagnier, S; Schmidt, PP; Atta, M; Mulliez, E; Lepape, L; Eliasson, R; Graslund, A; Fontecave, M; Reichard, P; Sjoberg, BM			The free radical of the anaerobic ribonucleotide reductase from Escherichia coli is at glycine 681	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE FORMATE-LYASE; S-ADENOSYLMETHIONINE; ACTIVATION; SULFUR; SYSTEM; GENE	The anaerobic ribonucleoside triphosphate reductase of Escherichia coli is an iron-sulfur protein carrying an oxygen-sensitive organic radical, which is essential for catalysis, The radical was tentatively proposed to be on glycine 681, based on a comparison with the glycyl radical-containing enzyme pyruvate formate-lyase. By EPR spectroscopy of selectively H-2- and C-13-labeled anaerobic ribonucleotide reductase, the radical was now unambiguously assigned to carbon-g of a glycine residue. The large H-1 hyperfine splitting (1.4 millitesla) was assigned to the alpha-proton, Site-directed mutagenesis was used to change glycine 681 into an alanine residue. In separate experiments, the two adjacent residues, cysteine 680 and tyrosine 682, were changed into serine and phenylalanine, respectively. All mutated proteins were retained on dATP-Sepharose, indicating that the mutant proteins had intact allosteric sites. They also contained amounts of iron comparable with the wild type reductase and showed the same iron-sulfur related spectrum, suggesting that the mutant proteins were properly folded. Of the three mutant proteins only the G681A protein completely lacked the detectable glycyl radical as well as enzyme activity. Our results identify glycine 681 as the stable free radical site in E. coli anaerobic ribonucleotide reductase.	UNIV STOCKHOLM,DEPT MOLEC BIOL,S-10691 STOCKHOLM,SWEDEN; UNIV GRENOBLE 1,LAB ETUD DYNAM & STRUCT & SELECT,URA CNRS 332,F-38041 GRENOBLE 9,FRANCE; KAROLINSKA INST,DEPT BIOCHEM 1,MED NOBEL INST,MBB,S-17177 STOCKHOLM,SWEDEN; UNIV STOCKHOLM,DEPT BIOPHYS,S-10691 STOCKHOLM,SWEDEN	Stockholm University; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Karolinska Institutet; Stockholm University				Sjoberg, Britt-Marie/0000-0001-5953-3360; Ollagnier de Choudens, Sandrine/0000-0002-0080-6659				BARONE V, 1995, J AM CHEM SOC, V117, P1083, DOI 10.1021/ja00108a026; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; BIANCHI V, 1993, J BACTERIOL, V175, P1590, DOI 10.1128/JB.175.6.1590-1595.1993; BIANCHI V, 1993, BIOCHEM BIOPH RES CO, V197, P792, DOI 10.1006/bbrc.1993.2548; ELIASSON R, 1994, J BIOL CHEM, V269, P26052; ELIASSON R, 1990, P NATL ACAD SCI USA, V87, P3314, DOI 10.1073/pnas.87.9.3314; ELIASSON R, 1992, J BIOL CHEM, V267, P25541; FREY M, 1994, J BIOL CHEM, V269, P12432; HARDER J, 1992, J BIOL CHEM, V267, P25548; Higuchi R., 1989, PCR TECHNOLOGY, P61; JORDAN A, 1994, P NATL ACAD SCI USA, V91, P12892, DOI 10.1073/pnas.91.26.12892; KING DS, 1995, BIOCHEM BIOPH RES CO, V206, P731, DOI 10.1006/bbrc.1995.1103; KNAPPE J, 1990, FEMS MICROBIOL LETT, V75, P383, DOI 10.1111/j.1574-6968.1990.tb04108.x; MULLIEZ E, 1995, P NATL ACAD SCI USA, V92, P8759, DOI 10.1073/pnas.92.19.8759; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; REICHARD P, 1993, J BIOL CHEM, V268, P8383; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SINCLAIR J, 1973, J CHEM PHYS, V59, P1569, DOI 10.1063/1.1680233; Sjoberg B. M., 1995, NUCLEIC ACIDS MOL BI, V9, P192; SJOBERG BM, 1994, STRUCTURE, V2, P793, DOI 10.1016/S0969-2126(94)00080-8; SUN XY, 1995, J BIOL CHEM, V270, P2443, DOI 10.1074/jbc.270.6.2443; SUN XY, 1993, P NATL ACAD SCI USA, V90, P577, DOI 10.1073/pnas.90.2.577; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; YOUNG P, 1994, J BIOL CHEM, V269, P20229	24	117	119	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6827	6831		10.1074/jbc.271.12.6827	http://dx.doi.org/10.1074/jbc.271.12.6827			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636106				2022-12-25	WOS:A1996UB15700041
J	Tomiyama, T; Shoji, A; Kataoka, K; Suwa, Y; Asano, S; Kaneko, H; Endo, N				Tomiyama, T; Shoji, A; Kataoka, K; Suwa, Y; Asano, S; Kaneko, H; Endo, N			Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin - Its possible function as a hydroxyl radical scavenger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELDERLY LEPROSY PATIENTS; SENILE PLAQUES; PEPTIDE; BRAIN	Aggregation of physiologically produced soluble amyloid beta protein (A beta) to insoluble, neurotoxic fibrils is a crucial step in the pathogenesis of Alzheimer's disease. Aggregation studies with synthetic A beta 1-40 peptide by the thioflavin T fluorescence assay and electron microscopy and cytotoxicity assays using rat pheochromocytoma PC12 cells showed that an antibiotic, rifampicin, and its derivatives, which possess a naphthohydroquinone or naphthoquinone structure, inhibited A beta 1-40 aggregation and neurotoxicity in a concentration-dependent manner, Hydroquinone, p-benzoquinone, and 1,4-dihydroxynaphthalene, which represent partial structures of the aromatic chromophore of rifampicin derivatives, also inhibited A beta 1-40 aggregation and neurotoxicity at comparable molar concentrations to rifampicin. Electron spin resonance spectrometric analysis revealed that the inhibitory activities of those agents correlated with their radical-scavenging ability on hydroxyl free radical, which was shown to be generated in cell-free incubation of A beta 1-40 peptide. These results suggest that at least one mechanism of rifampicin-mediated inhibition of A beta aggregation and neurotoxicity involves scavenging of free radicals and that rifampicin an/or appropriate hydroxyl radical scavengers may have therapeutic potential for Alzheimer's disease.			Tomiyama, T (corresponding author), TEIJIN INST BIOMED RES,4-3-2 ASAHIGAOKA,HINO,TOKYO 191,JAPAN.							BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; DYRKS T, 1992, J BIOL CHEM, V267, P18210; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y; HARBOUR JR, 1974, CAN J CHEM, V52, P3549, DOI 10.1139/v74-527; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; KIMURA T, 1993, LANCET, V342, P1364, DOI 10.1016/0140-6736(93)92274-W; LAGERCRA.C, 1969, ACTA CHEM SCAND, V23, P811, DOI 10.3891/acta.chem.scand.23-0811; Lancini G, 1977, STRUCTURE ACTIVITY R, P531; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MATTSON MP, 1995, BRAIN RES, V676, P219, DOI 10.1016/0006-8993(95)00148-J; MINDERMANN T, 1993, J ANTIMICROB CHEMOTH, V31, P731, DOI 10.1093/jac/31.5.731; NAMBA Y, 1992, LANCET, V340, P978, DOI 10.1016/0140-6736(92)92870-L; PIKE CJ, 1993, J NEUROSCI, V13, P1676; SCHUBERT D, 1995, P NATL ACAD SCI USA, V92, P1989, DOI 10.1073/pnas.92.6.1989; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHEARMAN MS, 1994, P NATL ACAD SCI USA, V91, P1470, DOI 10.1073/pnas.91.4.1470; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; TOMIYAMA T, 1994, BIOCHEM BIOPH RES CO, V204, P76, DOI 10.1006/bbrc.1994.2428	22	284	295	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6839	6844		10.1074/jbc.271.12.6839	http://dx.doi.org/10.1074/jbc.271.12.6839			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636108	hybrid			2022-12-25	WOS:A1996UB15700043
J	Ursitti, JA; Kotula, L; DeSilva, TM; Curtis, PJ; Speicher, DW				Ursitti, JA; Kotula, L; DeSilva, TM; Curtis, PJ; Speicher, DW			Mapping the human erythrocyte beta-spectrin dimer initiation site using recombinant peptides and correlation of its phasing with the alpha-actinin dimer site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL SPECTRIN; TETRAMER BINDING-SITE; MEMBRANE SKELETON; HEREDITARY ELLIPTOCYTOSIS; PLASMA-MEMBRANE; IDENTIFICATION; EXPRESSION; MUTATIONS; DOMAIN; ULTRASTRUCTURE	Human erythroid spectrin dimer assembly is initiated by the association of a specific region near the N-terminal of beta-spectrin with a complementary region near the C-terminal of cr-spectrin (Speicher, D. W, Weglarz, L,, and DeSilva, T, M, (1992) J, Biol, Chem. 267, 14775-14782), Both spectrin subunits consist primarily of tandem, 106-residue long, homologous, triple-helical motifs, In this study, the minimal region of beta-spectrin required for association with rw-spectrin was determined using recombinant- peptides, The start site (phasing) for construction of dimerization competent beta-spectrin peptides was particularly critical. The beginning of the first homologous motif for both beta-spectrin and the related dimerization site of alpha-actinin is approximately 8 residues earlier than most spectrin motifs, A four-motif beta-spectrin peptide (beta 1-4(+)) with this earlier starting point bound to full-length alpha-spectrin with a K-d of about 10 nM, while deletion of these first 8 residues reduced binding nearly 10-fold, N- and C-terminal truncations of one or more motifs from beta 1-4(+) showed that the first motif was essential for dimerization since its deletion abolished binding, but beta 1(+) alone could not associate with alpha-monomers, The first two motifs (beta 1-2(+)) represented the minimum lateral dimer assembly site with a K-d of about 230 nM for interaction with full-length ar-spectrin or an cu-spectrin nucleation site recombinant peptide, alpha 18-21, Each additional motif increased the dimerization affinity by approximately 5-fold, In addition to this strong inter-subunit dimer association, interactions between the helices of a single triple-helical motif are frequently strong enough to maintain a noncovalent complex after internal protease cleavage similar to the interact-ions thought to be involved in tetramer formation, Analysis of hydrodynamic radii of recombinant peptides containing differing numbers of motifs showed that a single motif had a Stokes radius of 2.35 nm, while each additional motif added only 0.85 nm to the Stokes radius, This is the first direct demonstration that spectrin's flexibility arises from regions between each triple helical motif rather than from within the segment itself and suggests that current models of inter-motif connections may need to be revised.	WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA	The Wistar Institute				Kotula, Leszek/0000-0002-7977-7124	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038794, F32HL008840, R01HL033884] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL33884, HL38794, HL08840] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLOISIO N, 1991, J CLIN INVEST, V87, P2169, DOI 10.1172/JCI115250; BARON MD, 1987, J BIOL CHEM, V262, P17623; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; BLOCH R J, 1992, Trends in Cell Biology, V2, P186, DOI 10.1016/0962-8924(92)90231-B; BYERS TJ, 1985, P NATL ACAD SCI USA, V82, P6153, DOI 10.1073/pnas.82.18.6153; DELAUNAY J, 1993, SEMIN HEMATOL, V30, P21; DIPAOLO BR, 1993, BLOOD, V82, P284, DOI 10.1182/blood.V82.1.284.bloodjournal821284; GARBARZ W, 1994, NATURE, V372, P620; GILMORE AP, 1994, EUR J BIOCHEM, V225, P235, DOI 10.1111/j.1432-1033.1994.00235.x; IMAMURA M, 1988, J BIOL CHEM, V263, P7800; KENNEDY SP, 1991, J CELL BIOL, V115, P267, DOI 10.1083/jcb.115.1.267; KENNEDY SP, 1994, J BIOL CHEM, V269, P11400; KOTULA L, 1993, J BIOL CHEM, V268, P14788; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU SC, 1987, J CELL BIOL, V104, P527, DOI 10.1083/jcb.104.3.527; LOMBARDO CR, 1994, J BIOL CHEM, V269, P29212; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Lux SE, 1995, BLOOD PRINCIPLES PRA, P1701; MAZDZANOWSKI J, 1992, ELECTROPHORESIS, V13, P59, DOI 10.1002/elps.1150130112; MORROW JS, 1980, P NATL ACAD SCI-BIOL, V77, P6592, DOI 10.1073/pnas.77.11.6592; PARQUET N, 1994, BLOOD, V84, P303; RANDON J, 1994, BRIT J HAEMATOL, V88, P534, DOI 10.1111/j.1365-2141.1994.tb05070.x; REIM DF, 1994, ANAL BIOCHEM, V216, P213, DOI 10.1006/abio.1994.1027; SAHR KE, 1990, J BIOL CHEM, V265, P4434; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEARS DE, 1986, BIOCHIM BIOPHYS ACTA, V870, P432, DOI 10.1016/0167-4838(86)90251-7; SHEN BW, 1986, J CELL BIOL, V102, P997, DOI 10.1083/jcb.102.3.997; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; SPEICHER DW, 1992, J BIOL CHEM, V267, P14775; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; SPEICHER DW, 1993, J BIOL CHEM, V268, P4227; TSE WT, 1990, J CLIN INVEST, V86, P909, DOI 10.1172/JCI114792; URSITTI JA, 1991, CELL MOTIL CYTOSKEL, V19, P227, DOI 10.1002/cm.970190402; VIEL A, 1994, P NATL ACAD SCI USA, V91, P10839, DOI 10.1073/pnas.91.23.10839; WILMOTTE R, 1993, J CLIN INVEST, V91, P2091, DOI 10.1172/JCI116432; WINKELMANN JC, 1993, BLOOD, V81, P3173; WINKELMANN JC, 1990, J BIOL CHEM, V265, P11827; WINOGRAD E, 1991, P NATL ACAD SCI USA, V88, P10788, DOI 10.1073/pnas.88.23.10788; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097; YOSHINO H, 1991, J BIOCHEM, V110, P553, DOI 10.1093/oxfordjournals.jbchem.a123618; YOSHINO H, 1984, J BIOL CHEM, V259, P4496	42	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6636	6644		10.1074/jbc.271.12.6636	http://dx.doi.org/10.1074/jbc.271.12.6636			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636080	hybrid			2022-12-25	WOS:A1996UB15700015
J	Duan, CM; Hawes, SB; Prevette, T; Clemmons, DR				Duan, CM; Hawes, SB; Prevette, T; Clemmons, DR			Insulin-like growth factor-I (IGF-I) regulates IGF-binding protein-5 synthesis through transcriptional activation of the gene in aortic smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOBLAST DIFFERENTIATION; RETINOBLASTOMA PROTEIN; BALLOON DENUDATION; MOLECULAR-CLONING; MESSENGER-RNA; RAT AORTA; EXPRESSION; IDENTIFICATION; FIBROBLASTS; SECRETION	Previous studies have shown that porcine aortic smooth muscle cells (SMCs) secrete two insulin-like growth factor-binding proteins (IGFBP), IGFBP-2 and -4, and that these IGFBPs modulate IGF-I-stimulated SMC proliferation and migration. In this study we demonstrate that porcine SMCs express IGFBP-5 mRNA and synthesize and secrete the protein, In this cell type, the biosynthesis of IGFBP-5 is up-regulated by IGF-I. This increase in IGFBP-5 synthesis is accompanied by an increase in the steady-state mRNA levels. The induction of IGFBP-5 mRNA by IGF-I is time- and dose-dependent and requires de novo protein synthesis, IGF-II and insulin also increase IGFBP-5 mRNA levels at high doses. An IGF-I analog with normal affinity for the IGF-I receptor but reduced affinity for IGFBPs evokes a similar increase. Another analog that binds to IGFBPs but not to the receptor has no effect, indicating that this effect of IGF-I is mediated through the IGF-I receptor. The IGF-I-induced IGFBP-5 gene expression is cell type-specific because IGF-I had no such effect in other cell types examined. Nuclear run-on assays revealed that IGF-I increased transcription rate of the IGFBP-5 gene, while IGF-I did not change the IGFBP-5 mRNA stability. Furthermore, the IGFBP-5 promoter was 3.5-fold more active in directing expression of the luciferase reporter gene in IGF-I-treated aortic SMCs as compared to control cells, whereas the luciferase activity remained the same in control- and IGF-I-treated fibroblasts. These results suggest that IGF-I up-regulates IGFBP-5 synthesis by transcriptionally activating the IGFBP-5 gene in aortic SMCs.			Duan, CM (corresponding author), UNIV N CAROLINA, DEPT MED, DIV ENDOCRINOL, CB 7170, CHAPEL HILL, NC 27599 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL026309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG002331, R37AG002331] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-26309] Funding Source: Medline; NIA NIH HHS [AG02331] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADASHI EY, 1994, MOL CELL ENDOCRINOL, V99, P279, DOI 10.1016/0303-7207(94)90018-3; ALEMANY J, 1990, P NATL ACAD SCI USA, V87, P3353, DOI 10.1073/pnas.87.9.3353; ALLANDER SV, 1994, J BIOL CHEM, V269, P10891; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARAI T, 1994, ENDOCRINOLOGY, V135, P2358, DOI 10.1210/en.135.6.2358; BACKELJAUW PF, 1993, ENDOCRINOLOGY, V132, P1677, DOI 10.1210/en.132.4.1677; BANSKOTA NK, 1989, DIABETES, V38, P123, DOI 10.2337/diabetes.38.1.123; BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; BORNFELDT KE, 1990, J ENDOCRINOL, V125, P381, DOI 10.1677/joe.0.1250381; BOURNER MJ, 1992, J CELL BIOCHEM, V48, P215; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CANALIS E, 1995, J BIOL CHEM, V270, P10771, DOI 10.1074/jbc.270.18.10771; CERCEK B, 1990, CIRC RES, V66, P1755, DOI 10.1161/01.RES.66.6.1755; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CLEMMONS DR, 1985, CIRC RES, V56, P418, DOI 10.1161/01.RES.56.3.418; CLEMMONS DR, 1985, ENDOCRINOLOGY, V117, P77, DOI 10.1210/endo-117-1-77; COHICK WS, 1993, J CELL PHYSIOL, V157, P52, DOI 10.1002/jcp.1041570107; COHICK WS, 1995, J CELL PHYSIOL, V164, P187, DOI 10.1002/jcp.1041640123; CONOVER CA, 1995, ENDOCRINOLOGY, V136, P1403, DOI 10.1210/en.136.4.1403; CONOVER CA, 1993, ENDOCRINOLOGY, V132, P2525, DOI 10.1210/en.132.6.2525; CONOVER CA, 1993, J CLIN ENDOCR METAB, V76, P1153, DOI 10.1210/jc.76.5.1153; DELAFONTAINE P, 1991, HYPERTENSION, V18, P742, DOI 10.1161/01.HYP.18.6.742; DONG Y, 1995, ENDOCRINOLOGY, V136, P2000, DOI 10.1210/en.136.5.2000; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DU J, 1995, CIRC RES, V76, P963, DOI 10.1161/01.RES.76.6.963; DUAN CM, 1995, J BIOL CHEM, V270, P24844, DOI 10.1074/jbc.270.42.24844; EPSTEIN SE, 1991, CIRCULATION, V84, P778, DOI 10.1161/01.CIR.84.2.778; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FIELDER PJ, 1993, ENDOCRINOLOGY, V133, P415, DOI 10.1210/en.133.1.415; FURLANETTO RW, 1994, MOL ENDOCRINOL, V8, P510, DOI 10.1210/me.8.4.510; GOCKERMAN A, 1995, CIRC RES, V76, P514, DOI 10.1161/01.RES.76.4.514; GOCKERMAN A, 1995, ENDOCRINOLOGY, V136, P4168, DOI 10.1210/en.136.10.4168; GRANT MB, 1994, CIRCULATION, V89, P1511, DOI 10.1161/01.CIR.89.4.1511; GREENBERG ME, 1994, CURRENT PROTOCOLS MO, V1; JAMES PL, 1993, J BIOL CHEM, V268, P22305; JENSEN DE, 1995, J BIOL CHEM, V270, P6555, DOI 10.1074/jbc.270.12.6555; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KHORSANDI MJ, 1992, J CLIN INVEST, V90, P1926, DOI 10.1172/JCI116070; KIEFER MC, 1991, BIOCHEM BIOPH RES CO, V176, P219, DOI 10.1016/0006-291X(91)90912-Q; KOU K, 1995, DNA CELL BIOL, V14, P241, DOI 10.1089/dna.1995.14.241; KOU K, 1994, GENOMICS, V20, P412, DOI 10.1006/geno.1994.1195; MARTIN JL, 1988, ENDOCRINOLOGY, V123, P1907, DOI 10.1210/endo-123-4-1907; MCCUSKER RH, 1988, J CELL PHYSIOL, V137, P505, DOI 10.1002/jcp.1041370316; MONNIER D, 1994, MOL CELL ENDOCRINOL, V104, P139, DOI 10.1016/0303-7207(94)90116-3; PARKER A, 1995, ENDOCRINOLOGY, V136, P2470, DOI 10.1210/en.136.6.2470; RECHLER MM, 1993, VITAM HORM, V47, P1, DOI 10.1016/S0083-6729(08)60444-6; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; ROTWEIN P, 1995, MOL ENDOCRINOL, V9, P913, DOI 10.1210/me.9.7.913; SANTISTEBAN P, 1987, J BIOL CHEM, V262, P4048; SHEIKH MS, 1992, BIOCHEM BIOPH RES CO, V188, P1122, DOI 10.1016/0006-291X(92)91348-T; SHEMER J, 1993, J CLIN ENDOCR METAB, V77, P1246, DOI 10.1210/jc.77.5.1246; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SIMMONS JG, 1995, MOL ENDOCRINOL, V9, P1157, DOI 10.1210/me.9.9.1157; SKAR R, 1994, MOL CELL ENDOCRINOL, V106, P213, DOI 10.1016/0303-7207(94)90205-4; TAMAROGLIO TA, 1994, EXP CELL RES, V215, P338, DOI 10.1006/excr.1994.1350; TOLLEFSEN SE, 1989, J BIOL CHEM, V264, P13810; URBAN RJ, 1994, J BIOL CHEM, V269, P25761; WOLFE BL, 1993, J BIOL CHEM, V268, P12418; YAMASHITA S, 1987, J CLIN INVEST, V79, P449, DOI 10.1172/JCI112832; ZHU X, 1993, BIOCHEM BIOPH RES CO, V190, P1045, DOI 10.1006/bbrc.1993.1154	62	78	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4280	4288						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626775				2022-12-25	WOS:A1996TW96000053
J	Lee, MH; Mori, S; Raychaudhuri, P				Lee, MH; Mori, S; Raychaudhuri, P			trans-Activation by the hnRNP K protein involves an increase in RNA synthesis from the reporter genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; BINDING PROTEIN; RIBONUCLEOPROTEINS; IDENTIFICATION; TRANSCRIPTION; DEFINITION; PARTICLES; SEQUENCES; CONTAINS; DOMAINS	The function of many of the pre-mRNA-binding proteins in mRNA biogenesis is unclear. We have analyzed the biochemical function of the hnRNP K protein by using a mouse cDNA clone. A previous study indicated that the expression of hnRNP K activates c-myc promoter in transient transfection assays. We show that the expression of hnRNP K results in a trans-activation of a variety of RNA polymerase II promoters; The trans-activation function depends on the sequences of hnRNP K that are also necessary for RNA binding. However, the RNA binding motifs are not sufficient for trans activation. We could identify a mutant that bound RNA in vitro but was impaired in its ability to trans-activate the reporter genes. The trans-activation was not a result of the stabilization of the reporter mRNA, because hnRNP K increased the steady-state level of the reporter mRNA without altering its decay rate. By doing nuclear run-on assays, we provide evidence that the hnRNP K protein trans-activates the reporter genes by increasing the level of transcription.	UNIV ILLINOIS,DEPT BIOCHEM,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NCI NIH HHS [CA55279] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055279] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI GR, 1990, EMBO J, V10, P3457; ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BARNETT SF, 1989, MOL CELL BIOL, V9, P492, DOI 10.1128/MCB.9.2.492; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONWAY G, 1988, MOL CELL BIOL, V8, P2884, DOI 10.1128/MCB.8.7.2884; CULLEN BR, 1991, FASEB J, V5, P2361, DOI 10.1096/fasebj.5.10.1712325; DEJGAARD K, 1994, J MOL BIOL, V236, P33, DOI 10.1006/jmbi.1994.1116; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HART RP, 1985, MOL CELL BIOL, V5, P2975, DOI 10.1128/MCB.5.11.2975; HUTCHISON N, 1985, CELL, V43, P471, DOI 10.1016/0092-8674(85)90177-1; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; OSTROWSKI J, 1994, J BIOL CHEM, V269, P17626; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; RAY SK, 1992, MOL CELL BIOL, V12, P4327, DOI 10.1128/MCB.12.10.4327; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875	31	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3420	3427						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631943				2022-12-25	WOS:A1996TV72400017
J	Maeda, M; Aubry, L; Insall, R; Gaskins, C; Devreotes, PN; Firtel, RA				Maeda, M; Aubry, L; Insall, R; Gaskins, C; Devreotes, PN; Firtel, RA			Seven helix chemoattractant receptors transiently stimulate mitogen-activated protein kinase in Dictyostelium - Role of heterotrimeric G proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-GENETIC-ANALYSIS; ADENYLYL CYCLASE; SUBUNIT	Mitogen-activated protein (MAP) kinases are involved in controlling a cell's responses to a variety of stimuli and can be activated by both protein tyrosine kinase and G protein-coupled receptors. It was shown previously that Dictyostelium MAP kinase ERK2 is required for normal activation of adenylyl cyclase and erk2 null cells are aggregation-deficient. In this manuscript, we show that the Dictyostelium MAP kinase ERK2 is rapidly and transiently activated in response to the chemoattractant cAMP. This response requires cAMP receptors, but is independent of the coupled G alpha 2 subunit and the only known G beta subunit. These data indicate that ligand-mediated receptor activation of adenylyl cyclase requires two receptor-dependent pathways, one of which requires heterotrimeric G proteins, including G alpha 2 and the only known G beta subunit, and the second of which requires ERK2. Our results suggest that ERK2 may be activated by a novel receptor-mediated pathway.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,DEPT BIOL,LA JOLLA,CA 92093; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	University of California System; University of California San Diego; Johns Hopkins University			Insall, Robert/G-5611-2011	Insall, Robert/0000-0003-4898-040X; Aubry, Laurence/0000-0001-7640-1706	NIGMS NIH HHS [GM37830, GM28007] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037830, R37GM028007, R01GM028007] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANHAASTERT PJM, 1992, ADENINE NUCLEOTIDES, P379; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; CHEN CY, 1993, J BIOL CHEM, V268, P7825; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CUBITT AB, 1992, COLD SPRING HARB SYM, V57, P177, DOI 10.1101/SQB.1992.057.01.023; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEVREOTES PN, 1994, NEURON, V12, P235, DOI 10.1016/0896-6273(94)90267-4; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FIRTEL RA, 1995, GENE DEV, V9, P1427, DOI 10.1101/gad.9.12.1427; GASKINS C, 1994, MOL CELL BIOL, V14, P6996, DOI 10.1128/MCB.14.10.6996; Gaskins C, 1996, GENE DEV, V10, P118, DOI 10.1101/gad.10.1.118; HADWIGER JA, 1994, P NATL ACAD SCI USA, V91, P10566, DOI 10.1073/pnas.91.22.10566; HARLOW E, 1988, ANTIBODIES LABORATOR; HERELD D, 1992, INT REV CYTOL, V137B, P35; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; INSALL R, 1994, J CELL BIOL, V126, P1537, DOI 10.1083/jcb.126.6.1537; INSALL RH, 1994, MOL BIOL CELL, V5, P703, DOI 10.1091/mbc.5.6.703; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KUMAGAI A, 1991, J BIOL CHEM, V266, P1220; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; LILLY PJ, 1994, J BIOL CHEM, V269, P14123; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEHDY MC, 1985, MOL CELL BIOL, V5, P705, DOI 10.1128/MCB.5.4.705; MILNE JLS, 1995, J BIOL CHEM, V270, P5926, DOI 10.1074/jbc.270.11.5926; OKAICHI K, 1992, MOL BIOL CELL, V3, P735, DOI 10.1091/mbc.3.7.735; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; SCHNITZLER GR, 1995, CELL, V81, P737, DOI 10.1016/0092-8674(95)90535-9; SEGALL JE, 1995, J CELL BIOL, V128, P405, DOI 10.1083/jcb.128.3.405; SOEDE RDM, 1994, DEVELOPMENT, V120, P1997; SUN TJ, 1990, J CELL BIOL, V110, P1549, DOI 10.1083/jcb.110.5.1549; SUN TJ, 1991, GENE DEV, V5, P572, DOI 10.1101/gad.5.4.572; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; THEIBERT A, 1986, J BIOL CHEM, V261, P5121; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; WU L, 1994, HDB EXPT PHARM, V108, P335; WU LJ, 1994, MOL BIOL CELL, V5, P691, DOI 10.1091/mbc.5.6.691; WU LJ, 1995, J CELL BIOL, V129, P1667, DOI 10.1083/jcb.129.6.1667	44	87	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3351	3354						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631932				2022-12-25	WOS:A1996TV72400006
J	Tillman, JB; Dhahbi, JM; Mote, PL; Walford, RL; Spindler, SR				Tillman, JB; Dhahbi, JM; Mote, PL; Walford, RL; Spindler, SR			Dietary calorie restriction in mice induces carbamyl phosphate synthetase I gene transcription tissue specifically	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER PROTEIN-SYNTHESIS; MESSENGER-RNA LEVELS; UREA CYCLE ENZYMES; GROWTH FACTOR-I; RAT-LIVER; FOOD RESTRICTION; CARBAMOYLPHOSPHATE SYNTHETASE; MORRIS HEPATOMA-5123D; MITOCHONDRIAL ENZYME; HORMONAL-REGULATION	Dietary calorie restriction (CR) delays age-related physiologic changes, increases maximum life span, and reduces cancer incidence, Here, we present the novel finding that chronic reduction of dietary calories by 50% without changing the intake of dietary protein induced the activity of mouse hepatic carbamyl phosphate synthetase I (CpsI) 5-fold, In liver, CpsI protein, mRNA, and gene transcription were each stimulated by similar to 3-fold, Thus, CR increased both the rate of gene transcription and the specific activity of the enzyme. Short-term feeding studies demonstrated that higher cpsI expression was due to CR and not consumption of more dietary protein, Intestinal CpsI activity was stimulated 2-fold, while its mRNA level did not change, suggesting enzyme activity or translation efficiency was stimulated. CpsI catalyzes the conversion of metabolic ammonia to carbamyl phosphate, the rate-limiting step in urea biosynthesis, cpsI induction suggests there is a shift in the metabolism of calorie-restricted animals toward protein catabolism. CpsI induction likely facilitates metabolic detoxification of ammonia, a strong neurotoxin, Enhanced protein turnover and metabolic detoxification may extend life span. Physiologic similarities between calorie-restricted and hibernating animals suggest the effects of CR may be part of a spectrum of adaptive responses that include hibernation.	UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92521; UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90024	University of California System; University of California Riverside; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA				Tillman, John/0000-0003-2912-2370	NIA NIH HHS [AG00424] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADCOCK MW, 1984, J BIOL CHEM, V259, P3471; BALAGE M, 1990, HORM METAB RES, V22, P207, DOI 10.1055/s-2007-1004886; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CRAIK JD, 1979, BIOCHEM J, V182, P503, DOI 10.1042/bj1820503; DEGROOT CJ, 1984, BIOCHEM BIOPH RES CO, V124, P882, DOI 10.1016/0006-291X(84)91040-4; GOPING IS, 1994, J BIOL CHEM, V269, P3891; GOPING IS, 1992, GENE, V118, P283, DOI 10.1016/0378-1119(92)90201-Y; GOULD GW, 1991, BIOCHEMISTRY-US, V30, P5139, DOI 10.1021/bi00235a004; HARRIS SB, 1994, MECH AGEING DEV, V73, P209, DOI 10.1016/0047-6374(94)90053-1; HAYDEN JM, 1995, J ENDOCRINOL, V145, P397, DOI 10.1677/joe.0.1450397; HIRASHIMA S, 1988, J BIOL CHEM, V263, P3858; Hochachka PW., 1987, METABOLIC ARREST CON; HURSTING SD, 1993, CANCER RES, V53, P2750; ISHIGAMI A, 1990, ARCH BIOCHEM BIOPHYS, V283, P362, DOI 10.1016/0003-9861(90)90655-I; JACKSON MJ, 1986, ANNU REV GENET, V20, P431, DOI 10.1146/annurev.ge.20.120186.002243; JONES ME, 1965, ANNU REV BIOCHEM, V34, P381; KINGSLEY TR, 1991, J GERONTOL, V46, pB135, DOI 10.1093/geronj/46.4.B135; KITAGAWA Y, 1987, EUR J BIOCHEM, V167, P19, DOI 10.1111/j.1432-1033.1987.tb13299.x; KITAGAWA Y, 1985, BIOCHIM BIOPHYS ACTA, V825, P148, DOI 10.1016/0167-4781(85)90098-3; KLIP A, 1994, FASEB J, V8, P43, DOI 10.1096/fasebj.8.1.8299889; KOIZUMI A, 1987, J NUTR, V117, P361, DOI 10.1093/jn/117.2.361; KOIZUMI A, 1992, J NUTR, V122, P1446, DOI 10.1093/jn/122.7.1446; KOIZUMI A, 1989, AGE, V12, P93, DOI 10.1007/BF02432371; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGACE M, 1992, GENE, V118, P231, DOI 10.1016/0378-1119(92)90193-S; LAMERS WH, 1981, MECH AGEING DEV, V15, P93, DOI 10.1016/0047-6374(81)90010-5; LEWIS SEM, 1985, EXP GERONTOL, V20, P253, DOI 10.1016/0531-5565(85)90050-6; LIU RK, 1972, GERONTOLOGY, V18, P363, DOI 10.1159/000211944; LUSTY CJ, 1978, EUR J BIOCHEM, V85, P373, DOI 10.1111/j.1432-1033.1978.tb12249.x; MARINEZRAMON A, 1990, J HISTOCHEM CYTOCHEM, V38, P371; MASORO EJ, 1989, J GERONTOL, V44, pB20, DOI 10.1093/geronj/44.1.B20; MASORO EJ, 1983, J NUTR, V113, P880, DOI 10.1093/jn/113.4.880; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOUSSEAU DD, 1994, P SOC EXP BIOL MED, V206, P329; Nuzum CT, 1976, UREA CYCLE, P325; NYUNOYA H, 1985, J BIOL CHEM, V260, P9346; PALEKAR AG, 1985, ARCH BIOCHEM BIOPHYS, V237, P430, DOI 10.1016/0003-9861(85)90296-6; RAYMOND Y, 1981, BIOCHIM BIOPHYS ACTA, V656, P111, DOI 10.1016/0005-2787(81)90033-2; ROZEN R, 1983, BIOCHIM BIOPHYS ACTA, V741, P47, DOI 10.1016/0167-4781(83)90008-8; RUGGERI BA, 1989, CANCER RES, V49, P4130; RYALL J, 1985, EUR J BIOCHEM, V152, P287, DOI 10.1111/j.1432-1033.1985.tb09196.x; RYALL J, 1984, J BIOL CHEM, V259, P9172; RYALL JC, 1986, EUR J BIOCHEM, V156, P453, DOI 10.1111/j.1432-1033.1986.tb09603.x; SABATINO F, 1991, J GERONTOL, V46, pB171, DOI 10.1093/geronj/46.5.B171; SCHIMKE RT, 1963, J BIOL CHEM, V238, P1021; SEILER N, 1993, NEUROCHEM RES, V18, P235, DOI 10.1007/BF00969079; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SPINDLER SR, 1990, J NUTR, V120, P1412, DOI 10.1093/jn/120.11.1412; SPINDLER SR, 1982, J BIOL CHEM, V257, P1627; SPINDLER SR, 1991, J GERONTOL, V46, pB233, DOI 10.1093/geronj/46.6.B233; STEINBERG RA, 1975, CELL, V5, P29, DOI 10.1016/0092-8674(75)90088-4; TAL M, 1990, J CLIN INVEST, V86, P986, DOI 10.1172/JCI114801; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TILLMAN JB, 1996, IN PRESS J NUTR; WALFORD RL, 1992, P NATL ACAD SCI USA, V89, P11533, DOI 10.1073/pnas.89.23.11533; WARD W, 1991, HEPATOLOGY, V14, P935, DOI 10.1002/hep.1840140529; WARD WF, 1988, J GERONTOL, V43, pB121, DOI 10.1093/geronj/43.5.B121; WARD WF, 1988, J GERONTOL, V43, pB50, DOI 10.1093/geronj/43.2.B50; WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854; WEINDRUCH R, 1988, RETARDATION AGING DI; WHITE BA, 1982, J BIOL CHEM, V257, P8569	63	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3500	3506						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631954	hybrid			2022-12-25	WOS:A1996TV72400028
J	Stewart, CEH; Rotwein, P				Stewart, CEH; Rotwein, P			Insulin-like growth factor-II is an autocrine survival factor for differentiating myoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-CELL DIFFERENTIATION; IGF-I; SKELETAL-MUSCLE; EXPRESSION; IDENTIFICATION; RECEPTOR; BINDING; GENE; ACTIVATION; APOPTOSIS	Recent studies indicate that insulin-like growth factor-II (IGF-II) acts as an autocrine differentiation factor for skeletal myoblasts in culture. IGF-II mRNA and protein are induced as early events in muscle differentiation, and the rate and extent of IGF-II secretion correlate with both biochemical and morphological differentiation. Here we show that IGF-II also functions as an essential survival factor during the transition from proliferating to differentiating myoblasts. Stably transfected C2 muscle cell lines were established in which a mouse IGF-II cDNA was expressed in the antisense orientation relative to the constitutively active Moloney sarcoma virus promoter. IGF-II antisense cells proliferated normally in growth medium containing 20% serum but underwent rapid death when placed in low serum differentiation medium. Death was accompanied by characteristic markers of apoptosis with more than 90% of cells showing DNA fragmentation within 12-16 h. Myoblast death was prevented by IGF-I, des [1-3] IGF-I, IGF-II, and insulin with a dose potency consistent with activation of the IGF-I receptor; death also could be blocked by the protein synthesis inhibitor, cycloheximide. Exogenous IGFs additionally stimulated passage through a single cell cycle and subsequently induced terminal differentiation. Cell survival and cell cycle progression also were enhanced by fibroblast growth factor-2 and platelet-derived growth factor-bb, but these peptides did not promote differentiation. Our results define a novel system for studying apoptotic cell death and its prevention by growth factors, underscore the importance of IGF action in minimizing inappropriate cell death, and indicate that shared signal transduction pathways may mediate myoblast survival in vitro.	WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOPHYS, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)			Rotwein, Peter/R-5783-2019; Stewart, Claire E/I-3177-2013	Rotwein, Peter/0000-0002-9505-1817; Stewart, Claire/0000-0002-8104-4819	NIDDK NIH HHS [R01 DK042748, 5 RO1-DK42748, DK20579] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579, P30DK020579, R01DK042748] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAXTER RC, 1993, TRENDS ENDOCRIN MET, V4, P91, DOI 10.1016/1043-2760(93)90085-S; BREIER BH, 1991, J ENDOCRINOL, V128, P347, DOI 10.1677/joe.0.1280347; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; COLEMAN ME, 1995, J BIOL CHEM, V270, P12109, DOI 10.1074/jbc.270.20.12109; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; DAUGHADAY WH, 1987, METHOD ENZYMOL, V146, P248; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; EWTON DZ, 1994, J CELL PHYSIOL, V161, P277, DOI 10.1002/jcp.1041610212; FLORINI JR, 1986, AM J PHYSIOL, V250, pC771, DOI 10.1152/ajpcell.1986.250.5.C771; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; Florini JR, 1995, DIABETES REV, V3, P73; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; JAMES PL, 1993, J BIOL CHEM, V268, P22305; JENNISCHE E, 1987, ACTA PHYSIOL SCAND, V129, P9, DOI 10.1111/j.1748-1716.1987.tb08034.x; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KIESS W, 1987, J BIOL CHEM, V262, P12745; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KOU K, 1993, MOL ENDOCRINOL, V7, P291, DOI 10.1210/me.7.2.291; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LEVINOVITZ A, 1992, MOL ENDOCRINOL, V6, P1227, DOI 10.1210/me.6.8.1227; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Montarras Didier, 1993, Comptes Rendus de l'Academie des Sciences Serie III Sciences de la Vie, V316, P1025; Nissley P, 1991, Growth Factors, V5, P29, DOI 10.3109/08977199109000269; POWELLBRAXTON L, 1993, GENE DEV, V7, P2609, DOI 10.1101/gad.7.12b.2609; QUINN LS, 1994, J CELL PHYSIOL, V159, P387, DOI 10.1002/jcp.1041590302; RESNICOFF M, 1995, CANCER RES, V55, P3739; RESNICOFF M, 1995, CANCER RES, V55, P2463; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; ROSEN KM, 1993, ENDOCRINOLOGY, V133, P474, DOI 10.1210/en.133.2.474; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; ROSENTHAL SM, 1991, J CLIN INVEST, V87, P1212, DOI 10.1172/JCI115121; ROSENTHAL SM, 1995, P NATL ACAD SCI USA, V92, P10307, DOI 10.1073/pnas.92.22.10307; SCHMID C, 1983, FEBS LETT, V161, P117, DOI 10.1016/0014-5793(83)80742-X; SELL C, 1995, CANCER RES, V55, P303; SMITH J, 1995, CELL DEATH DIFFER, V2, P243; TANAKA H, 1989, ENDOCRINOLOGY, V124, P870, DOI 10.1210/endo-124-2-870; TOLLEFSEN SE, 1989, P NATL ACAD SCI USA, V86, P1543, DOI 10.1073/pnas.86.5.1543; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VANDENBURGH HH, 1991, AM J PHYSIOL, V260, pC475, DOI 10.1152/ajpcell.1991.260.3.C475; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	52	187	193	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11330	11338		10.1074/jbc.271.19.11330	http://dx.doi.org/10.1074/jbc.271.19.11330			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626686	hybrid			2022-12-25	WOS:A1996UJ94400046
J	Warren, BS; Kusk, P; Wolford, RG; Hager, GL				Warren, BS; Kusk, P; Wolford, RG; Hager, GL			Purification and stabilization of transcriptionally active glucocorticoid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; PROTEIN; DNA; ACTIVATION; COMPLEXES; INVITRO; INVIVO	A major obstacle to the purification of glucocorticoid receptor (GR) is the very high nonspecific surface adsorption of this protein. This phenomenon is a property of the GR itself and does not reflect overall protein concentration or buffer conditions. We have observed that the zwitterionic detergent 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid (CHAPS) is unique in its ability to stabilize the receptor and largely eliminate loss to nonspecific adsorption. We have coupled this observation with a two-step purification method that allows efficient purification and stabilization of transcriptionally active glucocorticoid receptor. For this procedure, the GR first undergoes a major purifica tion by anion exchange chromatography following hormone binding and on-column receptor transformation. Second, the GR is resolved to homogeneity utilizing a hydrophobic interaction chromatography step which consists of a 2.5 M to 0 M NaCl gradient elution of contaminating proteins followed by displacement of GR by CHAPS. GR at both stages of purification was able to activate transcription from the glucocorticoid response element containing the promoter region of the long terminal repeat of the mouse mammary tumor virus. This simple and efficient methodology should be of a considerable advantage for studies of the biology of the active, full-length GR.	NCI, MOLEC VIROL LAB, HORMONE ACT & ONCOGENESIS SECT, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BANIAHMAD C, 1994, BIOTECHNIQUES, V16, P194; BERGLUND H, 1992, BIOCHEMISTRY-US, V31, P12001, DOI 10.1021/bi00163a007; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLSTEDTDUKE J, 1990, RECEPTOR PURIFICATIO, P37; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DeFranco DB, 1995, VITAM HORM, V51, P315, DOI 10.1016/S0083-6729(08)61043-2; DENIS M, 1990, J CHROMATOGR, V508, P97, DOI 10.1016/S0021-9673(00)91243-3; FORMSTECHER P, 1987, RECENT ADV STEROID H, P499; GRANDICS P, 1984, J BIOL CHEM, V259, P3173; HASSANAIN HH, 1993, ANAL BIOCHEM, V213, P162, DOI 10.1006/abio.1993.1400; HAYNES RC, 1985, GOODMAN GILMANS PHAR, P1459; HTUN H, 1996, IN PRESS P NATL ACAD; ING NH, 1992, J BIOL CHEM, V267, P17617; KUSK P, 1995, MOL ENDOCRINOL, V6, P1180; LITWACK G, 1990, RECEPTOR PURIFICATIO, V2; MILLER PA, 1984, BIOCHEMISTRY-US, V23, P6883, DOI 10.1021/bi00321a093; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; NEUGEBAUER J, 1988, GUIDE PROPERTIES USE, P25; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RANGARAJAN PN, 1992, MOL ENDOCRINOL, V6, P1451, DOI 10.1210/me.6.9.1451; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; THOMAS TC, 1990, METHOD ENZYMOL, V182, P499; TSAI SY, 1990, J BIOL CHEM, V265, P17055; WESTPHAL HM, 1984, EMBO J, V3, P1493, DOI 10.1002/j.1460-2075.1984.tb02001.x; WRANGE O, 1984, J BIOL CHEM, V259, P4534; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3	28	20	20	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11434	11440		10.1074/jbc.271.19.11434	http://dx.doi.org/10.1074/jbc.271.19.11434			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626700	hybrid			2022-12-25	WOS:A1996UJ94400060
J	Ma, L; Brosius, MA; Burgess, BK				Ma, L; Brosius, MA; Burgess, BK			Construction of a form of the MoFe protein of nitrogenase that accepts electrons from the Fe protein but does not reduce substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-MOLYBDENUM COFACTOR; AZOTOBACTER-VINELANDII; PARAMAGNETIC RESONANCE; CLOSTRIDIUM-PASTEURIANUM; KLEBSIELLA-PNEUMONIAE; CRYSTALLOGRAPHIC STRUCTURE; DINITROGENASE REDUCTASE; APODINITROGENASE; PURIFICATION; RESOLUTION	The direction of electron flow through nitrogenase is generally believed to be from the Fe protein to the P-clusters to the FeMo cofactor and then to substrate, In order to examine oxidation states of the P-clusters that might be involved in this pathway, we have constructed a form of the MoFe protein that contains a species called the MoFe cluster (Gavini, N., Ma, L., Watt, G., and Burgess, B. K. (1995) Biochemistry 33, 11842-11849) in place of FeMo cofactor, This MoFe cluster-containing protein was purified, and the presence of the cluster was con firmed by reisolation of the MoFe cluster followed by EPR spectroscopy, The protein does not reduce protons or acetylene, however, upon the addition of the Fe protein and MgATP, MgATP hydrolysis occurs at a rate 28% of the wild-type protein, As isolated in the presence of excess dithionite the MoFe cluster-containing protein is EPR silent, Upon addition of the Fe protein and MgATP ag = 1.94 EPR signal develops that integrates to about 1 spin per P-cluster, This signal only develops when both the Fe protein and MgATP are added and it arises from the P-clusters.	UNIV CALIF IRVINE, DEPT MOLEC BIOL & BIOCHEM, IRVINE, CA 92717 USA	University of California System; University of California Irvine					NIGMS NIH HHS [R01-GM-43144] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043144] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RM, 1993, J BIOL CHEM, V268, P23670; BOLIN JT, 1993, P NATL ACAD SCI USA, V90, P1078, DOI 10.1073/pnas.90.3.1078; BOLIN JT, 1993, ACS SYM SER, V535, P169; BURGESS BK, 1980, BIOCHIM BIOPHYS ACTA, V614, P196, DOI 10.1016/0005-2744(80)90180-1; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; CHAN MK, 1993, SCIENCE, V260, P792, DOI 10.1126/science.8484118; CLARK LJ, 1955, ANAL CHEM, V27, P2000, DOI 10.1021/ac60108a046; Dean D.R., 1992, BIOL NITROGEN FIXATI, P763; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; FISKE CH, 1952, J BIOL CHEM, V66, P325; GAVINI N, 1994, BIOCHEMISTRY-US, V33, P11842, DOI 10.1021/bi00205a021; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HALES BJ, 1989, J AM CHEM SOC, V111, P8519, DOI 10.1021/ja00204a035; HAWKES TR, 1983, BIOCHEM J, V209, P43, DOI 10.1042/bj2090043; HOMER MJ, 1993, J BACTERIOL, V175, P4907, DOI 10.1128/JB.175.15.4907-4910.1993; KIM CH, 1995, BIOCHEMISTRY-US, V34, P2798, DOI 10.1021/bi00009a008; KIM J, 1993, BIOCHEMISTRY-US, V32, P7104, DOI 10.1021/bi00079a006; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; MA L, 1994, J BIOL CHEM, V269, P18007; MORNINGSTAR JE, 1987, J AM CHEM SOC, V109, P6854, DOI 10.1021/ja00256a051; MORTENSON LE, 1973, BIOCHIM BIOPHYS ACTA, V292, P422, DOI 10.1016/0005-2728(73)90048-0; Newton WE, 1992, BIOL NITROGEN FIXATI, P877; ORMEJOHNSON WH, 1972, P NATL ACAD SCI USA, V69, P3142, DOI 10.1073/pnas.69.11.3142; ORMEJOHNSON WH, 1980, MOLYBDENUM MOLYBDENU, P427; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; ROBINSON AC, 1986, J BACTERIOL, V166, P180, DOI 10.1128/jb.166.1.180-186.1986; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; SHAH VK, 1981, P NATL ACAD SCI-BIOL, V78, P3438, DOI 10.1073/pnas.78.6.3438; SMITH BE, 1992, EUR J BIOCHEM, V205, P1, DOI 10.1111/j.1432-1033.1992.tb16746.x; SMITH BE, 1973, BIOCHEM J, V135, P331, DOI 10.1042/bj1350331; TAL S, 1991, J BIOL CHEM, V266, P10654; Thorneley R. N. F., 1985, MOLYBDENUM ENZYMES, P221; VANDEBOGART M, 1967, ANAL BIOCHEM, V20, P325, DOI 10.1016/0003-2697(67)90038-3; YATES MG, 1993, BIOL NITROGEN FIXATI, P685; ZUMFT WG, 1973, EUR J BIOCHEM, V35, P401, DOI 10.1111/j.1432-1033.1973.tb02852.x	37	24	24	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10528	10532		10.1074/jbc.271.18.10528	http://dx.doi.org/10.1074/jbc.271.18.10528			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631851	hybrid			2022-12-25	WOS:A1996UJ34200019
J	Kitamura, K; Singer, WD; Star, RA; Muallem, S; Miller, RT				Kitamura, K; Singer, WD; Star, RA; Muallem, S; Miller, RT			Induction of inducible nitric-oxide synthase by the heterotrimeric G protein G alpha(13)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT	While the functions of several G protein alpha subunits such as alpha(s) and alpha(q) are relatively well understood, the action of others such as alpha(13) remain largely undefined. Because of recent interest in regulation of nitric-oxide synthase (NOS) by G protein-coupled signaling systems and findings that receptors for two proinflammatory substances, thrombin and thromboxane couple to alpha(13), we studied the effect of alpha(13) on NOS activity in a renal epithelial cell line. We found that stable overexpression of alpha(13) or its GTPase-deficient mutant, alpha(13Q226L), in a continuous renal epithelial cell line (MCT) increased NOS activity. The increased NOS activity was due to increased expression of the macrophage-inducible form of NOS (iNOS). iNOS protein and activity were not increased in similar cells expressing an activated alpha(s) (alpha(sQ227L)) or were minimally increased in cells expressing activated alpha(i1) (alpha(i1Q204L)) and alpha(q) (alpha(qQ209L)), members of the three other G protein alpha chain families. Transient coexpression of alpha(13) or (alpha(13Q226L)) increased the activity of an iNOS promoter-CAT construct demonstrating that alpha(13) increases iNOS expression through transcription. Consequently, alpha(13) induces iNOS through a novel mechanism that is distinct from that of other G protein a chains and that may mediate the actions of G protein-dependent proinflammatory agents.	UNIV FLORIDA,J HILLIS MILLER HLTH CTR,DEPT MED,GAINESVILLE,FL 32610; UNIV FLORIDA,J HILLIS MILLER HLTH CTR,DEPT PHARMACOL,GAINESVILLE,FL 32610; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 75235	State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK39298, R29DK41726] Funding Source: Medline; NIGMS NIH HHS [F32-GM15359] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039298, R37DK039298, R29DK041726] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015359] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BROWN AM, 1988, AM J PHYSIOL, V254, pH401, DOI 10.1152/ajpheart.1988.254.3.H401; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAVERTY TP, 1988, J CELL BIOL, V107, P1359, DOI 10.1083/jcb.107.4.1359; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KITAMURA K, 1994, J CLIN INVEST, V94, P328, DOI 10.1172/JCI117325; KITAMURA K, 1995, AM J PHYSIOL, V268, P101; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MORRIS SM, 1994, AM J PHYSIOL, V266, pE829, DOI 10.1152/ajpendo.1994.266.6.E829; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; OFFERMANNS S, 1994, MOL CELL ENDOCRINOL, V100, P71, DOI 10.1016/0303-7207(94)90281-X; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Sambrook J., 2002, MOL CLONING LAB MANU; SINGER WD, 1994, J BIOL CHEM, V269, P19796; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; XU X, 1995, J BIOL CHEM, V270, P29169, DOI 10.1074/jbc.270.49.29169	27	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7412	7415		10.1074/jbc.271.13.7412	http://dx.doi.org/10.1074/jbc.271.13.7412			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631766	hybrid			2022-12-25	WOS:A1996UC77400034
J	Siddhanta, U; Wu, CQ; AbuSoud, HM; Zhang, JL; Ghosh, DK; Stuehr, DJ				Siddhanta, U; Wu, CQ; AbuSoud, HM; Zhang, JL; Ghosh, DK; Stuehr, DJ			Heme iron reduction and catalysis by a nitric oxide synthase heterodimer containing one reductase and two oxygenase domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Inducible nitric oxide (NO) synthase (iNOS) is comprised of an oxygenase domain containing heme, tetrahydrobiopterin, the substrate binding site, and a reductase domain containing FAD, FMN, calmodulin, and the NADPH binding site, Enzyme activity requires a dimeric interaction between two oxygenase domains with the reductase domains attached as monomeric extensions, To understand how dimerization activates iNOS, we synthesized an iNOS heterodimer comprised of one full-length subunit and one histidine-tagged subunit that was missing its reductase domain, The heterodimer was purified using nickel-Sepharose and 2',5'-ADP affinity chromatography, The heterodimer catalyzed NADPH-dependent NO synthesis from L-arginine at a rate of 52 +/- 6 nmol of NO/min/nmol of heme, which is half the rate of purified iNOS homodimer, Heterodimer NO synthesis was associated with reduction of only half of its heme iron by NADPH, in contrast with near complete heme iron reduction in an iNOS homodimer, Full-length MOS monomer preparations could not synthesize NO nor catalyze NADPH-dependent heme iron reduction. Thus, dimerization activates NO synthesis by enabling electrons to transfer between the reductase and oxygenase domains. Although a single reductase domain can reduce only one of two hemes in a dimer, this supports NO synthesis from L-arginine.	CASE WESTERN RESERVE UNIV,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106	Case Western Reserve University	Siddhanta, U (corresponding author), CLEVELAND CLIN RES INST,DEPT IMMUNOL,CLEVELAND,OH 44195, USA.				NATIONAL CANCER INSTITUTE [R01CA053914, R29CA053914] Funding Source: NIH RePORTER; NCI NIH HHS [CA53914] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; FISHER MT, 1985, J AM CHEM SOC, V107, P5018, DOI 10.1021/ja00303a045; Ghosh DK, 1996, BIOCHEMISTRY-US, V35, P1444, DOI 10.1021/bi9521295; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; GHOSH HM, 1995, BIOCHEMISTRY-US, V34, P11316; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; KERWIN JF, 1995, J MED CHEM, V38, P4343, DOI 10.1021/jm00022a001; KLATT P, 1994, J BIOL CHEM, V269, P1674; KLATT P, 1994, J BIOL CHEM, V269, P13861; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; KLATT P, 1993, J BIOL CHEM, V268, P1481; KRONCKE KD, 1995, BIOL CHEM H-S, V376, P327; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SHETA EA, 1994, J BIOL CHEM, V269, P15147; SLIGAR SG, 1986, CYTOCHROME P450 STRU, P429; SONO M, 1995, J BIOL CHEM, V270, P19943, DOI 10.1074/jbc.270.34.19943; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; WANG JL, 1993, J BIOL CHEM, V268, P22255; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P7160	30	78	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7309	7312		10.1074/jbc.271.13.7309	http://dx.doi.org/10.1074/jbc.271.13.7309			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631749	hybrid			2022-12-25	WOS:A1996UC77400017
J	Hess, JF; Casselman, JT; FitzGerald, PG				Hess, JF; Casselman, JT; FitzGerald, PG			Gene structure and cDNA sequence identify the beaded filament protein CP49 as a highly divergent type I intermediate filament protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LENS FIBER CELL; AMINO-ACID SEQUENCE; CHICK LENS; CYTOSKELETAL PROTEIN; PLASMA-MEMBRANE; ALPHA-CRYSTALLIN; SKIN DISEASES; BOVINE LENS; KERATIN; FILENSIN	The fiber cell of the vertebrate ocular lens assembles a cytoskeletal structure, the beaded filament, which contains two proteins unique to the fiber cell: CP49 (phakinin) and CP115/CP95 (filensin). We report here the complete primary sequence and gene structure for human CP49, These data show that CP49 is a member of the intermediate filament family, but highly unusual in several regards. 1) CP49 primary sequence does not permit unambiguous assignment to any existing class of intermediate filament protein, but exhibits a gene structure that is identical to the Type I cytokeratins. 2) CP49 essentially lacks one of the three major domains that characterize all intermediate filament proteins, the carboxyl terminal tail domain. 3) CP49 shows substitutions at 3 of 4 residues in the otherwise highly conserved intermediate filament protein motif LNDR. Notably, this divergence includes an Arg to Cys substitution that has only been observed in the mutant human cytokeratin K14, a mutation shown to cause the skin blistering seen in the genetic disorder Dowling-Meara epidermolysis bullosa simplex.	UNIV CALIF DAVIS,SCH MED,DEPT CELL BIOL & HUMAN ANAT,DAVIS,CA 95616	University of California System; University of California Davis					NATIONAL EYE INSTITUTE [R01EY008747] Funding Source: NIH RePORTER; NEI NIH HHS [EY08747] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALBERS K, 1992, INT REV CYTOL, V134, P243, DOI 10.1016/S0074-7696(08)62030-6; BADER BL, 1986, EMBO J, V5, P1865, DOI 10.1002/j.1460-2075.1986.tb04438.x; BLOEMENDAL H, 1984, CIBA F SYMP, V106, P177; BLOEMENDAL H, 1982, EXP EYE RES, V35, P61, DOI 10.1016/S0014-4835(82)80023-7; BRADLEY RH, 1979, EXP EYE RES, V28, P441, DOI 10.1016/0014-4835(79)90119-2; CARTER JM, 1995, EXP EYE RES, V60, P181, DOI 10.1016/S0014-4835(95)80009-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; DODEMONT H, 1990, EMBO J, V9, P4083, DOI 10.1002/j.1460-2075.1990.tb07630.x; ELLIS M, 1984, EXP EYE RES, V38, P195, DOI 10.1016/0014-4835(84)90103-9; FITZGERALD PG, 1989, CURR EYE RES, V8, P801, DOI 10.3109/02713688909000870; FITZGERALD PG, 1991, CURR EYE RES, V10, P417, DOI 10.3109/02713689109001750; FITZGERALD PG, 1988, CURR EYE RES, V7, P1243, DOI 10.3109/02713688809033228; FITZGERALD PG, 1990, CURR EYE RES, V9, P1083, DOI 10.3109/02713689008997582; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUCHS E, 1992, CELL, V69, P899, DOI 10.1016/0092-8674(92)90607-E; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; FUCHS E, 1983, CELL, V34, P332, DOI 10.1016/0092-8674(83)90367-7; FUCHS E, 1991, BIOCHEM SOC T, V19, P1112, DOI 10.1042/bst0191112; FUCHS E, 1994, J INVEST DERMATOL, V103, pS25, DOI 10.1111/1523-1747.ep12398924; GOPALAKRISHNAN S, 1992, CURR EYE RES, V11, P929, DOI 10.3109/02713689209033490; GOUMARI F, 1993, J CELL BIOL, V121, P847; HESS JF, 1993, CURR EYE RES, V12, P77, DOI 10.3109/02713689308999499; HESS JF, 1995, CURR EYE RES, V14, P11, DOI 10.3109/02713689508999909; IFEANYI F, 1990, CURR EYE RES, V9, P259, DOI 10.3109/02713689009044521; Ireland M, 1989, Lens Eye Toxic Res, V6, P623; IRELAND M, 1983, EXP EYE RES, V36, P531, DOI 10.1016/0014-4835(83)90046-5; IRELAND M, 1984, EXP EYE RES, V38, P637, DOI 10.1016/0014-4835(84)90182-9; KIBBELAAR MA, 1979, EUR J BIOCHEM, V95, P543, DOI 10.1111/j.1432-1033.1979.tb12995.x; KRIEG TM, 1985, J BIOL CHEM, V260, P5867; MAISEL H, 1984, CURR EYE RES, V3, P369, DOI 10.3109/02713688408997222; MAISEL H, 1977, EXPERIENTIA, V33, P525, DOI 10.1007/BF01922252; MAISEL H, 1972, EXP EYE RES, V14, P7, DOI 10.1016/0014-4835(72)90136-4; MARCHUK D, 1985, P NATL ACAD SCI USA, V82, P1609, DOI 10.1073/pnas.82.6.1609; MASAKI S, 1992, BIOCHEM BIOPH RES CO, V186, P190, DOI 10.1016/S0006-291X(05)80792-2; MERDES A, 1991, J CELL BIOL, V115, P397, DOI 10.1083/jcb.115.2.397; MERDES A, 1993, J CELL BIOL, V123, P1507, DOI 10.1083/jcb.123.6.1507; ORII H, 1993, CURR EYE RES, V12, P583, DOI 10.3109/02713689309001836; PARRY D A D, 1992, Current Opinion in Cell Biology, V4, P94, DOI 10.1016/0955-0674(92)90064-J; PARRY DAD, 1990, CELLULAR MOL BIOL IN, P175; RAFFERTY NS, 1974, J ULTRA MOL STRUCT R, V46, P239, DOI 10.1016/S0022-5320(74)80059-6; RAMAEKERS FCS, 1980, EXP CELL RES, V127, P309, DOI 10.1016/0014-4827(80)90437-1; REIGER M, 1988, J MOL BIOL, V204, P841; REMINGTON SG, 1993, J CELL SCI, V105, P1057; Sambrook J., 2002, MOL CLONING LAB MANU; SANDILANDS A, 1995, J CELL SCI, V108, P1397; SAUK JJ, 1984, J CELL BIOL, V99, P1590, DOI 10.1083/jcb.99.5.1590; SAWADA K, 1995, CURR EYE RES, V14, P545, DOI 10.3109/02713689508998401; STASIAK PC, 1989, J INVEST DERMATOL, V92, P707, DOI 10.1111/1523-1747.ep12721500; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Stewart M, 1993, CURR OPIN CELL BIOL, V5, P3, DOI 10.1016/S0955-0674(05)80002-X; Stewart M, 1990, CURR OPIN CELL BIOL, V2, P91, DOI 10.1016/S0955-0674(05)80037-7; WEBER K, 1991, BIOCHEM SOC T, V19, P1021, DOI 10.1042/bst0191021; WEBER K, 1985, ANN NY ACAD SCI, V455, P126, DOI 10.1111/j.1749-6632.1985.tb50408.x	54	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6729	6735		10.1074/jbc.271.12.6729	http://dx.doi.org/10.1074/jbc.271.12.6729			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636093	hybrid			2022-12-25	WOS:A1996UB15700028
J	Iobst, ST; Drickamer, K				Iobst, ST; Drickamer, K			Selective sugar binding to the carbohydrate recognition domains of the rat hepatic and macrophage asialoglycoprotein receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSE N-ACETYLGALACTOSAMINE; MOLECULAR-CLONING; LECTIN; EXPRESSION; GLYCOSIDES; SEQUENCE; PROTEINS; SITE; DNA	Asialoglycoprotein receptors on the surfaces of both hepatocytes and peritoneal macrophages bind terminal galactose residues of desialylated glycoproteins and mediate endocytosis and eventual degradation of these ligands. The hepatic receptor binds oligosaccharides with terminal N-acetylgalactosamine residues more tightly than ligands with terminal galactose residues, but the macrophage receptor shows no such differential binding affinity. Carbohydrate recognition domains from the macrophage receptor and the major subunit of the hepatic receptor have been expressed in a bacterial system and have been shown to retain the distinct binding selectivities of the receptors from which they derive. Binding of a series of N-acyl derivatives of galactosamine suggests that the a-substituent of these sugars interacts with the surface of the hepatic receptor with highest affinity binding observed for the N-propionyl derivative. Chimeric sugar-binding domains have been used to identify three regions of the hepatic receptor that are essential for establishing selectivity for N-acetylgalactosamine over galactose, Based on these results and the orientation of N-acetylgalactosamine when bound to an homologous galactose-binding mutant of rat serum mannose-binding protein, a fourth region likely to interact with N-acetylgalactosamine has been identified and probed by site-directed mutagenesis. The results of these studies define a binding pocket for the 2-substituent of N-acetylgalactosamine in the hepatic asialoglycoprotein receptor.	COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	Columbia University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042628] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CONNOLLY DT, 1982, J BIOL CHEM, V257, P939; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; HERZIG MCS, 1990, BIOCHEMISTRY-US, V29, P6437, DOI 10.1021/bi00479a015; HOLLAND EC, 1984, P NATL ACAD SCI-BIOL, V81, P7338, DOI 10.1073/pnas.81.23.7338; HORTON D, 1966, BIOCH PREP, V11, P1; II M, 1990, J BIOL CHEM, V265, P11295; IMAI Y, 1994, J IMMUNOL METHODS, V171, P23, DOI 10.1016/0022-1759(94)90224-0; IOBST ST, 1994, J BIOL CHEM, V269, P15512; KAWASAKI T, 1986, CARBOHYD RES, V151, P197, DOI 10.1016/S0008-6215(00)90340-9; Kolatkar AR, 1996, J BIOL CHEM, V271, P6679, DOI 10.1074/jbc.271.12.6679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RT, 1982, BIOCHEMISTRY-US, V21, P1045, DOI 10.1021/bi00534a034; Maniatis T., 1982, MOL CLONING; NEUBERGER A, 1971, CARBOHYD RES, V17, P89, DOI 10.1016/S0008-6215(00)81545-1; QUESENBERRY MS, 1992, J BIOL CHEM, V267, P10831; Sambrook J., 2002, MOL CLONING LAB MANU; SARKAR M, 1979, J BIOL CHEM, V254, P3170; SATO M, 1992, J BIOCHEM-TOKYO, V111, P331, DOI 10.1093/oxfordjournals.jbchem.a123758; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P10008; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WEIS WI, 1991, J BIOL CHEM, V266, P20678	25	67	94	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6686	6693		10.1074/jbc.271.12.6686	http://dx.doi.org/10.1074/jbc.271.12.6686			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636087	hybrid			2022-12-25	WOS:A1996UB15700022
J	Kitazume, S; Kitajima, K; Inoue, S; Haslam, SM; Morris, HR; Dell, A; Lennarz, WJ; Inoue, Y				Kitazume, S; Kitajima, K; Inoue, S; Haslam, SM; Morris, HR; Dell, A; Lennarz, WJ; Inoue, Y			The occurrence of novel 9-O-sulfated N-glycolylneuraminic acid-capped alpha 2->5-O-glycolyl-linked oligo/polyNeu5Gc chains in sea urchin egg cell surface glycoprotein - Identification of a new chain termination signal for polysialyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAINBOW-TROUT EGGS; ADHESION MOLECULE; POLYSIALIC ACID; CARBOHYDRATE UNITS; POLY(SIALIC ACID); MASS-SPECTROMETRY; PLASMA-MEMBRANE; SPERM; PURIFICATION; RECEPTOR	We report the isolation and structural characterization of an oligo/polysialic acid-containing glycopeptide fraction (designated ESP-Sia) prepared from the egg cell surface complex of the sea urchin, Hemicentrotus pulcherrimus, by exhaustive pronase treatment, The carbohydrate chains isolated from ESP-Sia were shown 60 consist of O-linked oligo/polysialic acid-containing glycan units and N-linked carbohydrate chains. The present studies have revealed that the O-linked oligo/polysialic acid-containing glycan chains derived from the ESP-Sia were similar to those present in egg jelly coat polysialylated glycoprotein in being composed of tandem repeats of N-glycolylneuraminic acid (Neu5Gc) glycosidically Linked in a novel fashion through the glycolyl group, (-->5-O(glycolyl)Neu5Gc alpha 2-->)(n). However, they differ from the egg jelly coat in two key respects. First, the average degree of polymerization of the oligo/polysialic acid chains of ESP-Sia is only 3; a value far lower than that found in the jelly coat glycoprotein (average degree of polymerization was about 20). Second, ESP-Sia is uniquely characterized by the presence of 9-O-sulfated N-glycolylneuraminic acid (Neu5Gc9HSO(3)) residues at the nonreducing termini of the (-->5-(Oglycolyl)Neu5Gc alpha 2-->)(n) chains. The terminal sialyl residues in the Neu5Gc9HSO(3) alpha 2-->(-->5-(Oglycolyl)Neu5Gc alpha 2-->)(n) chain s were totally resistant to exosialidases. The discovery of Neu5Gc9HSO(3), as the nonreducing terminal residue of oligo/poly(-->5-O(glycolyl)Neu5Gc alpha 2-->)(n) group is especially noteworthy in that Neu5Gc9HSO(3) appears to be of limited distribution among glycoconjugates. Following the earlier discovery of oligo/polysialic acid chains capped with KDN, i.e. KDN alpha 2-->(-->8Neu5Gc alpha 2-->)(n), found in rainbow trout egg polysialoglycoproteins, it now appears that the sulfated Neu5Gc can serve a similar capping function.	UNIV TOKYO,GRAD SCH SCI,DEPT BIOPHYS & BIOCHEM,TOKYO 113,JAPAN; SHOWA UNIV,SCH PHARMACEUT SCI,TOKYO 142,JAPAN; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOCHEM,LONDON SW7 2AZ,ENGLAND; SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794	University of Tokyo; Showa University; Imperial College London; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NIGMS NIH HHS [GM33184, GM33185] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033184, R37GM033185, R01GM033185] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; ANGATA T, 1994, GLYCOCONJUGATE J, V11, P493, DOI 10.1007/BF00731286; DETERING NK, 1977, J CELL BIOL, V75, P899, DOI 10.1083/jcb.75.3.899; DHUME ST, 1995, GLYCOBIOLOGY, V5, P11, DOI 10.1093/glycob/5.1.11; DUBOIS M, 1956, ANAL CHEM, V135, P243; FINNE J, 1982, METHOD ENZYMOL, V83, P269; FOLTZ KR, 1990, J CELL BIOL, V111, P2951, DOI 10.1083/jcb.111.6.2951; FOLTZ KR, 1993, DEV BIOL, V158, P46, DOI 10.1006/dbio.1993.1167; FOLTZ KR, 1993, SCIENCE, V259, P1421, DOI 10.1126/science.8383878; GROGAN T, 1994, LAB INVEST, V70, pA110; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; HAVERKAMP J, 1982, EUR J BIOCHEM, V122, P4851; IJUIN T, 1996, IN PRESS GLYCOCONJUG, V13; INOUE S, 1986, J BIOL CHEM, V261, P5256; INOUE S, 1979, CARBOHYD RES, V74, P361, DOI 10.1016/S0008-6215(00)84795-3; INOUE Y, 1993, POLYSIALIC ACID MICR, P171; JAMES WM, 1987, BIOCHEM BIOPH RES CO, V148, P817, DOI 10.1016/0006-291X(87)90949-1; JAQUES LW, 1980, CARBOHYD RES, V83, P21, DOI 10.1016/S0008-6215(00)85360-4; JENNINGS HJ, 1985, J IMMUNOL, V134, P2651; KINSEY WH, 1981, J CELL BIOL, V91, P325, DOI 10.1083/jcb.91.2.325; KITAJIMA K, 1992, ANAL BIOCHEM, V205, P244, DOI 10.1016/0003-2697(92)90430-F; KITAZUME S, 1994, J BIOL CHEM, V269, P10330; KITAZUME S, 1994, J BIOL CHEM, V269, P22712; KITAZUME S, 1992, ANAL BIOCHEM, V202, P25, DOI 10.1016/0003-2697(92)90200-Q; KITAZUME S, 1994, BIOCHEM BIOPH RES CO, V205, P893, DOI 10.1006/bbrc.1994.2748; KOCHETKOV NK, 1976, BIOCHIM BIOPHYS ACTA, V424, P274, DOI 10.1016/0005-2760(76)90195-8; KUBO H, 1990, J BIOCHEM-TOKYO, V108, P185, DOI 10.1093/oxfordjournals.jbchem.a123179; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; MOOLENAAR CECK, 1990, CANCER RES, V50, P1102; NADANO D, 1986, J BIOL CHEM, V261, P1550; NOMOTO H, 1982, ARCH BIOCHEM BIOPHYS, V218, P335, DOI 10.1016/0003-9861(82)90352-6; ROTH J, 1992, SCIENCE, V256, P673, DOI 10.1126/science.1585182; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; RUIZBRAVO N, 1986, DEV BIOL, V118, P202, DOI 10.1016/0012-1606(86)90088-6; SATO C, 1993, J BIOL CHEM, V268, P23675; SCOTT AA, 1994, J ACAD PATHOL, V70, pA120; SEGALL GK, 1979, DEV BIOL, V71, P33, DOI 10.1016/0012-1606(79)90080-0; SHIMAMURA M, 1983, BIOCHEMISTRY-US, V22, P959, DOI 10.1021/bi00273a039; SUNSHINE J, 1987, P NATL ACAD SCI USA, V84, P5986, DOI 10.1073/pnas.84.16.5986; SUZUKI S, 1960, J BIOL CHEM, V235, P2768; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; TARENTINO AL, 1993, TRENDS GLYCOSCI GLYC, V5, P163; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; UCHIDA Y, 1977, J BIOCHEM-TOKYO, V82, P1425, DOI 10.1093/oxfordjournals.jbchem.a131830; ZUBER C, 1992, J BIOL CHEM, V267, P9965	45	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6694	6701		10.1074/jbc.271.12.6694	http://dx.doi.org/10.1074/jbc.271.12.6694			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636088	hybrid			2022-12-25	WOS:A1996UB15700023
J	Morein, S; Andersson, AS; Rilfors, L; Lindblom, G				Morein, S; Andersson, AS; Rilfors, L; Lindblom, G			Wild-type Escherichia coli cells regulate the membrane lipid composition in a ''window'' between gel and non-lamellar structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; POLYMORPHIC PHASE-BEHAVIOR; P-31 NMR; ACHOLEPLASMA-LAIDLAWII; ETHER LIPIDS; FATTY-ACIDS; CLOSTRIDIUM-BUTYRICUM; LIQUID-CRYSTALLINE; NONLAMELLAR PHASES; BILAYER STABILITY	Escherichia coli strain K12 was grown at 17, 27, and 37 degrees C. The acyl chain composition of the membrane lipids varied with the growth temperature; the fraction of cis-vaccenoyl chains decreased, and the fraction of palmitoyl chains increased, when the growth temperature was increased. However, the polar head group composition did not change significantly, The equilibria between lamellar and reversed non-lamellar phases of lipids extracted from the inner membrane (IM), and from both the membranes (IOM), were studied with NMR and x-ray diffraction, At temperatures above the growth temperature the lipid extracts formed a reversed hexagonal phase, or a bicontinuous cubic phase, depending on the degree of hydration of the lipids, It was observed that: 1) at equal elevations above the growth temperature, IM lipid extracts, as well as IOM lipid extracts, have a nearly equal ability to form non-lamellar phases; 2) IM extracts have a stronger tendency than IOM extracts to form non lamellar phases; 3) non-lamellar phases are formed under conditions that are relatively close to the physiological ones; the membrane lipid monolayers are thus ''frustrated''; and 4) as a consequence of the change of the acyl chain structures, the temperature for the lamellar gel to liquid crystalline phase transition is changed simultaneously, and in the same direction, as the temperature for the lamellar to non-lamellar phase transition. With a too large fraction of saturated acyl chains the membrane lipids enter a gel state, and with a too large fraction of unsaturated acyl chains the lipids transform to non-lamellar phases, It is thus concluded that the regulation of the acyl chain composition in wild-type cells of E. coli is necessary for the organism to be able to grow in a ''window'' between a lamellar gel phase and reversed non-lamellar phases.	UMEA UNIV, DEPT PHYS CHEM, S-90187 UMEA, SWEDEN	Umea University								AIBARA S, 1972, BIOCHIM BIOPHYS ACTA, V270, P301; [Anonymous], 1992, INTERMOLECULAR SURFA; Ansell G.V., 1973, FORM FUNCTION PHOSPH; BARTON PG, 1975, J BIOL CHEM, V250, P4470; BRENTEL I, 1987, BIOCHIM BIOPHYS ACTA, V904, P401, DOI 10.1016/0005-2736(87)90390-7; BURNELL E, 1980, BIOCHIM BIOPHYS ACTA, V597, P492, DOI 10.1016/0005-2736(80)90222-9; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CRONAN JE, 1994, J BACTERIOL, V176, P3069, DOI 10.1128/JB.176.10.3069-3071.1994; CRONAN JE, 1987, ESCHERICHIA COLI SAL, V1, P474; CRONAN JE, 1987, ESCHERICHIA COLI SAL, V1, P31; CULLIS PR, 1976, BIOCHIM BIOPHYS ACTA, V436, P523, DOI 10.1016/0005-2736(76)90438-7; CULLIS PR, 1978, BIOCHIM BIOPHYS ACTA, V513, P31, DOI 10.1016/0005-2736(78)90109-8; DAS S, 1986, BIOCHEMISTRY-US, V25, P2882, DOI 10.1021/bi00358a022; DAVIS MTB, 1974, BIOCHIM BIOPHYS ACTA, V373, P224, DOI 10.1016/0005-2736(74)90147-3; DEKRUIJFF B, 1982, BIOCHIM BIOPHYS ACTA, V693, P1, DOI 10.1016/0005-2736(82)90464-3; ERIKSSON PO, 1985, CHEM PHYS LIPIDS, V37, P357, DOI 10.1016/0009-3084(85)90089-1; FABRIE CHJP, 1994, CHEM PHYS LIPIDS, V70, P133, DOI 10.1016/0009-3084(94)90081-7; GOLDFINE H, 1987, BIOCHEMISTRY-US, V26, P2814, DOI 10.1021/bi00384a024; GOLDFINE H, 1982, CURR TOP MEMBR TRANS, V17, P1; GOLDFINE H, 1987, BIOCHIM BIOPHYS ACTA, V904, P283, DOI 10.1016/0005-2736(87)90377-4; GRUNER SM, 1988, BIOCHEMISTRY-US, V27, P2853, DOI 10.1021/bi00408a029; GRUNER SM, 1985, P NATL ACAD SCI USA, V82, P3665, DOI 10.1073/pnas.82.11.3665; GULIK A, 1985, J MOL BIOL, V182, P131, DOI 10.1016/0022-2836(85)90032-4; HAUKSSON JB, 1994, BBA-LIPID LIPID MET, V1214, P124, DOI 10.1016/0005-2760(94)90035-3; HAUKSSON JB, 1995, BBA-LIPID LIPID MET, V1258, P1, DOI 10.1016/0005-2760(95)00074-M; HAUKSSON JB, 1994, BBA-LIPID LIPID MET, V1215, P341, DOI 10.1016/0005-2760(94)90063-9; HAZEL JR, 1990, PROG LIPID RES, V29, P167, DOI 10.1016/0163-7827(90)90002-3; HELFRICH W, 1973, Z NATURFORSCH C, VC 28, P693, DOI 10.1515/znc-1973-11-1209; IANZINI F, 1990, ARCH BIOCHEM BIOPHYS, V278, P1, DOI 10.1016/0003-9861(90)90223-L; ISHINAGA M, 1979, J BIOCHEM-TOKYO, V86, P161; ISRAELACHVILI JN, 1980, Q REV BIOPHYS, V13, P121, DOI 10.1017/S0033583500001645; ISRAELACHVILI JN, 1976, J CHEM SOC FARAD T 2, V72, P1525, DOI 10.1039/f29767201525; JACKSON MB, 1978, BIOCHIM BIOPHYS ACTA, V512, P472, DOI 10.1016/0005-2736(78)90157-8; JOHNSTON NC, 1988, BIOCHIM BIOPHYS ACTA, V961, P1, DOI 10.1016/0005-2760(88)90124-5; KARKHANIS YD, 1978, ANAL BIOCHEM, V85, P595, DOI 10.1016/0003-2697(78)90260-9; KILLIAN JA, 1992, BIOCHIM BIOPHYS ACTA, V1105, P253, DOI 10.1016/0005-2736(92)90202-W; KILLIAN JA, 1994, BBA-BIOMEMBRANES, V1189, P225; KOYNOVA R, 1994, CHEM PHYS LIPIDS, V69, P1, DOI 10.1016/0009-3084(94)90024-8; LEWIS RNAH, 1989, BIOCHEMISTRY-US, V28, P541, DOI 10.1021/bi00428a020; LINDBLOM G, 1989, BIOCHIM BIOPHYS ACTA, V988, P221, DOI 10.1016/0304-4157(89)90020-8; LINDBLOM G, 1986, BIOCHEMISTRY-US, V25, P7502, DOI 10.1021/bi00371a037; LINDBLOM G, 1994, PROG NUCL MAG RES SP, V26, P483, DOI 10.1016/0079-6565(94)80014-6; LINDBLOM G, 1992, ADV COLLOID INTERFAC, V41, P101, DOI 10.1016/0001-8686(92)80009-M; LINDBLOM G, 1993, J BIOL CHEM, V268, P16198; LINDBLOM G, 1991, BIOCHEMISTRY-US, V30, P10938, DOI 10.1021/bi00109a019; LUGTENBERG EJJ, 1976, BIOCHIM BIOPHYS ACTA, V441, P38, DOI 10.1016/0005-2760(76)90279-4; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; MARR AG, 1962, J BACTERIOL, V84, P1260, DOI 10.1128/JB.84.6.1260-1267.1962; McElhaney R.N., 1984, BIOMEMBRANE, V12, P249; MCLAUGHLIN AC, 1975, J MAGN RESON, V20, P146, DOI 10.1016/0022-2364(75)90162-6; MOREIN S, 1994, ANAL BIOCHEM, V216, P47, DOI 10.1006/abio.1994.1006; NAKAYAMA H, 1980, BIOCHIM BIOPHYS ACTA, V601, P1, DOI 10.1016/0005-2736(80)90508-8; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, V1, P7; Osborn M J, 1974, Methods Enzymol, V31, P642; OSTERBERG F, 1995, BBA-LIPID LIPID MET, V1257, P18, DOI 10.1016/0005-2760(95)00042-B; PLUSCHKE G, 1981, J BIOL CHEM, V256, P3207; RANCE M, 1983, J MAGN RESON, V52, P221, DOI 10.1016/0022-2364(83)90190-7; RANCK JL, 1984, BIOCHEMISTRY-US, V23, P4955, DOI 10.1021/bi00316a020; RAND RP, 1972, BIOCHIM BIOPHYS ACTA, V225, P484, DOI 10.1016/0005-2736(72)90152-6; RIETVELD AG, 1993, J BIOL CHEM, V268, P12427; RIETVELD AG, 1994, J BIOL CHEM, V269, P28670; RILFORS L, 1985, BIOCHIM BIOPHYS ACTA, V813, P151, DOI 10.1016/0005-2736(85)90228-7; RILFORS L, 1982, FEBS LETT, V149, P293, DOI 10.1016/0014-5793(82)81120-4; RILFORS L, 1994, BIOCHEMISTRY-US, V33, P6110, DOI 10.1021/bi00186a010; Rilfors L., 1984, Biomembranes, V12, P205; Rilfors L, 1993, Subcell Biochem, V20, P109; Seddon J.M., 1993, PHOSPHOLIPIDS HDB, P403; SEDDON JM, 1990, BIOCHIM BIOPHYS ACTA, V1031, P1, DOI 10.1016/0304-4157(90)90002-T; SIEGEL DP, 1989, BIOCHEMISTRY-US, V28, P5010, DOI 10.1021/bi00438a016; SILVIUS JR, 1982, LIPID PROTEIN INTERA, V2, P2339; SJOLUND M, 1989, BIOCHEMISTRY-US, V28, P1323; SMAAL EB, 1985, J LIPID RES, V26, P634; SUUTARI M, 1994, CRIT REV MICROBIOL, V20, P285, DOI 10.3109/10408419409113560; THURMOND RL, 1996, IN PRESS STRUCTURAL; WELLS MA, 1963, BIOCHEMISTRY-US, V2, P1259, DOI 10.1021/bi00906a015; WIESLANDER A, 1980, BIOCHEMISTRY-US, V19, P3650, DOI 10.1021/bi00557a002; WIESLANDER A, 1995, EUR J BIOCHEM, V227, P734, DOI 10.1111/j.1432-1033.1995.tb20196.x; [No title captured]	78	300	303	2	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6801	6809		10.1074/jbc.271.12.6801	http://dx.doi.org/10.1074/jbc.271.12.6801			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636103	hybrid			2022-12-25	WOS:A1996UB15700038
J	Panchenko, MV; StetlerStevenson, WG; Trubetskoy, OV; Gacheru, SN; Kagan, HM				Panchenko, MV; StetlerStevenson, WG; Trubetskoy, OV; Gacheru, SN; Kagan, HM			Metalloproteinase activity secreted by fibrogenic cells in the processing of prolysyl oxidase - Potential role of procollagen C-proteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STROMELYSIN CATALYTIC DOMAIN; PURIFIED LYSYL OXIDASE; AMINO-ACID-SEQUENCE; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR; INTERSTITIAL COLLAGENASE; PARTIAL-PURIFICATION; VACCINIA VIRUS; SMOOTH-MUSCLE; MESSENGER-RNA	Lysyl oxidase is secreted from fibrogenic cells as a 50-kDa proenzyme that is proteolytically processed to the mature enzyme in the extracellular space. To characterize the secreted proteinase activity, a truncated, recombinant form of lysyl oxidase was prepared as a proteinase substrate containing the sequence of the propeptide cleavage region, The processing proteinase activity secreted by cultured fibrogenic cells resists inhibitors of serine or aspartyl proteinases as well as tissue inhibitor of matrix metalloproteinases-2 (MMP-2) but is completely inhibited by metal ion chelators. Known metalloproteinases were tested for their activity toward this substrate. Carboxyl-terminal procollagen proteinase (C-proteinase), MMP-2, and conditioned fibrogenic cell culture medium cleave the lysyl oxidase substrate to the size of the mature enzyme. The NH2-terminal sequence generated by arterial smooth muscle conditioned medium and the C-proteinase but not by MMP-2, i.e. Asp-Asp Pro-Tyr, was identical to that previously identified in mature lysyl oxidase isolated from connective tissue, The C-proteinase activity against the model substrate was inhibited by a synthetic oligopeptide mimic of the cleavage sequence (Ac-Met-Val-Gly-Asp-Asp-Pro-Tyr-Asn-amide), whereas this peptide also inhibited the generation of lysyl oxidase activity in the medium of fetal rat lung fibroblasts in culture. In toto, these results identify a secreted metalloproteinase activity participating in the activation of prolysyl oxidase, identify inhibitors of the processing activity, and implicate procollagen C-proteinase in this role.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; NCI,NIH,PATHOL LAB,BETHESDA,MD 20892; OSTEOARTHRITIS SCI INC,CAMBRIDGE,MA 02139	Boston University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Stetler-Stevenson, William/AAE-3501-2020; Stetler-Stevenson, William G/H-6956-2012	Stetler-Stevenson, William/0000-0002-5500-5808; Stetler-Stevenson, William G/0000-0002-5500-5808; Panchenko, Maria/0000-0001-6247-6598	NHLBI NIH HHS [HL 13262, HL 46902] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046902, P01HL013262] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARONE LM, 1985, BIOCHIM BIOPHYS ACTA, V840, P245, DOI 10.1016/0304-4165(85)90125-4; BEDELLHOGAN D, 1993, J BIOL CHEM, V268, P10345; CHEN JM, 1991, J BIOL CHEM, V266, P5113; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; CONTENTE S, 1993, GENOMICS, V16, P401; CRONSHAW AD, 1995, BIOCHEM J, V306, P279, DOI 10.1042/bj3060279; DARLAK K, 1990, J BIOL CHEM, V265, P5199; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; EMONARD H, 1990, CELL MOL BIOL, V36, P131; EVANS CH, 1991, J SURG RES, V51, P399, DOI 10.1016/0022-4804(91)90140-H; FRIDMAN R, 1993, BIOCHEM J, V289, P411, DOI 10.1042/bj2890411; GALIS ZS, 1994, CIRC RES, V75, P181, DOI 10.1161/01.RES.75.1.181; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; HAMALAINEN ER, 1993, GENOMICS, V17, P544, DOI 10.1006/geno.1993.1369; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; KAGAN HM, 1980, J BIOL CHEM, V255, P3656; KAGAN HM, 1995, J CELL BIOCHEM, V59, P329, DOI 10.1002/jcb.240590305; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1, P321; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KESSLER E, 1986, COLLAGEN REL RES, V6, P249; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACKETT M, 1982, P NATL ACAD SCI-BIOL, V79, P7415, DOI 10.1073/pnas.79.23.7415; MARCY AI, 1991, BIOCHEMISTRY-US, V30, P6476, DOI 10.1021/bi00240a018; MARIANI TJ, 1992, MATRIX, V12, P242, DOI 10.1016/S0934-8832(11)80067-3; NAGAN N, 1994, J BIOL CHEM, V269, P22366; NJIEHA FK, 1982, BIOCHEMISTRY-US, V21, P757, DOI 10.1021/bi00533a028; OAKES BW, 1982, EUR J CELL BIOL, V27, P34; SIEGEL RC, 1974, P NATL ACAD SCI USA, V71, P4826, DOI 10.1073/pnas.71.12.4826; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; SULLIVAN KA, 1982, J BIOL CHEM, V257, P13520; TAKAHASHI S, 1994, J BIOCHEM-TOKYO, V116, P47, DOI 10.1093/oxfordjournals.jbchem.a124501; TRACKMAN PC, 1991, BIOCHEMISTRY-US, V30, P8282, DOI 10.1021/bi00247a025; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; TRACKMAN PC, 1992, J BIOL CHEM, V267, P8666; VATER CA, 1979, BIOCHEM J, V181, P639, DOI 10.1042/bj1810639; WEINGARTEN H, 1985, ANAL BIOCHEM, V147, P437, DOI 10.1016/0003-2697(85)90294-5; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WU Y, 1992, J BIOL CHEM, V267, P24199; YE QZ, 1992, BIOCHEMISTRY-US, V31, P11231, DOI 10.1021/bi00160a038	42	164	175	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7113	7119		10.1074/jbc.271.12.7113	http://dx.doi.org/10.1074/jbc.271.12.7113			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636146	hybrid			2022-12-25	WOS:A1996UB15700081
J	Rokaw, MD; Benos, DJ; Palevsky, PM; Cunningham, SA; West, ME; Johnson, JP				Rokaw, MD; Benos, DJ; Palevsky, PM; Cunningham, SA; West, ME; Johnson, JP			Regulation of a sodium channel-associated G-protein by aldosterone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LLC-PK1 RENAL-CELLS; APICAL MEMBRANE; ALPHA-SUBUNITS; GENE PROMOTER; NA+ CHANNELS; METHYLATION; MECHANISMS; TRANSPORT; INCREASES	The action of aldosterone to increase apical membrane permeability in responsive epithelia is thought to be due to activation of sodium channels. This channel is regulated, in part, by G-proteins, but it is not known if this mechanism is regulated by aldosterone. We report that aldosterone stimulates the expression of the 41-kDa alpha(i3) subunit of the heterotrimeric GTP-binding proteins in A-6 cells. Both mRNA and the total amount of this protein are increased by aldosterone. The G-protein is palmitoylated in response to the steroid, and the newly synthesized subunit is found to co-localize with the sodium channel. Aldosterone stimulation of sodium transport is significantly inhibited by inhibition of palmitoylation. These results suggest that aldosterone regulates sodium channel activity in epithelia through stimulation of the expression and post-translational targeting of a channel regulatory G-protein subunit.	UNIV PITTSBURGH, SCH MED, RENAL ELECTROLYTE DIV, LAB EPITHELIAL CELL BIOL, PITTSBURGH, PA 15213 USA; UNIV ALABAMA, DEPT PHYSIOL & BIOPHYS, BIRMINGHAM, AL 35292 USA; VET AFFAIRS MED CTR, RENAL SECT, PITTSBURGH, PA 15240 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Palevsky, Paul M./Q-1491-2019	Palevsky, Paul M./0000-0002-7334-5400	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK037206, R01DK037206, R01DK047874] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-47874, DK-37206] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHER C, 1988, P NATL ACAD SCI USA, V85, P7413, DOI 10.1073/pnas.85.19.7413; AUSIELLO DA, 1992, J BIOL CHEM, V267, P4759; BENOS DJ, 1986, P NATL ACAD SCI USA, V83, P8525, DOI 10.1073/pnas.83.22.8525; CANTIELLO HF, 1990, J BIOL CHEM, V265, P21624; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DUCHATELLE P, 1992, MOL CELL BIOCHEM, V114, P27; HOLTZMAN EJ, 1991, J BIOL CHEM, V266, P1763; HOLTZMAN EJ, 1993, J BIOL CHEM, V268, P3964; ISMAILOV II, 1994, J BIOL CHEM, V269, P22193; JOHNSON JP, 1992, PHARMACOL THERAPEUT, V53, P1, DOI 10.1016/0163-7258(92)90042-X; KENNEDY AE, 1990, FASEB J, V4, pA445; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEN EL, 1975, BIOCHEMISTRY-US, V14, P2749, DOI 10.1021/bi00683a030; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; ROKAW MD, 1994, CLIN RES, V42, pA319; Sambrook J, 1989, MOL CLONING LABORATO; SARIBANSOHRABY S, 1993, J BIOL CHEM, V268, P26613; SARIBANSOHRABY S, 1984, SCIENCE, V225, P745, DOI 10.1126/science.6463652; SCHAFER JA, 1992, KIDNEY INT, V41, P255, DOI 10.1038/ki.1992.37; SCOTT WN, 1979, J BIOL CHEM, V254, P4957; SOLTYSIAK RM, 1984, BIOCHIM BIOPHYS ACTA, V792, P214, DOI 10.1016/0005-2760(84)90225-X; SPIEGEL AM, 1991, TRENDS BIOCHEM SCI, V338, P341; STEELE RE, 1992, J TISSUE CULTURE MET, V14, P259; STEELE RE, 1986, AM J PHYSIOL, V251, pC186; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WIESMANN WP, 1985, AM J PHYSIOL, V248, pF43, DOI 10.1152/ajprenal.1985.248.1.F43; WILLIAMSON BM, 1985, EMBO J, V3, P2581; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; YATANI A, 1989, SCIENCE, V245, P71, DOI 10.1126/science.2544999; YOUNGSUK OH, 1993, AM J PHYSIOL, V265, pC85	33	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4491	4496						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626803				2022-12-25	WOS:A1996TW96000081
J	Hansen, S; Hupp, TR; Lane, DP				Hansen, S; Hupp, TR; Lane, DP			Allosteric regulation of the thermostability and DNA binding activity of human p53 by specific interacting proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE; MONOCLONAL-ANTIBODIES; SIMIAN VIRUS-40; ACTIVATING MUTATIONS; ESCHERICHIA-COLI; GENE-PRODUCT; MUTANT FORMS; CELL-CYCLE; EXPRESSION; CONFORMATION	Conformational stability is a prerequisite for the physiological activity of the tumor suppressor protein p53. p53 protein can be allosterically activated for DNA binding by phosphorylation or through noncovalent interaction with proteins such as DnaK the Escherichia coli homologue of the heat shock protein Hsp70. We present in vitro evidence for a rapid temperature-dependent change in the conformation and tetrameric nature of wild-type p53 upon incubation at 37 degrees C, which correlates with a permanent loss in DNA binding activity. We show that p53 is allosterically regulated for stabilization of the wild-type conformation and DNA binding activity at 37 degrees C by binding of two classes of ligands to regulatory sites on the N and C terminus of the molecule through which an intrinsic instability of p53 is neutralized. Deletion of the domain conferring instability at the C terminus is sufficient to confer enhanced stability to the total protein. DnaK binding to the C terminus can profoundly protect p53 at 37 degrees C from a temperature-dependent loss of the DNA binding activity but does not renature or activate denatured p53. In contrast, another activator of the DNA binding activity of latent p53, the monoclonal antibody PAb421, which also interacts with the C terminus of the protein, is not able to protect p53 from thermal denaturation. Two monoclonal antibodies to the N terminus of p53, PAb1801 and DO-1, do not activate the latent DNA binding function of p53 but can protect the p53 wild-type conformation at 37 degrees C. Thus, activation of the DNA binding function of p53 is not synonymous with protection from thermal denaturation, and therefore, both of these pathways may be used in cells to control the physiological activity of p53. The protection of p53 conformation from heat denaturation by interacting proteins suggests a novel mechanism by which p53 function could be regulated in vivo.	UNIV DUNDEE, INST MED SCI, DEPT BIOCHEM, CRC CELL TRANSFORMAT GRP, DUNDEE DD1 4HN, SCOTLAND	University of Dundee			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1994, MOL BIOL REP, V19, P23, DOI 10.1007/BF00987319; LEGROS Y, 1994, ONCOGENE, V9, P2071; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1990, ONCOGENE, V5, P1683; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT, P1; PACE CN, 1990, TRENDS BIOCHEM SCI, V15, P14, DOI 10.1016/0968-0004(90)90124-T; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; RASSOW J, 1995, TRENDS CELL BIOL, V5, P207, DOI 10.1016/S0962-8924(00)89001-7; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SOUSSI T, 1990, ONCOGENE, V5, P945; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; SUGITO K, 1995, FEBS LETT, V358, P161, DOI 10.1016/0014-5793(94)01417-Y; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	60	91	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3917	3924						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632013				2022-12-25	WOS:A1996TV72400087
J	Imanaka, T; Shiina, Y; Takano, T; Hashimoto, T; Osumi, T				Imanaka, T; Shiina, Y; Takano, T; Hashimoto, T; Osumi, T			Insertion of the 70-kDa peroxisomal membrane protein into peroxisomal membranes in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PEROXISOMES; ACYL-COA OXIDASE; TARGETING SIGNAL; ZELLWEGER SYNDROME; 3-KETOACYL-COA THIOLASE; ENDOPLASMIC-RETICULUM; FIREFLY LUCIFERASE; CARBOXY TERMINUS; IMPORT; BIOGENESIS	Biosynthesis and intracellular transport of 70-kDa peroxisomal membrane protein (PMP70) has been studied in rat hepatoma, H-4-II-E cells. Pulse-chase analysis showed that a newly synthesized S-35-PMP70 first appeared in the cytosolic fraction and was then transported into the peroxisomal fraction. The half-life of S-35-PMP70 in the cytosolic fraction was approximately 3 min. Integration of S-35-PMP70 into membranes occurred in the peroxisomal fraction and was completed within 30 min. No proteolytic processing of S-35-PMP70 was observed. An in vitro import system was reconstituted to characterize the insertion mechanism of PMP70 into peroxisomes. Peroxisomes isolated from rat liver were incubated at 26 degrees C with [S-35]methionine-labeled in vitro translation products of PMP70 mRNA in the presence of the cytosolic fraction. The peroxisomes were reisolated and insertion of S-35-PMP70 into the membrane was analyzed using a Na2CO3 procedure. The binding and insertion of S-35-PMP70 were dependent on temperature and incubation time and was specific for peroxisomes, Pretreatment of peroxisomes with trypsin and chymotrypsin almost abolished the binding and insertion of S-35-PMP70, The translation products contained several truncated S-35-PMP70s. The NH2 terminally truncated S-35-PMP70s, with a molecular mass greater than 50 kDa, bound to and inserted into peroxisomal membranes, whereas truncated S-35-PMP70s smaller than 45 kDa did not, These results suggest that PMP70 is post-translationally transported to peroxisomes without processing and inserted into peroxisomal membranes by a specific mechanism in which a proteinaceous receptor and a certain internal sequence of PMP70 are involved.	SHINSHU UNIV,SCH MED,DEPT BIOCHEM,MATSUMOTO,NAGANO 390,JAPAN; HIMEJI INST TECHNOL,DEPT LIFE SCI,KAMIGORI,HYOGO 67812,JAPAN	Shinshu University; University of Hyogo	Imanaka, T (corresponding author), TEIKYO UNIV,FAC PHARMACEUT SCI,DEPT MICROBIOL & MOLEC PATHOL,SAGAMIKO,KANAGAWA 19901,JAPAN.			Imanaka, Tsuneo/0000-0003-4677-1356				BORST P, 1989, BIOCHIM BIOPHYS ACTA, V1008, P1, DOI 10.1016/0167-4781(89)90163-2; De Duve C., 1955, BIOCHEM J, V60, P605; DIESTELKOTTER P, 1993, J CELL BIOL, V123, P1717, DOI 10.1083/jcb.123.6.1717; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FUJIKI Y, 1985, J BIOL CHEM, V260, P5603; FUJIKI Y, 1984, P NATL ACAD SCI-BIOL, V81, P7127, DOI 10.1073/pnas.81.22.7127; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; GARTNER J, 1991, PEDIATR RES, V29, P141; GOODMAN JM, 1984, J BIOL CHEM, V259, P8485; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; HARTL FU, 1987, ARCH BIOCHEM BIOPHYS, V255, P109, DOI 10.1016/0003-9861(87)90300-6; HASHIMOTO T, 1986, J BIOCHEM-TOKYO, V100, P301, DOI 10.1093/oxfordjournals.jbchem.a121716; IMANAKA T, 1987, J CELL BIOL, V105, P2915, DOI 10.1083/jcb.105.6.2915; IMANAKA T, 1991, BIOCHIM BIOPHYS ACTA, V1062, P264, DOI 10.1016/0005-2736(91)90401-S; IMANAKA T, 1992, BIOCHIM BIOPHYS ACTA, V1134, P197, DOI 10.1016/0167-4889(92)90176-C; JUST WW, 1967, PEROXISOMES BIOL MED, P402; KALDI K, 1993, FEBS LETT, V315, P217, DOI 10.1016/0014-5793(93)81167-X; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; Lazarow P. B., 1989, METABOLIC BASIS INHE, P1479; LAZAROW PB, 1982, ANN NY ACAD SCI, V386, P285, DOI 10.1111/j.1749-6632.1982.tb21423.x; LAZAROW PB, 1985, ANNU REV CELL BIOL, V1, P489, DOI 10.1146/annurev.cb.01.110185.002421; MCCAMMON MT, 1994, J CELL BIOL, V124, P915, DOI 10.1083/jcb.124.6.915; MIURA S, 1984, J BIOL CHEM, V259, P6397; MIURA S, 1994, EUR J BIOCHEM, V223, P141, DOI 10.1111/j.1432-1033.1994.tb18975.x; MIURA S, 1992, J BIOL CHEM, V267, P14405; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; SANTOS MJ, 1988, J BIOL CHEM, V263, P10502; SANTOS MJ, 1988, SCIENCE, V239, P1536, DOI 10.1126/science.3281254; SANTOS MJ, 1994, J BIOL CHEM, V269, P24890; SATO R, 1990, J BIOL CHEM, V265, P11880; SHORE GC, 1995, EUR J BIOCHEM, V227, P9, DOI 10.1111/j.1432-1033.1995.tb20354.x; SMALL GM, 1988, ANAL BIOCHEM, V169, P405, DOI 10.1016/0003-2697(88)90304-1; SOTO U, 1993, EXP CELL RES, V205, P66, DOI 10.1006/excr.1993.1059; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; SUZUKI Y, 1987, J BIOCHEM-TOKYO, V101, P491, DOI 10.1093/oxfordjournals.jbchem.a121935; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; TSUKAMOTO T, 1991, NATURE, V350, P77, DOI 10.1038/350077a0; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; WENDLAND M, 1993, J CELL BIOL, V120, P675, DOI 10.1083/jcb.120.3.675	41	112	114	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3706	3713						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631984				2022-12-25	WOS:A1996TV72400058
J	Shen, F; Seabra, MC				Shen, F; Seabra, MC			Mechanism of digeranylgeranylation of rab proteins - Formation of a complex between monogeranylgeranyl-rab and rab escort protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERANYLGERANYL TRANSFERASE; ALPHA-SUBUNIT; CDNA CLONING; COMPONENT-A; BINDING; CHOROIDEREMIA; PRENYLATION; TRANSPORT	Rab proteins are Ras-related small GTPases that are digeranylgeranylated at carboxyl-terminal cysteines, a modification essential for their action as molecular switches regulating intracellular vesicular transport, Geranylgeranylation of Rabs is a complex reaction that requires a catalytic Rab geranylgeranyl transferase (GGTase) and a Rab escort protein (REP), REP binds unprenylated Rab and presents it to Rab GGTase, After GG transfer, REP remains associated with diGG-Rab, which leads to insertion of the Rab into a specific membrane, We used recombinant Rab1a single cysteine mutants that accept only one GG group to study the mechanism of the digeranylgeranylation reaction. Using the prenylation assay, gel filtration chromatography, and density ultracentrifugation, we show that REP, but not Rab GGTase, forms a stable complex with unprenylated, monoGG- and diGG-Rab1a. The REP . monoGG-Rab1a complex is stable in the presence of detergents or phospholipids, whereas the REP . diGG-Rab1a complex partially dissociates under these conditions, The stoichiometry of the REP . Rab complex appears to be 1:1 before prenylation, Prenylation induces a change in complex stoichiometry, with the formation of a 2:2 or 2:1 REP . Rab complex, A possible mechanism by which Rab proteins are digeranylgeranylated is suggested by the current studies, We propose that each geranylgeranyl addition is an independent reaction that leads to the production of monoGG-Rab and diGG-Rab, respectively, The stability of the REP . monoGG-Rab complex prevents monoGG-Rab from dissociating from REP prior to the second geranylgeranylation reaction, ensuring efficient digeranylgeranylation of Rab substrates.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Seabra, Miguel C/M-3280-2013; Seabra, Miguel/AAC-3099-2019	Seabra, Miguel C/0000-0002-6404-4892; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARMSTRONG SA, 1995, METHOD ENZYMOL, V257, P30; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BERANGER F, 1994, J BIOL CHEM, V269, P13637; BROWN MS, 1993, NATURE, V366, P14, DOI 10.1038/366014a0; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CREMERS FPM, 1994, J BIOL CHEM, V269, P2111; Cremers Frans P. M., 1992, Human Molecular Genetics, V1, P71, DOI 10.1093/hmg/1.2.71; FARNSWORTH CC, 1994, P NATL ACAD SCI USA, V91, P11963, DOI 10.1073/pnas.91.25.11963; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; GIANNAKOUROS T, 1992, FEBS LETT, V297, P103, DOI 10.1016/0014-5793(92)80337-G; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KINSELLA BT, 1991, J BIOL CHEM, V266, P8540; MARSHALL CJ, 1993, SCIENCE, V259, P1865, DOI 10.1126/science.8456312; MOLENAAR CMT, 1988, EMBO J, V7, P971, DOI 10.1002/j.1460-2075.1988.tb02903.x; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; SANFORD JC, 1995, MOL BIOL CELL, V6, P71, DOI 10.1091/mbc.6.1.71; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SEABRA MC, 1995, J BIOL CHEM, V270, P24420, DOI 10.1074/jbc.270.41.24420; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; SMELAND TE, 1994, P NATL ACAD SCI USA, V91, P10712, DOI 10.1073/pnas.91.22.10712	29	85	86	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3692	3698						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631982				2022-12-25	WOS:A1996TV72400056
J	WarnCramer, BJ; Lampe, PD; Kurata, WE; Kanemitsu, MY; Loo, LWM; Eckhart, W; Lau, AF				WarnCramer, BJ; Lampe, PD; Kurata, WE; Kanemitsu, MY; Loo, LWM; Eckhart, W; Lau, AF			Characterization of the mitogen-activated protein kinase phosphorylation sites on the connexin-43 gap junction protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-DIFFRACTION; TYROSINE PHOSPHORYLATION; SUBSTRATE RECOGNITION; COMMUNICATION; INVITRO; DETERMINANTS; MUTAGENESIS; INHIBITION; PROMOTER; SEQUENCE	We have previously demonstrated that epidermal growth factor induced a rapid, transient decrease in gap junctional communication and increase in serine phosphorylation on the connexin-43 gap junction protein in T51B rat liver epithelial cells, The kinase(s) responsible for phosphorylation and specific serine targets in connexin-43 have not been identified. There are three consensus mitogen-activated protein (MAP) kinase serine phosphorylation sequences in the carboxyl-terminal tail of connexin-43 and purified MAP kinase phosphorylated connexin-43 in vitro on tryptic peptides that comigrated with a subset of peptides from connexin-43 phosphorylated in vivo in cells treated with epidermal growth factor. These data suggested that MAP kinase may phosphorylate connexin-43 directly in vivo, We have utilized a glutathione S-transferase fusion protein containing the cytoplasmic tail of connexin-43 to characterize MAP kinase phosphorylation. Site-directed mutagenesis, phosphotryptic peptide analysis, and peptide sequencing have confirmed that MAP kinase can phosphorylate connexin-43 at Ser(255), Ser(279), and Ser(282), which correspond to the consensus sites recognized earlier. Characterization of MAP kinase-mediated phosphorylation of connexin-43 has defined potential targets for phosphorylation in vivo following activation of the epidermal growth factor receptor and has provided the basis for studies of the effects of phosphorylation, at specific molecular sites, on the regulation of gap junctional communication.	UNIV HAWAII MANOA, SCH MED, DEPT MOLEC BIOL & GENET, HONOLULU, HI 96813 USA; FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98109 USA; SALK INST BIOL STUDIES, LA JOLLA, CA 92037 USA	University of Hawaii System; University of Hawaii Manoa; Fred Hutchinson Cancer Center; Salk Institute	WarnCramer, BJ (corresponding author), CANC RES CTR HAWAII, DEPT MOLEC CARCINOGENESIS, 1236 LAUHALA ST, HONOLULU, HI 96813 USA.				NCI NIH HHS [CA 52098, CA 13884, CA 09370] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052098, R37CA013884, R01CA013884, T32CA009370] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN NG, 1993, MOL CELL BIOCHEM, V128, P201, DOI 10.1007/BF01076771; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BEYER EC, 1990, J MEMBRANE BIOL, V116, P187, DOI 10.1007/BF01868459; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRISSETTE JL, 1991, MOL CELL BIOL, V11, P5364, DOI 10.1128/MCB.11.10.5364; BRITZCUNNINGHAM SH, 1995, NEW ENGL J MED, V332, P1323, DOI 10.1056/NEJM199505183322002; CASPAR DLD, 1977, J CELL BIOL, V74, P605, DOI 10.1083/jcb.74.2.605; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CROW DS, 1992, ONCOGENE, V7, P999; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FILSON AJ, 1990, CELL GROWTH DIFFER, V1, P661; FLAGGNEWTON JL, 1981, J MEMBRANE BIOL, V63, P105, DOI 10.1007/BF01969452; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HERTZBERG EI, 1988, MODERN CELL BIOL GAP, V7; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KANEMITSU MY, 1993, MOL BIOL CELL, V4, P837, DOI 10.1091/mbc.4.8.837; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KURATA WE, 1994, ONCOGENE, V9, P329; LAU AF, 1992, MOL BIOL CELL, V3, P865, DOI 10.1091/mbc.3.8.865; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; LOO LWM, 1995, J BIOL CHEM, V270, P12751, DOI 10.1074/jbc.270.21.12751; MAKOWSKI L, 1977, J CELL BIOL, V74, P629, DOI 10.1083/jcb.74.2.629; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PAGE E, 1986, HEART CARDIOVASCULAR; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAEZ JC, 1986, P NATL ACAD SCI USA, V83, P2473, DOI 10.1073/pnas.83.8.2473; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHANNON JD, 1995, TECH PROT CHEM, V6, P117, DOI 10.1016/S1080-8914(06)80017-7; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; TAKEDA A, 1989, J BIOCHEM-TOKYO, V106, P723, DOI 10.1093/oxfordjournals.jbchem.a122923; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772	49	244	250	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3779	3786						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631994				2022-12-25	WOS:A1996TV72400068
J	Wu, S; Moomaw, CR; Tomer, KB; Falck, JR; Zeldin, DC				Wu, S; Moomaw, CR; Tomer, KB; Falck, JR; Zeldin, DC			Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; ENDOGENOUS EPOXYEICOSATRIENOIC ACIDS; RAT-KIDNEY; ENANTIOFACIAL SELECTIVITY; STENOTOMUS-CHRYSOPS; COS CELLS; METABOLISM; OXYGENASE; IDENTIFICATION; LOCALIZATION	A cDNA encoding a human cytochrome P450 arachidonic acid epoxygenase was isolated from a human liver cDNA library. Sequence analysis revealed that this 1,876-base pair cDNA contained an open reading frame and encoded a new 502-amino acid protein designated CYP2J2. Blot hybridization analysis of RNA prepared from human tissues revealed that CYP2J2 was highly expressed in the heart. Recombinant CYP2J2 protein was prepared using the baculovirus expression system and purified to near electrophoretic homogeneity. The enzyme metabolized arachidonic acid predominantly via olefin epoxidation to all four regioisomeric cis-epoxyeicosatrienoic acids (catalytic turnover 65 pmol of product formed/nmol of cytochrome P450/min at 30 degrees C). Epoxidation of arachidonic acid by CYP2J2 at the 14,15-olefin was highly enantioselective for (14R,15S)-epoxyeicosatrienoic acid (76% optical purity). Immunoblotting of microsomal fractions prepared from human tissues using a polyclonal antibody raised against the recombinant hemoprotein confirmed primary expression of CYP2J2 protein in human heart. The in vivo significance of CYP2J2 was suggested by documenting the presence of epoxyeicosatrienoic acids in the human heart using gas chromatography/mass spectroscopy. importantly, the chirality of CYP2J2 products matched that of the epoxyeicosatrienoic acid enantiomers present, in vivo, in human heart. We propose that CYP2J2 is one of the enzymes responsible for epoxidation of endogenous arachidonic acid pools in human heart and that epoxyeicosatrienoic acids may, therefore, play important functional roles in cardiac physiology.	NIEHS, PULM PATHOBIOL LAB, NIH, RES TRIANGLE PK, NC 27709 USA; UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA; NIEHS, MOLEC BIOPHYS LAB, NIH, RES TRIANGLE PK, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Tomer, Kenneth B/E-8018-2013; Zeldin, Darryl C/Y-7091-2018	Zeldin, Darryl C/0000-0002-2087-7307; Falck, John/0000-0002-9219-7845	NIGMS NIH HHS [GM31278, GM37922] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM NG, 1987, J MOL CELL CARDIOL, V19, P73, DOI 10.1016/S0022-2828(87)80546-1; BAUER E, 1995, CHEM RES TOXICOL, V8, P136, DOI 10.1021/tx00043a018; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPDEVILA J, 1981, P NATL ACAD SCI-BIOL, V78, P5362, DOI 10.1073/pnas.78.9.5362; CAPDEVILA J, 1984, FEBS LETT, V178, P319, DOI 10.1016/0014-5793(84)80625-0; CAPDEVILA JH, 1991, METHOD ENZYMOL, V206, P441; CAPDEVILA JH, 1990, METHOD ENZYMOL, V187, P385; CAPDEVILA JH, 1992, J BIOL CHEM, V267, P21720; CAPDEVILA JH, 1990, J BIOL CHEM, V265, P10865; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; CAPDEVILA JH, 1986, ARCH BIOCHEM BIOPHYS, V231, P511; Capdevila Jorge H., 1995, P443; CARROLL MA, 1987, EUR J PHARMACOL, V138, P281, DOI 10.1016/0014-2999(87)90445-6; CATELLA F, 1990, P NATL ACAD SCI USA, V87, P5893, DOI 10.1073/pnas.87.15.5893; COMPTE J, 1978, BIOCHIMIE PARIS, V60, P1289; COREY EJ, 1980, J AM CHEM SOC, V102, P1433, DOI 10.1021/ja00524a043; DAIKH BE, 1994, J PHARMACOL EXP THER, V271, P1427; FALCK JR, 1990, METHOD ENZYMOL, V187, P357; FALCK JR, 1982, TETRAHEDRON LETT, V23, P1755, DOI 10.1016/S0040-4039(00)86732-5; FITZPATRICK FA, 1986, J BIOL CHEM, V261, P5334; FORRESTER LM, 1992, BIOCHEM J, V281, P359, DOI 10.1042/bj2810359; GEBREMEDHIN D, 1992, AM J PHYSIOL, V263, pH519, DOI 10.1152/ajpheart.1992.263.2.H519; GED C, 1988, BIOCHEMISTRY-US, V27, P6929, DOI 10.1021/bi00418a039; GONZALEZ FJ, 1988, NATURE, V331, P442, DOI 10.1038/331442a0; GONZALEZ FJ, 1991, METHOD ENZYMOL, V206, P93; GONZALEZ FJ, 1991, METHOD ENZYMOL, V206, P85; GUENGERICH FP, 1979, MOL PHARMACOL, V15, P154; GUENGERICH FP, 1992, LIFE SCI, V50, P1471; HAMMONDS TD, 1989, ANAL BIOCHEM, V182, P300, DOI 10.1016/0003-2697(89)90598-8; HECKER M, 1994, J PHYSIOL-LONDON, V481, P407, DOI 10.1113/jphysiol.1994.sp020449; HU SL, 1993, EUR J PHARMACOL, V230, P215, DOI 10.1016/0014-2999(93)90805-R; IMAOKA S, 1993, J PHARMACOL EXP THER, V267, P1012; KARARA A, 1989, J BIOL CHEM, V264, P19822; KARARA A, 1992, BIOCHEM BIOPH RES CO, V182, P1320, DOI 10.1016/0006-291X(92)91877-S; KARARA A, 1990, FEBS LETT, V268, P227, DOI 10.1016/0014-5793(90)81014-F; KARARA A, 1993, J BIOL CHEM, V268, P13565; KARMAZYN M, 1991, CAN J PHYSIOL PHARM, V69, P719, DOI 10.1139/y91-108; KARMAZYN M, 1984, J MOL CELL CARDIOL, V16, P1071, DOI 10.1016/S0022-2828(84)80019-X; KARMAZYN M, 1989, CAN J PHYSIOL PHARM, V67, P912, DOI 10.1139/y89-144; KATOH T, 1991, AM J PHYSIOL, V261, pF578, DOI 10.1152/ajprenal.1991.261.4.F578; KIKUTA Y, 1991, J BIOL CHEM, V266, P17821; KUTSKY P, 1983, PROSTAGLANDINS, V26, P13, DOI 10.1016/0090-6980(83)90070-9; LAETHEM RM, 1992, MOL PHARMACOL, V42, P958; LANIADOSCHWARTZMAN M, 1988, J BIOL CHEM, V263, P2536; LU AYH, 1979, PHARMACOL REV, V31, P277; MAKITA K, 1994, J CLIN INVEST, V94, P2414, DOI 10.1172/JCI117608; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCGIFF JC, 1991, ANNU REV PHARMACOL, V31, P339, DOI 10.1146/annurev.pa.31.040191.002011; MOFFAT MP, 1993, AM J PHYSIOL, V264, pH1154, DOI 10.1152/ajpheart.1993.264.4.H1154; MORRISON AR, 1981, P NATL ACAD SCI-BIOL, V78, P7375, DOI 10.1073/pnas.78.12.7375; MOSSET P, 1986, TETRAHEDRON LETT, V27, P6035, DOI 10.1016/S0040-4039(00)85391-5; MOUSTAKIS CA, 1985, J AM CHEM SOC, V107, P5283, DOI 10.1021/ja00304a048; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OLIW EH, 1981, J BIOL CHEM, V256, P9924; OLIW EH, 1994, PROG LIPID RES, V33, P329, DOI 10.1016/0163-7827(94)90029-9; OMURA T, 1964, J BIOL CHEM, V239, P2370; PATEL L, 1989, PROSTAGLANDINS, V38, P615, DOI 10.1016/0090-6980(89)90044-0; PORTER TD, 1991, METHOD ENZYMOL, V206, P108; PRITCHARD KA, 1990, BIOCHEM BIOPH RES CO, V167, P137, DOI 10.1016/0006-291X(90)91741-A; PROCTOR KG, 1987, CIRC RES, V60, P50, DOI 10.1161/01.RES.60.1.50; RIFKIND AB, 1994, J BIOL CHEM, V269, P3387; ROSOLOWSKY M, 1991, ADV PROSTAG THROMB L, V21, P213; SCHWARTZMAN ML, 1990, KIDNEY INT, V37, P94, DOI 10.1038/ki.1990.13; SERABJITSINGH CJ, 1979, J BIOL CHEM, V254, P9901; SHEPHARD EA, 1989, ANN HUM GENET, V53, P23, DOI 10.1111/j.1469-1809.1989.tb01119.x; SMOLOWITZ RM, 1991, DRUG METAB DISPOS, V19, P113; SRIVASTAVA PK, 1991, MOL PHARMACOL, V40, P69; STEGEMAN JJ, 1982, MOL PHARMACOL, V21, P517; UMBENHAUER DR, 1987, BIOCHEMISTRY-US, V26, P1094, DOI 10.1021/bi00378a016; Waterman M.R, 1991, METHOD ENZYMOL, V206, P100, DOI 10.1016/0076-6879(91)06081-d; WOLF CR, 1990, BIOCHEM SOC T, V18, P21, DOI 10.1042/bst0180021; ZELDIN DC, 1995, ARCH BIOCHEM BIOPHYS, V316, P443, DOI 10.1006/abbi.1995.1059; ZELDIN DC, 1993, J BIOL CHEM, V268, P6402; ZELDIN DC, 1995, J CLIN INVEST, V95, P2150, DOI 10.1172/JCI117904; ZELDIN DC, 1995, ARCH BIOCHEM BIOPHYS, V322, P76, DOI 10.1006/abbi.1995.1438	76	400	417	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3460	3468						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631948				2022-12-25	WOS:A1996TV72400022
J	Cunningham, JG; Meyer, SC; Fox, JEB				Cunningham, JG; Meyer, SC; Fox, JEB			The cytoplasmic domain of the alpha-subunit of glycoprotein (GP) Ib mediates attachment of the entire GP Ib-IX complex to the cytoskeleton and regulates von Willebrand factor-induced changes in cell morphology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEIN; THROMBIN-STIMULATED PLATELETS; VONWILLEBRAND-FACTOR BINDING; LEUCINE-RICH GLYCOPROTEINS; IIB-IIIA; MEMBRANE SKELETON; FACTOR-VIII; E-CADHERIN; ADHESION; AGGREGATION	The glycoprotein (GP) Ib-IX complex is one of the major platelet membrane glycoproteins. Its extracellular domain binds von Willebrand factor at a site of injury, an interaction that leads to activation of intracellular pathways. Its intracellular domain associates tightly with the platelet cytoskeleton through actin-binding protein. The goal of the present study was to investigate the role of the cytoplasmic domain of the GP Ib-IX complex and its interaction with the cytoskeleton. Cultured cells were transfected with the cDNAs coding for GP Ib(beta), GP IX, and full-length or truncated forms of GP Ib(alpha). Western blots of detergent-insoluble fractions of Triton X-100-lysed cells showed that deletion of amino acids Trp-570 to Ser-590 from the cytoplasmic domain of GP Ib(alpha) abolished the interaction of the entire GP Ib-IX complex with the cytoskeleton. Truncated GP Ib(alpha) that was unable to associate with the cytoskeleton retained its ability to associate with GP Ib(beta), to be inserted into the membrane, and to bind von Willebrand factor. Cells expressing GP Ib(alpha) changed their shape following adhesion to immobilized von Willebrand factor. Cells expressing truncated GP Ib(alpha) also changed their shape following adhesion but showed a very different morphology as compared to cells expressing full-length GP Ib(alpha). These results show that GP Ib-IX-von Willebrand factor interactions lead to cytoskeletal reorganizations, that the cytoplasmic domain of GP Ib(alpha) regulates these reorganizations, and that the cytoplasmic domain of GP Ib(alpha) is absolutely required for attachment of the GP Ib-IX complex to the cytoskeleton.	CLEVELAND CLIN FDN,CTR THROMBOSIS & VASC RES FF20,CLEVELAND,OH 44195; CHILDRENS HOSP,OAKLAND RES INST,OAKLAND,CA 94609; UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST CARDIOVASC RES,SAN FRANCISCO,CA 94143	Cleveland Clinic Foundation; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL030657, R37HL030657, R01HL030657, F32HL008605] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30657, 7 F32 HL08605] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AAKHUS AM, 1989, ELECTROPHORESIS, V10, P758, DOI 10.1002/elps.1150101105; ANDREWS RK, 1991, J BIOL CHEM, V266, P7144; ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8317, DOI 10.1021/bi00447a009; ANDREWS RK, 1992, J BIOL CHEM, V267, P18605; BAUER JS, 1993, J CELL BIOL, V122, P209, DOI 10.1083/jcb.122.1.209; BRINKHOUS KM, 1980, BLOOD, V55, P517; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; DELISSER HM, 1994, J CELL BIOL, V124, P195, DOI 10.1083/jcb.124.1.195; DEMARCO L, 1985, J CLIN INVEST, V75, P1198, DOI 10.1172/JCI111816; DU XP, 1994, J BIOL CHEM, V269, P18287; DU XP, 1987, BLOOD, V69, P1524; EZZELL RM, 1988, J BIOL CHEM, V263, P13303; FOX JEB, 1988, J BIOL CHEM, V263, P4882; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1985, J BIOL CHEM, V260, P1970; FOX JEB, 1989, J BIOL CHEM, V264, P9520; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FOX JEB, 1987, THROMB DIATH HAEMO, P175; GEORGE JN, 1984, NEW ENGL J MED, V311, P1084, DOI 10.1056/NEJM198410253111705; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; JACKSON SP, 1994, J BIOL CHEM, V269, P27093; JAFFE SH, 1990, P NATL ACAD SCI USA, V87, P3589, DOI 10.1073/pnas.87.9.3589; KAO KJ, 1979, J CLIN INVEST, V63, P656, DOI 10.1172/JCI109348; KOUNS WC, 1991, J BIOL CHEM, V266, P13891; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE JB, 1987, J LAB CLIN MED, V109, P495; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; LOPEZ JA, 1994, J BIOL CHEM, V269, P23716; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; MEYER S, 1993, J BIOL CHEM, V268, P20555; MEYER SC, 1995, J BIOL CHEM, V270, P14693, DOI 10.1074/jbc.270.24.14693; MURATA M, 1991, J BIOL CHEM, V266, P15474; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; OKITA JR, 1985, J CELL BIOL, V100, P317, DOI 10.1083/jcb.100.1.317; ROTH GJ, 1991, BLOOD, V77, P5; RUGGERI ZM, 1993, THROMB HAEMOSTASIS, V70, P119; SAKARIASSEN KS, 1986, BRIT J HAEMATOL, V63, P681, DOI 10.1111/j.1365-2141.1986.tb07552.x; SOLUM NO, 1983, BIOCHIM BIOPHYS ACTA, V729, P53, DOI 10.1016/0005-2736(83)90455-8; SOLUM NO, 1984, BIOCHIM BIOPHYS ACTA, V799, P209, DOI 10.1016/0304-4165(84)90263-0; TOBELEM G, 1976, NATURE, V263, P427, DOI 10.1038/263427a0; TORTI M, 1994, P NATL ACAD SCI USA, V91, P4239, DOI 10.1073/pnas.91.10.4239; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARDELL MR, 1989, J BIOL CHEM, V264, P15656; WEISS HJ, 1973, J CLIN INVEST, V52, P2697, DOI 10.1172/JCI107464; WEISS HJ, 1986, BLOOD, V67, P322; ZHANG J, 1992, J BIOL CHEM, V267, P4686	55	76	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11581	11587		10.1074/jbc.271.19.11581	http://dx.doi.org/10.1074/jbc.271.19.11581			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626721	hybrid			2022-12-25	WOS:A1996UJ94400081
J	Kundu, GC; Ji, IH; McCormick, DJ; Ji, TH				Kundu, GC; Ji, IH; McCormick, DJ; Ji, TH			Photoaffinity labeling of the lutropin receptor with synthetic peptide for carboxyl terminus of the human choriogonadotropin alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; HORMONE; SEQUENCE; BINDING; ACID	Human choriogonadotropin (hCG) consists of an alpha subunit and a beta subunit. The existing evidence from various studies using truncation, substitution, synthetic hormone peptides, and hCG crystals suggests that the C-terminal region of the alpha subunit contacts the luteinizing hormone/choriogonoadotropin (LH/CG) receptor and is involved in receptor activation. Despite a deluge of the speculation and the important role of the alpha C-terminal region, direct evidence for its interaction with the receptor has been elusive. Because of the significant biological activity, it is imperative to prove the interaction of the alpha C-terminal region. For this purpose, decamer peptides corresponding to the alpha subunit sequence from His(83) to Ser(92) (alpha(83-92)) were derivatized with the N-hydroxysuccinimide ester of 4-azidobenzoylglycine (ABG) and radioiodinated. The resulting ABG-I-125-alpha(83-92) was capable of binding and activating the LH/CG receptor. Furthermore, UV-sensitive ABG-I-125-alpha(83-92) exclusively photoaffinity-labeled an similar to 86-kDa molecule. This labeled molecule was shown to be the LH/CG receptor by various methods including immunoprecipitation by anti-LH/CG receptor antiserum. In addition, evidence is presented that the amino group of alpha Lys(91) of alpha(83-92) is in such close proximity to a carboxyl group of the receptor that this pair is cross-linked to form an amide, a zero length cross-link. This low affinity contact of alpha(83-92) and the receptor is sufficient for receptor activation and is crucial for the full understanding of the mechanistics of the receptor activation steps.	UNIV WYOMING,DEPT MOLEC BIOL,LARAMIE,WY 82071; MAYO CLIN,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905	University of Wyoming; Mayo Clinic			Kundu, Gopal C./ABA-9897-2020		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018702] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-18702] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CHAN KW, 1973, J BIOL CHEM, V248, P7930; CHARLESWORTH M, 1987, J BIOL CHEM, V270, P13409; CHEN F, 1992, MOL ENDOCRINOL, V6, P914, DOI 10.1210/me.6.6.914; JI I, 1981, P NATL ACAD SCI-BIOL, V78, P5465, DOI 10.1073/pnas.78.9.5465; JI IH, 1993, J BIOL CHEM, V268, P22971; JI IH, 1985, J BIOL CHEM, V260, P2815; JI L, 1980, P NATL ACAD SCI USA, V77, P7167; JI TH, 1983, METHOD ENZYMOL, V91, P580; KEUTMANN HT, 1989, MOL ENDOCRINOL, V3, P526, DOI 10.1210/mend-3-3-526; KIEHM DJ, 1977, J BIOL CHEM, V252, P8524; LAPTHORN AJ, 1994, NATURE, V369, P455, DOI 10.1038/369455a0; MEANS GE, 1971, CHEM MODIFICATION PR, P144; MORGAN FJ, 1975, J BIOL CHEM, V250, P5247; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; YOO J, 1991, J BIOL CHEM, V266, P17741; YOO JK, 1993, J BIOL CHEM, V268, P13034; ZHU HY, 1995, MOL ENDOCRINOL, V9, P141, DOI 10.1210/me.9.2.141	17	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11063	11066		10.1074/jbc.271.19.11063	http://dx.doi.org/10.1074/jbc.271.19.11063			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626648	hybrid			2022-12-25	WOS:A1996UJ94400008
J	Cole, AA; Chubinskaya, S; Schumacher, B; Huch, K; CsSzabo, G; Yao, J; Mikecz, K; Hasty, KA; Kuettner, KE				Cole, AA; Chubinskaya, S; Schumacher, B; Huch, K; CsSzabo, G; Yao, J; Mikecz, K; Hasty, KA; Kuettner, KE			Chondrocyte matrix metalloproteinase-8 - Human articular chondrocytes express neutrophil collagenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SYNOVIAL-FLUID; INTERGLOBULAR DOMAIN; SUBSTRATE-SPECIFICITY; AGGRECAN FRAGMENTS; CARTILAGE AGGRECAN; OSTEOARTHRITIS; DEGRADATION; POPULATIONS; PROTEINASE; RNA	This study confirms that normal human articular chondrocytes express neutrophil collagenase or matrix metalloproteinase-8 (MMP-8), a gene product previously thought to be expressed exclusively by neutrophil leukocytes. Both MMP-8 protein and mRNA were present in articular cartilages collected from normal human donors. Cartilage extracts were assayed by immunoblotting and by analysis of enzymatic activity on gelatin-substrate gels. Latent MMP-8 extracted from cartilage has a molecular mass of 55 kDa; active MMP-8 was identified at 46 and 42 kDa. In the absence of a reducing agent, MMP-8 migrated in a high molecular mass complex above 200 kDa. Northern blotting results demonstrated the expression of MMP-8 in chondrocytes, which could be up-regulated by stimulation with interleukin 1 beta. In addition, reverse transcription-polymerase chain reaction using nested primers and in situ hybridization revealed the presence of MMP-8 mRNA in chondrocytes. The presence of both MMP-8 protein and message in cartilage supports the concept that neutrophil collagenase could be the enzyme described as ''aggrecanase.''	RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT ORTHOPED SURG, RUSH MED COLL, CHICAGO, IL 60612 USA; UNIV TENNESSEE, CTR HLTH SCI, DEPT ANAT & NEUROBIOL, MEMPHIS, TN 38163 USA; VET ADM MED CTR, MEMPHIS, TN 38104 USA	Rush University; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center	Cole, AA (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT BIOCHEM, RUSH MED COLL, 1653 W CONGRESS PKWY, CHICAGO, IL 60612 USA.			Mikecz, Katalin/0000-0003-1506-4296	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI022603, R01AI022603, R23AI022603] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039239] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-22603] Funding Source: Medline; NIAMS NIH HHS [2-P50-AR-39239] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AYDELOTTE MB, 1988, CONNECT TISSUE RES, V18, P205, DOI 10.3109/03008208809016808; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BURRIS TS, 1995, T ORTHOP RES SOC, V20, P335; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUBINSKAYA S, 1995, T ORTHOP RES SOC, V20, P342; COLE AA, 1993, DEV BIOL, V159, P528, DOI 10.1006/dbio.1993.1261; Cole AA, 1995, ACTA ORTHOP SCAND, V66, P98, DOI 10.3109/17453679509157661; DEAN DD, 1989, MATRIX, V9, P366, DOI 10.1016/S0934-8832(89)80041-1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOSANG AJ, 1994, BIOCHEM J, V304, P347, DOI 10.1042/bj3040347; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; FOSANG AJ, 1993, BIOCHEM J, V295, P273, DOI 10.1042/bj2950273; FOSANG AJ, 1994, T ORTHOP RES SOC, V19, P48; FULOP C, 1993, J BIOL CHEM, V268, P17377; HASTY KA, 1987, J BIOL CHEM, V262, P10048; HASTY KA, 1990, ARTHRITIS RHEUM, V33, P388, DOI 10.1002/art.1780330312; HASTY KA, 1987, ARTHRITIS RHEUM, V30, P695, DOI 10.1002/art.1780300613; HASTY KA, 1990, J BIOL CHEM, V265, P11421; HIROSE T, 1993, P NATL ACAD SCI USA, V90, P2569, DOI 10.1073/pnas.90.7.2569; HORWITZ AL, 1977, P NATL ACAD SCI USA, V74, P897, DOI 10.1073/pnas.74.3.897; HUCH K, 1995, T ORTHOP RES SOC, V20, P338; LARK MW, 1995, J BIOL CHEM, V270, P2550, DOI 10.1074/jbc.270.6.2550; LOHMANDER LS, 1993, ARTHRITIS RHEUM, V36, P1214; MAINARDI CL, 1991, AM J MED SCI, V302, P171, DOI 10.1097/00000441-199109000-00010; SANDELL LJ, 1991, J CELL BIOL, V114, P1307, DOI 10.1083/jcb.114.6.1307; SANDY JD, 1992, J CLIN INVEST, V89, P1512, DOI 10.1172/JCI115742; SANDY JD, 1991, J BIOL CHEM, V266, P8198; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH GN, 1994, ANN NY ACAD SCI, V732, P436, DOI 10.1111/j.1749-6632.1994.tb24778.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOOLLEY DE, 1976, EUR J BIOCHEM, V69, P421, DOI 10.1111/j.1432-1033.1976.tb10926.x; YAO JL, 1992, CARDIOVASC RES, V26, P603, DOI 10.1093/cvr/26.6.603	32	162	164	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					11023	11026		10.1074/jbc.271.18.11023	http://dx.doi.org/10.1074/jbc.271.18.11023			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631924	hybrid			2022-12-25	WOS:A1996UJ34200092
J	Mehta, DP; Ichikawa, M; Salimath, PV; Etchison, JR; Haak, R; Manzi, A; Freeze, HH				Mehta, DP; Ichikawa, M; Salimath, PV; Etchison, JR; Haak, R; Manzi, A; Freeze, HH			A lysosomal cysteine proteinase from Dictyostelium discoideum contains N-acetylglucosamine-1-phosphate bound to serine but not mannose-6-phosphate on N-linked oligosaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL-ANALYSIS; ALPHA-MANNOSIDASE; ENZYMES; IDENTIFICATION; CHROMATOGRAPHY; GLYCOPROTEINS; PURIFICATION	Previous studies showed that vegetative Dictyostelium discoideum cells make a lysosomal proteinase, proteinase-1, that contains multiple GlcNAc-alpha-1-P residues in phosphodiester linkage to serine, We extended these studies and, in contrast to earlier reports, found that proteinase-1 contains 7.5 mol of Fuc, 8 mol of Man, 2 mol of Xyl, and 30 mol of GlcNAc per calculated mol of protein but no Man-6-P residues, The protein binds to con canavalin A and wheat germ agglutinin lectin affinity columns, and PNGase-F digestion released most of the mannose and xylose but little of the GlcNAc, beta-Elimination under reducing conditions released only GlcNAc-alpha-1-P, There was no evidence for the release of disaccharides or of fucitol, A rabbit antiserum and monoclonal antibodies prepared against proteinase-1 recognize GlcNAc-alpha-1-P residues in immunoblots and are specifically competed by UDP-GlcNAc or GlcNAc-alpha-1-P, Use of other monoclonal antibodies showed the presence of mannose-6-sulfate on N-linked sugar chains, and alpha-fucose residues on the protein, Thus, proteinase-1 has at least two types of modifications: GlcNAc-alpha-1-P Ser, which we call phosphoglycosylation, and N-linked oligosaccharides. This is the first purified lysosomal enzyme in Dictyostelium that does not contain Man-6-P residues, The GlcNAc-alpha-1-P-specific antibodies also recognize a group of developmentally regulated proteins, especially enriched in vegetative cells, Some of them are also lysosomal cysteine proteinases, and all bind to the GlcNAc-alpha-1-P-specific monoclonal antibody but not to the mammalian CI-Man-6-P receptor, Conversely, lysosomal enzymes that have Man-6-P do not bind to the GlcNAc-alpha-1-P-specific antibody, An exception to this is beta-N-acetylglucosaminidase, where 15% of the activity binds to this antibody, Thus, there appear to be two sets of lysosomal enzymes with distinct post-translational modifications.	LA JOLLA CANC RES FDN, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, CTR CANC, LA JOLLA, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego				Freeze, Hudson/0000-0001-6316-0501	PHS HHS [32485] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BENNETT VD, 1986, J BIOL CHEM, V261, P5355; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; CARDELLI JA, 1986, J CELL BIOL, V102, P1264, DOI 10.1083/jcb.102.4.1264; CARDELLI JA, 1993, ADV CELL MOL BIOL M, V1, P341; CARLSON DM, 1968, J BIOL CHEM, V243, P616; Clamp J R, 1971, Methods Biochem Anal, V19, P229, DOI 10.1002/9780470110386.ch3; CLAUSEN H, 1988, MOL IMMUNOL, V25, P199, DOI 10.1016/0161-5890(88)90068-5; DIMOND RL, 1974, J BIOL CHEM, V249, P5628; EY PL, 1986, METHOD ENZYMOL, V121, P497; FINN DJ, 1987, BIOCHEM BIOPH RES CO, V148, P834, DOI 10.1016/0006-291X(87)90951-X; FREEZE HH, 1980, J BIOL CHEM, V255, P1081; FREEZE HH, 1985, J BIOL CHEM, V260, P8857; FREEZE HH, 1986, J BIOL CHEM, V261, P127; FREEZE HH, 1983, J BIOL CHEM, V258, P4874; FREEZE HH, 1995, BIOCHEM BIOPH RES CO, V208, P384, DOI 10.1006/bbrc.1995.1349; FREEZE HH, 1991, J BIOL CHEM, V267, P4431; FREEZE HH, 1991, DEV GENET, V11, P463; FREEZE HH, 1993, CELL SURFACE CARBOHY, P285; GABEL CA, 1984, J BIOL CHEM, V259, P3762; GONZALEZYANES B, 1989, DEV BIOL, V133, P576, DOI 10.1016/0012-1606(89)90060-2; GUSTAFSON GL, 1984, METHOD ENZYMOL, V107, P172; GUSTAFSON GL, 1980, J BIOL CHEM, V255, P7208; GUSTAFSON GL, 1980, BIOCHEM BIOPH RES CO, V94, P1439, DOI 10.1016/0006-291X(80)90580-X; GUSTAFSON GL, 1979, J BIOL CHEM, V254, P2471; HARDY MR, 1989, METHOD ENZYMOL, V179, P76; Harlow E., 1988, ANTIBODIES LAB MANUA; JUDELSON HS, 1988, DIFFERENTIATION, V37, P7, DOI 10.1111/j.1432-0436.1988.tb00790.x; JUDELSON HS, 1988, ARCH BIOCHEM BIOPHYS, V253, P305; LOOMIS WF, 1975, DICTYOSTELIUM DISCOI, P105; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; MEHTA DP, 1995, ARCH BIOCHEM BIOPHYS, V321, P191, DOI 10.1006/abbi.1995.1385; MERELLO S, 1995, J BIOL CHEM, V270, P7281, DOI 10.1074/jbc.270.13.7281; MIERENDORF RC, 1983, J BIOL CHEM, V258, P5878; NORTH MJ, 1985, BIOCHEM SOC T, V23, P288; PARK JT, 1949, J BIOL CHEM, V181, P149; ROUX L, 1988, J BIOL CHEM, V263, P8879; SCHATZLE J, 1992, J BIOL CHEM, V267, P4000; SOUZA GM, 1995, J BIOL CHEM, V270, P28938, DOI 10.1074/jbc.270.48.28938; SPUDICH JA, 1987, METHOD CELL BIOL, V28, P9; STULTS NL, 1993, GLYCOBIOLOGY, V3, P589, DOI 10.1093/glycob/3.6.589; YOSHIMA H, 1979, ARCH BIOCHEM BIOPHYS, V194, P394, DOI 10.1016/0003-9861(79)90632-5	41	38	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10897	10903		10.1074/jbc.271.18.10897	http://dx.doi.org/10.1074/jbc.271.18.10897			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631906	hybrid			2022-12-25	WOS:A1996UJ34200074
J	Caniggia, I; Liu, J; Kuliszewski, M; Tanswell, AK; Post, M				Caniggia, I; Liu, J; Kuliszewski, M; Tanswell, AK; Post, M			Fetal lung fibroblasts selectively down-regulate proteoglycan synthesis in response to elevated oxygen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE PROTEOGLYCANS; GROWTH-FACTOR-BETA; GLYCOSAMINOGLYCAN SYNTHESIS; ARTICULAR-CARTILAGE; PULMONARY FIBROSIS; HYALURONIC-ACID; SMOOTH-MUSCLE; I BIGLYCAN; RAT LUNG; DECORIN	Cell proliferation is in part regulated by extracellular matrix, Therefore, it is possible that elevated O-2 may indirectly affect lung fibroblast growth via modulation of extracellular matrix, In the present study, we investigated the effect of elevated O-2 on the synthesis of glycosaminoglycans (GrAGs) and proteoglycans (PGs) by fetal lung fibroblasts. A 48-h exposure to greater than or equal to 50% O-2 reduced the incorporation of [H-3]glucosamine and (SO4)-S-35 into GAGs by fetal lung fibroblasts. The relative proportion of the individual GAG molecules was not altered by elevated O-2, Fibroblasts exposed to 50% O-2 secreted less [S-35]proteoglycans into the medium than controls. Specifically, the synthesis of the small soluble PG, biglycan, was decreased by exposure to 50% O-2. Fetal lung fibroblasts did not synthesize the small chondroitin/dermatan sulfate FG decorin, Elevated O-2 concentrations also reduced the synthesis of membrane- and matrix-associated PGs, Furthermore, exposure of fetal lung fibroblasts to greater than or equal to 50% O-2 resulted in a decreased mRNA expression for biglycan and versican core protein sequences, Ttl contrast, elevated O, increased the message for type I collagen and fibronectin without affecting that of p-actin. The inhibitory effect of elevated O-2 on biglycan mRNA and protein expression was overcome by incubating the cells in 3% O-2 after the 48-h exposure to 50% O-2. The latter treatment also reversed the increased mRNA expression of type I collagen associated with elevated O-2 but not that of fibronectin, These results demonstrate that fetal lung fibroblasts, in response to elevated oxygen concentrations, selectively down-regulate their GAG and PG synthesis and that this O-2 effect is reversible.	UNIV TORONTO,HOSP SICK CHILDREN,RES INST,DEPT PAEDIAT,MRC,GRP LUNG DEV,TORONTO,ON M5G 1X8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Caniggia, Isabella/G-6466-2013	Caniggia, Isabella/0000-0001-7340-2359				BASSET F, 1986, AM J PATHOL, V122, P443; BATES EJ, 1984, ANN RHEUM DIS, V43, P462, DOI 10.1136/ard.43.3.462; BENITZ WE, 1990, AM J RESP CELL MOL, V2, P13, DOI 10.1165/ajrcmb/2.1.13; BJERMER L, 1987, BRIT MED J, V295, P803, DOI 10.1136/bmj.295.6602.803; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; CANIGGIA I, 1991, AM J PHYSIOL, V261, pL424, DOI 10.1152/ajplung.1991.261.6.L424; CANIGGIA I, 1992, EXP CELL RES, V202, P252, DOI 10.1016/0014-4827(92)90072-G; CANTOR JO, 1980, P SOC EXP BIOL MED, V164, P1; CANTOR JO, 1983, P SOC EXP BIOL MED, V173, P362; CASTOR CW, 1983, IN VITRO CELL DEV B, V19, P462; CHANDRAKASAN G, 1991, CELL MOL BIOL, V37, P751; CHOI HU, 1989, J BIOL CHEM, V264, P2876; COPP AJ, 1988, DEV BIOL, V130, P583, DOI 10.1016/0012-1606(88)90353-3; CROUCH E, 1990, AM J PHYSIOL, V259, pL159, DOI 10.1152/ajplung.1990.259.4.L159; DURR RA, 1987, EXP MOL PATHOL, V47, P219, DOI 10.1016/0014-4800(87)90077-3; FAGER G, 1992, IN VITRO CELL DEV-AN, V28A, P168; FERRARA TB, 1992, AM J RESP CELL MOL, V6, P219, DOI 10.1165/ajrcmb/6.2.219; FISHER LW, 1989, J BIOL CHEM, V264, P4571; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; JARVELAINEN HT, 1991, J BIOL CHEM, V266, P23274; JUUL SE, 1991, LUNG SCI F, P413; KAHARI VM, 1991, J BIOL CHEM, V266, P10608; KASHIHARA N, 1992, P NATL ACAD SCI USA, V89, P6309, DOI 10.1073/pnas.89.14.6309; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KRUSIUS T, 1987, J BIOL CHEM, V262, P13120; LEE YJ, 1987, J CHROMATOGR-BIOMED, V419, P275, DOI 10.1016/0378-4347(87)80286-4; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MARGRAF LR, 1991, AM REV RESPIR DIS, V143, P391; MARTIN GR, 1989, PEPTIDE GROWTH FACTO, V2, P463; MAST BA, 1993, MATRIX, V13, P441, DOI 10.1016/S0934-8832(11)80110-1; MILLIGAN SA, 1995, EXP LUNG RES, V21, P559, DOI 10.3109/01902149509031759; MOORE AM, 1995, AM J PHYSIOL-LUNG C, V268, pL78, DOI 10.1152/ajplung.1995.268.1.L78; PANASYUK A, 1994, FREE RADICAL BIO MED, V16, P157, DOI 10.1016/0891-5849(94)90139-2; RILEY DJ, 1984, TOXICOL APPL PHARM, V75, P554, DOI 10.1016/0041-008X(84)90192-3; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; ROMARIS M, 1991, BIOCHIM BIOPHYS ACTA, V1093, P229, DOI 10.1016/0167-4889(91)90127-J; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SMITH CI, 1990, CELL DIFFER DEV, V32, P83, DOI 10.1016/0922-3371(90)90102-3; Snedecor GW, 1980, STAT METHODS, V7th; STEEL RGD, 1970, PRINCIPLES PROCEDURE; TANSWELL AK, 1990, BIOCHIM BIOPHYS ACTA, V1044, P269, DOI 10.1016/0005-2760(90)90313-M; THURLBECK WM, 1978, HUM PATHOL, V9, P492, DOI 10.1016/S0046-8177(78)80130-0; Toole B.P., 1981, CELL BIOL EXTRACELLU, P259, DOI DOI 10.1007/978-1-4613-0881-2_10; VENESSMEEHAN KA, 1994, AM J RESP CELL MOL, V11, P509, DOI 10.1165/ajrcmb.11.5.7946380; WESTERNGRENTHOR.G, 1993, J CLIN INVEST, V92, P623; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	49	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6625	6630		10.1074/jbc.271.12.6625	http://dx.doi.org/10.1074/jbc.271.12.6625			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636078	hybrid			2022-12-25	WOS:A1996UB15700013
J	Hughes, PE; DiazGonzalez, F; Leong, L; Wu, CY; McDonald, JA; Shattil, SJ; Ginsberg, MH				Hughes, PE; DiazGonzalez, F; Leong, L; Wu, CY; McDonald, JA; Shattil, SJ; Ginsberg, MH			Breaking the integrin hinge - A defined structural constraint regulates integrin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IIB-IIIA COMPLEX; EXTRACELLULAR-MATRIX; PLATELET ACTIVATION; CYTOPLASMIC DOMAIN; FOCAL ADHESIONS; GPIIB-IIIA; RECEPTOR; MODULATION; AFFINITY; MUTATION	Integrins are heterodimeric (alpha, beta) cell adhesion receptors, We demonstrate that point mutations in the cytoplasmic domains of both the alpha and beta subunits promote constitutive signaling by the integrin alpha(IIIb)beta(3). BY generating charge reversal mutations, we show these ''activating'' mutations may act by disrupting a potential salt bridge between the membrane-proximal portions of the alpha and beta subunit cytoplasmic domains, Thus, the modulation of specific interactions between the alpha and beta subunit cytoplasmic domains may regulate transmembrane signaling through integrins, In addition, these activating mutations induce dominant alterations in cellular behavior, such as the assembly of the extracellular matrix, Consequently, somatic mutations in integrin cytoplasmic domains could have profound effects in vivo on integrin-dependent functions such as matrix assembly, cell migration, and anchorage-dependent cell growth and survival.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; MAYO CLIN SCOTTSDALE, SAMUEL C JOHNSON MED RES CTR, SCOTTSDALE, AZ 85259 USA	Scripps Research Institute; Mayo Clinic; Mayo Clinic Phoenix			Diaz-Gonzalez, Federico/R-2382-2019	Diaz-Gonzalez, Federico/0000-0002-4139-9295; Leong, Lilley/0000-0003-1041-0110				ALIG L, 1992, J MED CHEM, V35, P4393, DOI 10.1021/jm00101a017; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BRIESEWITZ R, 1995, MOL BIOL CELL, V6, P997, DOI 10.1091/mbc.6.8.997; BROWN PJ, 1988, EXP CELL RES, V177, P303, DOI 10.1016/0014-4827(88)90464-8; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHEN YP, 1994, J BIOL CHEM, V269, P18307; CROWE DT, 1994, J BIOL CHEM, V269, P14411; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; HOGGER P, 1995, J BIOL CHEM, V270, P7405; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KADOWAKI H, 1989, GENE, V76, P161, DOI 10.1016/0378-1119(89)90018-8; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955-0674(92)90104-K; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; WU CY, 1993, J BIOL CHEM, V268, P21883; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; YAGHMAI R, 1992, P NATL ACAD SCI USA, V89, P7890, DOI 10.1073/pnas.89.17.7890	32	491	498	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6571	6574		10.1074/jbc.271.12.6571	http://dx.doi.org/10.1074/jbc.271.12.6571			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636068				2022-12-25	WOS:A1996UB15700003
J	Kolatkar, AR; Weis, WI				Kolatkar, AR; Weis, WI			Structural basis of galactose recognition by C-type animal lectins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING PROTEIN; MOLECULAR-CLONING; N-ACETYLGALACTOSAMINE; CDNA	The asialoglycoprotein receptors and many other C-type (Ca2+-dependent) animal lectins specifically recognize galactose- or N-acetylgalactosamine-terminated oligosaccharides. Analogous binding specificity can be engineered into the homologous rat mannose-binding protein A by changing three amino acids and inserting a glycine-rich loop (Iobst, S. T,, and Drickamer, K. (1994) J. Biol, Chem. 269, 15512-15519), Crystal structures of this mutant complexed with beta-methyl galactoside and N-acetylgalactosamine (GalNAc) reveal that as with wild-type mannose-binding proteins, the 3- and 4-OH groups of the sugar directly coordinate Ca2+ and form hydrogen bonds with amino acids that also serve as Ca2+ ligands, The different stereochemistry of the 3- and 4-OH groups in mannose and galactose, combined with a fixed Ca2+ coordination geometry, leads to different pyranose ring locations in the two cases. The glycine-rich loop provides selectivity against mannose by holding a critical tryptophan in a position optimal for packing with the apolar face of galactose but incompatible with mannose binding, The 2-acetamido substituent of GalNAc is in the vicinity of amino acid positions identified by site-directed mutagenesis (Iobst, S. T,, and Drickamer, K. (1996) J, Biol, Chem. 271, 6686-6693) as being important for the formation of a GalNAc-selective binding site.	STANFORD UNIV, SCH MED, DEPT BIOL STRUCT, STANFORD, CA 94305 USA	Stanford University			Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150	NIGMS NIH HHS [GM50565] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGYAL SJ, 1972, AUST J CHEM, V25, P1695, DOI 10.1071/CH9721695; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; DRICKAMER K, 1991, CELL, V67, P1029, DOI 10.1016/0092-8674(91)90278-7; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; HOYLE GW, 1988, J BIOL CHEM, V263, P7487; II M, 1990, J BIOL CHEM, V265, P11295; IOBST ST, 1994, J BIOL CHEM, V269, P15512; Iobst ST, 1996, J BIOL CHEM, V271, P6686, DOI 10.1074/jbc.271.12.6686; IOBST ST, 1994, J BIOL CHEM, V269, P15505; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE RT, 1991, J BIOL CHEM, V266, P4810; Ng KKS, 1996, J BIOL CHEM, V271, P663, DOI 10.1074/jbc.271.2.663; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; SATO M, 1992, J BIOCHEM-TOKYO, V111, P331, DOI 10.1093/oxfordjournals.jbchem.a123758; SHERIFF S, 1987, ACTA CRYSTALLOGR A, V43, P118, DOI 10.1107/S010876738709977X; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; VAVASSEUR F, 1990, INT J CANCER, V45, P744, DOI 10.1002/ijc.2910450429; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; WEISS WI, 1996, IN PRESS ANN REV BIO, V65	26	171	183	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6679	6685		10.1074/jbc.271.12.6679	http://dx.doi.org/10.1074/jbc.271.12.6679			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636086	hybrid			2022-12-25	WOS:A1996UB15700021
J	McCarter, JD; Withers, SG				McCarter, JD; Withers, SG			Unequivocal identification of Asp-214 as the catalytic nucleophile of Saccharomyces cerevisiae alpha-glucosidase using 5-fluoro glycosyl fluorides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGROBACTERIUM BETA-GLUCOSIDASE; ACID-SEQUENCE SIMILARITIES; SITE-DIRECTED MUTAGENESIS; ACTIVE-SITE; HYDROLASES; CLASSIFICATION; INHIBITORS; MECHANISM; AMYLASE; PEPTIDE	Yeast alpha-glucosidase is a member of a sequence-related family of alpha-glycosidases (Family 13) that includes important digestive alpha-amylases and alpha-glucosidases. These enzymes catalyze the hydrolysis of alpha-linked oligosaccharides by a two-step mechanism involving a glycosyl-enzyme intermediate. This intermediate can be trapped by use of 5-fluoro-alpha-D-glucosyl fluoride or 5-fluoro-beta-L-idosyl fluoride, members of a new class of mechanism-based glycosidase inactivators. Both of these trapped 5-fluoro glycosyl enzyme intermediates are catalytically competent, turning over when freed of excess inactivator and releasing free enzyme. Two glycosylated peptides in proteolytic digests of these trapped glycosyl enzyme intermediates were identified by use of neutral loss scans on an electrospray ionization triple quadrupole mass spectrometer. Further tandem mass spectrometric analysis in daughter ion scan mode allowed identification of Asp-214 as the catalytic nucleophile in yeast alpha-glucosidase, and this identification was confirmed by aminolysis of the labeled peptide and high resolution mass spectrometry. This residue is one of three active site carboxylates that are completely conserved in this family, thus confirming the role of Asp-214 and the equivalent residues in other family members as the catalytic nucleophile. The other two conserved carboxylates are likely involved in acid/base catalysis.	UNIV BRITISH COLUMBIA,DEPT CHEM,VANCOUVER,BC V6T 1Z1,CANADA	University of British Columbia								BUSCH KL, 1983, TANDEM MASS SPECTROM; GEBLER JC, 1992, J BIOL CHEM, V267, P11126; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HERMANS MMP, 1991, J BIOL CHEM, V266, P13507; HESS D, 1993, PROTEIN SCI, V2, P1342, DOI 10.1002/pro.5560020817; KADZIOLA A, 1994, J MOL BIOL, V239, P104, DOI 10.1006/jmbi.1994.1354; KEMPTON JB, 1992, BIOCHEMISTRY-US, V31, P9961, DOI 10.1021/bi00156a015; KLEIN C, 1992, BIOCHEMISTRY-US, V31, P8740, DOI 10.1021/bi00152a009; KONSTANTINIDIS A, 1991, BIOCHEM J, V279, P587, DOI 10.1042/bj2790587; Leatherbarrow R.J, 1990, GRAFIT VERSION 3 0; LEGLER G, 1990, ADV CARBOHYD CHEM BI, V48, P319, DOI 10.1016/S0065-2318(08)60034-7; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; McCarter JD, 1996, J AM CHEM SOC, V118, P241, DOI 10.1021/ja952732a; MCCARTER JD, 1995, THESIS U BRIT COLUMB; MIAO SC, 1994, J BIOL CHEM, V269, P10975; MIAO SC, 1994, BIOCHEMISTRY-US, V33, P7027, DOI 10.1021/bi00189a002; MOOSER G, 1991, J BIOL CHEM, V266, P8916; QIAN MX, 1993, J MOL BIOL, V231, P785, DOI 10.1006/jmbi.1993.1326; QIAN MX, 1994, BIOCHEMISTRY-US, V33, P6284, DOI 10.1021/bi00186a031; QUARONI A, 1976, J BIOL CHEM, V251, P3250; STREET IP, 1992, BIOCHEMISTRY-US, V31, P9970, DOI 10.1021/bi00156a016; SVENSSON B, 1993, J BIOTECHNOL, V29, P1, DOI 10.1016/0168-1656(93)90038-O; TAKASE K, 1992, BIOCHIM BIOPHYS ACTA, V1120, P281, DOI 10.1016/0167-4838(92)90249-D; WITHERS SG, 1992, BIOCHEMISTRY-US, V31, P9979, DOI 10.1021/bi00156a017; WITHERS SG, 1988, J BIOL CHEM, V263, P7929; WITHERS SG, 1995, PROTEIN SCI, V4, P361; YUAN JM, 1994, BIOCHEM J, V299, P527, DOI 10.1042/bj2990527	28	120	124	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6889	6894		10.1074/jbc.271.12.6889	http://dx.doi.org/10.1074/jbc.271.12.6889			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636115	hybrid			2022-12-25	WOS:A1996UB15700050
J	Kim, S; Dallmann, HG; McHenry, CS; Marians, KJ				Kim, S; Dallmann, HG; McHenry, CS; Marians, KJ			tau Protects beta in the leading-strand polymerase complex at the replication fork	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OKAZAKI FRAGMENT SIZE; ESCHERICHIA-COLI; III HOLOENZYME; DNA; PURIFICATION; SUBUNIT; PROTEINS; IDENTIFICATION; MECHANISM; TEMPLATE	Replication forks formed in the absence of the tau subunit of the DNA polymerase III holoenzyme produce shorter leading and lagging strands than when tau is present. We show that one reason for this is that in the absence of tau, but in the presence of the gamma-complex, leading-strand synthesis is no longer highly processive. In the absence of tau, the size of the leading strand becomes proportional to the concentration of beta and inversely proportional to the concentration of the gamma-complex. In addition, the beta in the leading-strand complex is no longer resistant to challenge by either anti-beta antibodies or poly(dA):oligo(dT). Thus, tau is required to cement a processive leading-strand complex, presumably by preventing removal of beta catalyzed by the gamma-complex.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,GRAD PROGRAM MOLEC BIOL,DENVER,CO 80262; MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Memorial Sloan Kettering Cancer Center	Kim, S (corresponding author), CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM MOL BIOL,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM34557, GM36255] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034557, R01GM036255, R01GM034557] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; ENGSTROM J, 1985, GENETICS, V113, P449; FAY PJ, 1981, J BIOL CHEM, V256, P976; HACKER KJ, 1994, J BIOL CHEM, V269, P24221; JOHANSON KO, 1982, J BIOL CHEM, V257, P2310; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MODEL P, 1974, J MOL BIOL, V83, P231, DOI 10.1016/0022-2836(74)90389-1; MOK M, 1987, J BIOL CHEM, V262, P16644; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; SAKABE K, 1966, BIOCHIM BIOPHYS ACTA, V129, P652; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4064; WU CA, 1992, J BIOL CHEM, V267, P4074; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	25	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4315	4318						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626779				2022-12-25	WOS:A1996TW96000057
J	Lee, MJ; Evans, M; Hla, T				Lee, MJ; Evans, M; Hla, T			The inducible G protein-coupled receptor edg-1 signals via the G(i)/nitrogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL-CELLS; GTP-BINDING PROTEIN; MAP KINASE; CANNABINOID RECEPTOR; ALPHA SUBUNIT; MITOGEN; CDNA; ANGIOGENESIS; PURIFICATION; EXPRESSION	The edg-1 gene encodes an inducible G protein-coupled receptor (GPR) homologue that is induced during the in vitro differentiation of human endothelial cells. The aim of this study was to investigate the G protein-coupling and -signaling properties of the edg-1 polypeptide. The third cytosolic loop (i(3)) of edg-1 associates with G(i alpha) and G(o alpha) polypeptides in a guanosine 5'-O-(thiotriphosphate)-sensitive manner. Immunoprecipitation of the edg-1 polypeptide in transfected cells results in the co-precipitation of G(i alpha 1) and G(i alpha 3) polypeptides. These data strongly suggest that edg-1 is capable of coupling to the G(i) pathway. Overexpression of the edg-1 GPR in human embryonic kidney 293 cells results in the sustained activation of the MAP kinase activity that is blocked by pertussis toxin treatment. Moreover, NIH3T3 cells permanently transfected with edg-1 exhibit enhanced MAP kinase and phospholipase A(2) activities. These data suggest that the G(i)/mitogen-activated protein kinase pathway is a major signaling pathway regulated by the orphan receptor edg-1.	AMER RED CROSS, JEROME H HOLLAND LAB, DEPT BIOL MOLEC, ROCKVILLE, MD 20855 USA	American Red Cross			Hla, Timothy/G-5873-2012	Hla, Timothy/0000-0001-8355-4065	NHLBI NIH HHS [HL 49094] Funding Source: Medline; NIDDK NIH HHS [DK 45659] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045659] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BURSTEIN ES, 1995, FEBS LETT, V363, P261, DOI 10.1016/0014-5793(95)00323-2; CLARK KL, 1993, MOL CELL BIOL, V13, P1; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CODINA J, 1987, SCIENCE, V236, P442, DOI 10.1126/science.2436299; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; CONN G, 1990, P NATL ACAD SCI USA, V87, P1323, DOI 10.1073/pnas.87.4.1323; CORVEN EJ, 1989, CELL, V59, P45; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; CUI Z, 1991, J BIOL CHEM, V266, P20276; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DOCTROW SR, 1987, J CELL BIOL, V104, P679, DOI 10.1083/jcb.104.3.679; EGGERICKX D, 1995, BIOCHEM J, V309, P837, DOI 10.1042/bj3090837; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HLA T, 1995, BBA-GENE STRUCT EXPR, V1260, P227, DOI 10.1016/0167-4781(94)00219-S; HLA T, 1990, J BIOL CHEM, V265, P9308; HLA T, 1990, BIOCHEM BIOPH RES CO, V167, P637, DOI 10.1016/0006-291X(90)92072-8; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HOWE LR, 1993, J BIOL CHEM, V268, P20717; IKEZU T, 1992, FEBS LETT, V311, P29, DOI 10.1016/0014-5793(92)81359-T; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KIM S, 1988, P NATL ACAD SCI USA, V85, P4153, DOI 10.1073/pnas.85.12.4153; KOLAKOWSKI LF, 1994, RECEPTOR CHANNEL, V2, P1; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUROSE H, 1991, BIOCHEMISTRY-US, V30, P3335, DOI 10.1021/bi00227a024; LADO DC, 1994, GENE, V149, P331, DOI 10.1016/0378-1119(94)90171-6; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; LAW SF, 1991, J BIOL CHEM, V266, P17885; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MACIAG T, 1982, J CELL BIOL, V94, P511, DOI 10.1083/jcb.94.3.511; MACIAG T, 1981, J CELL BIOL, V91, P420, DOI 10.1083/jcb.91.2.420; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MCKENZIE FR, 1992, SIGNAL TRANSDUCTION, P45; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; MONTESANO R, 1987, J CELL PHYSIOL, V130, P284, DOI 10.1002/jcp.1041300215; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; MORO O, 1993, J BIOL CHEM, V268, P22273; NICOSIA RF, 1987, AM J PATHOL, V128, P78; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; OKAZAKI H, 1993, BIOCHEM BIOPH RES CO, V190, P1104, DOI 10.1006/bbrc.1993.1163; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; ROSE MD, 1990, METHODS YEAST GENETI, P122; SA G, 1994, J BIOL CHEM, V269, P3219; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	61	145	152	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11272	11279		10.1074/jbc.271.19.11272	http://dx.doi.org/10.1074/jbc.271.19.11272			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626678	hybrid			2022-12-25	WOS:A1996UJ94400038
J	Beauparlant, P; Lin, RT; Hiscott, J				Beauparlant, P; Lin, RT; Hiscott, J			The role of the C-terminal domain of I kappa B alpha in protein degradation and stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; REL-ASSOCIATED PP40; DNA-BINDING; TRANSCRIPTION FACTOR; MYELOMONOBLASTIC CELLS; INHIBITOR; ACTIVATION; PRECURSOR; P105; PHOSPHORYLATION	In the present study, the role of the I kappa B alpha C terminus in NF-kappa B/I kappa B alpha regulation was examined in NIH 3T3 cells engineered to inducibly express wild type or mutated human I kappa B alpha proteins under the control of the tetracycline responsive promoter. Deletion studies demonstrated that the last C-terminal 30 amino acids (amino acids (aa) 288 to aa 317, deleted in I kappa B alpha Delta 3), including most of the PEST domain, were dispensible for I kappa B alpha function. However, deletions from aa 261 to 317 or aa 269 to 317 (I kappa B alpha Delta 1 and I kappa B alpha Delta 2 respectively), lacked the ability to dissociate NF-kappa B/DNA complexes in vitro and were unable to inhibit NF-kappa B dependent transcription. Moreover, I kappa B alpha Delta 1 and I kappa B alpha Delta 2 mutants were resistant to inducer-mediated degradation, Analysis of I kappa B alpha deletions in the presence of protein synthesis inhibitors revealed that, independently of stimulation, I kappa B alpha Delta 1 and I kappa B alpha Delta 2 had a half-life four times shorter than wild type I kappa B alpha and the interaction of I kappa B alpha Delta 1 and I kappa B alpha Delta 2 with p65 was dramatically decreased in vivo as measured by co-immunoprecipitation. Interestingly, protease inhibitors which block inducer-mediated degradation of I kappa B alpha also stabilized the turnover of I kappa B alpha Delta 1 and I kappa B alpha Delta 2. Based on these studies, we propose that in the absence of stimulation, the C-terminal domain between aa 269 and 287 may Play a role to protect I kappa B alpha from a constitutive protease activity.	SIR MORTIMER B DAVIS JEWISH HOSP,LADY DAVIS INST MED RES,TERRY FOX MOL ONCOL GRP,MONTREAL,PQ H3T 1E2,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3T 1E2,CANADA; MCGILL UNIV,DEPT MICROBIOL,MONTREAL,PQ H3T 1E2,CANADA	Lady Davis Institute; McGill University; McGill University; McGill University			Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503				ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BELVIN MP, 1995, GENE DEV, V9, P783, DOI 10.1101/gad.9.7.783; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CRESSMAN DE, 1993, ONCOGENE, V8, P2567; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; ERNST MK, 1995, MOL CELL BIOL, V15, P872; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GERONDAKIS S, 1993, CELL GROWTH DIFFER, V4, P617; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LIN RT, 1994, J BIOL CHEM, V269, P17542; LIN RT, 1995, J BIOL CHEM, V270, P3123, DOI 10.1074/jbc.270.7.3123; Lin RT, 1996, MOL CELL BIOL, V16, P1401; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; LINK E, 1992, J BIOL CHEM, V267, P239; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; NAUMANN M, 1993, ONCOGENE, V8, P2275; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PEPIN N, 1994, VIROLOGY, V204, P706, DOI 10.1006/viro.1994.1586; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROULSTON A, 1992, J EXP MED, V175, P751, DOI 10.1084/jem.175.3.751; ROULSTON A, 1993, J VIROL, V67, P5235, DOI 10.1128/JVI.67.9.5235-5246.1993; SACHDEV S, 1995, ONCOGENE, V11, P811; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZEICHNER SL, 1992, J VIROL, V66, P2268, DOI 10.1128/JVI.66.4.2268-2273.1992	55	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10690	10696		10.1074/jbc.271.18.10690	http://dx.doi.org/10.1074/jbc.271.18.10690			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631876	hybrid			2022-12-25	WOS:A1996UJ34200044
J	Ouyang, LH; Jacob, KK; Stanley, FM				Ouyang, LH; Jacob, KK; Stanley, FM			GABP mediates insulin-increased prolactin gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; THYROID-HORMONE; STIMULATION; EXPRESSION; ACTIVATION; RECEPTORS; ELEMENT; COMPLEX	The insulin-response element from the prolactin gene is identical to the Ets-binding site, and dominant-negative Ets protein inhibits insulin-increased prolactin gene expression. Immunoblotting identified the Ets-related transcription factor GABP in nuclear extracts from GH cells. Expression of GABP alpha and GABP beta 1 squelches insulin-increased prolactin gene expression. GABP alpha and GABP beta 1 bind the insulin-response element of the prolactin promoter, and anti-GABP alpha and anti-GABP beta 1 antibodies supershift a species seen with nuclear extracts from GH cells. GABP alpha immunoprecipitated from insulin-treated, P-32 labeled GH cells was phosphorylated 3-fold more than GABP alpha from control cells. There was no increase in phosphorylation of GABP beta in response to insulin. Mitogen-activated protein (MAP) kinase activity is increased 10-fold in insulin-treated GH4 cells. MAP kinase immunoprecipitated from control cells does not phosphorylate GABP alpha while MAP kinase immunoprecipitated from insulin-treated cells shows substantial phosphorylation of GABP alpha. These studies suggest that GABP mediates insulin-increased transcription of the prolactin gene. GABP may be regulated by MAP kinase phosphorylation.	NYU,MED CTR,DEPT MED,NEW YORK,NY 10016; NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	New York University; New York University				Stanley, Frederick/0000-0002-3684-2168	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043365] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43365] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; JACOB KK, 1995, MOL CELL ENDOCRINOL, V109, P175, DOI 10.1016/0303-7207(95)03500-7; JACOB KK, 1995, J BIOL CHEM, V270, P27773, DOI 10.1074/jbc.270.46.27773; JACOB KK, 1994, J BIOL CHEM, V269, P25515; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STANLEY F, 1988, J BIOL CHEM, V263, P13444; STANLEY F, 1989, MOL ENDOCRINOL, V3, P1627, DOI 10.1210/mend-3-10-1627; STANLEY FM, 1992, J BIOL CHEM, V267, P16719; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TRIESENBERG S, 1988, GENE DEV, V2, P720; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; WHITE MF, 1994, J BIOL CHEM, V269, P1	18	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10425	10428		10.1074/jbc.271.18.10425	http://dx.doi.org/10.1074/jbc.271.18.10425			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631833	hybrid			2022-12-25	WOS:A1996UJ34200001
J	Saito, M; Sato, R; Hisatome, I; Narahashi, T				Saito, M; Sato, R; Hisatome, I; Narahashi, T			RANTES and platelet-activating factor open Ca2+-activated K+ channels in eosinophils	FASEB JOURNAL			English	Article						EoL-1; G-protein; PAF; Ca2+-activated K+ channel; RANTES	CELL-LINE; ION CHANNELS; PATCH-CLAMP; CONDUCTANCE; LEUKOCYTES; MUSCLE; EOL-1; ACID	RANTES is a member of the low molecular cytokines and appears to be strictly a chemotactic and activating factor for eosinophils, We studied the effect of RANTES on the channel activity of the eosinophilic cell line (EoL-1 cells) using patch clamp techniques, Under cell-attached patch conditions, RANTES (20 ng/ml) activated channels in EoL-1 cells when applied to the recording pipette or to the bath, This channel was permeable to K+ with a unit conductance of 14 pS, and the reversal potential was close to the equilibrium potential for K+, The current-voltage relationship for this K+ channel was almost linear, showing little or no rectification. The open time and closed time histograms could be fitted to a single exponential function with time constants of 6.4 and 2.7 ms, respectively, Extracellular application of the calcium ionophore A23187 (1 mu M) under cell-attached patch conditions or an increase in intracellular Ca2+ concentration under inside-out patch conditions increased K+ channel activity in a manner similar to that caused by RANTES, indicating that the RANTES-activated channel was the Ca2+-activated K+ channel, Intracellular application of GTP gamma S (10 mu M) opened the Ca2+-activated K+ channels under inside-out patch conditions, Furthermore, RANTES failed to activate the K+ channels after the cells had been treated with pertussis toxin (100 ng/ml) for 2 h at 37 degrees C, These results suggest that RANTES opens the Ca2+-activated K+ channels of EoL-1 cells through activation of G-proteins.	NORTHWESTERN UNIV, SCH MED, DEPT MOLEC PHARMACOL & BIOL CHEM, CHICAGO, IL 60611 USA; UNIV PENN, DEPT MED, PHILADELPHIA, PA 19104 USA	Northwestern University; University of Pennsylvania								ALAM R, 1993, J IMMUNOL, V150, P3442; BARNES PJ, 1990, EOSINOPHILS ALLERGY, P144; BLATZ AL, 1986, NATURE, V323, P718, DOI 10.1038/323718a0; BROWN AM, 1988, AM J PHYSIOL, V254, pH401, DOI 10.1152/ajpheart.1988.254.3.H401; GALLIN EK, 1991, PHYSIOL REV, V71, P775, DOI 10.1152/physrev.1991.71.3.775; GARDNER P, 1990, ANNU REV IMMUNOL, V8, P231, DOI 10.1146/annurev.iy.08.040190.001311; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; HAMIL OP, 1981, J PHYSL, V319, P97; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KAY AB, 1985, CLIN EXP IMMUNOL, V62, P1; KROEGEL C, 1989, J IMMUNOL, V142, P3518; LUX HD, 1981, PFLUG ARCH EUR J PHY, V389, P293, DOI 10.1007/BF00584792; MARTY A, 1981, NATURE, V291, P497, DOI 10.1038/291497a0; MCCLOSKEY MA, 1990, J GEN PHYSIOL, V95, P205, DOI 10.1085/jgp.95.2.205; MCLEAN A, 1994, LANCET, V343, P189, DOI 10.1016/S0140-6736(94)90985-7; NAKAJIMA T, 1991, FEBS LETT, V289, P239, DOI 10.1016/0014-5793(91)81079-N; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; PAGE CP, 1988, J ALLERGY CLIN IMMUN, V81, P144, DOI 10.1016/0091-6749(88)90233-3; PALLOTTA BS, 1981, NATURE, V293, P471, DOI 10.1038/293471a0; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; SAITO H, 1985, BLOOD, V66, P1233; SATO R, 1990, AM J PHYSIOL, V259, pH1730, DOI 10.1152/ajpheart.1990.259.6.H1730; SATO R, 1994, J PHARMACOL EXP THER, V269, P1213; SHIKANO M, 1993, J IMMUNOL, V150, P3525; TORO L, 1993, HDB EXPT PHARM, P561; UI M, 1984, TRENDS PHARMACOL SCI, V5, P277, DOI 10.1016/0165-6147(84)90444-9; WARDLAW AJ, 1986, J CLIN INVEST, V78, P1701, DOI 10.1172/JCI112765; YOSHIE O, 1989, J LEUKOCYTE BIOL, V45, P10, DOI 10.1002/jlb.45.1.10	29	14	15	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1996	10	7					792	798		10.1096/fasebj.10.7.8635697	http://dx.doi.org/10.1096/fasebj.10.7.8635697			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UN798	8635697				2022-12-25	WOS:A1996UN79800014
J	Wang, TF; Guidotti, G				Wang, TF; Guidotti, G			CD39 is an ecto-(Ca2+,Mg2+)-apyrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR ATP; MOUSE LYMPHOCYTES; PLASMA-MEMBRANE; EXPRESSION; RESPONSES; RESISTANT	CD39, a 70- to 100-kDa molecule expressed primarily on activated lymphoid cells, was previously identified as a surface marker of Epstein Barr virus (EBV)-transformed B cells. In this report, we show that an ecto-(Ca2+,Mg2+)-apyrase activity is present on EBV-transformed B cells, but not on B or T lymphomas. The coincidence between CD39 expression and ecto-apyrase activity on immune cells suggests that CD39 may be an ecto-apyrase. This supposition is supported by the observation that the amino acid sequence of CD39 is significantly homologous to those of several newly identified nucleotide triphosphatases. Finally, we show that CD39 indeed has ecto-apyrase activity by expression in COS-7 cells.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University			Wang, Ting-Fang/ABI-3818-2020	Wang, Ting-Fang/0000-0001-6306-9505	NHLBI NIH HHS [HL08893] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ASAI T, 1995, J BIOL CHEM, V270, P11391, DOI 10.1074/jbc.270.19.11391; BARANKIEWICZ J, 1988, J BIOL CHEM, V263, P7094; BARANKIEWICZ J, 1990, ANN NY ACAD SCI, V603, P380; BERMUDES D, 1994, J BIOL CHEM, V269, P29252; CHEN JH, 1989, SCIENCE, V243, P657, DOI 10.1126/science.2464852; CHEN M, 1992, J BIOL CHEM, V267, P9684; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENNSING S, 1994, BLOOD, V83, P3826; DIVIRGILIO F, 1989, J IMMUNOL, V143, P1955; DIVIRGILIO F, 1995, IMMUNOL TODAY, V16, P524, DOI 10.1016/0167-5699(95)80045-X; DIVIRGILIO F, 1993, CELL TISSUE CULTUR B, V5; DOMBROWSKI KE, 1993, BIOCHEMISTRY-US, V32, P6515, DOI 10.1021/bi00077a004; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; FILLIPINI A, 1990, J BIOL CHEM, V267, P16081; Handa M, 1996, BIOCHEM BIOPH RES CO, V218, P916, DOI 10.1006/bbrc.1996.0162; IKEWAKI N, 1992, TISSUE ANTIGENS, V39, P174, DOI 10.1111/j.1399-0039.1992.tb01933.x; KANSAS GS, 1991, J IMMUNOL, V146, P2235; LIN SH, 1989, J BIOL CHEM, V264, P14403; LIN SH, 1985, J BIOL CHEM, V260, P976; LIN SH, 1989, CELL CALCIUM METABOL, P13; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MALISZEWSKI CR, 1994, J IMMUNOL, V153, P3574; OLAH ME, 1995, ANN REV PHARM TOXICO, V35, P518; PIZZO P, 1992, J IMMUNOL, V149, P3372; PLESNER L, 1995, INT REV CYTOL, V158, P1; REDDY NB, 1978, BIOCHIM BIOPHYS ACTA, V540, P371, DOI 10.1016/0304-4165(78)90167-8; ROWE M, 1982, INT J CANCER, V29, P373, DOI 10.1002/ijc.2910290403; Sambrook J., 2002, MOL CLONING LAB MANU; STOUT JG, 1994, J BIOCHEM BIOPH METH, V29, P61, DOI 10.1016/0165-022X(94)90057-4; ZANOVELLO P, 1990, J IMMUNOL, V145, P1545; ZHENG LM, 1991, J CELL BIOL, V112, P279, DOI 10.1083/jcb.112.2.279; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345	34	249	266	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9898	9901		10.1074/jbc.271.17.9898	http://dx.doi.org/10.1074/jbc.271.17.9898			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626624	hybrid			2022-12-25	WOS:A1996UG25700008
J	Costantini, P; Chernyak, BV; Petronilli, V; Bernardi, P				Costantini, P; Chernyak, BV; Petronilli, V; Bernardi, P			Modulation of the mitochondrial permeability transition pore by pyridine nucleotides and dithiol oxidation at two separate sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-INDUCED MEMBRANE TRANSITION; RAT-LIVER MITOCHONDRIA; CYCLOSPORINE-A; HEART-MITOCHONDRIA; DIVALENT-CATIONS; INNER MEMBRANE; REDOX STATE; CALCIUM; INHIBITION; CHANNELS	After accumulation of a Ca2+ load, the addition of uncoupler to respiring rat liver mitochondria is followed by opening of the permeability transition pore (MTP), a voltage-dependent channel sensitive to cyclosporin A. The channel's voltage threshold is profoundly affected under conditions of oxidative stress, with a shift to more negative values that may cause MTP opening at physiological membrane potentials. in this paper we further clarify the mechanisms by which oxidative agents affect the apparent voltage dependence of the MTP. We show that two sites can be experimentally distinguished. (i) A first site is in apparent oxidation-reduction equilibrium with the pyridine nucleotide (PN) pool (NADH/NAD + NADPH/NADP); PN oxidation is matched by increased MTP open probability under conditions where the glutathione pool is kept in the fully reduced state; this site can be blocked by N-ethylmaleimide but not by monobromobimane, a thiol-selective reagent, (ii) A second site coincides with the oxidation-reduction-sensitive dithiol we have recently identified (Petronilli, V., Costantini, P., Scorrano, L., Colonna, R,. Passamonti, S., and Bernardi, P. (1994) J. Biol. Chem. 269, 16638-16642); dithiol cross-linking at this site by arsenite or phenylarsine oxide is matched by increased MTP open probability under conditions where the PN pool is kept in the fully reduced state; at variance from the first, this site can be blocked by both N-ethlymaleimide and monobromobimane and is probably in equilibrium with the glutathione pool. Based on these findings, we reassess the mechanisms by which many oxidative agents affect the MTP and resolve conflicting reports on the relative role of PN and glutathione oxidation in the permeability transition within the framework of MTP (dys)regulation at two separate sites.	UNIV PADUA,SCH MED,DEPT BIOMED SCI,CNR,RIC UNIT STUDY PHYSIOL MITOCHONDRIA,I-35121 PADUA,ITALY; UNIV PADUA,SCH MED,DEPT BIOMED SCI,LAB BIOPHYS & MEMBRANE BIOL,I-35121 PADUA,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua			Petronilli, Valeria/C-3558-2015; Chernyak, Boris V/D-9917-2012; Bernardi, Paolo/C-3656-2008	Petronilli, Valeria/0000-0003-4026-6404; Chernyak, Boris V/0000-0003-1523-0864; Bernardi, Paolo/0000-0001-9187-3736				BEAL MF, 1993, TRENDS NEUROSCI, V16, P125, DOI 10.1016/0166-2236(93)90117-5; BEATRICE MC, 1984, J BIOL CHEM, V259, P1279; BEATRICE MC, 1980, J BIOL CHEM, V255, P8663; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; BERNARDI P, 1996, IN PRESS J BIOENERG; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; CARBONERA D, 1988, BIOCHIM BIOPHYS ACTA, V943, P245, DOI 10.1016/0005-2736(88)90556-1; CHERNYAK BV, 1995, FEBS LETT, V365, P75, DOI 10.1016/0014-5793(95)00411-2; COSTANTINI P, 1995, TOXICOLOGY, V99, P77, DOI 10.1016/0300-483X(94)02997-9; COSTANTINI P, 1995, FEBS LETT, V362, P239, DOI 10.1016/0014-5793(95)00256-9; CROMPTON M, 1988, BIOCHEM J, V255, P357; DAWSON TL, 1993, AM J PHYSIOL, V264, pC961, DOI 10.1152/ajpcell.1993.264.4.C961; DILISA F, 1995, J PHYSIOL-LONDON, V486, P1; DUCHEN MR, 1993, CARDIOVASC RES, V27, P1790, DOI 10.1093/cvr/27.10.1790; ESPOSTI MD, 1994, BIOCHEM J, V301, P161, DOI 10.1042/bj3010161; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; GRIFFITHS EJ, 1995, BIOCHEM J, V307, P93, DOI 10.1042/bj3070093; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HAWORTH RA, 1980, J MEMBRANE BIOL, V54, P231, DOI 10.1007/BF01870239; HOEK JB, 1988, BIOCHEM J, V254, P1; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4; KINNALLY KW, 1989, J BIOENERG BIOMEMBR, V21, P497, DOI 10.1007/BF00762521; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; LEE AC, 1994, J BIOL CHEM, V269, P30974; LEHNINGER AL, 1978, P NATL ACAD SCI USA, V75, P1690, DOI 10.1073/pnas.75.4.1690; LENARTOWICZ E, 1992, BIOCHEM BIOPH RES CO, V184, P1088, DOI 10.1016/0006-291X(92)90703-N; LOTSCHER HR, 1979, P NATL ACAD SCI USA, V76, P4340, DOI 10.1073/pnas.76.9.4340; MCCORMACK T, 1994, CELL, V79, P1133, DOI 10.1016/0092-8674(94)90004-3; MEURY J, 1990, ARCH MICROBIOL, V154, P475, DOI 10.1007/BF00245231; MILKMAN R, 1994, P NATL ACAD SCI USA, V91, P3510, DOI 10.1073/pnas.91.9.3510; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; NICHOLLS DG, 1980, BIOCHEM J, V188, P113, DOI 10.1042/bj1880113; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; PETRONILLI V, 1989, FEBS LETT, V259, P137, DOI 10.1016/0014-5793(89)81513-3; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; REED DJ, 1995, BBA-MOL BASIS DIS, V1271, P43, DOI 10.1016/0925-4439(95)00008-R; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; SCHWEIZER M, 1994, BIOCHEM PHARMACOL, V48, P967, DOI 10.1016/0006-2952(94)90367-0; SZABO I, 1992, J BIOL CHEM, V267, P2940; SZABO I, 1991, J BIOL CHEM, V266, P3376; SZABO I, 1993, FEBS LETT, V330, P201, DOI 10.1016/0014-5793(93)80273-W; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; WOLKOWICZ PE, 1980, J BIOL CHEM, V255, P348; ZAHLER WL, 1968, J BIOL CHEM, V243, P716; ZAHREBELSKI G, 1995, HEPATOLOGY, V21, P1361, DOI 10.1002/hep.1840210521; ZORATTI M, 1986, BIOCHEMISTRY-US, V25, P760, DOI 10.1021/bi00352a004; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	55	376	385	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6746	6751		10.1074/jbc.271.12.6746	http://dx.doi.org/10.1074/jbc.271.12.6746			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636095	hybrid			2022-12-25	WOS:A1996UB15700030
J	Philo, JS; Wen, J; Wypych, J; Schwartz, MG; Mendiaz, EA; Langley, KE				Philo, JS; Wen, J; Wypych, J; Schwartz, MG; Mendiaz, EA; Langley, KE			Human stem cell factor dimer forms a complex with two molecules of the extracellular domain of its receptor, kit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR DISULFIDE LINKAGES; TYROSINE KINASE RECEPTOR; HUMAN GROWTH-HORMONE; HAMSTER OVARY CELLS; ONCOGENE C-KIT; PROTO-ONCOGENE; W-LOCUS; GENE-PRODUCT; SI-LOCUS; LIGAND	Stem cell factor (SCF) is a cytokine that is active toward hematopoietic progenitor cells and other cell types, including germ cells, melanocytes, and mast cells, which express its receptor, the tyrosine kinase, Kit. SCF exists as noncovalently associated dimer at concentrations where it has been possible to study its quaternary structure; it stimulates dimerization and autophosphorylation of Kit at the cell surface, We have used recombinant versions of human SCF and human Kit extracellular domain (sKit) to study SCF-Kit interactions, By size exclusion chromatography, plus various physical chemical methods including light scattering, sedimentation equilibrium, and titration calorimetry, we demonstrate the formation of complexes containing a dimer of SCF (unglycosylated SCF1-165) plus two molecules of sKit, The concentrations of SCF and sKit in these studies were in the range of 0.35-16.2 mu M. The data are analyzed and discussed in the context of several possible models for complex formation, In particular, the sedimentation data are not consistent with a model involving cooperative binding. The K-d estimate for SCF-sKit interaction, obtained by sedimentation equilibrium, is about 17 nM at 25 degrees C, With glycosylated SCF1-165, the K-d is considerably higher.	AMGEN INC,THOUSAND OAKS,CA 91320	Amgen			Philo, John S/A-8804-2009	Philo, John S/0000-0003-3418-0356				ANDERSSON M, 1992, J BIOL CHEM, V267, P11260; ARAKAWA T, 1992, ANAL BIOCHEM, V203, P53, DOI 10.1016/0003-2697(92)90042-6; ARAKAWA T, 1991, J BIOL CHEM, V266, P18942; ARAKAWA T, 1994, ARCH BIOCHEM BIOPHYS, V308, P267, DOI 10.1006/abbi.1994.1037; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; BRIZZI MF, 1994, ONCOGENE, V9, P1583; BROUDY VC, 1994, BLOOD, V83, P2145; BROUDY VC, 1992, BLOOD, V80, P60; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DAS SK, 1982, J BIOL CHEM, V257, P13679; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOLCI S, 1991, NATURE, V352, P809, DOI 10.1038/352809a0; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FUJIO K, 1994, LAB INVEST, V70, P511; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GLOCKER MO, 1993, BIOCHEMISTRY-US, V32, P482, DOI 10.1021/bi00053a012; HANIU M, 1993, BIOCHEMISTRY-US, V32, P2431, DOI 10.1021/bi00060a039; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; JOHNSSON A, 1982, BIOCHEM BIOPH RES CO, V104, P66, DOI 10.1016/0006-291X(82)91941-6; LANGLEY KE, 1992, ARCH BIOCHEM BIOPHYS, V295, P21, DOI 10.1016/0003-9861(92)90482-C; LANGLEY KE, 1993, BLOOD, V81, P656; LAUE TM, 1992, ANAL ULTRACENTRIFUGA, V90; LAUFFENBURGER DA, 1993, RECEPTORS, P160; LEV S, 1993, MOL CELL BIOL, V13, P2224, DOI 10.1128/MCB.13.4.2224; LEV S, 1992, J BIOL CHEM, V267, P15970; LEV S, 1992, J BIOL CHEM, V267, P10866; LIU YC, 1993, BIOCHEM BIOPH RES CO, V197, P1094, DOI 10.1006/bbrc.1993.2590; LU HS, 1995, BIOCHEM J, V305, P563, DOI 10.1042/bj3050563; LU HS, 1992, ARCH BIOCHEM BIOPHYS, V298, P150, DOI 10.1016/0003-9861(92)90106-7; MAEDA H, 1992, DEVELOPMENT, V116, P369; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P299, DOI 10.1042/bj1130299; MATSUI Y, 1991, NATURE, V353, P750, DOI 10.1038/353750a0; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PHILO J, 1994, J BIOL CHEM, V269, P27840; ROSNET O, 1991, GENOMICS, V9, P380, DOI 10.1016/0888-7543(91)90270-O; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; TOKSOZ D, 1992, P NATL ACAD SCI USA, V89, P7350, DOI 10.1073/pnas.89.16.7350; TURNER AM, 1995, BLOOD, V85, P2052, DOI 10.1182/blood.V85.8.2052.bloodjournal8582052; TURNER AM, 1992, BLOOD, V80, P374; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDENBARK GR, 1992, ONCOGENE, V7, P1259; WARD SM, 1994, J PHYSIOL-LONDON, V480, P91, DOI 10.1113/jphysiol.1994.sp020343; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; WYPYCH J, 1995, BLOOD, V85, P66, DOI 10.1182/blood.V85.1.66.bloodjournal85166; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	52	53	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6895	6902		10.1074/jbc.271.12.6895	http://dx.doi.org/10.1074/jbc.271.12.6895			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636116	hybrid			2022-12-25	WOS:A1996UB15700051
J	Coleman, BA; Taylor, P				Coleman, BA; Taylor, P			Regulation of acetylcholinesterase expression during neuronal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; EMBRYONAL CARCINOMA-CELLS; MOLECULAR-FORMS; MAMMALIAN ACETYLCHOLINESTERASE; CAUDATE-NUCLEUS; BRAIN; GENE; MATURATION; PHENOTYPE; CORTEX	We have examined the developmental expression of acetylcholinesterase (AChE) during the process of neuronal differentiation from a pluripotent stem cell, P19 embryonic carcinoma cells form embryoid bodies, which, when cultured with retinoic acid, are induced to differentiate into neurons and glia. No AChE activity is present in the undifferentiated stem cells, and mRNA protection analyses do not detect AChE mRNA. Commitment to a neuronal differentiation pathway results in increased levels of AChE mRNA, production of a tetrameric form of the enzyme, and secretion of AChE into the culture medium. Concomitant with subsequent morphological differentiation into neurons, enzyme secretion diminishes and AChE becomes largely tethered to the neuronal cell membranes. The enzyme is attached to the cell surface as a globular tetramer. Its hydrodynamic properties are consistent with association through a noncatalytic hydrophobic subunit rather than anchorage by a glycophospholipid tail. No change in the rate of transcription of the Ache gene was detected during the course of differentiation, suggesting that the gene is actively transcribed at very early stages of development. Results suggest that stabilization of a labile mRNA governs the increase in AChE mRNA and gene product. The studies presented indicate that an early event in neuronal differentiation is the stabilization of the mRNA leading to expression of a secreted form of AChE. A subsequent step associated with neurite outgrowth results in a transition from secretion of the tetrameric enzyme to its localization on the cell membrane.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093	University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360, R01GM018360] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18360, GM24437] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSELMET A, 1994, J NEUROCHEM, V62, P2158; BEAR MF, 1985, J COMP NEUROL, V237, P519, DOI 10.1002/cne.902370408; BOSCHETTI N, 1994, NEUROCHEM RES, V19, P359, DOI 10.1007/BF00971586; BRIMIJOIN S, 1983, PROG NEUROBIOL, V21, P291, DOI 10.1016/0301-0082(83)90015-1; CHEUN JE, 1991, INT J DEV NEUROSCI, V9, P391, DOI 10.1016/0736-5748(91)90061-P; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Denis-Donini S, 1980, Curr Top Dev Biol, V16, P323; DIMPFEL W, 1977, J NEUROCHEM, V29, P329, DOI 10.1111/j.1471-4159.1977.tb09626.x; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FUENTES ME, 1993, NEURON, V10, P679, DOI 10.1016/0896-6273(93)90169-R; GENNARI K, 1987, J NEUROCHEM, V49, P12, DOI 10.1111/j.1471-4159.1987.tb03386.x; GREENBERG ME, 1987, CURRENT PROTOCOLS MO; GREENE LA, 1981, J BIOL CHEM, V256, P6363; HAMMOND P, 1994, P NATL ACAD SCI USA, V91, P10933, DOI 10.1073/pnas.91.23.10933; HOWE JG, 1986, P NATL ACAD SCI USA, V83, P9006, DOI 10.1073/pnas.83.23.9006; INESTROSA NC, 1987, J BIOL CHEM, V262, P4441; INESTROSA NC, 1994, NEUROSCI LETT, V173, P155, DOI 10.1016/0304-3940(94)90172-4; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; KARPEL R, 1994, EXP CELL RES, V210, P268, DOI 10.1006/excr.1994.1039; LAYER PG, 1995, PROG HISTOCHEM CYTOC, V29, P1; LAZAR M, 1980, J NEUROCHEM, V35, P1067, DOI 10.1111/j.1471-4159.1980.tb07860.x; LEVINE AJ, 1974, J CELL PHYSIOL, V84, P311, DOI 10.1002/jcp.1040840217; LI Y, 1993, J BIOL CHEM, V268, P5790; LI Y, 1991, J BIOL CHEM, V266, P23083; LIAO J, 1993, J NEUROCHEM, V61, P1127, DOI 10.1111/j.1471-4159.1993.tb03629.x; LUO ZG, 1994, J BIOL CHEM, V269, P27216; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MCBURNEY MW, 1988, J NEUROSCI, V8, P1063; RIEGER F, 1976, J NEUROCHEM, V27, P121, DOI 10.1111/j.1471-4159.1976.tb01553.x; ROBERTSON RT, 1985, DEV BRAIN RES, V21, P203, DOI 10.1016/0165-3806(85)90209-3; ROBERTSON RT, 1993, NEWS PHYSIOL SCI, V8, P266; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SHARMA S, 1988, DEV BIOL, V125, P246, DOI 10.1016/0012-1606(88)90208-4; STAINES WA, 1994, NEUROSCIENCE, V58, P735, DOI 10.1016/0306-4522(94)90451-0; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; TERESKY AK, 1974, J CELL PHYSIOL, V84, P319, DOI 10.1002/jcp.1040840218; WADE PD, 1980, DEV NEUROSCI-BASEL, V3, P101, DOI 10.1159/000112383	39	88	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4410	4416						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626792				2022-12-25	WOS:A1996TW96000070
J	Deissler, H; BehnKrappa, A; Doerfler, W				Deissler, H; BehnKrappa, A; Doerfler, W			Purification of nuclear proteins from human HeLa cells that bind specifically to the unstable tandem repeat (CGG), in the human FMR1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRAGILE-X-SYNDROME; DNA METHYLATION; CPG ISLAND; HUMAN-DISEASE; PATTERNS; TRANSCRIPTION; SEQUENCES; SITES; IDENTIFICATION; EXPRESSION	Autonomous expansions of trinucleotide repeats with the general structure 5'-d(CNG)(n)-3' are associated with several human genetic diseases. We have characterized nuclear proteins binding to the unstable 5'-d(CGG)(n)-3' repeat. Its expansion in the human FMR1 gene leads to the fragile X syndrome, one of the most frequent causes of mental retardation in human males. Electrophoretic mobility shift assays using nuclear extracts from several human and other mammalian cell lines and from primary human cells demonstrated specific binding to double-stranded DNA fragments containing only a 5'-d(CGG)(17)-3' repeat or the repeat and flanking genomic sequences of the human FMR1 gene. Protein binding was inhibited by complete methylation of the trinucleotide repeat. The complex formed with crude nuclear extract apparently did not contain the human transcription factor Sp1 that binds to a characteristic GC-rich sequence. A 20-kDa protein involved in specific binding to the double-stranded 5'-d(CGG)(17)-3' repeat was purified from HeLa nuclear extracts by DNA affinity chromatography.	UNIV COLOGNE, INST GENET, D-50931 COLOGNE, GERMANY	University of Cologne				Deissler, Heidrun/0000-0003-0086-7811				BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BARRETT P, 1987, NUCLEIC ACIDS RES, V15, P2719, DOI 10.1093/nar/15.6.2719; BEHNKRAPPA A, 1994, HUM MUTAT, V3, P19, DOI 10.1002/humu.1380030104; BEHNKRAPPA A, 1991, GENOMICS, V11, P1, DOI 10.1016/0888-7543(91)90095-V; BINGHAM PM, 1995, NAT GENET, V9, P191, DOI 10.1038/ng0295-191; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; CHAMBERLIN M, 1962, P NATL ACAD SCI USA, V48, P81, DOI 10.1073/pnas.48.1.81; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOERFLER W, 1991, BIOL CHEM H-S, V372, P557; EICK D, 1980, J VIROL, V36, P41, DOI 10.1128/JVI.36.1.41-49.1980; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HANSEN RS, 1992, HUM MOL GENET, V1, P571, DOI 10.1093/hmg/1.8.571; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; HORNSTRA IK, 1993, HUM MOL GENET, V2, P1659; JONES C, 1995, NATURE, V376, P145, DOI 10.1038/376145a0; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; KORNBERG A, 1964, P NATL ACAD SCI USA, V51, P315, DOI 10.1073/pnas.51.2.315; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; MITCHELL JE, 1995, NUCLEIC ACIDS RES, V23, P1876, DOI 10.1093/nar/23.11.1876; NANCARROW JK, 1995, HUM MOL GENET, V4, P367, DOI 10.1093/hmg/4.3.367; NANCARROW JK, 1994, SCIENCE, V264, P1938, DOI 10.1126/science.8009225; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; PARRISH JE, 1994, NAT GENET, V8, P229, DOI 10.1038/ng1194-229; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RICHARDS RI, 1993, HUM MOL GENET, V2, P1429, DOI 10.1093/hmg/2.9.1429; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; RIGGINS GJ, 1992, NAT GENET, V2, P186, DOI 10.1038/ng1192-186; SCHETTER C, 1993, J VIROL, V67, P6973, DOI 10.1128/JVI.67.12.6973-6978.1993; SCHLOTTERER C, 1992, NUCLEIC ACIDS RES, V20, P211, DOI 10.1093/nar/20.2.211; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; SUTHERLAND GR, 1979, AM J HUM GENET, V31, P125; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; WHITTAKER JL, 1984, MOL CELL BIOL, V4, P110, DOI 10.1128/MCB.4.1.110	43	40	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4327	4334						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626781				2022-12-25	WOS:A1996TW96000059
J	Fujita, M; Kiyono, T; Hayashi, Y; Ishibashi, M				Fujita, M; Kiyono, T; Hayashi, Y; Ishibashi, M			hCDC47, a human member of the MCM family - Dissociation of the nucleus-bound form during S phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; DNA-REPLICATION; SUBCELLULAR-LOCALIZATION; YEAST; PROTEINS; MAINTENANCE; MUTANTS; ANTIGEN; GENES	hCDC47 is a putative human homologue of yeast CDC47 and a member of the MCM protein family, which has been implicated in the regulatory machinery causing DNA to replicate only once in the S phase. In the present study, we performed an initial characterization of hCDC47. We found that hCDC47 protein was present in the nucleus of cultured human cells in two different forms; one extractable by a non-ionic detergent and the other resistant to such extraction and tightly associated with the nucleus. The levels of the nucleus-bound form gradually diminished during S phase progression, although the total amount of nuclear hCDC47 protein remained relatively constant, suggesting that the nucleus-bound form becomes dissociated from the nuclear structure during DNA replication. This behavior of hCDC47 protein is very similar to that of other mammalian MCM proteins reported recently. We also found that expression of hCDC47 mRNA was repressed in quiescent cells but was induced at the late G(1) to S phase by growth factor stimulation. Together, these findings indicate that hCDC47 protein together with other MCM proteins participates in the regulation of mammalian DNA replication.	AICHI CANC CTR,RES INST,LAB VIRAL ONCOL,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Aichi Cancer Center			Kiyono, Tohru/H-5834-2011	Fujita, Masatoshi/0000-0001-6617-2452				BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; BURKHART R, 1995, EUR J BIOCHEM, V228, P431; CHEN YR, 1992, P NATL ACAD SCI USA, V89, P10459, DOI 10.1073/pnas.89.21.10459; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COXON A, 1992, NUCLEIC ACIDS RES, V20, P5571, DOI 10.1093/nar/20.21.5571; DALTON S, 1995, P NATL ACAD SCI USA, V92, P2514, DOI 10.1073/pnas.92.7.2514; FUJITA M, 1995, ONCOGENE, V11, P15; GIBSON S, 1987, UCLA S MOL CELL BIOL, V47, P341; GIBSON SI, 1990, MOL CELL BIOL, V10, P5707, DOI 10.1128/MCB.10.11.5707; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HU B, 1993, NUCLEIC ACIDS RES, V21, P5289, DOI 10.1093/nar/21.23.5289-a; KIMURA H, 1995, NUCLEIC ACIDS RES, V23, P2097, DOI 10.1093/nar/23.12.2097; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MAINE GT, 1984, GENETICS, V106, P365; MERRILL GF, 1992, BIOESSAYS, V14, P823, DOI 10.1002/bies.950141206; MUSAHL C, 1995, EUR J BIOCHEM, V230, P1096, DOI 10.1111/j.1432-1033.1995.tb20660.x; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHULTE D, 1995, J CELL SCI, V108, P1381; SPRINGER PS, 1995, SCIENCE, V268, P877, DOI 10.1126/science.7754372; THOMMES P, 1992, NUCLEIC ACIDS RES, V20, P1069, DOI 10.1093/nar/20.5.1069; TODOROV IT, 1994, J CELL SCI, V107, P253; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149	31	68	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4349	4354						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626784				2022-12-25	WOS:A1996TW96000062
J	Petanceska, S; Canoll, P; Devi, LA				Petanceska, S; Canoll, P; Devi, LA			Expression of rat cathepsin S in phagocytic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENTATE GYRUS; CYSTEINE PROTEINASES; ALZHEIMERS-DISEASE; HEPARAN-SULFATE; BRAIN; CLONING; PROTEOGLYCAN; DEGRADATION; PLASTICITY; ACTIVATION	Cysteine lysosomal proteases are essential for turnover of intracellular and extracellular proteins. These enzymes are strongly implicated in normal and pathological processes involving tissue remodeling. Among the cysteine proteases, cathepsin S seems to be best suited for such a process since it retains most of its enzymatic activity at neutral pH. In situ hybridization analyses of the adult rat brain, spleen, and lung reveal that cathepsin S mRNA is preferentially expressed in cells of mononuclear-phagocytic origin. After entorhinal cortex lesion of adult rat brain (a paradigm for neuronal degeneration and reactive synaptogenesis), cathepsin S mRNA is dramatically increased in activated microglia in the deafferented dentate gyrus and in macrophages at the wound site, suggesting a role in lesion-induced tissue remodeling. This possibility is further supported by the finding that cathepsin S degrades a number of extracellular matrix molecules at neutral pH and by the finding that inflammatory mediators stimulate its secretion from the microglia and macrophages. These data suggest that cathepsin S is an important player in degenerative disorders associated with the cells of the mononuclear phagocytic system.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	New York University			Devi P, Lakshmi/GXM-5982-2022	Devi P, Lakshmi/0000-0001-9274-4776	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026880, R29NS026880, K04NS001788] Funding Source: NIH RePORTER; NINDS NIH HHS [NS K04 1788, NS 26880] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS DO, 1984, ANNU REV IMMUNOL, V2, P283, DOI 10.1146/annurev.immunol.2.1.283; AHMED NK, 1992, BIOCHEM PHARMACOL, V44, P1201, DOI 10.1016/0006-2952(92)90385-V; AMARAL DG, 1980, J COMP NEUROL, V194, P171, DOI 10.1002/cne.901940109; BROMME D, 1993, J BIOL CHEM, V268, P4832; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; CANOLL PD, 1993, DEV BRAIN RES, V75, P293, DOI 10.1016/0165-3806(93)90035-9; CARBONETTO S, 1984, TRENDS NEUROSCI, V7, P382, DOI 10.1016/S0166-2236(84)80061-2; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; FEDOROFF S, 1984, J NEUROSCI RES, V12, P15, DOI 10.1002/jnr.490120103; FONG D, 1991, BIOMED BIOCHIM ACTA, V50, P595; GEHRMANN J, 1991, ACTA NEUROPATHOL, V82, P442, DOI 10.1007/BF00293378; GRUMET M, 1994, J BIOL CHEM, V269, P12142; KATUNUMA N, 1989, INTRACELLULAR PROTEO; KIRSCHKE H, 1986, BIOCHEM J, V240, P455, DOI 10.1042/bj2400455; LAH TT, 1992, BIOL CHEM H-S, V373, P594; LEMERE CA, 1995, AM J PATHOL, V146, P848; LETOURNEAU PC, 1994, J NEUROSCI, V14, P915, DOI 10.1523/JNEUROSCI.14-03-00915.1994; LIESI P, 1984, EMBO J, V3, P683, DOI 10.1002/j.1460-2075.1984.tb01867.x; MACIEWICZ RA, 1990, FEBS LETT, V269, P189, DOI 10.1016/0014-5793(90)81151-D; MATTHEWS DA, 1976, BRAIN RES, V115, P1, DOI 10.1016/0006-8993(76)90819-2; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; NAKAJIMA K, 1992, J NEUROCHEM, V58, P1401, DOI 10.1111/j.1471-4159.1992.tb11356.x; PERRY HV, 1988, TRENDS NEUROSCI, V11, P85; PETANCESKA S, 1992, J BIOL CHEM, V267, P26038; PETANCESKA S, 1994, NEUROSCIENCE, V59, P729, DOI 10.1016/0306-4522(94)90190-2; QIAN F, 1991, BIOMED BIOCHIM ACTA, V50, P531; RAUCH U, 1992, J BIOL CHEM, V267, P19536; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; SACERDOTE P, 1993, GLIA, V9, P305, DOI 10.1002/glia.440090408; Sambrook J, 1989, MOL CLONING LABORATO; SHAFFER LM, 1993, 24 ANN M SOC NEUR, V19, P1008; SHI GP, 1992, J BIOL CHEM, V267, P7258; SHI GP, 1994, J BIOL CHEM, V269, P11530; Sloane B F, 1990, Semin Cancer Biol, V1, P137; SNOW AD, 1990, AM J PATHOL, V137, P1253; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; SU JH, 1992, NEUROSCIENCE, V51, P801, DOI 10.1016/0306-4522(92)90521-3; THOMAS EW, 1992, BRAIN RES REV, V9, P61; WIEDERANDERS B, 1992, J BIOL CHEM, V267, P13708; XIN XQ, 1992, ARCH BIOCHEM BIOPHYS, V299, P334, DOI 10.1016/0003-9861(92)90283-3	41	116	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4403	4409						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626791				2022-12-25	WOS:A1996TW96000069
J	Brizzi, MF; Aronica, MG; Rosso, A; Bagnara, GP; Yarden, Y; Pegoraro, L				Brizzi, MF; Aronica, MG; Rosso, A; Bagnara, GP; Yarden, Y; Pegoraro, L			Granulocyte-macrophage colony-stimulating factor stimulates JAK2 signaling pathway and rapidly activates p93(fes), STAT1 p91, and STAT3 p92 in polymorphonuclear leukocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; DNA-BINDING PROTEINS; HUMAN-NEUTROPHILS; INTERFERON-GAMMA; RESPIRATORY BURST; GROWTH-FACTOR; GM-CSF; TRANSDUCTION PATHWAY; TRANSCRIPTION FACTOR; MULTIPLE CYTOKINES	Granulocyte-macrophage colony-stimulating factor (GM-CSF), supports proliferation, differentiation, and functional activation of hemopoietic cells by its interaction with a heterodimeric receptor. Although GM-CSF receptor is devoid of tyrosine kinase enzymatic activity, GM-CSF-induced peripheral blood polymorphonuclear leukocytes (PMN) functional activation is mediated by the phosphorylation of a large number of intracellular signaling molecules. We have previously shown that JAK2 becomes tyrosine-phosphorylated in response to GM-CSF in PMN. In the present study we demonstrate that also the signal transducers and activators of transcription (STAT) family members STAT1 p91 and STAT3 p92 and the product of the c-fps/fes protooncogene become tyrosine-phosphorylated upon GM-CSF stimulation and physically associated with both GM-CSF receptor beta common subunit and JAK2. Moreover GM-CSF was able to induce JAK2 and p93(fes) catalytic activity. We also demonstrate that the association of the GM-CSF receptor beta common subunit with JAK2 is ligand-dependent. Finally we demonstrate that GM-CSF induces a DNA-binding complex that contains both p91 and p92, These results identify a new signal transduction pathway activated by GM-CSF and provide a mechanism for rapid activation of gene expression in GM-CSF-stimulated PMN.	UNIV TURIN,DIPARTIMENTO SCI BIOMED & ONCOL UMANA,SEZ CLIN,I-10126 TURIN,ITALY; UNIV BOLOGNA,IST ISTOL & EMBRIOL,CTR INTERDIPARTIMENTALE RIC GIORGIO PRODI,I-40126 BOLOGNA,ITALY; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	University of Turin; University of Bologna; Weizmann Institute of Science			YARDEN, YOSEF/K-1467-2012; Brizzi, Maria Felice/J-7882-2016					ARNAOUT MA, 1986, J CLIN INVEST, V78, P597, DOI 10.1172/JCI112615; BERKOW RL, 1990, BLOOD, V75, P2445; BRIZZI MF, 1994, J BIOL CHEM, V269, P31680; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CUI Y, 1994, J IMMUNOL, V152, P5420; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAHINDEN CA, 1988, J EXP MED, V167, P1281, DOI 10.1084/jem.167.4.1281; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DIPERSIO JF, 1988, J IMMUNOL, V140, P4315; FLEISCHMANN J, 1986, BLOOD, V68, P708; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOMEZCAMBRONERO J, 1991, J BIOL CHEM, V266, P6240; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HARPUR AG, 1992, ONCOGENE, V7, P1347; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KUBES P, 1990, AM J PHYSIOL, V259, pG859, DOI 10.1152/ajpgi.1990.259.5.G859; LAMB P, 1994, BLOOD, V83, P2063; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCOLL SR, 1990, J IMMUNOL, V145, P3047; MCCOLL SR, 1991, BLOOD, V78, P1842; MCCOLL SR, 1991, J IMMUNOL, V146, P1204; MIURA O, 1994, BLOOD, V84, P1501; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NACCACHE PH, 1994, BLOOD, V84, P616, DOI 10.1182/blood.V84.2.616.bloodjournal842616; NACCACHE PH, 1988, J IMMUNOL, V140, P3541; NACCACHE PH, 1990, BLOOD, V76, P2098; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; NATHAN CF, 1989, BLOOD, V73, P301; OKUDA K, 1991, BLOOD, V78, P1928; OKUDA K, 1992, BLOOD, V79, P2880; PALES E, 1991, EMBO J, V10, P2077; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; ROLLET E, 1994, J IMMUNOL, V153, P353; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SOCINSKI MA, 1988, BLOOD, V72, P691; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TIAN SS, 1994, BLOOD, V84, P1760; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERBRUGGEN T, 1995, BLOOD, V85, P1442, DOI 10.1182/blood.V85.6.1442.bloodjournal8561442; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEISBART RH, 1986, J IMMUNOL, V137, P3584; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WIRTHMUELLER U, 1989, J IMMUNOL, V142, P3213; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	63	123	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3562	3567						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631962				2022-12-25	WOS:A1996TV72400036
J	Costello, CA; Kelleher, NL; Abe, M; McLafferty, FW; Begley, TP				Costello, CA; Kelleher, NL; Abe, M; McLafferty, FW; Begley, TP			Mechanistic studies on thiaminase I - Overexpression and identification of the active site nucleophile	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BONDS; PROTEINS; CLEAVAGE; SEQUENCE; PEPTIDES; ANALOGS	Thiaminase I (EC 2.5.1.2) catalyzes the replacement of the thiazole moiety of thiamin with a wide variety of nucleophiles. Here we report the sequencing of a thiaminase I clone from Bacillus thiaminolyticus, the overexpression of the cloned gene in Escherichia coli, and the purification and characterization of the enzyme. Recombinant thiaminase I functions as a monomer with a K-m for thiamin of 3.7 +/- 0.6 mu M and a k(cat) of 34 s(-1). Electrospray ionization Fourier-transform mass spectrometry identified a single sequencing error and demonstrated heterogeneity, finding molecular weights of 42, 127, 42, 198, and 42,255 due to added Ala and Gly-Ala at the amino terminus. Similar analysis of the 4-amino-2-methyl-6-chloropyrimidine (8) inactivated enzyme indicated that the active site nucleophile involved in catalysis of the substitution reaction is located between Pro(79) and Thr(177). Subsequent cysteine-specific labeling and site-directed mutagenesis identified Cys(113) as the active site nucleophile.	CORNELL UNIV,BAKER LAB 120,DEPT CHEM,ITHACA,NY 14853; YAMAGUCHI UNIV,SCH MED,DEPT MICROBIOL,UBE,YAMAGUCHI 755,JAPAN	Cornell University; Yamaguchi University			Begley, Tadhg/B-5801-2015		NIDDK NIH HHS [DK44083] Funding Source: Medline; NIGMS NIH HHS [GM16609, T32 GM08384] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK044083, R56DK044083, R01DK044083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM016609, T32GM008384, R37GM016609] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE M, 1987, BIOCHIM BIOPHYS ACTA, V909, P213, DOI 10.1016/0167-4781(87)90080-7; BACKSTROM AD, 1995, J AM CHEM SOC, V117, P2351, DOI 10.1021/ja00113a025; BEU SC, 1993, J AM SOC MASS SPECTR, V4, P557, DOI 10.1016/1044-0305(93)85017-R; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN M, 1994, J BACTERIOL, V176, P5796, DOI 10.1128/JB.176.18.5796-5801.1994; DOUTHIT HA, 1966, ARCH BIOCHEM BIOPHYS, V113, P331, DOI 10.1016/0003-9861(66)90194-9; DUFFY P, 1981, AM J CLIN NUTR, V34, P1584, DOI 10.1093/ajcn/34.8.1584; EARL JW, 1994, NATURE, V368, P683, DOI 10.1038/368683a0; Evans W C, 1975, Vitam Horm, V33, P467; FUJITA A, 1972, J VITAMINOL, V18, P67, DOI 10.5925/jnsv1954.18.67; FUJITA A, 1954, ADV ENZYMOL REL S BI, V15, P389; HAYASHI R, 1957, NUTR REV, V15, P65, DOI 10.1111/j.1753-4887.1957.tb00468.x; HITZEMAN RA, 1983, SCIENCE, V219, P620, DOI 10.1126/science.6186023; HUTTER JA, 1987, BIOCHEMISTRY-US, V26, P1969, DOI 10.1021/bi00381a028; KELLEHER NL, 1995, J AM SOC MASS SPECTR, V6, P981, DOI 10.1016/1044-0305(95)00584-Z; KIMURA Y, 1987, EXPERIENTIA, V43, P888, DOI 10.1007/BF01951652; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEADER IG, 1970, METHODS ENZYMOL A, V18, P207; LIENHARD GE, 1970, BIOCHEMISTRY-US, V9, P3011, DOI 10.1021/bi00817a012; LINGAPPA VR, 1977, P NATL ACAD SCI USA, V74, P2432, DOI 10.1073/pnas.74.6.2432; LITTLE DP, 1994, ANAL CHEM, V66, P2809, DOI 10.1021/ac00090a004; MURATA K, 1982, ANN NY ACAD SCI, V378, P146, DOI 10.1111/j.1749-6632.1982.tb31193.x; NICEWONGER R, 1995, IN PRESS BIOORG CHEM; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; PUZACH SS, 1984, BIOCHEMISTRY-MOSCOW+, V49, P1010; SENKO MW, 1994, ANAL CHEM, V66, P2801, DOI 10.1021/ac00090a003; THANNHAUSER TW, 1984, ANAL BIOCHEM, V138, P181, DOI 10.1016/0003-2697(84)90786-3; THANNHAUSER TW, 1987, METHOD ENZYMOL, V143, P115; URAY G, 1993, BIOORG CHEM, V21, P294, DOI 10.1006/bioo.1993.1025; VANDERHORN PB, 1993, J BACTERIOL, V175, P982, DOI 10.1128/JB.175.4.982-992.1993; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; WITTLIFF J, 1970, METHOD ENZYMOL, V8, P229; WITTLIFF JL, 1968, BIOCHEMISTRY-US, V7, P736, DOI 10.1021/bi00842a032	35	50	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3445	3452						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631946	hybrid			2022-12-25	WOS:A1996TV72400020
J	Tsang, SX; Morris, GF; Lu, M; Morris, CB				Tsang, SX; Morris, GF; Lu, M; Morris, CB			TATA-dependent repression of human immunodeficiency virus type-1 transcription by the adenovirus E1A 243R oncoprotein	ONCOGENE			English	Article						transcription; E1A; HIV; gene regulation; TATA	LONG-TERMINAL REPEAT; NUCLEAR ANTIGEN PROMOTER; BINDING PROTEIN; ACTIVATES TRANSCRIPTION; FUNCTIONAL DOMAINS; CELLULAR PROTEINS; T-CELLS; GENE; EXPRESSION; IDENTIFICATION	Human adenovirus E1A oncoprotein activates or represses transcription from a variety of viral and cellular promoters by several complex mechanisms. The E1A products, 289R and 243R, have differential effects on transcription directed by the human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR). Previous reports indicate that repression of HIV-1 LTR-directed gene expression by E1A 243R is mediated through the kappa B enhancer elements located between nucleotides -105 and -82 relative to the transcription initiation start site (+1). Results from this study suggest a novel mechanism for transcriptional repression of the HIV-1 LTR by E1A 243R that is enhancer-independent and that is mediated through basal HIV-1 promoter elements. Transient expression assays, in which 5'-truncated or site-directed mutant HIV-1 LTR-CAT reporters were tested for their response to repression mediated by wild-type or mutant 243R, demonstrate that LTR sequences upstream of -31 relative to the transcription initiation start site (+1) and inclusive of the enhancer elements are dispensable for 243R-mediated repression. The ability of 243R to repress HIV-1 basal promoter activity requires both an intact N-terminus of E1A 243R and the TATA element within the HIV-1 promoter. These results support a novel mechanism for E1A 243R-induced transcriptional repression that is enhancer-independent and that targets directly the general transcription machinery.	TULANE UNIV, MED CTR, CTR CANC, DEPT LAB MED & PATHOL, NEW ORLEANS, LA 70112 USA; GEORGIA INST TECHNOL, SCH BIOL, ATLANTA, GA 30332 USA	Tulane University; University System of Georgia; Georgia Institute of Technology					NIAID NIH HHS [AI32880] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032880] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BASU A, 1993, J BIOL CHEM, V268, P4188; BERKHOUT B, 1992, J VIROL, V66, P139, DOI 10.1128/JVI.66.1.139-149.1992; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BOYER TG, 1993, GENE DEV, V7, P1810, DOI 10.1101/gad.7.9.1810; CHOW LT, 1979, J MOL BIOL, V134, P265, DOI 10.1016/0022-2836(79)90036-6; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FANG L, 1994, NATURE, V368, P520; GARCIA JA, 1987, EMBO J, V6, P3761, DOI 10.1002/j.1460-2075.1987.tb02711.x; GIACCA M, 1992, VIROLOGY, V186, P133, DOI 10.1016/0042-6822(92)90067-Y; GLENN GM, 1985, J VIROL, V56, P66, DOI 10.1128/JVI.56.1.66-74.1985; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARRICH D, 1989, J VIROL, V63, P2585, DOI 10.1128/JVI.63.6.2585-2591.1989; HERRMANN CH, 1989, MOL CELL BIOL, V9, P5412, DOI 10.1128/MCB.9.12.5412; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; INOSTROZA JA, 1992, CELL, V70, P477; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; JONES K A, 1989, New Biologist, V1, P127; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KANNABIRAN C, 1993, J VIROL, V67, P507, DOI 10.1128/JVI.67.1.507-515.1993; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KRAUS VB, 1994, P NATL ACAD SCI USA, V91, P6279, DOI 10.1073/pnas.91.14.6279; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MARGOLIS DM, 1994, J VIROL, V68, P905, DOI 10.1128/JVI.68.2.905-910.1994; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NABEL GJ, 1988, SCIENCE, V239, P1299, DOI 10.1126/science.2830675; NEVINS JR, 1991, TRENDS BIOCHEM SCI, V16, P435, DOI 10.1016/0968-0004(91)90171-Q; NEVINS JR, 1989, ADV VIRUS RES, V37, P35; NEVINS JR, 1992, SCIENCE, V258, P424; OKAMOTO T, 1990, VIROLOGY, V177, P606, DOI 10.1016/0042-6822(90)90526-W; RICE AP, 1988, P NATL ACAD SCI USA, V85, P4200, DOI 10.1073/pnas.85.12.4200; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SONG CZ, 1995, J VIROL, V69, P2907, DOI 10.1128/JVI.69.5.2907-2911.1995; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; VENTURA AM, 1990, P NATL ACAD SCI USA, V87, P1310, DOI 10.1073/pnas.87.4.1310; VESCHAMBRE P, 1995, J MOL BIOL, V250, P169, DOI 10.1006/jmbi.1995.0368; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHITE RJ, 1994, SCIENCE, V266, P448, DOI 10.1126/science.7939686; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WU F, 1988, J VIROL, V62, P218, DOI 10.1128/JVI.62.1.218-225.1988; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	58	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	1996	12	4					819	826						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632904				2022-12-25	WOS:A1996TW68600013
J	Quilliam, LA; Hisaka, MM; Zhong, S; Lowry, A; Mosteller, RD; Han, JW; Drugan, JK; Broek, D; Campbell, SL; Der, CJ				Quilliam, LA; Hisaka, MM; Zhong, S; Lowry, A; Mosteller, RD; Han, JW; Drugan, JK; Broek, D; Campbell, SL; Der, CJ			Involvement of the switch 2 domain of Ras in its interaction with guanine nucleotide exchange factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; CATALYTIC DOMAIN; GTP HYDROLYSIS; P21; PROTEIN; MUTANTS; RESIDUES; GAP; IDENTIFICATION; CEREVISIAE	While Ras proteins are activated by stimulated GDP release, which enables acquisition of the active GTP-bound state, little is known about how guanine nucleotide exchange factors (GEFs) interact with Ras to promote this exchange reaction. Here we report that mutations within the switch 2 domain of Ras (residues 62-69) inhibit activation of Ras by the mammalian GEFs, Sos1, and GRF/CDC25(Mm). While mutations in the 62-69 region blocked upstream activation of Ras, they did not disrupt Ras effector functions, including transcriptional activation and transformation of NIH 3T3 cells. Biochemical analysis indicated that the loss of GEF responsiveness of a Ras(69N) mutant was due to a loss of GEF binding, with no change in intrinsic nucleotide exchange activity. Furthermore, structural analysis of Ras(69N) using NMR spectroscopy indicated that mutation of residue 69 had a very localized effect on Ras structure that was limited to alpha-helix 2 of the switch 2 domain. Together, these results suggest that the switch 2 domain of Ras forms a direct interaction with GEFs.	INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT CHEM,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV SO CALIF,DEPT BIOCHEM,NORRIS CANC CTR,LOS ANGELES,CA 90033	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Southern California	Quilliam, LA (corresponding author), INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,635 BARNHILL DR,MS 410,INDIANAPOLIS,IN 46202, USA.		Quilliam, Lawrence/Q-4987-2019; Quilliam, Lawrence/B-6447-2015	campbell, sharon/0000-0003-0311-409X; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA050261, R29CA063139, R29CA064569] Funding Source: NIH RePORTER; NCI NIH HHS [CA64569, CA50261, CA63139] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CARLIER MF, 1987, BIOCHEMISTRY-US, V26, P4428, DOI 10.1021/bi00388a036; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHEN SY, 1994, ONCOGENE, V9, P2691; DELOSKEY RJ, 1994, ARCH BIOCHEM BIOPHYS, V311, P72, DOI 10.1006/abbi.1994.1210; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FASANO O, 1988, EMBO J, V7, P3375, DOI 10.1002/j.1460-2075.1988.tb03210.x; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HAUBRUCK H, 1991, BIOCHIM BIOPHYS ACTA, V1072, P215, DOI 10.1016/0304-419X(91)90015-D; HOWE LR, 1993, ONCOGENE, V8, P2583; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KRAULIS PJ, 1994, BIOCHEMISTRY-US, V33, P3515, DOI 10.1021/bi00178a008; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MOODIE SA, 1995, ONCOGENE, V11, P447; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; PARK WM, 1994, MOL CELL BIOL, V14, P8117, DOI 10.1128/MCB.14.12.8117; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; QUILLIAM LA, 1995, P NATL ACAD SCI USA, V92, P1272, DOI 10.1073/pnas.92.5.1272; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; REINSTEIN J, 1991, J BIOL CHEM, V266, P17700; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; STOUTEN PFW, 1993, FEBS LETT, V320, P1, DOI 10.1016/0014-5793(93)81644-F; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	44	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11076	11082		10.1074/jbc.271.19.11076	http://dx.doi.org/10.1074/jbc.271.19.11076			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626650	hybrid			2022-12-25	WOS:A1996UJ94400010
J	RodriguezCrespo, I; Gerber, NC; deMontellano, PRO				RodriguezCrespo, I; Gerber, NC; deMontellano, PRO			Endothelial nitric-oxide synthase - Expression in Escherichia coli, spectroscopic characterization, and role of tetrahydrobiopterin in dimer formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; NITROGEN-OXIDES; PURIFICATION; COFACTOR; ENZYME; FLAVIN; BRAIN; MYRISTOYLATION; IDENTIFICATION; FLAVOPROTEIN	Bovine endothelial nitric-oxide synthase (eNOS) expressed in Escherichia coli does not have the post-translational modifications found in the native enzyme and is free of tetrahydrobiopterin (BH4). In the presence of BH4, eNOS has an absorption maximum at 400 nm that shifts to 395 ma when the substrate L-arginine is added. The low-spin component of the spectrum of the BH4-free protein is decreased by the addition of BH4 without a corresponding increase in the high-spin component. Addition of BH4 decreases the low-spin population of eNOS even in the presence of excess L-arginine. These results indicate that BH4 directly modulates the heme environment, BH4-free eNOS is completely inactive, but catalytic activity is recovered when BH4 (EC(50) similar to 200 nM) is added. The spectroscopically determined binding constants for L-arginine are similar to 1.9 mu M in the presence and similar to>4.0 mu M in the absence of BH4. The BH4-supplemented enzyme has an activity of 90-120 nmol of citrulline min(-1) mg(-1) and K-m values of 3 and 14 mu M for L-arginine and N-hydroxy-L-arginine, respectively. Of particular interest is the finding by SDS-polyacrylamide gel electrophoresis that BH4-free eNOS exists in a monomer-dimer equilibrium very similar to that observed with the BH4-reconstituted protein, Addition of BH4 increases the percent of the dimer by only similar to 5%. The results establish that BH4, influences the heme environment and stabilizes the protein with respect to heme loss but is not required for dimer formation.	UNIV CALIF SAN FRANCISCO, SCH PHARM, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco			Rodriguez-Crespo, J. Ignacio/M-1966-2018	Rodriguez-Crespo, J. Ignacio/0000-0002-2582-129X	NIDDK NIH HHS [5 P30 DK26743] Funding Source: Medline; NIGMS NIH HHS [GM25515] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025515, R37GM025515] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUSCONI L, 1995, MOL PHARMACOL, V47, P655; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; CHEN PF, 1994, J BIOL CHEM, V269, P25062; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; GERBER NC, 1995, J BIOL CHEM, V270, P17791, DOI 10.1074/jbc.270.30.17791; GONZALEZ FJ, 1995, ANNU REV PHARMACOL, V35, P369, DOI 10.1146/annurev.pa.35.040195.002101; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; HEVEL JM, 1994, METHOD ENZYMOL, V233, P250; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KWON NS, 1989, J BIOL CHEM, V264, P20496; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LIU JW, 1995, BIOCHEMISTRY-US, V34, P12333, DOI 10.1021/bi00038a029; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MAYER B, 1991, FEBS LETT, V288, P187, DOI 10.1016/0014-5793(91)81031-3; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; NAKANE M, 1995, BIOCHEM BIOPH RES CO, V206, P511, DOI 10.1006/bbrc.1995.1073; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; RENAUD JP, 1993, BIOCHEM BIOPH RES CO, V192, P53, DOI 10.1006/bbrc.1993.1380; RIVEROSMORENO V, 1995, EUR J BIOCHEM, V230, P52; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; SAKAI N, 1993, MOL PHARMACOL, V43, P6; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SEO HG, 1995, BIOCHEM BIOPH RES CO, V208, P10, DOI 10.1006/bbrc.1995.1298; SESSA WC, 1993, CIRC RES, V72, P921, DOI 10.1161/01.RES.72.4.921; SESSA WC, 1992, J BIOL CHEM, V267, P15274; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; THONY B, 1992, BIOCHEM BIOPH RES CO, V189, P1437, DOI 10.1016/0006-291X(92)90235-D; VENEMA RC, 1995, J BIOL CHEM, V270, P14705, DOI 10.1074/jbc.270.24.14705; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WOLFF DJ, 1994, ARCH BIOCHEM BIOPHYS, V314, P360, DOI 10.1006/abbi.1994.1454	49	180	182	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11462	11467		10.1074/jbc.271.19.11462	http://dx.doi.org/10.1074/jbc.271.19.11462			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626704	hybrid			2022-12-25	WOS:A1996UJ94400064
J	Gu, Y; Sarnecki, C; Fleming, MA; Lippke, JA; Bleackley, RC; Su, MSS				Gu, Y; Sarnecki, C; Fleming, MA; Lippke, JA; Bleackley, RC; Su, MSS			Processing and activation of CMH-1 by granzyme B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EFFICIENT	Granzyme B plays an essential role in cytotoxic T lymphocyte (CTL)-mediated cell killing, Recent studies suggest that granzyme B may exert its effect by cleaving and activating CPP32, a member of the interleukin-1 beta-converting enzyme/Ced-3 family of cysteine proteases, We have examined the processing and activation of CMH-1, a close homologue of CPP32, by granzyme B in vitro, We have found that granzyme B specifically cleaves CMH-1 at Asp(198)-Ser(199) between the p20 and p12 and activates the cysteine protease, Cleavage between p20 and the prosequence of CMH-1 at Asp(23)-Ala(24) is autocatalytic and is not required for CMH-1 activity in vitro. The cleavage and activation of CMH-1 by granzyme B in vitro suggest that, in addition to CPP32, CMH-1 may also play a role in CTL-mediated cell killing.	VERTEX PHARMACEUT INC,CAMBRIDGE,MA 02139; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2H7,CANADA	Vertex Pharmaceuticals; University of Alberta								BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; CAPUTO A, 1993, J BIOL CHEM, V268, P17672; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; HANNA WL, 1993, PROTEIN EXPRES PURIF, V4, P394; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; SITKOVSKY MV, 1993, CYTOTOXIC CELLS; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	22	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10816	10820		10.1074/jbc.271.18.10816	http://dx.doi.org/10.1074/jbc.271.18.10816			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631895	hybrid			2022-12-25	WOS:A1996UJ34200063
J	Law, DA; NannizziAlaimo, L; Phillips, DR				Law, DA; NannizziAlaimo, L; Phillips, DR			Outside-in integrin signal transduction - alpha(IIb)beta(3)-(GP IIb-IIIa) tyrosine phosphorylation induced by platelet aggregation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; GLANZMANN THROMBASTHENIA; RECEPTOR; PROTEIN; ACTIVATION; FIBRINOGEN; ASSOCIATION; ADHESION; SUBUNIT; PEPTIDE	alpha(IIb)beta(3)-(GPIIb-IIIa) is the most abundant integrin expressed on platelets and plays a critical role in platelet aggregation and normal hemostasis. In response to platelet stimulation by agonists such as thrombin, alpha(IIb)beta(3) becomes a receptor for the adhesive proteins fibrinogen, von Willebrand factor, vitronectin, and fibronectin. Binding of extracellular matrix ligands allows the integrin to transmit a signal to the inside of the cell, but the exact mechanisms whereby integrins transduce these signals remain unclear. In this paper we demonstrate that the beta(3) subunit of alpha(IIb)beta(3) was phosphorylated on tyrosine residues in response to thrombin induced platelet aggregation. However, tyrosine phosphorylation was not observed when platelets were stimulated by thrombin in the presence of an inhibitor of aggregation. Phosphotyrosine was only detected when platelets were solubilized under protein-denaturing conditions, A peptide corresponding to residues 740-762 of the beta(3) cytoplasmic domain was capable of binding the signaling proteins SHC and GRB2, GRB2 binding occurred only when both tyrosine residues (Tyr-747 and Tyr-759) were phosphorylated. SHC binding also occurred to a peptide monophosphorylated at Tyr-759, The data suggest that tyrosine phosphorylation of an integrin beta subunit may be important in initiating outside in signaling cascades by inducing association of signaling components directly with the integrin.	COR THERAPEUT INC,S SAN FRANCISCO,CA 94080									CAEN JP, 1966, AM J MED, V41, P4, DOI 10.1016/0002-9343(66)90003-9; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHEN YP, 1994, BLOOD, V84, P1857; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10169, DOI 10.1073/pnas.89.21.10169; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1994, J BIOL CHEM, V269, P28859; COLLER BS, 1991, BLOOD, V77, P75; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; DORAHY DJ, 1995, BIOCHEM J, V309, P481, DOI 10.1042/bj3090481; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EVANS GA, 1995, J BIOL CHEM, V270, P28858, DOI 10.1074/jbc.270.48.28858; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FOX JEB, 1982, J BIOL CHEM, V257, P4120; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISENBERG WM, 1987, J CELL BIOL, V104, P1655, DOI 10.1083/jcb.104.6.1655; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; IZUHARA K, 1994, J BIOL CHEM, V269, P18623; JOHANSSON MW, 1994, J CELL BIOL, V126, P1299, DOI 10.1083/jcb.126.5.1299; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PARISE LV, 1990, BLOOD, V75, P2363; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PHILLIPS DR, 1977, J CLIN INVEST, V60, P535, DOI 10.1172/JCI108805; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SAXTON TM, 1994, J IMMUNOL, V153, P623; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; Shock David D., 1995, Blood, V86, p451A; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Williams Michael J., 1994, Trends in Cell Biology, V4, P109, DOI 10.1016/0962-8924(94)90059-0; YAMIGUCHI A, 1990, BIOCHIM BIOPHYS ACTA, V1054, P8; YLANNE J, 1995, J BIOL CHEM, V270, P9550; YLANNE J, 1993, J CELL BIOL, V122, P223, DOI 10.1083/jcb.122.1.223	48	207	209	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10811	10815		10.1074/jbc.271.18.10811	http://dx.doi.org/10.1074/jbc.271.18.10811			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631894	hybrid			2022-12-25	WOS:A1996UJ34200062
J	Rolin, S; HanocqQuertier, J; PaturiauxHanocq, F; Nolan, D; Salmon, D; Webb, H; Carrington, M; Voorheis, P; Pays, E				Rolin, S; HanocqQuertier, J; PaturiauxHanocq, F; Nolan, D; Salmon, D; Webb, H; Carrington, M; Voorheis, P; Pays, E			Simultaneous but independent activation of adenylate cyclase and glycosylphosphatidylinositol-phospholipase C under stress condition in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; VARIANT SURFACE GLYCOPROTEIN; BLOOD-STREAM; CYCLIC-AMP; GUANYLATE-CYCLASE; EXPRESSION SITE; PROCYCLIC FORMS; DIFFERENTIATION; MEMBRANE; DISTINCT	Previous observations suggested a concomitant relationship between the release of the variant surface glycoprotein (VSG) and the activation of adenylate cyclase in the bloodstream form of the parasitic protozoan Trypanosoma brucei, In order to evaluate this hypothesis, adenylate cyclase activity was measured in live trypanosomes subjected to different treatments known to induce the shedding of the VSG coat, namely low pH and trypsin digestion, In both cases adenylate cyclase activation occurred in parallel with the release of the VSG, The latter was found to be mediated by the glycosylphosphatidylinositol-specific phospholipase C that cleaves the glycosylphosphatidylinositol anchor of the protein (VSG lipase). Furthermore, both adenylate cyclase and VSG release were activated by the incubation of trypanosomes with specific inhibitors of protein kinase C, suggesting a repressive role for protein kinase C on both VSG lipase and adenylate cyclase activities. Significantly, in mutant trypanosomes lacking VSG lipase, adenylate cyclase was activated under conditions where VSG release did not occur. Moreover, VSG release was also found to occur in the absence of activation of the cyclase, as observed in the presence of low concentration of the thiol modifying reagent p-chloromercuriphenylsulfonic acid. These observations provide the first demonstration that release of the VSG in response to cellular stress is mediated by the VSG lipase and that while both release of the VSG and activation of adenylate cyclase occur in response to the same stimuli they are not obligatorily coupled.	UNIV BRUSSELS, DEPT MOLEC BIOL, B-1640 RHODE ST GENESE, BELGIUM; UNIV CAMBRIDGE, DEPT BIOCHEM, CAMBRIDGE CB2 1QW, ENGLAND; UNIV DUBLIN TRINITY COLL, DEPT BIOCHEM, DUBLIN 2, IRELAND	University of Cambridge; Trinity College Dublin			Salmon, Didier/M-5670-2013	Carrington, Mark/0000-0002-6435-7266; Nolan, Derek/0000-0002-3742-4304				ABOAGYEKWARTENG T, 1991, BIOCHEM J, V275, P7, DOI 10.1042/bj2750007; ALEXANDRE S, 1990, MOL BIOCHEM PARASIT, V43, P279, DOI 10.1016/0166-6851(90)90152-C; BALTZ T, 1976, ANN INST PASTEUR IMM, VC127, P761; BERGMEYER HU, 1974, METHOD ENZYMAT AN, V2, P762; BOWLES DJ, 1982, FEBS LETT, V139, P17, DOI 10.1016/0014-5793(82)80477-8; BOYNTON AL, 1983, ADV CYCLIC NUCL PROT, V15, P193; BRUN R, 1979, ACTA TROP, V36, P289; CARRINGTON M, 1991, CELL BIOL INT REP, V15, P1101, DOI 10.1016/0309-1651(91)90058-Q; CHOI EJ, 1993, BIOCHEMISTRY-US, V32, P1891, DOI 10.1021/bi00059a001; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; DANCHIN A, 1993, ADV SEC MESS PHOSPH, V27, P109; DEALMEIDA MLC, 1983, NATURE, V302, P349, DOI 10.1038/302349a0; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FROMMEL TO, 1988, EXP PARASITOL, V66, P213, DOI 10.1016/0014-4894(88)90093-8; GARBERS DL, 1989, J BIOL CHEM, V264, P9103; GONZALESPERDOMO M, 1988, EXP PARASITOL, V66, P205, DOI 10.1016/0014-4894(88)90092-6; HARDIE DG, 1993, PROTEIN PHOSPHORYLAT, P109; HERELD D, 1986, J BIOL CHEM, V261, P3813; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; KEITH K, 1990, MOL BIOCHEM PARASIT, V43, P107, DOI 10.1016/0166-6851(90)90135-9; KEMP BE, 1991, METHOD ENZYMOL, V201, P287; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; MacManus J P, 1978, Adv Cyclic Nucleotide Res, V9, P485; MANCINI PE, 1981, MOL BIOCHEM PARASIT, V3, P19, DOI 10.1016/0166-6851(81)90074-8; MARTIN BR, 1978, BIOCHEM J, V175, P207, DOI 10.1042/bj1750207; MORI T, 1980, J BIOL CHEM, V255, P8378; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; ONO Y, 1988, J BIOL CHEM, V263, P6927; OPPERDOES FR, 1977, EUR J BIOCHEM, V76, P21, DOI 10.1111/j.1432-1033.1977.tb11566.x; PAINDAVOINE P, 1992, MOL CELL BIOL, V12, P1218, DOI 10.1128/MCB.12.3.1218; PARSONS M, 1991, MOL BIOCHEM PARASIT, V45, P241, DOI 10.1016/0166-6851(91)90091-J; PARSONS M, 1994, MOL BIOCHEM PARASIT, V63, P69, DOI 10.1016/0166-6851(94)90009-4; PAYS E, 1989, CELL, V57, P835, DOI 10.1016/0092-8674(89)90798-8; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; RANGELALDAO R, 1987, MOL BIOCHEM PARASIT, V22, P39, DOI 10.1016/0166-6851(87)90067-3; REED SL, 1985, INFECT IMMUN, V49, P844, DOI 10.1128/IAI.49.3.844-847.1985; REINWALD E, 1985, EUR J BIOCHEM, V151, P385, DOI 10.1111/j.1432-1033.1985.tb09113.x; RICHARDSON JP, 1988, MOL BIOCHEM PARASIT, V31, P203, DOI 10.1016/0166-6851(88)90150-8; ROBISON GA, 1968, ANNU REV BIOCHEM, V37, P149, DOI 10.1146/annurev.bi.37.070168.001053; ROLIN S, 1993, MOL BIOCHEM PARASIT, V61, P115, DOI 10.1016/0166-6851(93)90164-S; ROLIN S, 1990, EXP PARASITOL, V71, P350, DOI 10.1016/0014-4894(90)90041-A; RUBEN L, 1991, J BIOL CHEM, V266, P24351; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SANCHEZ MA, 1995, J BIOL CHEM, V270, P17551, DOI 10.1074/jbc.270.29.17551; STRICKLER JE, 1975, SCIENCE, V190, P1110, DOI 10.1126/science.171773; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VICKERMAN K, 1969, J PROTOZOOL, V16, P54, DOI 10.1111/j.1550-7408.1969.tb02233.x; VOORHEIS HP, 1980, EUR J BIOCHEM, V113, P223, DOI 10.1111/j.1432-1033.1980.tb06160.x; VOORHEIS HP, 1982, EUR J BIOCHEM, V123, P371, DOI 10.1111/j.1432-1033.1982.tb19778.x; VOORHEIS HP, 1981, EUR J BIOCHEM, V116, P471, DOI 10.1111/j.1432-1033.1981.tb05360.x; VOORHEIS HP, 1982, J BIOL CHEM, V257, P2300; WADMAN IA, 1991, BIOCHEM J, V276, P621, DOI 10.1042/bj2760621; WALTER RD, 1978, TROPENMED PARASITOL, V29, P439; WALTER RD, 1982, MOL BIOCHEM PARASIT, V6, P287, DOI 10.1016/0166-6851(82)90061-5; WARD J, 1987, MOL BIOCHEM PARASIT, V23, P1, DOI 10.1016/0166-6851(87)90180-0; WHEELERALM E, 1992, J PROTOZOOL, V39, P413, DOI 10.1111/j.1550-7408.1992.tb01473.x; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604; ZAMZE SE, 1988, EUR J BIOCHEM, V176, P527, DOI 10.1111/j.1432-1033.1988.tb14310.x; ZHANG YH, 1991, J BIOL CHEM, V266, P22954; ZHANG YH, 1993, J BIOL CHEM, V268, P1786; ZIEGELBAUER K, 1993, BIOCHEMISTRY-US, V32, P3737, DOI 10.1021/bi00065a028; ZIEGELBAUER K, 1990, EUR J BIOCHEM, V192, P373, DOI 10.1111/j.1432-1033.1990.tb19237.x	65	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10844	10852		10.1074/jbc.271.18.10844	http://dx.doi.org/10.1074/jbc.271.18.10844			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631899	hybrid			2022-12-25	WOS:A1996UJ34200067
J	Sung, P; Guzder, SN; Prakash, L; Prakash, S				Sung, P; Guzder, SN; Prakash, L; Prakash, S			Reconstitution of TFIIH and requirement of its DNA helicase subunits, Rad3 and Rad25, in the incision step of nucleotide excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION; INITIATION; MUTATION; PROTEIN; ATPASE; YEAST; GENE	Yeast TFIIH is composed of six subunits: Rad3, Rad25, TFB1, SSL1, p55, and p38. In addition to TFIIH, we have purified a subassembly of the factor that lacks Rad3 and Rad25 and which we refer to as TFIIHi. In the in vitro nucleotide excision repair (NER) system that consists entirely of purified proteins, we show that neither TFIIHi nor a mixture of purified Rad3 and Rad25 proteins is active in NER but that the combination of TFIIHi with Rad3 and Rad25 promotes the incision of UV-damaged DNA. These results provide the first evidence for a direct requirement of Rad3, Rad25, and of one or more of the TFIIHi subunits in the incision step of NER. The NER efficacy of TFIIH is greatly diminished or abolished upon substitution of Rad3 with the rad3 Arg-48 mutant protein or Rad25 with the rad25 Arg-392 mutant protein, respectively, thus indicating a role of the Rad3 and Rad25 DNA helicase functions in the incision of damaged DNA. Our results further indicate that the carboxyl-terminal domain kinase (CTD) TFIIK is dispensable for the incision of damaged DNA in vitro. These studies reveal the differential requirement of Rad3 DNA helicase and CTD kinase activities in damage specific incision versus RNA polymerase II transcription.	UNIV TEXAS,MED BRANCH,SEALY CTR MOL SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston			Prakash, Louise/C-7891-2012; Prakash, Satya/C-6420-2013	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NCI NIH HHS [CA35035] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA035035, R01CA035035] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; HABRAKEN Y, 1995, J BIOL CHEM, V270, P30194; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; QIU HF, 1993, GENE DEV, V7, P2161, DOI 10.1101/gad.7.11.2161; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; SUNG P, 1994, J BIOL CHEM, V269, P8303; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; SWEDER KS, 1994, J BIOL CHEM, V269, P1852; WANG ZG, 1995, MOL CELL BIOL, V15, P2288; YOON H, 1992, GENE DEV, V6, P2463, DOI 10.1101/gad.6.12b.2463	20	58	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10821	10826		10.1074/jbc.271.18.10821	http://dx.doi.org/10.1074/jbc.271.18.10821			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631896	hybrid			2022-12-25	WOS:A1996UJ34200064
J	Waldmann, R; Champigny, G; Voilley, N; Lauritzen, I; Lazdunski, M				Waldmann, R; Champigny, G; Voilley, N; Lauritzen, I; Lazdunski, M			The mammalian degenerin MDEG, an amiloride-sensitive cation channel activated by mutations causing neurodegeneration in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION	Mutations of the degenerins (deg-1, mec-4, mec-10) are the major known causes of hereditary neurodegeneration in the nematode Caenorhabditis elegans, We cloned a neuronal degenerin (MDEG) from human and rat brain, MDEG is an amiloride sensitive cation channel permeable for Na+, K+, and Li+. This channel is activated by the same mutations which cause neurodegeneration in C. elegans, Like the hyperactive C. elegans degenerin mutants, constitutively active mutants of MDEG cause cell death, suggesting that gain of function of this novel neuronal ion channel might be involved in human forms of neurodegeneration.	INST PHARMACOL MOLEC & CELLULAIRE,UPR411 CNRS,F-06560 VALBONNE,FRANCE	Centre National de la Recherche Scientifique (CNRS)			Lauritzen, Inger/AFF-7261-2022; Lauritzen, Inger/AAE-9927-2022; Waldmann, Rainer/Q-2108-2016	Waldmann, Rainer/0000-0002-4599-2926; lauritzen, inger/0000-0002-2011-1387				BARGMANN CI, 1994, CELL, V78, P729; BARINAGA M, 1995, SCIENCE, V269, P917, DOI 10.1126/science.7638610; BARINAGA M, 1994, SCIENCE, V263, P756; BOOHER J, 1972, Neurobiology (Copenhagen), V2, P97; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; GARCIAANOVEROS J, 1995, CURR BIOL, V5, P441, DOI 10.1016/S0960-9822(95)00085-6; GARTY H, 1994, FASEB J, V8, P523; GOSLIN K, 1991, CULTURING NERVE CELL, P252; GUILLEMARE E, 1992, BIOCHEMISTRY-US, V31, P12463, DOI 10.1021/bi00164a024; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HENGARTNER MO, 1995, SCIENCE, V270, P931, DOI 10.1126/science.270.5238.931; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; JENTSCH TJ, 1994, NATURE, V367, P412, DOI 10.1038/367412a0; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; MARX J, 1993, SCIENCE, V262, P986; PRICE DA, 1977, SCIENCE, V197, P670, DOI 10.1126/science.877582; RENARD S, 1994, J BIOL CHEM, V269, P12981; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Van Broeckhoven C, 1995, NAT GENET, V11, P230; VANDEYAR MA, 1988, GENE, V65, P129, DOI 10.1016/0378-1119(88)90425-8; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; YANG HYT, 1985, P NATL ACAD SCI USA, V82, P7757, DOI 10.1073/pnas.82.22.7757	33	272	290	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10433	10436		10.1074/jbc.271.18.10433	http://dx.doi.org/10.1074/jbc.271.18.10433			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631835	hybrid			2022-12-25	WOS:A1996UJ34200003
J	Witcher, LL; Collins, R; Puttagunta, S; Mechanic, SE; Munson, M; Gumbiner, B; Cowin, P				Witcher, LL; Collins, R; Puttagunta, S; Mechanic, SE; Munson, M; Gumbiner, B; Cowin, P			Desmosomal cadherin binding domains of plakoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEGMENT POLARITY GENE; CELL-ADHESION MOLECULE; JUNCTIONAL PLAQUE PROTEIN; BETA-CATENIN; DROSOPHILA HOMOLOG; EPITHELIAL-CELLS; ARMADILLO; ASSOCIATION; UVOMORULIN; EXPRESSION	Plakoglobin is a major component of both desmosomes and adherens junctions. At these sites it binds to the cytoplasmic domains of cadherin cell-cell adhesion proteins and regulates their adhesive and cytoskeletal binding functions. Plakoglobin also forms distinct cytosolic protein complexes that function in pathways of tumor suppression and cell fate determination. Recent studies in Xenopus suggest that cadherins inhibit the signaling functions of plakoglobin presumably by sequestering this protein at the membrane and depleting its cytosolic pool. To understand the reciprocal regulation between desmosomal cadherins (desmoglein and desmocollin) and plakoglobin, we have sought to identify the binding domains involved in the formation of these protein complexes. Plakoglobin comprises 13 central repeats flanked by amino-terminal and carboxyl-terminal domains. Our results show that repeats 1-4 are involved in binding desmoglein-1. In contrast, the interaction of plakoglobin with desmocollin-1a is sensitive to deletion of either end of the central repeat domain. The binding sites for two adherens junction components, alpha-catenin and classical cadherins, overlap these sites. Competition among these proteins for binding sites on plakoglobin may therefore account for the distinct composition of adherens junctions and desmosomes.	NYU,MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016; NYU,MED CTR,RONALD O PERELMAN DEPT DERMATOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016; MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021	New York University; New York University; New York University; Memorial Sloan Kettering Cancer Center				Cowin, Pamela/0000-0002-1827-1154	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047429, R37GM037432, R01GM037432] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47429, GM37432] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; BUXTON RS, 1993, J CELL BIOL, V121, P481, DOI 10.1083/jcb.121.3.481; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; COWIN P, 1983, NATURE, V302, P148, DOI 10.1038/302148a0; COWIN P, 1994, P NATL ACAD SCI USA, V91, P10759, DOI 10.1073/pnas.91.23.10759; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GOODWIN LO, 1991, J BIOL CHEM, V266, P8408; HATZFELD M, 1994, J CELL SCI, V107, P2259; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; KAPPRELL HP, 1987, EUR J BIOCHEM, V166, P505, DOI 10.1111/j.1432-1033.1987.tb13543.x; KARNOVSKY A, 1995, P NATL ACAD SCI USA, V92, P4522, DOI 10.1073/pnas.92.10.4522; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; KOWALCZYK AP, 1994, J BIOL CHEM, V269, P31214; KUSSEL P, 1995, J CELL BIOL, V129, P1491, DOI 10.1083/jcb.129.6.1491; MATHUR M, 1994, J BIOL CHEM, V269, P14075; MCCREA PD, 1993, J CELL BIOL, V123, P477, DOI 10.1083/jcb.123.2.477; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MECHANIC S, 1991, P NATL ACAD SCI USA, V88, P4476, DOI 10.1073/pnas.88.10.4476; NIEHRS C, 1992, J BIOL CHEM, V267, P15938; ODA H, 1993, J CELL BIOL, V121, P1133, DOI 10.1083/jcb.121.5.1133; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PEIFER M, 1993, J CELL SCI, V105, P993; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; PIEPENHAGEN PA, 1993, J CELL SCI, V104, P751; POLAKIS P, 1995, CURR OPIN GENET DEV, V5, P66, DOI 10.1016/S0959-437X(95)90055-1; PUTTAGUNTA S, 1994, J BIOL CHEM, V269, P1949; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; RINGWALD M, 1991, NUCLEIC ACIDS RES, V19, P6533, DOI 10.1093/nar/19.23.6533; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; SACCO PA, 1995, J BIOL CHEM, V270, P20201, DOI 10.1074/jbc.270.34.20201; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHAPIRO L, 1995, P NATL ACAD SCI USA, V92, P6793, DOI 10.1073/pnas.92.15.6793; Sherman F., 1986, METHODS YEAST GENETI; SHORE EM, 1991, J BIOL CHEM, V266, P19672; SORKIN BC, 1991, P NATL ACAD SCI USA, V88, P11545, DOI 10.1073/pnas.88.24.11545; SORKIN BC, 1988, P NATL ACAD SCI USA, V85, P7617, DOI 10.1073/pnas.85.20.7617; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TROYANOVSKY SM, 1994, J CELL BIOL, V127, P151, DOI 10.1083/jcb.127.1.151; TROYANOVSKY SM, 1993, CELL, V72, P561, DOI 10.1016/0092-8674(93)90075-2; TROYANOVSKY SM, 1994, P NATL ACAD SCI USA, V91, P10790, DOI 10.1073/pnas.91.23.10790	51	93	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10904	10909		10.1074/jbc.271.18.10904	http://dx.doi.org/10.1074/jbc.271.18.10904			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631907				2022-12-25	WOS:A1996UJ34200075
J	Yan, SZ; Hahn, D; Huang, ZH; Tang, WJ				Yan, SZ; Hahn, D; Huang, ZH; Tang, WJ			Two cytoplasmic domains of mammalian adenylyl cyclase form a G(s alpha)- and forskolin-activated enzyme in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; CLONING; PURIFICATION	Mammalian adenylyl cyclases have two homologous cytoplasmic domains (C-1 and C-2). The first cytoplasmic domain of type I enzyme (IC1) and the second cytoplasmic domain of type II enzyme (IIC2-Delta 3, a construct in which 36 N-terminal amino acids of the C-2 region are deleted) were expressed and purified to homogeneity. Alone, each had no adenylyl cyclase activity; however, mixing of the two domains in vitro resulted in G(s alpha)- and forskolin activated enzyme activity. The turnover number for G(s alpha)- and forskolin-stimulated enzyme activity of the complex between IC1 and IIC2-Delta 3 was 8.2 s(-1). The concentration of IIC2-Delta 3 to achieve half-maximal activation of IC1 was 0.8 and 1.3 mu M when stimulated by forskolin and G(s alpha), respectively. The concentration of IIC2-Delta 3 needed to complex with IC1 was reduced 10-fold (0.08 mu M) when the enzyme was activated by both forskolin and G(s alpha), suggesting that G(s alpha) and forskolin increased the affinity of the two cytoplasmic domains for each other.	UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637	University of Chicago				Tang, Wei-Jen/0000-0002-8267-8995				BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALI JJ, 1994, J BIOL CHEM, V269, P12190; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GOTTESMAN S, 1990, METHOD ENZYMOL, V185, P119; Harlow E., 1988, ANTIBODIES LAB MANUA; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LEE E, 1994, METHOD ENZYMOL, V237, P146; PATERSON JM, 1995, BIOCHEM BIOPH RES CO, V214, P1000, DOI 10.1006/bbrc.1995.2385; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; WATSON PA, 1994, J BIOL CHEM, V269, P28893; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	26	90	91	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10941	10945		10.1074/jbc.271.18.10941	http://dx.doi.org/10.1074/jbc.271.18.10941			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631912	hybrid			2022-12-25	WOS:A1996UJ34200080
J	Charbit, A; Reizer, J; Saier, MH				Charbit, A; Reizer, J; Saier, MH			Function of the duplicated IIB domain and oligomeric structure of the fructose permease of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUGAR PHOSPHOTRANSFERASE SYSTEM; BACTERIAL PHOSPHOENOLPYRUVATE; SALMONELLA-TYPHIMURIUM; NUCLEOTIDE-SEQUENCE; ENZYME-II; RHODOBACTER-CAPSULATUS; PHOSPHORYLATION; PROTEINS; MUTANTS; GENE	The fructose permease of Escherichia coli, the fructose-specific Enzyme II of the phosphoenolpyruvate-dependent phosphotransferase system (PTS), contains a duplicated IIB domain, The protein therefore consists of three distinct domains, B', B, and C (N-terminal to C-terminal), joined by flexible linkers and is thus designated FruB'BC. The N-terminal B' domain was removed using molecular genetic techniques, and the truncated Enzyme II (FruBC) was characterized relative to the wild-type enzyme both in vivo and in vitro. In vivo, FruBC exhibited depressed fermentation characteristics at low fructose concentrations. [C-14]Fructose uptake measurements revealed reduced rates only when the permease was rate-limiting for transport. In vitro, FruBC exhibited a 10-fold lower affinity for its phosphoryl donating protein, the ILA-FPr diphosphoryl transfer protein (DTP), than was observed with the mild-type enzyme, and the maximal velocity of fructose phosphorylation was 7-fold depressed, Because the fructose-1-phosphate:[C-14]fructose transphosphorylation reaction appeared normal, we conclude that the loss of the B' domain primarily affected phosphoryl transfer between the IIA and IIB domains of the permease, A mutant FruBC derivative with cysteine 112 replaced by serine (C112S FruBC) was inactive as a phosphoryl carrier and a sugar transport protein, Expression of the plasmid-encoded mutant protein inhibited the in vivo activity of the chromosomally encoded wild-type fructose permease, but it did not observably affect the activities of the mannitol or glucitol PTS permeases or of non-PTS sugar permeases, Further, the presence of the detergent extracted mutant protein inhibited the activity of the detergent solubilized wild-type or FruBC enzyme, In contrast, the wild-type FruB'BC permease was apparently epistatic over the truncated FruBC permease in vivo, The experiments reported 1) show that the B' domain of the fructose permease functions to facilitate phosphoryl transfer between DTP and the permease, 2) establish the essentiality of cysteine 112 in the B domain of the permease, 3) provide evidence that a functional fructose permease consists of an oligomer in which both IIB domains must be active for the enzyme to catalyze normal rates of phosphoryl transfer and transport, 4) suggest that a single B' domain in the oligomeric Enzyme II is sufficient to allow high efficiency phosphoryl transfer between the IIA domain of DTP and the IIB domain of the permease, and 5) show that the B' domain is not important for oligomerization.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego				charbit, alain/0000-0001-5243-4861	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021702] Funding Source: NIH RePORTER; NIAID NIH HHS [WRO1 AI4176, 5RO1 AI21702] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOER H, 1994, J BIOL CHEM, V269, P17863; BUHR A, 1994, J BIOL CHEM, V269, P23437; CHIN AM, 1989, J BACTERIOL, V171, P2424, DOI 10.1128/jb.171.5.2424-2434.1989; DECRECYLAGARD V, 1991, J BIOL CHEM, V266, P18154; ERNI B, 1986, BIOCHEMISTRY-US, V25, P305, DOI 10.1021/bi00350a004; GACHELIN G, 1969, BIOCHEM BIOPH RES CO, V34, P382, DOI 10.1016/0006-291X(69)90392-1; GEERSE RH, 1989, MOL GEN GENET, V216, P517, DOI 10.1007/BF00334399; JACOBSON GR, 1983, J BIOL CHEM, V258, P748; LENGELER JW, 1994, BBA-BIOENERGETICS, V1188, P1, DOI 10.1016/0005-2728(94)90017-5; LEONARD JE, 1983, J BIOL CHEM, V258, P757; LOLKEMA JS, 1992, NEW COMPR BIOCH, V21, P135; MEINS M, 1993, J BIOL CHEM, V268, P11604; MITCHELL WJ, 1993, J BACTERIOL, V175, P2756; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; POWELL BS, 1995, J BIOL CHEM, V270, P4822, DOI 10.1074/jbc.270.9.4822; PRIOR TI, 1988, J GEN MICROBIOL, V134, P2757; REIZER J, 1992, J BIOL CHEM, V267, P9158; REIZER J, 1995, MICROBIOL-UK, V141, P961, DOI 10.1099/13500872-141-4-961; REIZER J, 1989, EMBO J, V8, P2111, DOI 10.1002/j.1460-2075.1989.tb03620.x; REIZER J, 1994, FEMS MICROBIOL LETT, V118, P159, DOI 10.1111/j.1574-6968.1994.tb06819.x; REIZER J, 1994, PROTEIN SCI, V3, P440; ROBILLARD GT, 1988, BIOCHIM BIOPHYS ACTA, V947, P493, DOI 10.1016/0304-4157(88)90005-6; Romano A. H., 1992, EVOLUTION METABOLIC, P143; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SAIER MH, 1994, MOL MICROBIOL, V13, P755; SAIER MH, 1977, J BIOL CHEM, V252, P8899; SAIER MH, 1977, J BACTERIOL, V131, P716, DOI 10.1128/JB.131.2.716-718.1977; SAIER MH, 1982, J CELL BIOCHEM, V18, P231, DOI 10.1002/jcb.1982.240180210; SAIER MH, 1985, J CELL BIOCHEM, V27, P43, DOI 10.1002/jcb.240270106; SAIER MH, 1970, J BIOL CHEM, V245, P5870; SAIER MH, 1977, BACTERIOL REV, V41, P856, DOI 10.1128/MMBR.41.4.856-871.1977; Sambrook J., 2002, MOL CLONING LAB MANU; SEGAL IH, 1975, ENZYME KINETICS BEHA, P684; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; TITGEMEYER F, 1994, RES MICROBIOL, V145, P89, DOI 10.1016/0923-2508(94)90001-9; TITGEMEYER F, 1995, MICROBIOL-SGM, V141, P51, DOI 10.1099/00221287-141-1-51; VANWEEGHEL RP, 1991, BIOCHEMISTRY-US, V30, P1768, DOI 10.1021/bi00221a006; WU LF, 1990, J MOL BIOL, V213, P687, DOI 10.1016/S0022-2836(05)80256-6; WU LF, 1990, J BACTERIOL, V172, P7167, DOI 10.1128/jb.172.12.7167-7178.1990; WU LF, 1990, MOL MICROBIOL, V4, P1219, DOI 10.1111/j.1365-2958.1990.tb00698.x	40	15	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9997	10003		10.1074/jbc.271.17.9997	http://dx.doi.org/10.1074/jbc.271.17.9997			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626640	hybrid			2022-12-25	WOS:A1996UG25700024
J	Heidenreich, KA; Kummer, JL				Heidenreich, KA; Kummer, JL			Inhibition of p38 mitogen-activated protein kinase by insulin in cultured fetal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; NEURITE FORMATION; FACTOR-II; RAS; SURVIVAL; P21	Insulin supports the survival and differentiation of many types of fetal neurons. To determine if mitogen-activated protein (MAP) kinases play a role in mediating the neurotrophic actions of insulin, we identified the MAP kinases present in fetal chick forebrain neurons and examined their regulation by insulin. Cell extracts were fractionated on Mono Q columns, and phosphotransferase activity was measured using myelin basic protein as the substrate. In control neurons, four peaks of MAP kinase activity were resolved, Peaks I, II, and IV were identified by immunoblotting as c-Jun N-terminal kinase (JNK), extracellular signal-related kinase (ERK), and p38 MAP kinase, respectively. Neurons treated with insulin showed a dramatic decrease, 80-90%, in p38 MAP kinase activity without significant changes in the other MAP kinase activities. Insulin decreased the phosphotyrosine content of p38 MAP kinase with maximal effects observed within 5 min. Pretreatment of neurons with sodium orthovanadate blocked the ability of insulin to inhibit the tyrosine phosphorylation and activity of p38 MAP kinase, suggesting that activation of a tyrosine or dual specific phosphatase is necessary for the inhibition of p38 MAP kinase by insulin. Since p38 MAP kinase has been recently implicated in neuronal cell apoptosis, negative regulation of this kinase by insulin may be critical for the neurotrophic actions of insulin.	VET AFFAIRS MED CTR,DENVER,CO 80220	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Heidenreich, KA (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL C236,4200 E 9TH AVE,DENVER,CO 80262, USA.							AIZENMAN Y, 1987, BRAIN RES, V406, P32, DOI 10.1016/0006-8993(87)90766-9; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HEIDENREICH KA, 1989, ENDOCRINOLOGY, V125, P1451, DOI 10.1210/endo-125-3-1451; HEIDENREICH KA, 1988, J NEUROCHEM, V51, P878, DOI 10.1111/j.1471-4159.1988.tb01824.x; HEIDENREICH KA, 1993, J BIOL CHEM, V268, P663; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; MILL JF, 1985, P NATL ACAD SCI USA, V82, P7126, DOI 10.1073/pnas.82.20.7126; PORRAS A, 1992, J BIOL CHEM, V267, P21124; RECIOPINTO E, 1986, J NEUROSCI, V6, P1211; ROBINSON LJ, 1994, ENDOCRINOLOGY, V135, P2568, DOI 10.1210/en.135.6.2568; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; WHITE MF, 1994, J BIOL CHEM, V269, P1; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	22	95	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9891	9894		10.1074/jbc.271.17.9891	http://dx.doi.org/10.1074/jbc.271.17.9891			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626622	hybrid			2022-12-25	WOS:A1996UG25700006
J	Cougnon, M; Planelles, G; Crowson, MS; Shull, GE; Rossier, BC; Jaisser, F				Cougnon, M; Planelles, G; Crowson, MS; Shull, GE; Rossier, BC; Jaisser, F			The rat distal colon P-ATPase alpha subunit encodes a ouabain-sensitive H+,K+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-K+-ATPASE; FUNCTIONAL EXPRESSION; GASTRIC H+,K+-ATPASE; POTASSIUM-DEPLETION; BETA-SUBUNIT; COLLECTING DUCT; KIDNEY; CELLS; NA,K-ATPASE; BINDING	The functional properties and the pharmacological profile of the recently cloned cDNA colonic P-ATPase alpha subunit (Crowson, M. S., and Shull, G. E. (1992) J. Biol. Chem. 267, 13740-13748) were investigated by using the Xenopus oocyte expression system, Xenopus oocytes were injected with alpha subunit cRNAs from Bufo marinus bladder or rat distal colon and/or with beta subunit cRNA from B. marinus bladder, Two days after injection, K+ uptake was measured by using Rb-86(+) as a K+ surrogate, and pH measurements were performed by means of ion-selective microelectrodes. Co-injection of alpha and beta subunit cRNAs lead to a large increase in Rb-86(+) uptake, an intracellular alkalinization, and an extracellular medium acidification, as compared to alpha or beta injection alone, These results indicate that the colonic P-ATPase alpha subunit, like the bladder alpha subunit, acts as a functional H+,K+-ATPase, and that co-expression of alpha and beta subunits is required for the function, External K+ activation of the Rb-86(+) uptake had a K-1/2 similar to 440 mu M for the bladder isoform (consistent with the previously reported value (Jaisser, F., Horisberger, J. D., Geering, K., and Rossier, B. C. (1933) J. Cell Biol. 123, 1421-1431)) and a K-1/2 similar to 730 mu M for the colonic isoform, Sch28080 was ineffective to reduce Rb-86(+) uptake whereas ouabain inhibited the activity expressed from rat colon alpha subunit with a K-i of 970 mu M when measured at the V-max of the enzyme, We conclude that, when expressed in Xenopus oocytes, the rat colon P-ATPase alpha subunit encodes a ouabain-sensitive H+,K+-ATPase.	UNIV PARIS 05,FAC MED NECKER,INSERM U323,F-75015 PARIS,FRANCE; UNIV CINCINNATI,COLL MED,CINCINNATI,OH 45267; INST PHARMACOL & TOXICOL,CH-1005 LAUSANNE,SWITZERLAND; INST CURIE,UMR144,F-75005 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Cincinnati; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite			Planelles, Gabrielle/F-9603-2013	Planelles, Gabrielle/0000-0002-7314-8837				AGARWAL R, 1994, GASTROENTEROLOGY, V107, P548, DOI 10.1016/0016-5085(94)90184-8; ANAGNOSTOPOULOS T, 1987, J PHYSIOL-LONDON, V393, P73, DOI 10.1113/jphysiol.1987.sp016811; BLANCO G, 1995, BIOCHEMISTRY-US, V34, P319, DOI 10.1021/bi00001a039; BLANCO G, 1994, J BIOL CHEM, V269, P23420; BLANCO G, 1993, P NATL ACAD SCI USA, V90, P1824, DOI 10.1073/pnas.90.5.1824; CALLAGHAN JM, 1995, AM J PHYSIOL-RENAL, V268, pF363, DOI 10.1152/ajprenal.1995.268.3.F363; CHEVAL L, 1991, AM J PHYSIOL, V260, pF800, DOI 10.1152/ajprenal.1991.260.6.F800; CHOW DC, 1993, AM J PHYSIOL, V265, pC1562, DOI 10.1152/ajpcell.1993.265.6.C1562; CHOW DC, 1992, AM J PHYSIOL, V263, pC39, DOI 10.1152/ajpcell.1992.263.1.C39; CORTAS N, 1971, BIOCHIM BIOPHYS ACTA, V249, P181, DOI 10.1016/0005-2736(71)90095-2; CROWSON MS, 1992, J BIOL CHEM, V267, P13740; DELCASTILLO JR, 1991, AM J PHYSIOL, V261, pG1005, DOI 10.1152/ajpgi.1991.261.6.G1005; DETOMASO AW, 1994, J CELL BIOL, V127, P55, DOI 10.1083/jcb.127.1.55; DOUCET A, 1987, AM J PHYSIOL, V253, pF418, DOI 10.1152/ajprenal.1987.253.3.F418; DUARTE CG, 1971, AM J PHYSIOL, V221, P632, DOI 10.1152/ajplegacy.1971.221.2.632; EAKLE KA, 1992, P NATL ACAD SCI USA, V89, P2834, DOI 10.1073/pnas.89.7.2834; FORBUSH B, 1983, CURR TOP MEMBR TRANS, V19, P167; GIFFORD JD, 1992, AM J PHYSIOL, V262, pF692, DOI 10.1152/ajprenal.1992.262.4.F692; HAYASHI M, 1987, AM J PHYSIOL, V252, pF447, DOI 10.1152/ajprenal.1987.252.3.F447; HAYASHI M, 1987, AM J PHYSIOL, V252, pF437, DOI 10.1152/ajprenal.1987.252.3.F437; HORISBERGER JD, 1991, P NATL ACAD SCI USA, V88, P8397, DOI 10.1073/pnas.88.19.8397; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JAISSER F, 1993, AM J PHYSIOL, V265, pC1080, DOI 10.1152/ajpcell.1993.265.4.C1080; JAISSER F, 1993, PFLUG ARCH EUR J PHY, V425, P446, DOI 10.1007/BF00374871; JAISSER F, 1993, J CELL BIOL, V123, P1421, DOI 10.1083/jcb.123.6.1421; JAISSER F, 1996, IN PRESS AM J PHYSL; KLAASSEN CHW, 1993, FEBS LETT, V329, P277, DOI 10.1016/0014-5793(93)80237-O; KRAUT JA, 1995, AM J PHYSIOL-RENAL, V268, pF581, DOI 10.1152/ajprenal.1995.268.4.F581; MARXER A, 1989, J CELL BIOL, V109, P1057, DOI 10.1083/jcb.109.3.1057; MATTHEWS PM, 1995, AM J PHYSIOL, V268, pC1207; RABON EC, 1990, ANNU REV PHYSIOL, V52, P321; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; STRIEDER N, 1974, PFLUG ARCH EUR J PHY, V349, P91, DOI 10.1007/BF00586621; SWEIRY JH, 1990, J PHYSIOL-LONDON, V423, P155, DOI 10.1113/jphysiol.1990.sp018016; TABUCHI Y, 1992, JPN J PHYSIOL, V42, P577, DOI 10.2170/jjphysiol.42.577; Wright FS, 1992, KIDNEY PHYSL PATHOPH, P2209; ZHOU XM, 1992, AM J PHYSIOL, V263, pF43, DOI 10.1152/ajprenal.1992.263.1.F43	38	104	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7277	7280		10.1074/jbc.271.13.7277	http://dx.doi.org/10.1074/jbc.271.13.7277			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631741	hybrid			2022-12-25	WOS:A1996UC77400009
J	deKruif, J; Logtenberg, T				deKruif, J; Logtenberg, T			Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; FRAGMENTS; MINIANTIBODIES; AVIDITY	This report describes the construction of leucine zipper-based dimerization cassettes for the conversion of recombinant monomeric scFv antibody fragments to bivalent and bispecific dimers. A truncated murine IgG3 hinge region and a Fos or Jun leucine zipper were cloned into four scFv fragments previously isolated from a synthetic antibody phage display library, Cysteine residues flanking the zipper region were introduced to covalently link dimerized scFv fragments. The secreted fusion proteins were shown to spontaneously and efficiently form stable Fos . Fos or Jun . Jun homodimers in the Escherichia coli periplasm at levels comparable to their monovalent counterparts. The bivalent (scFv)(2) fragments performed well in enzyme-linked immunosorbent assay, flowcytometric, and immunohistochemical analysis. Fos and Jun homodimer (scFv)(2) antibodies with different specificities could be reduced, reshuffled, and reoxidized to form preparations of functional bispecific (scFv)(2) Fos . Jun heterodimers. These Fos and Jun fusion protein cassettes provide a universal basis for the construction of dimeric scFv antibodies with enhanced avidity or dual specificity.			deKruif, J (corresponding author), UNIV UTRECHT, DEPT IMMUNOL, HP F03821, POB 85500, 3508 GA UTRECHT, NETHERLANDS.							BURTON DR, 1994, ADV IMMUNOL, V57, P189; CRAMERI R, 1993, GENE, V137, P69, DOI 10.1016/0378-1119(93)90253-Y; DEKRUIF J, 1995, P NATL ACAD SCI USA, V92, P3938, DOI 10.1073/pnas.92.9.3938; DERKUIF J, 1995, J MOL BIOL, V248, P97; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; Holliger Philipp, 1993, Current Opinion in Biotechnology, V4, P446, DOI 10.1016/0958-1669(93)90010-T; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; HOOGENBOOM HR, 1992, J MOL BIOL, V227, P381, DOI 10.1016/0022-2836(92)90894-P; HUSTON JS, 1991, METHOD ENZYMOL, V203, P46; KOSTELNY SA, 1992, J IMMUNOL, V148, P1547; KURUCZ I, 1995, J IMMUNOL, V154, P4576; MACK M, 1995, P NATL ACAD SCI USA, V92, P7021, DOI 10.1073/pnas.92.15.7021; MALLENDER WD, 1994, J BIOL CHEM, V269, P199; MEERMAN HJ, 1994, BIO-TECHNOL, V12, P1107, DOI 10.1038/nbt1194-1107; NERI D, 1995, J MOL BIOL, V246, P367, DOI 10.1006/jmbi.1994.0091; NEUBERGER MS, 1984, NATURE, V312, P604, DOI 10.1038/312604a0; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PACK P, 1993, BIO-TECHNOL, V11, P1271; PACK P, 1995, J MOL BIOL, V246, P28, DOI 10.1006/jmbi.1994.0062; PACK P, 1992, BIOCHEMISTRY-US, V31, P1579, DOI 10.1021/bi00121a001; PLUCKTHUN A, 1992, IMMUNOL REV, V130, P151, DOI 10.1111/j.1600-065X.1992.tb01525.x; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245	23	75	154	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7630	7634		10.1074/jbc.271.13.7630	http://dx.doi.org/10.1074/jbc.271.13.7630			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631798	hybrid			2022-12-25	WOS:A1996UC77400066
J	Dvir, A; Garrett, KP; Chalut, C; Egly, JM; Conaway, JW; Conaway, RC				Dvir, A; Garrett, KP; Chalut, C; Egly, JM; Conaway, JW; Conaway, RC			A role for ATP and TFIIH in activation of the RNA polymerase II preinitiation complex prior to transcription initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL-DOMAIN KINASE; MAJOR LATE PROMOTER; FACTOR-DELTA; RAT-LIVER; ABORTIVE INITIATION; RUNOFF TRANSCRIPTS; FACTOR-EPSILON; REQUIREMENT; INVITRO; MECHANISM	A requirement for an ATP cofactor in synthesis of the first 8-10 bonds of promoter-specific transcripts by RNA polymerase II is well established. Whether ATP is required for synthesis of the first phosphodiester bond or at a slightly later stage in synthesis of nascent transcripts, however, remains controversial. Goodrich and Tjian (Goodrich, J. A., and Tjian, R, (1994) Cell 77, 145-156) recently proposed that synthesis of the first phosphodiester bond of promoter-specific transcripts by RNA polymerase II is independent of ATP and general transcription factors TFIIE and TFIIH. Here we investigate this model, Taken together, our findings indicate that ATP, TFIIE, and TFIIH can have a profound effect on the efficiency of transcription initiation, First, we observe that synthesis of the first phosphodiester bond of transcripts initiated at the adenovirus 2 major late promoter depends strongly on ATP, TFIIE, and TFIIH in a transcription system reconstituted with RNA polymerase II, TFIIH, and recombinant TBP, TFIIB, TFIIE, and TFIIF. Second, we demonstrate that, in this enzyme system, ATP-dependent activation of transcription initiation can occur immediately prior to synthesis of the first phosphodiester bond of nascent transcripts, Finally, we demonstrate that the activated initiation complex is unstable and decays rapidly to an inactive state in the presence of the inhibitor ATP gamma S (adenosine 5'-O-(thio)triphosphate), even during reiterative synthesis of abortive transcripts.	OKLAHOMA MED RES FDN,PROGRAM MOLEC & CELL BIOL,OKLAHOMA CITY,OK 73104; CNRS,INSERM U184,F-67404 ILLKIRCH GRAFFENS,FRANCE	Oklahoma Medical Research Foundation; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)				Chalut, Christian/0000-0002-4849-1369; Conaway, Joan/0000-0002-2786-0663	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041628, R37GM041628] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41628] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; ERNST H, 1983, MOL CELL BIOL, V3, P2172, DOI 10.1128/MCB.3.12.2172; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FLORES O, 1992, J BIOL CHEM, V267, P2786; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; JACOB GA, 1994, J BIOL CHEM, V269, P3655; JACOB GA, 1991, J BIOL CHEM, V266, P22537; JIANG Y, 1995, J BIOL CHEM, V270, P27332, DOI 10.1074/jbc.270.45.27332; JIANG Y, 1993, J BIOL CHEM, V268, P6535; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; LUSE DS, 1987, J BIOL CHEM, V262, P14990; MAKELA TP, 1995, P NATL ACAD SCI USA, V92, P5174, DOI 10.1073/pnas.92.11.5174; MCCLURE WR, 1978, J BIOL CHEM, V253, P8941; PARVIN JD, 1994, J BIOL CHEM, V269, P18414; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PETERSON MG, 1991, NATURE, V354, P369; SAMUELS M, 1984, J BIOL CHEM, V259, P2517; SAWADOGO M, 1984, J BIOL CHEM, V259, P5321; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; TAN SY, 1994, BIOTECHNIQUES, V16, P824; TANTIN D, 1994, J BIOL CHEM, V269, P17397; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361	35	71	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7245	7248		10.1074/jbc.271.13.7245	http://dx.doi.org/10.1074/jbc.271.13.7245			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631733				2022-12-25	WOS:A1996UC77400001
J	Fujita, Y; Sasaki, T; Fukui, K; Kotani, H; Kimura, T; Hata, Y; Sudhof, TC; Scheller, RH; Takai, Y				Fujita, Y; Sasaki, T; Fukui, K; Kotani, H; Kimura, T; Hata, Y; Sudhof, TC; Scheller, RH; Takai, Y			Phosphorylation of Munc-18/n-Sec1/rbSec1 by protein kinase C - Its implication in regulating the interaction of Munc-18/n-Sec1/rbSec1 with syntaxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER; MAST-CELLS; RAT-BRAIN; CALCIUM; ACTIVATION; PURIFICATION; EXOCYTOSIS; CHROMATOGRAPHY; SYNAPTOTAGMIN; PHOSPHOLIPIDS	Munc-18/n-Sec1/rbSec1 interacts with syntaxin and this interaction inhibits the association of vesicle-associated membrane protein (VAMP)/synaptobrevin and synaptosomal-associated protein of 25 kDa (SNAP-25) with syntaxin. Syntaxin, VAMP, and SNAP-25 serve as soluble N-ethylmaleimide-sensitive fusion protein attachment protein (SNAP) receptors essential for docking and/or fusion of synaptic vesicles with the presynaptic plasma membrane. Genetic analyses in yeast, Caenorhabditis elegans, and Drosophila suggest that Munc-18 is essential for vesicle transport. On the other hand, protein kinase C (PKC) stimulates Ca2+-dependent exocytosis in various types of secretory cells. However, the modes of action of Munc-18 and PKC in vesicle transport have not been clarified. Here, we show that recombinant Munc-18 is phosphorylated by conventional PKC in a Ca2+- and phospholipid-dependent manner in a cell-free system. About 1 mol of phosphate is maximally incorporated into 1 mol of Munc-18. The major phosphorylation sites are Ser(306) and Ser(313). The Munc-18 complexed with syntaxin is not phosphorylated. The PKC-catalyzed phosphorylation of Munc-18 inhibits its interaction with syntaxin. These results suggest that the PKC-catalyzed phosphorylation of Munc-18 plays an important role in regulating the interaction of Munc-18 with syntaxin and thereby the docking and/or the fusion of synaptic vesicles with the presynaptic plasma membrane.	OSAKA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, SUITA, OSAKA 565, JAPAN; NATL INST PHYSIOL SCI, DEPT CELL PHYSIOL, OKAZAKI, AICHI 444, JAPAN; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DEPT MOLEC GENET, DALLAS, TX 75235 USA; STANFORD UNIV, MED CTR, HOWARD HUGHES MED INST, DEPT CELLULAR & MOLEC PHYSIOL, STANFORD, CA 94305 USA	Osaka University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; Stanford University			Fujita, Yasuyuki/A-4324-2012					AALTO MK, 1992, CELL, V68, P181, DOI 10.1016/0092-8674(92)90462-L; AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; AKAGAWA K, 1986, BRAIN RES, V383, P110, DOI 10.1016/0006-8993(86)90012-0; BAJJALIEH SM, 1995, J BIOL CHEM, V270, P1971, DOI 10.1074/jbc.270.5.1971; BECHTEL PJ, 1977, J BIOL CHEM, V252, P2691; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGOYNE RD, 1988, FEBS LETT, V238, P151, DOI 10.1016/0014-5793(88)80246-1; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GARCIA EP, 1995, J CELL BIOL, V129, P105, DOI 10.1083/jcb.129.1.105; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HOSONO R, 1992, J NEUROCHEM, V58, P1517, DOI 10.1111/j.1471-4159.1992.tb11373.x; HUANG KP, 1988, J BIOL CHEM, V263, P14839; INOUE A, 1992, J BIOL CHEM, V267, P10613; KAIBUCHI K, 1983, J BIOL CHEM, V258, P6701; KATAKAMI Y, 1984, BIOCHEM BIOPH RES CO, V121, P573, DOI 10.1016/0006-291X(84)90220-1; KATO M, 1994, BIOCHEM BIOPH RES CO, V205, P1776, DOI 10.1006/bbrc.1994.2875; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIKKAWA U, 1986, BIOCHEM BIOPH RES CO, V135, P636, DOI 10.1016/0006-291X(86)90040-9; KNIGHT DE, 1983, FEBS LETT, V160, P98, DOI 10.1016/0014-5793(83)80944-2; KOOPMANN WR, 1990, BIOCHEM J, V265, P365, DOI 10.1042/bj2650365; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PELHAM HRB, 1993, NATURE, V364, P582, DOI 10.1038/364582a0; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; POCOTTE SL, 1985, P NATL ACAD SCI USA, V82, P930, DOI 10.1073/pnas.82.3.930; ROTHMAN JE, 1994, NATURE, V372, P56; SALZBERG A, 1993, DEVELOPMENT, V117, P1309; SEKIGUCHI K, 1988, J BIOCHEM-TOKYO, V103, P759, DOI 10.1093/oxfordjournals.jbchem.a122343; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TAKAI Y, 1984, ADV CYCLIC NUCL PROT, V18, P119; TAKAI Y, 1977, J BIOL CHEM, V252, P7603; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; TAKAI Y, 1979, BIOCHEM BIOPH RES CO, V91, P1218, DOI 10.1016/0006-291X(79)91197-5; YAMAUCHI T, 1983, EUR J BIOCHEM, V132, P15, DOI 10.1111/j.1432-1033.1983.tb07319.x; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925	41	224	230	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7265	7268		10.1074/jbc.271.13.7265	http://dx.doi.org/10.1074/jbc.271.13.7265			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631738	hybrid			2022-12-25	WOS:A1996UC77400006
J	Ma, JJ; Tasch, JE; Tao, T; Zhao, JY; Xie, JX; Drumm, ML; Davis, PB				Ma, JJ; Tasch, JE; Tao, T; Zhao, JY; Xie, JX; Drumm, ML; Davis, PB			Phosphorylation-dependent block of cystic fibrosis transmembrane conductance regulator chloride channel by exogenous R domain protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CL CHANNEL; CFTR; GENE; INACTIVATION; CELLS	The cystic fibrosis transmembrane conductance regulator (CFTR) constitutes a linear conductance chloride channel, which is regulated by cAMP-dependent protein kinase phosphorylation at multiple sites located in the intracellular regulatory (R) domain, Studies in a lipid bilayer system, reported here, provide evidence for the control of CFTR chloride channel by its R domain, The exogenous R domain protein (encoded by exon 13 plus 85 base pairs of exon 14) interacted specifically with the CFTR molecule and inhibited the chloride conductance in a phosphorylation-dependent manner. Only the unphosphorylated R domain protein blocked the CFTR channel, Such functional interaction suggests that the putative gating particle of the CFTR chloride channel resides in the R domain.	CASE WESTERN RESERVE UNIV,DEPT PEDIAT,SCH MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT PHYSIOL & BIOPHYS,SCH MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT MOLEC BIOL & MICROBIOL,SCH MED,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045965, P30DK027651] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK45965, R01DK/HL49003, P30DK27651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ARMSTRONG CM, 1973, J GEN PHYSIOL, V62, P375, DOI 10.1085/jgp.62.4.375; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; DULHANTY AM, 1994, BIOCHEMISTRY-US, V33, P4072, DOI 10.1021/bi00179a036; GABRIEL SE, 1992, AM J PHYSIOL, V263, pC708, DOI 10.1152/ajpcell.1992.263.3.C708; GADSBY DC, 1994, TRENDS BIOCHEM SCI, V19, P513, DOI 10.1016/0968-0004(94)90141-4; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1993, J BIOL CHEM, V268, P20259; RIORDAN JR, 1989, SCIENCE, V245, P1066; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; Tao T, 1996, BIOPHYS J, V70, P743, DOI 10.1016/S0006-3495(96)79614-5; TILLY BC, 1992, J BIOL CHEM, V267, P9470; XIE JX, 1995, J BIOL CHEM, V270, P28084; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	20	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7351	7356		10.1074/jbc.271.13.7351	http://dx.doi.org/10.1074/jbc.271.13.7351			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631756	hybrid			2022-12-25	WOS:A1996UC77400024
J	Anderson, JT; Rogers, RP; Jarrett, HW				Anderson, JT; Rogers, RP; Jarrett, HW			Ca2+-calmodulin binds to the carboxyl-terminal domain of dystrophin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN COMPLEX; PROTEIN-KINASE; CROSS-LINKING; ACTIN-BINDING; CALMODULIN; SEQUENCE; SITE; PHOSPHODIESTERASE; PURIFICATION; FLUORESCENT	The unique COOH-terminal domain of dystrophin (mouse dystrophin protein sequences 3266-3678) was expressed as a chimeric fusion protein (with the maltose-binding protein), and its binding to calmodulin was assessed, This fusion protein, called DysS9, bound to calmodulin-Sepharose, bound biotinylated calmodulin, caused characteristic changes in the fluorescence emission spectrum of dansyl-calmodulin, and had an apparent affinity for dansyl-calmodulin of 54 nM. Binding in each case was Ca2+-dependent. The maltose-binding protein does not bind calmodulin, and thus binding resides in the dystrophin-derived sequences. Deletion mutation experiments further localize the high affinity calmodulin binding to mouse dystrophin protein sequences 3293-3349, and this domain contains regions with chemical characteristics found in the calmodulin-binding sequences in other proteins. The COOH-terminal domain provides sites of attachment of dystrophin to membrane proteins, and calmodulin binding may modulate these interactions.	UNIV TENNESSEE,DEPT BIOCHEM,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center								AHN AH, 1995, J CELL BIOL, V128, P363, DOI 10.1083/jcb.128.3.363; ANDERSON JP, 1987, J BIOL CHEM, V262, P6365; BENNETT MK, 1987, P NATL ACAD SCI USA, V84, P1794, DOI 10.1073/pnas.84.7.1794; BONETKERRACHE A, 1994, FEBS LETT, V355, P49, DOI 10.1016/0014-5793(94)01162-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CORRADO K, 1994, FEBS LETT, V344, P255, DOI 10.1016/0014-5793(94)00397-1; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FABBRIZIO E, 1993, BIOCHEMISTRY-US, V32, P10457, DOI 10.1021/bi00090a023; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; GRAF E, 1980, ARCH BIOCHEM BIOPHYS, V203, P719, DOI 10.1016/0003-9861(80)90231-3; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; Jarrett H W, 1980, Ann N Y Acad Sci, V356, P119, DOI 10.1111/j.1749-6632.1980.tb29605.x; JARRETT HW, 1995, J BIOL CHEM, V270, P5578, DOI 10.1074/jbc.270.10.5578; JARRETT HW, 1986, J BIOL CHEM, V261, P4967; JARRETT HW, 1991, J BIOL CHEM, V266, P362; JOHNSON JD, 1983, BIOCHEM J, V211, P473, DOI 10.1042/bj2110473; KAKIUCHI S, 1981, FEBS LETT, V132, P144, DOI 10.1016/0014-5793(81)80449-8; KAKIUCHI S, 1985, CALCIUM BIOL SYSTEMS, P275; KARINCH AM, 1990, J BIOL CHEM, V265, P11833; KINCAID RL, 1982, J BIOL CHEM, V257, P638; KINCAID RL, 1988, METHOD ENZYMOL, V159, P605; KOENIG M, 1989, AM J HUM GENET, V45, P498; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUISE M, 1993, BIOCHEM J, V293, P243, DOI 10.1042/bj2930243; MADHAVAN R, 1995, BIOCHEMISTRY-US, V34, P12204, DOI 10.1021/bi00038a014; MADHAVAN R, 1994, BIOCHEMISTRY-US, V33, P5797, DOI 10.1021/bi00185a018; MADHAVAN R, 1992, BIOCHEM BIOPH RES CO, V185, P753, DOI 10.1016/0006-291X(92)91690-R; MADHAVAN R, 1995, FASEB J, V9, pA1409; MEZGUELDI M, 1994, J BIOL CHEM, V269, P12824; MILNER RE, 1993, J BIOL CHEM, V268, P21901; Sambrook J., 2002, MOL CLONING LAB MANU; SENTER L, 1993, BIOCHEM BIOPH RES CO, V192, P899, DOI 10.1006/bbrc.1993.1500; SOBUE K, 1981, BIOCHEM BIOPH RES CO, V100, P1063, DOI 10.1016/0006-291X(81)91931-8; SUZUKI A, 1992, FEBS LETT, V308, P154, DOI 10.1016/0014-5793(92)81265-N; SUZUKI A, 1995, J CELL BIOL, V128, P373, DOI 10.1083/jcb.128.3.373; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; TAKIO K, 1986, BIOCHEMISTRY-US, V25, P8049, DOI 10.1021/bi00372a038; TINSLEY JM, 1994, P NATL ACAD SCI USA, V91, P8307, DOI 10.1073/pnas.91.18.8307; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WAGNER KR, 1994, J NEUROCHEM, V62, P1947; WAY M, 1992, FEBS LETT, V301, P243, DOI 10.1016/0014-5793(92)80249-G; WINDER SJ, 1995, FEBS LETT, V357, P125, DOI 10.1016/0014-5793(94)01347-4; WLASH MP, 1995, BIOCHEMISTRY-US, V34, P5561; YANG B, 1995, J BIOL CHEM, V270, P4975, DOI 10.1074/jbc.270.10.4975; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	47	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6605	6610		10.1074/jbc.271.12.6605	http://dx.doi.org/10.1074/jbc.271.12.6605			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636075	hybrid			2022-12-25	WOS:A1996UB15700010
J	Kelly, SE; Bachurski, CJ; Burhans, MS; Glasser, SW				Kelly, SE; Bachurski, CJ; Burhans, MS; Glasser, SW			Transcription of the lung-specific surfactant protein C gene is mediated by thyroid transcription factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; INSITU HYBRIDIZATION; SP-A; EXPRESSION; ELEMENTS; TISSUE; LOCALIZATION; SEQUENCE; PROMOTER; REGIONS	Surfactant protein C (SP-C) is expressed in alveolar Type II epithelial cells of the lung, In order to determine the mechanism(s) that regulate gene transcription, we have analyzed the activation of the murine SP-C promoter in mouse lung epithelial cells (RILE cells) and in HeLa cells after co-transfection with a vector expressing rat thyroid transcription factor-1 (TTF-1). TTF-1 transactivated SP-C-chloramphenicol acetyltransferase constructs containing -13 kilobase pairs to -320 base pairs (bp) of the 5' flanking region of the SP-C gene. Essential cis-acting elements were functionally localized to between -320 and -180 bp from the start of transcription by transfection analysis. Five DNase-protected regions, indicating multiple protein-DNA interactions within the -320 bp TTF-l-responsive region of the SP-C gene, were identified by I)Nase footprint analysis. A 40-bp segment of SP-C DNA from -197 to -158 linked to a heterologous promoter chloramphenicol acetyltransferase construct activated expression after co-transfection with CMV-TTF-1 in HeLa and RILE cells, The -197 to -158 segment contained two consensus TTF-1 sites, which were specifically identified as TTF-1 binding sites by gel retardation and antibody supershift with MLE cell nuclear extracts and purified TTF-1 homeodomain protein, Site-specific mutagenesis of either of the TTF-1 binding sites completely blocked activation by TTF-1, indicating both sites are required for TTF stimulation of SP-C transcription.	CHILDRENS HOSP,MED CTR,DIV PULM BIOL,TCHRF,CINCINNATI,OH 45229	Cincinnati Children's Hospital Medical Center				Bachurski, Cindy/0000-0002-3118-0636	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007752, R01HL050046, R29HL050046] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50046, HL07752] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNONE MI, 1995, J BIOL CHEM, V270, P12048, DOI 10.1074/jbc.270.20.12048; BEERS MF, 1992, AM J PHYSIOL, V263, pL151, DOI 10.1152/ajplung.1992.263.2.L151; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; CLEVIDENCE DE, 1994, DEV BIOL, V166, P195, DOI 10.1006/dbio.1994.1307; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; DAMANTE G, 1991, P NATL ACAD SCI USA, V88, P5388, DOI 10.1073/pnas.88.12.5388; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; GLASSER SW, 1990, J BIOL CHEM, V265, P21986; GLASSER SW, 1988, J BIOL CHEM, V263, P10326; GLASSER SW, 1991, AM J PHYSIOL, V261, pL349, DOI 10.1152/ajplung.1991.261.4.L349; IKEDA K, 1995, J BIOL CHEM, V270, P8108, DOI 10.1074/jbc.270.14.8108; KORFHAGEN TR, 1990, P NATL ACAD SCI USA, V87, P6122, DOI 10.1073/pnas.87.16.6122; KORFHAGEN TR, 1994, J CLIN INVEST, V93, P1691, DOI 10.1172/JCI117152; KORFHAGEN TR, 1992, AM J PHYSIOL, V263, pL546, DOI 10.1152/ajplung.1992.263.5.L546; KUROKI Y, 1994, J BIOL CHEM, V269, P25943; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; PHELPS DS, 1991, EXP LUNG RES, V17, P985, DOI 10.3109/01902149109064330; ROONEY SA, 1994, FASEB J, V8, P957, DOI 10.1096/fasebj.8.12.8088461; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHIMURA H, 1994, MOL ENDOCRINOL, V8, P1049, DOI 10.1210/me.8.8.1049; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; WHITSETT JA, 1992, PULMONARY SURFACTANT, P55; WIKENHEISER KA, 1992, CANCER RES, V52, P5342; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; WOHLFORDLENANE CL, 1992, AM J RESP CELL MOL, V7, P335, DOI 10.1165/ajrcmb/7.3.335; WOPHLFORDLENANE CL, 1992, AM J RESPIR CELL MOL, V6, P225; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	32	200	205	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6881	6888		10.1074/jbc.271.12.6881	http://dx.doi.org/10.1074/jbc.271.12.6881			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636114	hybrid			2022-12-25	WOS:A1996UB15700049
J	Bodovitz, S; Klein, WL				Bodovitz, S; Klein, WL			Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E POLYMORPHISM; ALZHEIMERS-DISEASE; PARENTERAL USE; SEQUENCE; CELLS; HYDROXYPROPYLCYCLODEXTRINS; PHOSPHORYLATION; IDENTIFICATION; MEMBRANES; TRANSPORT	Amyloid precursor protein (APP) and cholesterol metabolism are genetically linked to Alzheimer's disease, the latter through apolipoprotein E, a lipid and cholesterol transport protein. We have examined the hypothesis that the processing of APP is disrupted by elevated cholesterol, which is known to modulate the activity of several transmembrane proteins. In the current study, cholesterol, solubilized by methyl-beta-cyclodextrin or ethanol, was added to the culture media of APP 751 stably transfected HEK 293 cells. Radiolabeled APP and APP(sol) (the soluble N-terminal derivative following alpha-secretase cleavage) were precipitated from lysates and conditioned media of stably transfected HEK 293 cells; the relative levels were determined by quantitative densitometry following separation by SDS-polyacrylamide gel electrophoresis. The data show that cholesterol, solubilized by methyl-beta-cyclodextrin, greatly reduced the levels of APP(sol). Low doses of ethanol-solubilized cholesterol similarly caused a dramatic reduction of APP(sol). By contrast, levels of APP holoprotein remained the same or increased. The large decrease seen in APP(sol) production was not due to nonspecific inhibition of secretion because several secreted proteins increased in level. Cholesterol, which impedes membrane fluidity, may lower APP(sol) production by impeding the interaction of the substrate with its protease(s). If APP(sol) were to function trophically, as suggested by other studies, the current conclusion suggests that changes in cellular cholesterol levels in Alzheimer's disease could contribute to neuronal degeneration by decreasing the production of APP(sol).	NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,EVANSTON,IL 60208	Northwestern University					NIA NIH HHS [AG10481] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG010481] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON JP, 1992, J NEUROCHEM, V59, P2328; ANDERSON JP, 1991, NEUROSCI LETT, V128, P126, DOI 10.1016/0304-3940(91)90775-O; ARAKI W, 1991, BIOCHEM BIOPH RES CO, V181, P265, DOI 10.1016/S0006-291X(05)81412-3; BODOVITZ S, 1995, J NEUROCHEM, V64, P307; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P2252, DOI 10.1073/pnas.89.6.2252; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CRAIDO M, 1982, BIOCHEMISTRY-US, V21, P3622; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; DECAPRIO J, 1992, J LIPID RES, V33, P441; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FERREIRA A, 1993, J NEUROSCI, V13, P3112; FONG TM, 1986, BIOCHEMISTRY-US, V25, P830, DOI 10.1021/bi00352a015; GILLESPIE SL, 1992, BIOCHEM BIOPH RES CO, V187, P1285, DOI 10.1016/0006-291X(92)90442-N; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GREENBERG SM, 1994, P NATL ACAD SCI USA, V91, P7104, DOI 10.1073/pnas.91.15.7104; GRUNZE M, 1980, BIOCHIM BIOPHYS ACTA, V600, P860, DOI 10.1016/0005-2736(80)90489-7; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HERON DS, 1980, P NATL ACAD SCI-BIOL, V77, P7463, DOI 10.1073/pnas.77.12.7463; IRIE T, 1992, J PHARM SCI-US, V81, P524, DOI 10.1002/jps.2600810610; IRIE T, 1992, J PHARM SCI, V81, P521, DOI 10.1002/jps.2600810609; JAFFE AB, 1994, J BIOL CHEM, V269, P13065; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; LASA M, 1991, ENDOCRINOLOGY, V132, P1701; LEBLANC AC, 1992, J NEUROSCI RES, V31, P635, DOI 10.1002/jnr.490310407; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MITCHELL DC, 1990, BIOCHEMISTRY-US, V29, P9143, DOI 10.1021/bi00491a007; NINOMIYA H, 1993, J CELL BIOL, V121, P879, DOI 10.1083/jcb.121.4.879; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; NITSCH RM, 1993, P NATL ACAD SCI USA, V90, P5191, DOI 10.1073/pnas.90.11.5191; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; PIRTILIA T, 1995, J NEUROL SCI, V127, P90; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUBERT D, 1989, BIOCHEM BIOPH RES CO, V162, P83, DOI 10.1016/0006-291X(89)91965-7; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SING CF, 1985, AM J HUM GENET, V37, P268; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SPARKS DL, 1993, J NEUROPATH EXP NEUR, V52, P135, DOI 10.1097/00005072-199303000-00006; SPARKS DL, 1990, NEUROBIOL AGING, V11, P601, DOI 10.1016/0197-4580(90)90024-T; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; USAMI M, 1993, J NEUROCHEM, V61, P239, DOI 10.1111/j.1471-4159.1993.tb03560.x; UTERMANN G, 1994, CURR BIOL, V4, P362, DOI 10.1016/S0960-9822(00)00081-6; WANG R, 1991, J BIOL CHEM, V266, P16960; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; YEAGLE PL, 1991, BIOCHIMIE, V73, P1303, DOI 10.1016/0300-9084(91)90093-G	50	398	414	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4436	4440						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626795				2022-12-25	WOS:A1996TW96000073
J	Kuang, YN; Wu, YP; Jiang, HP; Wu, DQ				Kuang, YN; Wu, YP; Jiang, HP; Wu, DQ			Selective G protein coupling by C-C chemokine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; PHOSPHOLIPASE-C; ALPHA-SUBUNITS; FUNCTIONAL EXPRESSION; SIGNAL-TRANSDUCTION; COMPLEMENTARY-DNA; BETA-GAMMA; ACTIVATION; FAMILY; CELLS	The C-C chemokines are major mediators of chemotaxis of monocytes and some T cells in inflammatory reactions. The pathways by which the C-C chemokine receptors activate phospholipase C (PLC) were investigated in cotransfected COS-7 cells. The C-C chemokine receptor-1 (CKR-1), the MCP-1 receptor-A (MCP-1Ra), and MCP-1Rb can reconstitute ligand-induced accumulation of inositol phosphates with PLC beta 2 in a pertussis toxin-sensitive manner, presumably through G beta gamma released from the G(i) proteins. However, these three receptors demonstrated different specificity in coupling to the alpha subunits of the G(q) class. While none of the receptors can couple to G alpha q/11, MCP-1Rb can couple to both G alpha 14 and G alpha 16, but its splicing variant, MCP-1Rb, cannot. Since MCP-1Ra and -b differ only in their C-terminal intracellular domains, the C-terminal ends of MCP-1Rs determine G protein coupling specificity. CKR-1 can couple to G alpha 14 but not to G alpha 16, suggesting some of the C-C chemokine receptors, unlike the C-X-C chemokine receptors, discriminate against G alpha 16, a hematopoietic-specific G alpha subunit. The intriguing specificity in coupling of the G(q) class of G proteins implies that the chemokines may be involved in some distinct functions in vivo. The commonality of the chemokine receptors in coupling to the G(i)-G beta gamma-PLC beta 2 pathway provides a potential target for developing broad spectrum anti-inflammatory drugs.	UNIV ROCHESTER, DEPT PHARMACOL, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, DEPT PHYSIOL, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, DEPT BIOCHEM, ROCHESTER, NY 14642 USA; UNIV ROCHESTER, DEPT ONCOL, ROCHESTER, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester					NIGMS NIH HHS [GM53162429] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; FRANCI C, 1995, J IMMUNOL, V154, P6511; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; JIANG HP, 1994, J BIOL CHEM, V269, P7593; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; KRIZ R, 1990, CIBA F SYMP, V150, P112; LEE CH, 1992, J BIOL CHEM, V267, P16044; MURPHY PM, 1987, FEBS LETT, V221, P81, DOI 10.1016/0014-5793(87)80356-3; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; SCHALL TJ, 1994, CYTOKINE HDB, P419; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; UEDA N, 1994, J BIOL CHEM, V269, P4388; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1995, J BIOL CHEM, V270, P16008, DOI 10.1074/jbc.270.27.16008; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; WU DQ, 1995, J BIOL CHEM, V270, P9828, DOI 10.1074/jbc.270.17.9828; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811	31	163	166	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					3975	3978						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626727				2022-12-25	WOS:A1996TW96000005
J	Li, QT; Karam, SM; Gordon, JI				Li, QT; Karam, SM; Gordon, JI			Diphtheria toxin-mediated ablation of parietal cells in the stomach of transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE STOMACH; EPITHELIAL-CELLS; BETA-SUBUNIT; CORPUS; DYNAMICS; GENE; EXPRESSION; MIGRATION; LINEAGE	The self-renewing epithelial populations present in the gastric units of the mouse stomach are descended from a multipotent stem cell and undergo an orderly migration-associated differentiation followed by apoptosis, The steady state census of the three principal cell types (acid-producing parietal cells, mucus-producing pit cells, and pepsinogen and intrinsic factor-producing zymogenic cells) is accurately controlled, despite marked differences in the rates of migration of each lineage, A transgenic mouse model has been created to define functional interrelationships between the proliferation, differentiation, and death programs of these Lineages, Nucleotides -1035 to +24 of the noncatalytic beta subunit gene of mouse H+/K+-ATPase were used to direct expression of an attenuated diphtheria toxin A subunit in the parietal cell lineage, These transcriptional regulatory elements are not active in members of the pit and zymogenic lineages, Stomachs, prepared from postnatal day 28-80 transgenic mice and their normal littermates, were subjected to single- and multilabel immunohistochemical studies as well as qualitative and quantitative light and electron microscopic morphologic analyses, The toxin produced complete ablation of differentiated parietal cells, Loss of parietal cells was accompanied by a 5-fold increase in the number of undifferentiated granule-free cells located in the proliferative compartment of gastric units, This amplified population of granule-free cells included the multipotent stem cell as well as committed precursors of the pit and zymogenic lineages, Loss of mature parietal cells was also associated with (i) a block in the differentiation program of the zymogenic lineage with an accumulation of pre-neck cells and a depletion of their neck and mature zymogenic cell descendants, and (ii) an similar to 2-fold amplification of pit cells, These findings are consistent with the notion that epithelial homeostasis within gastric units is maintained by instructive interactions between their different cell lineages, Unlike pit and zymogenic cells, parietal cells complete their differentiation in the gastric unit's proliferative compartment before undergoing a bipolar migration along the unit, Thus, the mature parietal cell is in a strategic position to influence decision-making among gastric epithelial cell precursors and to modulate the migration-associated terminal differentiation programs of the pit and zymogenic lineages.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; KUWAIT UNIV,FAC MED,DEPT ANAT,SAFAT 13110,KUWAIT	Washington University (WUSTL); Kuwait University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK033487] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33487] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BREITMAN ML, 1990, MOL CELL BIOL, V10, P474, DOI 10.1128/MCB.10.2.474; CANFIELD VA, 1991, P NATL ACAD SCI USA, V88, P8247, DOI 10.1073/pnas.88.18.8247; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; FALK P, 1994, AM J PHYSIOL, V266, pG987, DOI 10.1152/ajpgi.1994.266.6.G987; FALK P, 1995, AM J PHYSIOL-GASTR L, V268, pG553, DOI 10.1152/ajpgi.1995.268.4.G553; FALK PG, 1995, P NATL ACAD SCI USA, V92, P1515, DOI 10.1073/pnas.92.5.1515; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; HOGAN B, 1986, MANIPULATING MOUSE E; KARAM SM, 1993, ANAT RECORD, V236, P280, DOI 10.1002/ar.1092360203; KARAM SM, 1993, ANAT REC, V236, P314, DOI 10.1002/ar.1092360205; KARAM SM, 1993, ANAT REC, V236, P333, DOI 10.1002/ar.1092360206; KARAM SM, 1993, ANAT REC, V236, P297, DOI 10.1002/ar.1092360204; KARAM SM, 1992, ANAT RECORD, V232, P231, DOI 10.1002/ar.1092320208; KARAM SM, 1993, ANAT REC, V236, P259, DOI 10.1002/ar.1092360202; LEE ER, 1982, AM J ANAT, V164, P187, DOI 10.1002/aja.1001640302; LI QT, 1995, J BIOL CHEM, V270, P15777, DOI 10.1074/jbc.270.26.15777; LORENZ RG, 1993, J BIOL CHEM, V268, P26559; MAXWELL F, 1987, MOL CELL BIOL, V7, P1576, DOI 10.1128/MCB.7.4.1576; MORLEY GP, 1992, J BIOL CHEM, V267, P1165	20	170	173	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3671	3676						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631979	hybrid			2022-12-25	WOS:A1996TV72400053
J	Patstone, G; Maher, P				Patstone, G; Maher, P			Copper and calcium binding motifs in the extracellular domains of fibroblast growth factor receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL SPECIFICITY; FGF RECEPTORS; FAMILY; PROTEINS; HEPARIN; UVOMORULIN; DIVERSITY; MECHANISM; CLONING; KINASE	High affinity fibroblast growth factor (FGF) receptors contain a cluster of acidic amino acids in their extracellular domains that is reminiscent of the calcium binding domains of some cell adhesion molecules. Based on this observation, we used a calcium blotting technique to show that FGFR-1 binds calcium and that calcium binding is not observed in a mutagenized form of the receptor that lacks the acidic box region. The acidic box also binds other divalent cations, including copper. This latter interaction appears unique since the binding of copper to FGFR-1 mediates the binding of the receptor to immobilized heparin. While this observation may help explain the angiogenic properties of copper, divalent cation binding to FGF receptors may also mediate the interaction between FGF receptors, cell adhesion molecules and other proteoglycan components of the extracellular matrix.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK018811] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 18811] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAIRD A, 1990, PEPTIDE GROWTH FACTO, V1, P369; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BYERS S, 1992, DEV BIOL, V152, P411, DOI 10.1016/0012-1606(92)90149-B; CHAUDHURI MM, 1993, J CELL PHYSIOL, V157, P209, DOI 10.1002/jcp.1041570202; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; FUCHS F, 1972, INT J PEPT PROT RES, V4, P147; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GULLINO PM, 1986, ANTICANCER RES, V6, P153; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNEKEN A, 1995, J CELL BIOL, V128, P1221, DOI 10.1083/jcb.128.6.1221; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HOU JZ, 1992, J BIOL CHEM, V267, P17804; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kemler R, 1989, CURR OPIN CELL BIOL, V1, P892, DOI 10.1016/0955-0674(89)90055-0; Kiefer M C, 1991, Growth Factors, V5, P115, DOI 10.3109/08977199109000276; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MCAUSLAN BR, 1980, EXP CELL RES, V130, P147, DOI 10.1016/0014-4827(80)90051-8; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; PARTANEN J, 1993, PHILOS T R SOC B, V340, P297, DOI 10.1098/rstb.1993.0071; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; RAJU KS, 1984, CANCER RES, V44, P1579; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; STUART DI, 1986, NATURE, V324, P84, DOI 10.1038/324084a0; TERRELL GE, 1991, MATRIX, V11, P108, DOI 10.1016/S0934-8832(11)80214-3; UENO H, 1992, J BIOL CHEM, V267, P1470; WAGNER JA, 1991, CURR TOP MICROBIOL, V165, P95; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; ZIMMER Y, 1993, J BIOL CHEM, V268, P7899	34	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3343	3346						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631930				2022-12-25	WOS:A1996TV72400004
J	Tangir, J; Muto, MG; Berkowitz, RS; Welch, WR; Bell, DA; Mok, SC				Tangir, J; Muto, MG; Berkowitz, RS; Welch, WR; Bell, DA; Mok, SC			A 400 kb novel deletion unit centromeric to the BRCA1 gene in sporadic epithelial ovarian cancer	ONCOGENE			English	Article						ovary; cancer; borderline; BRCA1; loss of heterozygosity	HETEROZYGOSITY; TUMORS	Allelic deletions on chromosome 17q21 in sporadic ovarian cancer are common, suggesting that inactivation of a tumor suppressor gene(s) in that region may be important for the etiology of these tumors. The recently identified BRCA1 gene on 17q21, involved in the development of familial breast/ovarian cancer, could be a candidate. However, inactivating mutations on BRCA1 in sporadic ovarian cancer has been rarely described. Furthermore, the potential relationship of BRCA1 gene to ovarian tumors of borderline malignancy remains also unclear. We constructed a highly detailed deletion map of chromosome 17q21 based on PCR amplification of eight polymorphic tandem repeat markers in a 650 kb area including three BRCA1 intragenic markers. DNA from 52 sporadic ovarian cancers and 26 borderline tumors, together with their corresponding normal control tissues were used. Only one borderline tumor showed loss of heterozygosity at one marker, whereas 65% of invasive ovarian cancers displayed allelic loss in at least one of the markers studied. A common deletion unit, located approximately 60 kb centromeric to BRCA1, was revealed. These results suggest that inactivation of the BRCA1 gene may not be responsible for the development of borderline ovarian tumors and that another tumor suppressor gene, located centromeric to the BRCA1 gene, may play a role in sporadic ovarian cancer development.	BRIGHAM & WOMENS HOSP, DEPT OBSTET GYNECOL & REPROD BIOL, LAB GYNECOL ONCOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, MASSACHUSETTS GEN HOSP, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital					NATIONAL CANCER INSTITUTE [R01CA063381] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA63381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1987, Am J Obstet Gynecol, V156, P263; BEWTRA C, 1992, INT J GYNECOL PATHOL, V11, P180, DOI 10.1097/00004347-199207000-00003; BOYD J, 1995, NAT GENET, V9, P335, DOI 10.1038/ng0495-335; COUCH FJ, 1994, GENOMICS, V24, P419, DOI 10.1006/geno.1994.1647; CROOP CS, 1995, CANCER LETT, V90, P51, DOI 10.1016/0304-3835(94)03677-B; CROPP CS, 1994, CANCER RES, V54, P2548; DODSON MK, 1993, CANCER RES, V53, P4456; EASTON DF, 1994, LANCET, V344, P761, DOI 10.1016/S0140-6736(94)92256-X; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; FRIEDMAN LS, 1995, GENOMICS, V25, P256, DOI 10.1016/0888-7543(95)80133-7; FRIEDMAN LS, 1994, CANCER RES, V54, P6374; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GODWIN AK, 1994, AM J HUM GENET, V55, P666; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; JACOB ANK, 1995, ONCOGENE, V11, P981; JACOBS IJ, 1993, CANCER RES, V53, P1218; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOK CH, 1992, CANCER RES, V52, P5119; MOK SCH, 1993, CANCER RES, V53, P1489; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; NEUHAUSEN SL, 1994, HUM MOL GENET, V3, P1919, DOI 10.1093/hmg/3.11.1919; RODABAUGH KJ, 1995, CANCER RES, V55, P2169; TAKAHASHI H, 1995, CANCER RES, V55, P2998; VOGELSTEIN B, 1994, CELL, V79, P1, DOI 10.1016/0092-8674(94)90393-X; WERTHEIM I, 1994, J NATL CANCER I, V86, P1549, DOI 10.1093/jnci/86.20.1549; 1995, CANCER FACTS FIGURES, P6	27	45	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	1996	12	4					735	740						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632895				2022-12-25	WOS:A1996TW68600004
J	Arribas, J; Coodly, L; Vollmer, P; Kishimoto, TK; RoseJohn, S; Massague, J				Arribas, J; Coodly, L; Vollmer, P; Kishimoto, TK; RoseJohn, S; Massague, J			Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ANCHORED GROWTH-FACTORS; TGF-ALPHA; MEMBRANE; CLEAVAGE; RECEPTOR; LIGAND; MECHANISMS; RELEASE; DISEASE	The extracellular domains of a diverse group of membrane proteins are shed in response to protein kinase C activators such as phorbol 12-myristate 13-acetate (PMA). The lack of sequence similarity in the cleavage sites suggests the involvement-of many proteases of diverse specificity in this process. However, a mutant Chinese hamster ovary cell line recently isolated for being defective in PMA-activated shedding of the membrane-anchored growth factor transforming growth factor alpha precursor (proTGF-alpha) is concomitantly defective in the shedding of many other unrelated membrane proteins. Here we show that independent mutagenesis and selection experiments yield shedding mutants having the same recessive phenotype and belonging to the same genetic complementation group. Furthermore, two structurally distinct agents, TAPI-2 and 1,10-phenanthroline, which are known to inhibit metalloproteases, block PMA-activated shedding of proTGF-alpha, cell adhesion receptor L-selectin, interleukin 6 receptor alpha subunit, beta-amyloid precursor protein, and an entire set of anonymous Chinese hamster ovary cell surface proteins. Certain serine protease inhibitors prevent release of these proteins by interfering with their maturation and transport to the cell surface but do not inhibit ectodomain shedding hom the cell surface. The results suggest the existence of a common system for membrane protein ectodomain shedding involving one or several proteolytic activities sensitive to metalloprotease inhibitors, whose ability to act can be disrupted by recessive mutations in a single gene.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021; UNIV MAINZ,FAK MED,MED KLIN 1,D-55101 MAINZ,GERMANY; BOEHRINGER INGELHEIM PHARMACEUT INC,DEPT IMMUNOL,RIDGEFIELD,CT 06877	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Johannes Gutenberg University of Mainz; Boehringer Ingelheim			Arribas, Joaquin/M-4482-2014; Rose-John, Stefan/A-7998-2010	Arribas, Joaquin/0000-0002-0504-0664; Rose-John, Stefan/0000-0002-7519-3279; Massague, Joan/0000-0001-9324-8408	NCI NIH HHS [CA53559] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053559] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; BAZIL V, 1994, J IMMUNOL, V152, P1314; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BOSENBERG MW, 1993, J CELL BIOL, V122, P95, DOI 10.1083/jcb.122.1.95; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; DINARELLO CA, 1995, CURR BIOL, V5, P587, DOI 10.1016/S0960-9822(95)00116-3; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; FERNANDEZBOTRAN R, 1991, FASEB J, V5, P2567, DOI 10.1096/fasebj.5.11.1868981; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GEARING AJH, 1993, IMMUNOL TODAY, V14, P506, DOI 10.1016/0167-5699(93)90267-O; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; IGNOTZ RA, 1986, P NATL ACAD SCI USA, V83, P6307, DOI 10.1073/pnas.83.17.6307; KAHN J, 1994, J CELL BIOL, V125, P461, DOI 10.1083/jcb.125.2.461; LECA G, 1995, J IMMUNOL, V154, P1069; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MULLBERG J, 1994, J IMMUNOL, V152, P4958; MULLBERG J, 1992, BIOCHEM BIOPH RES CO, V189, P794, DOI 10.1016/0006-291X(92)92272-Y; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PORTEU F, 1991, J BIOL CHEM, V266, P18846; Powers J.C., 1986, PROTEINASE INHIBITOR, P219; RAMCHANDRAN R, 1994, J BIOL CHEM, V269, P2125; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; SERRAPAGES C, 1994, J BIOL CHEM, V269, P23632; SISODIA SS, 1995, FASEB J, V9, P366, DOI 10.1096/fasebj.9.5.7896005; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SKEGGS LT, 1956, J EXP MED, V103, P295, DOI 10.1084/jem.103.3.295; STEIN J, 1991, ONCOGENE, V6, P601; STOYAN T, 1993, EUR J BIOCHEM, V216, P239, DOI 10.1111/j.1432-1033.1993.tb18138.x; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	36	361	369	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11376	11382		10.1074/jbc.271.19.11376	http://dx.doi.org/10.1074/jbc.271.19.11376			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626692	hybrid			2022-12-25	WOS:A1996UJ94400052
J	Ozer, J; Bolden, AH; Lieberman, PM				Ozer, J; Bolden, AH; Lieberman, PM			Transcription factor IIA mutations show activator-specific defects and reveal a IIA function distinct from stimulation of TBP-DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TFIID COMPLEX; BASIC REPEAT; SUBUNITS; DOMAIN; YEAST; PROTEIN; IDENTIFICATION; COACTIVATORS; INITIATION	The general transcription factor IIA (TFIIA) binds to the TATA binding protein (TBP) and mediates transcriptional activation by distinct classes of activators. To elucidate the function of TFIIA in transcriptional activation, point mutants were created in the human TFIIA-gamma subunit at positions conserved with the yeast homologue. We have identified a class of TFIIA mutants that stimulate TBP-DNA binding (T-A complex) but fail to support transcriptional activation by several different activators, suggesting that these mutants are defective in their ability to facilitate an activation step subsequent to TBP promoter binding, Point mutations of the hydrophobic core of conserved residues from 65 to 74 resulted in various activation-defective phenotypes. These residues were found to be important for TFIIA gamma-gamma interactions, suggesting that gamma-gamma interactions are critical for TFIIA function as a coactivator. A subset of these TFIIA-gamma mutations disrupted transcriptional activation by all activators tested, except for the Epstein-Barr virus encoded Zta protein. The gamma Y65F, gamma W72A, and gamma W72F mutants mediate Zta activation, but not GAL4-AH, AP-1, GAL4-CTF, or GAL4-VP16 activation. The gamma W72A mutant failed to stimulate TFIID-DNA binding (D-A complex) but was able to form a complex with TFIID and DNA in the presence of Zta (Z-D-A complex). Thus, the ability of Zta to activate transcription with gamma W72A appears to result fi om a unique ability to form the stable Z-D-A complex with this mutant. Our results show that different activators utilize the general factor TFIIA in unique ways and that TFIIA contributes transcription activation functions in addition to the facilitation of TBP-DNA binding.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; ROCHE INST MOLEC BIOL,NUTLEY,NJ 07110	The Wistar Institute								ARNDT KM, 1995, EMBO J, V14, P1490, DOI 10.1002/j.1460-2075.1995.tb07135.x; ASO T, 1994, EMBO J, V13, P435, DOI 10.1002/j.1460-2075.1994.tb06278.x; AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; BERNSTEIN R, 1994, J BIOL CHEM, V269, P24361; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAREY M, 1992, J VIROL, V66, P4803, DOI 10.1128/JVI.66.8.4803-4813.1992; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CHI TH, 1993, MOL CELL BIOL, V13, P7045, DOI 10.1128/MCB.13.11.7045; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; COLGAN J, 1992, GENE DEV, V6, P304, DOI 10.1101/gad.6.2.304; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; DEJONG J, 1995, P NATL ACAD SCI USA, V92, P3313, DOI 10.1073/pnas.92.8.3313; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; INOSTROZA JA, 1992, CELL, V70, P477; KAISER K, 1995, EMBO J, V14, P3520, DOI 10.1002/j.1460-2075.1995.tb07358.x; KANG JJ, 1995, MOL CELL BIOL, V15, P1234; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM TK, 1993, J BIOL CHEM, V268, P20866; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; KOBAYASHI N, 1995, MOL CELL BIOL, V15, P6465; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LEE M, 1995, MOL CELL BIOL, V15, P5461; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN P, 1994, MOL CELL BIOL, V14, P8365, DOI 10.1128/MCB.14.12.8365; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; MA DM, 1993, GENE DEV, V7, P2246, DOI 10.1101/gad.7.11.2246; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; OHKUMA Y, 1995, MOL CELL BIOL, V15, P4856; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; PUGH BF, 1992, J BIOL CHEM, V267, P679; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; RANISH JA, 1991, J BIOL CHEM, V266, P19320; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; STARGELL LA, 1995, SCIENCE, V269, P75, DOI 10.1126/science.7604282; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUN XQ, 1994, GENE DEV, V8, P2336, DOI 10.1101/gad.8.19.2336; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TANSEY WP, 1994, GENE DEV, V8, P2756, DOI 10.1101/gad.8.22.2756; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	67	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11182	11190		10.1074/jbc.271.19.11182	http://dx.doi.org/10.1074/jbc.271.19.11182			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626665	hybrid			2022-12-25	WOS:A1996UJ94400025
J	Boss, V; Talpade, DJ; Murphy, TJ				Boss, V; Talpade, DJ; Murphy, TJ			Induction of NFAT-mediated transcription by G(q)-coupled receptors in lymphoid and non-lymphoid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOSPORINE-A; NUCLEAR FACTOR; MUSCARINIC RECEPTOR; ACTIVATION; CALCINEURIN; IDENTIFICATION; SPECIFICITY; COMPLEX; PROTEIN; BINDING	The nuclear factor of activated T cells (NFAT) was discovered as an inducible transcription factor activated by antigen stimulation of the T cell receptor in lymphocytes. Stimulation of NFAT-mediated transcription is now reported in both lymphoid and non-lymphoid cells following activation of a neurotransmitter receptor. Carbachol induces robust luciferase responses in Jurkat and pheochromocytoma PC12 cells expressing an NFAT-luciferase reporter construct and a G(q)-coupled m3 muscarinic receptor. Cyclosporin blocks this response in PC12 cells, as in Jurkat cells. In PC12 cells expressing a G(i)-coupled m2 muscarinic receptor, carbachol induces NFAT-mediated luciferase activity that is strictly dependent upon co-expression of a chimeric G alpha(q)/alpha(i) subunit which confers G(q)-effector coupling on G(i)-linked receptors/ These findings suggest that neurotransmitters, autacoids, or hormones acting on G(q)-protein-coupled receptors may serve as physiological stimulators of NFAT in lymphoid and non lymphoid cells.	EMORY UNIV,SCH MED,DEPT PHARMACOL,ATLANTA,GA 30322	Emory University					NHLBI NIH HHS [HL48252, HL52810] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL048252, R01HL052810] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; BRAM RJ, 1994, NATURE, V371, P355, DOI 10.1038/371355a0; CHOI MSK, 1994, IMMUNITY, V1, P179, DOI 10.1016/1074-7613(94)90096-5; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COCKERILL GW, 1995, BLOOD, V86, P2689; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; DESAI DM, 1990, NATURE, V348, P66, DOI 10.1038/348066a0; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GOLDSMITH MA, 1989, J BIOL CHEM, V264, P17190; HO AM, 1994, J BIOL CHEM, V269, P28181; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MURPHY TJ, 1993, MOL PHARMACOL, V44, P1; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PINKASKRAMARSKI R, 1990, NEUROSCI LETT, V108, P335, DOI 10.1016/0304-3940(90)90663-T; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SZAMEL M, 1995, EUR J BIOCHEM, V228, P1; TAKEUCHI K, 1993, CIRC RES, V73, P612, DOI 10.1161/01.RES.73.4.612; VENTAKARAMAN L, 1994, IMMUNITY, V1, P189; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Weiss DL, 1996, MOL CELL BIOL, V16, P228; WU J, 1995, MOL CELL BIOL, V15, P4337; YASEEN NR, 1993, J BIOL CHEM, V268, P14285	28	58	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10429	10432		10.1074/jbc.271.18.10429	http://dx.doi.org/10.1074/jbc.271.18.10429			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631834	hybrid			2022-12-25	WOS:A1996UJ34200002
J	Liu, YP; Wang, Z; Rana, TM				Liu, YP; Wang, Z; Rana, TM			Visualizing a specific contact in the HIV-1 Tat protein fragment and trans-activation responsive region RNA complex by photocross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; MUTATIONAL ANALYSIS; MESSENGER-RNA; MAJOR GROOVE; CROSS-LINKING; GENE-PRODUCT; BASIC DOMAIN; RECOGNITION; TYPE-1	Replication of human immunodeficiency virus type 1 (HIV-1) requires specific interactions of Tat protein with the trans-activation responsive region (TAR) RNA, a stem-loop structure containing two helical stem regions separated by a trinucleotide bulge. The Tat protein contains a basic RNA-binding region (amino acids 49-57) located in the carboxyl-terminal half of the protein, and peptides containing this basic domain of Tat protein can bind TAR RNA with high affinities. We synthesized a 31-amino acid Tat fragment (amino acids 42-72) containing the basic region and part of flanking regulatory core domain that formed a specific complex with TAR RNA. Upon UV irradiation (254 nm), this Tat fragment cross-linked covalently with TAR RNA. Sites of cross-links were determined on both the TAR RNA and Tat protein fragment by RNA and protein sequencing, respectively. These results revealed that guanosine 26 of TAR RNA was cross-linked with tyrosine 47 of the Tat peptide. Our results provide the first physical evidence for a direct amino acid-base contact in Tat-TAR complex. Recently, orientation of the Tat-(42-72) was deter mined in our laboratory by psoralen Tat-(42-72) conjugate (Wang, Z., and Rana, T. M. (1995) J. Am. Chem. Soc. 117, 5438-5444). On the basis of our findings, we suggest a model in which Tat binds to TAR RNA by inserting the basic recognition sequence into the major groove with an orientation where lysine 41 in the core domain of Tat contacts the lower stem and Tyr(47) is close to G(26) of TAR RNA. The knowledge of the orientation of Tat and details of other interactions with TAR RNA in Tat-TAR complex has significant implications for understanding gene regulation in HIV-1.	RUTGERS STATE UNIV, UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT PHARMACOL, PISCATAWAY, NJ 08854 USA; RUTGERS STATE UNIV, BIOCHEM & MOL BIOL GRAD PROGRAM, PISCATAWAY, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick			Wang, Ting-Fang/ABI-3818-2020	Wang, Ting-Fang/0000-0001-6306-9505	NIAID NIH HHS [AI 34785] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI034785] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555; BASILION JP, 1994, P NATL ACAD SCI USA, V91, P574, DOI 10.1073/pnas.91.2.574; BAUDIN F, 1989, NUCLEIC ACIDS RES, V17, P2043, DOI 10.1093/nar/17.5.2043; BERKHOUT B, 1991, NUCLEIC ACIDS RES, V19, P6169, DOI 10.1093/nar/19.22.6169; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BLATTER EE, 1992, NATURE, V359, P650, DOI 10.1038/359650a0; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CHOW CS, 1992, BIOCHEMISTRY-US, V31, P972, DOI 10.1021/bi00119a005; CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128; CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; DELLING U, 1991, P NATL ACAD SCI USA, V88, P6234, DOI 10.1073/pnas.88.14.6234; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; ELANGOVAN B, 1992, J VIROL, V66, P2031, DOI 10.1128/JVI.66.4.2031-2036.1992; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FISHER AG, 1986, NATURE, V320, P367, DOI 10.1038/320367a0; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; GOTT JM, 1991, BIOCHEMISTRY-US, V30, P6290, DOI 10.1021/bi00239a030; GREENBERG JR, 1979, NUCLEIC ACIDS RES, V6, P715, DOI 10.1093/nar/6.2.715; HAMY F, 1993, J MOL BIOL, V230, P111, DOI 10.1006/jmbi.1993.1129; HAUBER J, 1988, J VIROL, V62, P673, DOI 10.1128/JVI.62.3.673-679.1988; HAUBER J, 1989, J VIROL, V63, P1181, DOI 10.1128/JVI.63.3.1181-1187.1989; HOWE PWA, 1994, EMBO J, V13, P3873, DOI 10.1002/j.1460-2075.1994.tb06698.x; JAKOBOVITS A, 1988, MOL CELL BIOL, V8, P2555, DOI 10.1128/MCB.8.6.2555; JEANG KT, 1993, J BIOL CHEM, V268, P24940; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KUCHINO Y, 1989, METHOD ENZYMOL, V180, P154; KUPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V17, P3551, DOI 10.1093/nar/17.9.3551; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; MUSIERFORSYTH K, 1991, SCIENCE, V253, P784, DOI 10.1126/science.1876835; NEENHOLD HR, 1995, BIOCHEMISTRY-US, V34, P6303, DOI 10.1021/bi00019a007; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PETERLIN BM, 1986, P NATL ACAD SCI USA, V83, P9734, DOI 10.1073/pnas.83.24.9734; PINOLROMA S, 1989, METHOD ENZYMOL, V180, P410; PUGLISI JD, 1993, P NATL ACAD SCI USA, V90, P3680, DOI 10.1073/pnas.90.8.3680; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; PUGLISI JD, 1992, SCIENCE, V90, P3680; RICE AP, 1990, J VIROL, V64, P1864, DOI 10.1128/JVI.64.4.1864-1868.1990; RICE AP, 1988, NATURE, V332, P551, DOI 10.1038/332551a0; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SELBY MJ, 1989, GENE DEV, V3, P547, DOI 10.1101/gad.3.4.547; SHARP PA, 1989, CELL, V59, P229, DOI 10.1016/0092-8674(89)90279-1; Smith K. C., 1976, PHOTOCHEM PHOTOBIOL, V2, P187; SUMNERSMITH M, 1991, J VIROL, V65, P5196, DOI 10.1128/JVI.65.10.5196-5202.1991; Tinoco I. Jr., 1990, Nucleic Acids and Molecular Biology, V4, P205; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; WANG ZY, 1995, J AM CHEM SOC, V117, P5438, DOI 10.1021/ja00125a002; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; WEEKS KM, 1993, SCIENCE, V261, P1574, DOI 10.1126/science.7690496; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WU HN, 1987, BIOCHEMISTRY-US, V26, P8221, DOI 10.1021/bi00399a030; WYATT JR, 1989, BIOESSAYS, V11, P100, DOI 10.1002/bies.950110406	64	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10391	10396		10.1074/jbc.271.17.10391	http://dx.doi.org/10.1074/jbc.271.17.10391			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626612	hybrid			2022-12-25	WOS:A1996UG25700084
J	Schieffer, B; Paxton, WG; Chai, Q; Marrero, MB; Bernstein, KE				Schieffer, B; Paxton, WG; Chai, Q; Marrero, MB; Bernstein, KE			Angiotensin II controls p21(ras) activity via pp60(c-src)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AORTIC SMOOTH-MUSCLE; GAP-ASSOCIATED PROTEINS; TYROSINE KINASES; CELLS; RAS; PHOSPHORYLATION; HYPERTROPHY; ACTIVATION; RECEPTOR; P190	Angiotensin II is the major effector peptide of the renin-angiotensin system, and it exerts its physiologic functions via a G protein-coupled cell surface receptor called AT(1). We found that in rat aortic smooth muscle cells, angiotensin II stimulated the formation of Ras-GTP, Ras-Raf-1 complex formation, and the tyrosine phosphorylation of two important has GTPase activating proteins (GAPs), p120 Ras-GAP and p190 Rho-GAP. Electroporation of anti-pp60(c-src) antibody into cultured, adherent smooth muscle cells blocked the angiotensin II stimulation of Ras-GAP and Rho-GAP tyrosine phosphorylation. In contrast electroporation of antibodies against c-Yes or c-Fyn had no effect. Anti-pp60(c-src) antibody also blocked angiotensin II-stimulated Ras activation and Ras Raf-1 complex formation. These data strongly suggest that a G protein-coupled receptor such as the AT(1) receptor can activate the Ras protein cascade via the tyrosine kinase pp60(c-src).	EMORY UNIV,DEPT PATHOL,ATLANTA,GA 30322; EMORY UNIV,CTR MOL & CELLULAR SIGNALLING,ATLANTA,GA 30322	Emory University; Emory University				Bernstein, Kenneth/0000-0001-8097-3272	NIDDK NIH HHS [DK45215, DK44280, DK39777] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044280, R37DK039777, P50DK045215, R01DK039777] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER RW, 1985, HYPERTENSION, V7, P447, DOI 10.1161/01.HYP.7.3.447; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; CHANG JH, 1993, ONCOGENE, V8, P959; DAEMEN MJAP, 1991, CIRC RES, V68, P450, DOI 10.1161/01.RES.68.2.450; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GIBBONS GH, 1990, CARDIOVASC DRUG THER, V4, P237, DOI 10.1007/BF01857638; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; ISHIDA Y, 1992, FEBS LETT, V310, P41, DOI 10.1016/0014-5793(92)81142-9; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; PEACH MJ, 1990, J CARDIOVASC PHARM S, V16, P25; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAAD MJA, 1995, BIOCHEM J, V310, P741, DOI 10.1042/bj3100741; SCHIEFFER B, 1994, CIRCULATION, V89, P2273, DOI 10.1161/01.CIR.89.5.2273; SCHIEFFER B, 1995, AM J PHYSIOL, V38, pH157; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; VAILLANCOURT RR, 1994, METHOD ENZYMOL, V238, P255	33	127	131	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10329	10333		10.1074/jbc.271.17.10329	http://dx.doi.org/10.1074/jbc.271.17.10329			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626602	hybrid			2022-12-25	WOS:A1996UG25700074
J	Brandish, PE; Burnham, MK; Lonsdale, JT; Southgate, R; Inukai, M; Bugg, TDH				Brandish, PE; Burnham, MK; Lonsdale, JT; Southgate, R; Inukai, M; Bugg, TDH			Slow binding inhibition of phospho-N-acetylmuramyl-pentapeptide-translocase (Escherichia coli) by mureidomycin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHEROPLAST FORMING ACTIVITY; CELL WALL PEPTIDOGLYCAN; PEPTIDYLNUCLEOSIDE ANTIBIOTICS; A-D; TRANSFERASE; RESISTANCE	Enzymes of the membrane cycle of reactions in bacterial peptidoglycan biosynthesis remain as unexploited potential targets for antibacterial agents, The first of these enzymes, phospho-N-acetylmuramyl-pentapeptide-translocase (EC 2.7.8.13), has been overexpressed in Escherichia cold and solubilized from particulate fractions, The work of W. A. Weppner and F. C. Neuhaus ((1977) J. Biol. Chem. 252, 2296-2303) has been extended to establish a usable routine fluorescence-based continuous assay for solubilized preparations, This assay has been used in the characterization of the natural product, mureidomycin A as a potent slow binding inhibitor of the enzyme with K-i and K-i* of 36 nM and 2 nM, respectively.	UNIV SOUTHAMPTON,DEPT CHEM,SOUTHAMPTON SO17 1BJ,HANTS,ENGLAND; SMITHKLINE BEECHAM PHARMACEUT,EPSOM KT18 5XQ,SURREY,ENGLAND; SMITHKLINE BEECHAM PHARMACEUT,BETCHWORTH RH3 7AJ,SURREY,ENGLAND; SANKYO CO LTD,BIOMED RES LABS,SHINAGAWA KU,TOKYO 140,JAPAN	University of Southampton; GlaxoSmithKline; GlaxoSmithKline; Daiichi Sankyo Company Limited								BANERJEE DK, 1989, J BIOL CHEM, V264, P2024; BUGG TDH, 1994, FEMS MICROBIOL LETT, V119, P255; BUGG TDH, 1992, NAT PROD REP, V9, P199, DOI 10.1039/np9920900199; DUNCAN K, 1988, BIOCHEMISTRY-US, V27, P3709, DOI 10.1021/bi00410a028; FLOURET B, 1981, ANAL BIOCHEM, V114, P59, DOI 10.1016/0003-2697(81)90451-6; HEYDANEK MG, 1970, BIOCHEMISTRY-US, V9, P3618, DOI 10.1021/bi00820a018; HEYDANEK MG, 1969, BIOCHEMISTRY-US, V8, P1474, DOI 10.1021/bi00832a024; HEYDANEK MG, 1969, BIOCHEMISTRY-US, V8, P1214, DOI 10.1021/bi00831a056; HIGASHI Y, 1967, P NATL ACAD SCI USA, V57, P1878, DOI 10.1073/pnas.57.6.1878; IKEDA M, 1991, J BACTERIOL, V173, P1021, DOI 10.1128/jb.173.3.1021-1026.1991; INUKAI M, 1993, ANTIMICROB AGENTS CH, V37, P980, DOI 10.1128/AAC.37.5.980; INUKAI M, 1989, J ANTIBIOT, V42, P662, DOI 10.7164/antibiotics.42.662; ISONO F, 1992, ANTIMICROB AGENTS CH, V36, P1024, DOI 10.1128/AAC.36.5.1024; ISONO F, 1989, J ANTIBIOT, V42, P674, DOI 10.7164/antibiotics.42.674; ISONO F, 1989, J ANTIBIOT, V42, P667, DOI 10.7164/antibiotics.42.667; KAUSHAL GP, 1985, J BIOL CHEM, V260, P6303; KIMURA K, 1989, AGR BIOL CHEM TOKYO, V53, P1811, DOI 10.1080/00021369.1989.10869560; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; LUGTENBE.EJ, 1972, J BACTERIOL, V109, P326, DOI 10.1128/JB.109.1.326-335.1972; MORRISON JF, 1987, ADV ENZYMOL RELAT AR, V57, P201; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; Penefsky H S, 1979, Methods Enzymol, V56, P527; PLESS DD, 1973, J BIOL CHEM, V248, P1568; Segel I.H., 1993, ENZYME KINETICS, P606; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRUVE WG, 1966, BIOCHEMISTRY-US, V5, P82, DOI 10.1021/bi00865a012; SWARTZ MN, 1994, P NATL ACAD SCI USA, V91, P2420, DOI 10.1073/pnas.91.7.2420; TAMURA G, 1976, AGR BIOL CHEM TOKYO, V40, P447, DOI 10.1080/00021369.1976.10862071; TANAKA H, 1979, BIOCHEM BIOPH RES CO, V86, P906; UBUKATA M, 1988, J AM CHEM SOC, V110, P4416, DOI 10.1021/ja00221a052; VERMA AK, 1977, J BIOL CHEM, V252, P7235; WEPPNER WA, 1977, J BIOL CHEM, V252, P2296	32	97	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7609	7614		10.1074/jbc.271.13.7609	http://dx.doi.org/10.1074/jbc.271.13.7609			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631795	hybrid			2022-12-25	WOS:A1996UC77400063
J	Stewart, L; Ireton, GC; Champoux, JJ				Stewart, L; Ireton, GC; Champoux, JJ			The domain organization of human topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; NUCLEOTIDE-SEQUENCE; CATALYTIC ACTIVITY; RECOGNITION SITES; CLEAVAGE INVITRO; BINDING SEQUENCE; SV40 DNA; CAMPTOTHECIN; SPECIFICITY; PREFERENCE	Using limited proteolysis, me show that the domain boundaries of human topoisomerase I closely parallel those predicted from sequence comparisons with other cellular Topo I enzymes. The enzyme is comprised of (i) an NH2-terminal domain (similar to 24 kDa), which is known to be dispensable for activity, (ii) the core domain (similar to 54 kDa), (iii) a linker region (similar to 3 kDa), and (iv) the COOH-terminal domain (similar to 10 kDa), which contains the active site tyrosine. The highly conserved core and COOH-terminal domains are resistant to proteolysis, while the unconserved NH2-terminal and linker domains are sensitive. Noncovalent binding of Topo I to plasmid DNA or to short duplex oligonucleotides decreases the sensitivity of the linker to proteolysis by approximately a factor of 10 but has no effect on proteolysis of the NH2-terminal domain, When the enzyme is covalently complexed to an 18 base pair single-stranded oligonucleotide, the linker region is sensitive to proteolysis whether or not duplex DNA is present. The net positive charge of the linker domain suggests that at a certain point in catalysis the linker may bind directly to DNA. Further, we show that limited subtilisin cleavage can generate a mixture of 60-kDa core and similar to 10-kDa COOH-terminal fragments, which retain a level. of topoisomerase activity that is nearly equal to undigested control samples, presumably because the two fragments remain associated after proteolytic cleavage, Thus, despite its potential role in DNA binding, the linker domain (in addition to the NH2-terminal domain) appears to be dispensable for topoisomerase activity, Finally, the limited proteolysis pattern of the human enzyme differs substantially from the limited proteolysis pattern of the vaccinia viral Topo I, indicating that the two enzymes belong to separate eukaryotic topoisomerase I subfamilies.	UNIV WASHINGTON,SCH MED,DEPT MICROBIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049156] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49156] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSNER J, 1992, J BIOL CHEM, V267, P12408; ANDERSEN AH, 1985, NUCLEIC ACIDS RES, V13, P1543, DOI 10.1093/nar/13.5.1543; BEDNAR J, 1994, J MOL BIOL, V235, P825, DOI 10.1006/jmbi.1994.1042; BEEN MD, 1984, NUCLEIC ACIDS RES, V12, P3097, DOI 10.1093/nar/12.7.3097; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CHRISTIANSEN K, 1993, J BIOL CHEM, V268, P9690; CHRISTIANSEN K, 1994, J BIOL CHEM, V269, P721; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; EDWARDS KA, 1982, NUCLEIC ACIDS RES, V10, P2565, DOI 10.1093/nar/10.8.2565; Harlow E., 1988, ANTIBODIES LAB MANUA; HERTZBERG RP, 1989, J MED CHEM, V32, P715, DOI 10.1021/jm00123a038; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; KIKUCHI A, 1993, MOLECULAR BIOLOGY OF DNA TOPOISOMERASES AND ITS APPLICATION CHEMOTHERAPY, P121; KJELDSEN E, 1988, J MOL BIOL, V202, P333, DOI 10.1016/0022-2836(88)90462-7; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MADDEN KR, 1995, EMBO J, V14, P5399, DOI 10.1002/j.1460-2075.1995.tb00224.x; MADDEN KR, 1992, CANCER RES, V52, P525; PARKER LH, 1993, J MOL BIOL, V231, P6, DOI 10.1006/jmbi.1993.1252; PEREZSTABLE C, 1988, NUCLEIC ACIDS RES, V16, P7975, DOI 10.1093/nar/16.16.7975; PORTER SE, 1989, MOL CELL BIOL, V9, P541, DOI 10.1128/MCB.9.2.541; SEKIGUCHI J, 1995, J BIOL CHEM, V270, P11636, DOI 10.1074/jbc.270.19.11636; SHARMA A, 1994, STRUCTURE, V2, P767, DOI 10.1016/S0969-2126(94)00077-8; SHEN CC, 1990, J MOL BIOL, V212, P67, DOI 10.1016/0022-2836(90)90305-6; SHUMAN S, 1991, J BIOL CHEM, V266, P1796; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; STEVNSNER T, 1989, J BIOL CHEM, V264, P10110; STEWART L, 1991, J VIROL, V65, P6218, DOI 10.1128/JVI.65.11.6218-6231.1991; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; SVEJSTRUP JQ, 1990, J BIOL CHEM, V265, P12529; TANIZAWA A, 1993, NUCLEIC ACIDS RES, V21, P5175; THOMSEN B, 1987, EMBO J, V6, P1817, DOI 10.1002/j.1460-2075.1987.tb02436.x; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x	36	151	154	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7602	7608		10.1074/jbc.271.13.7602	http://dx.doi.org/10.1074/jbc.271.13.7602			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631794	hybrid			2022-12-25	WOS:A1996UC77400062
J	Feehan, C; Darlak, K; Kahn, J; Walcheck, B; Spatola, AF; Kishimoto, TK				Feehan, C; Darlak, K; Kahn, J; Walcheck, B; Spatola, AF; Kishimoto, TK			Shedding of the lymphocyte L-selectin adhesion molecule is inhibited by a hydroxamic acid-based protease inhibitor - Identification with an L-selectin-alkaline phosphatase reporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHILS RELEASE; NODE HOMING RECEPTOR; SURFACE EXPRESSION; CELL ACTIVATION; FACTOR-ALPHA; PRECURSOR; PROTEINS; CLEAVAGE; CD43; MODULATION	Expression of the L-selectin adhesion molecule can be rapidly down-modulated by regulated proteolysis at a membrane-proximal site, The L-selectin secretase has remained undefined, and the secretase activity is resistant to a broad panel of common protease inhibitors, We have developed an L-selectin-alkaline phosphatase reporter, consisting of the ectodomain of human placental alkaline phosphatase fused to the membrane-proximal cleavage, transmembrane, and cytoplasmic domains of L-selectin, to aid in the screening for L-selectin secretase inhibitors, A hydroxamic acid-based metalloprotease inhibitor, KD-IX-73-4, inhibited release of the L-selectin-alkaline phosphatase reporter in a dose-dependent manner, The hydroxamic acid-based peptide was also found to inhibit wild type L-selectin down-regulation from the surfaces of phorbol myristate acetate-activated peripheral blood lymphocytes and phytohemagglutinin-stimulated lymphoblasts. Analysis of the proteolytic cleavage fragments of L-selectin confirmed that KD-IX-73-4 inhibited L-selectin proteolysis. Lymphocyte L-selectin was not down-regulated when co-cultured with formylmethionylleucylphenylalanine-stimulated neutrophils, suggesting that the putative secretase acts in cis with the membrane-bound L-selectin. These results suggest that the L-selectin secretase activity may involve a cell surface, zinc-dependent metalloprotease, although L-selectin shedding is not affected by EDTA and may be related to the recently described activity involved in processing of membrane-bound TNF-alpha.	BOEHRINGER INGELHEIM PHARMACEUT INC,DEPT IMMUNOL DIS,RIDGEFIELD,CT 06877; UNIV LOUISVILLE,DEPT CHEM & BIOCHEM,LOUISVILLE,KY 40292	Boehringer Ingelheim; University of Louisville								ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; BAZIL V, 1992, J IMMUNOL, V149, P747; BAZIL V, 1991, J IMMUNOL, V147, P1567; BAZIL V, 1993, P NATL ACAD SCI USA, V90, P3792, DOI 10.1073/pnas.90.9.3792; BAZIL V, 1994, J IMMUNOL, V152, P1314; BERG M, 1990, BLOOD, V76, P2381; BOSENBERG MW, 1993, J CELL BIOL, V122, P95, DOI 10.1083/jcb.122.1.95; CAMPANERO MR, 1991, EUR J IMMUNOL, V21, P3045, DOI 10.1002/eji.1830211222; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; DELPOZO MA, 1994, EUR J IMMUNOL, V24, P2586, DOI 10.1002/eji.1830241104; EHLERS MRW, 1991, P NATL ACAD SCI USA, V88, P1009, DOI 10.1073/pnas.88.3.1009; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GRIFFIN JD, 1990, J IMMUNOL, V145, P576; JUNG TM, 1990, J IMMUNOL, V144, P3130; JUTILA MA, 1989, J IMMUNOL, V143, P3318; KAHN J, 1994, J CELL BIOL, V125, P461, DOI 10.1083/jcb.125.2.461; KISHIMOTO TK, 1995, AGENT ACTION SUPPL, V47, P121; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MULLBERG J, 1994, J IMMUNOL, V152, P4958; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PORTEU F, 1990, J EXP MED, V172, P599, DOI 10.1084/jem.172.2.599; RAMCHANDRAN R, 1994, J BIOL CHEM, V269, P2125; RIEU P, 1992, EUR J IMMUNOL, V22, P3021, DOI 10.1002/eji.1830221138; SAHASRABUDHE SR, 1992, J BIOL CHEM, V267, P25602; SHIPP MA, 1991, BLOOD, V78, P1834; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SPATOLA AF, 1992, PEPTIDES CHEM BIOL, P820; SPERTINI O, 1991, LEUKEMIA, V5, P300	35	129	136	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7019	7024		10.1074/jbc.271.12.7019	http://dx.doi.org/10.1074/jbc.271.12.7019			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636132	hybrid			2022-12-25	WOS:A1996UB15700067
J	Tamechika, I; Itakura, M; Saruta, Y; Furukawa, M; Kato, A; Tachibana, S; Hirose, S				Tamechika, I; Itakura, M; Saruta, Y; Furukawa, M; Kato, A; Tachibana, S; Hirose, S			Accelerated evolution in inhibitor domains of porcine elafin family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STABLE PROTEINASE-INHIBITOR; ELASTASE-SPECIFIC INHIBITOR; REACTIVE CENTER REGIONS; AMINO-ACID-SEQUENCE; REPETITIVE SEQUENCES; PROTEASE INHIBITORS; HUMAN KERATINOCYTES; MOLECULAR-CLONING; CROSS-LINKING; PURIFICATION	Through the analysis of the porcine gene encoding the elastase inhibitor elafin, we demonstrated that there are at least three closely related members of the elafin family, and their genes have arisen by accelerated evolution. A porcine genomic DNA Library was screened with a previously cloned human elafin cDNA probe, and several positive clones were obtained that can be distinguished by a combination of restriction enzymes, Sequence analysis of these clones revealed the presence of three homologous members whose genes, all consisting of three exons and two introns, are almost identical except the exon 2 sequences encoding the inhibitor domain called ''WAP motif''; the intron sequences are related to each other with sequence similarities of 93-98%, whereas the exon 2 sequences exhibited only 60-77% similarities among the three members. The extreme divergence in the exon 2 sequences compared to the highly conserved intron sequences may be generated by accelerated mutations confined in a short stretch of the genes following recent duplication events of a single ancestral gene, An RNase protection assay indicated that the messages of the elafin family members are abundantly expressed in the trachea and intestine, suggesting that the most likely selective forces for the accelerated evolution are extrinsic proteinases produced by invasive microorganisms.	TOKYO INST TECHNOL, DEPT BIOL SCI, MIDORI KU, YOKOHAMA, KANAGAWA 226, JAPAN; EISAI & CO LTD, TSUKUBA RES LABS, TSUKUBA, IBARAKI 30026, JAPAN	Tokyo Institute of Technology; Eisai Co Ltd			Kato, Akira/E-6328-2010	Kato, Akira/0000-0002-9083-1443				AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARAKI K, 1989, BIOCHEM BIOPH RES CO, V164, P496, DOI 10.1016/0006-291X(89)91747-6; ARAKI K, 1990, BIOCHEM BIOPH RES CO, V172, P42, DOI 10.1016/S0006-291X(05)80170-6; BAIROCH A, 1994, NUCLEIC ACIDS RES, V22, P3583; BORRIELLO F, 1991, P NATL ACAD SCI USA, V88, P9417, DOI 10.1073/pnas.88.21.9417; BRACIAK TA, 1988, J BIOL CHEM, V263, P3999; CASTAGNARO A, 1992, J MOL BIOL, V224, P1003, DOI 10.1016/0022-2836(92)90465-V; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GOODMAN M, 1981, PROG BIOPHYS MOL BIO, V38, P105, DOI 10.1016/0079-6107(81)90012-2; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GRUTTER MG, 1988, EMBO J, V7, P345, DOI 10.1002/j.1460-2075.1988.tb02819.x; HILL RE, 1987, NATURE, V326, P96, DOI 10.1038/326096a0; HILL RE, 1984, NATURE, V311, P175, DOI 10.1038/311175a0; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; ITO O, 1990, PEPTIDE CHEMISTRY 1989, P353; JENSEN LS, 1989, J BIOL CHEM, V264, P15781; JIN L, 1990, MOL BIOL EVOL, V7, P82; KIMURA M, 1981, J MOL EVOL, V17, P110, DOI 10.1007/BF01732682; Kimura MA, 1985, NEUTRAL THEORY MOL E; KUROKI J, 1995, J BIOL CHEM, V270, P22428, DOI 10.1074/jbc.270.38.22428; LONG GL, 1984, BIOCHEMISTRY-US, V23, P4828, DOI 10.1021/bi00316a003; MOLHUIZEN HOF, 1993, J BIOL CHEM, V268, P12028; MOLHUIZEN HOF, 1995, BIOL CHEM H-S, V376, P1; NAKASHIMA K, 1993, P NATL ACAD SCI USA, V90, P5964, DOI 10.1073/pnas.90.13.5964; NAKASHIMA KI, 1995, P NATL ACAD SCI USA, V92, P5605, DOI 10.1073/pnas.92.12.5605; NARA K, 1994, J BIOCHEM, V115, P441, DOI 10.1093/oxfordjournals.jbchem.a124357; NEI M, 1986, MOL BIOL EVOL, V3, P418; Okada N, 1991, CURR OPIN GENET DEV, V1, P498, DOI 10.1016/S0959-437X(05)80198-4; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAY BK, 1994, J BIOL CHEM, V269, P22080; SAHEKI T, 1992, BIOCHEM BIOPH RES CO, V185, P240, DOI 10.1016/S0006-291X(05)80981-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHALKWIJK J, 1991, BIOCHIM BIOPHYS ACTA, V1096, P148, DOI 10.1016/0925-4439(91)90053-C; SEEMULLER U, 1986, FEBS LETT, V199, P43, DOI 10.1016/0014-5793(86)81220-0; SINGER DS, 1987, NUCLEIC ACIDS RES, V15, P2780, DOI 10.1093/nar/15.6.2780; SINGER MF, 1982, CELL, V28, P433, DOI 10.1016/0092-8674(82)90194-5; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; SUGIURA N, 1992, J BIOL CHEM, V267, P18067; SUZUKI Y, 1991, J BIOL CHEM, V266, P928; SUZUKI Y, 1990, J BIOCHEM, V107, P173, DOI 10.1093/oxfordjournals.jbchem.a123021; TAKAHASHI H, 1992, ANIM GENET, V23, P443, DOI 10.1111/j.1365-2052.1992.tb02164.x; TSUNEMI M, 1992, BIOCHEM BIOPH RES CO, V185, P967, DOI 10.1016/0006-291X(92)91721-2; WEINER AM, 1986, ANNU REV BIOCHEM, V55, P631, DOI 10.1146/annurev.bi.55.070186.003215; WIEDOW O, 1990, J BIOL CHEM, V265, P14791	45	42	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7012	7018		10.1074/jbc.271.12.7012	http://dx.doi.org/10.1074/jbc.271.12.7012			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636131	hybrid			2022-12-25	WOS:A1996UB15700066
J	Greene, EA; Spiegelman, GB				Greene, EA; Spiegelman, GB			The Spo0A protein of Bacillus subtilis inhibits transcription of the abrB gene without preventing binding of the polymerase to the promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RNA-POLYMERASE; LAC REPRESSOR; SPORULATION; INITIATION; EXPRESSION; PHOSPHORELAY; MECHANISM; CONTACTS; PRODUCT	Repression of transcription of the abrB gene is essential to expression of many of the postexponential genes in Bacillus. The repression is due to the activity of the response regulator protein Spo0A. We have used in vitro transcription and DNase I and hydroxyl radical footprinting to explore the mechanism of transcription inhibition. Spo0A binds to specific DNA sequences (0A boxes), and two such boxes are found downstream of the tandem promoters for the abrB gene. The data indicate that both RNA polymerase and Spo0A bind simultaneously to a DNA fragment containing the promoters and the 0A boxes. The Spo0A prevents the polymerase from inducing DNA strand denaturation at the promoter for the abrB gene.	UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER,BC V6T 1Z3,CANADA; UNIV BRITISH COLUMBIA,DEPT MICROBIOL & IMMUNOL,VANCOUVER,BC V6T 1Z3,CANADA	University of British Columbia; University of British Columbia								BIRD TH, 1993, MOL MICROBIOL, V9, P741, DOI 10.1111/j.1365-2958.1993.tb01734.x; BIRD TH, 1995, THESIS U BRIT COLUMB; BRODOLIN KL, 1993, NUCLEIC ACIDS RES, V21, P5748, DOI 10.1093/nar/21.24.5748; BROWN DP, 1994, MOL MICROBIOL, V14, P411, DOI 10.1111/j.1365-2958.1994.tb02176.x; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; CRAIG ML, 1995, BIOCHEMISTRY-US, V34, P15624, DOI 10.1021/bi00048a004; DOBINSON KF, 1985, J BIOL CHEM, V260, P5950; ERRINGTON J, 1993, MICROBIOL REV, V57, P1; FERRARI E, 1988, J BACTERIOL, V170, P289, DOI 10.1128/JB.170.1.289-295.1988; FERRARI FA, 1985, P NATL ACAD SCI USA, V82, P2647, DOI 10.1073/pnas.82.9.2647; Greenberg M. T., 1991, ROCHESTER S DEV PSYC, P21; GROMSLEY JK, 1994, J BIOL CHEM, V269, P16977; HOCH JA, 1993, ANNU REV MICROBIOL, V47, P441, DOI 10.1146/annurev.micro.47.1.441; HOCHSCHILD A, 1983, CELL, V32, P319, DOI 10.1016/0092-8674(83)90451-8; JUANG YL, 1994, J MOL BIOL, V235, P1470, DOI 10.1006/jmbi.1994.1102; LEE JY, 1991, CELL, V66, P793, DOI 10.1016/0092-8674(91)90122-F; MARAHIEL MA, 1987, J BACTERIOL, V169, P2215, DOI 10.1128/jb.169.5.2215-2222.1987; MATTHEWS KS, 1992, MICROBIOL REV, V56, P123, DOI 10.1128/MMBR.56.1.123-136.1992; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; OHLSEN KL, 1994, P NATL ACAD SCI USA, V91, P1756, DOI 10.1073/pnas.91.5.1756; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PEREGO M, 1988, MOL MICROBIOL, V2, P689, DOI 10.1111/j.1365-2958.1988.tb00079.x; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; PEREGO M, 1991, J BACTERIOL, V173, P2514, DOI 10.1128/jb.173.8.2514-2520.1991; PTASHNE M, 1992, GENETIC SWITCH, P20; Sambrook J., 2002, MOL CLONING LAB MANU; SCHICKOR P, 1990, EMBO J, V9, P2215, DOI 10.1002/j.1460-2075.1990.tb07391.x; SCHLAX PJ, 1995, J MOL BIOL, V245, P331, DOI 10.1006/jmbi.1994.0028; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; SQUIRES CL, 1975, J MOL BIOL, V11, P747; STRANEY DC, 1987, J MOL BIOL, V193, P267, DOI 10.1016/0022-2836(87)90218-X; STRANEY SB, 1987, CELL, V51, P699, DOI 10.1016/0092-8674(87)90093-6; STRAUCH M, 1990, P NATL ACAD SCI USA, V87, P1801, DOI 10.1073/pnas.87.5.1801; STRAUCH MA, 1993, MOL MICROBIOL, V7, P337, DOI 10.1111/j.1365-2958.1993.tb01125.x; STRAUCH MA, 1991, BIOL BACILLI, P105; STRAUCH MA, 1992, BACILLUS SUBTILIS MO, P767; TRACH K, 1991, RES MICROBIOL, V142, P815, DOI 10.1016/0923-2508(91)90060-N; TULLIUS TD, 1987, METHOD ENZYMOL, V155, P537; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; WHIPPLE FW, 1992, J MOL BIOL, V223, P399, DOI 10.1016/0022-2836(92)90660-C; ZUBER P, 1987, J BACTERIOL, V169, P2223, DOI 10.1128/jb.169.5.2223-2230.1987	41	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11455	11461		10.1074/jbc.271.19.11455	http://dx.doi.org/10.1074/jbc.271.19.11455			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626703	hybrid			2022-12-25	WOS:A1996UJ94400063
J	Donahue, BA; Fuchs, RPP; Reines, D; Hanawalt, PC				Donahue, BA; Fuchs, RPP; Reines, D; Hanawalt, PC			Effects of aminofluorene and acetylaminofluorene DNA adducts on transcriptional elongation by RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; EXCISION REPAIR; MUTATION SPECTRUM; MAMMALIAN-CELLS; INVITRO; STRAND; CARCINOGEN; GENE; TERMINATION; N-ACETOXY-N-2-ACETYLAMINOFLUORENE	A prominent model for the mechanism of transcription-coupled DNA repair proposes that an arrested RNA polymerase directs the nucleotide excision repair complex to the transcription-blocking lesion,The specific role for RNA polymerase II in this mechanism can be examined by comparing the extent of polymerase arrest with the extent of transcription-coupled repair for a specific DNA lesion, Previously we reported that a cyclobutane pyrimidine dimer that is repaired preferentially in transcribed genes is a strong block to transcript elongation by RNA pol II (Donahue, B. A., Yin, S.,Taylor, J.-S., Reines, D., and Hanawalt, P. C. (1994) Proc. Natl. Acad. Sci. U.S.A. 91, 8502-8506), Here we report the extent of RNA polymerase II arrest by the C-8 guanine DNA adduct formed by N-2-aminofluorene, a lesion that does not appear to be preferentially repaired, Templates for an in vitro transcription assay were constructed with either an N-2-aminofluorene adduct or the helix-distorting N-2-acetylaminofluorene adduct situated at a specific site downstream from the major late promoter of adenovirus, Consistent with the model for transcription-coupled repair, an aminofluorene adduct located on the transcribed strand was a weak pause site for RNA polymerase II, An acetylaminofluorene adduct located on the transcribed strand was an absolute block to transcriptional elongation, Either adduct located on the nontranscribed strand enhanced polymerase arrest at a nearby sequence specific pause site.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305; ECOLE SUPER BIOTECHNOL STRASBOURG,CNRS,UPR 9003,F-67400 ILLKIRCH GRAFFENS,FRANCE; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322	Stanford University; Centre National de la Recherche Scientifique (CNRS); Emory University			excellency, Your/R-2357-2019	excellency, Your/0000-0003-0832-6243	NCI NIH HHS [CA 44349] Funding Source: Medline; NIGMS NIH HHS [R01 GM046331] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046331] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BICHARA M, 1985, J MOL BIOL, V183, P341, DOI 10.1016/0022-2836(85)90005-1; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; CHEN YH, 1993, J BIOL CHEM, V268, P5849; CHEN YH, 1991, P NATL ACAD SCI USA, V88, P9583, DOI 10.1073/pnas.88.21.9583; DAUNE MP, 1981, JNCI-J NATL CANCER I, V58, P201; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; FUCHS R, 1972, BIOCHEMISTRY-US, V11, P2659, DOI 10.1021/bi00764a017; FUCHS RPP, 1981, NATURE, V294, P657, DOI 10.1038/294657a0; FUCHS RPP, 1976, BIOCHEMISTRY-US, V15, P3347, DOI 10.1021/bi00660a027; FUCHS RPP, 1984, EMBO J, V3, P757, DOI 10.1002/j.1460-2075.1984.tb01880.x; GAO SW, 1994, SCIENCE, V263, P1438, DOI 10.1126/science.8128226; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; GU WG, 1993, J BIOL CHEM, V268, P25604; HANAWALT P, 1993, CURR BIOL, V3, P67, DOI 10.1016/0960-9822(93)90156-I; HANAWALT PC, 1994, CURR BIOL, V4, P518, DOI 10.1016/S0960-9822(00)00112-3; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KOFFELSCHWARTZ N, 1984, J MOL BIOL, V177, P33, DOI 10.1016/0022-2836(84)90056-1; LINDSLEY JE, 1994, BIOCHEMISTRY-US, V33, P764, DOI 10.1021/bi00169a018; MAH MCM, 1991, P NATL ACAD SCI USA, V88, P10193, DOI 10.1073/pnas.88.22.10193; MAHER VM, 1975, J NATL CANCER I, V54, P1287, DOI 10.1093/jnci/54.6.1287; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MICHAELS ML, 1987, J BIOL CHEM, V262, P14648; OCONNOR D, 1985, P NATL ACAD SCI USA, V82, P2325, DOI 10.1073/pnas.82.8.2325; OGAWA HI, 1993, CARCINOGENESIS, V14, P2245, DOI 10.1093/carcin/14.11.2245; OHANDLEY SF, 1993, BIOCHEMISTRY-US, V32, P2481, DOI 10.1021/bi00061a005; POIRIER MC, 1980, MOL PHARMACOL, V18, P581; REINES D, 1991, J BIOL CHEM, V266, P10510; REINES D, 1994, TRANSCRIPTION MECHAN, P263; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1990, J BIOL CHEM, V265, P21330; SHIBUTANI S, 1993, J BIOL CHEM, V268, P11703; STRAUSS BS, 1990, CARCINOGENESIS, V11, P2103, DOI 10.1093/carcin/11.12.2103; TANG MS, 1989, J BIOL CHEM, V264, P14455; TANG MS, 1982, NATURE, V299, P646, DOI 10.1038/299646a0; TORNALETTI S, 1994, SCIENCE, V263, P1436, DOI 10.1126/science.8128225; TROELSTRA C, 1990, MOL CELL BIOL, V10, P5806, DOI 10.1128/MCB.10.11.5806; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VONHIPPEL PH, 1991, P NATL ACAD SCI USA, V88, P2307, DOI 10.1073/pnas.88.6.2307; VONHIPPEL PH, 1992, SCIENCE, V255, P809, DOI 10.1126/science.1536005; ZHOU W, 1995, CELL, V82, P577, DOI 10.1016/0092-8674(95)90030-6	42	59	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10588	10594		10.1074/jbc.271.18.10588	http://dx.doi.org/10.1074/jbc.271.18.10588			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631860	hybrid, Green Accepted			2022-12-25	WOS:A1996UJ34200028
J	Gelman, MS; Prives, JM				Gelman, MS; Prives, JM			Arrest of subunit folding and assembly of nicotinic acetylcholine receptors in cultured muscle cells by dithiothreitol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; GONADOTROPIN-BETA SUBUNIT; ENDOPLASMIC-RETICULUM; MEMBRANE GLYCOPROTEIN; BINDING-SITE; PROTEINS; OLIGOMERIZATION; HEMAGGLUTININ; KINETICS; PATHWAY	In this study we have used cultured muscle cells to investigate the role of disulfide bond formation in the sequence of molecular events leading to nicotinic acetylcholine receptor (AChR) assembly and surface expression, We have observed that disulfide bond formation in newly synthesized AChR alpha-subunits occurs 5-20 min after translation and that this modification can be blocked by dithiothreitol (DTT), a membrane-permeant thiol-reducing agent, DTT treatment was found to arrest AChR alpha-subunit conformational maturation, assembly, and appearance on the cell surface, showing that these events are dependent on prior formation of disulfide bonds, Subunits prevented from maturation by the reducing agent do not irreversibly misfold or aggregate, since upon removal of DTT, AChR alpha-subunits undergo formation of disulfide bonds and resume folding, oligomerization, and surface expression, We have previously found that nascent alpha-subunits form transient complexes with the molecular chaperone calnexin immediately after subunit synthesis (Gelman, M, S,, Chang, W,, Thomas, D. Y,, Bergeron, J, J, M,, and Prives, J, M, (1995) J, Biol, Chem, 270, 15085-15092) and have now observed that both the formation and the subsequent dissociation of these complexes are unaffected by DTT treatment, Thus, alpha-subunits appear to dissociate from calnexin independently of their undergoing disulfide bond formation and achieving conformational maturation, This finding together with the absence of irreversible misfolding of DTT arrested alpha-subunits suggests that calnexin may act to prevent misfolding by aiding in the initial folding events and is not an essential participant in the late stages of alpha-subunit maturation.	SUNY STONY BROOK,HLTH SCI CTR,DEPT PHARMACOL SCI,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NIGMS NIH HHS [GMO7518] Funding Source: Medline; NINDS NIH HHS [NS25945] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025945] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON DJ, 1981, P NATL ACAD SCI-BIOL, V78, P5598, DOI 10.1073/pnas.78.9.5598; ARUNACHALAM B, 1995, J BIOL CHEM, V270, P2784, DOI 10.1074/jbc.270.6.2784; BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BLOUNT P, 1990, J CELL BIOL, V111, P2613, DOI 10.1083/jcb.111.6.2613; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; CREIGHTON TE, 1988, BIOESSAYS, V8, P57, DOI 10.1002/bies.950080204; DEVREOTES PN, 1977, CELL, V10, P365, DOI 10.1016/0092-8674(77)90023-X; FORSAYETH JR, 1992, J CELL BIOL, V117, P841, DOI 10.1083/jcb.117.4.841; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; Gaut JR, 1993, CURR OPIN CELL BIOL, V5, P589, DOI 10.1016/0955-0674(93)90127-C; GELMAN MS, 1995, J BIOL CHEM, V270, P15085, DOI 10.1074/jbc.270.25.15085; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HUTH JR, 1992, J BIOL CHEM, V267, P21396; HUTH JR, 1992, J BIOL CHEM, V267, P8870; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; KAO PN, 1986, J BIOL CHEM, V261, P8085; KARLIN A, 1991, HARVEY LECT, V85, P71; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; KARLIN A, 1966, BIOCHIM BIOPHYS ACTA, V126, P525, DOI 10.1016/0926-6585(66)90010-0; KARLIN A, 1969, J GEN PHYSIOL, V54, pS245; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LE AQ, 1994, J BIOL CHEM, V269, P7514; LODISH HF, 1993, J BIOL CHEM, V268, P20598; MERLIE JP, 1986, J MEMBRANE BIOL, V91, P1, DOI 10.1007/BF01870209; MERLIE JP, 1981, J BIOL CHEM, V256, P3605; MERLIE JP, 1983, CELL, V34, P747, DOI 10.1016/0092-8674(83)90531-7; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; ONEILL MC, 1972, J CELL BIOL, V52, P52, DOI 10.1083/jcb.52.1.52; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PRIVES J, 1982, J CELL BIOL, V92, P231, DOI 10.1083/jcb.92.1.231; PRIVES JM, 1976, SURFACE MEMBRANE REC, P363; ROSS AF, 1987, J BIOL CHEM, V262, P14640; SEGAL MS, 1992, J CELL BIOL, V118, P227, DOI 10.1083/jcb.118.2.227; SMITH MM, 1987, J BIOL CHEM, V262, P4367; STROUD RM, 1990, BIOCHEMISTRY-US, V29, P11009, DOI 10.1021/bi00502a001; SUMIKAWA K, 1991, J BIOL CHEM, V267, P6286; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; TATU U, 1995, EMBO J, V14, P1340, DOI 10.1002/j.1460-2075.1995.tb07120.x; TZARTOS SJ, 1981, J BIOL CHEM, V256, P8635; WADA I, 1994, J BIOL CHEM, V269, P7464; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	48	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10709	10714		10.1074/jbc.271.18.10709	http://dx.doi.org/10.1074/jbc.271.18.10709			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631879	hybrid			2022-12-25	WOS:A1996UJ34200047
J	Mauviel, A; Chung, KY; Agarwal, A; Tamai, K; Uitto, J				Mauviel, A; Chung, KY; Agarwal, A; Tamai, K; Uitto, J			Cell-specific induction of distinct oncogenes of the Jun family is responsible for differential regulation of collagenase gene expression by transforming growth factor-beta in fibroblasts and keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-JUN; MESSENGER-RNA; POSTTRANSCRIPTIONAL REGULATION; TISSUE INHIBITOR; IV COLLAGENASE; FOS; METALLOPROTEINASES; DEXAMETHASONE; FACTOR-BETA-1; PROTEIN	Transforming growth factor-beta (TGF-beta) plays a major role in regulating connective tissue deposition by controlling both extracellular matrix production and degradation. In this study, we show that TGF-beta transcriptionally represses both basal and tumor necrosis factor-alpha-induced collagenase (matrix metalloprotease-1) gene expression in dermal fibroblasts in culture, whereas it activates its expression in epidermal keratinocytes. We demonstrate that this differential effect of TGF-beta on collagenase gene expression is due to a cell type-specific induction of distinct oncogenes of the Jun family, which participate in the formation of AP-1 complexes with different trans-activating properties. Specifically, our data indicate that the inhibitory effect of TGF-beta in fibroblasts is likely to be mediated by jun-B, based on the following observations: (a) TGF-beta induces high levels of jun-B expression and (b) over-expression of jun-B mimics TGF-beta effect in inhibiting basal collagenase promoter activity and preventing tumor necrosis factor-alpha-induced trans-activation of the collagenase promoter. In contrast, TGF-beta induction of collagenase gene expression in keratinocytes is preceded by transient elevation of c-jun proto-oncogene expression. Over-expression of c-jun leads to trans-activation of the collagenase promoter in both cell types, suggesting that c-jun is a ubiquitous inducer of collagenase gene expression. Transfection of keratinocytes with an antisense c-jun construct together with a collagenase promoter/reporter gene construct inhibits basal and TGF-beta induced up-regulation of the collagenase promoter activity, implying that c-jun mediates TGF-beta effect in this cell type. Collectively, our data suggest differential signaling pathways for TGF-beta in dermal fibroblasts and epidermal keratinocytes, leading to cell type-specific induction of two AP-1 components with opposite transcriptional activities.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON INST MOLEC MED,MOLEC DERMATOL SECT,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University	Mauviel, A (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT DERMATOL & CUTANEOUS BIOL,233 S 10TH ST,RM 430,PHILADELPHIA,PA 19107, USA.		MAUVIEL, Alain/F-6251-2013	Mauviel, Alain/0000-0002-0438-2793	NIAMS NIH HHS [T32-AR07561, R01-AR41439] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007561, R01AR041439] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARNARD JA, 1990, BIOCHIM BIOPHYS ACTA, V1032, P79, DOI 10.1016/0304-419X(90)90013-Q; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BOSSYWETZEL E, 1992, GENE DEV, V6, P2340, DOI 10.1101/gad.6.12a.2340; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BRINCKERHOFF CE, 1986, BIOCHEMISTRY-US, V25, P6378, DOI 10.1021/bi00369a006; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONCA W, 1989, J CLIN INVEST, V83, P1753, DOI 10.1172/JCI114077; DELANY AM, 1992, J CELL BIOCHEM, V50, P400, DOI 10.1002/jcb.240500409; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRISCH SM, 1990, ONCOGENE, V5, P75; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEBDA PA, 1988, J INVEST DERMATOL, V91, P440, DOI 10.1111/1523-1747.ep12476480; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; MELLSTROM B, 1991, ONCOGENE, V6, P1959; OVERALL CM, 1991, J BIOL CHEM, V266, P14064; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; PETERSON MJ, 1990, J INVEST DERMATOL, V97, P341; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; RYSECK RP, 1991, ONCOGENE, V6, P533; SAARIALHOKERE UK, 1992, J CLIN INVEST, V90, P1952, DOI 10.1172/JCI116073; SALO T, 1991, J BIOL CHEM, V266, P11436; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; WAHL SM, 1992, J CLIN IMMUNOL, V12, P61, DOI 10.1007/BF00918135; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	35	137	143	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10917	10923		10.1074/jbc.271.18.10917	http://dx.doi.org/10.1074/jbc.271.18.10917			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631909	hybrid			2022-12-25	WOS:A1996UJ34200077
J	Massillon, D; Barzilai, N; Chen, W; Hu, MZ; Rossetti, L				Massillon, D; Barzilai, N; Chen, W; Hu, MZ; Rossetti, L			Glucose regulates in vivo glucose-6-phosphatase gene expression in the liver of diabetic rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN; INHIBITION; NIDDM	Overproduction of glucose by the liver is the major cause of fasting hyperglycemia in both insulin-dependent and non-insulin-dependent diabetes mellitus. The distal enzymatic step in the process of glucose output is catalyzed by the glucose-6-phosphatase complex. We show here that 90% partially pancreatectomized diabetic rats have a >5-fold increase in the messenger RNA and a 3-4-fold increase in the protein level of the catalytic subunit of glucose-6-phosphatase in the liver. Normalization of the plasma glucose concentration in diabetic rats with either insulin or the glycosuric agent phlorizin normalized the hepatic glucose-6-phosphatase messenger RNA and protein within similar to 8 h. Conversely, phlorizin failed to decrease hepatic glucose-6-phosphatase gene expression in diabetic rats when the fall in the plasma glucose concentration was prevented by glucose infusion, These data indicate that in vivo gene expression of glucose-6-phosphatase in the diabetic liver is regulated by glucose independently from insulin, and thus prolonged hyperglycemia may result in overproduction of glucose via increased expression of this protein.	ALBERT EINSTEIN COLL MED,CTR DIABET RES & TRAINING,BRONX,NY 10461; ALBERT EINSTEIN COLL MED,DIV ENDOCRINOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NIDDK NIH HHS [DK 20541, DK 45024, DK 48321] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045024, R37DK048321, P30DK020541, R01DK048321, R29DK045024, P60DK020541] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHMORE J, 1954, P NATL ACAD SCI USA, V40, P673, DOI 10.1073/pnas.40.8.673; BARZILAI N, 1993, J BIOL CHEM, V268, P25019; BELL PM, 1986, J CLIN INVEST, V78, P1479, DOI 10.1172/JCI112739; BODE AM, 1992, J BIOL CHEM, V267, P2860; BONNERWEIR S, 1983, J CLIN INVEST, V71, P1544, DOI 10.1172/JCI110910; BURCHELL A, 1990, FASEB J, V4, P2978, DOI 10.1096/fasebj.4.12.2168325; CHAN TM, 1975, AM J PHYSIOL, V229, P1702, DOI 10.1152/ajplegacy.1975.229.6.1702; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DIAMOND MP, 1988, METABOLISM, V37, P28, DOI 10.1016/0026-0495(88)90025-X; Foglia Virgilio G., 1944, REV SOC ARGENTINA BIOL, V20, P21; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; FULCERI R, 1995, BIOCHEM J, V307, P391, DOI 10.1042/bj3070391; GARDNER LB, 1993, DIABETES, V42, P1614, DOI 10.2337/diabetes.42.11.1614; HABER BA, 1995, J CLIN INVEST, V95, P832, DOI 10.1172/JCI117733; HANSON TL, 1970, BIOCHIM BIOPHYS ACTA, V198, P66, DOI 10.1016/0005-2744(70)90033-1; JAHOOR F, 1990, AM J PHYSIOL, V258, pE288, DOI 10.1152/ajpendo.1990.258.2.E288; JENNSEN T, 1990, J CLIN INVEST, V86, P489; LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/bbrc.1994.1702; LANGE AJ, 1986, J BIOL CHEM, V261, P101; LEFRANCOISMARTINEZ AM, 1994, FASEB J, V8, P89, DOI 10.1096/fasebj.8.1.8299894; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; LIU ZQ, 1994, BIOCHEM BIOPH RES CO, V205, P680, DOI 10.1006/bbrc.1994.2719; MINASSIAN C, 1994, J BIOL CHEM, V269, P16585; MULLER S, 1995, J BACTERIOL, V177, P4517; PRIPBUUS C, 1995, EUR J BIOCHEM, V230, P309, DOI 10.1111/j.1432-1033.1995.tb20564.x; PUHAKAINEN I, 1991, DIABETES, V40, P1319, DOI 10.2337/diabetes.40.10.1319; ROSSETTI L, 1993, J CLIN INVEST, V92, P1126, DOI 10.1172/JCI116681; ROSSETTI L, 1990, J CLIN INVEST, V85, P1785, DOI 10.1172/JCI114636; ROSSETTI L, 1987, J CLIN INVEST, V79, P1610; SHELLY LL, 1993, J BIOL CHEM, V268, P482; WOLFE RB, 1986, J PARENTER ENTERAL N, V11, P109	31	148	151	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9871	9874		10.1074/jbc.271.17.9871	http://dx.doi.org/10.1074/jbc.271.17.9871			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626617	hybrid			2022-12-25	WOS:A1996UG25700001
J	Peppard, JV; Loo, P; Sills, MA; Munster, D; Pomponi, SA; Wright, AE				Peppard, JV; Loo, P; Sills, MA; Munster, D; Pomponi, SA; Wright, AE			Characterization of an interleukin 6 cytokine family antagonist protein from a marine sponge, Callyspongia sp.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-6 SIGNAL TRANSDUCER; ONCOSTATIN-M; RECEPTOR; GP130; IMMUNE; LIF	An inhibitor of IL-6 binding to the human hepatoma line HepG2 and myeloma cell line U266 was identified in a saline extract of the marine sponge, Callyspongia sp. Functional activity, measured through the increase in haptoglobin production by HepG2 cells stimulated with IL-6, could be strongly inhibited by the extract. Similarly, IL-6-induced production of IgM by the B cell line SKW6.4 was substantially reduced, In neither cell line was there evidence of toxicity produced by the extract. Other sponges of the Callyspongia species were found to contain analogous activity. The activity was destroyed by trypsin treatment or boiling of the extract, suggesting that the inhibition is due to a protein, When the binding of IL-6 to its receptor complex was dissected in. vitro, inhibition of binding of IL-6 to soluble receptor by the extract was not detected, but binding of the IL-6 . sIL-6R complex to soluble gp130 was inhibited in a dose-dependent fashion. This was borne out in cellular assays since the extract inhibited activation of HepG2 cells stimulated with oncostatin M or leukemia inhibitory factor, cytokines which also use gp130 for signal transduction. These results suggest that the Callyspongia extract contains a protein which blocks the interaction of the IL-6 family of cytokines with their signal transduction moiety, gp130, Elucidation of the structure and mode of action of such a protein would be helpful in designing gp130 antagonists to inhibit the functions of this cytokine family, overproduction of which has been associated with cancer and pathologies of autoimmune disease and AIDS.	HARBOR BRANCH OCEANOG INST INC,FT PIERCE,FL 34946	Harbor Branch Oceanographic Institute Foundation	Peppard, JV (corresponding author), CIBA GEIGY CORP,DIV PHARMACEUT,RES DEPT,556 MORRIS AVE,SUMMIT,NJ 07901, USA.							BAUMANN H, 1987, J IMMUNOL, V139, P4122; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEWEERDT WH, 1986, ZOOLOGISCHE VERHANDE, V225, P1; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Patterson P H, 1992, Curr Opin Neurobiol, V2, P94, DOI 10.1016/0959-4388(92)90169-L; PEPPARD JV, 1994, CELL IMMUNOL, V155, P253, DOI 10.1006/cimm.1994.1118; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TAGA T, 1992, CRIT REV IMMUNOL, V11, P265; van Soest RWM, 1980, STUD FAUNA CURACAO, V62, P1; YAMAMORI T, 1992, NEUROSCI RES, V15, P151, DOI 10.1016/0168-0102(92)90001-S	15	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7281	7284		10.1074/jbc.271.13.7281	http://dx.doi.org/10.1074/jbc.271.13.7281			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631742	hybrid			2022-12-25	WOS:A1996UC77400010
J	Sanchez, A; Alvarez, AM; Benito, M; Fabregat, I				Sanchez, A; Alvarez, AM; Benito, M; Fabregat, I			Apoptosis induced by transforming growth factor-beta in fetal hepatocyte primary cultures - Involvement of reactive oxygen intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; C-FOS EXPRESSION; PROLIFERATIVE CONDITIONS; GLUTATHIONE-REDUCTASE; REGRESSING LIVER; RAT HEPATOCYTES; FACTOR-BETA-1; HORMONES; GENE; GROWTH-FACTOR-BETA-1	Transforming growth factor-beta (TGF-beta), a growth regulator of fetal hepatocytes in primary culture, also regulates death of these cells. Dose-response analysis showed that the TGF-beta concentration needed to induce hepatocyte death (2.5 ng/ml) was 5 times that needed to inhibit growth in these cells (0.5 ng/ml). In response to TGF-beta, hepatocytes induced DNA fragmentation and the appearance of nuclei with a DNA content lower than 2C (diploid content), typical of a programmed cell death model. TGF-beta-induced apoptosis in fetal hepatocytes was preceded by an induction of reactive oxygen species production and a decrease in the glutathione intracellular content, indicating that this factor induces oxidative stress in fetal hepatocytes. Studies performed to analyze levels of c-fos mRNA, a gene whose expression is modulated by redox state, demonstrated that only high, apoptotic concentrations of TGF-beta (2.5 ng/ml) produced an increase in the mRNA Levels of this gene, the level of induction being similar to that found when cells were incubated in the presence of tert-butyl hydroperoxide. Gel mobility shift assays showed that the c-fos-induced expression was coincident with an increase in AP-1 activity. Finally, cell death induced by TGF-beta in fetal hepatocytes was partially blocked by radical scavengers, which decreased the percentage of apoptotic cells, whereas these agents did not modify the growth-inhibitory effect elicited by TGF-beta in these cells. In summary, the results presented in this paper provide evidence for the involvement of an oxidative process in the apoptosis elicited by TGF-beta in fetal hepatocytes.	UNIV COMPLUTENSE MADRID,DEPT BIOQUIM & BIOL MOLEC,INST BIOQUIM,CONSEJO SUPER INVEST CIENT,E-28040 MADRID,SPAIN; UNIV COMPLUTENSE MADRID,FAC FARM,CTR CITOMETRIA FLUJO,E-28040 MADRID,SPAIN	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Complutense University of Madrid			Sánchez, Aránzazu/H-7810-2015; Benito, Manuel/J-5637-2014; Alvarez-Barrientos, Alberto/L-9299-2014; Fabregat, Isabel/H-7038-2015	Sánchez, Aránzazu/0000-0001-9145-6633; Benito, Manuel/0000-0002-7218-406X; Alvarez-Barrientos, Alberto/0000-0003-4761-0212; Fabregat, Isabel/0000-0003-0136-8440				ABDELRAZZAK Z, 1994, MOL PHARMACOL, V46, P1100; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BANKS MF, 1994, J NUTR, V124, P378, DOI 10.1093/jn/124.3.378; BARKER CW, 1994, J BIOL CHEM, V269, P3985; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYANT PJ, 1988, DEV BIOL, V128, P386, DOI 10.1016/0012-1606(88)90300-4; BUROW S, 1987, EUR J CELL BIOL, V43, P128; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEAN RT, 1993, TRENDS BIOCHEM SCI, V18, P437, DOI 10.1016/0968-0004(93)90145-D; DEJUAN C, 1992, EXP CELL RES, V202, P495, DOI 10.1016/0014-4827(92)90104-G; DEJUAN C, 1994, BIOCHEM BIOPH RES CO, V204, P1364, DOI 10.1006/bbrc.1994.2614; DEJUAN C, 1992, J CELL PHYSIOL, V152, P95, DOI 10.1002/jcp.1041520113; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DRYSDALE BE, 1983, J IMMUNOL, V131, P2362; EKLOW L, 1984, EUR J BIOCHEM, V138, P459, DOI 10.1111/j.1432-1033.1984.tb07938.x; FABREGAT I, 1992, BIOCHEM BIOPH RES CO, V189, P684, DOI 10.1016/0006-291X(92)92255-V; FABREGAT I, 1985, ARCH BIOCHEM BIOPHYS, V236, P110, DOI 10.1016/0003-9861(85)90610-1; FUKUDA K, 1993, HEPATOLOGY, V18, P945, DOI 10.1002/hep.1840180428; GARCIARUIZ C, 1995, HEPATOLOGY, V21, P207, DOI 10.1002/hep.1840210133; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JAGODZINSKI LL, 1981, P NATL ACAD SCI-BIOL, V78, P3521, DOI 10.1073/pnas.78.6.3521; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; KORSMEYER SJ, 1992, BLOOD, V80, P879; KYPRIANOU N, 1989, MOL ENDOCRINOL, V3, P1515, DOI 10.1210/mend-3-10-1515; LACAL JC, 1984, P NATL ACAD SCI USA, V81, P6305; LYONS AB, 1992, CYTOMETRY, V13, P809; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MEYER M, 1994, CHEM-BIOL INTERACT, V91, P91, DOI 10.1016/0009-2797(94)90029-9; MOLERO C, 1993, J CELL PHYSIOL, V155, P197, DOI 10.1002/jcp.1041550125; MOLERO C, 1992, EXP CELL RES, V200, P295, DOI 10.1016/0014-4827(92)90175-8; MOULTON BC, 1994, ENDOCRINOLOGY, V134, P1055, DOI 10.1210/en.134.3.1055; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; OBERHAMMER F, 1991, CANCER RES, V51, P2478; OBERHAMMER F, 1993, HEPATOLOGY, V18, P1238; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; RONCERO C, 1989, BIOCHIM BIOPHYS ACTA, V1012, P320, DOI 10.1016/0167-4889(89)90115-8; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; SANCHEZ A, 1995, J CELL PHYSIOL, V165, P398, DOI 10.1002/jcp.1041650221; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STEINMAN HM, 1995, J BIOL CHEM, V270, P3487; THANNICKAL VJ, 1993, AM J PHYSIOL, V265, pL622, DOI 10.1152/ajplung.1993.265.6.L622; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; WEN P, 1994, MOL CELL BIOL, V14, P6616, DOI 10.1128/MCB.14.10.6616; WHITE E, 1993, GENE DEV, V7, P2277, DOI 10.1101/gad.7.12a.2277; YANAGIHARA K, 1992, CANCER RES, V52, P4042	53	246	251	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7416	7422		10.1074/jbc.271.13.7416	http://dx.doi.org/10.1074/jbc.271.13.7416			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631767	Green Published, hybrid			2022-12-25	WOS:A1996UC77400035
J	Usobiaga, P; Medrano, FJ; Gasset, M; Garcia, JL; Saiz, JL; Rivas, G; Laynez, J; Menendez, M				Usobiaga, P; Medrano, FJ; Gasset, M; Garcia, JL; Saiz, JL; Rivas, G; Laynez, J; Menendez, M			Structural organization of the major autolysin from Streptococcus pneumoniae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WALL LYTIC ENZYMES; PNEUMOCOCCAL AMIDASE; ESCHERICHIA-COLI; CHOLINE; PROTEIN; BACTERIOPHAGES; PURIFICATION; EXPRESSION; EVOLUTION; DYNAMICS	LytA amidase is the best known bacterial autolysin, It breaks down the N-acetylmuramoyl-L-alanine bonds in the peptidoglycan backbone of Streptococcus pneumoniae and requires the presence of choline residues in the cell-wall teichoic acids for activity. Genetic experiments have supported the hypothesis that its 36-kDa chain has evolved by the fusion of two independent modules: the NH2-terminal module, responsible for the catalytic activity, and the COOH-terminal module, involved in the attachment to the cell wall. The structural organization of LytA amidase and of its isolated COOH-aerminal module (C-LytA) and the variations induced by choline binding have been examined by differential scanning calorimetry and analytical ultracentrifugation. Deconvolution of calorimetric curves have revealed a folding of the polypeptide chain in several independent or quasi-independent cooperative domains, Elementary transitions in C-LytA are close but not identical to those assigned to the COOH-terminal module in the complete amidase, particularly in the absence of choline, These results indicate that the NH2-terminal region of the protein is important for attaining the native tertiary fold of the COOH terminus, Analytical ultracentrifugation studies have shown that LytA exhibits a monomer <----> dimer association equilibrium, through the COOH-terminal part of the molecule. Dimerization is regulated by choline interaction and involves the preferential binding of two molecules of choline per dimer, Sedimentation velocity experiments give frictional ratios of 1.1 for C-LytA monomer and 1.4 for C-LytA and LytA dimers; values that deviated from that of globular rigid particles, When considered together, present results give evidence that LytA amidase might be described as an elongated molecule consisting of at least four domains per subunit (two per module) designated here in as N1, N2, C1, and C2. Intersubunit cooperative interactions through the C2 domain in LytA dimer occur under all experimental conditions, while C-LytA requires the saturation of low affinity choline binding sites, The relevance of the structural features deduced here for LytA amidase is examined in connection with its biological function.	CSIC,INST QUIM FIS ROCASOLANO,E-28006 MADRID,SPAIN; CSIC,CTR INVEST BIOL,E-28006 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)			Menendez, Margarita/M-1795-2014; Medrano, Francisco Javier/ABF-9860-2020; Gasset, Maria/K-4339-2012; Rivas, German/AFL-7528-2022; Rivas, German/AAG-7458-2022; Gasset, Maria/I-2050-2014; Garcia Lopez, Jose Luis/G-9139-2015	Menendez, Margarita/0000-0002-3267-4443; Gasset, Maria/0000-0001-6436-4055; Rivas, German/0000-0003-3450-7478; Rivas, German/0000-0003-3450-7478; Gasset, Maria/0000-0001-6436-4055; Garcia Lopez, Jose Luis/0000-0002-9238-2485; Medrano, Francisco/0000-0002-8185-9751				BERRY AM, 1989, INFECT IMMUN, V57, P2324, DOI 10.1128/IAI.57.8.2324-2330.1989; BRIESE T, 1985, EUR J BIOCHEM, V146, P417, DOI 10.1111/j.1432-1033.1985.tb08668.x; DIAZ E, 1991, J BIOL CHEM, V266, P5464; DIAZ E, 1990, P NATL ACAD SCI USA, V87, P8125, DOI 10.1073/pnas.87.20.8125; DIAZ E, 1989, J BIOL CHEM, V264, P1236; FISHER N, 1993, EUR J BIOCHEM, V215, P851; FORMANEK H, 1983, TARGET PENICILLIN, P55; FREIRE E, 1990, ANNU REV BIOPHYS BIO, V19, P159; FREIRE E, 1989, COMMENTS MOL CELL BI, V6, P123; FUKADA H, 1983, J BIOL CHEM, V258, P3193; GARCIA E, 1988, P NATL ACAD SCI USA, V85, P914, DOI 10.1073/pnas.85.3.914; GARCIA JL, 1987, ARCH MICROBIOL, V149, P52, DOI 10.1007/BF00423136; GARCIA JL, 1994, J BACTERIOL, V176, P4066, DOI 10.1128/JB.176.13.4066-4072.1994; GARCIA P, 1986, GENE, V43, P265, DOI 10.1016/0378-1119(86)90215-5; GARCIA P, 1990, GENE, V86, P81, DOI 10.1016/0378-1119(90)90116-9; HU CQ, 1987, BIOCHEMISTRY-US, V26, P178, DOI 10.1021/bi00375a025; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LOPEZ R, 1992, FEMS MICROBIOL LETT, V100, P439, DOI 10.1016/0378-1097(92)90243-H; MARKIEWICZ Z, 1990, J BACTERIOL, V172, P2241, DOI 10.1128/jb.172.5.2241-2244.1990; Minton A.P., 1994, MODERN ANAL ULTRACEN, P81; PESSEN H, 1985, METHOD ENZYMOL, V117, P219; Rogers H., 1980, MICROBIAL CELL WALLS, P437; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZPUELLES JM, 1990, GENE, V89, P69, DOI 10.1016/0378-1119(90)90207-8; SANCHEZPUELLES JM, GENE, V61, P13; SANZ JM, 1988, FEBS LETT, V232, P308, DOI 10.1016/0014-5793(88)80759-2; SANZ JM, 1992, J BIOL CHEM, V268, P6125; SHAN F, 1990, LANCET, V335, P38; TANFORD C, 1961, PHYSICAL CHEMISTRY M, P254; TOMASZ A, 1971, P NATL ACAD SCI USA, V68, P1848, DOI 10.1073/pnas.68.8.1848; TOMASZ A, 1984, MICROBIAL CELL WALL, P3; WAXMAN E, 1993, BIOCHEMISTRY-US, V32, P3005, DOI 10.1021/bi00063a011; WYMAN J, 1990, BINDING LINKAGE, P46	35	52	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6832	6838		10.1074/jbc.271.12.6832	http://dx.doi.org/10.1074/jbc.271.12.6832			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636107	Green Published, hybrid			2022-12-25	WOS:A1996UB15700042
J	Genuario, RR; Perry, RP				Genuario, RR; Perry, RP			The GA-binding protein can serve as both an activator and repressor of ribosomal protein gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE ELEMENTS; PROMOTER; EXPRESSION; SUBUNITS; MOTIFS	The GA-binding protein (GABP), a heterodimeric transcription factor with widespread tissue distribution, has been found to be a strong positive regulator of several ribosomal protein (rp)-encoding genes. In such genes, e.g. the mouse rpL30 gene, the GABP-binding sites are located 40-80 base pairs upstream of the transcriptional start point. Potential GABP-binding sites are present in the promoters of numerous other rp genes, not only in upstream regions, but also in the immediate vicinity of the transcriptional start point. The mouse rpS16 gene is an example of the latter type. We demonstrate here that GABP binds to the rpS16 initiation region, and in so doing down-regulates rpS16 transcription both in vivo and in vitro. Supplementation of cell-free extracts with GABP inhibits transcription on rpS16 templates while concomitantly stimulating transcription on rpL30 templates. The repressive and stimulatory effects, which were proportional to the amount of GABP added, required both the GABP cu subunit and either a beta(1) or beta(2) subunit. Mutations of the rpS16 GABP-binding sites that abolish binding increased rpS16 promoter activity in vivo and in vitro, whereas mutations that strengthen GABP binding caused a reduction in promoter activity. The binding of GABP to the rpS16 initiation region does not significantly affect the positioning of the transcriptional start points. Taken together with earlier studies, these new findings indicate that GABP can have a dual role as repressor or activator of rp gene transcription.	FOX CHASE CANC CTR,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017330] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09035, CA-06927] Funding Source: Medline; NIAID NIH HHS [AI-17330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CARTER RS, 1992, J BIOL CHEM, V267, P23418; CARTER RS, 1994, J BIOL CHEM, V269, P4381; CHUNG S, 1991, GENE, V100, P173, DOI 10.1016/0378-1119(91)90363-G; DELABROUSSE FC, 1994, GENE DEV, V8, P1853, DOI 10.1101/gad.8.15.1853; Genuario R. Robert, 1993, Gene Expression, V3, P279; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; GUGNEJA S, 1995, MOL CELL BIOL, V15, P102, DOI 10.1128/MCB.15.1.102; HARIHARAN N, 1989, GENE DEV, V3, P1789, DOI 10.1101/gad.3.11.1789; HARIHARAN N, 1989, NUCLEIC ACIDS RES, V17, P5323, DOI 10.1093/nar/17.13.5323; HARIHARAN N, 1990, P NATL ACAD SCI USA, V87, P1526, DOI 10.1073/pnas.87.4.1526; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; MARCHIONI M, 1993, MOL CELL BIOL, V13, P6479, DOI 10.1128/MCB.13.10.6479; ROBERTS SGE, 1995, NATURE, V375, P105, DOI 10.1038/375105a0; SAFRANY G, 1995, EUR J BIOCHEM, V230, P1066, DOI 10.1111/j.1432-1033.1995.tb20657.x; SAWADA J, 1994, EMBO J, V13, P1396, DOI 10.1002/j.1460-2075.1994.tb06393.x; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380	23	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4388	4395						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626789				2022-12-25	WOS:A1996TW96000067
J	Sauma, S; Friedman, E				Sauma, S; Friedman, E			Increased expression of protein kinase C beta activates ERK3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; TYROSINE; AUTOPHOSPHORYLATION; DIFFERENTIATION; CARCINOGENESIS; SEQUENCES	In a prior study, we have shown that stable transfection of expression plasmids for protein kinase C beta 1 (PKC beta 1) or PKC beta 2 into differentiated colon cancer cells led to elevated levels of PKC beta 1 or PKC beta 2 protein and PKC beta kinase activities in the transfectants, without altering PKC alpha levels. PKC gamma is not found in these cells, so the major modulation was in PKC beta. PKC beta transfectant cells exhibited blocked differentiation, increased growth rate in athymic mice, and restoration of the basic fibroblast growth factor response pathway. In this study, we have extended the analysis of these PKC beta transfectants to the mitogen-activated protein kinase ERK3. Analysis of cell lysates on the mitogen-activated protein kinase substrate myelin basic protein by in gel kinase assay showed increased activity at 63 kDa, the size of ERK3, in each of two PKC beta 1 and each of two PKC beta 2 transfectants compared with the vector control transfectant. ERK3 was expressed at equal abundance in PRC beta 1, PKC beta 2, and control transfectant cells as demonstrated by Western blotting and by immunoprecipitation with anti-ERK3 monoclonal antibody. However, a >10-fold increase in ERK3 activity in each PKC beta transfectant was shown by immunoprecipitation with anti-ERK3 monoclonal antibody followed by either immune complex kinase assay or by in gel kinase assay. Thus, while overexpression of transfected PKC beta does not lead to overexpression of ERK3, it does lead to constitutive activation of ERK3. A causal link between PKC beta overexpression and ERK3 activation was established because 12-O-tetradecanoylphorbol-13-acetate treatment down-regulated both PKC and ERK3 activities in both PKC beta 1 transfectants. ERK3 activity was found in nuclear and membrane fractions in each PKC beta transfectant, in contrast to controls, perhaps accounting for constitutive activation of ERK3 in cells with elevated levels of PKC beta 1 or PKC beta 2.	MEM SLOAN KETTERING CANC CTR,LAB GASTROINTESTINAL TUMOR BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [R01CA045783, R01CA067405] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA45783, R01 CA67405] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CRAVEN PA, 1992, CANCER RES, V52, P2216; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOEI S, 1994, MOL CARCINOGEN, V11, P197; FRIEDMAN EA, 1981, CANCER RES, V41, P4588; GOLDSTEIN DR, 1995, CARCINOGENESIS, V16, P1121, DOI 10.1093/carcin/16.5.1121; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GUILLEM JG, 1988, CANCER RES, V48, P3964; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; KAHLRAINER P, 1994, CARCINOGENESIS, V15, P779, DOI 10.1093/carcin/15.4.779; KUBO K, 1987, FEBS LETT, V223, P138, DOI 10.1016/0014-5793(87)80524-0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE HS, 1993, J BIOL CHEM, V268, P5255; MURRAY NR, 1994, J BIOL CHEM, V269, P21385; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; OKA H, 1995, CANCER RES, V55, P4182; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; RESKA A, 1995, P NATL ACAD SCI USA, V92, P8881; SAUMA S, 1996, IN PRESS CELL GROWTH, V7; SAXON ML, 1994, J CELL BIOL, V126, P747, DOI 10.1083/jcb.126.3.747; SCHWARTZ GK, 1993, J NATL CANCER I, V85, P402, DOI 10.1093/jnci/85.5.402; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; YAN ZF, 1994, J BIOL CHEM, V269, P13231; ZHO G, 1995, J BIOL CHEM, V270, P12664; ZHU AX, 1994, MOL CELL BIOL, V14, P8202, DOI 10.1128/MCB.14.12.8202	31	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11422	11426		10.1074/jbc.271.19.11422	http://dx.doi.org/10.1074/jbc.271.19.11422			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626698	hybrid			2022-12-25	WOS:A1996UJ94400058
J	Seiffert, D				Seiffert, D			Hydrolysis of platelet vitronectin by calpain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; S-PROTEIN; IDENTIFICATION; CLEAVAGE; DOMAIN; SITE; EXPRESSION; SEQUENCE; HEPARIN; COMPLEX	Vitronectin (Vn) is not only a major adhesive glycoprotein present in platelets but also regulates proteolytic enzyme cascades, including the blood coagulation, fibrinolytic, and complement systems. In human platelet lysates prepared by freeze-thawing or by the addition of nonionic detergent, the Vn antigen content was drastically reduced in comparison with lysates prepared in tire presence of SDS, suggesting that Vn is hydrolyzed by platelet-associated enzymes. Exogenously added purified human Vn and Vn present in plasma were also cleaved by these enzyme systems. Degradation was mediated by a nonsecreted or membrane-associated protease system that was inhibited by E-64, EDTA, and leu-peptin but not inhibitors of serine and aspartic proteases, suggesting an involvement of calcium-dependent cysteine proteases. Consistently, calpastatin inhibited the hydrolysis of Vn, suggesting that Vn is a substrate for calpain. This was confirmed in a purified system. Vn was cleaved by calpains I and II in a dose- and time-dependent manner, resulting in defined Vn fragments with similar electrophoretic mobility in comparison with those detected in platelet lysates. Functional characterization of the calpain-hydrolyzed Vn revealed that while the type 1 plasminogen activator inhibitor binding activity was unchanged, the heparin and cell binding functions were destroyed. These results suggest that calpains released upon platelet membrane damage or upon tissue injury and necrosis differentially regulate functional domains of the Vn molecule.			Seiffert, D (corresponding author), SCRIPPS RES INST, DEPT VASC BIOL VB3, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL050704] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50704] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNES DW, 1983, P NATL ACAD SCI-BIOL, V80, P1362, DOI 10.1073/pnas.80.5.1362; CHAIN D, 1991, FEBS LETT, V285, P251, DOI 10.1016/0014-5793(91)80810-P; CHERNY RC, 1993, J BIOL CHEM, V268, P9725; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; GECHTMAN Z, 1993, FEBS LETT, V315, P293, DOI 10.1016/0014-5793(93)81181-X; Holmsen H., 1994, HEMOSTASIS THROMBOSI, P524; KAMBAYASHI J, 1989, METHOD ENZYMOL, V169, P442; KOST C, 1992, J BIOL CHEM, V267, P12098; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOSKUTOFF DJ, 1991, FIBRINOLYSIS, V5, P197, DOI 10.1016/0268-9499(91)90001-K; PARKER CJ, 1989, BRIT J HAEMATOL, V71, P245, DOI 10.1111/j.1365-2141.1989.tb04262.x; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; PREISSNER KT, 1989, BLOOD, V74, P1989; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SCHMAIER AH, 1990, BLOOD, V75, P1273; SEIFFERT D, 1990, J CELL BIOL, V111, P1283, DOI 10.1083/jcb.111.3.1283; SEIFFERT D, 1991, P NATL ACAD SCI USA, V88, P9402, DOI 10.1073/pnas.88.21.9402; SEIFFERT D, 1995, FEBS LETT, V368, P155, DOI 10.1016/0014-5793(95)00630-R; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; SIGURDARDOTTIR O, 1994, BBA-PROTEIN STRUCT M, V1208, P104, DOI 10.1016/0167-4838(94)90166-X; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; TOMASINI BR, 1990, PROGR HEMOSTASIS THR, P269; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; ZHAO Y, 1993, BIOCHEM BIOPH RES CO, V192, P575, DOI 10.1006/bbrc.1993.1454	28	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11170	11176		10.1074/jbc.271.19.11170	http://dx.doi.org/10.1074/jbc.271.19.11170			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626663				2022-12-25	WOS:A1996UJ94400023
J	Winston, J; Dong, F; Pledger, WJ				Winston, J; Dong, F; Pledger, WJ			Differential modulation of G(1) cyclins and the Cdk inhibitor p27(kip1) by platelet-derived growth factor and plasma factors in density-arrested fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-DIPLOID FIBROBLASTS; CELL-CYCLE; MAMMALIAN-CELLS; DNA-REPLICATION; PROTEIN-KINASE; TGF-BETA; G1; G(1)-CYCLINS; TRANSITION; EXPRESSION	Stimulation of quiescent Balb/c 3T3 fibroblasts into S phase requires the synergistic action of platelet-derived growth factor (PDGF) and progression factors found in platelet-poor plasma (PPP). Traverse of the G(1)/S phase boundary and the initiation of DNA replication require functional cyclin E-cyclin-dependent kinase (Cdk) 2 and cyclin A-Cdk2 complexes; however, the mechanisms by which PDGF and PPP regulate Cdk2 activation are not known. Density-arrested fibroblasts contain low levels of cyclins E and A, and high levels of the Cdk inhibitor p27(kip1). Exposure to PDGF, which stimulates cell cycle entry but not progression through G(1), induces the formation of cyclin D-1-Cdk4 complexes that bind p27(kip1) and titrate the pool of Kip1 available to inhibit Cdk2. In addition, PDGF stimulates a moderate transient reduction in the abundance of p27(kip1) protein, However, limited expression of cyclin E and cyclin A is observed after PDGF treatment, and in the absence of PPP, p27 levels are sufficient to bind and inactivate existing cyclin-Cdk complexes. Although plasma does not significantly increase the proportion of Kip1 bound to cyclin D-1-Cdk4, stimulation of PDGF-treated cells with plasma does overcome the threshold inhibition of p27(kip1) by further increasing the expression of cyclins E and A and decreasing the amount of Kip1 over a prolonged time period. Our results indicate that the distinct mitogenic activities of PDGF and PPP differentially influence the activation of cyclin E- and cyclin A-associated kinases that ultimately regulate entry into S phase.	UNIV S FLORIDA,H LEE MOFFIT CANC CTR & RES INST,TAMPA,FL 33612; UNIV S FLORIDA,DEPT BIOCHEM & MOLEC BIOL,TAMPA,FL 33612; UNIV S FLORIDA,DEPT MED MICROBIOL,TAMPA,FL 33612; VANDERBILT UNIV,DEPT CELL BIOL,NASHVILLE,TN 37232	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Vanderbilt University					NATIONAL CANCER INSTITUTE [R01CA067360] Funding Source: NIH RePORTER; NCI NIH HHS [CA67360] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJCHENBAUM F, 1993, CELL, V75, P817; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LEOF EB, 1982, J CELL BIOCHEM, V19, P93, DOI 10.1002/jcb.240190108; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSAUBO M, 1993, SCIENCE, V259, P1980; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON PYC, 1995, MOL BIOL CELL, V6, P1197; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1993, ONCOGENE, V8, P1593; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910	35	71	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11253	11260		10.1074/jbc.271.19.11253	http://dx.doi.org/10.1074/jbc.271.19.11253			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626675	hybrid			2022-12-25	WOS:A1996UJ94400035
J	Baum, LG; Derbin, K; Perillo, NL; Wu, T; Pang, M; Uittenbogaart, C				Baum, LG; Derbin, K; Perillo, NL; Wu, T; Pang, M; Uittenbogaart, C			Characterization of terminal sialic acid linkages on human thymocytes - Correlation between lectin-binding phenotype and sialyltransferase expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; HAMSTER OVARY CELLS; LINKED OLIGOSACCHARIDES; PEANUT AGGLUTININ; MOLECULAR-CLONING; GENE; GLYCOSYLATION; ALPHA-2,3-SIALYLTRANSFERASE; ANTIGEN; DIFFERENTIATION	T cell surface sialylation changes during maturation in the thymus, We have previously demonstrated increased expression of mRNA encoding the Gal beta 1, 3GalNAc alpha 2,3-sialyltransferase in mature medullary human thymocytes, compared with immature cortical thymocytes, For this enzyme, increased expression of transferase mRNA correlated with increased sialylation of O-glycans, We have now examined the pattern of expression in the human thymus of two additional sialyltransferases, the Gal beta 1,4GlcNAc alpha 2,6-sialyltransferase (ST6N) and the Gal beta 1,3/4GlcNAc alpha 2,3-sialyltransferase (ST3N), The patterns of mRNA expression were compared with the pattern of binding of two sialic acid-specific plant lectins, Sambucus nigra agglutinin and Maackia amurensis agglutinin, which preferentially recognize alpha 2,6- and alpha 2,3-linked sialic acids, respectively, on N-glycans, By in situ hybridization, mRNA encoding ST3N was detected uniformly throughout the thymus, All thymocytes bound M, amurensis agglutinin, demonstrating a direct correlation between the level of ST3N mRNA expression and cell-surface glycosylation, In contrast, mRNA encoding ST6N was also expressed uniformly throughout the thymus; however, only mature (CD3(hi)) medullary thymocytes bound S. nigra agglutinin, On mature thymocytes, S. nigra agglutinin appeared to bind primarily to the cell-surface glycoprotein CD45; since only the mature thymocytes expressed the CD45RA isoform, while both mature and immature populations expressed the CD45R0 isoform, CD45RA may be a preferred substrate for ST6N, These results demonstrate that glycoprotein sialylation is tightly regulated during T cell development and that the developmentally regulated expression of specific oligosaccharide structures on the cell surface may be influenced by expression of both the relevant glycosyltransferase and specific acceptor substrate.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Baum, LG (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL & LAB MED,10833 LECONTE AVE,LOS ANGELES,CA 90024, USA.				NCI NIH HHS [CA-16042] Funding Source: Medline; NIAID NIH HHS [AI-07126] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKASHI M, 1988, BLOOD, V72, P469; BAUM LG, 1995, J EXP MED, V181, P877, DOI 10.1084/jem.181.3.877; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BORREBAECK CAK, 1993, IMMUNOL TODAY, V14, P477, DOI 10.1016/0167-5699(93)90259-N; BOYD RL, 1991, IMMUNOL TODAY, V12, P71, DOI 10.1016/0167-5699(91)90161-L; Colin Hughes R., 1992, CURR OPIN STRUC BIOL, V2, P687, DOI 10.1016/0959-440X(92)90202-I; CUMMING D A, 1991, Glycobiology, V1, P115, DOI 10.1093/glycob/1.2.115; DAHMS NM, 1986, J BIOL CHEM, V261, P3186; DESPONT JP, 1975, CELL IMMUNOL, V17, P487, DOI 10.1016/S0008-8749(75)80052-9; DO KY, 1994, J BIOL CHEM, V269, P23456; FOX RI, 1983, J IMMUNOL, V131, P762; GALILI U, 1993, IMMUNOL TODAY, V14, P480, DOI 10.1016/0167-5699(93)90261-I; GILLESPIE W, 1993, J BIOL CHEM, V268, P3801; GOELZ S, 1994, J BIOL CHEM, V269, P1033; HANASAKI K, 1994, J BIOL CHEM, V269, P10637; IWAMORI M, 1989, J BIOCHEM-TOKYO, V105, P723, DOI 10.1093/oxfordjournals.jbchem.a122735; KANEKO Y, 1995, J HISTOCHEM CYTOCHEM, V43, P945, DOI 10.1177/43.9.7642967; KEPPLER OT, 1992, EUR J IMMUNOL, V22, P2777, DOI 10.1002/eji.1830221104; KIJIMOTOOCHIAI S, 1995, GLYCOBIOLOGY, V5, P443, DOI 10.1093/glycob/5.4.443; KITIGAWA H, 1994, J BIOL CHEM, V269, P17872; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LEE EU, 1989, J BIOL CHEM, V264, P13848; Lowe J B, 1991, Semin Cell Biol, V2, P289; LOWE JB, 1991, J BIOL CHEM, V266, P17467; OHANLON TP, 1989, J BIOL CHEM, V264, P17389; OHTA T, 1994, BIOCHEM BIOPH RES CO, V200, P1283, DOI 10.1006/bbrc.1994.1590; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; POWELL LD, 1994, J BIOL CHEM, V269, P10628; REISNER Y, 1976, CELL IMMUNOL, V25, P129, DOI 10.1016/0008-8749(76)90103-9; SASAKI K, 1993, J BIOL CHEM, V268, P22782; SATO T, 1993, BIOCHEMISTRY-US, V32, P12694, DOI 10.1021/bi00210a019; SAWADA R, 1993, J BIOL CHEM, V268, P12675; SGROI D, 1994, SCAND J IMMUNOL, V39, P433, DOI 10.1111/j.1365-3083.1994.tb03397.x; SGROI D, 1995, P NATL ACAD SCI USA, V92, P4026, DOI 10.1073/pnas.92.9.4026; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; SMITH DF, 1990, J BIOL CHEM, V265, P6225; STANLEY P, 1992, GLYCOBIOLOGY, V2, P99, DOI 10.1093/glycob/2.2.99; TAATJES DJ, 1988, J BIOL CHEM, V263, P6302; TERSTAPPEN LWMM, 1992, BLOOD, V79, P666; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; UENO Y, 1989, CELL IMMUNOL, V124, P239, DOI 10.1016/0008-8749(89)90128-7; UITTENBOGAART C H, 1990, International Immunology, V2, P1179, DOI 10.1093/intimm/2.12.1179; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; VEROSTEK MF, 1995, GLYCOBIOLOGY, V5, P671, DOI 10.1093/glycob/5.7.671; VOLLGER LW, 1993, CYTOKINE, V5, P157, DOI 10.1016/1043-4666(93)90055-A; WANG WC, 1988, J BIOL CHEM, V263, P4576; WANG XC, 1993, J BIOL CHEM, V268, P4355; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEN DX, 1992, J BIOL CHEM, V267, P21011; WHITEHEART SW, 1990, CELL IMMUNOL, V125, P337, DOI 10.1016/0008-8749(90)90089-A	52	86	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10793	10799		10.1074/jbc.271.18.10793	http://dx.doi.org/10.1074/jbc.271.18.10793			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631891	hybrid			2022-12-25	WOS:A1996UJ34200059
J	Chacko, GW; Brandt, JT; Coggeshall, KM; Anderson, CL				Chacko, GW; Brandt, JT; Coggeshall, KM; Anderson, CL			Phosphoinositide 3-kinase and p72(syk) noncovalently associate with the low affinity Fc gamma receptor on human platelets through an immunoreceptor tyrosine-based activation motif - Reconstitution with synthetic phosphopeptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; CELL-LINE; KINASE; THROMBIN; PHOSPHORYLATION; RII	Previously, we have demonstrated that the cytoplasmic tyrosine kinase p72(syk) is coupled to the platelet Fc receptor for IgG (Fc gamma RIIA) (Chacko, G. W., Duchemin, A. M., Coggeshall, K. M., Osborne, J. M., Brandt, J. T., and Anderson, C. L. (1994) J. Biol. Chem. 269, 32435-32440). Further analysis of the platelet activation by Fc gamma RIIA demonstrated that Fc gamma RIIA is also inducibly coupled to the serine/threonine and lipid kinase, phosphoinositide 3-kinase (PI 3-K), Activation of platelets with anti-Fc gamma RIIA. antibodies resulted in the noncovalent association of PI 3-K with Fc gamma RIIA as well as an increase in Fc gamma RIIA-associated PI 3-K activity, Binding of both p72(syk) and PI 3-K to Fc gamma RIIA was reconstituted with synthetic phosphopeptides corresponding to the sequence of the atypical immunoreceptor tyrosine-based activation motif (ITAM) in the cytoplasmic domain of Fc gamma RIIA, Our findings demonstrate that coupling of both p72(syk) and PI 3-K activities to Fc gamma RIIA is regulated by tyrosine phosphorylation of the ITAM, and we speculate that p72(syk) might act as an adapter to recruit PI 3-K to activated Fc gamma RIIA.	OHIO STATE UNIV,DEPT INTERNAL MED,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT PATHOL,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT MICROBIOL,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University			Chacko, George/I-4945-2014	Chacko, George/0000-0002-2127-1892	NCI NIH HHS [CA64268] Funding Source: Medline; NHLBI NIH HHS [R01-HL46652] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064268, R01CA064268] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046652] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGARWAL A, 1993, J BIOL CHEM, V268, P15900; ANDERSON CL, 1986, J BIOL CHEM, V261, P2856; ANDERSON CL, 1995, SEMIN THROMB HEMOST, V21, P1, DOI 10.1055/s-2007-1000374; BONNEMA JD, 1994, J EXP MED, V180, P1427, DOI 10.1084/jem.180.4.1427; BROOKS DG, 1989, J EXP MED, V170, P369; BUDDE P, 1994, EUR J CELL BIOL, V64, P45; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CASSEL DL, 1993, MOL IMMUNOL, V30, P451, DOI 10.1016/0161-5890(93)90113-P; CHACKO GW, 1994, J BIOL CHEM, V269, P32435; CHACKO GW, 1996, HUMAN FC RECEPTORS; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; CLARK EA, 1994, J BIOL CHEM, V269, P28859; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; FRY MJ, 1993, PHILOS T ROY SOC B, V340, P337, DOI 10.1098/rstb.1993.0076; FUJII C, 1994, EUR J BIOCHEM, V226, P243, DOI 10.1111/j.1432-1033.1994.tb20047.x; GHAZIZADEH S, 1995, BIOCHEM J, V305, P669, DOI 10.1042/bj3050669; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HUANG MM, 1992, J BIOL CHEM, V267, P5467; Indik Z K, 1995, Semin Immunol, V7, P45, DOI 10.1016/1044-5323(95)90007-1; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KANAKARAJ P, 1994, J EXP MED, V179, P551, DOI 10.1084/jem.179.2.551; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KIENER PA, 1993, J BIOL CHEM, V268, P24442; KING M, 1992, EXP HEMATOL, V20, P576; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LAW CL, 1994, J BIOL CHEM, V269, P12310; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; MCINTYRE EA, 1988, J IMMUNOL, V141, P4333; MITCHELL MA, 1994, BLOOD, V84, P1753; MULLER B, 1994, IMMUNOGENETICS, V39, P359; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; NINOMIYA N, 1994, J BIOL CHEM, V269, P22732; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; REZAUL K, 1994, THROMB HAEMOSTASIS, V72, P937; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TING AT, 1995, J BIOL CHEM, V270, P16415, DOI 10.1074/jbc.270.27.16415; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; VANDENHERIKOUDIJK IE, 1995, BLOOD, V86, P3302, DOI 10.1182/blood.V86.9.3302.bloodjournal8693302; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YAGI S, 1994, BIOCHEM BIOPH RES CO, V200, P28, DOI 10.1006/bbrc.1994.1409; YANAGA F, 1995, BIOCHEM J, V311, P471, DOI 10.1042/bj3110471; YANAGI S, 1994, EUR J BIOCHEM, V224, P329, DOI 10.1111/j.1432-1033.1994.00329.x; YANO H, 1993, J BIOL CHEM, V268, P25846; ZHANG J, 1995, J BIOL CHEM, V270, P22807, DOI 10.1074/jbc.270.39.22807; ZHANG J, 1992, J BIOL CHEM, V267, P4686; ZHANG J, 1993, J BIOL CHEM, V268, P22251	59	96	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10775	10781		10.1074/jbc.271.18.10775	http://dx.doi.org/10.1074/jbc.271.18.10775			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631888	hybrid			2022-12-25	WOS:A1996UJ34200056
J	Tomashek, JJ; Sonnenburg, JL; Artimovich, JM; Klionsky, DJ				Tomashek, JJ; Sonnenburg, JL; Artimovich, JM; Klionsky, DJ			Resolution of subunit interactions and cytoplasmic subcomplexes of the yeast vacuolar proton-translocating ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; SACCHAROMYCES-CEREVISIAE; ADENOSINE-TRIPHOSPHATASE; TRIFLUOPERAZINE RESISTANCE; MUTATIONAL ANALYSIS; CATALYTIC SUBUNIT; GENE ENCODES; MEMBRANE; MUTANTS; ACIDIFICATION	The vacuolar proton-translocating ATPase is the principal energization mechanism that enables the yeast vacuole to perform most of its physiological functions. We have undertaken an examination of subunit-subunit interactions and assembly states of this enzyme. Yeast two-hybrid data indicate that Vma1p and Vma2p interact with each other and that Vma4p interacts with itself. Three-hybrid data indicate that the Vma4p self-interaction is stabilized by both Vma1p and Vma2p. Native gel electrophoresis reveals numerous partial complexes not previously described. In addition to a large stable cytoplasmic complex seen in wild-type, Delta vma3 and Delta vma5 strains, we see partial complexes in the Delta vma4 and Delta vma7 strains. All larger complexes are lost in the Delta vma1, Delta vma2, and Delta vma8 strains. We designate the large complex seen in wild-type cells containing at least subunits Vma1p, Vma2p, Vma4p, Vma7p, and Vma8p as the definitive V-1 complex.	UNIV CALIF DAVIS,MICROBIOL SECT,DAVIS,CA 95616	University of California System; University of California Davis					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053396] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53396] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARAI H, 1988, J BIOL CHEM, V263, P8796; BACHHAWAT AK, 1993, YEAST, V9, P175, DOI 10.1002/yea.320090208; BARTEL PL, 1993, BIOTECHNIQUES, V214, P920; BAUERLE C, 1993, J BIOL CHEM, V268, P12749; BELTRAN C, 1992, J BIOL CHEM, V267, P774; BOWMAN EJ, 1995, BBA-BIOMEMBRANES, V1237, P95, DOI 10.1016/0005-2736(95)00108-F; DOHERTY RD, 1993, J BIOL CHEM, V268, P16845; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FOURY F, 1990, J BIOL CHEM, V265, P18554; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; GRAHAM LA, 1995, J BIOL CHEM, V270, P15037, DOI 10.1074/jbc.270.25.15037; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; GROMETELHANAN Z, 1992, J BIOENERG BIOMEMBR, V24, P447, DOI 10.1007/BF00762361; HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591; HARVEY WR, 1992, J EXP BIOL, V172, P1; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; HILL KJ, 1995, J BIOL CHEM, V270, P22329, DOI 10.1074/jbc.270.38.22329; HILL KJ, 1994, MOL BIOL CELL, V5, P1039, DOI 10.1091/mbc.5.9.1039; HIRATA R, 1993, J BIOL CHEM, V268, P961; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HO MN, 1993, J BIOL CHEM, V268, P18286; HO MN, 1993, J BIOL CHEM, V268, P221; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1995, J BIOL CHEM, V270, P17025; KANE PM, 1992, J BIOL CHEM, V267, P447; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KLIONSKY DJ, 1992, J BIOL CHEM, V267, P3416; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MARTINYBARON G, 1992, PLANT PHYSIOL, V99, P1635, DOI 10.1104/pp.99.4.1635; Miller JH., 1972, EXPT MOL GENETICS; MORANO KA, 1994, J CELL SCI, V107, P2813; MYERS M, 1993, J BIOL CHEM, V268, P9184; NELSON H, 1989, FEBS LETT, V247, P147, DOI 10.1016/0014-5793(89)81259-1; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON M, 1989, MOL CELL BIOL, V9, P384, DOI 10.1128/MCB.9.2.384; NELSON N, 1989, TRENDS BIOCHEM SCI, V14, P113, DOI 10.1016/0968-0004(89)90134-5; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; PRESTON RA, 1992, GENETICS, V131, P551; PRESTON RA, 1989, P NATL ACAD SCI USA, V86, P7027, DOI 10.1073/pnas.86.18.7027; PUOPOLO K, 1990, J BIOL CHEM, V265, P14836; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; SHIH CK, 1990, MOL CELL BIOL, V10, P3397, DOI 10.1128/MCB.10.7.3397; SHIH CK, 1988, MOL CELL BIOL, V8, P3094, DOI 10.1128/MCB.8.8.3094; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; UCHIDA E, 1988, J BIOL CHEM, V263, P45; UMEMOTO N, 1991, J BIOL CHEM, V266, P24526; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; YAVER DS, 1993, J BIOL CHEM, V268, P10564	54	58	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10397	10404		10.1074/jbc.271.17.10397	http://dx.doi.org/10.1074/jbc.271.17.10397			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626613	hybrid			2022-12-25	WOS:A1996UG25700085
J	Kobayashi, M; Habuchi, H; Habuchi, O; Saito, M; Kimata, K				Kobayashi, M; Habuchi, H; Habuchi, O; Saito, M; Kimata, K			Purification and characterization of heparan sulfate 2-sulfotransferase from cultured Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; CHICK-EMBRYO CHONDROCYTES; FACTOR BINDING DOMAINS; RAT-LIVER; CHONDROITIN 6-SULFOTRANSFERASE; N-SULFOTRANSFERASE; MOLECULAR-CLONING; O-SULFATION; BIOSYNTHESIS; EXPRESSION	Heparan sulfate 2-sulfotransferase, which catalyzes the transfer of sulfate from adenosine 3'-phosphate 5'-phosphosulfate to position 2 of L-iduronic acid residue in heparan sulfate, was purified 51,700-fold to apparent homogeneity with a 6% yield from cultured Chinese hamster ovary cells, The isolation procedure included a combination of affinity chromatography on heparin Sepharose CL-6B and 3',5'-ADP-agarose, which was repeated twice for each, and finally gel chromatography on Superose 12, Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the purified enzyme showed two protein bands with molecular masses of 47 and 44 kDa, Both proteins appeared to be glycoproteins, because their molecular masses decreased after N-glycanase digestion, When completely desulfated and N-resulfated heparin and mouse ngelbreth-Holm-Swarm tumor heparan sulfate were used as accepters, the purified enzyme transferred sulfate to position 2 of L-iduronic acid residue but did not transfer sulfate to the amino group of glucosamine residue or to position 6 of N-sulfoglucosamine residue, Heparan sulfates from pig aorta and bovine liver, however, were poor accepters, The enzyme showed no activities toward chondroitin, chondroitin sulfate, dermatan sulfate, and keratan sulfate, The optimal pH for the enzyme activity was around 5.5. The enzyme activity was minimally affected by dithiothreitol and was stimulated strongly by protamine. The K-m value for adenosine 5'-phosphate 5'-phosphosulfate was 0.20 mu M.	AICHI MED UNIV,INST MOLEC SCI MED,NAGAKUTE,AICHI 48011,JAPAN; AICHI UNIV EDUC,DEPT LIFE SCI,KARIYA,AICHI 448,JAPAN; HOKKAIDO UNIV,SCH MED,INST CANC,DIV BIOCHEM,SAPPORO,HOKKAIDO 060,JAPAN	Aichi Medical University; Aichi University Education; Hokkaido University								AVIEZER D, 1994, J BIOL CHEM, V269, P114; BENDIAK B, 1987, J BIOL CHEM, V262, P5775; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; DELFERT DM, 1985, ANAL BIOCHEM, V148, P303, DOI 10.1016/0003-2697(85)90233-7; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; GOHLER D, 1984, EUR J BIOCHEM, V138, P301, DOI 10.1111/j.1432-1033.1984.tb07915.x; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; HABUCHI O, 1980, BIOCHIM BIOPHYS ACTA, V616, P208, DOI 10.1016/0005-2744(80)90139-4; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; HABUCHI O, 1991, BIOCHIM BIOPHYS ACTA, V1133, P9; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; INOUE H, 1986, J BIOL CHEM, V261, P4460; ISHIHARA M, 1993, GLYCOBIOLOGY, V3, P83, DOI 10.1093/glycob/3.1.83; ISHIHARA M, 1993, J BIOL CHEM, V268, P20091; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KUSCHE M, 1988, J BIOL CHEM, V263, P15474; KUSCHE M, 1991, J BIOL CHEM, V266, P7400; KUSCHE M, 1990, J BIOL CHEM, V265, P15403; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMERS G, 1989, BIOCHEM J, V261, P389, DOI 10.1042/bj2610389; LIDHOLT K, 1992, BIOCHEM J, V287, P21, DOI 10.1042/bj2870021; Lindahl U., 1989, HEPARIN, P159; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MANDON E, 1994, J BIOL CHEM, V269, P11729; MANDON EC, 1994, P NATL ACAD SCI USA, V91, P10707, DOI 10.1073/pnas.91.22.10707; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; STROMINGER JL, 1959, J BIOL CHEM, V234, P3263; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WLAD H, 1994, J BIOL CHEM, V269, P24538	43	67	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7645	7653		10.1074/jbc.271.13.7645	http://dx.doi.org/10.1074/jbc.271.13.7645			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631801	hybrid			2022-12-25	WOS:A1996UC77400069
J	Reddy, ASN; Safadi, F; Narasimhulu, SB; Golovkin, M; Hu, X				Reddy, ASN; Safadi, F; Narasimhulu, SB; Golovkin, M; Hu, X			A novel plant calmodulin-binding protein with a kinesin heavy chain motor domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE; ARABIDOPSIS; EXPRESSION; SEQUENCES; IDENTIFICATION; DROSOPHILA; CALCIUM; FAMILY; CELLS; BRAIN	Calmodulin, a ubiquitous calcium-binding protein, regulates many diverse cellular functions by modulating the activity of the proteins that interact with it. Here, we report isolation of a cDNA encoding a novel kinesin-like calmodulin-binding protein (KCBP) from Arabidopsis using biotinylated calmodulin as a probe, Calcium-dependent binding of the cDNA encoded protein to calmodulin is confirmed by S-35-labeled calmodulin. Sequence analysis of a full-length cDNA indicates that it codes for a protein of 1261 amino acids, The predicted amino acid sequence of the KCBP has a domain of about 340 amino acids in the COOH terminus that shows significant sequence similarity with the motor domain of kinesin heavy chains and kinesin-like proteins and contains ATP and microtubule binding sites typical of these proteins. Outside the motor domain, the KCBP has no sequence similarity with any of the known kinesins, but contains a globular domain in the NH2 terminus and a putative coiled-coil region in the middle. By analyzing the calmodulin binding activity of truncated proteins expressed in Escherichia coli, the calmodulin binding region is mapped to a stretch of about 50 amino acid residues in the COOH terminus region of the protein. Using a synthetic peptide, the calmodulin binding domain is further narrowed down to a 23-amino acid stretch. The synthetic peptide binds to calmodulin with high affinity in a calcium-dependent manner as judged by electrophoretic mobility shift assay of calmodulin-peptide complex. The KCBP is coded by a single gene and is highly expressed in developing flowers and suspension cultured cells. Although many kinesin heavy chains and kinesin-like proteins have been extensively characterized at the biochemical and molecular level in evolutionarily distant organisms, none of them is known to bind calmodulin. The plant kinesin-like protein with a calmodulin binding domain and a unique amino-terminal region is a new member of the kinesin superfamily. The presence of a calmodulin-binding motif in a kinesin heavy chain-like protein suggests a role for calcium and calmodulin in kinesin-driven motor function(s) in plants.	COLORADO STATE UNIV,CELL & MOLEC BIOL PROGRAM,FT COLLINS,CO 80523	Colorado State University	Reddy, ASN (corresponding author), COLORADO STATE UNIV,DEPT BIOL,FT COLLINS,CO 80523, USA.		Safadi, Fayez/AAU-8699-2021	Reddy, Anireddy/0000-0002-4038-4091				ALLAN E, 1985, PLANTA, V165, P493, DOI 10.1007/BF00398094; BAUM G, 1993, J BIOL CHEM, V268, P19610; BETHKE PC, 1994, PLANT CELL, V6, P277, DOI 10.2307/3869645; BLOOM GS, 1994, PROTEIN PROFILE, V1, P1059; BOWLER C, 1994, PLANT CELL, V6, P1529, DOI 10.1105/tpc.6.11.1529; BRAAM J, 1990, CELL, V60, P357, DOI 10.1016/0092-8674(90)90587-5; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; CYR RJ, 1991, J CELL SCI, V100, P311; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DAUWALDER M, 1986, PLANTA, V168, P461, DOI 10.1007/BF00392265; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DURSO NA, 1994, PLANT CELL, V6, P893, DOI 10.1105/tpc.6.6.893; ENDOW SA, 1994, EMBO J, V13, P2708, DOI 10.1002/j.1460-2075.1994.tb06561.x; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; FORDHAMSKELTON AP, 1994, PLANT MOL BIOL REP, V12, P355; GILROY S, 1994, BIOESSAYS, V16, P677, DOI 10.1002/bies.950160914; GODDARD RH, 1994, PLANT PHYSIOL, V104, P1; GOODSON HV, 1994, J CELL SCI, V107, P1875; HANLEY RM, 1988, BIOCHEM BIOPH RES CO, V152, P122, DOI 10.1016/S0006-291X(88)80688-0; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; JENA PK, 1989, P NATL ACAD SCI USA, V86, P3644, DOI 10.1073/pnas.86.10.3644; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KOBAYASHI H, 1994, PLANTA, V194, P388, DOI 10.1007/BF00197540; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LING V, 1992, PLANT PHYSIOL, V100, P970, DOI 10.1104/pp.100.2.970; LING V, 1994, PLANT CELL, V6, P1135, DOI 10.1105/tpc.6.8.1135; LLOYD CW, 1991, CYTOSKELETAL BASIS P; LU YT, 1994, PLANT PHYSIOL BIOCH, V32, P413; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; LUKAS TJ, 1987, CALCIUM BINDING PROT, P533; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MALENCIK DA, 1983, BIOCHEM BIOPH RES CO, V114, P50, DOI 10.1016/0006-291X(83)91592-9; MALENCIK DA, 1984, BIOCHEMISTRY-US, V23, P2420, DOI 10.1021/bi00306a016; Marme D., 1983, CALCIUM CELL FUNCTIO, VIV, p263 ; MATTHIES HJG, 1993, J BIOL CHEM, V268, P11176; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; MITSUI H, 1994, PLANT MOL BIOL, V25, P865, DOI 10.1007/BF00028881; MITSUI H, 1993, MOL GEN GENET, V238, P362, DOI 10.1007/BF00291995; MUTO S, 1984, Z PFLANZENPHYSIOL, V114, P421, DOI 10.1016/S0044-328X(84)80062-8; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; NODA Y, 1995, J CELL BIOL, V129, P157, DOI 10.1083/jcb.129.1.157; OH SH, 1992, ARCH BIOCHEM BIOPHYS, V297, P28, DOI 10.1016/0003-9861(92)90636-B; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PATIL S, 1995, P NATL ACAD SCI USA, V92, P4897, DOI 10.1073/pnas.92.11.4897; Pereira Andrea, 1994, Modern Cell Biology, V13, P269; PERERA IY, 1992, PLANT MOL BIOL, V19, P649, DOI 10.1007/BF00026791; POOVAIAH BW, 1993, CRIT REV PLANT SCI, V12, P185, DOI 10.1080/713608046; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; REDDY ASN, 1994, BIOCHEM BIOPH RES CO, V199, P1089, DOI 10.1006/bbrc.1994.1342; REDDY ASN, 1993, PLANT SCI, V94, P109, DOI 10.1016/0168-9452(93)90012-O; REDDY ASN, 1995, P 6 INT C AR RES, P407; ROBERTS DM, 1986, CRIT REV PLANT SCI, V4, P311, DOI 10.1080/07352688609382230; ROBERTS DM, 1992, ANNU REV PLANT PHYS, V43, P375, DOI 10.1146/annurev.pp.43.060192.002111; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J., 2002, MOL CLONING LAB MANU; SAWIN KE, 1993, BIOESSAYS, V15, P399, DOI 10.1002/bies.950150606; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SEAGULL RW, 1989, CRIT REV PLANT SCI, V8, P131, DOI 10.1080/07352688909382273; SIKELA JM, 1987, P NATL ACAD SCI USA, V84, P3038, DOI 10.1073/pnas.84.9.3038; STEVENSON MA, 1990, MOL CELL BIOL, V10, P1234, DOI 10.1128/MCB.10.3.1234; STINEMETZ CL, 1987, PLANT PHYSIOL, V84, P1337, DOI 10.1104/pp.84.4.1337; STIRLING DA, 1994, EMBO J, V13, P4329, DOI 10.1002/j.1460-2075.1994.tb06753.x; STIRLING DA, 1992, MOL MICROBIOL, V6, P703, DOI 10.1111/j.1365-2958.1992.tb01519.x; TIEZZI A, 1992, CELL MOTIL CYTOSKEL, V21, P132, DOI 10.1002/cm.970210206; VALE RD, 1990, CELL, V60, P883, DOI 10.1016/0092-8674(90)90334-B; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALLEE RB, 1990, ANN REV BIOCH, V59, P906; VANTARD M, 1985, J CELL BIOL, V101, P488, DOI 10.1083/jcb.101.2.488; VERNOS I, 1995, TRENDS CELL BIOL, V5, P297, DOI 10.1016/S0962-8924(00)89045-5; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WALKER RG, 1993, P NATL ACAD SCI USA, V90, P2807, DOI 10.1073/pnas.90.7.2807; WALTHER Z, 1994, J CELL BIOL, V126, P175, DOI 10.1083/jcb.126.1.175; WATILLON B, 1993, PLANT PHYSIOL, V101, P1381, DOI 10.1104/pp.101.4.1381; WICK SM, 1985, PROTOPLASMA, V126, P198, DOI 10.1007/BF01281795; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	81	142	152	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7052	7060		10.1074/jbc.271.12.7052	http://dx.doi.org/10.1074/jbc.271.12.7052			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636137	hybrid			2022-12-25	WOS:A1996UB15700072
J	Walker, D; Chaddock, AM; Chaddock, JA; Roberts, LM; Lord, JM; Robinson, C				Walker, D; Chaddock, AM; Chaddock, JA; Roberts, LM; Lord, JM; Robinson, C			Ricin A chain fused to a chloroplast-targeting signal is unfolded on the chloroplast surface prior to import across the envelope membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-CHAIN; PRECURSOR PROTEINS; BINDING; TRANSLOCATION; ATP	The initial stages of chloroplast protein import involve the binding of precursor proteins to surface-bound receptors prior to translocation across the envelope membranes in a partially folded conformation, We have analyzed the unfolding process by examining the conformation of a construct, comprising the presequence of a chloroplast protein linked to ricin A chain, before and after binding to the chloroplast surface, We show that the presequence is highly susceptible to proteolysis in solution, probably reflecting a lack of tertiary structure, whereas the A chain passenger protein is resistant to extremely high concentrations of protease, unless deliberately unfolded using denaturant, The A chain moiety is furthermore active, indicating that the presence of the presequence does not prevent formation of a tightly folded, native state, In contrast, receptor-bound p33KRA (fusion protein comprising the 33-kDa presequence plus 22 residues of mature protein, linked to the A chain of ricin) is quantitatively digested by protease concentrations that have little effect on the A chain in solution, We conclude that protein unfolding can take place on the chloroplast surface in the absence of translocation and without the aid of soluble factors.	UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND	University of Warwick				Walker, Denise/0000-0003-1534-1679				AMERICA T, 1994, PLANT MOL BIOL, V24, P283, DOI 10.1007/BF00020168; CHADDOCK JA, 1993, PROTEIN ENG, V6, P425, DOI 10.1093/protein/6.4.425; CREIGHTON AM, 1995, J BIOL CHEM, V270, P1663, DOI 10.1074/jbc.270.4.1663; DELLACIOPPA G, 1986, P NATL ACAD SCI USA, V83, P6873, DOI 10.1073/pnas.83.18.6873; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; GRAY JC, 1995, TRENDS CELL BIOL, V5, P243, DOI 10.1016/S0962-8924(00)89018-2; GUERA A, 1993, PLANT MOL BIOL, V23, P309, DOI 10.1007/BF00029007; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; KATZIN BJ, 1991, PROTEINS, V10, P251, DOI 10.1002/prot.340100309; OLSEN LJ, 1989, J BIOL CHEM, V264, P6724; PELHAM H R B, 1992, Trends in Cell Biology, V2, P183, DOI 10.1016/0962-8924(92)90230-K; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; PILON M, 1992, J BIOL CHEM, V267, P19907; ROBERTS LM, 1991, FEBS LETT, V293, P134, DOI 10.1016/0014-5793(91)81169-9; ROBINSON C, 1994, PLANT MOL BIOL, V26, P15, DOI 10.1007/BF00039516; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNELL DJ, 1990, J CELL BIOL, V111, P1825, DOI 10.1083/jcb.111.5.1825; SCHNELL DJ, 1994, SCIENCE, V266, P1035; SEEDORF M, 1995, PLANT J, V7, P401, DOI 10.1046/j.1365-313X.1995.7030401.x; SIMPSON JC, 1995, J BIOL CHEM, V270, P20078, DOI 10.1074/jbc.270.34.20078; THEG SM, 1992, BIOCHEMISTRY-US, V31, P5053, DOI 10.1021/bi00136a018; THEG SM, 1989, J BIOL CHEM, V264, P6730; WU CB, 1994, J BIOL CHEM, V269, P32264	23	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4082	4085						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626744				2022-12-25	WOS:A1996TW96000022
J	Nakayama, J; Fukuda, MN; Hirabayashi, Y; Kanamori, A; Sasaki, K; Nishi, T; Fukuda, M				Nakayama, J; Fukuda, MN; Hirabayashi, Y; Kanamori, A; Sasaki, K; Nishi, T; Fukuda, M			Expression cloning of a human G(T3) - Synthase G(D3) and G(T3) are synthesized by a single enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; CELL-ADHESION; GANGLIOSIDE GD3; HUMAN-MELANOMA; RECEPTOR; ANTIGENS; GENE; GLYCOPROTEINS; GLYCOLIPIDS; PROTEINS	Gangliosides of the C series such as G(T3) are polysialylated glycosphingolipids whose synthesis is developmentally regulated. Here we report the expression cDNA cloning and characterization of G(T3) synthase that adds the second alpha-2,8-sialic acid to G(D3), NeuNAc alpha 2-->8NeuNAc alpha 2-->3Gal beta 1-->4Glc-Cer, thus forming G(T3), NeuNAc alpha 2-->8NeuNAc alpha 2-->8NeuNAc alpha 2-->3Gal beta 1-->4Glc-->Cer. Unexpectedly, the cloned cDNA was found to be identical to the cDNA that encodes G(D3) synthase. The newly identified enzyme was therefore named G(D3)/G(T3) synthase (G(D3)/G(T3)ST). G(D3)/G(T3)ST synthesized G(T3) most efficiently when G(M3), NeuNAc alpha 2-->3Gal beta 1-->4Glc-->Cer, was incubated as an acceptor, indicating that G(D3)/G(T3)ST is a polysialyltransferase that can transfer more than one sialic acid residue via alpha-2,8 linkage to gangliosides. Moreover, a longer period of incubation of G(D3) with G(D3)/G(T3)ST produced a significant amount of G(T3) and higher polysialogangliosides. Among various cell lines expressing G(D3)/G(T3)ST, higher polysialogangliosides including G(T3) were detected only in cell lines where the amount of G(D3)/G(T3) mRNA is sufficiently high. The expression of G(D3)/G(T3)ST mRNA among human tissues is highly restricted to fetal and adult brains. The G(D3)/G(T3)ST gene was found to be located at chromosome 12, region p12. Taken together, these results indicate that C series polysialogangliosides are synthesized by a ganglioside-specific polysialyltransferase, G(D3)/G(T3)ST, that is specifically expressed in neural tissues.	LA JOLLA CANC RES FDN, CANC RES CTR, GLYCOBIOL PROGRAM, LA JOLLA, CA 92037 USA; INST PHYS & CHEM RES, FRONTIER RES PROGRAM, WAKO, SAITAMA 35101, JAPAN; KYOWA HAKKO KOGYO CO LTD, TOKYO RES LABS, MACHIDA, TOKYO 194, JAPAN	Sanford Burnham Prebys Medical Discovery Institute; RIKEN; Kyowa Kirin Ltd				Hirabayashi, Yoshio/0000-0002-5774-7354	NCI NIH HHS [R01 CA33895] Funding Source: Medline; NIDDK NIH HHS [DK 37016] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033895] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037016] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDO S, 1979, J BIOL CHEM, V254, P2224; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BOUQUIER S, 1995, J BIOL CHEM, V270, P4632; BREMER EG, 1986, J BIOL CHEM, V261, P2434; CHERESH DA, 1986, J CELL BIOL, V102, P688, DOI 10.1083/jcb.102.3.688; CHRISTMANSON L, 1990, FEBS LETT, V267, P160, DOI 10.1016/0014-5793(90)80314-9; DUBOIS C, 1986, J BIOL CHEM, V261, P3826; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; EDELMAN GM, 1985, ANNU REV BIOCHEM, V54, P135, DOI 10.1146/annurev.bi.54.070185.001031; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FUKUDA M, 1984, BIOCHIM BIOPHYS ACTA, V780, P119, DOI 10.1016/0304-419X(84)90002-7; Fukuda M., 1992, CELL SURFACE CARBOHY; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; HARAYOKOYAMA M, 1995, J BIOL CHEM, V270, P8115, DOI 10.1074/jbc.270.14.8115; HIGA HH, 1985, VIROLOGY, V144, P279, DOI 10.1016/0042-6822(85)90325-3; HIRABAYASHI Y, 1988, J BIOCHEM, V104, P973, DOI 10.1093/oxfordjournals.jbchem.a122593; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JESSELL TM, 1990, ANNU REV NEUROSCI, V13, P227, DOI 10.1146/annurev.ne.13.030190.001303; KITAZUME S, 1994, J BIOL CHEM, V269, P10330; KOJIMA N, 1994, J BIOL CHEM, V269, P30451; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LOWE JB, 1994, MOL GLYCOBIOLOGY, P163; MCCOY RD, 1985, J BIOL CHEM, V260, P2695; MULERIS M, 1993, CANCER GENET CYTOGEN, V69, P161, DOI 10.1016/0165-4608(93)90097-6; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; NAKAYAMA J, 1993, J HISTOCHEM CYTOCHEM, V41, P1563, DOI 10.1177/41.10.8245415; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; OHTA S, 1993, CANCER IMMUNOL IMMUN, V36, P260, DOI 10.1007/BF01740908; ONDA M, 1995, GENE, V159, P225, DOI 10.1016/0378-1119(95)00075-H; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; PUKEL CS, 1982, J EXP MED, V155, P1133, DOI 10.1084/jem.155.4.1133; ROSNER H, 1985, DEV BRAIN RES, V18, P85, DOI 10.1016/0165-3806(85)90252-4; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIOLA H, 1988, CELL, V54, P235, DOI 10.1016/0092-8674(88)90556-9; SASAKI K, 1994, J BIOL CHEM, V269, P15950; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SCHACHTER H, 1994, MOL GLYCOBIOLOGY, P88; SPIEGEL S, 1987, P NATL ACAD SCI USA, V84, P141, DOI 10.1073/pnas.84.1.141; SUZUKI Y, 1986, J BIOL CHEM, V261, P7057; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; YAMASHIRO S, 1995, J BIOL CHEM, V270, P6149, DOI 10.1074/jbc.270.11.6149; YATES AJ, 1988, NEUROCHEM PATHOL, V8, P157	50	83	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3684	3691						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631981				2022-12-25	WOS:A1996TV72400055
J	Takeuchi, Y; Nakayama, K; Matsumoto, T				Takeuchi, Y; Nakayama, K; Matsumoto, T			Differentiation and cell surface expression of transforming growth factor-beta receptors are regulated by interaction with matrix collagen in murine osteoblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; MC3T3-E1 CELLS; EXTRACELLULAR-MATRIX; MODULATION; 1,25-DIHYDROXYVITAMIN-D3; IDENTIFICATION; PROLIFERATION; PROTEOGLYCANS; STIMULATION; PHENOTYPE	Although transforming growth factor (TGF)-beta enhances bone formation, it inhibits the differentiation of osteoblasts. To clarify the regulatory mechanism of osteoblastic differentiation and TGF-beta actions, the relationship among differentiation, TCF-beta actions, and matrix protein synthesis was examined using murine osteoblast like MC3T3-E1 cells. Alkaline phosphatase (ALP) activity continued to increase during long-term cultures, and the increase was closely associated with a reduction in cell surface TGF-beta receptors competent to bind TGF-beta. Both the stimulation of proteoglycan synthesis and the inhibition of ALP activity by TGF-beta were also suppressed, Collagen synthesis inhibitors and an anti-alpha 2 beta 1 integrin blocking antibody blocked the changes in ALP activity and TGF-beta receptors, and a DGEA peptide that interferes binding of collagen to alpha 2 beta 1 integrin also blocked the increase in ALP activity. Furthermore, when MC3T3-E1 cells were cultured on extracellular matrix layers obtained from these cells, all the differentiation-associated changes could be observed without collagen production, and the extracellular matrix-induced differentiation was also blocked by an anti-alpha 2 beta 1 integrin antibody. These results demonstrate that the interaction of cell surface alpha 2 beta 1 integrin with matrix collagen synthesized by osteoblasts themselves is involved in the osteoblastic differentiation and the reduction in cell surface receptors and actions of TGF-beta. It is suggested that matrix collagen synthesized under the stimulation by TGF-beta plays an important role in the regulation of osteoblastic differentiation and TGF-beta actions by differentiation-associated down-regulation of TGF-beta receptors.			Takeuchi, Y (corresponding author), UNIV TOKYO,SCH MED,DEPT INTERNAL MED 4,BUNKYO KU,3-28-6 MEJIRODAI,TOKYO 112,JAPAN.							BRANDES ME, 1991, J BIOL CHEM, V266, P19697; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; FRANCESCHI RT, 1994, J BONE MINER RES, V9, P843; FRIEDMAN SL, 1994, J BIOL CHEM, V269, P10551; GAZIT D, 1993, MOL ENDOCRINOL, V7, P189, DOI 10.1210/me.7.2.189; HARADA S, 1991, J BONE MINER RES, V6, P903; HARRIS SE, 1994, J BONE MINER RES, V9, P855; HOCK JM, 1990, ENDOCRINOLOGY, V126, P421, DOI 10.1210/endo-126-1-421; HU JS, 1990, J BIOL CHEM, V265, P7914; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IBARAKI K, 1992, J BONE MINER RES, V7, P743; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; JENNINGS JC, 1990, ENDOCRINOLOGY, V126, P1014, DOI 10.1210/endo-126-2-1014; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATSUMOTO T, 1991, BONE, V12, P27, DOI 10.1016/8756-3282(91)90051-J; MERCIER T, 1995, BBA-MOL CELL RES, V1266, P64, DOI 10.1016/0167-4889(94)00240-F; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; NODA M, 1989, ENDOCRINOLOGY, V124, P612, DOI 10.1210/endo-124-2-612; NODA M, 1989, ENDOCRINOLOGY, V124, P2991, DOI 10.1210/endo-124-6-2991; OLSON EN, 1993, MOL ENDOCRINOL, V7, P1369, DOI 10.1210/me.7.11.1369; OREFFO ROC, 1989, BIOCHEM BIOPH RES CO, V158, P817, DOI 10.1016/0006-291X(89)92795-2; OUE Y, 1994, BONE, V15, P361, DOI 10.1016/8756-3282(94)90301-8; OWEN TA, 1991, ENDOCRINOLOGY, V128, P1496, DOI 10.1210/endo-128-3-1496; QUARLES LD, 1992, J BONE MINER RES, V7, P683; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; SUVA LJ, 1993, J BONE MINER RES, V8, P379; TAKEUCHI Y, 1989, J BIOL CHEM, V264, P18407; TAKEUCHI Y, 1994, J BIOL CHEM, V269, P32634; TAKEUCHI Y, 1995, J CELL PHYSIOL, V162, P315, DOI 10.1002/jcp.1041620303; TAKEUCHI Y, 1990, BIOCHEM J, V266, P15, DOI 10.1042/bj2660015; TAKEUCHI Y, 1993, J BONE MINER RES, V8, P821; THIEDE MA, 1988, P NATL ACAD SCI USA, V85, P319, DOI 10.1073/pnas.85.2.319; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1988, J CELL BIOL, V106, P915, DOI 10.1083/jcb.106.3.915	43	156	162	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3938	3944						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632016				2022-12-25	WOS:A1996TV72400090
J	Doherty, AJ; Ashford, SR; Subramanya, HS; Wigley, DB				Doherty, AJ; Ashford, SR; Subramanya, HS; Wigley, DB			Bacteriophage T7 DNA ligase - Overexpression, purification, crystallization, and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC ACID LIGASE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; PHYSICAL CHARACTERIZATION; FUNCTIONAL EXPRESSION; POLYNUCLEOTIDE LIGASE; CATALYTIC DOMAIN; END LIGATION; BLUNT-END; ENZYME	The bacteriophage T7 DNA ligase gene was amplified using polymerase chain reaction-based methods and cloned into a T7 promoter-based expression vector. The protein was overexpressed to greater than 15% of total soluble protein and purified to homogeneity, yielding 60-70 mg of protein per liter of bacterial culture. An initial physical and biochemical characterization of the enzyme reveals that it exists as a monomer and can ligate nicked, cohesive, and blunt-ended DNA fragments. Inhibition of the enzyme activity by a nonhydrolyzable ATP analogue was also investigated. The enzyme has been crystallized from methoxypolyethylene glycol. The crystals are of the orthorhombic space group P2(1)2(1)2 and diffract to 2.6 Angstrom. The unit cell dimensions are a 66.1 Angstrom, b = 87.6 Angstrom, and c = 78.6 Angstrom with one monomer in the asymmetric unit (V-m = 2.77 Angstrom(3)/Da). This is the first member of the DNA ligase family of enzymes to be crystallized.	UNIV OXFORD,MOLEC BIOPHYS LAB,OXFORD OX1 3QU,ENGLAND	University of Oxford				Doherty, Aidan/0000-0002-6370-1109	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARANY F, 1991, GENE, V109, P1, DOI 10.1016/0378-1119(91)90582-V; BARNES DE, 1990, P NATL ACAD SCI USA, V87, P6679, DOI 10.1073/pnas.87.17.6679; BNAKS GR, 1986, BIOCHIM BIOPHYS ACTA, V826, P180; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; DERMODY JJ, 1979, J BACTERIOL, V139, P701, DOI 10.1128/JB.139.2.701-704.1979; DOHARTY AJ, 1995, NUCLEIC ACIDS RES, V23, P2074; DUNN JJ, 1981, J MOL BIOL, V148, P308; Engler M.J., 1982, ENZYMES, V15, P3, DOI [10.1016/S1874-6047(08)60273-5, DOI 10.1016/S1874-6047(08)60273-5]; FAREED GC, 1971, J BIOL CHEM, V246, P925; HARVEY CL, 1971, J BIOL CHEM, V246, P4523; HEAPHY S, 1987, BIOCHEMISTRY-US, V26, P1688, DOI 10.1021/bi00380a030; HINKLE DC, 1975, J BIOL CHEM, V250, P5523; ISHINO Y, 1986, MOL GEN GENET, V204, P1, DOI 10.1007/BF00330179; KLETZIN A, 1992, NUCLEIC ACIDS RES, V20, P5389, DOI 10.1093/nar/20.20.5389; KODAMA K, 1991, NUCLEIC ACIDS RES, V19, P6093, DOI 10.1093/nar/19.22.6093; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUER G, 1991, J BACTERIOL, V173, P5047, DOI 10.1128/jb.173.16.5047-5053.1991; LEHMAN IR, 1974, SCIENCE, V186, P790; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; LITTLE JW, 1967, P NATL ACAD SCI USA, V58, P2004, DOI 10.1073/pnas.58.5.2004; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MODRICH P, 1973, J BIOL CHEM, V248, P7495; MODRICH P, 1973, J BIOL CHEM, V248, P7502; OLIVERA BM, 1968, P NATL ACAD SCI USA, V61, P237, DOI 10.1073/pnas.61.1.237; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PANET A, 1973, BIOCHEMISTRY-US, V12, P5045, DOI 10.1021/bi00749a003; PHEIFFER BH, 1983, NUCLEIC ACIDS RES, V11, P7853, DOI 10.1093/nar/11.22.7853; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWER B, 1994, P NATL ACAD SCI USA, V91, P4328, DOI 10.1073/pnas.91.10.4328; SGARAMEL.V, 1970, P NATL ACAD SCI USA, V67, P1468, DOI 10.1073/pnas.67.3.1468; SHELDRICK G, 1982, CRYSTALLOGRAPHIC COM, P145; SHUMAN S, 1994, P NATL ACAD SCI USA, V91, P12046, DOI 10.1073/pnas.91.25.12046; SHUMAN S, 1980, J BIOL CHEM, V255, P1588; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; TOMKINSON AE, 1991, P NATL ACAD SCI USA, V88, P400, DOI 10.1073/pnas.88.2.400; WEISS B, 1968, J BIOL CHEM, V243, P4556; WOOD WB, 1966, J MOL BIOL, V16, P118, DOI 10.1016/S0022-2836(66)80267-X; YANG SW, 1992, J BIOL CHEM, V267, P8117; YANG SW, 1992, J BIOL CHEM, V267, P2345; ZIMMERMAN SB, 1983, P NATL ACAD SCI-BIOL, V80, P5852, DOI 10.1073/pnas.80.19.5852	43	38	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11083	11089		10.1074/jbc.271.19.11083	http://dx.doi.org/10.1074/jbc.271.19.11083			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626651	hybrid			2022-12-25	WOS:A1996UJ94400011
J	Kontush, A; Meyer, S; Finckh, B; Kohlschutter, A; Beisiegel, U				Kontush, A; Meyer, S; Finckh, B; Kohlschutter, A; Beisiegel, U			alpha-Tocopherol as a reductant for Cu(II) in human lipoproteins - Triggering role in the initiation of lipoprotein oxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; LIPID-PEROXIDATION; VITAMIN-E; PLASMA-LIPOPROTEINS; COPPER; PROOXIDANT; ANTIOXIDANT; BINDING; INVITRO; IRON	Initiation of lipid peroxidation by Cu(II) requires reduction of Cu(II) to Cu(I) as a first step. It is unclear, however, whether this reaction occurs in the course of lipoprotein oxidation. It is also unknown which reductant, if any, can drive the reduction of Cu(II) in this case. We found that Cu(II) was rapidly reduced to Cu(I) by all major human lipoproteins (high, low and very low density lipoproteins (HDL, LDL, and VLDL), and chylomicrons). Cu(II)-reducing activity was associated with a lipid moiety of the lipoproteins. The rates of Cu(II) reduction by different lipoproteins were similar when the lipoproteins were adjusted to similar alpha-tocopherol concentrations, Enriching lipoproteins with alpha-tocopherol considerably increased the rate of Cu(II) reduction. Cu(II) reduction by alpha-tocopherol-deficient LDL isolated from a patient with familial inherited vitamin E deficiency was found to occur much slower in comparison with LDL isolated from a donor with a normal plasma level of alpha-tocopherol. Initial rate of Cu(II) reduction by alpha-tocopherol-deficient LDL was found to be zero. Enriching LDL with ubiquinol-10 to concentrations close to those of alpha-tocopherol did not influence the reaction rate. When LDL was treated with ebselen to eliminate preformed lipid hydroperoxides, the reaction rate was also not changed significantly, Cu(II) reduction was accompanied by a consumption of lipoprotein alpha-tocopherol and accumulation of conjugated dienes in the samples. Increasing alpha-tocopherol content in lipoproteins slightly decreased the rate of conjugated diene accumulation in LDL and HDL and considerably increased it in VLDL. The results suggest that alpha-tocopherol plays a triggering role in the lipoprotein oxidation by Cu(II), providing its initial step as follows: alpha TocH + Cu(II) --> alpha Toc(.) + Cu(I) + H+. This reaction appears to diminish or totally eliminate the antioxidative activity of alpha-tocopherol in the course of lipoprotein oxidation.	UNIV HAMBURG, KRANKENHAUS EPPENDORF, MED KLIN, D-20246 HAMBURG, GERMANY; UNIV HAMBURG, KRANKENHAUS EPPENDORF, KINDERKLIN, D-20246 HAMBURG, GERMANY	University of Hamburg; University of Hamburg			Kohlschütter, Alfried/ABE-3495-2021; Kontush, Anatol/J-2198-2016; Kohlschütter, Alfried/ABH-5710-2020	Kohlschütter, Alfried/0000-0002-2700-0401; 				AVIRAM M, 1993, ATHEROSCLEROSIS, V98, P1, DOI 10.1016/0021-9150(93)90217-I; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BOWRY VW, 1993, J AM CHEM SOC, V115, P6029, DOI 10.1021/ja00067a019; BOWRY VW, 1992, BIOCHEM J, V288, P341, DOI 10.1042/bj2880341; Bruckdorfer K. Richard, 1993, Current Opinion in Lipidology, V4, P238, DOI 10.1097/00041433-199306000-00010; CHAPMAN MJ, 1986, METHOD ENZYMOL, V128, P70; COMINACINI L, 1991, CLIN CHIM ACTA, V204, P57, DOI 10.1016/0009-8981(91)90217-Z; CROFT KD, 1995, BBA-LIPID LIPID MET, V1254, P250, DOI 10.1016/0005-2760(94)00166-V; DIEBERROTHENEDER M, 1991, J LIPID RES, V32, P1325; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; ESTERBAUER H, 1991, AM J CLIN NUTR, V53, pS314, DOI 10.1093/ajcn/53.1.314S; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; Finckh B, 1995, ANAL BIOCHEM, V232, P210, DOI 10.1006/abio.1995.0009; Frei Balz B., 1993, P131; FUKUZAWA K, 1988, ARCH BIOCHEM BIOPHYS, V260, P153, DOI 10.1016/0003-9861(88)90436-5; FUKUZAWA K, 1993, J NUTR SCI VITAMINOL, V39, pS9, DOI 10.3177/jnsv.39.Supplement_S9; GOTTO AM, 1986, METHOD ENZYMOL, V128, P3; HALLIWELL B, 1995, AM J CLIN NUTR, V61, p670S, DOI 10.1093/ajcn/61.3.670S; Hochstein P, 1980, Ann N Y Acad Sci, V355, P240, DOI 10.1111/j.1749-6632.1980.tb21342.x; JESSUP W, 1993, BIOCHEM SOC T, V21, P321, DOI 10.1042/bst0210321; KLEINVELD HA, 1993, FREE RADICAL BIO MED, V15, P273, DOI 10.1016/0891-5849(93)90074-5; KOHLSCHUTTER A, 1988, J INHERIT METAB DIS, V11, P149, DOI 10.1007/BF01804221; Kontush A, 1996, FREE RADICAL RES, V24, P135, DOI 10.3109/10715769609088009; KONTUSH A, 1994, FEBS LETT, V341, P69, DOI 10.1016/0014-5793(94)80242-4; KONTUSH A, 1995, BBA-LIPID LIPID MET, V1258, P177, DOI 10.1016/0005-2760(95)00115-S; KUZUYA M, 1992, BIOCHIM BIOPHYS ACTA, V1123, P334, DOI 10.1016/0005-2760(92)90015-N; LENAZ G, 1992, BIOCHEM CELL BIOL, V70, P504, DOI 10.1139/o92-078; LEPAGE G, 1986, J LIPID RES, V27, P114; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYNCH SM, 1995, J BIOL CHEM, V270, P5158, DOI 10.1074/jbc.270.10.5158; MAIORINO M, 1993, FEBS LETT, V330, P174, DOI 10.1016/0014-5793(93)80267-X; MAIORINO M, 1995, FREE RADICAL BIO MED, V18, P67, DOI 10.1016/0891-5849(94)00103-Q; NIKI E, 1984, J BIOL CHEM, V259, P4177; OBRIEN PJ, 1969, CAN J BIOCHEM CELL B, V47, P485, DOI 10.1139/o69-076; OUAHCHI K, 1995, NAT GENET, V9, P141, DOI 10.1038/ng0295-141; PIFAT G, 1992, CHEM PHYS LIPIDS, V63, P159, DOI 10.1016/0009-3084(92)90032-K; PRINCEN HMG, 1992, ARTERIOSCLER THROMB, V12, P554, DOI 10.1161/01.ATV.12.5.554; RAHMAN A, 1989, CARCINOGENESIS, V10, P1833, DOI 10.1093/carcin/10.10.1833; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; SATTLER W, 1994, ARCH BIOCHEM BIOPHYS, V309, P214, DOI 10.1006/abbi.1994.1105; SPARROW CP, 1993, J LIPID RES, V34, P1219; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; THOMAS CE, 1991, J PHARMACOL EXP THER, V256, P1182; THOMAS JP, 1994, ARCH BIOCHEM BIOPHYS, V315, P244, DOI 10.1006/abbi.1994.1496; VOSSEN RCRM, 1993, LIPIDS, V28, P857, DOI 10.1007/BF02536243; WITZTUM JL, 1993, BRIT HEART J, V69, pS12; WOOD JL, 1995, FEBS LETT, V366, P75, DOI 10.1016/0014-5793(95)00494-T; YAMAMOTO K, 1988, BIOCHIM BIOPHYS ACTA, V958, P19, DOI 10.1016/0005-2760(88)90241-X; YOSHIDA Y, 1994, BBA-GEN SUBJECTS, V1200, P85, DOI 10.1016/0304-4165(94)90121-X	50	106	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11106	11112		10.1074/jbc.271.19.11106	http://dx.doi.org/10.1074/jbc.271.19.11106			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626654	hybrid			2022-12-25	WOS:A1996UJ94400014
J	Sugimoto, K; Honda, S; Yamamoto, T; Ueki, T; Monden, M; Kaji, A; Matsumoto, K; Nakamura, T				Sugimoto, K; Honda, S; Yamamoto, T; Ueki, T; Monden, M; Kaji, A; Matsumoto, K; Nakamura, T			Molecular cloning and characterization of a newly identified member of the cadherin family, PB-cadherin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; HEPATOCYTE GROWTH-FACTOR; DESMOSOMAL GLYCOPROTEIN; CYTOPLASMIC DOMAIN; SEQUENCE-ANALYSIS; NERVOUS-SYSTEM; GENE FAMILY; EXPRESSION; UVOMORULIN; CDNA	We have isolated cDNA clones encoding novel proteins belonging to the cadherin family. These novel proteins are encoded by two distinct mRNA species generated by alternative splicing from a single gene, and based on preferential expression in the pituitary gland and brain, we named it PB-cadherin. One mRNA species encodes long type PB-cadherin composed of 803 amino acid residues with a longer cytoplasmic domain, whereas the other species encodes short type PB-cadherin composed of 694 amino acid residues with a shorter cytoplasmic domain. Both long and short type PB-cadherin contain five repeats of a cadherin motif in the extracellular domain, the transmembrane domain, and the cytoplasmic domain, and the deduced amino acid sequences have a 30% homology to those of E-, N-, and P-cadherins. Although the primary structure of N-terminal amino acids is identical between long and short type PB-cadherin, the following structures in the cytoplasmic regions are completely different. The long type PB-cadherin but not the short type contains the putative catenin-binding domain. When these two distinct forms of PB-cadherins were stably expressed in L cells, L cells expressing long type PB-cadherin or short type PB-cadherin both acquired a Ca2+-dependent cell adhesion property, thereby indicating that both types of PB-cadherin are responsible for Ca2+-dependent cell adhesion. Persistent expression of PB-cadherin mRNA was found in the brain of rat embryos at least from embryonic day 15 to the postnatal period. In situ localization of PB-cadherin mRNA in the adult rat brain indicated that PB-cadherin mRNA is expressed in the inner granular layer of the olfactory bulb, Purkinje cell layer of the cerebellum, and in the pineal gland. PB-cadherin may play an important role in morphogenesis and tissue formation in neural and non-neural cells for the development and maintenance of the brain and neuroendocrine organs by regulating cell-cell adhesion.	OSAKA UNIV,SCH MED,BIOMED RES CTR,DIV BIOCHEM,SUITA,OSAKA 565,JAPAN; TSUMURA CO LTD,AMI,IBARAKI 30011,JAPAN; OSAKA UNIV,SCH MED,DEPT SURG 2,SUITA,OSAKA 565,JAPAN; UNIV PENN,SCH MED,DEPT MICROBIOL,PHILADELPHIA,PA 19104	Osaka University; Tsumura & Company; Osaka University; University of Pennsylvania			MATSUMOTO, Kunio/D-8441-2015	MATSUMOTO, Kunio/0000-0002-6532-4482				AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; COLLINS JE, 1991, J CELL BIOL, V113, P381, DOI 10.1083/jcb.113.2.381; DEGEN SJF, 1991, BIOCHEMISTRY-US, V30, P9781, DOI 10.1021/bi00104a030; GALLIN WJ, 1987, P NATL ACAD SCI USA, V84, P2808, DOI 10.1073/pnas.84.9.2808; GOODWIN L, 1990, BIOCHEM BIOPH RES CO, V173, P1224, DOI 10.1016/S0006-291X(05)80917-9; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; HONDA S, 1995, MOL BRAIN RES, V32, P197, DOI 10.1016/0169-328X(95)00075-4; INUZUKA H, 1991, NEURON, V7, P69, DOI 10.1016/0896-6273(91)90075-B; KOCH PJ, 1990, EUR J CELL BIOL, V53, P1; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; MATSUNAGA M, 1988, NEURON, V1, P289, DOI 10.1016/0896-6273(88)90077-3; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NAKAGAWA S, 1995, DEVELOPMENT, V121, P1321; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAPOLITANO EW, 1991, J CELL BIOL, V113, P893, DOI 10.1083/jcb.113.4.893; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; NOSE A, 1987, EMBO J, V6, P3655, DOI 10.1002/j.1460-2075.1987.tb02698.x; OKAZAKI M, 1994, J BIOL CHEM, V269, P12092; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; OZAWA M, 1990, J CELL BIOL, V111, P1645, DOI 10.1083/jcb.111.4.1645; PARKER AE, 1991, J BIOL CHEM, V266, P10438; RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896-6273(91)90291-7; REDIES C, 1993, DEV DYNAM, V197, P26, DOI 10.1002/aja.1001970104; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; SANO K, 1993, EMBO J, V12, P2249, DOI 10.1002/j.1460-2075.1993.tb05878.x; SHIMOYAMA Y, 1989, CANCER RES, V49, P2128; SHIOZAKI H, 1991, AM J PATHOL, V139, P17; SUZUKI S, 1991, CELL REGUL, V2, P261, DOI 10.1091/mbc.2.4.261; TAKEICHI M, 1977, J CELL BIOL, V75, P464, DOI 10.1083/jcb.75.2.464; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; YANAGITA K, 1993, J BIOL CHEM, V268, P21212	42	52	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11548	11556		10.1074/jbc.271.19.11548	http://dx.doi.org/10.1074/jbc.271.19.11548			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626716	hybrid			2022-12-25	WOS:A1996UJ94400076
J	Gum, R; Lengyel, E; Juarez, J; Chen, JH; Sato, H; Seiki, M; Boyd, D				Gum, R; Lengyel, E; Juarez, J; Chen, JH; Sato, H; Seiki, M; Boyd, D			Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV COLLAGENASE GENE; INFLAMMATORY CYTOKINES; MAP KINASE; C-JUN; EXPRESSION; CELLS; ENHANCER; FIBROBLASTS; INDUCTION; ONCOGENE	The 92-kDa type IV collagenase (92-kDa gelatinase B also referred to as MMP-9), which plays a critical role in extracellular matrix degradation, is regulated by growth factors that mediate their effects through the ras proto oncogene. The current study was undertaken to determine the transcriptional requirements for the induction of 92-kDa gelatinase B expression by an activated ras oncogene. Transfection of OVCAR-3 cells with an expression vector encoding an activated Ha-ras increased 92-kDa gelatinolytic activity and stimulated (over 10-fold) the activity of a CAT reporter driven by 670 nucleotides of 5' flanking sequence of the 92-kDa gelatinase B gene. Transient assays using a CAT reporter driven by 5' deleted fragments of the 92-kDa gelatinase B promoter indicated that a region spanning -634 to -531 was required for optimal induction of the promoter. The individual deletion, or mutation, of a PEA3/ets (-540) motif, AP-1 sites (-533, -79), a NF-kappa B (-600) consensus sequence, and a GT box (-52) substantially reduced the activation of the promoter by ras. An expression vector encoding the PEA3 transcription factor caused a 3-fold stimulation of the wild type but not the PEA3/ets-deleted 92-kDa gelatinase B promoter. Coexpression of a dominant negative c-jun antagonized the ras-dependent stimulation of the 92-kDa gelatinase B promoter-driven CAT reporter. The signaling pathway mediating the induction of 92-kDa gelatinase B promoter activity by ras was examined. The expression of a phosphatase (CL100) which inactivates multiple mitogen-activated protein kinase members abrogated the stimulation of 92-kDa gelatinase B promoter activity by ras, However, the expression of a kinase deficient mitogen-activated protein kinase kinase 1 (MEK1) did not prevent the activation of the 92-kDa gelatinase B promoter by ras and a constitutively activated c-raf expression vector was insufficient for 92-kDa gelatinase B promoter activation. Thus, the stimulation of the 92-kDa gelatinase B promoter by ras requires multiple elements including closely spaced PEA3/ets and AP-1 sites and is MEK1-independent.	MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; TECH UNIV MUNICH,DEPT OBSTET & GYNECOL,D-81675 MUNICH,GERMANY; TZU CHI COLL MED,INST MED RES,DEPT MOLEC BIOL,HUALIEN 970,TAIWAN; KANAZAWA UNIV,CANC RES INST,DEPT MOL VIROL & ONCOL,KANAZAWA,ISHIKAWA 920,JAPAN	University of Texas System; UTMD Anderson Cancer Center; Technical University of Munich; Tzu Chi University; Kanazawa University			Seiki, Motoharu/K-9443-2015; SATO, Hiroshi/D-8454-2015; Lengyel, Ernst/D-9220-2014	Lengyel, Ernst/0000-0001-8624-1507	NCI NIH HHS [R01CA58311] Funding Source: Medline; NIDCR NIH HHS [R01DE10845] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010845] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; ALESSI DR, 1993, ONCOGENE, V8, P2015; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; BERNHARD EJ, 1990, CANCER RES, V50, P3872; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENG T, 1995, NATURE, V371, P171; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FRIDMAN R, 1995, CANCER RES, V55, P2548; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GUO XJ, 1995, MOL CELL BIOL, V15, P476, DOI 10.1128/MCB.15.1.476; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; HURWITZ A, 1993, ENDOCRINOLOGY, V132, P2709, DOI 10.1210/en.132.6.2709; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; KRAMER B, 1995, J BIOL CHEM, V270, P6577; LENGYEL E, 1995, CANCER RES, V55, P963; LENGYEL E, 1995, J BIOL CHEM, V270, P23007, DOI 10.1074/jbc.270.39.23007; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; LYONS JG, 1993, J BIOL CHEM, V268, P19143; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; NERLOV C, 1991, ONCOGENE, V6, P1583; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; NICOLSON GL, 1990, ONCOGENE, V5, P747; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PANKOV R, 1994, P NATL ACAD SCI USA, V91, P873, DOI 10.1073/pnas.91.3.873; PYKE C, 1992, CANCER RES, V52, P1336; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO H, 1993, J BIOL CHEM, V268, P23460; SATO H, 1993, ONCOGENE, V8, P395; SOUDANT N, 1994, NUCLEIC ACIDS RES, V22, P3871, DOI 10.1093/nar/22.19.3871; STACEY DW, 1991, ONCOGENE, V6, P2297; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; TREMBLE P, 1995, J CELL BIOL, V129, P1707, DOI 10.1083/jcb.129.6.1707; UNEMORI EN, 1991, J CLIN INVEST, V88, P1656, DOI 10.1172/JCI115480; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WASYLYK C, 1992, CELL GROWTH DIFFER, V3, P617; WASYLYK C, 1994, ONCOGENE, V9, P3665; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; XIN J, 1995, GENE DEV, V6, P481	61	322	339	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10672	10680		10.1074/jbc.271.18.10672	http://dx.doi.org/10.1074/jbc.271.18.10672			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631874	hybrid			2022-12-25	WOS:A1996UJ34200042
J	Lecain, E; Chenivesse, X; Spagnoli, R; Pompon, D				Lecain, E; Chenivesse, X; Spagnoli, R; Pompon, D			Cloning by metabolic interference in yeast and enzymatic characterization of Arabidopsis thaliana sterol Delta 7-reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMIN-B RECEPTOR; SACCHAROMYCES-CEREVISIAE; CHOLESTEROL-BIOSYNTHESIS; MICROSOMAL-ENZYMES; GENE ENCODES; MEMBRANE; MUTANTS; PROTEIN; IDENTIFICATION; PURIFICATION	Reduction of the Delta 7 double bond of sterols, a key biosynthetic step in higher eukaryotes, is lacking in lower eukaryotes like the yeast Saccharomyces cerevisiae, leading to terminal sterols with a Delta 5,7-conjugated diene structure, Genes encoding two sterol reductases involved, respectively, in the reduction of sterol Delta 14 and Delta 24(28) double bonds have been cloned to date, but no sequence information was available on the enzyme responsible for Delta 7-bond reduction, This study presents the cloning of the NADPH-sterol Delta 7-reductase (Delta 7-red) from Arabidopsis thaliana, based on a metabolic interference approach in yeast, The principle is the functional expression of a plant cDNA library in the yeast strain FY1679-28C tolerant to sterol modifications and the selection of clones resistant to the polyene fungicide nystatin, The toxicity of this compound is dependent on the presence of Delta 5,7-unsaturated sterols in the yeast plasma membrane, One clone out of 10(5) transformants exhibits a cDNA-dependent alteration of cell sterol composition, The 1290-base pair cDNA open reading frame was isolated and sequenced, The corresponding protein presents a significant sequence similarity with yeast Delta 14- and Delta 24(28)-reductases and with human lamin B receptor. The coding sequence was extracted by polymerase chain reaction and inserted into a galactose-inducible yeast expression vector to optimize expression, Analysis using transformed wild type yeast or sterol altered mutants, indicated that Delta 5,7-ergosta- and cholesta-sterols are efficiently reduced in vivo, regardless of the structural variations on the side chain, No reductase activity was observed toward the Delta 14 or the Delta 5 positions of sterols, In vivo extensive Delta 7-reduction of the free and esterified pools of sterols was observed upon induction of the enzyme, Ergosterol present before induction was reduced into ergosta-5,22-dieneol, whereas ergosta-5-eneol is the new end product of sterol neosynthesis, indicating that the yeast Delta 22 desaturase may be no longer active on C-7-saturated sterols, In vitro tests indicated that Delta 7-reductase activity is preferentially associated with the endoplasmic reticulum membrane and confirmed the previous finding that NADPH is the reducing agent.	UNIV PARIS 06, CNRS, CTR MOLEC GENET, F-91198 GIF SUR YVETTE, FRANCE; ROUSSEL UCLAF, DEPT BIOTECHNOL, UNITE RECH BIOTECHNOL, F-93235 ROMAINVILLE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay								AOYAMA Y, 1994, BIOCHEM BIOPH RES CO, V201, P1320, DOI 10.1006/bbrc.1994.1848; AUFENANGER J, 1986, BIOCHEM PHARMACOL, V35, P911, DOI 10.1016/0006-2952(86)90076-6; BARD M, 1977, LIPIDS, V12, P645, DOI 10.1007/BF02533759; BOTTEMA CDK, 1985, BIOCHIM BIOPHYS ACTA, V813, P313, DOI 10.1016/0005-2736(85)90247-0; CHEN WN, 1991, YEAST, V7, P305, DOI 10.1002/yea.320070313; CLEJAN S, 1985, J BIOL CHEM, V260, P2884; CULLIN C, 1988, GENE, V65, P203, DOI 10.1016/0378-1119(88)90457-X; DAHL C, 1987, P NATL ACAD SCI USA, V84, P4012, DOI 10.1073/pnas.84.12.4012; DEMPSEY ME, 1969, METHOD ENZYMOL, V15, P501; FRYBERG M, 1973, J AM CHEM SOC, V95, P5745; GABER RF, 1989, MOL CELL BIOL, V9, P3447, DOI 10.1128/MCB.9.8.3447; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HARTMANN MA, 1987, METHOD ENZYMOL, V148, P632; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KAWATA S, 1986, J BIOL CHEM, V261, P3790; LADEVEZE V, 1993, LIPIDS, V28, P907, DOI 10.1007/BF02537499; LAI MH, 1994, GENE, V140, P41; LEES N D, 1989, Steroids, V53, P567, DOI 10.1016/0039-128X(89)90032-9; LEUTWILER LS, 1984, MOL GEN GENET, V194, P15, DOI 10.1007/BF00383491; LORENZ RT, 1989, J BACTERIOL, V171, P6169, DOI 10.1128/jb.171.11.6169-6173.1989; LORENZ RT, 1991, ANTIMICROB AGENTS CH, V35, P1532, DOI 10.1128/AAC.35.8.1532; LORENZ RT, 1992, DNA CELL BIOL, V11, P685, DOI 10.1089/dna.1992.11.685; MINET M, 1992, PLANT J, V2, P417; MOLZAHN SW, 1972, J GEN MICROBIOL, V72, P339, DOI 10.1099/00221287-72-2-339; OSUMI T, 1978, J BIOCHEM-TOKYO, V83, P681, DOI 10.1093/oxfordjournals.jbchem.a131961; PAIK YK, 1986, J BIOL CHEM, V261, P6470; PARKS LW, 1978, CRC CR REV MICROBIOL, V6, P301, DOI 10.3109/10408417809090625; PARKS LW, 1985, METHOD ENZYMOL, V111, P333; POPJAK G, 1989, J BIOL CHEM, V264, P6230; PRUITT RE, 1986, J MOL BIOL, V187, P169, DOI 10.1016/0022-2836(86)90226-3; REINHART MP, 1987, J BIOL CHEM, V262, P9649; ROCKMILL B, 1991, METHOD ENZYMOL, V194, P1456; RODRIGUEZ RJ, 1983, ARCH BIOCHEM BIOPHYS, V225, P861, DOI 10.1016/0003-9861(83)90099-1; SCHROEPFER GJ, 1982, ANNU REV BIOCHEM, V51, P555, DOI 10.1146/annurev.bi.51.070182.003011; SCHULER E, 1994, J BIOL CHEM, V269, P11312; SHIMANUKI M, 1992, MOL BIOL CELL, V3, P263, DOI 10.1091/mbc.3.3.263; SMITH DW, 1964, J PEDIATR-US, V64, P210, DOI 10.1016/S0022-3476(64)80264-X; SONO H, 1991, BIOCHIM BIOPHYS ACTA, V1078, P388, DOI 10.1016/0167-4838(91)90161-R; SOULLAM B, 1993, J CELL BIOL, V120, P1093, DOI 10.1083/jcb.120.5.1093; STEINBERG D, 1969, METHOD ENZYMOL, V15, P514; STOTZ A, 1990, GENE, V95, P91, DOI 10.1016/0378-1119(90)90418-Q; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; TATON M, 1991, BIOCHEM BIOPH RES CO, V181, P465, DOI 10.1016/S0006-291X(05)81442-1; THIERRY A, 1990, YEAST, V6, P521, DOI 10.1002/yea.320060609; TINT GS, 1994, NEW ENGL J MED, V330, P107, DOI 10.1056/NEJM199401133300205; WORMAN HJ, 1990, J CELL BIOL, V111, P1535, DOI 10.1083/jcb.111.4.1535; ZINSER E, 1993, J BACTERIOL, V175, P2853, DOI 10.1128/JB.175.10.2853-2858.1993	47	54	61	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10866	10873		10.1074/jbc.271.18.10866	http://dx.doi.org/10.1074/jbc.271.18.10866			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631902	hybrid			2022-12-25	WOS:A1996UJ34200070
J	Sarno, S; Vaglio, P; Meggio, F; Issinger, OG; Pinna, LA				Sarno, S; Vaglio, P; Meggio, F; Issinger, OG; Pinna, LA			Protein kinase CK2 mutants defective in substrate recognition - Purification and kinetic analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CYTOSOL; CASEIN KINASE-2; CONSENSUS SEQUENCES; BETA-SUBUNIT; CELLULAR-REGULATION; CATALYTIC SUBUNIT; SITE SPECIFICITY; PHOSPHORYLATION; IDENTIFICATION; MECHANISM	Five mutants of protein kinase CK2 alpha subunit in which altogether 14 basic residues were singly to quadruply replaced by alanines (K74A,K75A,K764,K77A; K79A, R80A,K83A; R191A/R195A,K198A; R228A; and R278A, K279AR280A) have been purified to near homogeneity either as such or after addition of the recombinant beta subunit, By this latter procedure five mutated tetrameric holoenzymes were obtained as judged from their subunit composition, sedimentation coefficient on sucrose gradient ultracentrifugation, and increased activity toward a specific peptide substrate as compared with the isolated alpha subunits, The kinetic constants and the phosphorylation efficiencies (V-max/K-m) of all the mutants with the parent peptide RRRADDSDDDDD and a series of derivatives, in which individual aspartic acids were replaced by alanines, have been determined, Three mutants, namely K74A,K75A,K76A,K77A; K79A,R80A, K83A; and R191A,R195A,K198A display dramatically lower phosphorylation efficiency and 8-50-fold higher K-m values with the parent peptide, symptomatic of reduced attitude to bind the peptide substrate as compared with CK2 wild type, Such differences either disappear or are attenuated if the mutants R191A,R195A, K198A; K79A,R80A,K83A; and K74A,K75A,K76A,K77A are assayed with the peptides RRRADDSADDDD, RRRADDSDDADD, and RRRADDSDDDAA, respectively, In contrast, the phosphorylation efficiencies of the other substituted peptides decrease more markedly with these mutants than with CK2 wild type, These data show that one or more of the basic residues clustered in the 191-198, 79-83, and 74-77 sequences are implicated in the recognition of the acidic determinants at positions +1, +3, and +4/+5, respectively, and that if these residues are mutated, the relevance of the other acidic residues surrounding serine is increased, In contrast the other two mutants, namely R228A and R278A,K279A, R280A, display with all the peptides V-max values higher than CK2 wild type, counterbalanced however by somewhat higher K-m values, It can be concluded from these data that all the five mutations performed are compatible with the reconstitution of tetrameric holoenzyme, but all of them influence the enzymatic efficiency of CK2 to different extents, Although the basic residues mutated in the 74-77, 79-83, and 191-198 sequences are clearly implicated in substrate recognition by interacting with acidic determinants at variable positions downstream from serine, the other basic residues seem to play a more elusive and/or indirect role in catalysis.	UNIV PADUA, DIPARTIMENTO CHIM BIOL, I-351321 PADUA, ITALY; CNR, CTR STUDIO FISIOL MITOCONDRIALE, I-351321 PADUA, ITALY; ODENSE UNIV, BIOKEMISK INST, DK-5230 ODENSE, DENMARK	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Southern Denmark				Vaglio, Philippe/0000-0003-2900-5596				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BOLDYREFF B, 1992, BIOCHEM BIOPH RES CO, V188, P228, DOI 10.1016/0006-291X(92)92374-7; BOLDYREFF B, 1993, BIOCHEMISTRY-US, V32, P12672, DOI 10.1021/bi00210a016; BOSSEMEYER D, 1995, FEBS LETT, V369, P57, DOI 10.1016/0014-5793(95)00580-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DOBROWOLSKA G, 1994, FEBS LETT, V355, P237, DOI 10.1016/0014-5793(94)01190-7; FERRARI S, 1987, EUR J BIOCHEM, V163, P481, DOI 10.1111/j.1432-1033.1987.tb10894.x; GALLAGHER PJ, 1993, J BIOL CHEM, V268, P26578; GATICA M, 1994, FEBS LETT, V339, P93, DOI 10.1016/0014-5793(94)80392-7; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GIBBS CS, 1991, BIOCHEMISTRY-US, V30, P5329, DOI 10.1021/bi00236a001; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HRUBEY TW, 1990, BIOCHEM BIOPH RES CO, V172, P190, DOI 10.1016/S0006-291X(05)80192-5; HU E, 1990, J BIOL CHEM, V265, P20609; HUANG CYF, 1995, J BIOL CHEM, V270, P7183, DOI 10.1074/jbc.270.13.7183; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; KEMP BE, 1994, TRENDS BIOCHEM SCI, V19, P440, DOI 10.1016/0968-0004(94)90126-0; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITCHFIELD DW, 1994, CELL MOL BIOL RES, V40, P373; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MARIN O, 1992, FEBS LETT, V301, P111, DOI 10.1016/0014-5793(92)80221-2; MARIN O, 1994, BIOCHEM BIOPH RES CO, V198, P898, DOI 10.1006/bbrc.1994.1128; MARIN O, 1995, FEBS LETT, V363, P111, DOI 10.1016/0014-5793(95)00295-K; MEGGIO F, 1984, EUR J BIOCHEM, V145, P593, DOI 10.1111/j.1432-1033.1984.tb08598.x; MEGGIO F, 1989, BIOCHIM BIOPHYS ACTA, V1010, P128, DOI 10.1016/0167-4889(89)90193-6; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; MEGGIO F, 1994, BIOCHEMISTRY-US, V33, P4336, DOI 10.1021/bi00180a030; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; PERICH JW, 1992, BIOCHEMISTRY-US, V31, P5893, DOI 10.1021/bi00140a027; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; SARNO S, 1995, BIOCHEM BIOPH RES CO, V206, P171, DOI 10.1006/bbrc.1995.1024; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TOMODA T, 1993, BIOCHIM BIOPHYS ACTA, V1175, P333, DOI 10.1016/0167-4889(93)90226-F; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; Vaglio P, 1996, FEBS LETT, V380, P25, DOI 10.1016/0014-5793(95)01542-6	42	111	114	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10595	10601		10.1074/jbc.271.18.10595	http://dx.doi.org/10.1074/jbc.271.18.10595			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631861	hybrid			2022-12-25	WOS:A1996UJ34200029
J	Katoh, T; Morita, F				Katoh, T; Morita, F			Roles of light chains in the activity and conformation of smooth muscle myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT INTERACTIONS; GIZZARD MYOSIN; HEAVY-CHAIN; BINDING; ACTIN; PHOSPHORYLATION; SUBFRAGMENT-1; PROTEIN; ALKALI; ATP	The 20-kDa regulatory (LC20) and 17-kDa essential (LC17) light chain subunits could be removed from porcine aorta smooth muscle myosin by the use of trifluoperazine and ammonium chloride. The isolated heavy chain rebound both light chains, resulting in the restoration of native properties. Experiments on reconstitution of the isolated heavy chain with LC17 and/or LC20 showed that both light chains were required for folding into the 10 S conformation and thus for the phosphorylation dependent filament format-ion of smooth muscle myosin. However, LC17 was not essential for the phosphorylation-dependent regulation of actin-activated ATPase activity and superprecipitation but was required for full regulation. LC17 and phosphorylated LC20 were found to act as activators, and dephosphorylated LC20 was found to act as a repressor of the motor activities of smooth muscle myosin.			Katoh, T (corresponding author), HOKKAIDO UNIV,GRAD SCH SCI,DIV CHEM,SAPPORO,HOKKAIDO 060,JAPAN.							ASHIBA G, 1985, BIOCHEMISTRY-US, V24, P6618, DOI 10.1021/bi00344a048; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; COLE DG, 1992, BIOCHEMISTRY-US, V31, P6186, DOI 10.1021/bi00142a003; GONZALEZROMO P, 1992, ANAL BIOCHEM, V200, P235, DOI 10.1016/0003-2697(92)90458-J; GRAND RJA, 1983, BIOCHEM J, V211, P267, DOI 10.1042/bj2110267; HASEGAWA Y, 1990, J BIOCHEM-TOKYO, V108, P909, DOI 10.1093/oxfordjournals.jbchem.a123313; HASEGAWA Y, 1988, J BIOCHEM-TOKYO, V103, P15, DOI 10.1093/oxfordjournals.jbchem.a122222; IKEBE M, 1994, J BIOL CHEM, V269, P28173; KATOH T, 1995, EUR J BIOCHEM, V227, P459, DOI 10.1111/j.1432-1033.1995.tb20410.x; KATOH T, 1995, EUR J BIOCHEM, V233, P123, DOI 10.1111/j.1432-1033.1995.123_1.x; KATOH T, 1995, J BIOCHEM-TOKYO, V118, P428, DOI 10.1093/oxfordjournals.jbchem.a124925; KATOH T, 1993, J BIOL CHEM, V268, P2380; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; LOWEY S, 1995, BIOPHYS J S, V68, P120; PASTRALANDIS SC, 1986, J BIOL CHEM, V261, P4811; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Trybus KM, 1991, CURR OPIN CELL BIOL, V3, P105, DOI 10.1016/0955-0674(91)90172-U; TRYBUS KM, 1988, J BIOL CHEM, V263, P16485; TRYBUS KM, 1987, J CELL BIOL, V105, P3007, DOI 10.1083/jcb.105.6.3007; TRYBUS KM, 1994, J CELL BIOL, V124, P963, DOI 10.1083/jcb.124.6.963; TRYBUS KM, 1993, J BIOL CHEM, V268, P4412; TRYBUS KM, 1994, J BIOL CHEM, V269, P20819; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; WAGNER PD, 1981, NATURE, V292, P560, DOI 10.1038/292560a0; WALLER GS, 1995, J BIOL CHEM, V270, P15348, DOI 10.1074/jbc.270.25.15348; WALLER GS, 1985, J BIOL CHEM, V260, P4368; WINKELMANN DA, 1983, CELL, V34, P295, DOI 10.1016/0092-8674(83)90160-5; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; YOSHIDA M, 1988, J BIOCHEM-TOKYO, V103, P380, DOI 10.1093/oxfordjournals.jbchem.a122278	33	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9992	9996		10.1074/jbc.271.17.9992	http://dx.doi.org/10.1074/jbc.271.17.9992			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626639	hybrid			2022-12-25	WOS:A1996UG25700023
J	Mary, J; Redeker, V; LeCaer, JP; Rossier, J; Schmitter, JM				Mary, J; Redeker, V; LeCaer, JP; Rossier, J; Schmitter, JM			Posttranslational modifications in the C-terminal tail of axonemal tubulin from sea urchin sperm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-TUBULIN; BETA-TUBULIN; BRAIN; ISOTYPE; IDENTIFICATION; EXPRESSION	After proteolytic digestion of sperm tubulin from sea urchin Paracentrotus lividus, C-terminal peptides were isolated by chromatographic separations. The peptides mere analyzed by Edman degradation and matrix-assisted laser desorption/ionization-time of flight mass spectrometry. About 70% of the isolated C-terminal peptides were unmodified. The remaining modified peptides have undergone a combination of numerous posttranslational modifications generating significant heterogeneity of sperm tubulin, alpha-Tubulin is modified by detyrosylation, release of the penultimate glutamate, polyglutamylation, and polyglycylation. Glycylation and glutamylation can coexist within one alpha-tubulin isoform, beta-Tubulin undergoes polyglycylation but was not observed to be polyglutamylated. The number of units posttranslationally added reaches 11 and 12 glycyl units on beta- and alpha-tubulin, respectively. This is different from the polyglycylation of axonemal tubulin in Paramecium cilia where up to 40 added glycyl units were observed both on alpha- and beta-tubulin.	ECOLE POLYTECH,CNRS,URA 1970,BIOCHIM LAB,F-91128 PALAISEAU,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut Polytechnique de Paris	Mary, J (corresponding author), ECOLE SUPER PHYS & CHIM IND VILLE PARIS,CNRS,URA 2054,LAB NEUROBIOL DIVERSITE CELLULAIRE,F-75231 PARIS 5,FRANCE.		Mary, Jean/H-2344-2011; Redeker, Virginie/L-8929-2018	Mary, Jean/0000-0002-2438-8383; Redeker, Virginie/0000-0003-2694-8388				ALEXANDER JE, 1991, P NATL ACAD SCI USA, V88, P4685, DOI 10.1073/pnas.88.11.4685; BARRA HS, 1973, J NEUROCHEM, V20, P97, DOI 10.1111/j.1471-4159.1973.tb12108.x; BRE MH, 1996, IN PRESS J CELL SCI; COWAN NJ, 1988, CYTOSKELETON CELL DI, P157; DIAZNIDO J, 1990, J BIOL CHEM, V265, P13949; DIBARNARDO MG, 1989, NUCLEIC ACIDS RES, V17, P5851; EDDE B, 1992, BIOCHEMISTRY-US, V31, P403, DOI 10.1021/bi00117a014; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; Gagnon C, 1995, J CELL BIOCH B S, V19B, P112; GEUENS G, 1989, J CELL BIOL, V108, P939, DOI 10.1083/jcb.108.3.939; GIANGUZZA F, 1989, Molecular Reproduction and Development, V1, P170, DOI 10.1002/mrd.1080010305; GIANGUZZA F, 1990, NUCLEIC ACIDS RES, V18, P4915, DOI 10.1093/nar/18.16.4915; HUITOREL P, 1995, J CELL BIOCH B, V19, P1080; LEDIZET M, 1987, P NATL ACAD SCI USA, V84, P5720, DOI 10.1073/pnas.84.16.5720; LUDUENA RF, 1988, FEBS LETT, V230, P142, DOI 10.1016/0014-5793(88)80658-6; MARY J, 1994, FEBS LETT, V353, P89, DOI 10.1016/0014-5793(94)01018-8; PATURLELAFANECHERE L, 1994, J CELL SCI, V107, P1529; PATURLELAFANECHERE L, 1991, BIOCHEMISTRY-US, V30, P10523, DOI 10.1021/bi00107a022; REDEKER V, 1992, FEBS LETT, V313, P185, DOI 10.1016/0014-5793(92)81441-N; REDEKER V, 1994, SCIENCE, V266, P1688, DOI 10.1126/science.7992051; RUDIGER M, 1992, FEBS LETT, V308, P101, DOI 10.1016/0014-5793(92)81061-P; RUDIGER M, 1995, FEBS LETT, V364, P147, DOI 10.1016/0014-5793(95)00373-H; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; ZHU NZ, 1992, MOL BIOL CELL, V3, P50	24	54	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9928	9933		10.1074/jbc.271.17.9928	http://dx.doi.org/10.1074/jbc.271.17.9928			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626629	hybrid			2022-12-25	WOS:A1996UG25700013
J	Bouillot, C; Prochiantz, A; Rougon, G; Allinquant, B				Bouillot, C; Prochiantz, A; Rougon, G; Allinquant, B			Axonal amyloid precursor protein expressed by neurons in vitro is present in a membrane fraction with caveolae-like properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTES NEURITE OUTGROWTH; EPITHELIAL-CELLS; MDCK CELLS; DIFFERENTIATION; TRANSPORT; ISOFORMS; ADHESION; SIGNAL; FORM; LINE	In cortical neurons differentiating in vitro, transmembrane amyloid precursor protein (APP) is distributed in two pools. Whereas the first pool is present in all cell compartments, the second pool is highly enriched in the axon and cell body. In an earlier study we demonstrated that this second pool, referred to as axonal-APP (Ax-APP), is present in the vicinity of the plasma membrane and colocalizes only partially with clathrin (Allinquant, B., Moya, K. L., Bouillot, C., and Prochiantz, A. (1994) J. Neurosci. 14, 6842-6854). In this report, using immunocytochemical and fractionation techniques we demonstrate that Ax-APP is present in microdomains enriched in the glypiated glycoprotein F3. The F3/Ax-APP microdomains are resistant to nonionic detergents and sediment at low density on a sucrose gradient. The two latter properties are reminiscent of those of caveolae, a type of plasmalemmal vesicle found in several cell types, but not previously described in the nervous system due to the absence of caveolin in neurons. The presence of Ax-APP in caveolae-like vesicles raises the possibility that APP serves as a transmembrane signaling molecule for GPI-linked glycoproteins. In addition, our data support new hypotheses on the endocytic pathways leading to the production of the amyloidogenic beta A4 peptide.	ECOLE NORMALE SUPER,CNRS,URA 1414,F-75230 PARIS 05,FRANCE; UNIV LUMINY,CNRS,UPR 9943,F-13288 MARSEILLE 09,FRANCE	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)			ROUGON, Genevieve/G-2578-2013	ROUGON, Genevieve/0000-0003-1316-8200				ALLINQUANT B, 1995, J CELL BIOL, V128, P919, DOI 10.1083/jcb.128.5.919; ALLINQUANT B, 1994, J NEUROSCI, V14, P6842; AMARATUNGA A, 1995, J BIOL CHEM, V270, P17268, DOI 10.1074/jbc.270.29.17268; Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BRABET P, 1990, J NEUROCHEM, V54, P1310, DOI 10.1111/j.1471-4159.1990.tb01964.x; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; DOHERTY P, 1989, J CELL BIOL, V109, P789, DOI 10.1083/jcb.109.2.789; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; DURBEC P, 1992, J CELL BIOL, V117, P877, DOI 10.1083/jcb.117.4.877; FERREIRA A, 1993, J NEUROSCI, V13, P3112; FRA AM, 1994, J BIOL CHEM, V269, P30745; GENNARINI G, 1989, J CELL BIOL, V109, P775, DOI 10.1083/jcb.109.2.775; GENNARINI G, 1991, NEURON, V6, P595, DOI 10.1016/0896-6273(91)90062-5; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HUNG AY, 1992, P NATL ACAD SCI USA, V89, P9439, DOI 10.1073/pnas.89.20.9439; JIN LW, 1994, J NEUROSCI, V14, P5461; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; KOO EH, 1994, J BIOL CHEM, V269, P17386; KURZCHALIA TV, 1994, FEBS LETT, V346, P88, DOI 10.1016/0014-5793(94)00466-8; LAFONT F, 1992, DEVELOPMENT, V114, P17; LAFONT F, 1994, PERSPECT DEV NEUROBI, V2, P259; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; MORIN PJ, 1993, J NEUROCHEM, V61, P464; MOYA KL, 1994, DEV BIOL, V161, P597, DOI 10.1006/dbio.1994.1055; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; OLIVE S, 1995, J NEUROCHEM, V65, P2307; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SHYNG SL, 1994, J CELL BIOL, V125, P1239, DOI 10.1083/jcb.125.6.1239; SISODIA SS, 1993, J NEUROSCI, V13, P3136; SMALL DH, 1994, J NEUROSCI, V14, P2117; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; SMART EJ, 1994, J CELL BIOL, V124, P307, DOI 10.1083/jcb.124.3.307; TIVERON MC, 1992, NATURE, V355, P745, DOI 10.1038/355745a0; TUREK JJ, 1993, J CELL SCI, V106, P423; VIOLETTE SM, 1992, P NATL ACAD SCI USA, V89, P3805, DOI 10.1073/pnas.89.9.3805	46	126	129	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7640	7644		10.1074/jbc.271.13.7640	http://dx.doi.org/10.1074/jbc.271.13.7640			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631800	hybrid			2022-12-25	WOS:A1996UC77400068
J	Hidalgo, E; Demple, B				Hidalgo, E; Demple, B			Activation of SoxR-dependent transcription in vitro by noncatalytic or NifS-mediated assembly of [2Fe-2S] clusters into Apo-SoxR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROXY-ACID DEHYDRATASE; IRON-SULFUR CLUSTER; FE-S CLUSTER; ESCHERICHIA-COLI; STRESS REGULON; SUPEROXIDE; BIOSYNTHESIS; INACTIVATION; PROTEIN; ENZYME	SoxR is a transcriptional activator that senses superoxide and nitric oxide stress in Escherichia coli. The active protein isolated from E. coli contains a pair of [2Fe-2S] clusters per SoxR dimer. Ne previously demonstrated that the iron-free protein (apo-SoxR), isolated during purification in thiol-containing buffers, binds soxS promoter DNA with an affinity equal to that of the metalloprotein (Fe-SoxR), but lacks significant ability to activate transcription in vitro, Here we demonstrate the reversibility of this process: the full transcriptional activity of SoxR can be restored by in vitro assembly of iron-sulfur clusters into the apoprotein. Two methods were used to synthesize the metallocenters of SoxR: (i) nonenzymatic, in which apo-SoxR, incubated in the presence of iron, inorganic sulfide, and a reducing agent, regained full transcriptional activity in 5-6 h; (ii) enzymatic, in which NifS protein of Azotobacter vinelandii regenerated active Fe-SoxR in as little as 2 min. Analysis by electron paramagnetic resonance spectroscopy indicated that binuclear [2Fe-2S] clusters were restored by both the enzymatic and nonenzymatic reconstitutions. A mutant SoxR protein missing one of its four cysteine residues failed to undergo either transcriptional activation or the formation of [2Fe-2S] centers, even in the presence of NifS. Thus, only the presence of an iron-sulfur center is required to restore transcriptional activity to apo-SoxR. Moreover, the catalytic generation of [2Fe-2S] centers extends the known specificity of this enzyme beyond that already shown for [4Fe-4S] centers. Catalytic generation of [2Fe-2S]-containing SoxR could allow for rapid activation of this transcription factor in vivo.	HARVARD UNIV, SCH PUBL HLTH, DEPT MOL & CELLULAR TOXICOL, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health			Hidalgo, Elena/K-2919-2014	Hidalgo, Elena/0000-0002-3768-6785	NCI NIH HHS [CA37831] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037831] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMABILECUEVAS CF, 1991, NUCLEIC ACIDS RES, V19, P4479, DOI 10.1093/nar/19.16.4479; BEINERT H, 1990, FASEB J, V4, P2483, DOI 10.1096/fasebj.4.8.2185975; BERNLOHR DA, 1981, BIOCHEMISTRY-US, V20, P5675, DOI 10.1021/bi00523a006; CHOU JH, 1993, J BACTERIOL, V175, P1026, DOI 10.1128/JB.175.4.1026-1031.1993; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; FLINT DH, 1993, J BIOL CHEM, V268, P25547; FLINT DH, 1993, J BIOL CHEM, V268, P14732; FLINT DH, 1993, J BIOL CHEM, V268, P22369; GARDNER PR, 1991, J BIOL CHEM, V266, P1478; GRANDONI JA, 1989, J BIOL CHEM, V264, P6058; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; HIDALGO E, 1995, J BIOL CHEM, V270, P20908, DOI 10.1074/jbc.270.36.20908; HIDALGO E, 1995, IN PRESS REGULATION; JOHNSON MK, 1994, ENCY INORGANIC CHEM, V4, P1896; KENNEDY C, 1992, MOL GEN GENET, V231, P494, DOI 10.1007/BF00292722; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LI ZY, 1994, J BIOL CHEM, V269, P18371; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; Ma D, 1996, MOL MICROBIOL, V19, P101, DOI 10.1046/j.1365-2958.1996.357881.x; NUNOSHIBA T, 1992, J BACTERIOL, V174, P6054, DOI 10.1128/JB.174.19.6054-6060.1992; NUNOSHIBA T, 1993, CANCER RES, V53, P3250; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9998; SANYAL I, 1994, BIOCHEMISTRY-US, V33, P3625, DOI 10.1021/bi00178a020; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; WU J, 1992, J BACTERIOL, V174, P3915, DOI 10.1128/jb.174.12.3915-3920.1992; WU J, 1995, J BIOL CHEM, V270, P10323, DOI 10.1074/jbc.270.17.10323; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031	30	73	78	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7269	7272		10.1074/jbc.271.13.7269	http://dx.doi.org/10.1074/jbc.271.13.7269			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631739	hybrid			2022-12-25	WOS:A1996UC77400007
J	Marta, M; Patamia, M; Lupi, A; Antenucci, M; DiIorio, M; Romeo, S; Petruzzelli, R; Pomponi, M; Giardina, B				Marta, M; Patamia, M; Lupi, A; Antenucci, M; DiIorio, M; Romeo, S; Petruzzelli, R; Pomponi, M; Giardina, B			Bovine hemoglobin cross-linked through the beta chains - Functional and structural aspects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPHOSPHATE-BINDING-SITE; 2-NOR-2-FORMYLPYRIDOXAL 5'-PHOSPHATE; HUMAN DEOXYHEMOGLOBIN; 2,3-DIPHOSPHOGLYCERATE; PROTEINS	2-Nor-2-formylpyridoxal (NFPLP) has been synthesized and coupled to bovine Hb according to the procedure developed by Benesch and Benesch (1). The reaction of bovine Db with NFPLP leads to a cross-linkage between the beta subunits, which greatly stabilizes the low affinity T state of the molecule and simultaneously abolishes the tendency of the tetramer to dissociate into alpha beta dimers. The functional properties, examined from both the equilibrium and kinetic points of view, indicate that the chemical modification affects the O-2 affinity, abolishes cooperativity, and induces a slight decrease of the Bohr effect. From modeling studies we are confronted with two different structural alternatives; the cross-link of beta chains may be formed between lysine 82 of beta(2) and the N terminus of methionine 2 of beta(1) or between the two lysine 82 residues of both beta(2) chains. Digestion of modified beta globin chains and isolation of the cross-linked peptide have showed that NFPLP cross-links Met-beta 2 and Lys-beta 82. This allowed discussion in some detail of the molecular basis of the Bohr effect of the modified bovine hemoglobin. On the whole, NFPLP-modified bovine Hb could be considered as a first step toward the synthesis of a potential blood substitute.	UNIV CATTOLICA SACRO CUORE, FAC MED, IST CHIM & CHIM CLIN, I-00168 ROME, ITALY; CNR, CTR STUDIO CHIM RECETTORI & MOLEC BIOL ATT, I-00168 ROME, ITALY; UNIV MILAN, FAC FARM, IST CHIM FARMACEUT & TOSSICOL, I-20131 MILAN, ITALY; UNIV CHIETI, IST SCI BIOCHIM, DIPARTIMENTO BIOL, I-66100 CHIETI, ITALY	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Consiglio Nazionale delle Ricerche (CNR); University of Milan; G d'Annunzio University of Chieti-Pescara			Lupi, Alessandro/N-6114-2019; Lupi, Alessandro/AAH-8299-2020; Romeo, Sergio/B-4478-2009	Lupi, Alessandro/0000-0003-3644-0449; Lupi, Alessandro/0000-0003-3644-0449; Romeo, Sergio/0000-0003-4692-7314; Marta, Maurizio/0000-0002-8872-3304; Patamia, Maria/0000-0003-2655-8056				ARNONE A, 1972, NATURE, V237, P146, DOI 10.1038/237146a0; ARNONE A, 1977, J MOL BIOL, V115, P627, DOI 10.1016/0022-2836(77)90107-3; Ascoli F, 1981, Methods Enzymol, V76, P72; BELLELLI A, 1987, J BIOL CHEM, V262, P2624; BENESCH R, 1984, P NATL ACAD SCI-BIOL, V81, P2941, DOI 10.1073/pnas.81.9.2941; BENESCH R, 1975, BIOCHEM BIOPH RES CO, V63, P1123, DOI 10.1016/0006-291X(75)90685-3; Benesch R, 1981, Methods Enzymol, V76, P147; BUNN HF, 1971, SCIENCE, V172, P1049, DOI 10.1126/science.172.3987.1049; DAVINO R, 1989, EUR J BIOCHEM, V179, P699, DOI 10.1111/j.1432-1033.1989.tb14603.x; FANELLI AR, 1964, ADV PROTEIN CHEM, V19, P73, DOI 10.1016/S0065-3233(08)60189-8; FEOLA M, 1983, SURG GYNECOL OBSTET, V157, P399; FRONTICELLI C, 1990, EUR J BIOCHEM, V193, P331, DOI 10.1111/j.1432-1033.1990.tb19342.x; FRONTICELLI C, 1986, BIOCHIM BIOPHYS ACTA, V874, P76, DOI 10.1016/0167-4838(86)90104-4; Giardina B, 1981, Methods Enzymol, V76, P417; GIBSON QH, 1959, PROG BIOPHYS MOL BIO, V9, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; NIGEN AM, 1980, J BIOL CHEM, V255, P5525; PERUTZ MF, 1980, J MOL BIOL, V136, P183, DOI 10.1016/0022-2836(80)90312-5; PERUTZ MF, 1993, J MOL BIOL, V233, P536, DOI 10.1006/jmbi.1993.1530; PERUTZ MF, 1980, J MOL BIOL, V138, P649, DOI 10.1016/S0022-2836(80)80022-2; POCKER A, 1973, J ORG CHEM, V38, P4295, DOI 10.1021/jo00964a019; SHELTON JB, 1981, J LIQ CHROMATOGR, V4, P1381, DOI 10.1080/01483918108059615; SLOVITER HA, 1982, FED PROC, V41, P652; VANDERPLAS J, 1987, TRANSFUSION, V27, P425	25	13	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7473	7478		10.1074/jbc.271.13.7473	http://dx.doi.org/10.1074/jbc.271.13.7473			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631776	hybrid			2022-12-25	WOS:A1996UC77400044
J	Roff, M; Thompson, J; Rodriguez, MS; Jacque, JM; Baleux, F; ArenzanaSeisdedos, F; Hay, RT				Roff, M; Thompson, J; Rodriguez, MS; Jacque, JM; Baleux, F; ArenzanaSeisdedos, F; Hay, RT			Role of I kappa B alpha ubiquitination in signal-induced activation of NF-kappa B in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN EBP1; DNA-BINDING; CYTOPLASMIC RETENTION; TRANSCRIPTION FACTOR; P50 PRECURSOR; P65 SUBUNIT; C-REL; INHIBITOR; P105; CLONING	In unstimulated cells, the transcript-ion factor NF-kappa B is held in the cytoplasm in an inactive state by the inhibitor protein I kappa B alpha. Stimulation of cells results in rapid phosphorylation and degradation of I kappa B alpha, thus releasing NF-kappa B, which translocates to the nucleus and activates transcription of responsive genes. Here we demonstrate that in cells where proteasomal degradation is inhibited, signal induction by tumor necrosis factor alpha results in the rapid accumulation of higher molecular weight forms of I kappa B alpha that dissociate from NF-kappa B and are consistent with ubiquitin conjugation. Removal of the high molecular weight forms of I kappa B alpha by a recombinant ubiquitin carboxyl-terminal hydrolase and reactivity of the immunopurified material with a monoclonal antibody specific for ubiquitin indicated that I kappa B alpha was conjugated to multiple copies of ubiquitin. Western blot analysis of immunopurified I kappa B alpha from cells expressing epitope-tagged versions of I kappa B alpha and ubiquitin revealed the presence of multiple copies of covalently bound tagged ubiquitin. An S32A/S36A mutant of I kappa B alpha that is neither phosphorylated nor degraded in response to signal induction fails to undergo inducible ubiquitination in vivo. Thus signal-induced activation of NF-kappa B involves phosphorylation-dependent ubiquitination of I kappa B alpha, which targets the protein for rapid degradation by the proteasome and releases NF-kappa B for translocation to the nucleus.	UNIV ST ANDREWS,SCH BIOL & MED SCI,ST ANDREWS KY16 9AL,FIFE,SCOTLAND; INST PASTEUR,UNITE IMMUNOL VIRALE,F-75015 PARIS,FRANCE; INST PASTEUR,UNITE CHIM ORGAN,F-75015 PARIS,FRANCE	University of St Andrews; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Arenzana-Seisdedos, Fernando/E-5835-2016; Jacque, Jean-Marc/B-6875-2008; Hay, Ronald/S-3233-2019; Hay, Ronald T/F-9338-2011	Hay, Ronald/0000-0001-7113-9024; Hay, Ronald T/0000-0001-7113-9024				ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CLARK L, 1989, J MOL BIOL, V206, P615, DOI 10.1016/0022-2836(89)90570-6; CLARK L, 1989, NUCLEIC ACIDS RES, V17, P499, DOI 10.1093/nar/17.2.499; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; FEHRENTZ JA, 1985, INT J PEPT PROT RES, V26, P236; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GUARINO LA, 1995, CELL, V80, P301, DOI 10.1016/0092-8674(95)90413-1; HANKE T, 1992, J GEN VIROL, V73, P653, DOI 10.1099/0022-1317-73-3-653; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; HAY RT, 1993, BIOCHEM SOC T, V21, P926, DOI 10.1042/bst0210926; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LASZLO L, 1990, FEBS LETT, V261, P365, DOI 10.1016/0014-5793(90)80593-8; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; LION HC, 1993, CURR OPIN CELL BIOL, V5, P477; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MATTHEWS JR, 1993, NUCLEIC ACIDS RES, V21, P1727, DOI 10.1093/nar/21.8.1727; MATTHEWS JR, 1993, NUCLEIC ACIDS RES, V21, P4516, DOI 10.1093/nar/21.19.4516; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; ZHANG N, 1993, DEV BIOL, V157, P214, DOI 10.1006/dbio.1993.1125	69	205	210	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7844	7850		10.1074/jbc.271.13.7844	http://dx.doi.org/10.1074/jbc.271.13.7844			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631829	hybrid			2022-12-25	WOS:A1996UC77400097
J	Hammer, JA; Jung, G				Hammer, JA; Jung, G			The sequence of the Dictyostelium myo J heavy chain gene predicts a novel, dimeric, unconventional myosin with a heavy chain molecular mass of 258 kDa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACANTHAMOEBA MYOSIN; LOCALIZATION; DISCOIDEUM; CALMODULIN; PROTEIN; ISOFORM; MUSCLE; DISRUPTION; ALIGNMENT; MOTILITY	The complete sequence of the Dictyostelium myo J heavy chain gene has been determined hom overlapping genomic clones. The gene spans similar to 7400 base pairs, is split by two small introns, and encodes a 2241-residue, 258-kDa heavy chain polypeptide that that is composed of an N-terminal 944-residue myosin head domain, a central 863-residue domain that is predicted to form an cu helical coiled-coil containing six hinges, and a C-terminal 434-residue globular domain. The head domain is notable in that it contains a similar to 30 residue insert near the nucleotide binding pocket, and five potential calmodulin/myosin light chain binding sites at the head/tail junction. The existence within the Myo J tail domain of both an extensive coiled-coil structure and a large globular domain suggests that this myosin is dimeric and incapable of self-assembly into filaments. While these properties, as well as the overall predicted structure of the Myo J protein, are reminiscent of class V myosins, the sequence of the 434-residue globular tail piece of Myo J shows no similarity to that of either yeast or vertebrate myosins V. Consistent with this, phylogenetic analyses based on myosin head sequence comparisons do not classify Myo J as a type V myosin. These and other sequence comparisons indicate that Myo J and two as-yet-unclassified unconventional myosins from Arabidopsis represent members of the newest class within the myosin superfamily (class XI). Northern blots analyses suggest that Myo J may function predominantly in vegetative Dictyostelium cells. Finally, Southern blot analyses suggest that Dictyostelium possesses another myosin that is very closely related to Myo J.			Hammer, JA (corresponding author), NHLBI,CELL BIOL LAB,NIH,SECT MOLEC CELL BIOL,BLDG 3,RM B1-22,BETHESDA,MD 20892, USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BROCKERHOFF SE, 1994, J CELL BIOL, V124, P315, DOI 10.1083/jcb.124.3.315; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; CHENEY RE, 1993, CELL MOTIL CYTOSKEL, V24, P215, DOI 10.1002/cm.970240402; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DOBERSTEIN SK, 1993, NATURE, V365, P841, DOI 10.1038/365841a0; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; FOK AK, 1993, J CELL SCI, V106, P1103; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; GOODSON HV, 1993, P NATL ACAD SCI USA, V90, P569; HAARER BK, 1994, J CELL SCI, V107, P1055; Hammer J A, 1991, Trends Cell Biol, V1, P50, DOI 10.1016/0962-8924(91)90089-R; HAMMER JA, 1994, J MUSCLE RES CELL M, V15, P1, DOI 10.1007/BF00123827; HAMMER JA, 1994, J CELL BIOL, V127, P1779, DOI 10.1083/jcb.127.6.1779; HAMMER JA, 1987, J CELL BIOL, V105, P913, DOI 10.1083/jcb.105.2.913; HASSON T, 1994, J CELL BIOL, V127, P425, DOI 10.1083/jcb.127.2.425; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; JUNG G, 1989, P NATL ACAD SCI USA, V86, P6186, DOI 10.1073/pnas.86.16.6186; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; JUNG G, 1993, J BIOL CHEM, V268, P14981; JUNG G, 1996, IN PRESS J CELL BIOL; KELLERMAN KA, 1992, J CELL BIOL, V119, P823, DOI 10.1083/jcb.119.4.823; Kimura MA, 1985, NEUTRAL THEORY MOL E; KINEKEMA M, 1994, PLANT MOL BIOL, V26, P2239; KINEKEMA M, 1994, J MOL BIOL, V239, P591; KNIGHT AE, 1993, J MOL BIOL, V231, P148, DOI 10.1006/jmbi.1993.1266; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MCLACHLAN AD, 1982, NATURE, V299, P226, DOI 10.1038/299226a0; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; MOOSEKER MS, IN PRESS ANN REV CEL; NOVAK KD, 1995, J CELL BIOL, V131, P1205, DOI 10.1083/jcb.131.5.1205; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETERSON MD, 1995, J CELL SCI, V108, P1093; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; PORTER JA, 1993, SCIENCE, V262, P1038, DOI 10.1126/science.8235618; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Solc CK, 1994, AUDIT NEUROSCI, V1, P63; SPUDICH JA, 1989, CELL REGUL, V1, P1; Spudich JA, 1987, METHODS CELL BIOL, V28; TITUS MA, 1989, CELL REGUL, V1, P55, DOI 10.1091/mbc.1.1.55; TITUS MA, 1994, P NATL ACAD SCI USA, V91, P9446, DOI 10.1073/pnas.91.20.9446; TITUS MA, 1993, MOL BIOL CELL, V4, P233, DOI 10.1091/mbc.4.2.233; Titus MA, 1993, CURR OPIN CELL BIOL, V5, P77, DOI 10.1016/S0955-0674(05)80011-0; URRUTIA RA, 1993, BIOCHIM BIOPHYS ACTA, V1173, P225, DOI 10.1016/0167-4781(93)90185-G; WARRICK HM, 1986, P NATL ACAD SCI USA, V83, P9433, DOI 10.1073/pnas.83.24.9433; WESSELS D, 1991, CELL MOTIL CYTOSKEL, V20, P301, DOI 10.1002/cm.970200406; WOLENSKI JS, 1995, TRENDS CELL BIOL, V5, P310, DOI 10.1016/S0962-8924(00)89053-4; ZHU QL, 1992, J CELL BIOL, V118, P347, DOI 10.1083/jcb.118.2.347	55	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7120	7127		10.1074/jbc.271.12.7120	http://dx.doi.org/10.1074/jbc.271.12.7120			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636147	hybrid			2022-12-25	WOS:A1996UB15700082
J	Watanabe, S; Okuno, S; Kitani, T; Fujisawa, H				Watanabe, S; Okuno, S; Kitani, T; Fujisawa, H			Inactivation of calmodulin-dependent protein kinase IV by autophosphorylation of serine 332 within the putative calmodulin-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; CEREBELLAR GRANULE CELLS; PHENOTYPIC SELECTION; BRAIN CALMODULIN; EXPRESSION; GENE; GR; PEPTIDES; SEQUENCE; PHOSPHOSERINE	When brain calmodulin-dependent protein kinase IV is incubated with calmodulin-dependent protein kinase IV kinase under the phosphorylation conditions in the presence of Ca2+/calmodulin, rapid initial incorporation of 1 mol of phosphate into 1 mol of the enzyme by the action of the kinase kinase occurs, resulting in marked activation of the enzyme, and the subsequent incorporation of more than 3 mol of phosphate by autophosphorylation occurs, resulting in no significant change in the activity (Okuno, S., Kitani, T., and Fujisawa, H. (1994) J. Biochem, (Tokyo) 116, 923-930; Okuno, S., Kitani, T., and Fujisawa, H. (1995) J. Biochem, (Tokyo) 117, 686-690), After the maximal phosphorylation, the continued incubation in the presence of excess EGTA resulted in additional autophosphorylation of the enzyme, leading to a complete loss of the Ca2+/calmodulin-dependent activity, while causing no significant change in the Ca2+/calmodulin-independent activity. The amino acid sequence analysis revealed that the autophosphorylation after removal of Ca2+ occurred on Ser(332), Ser(333), Ser(337), and Ser(341), Analysis by site-directed mutagenesis clearly showed that the autophosphorylation site responsible for the inactivation is Ser(332). Thus, calmodulin-dependent protein kinase IV activated by the kinase kinase may lose its Ca2+/calmodulin-dependent activity by autophosphorylation on Ser(332) located within the putative calmodulin-binding domain in the absence of Ca2+.			Watanabe, S (corresponding author), ASAHIKAWA MED COLL, DEPT BIOCHEM, ASAHIKAWA, HOKKAIDO 078, JAPAN.							BLAND MM, 1994, GENE, V142, P191, DOI 10.1016/0378-1119(94)90260-7; COLBRAN RJ, 1993, J BIOL CHEM, V268, P7163; COLBRAN RJ, 1990, J BIOL CHEM, V265, P11213; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; Corbin J D, 1974, Methods Enzymol, V38, P287; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P17592; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HASHIMOTO Y, 1987, ARCH BIOCHEM BIOPHYS, V252, P418, DOI 10.1016/0003-9861(87)90048-8; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; IKEDA A, 1991, J BIOL CHEM, V266, P11582; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; KAMESHITA I, 1993, J BIOCHEM-TOKYO, V113, P583, DOI 10.1093/oxfordjournals.jbchem.a124087; KATOH T, 1991, J BIOL CHEM, V266, P3039; KINCAID RL, 1988, METHOD ENZYMOL, V159, P605; KITANI T, 1995, J BIOCHEM-TOKYO, V117, P1070, DOI 10.1093/oxfordjournals.jbchem.a124808; KITANI T, 1994, J BIOCHEM-TOKYO, V115, P637, DOI 10.1093/oxfordjournals.jbchem.a124387; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KWIATKOWSKI AP, 1988, J BIOL CHEM, V263, P6484; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANGELS LA, 1992, J BIOL CHEM, V267, P5847; MCDONALD OB, 1993, J BIOL CHEM, V268, P10054; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; MEYER HE, 1991, METHOD ENZYMOL, V201, P169; MIYANO O, 1992, J BIOL CHEM, V267, P1198; MOSIALOS G, 1994, J VIROL, V68, P1697, DOI 10.1128/JVI.68.3.1697-1705.1994; NAKAMURA Y, 1995, NEUROSCIENCE, V68, P181, DOI 10.1016/0306-4522(95)00092-W; OHMSTEDE CA, 1991, P NATL ACAD SCI USA, V88, P5784, DOI 10.1073/pnas.88.13.5784; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; OKUNO S, 1994, J BIOCHEM, V116, P923, DOI 10.1093/oxfordjournals.jbchem.a124617; OKUNO S, 1995, J BIOCHEM-TOKYO, V117, P686, DOI 10.1093/oxfordjournals.jbchem.a124764; PATTON BL, 1990, J BIOL CHEM, V265, P11204; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SAKAGAMI H, 1993, MOL BRAIN RES, V19, P215, DOI 10.1016/0169-328X(93)90029-O; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SIKELA JM, 1987, P NATL ACAD SCI USA, V84, P3038, DOI 10.1073/pnas.84.9.3038; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TODHUNTER JA, 1977, BIOCHIM BIOPHYS ACTA, V485, P87, DOI 10.1016/0005-2744(77)90195-4; VANTHOFF JH, 1884, ETUDES DYNAMIQUE CHI, P87	46	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6903	6910		10.1074/jbc.271.12.6903	http://dx.doi.org/10.1074/jbc.271.12.6903			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636117	hybrid			2022-12-25	WOS:A1996UB15700052
J	Lesage, F; Guillemare, E; Fink, M; Duprat, F; Lazdunski, M; Romey, G; Barhanin, J				Lesage, F; Guillemare, E; Fink, M; Duprat, F; Lazdunski, M; Romey, G; Barhanin, J			A pH-sensitive yeast outward rectifier K+ channel with two pore domains and novel gating properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNELS; PLASMA-MEMBRANE; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL EXPRESSION; GUARD-CELLS; TRANSPORT; CLONING	YORK is a newly cloned K+ channel from yeast. Unlike all other cloned K+ channels, it has two pore domains instead of one. It displays eight transmembrane segments arranged like a covalent assembly of a Shaker-type voltage-dependent K+ channel (without S4 transmembrane segments) with an inward rectifier K+ channel, When expressed in Xenopus oocytes, YORK does not pass inward currents; it conducts only K+-selective outward currents, However, the mechanism responsible for this strict outward rectification is unusual. Like inward rectifiers, its activation potential threshold closely follows the K+ equilibrium potential. Unlike inward rectifiers, the rectification is not due to a voltage-dependent Mg2+ block, The blocking element is probably intrinsic to the YORK protein itself, YORK activity is decreased at acidic internal pH, with a pK(alpha) of 6.5. Pharmacological and regulation properties were analyzed. Ba2+ ions and quinine block YORK currents through high and low affinity sites, while tetraethylammonium displays only one affinity for blocking. Activation of protein kinase C indirectly produces an increase of the current, while protein kinase A activation has no effect.	CNRS,INST PHARMACOL MOLEC & CELLULAIRE,F-06560 VALBONNE,FRANCE	Centre National de la Recherche Scientifique (CNRS)			Lesage, Florian/P-9780-2019; Lesage, Florian/D-5097-2011; Duprat, Fabrice/D-1221-2013	Lesage, Florian/0000-0002-4406-7106; Lesage, Florian/0000-0002-4406-7106; Duprat, Fabrice/0000-0001-8774-1220				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; ATTALI B, 1992, FEBS LETT, V303, P229, DOI 10.1016/0014-5793(92)80526-M; ATTALI B, 1995, P NATL ACAD SCI USA, V92, P6092, DOI 10.1073/pnas.92.13.6092; BERTL A, 1993, J MEMBRANE BIOL, V132, P183; BLATT MR, 1993, PLANTA, V191, P330, DOI 10.1007/BF00195690; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; CHAMBARD JC, 1990, NUCLEIC ACIDS RES, V18, P5282, DOI 10.1093/nar/18.17.5282; CHANDY KG, 1995, CRC HDB RECEPTORS CH; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; DUPRAT F, 1995, BIOCHEM BIOPH RES CO, V212, P657, DOI 10.1006/bbrc.1995.2019; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; GUSTIN MC, 1986, SCIENCE, V233, P1195, DOI 10.1126/science.2426783; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; Hille B., 1992, IONIC CHANNELS EXCIT; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; JEGLA T, 1995, RECEPTOR CHANNEL, V3, P51; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; MATSUDA H, 1991, ANNU REV PHYSIOL, V53, P289, DOI 10.1146/annurev.ph.53.030191.001445; MILKMAN R, 1994, P NATL ACAD SCI USA, V91, P3510, DOI 10.1073/pnas.91.9.3510; MIOSGA T, 1994, YEAST, V10, P965, DOI 10.1002/yea.320100712; NICHOLS CG, 1994, J PHYSIOL-LONDON, V476, P399, DOI 10.1113/jphysiol.1994.sp020141; PASCUAL JM, 1995, NEURON, V14, P1055, DOI 10.1016/0896-6273(95)90344-5; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; PONGS O, 1993, J MEMBRANE BIOL, V136, P1; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; SCHROEDER JI, 1988, J GEN PHYSIOL, V92, P667, DOI 10.1085/jgp.92.5.667; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; SERRANO R, 1977, EUR J BIOCHEM, V80, P97, DOI 10.1111/j.1432-1033.1977.tb11861.x; SIGEL E, 1990, J MEMBRANE BIOL, V117, P201, DOI 10.1007/BF01868451; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; VANDEMORTEL JBJ, 1988, BIOCHIM BIOPHYS ACTA, V936, P421, DOI 10.1016/0005-2728(88)90019-9	37	91	95	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4183	4187						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626760				2022-12-25	WOS:A1996TW96000038
J	Hugunin, M; Quintal, LJ; Mankovich, JA; Ghayur, T				Hugunin, M; Quintal, LJ; Mankovich, JA; Ghayur, T			Protease activity of in vitro transcribed and translated Caenorhabditis elegans cell death gene (ced-3) product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA; EXPRESSION; ACTIVATION; SEQUENCE; ENCODES; CLONING; ENZYME; CDNA	The Caenorhabditis elegans cell death gene, ced-3, encodes one of the two proteins required for apoptosis in this organism. The primary sequence similarities between Ced-3 and the mammalian interleukin-1 beta converting enzyme (ICE) suggest that these two proteins may have functionally similar active sites and that Ced-3 may function as a cysteine protease, Here we report that in vitro transcribed and translated Ced-S protein (p56) underwent rapid processing to smaller fragments. Replacement of the predicted active site cysteine of Ced-3 with serine (C364S) prevented the generation of smaller proteolytic fragments, suggesting that the processing might be an autocatalytic process. Peptide aldehydes with aspartic acid at the P1 position blocked Ced-3 autocatalysis. Furthermore, the protease inhibition profile of Ced-3 was similar to the profile reported for ICE. These functional data demonstrate that Ced-3 is an Asp-dependent cysteine protease with substrate specificity similar to that of ICE. Aurintricarboxylic acid, an inhibitor of apoptosis in mammalian cells, blocked Ced-3 autocatalytic activity, suggesting that an aurintricarboxylic acid-sensitive Ced-3/ICE-related protease might be involved in the apoptosis pathway(s) in mammalian cells.	BASF BIORES CORP,WORCESTER,MA 01605	BASF								AYALA JM, 1994, J IMMUNOL, V153, P2592; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; BLACK RA, 1991, Patent No. 15577; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; COHEN JJ, 1984, J IMMUNOL, V132, P38; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GALLI G, 1993, EXP CELL RES, V204, P54, DOI 10.1006/excr.1993.1008; GRAY PW, 1986, J IMMUNOL, V137, P3644; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOWARD AD, 1991, J IMMUNOL, V147, P2964; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MOGIL RJ, 1994, J IMMUNOL, V152, P1674; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; ROLANDO AM, 1993, J CELL BIOCHEM, V18, P147; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YAMIN TT, 1994, FASEB J, V8, P644; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	38	42	45	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3517	3522						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631956	hybrid			2022-12-25	WOS:A1996TV72400030
J	Marhamati, DJ; Sonenshein, GE				Marhamati, DJ; Sonenshein, GE			B-Myb expression in vascular smooth muscle cells occurs in a cell cycle-dependent fashion and down-regulates promoter activity of type I collagen genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYB; MESSENGER-RNA; HEMATOPOIETIC-CELLS; FUNCTIONAL-ANALYSIS; PROTO-ONCOGENE; LYSYL OXIDASE; GROWTH-FACTOR; V-MYB; A-MYB; DNA	The members of the Myb family of transcription factors are defined by homology in the DNA-binding domain; all bind the Myb-binding site (MBS) sequence (YG(A/G)C(A/C/G)GTT(G/A)). Here we report that cultured bovine vascular smooth muscle cells (SMCs) express B-myb. Levels of B-myb RNA found in exponential growth were reduced dramatically in serum-deprived quiescent SMCs; B-myb mRNA levels increased in the cell cycle during the late G(1) to S phase transition following restimulation with serum, epidermal growth factor, or phorbol ester plus insulin-like growth factor-1. Changes in the rate of B-myb gene transcription could account for part of the observed increase following serum addition. Treatment of SMC cultures with actinomycin D indicated a >4-h half-life for B-myb mRNA during the S phase of the cell cycle. Cotransfection of either a bovine or human B-myb expression vector down-regulated the activity of a multimerized MBS element-driven reporter construct in SMCs. Putative MBS elements were detected upstream of the promoters of the two chains of type I collagen, which we have found to be expressed inversely with growth state of the SMC (Kindy, M. S., Chang, C.-J., and Sonenshein, G. E. (1988) J. Biol. Chem. 263, 11426-11430). In cotransfection experiments, B-myb expression down-regulated the promoter activity of alpha 1(I) and alpha 2(I) collagen constructs an average of 92 and 82%, respectively. Thus, B-myb represents a potential link in the observed inverse relationship between collagen gene expression and growth of vascular SMCs.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Boston University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007429, P01HL013262] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL13262, HL07429] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS SL, 1982, CELL, V30, P373, DOI 10.1016/0092-8674(82)90235-5; ALTERMAN RBM, 1984, MOL CELL BIOL, V4, P123, DOI 10.1128/MCB.4.1.123; ANG AH, 1990, BIOCHEM J, V265, P461, DOI 10.1042/bj2650461; ARSURA M, 1992, BLOOD, V79, P2708; ARSURA M, 1994, BLOOD, V83, P1778, DOI 10.1182/blood.V83.7.1778.bloodjournal8371778; BEDALOV A, 1994, J BIOL CHEM, V269, P4903; BELDEKAS JC, 1982, J BIOL CHEM, V257, P2252; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BOAST S, 1990, J BIOL CHEM, V265, P13351; BROWN KE, 1992, J BIOL CHEM, V267, P4625; BROWN KE, 1991, J BIOL CHEM, V266, P23268; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CHANG CJ, 1991, MATRIX, V11, P242, DOI 10.1016/S0934-8832(11)80231-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GOLAY J, 1991, BLOOD, V77, P149; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; HUGHES AFW, 1942, J ANAT, V77, P266; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; JONES PA, 1979, P NATL ACAD SCI USA, V76, P353, DOI 10.1073/pnas.76.1.353; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KENYON K, 1991, SCIENCE, V253, P802, DOI 10.1126/science.1678898; KINDY MS, 1986, J BIOL CHEM, V261, P2865; KINDY MS, 1988, J BIOL CHEM, V263, P11426; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAWRENCE R, 1994, J BIOL CHEM, V269, P9603; LAWRENCE R, 1994, J BIOL CHEM, V269, P28913; LEHRACH H, 1979, BIOCHEMISTRY-US, V18, P3146, DOI 10.1021/bi00581a036; LEOF EB, 1982, EXP CELL RES, V141, P107, DOI 10.1016/0014-4827(82)90073-8; LIAU G, 1989, J BIOL CHEM, V264, P10315; LICHTLER A, 1989, J BIOL CHEM, V264, P3072; MCCONLOGUE L, 1984, P NATL ACAD SCI-BIOL, V81, P540, DOI 10.1073/pnas.81.2.540; MISKULIN M, 1986, BIOCHEMISTRY-US, V25, P1408, DOI 10.1021/bi00354a033; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; POOLE JCF, 1971, AM J PATHOL, V62, P391; REILLY CF, 1989, J BIOL CHEM, V264, P6990; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHWARTZ SM, 1985, ANN NY ACAD SCI, V454, P292, DOI 10.1111/j.1749-6632.1985.tb11869.x; SLACK JL, 1992, MOL CELL BIOL, V12, P4714, DOI 10.1128/MCB.12.10.4714; STEPP MA, 1986, J BIOL CHEM, V261, P6542; STRAUSS BH, 1994, CIRC RES, V75, P650, DOI 10.1161/01.RES.75.4.650; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; TASHIRO S, 1995, ONCOGENE, V10, P1699; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WU Y, 1992, J BIOL CHEM, V267, P24199	61	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3359	3365						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631934				2022-12-25	WOS:A1996TV72400008
J	Taylor, JM; JacobMosier, GG; Lawton, RG; VanDort, M; Neubig, RR				Taylor, JM; JacobMosier, GG; Lawton, RG; VanDort, M; Neubig, RR			Receptor and membrane interaction sites on G beta - A receptor-derived peptide binds to the carboxyl terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEIN; GAMMA-SUBUNIT; SYNTHETIC PEPTIDES; BOVINE BRAIN; ALPHA-SUBUNITS; HIGH-AFFINITY; RHODOPSIN; IDENTIFICATION; TRANSDUCIN; DOMAIN	The functional organization of G beta gamma is poorly understood, Regions of bovine brain G beta gamma that interact with a photoaffinity derivative of an alpha(2)-adrenergic receptor-derived peptide from the third intracellular loop (diazo-pyruvoyl-modified peptide Q (DAP-Q)) and a hydrophobic membrane probe (3-trifluoromethyl-3-(m-iodophenyl)diazirine (TID)) were examined. We previously showed that DAP-Q cross-links to specific, competable sites on both the alpha and beta subunits of G(o)/G(i) but not on the gamma subunit and that beta gamma subunit was required for stimulation of G(o)/G(i) GTPase activity (Taylor, J. M., Jacob Mosier, G. G., Lawton, R. G., Remmers, A. E., and Neubig, R. R. (1994) J. Biol. Chem. 269, 27618-27624). Similarly, we show here that the membrane-associated photoprobe [I-125]TID labels alpha and beta but not gamma. We have now mapped the sites of incorporation of DAP-Q and TID into the beta subunit, TID labels both the 14-kDa amino-terminal and the 23-kDa carboxyl-terminal fragments from a partial tryptic digest of beta while DAP-Q labels only the carboxyl-terminal fragment, Further mapping with endopeptidase Lys C reveals substantial labeling of multiple fragments by TID while DAP-Q labels predominantly a similar to 6-kDa fragment within the carboxyl-terminal 60 amino acids of beta(1). Thus, regions within the 7th (or possibly 6th) WD-40 repeat of the beta subunit of G protein interact with the receptor-derived peptide while membrane interaction involves multiple sites throughout the beta subunit.	UNIV MICHIGAN,DEPT PHARMACOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT NUCL MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Taylor, Joan/0000-0002-8794-5167; Neubig, Richard/0000-0003-0501-0008	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046417] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557] Funding Source: NIH RePORTER; NHLBI NIH HHS [HLGM46417] Funding Source: Medline; NIAMS NIH HHS [P60-AR20557] Funding Source: Medline; NIGMS NIH HHS [GM39561] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; CLEVELAND DW, 1983, METHOD ENZYMOL, V96, P222; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; FRIELLE T, 1983, BIOCHEMISTRY-US, V22, P5709, DOI 10.1021/bi00294a005; GARCIAHIGUERA I, 1995, J BIOL CHEM, V271, P528; GARRITSEN A, 1994, J BIOL CHEM, V269, P24418; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HETHIER H, 1992, EUR J BIOCHEM, V204, P1169; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P12655; IKEZU T, 1992, FEBS LETT, V311, P29, DOI 10.1016/0014-5793(92)81359-T; KATZ A, 1995, P NATL ACAD SCI USA, V92, P1998, DOI 10.1073/pnas.92.6.1998; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KIM MH, 1987, BIOCHEMISTRY-US, V26, P3664, DOI 10.1021/bi00386a061; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; KISSELEV OG, 1994, J BIOL CHEM, V269, P21399; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KWON G, 1993, BIOCHEMISTRY-US, V32, P2401, DOI 10.1021/bi00060a035; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCONAHEY P, 1980, IMMUNOCHEMICAL TEC A, V70, P210; MOSIER GGJ, 1995, J ORG CHEM, V60, P6953, DOI 10.1021/jo00126a055; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; PALM D, 1990, FEBS LETT, V261, P294, DOI 10.1016/0014-5793(90)80575-4; PALM D, 1989, FEBS LETT, V254, P89, DOI 10.1016/0014-5793(89)81015-4; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; ROOF DJ, 1985, J BIOL CHEM, V260, P6242; Roth J, 1975, Methods Enzymol, V37, P223; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHENKER A, 1991, J BIOL CHEM, V266, P802; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SPIEGEL AM, 1994, G PROTEINS, P77; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; STRADER CD, 1987, J BIOL CHEM, V262, P16439; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; TAYLOR JM, 1994, J BIOL CHEM, V269, P27618; TAYLOR JM, 1994, PEPTIDES, V15, P829, DOI 10.1016/0196-9781(94)90038-8; THOMAS TC, 1993, BIOCHEMISTRY-US, V32, P8628, DOI 10.1021/bi00084a034; WADE SM, 1994, MOL PHARMACOL, V45, P1191; YAMAUCHI J, 1995, BIOCHEM BIOPH RES CO, V214, P694, DOI 10.1006/bbrc.1995.2341; YI F, 1991, J BIOL CHEM, V266, P3900	49	95	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3336	3339						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631928				2022-12-25	WOS:A1996TV72400002
J	Tsai, HL; Kou, GH; Chen, SC; Wu, CW; Lin, YS				Tsai, HL; Kou, GH; Chen, SC; Wu, CW; Lin, YS			Human cytomegalovirus immediate-early protein IE2 tethers a transcriptional repression domain to p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TUMOR SUPPRESSOR PROTEIN; DNA-BINDING PROTEIN; GENE AMPLIFICATION; CAP SITE; EXPRESSION; SEQUENCE; PROMOTER; PRODUCT; TRANSFORMATION	The IE2 gene of human cytomegalovirus has been implicated in the development of coronary restenosis, and the gene product appears to inhibit p53-dependent transactivation. Here we describe an analysis of the IE2 p53 interaction. Repression of p53 function by IE2 requires two separable domains of IE2. The N terminus of IE2 interacts with p53. IE2 has little effect on the ability of p53 to bind specific DNA sequences. Reduction of the transactivation activity of p53 is caused by a transcriptional repression function contributed by the C-terminal domain of IE2, These findings suggest that IE2 may function as a transcriptional repressor, which is recruited to p53's target genes by interacting with p53.	ACAD SINICA, INST BIOMED SCI, TAIPEI 11529, TAIWAN; NATL TAIWAN UNIV, DEPT ZOOL, TAIPEI 10764, TAIWAN	Academia Sinica - Taiwan; National Taiwan University								AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; ALBRECHT T, 1993, MOL ASPECTS HUMAN CY; ALLDAY MJ, 1995, EMBO J, V14, P1382, DOI 10.1002/j.1460-2075.1995.tb07124.x; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BECKER Y, 1993, MOL ASPECTS HUMAN CY; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HAGEMEIER C, 1994, EMBO J, V13, P2897, DOI 10.1002/j.1460-2075.1994.tb06584.x; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HSU YS, 1995, J BIOL CHEM, V270, P6966, DOI 10.1074/jbc.270.12.6966; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANG D, 1993, J VIROL, V67, P323, DOI 10.1128/JVI.67.1.323-331.1993; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LICHT JD, 1994, MOL CELL BIOL, V14, P4057, DOI 10.1128/MCB.14.6.4057; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUKAC DM, 1994, J VIROL, V68, P5184, DOI 10.1128/JVI.68.8.5184-5193.1994; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; PIZZORNO MC, 1991, J VIROL, V65, P3839, DOI 10.1128/JVI.65.7.3839-3852.1991; PIZZORNO MC, 1990, J VIROL, V64, P6154, DOI 10.1128/JVI.64.12.6154-6165.1990; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; Stenberg R.M., 1993, MOL ASPECTS HUMAN CY, VVolume 2, P330; STJEOR SC, 1977, J GEN VIROL, V37, P65, DOI 10.1099/0022-1317-37-1-65; STJEOR SC, 1974, J VIROL, V13, P353, DOI 10.1128/JVI.13.2.353-362.1974; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WATHEN MW, 1982, J VIROL, V41, P462, DOI 10.1128/JVI.41.2.462-477.1982; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHANG Q, 1994, MOL CELL BIOL, V14, P1929, DOI 10.1128/MCB.14.3.1929; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	57	100	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3534	3540						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631958				2022-12-25	WOS:A1996TV72400032
J	Perletti, GP; Folini, M; Lin, HC; Mischak, H; Piccinini, F; Tashjian, AH				Perletti, GP; Folini, M; Lin, HC; Mischak, H; Piccinini, F; Tashjian, AH			Overexpression of protein kinase C epsilon is oncogenic in rat colonic epithelial cells	ONCOGENE			English	Article						signal transduction; ras; colon cancer; tumorigenesis	TRANSFORM FIBROBLASTS; HA-RAS; EXPRESSION; GROWTH; ALPHA; MODEL	We have analysed the expression of five protein kinase C [PKC] isoforms in an in vitro model using nontumorigenic rat colonic epithelial cells FRC/TEX CL D [D/ WT] and in the related tumorigenic Ha-ras-transformed FRC/TEX CL D/H-ras line [D/ras]. The PKC subspecies alpha, delta, epsilon and zeta were expressed at the protein level in both D/WT and D/ras cells, while beta PKC was undetectable in both lines. The levels of expression of the delta and zeta isoforms were similar in D/WT and D/ras cells. alpha PKC expression was decreased and epsilon PKC was increased in D/ras cells compared to the D/WT line, To assess whether overexpression of epsilon PKC was linked to the transformed phenotype, we have generated from D/WT cells two clones (D/epsilon-5 and D/epsilon-9) which stably overexpress epsilon PKC about fivefold. Overexpression of epsilon PKC caused marked morphological changes in both transfected clones, which were accompanied by increased saturation densities and anchorage-independent colony formation in semisolid agar. These growth effects were attenuated or reversed by chronic incubation with phorbol 12-myristate 13-acetate. Furthermore, D/epsilon-5 and D/epsilon-9 cells formed tumors in athymic nude mice with 100% incidence while the parental D/WT or vector alone (D/MV12) controls produced no tumors. We conclude that epsilon PKC can act as an oncoprotein when modestly overproduced in nontumorigenic D/WT colonic cells, and that this isoform of PKC may be linked to ras-modulated signal transduction leading to neoplastic transformation in colonic epithelium.	HARVARD UNIV,SCH PUBL HLTH,DEPT MOLEC & CELLULAR TOXICOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; GSF,FORSCHUNGSZENTRUM HAEMATOL,INST CLIN MOL BIOL & TUMOR GENET,D-81377 MUNICH,GERMANY; UNIV MILAN,IST FARMACOL,MILAN,ITALY	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Milan			Mischak, Harald/E-8685-2011; Folini, Marco/B-9607-2017	Folini, Marco/0000-0002-1811-4407; Mischak, Harald/0000-0003-0323-0306	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES00002] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; CACACE AM, 1993, ONCOGENE, V8, P2095; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; CRAVEN PA, 1992, CANCER RES, V52, P2216; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIDSON LA, 1994, ARCH BIOCHEM BIOPHYS, V312, P547, DOI 10.1006/abbi.1994.1344; DELAGE S, 1993, CANCER RES, V53, P2762; DENT P, 1995, MOL CELL BIOL, V15, P4125; DOI S, 1994, CARCINOGENESIS, V11, P197; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1992, FASEB J, V6, P2783, DOI 10.1096/fasebj.6.10.1321771; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; KLINGEL R, 1991, GUT, V62, P1508; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KURANAMI M, 1995, J SURG RES, V58, P233, DOI 10.1006/jsre.1995.1036; KURANAMI M, 1995, AM J SURG, V169, P57, DOI 10.1016/S0002-9610(99)80110-X; LIAO L, 1994, CELL GROWTH DIFFER, V5, P1185; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MONNAT M, 1987, INT J CANCER, V40, P293, DOI 10.1002/ijc.2910400302; MONTANER S, 1995, ONCOGENE, V10, P2213; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PONGRACZ J, 1995, INT J CANCER, V61, P35, DOI 10.1002/ijc.2910610107; PORIES SE, 1993, GASTROENTEROLOGY, V104, P1346, DOI 10.1016/0016-5085(93)90343-B; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SCHAEFFER WI, 1976, CANCER LETT, V1, P259; SPANDIDOS DA, 1984, BRIT J CANCER, V49, P681, DOI 10.1038/bjc.1984.108; TOKER A, 1994, J BIOL CHEM, V269, P32358	31	94	97	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					847	854						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632907				2022-12-25	WOS:A1996TW68600016
J	Hallier, M; Tavitian, A; MoreauGachelin, F				Hallier, M; Tavitian, A; MoreauGachelin, F			The transcription factor Spi-1/PU.1 binds RNA and interferes with the RNA-binding protein p54(nrb)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICING FACTOR; POLYMERASE-II; FUSION; TRANSLOCATION; LIPOSARCOMA; ONCOGENE; INVITRO; CLONING; DOMAIN; FAMILY	The protooncogene for Spi-1/PU.1 is an Ets-related transcription factor overexpressed during Friend erythroleukemia. The molecular basis by which Spi-1/PU.1 is involved in the erythroleukemic process remains to be elucidated. By using an immobilized protein binding assay, we have identified a 55-kDa protein as a putative partner of Spi-1/PU.1 protein. Microsequence analysis revealed that this 55-kDa protein was p54(nrb) (nuclear RNA-binding protein, 54 kDa) a RNA-binding protein highly similar to the splicing factor PSF (polypyrimidine tract-binding protein-associated splicing factor). In this paper, we show that Spi-1/PU.1 impedes the binding of p54(nrb) to RNA and alters the splicing process in vitro. Moreover, we present evidence that the transcriptional factor Spi-1/PU.1, unlike other Ets proteins, is able to bind RNA. Altogether, these results raise the intriguing possibility that the functional interference observed between Spi-1/PU.1 and RNA-binding proteins might represent a novel mechanism in malignant erythropoiesis.	INST CURIE,INSERM,U248,F-75231 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			Hallier, Marc/L-2031-2015					BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DELGADO MD, 1994, ONCOGENE, V9, P1723; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONG BH, 1993, NUCLEIC ACIDS RES, V21, P4085, DOI 10.1093/nar/21.17.4085; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; ICHIKAWA H, 1994, CANCER RES, V54, P2865; JIMENEZ B, 1991, INT J CANCER, V49, P471, DOI 10.1002/ijc.2910490327; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1996, MOL CELL BIOL, V16; OHNO T, 1994, ONCOGENE, V9, P3087; PATTON JG, 1993, GENE DEV, V7, P393, DOI 10.1101/gad.7.3.393; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	25	72	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11177	11181		10.1074/jbc.271.19.11177	http://dx.doi.org/10.1074/jbc.271.19.11177			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626664	hybrid			2022-12-25	WOS:A1996UJ94400024
J	Bateman, A; MacLeod, RJ; Lembessis, P; Hu, J; Esch, F; Solomon, S				Bateman, A; MacLeod, RJ; Lembessis, P; Hu, J; Esch, F; Solomon, S			The isolation and characterization of a novel corticostatin/defensin-like peptide from the kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDES; HUMAN-NEUTROPHILS; BIOLOGICAL-ACTIVITY; APICAL MEMBRANE; CA-2+ CHANNELS; MESSENGER-RNA; HOST DEFENSE; PANETH CELLS; BONE-MARROW; PURIFICATION	We report the isolation and characterization of RK-1, a novel peptide found in the kidney. RK-1 is related to the corticostatin/defensins and has the sequence MPC SCKKYCDPWEVIDGSCGLFNSKYICCREK but differs from the very cationic corticostatins/defensins in having only one arginine and a calculated charge at pH 7 of +1. Like some myeloid corticostatin/defensins RK-1 inhibits the growth of Escherichia coli. Since corticostatin/defensins effect ion flux in responsive epithelia we used volume changes in villus enterocytes as a model system to study the effects of RK-1 on ion channels in epithelial cells. At concentrations greater than or equal to 10(-9) M RK-1 decreased enterocyte volume in a dose-dependent manner through a pathway that requires extracellular calcium and is inhibited by niguldipine, a dihydropyridine-sensitive ''L''-type Ca2+-channel blocker. In other assay systems for corticostatin/defensins, such as the inhibition of adrenocorticotropin-stimulated steroidogenesis, or cell lysis, RK-1 was inactive or only weakly active. These results demonstrate the existence of a novel system of biologically active peptides in the kidney represented by RK-1 which is antimicrobial and can activate epithelial ion channels in vitro.	MCGILL UNIV, MONTREAL CHILDRENS HOSP, RES INST, DEPT PEDIAT, MONTREAL, PQ H3H 1P3, CANADA; UCL, EISAI LONDON RES LABS, LONDON WC1E 6BT, ENGLAND	McGill University; Eisai Co Ltd; University of London; University College London	Bateman, A (corresponding author), MCGILL UNIV, ROYAL VICTORIA HOSP,DEPT MED,ENDOCRINE LAB, RM L 2 05, 687 PINE AVE W, MONTREAL, PQ H3A 1A1, CANADA.			Bateman, Andrew/0000-0003-0597-769X; Lembessis, Panagiotis/0000-0001-8972-3499				BACSKAI BJ, 1990, NATURE, V347, P388, DOI 10.1038/347388a0; BATEMAN A, 1992, PEPTIDES, V13, P133, DOI 10.1016/0196-9781(92)90152-S; BATEMAN A, 1991, REGUL PEPTIDES, V35, P135, DOI 10.1016/0167-0115(91)90476-W; BELCOURT D, 1992, REGUL PEPTIDES, V40, P87, DOI 10.1016/0167-0115(92)90086-A; BOER R, 1989, EUR J PHARM-MOLEC PH, V172, P131, DOI 10.1016/0922-4106(89)90004-7; DESAUVAGE FJ, 1992, P NATL ACAD SCI USA, V89, P9089, DOI 10.1073/pnas.89.19.9089; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; EISENHAUER PB, 1989, INFECT IMMUN, V57, P2021, DOI 10.1128/IAI.57.7.2021-2027.1989; FRINDT G, 1987, AM J PHYSIOL, V252, pF458, DOI 10.1152/ajprenal.1987.252.3.F458; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; GATTI RG, 1992, ARCH GERONTOL GERIAT, V3, P159; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; HU J, 1991, BIOCHEM BIOPH RES CO, V180, P558; HUNTER M, 1986, AM J PHYSIOL, V251, pF725, DOI 10.1152/ajprenal.1986.251.4.F725; HUTTNER KM, 1994, GENOMICS, V19, P448, DOI 10.1006/geno.1994.1093; JONES DE, 1993, FEBS LETT, V315, P187, DOI 10.1016/0014-5793(93)81160-2; JONES DE, 1992, J BIOL CHEM, V267, P23216; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; LEHRER RI, 1983, INFECT IMMUN, V42, P10, DOI 10.1128/IAI.42.1.10-14.1983; LEHRER RI, 1990, BLOOD, V76, P2169; MACLEOD RJ, 1992, J MEMBRANE BIOL, V130, P23; MACLEOD RJ, 1990, AM J PHYSIOL, V258, pG665, DOI 10.1152/ajpgi.1990.258.5.G665; MACLEOD RJ, 1991, P NATL ACAD SCI USA, V88, P552, DOI 10.1073/pnas.88.2.552; MCCARTY NA, 1990, AM J PHYSIOL, V259, pF950, DOI 10.1152/ajprenal.1990.259.6.F950; OUELLETTE AJ, 1989, J CELL BIOL, V108, P1687, DOI 10.1083/jcb.108.5.1687; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; SELSTED ME, 1985, J BIOL CHEM, V260, P4579; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SINGH A, 1988, BIOCHEM BIOPH RES CO, V155, P524, DOI 10.1016/S0006-291X(88)81118-5; STEINHAUSEN M, 1989, PROG APPL MICROCIRC, V14, P25; SUSSMAN M, 1979, RENAL DISEASE, P400; TANIGUCHI J, 1989, AM J PHYSIOL, V257, pF347, DOI 10.1152/ajprenal.1989.257.3.F347; TATEMOTO K, 1978, P NATL ACAD SCI USA, V75, P4115, DOI 10.1073/pnas.75.9.4115; TERRITO MC, 1989, J CLIN INVEST, V84, P2017, DOI 10.1172/JCI114394; TOMINAGA T, 1990, J ENDOCRINOL, V125, P287, DOI 10.1677/joe.0.1250287; WILDE CG, 1989, J BIOL CHEM, V264, P11200; YAMASHITA T, 1989, INFECT IMMUN, V57, P2405, DOI 10.1128/IAI.57.8.2405-2409.1989; YU ASL, 1992, P NATL ACAD SCI USA, V89, P10494, DOI 10.1073/pnas.89.21.10494; YU YM, 1989, AM J PHYSIOL, V257, pF1094, DOI 10.1152/ajprenal.1989.257.6.F1094; ZHU QH, 1988, P NATL ACAD SCI USA, V85, P592, DOI 10.1073/pnas.85.2.592; ZHU QZ, 1992, ENDOCRINOLOGY, V130, P1413, DOI 10.1210/en.130.3.1413	43	39	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10654	10659		10.1074/jbc.271.18.10654	http://dx.doi.org/10.1074/jbc.271.18.10654			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631871	hybrid			2022-12-25	WOS:A1996UJ34200039
J	Judelson, C; Privalsky, ML				Judelson, C; Privalsky, ML			DNA recognition by normal and oncogenic thyroid hormone receptors - Unexpected diversity in half-site specificity controlled by non-zinc-finger determinants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; RESPONSE ELEMENTS; AMINO-ACIDS; GLUCOCORTICOID RECEPTOR; NUCLEAR RECEPTORS; ESTROGEN-RECEPTOR; GENE-EXPRESSION; HIGH-AFFINITY; C-ERBA; BINDING	The nuclear hormone receptors regulate target gene expression in response to hormones of extracellular origin. The DNA binding specificity of these receptors therefore plays the critical role of defining the precise repertoire of target genes that respond to a given hormone. We report here an analysis of the DNA binding specificity of the thyroid hormone receptor (c-ErbA protein) and that of an oncogenic derivative, the v-ErbA protein. These otherwise closely similar proteins exhibit quite divergent DNA sequence specificities at multiple positions within the DNA binding site. The thyroid hormone receptor (c-ErbA protein) exhibits a particularly broad DNA specificity, whereas the v-ErbA protein is comparatively quite specific. Intriguingly, these differences in DNA recognition largely map to an N-terminal receptor domain not traditionally implicated in DNA binding, and are further influenced by heterodimer formation with retinoid X receptors. We propose that the N terminus of nuclear hormone receptors plays an critical role in DNA recognition by altering the conformation of the receptor domains that make the actual base-specific contacts.	UNIV CALIF DAVIS,DIV BIOL SCI,MICROBIOL SECT,DAVIS,CA 95616	University of California System; University of California Davis					NCI NIH HHS [CA53394] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053394, R01CA053394] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; CARLSONJURICA MA, 1990, ENDOCR REV, V11, P201; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; CHEN HW, 1995, P NATL ACAD SCI USA, V92, P422, DOI 10.1073/pnas.92.2.422; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GEWIRTH DT, 1995, STRUCT BIOL, V2, P386; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; IKEDA M, 1994, ENDOCRINOLOGY, V135, P1628, DOI 10.1210/en.135.4.1628; KATZ RW, 1995, J BIOL CHEM, V270, P5238, DOI 10.1074/jbc.270.10.5238; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KIM HS, 1992, MOL ENDOCRINOL, V6, P1489, DOI 10.1210/me.6.9.1489; LAZAR MA, 1990, J CLIN INVEST, V86, P1777, DOI 10.1172/JCI114906; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MANGELSDORF DJ, 1993, RECENT PROG HORM RES, V48, P99; MCBROOM LDB, 1995, MOL CELL BIOL, V15, P796; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NELSON CC, 1995, J BIOL CHEM, V270, P16981, DOI 10.1074/jbc.270.28.16981; NELSON CC, 1995, J BIOL CHEM, V270, P16988, DOI 10.1074/jbc.270.28.16988; NELSON CC, 1994, MOL ENDOCRINOL, V8, P829, DOI 10.1210/me.8.7.829; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SANDE S, 1993, J VIROL, V67, P1067, DOI 10.1128/JVI.67.2.1067-1074.1993; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; SCHROEDER C, 1992, ONCOGENE, V7, P217; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCHWABE JWR, 1995, STRUCTURE, V3, P201, DOI 10.1016/S0969-2126(01)00150-2; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; SMITMCBRIDE Z, 1994, MOL ENDOCRINOL, V8, P819, DOI 10.1210/me.8.7.819; SUBAUSTE JS, 1995, J BIOL CHEM, V270, P7957, DOI 10.1074/jbc.270.14.7957; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WONG CW, 1995, MOL ENDOCRINOL, V9, P551, DOI 10.1210/me.9.5.551; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; ZHANG XK, 1993, RECEPTOR, V3, P183	47	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10800	10805		10.1074/jbc.271.18.10800	http://dx.doi.org/10.1074/jbc.271.18.10800			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631892	hybrid			2022-12-25	WOS:A1996UJ34200060
J	Loh, C; Shaw, KTY; Carew, J; Viola, JPB; Luo, C; Perrino, BA; Rao, A				Loh, C; Shaw, KTY; Carew, J; Viola, JPB; Luo, C; Perrino, BA; Rao, A			Calcineurin binds the transcription factor NFAT1 and reversibly regulates its activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOSPORINE-A; LYMPHOCYTES-T; PHOSPHATASE-ACTIVITY; MESSENGER-RNA; ACTIVATION; PROTEIN; FK506; TARGET; FK-506; COMPLEXES	NFAT1 (previously termed NFATp) is a cytoplasmic transcription factor involved in the induction of cytokine genes. We have previously shown that the dephosphorylation of NFAT1, accompanied by its nuclear translocation and increased DNA binding activity, is regulated by calcium- and calcineurin-dependent mechanisms, as each of these hallmarks of NFAT1 activation is elicited by ionomycin and blocked by the immunosuppressive drugs cyclosporin A and FK506 (Shaw, K. T.-Y., Ho, A. M., Raghavan, A., Kim, J., Jain, J., Park, J., Sharma, S., Rao, A., and Hogan, P. G. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 11205-11209). Here we show that the activation state of NFAT1 in T cells is remarkably sensitive to the level of calcineurin activity. Addition of cyclosporin A, even in the presence of ongoing ionomycin stimulation, results in rephosphorylation of NFAT1, its reappearance in the cytoplasm, and a return of its DNA binding activity to low levels. Similar effects are observed upon removal of ionomycin or addition of EGTA. We also demonstrate a direct interaction between calcineurin and NFAT1 that is consistent with a direct enzyme-substrate relation between these two proteins and that may underlie the sensitivity of NFAT1 activation to the level of calcineurin activity. The NFAT1-calcineurin interaction, which involves an N-terminal region of NFAT1 conserved in other NFAT family proteins, may provide a target for the design of novel immunosuppressive drugs.	HARVARD UNIV,SCH MED,CTR BLOOD RES,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV MOL & CELLULAR BIOL,BOSTON,MA 02115; OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Oregon Health & Science University			Viola, Joao P.B./AAP-4125-2020	Viola, Joao P.B./0000-0002-0698-3146	NCI NIH HHS [CA42471] Funding Source: Medline; NIGMS NIH HHS [GM46227] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042471, R37CA042471] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAMBURU J, 1995, J EXP MED, V182, P801, DOI 10.1084/jem.182.3.801; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P111; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; CHOI MSK, 1994, IMMUNITY, V1, P179, DOI 10.1016/1074-7613(94)90096-5; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; GOLDFELD AE, 1994, J EXP MED, V180, P763, DOI 10.1084/jem.180.2.763; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HO AM, 1994, J BIOL CHEM, V269, P28181; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; HUTCHINSON LE, 1995, J BIOL CHEM, V270, P16333, DOI 10.1074/jbc.270.27.16333; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KAYE RE, 1992, P NATL ACAD SCI USA, V89, P8542, DOI 10.1073/pnas.89.18.8542; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LIU J, 1993, IMMUNOL TODAY, V14, P290, DOI 10.1016/0167-5699(93)90048-P; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LOH C, 1994, J BIOL CHEM, V269, P8817; MASON MJ, 1993, BIOCHEM J, V296, P33, DOI 10.1042/bj2960033; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MORGAN AJ, 1994, BIOCHEM J, V300, P665, DOI 10.1042/bj3000665; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PARK JC, 1995, J BIOL CHEM, V270, P20653, DOI 10.1074/jbc.270.35.20653; RAO A, 1984, J EXP MED, V159, P479, DOI 10.1084/jem.159.2.479; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHAW J, 1987, MOL IMMUNOL, V24, P409, DOI 10.1016/0161-5890(87)90014-9; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; TOCCI MJ, 1989, J IMMUNOL, V143, P718; UMLAUF SW, 1995, MOL CELL BIOL, V15, P3197; VENKATARAMAN L, 1994, IMMUNITY, V1, P189, DOI 10.1016/1074-7613(94)90097-3; Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274; Zhou Songyang, 1995, Nature (London), V373, P536	54	259	268	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10884	10891		10.1074/jbc.271.18.10884	http://dx.doi.org/10.1074/jbc.271.18.10884			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631904	hybrid			2022-12-25	WOS:A1996UJ34200072
J	Reilly, TJ; Baron, GS; Nano, FE; Kuhlenschmidt, MS				Reilly, TJ; Baron, GS; Nano, FE; Kuhlenschmidt, MS			Characterization and sequencing of a respiratory burst-inhibiting acid phosphatase from Francisella tularensis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOLYTIC PHOSPHOLIPASE-C; PSEUDOMONAS-AERUGINOSA; LEISHMANIA-DONOVANI; HUMAN-NEUTROPHILS; PROTEINS; IDENTIFICATION; HYDROLYSIS; BACTERIA; KINETICS; ENZYME	Acid phosphatases (Acp) of intracellular pathogens have recently been implicated as virulence factors that enhance intracellular survival through suppression of the respiratory burst. We describe here the identification, purification, characterization, and sequencing of a novel burst-inhibiting acid phosphatase from the facultative intracellular bacterium, Francisella tularensis. Similar to other the burst-inhibiting Acps, F. tularensis Acp (AcpA) is tartrate-resistant and has broad substrate specificity. The AcpA enzyme is unique, however, in that it is easily released from the bacterial cell in soluble form, is a basic enzyme, suppresses the respiratory burst of not only fMet-Leu-Phe but also phorbol 12-myristate 13-acetate-stimulated neutrophils and does not fit into any of the three currently recognized classes of acid phosphatase. We also report the complete nucleotide sequence of the gene acpA, encoding AcpA, and the deduced primary structure of its encoded polypeptide. Comparative sequence analyses of AcpA is discussed. To our knowledge, this is the first report describing the cloning and sequencing of a burst-inhibiting acid phosphatase.	UNIV ILLINOIS, COLL VET MED, DEPT PATHOBIOL, URBANA, IL 61801 USA; UNIV VICTORIA, DEPT BIOCHEM & MICROBIOL, VICTORIA, BC V8W 3P6, CANADA	University of Illinois System; University of Illinois Urbana-Champaign; University of Victoria				Kuhlenschmidt, Mark/0000-0003-1196-0763				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANTHONY LSD, 1991, INFECT IMMUN, V59, P3291, DOI 10.1128/IAI.59.9.3291-3296.1991; BACA OG, 1993, INFECT IMMUN, V61, P4232, DOI 10.1128/IAI.61.10.4232-4239.1993; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BROOKS SPJ, 1992, BIOTECHNIQUES, V13, P906; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COLIGAN JE, 1995, CURRENT PROTOCOLS IM, V2; CONLAN JW, 1992, INFECT IMMUN, V60, P5164, DOI 10.1128/IAI.60.12.5164-5171.1992; DAS S, 1986, MOL BIOCHEM PARASIT, V20, P143, DOI 10.1016/0166-6851(86)90026-5; DIPIETRO DL, 1967, J BIOL CHEM, V242, P3391; DOCAMPO R, 1976, EXPERIENTIA, V32, P972, DOI 10.1007/BF01933918; DOWLING JN, 1992, MICROBIOL REV, V56, P32, DOI 10.1128/MMBR.56.1.32-60.1992; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; FORSMAN M, 1994, INT J SYST BACTERIOL, V44, P38, DOI 10.1099/00207713-44-1-38; GLEW RH, 1982, COMP BIOCHEM PHYS B, V72, P581, DOI 10.1016/0305-0491(82)90510-7; HOLLIS DG, 1989, J CLIN MICROBIOL, V27, P1601, DOI 10.1128/JCM.27.7.1601-1608.1989; KURIOKA S, 1976, ANAL BIOCHEM, V75, P281, DOI 10.1016/0003-2697(76)90078-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LAWRENCE GL, 1981, ARCH BIOCHEM BIOPHYS, V206, P122, DOI 10.1016/0003-9861(81)90073-4; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MDLULI KE, 1994, MICROBIOL-SGM, V140, P3309, DOI 10.1099/13500872-140-12-3309; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; NANO FE, 1988, MICROB PATHOGENESIS, V5, P109, DOI 10.1016/0882-4010(88)90013-7; NEWBURGER PE, 1980, BLOOD, V55, P85; OSTROFF RM, 1990, J BACTERIOL, V172, P5915, DOI 10.1128/jb.172.10.5915-5923.1990; OSTROFF RM, 1987, J BACTERIOL, V169, P4597, DOI 10.1128/jb.169.10.4597-4601.1987; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; REMALEY AT, 1985, J BIOL CHEM, V260, P880; SAHA AK, 1985, J CLIN MICROBIOL, V22, P329, DOI 10.1128/JCM.22.3.329-332.1985; SAHA AK, 1985, ARCH BIOCHEM BIOPHYS, V243, P150, DOI 10.1016/0003-9861(85)90783-0; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHAPIRO SZ, 1992, INFECT IMMUN, V60, P3921, DOI 10.1128/IAI.60.9.3921-3924.1992; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STONE KL, 1993, PRACTICAL GUIDE PROT, P45; SUZUKI Y, 1980, J CLIN INVEST, V66, P1409, DOI 10.1172/JCI109994; TAINER J, 1994, NATURE, V370, P506, DOI 10.1038/370506a0; TIAN ZP, 1993, INT J PEPT PROT RES, V42, P155; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VINCENT JB, 1990, CHEM REV, V90, P1447, DOI 10.1021/cr00106a004; VINCENT JB, 1992, TRENDS BIOCHEM SCI, V17, P105, DOI 10.1016/0968-0004(92)90246-6	42	123	134	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10973	10983		10.1074/jbc.271.18.10973	http://dx.doi.org/10.1074/jbc.271.18.10973			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631917	hybrid			2022-12-25	WOS:A1996UJ34200085
J	Wilson, JE; Schwab, DA				Wilson, JE; Schwab, DA			Functional interaction of hexokinase with ATP requires participation by both small and large lobes of the enzyme: Implications for other proteins using the actin fold as a nucleotide binding motif	FASEB JOURNAL			English	Article						ATP; binding; hexokinase; binding of ATP	SHOCK COGNATE PROTEIN; RAT-BRAIN HEXOKINASE; AMINO-ACID SEQUENCE; YEAST HEXOKINASE; CLONED CDNA; FRAGMENT; DOMAIN	The actin fold is a structural motif involved in binding of ATP to an otherwise diverse family of proteins that includes hexokinase, actin, and the 70 kDa heat shock protein, Previous analyses have focused attention on a hydrophobic pocket within the large lobe of hexokinase (and analogous regions in other proteins possessing the actin fold motif) as the site for binding of the adenine moiety, However, there is reason to believe that binding of. the adenine moiety also involves a beta-sheet region located in the small lobe of hexokinase, It is postulated that functional interaction with ATP, required for catalysis, involves interactions with both regions, The expected structural consequences provide a basis for explaining the kinetic mechanism suggested for this enzyme, i.e., although both substrates can bind independently, the preferred kinetic pathway is not random but ordered, with glucose binding first, The structural features postulated to be involved in binding of ATP to hexokinase are also found in other proteins possessing the actin fold motif, Interaction of the nucleotide with the beta-sheet region, analogous to that found in the ''small lobe'' of hexokinase, may induce functionally important conformational changes in other proteins employing the actin fold as a nucleotide binding motif.			Wilson, JE (corresponding author), MICHIGAN STATE UNIV,DEPT BIOCHEM,301 BIOCHEM BLDG,E LANSING,MI 48824, USA.				NINDS NIH HHS [NS09910] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009910] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON CM, 1979, SCIENCE, V204, P375, DOI 10.1126/science.220706; ARORA KK, 1990, J BIOL CHEM, V265, P5324; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; FLAHERTY KM, 1991, P NATL ACAD SCI USA, V88, P5041, DOI 10.1073/pnas.88.11.5041; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; HARRISON RW, 1985, THESIS YALE U NEW HA; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; JONES JP, 1991, BIOCHEMISTRY-US, V30, P3634, DOI 10.1021/bi00229a007; KABSCH W, 1995, FASEB J, V9, P167, DOI 10.1096/fasebj.9.2.7781919; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; SCHWAB DA, 1989, P NATL ACAD SCI USA, V86, P2563, DOI 10.1073/pnas.86.8.2563; SCHWAB DA, 1988, J BIOL CHEM, V263, P3220; SHOHAM M, 1980, J MOL BIOL, V140, P1, DOI 10.1016/0022-2836(80)90353-8; STEITZ TA, 1981, PHILOS T ROY SOC B, V293, P43, DOI 10.1098/rstb.1981.0058; TAYLOR KB, 1983, EUR J BIOCHEM, V134, P571, DOI 10.1111/j.1432-1033.1983.tb07604.x; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776	17	14	14	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1996	10	7					799	801		10.1096/fasebj.10.7.8635698	http://dx.doi.org/10.1096/fasebj.10.7.8635698			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UN798	8635698				2022-12-25	WOS:A1996UN79800015
J	Chiang, HL; Schekman, R; Hamamoto, S				Chiang, HL; Schekman, R; Hamamoto, S			Selective uptake of cytosolic, peroxisomal, and plasma membrane proteins into the yeast lysosome for degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CATABOLITE INACTIVATION; AUTOPHAGIC VACUOLE; RAT-LIVER; PEPTIDE SEQUENCES; MUTANTS; PROTEOLYSIS; SYSTEM; MECHANISMS; ENZYME	When glucose-starved cells are replenished with glucose, the key gluconeogenic enzyme, fructose-1,6-bisphosphatase (FBPase), is selectively targeted from the cytosol to the yeast lysosome (vacuole) for degradation, The glucose-induced targeting of FBPase to the vacuole for degradation occurs in cells grown under a variety of metabolic conditions. Immunoelectron microscopic studies demonstrate that the uptake of FBPase by the vacuole is mediated in part by an autophagic process, FBPase can be found on the vacuolar membrane and also at the sites of membrane invaginations, Furthermore, FBPase is associated with different forms of vesicles, which are induced to accumulate inside the vacuole, We have identified peroxisomes as the organelles that are delivered to the vacuole for degradation when cells are replenished with glucose, Ultrastructural studies indicate that peroxisomes are engulfed by the vacuole by an autophagic process, leading to the destruction of whole organelles in the vacuole. Furthermore, the galactose transporter (Gal2p) is also delivered from the plasma membrane to the vacuole for degradation in response to glucose. Gal2p is delivered to the vacuole through the endocytic pathway, as mutants defective in receptor-mediated endocytosis fail to degrade Gal2p in response to glucose.	UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley	Chiang, HL (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049267] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM 49267] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLBERG J, 1982, LAB INVEST, V47, P523; AHLBERG J, 1982, EXP CELL RES, V142, P373, DOI 10.1016/0014-4827(82)90379-2; BORMANN C, 1978, ARCH MICROBIOL, V117, P67, DOI 10.1007/BF00689353; BUSTURIA A, 1985, BIOCHIM BIOPHYS ACTA, V820, P324, DOI 10.1016/0005-2736(85)90128-2; CHIANG HL, 1988, J BIOL CHEM, V263, P6797; CHIANG HL, 1994, NATURE, V369, P284, DOI 10.1038/369284a0; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391; CHVATCHKO Y, 1986, CELL, V46, P355, DOI 10.1016/0092-8674(86)90656-2; CUERVO AM, 1994, J BIOL CHEM, V269, P26374; DELAGUERRA R, 1988, FEBS LETT, V242, P149, DOI 10.1016/0014-5793(88)81004-4; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; DULIC V, 1989, EMBO J, V8, P1349, DOI 10.1002/j.1460-2075.1989.tb03515.x; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; DUNN WA, 1990, J CELL BIOL, V110, P1935, DOI 10.1083/jcb.110.6.1935; ERDMANN R, 1989, P NATL ACAD SCI USA, V86, P5419, DOI 10.1073/pnas.86.14.5419; FERGUSON JJ, 1967, EUR J BIOCHEM, V1, P21, DOI 10.1111/j.1432-1033.1967.tb00037.x; FINLEY D, 1985, TRENDS BIOCHEM SCI, V10, P343, DOI 10.1016/0968-0004(85)90108-2; FRANCOIS J, 1991, YEAST, V7, P575, DOI 10.1002/yea.320070605; FUNAGUMA T, 1985, BIOCHEM BIOPH RES CO, V130, P467, DOI 10.1016/0006-291X(85)90440-1; FUNAYAMA S, 1980, EUR J BIOCHEM, V109, P61, DOI 10.1111/j.1432-1033.1980.tb04767.x; GANCEDO C, 1971, J BACTERIOL, V107, P401, DOI 10.1128/JB.107.2.401-405.1971; HASILIK A, 1978, EUR J BIOCHEM, V85, P599, DOI 10.1111/j.1432-1033.1978.tb12275.x; HEMMINGS BA, 1981, P NATL ACAD SCI-BIOL, V78, P435, DOI 10.1073/pnas.78.1.435; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOHFELD J, 1991, J CELL BIOL, V114, P1167, DOI 10.1083/jcb.114.6.1167; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, P193; JONES EW, 1991, J BIOL CHEM, V266, P7963; JONES EW, 1977, GENETICS, V85, P23; KOMINAMI E, 1983, J BIOL CHEM, V258, P6093; KOPITZ J, 1990, J CELL BIOL, V111, P841; LATTERICH M, 1991, MOL MICROBIOL, V5, P2417, DOI 10.1111/j.1365-2958.1991.tb02087.x; MATERN H, 1977, J BIOL CHEM, V252, P6399; MORTIMORE GE, 1981, J BIOL CHEM, V256, P7659; MULLER M, 1981, J BIOL CHEM, V256, P723; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; RAMOS J, 1988, J BACTERIOL, V170, P3575; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; SCHORK SM, 1994, FEBS LETT, V349, P270, DOI 10.1016/0014-5793(94)00668-7; Seglen P O, 1990, Semin Cell Biol, V1, P441; SURMACZ CA, 1987, BIOCHEM J, V242, P453, DOI 10.1042/bj2420453; TERLECKY SR, 1992, J BIOL CHEM, V267, P9202; TUTTLE DL, 1995, J CELL SCI, V108, P25; VEENHUIS M, 1983, ARCH MICROBIOL, V134, P193, DOI 10.1007/BF00407757	44	88	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9934	9941		10.1074/jbc.271.17.9934	http://dx.doi.org/10.1074/jbc.271.17.9934			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626630	hybrid			2022-12-25	WOS:A1996UG25700014
J	Ghosh, S; Toth, C; Peterlin, BM; Seto, E				Ghosh, S; Toth, C; Peterlin, BM; Seto, E			Synergistic activation of transcription by the mutant and wild-type minimal transcriptional activation domain of VP16	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS REGULATORY PROTEIN; GENE-EXPRESSION; FACTOR-TFIIB; AMINO-ACIDS; BINDING; VMW65; TAT; SEQUENCE	VP16 activates transcription by stimulating initiation, and for this function the aromatic residue at position 442 within its activation domain is critical. Recent studies have suggested that VP16 also stimulates transcriptional elongation. It has been shown that VP16 can activate transcription tethered downstream of the transcription start site to RNA. Here, we analyze the synergistic activation features of hybrid VP16 fusion proteins when tethered simultaneously to RNA downstream of the start site and to DNA upstream of a promoter in order to investigate its role in postinitiation control of transcription. Upon targeting the VP16 activation domain simultaneously to both DNA and RNA, high levels of transcriptional synergism is observed. Importantly, a transcription-defective VP16 minimal activation domain (amino acids 413-453) mutated at critical residue 442 (phenylalanine --> proline) maintained synergism, when bound to RNA, with the DNA-bound wild-type VP16 minimal activation domain. Targeting of this ''functionally defective'' VP16 minimal activation domain via RNA and an intact activation domain via DNA allowed us to uncover a postinitiation activity for VP16 not previously detected in DNA targeting studies. We suggest that, in addition to stimulating initiation, VP16 also acts at a postinitiation step involving residues other than the critical residue at position 442 within the same 41-amino acid minimal activation domain (amino acids 413-453) required for initiation.	UNIV TEXAS,HLTH SCI CTR,CTR MOLEC MED,SAN ANTONIO,TX 78245; UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of Texas System; University of Texas Health San Antonio; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Ghosh, S (corresponding author), UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,15355 LAMBDA DR,SAN ANTONIO,TX 78245, USA.							CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; EICK D, 1994, TRENDS GENET, V10, P292, DOI 10.1016/0168-9525(90)90013-V; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GHOSH S, 1993, J MOL BIOL, V234, P610, DOI 10.1006/jmbi.1993.1615; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GREAVES R, 1989, J VIROL, V63, P1641, DOI 10.1128/JVI.63.4.1641-1650.1989; HERSCHLAG D, 1993, GENE DEV, V7, P173, DOI 10.1101/gad.7.2.173; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JIANG Y, 1994, J BIOL CHEM, V269, P5505; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZPESCADOR R, 1985, SCIENCE, V227, P484, DOI 10.1126/science.2578227; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; THOMPSON CC, 1992, TRENDS GENET, V8, P232, DOI 10.1016/0168-9525(92)90121-J; TILEY LS, 1992, GENE DEV, V6, P2077, DOI 10.1101/gad.6.11.2077; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; WALKER S, 1993, MOL CELL BIOL, V13, P5233, DOI 10.1128/MCB.13.9.5233; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x	34	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9911	9918		10.1074/jbc.271.17.9911	http://dx.doi.org/10.1074/jbc.271.17.9911			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626627	hybrid			2022-12-25	WOS:A1996UG25700011
J	KochNolte, F; Petersen, D; Balasubramanian, S; Haag, F; Kahlke, D; Willer, T; Kastelein, R; Bazan, F; Thiele, HG				KochNolte, F; Petersen, D; Balasubramanian, S; Haag, F; Kahlke, D; Willer, T; Kastelein, R; Bazan, F; Thiele, HG			Mouse T cell membrane proteins Rt6-1 and Rt6-2 are arginine protein mono(ADPribosyl)transferases and share secondary structure motifs with ADP-ribosylating bacterial toxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; DIPHTHERIA-TOXIN; SKELETAL-MUSCLE; CRYSTAL-STRUCTURE; PERTUSSIS TOXIN; LYMPHOCYTES-T; BINDING-SITE; RIBOSYLTRANSFERASE; RAT; NAD	Mono ADP-ribosylation is a posttranslational protein modification that has been implicated in the regulation of key biological functions in bacteria as well as in animals, Recently, the first cDNAs for eucaryotic mono(ADPribosyl)transferases were cloned and found to exhibit significant sequence similarity only to one other known protein, the T cell differentiation antigen Rt6, In this paper we describe secondary structure analyses of Rt6 and related proteins and show conserved structure motifs and amino acid residues consistent with a common ancestry of these eucaryotic proteins and bacterial ADP-ribosyltransferases. Moreover, we have expressed soluble mouse Rt6-1 and Rt6-2 gene products in which C-terminal tags (FLAG-His(6)) replace the native glycosylphosphatidylinositol anchor signal sequences. Purified recombinant Rt6-2, but not Rt6-1, shows NAD(+) glycohydrolase activity, which is inhibited by the arginine analogue agmatine. Immunoprecipitation of recombinant Rt6-1 and Rt6-2 with anti-FLAG M2 antibody followed by incubation with [P-32]NAD(+) leads to rapid and covalent incorporation of radioactivity into the light chain of the M2 antibody, The bound label is resistant to treatment with HgCl2 but sensitive to NH2OH, characteristic of arginine-linked ADP-ribosylation. These results demonstrate that Rt6-1 and Rt6-2 possess the enzymatic activities typical for NAD(+)-dependent arginine/protein mono(ADPribosyl)transferases (EC 2.4.2.31), They are the first such enzymes to be molecularly characterized in the immune system.	UNIV HAMBURG HOSP, DEPT IMMUNOL, MED CLIN, D-20246 HAMBURG, GERMANY; DNAX RES INST MOLEC & CELLULAR BIOL INC, PALO ALTO, CA 94304 USA	University of Hamburg; University Medical Center Hamburg-Eppendorf; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Bazan, J. Fernando/B-4562-2010	Koch-Nolte, Friedrich/0000-0003-1730-6674				ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; ANTOINE R, 1993, J BIOL CHEM, V268, P24149; BARBIERI JT, 1989, INFECT IMMUN, V57, P3549, DOI 10.1128/IAI.57.11.3549-3554.1989; BLANKE SR, 1994, BIOCHEMISTRY-US, V33, P5155, DOI 10.1021/bi00183a019; BURNETTE WN, 1988, SCIENCE, V242, P72, DOI 10.1126/science.2459776; BUTCHER GW, 1977, RAT NEWS LETT, V1, P12; CARROLL SF, 1984, P NATL ACAD SCI-BIOL, V81, P3307, DOI 10.1073/pnas.81.11.3307; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; DOMENIGHINI M, 1994, MOL MICROBIOL, V14, P41, DOI 10.1111/j.1365-2958.1994.tb01265.x; DONG C, 1994, INT IMMUNOL, V6, P1353, DOI 10.1093/intimm/6.9.1353; EVANS RJ, 1992, NATURE, V357, P503, DOI 10.1038/357503a0; FANGMANN J, 1991, EUR J IMMUNOL, V21, P753, DOI 10.1002/eji.1830210331; GODEAU F, 1984, ANAL BIOCHEM, V137, P287, DOI 10.1016/0003-2697(84)90087-3; GREINER DL, 1987, J EXP MED, V166, P461, DOI 10.1084/jem.166.2.461; GRIMALDI JC, 1995, J IMMUNOL, V155, P811; HAAG F, 1995, EUR J IMMUNOL, V25, P2355, DOI 10.1002/eji.1830250835; HAAG F, 1990, NUCLEIC ACIDS RES, V18, P1047, DOI 10.1093/nar/18.4.1047; HOPP TP, 1988, BIOTECHNOLOGY, V6, P205; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; JACOBSON MK, 1989, ADP RIBOSE TRANSFER; KAISHO T, 1994, P NATL ACAD SCI USA, V91, P5325, DOI 10.1073/pnas.91.12.5325; KASHAN A, 1989, IMMUNOL LETT, V23, P133, DOI 10.1016/0165-2478(89)90125-9; KLEBL BM, 1994, FEBS LETT, V342, P66, DOI 10.1016/0014-5793(94)80586-5; KOCH F, 1990, P NATL ACAD SCI USA, V87, P964, DOI 10.1073/pnas.87.3.964; KOCH F, 1986, J EXP MED, V164, P1338, DOI 10.1084/jem.164.4.1338; KOCHNOLTE F, 1995, INT IMMUNOL, V7, P883, DOI 10.1093/intimm/7.5.883; KOCHNOLTE F, IN PRESS MOL IMMUNOL; MAEHAMA T, 1991, J BIOL CHEM, V266, P10062; MAEHAMA T, 1995, J BIOL CHEM, V270, P22747, DOI 10.1074/jbc.270.39.22747; MCMAHON KK, 1993, BIOCHEM J, V293, P789, DOI 10.1042/bj2930789; MEYER T, 1988, BIOL CHEM H-S, V369, P579, DOI 10.1515/bchm3.1988.369.2.579; Moss J, 1990, ADP RIBOSYLATING TOX; PAPINI E, 1989, J BIOL CHEM, V264, P12385; PAYNE DM, 1985, BIOCHEMISTRY-US, V24, P7540, DOI 10.1021/bi00347a006; PETERSON JE, 1990, J BIOL CHEM, V265, P17062; QUIST EE, 1994, J MOL CELL CARDIOL, V26, P251, DOI 10.1006/jmcc.1994.1028; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; SANDER C, 1994, NUCLEIC ACIDS RES, V22, P3597; SCHUMAN EM, 1994, P NATL ACAD SCI USA, V91, P11958, DOI 10.1073/pnas.91.25.11958; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SOMAN G, 1991, BIOCHEM BIOPH RES CO, V176, P301, DOI 10.1016/0006-291X(91)90924-V; STEIN PE, 1994, STRUCTURE, V2, P45, DOI 10.1016/S0969-2126(00)00007-1; TAKADA T, 1994, J BIOL CHEM, V269, P9420; TAKADA T, 1995, J BIOL CHEM, V270, P541, DOI 10.1074/jbc.270.2.541; THIELE HG, 1987, TRANSPLANT P, V19, P3157; TSUCHIYA M, 1994, J BIOL CHEM, V269, P27451; TWETEN RK, 1985, J BIOL CHEM, V260, P392; WANG J, 1994, J IMMUNOL, V153, P4048; WEISS MS, 1995, BIOCHEMISTRY-US, V34, P773, DOI 10.1021/bi00003a010; WONIGEIT K, 1987, TRANSPLANT P, V19, P296; YANG XD, 1994, P NATL ACAD SCI USA, V91, P12604, DOI 10.1073/pnas.91.26.12604; YOST DA, 1983, J BIOL CHEM, V258, P4926; ZOLKIEWSKA A, 1993, J BIOL CHEM, V268, P25273; ZOLKIEWSKA A, 1992, P NATL ACAD SCI USA, V89, P11352, DOI 10.1073/pnas.89.23.11352	54	99	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7686	7693		10.1074/jbc.271.13.7686	http://dx.doi.org/10.1074/jbc.271.13.7686			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631807	hybrid			2022-12-25	WOS:A1996UC77400075
J	Turner, JR; Lencer, WI; Carlson, S; Madara, JL				Turner, JR; Lencer, WI; Carlson, S; Madara, JL			Carboxyl-terminal vesicular stomatitis virus G protein-tagged intestinal Na+-dependent glucose cotransporter (SGLT1) - Maintenance of surface expression and global transport function with selective perturbation of transport kinetics and polarized expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE PROTEINS; CELL-LINE CACO-2; IN-VITRO MODEL; BRUSH-BORDER; CYTOPLASMIC DOMAIN; NA+/GLUCOSE COTRANSPORTER; ESCHERICHIA-COLI; LOCALIZATION; CYTOSKELETON; SUBSTRATE	The Na+-dependent glucose transporter (SGLT1) mediates absorption of luminal glucose by the intestine. However, available intestinal cell Lines that recapitulate a monolayer phenotype only express SGLT1 at low levels. Thus, to facilitate studies of the biology of SGLT1 function in epithelial monolayers, we engineered an epitope-tagged construct containing the YTDIEMNRLGK sequence (from the vesicular stomatitis virus G protein). The tag was placed at the carboxyl terminus since this is the least conserved portion of SGLT1. Transiently transfected COS-1 cells demonstrated surface expression of the immunoreactive protein and enhanced Na+-dependent glucose uptake that was phloridzin-sensitive (a specific competitive inhibitor of SGLT1). However, subsequent detailed analyses of epitope-tagged SGLT1 using stably transfected clones derived from the Caco-2 human intestinal epithelial cell line revealed substantial effects of the epitope on critical functions of SGLT1. When compared with native SGLT1 transfectants, the apparent K-m for sugar transport was increased 23-fold (313 mu M to 7.37 mM for native versus epitope-tagged SGLT1). In contrast, the apparent K-Na for epitope-tagged SGLT1 was similar to that for native SGLT1. Permeabilization studies indicated that the C-terminal epitope tag was intracellular and thus could not directly disrupt extracellular ligand-binding sites. Immunolocalization and functional assays designed to detect polarized surface expression indicated that epitope tagging resulted in loss of apical targeting and enrichment of basolateral expression. Functional isolation of the small apical pool of epitope-tagged SGLT1 (by selective inhibition of basolateral epitope-tagged SGLT1) revealed that, despite the documented kinetic alterations in sugar transport, epitope-tagged SGLT1 could promote absorptive Na+ currents. These data show that 1) the C terminus of SGLT1 is intracellular; 2) disruption of protein structure by addition of a C-terminal tag leads to selective modifications of SGLT1 function; 3) the kinetics of sugar transport can be altered independently of influences on the Na+-binding site of SGLT1; and 4) the weak basolateral targeting sequence present within the epitope tag is dominant over endogenous SGLT1 apical targeting information and can direct polytopic membrane protein localization. The data also caution that subtle effects of foreign sequences must be considered when epitope tagging polytopic membrane proteins.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; CHILDRENS HOSP,COMBINED PROGRAM PEDIAT GASTROENTEROL & NUTR,BOSTON,MA 02115; HARVARD UNIV,CTR DIGEST DIS,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University	Turner, JR (corresponding author), BRIGHAM & WOMENS HOSP,DEPT PATHOL,DIV GASTROINTESTINAL PATHOL,75 FRANCIS ST,BOSTON,MA 02115, USA.		Turner, Jerrold R/A-6895-2009	Turner, Jerrold R/0000-0003-0627-9455; Lencer, Wayne/0000-0001-7346-2730	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035932] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL0 7627] Funding Source: Medline; NIDDK NIH HHS [R01 DK35932, R01 DK41086] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROTLAROCHE E, 1987, BIOCHIM BIOPHYS ACTA, V904, P71, DOI 10.1016/0005-2736(87)90088-5; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; GELI V, 1988, P NATL ACAD SCI USA, V85, P689, DOI 10.1073/pnas.85.3.689; HANADA K, 1992, BIOCHIM BIOPHYS ACTA, V1105, P61, DOI 10.1016/0005-2736(92)90162-F; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEDIGER MA, 1994, PHYSIOL REV, V74, P993, DOI 10.1152/physrev.1994.74.4.993; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; IKEDA TS, 1989, J MEMBRANE BIOL, V110, P87, DOI 10.1007/BF01870995; KIMMICH GA, 1981, AM J PHYSIOL, V241, pC227, DOI 10.1152/ajpcell.1981.241.5.C227; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; LEBIVIC A, 1990, J CELL BIOL, V111, P1351, DOI 10.1083/jcb.111.4.1351; LEE WS, 1994, J BIOL CHEM, V269, P12032; MACDONALD RS, 1993, J RECEPTOR RES, V13, P1093, DOI 10.3109/10799899309063266; MADARA JL, 1989, J CLIN INVEST, V83, P724, DOI 10.1172/JCI113938; MATTER K, 1990, CELL, V60, P429, DOI 10.1016/0092-8674(90)90594-5; MEICHSNER M, 1993, NEUROSCIENCE, V54, P873, DOI 10.1016/0306-4522(93)90581-Y; MONLAUZEUR L, 1995, J BIOL CHEM, V270, P12219, DOI 10.1074/jbc.270.20.12219; OHSAWA M, 1988, J BACTERIOL, V170, P5185, DOI 10.1128/jb.170.11.5185-5191.1988; PETERSON MD, 1993, J CELL SCI, V105, P461; PETERSON MD, 1992, J CELL SCI, V102, P581; PETERSON MD, 1993, J CELL SCI, V105, P445; PINTO M, 1983, BIOL CELL, V47, P323; RILEY SA, 1991, BIOCHIM BIOPHYS ACTA, V1066, P175, DOI 10.1016/0005-2736(91)90184-A; TAKATA K, 1992, CELL TISSUE RES, V267, P3, DOI 10.1007/BF00318685; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; TOGGENBURGER G, 1982, BIOCHIM BIOPHYS ACTA, V688, P557, DOI 10.1016/0005-2736(82)90367-4; TURK E, 1994, J BIOL CHEM, V269, P15204; TURK E, 1991, NATURE, V350, P354, DOI 10.1038/350354a0; WADZINSKI BE, 1992, J BIOL CHEM, V267, P16883; WEISZ OA, 1992, J BIOL CHEM, V267, P22282; WRIGHT EM, 1993, ANNU REV PHYSIOL, V55, P575, DOI 10.1146/annurev.ph.55.030193.003043; WRIGHT EM, 1994, J EXP BIOL, V196, P197; YAMATO I, 1990, J BIOL CHEM, V262, P2450	36	52	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7738	7744		10.1074/jbc.271.13.7738	http://dx.doi.org/10.1074/jbc.271.13.7738			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631815	hybrid, Green Published			2022-12-25	WOS:A1996UC77400083
J	Herrmann, C; Horn, G; Spaargaren, M; Wittinghofer, A				Herrmann, C; Horn, G; Spaargaren, M; Wittinghofer, A			Differential interaction of the Ras family GTP-binding proteins H-Ras, Rap1A, and R-Ras with the putative effector molecules Raf kinase and Ral-guanine nucleotide exchange factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING PROTEIN; RAS-P21 GTPASE; P21(RAS); DOMAIN; ASSOCIATION; INHIBITION; MECHANISM; GENE; P21	The interactions of H-Ras, R-Ras, and Rap1A with the Ras-binding domains (RED) of the c-Raf kinase and of the Ral guanine nucleotide exchange factor (RGF) was studied biochemically in solution, From deletion cloning the RGF-RBD was defined as a 97-amino acid-long fragment from the C-terminal end of the human RGF, which is an independent folding domain with high stability. Interestingly, whereas H-Ras binds with high affinity (K-D = 20 nM) to Raf-RBD and with low affinity (K-D = 1 mu M) to RGF-RBD, Rap1A shows the opposite behavior, The binding of both RBDs to R-Ras is weak and shows no specificity. The interaction between Rap1A and RGF-RBD shows similar characteristics to the Ras-Raf interaction because it is blocked by mutations in the effector region (D38A) and it inhibits the dissociation of guanine nucleotide, which is the basis for the quantitative measurements in this work, Furthermore, the binding of RGF-RBD inhibits the interaction between Rap1A and Rap-GAP. As long as the cellular localizations of the different proteins and their biological functions are not clarified, these biochemical data seem to indicate that Ral-guanine nucleotide exchange factors is an effector molecule of Rap1A rather than of H-Ras.	UNIV UTRECHT, PHYSIOL CHEM LAB, 3584 CG UTRECHT, NETHERLANDS	Utrecht University	Herrmann, C (corresponding author), MAX PLANCK INST MOLEK PHYSIOL, RHEINLANDDAMM 201, D-44139 DORTMUND, GERMANY.		Spaargaren, Marcel/AAU-1298-2021	Spaargaren, Marcel/0000-0002-3135-5109				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COX AD, 1994, ONCOGENE, V9, P3281; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; FISCHER TH, 1994, J BIOL CHEM, V269, P17257; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HATA Y, 1990, J BIOL CHEM, V265, P7104; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; JOHN J, 1988, J BIOL CHEM, V263, P11792; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KIM S, 1990, MOL CELL BIOL, V10, P2645, DOI 10.1128/MCB.10.6.2645; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; PIZON V, 1994, J CELL SCI, V107, P1661; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RENSLAND H, 1992, POSSIBILITIES LIMITA; REY I, 1994, ONCOGENE, V9, P685; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SAEZ R, 1994, ONCOGENE, V9, P2977; SCHEFFLER JE, 1994, J BIOL CHEM, V269, P22340; SHIROUZU M, 1994, ONCOGENE, V9, P2153; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; SPAARGAREN M, 1994, BIOCHEM J, V300, P303, DOI 10.1042/bj3000303; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TORTI M, 1992, P NATL ACAD SCI USA, V89, P7796, DOI 10.1073/pnas.89.16.7796; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VANAELST L, 1994, COLD SPRING HARB SYM, V59, P181, DOI 10.1101/SQB.1994.059.01.022; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WITTINGHOFER A, 1995, FEBS LETT, V369, P52, DOI 10.1016/0014-5793(95)00667-X; YAMASAKI K, 1994, BIOCHEMISTRY-US, V33, P65, DOI 10.1021/bi00167a009; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	57	302	306	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6794	6800		10.1074/jbc.271.12.6794	http://dx.doi.org/10.1074/jbc.271.12.6794			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636102				2022-12-25	WOS:A1996UB15700037
J	Lanza, A; Tornaletti, S; Rodolfo, C; Scanavini, MC; Pedrini, AM				Lanza, A; Tornaletti, S; Rodolfo, C; Scanavini, MC; Pedrini, AM			Human DNA topoisomerase I-mediated cleavages stimulated by ultraviolet light-induced DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SISTER-CHROMATID EXCHANGE; XERODERMA PIGMENTOSUM; MICROCOCCUS-LUTEUS; PYRIMIDINE DIMERS; HUMAN FIBROBLASTS; SIMIAN VIRUS-40; REPAIR; CAMPTOTHECIN; BREAKAGE; MECHANISM	DNA topoisomerases have been proposed as the proteins involved in the formation of the DNA-protein cross-links detected after ultraviolet light (UV) irradiation of cellular DNA. This possibility has been investigated by studying the effects of UV-induced DNA damage on human DNA topoisomerase I action, UV lesions impaired the enzyme's ability to relax negatively supercoiled DNA. Decreased relaxation activity correlated with the stimulation of cleavable complexes, Accumulation of cleavable complexes resulted from blockage of the rejoining step of the cleavage-religation reaction, Mapping of cleavage sites on the pAT153 genome indicated UV-induced cleavage at discrete positions corresponding to sites stimulated also by the topoisomerase I inhibitor camptothecin, except for one, Subsequent analysis at nucleotide level within the sequence encompassing the UV-specific cleavage site revealed the precise positions of sites stimulated by camptothecin with respect to those specific for UV irradiation, Interestingly, one of the UV-stimulated cleavage sites was formed within a sequence that did not contain dimerized pyrimidines, suggesting transmission of the distortion, caused by photodamage to DNA, into the neighboring sequences, These results support the proposal that DNA structural alterations induced by UV lesions can be sufficient stimulus to induce cross-linking of topoisomerase I to cellular DNA.	CNR,IST GENET BIOCHIM & EVOLUZIONIST,I-27100 PAVIA,ITALY	Consiglio Nazionale delle Ricerche (CNR)			Rodolfo, Carlo/H-8953-2019; Lanza, Annalisa/AAJ-3298-2020	Rodolfo, Carlo/0000-0001-7087-545X; Lanza, Annalisa/0000-0003-1422-6994	Telethon [E.0197] Funding Source: Medline	Telethon(Fondazione Telethon)		Andersen A H, 1994, Adv Pharmacol, V29A, P83; ANDERSON RD, 1994, MUTAT RES-FUND MOL M, V309, P109, DOI 10.1016/0027-5107(94)90048-5; BEEN MD, 1984, J MOL BIOL, V180, P515, DOI 10.1016/0022-2836(84)90025-1; BRASH DE, 1988, DNA REPAIR LABORATOR, P327; CAMILLONI G, 1991, BIOCHIM BIOPHYS ACTA, V1129, P73, DOI 10.1016/0167-4781(91)90214-7; CAMILLONI G, 1989, P NATL ACAD SCI USA, V86, P3080, DOI 10.1073/pnas.86.9.3080; CASERTA M, 1994, J CELL BIOCHEM, V55, P93, DOI 10.1002/jcb.240550111; CASERTA M, 1989, NUCLEIC ACIDS RES, V17, P8463, DOI 10.1093/nar/17.21.8463; Champoux J J, 1994, Adv Pharmacol, V29A, P71; CHAMPOUX JJ, 1977, P NATL ACAD SCI USA, V74, P3800, DOI 10.1073/pnas.74.9.3800; CHRISTIANSEN K, 1993, J BIOL CHEM, V268, P9690; CIARROCCHI G, 1982, J MOL BIOL, V155, P177, DOI 10.1016/0022-2836(82)90445-4; CLEAVER JE, 1981, EXP CELL RES, V136, P27, DOI 10.1016/0014-4827(81)90034-3; CLEAVER JE, 1983, J MOL BIOL, V170, P305, DOI 10.1016/S0022-2836(83)80150-8; CODERONI S, 1993, MOL BIOL REP, V17, P129, DOI 10.1007/BF00996220; CORBETT AH, 1991, J BIOL CHEM, V266, P19666; DEGRASSI F, 1989, MUTAT RES, V211, P125, DOI 10.1016/0027-5107(89)90112-7; DILLEHAY LE, 1989, MUTAT RES, V215, P15, DOI 10.1016/0027-5107(89)90213-3; DOWNES CS, 1988, BIOESSAYS, V8, P179, DOI 10.1002/bies.950080602; EDWARDS KA, 1982, NUCLEIC ACIDS RES, V10, P2565, DOI 10.1093/nar/10.8.2565; FORNACE AJ, 1976, BIOCHIM BIOPHYS ACTA, V435, P95, DOI 10.1016/0005-2787(76)90196-9; FORNACE AJ, 1976, P NATL ACAD SCI USA, V73, P39, DOI 10.1073/pnas.73.1.39; GRAFSTROM RH, 1982, J BIOL CHEM, V257, P13465; HASELTINE WA, 1980, NATURE, V285, P634, DOI 10.1038/285634a0; HOLDEN HE, 1989, ENVIRON MOL MUTAGEN, V13, P238, DOI 10.1002/em.2850130308; HSIANG YH, 1988, CANCER RES, V48, P1722; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Ikeda H, 1994, Adv Pharmacol, V29A, P147; ISHII K, 1983, J BIOL CHEM, V258, P2728; KAUFMANN WK, 1989, CARCINOGENESIS, V10, P1, DOI 10.1093/carcin/10.1.1; KROGH S, 1991, NUCLEIC ACIDS RES, V19, P1235, DOI 10.1093/nar/19.6.1235; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LIU LF, 1990, DNA TOPOLOGY ITS BIO, P371; MAXWELL A, 1986, ADV PROTEIN CHEM, V38, P69, DOI 10.1016/S0065-3233(08)60526-4; PEARLMAN DA, 1985, SCIENCE, V227, P1304, DOI 10.1126/science.3975615; PEDRINI AM, 1983, P NATL ACAD SCI-BIOL, V80, P1787, DOI 10.1073/pnas.80.7.1787; PEDRINI AM, 1984, PROTEINS INVOLVED DN, P449; PEDRINI AM, 1986, MECHANISMS DNA DAMAG, P295; PERINI R, 1993, J MOL BIOL, V231, P634, DOI 10.1006/jmbi.1993.1315; Pommier Y, 1994, Adv Pharmacol, V29B, P73; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; RODOLFO C, 1994, NUCLEIC ACIDS RES, V22, P314, DOI 10.1093/nar/22.3.314; ROSENSTEIN BS, 1991, PHOTOBIOLOGY, P27; SAGE E, 1993, PHOTOCHEM PHOTOBIOL, V57, P163, DOI 10.1111/j.1751-1097.1993.tb02273.x; Sambrook J., 2002, MOL CLONING LAB MANU; SHEN CC, 1990, J MOL BIOL, V212, P67, DOI 10.1016/0022-2836(90)90305-6; STEVNSNER T, 1993, CARCINOGENESIS, V14, P1841, DOI 10.1093/carcin/14.9.1841; THIELMANN HW, 1993, CARCINOGENESIS, V14, P2341, DOI 10.1093/carcin/14.11.2341; WANG CI, 1991, P NATL ACAD SCI USA, V88, P9072, DOI 10.1073/pnas.88.20.9072; YEH YC, 1994, J BIOL CHEM, V269, P15498	50	63	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6978	6986		10.1074/jbc.271.12.6978	http://dx.doi.org/10.1074/jbc.271.12.6978			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636127	hybrid			2022-12-25	WOS:A1996UB15700062
J	Powell, W; Reines, D				Powell, W; Reines, D			Mutations in the second largest subunit of RNA polymerase II cause 6-azauracil sensitivity in yeast and increased transcriptional arrest in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION FACTOR-SII; TERMINATION SITES; SACCHAROMYCES-CEREVISIAE; INVITRO TRANSCRIPTION; CALF THYMUS; COMPLEXES; DNA; PURIFICATION; INITIATION; INHIBITION	Yeast RNA polymerase II enzymes containing single amino acid substitutions in the second largest subunit were analyzed in vitro for elongation-related defects. Mutants were chosen for analysis based on their ability to render yeast cells sensitive to growth on medium containing 6-azauracil. RNA polymerase II purified from three different 6-azauracil-sensitive yeast strains displayed increased arrest at well characterized arrest sites in vitro. The extent of this defect did not correlate with sensitivity to growth in the presence of 6-azauracil. The most severe effect resulted from mutation rpb2-10 (P1018S), which occurs in region H, a domain highly conserved between prokaryotic and eukaryotic RNA polymerases that is associated with nucleotide binding. The average elongation rate of this mutant enzyme is also slower than wild type. We suggest that the slowed elongation rate and an increase in dwell time of elongating pol II leads to rpbB-10's arrest-prone phenotype. This mutant enzyme can respond to SII for transcriptional read-through and carry out SII-activated nascent RNA cleavage.	EMORY UNIV,SCH MED,GRAD PROGRAM BIOCHEM & MOLEC BIOL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University; Emory University			excellency, Your/R-2357-2019	excellency, Your/0000-0003-0832-6243; Powell, Wade H./0000-0002-3727-2822	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046331] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM046331, GM46331] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; CHEN Y, 1993, MOL CELL BIOL, V13, P4214, DOI 10.1128/MCB.13.7.4214; CHRISTIE KR, 1994, J BIOL CHEM, V269, P936; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; CONAWAY RC, 1996, IN PRESS METHODS ENZ; COULTER DE, 1985, J BIOL CHEM, V260, P3190; DEDRICK RL, 1985, BIOCHEMISTRY-US, V24, P2245, DOI 10.1021/bi00330a019; DEDRICK RL, 1987, J BIOL CHEM, V262, P9098; DEUSCHLE U, 1990, SCIENCE, V248, P480, DOI 10.1126/science.2158670; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; FLORES O, 1989, J BIOL CHEM, V264, P8913; Gu WG, 1995, J BIOL CHEM, V270, P30441, DOI 10.1074/jbc.270.51.30441; GU WG, 1995, J BIOL CHEM, V270, P11238, DOI 10.1074/jbc.270.19.11238; GU WG, 1993, J BIOL CHEM, V268, P25604; GUO HL, 1993, J BIOL CHEM, V268, P18762; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; IWABE N, 1991, J MOL EVOL, V32, P700; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; JIN DJ, 1991, J BIOL CHEM, V266, P14478; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; Kane C. M., 1994, TRANSCRIPTION MECH R, P279; KUHN A, 1990, NATURE, V344, P559, DOI 10.1038/344559a0; MOTE J, 1994, J MOL BIOL, V236, P725, DOI 10.1006/jmbi.1994.1185; NAKANISHI T, 1992, J BIOL CHEM, V267, P13200; NUDLER E, 1995, JCELL, V81, P351; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; REINES D, 1987, J MOL BIOL, V196, P299, DOI 10.1016/0022-2836(87)90691-7; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; REINES D, 1991, J BIOL CHEM, V266, P10510; REINES D, 1994, TRANSCRIPTION MECHAN, P263; RUDD MD, 1994, P NATL ACAD SCI USA, V91, P8057, DOI 10.1073/pnas.91.17.8057; RUET A, 1978, EUR J BIOCHEM, V90, P325, DOI 10.1111/j.1432-1033.1978.tb12608.x; SAWADOGO M, 1980, J BIOL CHEM, V255, P12; SCAFE C, 1990, MOL CELL BIOL, V10, P1010, DOI 10.1128/MCB.10.3.1010; SCAFE C, 1990, MOL CELL BIOL, V10, P1271; SCHWARTZ LB, 1974, J BIOL CHEM, V249, P5889; SHAABAN SA, 1995, MOL CELL BIOL, V15, P1467; SIDOW A, 1994, CURR BIOL, V4, P596, DOI 10.1016/S0960-9822(00)00131-7; SIVARAMAN L, 1990, J BIOL CHEM, V265, P14554; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; TAN SY, 1995, P NATL ACAD SCI USA, V92, P6042, DOI 10.1073/pnas.92.13.6042; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; TREICH I, 1992, NUCLEIC ACIDS RES, V20, P4721, DOI 10.1093/nar/20.18.4721; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; WIEST DK, 1992, J BIOL CHEM, V267, P7733; WIEST DK, 1990, MOL CELL BIOL, V10, P5782, DOI 10.1128/MCB.10.11.5782	55	87	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6866	6873		10.1074/jbc.271.12.6866	http://dx.doi.org/10.1074/jbc.271.12.6866			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636112	Green Accepted, hybrid			2022-12-25	WOS:A1996UB15700047
J	Yan, K; Kalyanaraman, V; Gautam, N				Yan, K; Kalyanaraman, V; Gautam, N			Differential ability to form the G protein beta gamma complex among members of the beta and gamma subunit families	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; 3RD FORM; CDNA; IDENTIFICATION; TRANSDUCIN; DIVERSITY; SEQUENCE; BINDING; HOMOLOGY	We have determined the relative abilities of several members of the G protein beta and gamma subunit families to associate with each other using the yeast two-hybrid system. We show first that the mammalian beta 1 and gamma 3 fusion proteins form a complex in yeast and that formation of the complex activates the reporter gene for beta-galactosidase. Second, the magnitude of reporter activity stimulated by various combinations of beta and gamma subunit types varies widely. Third, the reporter activity evoked by a particular combination of beta and gamma subunit types is not correlated with the expression levels of these sub-unit types in the yeast cells. Finally, the reporter activity shows a direct relationship with the amount of hybrid py complex formed in the cell as determined by immunoprecipitation, These results suggest that different beta and gamma subunit types interact with each other with widely varying abilities, and this in combination with the level of expression of a subunit type in a mammalian cell determines which G protein will be active in that cell. The strong preference of all gamma subunit types for the beta 1 subunit type explains the preponderence of this subunit type in most G proteins.	WASHINGTON UNIV, SCH MED, DEPT ANESTHESIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)								BECKER DM, 1991, METHOD ENZYMOL, V194, P182; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CERIONE RA, 1987, BIOCHEMISTRY-US, V26, P1485, DOI 10.1021/bi00379a041; CLARK KL, 1993, MOL CELL BIOL, V13, P1; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; FLICK JS, 1990, MOL CELL BIOL, V10, P4757, DOI 10.1128/MCB.10.9.4757; FONG HKW, 1987, P NATL ACAD SCI USA, V84, P3792, DOI 10.1073/pnas.84.11.3792; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; GAO B, 1987, P NATL ACAD SCI USA, V84, P6122, DOI 10.1073/pnas.84.17.6122; GARRITSEN A, 1994, J BIOL CHEM, V269, P24418; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HARPER JW, 1993, CELL, V75, P805; HEKMAN M, 1987, EUR J BIOCHEM, V169, P431, DOI 10.1111/j.1432-1033.1987.tb13630.x; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; JARVIS EE, 1988, MOL CELL BIOL, V8, P309, DOI 10.1128/MCB.8.1.309; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KALYANARAMAN S, 1995, BIOCHEM BIOPH RES CO, V216, P126, DOI 10.1006/bbrc.1995.2600; KATZ A, 1995, P NATL ACAD SCI USA, V92, P1998, DOI 10.1073/pnas.92.6.1998; KISSELEV O, 1995, P NATL ACAD SCI USA, V92, P9102, DOI 10.1073/pnas.92.20.9102; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; LEE RH, 1992, J BIOL CHEM, V267, P24776; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; LI B, 1993, FASEB J, V7, P957, DOI 10.1096/fasebj.7.10.8344494; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OMER CA, 1994, MOL MICROBIOL, V11, P219, DOI 10.1111/j.1365-2958.1994.tb00302.x; PENG YW, 1992, P NATL ACAD SCI USA, V89, P10882, DOI 10.1073/pnas.89.22.10882; PRINTEN JA, 1994, GENETICS, V138, P609; PRONIN AN, 1993, FEBS LETT, V328, P89, DOI 10.1016/0014-5793(93)80971-V; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; PRONIN AN, 1994, METHOD ENZYMOL, V237, P482; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SPRING DJ, 1994, J BIOL CHEM, V269, P22882; SUGIMOTO K, 1985, FEBS LETT, V191, P235, DOI 10.1016/0014-5793(85)80015-6; TAMIR H, 1991, BIOCHEMISTRY-US, V30, P3929, DOI 10.1021/bi00230a018; VONWEIZSACKER E, 1992, BIOCHEM BIOPH RES CO, V183, P350, DOI 10.1016/0006-291X(92)91650-F; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P1936, DOI 10.1073/pnas.82.7.1936	44	81	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7141	7146		10.1074/jbc.271.12.7141	http://dx.doi.org/10.1074/jbc.271.12.7141			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636150				2022-12-25	WOS:A1996UB15700085
J	Choi, JY; Stukey, J; Hwang, SY; Martin, CE				Choi, JY; Stukey, J; Hwang, SY; Martin, CE			Regulatory elements that control transcription activation and unsaturated fatty acid-mediated repression of the Saccharomyces cerevisiae OLE1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; YEAST; DISRUPTION; TRANSFORMATION; DESATURASE; EXPRESSION; DEFICIENT; CLONING; CELLS; RNA	In Saccharomyces cerevisiae, unsaturated fatty acids are formed from saturated acyl-CoA precursors by Ole1p, a Delta-9 fatty acid desaturase, OLE1 mRNA levels are differentially regulated by the addition of saturated or unsaturated fatty acids to the growth medium, One component of this regulation system involves the control of OLE1 transcription, Saturated fatty acids induce a 1.6-fold increase in transcription activity, whereas a large family of unsaturated fatty acids repress OLE1 transcription as much as 60-fold, A deletion analysis of OLE1 promoter::lacZ fusion reporter genes identified a 111-base pair (bp) fatty acid-regulated (FAR) region approximately 580 bp upstream of the start codon that is essential for transcription activation and unsaturated fatty acid repression, Deletion of an 88-bp sequence within that region resulted in a complete loss in transcription activation and unsaturated fatty acid regulation, The 111-bp FAR element strongly activates transcription and confers unsaturated fatty acid regulation on a heterologous CYC1 promoter test plasmid, Essential elements required for unsaturated fatty acid repression of OLE1 were found in the 5' and 3' region of the 111-bp sequence, The FAR element-mediated activation and fatty acid repression of transcription was found to be closely tied to fatty acyl-CoA metabolism, Two fatty acid activation genes, FAA1 and FAA4, were found to be essential for unsaturated fatty acid repression of OLE1 through the FAR sequences, Disruption of either gene results in reduced levels of unsaturated fatty acid repression; disruption of both genes completely blocks the regulatory response, Acyl-CoA binding protein (ACBP) plays a role in determining the level of FAR element activated transcription, Disruption of the ACBP gene causes a >5-fold activation of OLE1 transcription and a similar increase in OLE1 mRNA levels. Unsaturated fatty acid repression of OLE1 transcription, however, is not affected by the disrupted ACBP gene. These studies show that promoter elements responsible for unsaturated fatty acid-mediated transcription repression are tightly linked to OLE1 activation sequences and that OLE1 transcription levels are closely tied to acyl-CoA metabolism.	RUTGERS STATE UNIV, DEPT BIOL SCI, BUR BIOL RES, NELSON BIOL LAB, PISCATAWAY, NJ 08855 USA	Rutgers State University New Brunswick					NIGMS NIH HHS [GM45768] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045768] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTHINGTON BA, 1991, GENE, V102, P39, DOI 10.1016/0378-1119(91)90535-J; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BOSSIE MA, 1989, J BACTERIOL, V171, P6409, DOI 10.1128/jb.171.12.6409-6413.1989; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWSE J, 1986, PLANT PHYSIOL, V81, P859, DOI 10.1104/pp.81.3.859; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P5086, DOI 10.1128/MCB.8.12.5086; CHIRALA SS, 1992, P NATL ACAD SCI USA, V89, P10232, DOI 10.1073/pnas.89.21.10232; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Guarante L., 1992, MOL CELLULAR BIOL YE, P49; Hablacher M, 1993, J BIOL CHEM, V268, P10946; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON DR, 1994, J CELL BIOL, V127, P751, DOI 10.1083/jcb.127.3.751; KAMIRYO T, 1976, P NATL ACAD SCI USA, V73, P386, DOI 10.1073/pnas.73.2.386; KNOLL LJ, 1995, J BIOL CHEM, V270, P10861, DOI 10.1074/jbc.270.18.10861; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; Maniatis T, 1989, MOL CLONING; MCDONOUGH VM, 1992, J BIOL CHEM, V267, P5931; Miller JH., 1972, EXPT MOL GENETICS; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; Numa S, 1984, FATTY ACID METABOLIS, P1; ROSENDAL J, 1993, BIOCHEM J, V290, P321, DOI 10.1042/bj2900321; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHNEIDER JC, 1991, MOL CELL BIOL, V11, P4934, DOI 10.1128/MCB.11.10.4934; SCHULLER HJ, 1994, EUR J BIOCHEM, V225, P213, DOI 10.1111/j.1432-1033.1994.00213.x; SMITH SJ, 1993, YEAST, V9, P1177, DOI 10.1002/yea.320091104; STRUHL K, 1986, BIOTECHNOLOGY, V9, P35; TURI TG, 1992, J BIOL CHEM, V267, P2046	30	123	133	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3581	3589						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631965				2022-12-25	WOS:A1996TV72400039
J	Cotto, JJ; Kline, M; Morimoto, RI				Cotto, JJ; Kline, M; Morimoto, RI			Activation of heat shock factor 1 DNA binding precedes stress-induced serine phosphorylation - Evidence for a multistep pathway of regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; GENE-TRANSCRIPTION; MOLECULAR-CLONING; COILED-COIL; HELA-CELLS; YEAST; OLIGOMERIZATION; EXPRESSION; PROMOTER; PROTEIN	Exposure of mammalian cells in culture to the antiinflammatory drugs sodium salicylate or indomethacin results in activation of heat shock factor 1 (HSF1) DNA binding activity. We have previously shown that the drug-induced HSF1 becomes associated with the heat shock elements of the hsp70 promoter, yet transcription of the hsp70 gene is not induced (Jurivich, D. A., Sistonen, L., Kroes, R. A., and Morimoto, R. I. (1992) Science 255, 1243-1245). In this study, we have examined the basis for uncoupling the heat shock transcriptional response. Comparison of heat shock and drug-induced forms of HSF1 has revealed that the transcriptionally inert drug-induced HSF1 is constitutively but not inducibly serine-phosphorylated, whereas heat shock-induced HSF1 is both constitutively and inducibly serine-phosphorylated. The transcriptionally inert intermediate represented by drug-induced HSF1 can be converted to the transcriptionally active state by a subsequent exposure to heat shock. The only detectable change in HSF1 is the acquisition of inducible serine phosphorylation. These data reveal that acquisition of the trimeric DNA binding state of HSF1 is independent of and precedes inducible phosphorylation and furthermore that inducible phosphorylation correlates with transcriptional activation.	NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELL BIOL, EVANSTON, IL 60208 USA	Northwestern University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038109, R01GM038109] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38109] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAVAYA K, 1991, GENE DEV, V5, P2117, DOI 10.1101/gad.5.11.2117; AMICI C, 1995, CANCER RES, V55, P4452; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; GIARDINA C, 1995, J BIOL CHEM, V270, P10369, DOI 10.1074/jbc.270.18.10369; GIARDINA C, 1995, MOL CELL BIOL, V15, P2737; GOLDENBERG CJ, 1988, J BIOL CHEM, V263, P19734; GREEN M, 1995, MOL CELL BIOL, V15, P3354; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HOJ A, 1994, EMBO J, V13, P2617; Jurivich D.A., 1994, BIOL HEAT SHOCK PROT, P417; JURIVICH DA, 1994, P NATL ACAD SCI USA, V91, P2280, DOI 10.1073/pnas.91.6.2280; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; KINGSTON RE, 1987, MOL CELL BIOL, V7, P1530, DOI 10.1128/MCB.7.4.1530; KROEGER PE, 1994, MOL CELL BIOL, V14, P7592, DOI 10.1128/MCB.14.11.7592; KROPP E, 1994, SCIENCE, V265, P956; LEE BS, 1995, P NATL ACAD SCI USA, V92, P7207, DOI 10.1073/pnas.92.16.7207; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; MEZGER V, 1994, DEV BIOL, V166, P819, DOI 10.1006/dbio.1994.1361; MORIMOTO R I, 1990, P1; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; MURPHY SP, 1994, MOL CELL BIOL, V14, P5309, DOI 10.1128/MCB.14.8.5309; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; NIETOSOTELO J, 1990, CELL, V62, P807, DOI 10.1016/0092-8674(90)90124-W; PELHAM HRB, 1982, CELL, V30, P517, DOI 10.1016/0092-8674(82)90249-5; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SARGE KD, 1994, BIOL REPROD, V50, P1334, DOI 10.1095/biolreprod50.6.1334; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHARF KD, 1990, EMBO J, V9, P4495, DOI 10.1002/j.1460-2075.1990.tb07900.x; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SHI YH, 1995, MOL CELL BIOL, V15, P4309; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; SISTONEN L, 1992, MOL CELL BIOL, V12, P4104, DOI 10.1128/MCB.12.9.4104; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; WEISSMANN G, 1991, SCI AM, V264, P84, DOI 10.1038/scientificamerican0191-84; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; ZIMARINO V, 1990, MOL CELL BIOL, V10, P752, DOI 10.1128/MCB.10.2.752; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557	49	245	251	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3355	3358						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631933				2022-12-25	WOS:A1996TV72400007
J	Toma, L; Pinhal, MAS; Dietrich, CP; Nader, HB; Hirschberg, CB				Toma, L; Pinhal, MAS; Dietrich, CP; Nader, HB; Hirschberg, CB			Transport of UDP-galactose into the Golgi lumen regulates the biosynthesis of proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL MUTANT DEFICIENT; HEPARAN-SULFATE; CHONDROITIN SULFATE; ENDOPLASMIC-RETICULUM; BASEMENT-MEMBRANE; KERATAN SULFATES; PURIFICATION; APPARATUS; OLIGOSACCHARIDES; RECONSTITUTION	The lumen of the Golgi apparatus is the subcellular site where galactose is transferred, from UDP-galactose, to the oligosaccharide chains of glycoproteins, glycolipids, and proteoglycans. The nucleotide sugar, which is synthesized in the cytosol, must first be transported into the Golgi lumen by a specific UDP-galactose transporter, Previously, a mutant polarized epithelial cell (MDCKII-RCA(r)) with a 2% residual rate of transport of UDP-galactose into the lumen of Golgi vesicles was described (Brandli, A. W., Hansson, G. C., Rodriquez-Boulan, E., and Simons, K. (1988) J. Biol. Chem. 263, 16283-16290). The mutant has an enrichment in glucosyl ceramide and cell surface glycoconjugates bearing terminal N-acetylglucosamine, as well as a 75% reduction in sialylation of cell surface glycoproteins and glycosphingolipids. We have now studied the biosynthesis of galactose containing proteoglycans in this mutant and the corresponding parental cell line. Wild-type Madin-Darby canine kidney cells synthesize significant amounts of chondroitin sulfate, heparan sulfate, and keratan sulfate, while the above mutant synthesizes chondroitin sulfate and heparan sulfate but not keratan sulfate, the only proteoglycan containing galactose in its glycosaminoglycan polymer, The mutant also synthesizes chondroitin 6-sulfate rather than only chondroitin 4-sulfate as wild-type cells. Together, the above results demonstrate that the Golgi membrane UDP-galactose transporter is rate-limiting in the supply of UDP-galactose into the Golgi lumen; this in turn results in selective galactosylation of macromolecules. Apparently, the K-m for galactosyltransferases involved in the synthesis of Linkage regions of heparan sulfate and chondroitin sulfate are significantly lower than those participating in the synthesis of keratan sulfate polymer, glycoproteins, and glycolipids. The results also suggest that the 6-O-sulfotransferases, in the absence of their natural substrates (keratan sulfate) may catalyze the sulfation of chondroitin 4-sulfate as alternative substrate.	UNIV MASSACHUSETTS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01655; UNIFESP,ESCOLA PAULISTA MED,SAO PAULO,BRAZIL	University of Massachusetts System; University of Massachusetts Worcester; Universidade Federal de Sao Paulo (UNIFESP)			Nader, Helena Bonciani/D-9253-2012; Pinhal, Maria Aparecida Silva/J-1797-2012	Pinhal, Maria Aparecida Silva/0000-0003-4001-1663; NADER, HELENA/0000-0002-7569-2166; Hirschberg, Carlos/0000-0003-2299-7721	NIGMS NIH HHS [GM 34396] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRANDLI AW, 1988, J BIOL CHEM, V263, P16283; BRILES EB, 1977, J BIOL CHEM, V252, P1107; BRILES EB, 1981, BIOCHEM BIOPH RES CO, V103, P38, DOI 10.1016/0006-291X(81)91657-0; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DIETRICH CP, 1977, BIOCHEM BIOPH RES CO, V75, P329, DOI 10.1016/0006-291X(77)91046-4; DIETRICH CP, 1983, BIOCHEM BIOPH RES CO, V111, P865, DOI 10.1016/0006-291X(83)91379-7; FRANSSON LA, 1985, J BIOL CHEM, V260, P4722; GOWDA DC, 1986, J BIOL CHEM, V261, P4926; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; HORTON DSPQ, 1986, EUR J BIOCHEM, V161, P139, DOI 10.1111/j.1432-1033.1986.tb10134.x; KANWAR YS, 1980, J CELL BIOL, V86, P688, DOI 10.1083/jcb.86.2.688; KLEINMAN HK, 1983, BIOCHEMISTRY-US, V22, P4969, DOI 10.1021/bi00290a014; KRAMER PM, 1971, BIOCHEMISTRY-US, V10, P1437; LEBARON RG, 1989, J BIOL CHEM, V264, P7950; MCGARRITY GJ, 1982, EXP CELL RES, V139, P199, DOI 10.1016/0014-4827(82)90333-0; MEYER K, 1970, CHEM MOL BIOL INTERC, V1, P15; MICHELACCI YM, 1986, INT J BIOL MACROMOL, V8, P108, DOI 10.1016/0141-8130(86)90008-5; MILLA ME, 1992, J BIOL CHEM, V267, P103; NADER HB, 1984, J BIOL CHEM, V259, P1431; NADER HB, 1990, J BIOL CHEM, V265, P16807; NADER HB, 1989, J CELL PHYSIOL, V140, P305, DOI 10.1002/jcp.1041400216; NAKAZAWA K, 1975, J BIOL CHEM, V250, P912; Nakazawa K., 1989, KERATAN SULPHATE CHE, P99; NUWAYHID N, 1986, J BIOL CHEM, V261, P2936; OBRINK B, 1975, CONNECT TISSUE RES, V3, P187, DOI 10.3109/03008207509152178; OEGEMA TR, 1984, J BIOL CHEM, V259, P1720; SENO N, 1965, J BIOL CHEM, V240, P1005; STNALEY P, 1980, ACS SYM SER, V28, P214; TAI GH, 1993, BIOCHEM J, V291, P889, DOI 10.1042/bj2910889; TODA N, 1970, BIOCHIM BIOPHYS ACTA, V208, P227, DOI 10.1016/0304-4165(70)90241-2	31	80	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3897	3901						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632010				2022-12-25	WOS:A1996TV72400084
J	Michieli, P; Li, WQ; Lorenzi, MV; Miki, T; Zakut, R; Givol, D; Pierce, JH				Michieli, P; Li, WQ; Lorenzi, MV; Miki, T; Zakut, R; Givol, D; Pierce, JH			Inhibition of oncogene-mediated transformation by ectopic expression of p21(Waf1) in NIH3T3 cells	ONCOGENE			English	Article						cellular transformation; oncogenes; tumor suppressor genes; p53 effectors; cyclin-dependent kinase inhibitors	PROTEIN; FIBROBLASTS; RAS; P21; DIFFERENTIATION; LOCALIZATION; KINASES; P53	The p53-regulated p21(Waf1) protein is a universal inhibitor of cyclin-dependent kinases (CDKs). To study the potential tumor-suppressive properties of CDK inhibitors, the ability of p21(Waf1) to interfere with oncogene-mediated cellular transformation was analysed in the NIH3T3 cell system. Cotransfection of waf1 together with activated ras or several other oncogenes into NIH3T3 cells potently inhibited the formation of transformed foci in a dose-dependent manner, Expression of the CDK-binding N-terminal half of p21(Waf1) (N-p21(Waf1)) was necessary and sufficient to inhibit Ras-induced focus formation. In contrast, expression of the C-terminal domain (C-p21(Waf1)) had no effect on Ras-induced focus formation. Immunofluorescence analysis revealed that ectopically expressed p21(Waf1) and C-p21(Waf1) were localized in the nucleus, while N-p21(Waf1) was found in the cytoplasm, with the tendency to accumulate around the nuclear membrane. Surprisingly, stable NIH3T3 transfectants expressing ectopic p21(Waf1) grew at the same rate and displayed similar cell cycle distribution as NIH3T3 cells transfected with the same vector containing no insert. However ectopic p21(Waf1) expression did inhibit Ras-mediated anchorage-independent colony formation, indicating that p21(Waf1) can selectively interfere with oncogene-mediated transformation without affecting NIH3T3 cell growth, at least at the levels of p21(Waf1) expression experiments. Transient NIH3T3 cells inhibited Ras-indnced transcription from a E2F-responsive element but not from a serum-responsive element, indicating that p21(Waf1) acts downstream of early transcriptional events induced by Ras but upstream of E2F-controlled gene transcription. These results provide evidence that p21(Waf1) potently suppresses oncogene-mediated cellular transformation of NIH3T3 cells and that it may do so by inhibiting E2F-driven transcription of S phase genes.	WEIZMANN INST SCI,DEPT MOLEC CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science	Michieli, P (corresponding author), NCI,CELLULAR & MOLEC BIOL LAB,NIH,BLDG 37,BETHESDA,MD 20892, USA.		Michieli, Paolo/A-2588-2011	Michieli, Paolo/0000-0002-3093-8871				ATADJA PW, 1994, MOL CELL BIOL, V14, P4991, DOI 10.1128/MCB.14.7.4991; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BLAM SB, 1988, ONCOGENE, V3, P129; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHEDID M, 1994, ONCOGENE, V9, P3021; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CUADRADO A, 1993, ONCOGENE, V8, P2443; CURRAN T, 1984, CELL, V36, P259; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; GRANA X, 1995, ONCOGENE, V11, P211; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; JIANG HP, 1994, ONCOGENE, V9, P3397; LACAL JC, 1986, P NATL ACAD SCI USA, V83, P5400, DOI 10.1073/pnas.83.15.5400; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; LATHANGUE NB, 1990, NUCLEIC ACIDS RES, V18, P2929, DOI 10.1093/nar/18.10.2929; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; MICHIELI P, 1994, CANCER RES, V54, P3391; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; NEVINS JR, 1992, SCIENCE, V258, P424; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAKUT R, 1995, ONCOGENE, V11, P393; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	49	39	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					775	784						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632899				2022-12-25	WOS:A1996TW68600008
J	Chen, JCR; Zhang, JP; Stephens, RS				Chen, JCR; Zhang, JP; Stephens, RS			Structural requirements of heparin binding to Chlamydia trachomatis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; SULFATE PROTEOGLYCANS; HUMAN CYTOMEGALOVIRUS; HOST-CELLS; SURFACE; INFECTION; ADHESION; SEQUENCE	Heparin is a functional and structural analog of the Chlamydia trachomatis heparan sulfate-like attachment ligand that mediates infectivity by bridging chlamydiae to eukaryotic cells. The binding of heparin to the Chlamydia organism's surface was characterized by a direct binding assay, Although for two C. trachomatis biovars the binding by heparin was saturable, trachoma biovar organisms bound twice the amount of heparin than lymphogranuloma venereum biovar organisms. To probe the structural nature of the heparan sulfate-like ligand interactions, a range of heparin-derived oligosaccharides and sulfation-modified species of heparin were compared for their ability to compete with [H-3]heparin for binding to chlamydial organisms and for inhibition of chlamydial attachment and infection of eukaryotic host cells. The assays revealed that a decasaccharide was the minimal chain length required to effectively bind C. trachomatis organisms, compete with the host cell receptor and rescue infectivity. In addition, a moderately sulfated adhesin analog, N-desulfated, N-acetylated heparin, was able to compete with chlamydial organisms for host cell receptors, whereas this derivative could not compete with [H-3]heparin for binding to chlamydial organisms. These results indicate that the specificity of the eukaryotic cell receptor and the chlamydial surface acceptor differ in their fine-structure requirements of ligand binding, and that the size and sulfation density of the heparan sulfate-like Ligand each contribute to its ability to bind and bridge chlamydiae to eukaryotic cells.	UNIV CALIF BERKELEY, PROGRAM INFECT DIS, BERKELEY, CA 94720 USA; UNIV SAN FRANCISCO, DEPT LAB MED, SAN FRANCISCO, CA 94143 USA; UNIV SAN FRANCISCO, FRANCIS I PROCTOR FDN, SAN FRANCISCO, CA 94143 USA	University of California System; University of California Berkeley; University of San Francisco; University of San Francisco					NATIONAL EYE INSTITUTE [R01EY007757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032943] Funding Source: NIH RePORTER; NEI NIH HHS [EY07757] Funding Source: Medline; NIAID NIH HHS [AI32943] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAE JH, 1994, BIOCHEM J, V301, P121, DOI 10.1042/bj3010121; CARDIN AD, 1991, METHOD ENZYMOL, V203, P556; CHEN JCR, 1994, MOL MICROBIOL, V11, P501, DOI 10.1111/j.1365-2958.1994.tb00331.x; COMPTON T, 1993, VIROLOGY, V193, P834, DOI 10.1006/viro.1993.1192; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287; HOOK M, 1984, ANNU REV BIOCHEM, V53, P847; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOEHLER JE, 1990, J BIOL CHEM, V265, P13206; KOLIAKOS GG, 1989, J BIOL CHEM, V264, P2313; KUO CC, 1976, INFECT IMMUN, V13, P1103, DOI 10.1128/IAI.13.4.1103-1109.1976; LINDAHL U, 1991, THROMB HAEMOSTASIS, V66, P44; LOVE DC, 1993, J CELL BIOL, V123, P759, DOI 10.1083/jcb.123.3.759; LYCKE E, 1991, J GEN VIROL, V72, P1131, DOI 10.1099/0022-1317-72-5-1131; MENOZZI FD, 1991, FEMS MICROBIOL LETT, V78, P59; MOULDER JW, 1991, MICROBIOL REV, V55, P143, DOI 10.1128/MMBR.55.1.143-190.1991; MUKHOPADHYAY NK, 1989, BIOCHEM J, V264, P517, DOI 10.1042/bj2640517; NEYTS J, 1992, VIROLOGY, V189, P48, DOI 10.1016/0042-6822(92)90680-N; ORTEGABARRIA E, 1991, CELL, V67, P411, DOI 10.1016/0092-8674(91)90192-2; OSCARSSON LG, 1989, J BIOL CHEM, V264, P296; PATEL M, 1993, AIDS RES HUM RETROV, V9, P167, DOI 10.1089/aid.1993.9.167; SCHACHTER J, 1990, WESTERN J MED, V153, P523; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; SODERLUND G, 1982, INFECT IMMUN, V36, P893; VARELAS JB, 1991, ANAL BIOCHEM, V197, P396, DOI 10.1016/0003-2697(91)90410-U; ZHANG JP, 1992, CELL, V69, P861, DOI 10.1016/0092-8674(92)90296-O; ZHU ZL, 1995, P NATL ACAD SCI USA, V92, P3546, DOI 10.1073/pnas.92.8.3546	28	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11134	11140		10.1074/jbc.271.19.11134	http://dx.doi.org/10.1074/jbc.271.19.11134			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626658	hybrid			2022-12-25	WOS:A1996UJ94400018
J	Dietrich, J; Hou, XH; Wegener, AMK; Pedersen, LO; Odum, N; Geisler, C				Dietrich, J; Hou, XH; Wegener, AMK; Pedersen, LO; Odum, N; Geisler, C			Molecular characterization of the di-leucine-based internalization motif of the T cell receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN LYMPHOCYTES-T; FACTOR-II RECEPTOR; ANTIGEN RECEPTOR; PHOSPHOLIPASE C-GAMMA-1; SUBSTRATE-SPECIFICITY; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; CYTOPLASMIC TAIL; SYNTHETIC PEPTIDES	Several cell surface receptors including the T cell receptor (TCR) are phosphorylated and down-regulated following activation of protein kinases. We have recently shown that both phosphorylation of Ser-126 and the presence of the di-leucine sequence Leu-131 and Leu-132 in CD3 gamma are required for protein kinase C (PKC)-mediated TCR down-regulation. To identify additional residues required for PKC-mediated phosphorylation of CD3 gamma and for TCR down-regulation, an alanine scanning of CD3 gamma was done. Mutations of Arg-124, Ser-126, Lys-128, and Gln-129 inhibited both phosphorylation and TCR down-regulation, whereas mutation of Asp-127 only inhibited down-regulation. Further analyses demonstrated a discrepancy between the ability to be phosphorylated on CD3 gamma and to down-regulate the TCR in several transfectants. Phosphorylation was not as strictly dependent on the nature and position of the phosphoacceptor group and basic residues as were the subsequent steps involved in TCR down-regulation. Our results suggest that PKC-mediated TCR down-regulation may be regarded as a two-step process. 1) Recognition and phosphorylation of CD3 gamma by PKC. In this process Arg-124, Ser-126, Lys-128, and Gln-129 are important. 2) Recognition of phosphorylated CD3 gamma by molecules involved in receptor internalization. In this process Ser(P)-126, Asp-127, Leu-131, and Leu-132 are important.	UNIV COPENHAGEN, PANUM INST, INST MED MICROBIOL & IMMUNOL, DK-2200 COPENHAGEN, DENMARK	University of Copenhagen			Geisler, Carsten/A-7056-2012	Geisler, Carsten/0000-0002-8472-0771				ABRAHAM RT, 1992, TRENDS BIOCHEM SCI, V17, P434, DOI 10.1016/0968-0004(92)90015-2; AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; ALEXANDER DR, 1992, BIOCHEM J, V288, P69, DOI 10.1042/bj2880069; ANDO I, 1985, EUR J IMMUNOL, V15, P196, DOI 10.1002/eji.1830150217; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BOYER C, 1991, EUR J IMMUNOL, V21, P1623, DOI 10.1002/eji.1830210707; BREMNES B, 1994, J CELL SCI, V107, P2021; CANTRELL D, 1987, NATURE, V325, P540, DOI 10.1038/325540a0; CANTRELL DA, 1989, J IMMUNOL, V142, P1626; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; DAVIES AA, 1987, J BIOL CHEM, V262, P10918; DEMBIC Z, 1986, NATURE, V320, P232, DOI 10.1038/320232a0; Dietrich J, 1996, J CELL BIOL, V132, P299, DOI 10.1083/jcb.132.3.299; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; FERRARI S, 1985, FEBS LETT, V184, P72, DOI 10.1016/0014-5793(85)80656-6; FINKENZELLER G, 1990, NUCLEIC ACIDS RES, V18, P2183, DOI 10.1093/nar/18.8.2183; GEISLER C, 1992, J IMMUNOL, V148, P2437; GEISLER C, 1988, SCAND J IMMUNOL, V27, P685, DOI 10.1111/j.1365-3083.1988.tb02402.x; GEISLER C, 1992, J IMMUNOL, V148, P3469; GRAFF JM, 1991, J BIOL CHEM, V266, P14390; HOU XH, 1994, EUR J IMMUNOL, V24, P1228, DOI 10.1002/eji.1830240534; HOUSE C, 1987, J BIOL CHEM, V262, P772; HSIEH JC, 1993, J BIOL CHEM, V268, P15118; IMBODEN JB, 1985, J EXP MED, V161, P446, DOI 10.1084/jem.161.3.446; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KEMP BE, 1994, TRENDS BIOCHEM SCI, V19, P440, DOI 10.1016/0968-0004(94)90126-0; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KONING F, 1990, EUR J IMMUNOL, V20, P299, DOI 10.1002/eji.1830200211; KRANGEL MS, 1987, J EXP MED, V165, P1141, DOI 10.1084/jem.165.4.1141; KRISSANSEN GW, 1986, EMBO J, V5, P1799, DOI 10.1002/j.1460-2075.1986.tb04429.x; KUBO K, 1987, FEBS LETT, V223, P138, DOI 10.1016/0014-5793(87)80524-0; KUHLMANN J, 1993, SCAND J IMMUNOL, V37, P271, DOI 10.1111/j.1365-3083.1993.tb01766.x; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; MALISSEN B, 1993, CURR OPIN IMMUNOL, V5, P324, DOI 10.1016/0952-7915(93)90049-X; MANOLIOS N, 1991, EMBO J, V10, P1643, DOI 10.1002/j.1460-2075.1991.tb07687.x; MARAIS RM, 1990, FEBS LETT, V277, P151, DOI 10.1016/0014-5793(90)80831-3; MINAMI Y, 1987, J BIOL CHEM, V262, P13342; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OBRIAN CA, 1984, BIOCHEM BIOPH RES CO, V124, P296, DOI 10.1016/0006-291X(84)90951-3; ORR JW, 1994, J BIOL CHEM, V269, P8383; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PIETERS J, 1993, J CELL SCI, V106, P831; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; REINHERZ EL, 1982, CELL, V30, P735, DOI 10.1016/0092-8674(82)90278-1; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SHIN JY, 1991, J BIOL CHEM, V266, P10658; TELERMAN A, 1987, EUR J IMMUNOL, V17, P991, DOI 10.1002/eji.1830170715; TURNER RS, 1985, J BIOL CHEM, V260, P1503; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; VEGA MA, 1991, J BIOL CHEM, V266, P16269; WEGENER AMK, 1995, J BIOL CHEM, V270, P4675, DOI 10.1074/jbc.270.9.4675; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; ZANDERS ED, 1983, NATURE, V303, P625, DOI 10.1038/303625a0	64	55	55	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11441	11448		10.1074/jbc.271.19.11441	http://dx.doi.org/10.1074/jbc.271.19.11441			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626701	hybrid			2022-12-25	WOS:A1996UJ94400061
J	Pfefferkorn, LC; Swink, SL				Pfefferkorn, LC; Swink, SL			Intracluster restriction of Fc receptor gamma-chain tyrosine phosphorylation subverted by a protein-tyrosine phosphatase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADPH OXIDASE ACTIVITY; TRANSIENT ACTIVATION; RAT ADIPOCYTES; VANADATE; CELLS; H2O2; DEPHOSPHORYLATION; BINDING; KINASE; RI	This study shows that aggregation of U937 cell high affinity IgG Fc receptor (Fc gamma RI) results in the transient tyrosine phosphorylation of Fc gamma RI gamma-chain but not the phosphorylation of gamma-chains associated with nonaggregated IgA Fc receptors (Fc alpha R) on the same cells. Thus, normally, tyrosine phosphorylation of gamma-chains is limited to FcR in aggregates, In contrast, aggregation of Fc gamma RI in the presence of vanadate induced the sustained tyrosine phosphorylation of Fc gamma RI gamma-chains and the rapid and extensive phosphorylation of nonaggregated Fc alpha R gamma-chains and low affinity IgG Fc receptors (Fc gamma RII). This global phosphorylation of motifs on nonaggregated FcR was also detected upon aggregation of Fc alpha R or Fc gamma RII, which induced the phosphorylation of nonaggregated Fc gamma RI gamma-chains. Vanadate prevented dephosphorylation of proteins and increased kinase activity in stimulated cells, Evidence failed to support alternative explanations such as acquisition of phospho-gamma through subunit exchange or a coalescence of nonaggregated with aggregated FcR, It is likely, therefore, that activated kinases interacted with nonaggregated FcR in stimulated cells. Pervanadate induced the tyrosine phosphorylation of gamma-chains in the absence of FcR crosslinking, indicating that the kinases could be activated by phosphatase inhibition and could react with nonaggregated substrates. We conclude that under normal conditions there is a vanadate-sensitive mechanism that prevents tyrosine phosphorylation of nonaggregated FcR gamma-chain motifs in activated cells, restricting their phosphorylation to aggregates.			Pfefferkorn, LC (corresponding author), DARTMOUTH COLL SCH MED, DEPT MICROBIOL BORWELL, HANOVER, NH 03756 USA.				NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI029455] Funding Source: NIH RePORTER; NCI NIH HHS [CA23108] Funding Source: Medline; NIAID NIH HHS [AI29455] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		DUCHEMIN AM, 1994, J BIOL CHEM, V269, P12111; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; GORTER A, 1987, IMMUNOLOGY, V61, P303; GUYRE PM, 1983, J CLIN INVEST, V72, P393, DOI 10.1172/JCI110980; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HUANG MM, 1992, J BIOL CHEM, V267, P5467; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KADOTA S, 1987, J BIOL CHEM, V262, P8252; KENT UM, 1994, P NATL ACAD SCI USA, V91, P3087, DOI 10.1073/pnas.91.8.3087; METZGER H, 1992, J IMMUNOL, V149, P1477; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; PAOLINI R, 1992, P NATL ACAD SCI USA, V89, P10733, DOI 10.1073/pnas.89.22.10733; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PFEFFERKORN LC, 1994, J IMMUNOL, V153, P3228; PFEFFERKORN LC, 1990, MOL IMMUNOL, V27, P263, DOI 10.1016/0161-5890(90)90139-Q; PFEFFERKORN LC, 1989, J BIOL CHEM, V264, P14112; PFEFFERKORN LC, 1989, J IMMUNOL, V143, P2640; PFEFFERKORN LC, 1995, J BIOL CHEM, V270, P8164, DOI 10.1074/jbc.270.14.8164; PFEFFERKORN LC, 1995, 9 INT C IMM SAN FRAN, pA68; PRIBLUDA VS, 1992, P NATL ACAD SCI USA, V89, P11446, DOI 10.1073/pnas.89.23.11446; PRIBLUDA VS, 1994, P NATL ACAD SCI USA, V91, P11246, DOI 10.1073/pnas.91.23.11246; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SHEN L, 1989, J IMMUNOL, V143, P4117; SWIETER M, 1995, J IMMUNOL, V155, P5330; VANDEWINKEL JGJ, 1993, IMMUNOL TODAY, V14, P215, DOI 10.1016/0167-5699(93)90166-I; VANDEWINKEL JGJ, 1991, J LEUKOCYTE BIOL, V49, P511, DOI 10.1002/jlb.49.5.511; WANG AVT, 1994, J EXP MED, V180, P1165, DOI 10.1084/jem.180.3.1165; WOFSY C, 1995, J BIOL CHEM, V270, P20264, DOI 10.1074/jbc.270.35.20264; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZICK Y, 1990, BIOCHEMISTRY-US, V29, P10240, DOI 10.1021/bi00496a013	34	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11099	11105		10.1074/jbc.271.19.11099	http://dx.doi.org/10.1074/jbc.271.19.11099			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626653	hybrid			2022-12-25	WOS:A1996UJ94400013
J	Xie, Z; Price, DH				Xie, Z; Price, DH			Purification of an RNA polymerase II transcript release factor from Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION COMPLEXES; TERMINATION FACTOR; HUMAN MITOCHONDRIA; GENE-EXPRESSION; PROTEIN; INVITRO; RHO	Factor 2 was previously identified in Drosophila K-c cell nuclear extract (KcN) as an activity suppressing the appearance of long transcripts (Price, D. H., Sluder, A. E., and Greenleaf, A. L. (1987) J. Biol. Chem. 262, 3244-3255). A 154-kDa protein with factor 2 activity was purified to apparent homogeneity from KcN. An immobilized template assay indicated that factor 2 caused the release of transcripts by RNA polymerase II in an ATP-dependent manner. Some early elongation complexes were resistant to factor 2 action but became sensitive after treatment with 1 M KCl. In the absence of factor 2, transcription complexes still exhibited a low degree of processivity suggesting that factor 2 was only partially responsible for abortive elongation.			Xie, Z (corresponding author), UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242, USA.		Price, David H/F-6173-2010	Price, David/0000-0002-5597-385X	NIGMS NIH HHS [R01-GM35500] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTSCH I, 1988, MOL CELL BIOL, V8, P3891, DOI 10.1128/MCB.8.9.3891; COPPOLA JA, 1983, P NATL ACAD SCI-BIOL, V80, P1251, DOI 10.1073/pnas.80.5.1251; DAGA A, 1993, J BIOL CHEM, V268, P8123; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; HAGLER J, 1994, J BIOL CHEM, V269, P10050; KEPHART DD, 1992, MOL CELL BIOL, V12, P2067, DOI 10.1128/MCB.12.5.2067; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KRUSE B, 1989, CELL, V58, P391, DOI 10.1016/0092-8674(89)90853-2; KUHN A, 1990, NATURE, V344, P559, DOI 10.1038/344559a0; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; PLATT T, 1986, ANNU REV BIOCHEM, V55, P339, DOI 10.1146/annurev.bi.55.070186.002011; PRICE DH, 1987, J BIOL CHEM, V262, P3244; RICHARDSON JP, 1980, BIOCHEMISTRY-US, V19, P4293, DOI 10.1021/bi00559a022; RICHARDSON JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P127, DOI 10.1016/0167-4781(90)90048-7; SELBY CP, 1995, J BIOL CHEM, V270, P4890, DOI 10.1074/jbc.270.9.4890; SELBY CP, 1995, J BIOL CHEM, V270, P4882, DOI 10.1074/jbc.270.9.4882; SLUDER AE, 1988, J BIOL CHEM, V263, P9917; SPENCER CA, 1990, ONCOGENE, V5, P777; WRIGHT S, 1993, MOL BIOL CELL, V4, P661, DOI 10.1091/mbc.4.7.661; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241	21	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11043	11046		10.1074/jbc.271.19.11043	http://dx.doi.org/10.1074/jbc.271.19.11043			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626643	hybrid			2022-12-25	WOS:A1996UJ94400003
J	Benbow, U; Buttice, G; Nagase, H; Kurkinen, M				Benbow, U; Buttice, G; Nagase, H; Kurkinen, M			Characterization of the 46-kDa intermediates of matrix metalloproteinase 3 (stromelysin 1) obtained by site-directed mutation of phenylalanine 83	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHEUMATOID SYNOVIAL FIBROBLASTS; TISSUE INHIBITOR; CYSTEINE SWITCH; ACTIVATION; COLLAGENASE; MECHANISMS; PROCOLLAGENASE; PURIFICATION; EXPRESSION; PRECURSOR	The precursor of matrix metalloproteinase 3 (MMP-3/stromelysin 1) is activated in vitro by proteinases or mercurial compounds by stepwise processes which include the initial formation of short-lived intermediates and the subsequent intermolecular cleavage of the His(82)-Phe(83) bond to generate the fully activated mature MMP-3 (Nagase, H., Enghild, J. J., Suzuki, K., and Salvesen, G. (1990) Biochemistry 29, 5783-5789), To study the enzymatic properties of the intermediates we have mutated either His(82) or Phe(83) to Arg to obtain a stable MMP-3 intermediate, The mutant proteins were expressed in Chinese hamster ovary K-1 cells using a mammalian expression system. The proMMP-3(H82R) mutant was activated by chymotrypsin, elastase, and 4-aminophenylmercuric acetate to the 45-kDa MMP-3 with similar mechanism and kinetics as the wild-type. In contrast, the activation of the proMMP-3(F83R) mutant by proteinases or 4-aminophenylmercuric acetate resulted in 46-kDa forms, which retained 13, 14, or 15 amino acids of the pro-domain depending on the activators, The proteinase-activated MMP-3(F83R) intermediates exhibited little enzymatic activity, but they were partially active after treatment with SH-reacting reagents. These molecules could bind to the tissue inhibitor of metalloproteinases-1 and alpha(2)-macroglobulin. However, the SH group of Cys(75) of the intermediates was not modified by SH-reagents, indicating that the enzymatic activity generated by SH-reagents resulted from molecular perturbation of the enzyme rather than their interaction with Cys(75). When gelatin and transferrin were digested with the 46-kDa intermediates the products were different from those generated by the wild-type MMP-3, suggesting an alteration in substrate specificity, The treatment of proMMP-3 with trypsin resulted in the formation of a 45-kDa MMP-3 with an NH2-terminal Thr(85), whose activity and substrate specificity were similar to those of the 46-kDa MMP-3(F83R) obtained from the proMMP-3(F83R) mutant. These observations indicate that the correct processing at the His(82)-Phe(83) bond is critical for expression of the full activity and the specificity of MMP-3.	UNIV KANSAS,MED CTR,DEPT BIOCHEM,KANSAS CITY,KS 66160; UNIV KANSAS,MED CTR,DEPT MOLEC BIOL,KANSAS CITY,KS 66160; WAYNE STATE UNIV,SCH MED,CTR MOL MED & GENET,DETROIT,MI 48202	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; Wayne State University				Buttice', Giovanna/0000-0001-6550-5585	NIAMS NIH HHS [AR39189, AR40994] Funding Source: Medline; NICHD NIH HHS [HD24442] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024442] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039189, R01AR040994] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; CHEN LC, 1993, BIOCHEMISTRY-US, V32, P10289, DOI 10.1021/bi00090a003; COCKETT MI, 1990, BIO-TECHNOL, V8, P662, DOI 10.1038/nbt0790-662; CRABBE T, 1992, BIOCHEMISTRY-US, V31, P8500, DOI 10.1021/bi00151a017; DAVIS GE, 1990, CANCER RES, V50, P1113; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; FIRESTEIN GS, 1991, ARTHRITIS RHEUM, V34, P1094, DOI 10.1002/art.1780340905; GRAVALLESE EM, 1991, ARTHRITIS RHEUM-US, V34, P1076, DOI 10.1002/art.1780340903; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ITO A, 1988, ARCH BIOCHEM BIOPHYS, V267, P211, DOI 10.1016/0003-9861(88)90025-2; KNAUPER V, 1993, BIOCHEM J, V295, P581; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCACHREN SS, 1991, ARTHRITIS RHEUM-US, V34, P1085; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; NAGASE H, 1995, METHOD ENZYMOL, V248, P449; NAGASE H, 1994, J BIOL CHEM, V269, P20952; NAGASE H, 1990, BIOCHEMISTRY-US, V29, P5783, DOI 10.1021/bi00476a020; NIEDZWIECKI L, 1992, BIOCHEMISTRY-US, V31, P12618, DOI 10.1021/bi00165a011; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OKADA Y, 1988, BIOCHEM J, V254, P731, DOI 10.1042/bj2540731; OKADA Y, 1992, LAB INVEST, V66, P680; OKADA Y, 1989, ANN RHEUM DIS, V48, P645, DOI 10.1136/ard.48.8.645; OKADA Y, 1986, J BIOL CHEM, V261, P14245; REINEMER P, 1994, FEBS LETT, V338, P227, DOI 10.1016/0014-5793(94)80370-6; SAARINEN J, 1994, J BIOL CHEM, V269, P18134; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUS J, 1988, J BIOL CHEM, V263, P6742; SHAPIRO SD, 1995, J BIOL CHEM, V270, P6351, DOI 10.1074/jbc.270.11.6351; SIRI A, 1995, J BIOL CHEM, V270, P8650, DOI 10.1074/jbc.270.15.8650; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; SUZUKI K, 1995, BIOCHEM J, V305, P301, DOI 10.1042/bj3050301; SUZUKI K, 1990, BIOCHEMISTRY-US, V29, P10261, DOI 10.1021/bi00496a016; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WALAKOVITS LA, 1992, ARTHRITIS RHEUM, V35, P35, DOI 10.1002/art.1780350106; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WU JJ, 1991, J BIOL CHEM, V266, P5625	45	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10715	10722		10.1074/jbc.271.18.10715	http://dx.doi.org/10.1074/jbc.271.18.10715			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631880	hybrid			2022-12-25	WOS:A1996UJ34200048
J	Kimura, K; Saijo, M; Tanaka, M; Enomoto, T				Kimura, K; Saijo, M; Tanaka, M; Enomoto, T			Phosphorylation-independent stimulation of DNA topoisomerase II alpha activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; CYCLE-DEPENDENT PHOSPHORYLATION; FISSION YEAST; ATP HYDROLYSIS; PHORBOL ESTER; CELLS; ENZYME; CONDENSATION; SEPARATION; INVITRO	It has been suggested that casein kinase II phosphorylates DNA topoisomerase II alpha (topo II alpha) in mouse FM3A cells, by comparison of phosphopeptide maps of topo II alpha labeled in intact cells and of topo II alpha phosphorylated by various kinases in vitro. The phosphorylation of purified topo II alpha by casein kinase II, which attached a maximum of two phosphate groups per topo II alpha molecule, had no effect on the activity of topo II alpha. Dephosphorylation of purified topo II alpha by potato acid phosphatase, which almost completely dephosphorylated the topo II alpha, did not reduce the activity of topo II alpha. The incubation itself, regardless of phosphorylation or dephosphorylation status, stimulated the enzyme activity in both reactions. Topo II alpha activity was stimulated by incubation in a medium containing low concentrations of glycerol but not in that containing high concentrations of glycerol, such as the 50% in which purified topo II alpha is stored. The stimulation of topo II alpha activity by incubation was dependent on the concentration of topo II alpha, requiring a relatively high concentration of topo II alpha.	UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,TOKYO 113,JAPAN; MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN	University of Tokyo								ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; ACKERMAN P, 1988, J BIOL CHEM, V263, P12653; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; BERNARDI R, 1995, INT J ONCOL, V6, P203; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; BOJANOWSKI K, 1993, J BIOL CHEM, V268, P22920; BURDEN DA, 1993, BIOCHEM J, V293, P297, DOI 10.1042/bj2930297; BURDEN DA, 1994, BIOCHEMISTRY-US, V33, P14651, DOI 10.1021/bi00253a001; CARDENAS ME, 1992, EMBO J, V11, P1785, DOI 10.1002/j.1460-2075.1992.tb05230.x; CARDENAS ME, 1993, J CELL SCI, V104, P533; CARON PR, 1994, MOL CELL BIOL, V14, P3197, DOI 10.1128/MCB.14.5.3197; CORBETT AH, 1992, J BIOL CHEM, V267, P20513; CORBETT AH, 1993, BIOCHEMISTRY-US, V32, P2090, DOI 10.1021/bi00059a029; CRENSHAW DG, 1993, J BIOL CHEM, V268, P21328; DEVORE RF, 1992, CANCER RES, V52, P2156; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; DRAKE FH, 1987, J BIOL CHEM, V262, P16739; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; FRERE V, 1995, J BIOL CHEM, V270, P17502, DOI 10.1074/jbc.270.29.17502; HECK MMS, 1989, J BIOL CHEM, V264, P15161; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; KIMURA K, 1994, J BIOL CHEM, V269, P24523; KROLL DJ, 1991, J BIOL CHEM, V266, P7957; LAMHASNI S, 1995, BIOCHEMISTRY-US, V34, P3632, DOI 10.1021/bi00011a018; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; ROTTMANN M, 1987, EMBO J, V6, P3939, DOI 10.1002/j.1460-2075.1987.tb02735.x; SAHYOUN N, 1986, P NATL ACAD SCI USA, V83, P1603, DOI 10.1073/pnas.83.6.1603; SAIJO M, 1990, BIOCHEMISTRY-US, V29, P583, DOI 10.1021/bi00454a036; SAIJO M, 1992, BIOCHEMISTRY-US, V31, P359, DOI 10.1021/bi00117a007; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SHIOZAKI K, 1992, J CELL BIOL, V119, P1023, DOI 10.1083/jcb.119.5.1023; SHIOZAKI K, 1991, MOL CELL BIOL, V11, P6093, DOI 10.1128/MCB.11.12.6093; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; TAKENO H, 1991, CANCER RES, V51, P3951; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; VASSETZKY YS, 1994, MOL CELL BIOL, V14, P6962, DOI 10.1128/MCB.14.10.6962; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; WELLS NJ, 1994, J BIOL CHEM, V269, P29746; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839	45	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10990	10995		10.1074/jbc.271.18.10990	http://dx.doi.org/10.1074/jbc.271.18.10990			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631919	hybrid			2022-12-25	WOS:A1996UJ34200087
J	Yamamoto, F; McNeill, PD				Yamamoto, F; McNeill, PD			Amino acid residue at codon 268 determines both activity and nucleotide-sugar donor substrate specificity of human histo-blood group A and B transferases - In vitro mutagenesis study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR GENETIC-ANALYSIS; GROUP SYSTEM; GROUP-A; ABO; DNA; CLONING; ALLELES	Histo-blood group A transferase produces A antigens and transfers GalNAc to the acceptor substrate, H structures of glycolipids and glycoproteins, B transferase transfers galactose in place of GalNAc to the same acceptor substrate to synthesize B antigens. We have previously identified four amino acid substitutions between human A and B transferases. Out of these four, substitutions at the last two positions (codons 266 and 268) were found to be crucial for the different donor nucleotide-sugar specificities between A and B transferases as analyzed by gene transfer of chimeric A-B transferase genes. In the present study, we have in vitro mutagenized codon 268 of these two transferase cDNA expression constructs (glycine and alanine in A and B transferases, respectively) and produced substitution constructs with every possible amino acid residue at this position, We examined the activity and specificity of each construct by gene transfer followed by immunodetection of A and B antigens and in vitro enzymatic assay, Amino acid substitution constructs on the A transferase backbone with alanine, serine, and cysteine expressed enzymes with A and B transferase activities. Weak A activity was detected with histidine and phenylalanine constructs while weak B activity was detected with asparagine and threonine constructs, All the other amino acid substitutions at codon 268 on the A transferase backbone showed neither A nor B activity, The glycine construct on the B transferase backbone expressed both A and B transferase activities, Some substitution constructs on the B transferase backbone maintained B activity while some other substitutions abolished the activity. These results show that the side chain of the amino acid residue at 268 of the human A and B transferases is responsible for determining both activity and nucleotide-sugar donor substrate specificity and strongly suggest its direct involvement in the recognition of and binding to the sugar moiety of the nucleotide-sugars.	UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT PATHOBIOL,SEATTLE,WA 98195; BIOMEMBRANE INST,SEATTLE,WA 98119	University of Washington; University of Washington Seattle	Yamamoto, F (corresponding author), LA JOLLA CANC RES FDN,BURNHAM INST,10901 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Yamamoto, Fumiichiro/F-1478-2016	Yamamoto, Fumiichiro/0000-0001-9690-7034				Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; CHANG JG, 1992, BLOOD, V79, P2176, DOI 10.1182/blood.V79.8.2176.bloodjournal7982176; CROUSE C, 1995, BIOTECHNIQUES, V18, P478; GREENWELL P, 1986, CARBOHYD RES, V149, P149, DOI 10.1016/S0008-6215(00)90375-6; GRUNNET N, 1994, VOX SANG, V67, P210, DOI 10.1111/j.1423-0410.1994.tb01662.x; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; HAWLEY-NELSON P, 1993, FOCUS MADISON, V15, P73; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KOMINATO Y, 1992, BIOCHEM BIOPH RES CO, V189, P154, DOI 10.1016/0006-291X(92)91538-2; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LIM K, 1989, BIOTECHNIQUES, V7, P576; STRONCEK DF, 1995, TRANSFUSION, V35, P231, DOI 10.1046/j.1537-2995.1995.35395184280.x; Stroup M, 1987, SCI FORUM BLOOD GROU; UGOZZOLI L, 1992, GENOMICS, V12, P670, DOI 10.1016/0888-7543(92)90292-Z; Watkins W M, 1980, Adv Hum Genet, V10, P1; YAMAMOTO F, 1990, J BIOL CHEM, V265, P19257; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YAMAMOTO F, 1993, VOX SANG, V64, P171, DOI 10.1111/j.1423-0410.1993.tb05157.x; YAMAMOTO F, 1995, VOX SANG, V69, P1, DOI 10.1111/j.1423-0410.1995.tb00339.x; YAMAMOTO F, 1990, J BIOL CHEM, V265, P1146; YAMAMOTO F, 1992, BIOCHEM BIOPH RES CO, V187, P366, DOI 10.1016/S0006-291X(05)81502-5; YAMAMOTO F, 1993, VOX SANG, V64, P175, DOI 10.1111/j.1423-0410.1993.tb05158.x; YAMAMOTO FI, 1993, VOX SANG, V64, P120, DOI 10.1111/j.1423-0410.1993.tb02529.x; YAMAMOTO FI, 1993, VOX SANG, V64, P116, DOI 10.1111/j.1423-0410.1993.tb02528.x	24	78	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10515	10520		10.1074/jbc.271.18.10515	http://dx.doi.org/10.1074/jbc.271.18.10515			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631849	hybrid			2022-12-25	WOS:A1996UJ34200017
J	Wieprecht, M; Wieder, T; Paul, C; Geilen, CC; Orfanos, CE				Wieprecht, M; Wieder, T; Paul, C; Geilen, CC; Orfanos, CE			Evidence for phosphorylation of CTP:phosphocholine cytidylyltransferase by multiple proline-directed protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER CTP; HELA-CELLS; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; INDUCED INHIBITION; OKADAIC ACID; HEPATOCYTES; DIACYLGLYCEROL; TRANSLOCATION; EXPRESSION; CYTIDYLTRANSFERASE	Reversible phosphorylation of CTP:phosphocholine cytidylyltransferase, the rate-limiting enzyme of phosphatidylcholine biosynthesis, is thought to play a role in regulating its activity. In the present study, the hypothesis that proline-directed kinases play a major role in phosphorylating cytidylyltransferase is substantiated using a c-Ha-ras-transfected clone of the human keratinocyte cell line HaCaT. Cellular extracts from epidermal growth factor-stimulated HaCaT cells and from ras-transfected HaCaT cells phosphorylated cytidylyltransferase much stronger as compared with extracts from quiescent HaCaT cells, The tryptic phosphopeptide pattern of cytidylyltransferase phosphorylated by cell-free extracts from ras-transfected HaCaT cells was similar compared with the patterns of cytidylyltransferase phosphorylated by p44(mpk) mitogen-activated protein kinase and p34(cdc2) kinase in vitro, whereas in the case of casein kinase II the pattern was different, Furthermore, in c-Ha-ras-transfected HaCaT cells the in. vivo phosphorylation state of cytidylyltransferase was 2-fold higher as compared with untransfected HaCaT cells, This higher phosphorylation of cytidylyltransferase in the ras-transfected clone was reduced to a level below the phosphorylation of cytidylyltransferase in untransfected cells, using olomoucine, a specific inhibitor of proline-directed kinases. The reduced phosphorylation of cytidylyltransferase in olomoucine-treated cells correlated with an enhanced stimulation of enzyme activity by oleic acid.	FREE UNIV BERLIN, UNIV MED CTR BENJAMIN FRANKLIN, DEPT DERMATOL, D-12200 BERLIN, GERMANY; FREE UNIV BERLIN, UNIV MED CTR BENJAMIN FRANKLIN, INST BIOCHEM & MOLEC BIOL, D-12200 BERLIN, GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin								BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOUKAMP P, 1990, CANCER RES, V50, P2840; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CORNELL R, 1987, BIOCHIM BIOPHYS ACTA, V919, P26, DOI 10.1016/0005-2760(87)90214-1; DUBOIS MF, 1993, FEBS LETT, V324, P191, DOI 10.1016/0014-5793(93)81391-C; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; GEILEN CC, 1992, J BIOL CHEM, V267, P6719; GROBLEWSKI GE, 1995, J BIOL CHEM, V270, P1437, DOI 10.1074/jbc.270.3.1437; HATCH GM, 1992, J BIOL CHEM, V267, P15751; HATCH GM, 1990, BIOCHIM BIOPHYS ACTA, V1042, P374, DOI 10.1016/0005-2760(90)90167-V; HOUWELING M, 1994, J BIOL CHEM, V269, P7544; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; JAMIL H, 1993, BIOCHEM J, V291, P419, DOI 10.1042/bj2910419; JAMIL H, 1992, J BIOL CHEM, V267, P1752; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCHE MM, 1993, ARCH BIOCHEM BIOPHYS, V301, P114, DOI 10.1006/abbi.1993.1122; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; PELECH SL, 1982, J BIOL CHEM, V257, P4198; SANGHERA JS, 1989, J BIOL CHEM, V264, P1215; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOHAL PS, 1990, J BIOL CHEM, V265, P11746; SWEITZER TD, 1994, ARCH BIOCHEM BIOPHYS, V311, P107, DOI 10.1006/abbi.1994.1215; TRONCHERE H, 1994, BBA-LIPID LIPID MET, V1212, P137, DOI 10.1016/0005-2760(94)90248-8; UTAL AK, 1991, J BIOL CHEM, V266, P24084; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; WANG YL, 1993, J BIOL CHEM, V268, P5512; WATKINS JD, 1992, ARCH BIOCHEM BIOPHYS, V292, P360, DOI 10.1016/0003-9861(92)90003-F; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WATKINS JD, 1990, J BIOL CHEM, V265, P2190; WIEDER T, 1994, FEBS LETT, V345, P207, DOI 10.1016/0014-5793(94)00433-1; WIEPRECHT M, 1994, BIOCHEM J, V297, P241, DOI 10.1042/bj2970241; WIEPRECHT M, 1994, FEBS LETT, V353, P221, DOI 10.1016/0014-5793(94)01040-4; YANG W, 1995, J BIOL CHEM, V270, P16503, DOI 10.1074/jbc.270.28.16503	35	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9955	9961		10.1074/jbc.271.17.9955	http://dx.doi.org/10.1074/jbc.271.17.9955			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626633	hybrid			2022-12-25	WOS:A1996UG25700017
J	Keyt, BA; Berleau, LT; Nguyen, HV; Chen, H; Heinsohn, H; Vandlen, R; Ferrara, N				Keyt, BA; Berleau, LT; Nguyen, HV; Chen, H; Heinsohn, H; Vandlen, R; Ferrara, N			The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR FAMILY; ANGIOGENESIS; PROTEINS; BINDING; CELLS; FORMS; COMPARTMENTALIZATION; DIFFERENTIATION; EXPRESSION; MEMBRANE	Vascular endothelial growth factor (VEGF) is a potent and specific mitogen for endothelial cells. VEGF is synthesized and secreted by many differentiated cells in response to a variety of stimuli including hypoxia. VEGF is expressed in a variety of tissues as multiple homodimeric forms (121, 165, 189, and 206 amino acids/monomer) resulting from alternative RNA splicing. VEGF(121) is a soluble mitogen that does not bind heparin; the longer forms of VEGF bind heparin with progressively higher affinity. The higher molecular weight forms of VEGF can be cleaved by plasmin to release a diffusible form(s) of VEGF. We characterized the proteolysis of VEGF by plasmin and other proteases. Thrombin, elastase, and collagenase did not cleave VEGF, whereas trypsin generated a series of smaller fragments. The isolated plasmin fragments of VEGF were compared with respect to heparin binding, interaction with soluble VEGF receptors, and ability to promote endothelial cell mitogenesis. Plasmin yields two fragments of VEGF as indicated by reverse phase high performance liquid chromatography and SDS-polyacrylamide gel electrophoresis: an amino-terminal homodimeric protein containing receptor binding determinants and a carboxyl-terminal polypeptide which bound heparin. Amino-terminal sequencing of the carboxyl-terminal peptide identified the plasmin cleavage site as Arg(110)-Ala(111). A heterodimeric form of VEGF(165/110), was isolated from partial plasmin digests of VEGF(165). The carboxyl-terminal polypeptide (111-165) displayed no affinity for soluble kinase domain region (KDR) or Fms-like tyrosine kinase (FLT-1) receptors. The various isoforms of VEGF (165, 165/110, 110, and 121) bound soluble kinase domain region receptor with similar affinity (approximately 30 pM). In contrast, soluble FLT-1 receptor differentiated VEGF isoforms (165, 165/110, 110, and 121) with apparent affinities of 10, 30, 120, and 200 pM, respectively. Endothelial cell mitogenic potencies of VEGF(110) and VEGF(121) were decreased more than 100-fold compared to that of VEGF(165). The present findings indicate that removal of the carboxyl-terminal domain, whether it is due to alternative splicing of mRNA or to proteolysis, is associated with a significant loss in bioactivity.	GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT PROC SCI,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech	Keyt, BA (corresponding author), GENENTECH INC,DEPT CARDIOVASC RES,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA.							ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; BREIER G, 1992, DEVELOPMENT, V114, P521; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1993, J CLIN INVEST, V91, P160, DOI 10.1172/JCI116166; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1993, ONCOGENE, V8, P925; Matrisian L.M., 1990, Current Topics in Developmental Biology, V24, P219, DOI 10.1016/S0070-2153(08)60089-7; MIGNATTI P, 1989, J CELL BIOL, V108, P671, DOI 10.1083/jcb.108.2.671; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PARK JE, 1994, J BIOL CHEM, V269, P25646; PHILLIPS HS, 1990, ENDOCRINOLOGY, V127, P965, DOI 10.1210/endo-127-2-965; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; RATHJEN PD, 1990, CELL, V62, P1105, DOI 10.1016/0092-8674(90)90387-T; SASISEKHARAN R, 1994, P NATL ACAD SCI USA, V91, P1524, DOI 10.1073/pnas.91.4.1524; SOKER S, 1994, BIOCHEM BIOPH RES CO, V203, P1339, DOI 10.1006/bbrc.1994.2329; TESSLER S, 1994, J BIOL CHEM, V269, P12456; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988	35	508	549	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7788	7795		10.1074/jbc.271.13.7788	http://dx.doi.org/10.1074/jbc.271.13.7788			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631822				2022-12-25	WOS:A1996UC77400090
J	Halvorson, LM; Kaiser, UB; Chin, WW				Halvorson, LM; Kaiser, UB; Chin, WW			Stimulation of luteinizing hormone beta gene promoter activity by the orphan nuclear receptor, steroidogenic factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT GENE; FACTOR-I; TRANSGENIC MICE; MAMMALIAN-CELLS; KEY REGULATOR; EXPRESSION; PITUITARY; GONADOTROPIN; EVOLUTION; ELEMENTS	The orphan nuclear receptor, steroidogenic factor-1 (SF-1), is expressed in the pituitary and in the gonadotrope precursor cell line, alpha T3-1, where it is believed to enhance expression of the common gonadotropin alpha-subunit gene through transactivation of the gonadotrope-specific element (GSE), Sequence analysis of the rat luteinizing hormone beta-subunit (LH beta) gene promoter revealed the presence of a consensus GSE at -127 to -119 (TGACCTTGT). We have demonstrated the ability of SF-l to bind specifically to this putative GSE sequence by electrophoretic mobility shift assay, utilizing both alpha T3-1 nuclear extracts and in vitro translated SF-l. In addition, mutation of the putative LH beta-GSE (TGAAATTGT) eliminated specific DNA binding, To examine the ability of SF-l to enhance LHP promoter activity, CV-1 cells, which lack endogenous SF-l, were cotransfected with an SF-l-containing expression vector and an LH beta-luciferase reporter construct, When cotransfected with -209/+5 of the LH beta promoter, SF-1 increased luciferase activity by 56-fold, SF-1 responsiveness was markedly diminished with loss of the putative GSE region in deletion constructs and in the presence of a two base pair mutation, analogous to the mutation which eliminated DNA binding, Finally, the LH beta-GSE was able to confer SF-1 responsiveness on a heterologous minimal growth hormone promoter, GH50 (57-fold), We conclude that SF-l both binds to and transactivates the rat LHP promoter, These data suggest that SF-1 may participate in the expression of the LH beta gene by the gonadotrope.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115; TUFTS UNIV,SCH MED,DEPT OBSTET & GYNECOL,BOSTON,MA 02111	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Tufts University	Halvorson, LM (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV GENET,GW THORN RES BLDG,RM 913,20 SHATTUCK ST,BOSTON,MA 02115, USA.				NICHD NIH HHS [HD00849, HD19938] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD000849, R01HD019938, R37HD019938] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BARNHART KM, 1994, MOL ENDOCRINOL, V8, P878, DOI 10.1210/me.8.7.878; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BROWN P, 1993, MOL CELL ENDOCRINOL, V93, P157, DOI 10.1016/0303-7207(93)90119-5; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GHARIB SD, 1990, ENDOCR REV, V11, P177, DOI 10.1210/edrv-11-1-177; HONDA S, 1993, J BIOL CHEM, V268, P7494; HORN F, 1992, MOL CELL BIOL, V12, P2143, DOI 10.1128/MCB.12.5.2143; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; IKEDA Y, 1995, MOL ENDOCRINOL, V9, P478, DOI 10.1210/me.9.4.478; INGRAHAM HA, 1994, GENE DEV, V8, P2302, DOI 10.1101/gad.8.19.2302; JAMESON L, 1984, J BIOL CHEM, V259, P5474; KAY TWH, 1992, MOL ENDOCRINOL, V6, P1767, DOI 10.1210/me.6.11.1767; KERI RA, 1994, MOL ENDOCRINOL, V8, P1807, DOI 10.1210/me.8.12.1807; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LYNCH JP, 1993, MOL ENDOCRINOL, V7, P776, DOI 10.1210/me.7.6.776; MORRIS AE, 1990, GENE, V94, P289, DOI 10.1016/0378-1119(90)90400-L; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; RICE DA, 1991, MOL ENDOCRINOL, V5, P1552, DOI 10.1210/mend-5-10-1552; Sambrook J., 2002, MOL CLONING LAB MANU; SCHODERBEK WE, 1992, MOL ENDOCRINOL, V6, P893, DOI 10.1210/me.6.6.893; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; SUEN CS, 1994, J BIOL CHEM, V269, P1314; SUEN CS, 1993, MOL CELL BIOL, V13, P1719, DOI 10.1128/MCB.13.3.1719; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; VIRGIN JB, 1985, J BIOL CHEM, V260, P7072; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597	32	154	158	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6645	6650		10.1074/jbc.271.12.6645	http://dx.doi.org/10.1074/jbc.271.12.6645			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636081	hybrid			2022-12-25	WOS:A1996UB15700016
J	Hawdon, JM; Jones, BF; Hoffman, DR; Hotez, PJ				Hawdon, JM; Jones, BF; Hoffman, DR; Hotez, PJ			Cloning and characterization of Ancylostoma-secreted protein - A novel protein associated with the transition to parasitism by infective hookworm larvae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; HYMENOPTERA VENOM; TRICHOSTRONGYLUS-COLUBRIFORMIS; TRICHINELLA-SPIRALIS; MOLECULAR-CLONING; 3RD-STAGE LARVAE; CROSS-REACTIVITY; ALLERGENS; PRODUCTS; PURIFICATION	The developmentally arrested third stage infective larva of hookworms resumes development upon entry into the definitive host. This transition to parasitism can be modeled in vitro by stimulating infective larvae with a low molecular weight ultrafiltrate of host serum together with methylated glutathione analogues. When stimulated to resume development in vitro, activated larvae of the hookworm Ancylostoma caninum released a 42-kDa protein, termed Ancylostoma-secreted protein (ASP). ASP was the major protein released by activated hookworm larvae, Degenerate oligonucleotide primers, based on a partial internal amino acid sequence of the protein, were used together with flanking vector sequence primers to amplify a fragment hom a third stage larval cDNA library by polymerase chain reaction. The fragment was used as a probe to isolate a longer done from the larval cDNA library. The full-length ASP cDNA was found to encode a 424-amino acid protein with homology to the antigen 5/antigen 3 family of proteins from hymenopteran venoms and a family of cysteine-rich secretory proteins. ASP was expressed in bacterial cells, and a polyclonal antiserum against purified recombinant ASP was produced. The antiserum, which was demonstrated to be specific for ASP, was used as a probe to measure the kinetics of ASP release by hookworm larvae. ASP is released within 30 min of stimulation, with the majority released by 4 h. Low levels of ASP were released continuously following activation, but only if the stimuli were present in the incubation medium. The compound 4,7-phenanthroline, previously shown to inhibit larval activation, also inhibited release of ASP. The specific, rapid release of ASP by activated infective larvae suggests that this molecule occupies a critical and central role in the transition from the external environment to parasitism.	E CAROLINA UNIV, DEPT PATHOL & LAB MED, GREENVILLE, NC 27858 USA	University of North Carolina; East Carolina University	Hawdon, JM (corresponding author), YALE UNIV, SCH MED,DEPT PEDIAT,MED HELMINTHOL LAB,501 LEPH, 60 COLL ST, NEW HAVEN, CT 06520 USA.		Hawdon, John/I-1201-2019	Hawdon, John/0000-0002-6164-1413; Hotez, Peter/0000-0001-8770-1042	NIAID NIH HHS [R29AI32726, F32AI08561] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008561, R29AI032726] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABE T, 1982, BIOCHEMISTRY-US, V21, P1693, DOI 10.1021/bi00536a034; ARNHEIM N, 1992, ANNU REV BIOCHEM, V61, P131, DOI 10.1146/annurev.bi.61.070192.001023; BEKTESH S, 1988, GENE DEV, V2, P1277, DOI 10.1101/gad.2.10.1277; BROOKS DE, 1986, EUR J BIOCHEM, V161, P13, DOI 10.1111/j.1432-1033.1986.tb10118.x; CHAREST NJ, 1988, MOL ENDOCRINOL, V2, P999, DOI 10.1210/mend-2-10-999; CORNELISSEN BJC, 1987, NUCLEIC ACIDS RES, V15, P6799, DOI 10.1093/nar/15.17.6799; DOPHEIDE TAA, 1991, MOL BIOCHEM PARASIT, V45, P101, DOI 10.1016/0166-6851(91)90031-Z; FANG KSY, 1988, P NATL ACAD SCI USA, V85, P895, DOI 10.1073/pnas.85.3.895; FRENKEL MJ, 1992, MOL BIOCHEM PARASIT, V50, P27, DOI 10.1016/0166-6851(92)90241-B; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAMBLE HR, 1986, AM J VET RES, V47, P2396; GASBARRE LC, 1985, INFECT IMMUN, V48, P540, DOI 10.1128/IAI.48.2.540-545.1985; HAENDLER B, 1993, ENDOCRINOLOGY, V133, P192, DOI 10.1210/en.133.1.192; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; Hawdon J.M., 1991, P274; HAWDON JM, 1990, J PARASITOL, V76, P394, DOI 10.2307/3282673; HAWDON JM, 1991, J HELMINTHOL SOC W, V58, P140; HAWDON JM, 1995, MOL BIOCHEM PARASIT, V69, P127, DOI 10.1016/0166-6851(94)00203-Y; HAWDON JM, 1992, EXP PARASITOL, V75, P40, DOI 10.1016/0014-4894(92)90120-Y; HAWDON JM, 1995, EXP PARASITOL, V80, P205, DOI 10.1006/expr.1995.1025; HAWDON JM, 1993, EXP PARASITOL, V77, P489, DOI 10.1006/expr.1993.1110; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V92, P707, DOI 10.1016/0091-6749(93)90014-7; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P611, DOI 10.1016/0091-6749(85)90038-7; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P599, DOI 10.1016/0091-6749(85)90036-3; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V91, P71, DOI 10.1016/0091-6749(93)90298-T; JAIN R, 1992, BIOTECHNIQUES, V12, P58; KASAHARA M, 1989, GENOMICS, V5, P527, DOI 10.1016/0888-7543(89)90019-0; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIGHTOWLERS MW, 1988, PARASITOLOGY, V96, pS123, DOI 10.1017/S0031182000086017; Miller T. A., 1971, Adv Parasitology, V9, P153, DOI 10.1016/S0065-308X(08)60161-X; MIZUKI N, 1992, MOL CELL ENDOCRINOL, V89, P25, DOI 10.1016/0303-7207(92)90207-M; MONROY FG, 1989, INT J PARASITOL, V19, P125, DOI 10.1016/0020-7519(89)90030-1; MORRISSETTE J, 1995, BIOPHYS J, V68, P2280, DOI 10.1016/S0006-3495(95)80410-8; MOYLE M, 1994, J BIOL CHEM, V269, P10008; NILSEN TW, 1993, ANNU REV MICROBIOL, V47, P413, DOI 10.1146/annurev.mi.47.100193.002213; ODONNELL IJ, 1989, INT J PARASITOL, V19, P793, DOI 10.1016/0020-7519(89)90068-4; RAYBOURNE R, 1986, EXP PARASITOL, V62, P92, DOI 10.1016/0014-4894(86)90012-3; RHOADS ML, 1983, EXP PARASITOL, V56, P41, DOI 10.1016/0014-4894(83)90095-4; RIEU P, 1994, J CELL BIOL, V127, P2081, DOI 10.1083/jcb.127.6.2081; Rogers W. P., 1968, Advances in Parasitology, V6, P327; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVIN KW, 1990, MOL BIOCHEM PARASIT, V41, P167, DOI 10.1016/0166-6851(90)90179-P; SHORT JM, 1992, METHOD ENZYMOL, V216, P495; SOMMERVILLE RI, 1987, ADV PARASIT, V26, P239, DOI 10.1016/S0065-308X(08)60298-5; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; TEMPLETON NS, 1993, BIOTECHNIQUES, V15, P52; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URBAN JF, 1992, IMMUNOL REV, V127, P205, DOI 10.1111/j.1600-065X.1992.tb01415.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILLIAMS KR, 1995, TECH PROT CHEM, V6, P143, DOI 10.1016/S1080-8914(06)80020-7	53	223	232	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6672	6678		10.1074/jbc.271.12.6672	http://dx.doi.org/10.1074/jbc.271.12.6672			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636085	hybrid, Green Published			2022-12-25	WOS:A1996UB15700020
J	Howitt, SM; Rodgers, AJW; Jeffrey, PD; Cox, GB				Howitt, SM; Rodgers, AJW; Jeffrey, PD; Cox, GB			A mutation in which alanine 128 is replaced by aspartic acid abolishes dimerization of the b-subunit of the F0F1-ATPase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; ADENOSINE-TRIPHOSPHATASE; NUCLEOTIDE-SEQUENCE; UNC OPERON; C-SUBUNIT; SYNTHASE; PERMEABILITY; ORGANIZATION; PORTION; GENES	Site-directed mutagenesis was used to investigate the roles of a short, series of hydrophobic amino acids in the b-subunit of the Escherichia coli F0F1-ATPase. A mutation affecting one of these, G131D, had been previously characterized and was found to interrupt assembly of the F0F1-ATPase (Jans, D. A., Hatch, L., Fimmel, A. L., Gibson, D., and Cox, G. B. (1985) J. Bacteriol. 162, 420-426). To extend this work, aspartic acid was substituted for each one of the residues from positions 124 to 132. The properties of mutants in this series are consistent with the region hom Val(124) to Gly(131) forming an alpha-helix. Two of the mutations, V124D and A128D, resulted in a similar phenotype to the G131D mutation. This suggested that Val(124), Ala(128), and Gly(131) form a helical face which may have a role in inter- or intrasubunit interactions, This was tested by overexpressing and purifying the cytoplasmic domains of the wild type and A128D mutant b-subunits. Sedimentation equilibrium centrifugation indicated that the wild type domain formed a dimer whereas the mutant was present as a monomer.			Howitt, SM (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV BIOCHEM & MOLEC BIOL,GPO BOX 334,CANBERRA,ACT 2601,AUSTRALIA.		Howitt, Susan M/C-9308-2009; Rodgers, Andrew/AAT-8756-2021; Rodgers, Andrew/H-3527-2013	Howitt, Susan M/0000-0002-2192-2317; Rodgers, Andrew/0000-0003-2063-4521; Rodgers, Andrew/0000-0002-8897-6221				BRUSILOW WSA, 1989, J BIOL CHEM, V264, P1528; COX GB, 1983, BIOCHEM J, V216, P143, DOI 10.1042/bj2160143; COX GB, 1984, BIOCHIM BIOPHYS ACTA, V768, P201, DOI 10.1016/0304-4173(84)90016-8; COX GB, 1970, BIOCHEM J, V177, P551; COZENS AL, 1987, J MOL BIOL, V194, P359, DOI 10.1016/0022-2836(87)90667-X; DUNN SD, 1992, J BIOL CHEM, V267, P7630; GIBSON F, 1977, BIOCHEM J, V164, P193, DOI 10.1042/bj1640193; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HATCH L, 1993, BIOCHIM BIOPHYS ACTA, V1141, P183, DOI 10.1016/0005-2728(93)90041-D; HERRMANN RG, 1993, FEBS LETT, V326, P192, DOI 10.1016/0014-5793(93)81789-3; HOWITT SM, 1990, BIOCHIM BIOPHYS ACTA, V1015, P264, DOI 10.1016/0005-2728(90)90030-8; JANS DA, 1984, BIOCHEM J, V221, P43, DOI 10.1042/bj2210043; JANS DA, 1983, BIOCHEM J, V211, P717, DOI 10.1042/bj2110717; JANS DA, 1984, J BACTERIOL, V160, P764, DOI 10.1128/JB.160.2.764-770.1984; KRUMHOLZ LR, 1989, NUCLEIC ACIDS RES, V17, P7993, DOI 10.1093/nar/17.19.7993; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LURIA SE, 1957, J BACTERIOL, V74, P461, DOI 10.1002/path.1700740226; MCCORMICK KA, 1991, J BACTERIOL, V173, P7240, DOI 10.1128/jb.173.22.7240-7248.1991; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; PILLER SC, 1995, P NATL ACAD SCI USA, V93, P111; PORTER ACG, 1985, J BIOL CHEM, V260, P8182; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER E, 1985, EMBO J, V4, P515, DOI 10.1002/j.1460-2075.1985.tb03658.x; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WALKER JE, 1982, NATURE, V298, P867, DOI 10.1038/298867a0; WILKENS S, 1994, FEBS LETT, V354, P37, DOI 10.1016/0014-5793(94)01059-5	29	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7038	7042		10.1074/jbc.271.12.7038	http://dx.doi.org/10.1074/jbc.271.12.7038			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636135	hybrid			2022-12-25	WOS:A1996UB15700070
J	Zhao, X; Siu, CH				Zhao, X; Siu, CH			Differential effects of two hydrocephalus/MASA syndrome-related mutations on the homophilic binding and neuritogenic activities of the cell adhesion molecule L1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN SUPERFAMILY; HOMOPHILIC BINDING; NEURITE OUTGROWTH; IG SUPERFAMILY; NG-CAM; DOMAINS; EXPRESSION; NEURONS; MEMBER	The cell adhesion molecule L1 plays an important role in neural development, We have previously demonstrated that the second immunoglobulin-like domain (Ig2) of L1 contains both hemophilic binding and neuritogenic activities (Zhao, X, and Siu, C,-H. (1995) J, Biol, Chem. 270, 29413-29421), Recently, two mutations (R184Q and H210Q) within the Ig2 region of the human L1 gene have been shown to be responsible for X-linked hydrocephalus and the related MASA (mental retardation, aphasia, shuffling gait, and adducted thumbs) syndrome, Glutathione S-transferase-Ig2 fusion proteins containing these mutations were used to evaluate their effects on L1, The homophilic binding activity of fusion proteins and their ability to promote neurite outgrowth from retinal cells were examined. The R184Q mutation led to a complete loss of both homophilic binding and neuritogenic activities, while the H210Q mutation resulted only in a partial loss, These results provide, for the first time, direct demonstration of the deleterious effects of hydrocephalus/MASA mutations on two intrinsic properties of L1.	UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, TORONTO, ON M5G 1L6, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO, ON M5G 1L6, CANADA	University of Toronto; University of Toronto								APPEL F, 1993, J NEUROSCI, V13, P4764; BIEBER AJ, 1989, CELL, V59, P447, DOI 10.1016/0092-8674(89)90029-9; BRUMMENDORF T, 1993, NEURON, V10, P711; BURGOON MP, 1995, J CELL BIOL, V130, P733, DOI 10.1083/jcb.130.3.733; BURGOON MP, 1991, J CELL BIOL, V112, P1017, DOI 10.1083/jcb.112.5.1017; DAVIS JQ, 1994, J BIOL CHEM, V269, P27163; DJABALI M, 1990, GENOMICS, V7, P587, DOI 10.1016/0888-7543(90)90203-7; DOHERTY P, 1995, NEURON, V14, P57, DOI 10.1016/0896-6273(95)90240-6; FELSENFELD DP, 1994, NEURON, V12, P675, DOI 10.1016/0896-6273(94)90222-4; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; GRUMET M, 1993, CELL ADHES COMMUN, V1, P177, DOI 10.3109/15419069309095693; GRUMET M, 1988, J CELL BIOL, V106, P487, DOI 10.1083/jcb.106.2.487; HIRSCH E, 1994, DEV DYNAM, V201, P108, DOI 10.1002/aja.1002010203; HLAVIN ML, 1991, GENOMICS, V11, P416, DOI 10.1016/0888-7543(91)90150-D; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; JOUET M, 1994, NAT GENET, V7, P402, DOI 10.1038/ng0794-402; JOUET M, 1995, AM J HUM GENET, V56, P1304; KADMON G, 1990, J CELL BIOL, V110, P193, DOI 10.1083/jcb.110.1.193; KUHN TB, 1991, J CELL BIOL, V115, P1113, DOI 10.1083/jcb.115.4.1113; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; MIURA M, 1992, J BIOL CHEM, V267, P10752; MONTGOMERY AMP, 1996, IN PRESS J CELL BIOL; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; PRINCE JT, 1991, J NEUROSCI RES, V30, P567, DOI 10.1002/jnr.490300315; RAO Y, 1992, J CELL BIOL, V118, P937, DOI 10.1083/jcb.118.4.937; RAO Y, 1994, J BIOL CHEM, V269, P27540; SANDIG M, 1994, J BIOL CHEM, V269, P14841; VITS L, 1994, NAT GENET, V7, P408, DOI 10.1038/ng0794-408; WONG EV, 1995, TRENDS NEUROSCI, V18, P168, DOI 10.1016/0166-2236(95)93896-6; ZHAO XO, 1995, J BIOL CHEM, V270, P29413, DOI 10.1074/jbc.270.49.29413; ZHOU H, 1993, J CELL BIOL, V122, P951, DOI 10.1083/jcb.122.4.951	31	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6563	6566		10.1074/jbc.271.12.6563	http://dx.doi.org/10.1074/jbc.271.12.6563			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636066	hybrid			2022-12-25	WOS:A1996UB15700001
J	Stancato, LF; David, M; CarterSu, C; Larner, AC; Pratt, WB				Stancato, LF; David, M; CarterSu, C; Larner, AC; Pratt, WB			Preassociation of STAT1 with STATE and STAT3 in separate signalling complexes prior to cytokine stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; INTERFERON-ALPHA; TRANSCRIPTIONAL ACTIVATOR; GLUCOCORTICOID RECEPTOR; PROTEINS; ISGF-3	A variety of cytokines and growth factors act through an induction of gene expression mediated by a family of latent transcription factors called STAT (signal transducers and activators of transcription) proteins. Ligand-induced tyrosine phosphorylation of the STATs promotes their homodimer and heterodimer formation and subsequent nuclear translocation. We demonstrate here that STAT protein heterocomplexes exist prior to cytokine treatment, When unstimulated HeLa cells are ruptured in hypotonic buffer without salt or detergent, immunoadsorption of either STAT1 or STAT2 from the resulting cytosol yields coimmunoadsorption of the other STAT protein, Similarly, STAT1-STAT3 heterocomplexes are coimmunoadsorbed from hypotonic cytosol, STAT1 and STAT2 or STAT1 and STAT3 translated in reticulocyte lysate spontaneously form heterocomplexes when the translation lysates are mixed at 0 degrees C, Our data suggest that interferon-alpha/beta-induced tyrosine phosphorylation increases the stability of a preexisting, latent, STAT1-STAT2 signaling complex. Newly translated STAT1 binds in equilibrium fashion to STAT2 and STAT3, but we show that STAT2 and STAT3 exist in separate heterocomplexes with STAT1, consistent with a model in which STAT1 contains a common binding site for other STAT proteins.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT PHYSIOL,ANN ARBOR,MI 48109; US FDA,DIV CYTOKINE BIOL,BETHESDA,MD 20892	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; US Food & Drug Administration (FDA)					NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034171, R01DK034171] Funding Source: NIH RePORTER; NCI NIH HHS [CA28010, R01 CA028010] Funding Source: Medline; NIDDK NIH HHS [DK34171, R01 DK034171] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CAMPBELL GS, 1995, P NATL ACAD SCI USA, V270, P3974; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DAVID M, 1992, SCIENCE, V257, P813, DOI 10.1126/science.1496402; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; IHLE JN, 1994, TRENDS ENDOCRIN MET, V5, P137, DOI 10.1016/1043-2760(94)90096-5; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; PRATT WB, 1993, J BIOL CHEM, V268, P21455; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1994, CURR OPIN CELL BIOL, V6, P253, DOI 10.1016/0955-0674(94)90144-9; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STANCATO LF, 1993, J BIOL CHEM, V268, P21711	21	111	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4134	4137						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626752				2022-12-25	WOS:A1996TW96000030
J	Usachenko, SI; Gavin, IM; Bavykin, SG				Usachenko, SI; Gavin, IM; Bavykin, SG			Alterations in nucleosome core structure in linker histone-depleted chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SILENT MATING LOCI; SACCHAROMYCES-CEREVISIAE; PRIMARY ORGANIZATION; YEAST CHROMATIN; DNASE-I; TRANSCRIPTION; ACETYLATION; PLANT; GENE; PROTEIN	We have previously shown that the sequential arrangement of histone-DNA contacts is essentially the same in the nucleosomal core of sea urchin sperm nuclei, where chromatin is highly condensed and repressed, and in nuclei hom lily bud sepals or yeast, where chromatin is highly active in transcription and replication and is significantly or completely depleted of histone H1, However, the difference in the strength of some histone-DNA contacts has not been understood or discussed, In this work, we demonstrate that some of these differences are due to a conformational change in the nucleosomal core. We show that the nucleosomal core in linker histone-depleted chromatin is in a different conformational state compared with the nucleosomal core in folded chromatin or in isolated core nucleosomes, This conformational state is characterized by altered strengths in the histone H4 and H2A/H2B contacts with the regions of sharply bent nucleosomal DNA around sites +/-1 and +/-4 and site +/-5, respectively, We demonstrate that this conformation, which we call the ''stretched nucleosome,'' is a general feature of unfolded linker histone-depleted chromatin and may occur during chromatin activation, Our results suggest that this nucleosome structural alteration does not depend on chromatin sources and histone variants studied in this work, In addition, we show that this alteration is reversible and is caused by the stretching of Linker DNA during chromatin unfolding.	RUSSIAN ACAD SCI, VA ENGELHARDT MOLEC BIOL INST, MOSCOW 117984, RUSSIA	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS								ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; ALLAN J, 1980, P NATL ACAD SCI-BIOL, V77, P885, DOI 10.1073/pnas.77.2.885; BATES DL, 1981, NUCLEIC ACIDS RES, V9, P5883, DOI 10.1093/nar/9.22.5883; BAVYKIN S, 1993, P NATL ACAD SCI USA, V90, P3918, DOI 10.1073/pnas.90.9.3918; BAVYKIN SG, 1985, NUCLEIC ACIDS RES, V13, P3439, DOI 10.1093/nar/13.10.3439; BAVYKIN SG, 1990, J MOL BIOL, V212, P495, DOI 10.1016/0022-2836(90)90328-J; BAVYKIN SG, 1988, FEBS LETT, V228, P149, DOI 10.1016/0014-5793(88)80605-7; BECKER PB, 1994, BIOESSAYS, V16, P541, DOI 10.1002/bies.950160807; BELYAVSKY AV, 1980, J MOL BIOL, V139, P519, DOI 10.1016/0022-2836(80)90144-8; BOLUND LA, 1973, EUR J BIOCHEM, V35, P546, DOI 10.1111/j.1432-1033.1973.tb02871.x; BRADBURY EM, 1992, BIOESSAYS, V14, P9; CERTA U, 1984, NUCLEIC ACIDS RES, V12, P7975, DOI 10.1093/nar/12.21.7975; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; DAVIE JR, 1982, ANAL BIOCHEM, V120, P276, DOI 10.1016/0003-2697(82)90348-7; EBRALIDSE KK, 1988, NATURE, V331, P365, DOI 10.1038/331365a0; ERICSSON C, 1990, CELL, V60, P73, DOI 10.1016/0092-8674(90)90717-S; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GREYLING HJ, 1983, EUR J BIOCHEM, V137, P221, DOI 10.1111/j.1432-1033.1983.tb07818.x; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; GRUNSTEIN M, 1990, TRENDS GENET, V6, P395, DOI 10.1016/0168-9525(90)90299-L; HAYES JJ, 1992, BIOESSAYS, V14, P597, DOI 10.1002/bies.950140905; HEREFORD LM, 1977, CELL, V10, P453, DOI 10.1016/0092-8674(77)90032-0; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; LEE MS, 1991, EMBO J, V10, P607, DOI 10.1002/j.1460-2075.1991.tb07988.x; LOHR D, 1979, P NATL ACAD SCI USA, V76, P4285, DOI 10.1073/pnas.76.9.4285; LOHR D, 1979, P NATL ACAD SCI USA, V76, P6326, DOI 10.1073/pnas.76.12.6326; MCGHEE JD, 1983, CELL, V33, P831, DOI 10.1016/0092-8674(83)90025-9; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MIRZABEKOV AD, 1989, METHOD ENZYMOL, V170, P386; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; POCCIA DL, 1992, TRENDS BIOCHEM SCI, V17, P223, DOI 10.1016/0968-0004(92)90382-J; PRIOR CP, 1983, CELL, V34, P1033, DOI 10.1016/0092-8674(83)90561-5; PRUNELL A, 1979, SCIENCE, V204, P855, DOI 10.1126/science.441739; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; Sambrook J, 1989, MOL CLONING LAB MANU, pE3; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; SPIKER S, 1976, ARCH BIOCHEM BIOPHYS, V176, P510, DOI 10.1016/0003-9861(76)90194-6; SPIKER S, 1985, ANNU REV PLANT PHYS, V36, P235; STEINMETZ M, 1978, EUR J BIOCHEM, V83, P615, DOI 10.1111/j.1432-1033.1978.tb12131.x; STRICKLAND M, 1978, EUR J BIOCHEM, V89, P443, DOI 10.1111/j.1432-1033.1978.tb12547.x; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THOMA F, 1991, TRENDS GENET, V7, P175, DOI 10.1016/0168-9525(91)90429-T; THOMA F, 1988, ARCHITECTURE EUKARYO, P163; TURNER BM, 1991, J CELL SCI, V99, P13; USACHENKO SI, 1994, P NATL ACAD SCI USA, V91, P6845, DOI 10.1073/pnas.91.15.6845; WIDOM J, 1985, CELL, V43, P207, DOI 10.1016/0092-8674(85)90025-X; WIDOM J, 1989, ANNU REV BIOPHYS BIO, V18, P365, DOI 10.1146/annurev.biophys.18.1.365; WINTERSBERGER U, 1973, EUR J BIOCHEM, V33, P123, DOI 10.1111/j.1432-1033.1973.tb02663.x; WORCEL A, 1977, CELL, V12, P83, DOI 10.1016/0092-8674(77)90187-8; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; WU RS, 1986, CRIT REV BIOCHEM MOL, V20, P201, DOI 10.3109/10409238609083735; ZLATANOVA J, 1992, J CELL SCI, V103, P889	57	24	24	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3831	3836						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632001				2022-12-25	WOS:A1996TV72400075
J	Kunapuli, SP; Bradford, HN; Jameson, BA; DeLaCadena, RA; Rick, L; Wassell, RP; Colman, RW				Kunapuli, SP; Bradford, HN; Jameson, BA; DeLaCadena, RA; Rick, L; Wassell, RP; Colman, RW			Thrombin-induced platelet aggregation is inhibited by the heptapeptide Leu(271)-ALa(277) of domain 3 in the heavy chain of high molecular weight kininogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; CYSTEINE PROTEINASES; COAGULANT ACTIVITY; BINDING-SITE; ACTIVATION; RECEPTOR; CALPAIN; IDENTIFICATION; CYSTATIN; CONTAINS	The ability of kininogens to modulate thrombin-induced aggregation of human platelets has been assigned to domain 3 (D3) in the common heavy chain coded for by exons 7, 8, and 9 of kininogen gene. We expressed each of the exons 7, 8, and 9, and various combinations as glutathione S-transferase fusion proteins in Escherichia coli. Each of the exon products 7 (Lys(236)-Gln(292)), 8 (Va1(293)-Gly(328)), and 9 (Gln(329)-Met(357)), and their combinations were evaluated for the ability to inhibit thrombin induced platelet aggregation. Only products containing exon 7 inhibited platelet aggregation induced by thrombin with an IC50 of >20 mu M. A deletion mutant of exon 7 product, polypeptide 7A product (Lys(236)-Lys(270)) did not block thrombin-induced platelet aggregation, while 7B product (Thr-(255)-Gln(292)) and 7C product (Leu(271)-Gln(292)) inhibited aggregation. These findings indicated that the inhibitory activity is localized to residues Leu(271)-Gln(292). Peptides Phe(279)-Ile(283) and Phe(281)-Gln(292) did not block thrombin, and Asn(275)-Phe(279) had only minimal inhibitory activity. A heptapeptide Leu(271)-Ala(277) inhibited thrombin-induced aggregation of platelets with an IC50 of 65 mu M. The effect is specific for the. activation of platelets by thrombin but not ADP or collagen. No evidence for a thrombin-kininogen complex was found, and neither HK nor its derivatives directly inhibited thrombin activity. Knowledge of the critical sequence of kininogen should allow design of compounds that can modulate thrombin activation of platelets.	TEMPLE UNIV, SCH MED, SOL SHERRY THROMBOSIS RES CTR, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, DEPT MED, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, DEPT PATHOL, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, DEPT PHYSIOL, PHILADELPHIA, PA 19140 USA; ARES ADV TECHNOL, RANDOLPH, MA 02368 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University				Bradford, Harlan/0000-0001-5582-278X	NHLBI NIH HHS [HL45486] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL045486] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; BRADFORD HN, 1990, BIOCHEM J, V270, P83, DOI 10.1042/bj2700083; BRADFORD HN, 1993, J BIOL CHEM, V268, P26546; COLMAN RW, 1984, J CLIN INVEST, V73, P1249, DOI 10.1172/JCI111326; COLMAN RW, 1970, J BIOL CHEM, V245, P5941; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; DANIEL JL, 1984, J BIOL CHEM, V259, P9826; DELACADENA RA, 1994, THROMB HAEMOSTASIS, V72, P125; DELACADENA RA, 1993, THROMB HAEMOSTASIS, V69, P781; DELACADENA RA, 1994, HEMOSTASIS THROMBOSI, P224; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GASH AK, 1986, AM J CARDIOL, V57, P175, DOI 10.1016/0002-9149(86)90975-6; GUSTAFSON EJ, 1986, J CLIN INVEST, V78, P310, DOI 10.1172/JCI112567; GUSTAFSON EJ, 1989, J CLIN INVEST, V84, P28, DOI 10.1172/JCI114151; HANSON SR, 1988, J CLIN INVEST, V81, P149, DOI 10.1172/JCI113286; HASAN AAK, 1995, BLOOD, V85, P3134, DOI 10.1182/blood.V85.11.3134.bloodjournal85113134; HERAS M, 1989, CIRCULATION, V79, P657, DOI 10.1161/01.CIR.79.3.657; HERWALD H, 1995, J BIOL CHEM, V270, P14634; Holmsen H., 1994, HEMOSTASIS THROMBOSI, P524; HUMPHRIES JE, 1994, FIBRINOLYSIS, V8, P245, DOI 10.1016/0268-9499(94)90050-7; ISHIGURO H, 1987, BIOCHEMISTRY-US, V26, P7021, DOI 10.1021/bi00396a025; JAMIESON GA, 1978, J CLIN INVEST, V61, P861, DOI 10.1172/JCI109000; JIANG YP, 1992, J BIOL CHEM, V267, P3712; KERBIRIOUNABIAS DM, 1984, BRIT J HAEMATOL, V56, P273, DOI 10.1111/j.1365-2141.1984.tb03955.x; KIKUMOTO R, 1984, BIOCHEMISTRY-US, V23, P85, DOI 10.1021/bi00296a014; KITAMURA N, 1985, J BIOL CHEM, V260, P8610; KUNAPULI SP, 1993, J BIOL CHEM, V268, P2486; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARKWARDT F, 1991, THROMB HAEMOSTASIS, V66, P141; MELONI FJ, 1991, J BIOL CHEM, V266, P6786; NURDEN AT, 1974, BRIT J HAEMATOL, V28, P253, DOI 10.1111/j.1365-2141.1974.tb06660.x; PAGE JD, 1994, ARCH BIOCHEM BIOPHYS, V314, P159, DOI 10.1006/abbi.1994.1424; PARKER RC, 1962, METHODS TISSUE CULTU; PHILLIPS DR, 1975, NATURE, V257, P599, DOI 10.1038/257599a0; PURI RN, 1993, BLOOD COAGUL FIBRIN, V4, P495; SALVESEN G, 1986, BIOCHEM J, V234, P429, DOI 10.1042/bj2340429; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMAIER AH, 1986, J CLIN INVEST, V77, P1565, DOI 10.1172/JCI112472; SCHMAIER AH, 1987, J BIOL CHEM, V262, P1405; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; SCOTT CF, 1985, J BIOL CHEM, V260, P856; SCOTT CF, 1984, J CLIN INVEST, V73, P954, DOI 10.1172/JCI111319; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAIT JF, 1987, J BIOL CHEM, V262, P11651; TAKAGAKI Y, 1985, J BIOL CHEM, V260, P8601; TAKAMATSU J, 1986, J CLIN INVEST, V77, P362, DOI 10.1172/JCI112313; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WACHTFOGEL YT, 1994, J BIOL CHEM, V269, P19307	50	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11228	11235		10.1074/jbc.271.19.11228	http://dx.doi.org/10.1074/jbc.271.19.11228			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626672	hybrid			2022-12-25	WOS:A1996UJ94400032
J	Matsunaga, T; Park, CH; Bessho, T; Mu, D; Sancar, A				Matsunaga, T; Park, CH; Bessho, T; Mu, D; Sancar, A			Replication protein A confers structure-specific endonuclease activities to the XPF-ERCC1 and XPG subunits of human DNA repair excision nucleases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								XPF-ERCC1 and XPG proteins are nucleases that are involved in human nucleotide excision repair. In this study, we characterized the structure-specific junction-cutting activities of both nucleases using DNA substrates containing a bubble or loop structure. We found that the junction-cutting activities of XPF-ERCC1 and XPG were greatly stimulated by human replication protein A (RPA), while heterologous single-stranded DNA-binding proteins could not substitute for human RPA. To test for specific interaction between RPA and XPF-ERCC1 as is known to occur between RPA and XPG, we employed a pull-down assay with immobilized ''bubble'' substrate. We found that the binding of XPF-ERCC1 complex to the bubble substrate was enhanced by RPA, suggesting a possible mechanism for RPA in the excision nuclease system, that is the targeting of the nuclease subunits to their specific sites of action. Furthermore, the RPA-promoted junction cutting by XPF-ERCC1 and XPG nucleases was observed with ''loop'' substrates as well, raising the possibility that XPF-ERCC1, XPG, and RPA may function in removing loop structures from DNA, independent of the other subunits of the human excinuclease.	UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine			Mu, David/E-8933-2011	Mu, David/0000-0002-7762-0182	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032833] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32833] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; FRIEDBERG EC, 1995, DNA REPAIR; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; HABRAKEN Y, 1994, NUCLEIC ACIDS RES, V22, P3312, DOI 10.1093/nar/22.16.3312; HABRAKEN Y, 1994, J BIOL CHEM, V269, P31342; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LI L, 1995, MOL CELL BIOL, V15, P5396; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; MATSUNAGA T, 1995, J BIOL CHEM, V270, P20862, DOI 10.1074/jbc.270.35.20862; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; NAGAI A, 1995, BIOCHEM BIOPH RES CO, V211, P960, DOI 10.1006/bbrc.1995.1905; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PARK CH, 1994, P NATL ACAD SCI USA, V91, P5017, DOI 10.1073/pnas.91.11.5017; PARK CH, 1993, NUCLEIC ACIDS RES, V21, P5110, DOI 10.1093/nar/21.22.5110; PARK CH, 1995, J BIOL CHEM, V270, P22657, DOI 10.1074/jbc.270.39.22657; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SZANKASI P, 1995, SCIENCE, V267, P1166, DOI 10.1126/science.7855597; UMAR A, 1994, SCIENCE, V266, P814, DOI 10.1126/science.7973637	27	160	163	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11047	11050		10.1074/jbc.271.19.11047	http://dx.doi.org/10.1074/jbc.271.19.11047			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626644	Green Published, hybrid			2022-12-25	WOS:A1996UJ94400004
J	Peng, M; Huang, L; Xie, Z; Huang, WH; Askari, A				Peng, M; Huang, L; Xie, Z; Huang, WH; Askari, A			Partial inhibition of Na+/K+-ATPase by ouabain induces the Ca2+-dependent expressions of early-response genes in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT MYOCARDIAL-CELLS; SIGNAL-TRANSDUCTION PATHWAYS; SODIUM-PUMP INHIBITION; CHICK HEART-CELLS; C-FOS; PARACRINE MECHANISM; 5'-FLANKING REGION; PROTEIN-SYNTHESIS; CATION-TRANSPORT; 2ND MESSENGERS	Exposure of neonatal rat cardiac myocytes to ouabain concentrations that caused partial inhibition of Na+/K+-ATPase but no loss of viability, increased c-fos and c-jun mRNAs and the transcription factor AP-1. The increased mRNAs were proportional to the extent of inhibition of Na+/K+-ATPase and the resulting rise in steady state intracellular Ca2+ concentration. The rapid and sustained increase of c-fos mRNA was shown to be due to increased transcriptional rate. Induction of c-fos by ouabain was prevented when either extracellular or intracellular Ca2' was lowered and was attenuated by pretreatment of myocytes with a phorbol ester under conditions known to down-regulate protein kinase C. Exposure to ouabain for 24-48 h also increased total transcriptional activity and protein content of myocytes. The findings suggest that the same signal responsible for the positive inotropic action of ouabain, i.e, net influx of Ca2+ caused by partial inhibition of Na+/K+-ATPase, also initiates the rapid protein kinase C-dependent inductions of the early-response genes, the subsequent regulations of other cardiac genes by the resulting transcription factors, and stimulation of myocyte growth. Whether these hitherto unrecognized effects of cardiac glycosides are obtained in the intact heart and their relevance to the therapeutic uses of these drugs remain to be determined.	MED COLL OHIO,DEPT PHARMACOL,TOLEDO,OH 43699						NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-36573] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKERA T, 1991, LIFE SCI, V48, P97, DOI 10.1016/0024-3205(91)90402-W; ALLO SN, 1992, AM J PHYSIOL, V263, pC319, DOI 10.1152/ajpcell.1992.263.2.C319; ARYSTARKHOVA E, 1994, SODIUM PUMP, P230; BARRY WH, 1985, CIRC RES, V56, P231, DOI 10.1161/01.RES.56.2.231; BIEDERT S, 1979, J GEN PHYSIOL, V74, P479, DOI 10.1085/jgp.74.4.479; BISHOPRIC NH, 1992, MOL CELL BIOL, V12, P292; BLAUSTEIN MP, 1993, AM J PHYSIOL, V264, pC1367, DOI 10.1152/ajpcell.1993.264.6.C1367; BROWN JH, 1992, TRENDS CARDIOVAS MED, V2, P209, DOI 10.1016/1050-1738(92)90026-O; CAYANIS E, 1992, J MEMBRANE BIOL, V125, P163; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; EISNER DA, 1992, HEART CARDIOVASCULAR, V1, P863; GOLOMB E, 1994, AM J HYPERTENS, V7, P69, DOI 10.1093/ajh/7.1.69; GOSWAMI SK, 1992, CELL MOL BIOL, V38, P49; GOTOH H, 1993, BIOCHEM BIOPH RES CO, V194, P72, DOI 10.1006/bbrc.1993.1786; HELLER M, 1988, BIOCHIM BIOPHYS ACTA, V939, P595, DOI 10.1016/0005-2736(88)90107-1; HENRICH CJ, 1988, J MOL CELL CARDIOL, V20, P1981; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KAPLAN JG, 1978, ANNU REV PHYSIOL, V40, P19, DOI 10.1146/annurev.ph.40.030178.000315; KATZ AM, 1994, ANN INTERN MED, V121, P363, DOI 10.7326/0003-4819-121-5-199409010-00009; KENT RL, 1989, CIRC RES, V64, P74, DOI 10.1161/01.RES.64.1.74; KIM D, 1984, CIRC RES, V55, P39, DOI 10.1161/01.RES.55.1.39; KIM D, 1987, CIRC RES, V60, P185, DOI 10.1161/01.RES.60.2.185; KIRTANE A, 1994, J MEMBRANE BIOL, V137, P9; KOVACICMILIVOJEVIC B, 1992, MOL CELL BIOL, V12, P292, DOI 10.1128/MCB.12.1.292; LACHANT NA, 1995, AM J HEMATOL, V49, P56, DOI 10.1002/ajh.2830490110; LEE G, 1994, MOL CELL BIOL, V14, P4579, DOI 10.1128/MCB.14.7.4579; LEE HR, 1988, J BIOL CHEM, V263, P7352; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCALL D, 1979, AM J PHYSIOL, V236, pC87, DOI 10.1152/ajpcell.1979.236.1.C87; MCDERMOTT PJ, 1989, CIRC RES, V64, P542, DOI 10.1161/01.RES.64.3.542; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; NAKAGAWA Y, 1992, J BIOL CHEM, V267, P8785; NG YC, 1987, AM J PHYSIOL, V252, pH1016; ORLOWSKI J, 1990, J BIOL CHEM, V265, P3462; OTANI H, 1989, MOL CELL BIOCHEM, V90, P111; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; PENG M, 1995, CELL MOL BIOL RES, V41, P189; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; PUCEAT M, 1991, BIOCHEM J, V274, P55, DOI 10.1042/bj2740055; PUCEAT M, 1994, J BIOL CHEM, V269, P16938; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SCHUNKERT H, 1995, CIRC RES, V76, P489, DOI 10.1161/01.RES.76.3.489; Schwartz A, 1988, Prog Clin Biol Res, V268B, P321; SHUBEITA HE, 1990, J BIOL CHEM, V265, P20555; SHULL MM, 1990, GENOMICS, V6, P451, DOI 10.1016/0888-7543(90)90475-A; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; SIMPSON PC, 1991, MOL CELL BIOCHEM, V104, P35; THOMPSON MA, 1995, J BIOL CHEM, V270, P4224, DOI 10.1074/jbc.270.9.4224; VANBILSEN M, 1993, CARDIOVASC RES, V27, P1140; VEMURI R, 1989, AM J PHYSIOL, V256, pC1273, DOI 10.1152/ajpcell.1989.256.6.C1273; WEBSTER KA, 1993, J BIOL CHEM, V268, P16852; XIE ZJ, 1989, ANAL BIOCHEM, V183, P215, DOI 10.1016/0003-2697(89)90470-3; YAGAWA Y, 1990, BIOCHIM BIOPHYS ACTA, V1049, P286, DOI 10.1016/0167-4781(90)90099-N; ZHENG JS, 1994, CIRC RES, V74, P1034, DOI 10.1161/01.RES.74.6.1034	59	170	175	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10372	10378		10.1074/jbc.271.17.10372	http://dx.doi.org/10.1074/jbc.271.17.10372			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626609	hybrid			2022-12-25	WOS:A1996UG25700081
J	Belan, PV; Gerasimenko, OV; Tepikin, AV; Petersen, OH				Belan, PV; Gerasimenko, OV; Tepikin, AV; Petersen, OH			Localization of Ca2+ extrusion sites in pancreatic acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXOCRINE PANCREAS; INOSITOL TRISPHOSPHATE; PLASMA-MEMBRANE; CALCIUM; SECRETION; OSCILLATIONS; RELEASE; PUMP	We have investigated the localization of Ca2+ extrusion sites in mouse pancreatic acinar cells, Employing a new technique, in which high resolution localization of cellular Ca2+ exit is achieved by confocal microscopy and a Ca2+-sensitive fluorescent probe coupled to heavy dextran to slow down diffusion of extracellular Ca2+, it is shown directly that the secretory pole (secretory granule area) is the major site for Ca2+ extrusion following agonist stimulation, This Ca2+ extrusion appears not to be a consequence of exocytosis, as assessment of secretion under our experimental conditions (low external Ca2+ concentration, room temperature) using the technique of monitoring quinacrine fluorescence shows little loss of secretory granules in spite of sustained Ca2+ exit. We conclude that Ca2+ is primarily extruded by Ca2+ pumps from the secretory pole and propose that this process is useful for maintaining a high Ca2+ concentration in the acinar lumen, which is necessary for promotion of endocytosis.	UNIV LIVERPOOL,MRC,SECRETORY CONTROL RES GRP,PHYSIOL LAB,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool			Gerasimenko, Oleg/A-6622-2010; Belan, Pavel/AAV-3522-2021; Petersen, Ole H/E-8708-2010	Gerasimenko, Oleg/0000-0003-2573-8258; Belan, Pavel/0000-0001-5429-3716; Petersen, Ole/0000-0002-6998-0380; Tepikin, Alexei/0000-0002-8172-7513	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOKVIST K, 1995, EMBO J, V14, P50, DOI 10.1002/j.1460-2075.1995.tb06974.x; BOLENDER RP, 1974, J CELL BIOL, V61, P269, DOI 10.1083/jcb.61.2.269; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CHANG A, 1989, HDB PHYSL GASTROINTE, V3, P531; ENYEDI A, 1994, J BIOL CHEM, V269, P41; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; Humbert JP, 1996, J BIOL CHEM, V271, P478, DOI 10.1074/jbc.271.1.478; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; MARUYAMA Y, 1993, EMBO J, V12, P3017, DOI 10.1002/j.1460-2075.1993.tb05970.x; MARUYAMA Y, 1989, PFLUG ARCH EUR J PHY, V413, P438, DOI 10.1007/BF00584496; MUALLEM S, 1989, ANNU REV PHYSIOL, V51, P83; NICAISE G, 1992, BIOL CELL, V75, P89, DOI 10.1016/0248-4900(92)90128-N; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; TEPIKIN AV, 1992, J BIOL CHEM, V267, P3569; TEPIKIN AV, 1992, J BIOL CHEM, V267, P14073; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; TOESCU EC, 1995, J BIOL CHEM, V270, P8528, DOI 10.1074/jbc.270.15.8528; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; UEDA N, 1977, PFLUG ARCH EUR J PHY, V370, P179, DOI 10.1007/BF00581692; YOO SH, 1990, J BIOL CHEM, V265, P13446; ZHANG BX, 1992, J BIOL CHEM, V267, P15419	25	66	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7615	7619		10.1074/jbc.271.13.7615	http://dx.doi.org/10.1074/jbc.271.13.7615			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631796				2022-12-25	WOS:A1996UC77400064
J	Cartier, GE; Yoshikami, DJ; Gray, WR; Luo, SQ; Olivera, BM; McIntosh, JM				Cartier, GE; Yoshikami, DJ; Gray, WR; Luo, SQ; Olivera, BM; McIntosh, JM			A new alpha-conotoxin which targets alpha 3 beta 2 nicotinic acetylcholine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT; LOPHOTOXIN; EXPRESSION; DIVERSITY; PEPTIDES; TOXINS; PROBES; BRAIN; VENOM	We have isolated a 16-amino acid peptide from the venom of the marine snail Conus magus which potently blocks nicotinic acetylcholine receptors (nAChRs) composed of alpha 3 beta 2 subunits. This peptide, named alpha-conotoxin MII, was identified by electrophysiologically screening venom fractions against cloned nicotinic receptors expressed in Xenopus oocytes. The peptide's structure, which has been confirmed by mass spectrometry and total chemical synthesis, differs significantly from those of all previously isolated alpha-conotoxins. Disulfide bridging, however, is conserved. The toxin blocks the response to acetylcholine in oocytes expressing alpha 3 beta 2 nAChRs with an IC50 of 0.5 nM and is 2-4 orders of magnitude less potent on other nAChR subunit combinations. We have recently reported the isolation and characterization of alpha-conotoxin ImI, which selectively targets homomeric alpha 7 neuronal nAChRs. Yet other alpha-conotoxins selectively block the muscle subtype of nAChR. Thus, it is increasingly apparent that alpha-conotoxins represent a significant resource for ligands with which to probe structure-function relationships of various nAChR subtypes.	UNIV UTAH, DEPT BIOL, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, DEPT PSYCHIAT, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					PHS HHS [P01 48677] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; ABRAMSON SN, 1988, J BIOL CHEM, V263, P18568; Arneric Stephen P., 1995, P95; BOULTER J, 1986, NATURE, V319, P368, DOI 10.1038/319368a0; CHANGEUX JP, 1993, SCI AM, V269, P58, DOI 10.1038/scientificamerican1193-58; CHIAPPINELLI VA, 1993, NATURAL SYNTHETIC NE, P66; CRUZ LJ, 1985, J TOXICOL-TOXIN REV, V4, P107, DOI 10.3109/15569548509014416; DENERIS ES, 1988, NEURON, V1, P45, DOI 10.1016/0896-6273(88)90208-5; DUVOISIN RM, 1989, NEURON, V3, P487, DOI 10.1016/0896-6273(89)90207-9; ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X; FAINZILBER M, 1994, BIOCHEMISTRY-US, V33, P9523, DOI 10.1021/bi00198a018; FENICAL W, 1981, SCIENCE, V212, P1512, DOI 10.1126/science.6112796; FIORDALISI JJ, 1994, BIOCHEMISTRY-US, V33, P12962, DOI 10.1021/bi00248a004; GERZANICH V, 1994, MOL PHARMACOL, V45, P212; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; GOLDMAN D, 1987, CELL, V48, P965, DOI 10.1016/0092-8674(87)90705-7; GRAY WR, 1983, J BIOL CHEM, V258, P2247; GRAY WR, 1981, J BIOL CHEM, V256, P4734; GRAY WR, 1995, J NEUR ABSTR, V21, P10; GROEBE DR, 1995, MOL PHARMACOL, V48, P105; HANN RM, 1994, BIOCHEMISTRY-US, V33, P14058, DOI 10.1021/bi00251a014; HOPKINS C, 1995, J BIOL CHEM, V270, P22361, DOI 10.1074/jbc.270.38.22361; JOHNSON DS, 1995, MOL PHARMACOL, V48, P194; KOSUGE T, 1981, TETRAHEDRON LETT, V22, P3417, DOI 10.1016/S0040-4039(01)81920-1; KREIENKAMP HJ, 1994, J BIOL CHEM, V269, P8108; LUETJE CW, 1990, J NEUROCHEM, V55, P632, DOI 10.1111/j.1471-4159.1990.tb04180.x; MARTINEZ JS, 1995, BIOCHEMISTRY-US, V34, P14519, DOI 10.1021/bi00044a030; MCINTOSH JM, 1994, J BIOL CHEM, V269, P16733; MCINTOSH M, 1982, ARCH BIOCHEM BIOPHYS, V218, P329, DOI 10.1016/0003-9861(82)90351-4; MYERS RA, 1991, BIOCHEMISTRY-US, V30, P9370, DOI 10.1021/bi00102a034; MYERS RA, 1993, CHEM REV, V93, P1923, DOI 10.1021/cr00021a013; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; PATRICK J, 1987, ANN NY ACAD SCI, V505, P194, DOI 10.1111/j.1749-6632.1987.tb51292.x; RAMILO CA, 1992, BIOCHEMISTRY-US, V31, P9919, DOI 10.1021/bi00156a009; SEGUELA P, 1993, J NEUROSCI, V13, P596; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; Taylor P., 1990, PHARMACOL BASIS THER, P166; WADA K, 1988, SCIENCE, V240, P330, DOI 10.1126/science.2832952; WARD JM, 1990, FEBS LETT, V270, P45, DOI 10.1016/0014-5793(90)81231-C; ZAFARALLA GC, 1988, BIOCHEMISTRY-US, V27, P7102, DOI 10.1021/bi00418a065	40	440	458	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7522	7528		10.1074/jbc.271.13.7522	http://dx.doi.org/10.1074/jbc.271.13.7522			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631783				2022-12-25	WOS:A1996UC77400051
J	Abe, K; Ruan, ZS; Maloney, PC				Abe, K; Ruan, ZS; Maloney, PC			Cloning, sequencing, and expression in Escherichia coli of OxlT, the oxalate:formate exchange protein of Oxalobacter formigenes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; RECONSTITUTION; DECARBOXYLASE; PURIFICATION; ANTIPORT; GENE	OxlT is the oxalate/formate exchange protein that represents the vectorial component of a proton-motive metabolic cycle in Oxalobacter formigenes. Here we report the cloning and sequencing of OxlT and describe its expression in Escherichia coli. The OxlT amino acid sequence specifies a polytopic hydrophobic protein of 418 residues with a mass of 44,128 daltons. Analysis of hydropathy and consideration of the distribution of charged residues suggests an OxlT secondary structure having 12 transmembrane segments, oriented so that the N and C termini face the cytoplasm. Expression of OxlT in E. coli coincides with appearance of a capacity to carry out the self-exchange of oxalate and the heterologous, electrogenic exchange of oxalate with formate. The unusually high velocity of OxlT-mediated transport is also preserved in E. coli. We conclude that the essential features of OxlT are retained on its expression in E. coli.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205	Johns Hopkins University					NIGMS NIH HHS [GM24195] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM024195, R01GM024195] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALLISON MJ, 1985, ARCH MICROBIOL, V141, P1, DOI 10.1007/BF00446731; AMBUDKAR SV, 1990, J BIOL CHEM, V265, P12287; AMBUDKAR SV, 1986, J BIOL CHEM, V261, P79; ANANTHARAM V, 1989, J BIOL CHEM, V264, P7244; BAETZ AL, 1989, J BACTERIOL, V171, P2605, DOI 10.1128/jb.171.5.2605-2608.1989; Bjerrum OJ, 1986, ANAL ELECTROPHORESIS, P315; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; Harlow E., 1988, ANTIBODIES LAB MANUA; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; JUNG K, 1994, BIOCHEMISTRY-US, V33, P3980, DOI 10.1021/bi00179a026; KUHNER CH, 1987, ANN M AM SOC MICR WA; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUNG HY, 1991, AM J KIDNEY DIS, V17, P381, DOI 10.1016/S0272-6386(12)80627-5; MALONEY PC, 1994, CURR OPIN CELL BIOL, V6, P571, DOI 10.1016/0955-0674(94)90079-5; MALONEY PC, 1996, ESCHERICHIA COLI SAL, P1130; ROST B, 1995, PROTEIN SCI, V4, P521; RUAN ZS, 1992, J BIOL CHEM, V267, P10537; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARERO JP, 1995, J BACTERIOL, V177, P297; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; VARADHACHARY A, 1990, MOL MICROBIOL, V4, P1407, DOI 10.1111/j.1365-2958.1990.tb00720.x; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; YAN RT, 1993, CELL, V75, P37, DOI 10.1016/S0092-8674(05)80082-0; YAN RT, 1995, P NATL ACAD SCI USA, V92, P5973, DOI 10.1073/pnas.92.13.5973	29	54	58	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6789	6793		10.1074/jbc.271.12.6789	http://dx.doi.org/10.1074/jbc.271.12.6789			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636101	hybrid			2022-12-25	WOS:A1996UB15700036
J	Malek, SN; Yang, CH; Earnshaw, WC; Kozak, CA; Desiderio, S				Malek, SN; Yang, CH; Earnshaw, WC; Kozak, CA; Desiderio, S			p150(TSP), conserved nuclear phosphoprotein that contains multiple tetratricopeptide repeats and binds specifically to SH2 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHORYLATED PEPTIDES; AFFINITY PHOSPHOTYROSYL PEPTIDE; NUCLEOTIDE EXCHANGE; ADAPTER PROTEIN; RECEPTOR; GRB2; SOS; TRANSFORMATION; RECOGNITION; ACTIVATOR	Src homology 2 (SH2) domains are structural modules that function in the assembly of multicomponent signaling complexes by binding to specific phosphopeptides. The tetratricopeptide repeat (TPR) is a distinct structural motif that has been suggested to mediate protein-protein interactions, Among SH2-binding phosphoproteins purified from the mouse B cell lymphoma A20, a 150-kDa species was identified and the corresponding complementary DNA (cDNA) was molecularly cloned, This protein encoded by this cDNA, which we have termed p150(TSP) (for TPR-containing, SH2-binding phosphoprotein), is located predominantly in the nucleus and is highly conserved in evolution, The gene encoding p150(TSP) (Tsp) was mapped to chromosome 7 of the mouse with gene order: centromere-Tyr-Wnt11-Tsp-Zp2. The amino-terminal two-thirds of p150(TSP) consist almost entirely of tandemly arranged TPR units, which mediate specific, homotypic protein interactions in transfected cells. The carboxyl-terminal third of p150(TSP) which is serine- and glutamic acid-rich, is essential for SH2 binding; this interaction is dependent on serine/threonine phosphorylation but independent of tyrosine phosphorylation, The sequence and binding properties of p150(TSP) suggest that it may mediate interactions between TPR-containing and SH2-containing proteins.	JOHNS HOPKINS UNIV, SCH MED, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT CELL BIOL & ANAT, BALTIMORE, MD 21205 USA; NIAID, NIH, MOLEC MICROBIOL LAB, BETHESDA, MD 20892 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Earnshaw, William/AAY-7438-2020	Earnshaw, William/0000-0002-7191-0621				ADAMSON MC, 1994, GENOMICS, V24, P9, DOI 10.1006/geno.1994.1575; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CACERES A, 1984, J NEUROSCI, V4, P394; CASAMAYOR A, 1995, YEAST, V11, P1281, DOI 10.1002/yea.320111308; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; Green E., 1981, GENETICS PROBABILITY, DOI 10.1007/978-1-349-04904-2; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KOZAK CA, 1995, GENOMICS, V25, P66, DOI 10.1016/0888-7543(95)80110-8; LAMB JR, 1994, EMBO J, V13, P4321, DOI 10.1002/j.1460-2075.1994.tb06752.x; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MALEK SN, 1994, J BIOL CHEM, V269, P33009; MALEK SN, 1993, J BIOL CHEM, V268, P22557; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	36	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6952	6962		10.1074/jbc.271.12.6952	http://dx.doi.org/10.1074/jbc.271.12.6952			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636124	hybrid			2022-12-25	WOS:A1996UB15700059
J	MarzalCasacuberta, A; BlancoVaca, F; Ishida, BY; JulveGil, J; Shen, JH; CalvetMarquez, S; GonzalezSastre, F; Chan, L				MarzalCasacuberta, A; BlancoVaca, F; Ishida, BY; JulveGil, J; Shen, JH; CalvetMarquez, S; GonzalezSastre, F; Chan, L			Functional lecithin:cholesterol acyltransferase deficiency and high density lipoprotein deficiency in transgenic mice overexpressing human apolipoprotein A-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA-LIPOPROTEINS; FISH EYE SYNDROME; HEPATIC LIPASE; ESTERIFICATION RATE; SERUM-LIPOPROTEINS; TANGIER DISEASE; GENE; HDL; EXPRESSION; TRANSPORT	The concentration of high density lipoproteins (HDL) is inversely related to the risk of atherosclerosis, The two major protein components of HDL are apolipoprotein (apo) A-I and apoA-II. To study the role of apoA-II in lipoprotein metabolism and atherosclerosis, we have developed three lines of C57BL/6 transgenic mice expressing human apoA-II (lines 25.3, 21.5, and 11.1). Northern blot experiments showed that human apoA-II mRNA was present only in the liver of transgenic mice, SDS-polyacrylamide gel electrophoresis and Western blot analysis demonstrated a 17.4-kDa human apoA-II in the HDL fraction of the plasma of transgenic mice, After 3 months on a regular chow, the plasma concentrations of human apoA-II were 21 +/- 4 mg/dl in the 25.3 line, 51 +/- 6 mg/dl in the 21.5 line, and 74 +/- 4 mg/dl in the 11.1 line. The concentration of cholesterol in plasma was significantly lower in transgenic mice than in control mice because of a decrease in HDL cholesterol that was greatest in the Line that expressed the most apoA-II (23 mg/dl in the 11.1 line versus 63 mg/dl in control mice). There was also a reduction in the plasma concentration of mouse apoA-I (32 +/- 2, 56 +/- 9, 91 +/- 7, and 111 +/- 2 mg/dl for lines 11.1, 21.5, 25.3, and control mice, respectively) that was inversely correlated with the amount of human apoA-II expressed, Additional changes in plasma lipid/lipoprotein profile noted in line 11.1 that expressed the highest level of human apoA-II include elevated triglyceride, increased proportion of total plasma, and RDL free cholesterol and a marked (>10-fold) reduction in mouse apoA-II. Total endogenous plasma lecithin:cholesterol acyltransferase (LCAT) activity was reduced to a level directly correlated with the degree of increased plasma human apoA-II in the transgenic lines, LCAT activity toward erogenous substrate was, however, only slightly decreased, The biochemical changes in the 11.1 line, which is markedly deficient in plasma apoA-I, an activator for LCAT, are reminiscent of those in patients with partial LCAT deficiency, Feeding the transgenic mice a high fat, high cholesterol diet maintained the mouse apoA-I concentration at a normal level (69 +/- 14 mg/dl in line 11.1 compared with 71 +/- 6 mg/dl in non-transgenic controls) and prevented the appearance of HDL deficiency, All this happened in the presence of a persistently high plasma human apoA-II (96 +/- 14 mg/dl), Paradoxical HDL elevation by high fat diets has been observed in humans and is reproduced in human apoA-II overexpressing transgenic mice but not in control mice. Finally, HDL size and morphology varied substantially in the three transgenic lines, indicating the importance of apoA-II concentration in the modulation of HDL formation, The LCAT and HDL deficiencies observed in this study indicate that apoA-II plays a dynamic role in the regulation of plasma HDL metabolism.	BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MED, HOUSTON, TX 77030 USA; UNIV AUTONOMA BARCELONA, DEPT BIOQUIM & BIOL MOLEC, E-08025 BARCELONA, SPAIN; HOSP SANTA CRUZ & SAN PABLO, INST RECERA, E-08025 BARCELONA, SPAIN; UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DIV RES MED & RADIAT BIOPHYS, BERKELEY, CA 94720 USA; UNIV AUTONOMA BARCELONA, UNITAT ANAT & EMBRIOL, E-08193 BARCELONA, SPAIN; HOSP SANTA CRUZ & SAN PABLO, SERV BIOQUIM, E-08025 BARCELONA, SPAIN	Baylor College of Medicine; Baylor College of Medicine; Autonomous University of Barcelona; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Autonomous University of Barcelona			Julve, Josep/I-1003-2017; Blanco-Vaca, Francisco/AAC-2600-2022	Julve, Josep/0000-0002-6531-2246; Blanco-Vaca, Francisco/0000-0001-7380-5385	NHLBI NIH HHS [HL47443, HL16512] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL047443, R01HL016512, R37HL016512] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACHORIK PS, 1982, CLIN CHEM, V28, P1375; BEKAERT ED, 1992, BIOCHIM BIOPHYS ACTA, V1126, P105, DOI 10.1016/0005-2760(92)90223-I; BLANCOVACA F, 1992, J LIPID RES, V33, P1785; BOLIN DJ, 1994, J BIOL CHEM, V269, P7429; BREWER HB, 1972, P NATL ACAD SCI USA, V69, P1304, DOI 10.1073/pnas.69.5.1304; BROWN WV, 1969, J BIOL CHEM, V244, P5687; BUSCH SJ, 1994, J BIOL CHEM, V269, P16376; CARSON SD, 1987, J BIOL CHEM, V262, P718; CHAJEKSHAUL T, 1991, P NATL ACAD SCI USA, V88, P6731, DOI 10.1073/pnas.88.15.6731; CHENG ML, 1988, BIOCHEM GENET, V26, P657, DOI 10.1007/BF00553867; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; CHEUNG MC, 1993, J CLIN INVEST, V91, P522, DOI 10.1172/JCI116231; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAY MA, 1991, ARTERIOSCLER THROMB, V11, P415, DOI 10.1161/01.ATV.11.2.415; CZARNECKA H, 1995, BIOCHEMISTRY-US, V34, P4385, DOI 10.1021/bi00013a030; DEEB SS, 1990, AM J HUM GENET, V46, P822; DOBIASOVA M, 1992, J LIPID RES, V33, P1411; DOBIASOVA M, 1986, PHYSIOL BOHEMOSLOV, V35, P319; FONTANALSFERRER N, 1988, CLIN CHEM, V34, P1753; FORTE TM, 1984, ARTERIOSCLEROSIS, V4, P130, DOI 10.1161/01.ATV.4.2.130; FORTE TM, 1995, J LIPID RES, V36, P148; FORTE TM, 1986, METHOD ENZYMOL, V128, P442; FRANCONE OL, 1995, J CLIN INVEST, V96, P1440, DOI 10.1172/JCI118180; FRUCHART JC, 1993, CIRCULATION, V87, P22; FUNKE H, 1991, J CLIN INVEST, V87, P371, DOI 10.1172/JCI114997; GLASS CK, 1983, J BIOL CHEM, V258, P7161; Glomset J.A., 1995, METABOLIC MOL BASES, Vseventh, P1933; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; HARA H, 1992, LIPIDS, V27, P302, DOI 10.1007/BF02536480; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HAYEK T, 1993, J CLIN INVEST, V91, P1665, DOI 10.1172/JCI116375; HEDRICK CC, 1993, J BIOL CHEM, V268, P20676; HOROWITZ BS, 1993, J CLIN INVEST, V91, P1743, DOI 10.1172/JCI116384; HUSSAIN MM, 1990, BIOCHEMISTRY-US, V29, P209, DOI 10.1021/bi00453a029; IKEWAKI K, 1995, ARTERIOSCL THROM VAS, V15, P306, DOI 10.1161/01.ATV.15.3.306; ISHIDA BY, 1992, J LIPID RES, V33, P1073; JAHN CE, 1983, EUR J BIOCHEM, V131, P25, DOI 10.1111/j.1432-1033.1983.tb07227.x; KLEIN HG, 1992, J CLIN INVEST, V89, P499, DOI 10.1172/JCI115612; KLEIN HG, 1993, J CLIN INVEST, V92, P479, DOI 10.1172/JCI116591; KNOTT TJ, 1985, NUCLEIC ACIDS RES, V13, P6387, DOI 10.1093/nar/13.17.6387; LAGOCKI PA, 1980, J BIOL CHEM, V255, P3701; LAGROST L, 1994, J BIOL CHEM, V269, P3189; LEBOEUF RC, 1983, J BIOL CHEM, V258, P5063; MILLER CG, 1987, J LIPID RES, V28, P311; MILLER GJ, 1975, LANCET, V1, P16; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; MINNICH A, 1992, J BIOL CHEM, V267, P16553; MOWRI HO, 1992, J LIPID RES, V33, P1269; OHTA T, 1994, ARTERIOSCLER THROMB, V14, P1137, DOI 10.1161/01.ATV.14.7.1137; PAIGEN B, 1987, ATHEROSCLEROSIS, V64, P215, DOI 10.1016/0021-9150(87)90249-8; PARKS JS, 1995, J LIPID RES, V36, P349; PONSIN G, 1993, J BIOL CHEM, V268, P3114; QU SJ, 1993, BIOCHEMISTRY-US, V32, P3089, DOI 10.1021/bi00063a021; ROSSENEU M, 1981, EUR J BIOCHEM, V117, P347, DOI 10.1111/j.1432-1033.1981.tb06344.x; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; RYE KA, 1993, BIOCHIM BIOPHYS ACTA, V1167, P316, DOI 10.1016/0005-2760(93)90235-2; Scanu A M, 1980, Ann N Y Acad Sci, V348, P160, DOI 10.1111/j.1749-6632.1980.tb21298.x; Schultz Joshua R., 1994, Current Opinion in Lipidology, V5, P126, DOI 10.1097/00041433-199404000-00009; SCHULTZ JR, 1993, NATURE, V365, P762, DOI 10.1038/365762a0; SCHULTZ JR, 1992, J BIOL CHEM, V267, P21630; SERRATSERRAT J, 1993, ATHEROSCLEROSIS, V101, P43, DOI 10.1016/0021-9150(93)90100-9; STOLTZFUS LJ, 1994, CIRCULATION, V90, P81; TAILLEUX A, 1994, CIRCULATION, V90, P81; THUREN T, 1991, J BIOL CHEM, V266, P4853; VADIVELOO PK, 1993, BIOCHEMISTRY-US, V32, P9480, DOI 10.1021/bi00087a028; WANG CS, 1987, BIOCHIM BIOPHYS ACTA, V920, P9, DOI 10.1016/0005-2760(87)90305-5; WARDEN CH, 1993, SCIENCE, V261, P469, DOI 10.1126/science.8332912; WARDEN CH, 1993, P NATL ACAD SCI USA, V90, P10886, DOI 10.1073/pnas.90.22.10886; WEISGRABER KH, 1978, J BIOL CHEM, V253, P6281; ZHONG SB, 1994, J CLIN INVEST, V94, P2457, DOI 10.1172/JCI117614	70	67	67	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6720	6728		10.1074/jbc.271.12.6720	http://dx.doi.org/10.1074/jbc.271.12.6720			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636092	hybrid			2022-12-25	WOS:A1996UB15700027
J	Schuur, ER; Henderson, GA; Kmetec, LA; Miller, JD; Lamparski, HG; Henderson, DR				Schuur, ER; Henderson, GA; Kmetec, LA; Miller, JD; Lamparski, HG; Henderson, DR			Prostate-specific antigen expression is regulated by an upstream enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROGEN RESPONSE ELEMENT; ADENOCARCINOMA CELL-LINE; GENE-EXPRESSION; CARCINOMA; LNCAP; KALLIKREIN; CANCER; RNA; DNA	Prostate cancer can be detected using assays for blood-borne prostate-specific antigen (PSA), which is the clinically most useful diagnostic marker of malignant disease, This paper characterizes the 5'-flanking prostate-specific enhancer which controls expression of the human PSA gene This enhancer, located between -5824 and -3738, is androgen-responsive and requires a promoter for activity, Inductions of 12-100-fold activity occur at 1 nM concentrations of the testosterone analog R1881. The enhancer demonstrated tissue specificity as judged by transfections of several human cell lines. Electrophoretic mobility shift assays comparing nuclear extracts from breast cancer cells MCF-7, and prostate cancer cells LNCaP, showed three regions of prostate-specific binding, These three regions are -4168 to -4797 (region I), -4710 to 4479 (region II), and -4168 to -3801 (region III), Region III contained a putative androgen response element at -4136 that markedly affected activity if mutated, These data suggest that prostate-specific gene expression may involve interaction of prostate-specific proteins or protein complexes with the enhancer in addition to binding of the androgen receptor to androgen response elements.	CALYDON INC, MENLO PK, CA 94025 USA; STANFORD UNIV, SCH MED, DEPT SURG, STANFORD, CA 94305 USA	Stanford University								ABMAYR SM, 1994, CURRENT PROTOCOLS MO, V2; AN GH, 1982, MOL CELL BIOL, V2, P1628, DOI 10.1128/MCB.2.12.1628; ANDRIOLE GL, 1991, ANNU REV MED, V42, P9, DOI 10.1146/annurev.med.42.1.9; ATCHISON ML, 1988, ANNU REV CELL BIOL, V4, P127, DOI 10.1146/annurev.cellbio.4.1.127; AUMULLER G, 1990, PROSTATE, V17, P31, DOI 10.1002/pros.2990170105; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; CATALONA WJ, 1994, NEW ENGL J MED, V331, P996; CLAESSENS F, 1989, BIOCHEM BIOPH RES CO, V164, P833, DOI 10.1016/0006-291X(89)91534-9; DIGBY M, 1989, NUCLEIC ACIDS RES, V17, P2137, DOI 10.1093/nar/17.5.2137; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FABRE S, 1994, J BIOL CHEM, V269, P5857; FREEDMAN RS, 1978, CANCER, V42, P2352, DOI 10.1002/1097-0142(197811)42:5<2352::AID-CNCR2820420536>3.0.CO;2-#; GAFFNEY EV, 1979, JNCI-J NATL CANCER I, V63, P913; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HAM J, 1988, NUCLEIC ACIDS RES, V16, P5263, DOI 10.1093/nar/16.12.5263; HENTTU P, 1992, ENDOCRINOLOGY, V130, P766, DOI 10.1210/en.130.2.766; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; HSIEH JT, 1993, CANCER RES, V53, P2852; KINGSTON RE, 1994, CURRENT PROTOCOLS MO, V2; LIEBER M, 1975, INT J CANCER, V15, P741, DOI 10.1002/ijc.2910150505; LUNDWALL A, 1989, BIOCHEM BIOPH RES CO, V161, P1151, DOI 10.1016/0006-291X(89)91362-4; LUNDWALL A, 1987, FEBS LETT, V214, P317, DOI 10.1016/0014-5793(87)80078-9; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MICKEY DD, 1977, CANCER RES, V37, P4049; MONTGOMERY BT, 1992, PROSTATE, V21, P63, DOI 10.1002/pros.2990210107; MURTHA P, 1993, BIOCHEMISTRY-US, V32, P6459, DOI 10.1021/bi00076a020; PAPSIDERO LD, 1981, J NATL CANCER I, V66, P37; REIGMAN PHJ, 1989, BIOCHEM BIOPH RES CO, V159, P95, DOI 10.1016/0006-291X(89)92409-1; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; SCHUUR ER, 1993, CELL GROWTH DIFFER, V4, P761; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TRAPMAN J, 1992, PROSTATE, P159; YOUNG CYF, 1992, BIOCHEMISTRY-US, V31, P818, DOI 10.1021/bi00118a026	35	258	288	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7043	7051		10.1074/jbc.271.12.7043	http://dx.doi.org/10.1074/jbc.271.12.7043			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636136	hybrid			2022-12-25	WOS:A1996UB15700071
J	Vasilescu, S; Ptushkina, M; Linz, B; Muller, PP; McCarthy, JEG				Vasilescu, S; Ptushkina, M; Linz, B; Muller, PP; McCarthy, JEG			Mutants of eukaryotic initiation factor eIF-4E with altered mRNA cap binding specificity reprogram mRNA selection by ribosomes in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; RNA 5' CAP; MESSENGER-RNA; PROTEIN-SYNTHESIS; SECONDARY STRUCTURE; ESCHERICHIA-COLI; TRANSLATION; YEAST; EXPRESSION; PURIFICATION	Recognition of the 5'-end of eukaryotic mRNA by the ribosomal 43 S preinitiation complex involves the eukaryotic translation initiation factor elF-4E (eIF-4 alpha). Deletion mutants of the eIF-4E gene of Saccharomyces cerevisiae (CDC33) encoded proteins with reduced affinity for the 5'-cap. One of these mutant proteins lacked any detectable binding to a cap analogue binding column, yet was still able to support cell growth. More than 17% of the total eIF-4E amino acid sequence could be removed without fully inactivating this factor, At least 30 of the N-terminal amino acids are not essential for function, The minimal functional eIF-4E protein segment therefore comprises at most 176 amino acids. The translation and growth defects of the deletion mutants could be at least partially compensated by increases in eIF-4E synthesis, possibly due to a mass-action effect on mRNA binding. Electroporation of yeast spheroplasts with in vitro synthesized mRNA allowed us to characterize the ability of elF-4E mutant strains to distinguish between capped and uncapped mRNAs in vivo. Our data show that the cap specificity of eIF-4E determines to what extent the translational apparatus differentiates between capped and uncapped mRNAs and indicate the minimum relative mRNA (cap) binding activity of eIF-4E required for yeast cell viability.	GESELL BIOTECHNOL FORSCH MBH, NATL BIOTECHNOL RES CTR, DEPT GENE EXPRESS, D-38124 BRAUNSCHWEIG, GERMANY	Gesellschaft fur Biotechnologische Forschung mbH			Mueller, Peter P./H-8656-2019	Mueller, Peter P./0000-0002-1209-7546				ALTMANN M, 1985, BIOCHEMISTRY-US, V24, P6085, DOI 10.1021/bi00343a009; ALTMANN M, 1989, MOL CELL BIOL, V9, P4467, DOI 10.1128/MCB.9.10.4467; ALTMANN M, 1988, J BIOL CHEM, V263, P17229; ALTMANN M, 1989, J BIOL CHEM, V264, P12145; ALTMANN M, 1993, TRENDS BIOCHEM SCI, V18, P429, DOI 10.1016/0968-0004(93)90143-B; BELEV TN, 1991, PLASMID, V26, P147, DOI 10.1016/0147-619X(91)90056-3; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DOBSON MJ, 1983, NUCLEIC ACIDS RES, V11, P2287, DOI 10.1093/nar/11.8.2287; DUNCAN R, 1987, J BIOL CHEM, V262, P380; EDERY I, 1988, GENE, V74, P517, DOI 10.1016/0378-1119(88)90184-9; EVERETT JG, 1992, YEAST, V8, P1007, DOI 10.1002/yea.320081203; GASIOR E, 1979, J BIOL CHEM, V254, P3965; GOYER C, 1989, J BIOL CHEM, V264, P7603; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; Guthrie C., 1991, METHOD ENZYMOL, V194, P21; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; ISHIDA T, 1983, BIOCHEM BIOPH RES CO, V115, P849, DOI 10.1016/S0006-291X(83)80012-6; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG V, 1994, J BIOL CHEM, V269, P6117; LANKER S, 1992, J BIOL CHEM, V267, P21167; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; OLIVEIRA CC, 1993, MOL MICROBIOL, V9, P521, DOI 10.1111/j.1365-2958.1993.tb01713.x; OLIVEIRA CC, 1993, NUCLEIC ACIDS RES, V21, P5316, DOI 10.1093/nar/21.23.5316; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; RHOADS RE, 1993, PROG NUCLEIC ACID RE, V46, P183, DOI 10.1016/S0079-6603(08)61022-3; SAFER B, 1989, EUR J BIOCHEM, V186, P1, DOI 10.1111/j.1432-1033.1989.tb15169.x; SAGLIOCCO FA, 1993, J BIOL CHEM, V268, P26522; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDENHEUVEL J, 1995, BBA-GENE STRUCT EXPR, V1261, P337, DOI 10.1016/0167-4781(95)00026-D; ZANCHIN NIT, 1995, J BIOL CHEM, V270, P26505, DOI 10.1074/jbc.270.44.26505; ZHONG T, 1993, CELL, V73, P1175, DOI 10.1016/0092-8674(93)90646-8	41	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7030	7037		10.1074/jbc.271.12.7030	http://dx.doi.org/10.1074/jbc.271.12.7030			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636134	hybrid			2022-12-25	WOS:A1996UB15700069
J	Luo, CM; Tang, W; Mekeel, KL; DeFrank, JS; Anne, RP; Powell, SN				Luo, CM; Tang, W; Mekeel, KL; DeFrank, JS; Anne, RP; Powell, SN			High frequency and error-prone DNA recombination in ataxia telangiectasia cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; IONIZING-RADIATION; V(D)J RECOMBINATION; HOMOLOGOUS RECOMBINATION; SCID MUTATION; UV; IRRADIATION; DEFECTS; P53; INSTABILITY	The only specific DNA repair defect found in ataxia telangiectasia (A-T) cells is mis-repair of cleaved DNA In this report we measured DNA recombination, given its role in DNA repair and genetic instability. Using plasmids containing selectable reporter genes, we found a higher frequency of both chromosomal recombination (>100 times) and extra-chromosomal recombination (27 times) in SV40-transformed A-T cell lines compared with in an SV40-transformed normal fibroblast cell line. Southern analysis of single A-T colonies exhibiting postintegration recombination revealed that 24/27 had undergone aberrant rearrangements; recombination in normal fibroblast colonies was achieved by gene conversion in 8/11 clones and 10/11 clones showed unchanged copies of the plasmid. Using co-transfection of two integrating plasmids, each containing a separate deletion in the xgprt reporter gene, the 27 times difference in extrachromosomal recombination was found when the plasmids were cleaved at a distance from the reporter gene. When the plasmids were cleaved within the reporter gene, the co-transfection frequency was reduced in A-T, but was increased in normal cells. We conclude that A-T cell lines have not only a high frequency chromosomal and extra-chromosomal recombination, but also exhibit error-prone recombination of cleaved DNA.	HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, DEPT RADIAT ONCOL, BOSTON, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital					NCI NIH HHS [CA58985] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058985] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; COLE J, 1976, MUTAT RES, V41, P377, DOI 10.1016/0027-5107(76)90110-X; COX R, 1984, BRIT J CANCER, V49, P67; DASGUPTA UB, 1980, MOL GEN GENET, V178, P617, DOI 10.1007/BF00337869; DEBENHAM PG, 1987, J CELL SCI, P177; EDWARDS MJ, 1980, NATURE, V287, P745, DOI 10.1038/287745a0; GATTI RA, 1994, INT J RADIAT BIOL, V66, pS57, DOI 10.1080/09553009414551861; HAMILTON AA, 1987, MOL CELL BIOL, V7, P1409, DOI 10.1128/MCB.7.4.1409; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; HSIEH CL, 1993, J BIOL CHEM, V268, P20105; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1993, ONCOGENE, V8, P3307; LIPKOWITZ S, 1992, P NATL ACAD SCI USA, V89, P5301, DOI 10.1073/pnas.89.12.5301; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MEYN MS, 1994, INT J RADIAT BIOL, V66, pS141; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; NASRIN N, 1994, CANCER GENET CYTOGEN, V77, P14, DOI 10.1016/0165-4608(94)90142-2; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; POWELL S, 1993, MUTAT RES, V294, P9, DOI 10.1016/0921-8777(93)90053-J; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TAYLOR AMR, 1976, NATURE, V260, P441, DOI 10.1038/260441a0; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; TAYLOR AMR, 1994, INT J RADIAT BIOL, V65, P65, DOI 10.1080/09553009414550091; TAYLOR AMR, 1978, MUTAT RES, V50, P407, DOI 10.1016/0027-5107(78)90045-3; THACKER J, 1994, INT J RADIAT BIOL, V66, pS87; THACKER J, 1989, MUTAT RES, V220, P187, DOI 10.1016/0165-1110(89)90024-9; TIMME TL, 1989, PLASMID, V22, P1, DOI 10.1016/0147-619X(89)90030-9; TSUJIMURA T, 1990, P NATL ACAD SCI USA, V87, P1566, DOI 10.1073/pnas.87.4.1566; WAHLS WP, 1990, SOMAT CELL MOLEC GEN, V16, P321, DOI 10.1007/BF01232460	33	68	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4497	4503						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626804				2022-12-25	WOS:A1996TW96000082
J	Berthelsen, J; Vandekerkhove, J; Blasi, F				Berthelsen, J; Vandekerkhove, J; Blasi, F			Purification and characterization of UEF3, a novel factor involved in the regulation of the urokinase and other AP-1 controlled promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR GENE; TRANSCRIPTION FACTOR; RNA-POLYMERASE; BINDING-SITES; PHORBOL-ESTER; ELEMENT; EXPRESSION; INDUCTION; ENHANCER; MOUSE	Basal as well as induced transcription from the human urokinase type plasminogen activator gene requires an enhancer containing two elements, a combined PEA3/AP-1 and a consensus AP-1 site. The integrity of each of these binding sites as well as their cooperation is required for activating transcription. The two elements are separated by a 74-base pair cooperation mediating (COM) region required for the cooperation between the transactivating sites. The COM region contains binding sites for four different unidentified urokinase-type plasminogen activator enhancer factors (UEF 1 to 4), all four required for correct COM activity. We have purified UEF3 from HeLa nuclear extracts by several chromatographic steps including DNA affinity purification. Purification and UV cross-linking data showed that UEF3 is a complex of three polypeptides (p40, p50, and p64). Amino acid sequence from one peptide of p64 was obtained, which showed no homology to other known proteins. Both crude and purified UEF3 specifically bound to the sequence TGACAG as shown by electrophoretic mobility shifts and methylation interference studies. DNA-binding specificity of purified UEF3 was identical to that of NIP, a non-characterized factor binding and regulating multiple AP-1-regulated promoters like stromelysin and interleukin-3. Thus UEF3 appears to be a general DNA-binding factor involved in modulating the transcriptional response of AP-1 containing promoters.	UNIV MILAN,DEPT GENET & BIOL MICROORGANISMS,I-20135 MILAN,ITALY; IST SCI SAN RAFFAELE,DIBIT,I-20132 MILAN,ITALY; UNIV COPENHAGEN,DEPT MOLEC CELL BIOL,DK-1353 COPENHAGEN,DENMARK; STATE UNIV GHENT,GENET LAB,B-9000 GHENT,BELGIUM	University of Milan; Vita-Salute San Raffaele University; University of Copenhagen; Ghent University				Blasi, Francesco/0000-0001-9406-1784				BAUW G, 1989, P NATL ACAD SCI USA, V86, P7701, DOI 10.1073/pnas.86.20.7701; Blasi F, 1990, Semin Cancer Biol, V1, P117; CASSADY AI, 1991, NUCLEIC ACIDS RES, V19, P6839, DOI 10.1093/nar/19.24.6839; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GOTTSCHALK LR, 1993, J EXP MED, V178, P1681, DOI 10.1084/jem.178.5.1681; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HANSEN SK, 1994, MOL CELL BIOL, V14, P2593, DOI 10.1128/MCB.14.4.2593; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P588; LARSSON LI, 1984, J CELL BIOL, V98, P894, DOI 10.1083/jcb.98.3.894; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; MATSUDAIRA P, 1978, ANAL BIOCHEM, V87, P1386; NERLOV C, 1991, ONCOGENE, V6, P1583; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; NOMIYAMA H, 1993, MOL CELL BIOL, V13, P2787, DOI 10.1128/MCB.13.5.2787; RITTER LM, 1995, MOL CELL BIOL, V15, P3110; RORTH P, 1990, NUCLEIC ACIDS RES, V18, P5009, DOI 10.1093/nar/18.17.5009; Sambrook J, 1989, MOL CLONING LABORATO; SAPPINO AP, 1989, J CELL BIOL, V109, P2471, DOI 10.1083/jcb.109.5.2471; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699	23	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3822	3830						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632000				2022-12-25	WOS:A1996TV72400074
J	Coquil, JF; Mauger, JP; Claret, M				Coquil, JF; Mauger, JP; Claret, M			Inositol 1,4,5-trisphosphate slowly converts its receptor to a state of higher affinity in sheep cerebellum membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM DEPRESSION; METABOTROPIC GLUTAMATE RECEPTORS; CALCIUM RELEASE; TRISPHOSPHATE RECEPTOR; INSP3 RECEPTOR; PURKINJE-CELLS; FUNCTIONAL-CHARACTERIZATION; ENDOPLASMIC-RETICULUM; CA2+ STORES; BINDING	Incubation of cerebellar microsomes with D-myo-inositol 1,4,5-trisphosphate (InsP(3)) (0.01-1 mu M), at 4 or 20 degrees C in a cytosolic-like medium devoid of Ca2+ and Mg2+, followed by InsP(3) removal, induced an increase in InsP(3) binding determined with 1 nM [H-3]InsP(3). At 20 degrees C, and pH 7.1, maximal stimulation (1.5-2.5-fold) was obtained with 1 mu M InsP(3), and the EC(50) was 60 +/- 5 mu M. Several lines of evidence suggested that the activating site is identical with the InsP(3) binding site: (i) activation and binding exhibited the same inositol phosphate specificity; (ii) addition of decavanadate, a competitive inhibitor of [H-3]InsP(3) binding, to the preincubation mixture, prevented the activating effect of InsP(3); (iii) the concentration of InsP(3) giving half-maximal activation was close to that giving half-maximal InsP(3) binding. The time course of activation was found to be much slower than that of binding. While a t(1/2) less than 0.4 s has been measured recently at neutral pH and 20 degrees C for binding of 0.5 nM [H-3]InsP(3) (Hannaert-Merah, Z., Coquil, J.-F., Combettes, L., Claret, M., Mauger, J.-P., and Champeil, P. (1994) J. Biol. Chem. 269, 29642-29649), a 20-s preincubation with 1 mu M InsP(3) was required to half-maximally stimulate binding. Under the present conditions, the InsP(3)-induced binding increase was only partially reversible. However, this effect was not blocked by antiproteases suggesting that it did not involve proteolysis. Taking advantage of the marked difference in the kinetics of InsP(3) binding and InsP(3)-dependent activation, we performed binding experiments on a short period (3 s) to determine the effect of InsP(3) pretreatment on the binding parameters. The data showed that this treatment increased the affinity of the receptor without changing the number of binding sites (control: K-D = 107 nM, B-max = 28 pmol/mg of protein; after preincubation with 1 mu M InsP(3): K-D = 53 nM, B-max = 32 pmol/mg of protein). The two states of the receptor bound InsP(3) with a Hill coefficient close to 1 on a 3-s scale. In agreement with the effect of InsP(3) pretreatment, equilibrium binding experiments performed on 10-min incubations revealed an apparent positive cooperative behavior (apparent Hill coefficient = 1.6; apparent K-D = 66 nM). These results report a new regulatory process of the InsP(3) receptor in cerebellum occurring independently of Ca2+ and on a relatively long time scale.			Coquil, JF (corresponding author), UNIV PARIS 11, INSERM, U274, UNITE RECH, F-91405 ORSAY, FRANCE.							ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; COMBETTES L, 1994, J BIOL CHEM, V269, P17561; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; DANIEL H, 1992, EXP BRAIN RES, V90, P327; DANOFF SK, 1988, BIOCHEM J, V254, P701, DOI 10.1042/bj2540701; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; FERRIS CD, 1990, P NATL ACAD SCI USA, V87, P2147, DOI 10.1073/pnas.87.6.2147; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FOHR KJ, 1989, BIOCHEM J, V262, P83; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GUILLEMETTE G, 1989, MOL PHARMACOL, V35, P339; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; HANNAERTMERAH Z, 1994, J BIOL CHEM, V269, P29642; HILLY M, 1993, J BIOL CHEM, V268, P16488; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; ITO M, 1989, ANNU REV NEUROSCI, V12, P85, DOI 10.1146/annurev.ne.12.030189.000505; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; JOSEPH SK, 1989, BIOCHEM J, V258, P261, DOI 10.1042/bj2580261; JOSEPH SK, 1993, J BIOL CHEM, V268, P23059; KAPLIN AI, 1994, J BIOL CHEM, V269, P28972; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; KATO N, 1993, P NATL ACAD SCI USA, V90, P3650, DOI 10.1073/pnas.90.8.3650; KOGA T, 1994, J BIOL CHEM, V269, P11640; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; MARSHALL ICB, 1993, J BIOL CHEM, V268, P13214; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MOUREY RJ, 1990, BIOCHEM J, V272, P383, DOI 10.1042/bj2720383; NAHORSKI SR, 1989, TRENDS PHARMACOL SCI, V10, P139, DOI 10.1016/0165-6147(89)90165-X; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; OTSU H, 1990, CELL STRUCT FUNCT, V15, P163, DOI 10.1247/csf.15.163; PARKER I, 1989, J NEUROSCI, V9, P4068; PIETRI F, 1990, J BIOL CHEM, V265, P17478; RENARD DC, 1992, BIOCHEM J, V284, P507, DOI 10.1042/bj2840507; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; ROUXEL FP, 1992, J BIOL CHEM, V267, P20017; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; SWILLENS S, 1992, TRENDS PHARMACOL SCI, V13, P430, DOI 10.1016/0165-6147(92)90139-W; TAKEI K, 1994, NEURON, V12, P327, DOI 10.1016/0896-6273(94)90275-5; TAKEI K, 1992, J NEUROSCI, V12, P489; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; VILLA A, 1991, J CELL BIOL, V113, P779, DOI 10.1083/jcb.113.4.779; WATRAS J, 1994, BIOCHEMISTRY-US, V33, P14359, DOI 10.1021/bi00251a050; WILLARS GB, 1995, BRIT J PHARMACOL, V114, P1133, DOI 10.1111/j.1476-5381.1995.tb13325.x; WORLEY PF, 1987, J BIOL CHEM, V262, P12132	59	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3568	3574						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631963				2022-12-25	WOS:A1996TV72400037
J	Tian, MX; Martin, GS				Tian, MX; Martin, GS			Reduced phosphotyrosine binding by the v-Src SH2 domain is compatible with wild-type transformation	ONCOGENE			English	Article						Src; SH2 domain; phosphotyrosine; transformation	TYROSINE-PHOSPHORYLATED PEPTIDES; ROUS-SARCOMA VIRUS; SIGNAL-TRANSDUCTION; HOMOLOGY REGION-2; KINASE-ACTIVITY; C-SRC; MUTAGENESIS; INSERTION; MUTATIONS; MUTANTS	The SH2 domain of v-Src binds phosphotyrosyl-proteins in vivo and in vitro. The function of this domain is necessary for transformation of Rat-2 cells and for morphologically wild-type transformation of chicken embryo fibroblasts (CEF). The phosphate group of phosphotyrosine interacts directly with a conserved arginine residue in the FLVRES motif of the SH2 domain, R175 in v-Src. To examine the role of phosphotyrosine binding in transformation by v-Src, we have characterized the effects of R175 mutations on the transforming ability of v-Src and on the interaction of the v-Src SH2 domain with phosphotyrosyl-proteins. The R175H mutation, and to a lesser extent the R175K mutation, reduced but did not eliminate the binding of phosphotyrosyl-proteins to the v-Src SH2 domain. However neither mutation affected transformation of CEF or Rat-2 cells by v-Src and neither mutation resulted in major changes in the level or pattern of protein-tyrosine phosphorylation in transformed CEF. In contrast, the R175E mutant of v-Src induced fusiform transformation of CEF and failed to transform Rat-2 cells; the mutant SH2 domain was insoluble when expressed in bacteria, suggesting that the R175E mutation disrupts the structure of the v-Src SH2 domain. We conclude that, although the Arg residue in the FLVRES motif is invariant in most if not all SH2 domains, at position 175 in the v-Src SH2 domain residues other than arginine can support the binding of phosphotyrosyl-proteins, albeit at reduced levels. Furthermore under the expression conditions normally used, that is when v-Src is expressed under the-control of a retroviral LTR, the reduced binding of phosphotyrosyl-proteins is compatible with wild-type transformation.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley					NATIONAL CANCER INSTITUTE [R37CA017542, R01CA017542] Funding Source: NIH RePORTER; NCI NIH HHS [CA17542] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BOEUF H, 1995, ONCOGENE, V10, P433; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COURTNEIDGE SA, 1994, SEMIN CANCER BIOL, V5, P239; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HUGHES S, 1984, VIROLOGY, V136, P89, DOI 10.1016/0042-6822(84)90250-2; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JAKOBOVITS EB, 1984, CELL, V38, P757, DOI 10.1016/0092-8674(84)90271-X; JHAPPAN C, 1986, J VIROL, V60, P750, DOI 10.1128/JVI.60.2.750-753.1986; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LIEBL EC, 1992, J VIROL, V66, P4315, DOI 10.1128/JVI.66.7.4315-4324.1992; LIEBL EC, 1993, VIROLOGY, V195, P265, DOI 10.1006/viro.1993.1371; LIU XQ, 1994, RECENT PROG HORM RES, V49, P149; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORTON CJ, 1994, CURR BIOL, V4, P615, DOI 10.1016/S0960-9822(00)00134-2; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; OKAMURA H, 1994, ONCOGENE, V9, P2293; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; TEMIN HM, 1960, VIROLOGY, V10, P182, DOI 10.1016/0042-6822(60)90038-6; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VERDERAME MF, 1994, ONCOGENE, V9, P175; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	40	13	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	1996	12	4					727	734						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632894				2022-12-25	WOS:A1996TW68600003
J	Shin, WS; Hong, YH; Peng, HB; DeCaterina, R; Libby, P; Liao, JK				Shin, WS; Hong, YH; Peng, HB; DeCaterina, R; Libby, P; Liao, JK			Nitric oxide attenuates vascular smooth muscle cell activation by interferon-gamma - The role of constitutive NF-kappa B activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADHESION MOLECULE-1 VCAM-1; TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; GENE-EXPRESSION; NUCLEAR FACTOR; ATHEROSCLEROTIC PLAQUES; BALLOON INJURY; MACROPHAGES; MECHANISM; ATHEROGENESIS	Atherogenesis involves cellular immune responses and altered vascular smooth muscle cell (SMC) function. Cytokines such as interleukin (IL)-1 alpha and interferon-gamma (TFN-gamma) may contribute to this process by activating SMC. To determine whether the anti-atherogenic mediator, nitric oxide ((NO)-N-.), can modulate cytokine-induced SMC activation, we investigated the effects of various (NO)-N-.-generating compounds on the expression of intercellular and vascular cell adhesion molecules (ICAM-1 and VCAM-1). Induction of ICAM-1 expression by IL-1 alpha and VCAM-1 expression by IFN-gamma was attenuated by (NO)-N-. donors but not by cGMP analogues. Nuclear run-on assays and transfection studies using various VCAM-1 promoter constructs linked to the chloramphenicol acetyltransferase reporter gene showed that (NO)-N-. repressed IFN-gamma-induced VCAM-1 gene transcription, in part, through inhibition of nuclear factor-kappa B (NF-kappa B). Electrophoretic mobility shift assay revealed that SMC possess basal constitutive NF-kappa B activity, which was augmented by treatment with IL-1 alpha. In contrast, IFN-gamma induced and activated interferon regulatory factor (IRF)-1 but had little effect on basal constitutive NF-kappa B activity. (NO)-N-. donors had no inhibitory effect on IRF-1 activation but did inhibit basal and IL-1 alpha-stimulated NF-kappa B activation. These findings suggest that the induction of ICAM-1 and VCAM-1 expression requires NF-kappa B activation and that (NO)-N-. attenuates IFN-gamma-induced VCAM-1 expression primarily by inhibiting basal constitutive NF-kappa B activity in SMC.	BRIGHAM & WOMENS HOSP, DIV CARDIOVASC, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School			Libby, Peter/AAY-6404-2021; De Caterina, Raffaele/K-3857-2016	Libby, Peter/0000-0002-1502-502X; De Caterina, Raffaele/0000-0003-1637-574X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052233] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-05280, HL-52233] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BELLAS RE, 1995, J CLIN INVEST, V96, P2521, DOI 10.1172/JCI118313; BENNETT MR, 1994, CIRC RES, V74, P525, DOI 10.1161/01.RES.74.3.525; BRUNE B, 1989, J BIOL CHEM, V264, P8455; COLLINS T, 1993, LAB INVEST, V68, P499; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FREYSCHUSS A, 1993, J CLIN INVEST, V91, P1282, DOI 10.1172/JCI116326; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GARG UC, 1991, J BIOL CHEM, V266, P9; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; IADEMARCO MF, 1992, J BIOL CHEM, V267, P16323; IGNARRO LJ, 1991, BLOOD VESSELS, V28, P67; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; KAHARI VM, 1990, J CLIN INVEST, V86, P1489, DOI 10.1172/JCI114866; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LAWRENCE R, 1994, J BIOL CHEM, V269, P28913; LI HM, 1993, AM J PATHOL, V143, P1551; LIBBY P, 1983, J CELL PHYSIOL, V115, P217, DOI 10.1002/jcp.1041150217; LIBBY P, 1992, CIRCULATION, V86, P47; LIBBY P, 1991, LAB INVEST, V64, P5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NAKAKI T, 1990, EUR J PHARM-MOLEC PH, V189, P347, DOI 10.1016/0922-4106(90)90031-R; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; OBRIEN KD, 1993, J CLIN INVEST, V92, P945, DOI 10.1172/JCI116670; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; PENG HB, 1995, J BIOL CHEM, V270, P17050, DOI 10.1074/jbc.270.28.17050; POSTON RN, 1992, AM J PATHOL, V140, P665; PRINTSEVA OY, 1992, AM J PATHOL, V140, P889; RADOMSKI MW, 1992, BRIT J PHARMACOL, V107, P745, DOI 10.1111/j.1476-5381.1992.tb14517.x; RASBAND W, 1993, NIH IMAGE VERSION 1; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA H, 1993, CIRCULATION, V88, P1788, DOI 10.1161/01.CIR.88.4.1788; TIPPING PG, 1993, AM J PATHOL, V142, P1721; TSAO PS, 1994, CIRCULATION, V89, P2176, DOI 10.1161/01.CIR.89.5.2176; VONDERLEYEN HE, 1995, P NATL ACAD SCI USA, V92, P1137, DOI 10.1073/pnas.92.4.1137; WARNER SJC, 1989, ARTERIOSCLEROSIS, V9, P279, DOI 10.1161/01.ATV.9.3.279; WARNER SJC, 1989, J CLIN INVEST, V83, P1174, DOI 10.1172/JCI113998	49	131	135	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11317	11324		10.1074/jbc.271.19.11317	http://dx.doi.org/10.1074/jbc.271.19.11317			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626684	hybrid			2022-12-25	WOS:A1996UJ94400044
J	Yang, XY; Mackins, JY; Li, QJ; Antony, AC				Yang, XY; Mackins, JY; Li, QJ; Antony, AC			Isolation and characterization of a folate receptor-directed metalloprotease from human placenta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEINS; MEMBRANE-PROTEINS; HUMAN-MILK; KB CELLS; IDENTIFICATION; CONVERSION; PROTEASE; INVITRO	Glycosyl-phosphatidylinositol-anchored hydrophobic placental folate receptors (PFRs), which have an important functional role in maternal-to-fetal transplacental folate transport, can be converted to soluble hydrophilic forms by a placental metalloprotease. Using a Triton X-114 temperature-induced phase separation assay to monitor enzyme-mediated conversion of radiolabeled hydrophobic PFR into hydrophilic PFR, a metalloenzyme was isolated to apparent homogeneity from Triton X-114-solubilized human placenta using concanavalin A-Sepharose and reverse-phase high performance liquid chromatography (HPLC) as major purification steps. The purified hydrophobic enzyme eluted as a single protein peak on reverse-phase HPLC and SDS-polyacrylamide gel electrophoresis revealed a single 63,000 M(r) species, which was reduced to 58,000 M(r) following de glycosylation, findings comparable with amino acid analysis (M(r) similar to 59,000). The metalloenzyme was activated by Mg2+, Zn2+, Mn2+, and Ca2+, optimally at physiologic pH; it also exhibited EDTA-sensitive endoproteolytic cleavage of [H-3]leucine-labeled full-length nascent PFR polypeptide generated in vitro in the absence of microsomes. Rabbit polyclonal anti-metalloprotease antiserum specifically immunoprecipitated I-125-metalloprotease and recognized cross-reacting moieties on plasma membranes of normal human hematopoietic progenitor cells and human cervical carcinoma cells, both of which also express FR.	INDIANA UNIV,SCH MED,DEPT MED,DIV HEMATOL ONCOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL CANCER INSTITUTE [R01CA058919] Funding Source: NIH RePORTER; NCI NIH HHS [CA58919] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONY AC, 1992, BLOOD, V79, P2807; ANTONY AC, 1987, J CLIN INVEST, V80, P711, DOI 10.1172/JCI113126; ANTONY AC, 1994, BIOCHEM J, V298, P9, DOI 10.1042/bj2980009; ANTONY AC, 1991, J CLIN INVEST, V87, P313, DOI 10.1172/JCI114989; ANTONY AC, 1982, J BIOL CHEM, V257, P81; ANTONY AC, 1987, J CLIN INVEST, V80, P1618, DOI 10.1172/JCI113249; ANTONY AC, 1989, J BIOL CHEM, V264, P1911; ANTONY AC, 1987, ANAL BIOCHEM, V162, P224, DOI 10.1016/0003-2697(87)90031-5; ANTONY AC, 1981, J BIOL CHEM, V256, P9684; BORDIER C, 1981, J BIOL CHEM, V256, P1604; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; ELWOOD PC, 1991, J BIOL CHEM, V266, P2346; ELWOOD PC, 1986, J BIOL CHEM, V261, P10081; GRANDA JL, 1990, CONNECT TISSUE RES, V24, P249, DOI 10.3109/03008209009152153; HANSEN SI, 1992, BIOSCIENCE REP, V12, P87, DOI 10.1007/BF02351212; HENDERSON GB, 1984, J BIOL CHEM, V259, P4558; HENDERSON GI, 1995, J LAB CLIN MED, V126, P184; KANE MA, 1988, J CLIN INVEST, V81, P1398, DOI 10.1172/JCI113469; LALA PK, 1990, CANCER METAST REV, V9, P369, DOI 10.1007/BF00049525; LEE HC, 1992, BIOCHEMISTRY-US, V31, P3236, DOI 10.1021/bi00127a027; LUHRS CA, 1989, J BIOL CHEM, V264, P21446; LUHRS CA, 1987, P NATL ACAD SCI USA, V84, P6546, DOI 10.1073/pnas.84.18.6546; MOORE S, 1963, METHOD ENZYMOL, V6, P819, DOI 10.1016/0076-6879(63)06257-1; Sambrook J., 2002, MOL CLONING LAB MANU; SUN XL, 1995, J CLIN INVEST, V96, P1535, DOI 10.1172/JCI118192; TZINIA AK, 1991, MOL BIOCHEM PARASIT, V47, P83, DOI 10.1016/0166-6851(91)90150-5; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; VERMA RS, 1991, J BIOL CHEM, V266, P12522; VERMA RS, 1992, J BIOL CHEM, V267, P4119; ZHOU N E, 1990, Peptide Research, V3, P8; ZIEGELBAUER K, 1992, J BIOL CHEM, V267, P10791	32	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11493	11499		10.1074/jbc.271.19.11493	http://dx.doi.org/10.1074/jbc.271.19.11493			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626708	hybrid			2022-12-25	WOS:A1996UJ94400068
J	Kayo, T; Sawada, Y; Suzuki, Y; Suda, M; Tanaka, S; Konda, Y; Miyazaki, J; Takeuchi, T				Kayo, T; Sawada, Y; Suzuki, Y; Suda, M; Tanaka, S; Konda, Y; Miyazaki, J; Takeuchi, T			Proprotein-processing endoprotease furin decreases regulated secretory pathway-specific proteins in the pancreatic beta cell line MIN6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN-SECRETION; PROHORMONE CONVERTASES; PROINSULIN; EXPRESSION; CLEAVAGE; GLUCOSE; BIOSYNTHESIS; CALCIUM; SITE; PC2	Prohormone convertases PC2 and PC3, yeast Kex2-family endoproteases specific to the regulated secretory pathway, cleave proinsulin to insulin in the secretory granules of pancreatic beta cells. The well-differentiated beta cell line MIN6 expresses PC2 and PC3 and another regulated secretory pathway-specific protein chromogranin A. Furin, another yeast Kex2 endoprotease, exists in the trans-Golgi networks of many cell types, The beta cell line RINm5F (a cell line that is less differentiated than the MIN6 cell line) does not express the regulated pathway-specific proteins, but strongly expresses furin. We suspected that furin expression may cause the decrement of regulated secretory pathway-specific proteins, To test this hypothesis, we expressed a furin cDNA with a metallothionein promoter in MIN6 cells. With Zn2+ stimulation of furin expression, the messages of PC2, PC3, and chromogranin A decreased, and the processing of proinsulin to mature insulin became less efficient. The furin-expressing MIN6 cells exhibited less insulin content and weakened insulin secretion in response to a high glucose concentration. The conditioned medium from furin-expressing MIN6 cells also exerted a decrease of PC2 and PC3 expression in unaltered MIN6 cells. Thus, proteins cleaved by furin inside the cells or by truncated furin shed into the culture medium appear to cause decreased PC2 and PC3 expression, insulin content, and glucose-responsive insulin secretion in MIN6 cells.	GUNMA UNIV,INST MOL & CELLULAR REGULAT,DEPT MOLEC MED,MAEBASHI,GUMMA 371,JAPAN; GUNMA UNIV,INST MOL & CELLULAR REGULAT,DEPT CELL BIOL,MAEBASHI,GUMMA 371,JAPAN; TOHOKU UNIV,INST DEV AGING & CANC,SENDAI,MIYAGI 980,JAPAN	Gunma University; Gunma University; Tohoku University			Miyazaki, Jun-ichi/N-1976-2015	Miyazaki, Jun-ichi/0000-0003-2475-589X				BENJANNET S, 1993, BIOCHEM J, V294, P735, DOI 10.1042/bj2940735; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CLARK SA, 1990, ENDOCRINOLOGY, V127, P2779, DOI 10.1210/endo-127-6-2779; DAVIDSON HW, 1987, BIOCHEM J, V245, P575, DOI 10.1042/bj2450575; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618; GAZDAR AF, 1980, P NATL ACAD SCI-BIOL, V77, P3519, DOI 10.1073/pnas.77.6.3519; GOLD G, 1984, DIABETES, V33, P556, DOI 10.2337/diabetes.33.6.556; HALBAN PA, 1990, TRENDS ENDOCRIN MET, V1, P261, DOI 10.1016/1043-2760(90)90007-P; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; IRMINGER JC, 1994, J BIOL CHEM, V269, P1756; ISHIHARA H, 1994, J BIOL CHEM, V269, P3081; LEVY JC, 1993, DIABETES, V42, P162, DOI 10.2337/diabetes.42.1.162; LING ZD, 1994, ENDOCRINOLOGY, V134, P2614, DOI 10.1210/en.134.6.2614; MALAISSE WJ, 1990, PEPTIDE HORMONE SECR, P211; MATSUUCHI L, 1991, J CELL BIOL, V112, P843, DOI 10.1083/jcb.112.5.843; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; MIZUNO K, 1987, BIOCHEM BIOPH RES CO, V144, P807, DOI 10.1016/S0006-291X(87)80036-0; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; NAGAMUNE H, 1995, ENDOCRINOLOGY, V136, P357, DOI 10.1210/en.136.1.357; NAKAYAMA K, 1991, J BIOCHEM, V109, P803, DOI 10.1093/oxfordjournals.jbchem.a123461; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; ORCI L, 1985, CELL, V42, P671, DOI 10.1016/0092-8674(85)90124-2; OTONKOSKI T, 1994, DIABETES, V43, P1164, DOI 10.2337/diabetes.43.9.1164; OUAFIK H, 1987, P NATL ACAD SCI USA, V84, P261; PARMER RJ, 1989, HYPERTENSION, V14, P435, DOI 10.1161/01.HYP.14.4.435; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; PRAZ GA, 1983, BIOCHEM J, V210, P345, DOI 10.1042/bj2100345; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCAMMELL JG, 1993, TRENDS ENDOCRIN MET, V4, P14, DOI 10.1016/1043-2760(93)90058-M; SEIDAH NG, 1992, TRENDS ENDOCRIN MET, V3, P133, DOI 10.1016/1043-2760(92)90102-7; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHEN FS, 1993, J BIOL CHEM, V268, P24910; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; SMEEKENS SP, 1993, BIO-TECHNOL, V11, P182, DOI 10.1038/nbt0293-182; TSUJI A, 1994, BIOCHEM BIOPH RES CO, V200, P943, DOI 10.1006/bbrc.1994.1541; WANG JL, 1993, J BIOL CHEM, V268, P7785; YANAGITA M, 1993, ENDOCRINOLOGY, V133, P639, DOI 10.1210/en.133.2.639; ZHANG HJ, 1989, DIABETES, V38, P44, DOI 10.2337/diabetes.38.1.44	45	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10731	10737		10.1074/jbc.271.18.10731	http://dx.doi.org/10.1074/jbc.271.18.10731			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631882	hybrid			2022-12-25	WOS:A1996UJ34200050
J	Kharat, I; Saatcioglu, F				Kharat, I; Saatcioglu, F			Antiestrogenic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin are mediated by direct transcriptional interference with the liganded estrogen receptor - Cross-talk between aryl hydrocarbon- and estrogen-mediated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER-CELLS; AH-RECEPTOR; GLUCOCORTICOID RECEPTOR; POSSIBLE MECHANISM; CIGARETTE-SMOKING; BINDING ACTIVITY; DNA-SEQUENCE; MCF-7 CELLS; FEMALE RAT; GENE	Aryl hydrocarbon receptor (AhR) ligands have diverse biological effects including striking antiestrogenic activity. We have investigated at the molecular level the antiestrogenic activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). We show that the previously documented TCDD-mediated decrease in estradiol-inducible gene products such as cathepsin D (cat D) is due to a sharp decline in mRNA accumulation despite any change in estrogen receptor (ER) mRNA levels. The decline in cat D mRNA level is most likely due to a decrease in transcription of the cat D gene since TCDD blocks the ability of ER to transactivate from an estrogen response element. AhR is required for this activity as TCDD is no longer antiestrogenic in a mutant cell line that is deficient in functional AhR. We provide evidence that the loss of transactivation potential by ER in the presence of TCDD is due to a sharp decrease in its ability to bind to an estrogen response element. Reciprocally, estradiol treatment blocked TCDD-induced accumulation of CYP1A1 mRNA and AhR-mediated activation of the CYP1A1 promoter. This is due to the ability of liganded ER to interfere with the binding of AhR to the xenobiotic response element. These results provide a molecular mechanism for the antiestrogenic effects of TCDD and demonstrate the presence of a two-way crosstalk between the intracellular signaling pathways involving estrogens and aryl hydrocarbons.	UNIV CALIF SAN DIEGO, SCH MED, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; MAHARISHI INT UNIV, MOLEC BIOL LAB, FAIRFIELD, IA 52557 USA	University of California System; University of California San Diego					NCI NIH HHS [R01-CA-38655] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038655] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; ALEXANDERBRIDGES M, 1992, ADV ENZYME REGUL, V32, P149; ASTROFF B, 1990, BIOCHEM PHARMACOL, V39, P485, DOI 10.1016/0006-2952(90)90054-O; ASTROFF B, 1990, MOL CELL ENDOCRINOL, V72, P247, DOI 10.1016/0303-7207(90)90149-3; ASTROFF B, 1988, TOXICOL APPL PHARM, V95, P435, DOI 10.1016/0041-008X(88)90361-4; BIEGEL L, 1990, J STEROID BIOCHEM, V37, P725, DOI 10.1016/0960-0760(90)90357-Q; BJELDANES LF, 1991, P NATL ACAD SCI USA, V88, P9543, DOI 10.1073/pnas.88.21.9543; BRESNICK E, 1990, CARCINOGENESIS, V11, P1159, DOI 10.1093/carcin/11.7.1159; BRINTON LA, 1993, AM J EPIDEMIOL, V137, P281, DOI 10.1093/oxfordjournals.aje.a116675; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CAVAILLES V, 1993, P NATL ACAD SCI USA, V90, P203, DOI 10.1073/pnas.90.1.203; CLARK AR, 1993, BIOCHEM J, V296, P521, DOI 10.1042/bj2960521; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; GALLO MA, 1986, TOXICOL LETT, V32, P123, DOI 10.1016/0378-4274(86)90058-5; GIERTHY JF, 1988, BREAST CANCER RES TR, V12, P227, DOI 10.1007/BF01805943; GIERTHY JF, 1987, CANCER RES, V47, P6198; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; GUENGERICH FP, 1989, ANNU REV PHARMACOL, V29, P241; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HANKINSON O, 1985, J BIOL CHEM, V260, P1790; HARRIS M, 1990, CANCER RES, V50, P3579; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LANIGAN TM, 1993, MOL CELL BIOL, V13, P6079, DOI 10.1128/MCB.13.10.6079; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MARTINEZ E, 1987, EMBO J, V6, P3719, DOI 10.1002/j.1460-2075.1987.tb02706.x; MICHNOVICZ JJ, 1986, NEW ENGL J MED, V315, P1305, DOI 10.1056/NEJM198611203152101; MUTO H, 1989, ARCH ENVIRON HEALTH, V44, P171, DOI 10.1080/00039896.1989.9935882; *NAT TOX PROGR, 1982, BIOASS 2 3 7 8 TETR; PASCO DS, 1993, J BIOL CHEM, V268, P1053; PELKONEN O, 1982, PHARMACOL REV, V34, P189; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; PYYKKO K, 1989, CYTOCHROME P-450 : BIOCHEMISTRY AND BIOPHYSICS /, P528; REICK M, 1994, MOL CELL BIOL, V14, P5653, DOI 10.1128/MCB.14.9.5653; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; ROMKES M, 1987, TOXICOL APPL PHARM, V87, P306, DOI 10.1016/0041-008X(87)90292-4; ROMKES M, 1988, TOXICOL APPL PHARM, V92, P368, DOI 10.1016/0041-008X(88)90177-9; SAATCIOGLU F, 1990, J BIOL CHEM, V265, P9251; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SAATCIOGLU F, 1990, MOL CELL BIOL, V10, P6408, DOI 10.1128/MCB.10.12.6408; SPINK DC, 1990, P NATL ACAD SCI USA, V87, P6917, DOI 10.1073/pnas.87.17.6917; SPINK DC, 1992, ARCH BIOCHEM BIOPHYS, V293, P342, DOI 10.1016/0003-9861(92)90404-K; STAUBER C, 1992, NEW BIOL, V4, P527; Tourmaa TE, 1995, NUTR HLTH, V10, P105; VESSEY M, 1983, BRIT J CANCER, V47, P455, DOI 10.1038/bjc.1983.74; WANG X, 1993, MOL CELL ENDOCRINOL, V96, P159, DOI 10.1016/0303-7207(93)90106-T; WHITE TEK, 1993, BIOCHEM BIOPH RES CO, V193, P956, DOI 10.1006/bbrc.1993.1718; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003; WIELAND S, 1991, EMBO J, V10, P2513, DOI 10.1002/j.1460-2075.1991.tb07791.x; ZACHAREWSKI T, 1992, TOXICOL APPL PHARM, V113, P311, DOI 10.1016/0041-008X(92)90130-K; ZACHAREWSKI T, 1991, BIOCHEM PHARMACOL, V41, P1931, DOI 10.1016/0006-2952(91)90133-P	52	175	183	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10533	10537		10.1074/jbc.271.18.10533	http://dx.doi.org/10.1074/jbc.271.18.10533			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631852	hybrid			2022-12-25	WOS:A1996UJ34200020
J	May, JM; Qu, ZC; Morrow, JD				May, JM; Qu, ZC; Morrow, JD			Interaction of ascorbate and alpha-tocopherol in resealed human erythrocyte ghosts - Transmembrane electron transfer and protection from lipid peroxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED BLOOD-CELLS; VITAMIN-E; ACCEPTOR OXIDOREDUCTASE; MEMBRANE DAMAGE; LIPOSOMES; ANTIOXIDANT; REDUCTION; PLASMA; NADH; ACID	A role for ascorbate-derived electrons in protection against oxidative damage to membrane lipids was investigated in resealed human erythrocyte ghosts, Incubation of resealed ghosts with the membrane-impermeant oxidant ferricyanide doubled the ghost membrane concentration of F-2-isoprostanes, a sensitive marker of lipid peroxidation, Incorporation of ascorbate into ghosts during resealing largely prevented F-2-isoprostane formation due to extravesicular ferricyanide. This protection was associated with a rapid transmembrane oxidation of intravesicular ascorbate by extravesicular ferricyanide. Transmembrane electron transfer, which was measured indirectly as ascorbate-dependent ferricyanide reduction, correlated with the content of alpha-tocopherol in the ghost membrane in several respects, First, ascorbate resealed within ghosts protected against ferricyanide-induced oxidation of endogenous alpha-tocopherol in the ghost membrane, Second, when exogenous alpha-tocopherol was incorporated into the ghost membrane during the resealing step, subsequent ferricyanide reduction was enhanced, Last, incubation of intact erythrocytes with soybean phospholipid liposomes, followed by resealed ghost preparation, caused a proportional decrease in both the membrane content of alpha-tocopherol and in ferricyanide reduction, Incorporation of exogenous alpha-tocopherol during resealing of ghosts prepared from liposome-treated cells completely restored the ferricyanide-reducing capacity of the ghosts. These results suggest that the transmembrane transfer of ascorbate-derived electrons in erythrocyte ghosts is dependent in part on alpha-tocopherol and that such transfer may help to protect the erythrocyte membrane against oxidant stress originating outside the cell.			May, JM (corresponding author), VANDERBILT UNIV,SCH MED,DEPT MED,715 MED RES BLDG 2,NASHVILLE,TN 37232, USA.				NIDDK NIH HHS [DK 26657, DK 50435, DK 48831] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026657, R01DK050435, R01DK048831] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGAR NS, 1986, J CLIN INVEST, V77, P319, DOI 10.1172/JCI112294; Agutter PS, 1979, BIOCHEM SOC T, V7, P710, DOI 10.1042/bst0070710; AVRON M, 1963, ANAL BIOCHEM, V6, P549, DOI 10.1016/0003-2697(63)90149-0; BIERI JG, 1976, VITAM HORM, V34, P31, DOI 10.1016/S0083-6729(08)60072-2; CLEMENS MR, 1987, CHEM PHYS LIPIDS, V45, P251, DOI 10.1016/0009-3084(87)90068-5; CRANE FL, 1985, ENZYMES BIOL MEMBR, P465; DOBA T, 1985, BIOCHIM BIOPHYS ACTA, V835, P298, DOI 10.1016/0005-2760(85)90285-1; FEE JA, 1972, BIOCHEM BIOPH RES CO, V49, P150, DOI 10.1016/0006-291X(72)90022-8; FREI B, 1990, P NATL ACAD SCI USA, V87, P4879, DOI 10.1073/pnas.87.12.4879; GREBING C, 1984, J BIOENERG BIOMEMBR, V16, P517, DOI 10.1007/BF00743243; HATAM LJ, 1979, J LIPID RES, V20, P639; HODGSON LL, 1995, J CELL PHYSIOL, V162, P181, DOI 10.1002/jcp.1041620204; HUGHES RE, 1968, BRIT J HAEMATOL, V14, P247, DOI 10.1111/j.1365-2141.1968.tb01494.x; IHEANACHO EN, 1995, FREE RADICAL BIO MED, V18, P543, DOI 10.1016/0891-5849(94)00182-J; ILANI A, 1987, BIOPHYS J, V51, P161, DOI 10.1016/S0006-3495(87)83321-0; JAIN SK, 1989, J BIOL CHEM, V264, P21340; KAGAN VE, 1990, ARCH BIOCHEM BIOPHYS, V280, P147, DOI 10.1016/0003-9861(90)90529-8; KAGAN VE, 1990, METHOD ENZYMOL, V186, P355; KAYDEN HJ, 1973, J LIPID RES, V14, P533; KITABCHI AE, 1982, BIOCHIM BIOPHYS ACTA, V684, P200, DOI 10.1016/0005-2736(82)90006-2; KITAJIMA S, 1981, ARCH BIOCHEM BIOPHYS, V210, P330, DOI 10.1016/0003-9861(81)90196-X; KOBAYASHI T, 1985, BIOCHIM BIOPHYS ACTA, V814, P170, DOI 10.1016/0005-2736(85)90433-X; KOJIMA N, 1979, J BIOL CHEM, V254, P8847; LANG JK, 1986, ANAL BIOCHEM, V157, P106, DOI 10.1016/0003-2697(86)90203-4; LEUNG HW, 1981, BIOCHIM BIOPHYS ACTA, V664, P266; LEVINE M, 1986, NEW ENGL J MED, V314, P892, DOI 10.1056/NEJM198604033141407; LITTLE C, 1968, BIOCHEM BIOPH RES CO, V31, P145, DOI 10.1016/0006-291X(68)90721-3; LONGMIRE AW, 1994, BIOCHEM PHARMACOL, V47, P1173, DOI 10.1016/0006-2952(94)90389-1; LYNCH SM, 1994, J CLIN INVEST, V93, P998, DOI 10.1172/JCI117107; MAY JM, 1995, BBA-BIOMEMBRANES, V1238, P127, DOI 10.1016/0005-2736(95)00120-R; MAYU JM, 1995, BIOCHEMISTRY-US, V34, P12721; MCGOWN EL, 1990, BIOCHIM BIOPHYS ACTA, V1036, P202, DOI 10.1016/0304-4165(90)90035-U; MEISTER A, 1994, J BIOL CHEM, V269, P9397; MISHRA RK, 1969, J MEMBRANE BIOL, V1, P214, DOI 10.1007/BF01869782; MORROW JD, 1992, J CLIN INVEST, V90, P2502, DOI 10.1172/JCI116143; MORROW JD, 1994, METHOD ENZYMOL, V233, P163; NIKI E, 1987, CHEM PHYS LIPIDS, V44, P227, DOI 10.1016/0009-3084(87)90052-1; NIKI E, 1988, J BIOL CHEM, V263, P19809; OKAMURA M, 1979, J NUTR SCI VITAMINOL, V25, P269, DOI 10.3177/jnsv.25.269; ORRINGER EP, 1979, J CLIN INVEST, V63, P53, DOI 10.1172/JCI109277; Pachla L A, 1979, Methods Enzymol, V62, P15, DOI 10.1016/0076-6879(79)62183-3; PACKER JE, 1979, NATURE, V278, P737, DOI 10.1038/278737a0; SCHIPFER W, 1985, INT J BIOCHEM, V17, P819, DOI 10.1016/0020-711X(85)90270-8; SNYDER LM, 1988, BIOCHIM BIOPHYS ACTA, V937, P229, DOI 10.1016/0005-2736(88)90245-3; Steck T L, 1974, Methods Enzymol, V31, P172; STOCKER R, 1986, BIOCHIM BIOPHYS ACTA, V876, P294, DOI 10.1016/0005-2760(86)90287-0; SUN IL, 1992, P NATL ACAD SCI USA, V89, P11126, DOI 10.1073/pnas.89.23.11126; SZEKELY M, 1952, ACTA PHYSIOL HUNG, V3, P571; TOMODA A, 1980, EXPERIENTIA, V36, P1345, DOI 10.1007/BF01960088; URSINI F, 1982, BIOCHIM BIOPHYS ACTA, V710, P197, DOI 10.1016/0005-2760(82)90150-3; VANDENBERG JJM, 1990, CHEM PHYS LIPIDS, V53, P309, DOI 10.1016/0009-3084(90)90028-P; WANG CS, 1978, J SUPRAMOL STR CELL, V9, P1, DOI 10.1002/jss.400090102; WOLFF SP, 1994, METHOD ENZYMOL, V233, P182	53	55	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10577	10582		10.1074/jbc.271.18.10577	http://dx.doi.org/10.1074/jbc.271.18.10577			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631858	hybrid			2022-12-25	WOS:A1996UJ34200026
J	Mora, C; Chillaron, J; Calonge, MJ; Forgo, J; Testar, X; Nunes, V; Murer, H; Zorzano, A; Palacin, M				Mora, C; Chillaron, J; Calonge, MJ; Forgo, J; Testar, X; Nunes, V; Murer, H; Zorzano, A; Palacin, M			The rBAT gene is responsible for L-cystine uptake via the b(0,+)-like amino acid transport system in a ''renal proximal tubular'' cell line (OK cells)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER MEMBRANE-VESICLES; XENOPUS-LAEVIS OOCYTES; RABBIT KIDNEY CORTEX; EXPRESSION CLONING; RAT-KIDNEY; STRAIGHT TUBULES; HIGH-AFFINITY; HEAVY-CHAIN; CDNA; LYSINE	Several studies have shown that the cRNA of human, rabbit, or rat rBAT induces in Xenopus oocytes sodium-independent, high affinity uptake of L-cystine via a system b(0,+)-like amino acid exchanger. We have shown that mutations in rBAT cause type I cystinuria (Calonge, M. J., Gasparini, P., Chillaron, J., Chillon, M., Gallucci, M., Rousaud, F., Zelante, L., Testar, X., Dallapiccola, B., Di Silverio, F., Barcelo, P., Estivill, X., Zorzano, A., Nunes, V., and Palacin, M. (1994) Nat. Genet. 6, 420-425; Calonge, M. J., Volipini, V., Bisceglia, L., Rousaud, F., De Sanctis, L., Beccia, E., Zelante, L., Testar, X., Zorzano, A., Estivill, X., Gasparini, P., Nunes, V., and Palacin, M. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 9667-9671). Apart from oocytes, no other expression system has been used for transfection of functional rBAT activity. Furthermore, the b(0,+)-like transport activity has not been clearly described in the kidney or intestine. Here, we report that a ''proximal tubular-like'' cell line derived from opossum kidney (OR cells) expresses an rBAT transcript. Poly(A)(+) RNA from OK cells induced system b(0,+)-like transport activity in oocytes. This was hybrid-depleted by human rBAT antisense oligonucleotides. A polymerase chain reaction amplified cDNA fragment (similar to 700 base pairs) from OK cell RNA corresponds to an rBAT protein fragment 65-69% identical to those from human, rabbit and rat kidneys. We have also examined transport of L-cystine in OK cells and found characteristics very similar to the amino acid exchanger activity induced by rBAT cRNA in oocytes. Uptake of L-cystine was of high affinity, sodium-independent and shared with L-arginine and L-leucine. It was trans-stimulated by amino acids with the same specificity as rBAT-induced transport activity in oocytes. Furthermore, it was localized to the apical pole of confluent OK cells. To demonstrate that the rBAT protein is functionally related to this transport activity, we have transfected OK cells with human rBAT antisense and sense sequences. Transfection with rBAT antisense, but not with rBAT sense, resulted in the specific reduction of rBAT mRNA expression and b(0,+)-like transport activity. These results demonstrate that rBAT is functionally related to the L-cystine uptake via system b(0,+)-like in the apical pole of the renal OK cell line.	UNIV BARCELONA,FAC BIOL,DEPT BIOCHEM & MOLEC BIOL,E-08028 BARCELONA,SPAIN; UNIV ZURICH,DEPT PHYSIOL,CH-8057 ZURICH,SWITZERLAND; INST RECERCA ONCOL,DEPT MOLEC GENET,E-08907 LHOSPITALET LLOBR,BARCELONA,SPAIN	University of Barcelona; University of Zurich			Mora, Conchi/A-8280-2010; Nunes, Virginia/D-4356-2014; Chillaron, Josep/ABF-7663-2021; Zorzano, Antonio/R-5479-2018; Nunes, Virginia/AAD-1014-2019; Palacín, Manuel/G-9786-2015	Mora, Conchi/0000-0002-5644-0537; Nunes, Virginia/0000-0002-5747-9310; Chillaron, Josep/0000-0003-3068-7598; Nunes, Virginia/0000-0002-5747-9310; Palacin, Manuel/0000-0002-8670-293X				AHMED A, 1995, J BIOL CHEM, V270, P8482, DOI 10.1074/jbc.270.15.8482; BERTRAN J, 1993, J BIOL CHEM, V268, P14842; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; BERTRAN J, 1992, BIOCHEM J, V281, P717, DOI 10.1042/bj2810717; BIBER J, 1985, AM J PHYSIOL, V249, pC430, DOI 10.1152/ajpcell.1985.249.5.C430; BOVEE KC, 1984, METABOLISM, V33, P602, DOI 10.1016/0026-0495(84)90056-8; BUSCH AE, 1994, J BIOL CHEM, V269, P25581; CALONGE MJ, 1995, P NATL ACAD SCI USA, V92, P9667, DOI 10.1073/pnas.92.21.9667; CALONGE MT, 1994, NAT GENET, V6, P420, DOI 10.1038/ng0494-420; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COADY MJ, 1994, FEBS LETT, V356, P174, DOI 10.1016/0014-5793(94)01262-8; COICADAN L, 1980, PEDIATR RES, V14, P109, DOI 10.1203/00006450-198002000-00008; DEVES R, 1992, J PHYSIOL-LONDON, V454, P491, DOI 10.1113/jphysiol.1992.sp019275; FOREMAN JW, 1980, METABOLISM, V29, P53, DOI 10.1016/0026-0495(80)90098-0; FURLONG TJ, 1990, AM J PHYSIOL, V258, pF321, DOI 10.1152/ajprenal.1990.258.2.F321; FURRIOLS M, 1993, J BIOL CHEM, V268, P27060; GASPARINI P, 1995, AM J HUM GENET, V57, P781; KOYAMA H, 1978, IN VITRO CELL DEV B, V14, P239; LEE WS, 1993, J CLIN INVEST, V91, P1959, DOI 10.1172/JCI116415; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCKUSICK VA, 1990, MENDELIAN INHERITANC, P1128; MCNAMARA PD, 1992, BIOCHIM BIOPHYS ACTA, V1103, P101, DOI 10.1016/0005-2736(92)90062-Q; MCNAMARA PD, 1981, BIOCHEM J, V194, P443, DOI 10.1042/bj1940443; MOSCKOVITZ R, 1993, P NATL ACAD SCI USA, V90, P4022, DOI 10.1073/pnas.90.9.4022; MOSCKOVITZ R, 1994, FASEB J, V8, P1069, DOI 10.1096/fasebj.8.13.7926373; OZEGOVIC B, 1982, BIOSCIENCE REP, V2, P913, DOI 10.1007/BF01114898; PALACIN M, 1994, J EXP BIOL, V196, P123; PICKEL VM, 1993, P NATL ACAD SCI USA, V90, P7779, DOI 10.1073/pnas.90.16.7779; PRAS E, 1995, AM J HUM GENET, V56, P1297; PRAS E, 1994, NAT GENET, V6, P415, DOI 10.1038/ng0494-415; ROSENBERG LE, 1965, NEW ENGL J MED, V273, P1239, DOI 10.1056/NEJM196512022732303; ROSENBERG LE, 1966, J CLIN INVEST, V45, P365, DOI 10.1172/JCI105351; SCHAFER JA, 1984, PFLUG ARCH EUR J PHY, V401, P143, DOI 10.1007/BF00583874; SEGAL S, 1968, P NATL ACAD SCI USA, V59, P231, DOI 10.1073/pnas.59.1.231; SEGAL S, 1977, SCIENCE, V197, P169, DOI 10.1126/science.877548; SEGAL S, 1995, METABOLIC MOL BASES, V3, P3581; SILBERNAGL S, 1988, PHYSIOL REV, V68, P911, DOI 10.1152/physrev.1988.68.3.911; STATES B, 1990, J CELL PHYSIOL, V143, P555, DOI 10.1002/jcp.1041430321; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; TEIXEIRA S, 1987, J BIOL CHEM, V262, P9574; THIER S, 1964, SCIENCE, V143, P482, DOI 10.1126/science.143.3605.482; VOLKL H, 1982, PFLUG ARCH EUR J PHY, V395, P190, DOI 10.1007/BF00584808; WANG Y, 1995, FEBS LETT, V368, P389, DOI 10.1016/0014-5793(95)00685-3; WEBBER WA, 1961, AM J PHYSIOL, V200, P380, DOI 10.1152/ajplegacy.1961.200.2.380; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; WRIGHT EM, 1994, NAT GENET, V6, P328, DOI 10.1038/ng0494-328	47	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10569	10576		10.1074/jbc.271.18.10569	http://dx.doi.org/10.1074/jbc.271.18.10569			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631857	hybrid, Green Accepted, Green Published			2022-12-25	WOS:A1996UJ34200025
J	Sun, XJ; Pons, S; Asano, T; Myers, MG; Glasheen, E; White, MF				Sun, XJ; Pons, S; Asano, T; Myers, MG; Glasheen, E; White, MF			The fyn tyrosine kinase binds Irs-1 and forms a distinct signaling complex during insulin stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-SRC ACTIVITY; HEMATOPOIETIC-CELLS; CATALYTIC ACTIVITY; SH3 DOMAINS; MUTANT MICE; RECEPTOR; PROTEIN; PHOSPHORYLATION; ASSOCIATION; EXPRESSION	Irs-proteins link the receptors for insulin/IGF-1, growth hormones, and several interleukins and interferons to signaling proteins that contain Src homology-2 (SH2). To identify new Irs-1-binding proteins, we screened a mouse embryo expression library with recombinant [P-32]Irs-1, which revealed a specific association between p59(fyn) and Irs-1. The SH2 domain in p59(fyn) bound to phosphorylated Tyr(895) and Tyr(1172), which are located in YXX(L/I) motifs. Mutation of p59(fyn) at the COOH-terminal tyrosine phosphorylation site (Tyr(531)) enhanced its binding to Irs-1 during insulin stimulation. Binding experiments with various SH2 proteins revealed that Grb-2 was largely excluded from Irs-1 complexes containing p59(fyn), whereas Grb-2 and p85 occurred in the same Irs-1 complex, By comparison with the insulin receptor, p59(fyn) kinase phosphorylated a unique cohort of tyrosine residues in Irs-1. These results outline a role for p59(fyn) or other related Src-kinases during insulin and cytokine signaling.	JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,PROGRAM CELL & DEV BIOL,BOSTON,MA 02215	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Pons, Sebastian/K-7794-2014	Pons, Sebastian/0000-0003-1027-0621	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK038712, R01DK038712, R01DK043808, R29DK038712] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38712, DK 43808] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; CHENG SH, 1991, J VIROL, V65, P170, DOI 10.1128/JVI.65.1.170-179.1991; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COURTNEIDGE SA, 1991, CELL GROWTH DIFFER, V2, P483; FEENER EP, 1993, J BIOL CHEM, V268, P11256; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; KEEGAN AD, 1993, RES IMMUNOL, V144, P590, DOI 10.1016/S0923-2494(05)80008-2; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; MYERS MG, 1995, TRENDS ENDOCRIN MET, V6, P209, DOI 10.1016/1043-2760(95)00092-V; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; MYERS MG, 1994, J BIOL CHEM, V269, P28783; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; PONS S, 1995, MOL CELL BIOL, V15, P4453; RUBINFELD B, 1992, MOL CELL BIOL, V12, P4634, DOI 10.1128/MCB.12.10.4634; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; UMEMORI H, 1994, NATURE, V367, P572, DOI 10.1038/367572a0; VEILLETTE A, 1992, ONCOGENE, V7, P971; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0; Zhou-Li Fei, 1995, Molecular and Cellular Biology, V15, P4232	47	110	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10583	10587		10.1074/jbc.271.18.10583	http://dx.doi.org/10.1074/jbc.271.18.10583			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631859	hybrid			2022-12-25	WOS:A1996UJ34200027
J	BarreraHernandez, G; Wanke, IE; Wong, NCW				BarreraHernandez, G; Wanke, IE; Wong, NCW			Effects of diabetes mellitus on hepatocyte nuclear factor 1 decrease albumin gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-1-ANTITRYPSIN GENE; LIVER-SPECIFIC TRANSCRIPTION; EUKARYOTIC PROTEIN-SYNTHESIS; CELL-SPECIFIC EXPRESSION; FACTOR-I; INVITRO TRANSCRIPTION; PHOSPHOENOLPYRUVATE CARBOXYKINASE; MESSENGER-RNA; PROMOTER; RATS	We have previously reported that albumin gene transcription is reduced in diabetes mellitus (DM), The present study explored the mechanism by which albumin gene transcription is down-regulated in DM. Deletional studies and displacement of factors binding to site B of the albumin promoter indicated that the repressive effects of DM are mediated by nuclear factors binding to this site. Since hepatocyte nuclear factor 1 (HNF1) activates albumin promoter activity and is the predominant factor binding to site B, we examined HNF1. The abundance and binding activity of HNF1 were reduced in hepatonuclear extracts from diabetic compared to control rats, However, HNF1 mRNA levels were unchanged, suggesting that the effect of DM on HNF1 is at the posttranscriptional level. Extracts from diabetic animals also contained another protein, distinct from HNF1 and vHNF1, which bound to site B in gel retardation studies, In summary, our studies demonstrate that the reduced abundance and binding activity of HNF1 correlates with decreased albumin gene transcription in DM.	UNIV CALGARY,DEPT MED,CALGARY,AB T2N 4N1,CANADA; UNIV CALGARY,DEPT MED BIOCHEM,CALGARY,AB T2N 4N1,CANADA	University of Calgary; University of Calgary								BAUMHUETER S, 1988, EMBO J, V7, P2485, DOI 10.1002/j.1460-2075.1988.tb03095.x; BEALE EG, 1992, FASEB J, V6, P3330, DOI 10.1096/fasebj.6.15.1281456; BERNIER D, 1993, MOL CELL BIOL, V13, P1619, DOI 10.1128/MCB.13.3.1619; BOSCH F, 1995, DIABETES, V44, P267, DOI 10.2337/diabetes.44.3.267; BRETHERTONWATT D, 1989, DIABETOLOGIA, V32, P881, DOI 10.1007/BF00297454; BURKE PA, 1994, SURGERY, V116, P285; CARMASSI F, 1992, THROMB RES, V67, P643, DOI 10.1016/0049-3848(92)90068-L; CEREGHINI S, 1992, DEVELOPMENT, V116, P783; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CEREGHINI S, 1990, EMBO J, V9, P2257, DOI 10.1002/j.1460-2075.1990.tb07396.x; CHAN J, 1993, NUCLEIC ACIDS RES, V21, P1205, DOI 10.1093/nar/21.5.1205; CHAN L, 1995, BIOCHIMIE, V77, P75, DOI 10.1016/0300-9084(96)88107-7; CIMBALA MA, 1982, J BIOL CHEM, V257, P7629; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DALMON J, 1993, MOL CELL BIOL, V13, P1183, DOI 10.1128/MCB.13.2.1183; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; DILLMANN WH, 1988, DIABETES METAB REV, V4, P789, DOI 10.1002/dmr.5610040807; DOLLE P, 1990, CELL, V60, P809, DOI 10.1016/0092-8674(90)90095-V; FELDMAN ST, 1992, INVEST OPHTH VIS SCI, V33, P3307; FINOTTI P, 1992, DIABETES RES CLIN PR, V18, P35, DOI 10.1016/0168-8227(92)90053-T; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HERBST RS, 1991, NEW BIOL, V3, P289; ICHIKAWA K, 1991, J MOL ENDOCRINOL, V7, P123, DOI 10.1677/jme.0.0070123; IZBAN MG, 1989, J BIOL CHEM, V264, P9171; JOHNSON PF, 1990, CELL GROWTH DIFFER, V1, P47; JOHNSON TR, 1991, P NATL ACAD SCI USA, V88, P5287, DOI 10.1073/pnas.88.12.5287; KUO CJ, 1990, P NATL ACAD SCI USA, V87, P9838, DOI 10.1073/pnas.87.24.9838; KUO CJ, 1991, EMBO J, V10, P2231, DOI 10.1002/j.1460-2075.1991.tb07759.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI Y, 1988, MOL CELL BIOL, V8, P4362, DOI 10.1128/MCB.8.10.4362; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MURTY CVR, 1986, BIOCHEMISTRY-US, V25, P4376, DOI 10.1021/bi00363a030; NAHON JL, 1987, BIOCHIMIE, V69, P445, DOI 10.1016/0300-9084(87)90082-4; NAKABAYASHI H, 1991, MOL CELL BIOL, V11, P5885, DOI 10.1128/MCB.11.12.5885; NGUYEN V, 1994, EXP EYE RES, V59, P335, DOI 10.1006/exer.1994.1115; PATEL YM, 1994, J BIOL CHEM, V269, P5619; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; PIETRANGELO A, 1994, P NATL ACAD SCI USA, V91, P182, DOI 10.1073/pnas.91.1.182; RECKELHOFF JF, 1993, DIABETES, V42, P1425, DOI 10.2337/diabetes.42.10.1425; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RINGEISEN F, 1993, J BIOL CHEM, V268, P25706; ROMNEY JS, 1992, THESIS U CALGARY CAL; ROY S, 1990, P NATL ACAD SCI USA, V87, P404, DOI 10.1073/pnas.87.1.404; ROY S, 1994, J BIOL CHEM, V269, P691; Sambrook J., 2002, MOL CLONING LAB MANU; SCHORPP M, 1988, J MOL BIOL, V202, P307, DOI 10.1016/0022-2836(88)90460-3; SHEN RF, 1987, NUCLEIC ACIDS RES, V15, P8399, DOI 10.1093/nar/15.20.8399; SPARKS JD, 1992, J CLIN INVEST, V89, P1418, DOI 10.1172/JCI115731; STAUBER WT, 1985, HISTOCHEM J, V17, P613, DOI 10.1007/BF01003201; THORNGATE FE, 1994, P NATL ACAD SCI USA, V91, P5392, DOI 10.1073/pnas.91.12.5392; TRONCHE F, 1992, BIOESSAYS, V14, P579, DOI 10.1002/bies.950140902; TRONCHE F, 1989, MOL CELL BIOL, V9, P4759, DOI 10.1128/MCB.9.11.4759; TRONCHE F, 1990, MOL BIOL MED, V7, P173; VALERA A, 1993, J CLIN INVEST, V92, P4, DOI 10.1172/JCI116580; WANKE IE, 1991, J BIOL CHEM, V266, P6068; WHITE JD, 1990, ENDOCRINOLOGY, V126, P765, DOI 10.1210/endo-126-2-765; WUARIN J, 1990, J MOL BIOL, V214, P865, DOI 10.1016/0022-2836(90)90341-I; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807	67	18	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9969	9975		10.1074/jbc.271.17.9969	http://dx.doi.org/10.1074/jbc.271.17.9969			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626635	hybrid			2022-12-25	WOS:A1996UG25700019
J	Ribon, V; Saltiel, AR				Ribon, V; Saltiel, AR			Nerve growth factor stimulates the tyrosine phosphorylation of endogenous Crk-II and augments its association with p130(Cas) in PC-12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; SH3 DOMAINS; NEURONAL DIFFERENTIATION; ONCOGENE PRODUCT; PHOSPHOLIPASE-C; V-CRK; RECEPTOR; BINDING; IDENTIFICATION; PAXILLIN	The cellular homologs of the v-Crk oncogene product consist primarily of Src homology region 2 (SH2)(1) and 3 (SH3) domains, v-Crk overexpression causes cell trans formation and elevation of tyrosine phosphorylation in fibroblasts and accelerates differentiation of PC-12 cells in response to nerve growth factor (NGF), To further explore the role of Crk in NGF-induced PC-12 cell differentiation, we found that both NGF and epidermal growth factor stimulate the tyrosine phosphorylation of endogenous Crk II. Moreover, hormone stimulation enhanced the specific association of Crk proteins with the tyrosine-phosphorylated p130(Cas), the major phosphotyrosine-containing protein in cells transformed with v-Crk. This interaction is mediated by the SH2 domain of Crk and can be inhibited with a phosphopeptide containing the Crk-SH2 binding motif. Furthermore, the Crk-SH2 domain binds tyrosine-phosphorylated paxillin, a cytoskeletal protein, following treatment of PC-12 cells with NGF or epidermal growth factor. These data suggest that Crk functions in a number of signaling processes in PC-12 cells.	WARNER LAMBERT PARKE DAVIS, PHARMACEUT RES DIV, DEPT SIGNAL TRANSDUCT, ANN ARBOR, MI 48105 USA; UNIV MICHIGAN, SCH MED, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA	Pfizer; University of Michigan System; University of Michigan			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; FAJARDO JE, 1993, MOL CELL BIOL, V13, P7295, DOI 10.1128/MCB.13.12.7295; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; HU Q, 1995, MOL CELL BIOL, V14, P1964; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATSUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCNAMARA DJ, 1993, INT J PEPT PROT RES, V42, P240; MOCHAMMADI M, 1992, NATURE, V358, P681; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OHMICHI M, 1991, J BIOL CHEM, V266, P14858; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RANKIN S, 1994, J BIOL CHEM, V269, P704; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; RIBON V, 1994, MOL CELL NEUROSCI, V5, P277, DOI 10.1006/mcne.1994.1032; ROSEN MK, 1995, SCIENCE, V374, P477; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALTIEL AR, 1994, BIOESSAYS, V16, P405, DOI 10.1002/bies.950160608; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	47	66	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7375	7380		10.1074/jbc.271.13.7375	http://dx.doi.org/10.1074/jbc.271.13.7375			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631760	hybrid			2022-12-25	WOS:A1996UC77400028
J	Esser, V; Brown, NF; Cowan, AT; Foster, DW; McGarry, JD				Esser, V; Brown, NF; Cowan, AT; Foster, DW; McGarry, JD			Expression of a cDNA isolated from rat brown adipose tissue and heart identifies the product as the muscle isoform of carnitine palmitoyltransferase I (M-CPT I) - M-CPT I is the predominant CPT I isoform expressed in both white (epididymal) and brown adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALONYL-COA; ENZYME-SYSTEM; LIVER; CLONING; ACID; DNA; OCTANOYLTRANSFERASE; SENSITIVITY; INHIBITORS; DEFICIENCY	We set out to determine if the cDNA encoding a carnitine palmitoyltransferase (CPT)-like protein recently isolated from rat brown adipose tissue (BAT) by Yamazaki ct al, (Yamazaki, N., Shinohara, Y., Shima, A., and Terada, H. (1995) FEES Lett. 363, 41-45) actually encodes the muscle isoform of mitochondrial CPT I (M-CPT I), To this end, a cDNA essentially identical to the original EAT clone was isolated from a rat heart library. When expressed in COS cells, the novel cDNA and our previously described cDNA for rat liver CPT I (L-CPT I) gave rise to products with the same kinetic characteristics (sensitivity to malonyl-CoA and K-m for carnitine) as CPT I in skeletal muscle and liver mitochondria, respectively. When labeled with [H-3]etomoxir, recombinant L-CPT I and putative M-CPT I, although having approximately the same predicated masses (88.2 kDa), migrated differently on SDS gels, as did CPT I from liver and muscle mitochondria The same was true for the products of in vitro transcription and translation of the L-CPT I and putative M-CPT I cDNAs. We conclude that the BAT cDNA does in fact encode M-CPT I. Northern blots using L- and M-CPT I cDNA probes revealed the presence of L-CPT I mRNA in liver and heart and its absence from skeletal muscle and BAT. M-CPT I mRNA, which was absent from liver, was readily detected in skeletal muscle and was particularly strong in heart and BAT. Whereas the signal for L-CPT I was more abundant than that for M-CPT I in RNA isolated from whole epididymal fat pad, this was reversed in purified adipocytes from this source, These findings, coupled with the kinetic properties and migration profiles on SDS gels of CPT I in brown and white adipocytes, indicate that the muscle form of the enzyme is the dominant, if not exclusive, species in both cell types.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,GIFFORD LABS,CTR DIABET RES,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,GIFFORD LABS,CTR DIABET RES,DALLAS,TX 75235	Diabetes & Endocrine Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Diabetes & Endocrine Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIDDK NIH HHS [DK18573] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018573, R01DK018573] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BERGMAN AJIW, 1994, PEDIATR RES, V36, P582, DOI 10.1203/00006450-199411000-00007; BRITTON CH, 1995, P NATL ACAD SCI USA, V92, P1984, DOI 10.1073/pnas.92.6.1984; BROWN NF, 1991, J BIOL CHEM, V266, P15446; BROWN NF, 1995, J BIOL CHEM, V270, P8952, DOI 10.1074/jbc.270.15.8952; BROWN NF, 1994, J BIOL CHEM, V269, P19157; BROWN NF, 1993, BIOCHEM J, V294, P79, DOI 10.1042/bj2940079; BROWN NF, 1994, J BIOL CHEM, V269, P26438; CHATTERJEE B, 1988, BIOCHEMISTRY-US, V27, P9000, DOI 10.1021/bi00425a018; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORR PB, 1995, HERZ, V20, P156; CORTI O, 1994, GENOMICS, V23, P94, DOI 10.1006/geno.1994.1463; DEMAUGRE F, 1988, PEDIATR RES, V24, P308, DOI 10.1203/00006450-198809000-00006; ESSER V, 1993, J BIOL CHEM, V268, P5817; FALIKBORENSTEIN ZC, 1992, NEW ENGL J MED, V327, P24, DOI 10.1056/NEJM199207023270105; FINOCCHIARO G, 1991, P NATL ACAD SCI USA, V88, P661, DOI 10.1073/pnas.88.2.661; FOLEY JE, 1992, DIABETES CARE, V15, P773, DOI 10.2337/diacare.15.6.773; GHADIMINEJAD I, 1991, BIOCHEM J, V277, P611, DOI 10.1042/bj2770611; JOHNSON TM, 1995, BIOCHEM J, V305, P439, DOI 10.1042/bj3050439; LEY TJ, 1982, P NATL ACAD SCI-BIOL, V79, P4775, DOI 10.1073/pnas.79.15.4775; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGARRY JD, 1973, J CLIN INVEST, V52, P877, DOI 10.1172/JCI107252; MCGARRY JD, 1983, BIOCHEM J, V214, P21, DOI 10.1042/bj2140021; MCGARRY JD, 1995, BIOCHEM SOC T, V23, P321, DOI 10.1042/bst0230321; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MURTHY MSR, 1994, BIOCHEM J, V304, P31, DOI 10.1042/bj3040031; MURTHY MSR, 1994, J BIOL CHEM, V269, P18283; RODBELL M, 1964, J BIOL CHEM, V239, P375; SAGGERSON ED, 1981, FEBS LETT, V129, P229, DOI 10.1016/0014-5793(81)80171-8; SAGGERSON ED, 1982, BIOCHEM J, V208, P673, DOI 10.1042/bj2080673; SAGGERSON ED, 1982, BIOCHEM J, V204, P373, DOI 10.1042/bj2040373; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WEIS BC, 1994, J BIOL CHEM, V269, P26443; WEIS BC, 1994, J BIOL CHEM, V269, P18712; WOELTJE KF, 1987, J BIOL CHEM, V262, P9822; WOELTJE KF, 1990, J BIOL CHEM, V265, P10720; WOELTJE KF, 1990, J BIOL CHEM, V265, P10714; YAMAZAKI N, 1995, FEBS LETT, V363, P41, DOI 10.1016/0014-5793(95)00277-G	41	132	135	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6972	6977		10.1074/jbc.271.12.6972	http://dx.doi.org/10.1074/jbc.271.12.6972			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636126	hybrid			2022-12-25	WOS:A1996UB15700061
J	Gibson, S; August, A; Branch, D; Dupont, B; Mills, GB				Gibson, S; August, A; Branch, D; Dupont, B; Mills, GB			Functional LCK is required for optimal CD28-mediated activation of the TEC family tyrosine kinase EMT/ITK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; SIGNAL-TRANSDUCTION; CD28 RECEPTOR; PROTEIN-KINASE; EXPRESSION; PHOSPHORYLATION; PROLIFERATION; LYMPHOCYTES; ANTIGEN; CLONING	Activation of CD28 on T lymphocytes initiates a cascade of intracellular events, which in concert with activation of the T cell receptor, culminates in production of cytokines and a functional immune response. One of the earliest biochemical changes observed following stimulation of CD28 is tyrosine phosphorylation. We have demonstrated that both the LCK and the EMT/ITK/TSK (EMT) intracellular tyrosine kinases are activated following cross-linking of CD28. Utilizing somatic cell mutants lacking LCK, we demonstrate that functional LCK is required for CD28-induced activation of EMT as evidenced by increased tyrosine phosphorylation and kinase activity. In support of a role for LCK in EMT activation, reconstitution of a LCK-negative Jurkat T cell line by transfection with normal LCK recreates CD28-mediated EMT activation. Furthermore, co-transfection of LCK and EMT into COS-7 cells showed that EMT becomes phosphorylated in the presence of LCK. In addition, increases in EMT association with CD28 were eliminated in a LCK-negative Jurkat cell line, but were restored following transfection of wild type LCK. The data are most compatible with a model in which LCK, either directly or indirectly, initiates EMT activation and association with CD28 following ligation of CD28.	UNIV TEXAS,MD ANDERSON CANC CTR,DIV MED,HOUSTON,TX 77030; UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO,ON M5G 2C4,CANADA; TORONTO HOSP,TORONTO,ON M5G 2C4,CANADA; MEM SLOAN KETTERING INST CANC RES,PROGRAM IMMUNOL,NEW YORK,NY 10021; ROCKEFELLER UNIV,MOLEC ONCOL LAB,NEW YORK,NY 10021; CANADIAN RES CROSS,TORONTO,ON M5G 2C4,CANADA	University of Texas System; UTMD Anderson Cancer Center; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Memorial Sloan Kettering Cancer Center; Rockefeller University				Gibson, Spencer/0000-0003-0119-732X	NCI NIH HHS [CA08748, CA22507] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA022507, P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; AUGUST A, 1994, INT IMMUNOL, V6, P769, DOI 10.1093/intimm/6.5.769; AUGUST A, 1994, BIOCHEM BIOPH RES CO, V199, P1466, DOI 10.1006/bbrc.1994.1396; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; BRANCH DR, 1995, J IMMUNOL, V154, P3678; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; FARGNOLI J, 1995, J BIOL CHEM, V270, P26533, DOI 10.1074/jbc.270.44.26533; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; GIBSON S, 1993, BLOOD, V82, P1561; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; KAWAKAMI Y, 1995, J IMMUNOL, V155, P3556; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LU YL, 1992, J IMMUNOL, V149, P24; MILLS GB, 1992, J BIOL CHEM, V267, P16000; MUSTELIN T, 1993, TRENDS BIOCHEM SCI, V18, P215, DOI 10.1016/0968-0004(93)90192-P; NUNES JA, 1994, J EXP MED, V180, P1067, DOI 10.1084/jem.180.3.1067; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; PIKE LJ, 1986, J BIOL CHEM, V261, P3782; PRASAD KVS, 1994, P NATL ACAD SCI USA, V91, P2834, DOI 10.1073/pnas.91.7.2834; RAAB M, 1995, P NATL ACAD SCI USA, V92, P8891, DOI 10.1073/pnas.92.19.8891; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHMANDT R, 1994, J IMMUNOL, V152, P96; SCHNEIDER H, 1995, EUR J IMMUNOL, V25, P1044, DOI 10.1002/eji.1830250428; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; SHI YF, 1995, J IMMUNOL, V155, P1829; SIEGEL JN, 1993, J IMMUNOL, V151, P4116; STEIN PH, 1994, MOL CELL BIOL, V14, P3392, DOI 10.1128/MCB.14.5.3392; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TRUITT KE, 1994, J EXP MED, V179, P1071, DOI 10.1084/jem.179.3.1071; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VANDENBERGHE P, 1992, J EXP MED, V175, P951, DOI 10.1084/jem.175.4.951; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YAMADA N, 1993, BIOCHEM BIOPH RES CO, V192, P231, DOI 10.1006/bbrc.1993.1404; YANG WY, 1995, J BIOL CHEM, V270, P20832, DOI 10.1074/jbc.270.35.20832; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175	44	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7079	7083		10.1074/jbc.271.12.7079	http://dx.doi.org/10.1074/jbc.271.12.7079			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636141	hybrid			2022-12-25	WOS:A1996UB15700076
J	Guyton, KZ; Liu, YS; Gorospe, M; Xu, QB; Holbrook, NJ				Guyton, KZ; Liu, YS; Gorospe, M; Xu, QB; Holbrook, NJ			Activation of mitogen-activated protein kinase by H2O2 - Role in cell survival following oxidant injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; GENE-PRODUCT; PHOSPHORYLATION; CARCINOGENESIS; EXPRESSION; PATHWAY; RAS	The mitogen-activated protein kinase (MAPK) family is comprised of key regulatory proteins that control the cellular response to both proliferation and stress signals. In this study we investigated the factors controlling MAPK activation by H2O2 and explored the impact of altering the pathways to kinase activation on cell survival following H2O2 exposure. Potent activation (10-20-fold) of extracellular signal-regulated protein kinase (ERK2) occurred within 10 min of H2O2 treatment, whereupon rapid inactivation ensued, H2O2 activated ERK2 in several cell types and also moderately activated (3-5-fold) both c-Jun N-terminal kinase and p38/RK/CSBP, Additionally, H2O2 increased the mRNA expression of MAPK-dependent genes c-jun, c-fos, and MAPK phosphatase-1. Suramin pretreatment completely inhibited H2O2 stimulation of ERK2, highlighting a role for growth factor receptors in this activation, Further, ERK2 activation by H2O2 was blocked by pretreatment with either N-acetyl-cysteine, o-phenanthroline, or mannitol, indicating that metal-catalyzed free radical formation mediates the initiation of signal transduction by H2O2. H2O2-stimulated activation of ERK2 was abolished in PC12 cells by inducible or constitutive expression of the dominant negative Ras-N-17 allele. Interestingly, PC12/Ras-N-17 cells were more sensitive than wild-type PC12 cells to H2O2 toxicity. Moreover, NIH 3T3 cells expressing constitutively active MAPK kinase (MEK, the immediate upstream regulator of ERK) were more resistant to H2O2 toxicity, while those expressing kinase-defective MEK were more sensitive, than cells expressing wild-type MEK. Taken together, these studies provide insight into mechanisms of MAPK regulation by H2O2 and suggest that ERK plays a critical role in cell survival following oxidant injury.	NIA,GERONTOL RES CTR,GENE EXPRESS & AGING SECT,NIH,BALTIMORE,MD 21224	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)			Liu, Yusen/E-3527-2011	Liu, Yusen/0000-0002-0994-0109				ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; BOULIKAS T, 1995, INT J ONCOL, V6, P271; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CADENAS E, 1989, ANNU REV BIOCHEM, V58, P79, DOI 10.1146/annurev.bi.58.070189.000455; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CERUTTI PA, 1989, ENVIRON HEALTH PERSP, V81, P39, DOI 10.2307/3430802; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GUYTON KZ, 1993, BRIT MED BULL, V49, P523, DOI 10.1093/oxfordjournals.bmb.a072628; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KEHRER JP, 1993, CRIT REV TOXICOL, V23, P21, DOI 10.3109/10408449309104073; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEWIS T, 1995, J CELL SCI, V108, P2885; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; LOS M, 1995, EUR J IMMUNOL, V25, P159, DOI 10.1002/eji.1830250127; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; NAKASHIMA I, 1994, J IMMUNOL, V152, P1064; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; OKA H, 1995, CANCER RES, V55, P4182; PAHL HL, 1994, BIOESSAYS, V16, P497, DOI 10.1002/bies.950160709; Ross R., 1980, HDB PHYSL CARDIOVA 2, P69; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SCHIEVEN GL, 1993, J BIOL CHEM, V268, P16688; SCHIEVEN GL, 1994, TRENDS ENDOCRIN MET, V5, P383, DOI 10.1016/1043-2760(94)90106-6; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHIBANUMA M, 1988, ONCOGENE, V3, P17; STAAL FJT, 1994, P NATL ACAD SCI USA, V91, P3619, DOI 10.1073/pnas.91.9.3619; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SZEBERENYI J, 1992, ONCOGENE, V7, P2105; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324	42	1111	1138	2	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4138	4142		10.1074/jbc.271.7.3604	http://dx.doi.org/10.1074/jbc.271.7.3604			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626753	hybrid			2022-12-25	WOS:A1996TW96000031
J	Trapani, JA; Browne, KA; Smyth, MJ; Jans, DA				Trapani, JA; Browne, KA; Smyth, MJ; Jans, DA			Localization of granzyme B in the nucleus - A putative role in the mechanism of cytotoxic lymphocyte-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SV40 T-ANTIGEN; NATURAL-KILLER-CELLS; SERINE ESTERASE GENE; MOLECULAR-CLONING; LYTIC GRANULES; PROTEIN-TRANSPORT; SEQUENCES; IDENTIFICATION; PROTEASES; RECEPTOR	One mechanism used by cytotoxic T cells and natural killer cells to kill target cells involves synergy between the pore-forming protein, perforin, and a serine protease termed granzyme B, both constituents of the cytoplasmic granules of cytolytic lymphocytes, Exposing susceptible cells to perforin and granzyme B results in apoptosis, the morphological consequences of which are most clearly seen in the nucleus, It is conventionally accepted that perforin acts by perforating the target cell membrane; however, the site and mode of action of granzyme B are unknown, We have addressed this issue using Western blotting, proteolytic assays, and confocal laser scanning microscopy to demonstrate that purified human granzyme B can be taken up in large amounts and bound within nuclei, By contrast, perforin and non-granzyme serine proteases did not undergo nuclear uptake, Both unglycosylated human granzyme B (26 kDa) and that bearing high mannose glycosylation (32 kDa) were internalized and bound within nuclei, but forms greater than 32 kDa with complex carbohydrate addition were excluded, The uptake of granzymes was not dependent on net charge, as nuclei absorbed similar quantities of granzyme B at neutral pH and through a range of basic pHs but did not take up other very basic serine proteases such as the mouse mast cell protease 5, Confocal laser scanning microscopy indicated nuclear and nucleolar accumulation of fluoresceinated granzyme B by isolated nuclei, Measurement of the kinetics of nuclear import using an in vitro nuclear transport assay indicated maximal levels of nuclear accumulation of granzyme about 2.5-fold above those in the cytoplasm and nucleolar accumulation a further 3-4-fold higher, Nuclear and nucleolar accumulation were exceedingly rapid, reaching half-maximal levels within 3.3 and 7.5 min, respectively, implying that nuclear accumulation probably occurs prior to transport to the nucleolus, Our observations may provide a mechanism explaining how aspartate-specific cell death proteases access the nuclear substrate poly(ADP-ribose) polymerase, the cleavage of which is an early event in apoptosis.	JOHN CURTIN SCH MED RES,DIV BIOCHEM & MOLEC BIOL,NUCL TARGETING LAB,CANBERRA,ACT 2600,AUSTRALIA	Australian National University; John Curtin School of Medical Research	Trapani, JA (corresponding author), AUSTIN RES INST,CELLULAR CYTOTOX LAB,STUDLEY RD,HEIDELBERG,VIC 3084,AUSTRALIA.		Smyth, Mark J/H-8709-2014	Smyth, Mark J/0000-0001-7098-7240; Trapani, Joseph/0000-0003-0983-1532				BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BURKHARDT JK, 1990, J CELL BIOL, V111, P2327, DOI 10.1083/jcb.111.6.2327; CHANG TW, 1980, J IMMUNOL, V124, P870; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DUKE RC, 1988, J IMMUNOL, V141, P2191; DUKE RC, 1989, J EXP MED, V170, P145; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; FEILOTTER H, 1992, BIOCHEM CELL BIOL, V70, P954, DOI 10.1139/o92-140; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GEISBERG M, 1991, TISSUE ANTIGENS, V35, P229; GREEN GDJ, 1979, ANAL BIOCHEM, V93, P223, DOI 10.1016/S0003-2697(79)80070-6; GRIFFITHS GM, 1993, J CELL BIOL, V120, P885, DOI 10.1083/jcb.120.4.885; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HUANG RY, 1991, EUR J IMMUNOL, V21, P1611, DOI 10.1002/eji.1830210706; HUDIG D, 1991, J IMMUNOL, V147, P1360; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JANS DA, 1994, ONCOGENE, V9, P2961; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; JANS DA, 1995, IN PRESS J BIOL CHEM; JANS DA, 1995, IN PRESS SCI INT; JANS DA, 1995, IN PRESS BIOCH J; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KAUFMANN SH, 1993, CANCER RES, V53, P3976; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LIU CC, 1986, J EXP MED, V164, P2061, DOI 10.1084/jem.164.6.2061; LIU CC, 1989, J EXP MED, V170, P2105, DOI 10.1084/jem.170.6.2105; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; MILLER M, 1991, PHYSIOL REV, V71, P909, DOI 10.1152/physrev.1991.71.3.909; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NAKAJIMA H, 1994, J IMMUNOL, V152, P1057; NAKAJIMA H, 1995, J EXP MED, V181, P1905, DOI 10.1084/jem.181.5.1905; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NORTHEMANN W, 1985, J BIOL CHEM, V260, P6200; OJCIUS DM, 1991, J IMMUNOL, V146, P4427; PASTERNACK MS, 1991, J BIOL CHEM, V266, P14703; PODACK ER, 1985, IMMUNOL TODAY, V6, P21, DOI 10.1016/0167-5699(85)90164-1; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SALI A, 1993, J BIOL CHEM, V268, P9023; SHI L, 1994, SCIENCE, V243, P1443; SHI L, 1991, J EXP MED, V175, P553; SHIVER JW, 1992, CELL, V71, P315, DOI 10.1016/0092-8674(92)90359-K; SMYTH MJ, 1992, J BIOL CHEM, V267, P24418; SMYTH MJ, 1995, IMMUNOL TODAY, V16, P202, DOI 10.1016/0167-5699(95)80122-7; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TRAPANI JA, 1994, J BIOL CHEM, V269, P18359; TRAPANI JA, 1993, BIOCHEM BIOPH RES CO, V195, P910, DOI 10.1006/bbrc.1993.2131; TRAPANI JA, 1988, P NATL ACAD SCI USA, V85, P6924, DOI 10.1073/pnas.85.18.6924; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WARREN G, 1987, NATURE, V327, P17, DOI 10.1038/327017a0; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; XUE ZX, 1993, EUR J CELL BIOL, V62, P13; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YOUNG JD, 1986, CELL, V46, P641, DOI 10.1016/0092-8674(86)90336-3; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YURT RW, 1977, J BIOL CHEM, V252, P518	60	100	105	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4127	4133						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626751				2022-12-25	WOS:A1996TW96000029
J	Cabado, AG; Yu, FH; Kapus, A; Lukacs, G; Grinstein, S; Orlowski, J				Cabado, AG; Yu, FH; Kapus, A; Lukacs, G; Grinstein, S; Orlowski, J			Distinct structural domains confer cAMP sensitivity and ATP dependence to the Na+/H+ exchanger NHE3 isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT NA/H EXCHANGER; CELL-VOLUME REGULATION; H+ EXCHANGER; INTRACELLULAR PH; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; ANTIPORTER; PHOSPHORYLATION; ACTIVATION; INHIBITION	Agents known to increase cAMP levels in renal and intestinal epithelia decrease sodium absorption by inhibiting NHE3, an isoform of the Na+/H+ exchanger ex pressed at high levels in apical membranes of these cells. In contrast, the ubiquitous, housekeeping isoform of the exchanger (NHE1) is stimulated by cAMP in some cell types. Optimal activity of NHE3 as well as NHE1 requires the presence of ATP, To gain insight into the molecular mechanisms of ATP dependence and cAMP regulation of NHE3, a series of mutations were constructed by progressively truncating segments of the C-terminal cytoplasmic domain of the transporter at amino acid positions 684, 638, and 579 (named NHE3 Delta 684, NHE3 Delta 638, and NHE3 Delta 579). In addition, chimeric antiporters were constructed with the N-terminal transmembrane domain of NHE3 linked to the entire cytoplasmic region of NHE1 (chimera NHE3/1) or vice versa (chimera NHE1/3). These constructs were heterologously expressed in antiport-deficient Chinese hamster ovary cells, and their activities were assessed by fluorimetric measurements of intracellular pH and by radioisotope determinations of Na+ influx. Forskolin, which directly stimulates adenylate cyclase, inhibited NHE3 as well as NHE1/3, but not NHE3/1, suggesting that the cytoplasmic domain of NHE3 was sufficient to confer sensitivity to inhibition by cAMP. Forskolin also inhibited the truncated mutant NHE3 Delta 684 to an extent similar to that for wild type NHE3. However, the inhibitory effect was greatly reduced in NHE3 Delta 638 and more profound truncations (NHE3 Delta 579) obliterated the effect of forskolin. These findings suggest that a region found between amino acids 579 and 684 is essential for the cAMP response of NHE3. In contrast, comparable ATP dependence was observed in all exchanger constructs examined, These observations indicate that ATP dependence is conferred by a region of the molecule in or adjacent to the transmembrane domain, which is most conserved between isoforms. It is concluded that different sites, and therefore different mechanisms, underlie inhibition of NHE3 by cAMP and by depletion of ATP.	HOSP SICK CHILDREN,DIV CELL BIOL,RES INST,TORONTO,ON M5G 1X8,CANADA; MCGILL UNIV,DEPT PHYSIOL,MONTREAL,PQ H3G 1Y6,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McGill University; University of Toronto				Lukacs, Gergely/0000-0003-0900-0675; Yu, Frank/0000-0001-9306-1731; Orlowski, John/0000-0001-7371-175X				ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; AZARANI A, 1995, J BIOL CHEM, V270, P23166, DOI 10.1074/jbc.270.39.23166; AZARANI A, 1995, J BIOL CHEM, V270, P20004, DOI 10.1074/jbc.270.34.20004; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; BIEMERSDERFER D, 1993, AM J PHYSIOL, V265, pF833; BOOKSTEIN C, 1994, J CLIN INVEST, V93, P106, DOI 10.1172/JCI116933; BORGESE F, 1992, P NATL ACAD SCI USA, V89, P6765, DOI 10.1073/pnas.89.15.6765; BORGESE F, 1994, P NATL ACAD SCI USA, V91, P5431, DOI 10.1073/pnas.91.12.5431; BORON WF, 1983, J MEMBRANE BIOL, V72, P1, DOI 10.1007/BF01870311; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; COUNILLON L, 1994, BIOCHEMISTRY-US, V33, P10463, DOI 10.1021/bi00200a030; COUNILLON L, 1993, P NATL ACAD SCI USA, V90, P4508, DOI 10.1073/pnas.90.10.4508; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; FRANCHI A, 1986, P NATL ACAD SCI USA, V83, P9388, DOI 10.1073/pnas.83.24.9388; GRINSTEIN S, 1993, EMBO J, V12, P5209, DOI 10.1002/j.1460-2075.1993.tb06216.x; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GRINSTEIN S, 1985, J CELL BIOL, V101, P269, DOI 10.1083/jcb.101.1.269; HELMLEKOLB C, 1990, PFLUG ARCH EUR J PHY, V415, P461, DOI 10.1007/BF00373624; KAPUS A, 1994, J BIOL CHEM, V269, P23544; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KLANKE CA, 1995, GENOMICS, V25, P615, DOI 10.1016/0888-7543(95)80002-4; KNICKELBEIN RG, 1988, J CLIN INVEST, V82, P2158, DOI 10.1172/JCI113838; LEVINE SA, 1995, J BIOL CHEM, V270, P13716, DOI 10.1074/jbc.270.23.13716; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; OSS GG, 1994, J BIOL CHEM, V269, P8741; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SOLEIMANI M, 1994, J BIOL CHEM, V269, P15613; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TSE CM, 1993, J BIOL CHEM, V268, P11917; WAKABAYASHI S, 1992, REV PHYSIOL BIOCH P, V119, P157; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; WANG Z, 1993, J BIOL CHEM, V268, P11925; WEINMAN EJ, 1987, AM J PHYSIOL, V252, pF19, DOI 10.1152/ajprenal.1987.252.1.F19; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WEINMAN EJ, 1993, ANNU REV PHYSIOL, V55, P289, DOI 10.1146/annurev.ph.55.030193.001445; WEINMAN EJ, 1990, AM J PHYSIOL, V258, pF1254; YUN CHC, 1993, BIOCHEM BIOPH RES CO, V193, P532, DOI 10.1006/bbrc.1993.1656	48	75	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3590	3599						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631966				2022-12-25	WOS:A1996TV72400040
J	McGinnity, DF; Devreese, B; Prazeres, S; VanBeeumen, J; Moura, I; Moura, JJG; Pettigrew, GW				McGinnity, DF; Devreese, B; Prazeres, S; VanBeeumen, J; Moura, I; Moura, JJG; Pettigrew, GW			A single histidine is required for activity of cytochrome c peroxidase from Paracoccus denitrificans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA; RESIDUES; DEHYDROGENASE; PREDICTION; MECHANISM; ALGORITHM; PROTEINS	The diheme cytochrome c peroxidase from Paracoccus denitrificans was modified with the histidine-specific reagent diethyl pyrocarbonate. At low excess of reagent, 1 mol of histidine was modified in the oxidized enzyme, and modification was associated with loss of the ability to form the active state. With time, the modification reversed, and the ability to form the active state was recovered, The agreement between the spectrophotometric measurement of histidine modification and radioactive incorporation using a radiolabeled reagent indicated Little modification of other amino acids. However, the reversal of histidine modification observed spectrophotometrically was not matched by loss of radioactivity, and we propose a slow transfer of the ethoxyformyl group to an unidentified amino acid. The presence of CN- bound to the active peroxidatic site of the enzyme led to complete protection of the essential histidine from modification. Limited subtilisin treatment of the native enzyme followed by tryptic digest of the C-terminal fragment (residues 251-338) showed that radioactivity was located in a peptide containing a single histidine at position 275. We propose that this conserved residue, in a highly conserved region, is central to the function of the active mixed-valence state.	UNIV EDINBURGH,ROYAL DICK SCH VET STUDIES,DEPT PRECLIN VET SCI,EDINBURGH EH9 1QH,MIDLOTHIAN,SCOTLAND; DEPT BIOCHEM PHYSIOL & MICROBIOL,B-9000 GHENT,BELGIUM; UNIV NOVA LISBOA,FAC CIENCIAS & TECNOL,DEPT QUIM,P-2825 MONTE DE CAPARICA,PORTUGAL	University of Edinburgh; Universidade Nova de Lisboa			Moura, José J G/D-6426-2013; Moura, Isabel/D-6339-2013; Devreese, Bart/B-2011-2009; Devreese, Bart/K-2841-2019	Moura, José J G/0000-0002-4726-2388; Moura, Isabel/0000-0003-0971-4977; Devreese, Bart/0000-0002-9764-2581; Devreese, Bart/0000-0002-9764-2581	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BHATTACHARYYA DK, 1992, J BIOL CHEM, V267, P9800; BOSSHARD HR, 1984, J BIOL CHEM, V259, P5683; BURSTEIN Y, 1974, BIOCHEMISTRY-US, V13, P205, DOI 10.1021/bi00698a030; COULSON AFW, 1971, J BIOL CHEM, V246, P917; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; ELLFOLK N, 1991, BIOCHIM BIOPHYS ACTA, V1080, P68, DOI 10.1016/0167-4838(91)90113-E; ELLFOLK N, 1983, BIOCHIM BIOPHYS ACTA, V743, P23, DOI 10.1016/0167-4838(83)90413-2; ELLFOLK N, 1984, BIOCHIM BIOPHYS ACTA, V784, P62, DOI 10.1016/0167-4838(84)90173-0; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FOOTE N, 1984, BIOCHEM J, V223, P369, DOI 10.1042/bj2230369; FOOTE N, 1985, BIOCHEM J, V230, P227, DOI 10.1042/bj2300227; FUKUYAMA K, 1995, J BIOL CHEM, V270, P21884, DOI 10.1074/jbc.270.37.21884; FULOP V, 1995, STRUCTURE, V3, P1225, DOI 10.1016/S0969-2126(01)00258-1; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; GILMOUR R, 1994, BIOCHEM J, V300, P907, DOI 10.1042/bj3000907; Gilmour R, 1995, EUR J BIOCHEM, V234, P878, DOI 10.1111/j.1432-1033.1995.878_a.x; GILMOUR R, 1993, BIOCHEM J, V294, P745, DOI 10.1042/bj2940745; GOODHEW CF, 1990, BIOCHEM J, V271, P707, DOI 10.1042/bj2710707; HEGYI G, 1974, EUR J BIOCHEM, V44, P7, DOI 10.1111/j.1432-1033.1974.tb03452.x; HOLBROOK JJ, 1973, BIOCHEM J, V131, P729, DOI 10.1042/bj1310729; LEVIN JM, 1986, FEBS LETT, V205, P303, DOI 10.1016/0014-5793(86)80917-6; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; MILES EDW, 1972, METHOD ENZYMOL, V25, P44; MORE C, 1990, J MAGN RESON, V90, P486, DOI 10.1016/0022-2364(90)90053-C; OVADI J, 1969, ACTA BIOCHIM BIOPHYS, V4, P265; PETTIGREW GW, 1982, BIOCHEM J, V201, P9, DOI 10.1042/bj2010009; POULOS TL, 1993, J BIOL CHEM, V268, P4429; PRAZERES S, 1995, J BIOL CHEM, V270, P24264, DOI 10.1074/jbc.270.41.24264; RIDOUT CJ, 1995, FEBS LETT, V365, P152, DOI 10.1016/0014-5793(95)00461-H; RONNBERG M, 1981, ARCH BIOCHEM BIOPHYS, V207, P197, DOI 10.1016/0003-9861(81)90025-4; TUDBALL N, 1972, BIOCHEM J, V129, P419, DOI 10.1042/bj1290419	32	16	16	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11126	11133		10.1074/jbc.271.19.11126	http://dx.doi.org/10.1074/jbc.271.19.11126			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626657	hybrid			2022-12-25	WOS:A1996UJ94400017
J	Shearwin, KE; Egan, JB				Shearwin, KE; Egan, JB			Purification and self-association equilibria of the lysis-lysogeny switch proteins of coliphage 186	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMBDA CI-REPRESSOR; GENE-EXPRESSION; TEMPERATE COLIPHAGE-186; BACTERIOPHAGE-MU; DNA; BINDING; NER; SEQUENCE	The CI repressor protein, responsible for maintenance of the lysogenic state, and the Apl protein, required for efficient prophage induction, are the two control proteins of the lysis-lysogeny transcriptional switch of coliphage 186. These proteins have been overexpressed, purified, and their self-association behavior examined by sedimentation equilibrium. Phage 186 CI dimers self-associate in solution through tetramers to octamers in a concerted process. The Apl protein of 186 is an unusual example of a helix-turn-helix protein which is monomeric in solution.	UNIV ADELAIDE,DEPT BIOCHEM,ADELAIDE,SA 5005,AUSTRALIA	University of Adelaide			Shearwin, Keith/AAS-1247-2021	Shearwin, Keith/0000-0002-7736-2742				ABBOTT J, 1993, BIOCHEMISTRY-US, V32, P9649, DOI 10.1021/bi00088a017; ALLET B, 1988, GENE, V65, P259, DOI 10.1016/0378-1119(88)90462-3; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; BURZ DS, 1994, BIOCHEMISTRY-US, V33, P8406, DOI 10.1021/bi00194a004; DIBBENS JA, 1992, MOL MICROBIOL, V6, P2643, DOI 10.1111/j.1365-2958.1992.tb01441.x; Dodd IB, 1996, J BIOL CHEM, V271, P11532, DOI 10.1074/jbc.271.19.11532; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; DODD IB, 1993, MOL MICROBIOL, V10, P1139, DOI 10.1111/j.1365-2958.1993.tb00983.x; DODD IB, 1990, J MOL BIOL, V214, P27, DOI 10.1016/0022-2836(90)90144-B; ESPOSITO D, 1994, MOL MICROBIOL, V13, P685, DOI 10.1111/j.1365-2958.1994.tb00462.x; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; GOOSEN N, 1986, J BACTERIOL, V167, P503, DOI 10.1128/jb.167.2.503-507.1986; HARRISON SC, 1992, TRANSCRIPTIONAL REGU; HEXNER PE, 1961, P NATL ACAD SCI USA, V47, P1848, DOI 10.1073/pnas.47.11.1848; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KALIONIS B, 1986, J MOL BIOL, V191, P199, DOI 10.1016/0022-2836(86)90257-3; KUKOLJ G, 1992, J BIOL CHEM, V267, P17827; KUKOLJ G, 1989, EMBO J, V8, P3141, DOI 10.1002/j.1460-2075.1989.tb08467.x; LAMONT I, 1989, P NATL ACAD SCI USA, V86, P5492, DOI 10.1073/pnas.86.14.5492; LAUE TM, 1993, BIOCHEMISTRY-US, V32, P2469, DOI 10.1021/bi00061a003; McKnight S.L., 1992, TRANSCRIPTIONAL REGU; PTASHNE M, 1992, GENETIC SWITCH GENE; RICHARDSON H, 1989, J MOL BIOL, V206, P59, DOI 10.1016/0022-2836(89)90523-8; SENEAR DF, 1993, BIOCHEMISTRY-US, V32, P6179, DOI 10.1021/bi00075a010; STRZELECKA TE, 1995, BIOCHEMISTRY-US, V34, P2946, DOI 10.1021/bi00009a026; STUDIER RW, 1990, METHOD ENZYMOL, V185, P60; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303; ZAMYATNIN AA, 1984, ANNU REV BIOPHYS BIO, V13, P145, DOI 10.1146/annurev.bb.13.060184.001045	28	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11525	11531		10.1074/jbc.271.19.11525	http://dx.doi.org/10.1074/jbc.271.19.11525			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626713	hybrid			2022-12-25	WOS:A1996UJ94400073
J	Wheeler, LJ; Ray, NB; Ungermann, C; Hendricks, SP; Bernard, MA; Hanson, ES; Mathews, CK				Wheeler, LJ; Ray, NB; Ungermann, C; Hendricks, SP; Bernard, MA; Hanson, ES; Mathews, CK			T4 phage gene 32 protein as a candidate organizing factor for the Deoxyribonucleoside triphosphate synthetase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DEOXYCYTIDYLATE HYDROXYMETHYLASE; BACTERIOPHAGE-T4 PROTEINS; THYMIDYLATE SYNTHASE; DNA-REPLICATION; PURIFICATION; CLONING; OVERPRODUCTION; RECOMBINATION; EXPRESSION	After T4 bacteriophage infection of Escherichia coli, the enzymes of deoxyribonucleoside triphosphate biosynthesis form a multienzyme complex that we call T4 deoxyribonucleoside triphosphate (dNTP) synthetase, At least eight phage-coded enzymes and two enzymes of host origin are found in this 1.5-mDa complex. The complex may shuttle dNTPs to DNA replication sites, because replication draws from small pools, which are probably highly localized. Several specific protein-protein contacts within the complex are described in this paper. We have studied protein-protein interactions in the complex by immobilizing individual enzymes and identifying radiolabeled T4 proteins that are retained by columns of these respective affinity ligands. Elsewhere we have described interactions involving three T4 enzymes found in the complex. In this paper we describe similar analysis of five more proteins: dihydrofolate reductase, dCTPase-dUTPase, deoxyribonucleoside monophosphokinase, ribonucleotide reductase, and E. coli nucleoside diphosphokinase,. All eight proteins analyzed to date retain single-strand DNA-binding protein (gp32), the product of T4 gene 32. At least one T4 protein, thymidylate synthase, binds directly to gp32, as shown by affinity chromatographic analysis of the two purified proteins. Among its several roles, gp32 stabilizes single-strand template DNA ahead of a replicating DNA polymerase, Our data suggest a model in which dNTP synthetase complexes, probably more than one per growing DNA chain, are drawn to replication forks via their affinity for gp32 and hence are localized so as to produce dNTPs at their sites of utilization, immediately ahead of growing DNA 3' termini.	OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331	Oregon State University				Bernard, Mark/0000-0001-7141-2975				ALLEN JR, 1983, J BIOL CHEM, V258, P5746; BELFORT M, 1983, J BIOL CHEM, V258, P2045; BRUSH GS, 1990, J BACTERIOL, V172, P2935, DOI 10.1128/jb.172.6.2935-2939.1990; CHIU CS, 1982, J BIOL CHEM, V257, P5087; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; GARY TP, 1992, THESIS VANDERBILT U; HAMA H, 1991, GENE, V105, P31, DOI 10.1016/0378-1119(91)90510-I; HANSON E, 1994, J BIOL CHEM, V269, P30999; HANSOU ES, 1994, THESIS OREGON STATE; HOFFMANN HJ, 1992, P NATL ACAD SCI USA, V89, P12108, DOI 10.1073/pnas.89.24.12108; HURLEY JM, 1993, J MOL BIOL, V229, P398, DOI 10.1006/jmbi.1993.1042; JI JP, 1993, MUTAT RES, V294, P247, DOI 10.1016/0921-8777(93)90007-4; Karpel R.L., 1990, BIOL NONSPECIFIC DNA, P103; KERNBERG A, 1992, DNA REPLICATION, P324; KRASSA KB, 1991, P NATL ACAD SCI USA, V88, P4010, DOI 10.1073/pnas.88.9.4010; KREUZER KN, 1994, MOL BIOL BACTERIOPHA, P28; LOHMAN TM, 1984, BIOCHEMISTRY-US, V23, P4665, DOI 10.1021/bi00315a023; MATHEWS CK, 1993, PROG NUCLEIC ACID RE, V44, P167, DOI 10.1016/S0079-6603(08)60220-2; MATHEWS CK, 1993, J BACTERIOL, V175, P6377, DOI 10.1128/jb.175.20.6377-6381.1993; MILLER RC, 1972, J VIROL, V10, P920, DOI 10.1128/JVI.10.5.920-924.1972; Moen L K, 1988, J Mol Recognit, V1, P48, DOI 10.1002/jmr.300010109; PUROHIT S, 1984, J BIOL CHEM, V259, P6261; RAY NB, 1992, THESIS OREGON STATE; REDDY GPV, 1978, J BIOL CHEM, V253, P3461; RICHEY B, 1987, J BIOL CHEM, V262, P7157; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SHAMOO Y, 1986, P NATL ACAD SCI USA, V83, P8844, DOI 10.1073/pnas.83.23.8844; TSENG MJ, 1992, J BACTERIOL, V174, P5740, DOI 10.1128/JB.174.17.5740-5744.1992; UNGERMANN C, 1993, THESIS OREGON STATE; WARNER HR, 1966, P NATL ACAD SCI USA, V56, P1233, DOI 10.1073/pnas.56.4.1233; WERNER R, 1968, J MOL BIOL, V33, P679, DOI 10.1016/0022-2836(68)90313-6; WHEELER L, 1992, J BIOL CHEM, V267, P7664; YONESAKI T, 1985, EUR J BIOCHEM, V148, P127, DOI 10.1111/j.1432-1033.1985.tb08816.x; YOUNG JP, 1992, J BIOL CHEM, V267, P10786	34	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11156	11162		10.1074/jbc.271.19.11156	http://dx.doi.org/10.1074/jbc.271.19.11156			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626661				2022-12-25	WOS:A1996UJ94400021
J	DeNichilo, MO; Yamada, KM				DeNichilo, MO; Yamada, KM			Integrin alpha(v)beta(5)-dependent serine phosphorylation of paxillin in cultured human macrophages adherent to vitronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; CELL-ADHESION; EXTRACELLULAR-MATRIX; SIGNAL TRANSDUCTION; FOCAL ADHESIONS; FIBRONECTIN; EXPRESSION; FIBROBLASTS; MODULATION; PP125(FAK)	The macrophage colony-stimulating factor (M-CSF) is able tct induce the expression of the alpha(v) beta(5) integrin receptor on the surface of cultured human macrophages (De Nichilo, M. O., and Burns, G. F. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2517-2521). In the present study, we establish that the adhesion of M-CSF-treated macrophages to vitronectin is mediated by the integrin alpha(v) beta(5), and show by indirect immunofluorescence analysis that alpha(v) beta(5) and the cytoskeletal protein paxillin localize to focal contacts upon adhesion to vitronectin. Immunoprecipitation and Western blot analysis revealed that M-CSF-treated macrophages do not express focal adhesion kinase (FAK), thereby providing direct evidence for integrin dependent localization of paxillin to focal contacts in the absence of FAK expression. Investigation of paxillin phosphorylation by two dimensional phosphoamino acid analysis indicates that paxillin is 99% phosphorylated on serine residue(s) in response to vitronectin adhesion, and only 1% phosphorylated on tyrosine. Stimulation of protein kinase C (PKC) activity with the phorbol ester phorbol 12-myristate 13-acetate enhances paxillin phosphorylation, while two selective inhibitors of PKC, GF109203X and chelerythrine chloride, effectively block the phosphorylation of paxillin induced in response to vitronectin adhesion. Taken together, these data demonstrate that in M-CSF-treated macrophages adherent to vitronectin, paxillin localizes to focal contacts in the absence of FAK expression and is predominantly phosphorylated on serine residue(s) in a PKC-dependent manner.			DeNichilo, MO (corresponding author), NIDR, DEV BIOL LAB,NIH,BLDG 30,RM 404, 30 CONVENT DR MSC 4370, BETHESDA, MD 20892 USA.			Yamada, Kenneth/0000-0003-1512-6805				BARRY ST, 1994, J CELL SCI, V107, P2033; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BURNS GF, 1988, J CELL BIOL, V107, P1225, DOI 10.1083/jcb.107.3.1225; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHOI KG, 1993, P NATL ACAD SCI USA, V90, P5747, DOI 10.1073/pnas.90.12.5747; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; DENICHILO MO, 1993, P NATL ACAD SCI USA, V90, P2517, DOI 10.1073/pnas.90.6.2517; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ILLC D, 1995, NATURE, V377, P539; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KHARBANDA S, 1995, P NATL ACAD SCI USA, V92, P6132, DOI 10.1073/pnas.92.13.6132; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KRISSANSEN GW, 1990, INT IMMUNOL, V2, P267, DOI 10.1093/intimm/2.3.267; LIN TH, 1994, J CELL BIOL, V126, P1585, DOI 10.1083/jcb.126.6.1585; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MERCURIO AM, 1988, J CELL BIOL, V107, P1873, DOI 10.1083/jcb.107.5.1873; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SIEGEL JN, 1991, CURRENT PROTOCOLS IM; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TURNER CE, 1995, J CELL SCI, V108, P333; TURNER CE, 1993, J CELL SCI, V105, P637; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, J CELL SCI, V107, P1583; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; VUORI K, 1993, J BIOL CHEM, V268, P21459; WAHL LM, 1991, CURRENT PROTOCOLS IM; WAHL SM, 1987, J IMMUNOL, V139, P1342; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WOODS A, 1992, J CELL SCI, V101, P277; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; ZACHARY I, 1993, J BIOL CHEM, V268, P22060	47	102	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					11016	11022		10.1074/jbc.271.18.11016	http://dx.doi.org/10.1074/jbc.271.18.11016			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631923	hybrid			2022-12-25	WOS:A1996UJ34200091
J	Golabek, AA; Soto, C; Vogel, T; Wisniewski, T				Golabek, AA; Soto, C; Vogel, T; Wisniewski, T			The interaction between apolipoprotein E and Alzheimer's amyloid beta-peptide is dependent on beta-peptide conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBROSPINAL-FLUID; FIBRIL FORMATION; TYPE-4 ALLELE; DISEASE; PROTEIN; AGGREGATION; DEPOSITS; BINDING; GENE; PRECURSOR	An important feature of Alzheimer's disease (AD) is the cerebral deposition of amyloid. The main component of the amyloid is a 39-44-amino acid residue protein called amyloid beta (A beta), which also exists as a normal protein in biological fluids, known as soluble A beta. A major risk factor for late-onset AD is the inheritance of the apolipoprotein (ape) E4 isotype of apoE. How apoE is involved in the pathogenesis of AD is unclear; however, evidence exists for a direct apoE/A beta interaction. We and others have shown that apoE copurifies with A beta from AD amyloid plaques and that under certain in vitro conditions apoE promotes a beta-sheet structure in A beta peptides. Currently we document the high affinity binding of A beta peptides to both human recombinant apoE3 and -E4 with a K-D of 20 nM. This interaction is greatly influenced by the conformational state of the A beta peptide used. Furthermore, we show that the fibril modulating effect of apoE is also influenced by the initial secondary structure of the A beta peptide. The preferential binding of apoE to A beta peptides with a beta-sheet conformation can in part explain the copurification of A beta and apoE from AD amyloid plaques.	NYU, MED CTR, DEPT NEUROL, NEW YORK, NY 10016 USA; BIOTECHNOL GEN LTD, REHOVOT, ISRAEL; POLISH ACAD SCI, MED RES CTR, DEPT NEUROPATHOL, WARSAW, POLAND	New York University; Polish Academy of Sciences			Wisniewski, Thomas/Q-6525-2019	Wisniewski, Thomas/0000-0002-3379-8966	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005891, K08AG000542, R37AG005891] Funding Source: NIH RePORTER; NIA NIH HHS [AG00542, AG05891] Funding Source: Medline; NINDS NIH HHS [NS30455] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGGERBECK LP, 1988, J MOL BIOL, V202, P179, DOI 10.1016/0022-2836(88)90531-1; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BURDICK D, 1992, J BIOL CHEM, V267, P546; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; CASTANO EM, 1995, J BIOL CHEM, V270, P17610, DOI 10.1074/jbc.270.29.17610; CASTANO EM, 1995, BIOCHEM J, V306, P599, DOI 10.1042/bj3060599; CASTANO EM, 1986, BIOCHEM BIOPH RES CO, V141, P782, DOI 10.1016/S0006-291X(86)80241-8; CLEMENTS A, 1993, NEUROSCI LETT, V161, P17, DOI 10.1016/0304-3940(93)90129-9; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; EXLEY C, 1993, FEBS LETT, V324, P293, DOI 10.1016/0014-5793(93)80137-J; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLABEK A, 1995, NEUROSCI LETT, V191, P79, DOI 10.1016/0304-3940(95)11565-7; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KAMINO K, 1992, AM J HUM GENET, V51, P998; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; LADU MJ, 1994, J BIOL CHEM, V269, P23403; LADU MJ, 1995, J BIOL CHEM, V270, P9039, DOI 10.1074/jbc.270.16.9039; LEE JP, 1995, BIOCHEMISTRY-US, V34, P5191, DOI 10.1021/bi00015a033; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; LUNDKATZ S, 1993, J BIOL CHEM, V268, P23008; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; Mahley Robert W., 1995, Current Opinion in Lipidology, V6, P86, DOI 10.1097/00041433-199504000-00005; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAK K, 1994, BRAIN RES, V667, P138, DOI 10.1016/0006-8993(94)91725-6; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MATSUBARA E, 1995, J BIOL CHEM, V270, P7563, DOI 10.1074/jbc.270.13.7563; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MURPHY GM, 1994, AM J PATHOL, V144, P1082; NAIKI H, 1993, LAB INVEST, V68, P332; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; NASLUND J, 1995, NEURON, V15, P219, DOI 10.1016/0896-6273(95)90079-9; NATHAN BP, 1995, J BIOL CHEM, V270, P19791, DOI 10.1074/jbc.270.34.19791; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; PRELLI F, 1988, J NEUROCHEM, V51, P648, DOI 10.1111/j.1471-4159.1988.tb01087.x; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROHER AE, 1993, J NEUROCHEM, V61, P1916, DOI 10.1111/j.1471-4159.1993.tb09834.x; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; SATO C, 1995, NEUROSCI LETT, V200, P105, DOI 10.1016/0304-3940(95)12089-M; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SHURAEV VV, 1996, IN PRESS FEBS LETT; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; Soto C, 1996, BIOCHEM J, V314, P701, DOI 10.1042/bj3140701; SOTO C, 1995, FEBS LETT, V371, P110, DOI 10.1016/0014-5793(95)00863-5; SOTO C, 1995, NEUROSCI LETT, V186, P115, DOI 10.1016/0304-3940(95)11299-C; SOTO C, 1996, IN PRESS NEUROREPORT; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; TABATON M, 1994, BIOCHEM BIOPH RES CO, V200, P1598, DOI 10.1006/bbrc.1994.1634; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P1965, DOI 10.1111/j.1471-4159.1993.tb09841.x; VOGEL T, 1985, P NATL ACAD SCI USA, V82, P8696, DOI 10.1073/pnas.82.24.8696; WISNIEWSKI T, 1995, LANCET, V345, P956, DOI 10.1016/S0140-6736(95)90701-7; WISNIEWSKI T, 1995, AM J PATHOL, V147, P238; Wisniewski T, 1996, BIOCHEM J, V313, P575, DOI 10.1042/bj3130575; WISNIEWSKI T, 1993, ANN NEUROL, V34, P631, DOI 10.1002/ana.410340422; WISNIEWSKI T, 1991, BIOCHEM BIOPH RES CO, V179, P1247, DOI 10.1016/0006-291X(91)91706-I; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; WISNIEWSKI T, 1993, BIOCHEM BIOPH RES CO, V192, P359, DOI 10.1006/bbrc.1993.1423; WISNIEWSKI T, 1994, ANN NEUROL, V35, P245, DOI 10.1002/ana.410350223; YANG FS, 1994, NEUROREPORT, V5, P2117, DOI 10.1097/00001756-199410270-00032; YOUNKIN SG, 1995, ANN NEUROL, V37, P287, DOI 10.1002/ana.410370303	73	115	126	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10602	10606		10.1074/jbc.271.18.10602	http://dx.doi.org/10.1074/jbc.271.18.10602			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631862				2022-12-25	WOS:A1996UJ34200030
J	Sugahara, T; Sato, A; Kudo, M; BenMenahem, D; Pixley, MR; Hsueh, AJW; Boime, I				Sugahara, T; Sato, A; Kudo, M; BenMenahem, D; Pixley, MR; Hsueh, AJW; Boime, I			Expression of biologically active fusion genes encoding the common alpha subunit and the follicle-stimulating hormone beta subunit - Role of a linker sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; GLYCOPROTEIN HORMONES; MONOCLONAL-ANTIBODIES; LUTEINIZING-HORMONE; ESCHERICHIA-COLI; GRANULOSA-CELLS; FOLLITROPIN; RECEPTOR; PROTEIN; BINDING	The gonadotropin/thyrotropin hormone family is characterized by a heterodimeric structure composed of a common alpha subunit noncovalently linked to a hormone-specific beta subunit, The conformation of the heterodimer is essential for controlling secretion, hormone-specific post-translational modifications, and signal transduction. Structure function studies of follicle-stimulating hormone (FSH) and the other glycoprotein hormones are often hampered by mutagenesis-induced defects in subunit combination, Thus, the ability to overcome the limitation of subunit assembly would expand the range of structure-activity relationships that can be performed on these hormones, Here we converted the FSH heterodimer to a single chain by genetically fusing the carboxyl end of the FSH beta subunit to the amino end of the alpha subunit in the presence or absence of a linker sequence, In the absence of the CTP linker, the secretion rate was decreased over 3-fold. Unexpectedly, however, receptor binding/signal transduction was unaffected by the absence of the linker, These data show that the single-chain FSH was secreted efficiently and is biologically active and that the conformation determinants required for secretion and biologic activity are not the same.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL)				Ben-Menahem, David/0000-0002-8985-0591	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD092922] Funding Source: NIH RePORTER; NICHD NIH HHS [N01-HD92922] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARGOS P, 1990, J MOL BIOL, V211, P943, DOI 10.1016/0022-2836(90)90085-Z; ARORA N, 1994, J BIOL CHEM, V269, P26165; BAENZIGER JU, 1988, BIOCHIM BIOPHYS ACTA, V947, P287, DOI 10.1016/0304-4157(88)90012-3; BENKIRANE MM, 1987, ENDOCRINOLOGY, V12, P1171; BENMENAHEM D, 1996, IN PRESS TRENDS ENDO; BIELINSKA M, 1994, MOL ENDOCRINOL, V8, P919, DOI 10.1210/me.8.7.919; BIELINSKA M, 1996, J CELL BIOL, V111, P330; BIELINSKA M, 1995, GLYCOPROTEINS A, V29, P565; CHEN F, 1992, MOL ENDOCRINOL, V6, P914, DOI 10.1210/me.6.6.914; CORLESS CL, 1987, J CELL BIOL, V104, P1173, DOI 10.1083/jcb.104.5.1173; DAVOREN JB, 1985, BIOL REPROD, V33, P37, DOI 10.1095/biolreprod33.1.37; EHRLICH PH, 1985, AM J REPROD IM MIC, V8, P48; FARES FA, 1992, P NATL ACAD SCI USA, V89, P4303; FURUHASHI M, 1994, J BIOL CHEM, V269, P25543; FURUHASHI M, 1995, MOL ENDOCRINOL, V9, P56; HALLEWELL RA, 1989, J BIOL CHEM, V264, P5260; HARIKRISHNA JA, 1993, DNA CELL BIOL, V12, P371, DOI 10.1089/dna.1993.12.371; HOJO H, 1985, ENDOCRINOLOGY, V117, P2428, DOI 10.1210/endo-117-6-2428; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; HUTH JR, 1992, J BIOL CHEM, V267, P8870; JIA XC, 1991, MOL ENDOCRINOL, V5, P759, DOI 10.1210/mend-5-6-759; KEENE JL, 1989, J BIOL CHEM, V264, P4769; LAPTHORN A, 1994, NATURE, P455; MATZUK MM, 1990, ENDOCRINOLOGY, V126, P376, DOI 10.1210/endo-126-1-376; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; POMERANTZ JL, 1995, SCIENCE, V267, P93, DOI 10.1126/science.7809612; RAO MC, 1977, ENDOCRINOLOGY, V101, P512, DOI 10.1210/endo-101-2-512; SANO T, 1992, P NATL ACAD SCI USA, V89, P1534, DOI 10.1073/pnas.89.5.1534; SCHIMMEL P, 1992, PROTEIN SCI, V1, P1387, DOI 10.1002/pro.5560011018; SOMOZA JR, 1993, J MOL BIOL, V234, P390, DOI 10.1006/jmbi.1993.1594; STRICKLAND TW, 1982, ENDOCRINOLOGY, V111, P95, DOI 10.1210/endo-111-1-95; SUGAHARA T, 1995, P NATL ACAD SCI USA, V92, P2041, DOI 10.1073/pnas.92.6.2041; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; TILLY JL, 1992, ENDOCRINOLOGY, V131, P799, DOI 10.1210/en.131.2.799; TOTH MJ, 1986, J BIOL CHEM, V261, P6643; WHITLOW M, 1991, Methods (Orlando), V2, P97, DOI 10.1016/S1046-2023(05)80209-9; WU H, 1994, STRUCTURE, V2, P545, DOI 10.1016/S0969-2126(00)00054-X; YEH P, 1992, P NATL ACAD SCI USA, V89, P1904, DOI 10.1073/pnas.89.5.1904; YOO JK, 1993, J BIOL CHEM, V268, P13034	40	64	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10445	10448		10.1074/jbc.271.18.10445	http://dx.doi.org/10.1074/jbc.271.18.10445			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631838	hybrid			2022-12-25	WOS:A1996UJ34200006
J	Yablonski, MJ; Pasek, DA; Han, BD; Jones, ME; Traut, TW				Yablonski, MJ; Pasek, DA; Han, BD; Jones, ME; Traut, TW			Intrinsic activity and stability of bifunctional human UMP synthase and its two separate catalytic domains, orotate phosphoribosyltransferasee and orotidine-5'-phosphate decarboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URIDINE 5'-PHOSPHATE SYNTHASE; AFFINITY-CHROMATOGRAPHY; CONFORMATION STATES; KINETIC MECHANISM; PURIFICATION; YEAST; 5'-MONOPHOSPHATE; PROTEIN; AGGREGATION; DEPENDENCE	Human UMP synthase is a bifunctional protein containing two separate catalytic domains, orotate phosphoribosyltransferase (EC 2.4.2.10) and orotidine-5'-phosphate decarboxylase (EC 4.1.1.23), These studies address the question of why the last two reactions in pyrimidine nucleotide synthesis are catalyzed by a bi-functional enzyme in mammalian cells, but by two separate enzymes in microorganisms, From existing data on subunit associations of the respective enzymes and calculations showing the molar concentration of enzyme to be far lower in mammalian cells than in microorganisms, we hypothesize that the covalent union in UMP synthase stabilizes the domains containing the respective catalytic centers, Evidence supporting this hypothesis comes from studies of stability of enzyme activity in vitro, at physiological concentrations, of UMP synthase, the two isolated catalytic domains prepared by site-directed mutagenesis of UMP synthase, and the yeast ODCase, The two engineered domains have activities very similar to the native UMP synthase, but unlike the bifunctional protein, the domains are quite unstable under conditions promoting the dissociated monomer.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill								BELL JB, 1991, J BIOL CHEM, V266, P12662; BHATIA MB, 1990, BIOCHEMISTRY-US, V29, P10480, DOI 10.1021/bi00498a009; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODY RS, 1979, J BIOL CHEM, V254, P4238; CREASEY WA, 1961, J BIOL CHEM, V236, P2058; DONOVAN WP, 1983, J BACTERIOL, V156, P620, DOI 10.1128/JB.156.2.620-624.1983; FLOYD EE, 1985, J BIOL CHEM, V260, P9443; HAN BD, 1995, BIOCHEMISTRY-US, V34, P10835, DOI 10.1021/bi00034a016; Jones M E, 1978, Methods Enzymol, V51, P155; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIVINGSTONE LR, 1987, J BIOL CHEM, V262, P15726; MCCLARD RW, 1980, BIOCHEMISTRY-US, V19, P4699, DOI 10.1021/bi00561a024; PETERS GJ, 1979, INT J BIOCHEM, V10, P885, DOI 10.1016/0020-711X(79)90118-6; POTVIN BW, 1978, BIOCHEM PHARMACOL, V27, P655, DOI 10.1016/0006-2952(78)90501-4; REYES P, 1975, J BIOL CHEM, V250, P5097; SHIMOSAKA M, 1985, J BIOCHEM, V98, P1689, DOI 10.1093/oxfordjournals.jbchem.a135440; SMILEY JA, 1992, BIOCHEMISTRY-US, V31, P12162, DOI 10.1021/bi00163a027; SWANSON JA, 1991, J CELL BIOL, V115, P941, DOI 10.1083/jcb.115.4.941; TIPOE GL, 1992, J ANAT, V181, P189; TRAUT TW, 1980, BIOCHEMISTRY-US, V19, P6068, DOI 10.1021/bi00567a019; Traut TW, 1996, PROG NUCLEIC ACID RE, V53, P1, DOI 10.1016/S0079-6603(08)60142-7; TRAUT TW, 1994, CRIT REV BIOCHEM MOL, V29, P125, DOI 10.3109/10409239409086799; TRAUT TW, 1977, J BIOL CHEM, V252, P8374; TRAUT TW, 1980, BIOCHEMISTRY-US, V19, P6062, DOI 10.1021/bi00567a018; TRAUT TW, 1989, ARCH BIOCHEM BIOPHYS, V268, P108, DOI 10.1016/0003-9861(89)90570-5; TRAUT TW, 1979, J BIOL CHEM, V254, P1143; UMEZU K, 1971, J BIOCHEM, V70, P249, DOI 10.1093/oxfordjournals.jbchem.a129637; VICTOR J, 1979, J BIOL CHEM, V254, P2647; Walenta S, 1989, Adv Exp Med Biol, V248, P847; 1991, J THEOR BIOL, V152, P1	30	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10704	10708		10.1074/jbc.271.18.10704	http://dx.doi.org/10.1074/jbc.271.18.10704			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631878	hybrid, Green Published			2022-12-25	WOS:A1996UJ34200046
J	Kamai, Y; Mikawa, S; Endo, K; Sakai, H; Komano, T				Kamai, Y; Mikawa, S; Endo, K; Sakai, H; Komano, T			Regulation of insulin-like growth factor-I expression in mouse preadipocyte Ob1771 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE CONVERSION; GENE-EXPRESSION; 3T3 CELLS; GLYCEROPHOSPHATE DEHYDROGENASE; RECEPTOR-BINDING; HUMAN-SERUM; HORMONE; DIFFERENTIATION; SEQUENCE; FIBROBLASTS	In mouse preadipocyte Ob1771 cells, transcription of the insulin-libe growth factor-I (IGF-I) gene was stimulated by growth hormone (GH), and IGF-I protein combined with GH in medium was required for their differentiation to adipocytes. During induction of the differentiation, the intracellular expression of each class of IGF-I mRNA was analyzed by reverse transcriptase-polymerase chain reaction, When the cells were cultured in the presence of GH, the class 1del. IGF-I mRNA was a major molecular species among IGF-I mRNAs, In the presence of both GH and IGF-I, the splicing pattern of IGF-I mRNA changed from class 1del. to class 1. Moreover, as detected by Western blotting, the IGF-I protein was present in cells and in the medium only when the cells were cultured in the presence of both GH and IGF-I, We found that IGF-I secreted from Ob1771 cells could act in an autocrine/paracrine fashion and induce the differentiation of other Ob1771 cells, It was demonstrated that the translation efficiency of class 1 mRNA was higher than that of class 1del. mRNA in vitro. These results suggested that stimulation with exogenous IGF-I in the presence of GH was required for the production of class 1 IGF-I mRNA and that the production of the IGF-I protein was activated by increasing the translation efficiency through shifting the splicing pattern of IGF-I mRNA from class 1del. to class 1. Exogenous IGF-I triggered the differentiation by initiating the synthesis of endogenous IGF-I.	KYOTO UNIV,DEPT AGR CHEM,BIOCHEM LAB,FAC AGR,KYOTO 60601,JAPAN	Kyoto University								ADAMO ML, 1991, BIOCHEM BIOPH RES CO, V176, P887, DOI 10.1016/S0006-291X(05)80269-4; AMRI EZ, 1986, BIOCHEM J, V238, P115, DOI 10.1042/bj2380115; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BLUNDELL TL, 1978, P NATL ACAD SCI USA, V75, P180, DOI 10.1073/pnas.75.1.180; BUCCI C, 1989, NUCLEIC ACIDS RES, V17, P3596, DOI 10.1093/nar/17.9.3596; CASELLA SJ, 1987, DNA-J MOLEC CELL BIO, V6, P325, DOI 10.1089/dna.1987.6.325; CHALFANT CE, 1995, J BIOL CHEM, V270, P13326, DOI 10.1074/jbc.270.22.13326; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIAMOND RH, 1993, J BIOL CHEM, V268, P15185; DOGLIO A, 1986, BIOCHEM J, V238, P123, DOI 10.1042/bj2380123; DOGLIO A, 1987, EMBO J, V6, P4011, DOI 10.1002/j.1460-2075.1987.tb02744.x; DOGLIO A, 1989, P NATL ACAD SCI USA, V86, P1148, DOI 10.1073/pnas.86.4.1148; FOYT HL, 1991, J BIOL CHEM, V266, P7300; FROESCH ER, 1985, ANNU REV PHYSIOL, V47, P443; HAUNER H, 1986, INT J OBESITY, V10, P323; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; ISAKSSON OGP, 1982, SCIENCE, V216, P1237, DOI 10.1126/science.7079756; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; KOZAK LP, 1974, J BIOL CHEM, V249, P7775; KURIHARCUCH W, 1978, CELL, V14, P53, DOI 10.1016/0092-8674(78)90300-8; MATHEWS LS, 1986, P NATL ACAD SCI USA, V83, P9343, DOI 10.1073/pnas.83.24.9343; MORIKAWA M, 1982, CELL, V29, P783, DOI 10.1016/0092-8674(82)90440-8; NIXON T, 1984, ENDOCRINOLOGY, V114, P527, DOI 10.1210/endo-114-2-527; PAIRAULT J, 1979, P NATL ACAD SCI USA, V76, P5138, DOI 10.1073/pnas.76.10.5138; PRADINESFIGUERES A, 1990, J LIPID RES, V31, P1283; ROBERTS CT, 1987, MOL ENDOCRINOL, V1, P243, DOI 10.1210/mend-1-3-243; ROBERTS CT, 1987, BIOCHEM BIOPH RES CO, V146, P1154, DOI 10.1016/0006-291X(87)90768-6; SCHMIDT W, 1990, J BIOL CHEM, V265, P15489; SCHOENLE E, 1982, NATURE, V296, P252, DOI 10.1038/296252a0; SELL SM, 1994, J BIOL CHEM, V269, P30769; SHIMATSU A, 1987, NUCLEIC ACIDS RES, V15, P7196, DOI 10.1093/nar/15.17.7196; SHIMATSU A, 1987, J BIOL CHEM, V262, P7894; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WISE LS, 1979, J BIOL CHEM, V254, P273; ZAPF J, 1978, EUR J BIOCHEM, V87, P285, DOI 10.1111/j.1432-1033.1978.tb12377.x; ZEZULAK KM, 1986, SCIENCE, V233, P551, DOI 10.1126/science.3726546	36	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9883	9886		10.1074/jbc.271.17.9883	http://dx.doi.org/10.1074/jbc.271.17.9883			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626620	hybrid			2022-12-25	WOS:A1996UG25700004
J	Kang, SH; Brown, DA; Kitajima, I; Xu, X; Heidenreich, O; Gryaznov, S; Nerenberg, M				Kang, SH; Brown, DA; Kitajima, I; Xu, X; Heidenreich, O; Gryaznov, S; Nerenberg, M			Binding and functional effects of transcriptional factor Sp1 on the murine interleukin-8 promotor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; 3 C/EBP ISOFORMS; GENE-EXPRESSION; DNA-BINDING; HUMAN-FIBROBLASTS; NUCLEAR PROTEINS; SV40 ENHANCER; VIRUS TYPE-1; IL-6 GENE; NF-IL6	The NF-kappa B and NF-IL6 elements have previously been shown to play an important role in regulation of both the mouse and human interleukin-6 gene. Between these two elements lies a G/C-rich sequence, which contains three repeats of the element CCACC, protein binding to which has not been previously characterized. In this study we demonstrate that the transcription factor Sp1 binds to these repeats and plays an important role in basal and in inducible expression of the murine interleukin-6 gene.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; LYNX THERAPEUT, HAYWARD, CA 94545 USA	Scripps Research Institute			Heidenreich, Olaf/AAP-5045-2021	Heidenreich, Olaf/0000-0001-5404-6483				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, SEMIN CANCER BIOL, V1, P17; ALAM T, 1992, J BIOL CHEM, V267, P5021; BETTS JC, 1993, J BIOL CHEM, V268, P25624; BIDWELL JP, 1993, P NATL ACAD SCI USA, V90, P3162, DOI 10.1073/pnas.90.8.3162; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROWN DA, 1994, J BIOL CHEM, V269, P26801; BROWN DA, 1994, TRANSGENICS, V1, P377; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; DAILEY L, 1988, GENE DEV, V2, P1700, DOI 10.1101/gad.2.12b.1700; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; ELIAS JA, 1990, J IMMUNOL, V145, P161; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; HAEGEMAN G, 1986, EUR J BIOCHEM, V159, P625, DOI 10.1111/j.1432-1033.1986.tb09931.x; HSU W, 1993, MOL CELL BIOL, V13, P2515, DOI 10.1128/MCB.13.4.2515; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; JUAN TSC, 1993, P NATL ACAD SCI USA, V90, P2584, DOI 10.1073/pnas.90.7.2584; KANG SH, 1995, NUCLEIC ACIDS RES, V23, P2344, DOI 10.1093/nar/23.12.2344; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KITAJIMA I, 1992, J BIOL CHEM, V267, P25881; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LUST JA, 1994, MAYO CLIN PROC, V69, P691, DOI 10.1016/S0025-6196(12)61351-2; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MERCURIO F, 1989, EMBO J, V8, P1455, DOI 10.1002/j.1460-2075.1989.tb03528.x; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NARDELLI J, 1991, NATURE, V349, P175, DOI 10.1038/349175a0; NAUMANN M, 1993, ONCOGENE, V8, P2275; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; ROSALES R, 1987, EMBO J, V6, P3015, DOI 10.1002/j.1460-2075.1987.tb02607.x; SEHGAL PB, 1990, P SOC EXP BIOL MED, V195, P183; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TANABE O, 1988, J IMMUNOL, V141, P3875; TANIMURA A, 1993, J VIROL, V67, P5375, DOI 10.1128/JVI.67.9.5375-5382.1993; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; VANWIJNEN AJ, 1993, BIOCHEMISTRY-US, V32, P8397, DOI 10.1021/bi00084a003; WALTHER Z, 1988, J IMMUNOL, V140, P974; WANG YK, 1993, MOL CELL BIOL, V13, P5691, DOI 10.1128/MCB.13.9.5691; XU X, 1995, J CLIN INVEST, V96, P1548, DOI 10.1172/JCI118193; XU X, 1994, MOL CELL BIOL, V14, P5371, DOI 10.1128/MCB.14.8.5371; Xu X, 1996, BIOTECHNIQUES, V20, P44; YAMAGUCHI Y, 1994, J BIOL CHEM, V269, P19410; YANG J, 1994, J IMMUNOL, V152, P943; YASUKAWA K, 1987, EMBO J, V6, P2939, DOI 10.1002/j.1460-2075.1987.tb02598.x; ZILBERSTEIN A, 1986, EMBO J, V5, P2529, DOI 10.1002/j.1460-2075.1986.tb04531.x	55	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7330	7335		10.1074/jbc.271.13.7330	http://dx.doi.org/10.1074/jbc.271.13.7330			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631753				2022-12-25	WOS:A1996UC77400021
J	Lee, KD; Oh, YK; Portnoy, DA; Swanson, JA				Lee, KD; Oh, YK; Portnoy, DA; Swanson, JA			Delivery of macromolecules into cytosol using liposomes containing hemolysin from Listeria monocytogenes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PH-SENSITIVE LIPOSOMES; BACILLUS-SUBTILIS; TUBULAR LYSOSOMES; MHC PRESENTATION; MAMMALIAN-CELLS; ENDOCYTOSIS; MACROPHAGES; ANTIGENS; BINDING; GROWTH	The cytosolic space of cells is an important but relatively inaccessible target for the delivery of therapeutic macromolecules. Here we describe the efficient delivery of macromolecules into the cytosolic space of macrophages from liposomes that contain listeriolysin O (LLO), the hemolytic protein of Listeria monocytogenes that normally mediates bacterial passage from phagosomes into cytosol, LLO was purified and encapsulated inside pH-sensitive liposomes, along with other molecules to be delivered, When internalized by bone marrow-derived macrophages, these liposomes rapidly released encapsulated fluorescent dye, first into endosomes and then into the cytosol, without measurably harming the cells. Furthermore, these liposomes efficiently delivered encapsulated ovalbumin to the cytosolic pathway of antigen processing and presentation, as measured by the major histocompatibility complex (MHC) class I-restricted presentation of peptides derived from ovalbumin. Delivery was significantly better than that obtained by other currently available liposome formulations, LLO-containing liposomes should therefore provide an efficient vehicle for delivery of antigens or therapeutic molecules in vivo.	UNIV PENN,DEPT MICROBIOL,PHILADELPHIA,PA 19104	University of Pennsylvania	Lee, KD (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,220 LONGWOOD AVE,BOSTON,MA 02115, USA.		Swanson, Joel A/P-4362-2014; Oh, Yu Kyoung/G-8754-2013	Swanson, Joel A/0000-0003-0900-8212; 				BIELECKI J, 1990, NATURE, V345, P175, DOI 10.1038/345175a0; CAMILLI A, 1991, J EXP MED, V173, P751, DOI 10.1084/jem.173.3.751; CHU CJ, 1990, PHARM RES-DORDR, V7, P824, DOI 10.1023/A:1015908831507; DALEKE DL, 1990, BIOCHIM BIOPHYS ACTA, V1024, P352, DOI 10.1016/0005-2736(90)90365-U; GAILLARD JL, 1986, INFECT IMMUN, V52, P50, DOI 10.1128/IAI.52.1.50-55.1986; GEOFFROY C, 1987, INFECT IMMUN, V55, P1641, DOI 10.1128/IAI.55.7.1641-1646.1987; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GOLDFINE H, 1995, P NATL ACAD SCI USA, V92, P2979, DOI 10.1073/pnas.92.7.2979; Gregoriadis G, 1993, LIPOSOME TECHNOLOGY; HARDING CV, 1991, J IMMUNOL, V147, P2860; HARDING CV, 1994, METHOD CELL BIOL, V45, P313; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; JONES S, 1994, INFECT IMMUN, V62, P5608, DOI 10.1128/IAI.62.12.5608-5613.1994; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; LASIC DD, 1995, SCIENCE, V267, P1275, DOI 10.1126/science.7871422; LEE KD, 1992, BIOCHIM BIOPHYS ACTA, V1103, P185, DOI 10.1016/0005-2736(92)90086-2; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; OLSON F, 1979, BIOCHIM BIOPHYS ACTA, V557, P9, DOI 10.1016/0005-2736(79)90085-3; PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11460, DOI 10.1073/pnas.88.24.11460; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; PORTNOY DA, 1992, INFECT IMMUN, V60, P2710, DOI 10.1128/IAI.60.7.2710-2717.1992; PORTNOY DA, 1994, ANN NY ACAD SCI, V730, P15, DOI 10.1111/j.1749-6632.1994.tb44235.x; RACOOSIN EL, 1993, J CELL BIOL, V121, P1011, DOI 10.1083/jcb.121.5.1011; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SMITH GA, 1995, INFECT IMMUN, V63, P4231, DOI 10.1128/IAI.63.11.4231-4237.1995; STRAUBINGER RM, 1983, CELL, V32, P1069, DOI 10.1016/0092-8674(83)90291-X; STRAUBINGER RM, 1993, METHOD ENZYMOL, V221, P361, DOI 10.1016/0076-6879(93)21030-C; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149	31	93	113	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7249	7252		10.1074/jbc.271.13.7249	http://dx.doi.org/10.1074/jbc.271.13.7249			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631734	hybrid			2022-12-25	WOS:A1996UC77400002
J	Ridge, KD; Lee, SSJ; Abdulaev, NG				Ridge, KD; Lee, SSJ; Abdulaev, NG			Examining rhodopsin folding and assembly through expression of polypeptide fragments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT RETINITIS-PIGMENTOSA; BOVINE RHODOPSIN; MONOCLONAL-ANTIBODIES; TRANSGENIC MICE; SIGNAL SEQUENCE; PROTEINS; GENE; MUTATIONS; MEMBRANES; CHAIN	Previous work on the expression of bovine opsin fragments separated in the cytoplasmic region has allowed the identification of specific polypeptide segments that contain sufficient information to fold independently, insert into a membrane, and assemble to form a functional photoreceptor. To further examine the contributions of these and other polypeptide segments to the mechanism of opsin folding and assembly, we have constructed 20 additional opsin gene fragments where the points of separation occur in the intradiscal, transmembrane, and cytoplasmic regions. Nineteen of these fragments were stably expressed in COS-1 cells. A five-helix fragment was stably produced only after coexpression with its complementary two-helix fragment. Two fragments composed of the amino-terminal region and the first transmembrane helix were not N-glycosylated and were only partially membrane integrated. One of the singly expressed fragments, which is truncated after the retinal attachment site, bound 11-cis-retinal. Of the coexpressed complementary fragments, only those separated in the second intradiscal and third cytoplasmic regions formed noncovalently linked rhodopsins. Both of these pigments showed reduced transducin activation. Therefore, while many opsin fragments contain enough information to fold and insert into a membrane, only those separated at specific locations assemble to a retinal-binding opsin.	UNIV MARYLAND, MARYLAND BIOTECHNOL INST, ROCKVILLE, MD 20850 USA		Ridge, KD (corresponding author), NATL INST STAND & TECHNOL, CTR ADV RES BIOTECHNOL, BOULDER, CO 80303 USA.				NEI NIH HHS [EY 11112] Funding Source: Medline; NATIONAL EYE INSTITUTE [R29EY011112, R55EY011112] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMUS G, 1991, VISION RES, V31, P17, DOI 10.1016/0042-6989(91)90069-H; ANUKANTH A, 1994, J BIOL CHEM, V269, P19738; AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P5783, DOI 10.1073/pnas.84.16.5783; BERTOLAET BL, 1995, BIOCHEMISTRY-US, V34, P5736, DOI 10.1021/bi00017a005; BHATTACHARYA S, 1992, J BIOL CHEM, V267, P6763; BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BORJIGIN J, 1994, J BIOL CHEM, V269, P14715; CHABRE M, 1979, VISION RES, V19, P1005, DOI 10.1016/0042-6989(79)90226-8; DOI T, 1990, P NATL ACAD SCI USA, V87, P4991, DOI 10.1073/pnas.87.13.4991; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; FUKUDA MN, 1979, J BIOL CHEM, V254, P8201; HARGRAVE PA, 1992, INT REV CYTOL, V137B, P49; HARGRAVE PA, 1983, BIOPHYS STRUCT MECH, V9, P235, DOI 10.1007/BF00535659; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P6121, DOI 10.1021/bi00186a011; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KURADA P, 1995, NEURON, V14, P571, DOI 10.1016/0896-6273(95)90313-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIRD DW, 1987, P MEMBRANE PROTEIN S, P45; LI TS, 1995, P NATL ACAD SCI USA, V92, P3551, DOI 10.1073/pnas.92.8.3551; MACKE JP, 1993, AM J HUM GENET, V53, P80; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIN KC, 1993, J BIOL CHEM, V268, P9400; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; NAASH MI, 1993, P NATL ACAD SCI USA, V90, P5499, DOI 10.1073/pnas.90.12.5499; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; OLSSON JE, 1992, NEURON, V9, P815, DOI 10.1016/0896-6273(92)90236-7; OVCHINNIKOV YA, 1982, BIOORG KHIM+, V8, P1011; OVCHINNIKOV YA, 1982, FEBS LETT, V148, P179, DOI 10.1016/0014-5793(82)80805-3; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P3261, DOI 10.1021/bi00010a016; RIDGE KD, 1995, P NATL ACAD SCI USA, V92, P3204, DOI 10.1073/pnas.92.8.3204; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; ROSENFELD PJ, 1992, NAT GENET, V1, P209, DOI 10.1038/ng0692-209; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHONEBERG T, 1995, J BIOL CHEM, V270, P18000; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; SUNG CH, 1993, J BIOL CHEM, V268, P26645; SUNG CH, 1994, J NEUROSCI, V14, P5818; TSUNASAWA S, 1980, BIOCHIM BIOPHYS ACTA, V624, P218, DOI 10.1016/0005-2795(80)90241-X; UNGER VM, 1995, BIOPHYS J, V68, P1776, DOI 10.1016/S0006-3495(95)80354-1; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WANG JK, 1980, BIOCHEMISTRY-US, V19, P5111, DOI 10.1021/bi00563a027; WASHBURN T, 1989, J BIOL CHEM, V264, P15464; WEISS ER, 1994, BIOCHEMISTRY-US, V33, P7587, DOI 10.1021/bi00190a011; WRUBEL W, 1990, J BACTERIOL, V172, P5374, DOI 10.1128/jb.172.9.5374-5381.1990; YU HB, 1995, BIOCHEMISTRY-US, V34, P14963, DOI 10.1021/bi00046a002; ZEN KH, 1994, BIOCHEMISTRY-US, V33, P8198, DOI 10.1021/bi00193a005	61	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7860	7867		10.1074/jbc.271.13.7860	http://dx.doi.org/10.1074/jbc.271.13.7860			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631831	hybrid			2022-12-25	WOS:A1996UC77400099
J	Ahn, J; Mundigl, O; Muth, TR; Rudnick, G; Caplan, MJ				Ahn, J; Mundigl, O; Muth, TR; Rudnick, G; Caplan, MJ			Polarized expression of GABA transporters in Madin-Darby canine kidney cells and cultured hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; MICROTUBULE-ASSOCIATED PROTEIN-2; RAT-BRAIN; DOPAMINE TRANSPORTER; GLYCINE TRANSPORTER; IMMUNOCYTOCHEMICAL LOCALIZATION; MOLECULAR-CLONING; PLASMA-MEMBRANE; MOUSE-BRAIN; COLOCALIZATION	At least three high affinity Na+- and Cl--dependent gamma-aminobutyric acid (GASA) transporters are known to exist in the rat and mouse brain, These transporters share 50-65% amino acid sequence identity with the kidney betaine transporter which also transports GABA but with lower affinity. The betaine transporter (BGT) is expressed on the basolateral surface of polarized Madin-Darby canine kidney (MDCK) cells. Recent evidence suggests that the signals and mechanisms involved in membrane protein sorting share many functional characteristics in polarized neurons and epithelial cells, It was previously shown that the rat GABA transporter GAT-1 is located in the presynaptic membrane of axons where it plays a role in terminating GABAergic neurotransmission, When expressed in MDCK cells by transfection, GAT-1 was sorted to the apical membrane, In this report, we have localized the other two GABA transporters, GAT-2 and GAT-3, in transfected MDCK cells by GABA uptake, immunofluorescence, and cell surface biotinylation. GAT-3, like GAT-1, localized to the apical membrane of MDCK cells while GAT-2, like BGT, localized to the basolateral membrane, We have also expressed BGT in low density cultures of hippocampal neurons by microinjection and immunolocalized it to the dendrites, The distribution of GAT-3 in these neurons after transfection was axonal as well as somatodendritic. These results indicate that highly homologous subtypes of GABA transporters are sorted differently when expressed in epithelial cells or neurons and suggest that these two cell types share the capacity to distinguish among these isoforms and target them to distinct destinations.	YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510	Yale University; Yale University; Yale University				Caplan, Michael/0000-0001-5768-4405; Muth, Theodore/0000-0002-6882-1193	NIGMS NIH HHS [GM-42136] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042136] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BORDEN LA, 1992, J BIOL CHEM, V267, P21098; BORDEN LA, 1995, J NEUROCHEM, V64, P977; BORDEN LA, 1995, IN PRESS RECEPTORS C; CACERES A, 1986, J NEUROSCI, V6, P714; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CLARK JA, 1992, NEURON, V9, P337, DOI 10.1016/0896-6273(92)90172-A; CRAIG AM, 1995, NATURE, V375, P592, DOI 10.1038/375592a0; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; FERREIRA A, 1993, J NEUROSCI, V13, P3112; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; FREMEAU RT, 1992, NEURON, V8, P915, DOI 10.1016/0896-6273(92)90206-S; GOSLIN K, 1990, CULTURING NERVE CELL, P251; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUASTELLA J, 1992, P NATL ACAD SCI USA, V89, P7189, DOI 10.1073/pnas.89.15.7189; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HAASS C, 1994, P NATL ACAD SCI USA, V91, P1564, DOI 10.1073/pnas.91.4.1564; HOFFMAN BJ, 1991, SCIENCE, V254, P79; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; IVERSEN LL, 1975, BIOCHEM PHARMACOL, V24, P933, DOI 10.1016/0006-2952(75)90422-0; IVERSEN LL, 1971, BRIT J PHARMACOL, V41, P571, DOI 10.1111/j.1476-5381.1971.tb07066.x; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU QR, 1993, J BIOL CHEM, V268, P2106; LIU QR, 1992, FEBS LETT, V305, P110, DOI 10.1016/0014-5793(92)80875-H; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; OLKKONEN VM, 1993, J NEUROSCI RES, V35, P445, DOI 10.1002/jnr.490350412; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PIETRINI G, 1994, J BIOL CHEM, V269, P4668; PIETRINI G, 1992, P NATL ACAD SCI USA, V89, P8414, DOI 10.1073/pnas.89.18.8414; PUDDINGTON L, 1987, P NATL ACAD SCI USA, V84, P2756; RADIAN R, 1990, J NEUROSCI, V10, P1319; ROBERTS E, 1974, BIOCHEM PHARMACOL, V23, P2637, DOI 10.1016/0006-2952(74)90033-1; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SMITH KE, 1992, MOL PHARMACOL, V42, P563; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; USDIN TB, 1991, P NATL ACAD SCI USA, V88, P11168, DOI 10.1073/pnas.88.24.11168; WECLEWICZ K, 1993, J NEUROSCI RES, V36, P173, DOI 10.1002/jnr.490360207; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649; YAMAUCHI A, 1991, AM J PHYSIOL, V261, pF197, DOI 10.1152/ajprenal.1991.261.1.F197	50	53	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6917	6924		10.1074/jbc.271.12.6917	http://dx.doi.org/10.1074/jbc.271.12.6917			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636119	hybrid			2022-12-25	WOS:A1996UB15700054
J	Aslund, F; Nordstrand, K; Berndt, KD; Nikkola, M; Bergman, T; Ponstingl, H; Jornvall, H; Otting, G; Holmgren, A				Aslund, F; Nordstrand, K; Berndt, KD; Nikkola, M; Bergman, T; Ponstingl, H; Jornvall, H; Otting, G; Holmgren, A			Glutaredoxin-3 from Escherichia coli - Amino acid sequence, H-1 and N-15 NMR assignments, and structural analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE DETERMINATION; GLUTATHIONE-DEPENDENT SYNTHESIS; PROTON PROTON DISTANCES; 3-DIMENSIONAL STRUCTURE; HUMAN THIOREDOXIN; MIXED DISULFIDE; PROTEINS; SPECTROSCOPY; DEOXYRIBONUCLEOTIDES; PURIFICATION	The primary and secondary structure of glutaredoxin-3 (Grx3), a glutathione-disulfide oxidoreductase from Escherichia coli, has been determined. The amino acid sequence of Grx3 consists of 82 residues and contains a redox-active motif, Cys-Pro-Tyr-Cys, typical of the glutaredoxin family. Sequence comparison reveals a homology (33% identity) to that of glutaredoxin-1 (Grx1) from E. coli as well as to other members of the thioredoxin superfamily. in addition to the active site cysteine residues, Grx3 contains one additional cysteine (Cys(65)) corresponding to one of the two non-active site (or structural) cysteine residues present in mammalian glutaredoxins. The sequence-specific H-1 and N-15 nuclear magnetic resonance assignments of reduced Grx3 have been obtained. From a combined analysis of chemical shifts, (3)J(HN alpha) coupling constants, sequential and medium range NOEs, and amide proton exchange rates, the secondary structure of reduced Grx3 was determined and found to be very similar to that inferred from amino acid sequence comparison to homologous proteins. The consequences of the proposed structural similarity to Grx1 are that Grx3, while possessing a largely intact GSH binding cleft, would have a very different spatial distribution of charged residues, most notably surrounding the active site cysteine residues and occurring in the proposed hydrophobic protein-protein interaction area. These differences may contribute to the observed very low K-cat of Grx3 as a reductant of insulin disulfides or as a hydrogen donor for ribonucleotide reductase. Thus, despite an identical active site disulfide motif and a similar secondary structure and tertiary fold, Grx3 and Grxl display large functional differences in in vitro protein disulfide oxide-reduction reactions.	KAROLINSKA INST, MED NOBEL INST BIOCHEM, DEPT MED BIOCHEM & BIOPHYS, S-17177 STOCKHOLM, SWEDEN; SWEDISH UNIV AGR SCI, CTR BIOMED, DEPT MOLEC BIOL, S-75124 UPPSALA, SWEDEN	Karolinska Institutet; Swedish University of Agricultural Sciences			Otting, Gottfried/H-8413-2014; Berndt, Kurt/J-8574-2015	Otting, Gottfried/0000-0002-0563-0146; Berndt, Kurt/0000-0002-3049-967X				ABERG A, 1989, J BIOL CHEM, V264, P12249; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BILLETER M, 1982, J MOL BIOL, V155, P321, DOI 10.1016/0022-2836(82)90008-0; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BODENHAUSEN G, 1984, J MAGN RESON, V58, P370, DOI 10.1016/0022-2364(84)90142-2; BRIAND J, 1991, CHEM PHYS LETT, V185, P276, DOI 10.1016/S0009-2614(91)85060-A; BROWN NC, 1969, EUR J BIOCHEM, V9, P561, DOI 10.1111/j.1432-1033.1969.tb00646.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BUSHWELLER JH, 1994, J MOL BIOL, V235, P1585, DOI 10.1006/jmbi.1994.1108; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Creighton T E, 1986, Methods Enzymol, V131, P83; ECCLES C, 1991, Journal of Biomolecular NMR, V1, P111, DOI 10.1007/BF01877224; EKLUND H, 1984, EMBO J, V3, P1443, DOI 10.1002/j.1460-2075.1984.tb01994.x; Ernst R. R., 1987, PRINCIPLES NUCL MAGN; FORMANKAY JD, 1989, BIOCHEMISTRY-US, V28, P7088, DOI 10.1021/bi00443a045; GLEASON FK, 1988, FEMS MICROBIOL LETT, V54, P271, DOI 10.1111/j.1574-6968.1988.tb02747.x; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; GUNTERT P, 1992, J BIOMOL NMR, V2, P619, DOI 10.1007/BF02192850; HARPER ET, 1993, BIOCHEMISTRY-US, V32, P7605, DOI 10.1021/bi00081a001; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; HOLLENBERG CP, 1992, EMBO GENBANK DDBJ DA; HOLMGREN A, 1975, P NATL ACAD SCI USA, V72, P2305, DOI 10.1073/pnas.72.6.2305; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; HOLMGREN A, 1979, J BIOL CHEM, V254, P3664; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOOG JO, 1983, EUR J BIOCHEM, V136, P223, DOI 10.1111/j.1432-1033.1983.tb07730.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LIN TY, 1989, BIOCHEMISTRY-US, V28, P5282, DOI 10.1021/bi00438a054; LUTHMAN M, 1982, J BIOL CHEM, V257, P6686; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; MESSERLE BA, 1989, J MAGN RESON, V85, P608, DOI 10.1016/0022-2364(89)90252-7; MIRANDAVIZUETE A, 1994, J BIOL CHEM, V269, P16631; MULLER N, 1986, J AM CHEM SOC, V108, P6482, DOI 10.1021/ja00281a006; NIKKOLA M, 1991, J BIOL CHEM, V266, P16105; NORDSTRAND K, IN PRESS EUR J BIOPH; ORENGO CA, 1994, NATURE, V372, P631, DOI 10.1038/372631a0; OSAPAY K, 1994, J MOL BIOL, V244, P183, DOI 10.1006/jmbi.1994.1718; PADILLA CA, 1995, EUR J BIOCHEM, V227, P27, DOI 10.1111/j.1432-1033.1995.tb20356.x; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; RUSSEL M, 1988, P NATL ACAD SCI USA, V85, P990, DOI 10.1073/pnas.85.4.990; SJOBERG BM, 1972, J BIOL CHEM, V247, P8063; SODANO P, 1991, J MOL BIOL, V221, P1311; SODERBERG BO, 1978, P NATL ACAD SCI USA, V75, P5827, DOI 10.1073/pnas.75.12.5827; SZILAGYI L, 1995, PROG NUCL MAG RES SP, V27, P325, DOI 10.1016/0079-6565(95)01011-2; SZYPERSKI T, 1992, J MAGN RESON, V99, P552, DOI 10.1016/0022-2364(92)90209-P; Thelander L, 1978, Methods Enzymol, V51, P227; WILLIAMSON MP, 1993, J MAGN RESON SER B, V101, P63, DOI 10.1006/jmrb.1993.1008; WILLIAMSON MP, 1995, J MOL BIOL, V247, P541, DOI 10.1006/jmbi.1995.0160; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; WUNDERLICH M, 1993, J MOL BIOL, V233, P559, DOI 10.1006/jmbi.1993.1535; WUTHRICH K, 1984, J MOL BIOL, V180, P715, DOI 10.1016/0022-2836(84)90034-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC; XIA TH, 1992, PROTEIN SCI, V1, P310; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	62	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6736	6745		10.1074/jbc.271.12.6736	http://dx.doi.org/10.1074/jbc.271.12.6736			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636094	hybrid			2022-12-25	WOS:A1996UB15700029
J	Bergeron, A; Champetier, S; LaRue, H; Fradet, Y				Bergeron, A; Champetier, S; LaRue, H; Fradet, Y			MAUB is a new mucin antigen associated with bladder cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-ASSOCIATED GLYCOPROTEIN; POLYMORPHIC EPITHELIAL MUCIN; MONOCLONAL-ANTIBODY B72.3; MOLECULAR-CLONING; INTESTINAL MUCIN; GENE-EXPRESSION; DIFFERENTIATION ANTIGENS; IMMUNOLOGICAL PROPERTIES; CARBOHYDRATE ANTIGENS; MEMBRANE ANTIGEN	The M344 tumor-associated antigen, expressed in 70% of superficial bladder tumors, is a sialylated carbohydrate present on a high molecular mass thiol-reducible secreted mucin, which we named MAUB for mucin antigen of the urinary bladder, Herein we studied the relationship between MAUB and other known mucins in the MGH-U3 bladder cancer line where MAUB expression is modulated by culture conditions, Northern blots, immunoradiometric assays, and Western blots showed that only MUC1 and MUC2 are expressed in this MAUB-positive cell line, MUC1 differs from MAUB by its molecular mass and its non-oligomeric nature, while MUC2 has similar molecular mass and response to culture conditions. However, in double determinant immunoradiometric assays, MAUB and MUC2 did not cross react. Moreover, confocal microscopy showed different subcellular localization of the two antigens, Treatment of MGH-U3 cells with MUC2 antisense oligodeoxynucleotides resulted in decreased expression of MUGS and increased expression of MAUB, ruling out the possibility that monoclonal antibody M344 recognizes a different glycosylated form of MUC2, In addition, we identified a tumor specimen expressing MAUB but no MUC2 antigen or mRNA. Together, these results suggest that there is expression of at least three mucins in MGH-U3 cells and that MAUB is a cancer-associated mucin distinct from those identified so far.	HOP HOTEL DIEU, CTR RECH, LAB UROONCOL EXPT, QUEBEC CITY, PQ G1R 2J6, CANADA					Fradet, Yves/0000-0002-7581-2500; Bergeron, Alain/0000-0002-2875-0773				ABE M, 1989, CANCER RES, V49, P2834; Allard P, 1995, CLIN CANCER RES, V1, P1195; ANAGNOSTAKI E, 1990, BRIT J CANCER, V62, P52; APOSTOLOPOULOS V, 1994, CRIT REV IMMUNOL, V14, P293, DOI 10.1615/CritRevImmunol.v14.i3-4.40; ARKLIE J, 1981, INT J CANCER, V28, P23, DOI 10.1002/ijc.2910280105; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BALAGUE C, 1994, GASTROENTEROLOGY, V106, P1054, DOI 10.1016/0016-5085(94)90767-6; BECKETT ML, 1991, CANCER RES, V51, P1326; BLANK M, 1994, INT J CANCER, V59, P301, DOI 10.1002/ijc.2910590302; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; BONNER RB, 1993, CANCER, V72, P2461, DOI 10.1002/1097-0142(19931015)72:8<2461::AID-CNCR2820720826>3.0.CO;2-C; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCHELL J, 1987, CANCER RES, V47, P5476; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BYRD JC, 1991, CANCER RES, V51, P1026; CARBIN BE, 1987, UROL RES, V15, P191; CARRATO C, 1994, GASTROENTEROLOGY, V107, P160, DOI 10.1016/0016-5085(94)90073-6; CHANG SK, 1994, GASTROENTEROLOGY, V107, P28, DOI 10.1016/0016-5085(94)90057-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONN IG, 1988, J CLIN PATHOL, V41, P1191, DOI 10.1136/jcp.41.11.1191; CORDONCARDO C, 1992, AM J PATHOL, V140, P375; CREPIN M, 1990, BIORHEOLOGY, V27, P471; DAVIS HM, 1986, CANCER RES, V46, P6143; DEVINE P L, 1990, Journal of Tumor Marker Oncology, V5, P11; DEVINE PL, 1993, BRIT J CANCER, V67, P1182, DOI 10.1038/bjc.1993.223; DEVINE PL, 1992, BIOESSAYS, V14, P619, DOI 10.1002/bies.950140909; DURRANT LG, 1994, EUR J CANCER, V30A, P355, DOI 10.1016/0959-8049(94)90256-9; FEIZI T, 1987, BIOCHEM J, V245, P1; Fradet Y, 1993, Semin Urol, V11, P145; FRADET Y, 1987, P NATL ACAD SCI USA, V84, P7227, DOI 10.1073/pnas.84.20.7227; FRADET Y, 1990, INT J CANCER, V46, P990, DOI 10.1002/ijc.2910460607; Fradet Y, 1992, Semin Urol, V10, P28; FRADET Y, 1995, CURR OPIN UROL, V5, P267; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GAMBUS G, 1993, GASTROENTEROLOGY, V104, P93; GAMBUS G, 1995, INT J CANCER, V60, P146, DOI 10.1002/ijc.2910600122; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GENDLER SJ, 1987, P NATL ACAD SCI USA, V84, P6060, DOI 10.1073/pnas.84.17.6060; GOLD DV, 1988, TUMOR BIOL, V9, P137, DOI 10.1159/000217554; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1992, J BIOL CHEM, V267, P21375; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HAND PH, 1985, CANCER RES, V45, P833; HANSKI C, 1993, CANCER RES, V53, P4082; HERR HW, 1995, J CLIN ONCOL, V13, P1404, DOI 10.1200/JCO.1995.13.6.1404; HILKENS J, 1984, INT J CANCER, V34, P197, DOI 10.1002/ijc.2910340210; HO SB, 1993, CANCER RES, V53, P641; HO SB, 1995, CANCER RES, V55, P2681; HODGSON CP, 1987, NUCLEIC ACIDS RES, V15, P6295, DOI 10.1093/nar/15.15.6295; ITOKU KA, 1992, HEMATOL ONCOL CLIN N, V6, P99, DOI 10.1016/S0889-8588(18)30365-4; ITZKOWITZ S, 1992, APMIS, V100, P173; JACOBS EL, 1991, CURR PROBL CANCER, V15, P300; JEROME KR, 1992, CANCER RES, V52, P5985; JOHNSON VG, 1986, CANCER RES, V46, P850; KIM YS, 1992, J CELL BIOCHEM, P91; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamerz Rolf, 1993, In Vivo (Athens), V7, P607; LAN MS, 1985, CANCER RES, V45, P305; LAN MS, 1990, CANCER RES, V50, P2997; LEONI F, 1988, HYBRIDOMA, V7, P129, DOI 10.1089/hyb.1988.7.129; LIN CW, 1985, CANCER RES, V45, P5070; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; MIOTTI S, 1985, CANCER RES, V45, P826; OGATA S, 1992, CANCER RES, V52, P5971; PEREY L, 1992, CANCER RES, V52, P2563; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; PRAT M, 1989, INT J CANCER, V44, P67, DOI 10.1002/ijc.2910440113; PRAT M, 1989, CANCER RES, V49, P1415; RAO JY, 1993, P NATL ACAD SCI USA, V90, P8287, DOI 10.1073/pnas.90.17.8287; ROSE MC, 1992, AM J PHYSIOL, V263, pL413, DOI 10.1152/ajplung.1992.263.4.L413; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAMUEL J, 1990, CANCER RES, V50, P4801; SINGHAL A, 1990, BIOESSAYS, V12, P223, DOI 10.1002/bies.950120506; SOLOWAY MS, 1992, J CELL BIOCHEM, P120; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; TAKASHI M, 1987, UROL INT, V42, P170, DOI 10.1159/000281888; TAYLORPAPADIMITRIOU J, 1993, ANN NY ACAD SCI, V690, P69; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; VERMA M, 1994, GLYCOCONJUGATE J, V11, P172, DOI 10.1007/BF00731215; WALSH MD, 1994, BRIT J UROL, V73, P256, DOI 10.1111/j.1464-410X.1994.tb07514.x; WURZNER R, 1990, J IMMUNOL METHODS, V126, P231, DOI 10.1016/0022-1759(90)90155-O; XING PX, 1992, J NATL CANCER I, V84, P699, DOI 10.1093/jnci/84.9.699; YONEZAWA S, 1991, BIOCHEM J, V276, P599, DOI 10.1042/bj2760599	86	17	22	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6933	6940		10.1074/jbc.271.12.6933	http://dx.doi.org/10.1074/jbc.271.12.6933			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636121	hybrid			2022-12-25	WOS:A1996UB15700056
J	Saklatvala, J; Rawlinson, L; Waller, RJ; Sarsfield, S; Lee, JC; Morton, LF; Barnes, MJ; Farndale, RW				Saklatvala, J; Rawlinson, L; Waller, RJ; Sarsfield, S; Lee, JC; Morton, LF; Barnes, MJ; Farndale, RW			Role for p38 mitogen-activated protein kinase in platelet aggregation caused by collagen or a thromboxane analogue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								p38 mitogen-activated protein kinase (MAPK) was identified in platelets on the basis of (a) its reactivity with antibodies to C-terminal and N-terminal peptides, and (b) its ability to activate MAPK-activated protein kinase-2, which phosphorylates the small heat shock protein, hsp27. p38 MAPK was activated in platelets by collagen fibers, a collagen-related cross-linked peptide, thrombin, or the thromboxane analogue U46619. A highly specific inhibitor of p38 MAPK, a pyridinyl imidazole known as SB203580, inhibited the platelet enzyme in vitro (IC50 similar to 0.5 mu M). At similar concentrations it also inhibited agonist-stimulated phosphorylation of hsp27 in platelets, and platelet aggregation and secretion induced by minimal aggregatory concentrations of collagen or U46619, but not thrombin. Inhibition of aggregation was overcome by increasing agonist dose. SB203580 might act by inhibiting thromboxane generation, but this was only inhibited by 10-20% at low agonist concentrations. p38 MAPK provides a crucial signal, which is necessary for aggregation caused by minimal concentrations of collagen fibers or U46619. Thrombin or high doses of these agonists generate signals that bypass the enzyme, or render the enzyme no longer rate-limiting.	SMITHKLINE BEECHAM PHARMACEUT,DEPT CELLULAR BIOCHEM,KING OF PRUSSIA,PA 19406; STRANGEWAYS RES LAB,CAMBRIDGE CB1 4RN,ENGLAND; UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND	GlaxoSmithKline; University of Cambridge	Saklatvala, J (corresponding author), BABRAHAM INST,DEPT DEV & SIGNALLING,CYTOKINE LAB,CAMBRIDGE CB2 4AT,ENGLAND.							BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KNAUF U, 1994, EMBO J, V13, P54, DOI 10.1002/j.1460-2075.1994.tb06234.x; KRAMER RM, 1995, J BIOL CHEM, V270, P14816, DOI 10.1074/jbc.270.24.14816; KRAMER RM, 1995, J BIOL CHEM, V270, P27895; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEE JC, 1993, ANN NY ACAD SCI, V696, P149; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; PAPKOFF J, 1994, MOL CELL BIOL, V14, P463, DOI 10.1128/MCB.14.1.463; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; TANDON NN, 1989, J BIOL CHEM, V264, P7576; ZHU Y, 1994, BLOOD, V84, P3715, DOI 10.1182/blood.V84.11.3715.bloodjournal84113715	24	257	261	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6586	6589		10.1074/jbc.271.12.6586	http://dx.doi.org/10.1074/jbc.271.12.6586			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636072	hybrid			2022-12-25	WOS:A1996UB15700007
J	Brandes, HK; Larimer, FW; Hartman, FC				Brandes, HK; Larimer, FW; Hartman, FC			The molecular pathway for the regulation of phosphoribulokinase by thioredoxin f	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RIBULOSE-5-PHOSPHATE KINASE; SPINACH PHOSPHORIBULOKINASE; CYSTEINYL RESIDUE; ACTIVE-CENTER; REDUCED FORM; SITE; IDENTIFICATION; PHOTOSYNTHESIS; SULFHYDRYL	Phosphoribulokinase (PRK) is one of several plant enzymes that is regulated by thiol-disulfide exchange as mediated by thioredoxin, which contains spatially vicinal, redox-active cysteinyl residues, In an earlier study (Brandes, H. K., Larimer, F. W., Geck, M. K., Stringer, C. D., Schurmann, P., and Hartman, F. C. (1993) J. Biol. Chem, 268, 18411-18414), our laboratory identified Cys-46 of thioredoxin f (Trx), as opposed to the other candidate Cys-49, as the primary nucleophile that attacks the disulfide of target proteins. The goal of the present study was to identify which of the two redox-active cysteinyl residues of PRK (Cys-16 or Cys-55) is paired with Cys-46 of Trx in the interprotein disulfide intermediate of the overall oxidation-reduction pathway. Incubation of a mixture of the C16S mutant of PRK and the C49S mutant of Trx with Cu2+ results in covalent complex formation as detected by SDS-polyacrylamide gel electrophoresis. Complexation is fully reversible by dithiothreitol and is retarded by ligands for PRK. Under the same conditions, Cu2+ induces very little complex formation between the following pairs of mutants: C16S PRK/C46S Trx, C55S PRK/C49S Trx, and C55S PRK/C46S Trx. When either 5-thio-2-nitrobenzoate-derivatized C16S or C55S PRK, as mimics of the oxidized (disulfide) form of the enzyme, is mixed with C49S Trx, stable covalent complex formation occurs only with the C16S PRK. Thus, two independent approaches identify Cys-55 of PRK in the intermolecular disulfide pairing with Trx.	OAK RIDGE NATL LAB,DIV BIOL,PROT ENGN PROGRAM,OAK RIDGE,TN 37831; UNIV TENNESSEE,GRAD SCH BIOMED SCI,OAK RIDGE,TN 37831	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville								BRANDES HK, 1993, J BIOL CHEM, V268, P18411; BRANDES HK, 1996, IN PRESS J BIOL CHEM, V271; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V31, P341, DOI 10.1146/annurev.pp.31.060180.002013; BUCHANAN BB, 1991, ARCH BIOCHEM BIOPHYS, V288, P1, DOI 10.1016/0003-9861(91)90157-E; BUCHANAN BB, 1984, BIOSCIENCE, V34, P378, DOI 10.2307/1309730; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; HOLMGREN A, 1972, J BIOL CHEM, V247, P1992; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; KALLIS GB, 1980, J BIOL CHEM, V255, P261; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KOBASHI K, 1968, BIOCHIM BIOPHYS ACTA, V158, P239, DOI 10.1016/0304-4165(68)90136-0; KRIEGER TJ, 1987, ARCH BIOCHEM BIOPHYS, V256, P362, DOI 10.1016/0003-9861(87)90457-7; KRIEGER TJ, 1987, BIOCHIM BIOPHYS ACTA, V915, P112, DOI 10.1016/0167-4838(87)90130-0; LI HM, 1993, BIOCHEMISTRY-US, V32, P5800, DOI 10.1021/bi00073a012; MILANEZ S, 1988, GENE, V66, P55, DOI 10.1016/0378-1119(88)90224-7; PONTREMOLI S, 1962, J BIOL CHEM, V237, P643; PORTER MA, 1988, J BIOL CHEM, V263, P14846; PORTER MA, 1986, ARCH BIOCHEM BIOPHYS, V245, P14, DOI 10.1016/0003-9861(86)90185-2; PORTER MA, 1988, J BIOL CHEM, V263, P123; PORTER MA, 1986, BIOCHEMISTRY-US, V25, P7314, DOI 10.1021/bi00371a011; PORTER MA, 1990, ARCH BIOCHEM BIOPHYS, V281, P330, DOI 10.1016/0003-9861(90)90452-5; PORTER MA, 1990, J PROTEIN CHEM, V9, P445, DOI 10.1007/BF01024620; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; RACKER E., 1957, ARCH BIOCHEM AND BIOPHYS, V69, P300, DOI 10.1016/0003-9861(57)90496-4; REUTIMANN H, 1981, J BIOL CHEM, V256, P6796; WYNN R, 1995, BIOCHEMISTRY-US, V34, P11807, DOI 10.1021/bi00037a019; YANG YF, 1991, J BIOL CHEM, V266, P12759	28	71	72	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3333	3335						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631927				2022-12-25	WOS:A1996TV72400001
J	Koshy, KM; Boggs, JM				Koshy, KM; Boggs, JM			Investigation of the calcium-mediated association between the carbohydrate head groups of galactosylceramide and galactosylceramide I-3 sulfate by electrospray ionization mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; CEREBROSIDE SULFATE; MELANOMA-CELLS; RECOGNITION; DIGALACTOSYLDIACYLGLYCEROL; MECHANISMS; CATIONS; BINDING	Calcium has been shown previously to cause aggregation of phosphatidylcholine/cholesterol liposomes containing galactosylceramide (GalCer) with similar liposomes containing cerebroside sulfate (galactosylceramide I-3 sulfate) (CBS), suggesting that it mediates a carbohydrate-carbohydrate association between these two glycolipids. In order to determine if such an association occurs, the noncovalent complexes formed on addition of calcium chloride to GalCer and CBS in methanol were examined by positive and negative ion spray mass spectrometry, Monomeric Ca2+ complexes of both lipids were observed. In addition, Ca2+ also caused oligomerization of GalCer. Oligomerization of CBS anion was not seen, but dimers would not have been observed, as they would be neutral. However, Ca2+ caused heterotypic complexation of GalCer and CBS, Although these heterotypic complexes were of low abundance in methanol compared with the other monomeric and homotypic oligomeric positive ions formed at low declustering potentials, the heterotypic dimer [GalCer . CBS . Ca2+-H](+) had the greatest stability of all oligomers formed and was the only one to survive at high declustering potentials. Na+ did not cause oligomerization of GalCer in methanol indicating that the complexes of GalCer with Ca2+ are not caused by van der Waals interactions between the lipid moieties. GalCer and CBS are present in high concentrations in myelin, This Ca2+-mediated carbohydrate-carbohydrate interaction, which can bridge apposing bilayers, may be involved in adhesion of the extracellular surfaces of the myelin sheath.	HOSP SICK CHILDREN,RES INST,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO,ON M5G 1L5,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto								ANGYAL SJ, 1971, J CHEM SOC CHEM COMM, P500, DOI 10.1039/c29710000500; ANGYAL SJ, 1972, AUST J CHEM, V25, P1957, DOI 10.1071/CH9721957; [Anonymous], 1966, ADV CARBOHYD CHEM, V21, P209; BREWER GJ, 1992, BIOCHEMISTRY-US, V31, P1816, DOI 10.1021/bi00121a033; CAMILLERI P, 1993, RAPID COMMUN MASS SP, V7, P949, DOI 10.1002/rcm.1290071017; CAMILLERI P, 1994, FEBS LETT, V341, P256, DOI 10.1016/0014-5793(94)80467-2; COOK WJ, 1977, METAL LIGAND INTER 2, P231; COOK WJ, 1972, J AM CHEM SOC, V95, P6442; DAMMER U, 1995, SCIENCE, V267, P1173, DOI 10.1126/science.7855599; DOMOVS KB, 1960, J DAIRY SCI, V43, P1216, DOI 10.3168/jds.S0022-0302(60)90307-6; EGGENS I, 1989, J BIOL CHEM, V264, P9476; GRANT GT, 1973, FEBS LETT, V32, P195, DOI 10.1016/0014-5793(73)80770-7; GUPTA D, 1994, BIOCHEMISTRY-US, V33, P2503, DOI 10.1021/bi00175a020; HAKOMORI S, 1991, PURE APPL CHEM, V63, P473, DOI 10.1351/pac199163040473; HUANG RTC, 1978, NATURE, V276, P624, DOI 10.1038/276624a0; KOJIMA N, 1992, J BIOL CHEM, V267, P17264; KOJIMA N, 1989, J BIOL CHEM, V264, P20159; KOJIMA N, 1991, J BIOL CHEM, V266, P17552; KOPACZYK KC, 1965, J LIPID RES, V6, P140; KOSHY KM, 1983, CHEM PHYS LIPIDS, V34, P41, DOI 10.1016/0009-3084(83)90058-0; MENIKH A, 1993, EUR BIOPHYS J BIOPHY, V22, P249, DOI 10.1007/BF00180259; MISEVIC GN, 1993, J BIOL CHEM, V268, P4922; Norton W.T., 1977, MYELIN, P161; SIUZDAK G, 1993, J AM CHEM SOC, V115, P2877, DOI 10.1021/ja00060a040; SIUZDAK G, 1994, BIOORG MED CHEM LETT, V4, P2863, DOI 10.1016/S0960-894X(01)80829-5; SMITH RD, 1992, ORG MASS SPECTROM, V27, P811, DOI 10.1002/oms.1210270709; SMITH RD, 1993, BIOL MASS SPECTROM, V22, P493, DOI 10.1002/bms.1200220902; STEWART RJ, 1993, BIOCHEMISTRY-US, V32, P10666, DOI 10.1021/bi00091a017; VALENT BS, 1974, PLANT PHYSIOL, V54, P105, DOI 10.1104/pp.54.1.105; WEBB MS, 1988, BIOCHIM BIOPHYS ACTA, V938, P323, DOI 10.1016/0005-2736(88)90130-7; WHITFIELD DM, 1993, COORDIN CHEM REV, V122, P171, DOI 10.1016/0010-8545(93)80045-7; WORMALD MR, 1991, BIOCHEM BIOPH RES CO, V180, P1214, DOI 10.1016/S0006-291X(05)81325-7	32	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3496	3499						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631953				2022-12-25	WOS:A1996TV72400027
J	Tobin, AB; Keys, B; Nahorski, SR				Tobin, AB; Keys, B; Nahorski, SR			Identification of a novel receptor kinase that phosphorylates a phospholipase C-linked muscarinic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC CHOLECYSTOKININ RECEPTOR; INOSITOL POLYPHOSPHATE METABOLISM; CHOLINERGIC RECEPTORS; PHOSPHOINOSITIDASE-C; PROTEIN-KINASE; DESENSITIZATION; INHIBITION; CELLS; DOMAIN	Phosphorylation of G-protein-linked receptors is thought to play a central role in receptor regulation and desensitization. Unlike the case of the extensively studied beta-adrenergic receptor/adenylate cyclase pathway, in which receptor-specific phosphorylation is known to be mediated by beta-adrenergic receptor kinase (beta-ARK), the kinases responsible for phosphorylation of phospholipase C-linked receptors have yet to be identified, although a role for beta-ARK has been implicated. This study describes the purification of a novel 40-kDa receptor kinase from porcine cerebellum that is able to phosphorylate the phospholipase C-linked m3-muscarinic receptor in an agonist-dependent manner. The assay for kinase activity was based on the ability of the kinase to phosphorylate a bacterial fusion protein, Ex-m3, containing amino acids Ser(345)-Leu(463) of the third intracellular loop of the m3-muscarinic receptor. Purification of the muscarinic receptor kinase from a high speed supernatant fraction of porcine cerebellum was achieved using the following steps: (i) 30-60% ammonium sulfate cut and successive chromatography on (ii) butyl-Sepharose (iii) Resource Q, (iv) Resource S, and (v) heparin-Sepharose. The purified protein kinase represented an similar to 18,600-fold purification and was a single polypeptide with a molecular weight of similar to 40 kDa. Based on the chromatographic mobility, molecular weight, and kinase inhibitor studies, the kinase, designated MRK, was shown to be distinct from previously characterized second messenger regulated protein kinases, beta-ARK, and other members of the G-protein-linked receptor kinase family. It therefore represents a new class of receptor kinase.			Tobin, AB (corresponding author), UNIV LEICESTER,DEPT CELL PHYSIOL & PHARMACOL,POB 138,MED SCI BLDG,UNIV RD,LEICESTER LE1 9HN,LEICS,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALALUF S, 1995, FEBS LETT, V367, P301, DOI 10.1016/0014-5793(95)00575-T; ALBAS J, 1995, J BIOL CHEM, V270, P8944; ALI H, 1994, J BIOL CHEM, V269, P24557; BALLA T, 1988, J BIOL CHEM, V263, P4083; BENOVIC JL, 1989, J BIOL CHEM, V264, P6707; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; DEBBURMAN SK, 1995, MOL PHARMACOL, V47, P224; FISHER SK, 1994, NEUROCHEM RES, V19, P549, DOI 10.1007/BF00971329; GATES LK, 1993, AM J PHYSIOL, V264, pG840, DOI 10.1152/ajpgi.1993.264.5.G840; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HOFFMANN EK, 1984, J MEMBRANE BIOL, V78, P211, DOI 10.1007/BF01925969; INGLESE J, 1993, J BIOL CHEM, V268, P23737; ISHII K, 1994, J BIOL CHEM, V269, P1125; KISHIMOTO A, 1987, J BIOL CHEM, V262, P1344; KLUEPPELBERG UG, 1991, J BIOL CHEM, V266, P2403; KUMAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KWATRA MM, 1993, J BIOL CHEM, V268, P91961; LAMBERT DG, 1990, BIOCHEM J, V265, P555, DOI 10.1042/bj2650555; LATTION AL, 1994, J BIOL CHEM, V269, P22887; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOUDON RP, 1994, J BIOL CHEM, V269, P22691; MENNITI FS, 1991, MOL PHARMACOL, V40, P727; MORGAN RO, 1987, J BIOL CHEM, V262, P1166; MORO O, 1993, J BIOL CHEM, V268, P6862; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; TOBIN AB, 1995, BRIT J PHARMACOL, V116, P1723, DOI 10.1111/j.1476-5381.1995.tb16654.x; TOBIN AB, 1993, J BIOL CHEM, V268, P9817; TOBIN AB, 1993, FEBS LETT, V335, P353, DOI 10.1016/0014-5793(93)80418-T; TOBIN AB, 1992, MOL PHARMACOL, V42, P1042; VOURETCRAVIARI V, 1995, J BIOL CHEM, V270, P8367, DOI 10.1074/jbc.270.14.8367; WAUGH MG, 1995, BRIT J PHARMACOL, V114, pP143; WOJCIKIEWICZ RJH, 1994, J NEUROCHEM, V63, P177; WOJCIKIEWICZ RJH, 1993, TRENDS PHARMACOL SCI, V14, P279, DOI 10.1016/0165-6147(93)90131-3	40	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3907	3916						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632012				2022-12-25	WOS:A1996TV72400086
J	Gill, DJ; Low, BC; Grigor, MR				Gill, DJ; Low, BC; Grigor, MR			Interleukin-1 beta and tumor necrosis factor-alpha stimulate the cat-2 gene of the L-arginine transporter in cultured vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; CATIONIC AMINO-ACIDS; RELAXING FACTOR; ANGIOTENSIN-II; RECEPTOR; RAT; MACROPHAGES; EXPRESSION; INDUCTION; MEMBRANE	The production of nitric oxide (NO) from L-arginine by nitric oxide synthase (NOS) in cytokine-stimulated vascular smooth muscle cells (VSMC) is thought to play an important role in the pathophysiology of several vascular disease states including septic shock. This study examines the relationship between cytokine-stimulated NO production and L-arginine transport in cultured VSMC. Cultured VSMC from rat aorta were stimulated with interleukin-1 beta, tumor necrosis factor-alpha, and/or angiotensin II (Ang II); and the accumulation of nitrite, a stable product of NO metabolism, in the culture media and the rates of net L-arginine uptake were measured. Interleukin-1 beta and tumor necrosis factor-alpha, alone or in combination, stimulated both the uptake of L-arginine and the accumulation of nitrite in the culture media in a dose-dependent manner. Inhibition of NOS activity by substituted analogues of L-arginine had no effect on cytokine-stimulated L-arginine transport. Ang II in the presence of cytokines up-regulated L-arginine transport while inhibiting nitrite accumulation. Two forms of the L-arginine transporter, cat-1b and cat-2, are expressed in VSMC. Northern analysis revealed that the cytokine-stimulated increase in L-arginine transport coincided with increased levels of cat-2 mRNA. In contrast, cat-1b does not appear to be regulated by cytokines at the mRNA level, although significant increases in response to Ang II were observed. These results show that, while cytokines can stimulate both NOS activity and L-arginine uptake, NO production is not required to signal the increase in L-arginine transport. Furthermore, Ang II and cytokine stimulation of L-arginine uptake involves the differential regulation of the cationic amino acid transporter (cat) genes.	UNIV OTAGO,DEPT BIOCHEM,DUNEDIN 9001,NEW ZEALAND; UNIV OTAGO,CTR GENE RES,DUNEDIN 9001,NEW ZEALAND	University of Otago; University of Otago			Low, Boon Chuan/AAU-7685-2021; Low, Boon Chuan/H-8049-2012	Low, Boon Chuan/0000-0003-0756-096X; Low, Boon Chuan/0000-0003-0756-096X; Gill, Denzil/0000-0001-5826-4103				ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BAYDOUN AR, 1993, BRIT J PHARMACOL, V110, P1401, DOI 10.1111/j.1476-5381.1993.tb13976.x; BEASLEY D, 1994, AM J PHYSIOL, V266, pR1197, DOI 10.1152/ajpregu.1994.266.4.R1197; BEASLEY D, 1991, J CLIN INVEST, V87, P602, DOI 10.1172/JCI115036; BOGLE RG, 1992, BIOCHEM J, V284, P15, DOI 10.1042/bj2840015; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; DURANTE W, 1995, AM J PHYSIOL-HEART C, V268, pH1158; FINLEY KD, 1995, P NATL ACAD SCI USA, V92, P9378, DOI 10.1073/pnas.92.20.9378; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; HARRIS EL, 1990, BIOCHEM BIOPH RES CO, V170, P1249, DOI 10.1016/0006-291X(90)90528-U; HATTORI Y, 1994, J BIOL CHEM, V269, P9405; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Kakuda DK, 1993, TRANSGENE, V1, P91; KILBERG MS, 1993, ANN REV NUTR, V13, P136; KOIDE M, 1993, FEBS LETT, V318, P213, DOI 10.1016/0014-5793(93)80514-U; LOW BC, 1992, J BIOL CHEM, V267, P20740; LOW BC, 1995, J BIOL CHEM, V270, P27577, DOI 10.1074/jbc.270.46.27577; LOW BC, 1993, J CELL PHYSIOL, V156, P626, DOI 10.1002/jcp.1041560323; LOW BC, 1994, J BIOL CHEM, V269, P32098; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MACLEOD CL, 1990, MOL CELL BIOL, V10, P3663, DOI 10.1128/MCB.10.7.3663; MACLEOD CL, 1994, J EXP BIOL, V196, P109; NAKAYAMA I, 1994, J BIOL CHEM, V269, P11628; PETROS A, 1994, CARDIOVASC RES, V28, P34, DOI 10.1093/cvr/28.1.34; SATO H, 1991, BIOCHIM BIOPHYS ACTA, V1069, P46, DOI 10.1016/0005-2736(91)90102-E; SCHINI VB, 1993, EUR HEART J, V14, P16; SCHINI VB, 1991, BIOCHEM BIOPH RES CO, V176, P114, DOI 10.1016/0006-291X(91)90897-G; SIRSJO A, 1994, FEBS LETT, V338, P191, DOI 10.1016/0014-5793(94)80363-3; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; VANWINKLE LJ, 1995, BBA-BIOMEMBRANES, V1233, P213, DOI 10.1016/0005-2736(94)00303-7; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WANG WW, 1995, BIOCHEM BIOPH RES CO, V210, P1009, DOI 10.1006/bbrc.1995.1757; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; WHITE MF, 1985, BIOCHIM BIOPHYS ACTA, V822, P355, DOI 10.1016/0304-4157(85)90015-2; WU JY, 1994, J VIROL, V68, P1615, DOI 10.1128/JVI.68.3.1615-1623.1994; ZAR JH, 1974, BIOSTAT ANAL, P151	37	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11280	11283		10.1074/jbc.271.19.11280	http://dx.doi.org/10.1074/jbc.271.19.11280			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626679	hybrid			2022-12-25	WOS:A1996UJ94400039
J	Spiro, RG; Zhu, Q; Bhoyroo, V; Soling, HD				Spiro, RG; Zhu, Q; Bhoyroo, V; Soling, HD			Definition of the lectin-like properties of the molecular chaperone, calreticulin, and demonstration of its copurification with endomannosidase from rat liver Golgi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; ALPHA-D-MANNOSIDASE; ENDOPLASMIC-RETICULUM; GLYCOPROTEIN-BIOSYNTHESIS; BINDING-PROTEIN; GLUCOSE; COMPLEX; CELLS; GLYCOSYLATION; MATURATION	Calreticulin was identified by immunochemical and sequence analyses to be the higher molecular mass (60 kDa) component of the polypeptide doublet previously observed in a rat liver Golgi endomannosidase preparation obtained by chromatography on a Glc alpha 1-->3Man-containing matrix. The affinity for this saccharide ligand, which paralleled that of endomannosidase and was also observed with purified rat liver calreticulin, suggested that this chaperone has lectin-like binding properties. Studies carried out with immobilized calreticulin and a series of radiolabeled oligosaccharides derived from N-linked carbohydrate units revealed that interactions with this protein were limited to monoglucosylated polymannose components. Although optimal binding occurred with Glc(1)Man(9)GlcNAc, substantial interaction with calreticulin was retained after sequential trimming of the polymannose portion down to the Glc(1)Man(5)GlcNAc stage. The alpha 1-->6-mannose branch point of the oligosaccharide core, however, appeared to be essential for recognition as Glc(1)Man(4)GlcNAc did not interact with the calreticulin. The carbohydrate-peptide linkage region had no discernible influence on binding as monoglucosylated oligosaccharides in N-glycosidic linkage interacted with the chaperone to the same extent as in their unconjugated state. The immobilized calreticulin proved to be a highly effective tool for sorting out monoglucosylated polymannose oligosaccharides or glycopeptides from complex mixtures of processing intermediates. The copurification of calreticulin and endomannosidase from a Golgi fraction in comparable amounts and the strikingly similar saccharide specificities of the chaperone and the processing enzyme have suggested a tentative model for the dissociation through glucose removal of calreticulin-glycoprotein complexes in a post-endoplasmic reticulum locale; in this scheme, deglucosylation would be brought about by the action of endomannosidase rather than glucosidase II.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02215 USA; UNIV GOTTINGEN, ZENTRUM INNERE MED, BIOCHEM ABT, D-3400 GOTTINGEN, GERMANY	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Gottingen	Spiro, RG (corresponding author), JOSLIN DIABET CTR, ELLIOTT P JOSLIN RES LAB, 1 JOSLIN PL, BOSTON, MA 02215 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017477, R01DK017325] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 17325, DK 17477] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANUMULA KR, 1983, J BIOL CHEM, V258, P5274; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; Burns K, 1994, Trends Cell Biol, V4, P152; DePierre J., 1976, BIOCH ANAL MEMBRANES, P79; DUPUIS M, 1993, J EXP MED, V177, P1, DOI 10.1084/jem.177.1.1; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; GODELAINE D, 1981, J BIOL CHEM, V256, P161; Goldstein I., 1986, LECTINS, DOI DOI 10.1016/B978-0-12-449945-4.50007-5; GRINNA LS, 1980, J BIOL CHEM, V255, P2255; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HIRAIZUMI S, 1994, J BIOL CHEM, V269, P4697; HUOVILA APJ, 1992, J CELL BIOL, V118, P1305, DOI 10.1083/jcb.118.6.1305; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; LUBAS WA, 1988, J BIOL CHEM, V263, P3990; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MOHAN PS, 1986, J BIOL CHEM, V261, P4328; MOORE SEH, 1990, J BIOL CHEM, V265, P13104; MOORE SEH, 1993, J BIOL CHEM, V268, P3809; MOORE SEH, 1994, J BIOL CHEM, V269, P12715; MOOS M, 1988, J BIOL CHEM, V263, P6005; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; NAKAMURA M, 1993, EXP CELL RES, V205, P101, DOI 10.1006/excr.1993.1063; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PETER F, 1992, J BIOL CHEM, V267, P10631; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; RABOUILLE C, 1992, J BIOL CHEM, V267, P11573; SASAK VW, 1985, BIOCHEM J, V232, P759, DOI 10.1042/bj2320759; SPIRO MJ, 1985, J BIOL CHEM, V260, P5808; SPIRO MJ, 1979, J BIOL CHEM, V254, P7668; SPIRO MJ, 1976, J BIOL CHEM, V251, P6400; SPIRO RG, 1983, J BIOL CHEM, V258, P9469; STROUS GJ, 1987, J BIOL CHEM, V262, P3620; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TULSIANI DRP, 1977, J BIOL CHEM, V252, P3227; TURCO SJ, 1977, P NATL ACAD SCI USA, V74, P4411, DOI 10.1073/pnas.74.10.4411; VAN PN, 1989, J BIOL CHEM, V264, P17494; WADA I, 1995, J BIOL CHEM, V270, P20298, DOI 10.1074/jbc.270.35.20298; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; Weng SA, 1996, ARCH BIOCHEM BIOPHYS, V325, P113, DOI 10.1006/abbi.1996.0014; WENG SA, 1993, J BIOL CHEM, V268, P25656; WHITE TK, 1995, J BIOL CHEM, V270, P15926, DOI 10.1074/jbc.270.27.15926; WIEST DL, 1995, EMBO J, V14, P3425, DOI 10.1002/j.1460-2075.1995.tb07348.x; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	51	245	252	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11588	11594		10.1074/jbc.271.19.11588	http://dx.doi.org/10.1074/jbc.271.19.11588			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626722	hybrid			2022-12-25	WOS:A1996UJ94400082
J	Baier, LJ; Bogardus, C; Sacchettini, JC				Baier, LJ; Bogardus, C; Sacchettini, JC			A polymorphism in the human intestinal fatty acid binding protein alters fatty acid transport across Caco-2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINE CACO-2; DIFFERENTIATION; METABOLISM; INSULIN; GLUCOSE; EXPRESSION	The human intestinal fatty acid binding protein (IFABP) binds long-chain fatty acids in vitro, but its intracellular function has remained speculative. A poly morphism in the gene that encodes IFABP results in an alanine (Ala(54)) to threonine (Thr(54)) substitution at codon 54 that alters the in vitro binding affinity of the protein for long-chain fatty acids. To identify potential functional variability between Ala(54) and Thr(54) IFABP, we established permanently transfected Caco-2 cell lines that express either Ala(54) or Thr(54) IFABP. We found that Caco-2 cells expressing Thr(54) IFABP transport long-chain fatty acids and secrete triglycerides to a greater degree than Caco-2 cells expressing Ala(54) IFABP. These results provide the first demonstration that IFABP participates in the intracellular transport of long-chain fatty acids. In addition, the observed increase in transport of fatty acids across cells expressing Thr(54) IFABP suggests a plausible physiologic mechanism for our prior observation that Pima Indians with a Thr(54) IFABP genotype have increased post-absorptive lipid oxidation rates and are more insulin-resistant than Pimas with a Ala(54) IFABP genotype.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT BIOCHEM, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Baier, LJ (corresponding author), NIDDK, NATL INST HLTH, 4212 N 16TH ST, PHOENIX, AZ 85016 USA.							ABBOTT WGH, 1987, DIABETES, V36, P897, DOI 10.2337/diabetes.36.8.897; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; BAIER LJ, 1995, J CLIN INVEST, V95, P1281, DOI 10.1172/JCI117778; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BODEN G, 1994, J CLIN INVEST, V93, P2438, DOI 10.1172/JCI117252; CAREY MC, 1983, ANNU REV PHYSIOL, V45, P651, DOI 10.1146/annurev.ph.45.030183.003251; FERRANNINI E, 1983, J CLIN INVEST, V72, P1737, DOI 10.1172/JCI111133; HAMILTON JA, 1994, J BIOL CHEM, V269, P20852; HUGHES TE, 1987, J BIOL CHEM, V262, P3762; KELLEY DE, 1993, J CLIN INVEST, V92, P91, DOI 10.1172/JCI116603; LEVIN MS, 1992, J LIPID RES, V33, P9; LEVY E, 1995, FASEB J, V9, P626, DOI 10.1096/fasebj.9.8.7768354; LILLIOJA S, 1985, J CLIN INVEST, V75, P1106, DOI 10.1172/JCI111804; LOWE JB, 1987, J BIOL CHEM, V262, P5931; OLEFSKY JM, 1974, AM J MED, V57, P551, DOI 10.1016/0002-9343(74)90006-0; PIATTI PM, 1995, METABOLISM, V44, P883, DOI 10.1016/0026-0495(95)90241-4; PINTO M, 1983, BIOL CELL, V47, P323; RICHIERI GV, 1994, J BIOL CHEM, V269, P23918; SACCHETTINI JC, 1993, J BIOL CHEM, V268, P18399; SCHAFFER JE, 1994, CELL, V79, P427, DOI 10.1016/0092-8674(94)90252-6; STREMMEL W, 1985, P NATL ACAD SCI USA, V82, P4, DOI 10.1073/pnas.82.1.4; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060; TRABER MG, 1987, J LIPID RES, V28, P1350; TROTTER PJ, 1993, J BIOL CHEM, V268, P10017; TROTTER PJ, 1991, J LIPID RES, V32, P293; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; VANNIEUWENHOVEN FA, 1995, BIOCHEM BIOPH RES CO, V207, P747, DOI 10.1006/bbrc.1995.1250	27	145	150	1	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10892	10896		10.1074/jbc.271.18.10892	http://dx.doi.org/10.1074/jbc.271.18.10892			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631905				2022-12-25	WOS:A1996UJ34200073
J	Hallenbeck, PL; Minucci, S; Lippoldt, P; Phyillaier, M; Horn, V; Ozato, K; Nikodem, VM				Hallenbeck, PL; Minucci, S; Lippoldt, P; Phyillaier, M; Horn, V; Ozato, K; Nikodem, VM			Differential 9-cis-retinoic acid-dependent transcriptional activation by murine retinoid X receptor alpha (RXR alpha) and RXR beta - Role of cell type and RXR domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; DIRECT REPEAT; DNA-BINDING; GENE; RAR; HETERODIMERIZATION; PROTEIN	The 9-cis-retinoic acid (9cRA)-inducible enhancer of the rat cellular retinol-binding protein type II gene (CRBP II) was shown to be differentially regulated by the murine retinoid X receptor alpha (RXR alpha) as compared with RXR beta. Transient transfection assays performed in NIH 3T3 fibroblast cells demonstrated that RXR alpha yielded a high level of 9cRA-dependent transcription of a reporter gene linked to the CRBP II enhancer, when compared with RXR beta. This effect was cell type-dependent, since both receptors elicited comparable transcriptional activation of the same reporter in P19 embryonal carcinoma cells, To further explore the structural determinants responsible for the differences between these two receptors, a series of chimeric receptor constructs mere made, Co-transfection assays utilizing these chimeras demonstrated that both the N terminus and the hinge region connecting the DNA binding domain with the ligand binding domain of RXR alpha were responsible for the high level of 9cRA-dependent transcription observed in MH 3T3 cells, Furthermore, the hinge region of RXR alpha was shown to be necessary to repress, in the absence of hormone, the transcriptional activation function located in the N-terminal domain of RXR alpha. These results stress the importance of functional links between different RXR domains and suggest an RXR subtype and cell type dependent specificity in the control of the 9cRA response.	NIDDK,GENET & BIOCHEM BRANCH,BETHESDA,MD 20892; NICHHD,LAB MOL GROWTH REGULAT,NIH,BETHESDA,MD 20892; DEPT VET AFFAIRS MED CTR,ORAL PATHOL RES LAB,WASHINGTON,DC 20422	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Minucci, Saverio/J-9669-2012					BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN HW, 1995, P NATL ACAD SCI USA, V92, P422, DOI 10.1073/pnas.92.2.422; DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; HALLENBECK PL, 1993, J BIOL CHEM, V268, P3825; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; KEAVENEY M, 1995, INDUCIBLE GENE EXPRE, V2, P182; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LEE M, 1994, SCIENCE, V260, P1117; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MEDIN JA, 1994, MOL CELL ENDOCRINOL, V105, P27, DOI 10.1016/0303-7207(94)90032-9; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	25	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10503	10507		10.1074/jbc.271.18.10503	http://dx.doi.org/10.1074/jbc.271.18.10503			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631847	hybrid			2022-12-25	WOS:A1996UJ34200015
J	Jiang, YH; Yu, VC; Buchholz, F; OConnell, S; Rhodes, SJ; Candeloro, C; Xia, YR; Lusis, AJ; Rosenfeld, MG				Jiang, YH; Yu, VC; Buchholz, F; OConnell, S; Rhodes, SJ; Candeloro, C; Xia, YR; Lusis, AJ; Rosenfeld, MG			A novel family of Cys-Cys, His-Cys zinc finger transcription factors expressed in developing nervous system and pituitary gland	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTOR; THYROID-HORMONE; BINDING-PROTEIN; MAMMALIAN-CELLS; X-RECEPTOR; RXR-BETA; GENE; DNA; SEQUENCE; PURIFICATION	A screen designed to identify proteins that specifically bind to retinoic acid response elements resulted in the identification of a rat cDNA encoding a novel protein containing six Cys-Cys, His-Cys zinc fingers, This gene is expressed in a restricted fashion exhibiting distinct temporal and spatial patterns in the developing nervous system, primarily brain, spinal cord, sensory ganglia, retina, and nasal epithelia, as well as in the pituitary, and is referred to as neural zinc finger factor 1 (NZF-1), NZF-1 binds specifically to a cis-regulatory element of the beta-retinoic acid receptor (RAR beta) gene, as well as to other related DNA elements, including two in the upstream enhancer region of the mouse Pit-1 gene. In heterologous cells, NZF-1 activates transcription from promoters containing specific binding sequences and can synergize with other factors, such as Pit-1, to regulate gene expression, These results suggest that NZF-1 may exert regulatory roles in the developing and mature nervous system and in the pituitary gland, Identification of a second mouse gene highly homologous to NZF-1, encoded by a distinct genomic locus, reveals a dispersed gene family encoding proteins containing Cys-Cys, His-Cys motifs.	UNIV CALIF SAN DIEGO,SCH MED,HOWARD HUGHES MED INST,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Buchholz, Frank/B-4700-2017; Yu, Victor/A-7899-2015	Buchholz, Frank/0000-0002-4577-3344; Yu, Victor/0000-0003-3270-4734				BERG JM, 1990, J BIOL CHEM, V265, P6513; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EMESON RB, 1989, NATURE, V341, P76, DOI 10.1038/341076a0; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HENDERSON LE, 1981, J BIOL CHEM, V256, P8400; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KIM JG, 1992, MOL CELL BIOL, V12, P5632, DOI 10.1128/MCB.12.12.5632; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MILLER J, 1985, EMBO J, V4, P2961; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; TREISMAN J, 1989, NATURE, V341, P335, DOI 10.1038/341335a0; WARDEN CH, 1993, GENOMICS, V18, P295, DOI 10.1006/geno.1993.1469; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	30	57	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10723	10730		10.1074/jbc.271.18.10723	http://dx.doi.org/10.1074/jbc.271.18.10723			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631881	hybrid			2022-12-25	WOS:A1996UJ34200049
J	Tozzo, E; Kahn, BB; Pilch, PF; Kandror, KV				Tozzo, E; Kahn, BB; Pilch, PF; Kandror, KV			Glut4 is targeted to specific vesicles in adipocytes of transgenic mice overexpressing Glut4 selectively in adipose tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-STIMULATED TRANSLOCATION; REGULATABLE GLUCOSE TRANSPORTER; ISOLATED RAT ADIPOCYTES; INTRACELLULAR SEQUESTRATION; SUBCELLULAR TRAFFICKING; NH2 TERMINUS; 3T3-L1 CELLS; PROTEINS; IDENTIFICATION; LOCALIZATION	Adipocytes of transgenic mice overexpressing Glut4 selectively in adipose tissue (Shepherd, P. R., Gnudi, L., Tozzo, E., Yang, H., Leach, F., and Kahn, B. B. (1993) J. Biol. Chem, 268, 22243-22246) have 15-20-fold more Glut4 than normal adipocytes. To study compartmentalization of intracellular Glut4 in these cells, we fractionated light microsomes prepared from transgenic and normal adipocytes in velocity and density sucrose gradients, Glut4-containing intracellular membranes from both cell types have a specific and narrow distribution in these gradients, i.e. behave as homogeneous vesicles with identical sedimentation coefficients and different buoyant densities, Immunoadsorption of Glut4-containing vesicles with covalently immobilized monoclonal anti-transporter antibody demonstrated that the total polypeptide composition of these vesicles from transgenic and normal cells was identical, with the exception of Glut4 itself, which was much more abundant in the transgenic cells. Both preparations also had comparable levels of secretory carrier membrane proteins and of aminopeptidase activity (gp160). Glut4-containing vesicles from both normal and transgenic adipocytes excluded Glut1, which in both cell types formed a different vesicle population, Thus, even under conditions of high level overexpression, Glut4 is still specifically targeted to the same unique type of structurally defined insulin sensitive vesicles as in normal cells.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,DIABET UNIT,BOSTON,MA 02215	Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School				Pilch, Paul/0000-0003-1997-0499; Kandror, Konstantin/0000-0002-8601-9313	NIDDK NIH HHS [P30 DK-46200, DK-30425, R01 DK043051, DK-43051] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030425, R01DK043051, P30DK046200, R37DK043051] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASANO T, 1992, J BIOL CHEM, V267, P19636; BELL GI, 1993, J BIOL CHEM, V268, P19161; BIRNBAUM MJ, 1992, INT REV CYTOL, V137A, P239; CZECH MP, 1993, J BIOL CHEM, V268, P9187; CZECH MP, 1993, J CELL BIOL, V123, P127, DOI 10.1083/jcb.123.1.127; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; HOLMAN GD, 1994, BIOESSAYS, V16, P753, DOI 10.1002/bies.950161010; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; JAMES DE, 1994, J CELL BIOL, V126, P1123, DOI 10.1083/jcb.126.5.1123; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KANDROR K, 1994, J BIOL CHEM, V269, P138; KANDROR KV, 1995, J CELL BIOL, V129, P999, DOI 10.1083/jcb.129.4.999; KANDROR KV, 1994, J BIOL CHEM, V269, P30777; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Little G H, 1976, Methods Enzymol, V45, P495; MARSHALL BA, 1993, J BIOL CHEM, V268, P26193; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; PIPER RC, 1992, J CELL BIOL, V117, P729, DOI 10.1083/jcb.117.4.729; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; SATOH S, 1993, J BIOL CHEM, V268, P17820; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMITH RM, 1991, P NATL ACAD SCI USA, V88, P6893, DOI 10.1073/pnas.88.15.6893; STEPHENS JM, 1995, ENDOCR REV, V16, P529, DOI 10.1210/er.16.4.529; THOIDIS G, 1993, J BIOL CHEM, V268, P11691; TOZZO E, 1995, AM J PHYSIOL-ENDOC M, V268, pE956, DOI 10.1152/ajpendo.1995.268.5.E956; VERHEY KJ, 1993, J CELL BIOL, V123, P137, DOI 10.1083/jcb.123.1.137; YANG J, 1993, J BIOL CHEM, V268, P4600; YANG J, 1992, J BIOL CHEM, V267, P10393; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	36	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10490	10494		10.1074/jbc.271.18.10490	http://dx.doi.org/10.1074/jbc.271.18.10490			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631845	hybrid			2022-12-25	WOS:A1996UJ34200013
J	Annunziato, F; Manetti, R; Tomasevic, L; Giudizi, MG; Biagiotti, R; Gianno, V; Germano, P; Mavilia, C; Maggi, E; Romagnani, S				Annunziato, F; Manetti, R; Tomasevic, L; Giudizi, MG; Biagiotti, R; Gianno, V; Germano, P; Mavilia, C; Maggi, E; Romagnani, S			Expression and release of LAG-3-encoded protein by human CD4(+) T cells are associated with IFN-gamma production	FASEB JOURNAL			English	Article						membrane LAG-3; soluble LAG-3; human Th1/Th2 cells; IL-4; IFN-gamma	TUMOR-NECROSIS-FACTOR; CYTOKINE PRODUCTION; HUMAN TH1; HELPER; ACTIVATION; RECEPTOR; PROFILE; CLONES	The lymphocyte activation gene (LAG)-3 is a member of the immunoglobulin superfamily that is selectively transcribed in human activated T and NK cells, In this wort, the possibility that LAG-3 expression by human CD4(+) T cells was preferentially related to one or another phenotype of cytokine secretion was investigated, Surface LAG-3 expression correlated with IFN-gamma, but not IL-4, production in antigen-stimulated T cells and it was upregulated by IL-12, Most activated CD4(+) T cell clones with established Th1 or Th0 profiles of cytokine secretion expressed LAG-3 on their surface, whereas the great majority of Th2 clones showed neither surface LAG-3 nor LAG-3 mRNA expression, After activation, the majority of CD4+ T cell clones also released soluble LAG-3-related peptides, and such a release correlated positively with the production of IFN-gamma and inversely with the production of IL-4. Thus, LAG-3 expression by activated CD4+ human T cells appear to be preferentially associated with the differentiation/activation pathway leading to the production of IFN-gamma.	UNIV FLORENCE,IST CLIN MED 3,CATTEDRA IMMUNOL CLIN & ALLERGOL,SERV IMMUNOALLERGOL,I-50134 FLORENCE,ITALY	University of Florence			Annunziato, Francesco/C-1155-2013; Maggi, Enrico/AAA-8045-2019	Maggi, Enrico/0000-0002-1824-3583; Annunziato, Francesco/0000-0001-8798-7589				BAIXERAS E, 1992, J EXP MED, V176, P327, DOI 10.1084/jem.176.2.327; CAPPIO FC, 1995, CLIN EXP RHEUMATOL, V13, P339; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; DELPRETE G, 1995, J EXP MED, V182, P1655, DOI 10.1084/jem.182.6.1655; DELPRETE G, 1995, FASEB J, V9, P81, DOI 10.1096/fasebj.9.1.7821763; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; GRIFFIN DE, 1993, J INFECT DIS, V168, P275, DOI 10.1093/infdis/168.2.275; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HUARD B, 1995, EUR J IMMUNOL, V25, P2718, DOI 10.1002/eji.1830250949; HUARD B, 1994, IMMUNOGENETICS, V39, P213; HUARD B, 1994, EUR J IMMUNOL, V24, P3216, DOI 10.1002/eji.1830241246; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; MAGGI E, 1995, IMMUNITY, V3, P251, DOI 10.1016/1074-7613(95)90094-2; MAGGI E, 1992, J IMMUNOL, V148, P2142; MANETTI R, 1994, J EXP MED, V179, P1273, DOI 10.1084/jem.179.4.1273; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MILLS JA, 1994, NEW ENGL J MED, V330, P1871, DOI 10.1056/NEJM199406303302608; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PICCINNI MP, 1995, J IMMUNOL, V155, P128; PIZZOLO G, 1994, AIDS, V8, P741, DOI 10.1097/00002030-199406000-00003; ROMAGNANI S, 1995, J LEUKOCYTE BIOL, V57, P726, DOI 10.1002/jlb.57.5.726; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; SCHANDENE L, 1993, EUR J IMMUNOL, V23, P56, DOI 10.1002/eji.1830230110; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SELMAJ K, 1991, J CLIN INVEST, V87, P949, DOI 10.1172/JCI115102; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SWAIN SL, 1993, RES IMMUNOL, V144, P616, DOI 10.1016/S0923-2494(05)80013-6; TRIEBEL F, 1990, J EXP MED, V171, P1393, DOI 10.1084/jem.171.5.1393; VANDERHEIJDEN FL, 1991, J INVEST DERMATOL, V97, P389, DOI 10.1111/1523-1747.ep12480966	32	77	83	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	MAY	1996	10	7					769	776		10.1096/fasebj.10.7.8635694	http://dx.doi.org/10.1096/fasebj.10.7.8635694			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UN798	8635694				2022-12-25	WOS:A1996UN79800011
J	Bouziane, M; Cherny, DI; Mouscadet, JF; Auclair, C				Bouziane, M; Cherny, DI; Mouscadet, JF; Auclair, C			Alternate strand DNA triple helix-mediated inhibition of HIV-1 U5 long terminal repeat integration in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-MICROSCOPY; ESCHERICHIA-COLI; INVITRO ASSAY; DUPLEX DNA; RECOGNITION; PROTEIN; OLIGONUCLEOTIDES; OXAZOLOPYRIDOCARBAZOLE; ANALOGS; BINDING	Integration of the human immunodeficiency virus (HIV) DNA into the host genome is an obligatory process in the replicative life cycle of the virus. This event is mediated in vitro by integrase, a viral protein which binds to specific sequences located on both extremities of the DNA long terminal repeats (LTRs). These sites are highly conserved in all HIV genomes and thus provide potential targets for the selective inhibition of integration. The integrase-binding site located on the HIV-1 U5 LTR end contains two adjacent purine tracts on opposite strands, 5'... GGAAAATCTCT-3'/3'-CCTTTTA- GAGA.,,5', in parallel orientations. A single strand oligonucleotide 5'-GGTTTTTGTGT-3' was designed to associate with these tracts via its ability to form a continuous alternate strand DNA tripler. Under neutral pH and physiological temperature, the oligonucleotide, tagged with an intercalator chromophore oxazolopyridocarbazole, formed a stable tripler with the target DNA. The occurrence of this unusual tripler was demonstrated by both DNase I footprinting and electron microscopy. The tripler inhibits the two steps of the integrase-mediated reactions, namely, the endonucleolytic cleavage of the dinucleotide 5'-GT-3' from the 3' end of the integration substrate and the integration of the substrate into the heterologous target DNA. The midpoints for both inhibition reactions were observed at oligonucleotide concentrations of 50-100 nM. We believe that these results open new possibilities for the specific targeting of viral DNA LTR ends with the view of inhibiting integration under physiological conditions.	INST GUSTAVE ROUSSY, LAB PHYSICOCHIM & PHARMACOL MACROMOL BIOL, CNRS URA 147, F-94805 VILLEJUIF, FRANCE	UNICANCER; Gustave Roussy								AUCLAIR C, 1984, J MED CHEM, V27, P1161, DOI 10.1021/jm00375a013; BEAL PA, 1992, J AM CHEM SOC, V114, P4979; BROWN PO, 1990, CURR TOP MICROBIOL, V157, P19; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; CARTEAU S, 1993, ARCH BIOCHEM BIOPHYS, V300, P756, DOI 10.1006/abbi.1993.1105; CARTEAU S, 1994, BIOCHEM PHARMACOL, V47, P1821, DOI 10.1016/0006-2952(94)90311-5; CARTEAU S, 1993, ARCH BIOCHEM BIOPHYS, V305, P606, DOI 10.1006/abbi.1993.1468; CARTEAU S, 1993, BIOCHEM BIOPH RES CO, V192, P1409, DOI 10.1006/bbrc.1993.1573; CAZENAVE C, 1991, ANTISENSE NUCLEIC AC, P47; Cherney Dmitry I., 1994, Journal of Molecular Recognition, V7, P171, DOI 10.1002/jmr.300070304; CHERNY DI, 1993, J MOL BIOL, V230, P379, DOI 10.1006/jmbi.1993.1154; CRAIGIE R, 1991, NUCLEIC ACIDS RES, V19, P2729, DOI 10.1093/nar/19.10.2729; CUSHMAN M, 1992, BIOCHEM BIOPH RES CO, V185, P85, DOI 10.1016/S0006-291X(05)80958-1; CUSHMAN M, 1995, J MED CHEM, V38, P443, DOI 10.1021/jm00003a007; DELAIN E, 1992, MICROSC MICROANAL M, V3, P175, DOI 10.1051/mmm:0199200302-3017500; Delain E, 1995, VISUALIZATION NUCL A, P35; DEMIDOV VV, 1994, NUCLEIC ACIDS RES, V22, P5218, DOI 10.1093/nar/22.24.5218; DUBOCHET J, 1971, J ULTRA MOL STRUCT R, V35, P147, DOI 10.1016/S0022-5320(71)80148-X; FESEN MR, 1993, P NATL ACAD SCI USA, V90, P2399, DOI 10.1073/pnas.90.6.2399; GAUTIER C, 1987, NUCLEIC ACIDS RES, V15, P6625, DOI 10.1093/nar/15.16.6625; HORNE DA, 1990, J AM CHEM SOC, V112, P2435, DOI 10.1021/ja00162a063; JAYASENA SD, 1993, BIOCHEMISTRY-US, V32, P2800, DOI 10.1021/bi00062a010; JAYASENA SD, 1992, NUCLEIC ACIDS RES, V20, P5279, DOI 10.1093/nar/20.20.5279; JAYASENA SD, 1992, BIOCHEMISTRY-US, V31, P320, DOI 10.1021/bi00117a002; LAFEMINA RL, 1995, ANTIMICROB AGENTS CH, V39, P320, DOI 10.1128/AAC.39.2.320; MAZUMDER A, 1995, AIDS RES HUM RETROV, V11, P115, DOI 10.1089/aid.1995.11.115; MOUSCADET JF, 1994, J BIOL CHEM, V269, P21635; MOUSCADET JF, 1994, BIOCHEMISTRY-US, V33, P4187, DOI 10.1021/bi00180a011; OLIVAS WM, 1994, BIOCHEMISTRY-US, V33, P983, DOI 10.1021/bi00170a017; ONO A, 1991, BIOCHEMISTRY-US, V30, P9914, DOI 10.1021/bi00105a015; SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119; SHERMAN PA, 1992, J VIROL, V66, P3593, DOI 10.1128/JVI.66.6.3593-3601.1992; SUBRA F, 1993, BIOCHEM PHARMACOL, V45, P93, DOI 10.1016/0006-2952(93)90381-6; SUN JS, 1991, CR ACAD SCI III-VIE, V313, P585; SUN JS, 1995, JERUS SYM Q, V27, P267; THUONG NT, 1993, ANGEW CHEM INT EDIT, V32, P666, DOI 10.1002/anie.199306661; TSO POP, 1992, ANN NY ACAD SCI, V660, P159; VINCENT KA, 1993, J VIROL, V67, P425, DOI 10.1128/JVI.67.1.425-437.1993; WASHBROOK E, 1994, NUCLEIC ACIDS RES, V22, P3977, DOI 10.1093/nar/22.19.3977; WASHBROOK E, 1994, BIOCHEM J, V301, P569, DOI 10.1042/bj3010569; WILLIAMSON JR, 1990, NUCLEIC ACIDS RES, V18, P379, DOI 10.1093/nar/18.2.379	41	35	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10359	10364		10.1074/jbc.271.17.10359	http://dx.doi.org/10.1074/jbc.271.17.10359			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626607	hybrid			2022-12-25	WOS:A1996UG25700079
J	Mikusova, K; Mikus, M; Besra, GS; Hancock, I; Brennan, PJ				Mikusova, K; Mikus, M; Besra, GS; Hancock, I; Brennan, PJ			Biosynthesis of the linkage region of the mycobacterial cell wall	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEICHOIC-ACID; STRUCTURAL FEATURES; PEPTIDOGLYCAN; TUBERCULOSIS; ARABINOGALACTAN; SMEGMATIS; ANTIGENICITY; TUNICAMYCIN; INHIBITION; NOCARDIA	The ''core'' structure of the cell wall of Mycobacterium and related genera is unique among prokaryotes, consisting of a covalently linked complex of mycolic acids, D-arabinan and D-galactan (mycolylarabinogalactan, mAG), which, in turn, is linked to peptidoglycan via a special linkage unit, -alpha-L-Rhap(1-->3)-D-GlcNAc-P-. Little is known of the biosynthesis of this complex, although it is the site of action of several common anti-tuberculosis drugs. Isolated cell membranes of Mycobacterium smegmatis catalyzed the incorporation of [C-14]GlcNAc from UDP-[C-14]GlcNAc into two glycolipids (1 and 2) and of [C-14]Rha from TDP-[C-14]Rha into glycolipid 2. These products were characterized as polyprenol-P-P-GlcNAc (glycolipid 1) and polyprenol-P-P-GlcNAc-Rha (glycolipid 2) based on sensitivity of synthesis to tunicamycin, chromatographic characterization of the products of mild acid hydrolysis, and mass spectral analysis of the glycosyl and polyprenyl units. Glycolipids 1 and 2 were shown to be precursors of the linkage unit in polymerized cell wall. The inclusion in the assays of UDP-[C-14]Galp and a preparation of cell walls allowed the incorporation of [C-14]Gal into two further glycolipids (3 and 4). Preliminary evidence indicates a precursor-product relationship among glycolipids 1, 2, 3, and 4. Thus, the first steps in the biosynthesis of the mycobacterial cell wall involve synthesis of the linkage disaccharide on a polyprenyl-P-P carrier followed by growth of the galactan unit. Assays are thus defined for the screening of new anti-tuberculosis drugs active against cell wall synthesis.	COLORADO STATE UNIV, DEPT MICROBIOL, FT COLLINS, CO 80523 USA; UNIV NEWCASTLE UPON TYNE, DEPT MICROBIOL, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND	Colorado State University; Newcastle University - UK			Mikusova, Katarina/I-3622-2014	Besra, Gurdyal/0000-0002-5605-0395	NIAID NIH HHS [AI 30189, AI 18357] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI018357, R01AI018357, U01AI030189, R37AI018357] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Archibald A. R., 1993, P381; Aspinall GO, 1995, ADV CARBOHYD CHEM BI, V51, P169, DOI 10.1016/S0065-2318(08)60194-8; Ballou C, 1976, Adv Microb Physiol, V14, P93, DOI 10.1016/S0065-2911(08)60227-1; BESRA GS, 1995, BIOCHEMISTRY-US, V34, P4257, DOI 10.1021/bi00013a015; BESRA GS, 1994, P NATL ACAD SCI USA, V91, P12735, DOI 10.1073/pnas.91.26.12735; BLOCH AB, 1994, JAMA-J AM MED ASSOC, V271, P665, DOI 10.1001/jama.271.9.665; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; COLEY J, 1978, FEBS LETT, V88, P1, DOI 10.1016/0014-5793(78)80594-8; DAFFE M, 1990, J BIOL CHEM, V265, P6734; DAFFE M, 1993, CARBOHYD RES, V249, P383, DOI 10.1016/0008-6215(93)84102-C; DAWSON RMC, 1959, DATA BIOCH RES, P470; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; DITTMER JC, 1964, J LIPID RES, V5, P126; DUNPHY PJ, 1966, CHEM IND-LONDON, P1549; FOLCH J, 1957, J BIOL CHEM, V226, P497; FUJIOKA M, 1985, J GEN MICROBIOL, V131, P1323; HANCOCK IC, 1976, FEBS LETT, V69, P75, DOI 10.1016/0014-5793(76)80657-6; HIRSCHFIELD GR, 1990, J BACTERIOL, V172, P1005, DOI 10.1128/jb.172.2.1005-1013.1990; KANETSUNA F, 1970, BIOCHIM BIOPHYS ACTA, V208, P434; KNO SC, 1974, BIOCHEM BIOPH RES CO, V58, P287; KOJIMA N, 1983, J BIOL CHEM, V258, P9043; KOJIMA N, 1985, J BACTERIOL, V161, P299, DOI 10.1128/JB.161.1.299-306.1985; LEHLE L, 1980, EUR J BIOCHEM, V109, P589, DOI 10.1111/j.1432-1033.1980.tb04832.x; LIU TY, 1967, J BIOL CHEM, V242, P471; LUNDBLAD A, 1975, BIOMED MASS SPECTROM, V2, P285, DOI 10.1002/bms.1200020602; MCARTHUR HAI, 1980, FEBS LETT, V111, P317, DOI 10.1016/0014-5793(80)80818-0; MCNEIL M, 1990, J BIOL CHEM, V265, P18200; MCNEIL M, 1991, J BIOL CHEM, V266, P13217; MCNEIL M, 1987, J BIOL CHEM, V262, P2630; MCNEIL M, 1989, METHOD ENZYMOL, V179, P215; MCNEIL MR, 1991, RES MICROBIOL, V142, P451, DOI 10.1016/0923-2508(91)90120-Y; MIKUSOVA K, 1995, ANTIMICROB AGENTS CH, V39, P2484, DOI 10.1128/AAC.39.11.2484; OKAZAKI R, 1962, J BIOL CHEM, V237, P3014; SARVAS M, 1971, J BACTERIOL, V105, P1063, DOI 10.1128/JB.105.3.1063-1072.1971; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SCHULTZ J, 1974, ARCH BIOCHEM BIOPHYS, V160, P311, DOI 10.1016/S0003-9861(74)80039-1; SCHULTZ JC, 1975, BIOCHIM BIOPHYS ACTA, V381, P175, DOI 10.1016/0304-4165(75)90199-3; STEVENSON G, 1994, J BACTERIOL, V176, P4144, DOI 10.1128/JB.176.13.4144-4156.1994; TAKATSUKI A, 1975, AGR BIOL CHEM TOKYO, V39, P2089, DOI 10.1080/00021369.1975.10861914; TAKAYAMA K, 1973, BIOCHIM BIOPHYS ACTA, V316, P212, DOI 10.1016/0005-2760(73)90011-8; TAKAYAMA K, 1970, J BIOL CHEM, V245, P6251; TAKAYAMA K, 1975, J LIPID RES, V16, P308; TREJO AG, 1970, BIOCHEM J, V117, P637, DOI 10.1042/bj1170637; WARD JB, 1977, FEBS LETT, V78, P151, DOI 10.1016/0014-5793(77)80294-9; WHEELER PR, 1993, BIOCHIM BIOPHYS ACTA, V1167, P182, DOI 10.1016/0005-2760(93)90160-B; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328; YAMAMORI S, 1978, J BIOL CHEM, V254, P6516	48	130	137	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7820	7828		10.1074/jbc.271.13.7820	http://dx.doi.org/10.1074/jbc.271.13.7820			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631826	hybrid			2022-12-25	WOS:A1996UC77400094
J	Graziani, A; Galimi, F; Medico, E; Cottone, E; Gramaglia, D; Boccaccio, C; Comoglio, PM				Graziani, A; Galimi, F; Medico, E; Cottone, E; Gramaglia, D; Boccaccio, C; Comoglio, PM			The HIV-1 Nef protein interferes with phosphatidylinositol 3-kinase activation 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; GROWTH-FACTOR RECEPTOR; SIGNAL TRANSDUCTION; TRANSGENIC MICE; GENE	nef is a human immunodeficiency virus (HIV) gene encoding a 27-kDa myristoylated protein with structural features of a signal transducing molecule, but whose functions are largely unknown. We studied the interactions of Nef with the signal transduction pathways triggered by the platelet-derived growth factor (PDGF) receptor. The association of phosphatidylinositol (PI) S-kinase with the activated receptor was severely impaired by nef expression. Conversely, PDGF-induced receptor tyrosine phosphorylation, binding to phospholipase C-gamma and to Res-GAP were not modified. Microtubule-associated protein kinase activation and intracellular calcium influx in response to PDGF were either unaffected or only slightly enhanced. Nef significantly reduced the proliferative response to the growth factor, white the chemotactic response was unchanged. These data show that Nef affects selectively the PI 3-kinase signaling pathway and suggest that this interference results in some of the HIV adverse effects on host cell functions.	UNIV TURIN,SCH MED,INST CANC RES & TREATMENT,I-10126 TURIN,ITALY	University of Turin			Graziani, Andrea/AAB-6301-2022; Medico, Enzo/AAC-3185-2021; GRAMAGLIA, DANIELA/A-6354-2012; Galimi, Francesco/J-4238-2012; graziani, andrea/B-2554-2009; Boccaccio, Carla/AHE-7875-2022	Graziani, Andrea/0000-0002-6302-2317; Medico, Enzo/0000-0002-3917-2438; graziani, andrea/0000-0002-6302-2317; Boccaccio, Carla/0000-0003-2620-9083; Comoglio, Paolo/0000-0002-7056-5328; Gramaglia, Daniela/0000-0001-6259-0059				BANDRES JC, 1994, J VIROL, V68, P3243, DOI 10.1128/JVI.68.5.3243-3249.1994; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; BERK BC, 1986, SCIENCE, V232, P87, DOI 10.1126/science.3485309; BRADY HJM, 1993, EMBO J, V12, P4923, DOI 10.1002/j.1460-2075.1993.tb06186.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHOWERS MY, 1994, J VIROL, V68, P2906, DOI 10.1128/JVI.68.5.2906-2914.1994; CONNOR JA, 1987, J BIOL CHEM, V262, P2919; DE SK, 1994, J BIOL CHEM, V269, P6656; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DU ZJ, 1995, CELL, V82, P665, DOI 10.1016/0092-8674(95)90038-1; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GREENWAY A, 1995, J VIROL, V69, P1842, DOI 10.1128/JVI.69.3.1842-1850.1995; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LURIA S, 1991, P NATL ACAD SCI USA, V88, P5326, DOI 10.1073/pnas.88.12.5326; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; NEIDERMAN TM, 1993, VIROLOGY, V197, P420; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; SAWAI ET, 1994, P NATL ACAD SCI USA, V91, P1539, DOI 10.1073/pnas.91.4.1539; SKOWRONSKI J, 1993, EMBO J, V12, P703, DOI 10.1002/j.1460-2075.1993.tb05704.x; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; TRONO D, 1995, CELL, V82, P189, DOI 10.1016/0092-8674(95)90306-2; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZAZOPOULOS E, 1993, VIROLOGY, V194, P20, DOI 10.1006/viro.1993.1230; ZAZOPOULOS E, 1992, P NATL ACAD SCI USA, V89, P6634, DOI 10.1073/pnas.89.14.6634	32	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6590	6593		10.1074/jbc.271.12.6590	http://dx.doi.org/10.1074/jbc.271.12.6590			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636073	hybrid			2022-12-25	WOS:A1996UB15700008
J	Lee, JH; Jang, SI; Yang, JM; Markova, NG; Steinert, PM				Lee, JH; Jang, SI; Yang, JM; Markova, NG; Steinert, PM			The proximal promoter of the human transglutaminase 3 gene - Stratified squamous epithelial-specific expression in cultured cells is mediated by binding of Sp1 and ets transcription factors to a proximal promoter element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL TRANSGLUTAMINASE; HAIR FOLLICLE TRANSGLUTAMINASES; AMINO-ACID-SEQUENCE; KERATINOCYTE TRANSGLUTAMINASE; TRANSGENIC MICE; RETINOIC ACID; GUINEA-PIG; PROTRANSGLUTAMINASE-E; ENVELOPE PRECURSOR; HUMAN LORICRIN	The transglutaminase 3 enzyme is expressed during the late stages of the terminal differentiation of the epidermis and in certain cell types of the hair follicle. The enzyme is thought to be critically involved in the crosslinking of structural proteins and in the formation of the cornified cell envelope, thereby contributing to rigid structures that play vital roles in shape determination and/or barrier functions. To explore the mechanisms regulating the expression of the transglutaminase 3 gene (TGM3), 3.0 kilobase pairs of sequences upstream from the transcription start site were assessed for their ability to control the expression of a chloramphenicol acetyltransferase reporter gene. Deletion analyses in transiently transfected epidermal keratinocytes defined sequences between -126 and -91 as the proximal promoter region of the gene, and which can confer epithelial-specific expression to the TGM3 gene in vitro. Mutation and DNA-protein binding analyses indicated that a complex interaction between adjacent Sp1- and ets-like recognition motifs with their cognate binding factors is required for the function of the TGM3 promoter. As these TGM3 sequences can confer promoter/enhancer activity to reporter genes at a level comparable to the powerful SV40 promoter, they may be useful for gene therapy in keratinocytes.	NIAMS, NIH, SKIN BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)								ANSIEAU S, 1993, GENOMICS, V18, P537, DOI 10.1016/S0888-7543(11)80010-8; AUBER L., 1952, TRANS ROY SOC EDINBURGH, V62, P191; Ausubel FM, 1991, CURRENT PROTOCOLS MO; BIRBECK MSC, 1957, J BIOPHYS BIOCHEM CY, V3, P203, DOI 10.1083/jcb.3.2.203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYRNE C, 1993, MOL CELL BIOL, V13, P3176, DOI 10.1128/MCB.13.6.3176; CANDI E, 1995, J BIOL CHEM, V270, P26382, DOI 10.1074/jbc.270.44.26382; CARDINALI M, 1990, CANCER RES, V50, P8010; CHAKRAVARTY R, 1989, J BIOL CHEM, V264, P625; CHANG SK, 1986, J BIOL CHEM, V261, P8112; CHUNG SI, 1972, ANN NY ACAD SCI, V202, P240, DOI 10.1111/j.1749-6632.1972.tb16338.x; CHUNG SI, 1972, P NATL ACAD SCI USA, V69, P303, DOI 10.1073/pnas.69.2.303; CURTIS CG, 1974, BIOCHEMISTRY-US, V13, P3257, DOI 10.1021/bi00713a012; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; DITTMER J, 1994, J BIOL CHEM, V269, P21428; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; FIETZ MJ, 1993, J CELL BIOL, V121, P855, DOI 10.1083/jcb.121.4.855; FLOYD EE, 1989, MOL CELL BIOL, V9, P4846, DOI 10.1128/MCB.9.11.4846; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GENTILE V, 1991, J BIOL CHEM, V266, P478; GENTILE V, 1992, J CELL BIOL, V56, P170; GRECO MA, 1995, J INVEST DERMATOL, V104, P204, DOI 10.1111/1523-1747.ep12612759; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; JANG SI, 1995, J INVEST DERMATOL, V104, P676; JETTEN AM, 1986, J BIOL CHEM, V261, P5097; KIM HC, 1990, J BIOL CHEM, V265, P21971; KIM HC, 1991, J BIOL CHEM, V266, P536; KIM IG, 1993, J BIOL CHEM, V268, P12682; KIM IG, 1992, J BIOL CHEM, V267, P7710; KIM IG, 1994, J INVEST DERMATOL, V103, P137, DOI 10.1111/1523-1747.ep12392470; KIM SY, 1995, J BIOL CHEM, V270, P18026, DOI 10.1074/jbc.270.30.18026; LEE SC, 1993, J BIOL CHEM, V268, P12164; LICHTI U, 1988, CANCER RES, V48, P74; LICHTI U, 1991, ANN NY ACAD SCI, V642, P82; LICHTI U, 1985, J BIOL CHEM, V260, P1422; LIEW FM, 1992, EXP CELL RES, V202, P310, DOI 10.1016/0014-4827(92)90080-R; LU S, 1995, J BIOL CHEM, V270, P9748, DOI 10.1074/jbc.270.17.9748; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARKOVA NG, 1993, MOL CELL BIOL, V13, P613, DOI 10.1128/MCB.13.1.613; MARVIN KW, 1992, P NATL ACAD SCI USA, V89, P11026, DOI 10.1073/pnas.89.22.11026; NEGI M, 1985, J INVEST DERMATOL, V85, P75, DOI 10.1111/1523-1747.ep12275357; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; OGAWA H, 1976, J BIOL CHEM, V251, P7281; Ohtsuki Mamitaro, 1993, Gene Expression, V3, P201; PETERSON LL, 1984, MOL CELL BIOCHEM, V58, P99, DOI 10.1007/BF00240609; PHILLIPS MA, 1990, P NATL ACAD SCI USA, V87, P9333, DOI 10.1073/pnas.87.23.9333; PHILLIPS MA, 1992, J BIOL CHEM, V267, P2282; POLAKOWSKA RR, 1992, P NATL ACAD SCI USA, V89, P4476, DOI 10.1073/pnas.89.10.4476; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; Reichert Uwe, 1993, P107; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; ROOP D, 1995, SCIENCE, V267, P474, DOI 10.1126/science.7529942; ROTHNAGEL JA, 1986, J CELL BIOL, V102, P1419, DOI 10.1083/jcb.102.4.1419; RUSSELL LJ, 1994, AM J HUM GENET, V55, P1146; RUSSELL LJ, 1995, NAT GENET, V9, P279, DOI 10.1038/ng0395-279; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT R, 1988, J INVEST DERMATOL, V90, P475, DOI 10.1111/1523-1747.ep12460936; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Steinert P M, 1995, Cell Death Differ, V2, P33; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; STEINERT PM, 1971, J INVEST DERMATOL, V56, P49, DOI 10.1111/1523-1747.ep12291902; STEVEN AC, 1994, J CELL SCI, V107, P693; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; VASYLYK B, 1993, EUR J BIOCHEM, V211, P7; WANG M, 1994, GENOMICS, V23, P721, DOI 10.1006/geno.1994.1571; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; YAMADA K, 1994, BIOCHEM MOL BIOL INT, V34, P827; YAMANISHI K, 1992, J BIOL CHEM, V267, P17858; YONEDA K, 1992, J BIOL CHEM, V267, P18060; YONEDA K, 1993, P NATL ACAD SCI USA, V90, P10754, DOI 10.1073/pnas.90.22.10754; ZHANG LX, 1995, J BIOL CHEM, V270, P6022, DOI 10.1074/jbc.270.11.6022	75	90	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4561	4568						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626812				2022-12-25	WOS:A1996TW96000090
J	Li, XQ; Coffino, P				Li, XQ; Coffino, P			Identification of a region of p53 that confers lability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; CELLULAR TUMOR-ANTIGEN; ORNITHINE DECARBOXYLASE; INTRACELLULAR DEGRADATION; E6 ONCOPROTEIN; INHIBITORY PROTEIN; CELLS; UBIQUITINATION; ASSOCIATION; PROTEOLYSIS	Degradation provides one means for controlling the cellular level of the p53 tumor suppressor. Here we have determined a structural element of p53 required for degradation. To create a substrate amenable to in vitro analysis of proteolysis, we appended to p53 the N terminus of antizyme, a protein that binds to and induces degradation of mammalian ornithine decarboxylase (ODC). We found using deletion analysis that an element within amino acids 100-150 is required for degradation of the fusion protein. A monoclonal antibody (PAb246) that binds close to this region prevents the degradation induced by human papillomavirus 16 E6 protein. Furthermore, we found that amino acids 100-150 of p53 can function as an independent domain to induce Trypanosoma brucei ODC, a stable protein, to be degraded in vivo or, by cooperating with an antizyme binding domain of ODC, to confer polyamine-dependent regulation.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	Li, XQ (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143, USA.			Coffino, Philip/0000-0003-0344-5083	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045335] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM45335] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; BLUMENFELD N, 1994, J BIOL CHEM, V269, P9574; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FONG WF, 1976, BIOCHIM BIOPHYS ACTA, V428, P456, DOI 10.1016/0304-4165(76)90054-4; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; GHODA L, 1992, MOL CELL BIOL, V12, P2178, DOI 10.1128/MCB.12.5.2178; GHODA L, 1990, J BIOL CHEM, V265, P11823; GLASS JR, 1987, J CELL PHYSIOL, V130, P133, DOI 10.1002/jcp.1041300119; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HELLER JS, 1976, P NATL ACAD SCI USA, V73, P1858, DOI 10.1073/pnas.73.6.1858; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI X, 1990, MOL CELL BIOL, V12, P3556; LI XQ, 1993, MOL CELL BIOL, V13, P2377, DOI 10.1128/MCB.13.4.2377; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; Li XQ, 1996, J BIOL CHEM, V271, P4441; LOETSCHER P, 1991, J BIOL CHEM, V266, P11213; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1992, BIOCHEM J, V283, P661, DOI 10.1042/bj2830661; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; RUSSNAK R, 1990, GENE DEV, V4, P764, DOI 10.1101/gad.4.5.764; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SEELY JE, 1983, J BIOL CHEM, V258, P2496; STEGLICH C, 1982, J BIOL CHEM, V257, P4603; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	41	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4447	4451						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626797				2022-12-25	WOS:A1996TW96000075
J	Regan, LM; OBrien, LM; Beattie, TL; Sudhakar, K; Walker, FJ; Fay, PJ				Regan, LM; OBrien, LM; Beattie, TL; Sudhakar, K; Walker, FJ; Fay, PJ			Activated protein C-catalyzed proteolysis of factor VIIIa alters its interactions within factor xase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE FACTOR-VIII; FACTOR-VA; FACTOR-IXA; BLOOD-COAGULATION; A1/A3-C1-C2 DIMER; LIGHT-CHAIN; A2 SUBUNIT; INACTIVATION; THROMBIN; BINDING	Factor VIIIa, the cofactor for the factor IXa-dependent conversion of factor X to factor Xa, is proteolytically inactivated by activated protein C (APC), APC cleaves at two sites in factor VIIIa, Arg(336), near the C terminus of the A1 subunit; and Arg(562), bisecting the A2 subunit (Fay, P., Smudzin, T., and Walker, F. (1991) J. Biol. Chem. 266, 20139-20145), Factor VIIIa increased the fluorescence anisotropy of fluorescein-Phe Phe Arg factor IXa (Fl-FFR-FIXa; K-d = 42.4 nM), whereas cleavage of factor VIIIa by APC eliminated this property, Isolation of the APC-cleaved A1/A3-C1-C2 dimer (A1(336)/A3-C1-C2), and the fragments derived from cleaved A2 subunit (A2(N)/A2(C)), permitted dissection of the roles of individual cleavages in cofactor inactivation, Intact A1/A3-C1-C2 dimer increased Fl-FFR-FIXa anisotropy and bound factor X in a solid phase assay, while these activities were absent in the A1(336)/A3-C1-C2. However, the residues removed by this cleavage, Met(337)-Arg(372), did not directly participate in these functions since neither a synthetic peptide to this sequence nor an anti-peptide polyclonal antibody blocked these activities using intact dimer, CD spectral analysis of the intact and truncated dimers indicated reduced alpha and/or beta content in the latter, The A1/A3-C1-C2 dimer plus A2 subunit reconstitutes cofactor activity and produced a factor VIIIa-like effect on the anisotropy of Fl-FFR-FIXa, However, when A2 was replaced by the A2(N)/A2(C) fragments, the resulting fluorescence signal was equivalent to that observed with the dimer alone, These results indicate that APC inactivates the cofactor at two levels within the intrinsic factor Xase complex, Cleavage of either subunit modulates the factor IXa active site, suggesting an essential synergy of interactive sites in factor VIIIa, Furthermore, cleavage of the A1 site alters the conformation of a factor X binding site within that subunit, thereby reducing the affinity of cofactor for substrate.	UNIV ROCHESTER,MED CTR,SCH MED,DEPT MED,HEMATOL UNIT,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV CONNECTICUT,HLTH SCI CTR,AMER RED CROSS,BLOOD SERV,FARMINGTON,CT 06032; UNIV CONNECTICUT,HLTH SCI CTR,DEPT MED,FARMINGTON,CT 06032; UNIV CONNECTICUT,HLTH SCI CTR,DEPT LAB MED,FARMINGTON,CT 06032	University of Rochester; University of Rochester; American Red Cross; University of Connecticut; University of Connecticut; University of Connecticut					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030616, R01HL038199] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30616, HL 07152, HL 38199] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; BERTINA RM, 1984, BIOCHEM BIOPH RES CO, V125, P177, DOI 10.1016/S0006-291X(84)80351-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASILLAS G, 1971, COAGULATION, V4, P107; CURTIS JE, 1994, J BIOL CHEM, V269, P6246; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FASS DN, 1982, BLOOD, V59, P594; FAY PJ, 1993, J BIOL CHEM, V268, P17861; FAY PJ, 1994, J BIOL CHEM, V269, P20522; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FAY PJ, 1989, BIOCHIM BIOPHYS ACTA, V294, P142; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; KALAFATIS M, 1995, J BIOL CHEM, V270, P4053, DOI 10.1074/jbc.270.8.4053; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; LAMPHEAR BJ, 1992, J BIOL CHEM, V267, P3725; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1994, J CLIN INVEST, V93, P2497, DOI 10.1172/JCI117259; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; MESTERS RM, 1993, BIOCHEMISTRY-US, V32, P12656, DOI 10.1021/bi00210a014; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; NESHEIM ME, 1982, J BIOL CHEM, V257, P1443; OBRIEN LM, 1995, J BIOL CHEM, V270, P27087, DOI 10.1074/jbc.270.45.27087; ODEGAARD B, 1987, J BIOL CHEM, V262, P11233; PITTMAN DD, 1992, BLOOD, V79, P389; REGAN LM, 1995, J BIOL CHEM, V270, P8546, DOI 10.1074/jbc.270.15.8546; REGAN LM, 1994, J BIOL CHEM, V269, P9445; SCANDELLA D, 1993, BLOOD, V82, P1767; TOOLE JJ, 1984, NATURE, V312, P334; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WALKER FJ, 1979, BIOCHIM BIOPHYS ACTA, V571, P333, DOI 10.1016/0005-2744(79)90103-7; WALKER FJ, 1990, J BIOL CHEM, V265, P1484; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	43	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					3982	3987						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626729				2022-12-25	WOS:A1996TW96000007
J	Bennett, BD; Jetton, TL; Ying, GT; Magnuson, MA; Piston, DW				Bennett, BD; Jetton, TL; Ying, GT; Magnuson, MA; Piston, DW			Quantitative subcellular imaging of glucose metabolism within intact pancreatic islets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CELLS; B-CELLS; ELECTRICAL-ACTIVITY; INSULIN-SECRETION; GLUCOKINASE; HETEROGENEITY; STIMULATION; CHANNELS; SENSOR; CA2+	Studies of dispersed beta cells have been used to infer their behavior in the intact pancreatic islet. When dispersed, beta cells exhibit multiple metabolic glucose-response populations with different insulin secretion properties, This has led to a model for glucose-dependent insulin secretion hom the islet based on a step-wise recruitment of individual beta cells. However, previously reported synchronous and uniform Ca2+ activity and electrical responses indicate that beta cell behavior within intact islets is more uniform. Therefore, uncertainty remains whether beta cell metabolic heterogeneity is functionally important in intact islets. We have used two-photon excitation microscopy to measure and compare the glucose-induced NAD(P)H autofluorescence response in dispersed beta cells and within intact islets, Over 90% of beta cells in intact islets responded to glucose with significantly elevated NAD(P)H levels, compared with less than 70% of dispersed beta cells, In addition, all responding beta cells within intact islets exhibited a sigmoidal glucose dose response behavior with inflection points of similar to 8 mM glucose, These results suggest that beta cell heterogeneity may be functionally less important in the intact islet than has been predicted hom studies of dispersed beta cells and support the role of glucokinase as the rate-limiting enzyme in the beta cell glucose response.	VANDERBILT UNIV,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Vanderbilt University			Magnuson, Mark A/B-1335-2009; Magnuson, Mark/AAY-7172-2021	Magnuson, Mark A/0000-0002-8824-6499; Magnuson, Mark/0000-0002-8824-6499	NIDDK NIH HHS [DK42502, DK42612] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042612] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balaban R. S., 1990, NONINVASIVE TECHNIQU, P213; COORE HG, 1964, BIOCHEM J, V93, P66, DOI 10.1042/bj0930066; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Denk Winfried, 1995, P445; DUCHEN MR, 1993, BIOCHEM J, V294, P35, DOI 10.1042/bj2940035; GILON P, 1992, J BIOL CHEM, V267, P20713; HENQUIN JC, 1990, PFLUG ARCH EUR J PHY, V416, P568, DOI 10.1007/BF00382691; JETTON TL, 1992, P NATL ACAD SCI USA, V89, P2619, DOI 10.1073/pnas.89.7.2619; KIEKENS R, 1992, J CLIN INVEST, V89, P117, DOI 10.1172/JCI115551; MALAISSE WJ, 1991, ENDOCRINE PANCREAS, P73; MATSCHIN.FM, 1968, J BIOL CHEM, V243, P2730; MATSCHINSKY F, 1993, J CLIN INVEST, V92, P2092, DOI 10.1172/JCI116809; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MEDA P, 1984, Q J EXP PHYSIOL CMS, V69, P719; PIPELEERS D, 1994, DIABETOLOGIA, V37, pS57, DOI 10.1007/BF00400827; PISTON DW, 1995, J MICROSC SOC AM, V1, P25; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; RANDLE PJ, 1993, DIABETOLOGIA, V36, P269, DOI 10.1007/BF00400227; Sandison David R., 1995, P39; SANTOS RM, 1991, PFLUG ARCH EUR J PHY, V418, P417, DOI 10.1007/BF00550880; SHARP DW, 1973, TRANSPLANTATION, V16, P686; STEFAN Y, 1987, J CLIN INVEST, V80, P175, DOI 10.1172/JCI113045; VANSCHRAVENDIJK CFH, 1992, J BIOL CHEM, V267, P21344	23	156	160	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3647	3651						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631975				2022-12-25	WOS:A1996TV72400049
J	Larson, PJ; StanfieldOakley, SA; VanDusen, WJ; Kasper, CK; Smith, KJ; Monroe, DM; High, KA				Larson, PJ; StanfieldOakley, SA; VanDusen, WJ; Kasper, CK; Smith, KJ; Monroe, DM; High, KA			Structural integrity of the gamma-carboxyglutamic acid domain of human blood coagulation factor IXa is required for its binding to cofactor VIIIa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYLATION RECOGNITION SITE; K-DEPENDENT PROTEINS; X ACTIVATION SYSTEM; HEMOPHILIA-B; MONOCLONAL-ANTIBODIES; MOLECULAR-BASIS; PROPEPTIDE; PROTHROMBIN; INVITRO; METAL	This report describes the analysis of a novel mutant human factor IX protein from a patient with hemophilia B (factor IX activity <1%; factor IX antigen 45%), Enzymatic amplification of all eight exons of the factor IX gene followed by direct sequence analysis reveals a single nucleotide change (a guanine --> adenine transition) in exon 2 at nucleotide 6409 which results in a glycine --> arginine substitution at amino acid 12 in the gamma-carboxyglutamic acid rich (Gla) domain of the mature protein. Factor IX was isolated by immunoaffinity chromatography from plasma obtained from the proband, The purified protein is indistinguishable from normal factor IX by polyacrylamide gel electrophoresis, Characterization of the variant in purified component assays reveals that it is activated normally by its physiologic activator factor XIa, but its phospholipid-dependent activation by the factor VIIa-tissue factor complex is diminished, In the presence of phospholipid and 5 mar Ca2+, the activities of variant and normal plasma-derived factor IX are similar; however, in the presence of activated factor VIIIa (intrinsic tenase complex), the normal augmentation of the cleavage of the specific substrate of factor IX factor X, is not observed. The determination of the association constants for normal and variant factor IXa with factor VIIIa shows that the affinity of the activated variant factor IX for the cofactor factor VIIIa is 172-fold lower than normal, Competition studies using active site-inactivated factor IXas in the intrinsic tenase complex confirm that the defect in the variant protein is in its binding to factor VIIIa. We conclude that the structural integrity of the Gla domain of human factor IX is critical for the normal binding of factor IXa to factor VIIIa in the intrinsic tenase complex, In addition, a glycine at amino acid 12 is necessary for normal activation of factor IX by the factor VIIa-tissue factor complex.	UNIV PENN,DEPT PEDIAT,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PATHOL,PHILADELPHIA,PA 19104; UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,CHAPEL HILL,NC 27599; MERCK & CO INC,W POINT,PA 19486; UNIV NEW MEXICO,DEPT MED,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,DEPT PATHOL,ALBUQUERQUE,NM 87131; UNIV SO CALIF,ORTHOPED HOSP,LOS ANGELES,CA 90007	University of Pennsylvania; University of Pennsylvania; University of North Carolina; University of North Carolina Chapel Hill; Merck & Company; University of New Mexico; University of New Mexico; University of Southern California	Larson, PJ (corresponding author), CHILDRENS HOSP PHILADELPHIA,DIV HEMATOL,324 S 34TH ST,PHILADELPHIA,PA 19104, USA.		High, Katherine A./AAB-9322-2020	Monroe, Dougald/0000-0002-0493-2943	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048322, P01HL006350, F32HL008510] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL48322, NRSA HL08510, P01 HL06350] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEALS JM, 1989, ARCH BIOCHEM BIOPHYS, V268, P485, DOI 10.1016/0003-9861(89)90316-0; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BENTLEY AK, 1986, CELL, V45, P343, DOI 10.1016/0092-8674(86)90319-3; BOROWSKI M, 1985, J BIOL CHEM, V260, P9258; BRAUNSTEIN KM, 1981, J CLIN INVEST, V68, P1420, DOI 10.1172/JCI110393; CHAN V, 1991, BRIT J HAEMATOL, V79, P63, DOI 10.1111/j.1365-2141.1991.tb08008.x; CHEUNG WF, 1992, J BIOL CHEM, V267, P20529; CHURCH WR, 1988, J BIOL CHEM, V263, P6259; CHURCH WR, 1989, J BIOL CHEM, V264, P17882; CURTIS JE, 1994, J BIOL CHEM, V269, P6246; DIUGUID DL, 1986, P NATL ACAD SCI USA, V83, P5803, DOI 10.1073/pnas.83.16.5803; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; FOSTER DC, 1987, BIOCHEMISTRY-US, V26, P7003, DOI 10.1021/bi00396a022; FRAZIER D, 1989, BLOOD, V74, P971; FURIE B, 1990, BLOOD, V75, P1753; GIANNELLI F, 1993, NUCLEIC ACIDS RES, V21, P3075, DOI 10.1093/nar/21.13.3075; GRIFFITH MJ, 1982, THROMB RES, V27, P289, DOI 10.1016/0049-3848(82)90076-7; GRIFFITH MJ, 1985, J CLIN INVEST, V75, P4, DOI 10.1172/JCI111694; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HUBBARD BR, 1989, J BIOL CHEM, V264, P14145; HUBER P, 1990, J BIOL CHEM, V265, P12467; JORGENSEN MJ, 1987, CELL, V48, P185, DOI 10.1016/0092-8674(87)90422-3; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; LOZIER JN, 1990, BLOOD, V75, P1097; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MERTENS K, 1985, THROMB HAEMOSTASIS, V54, P654; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NEUENSCHWANDER PF, 1992, J BIOL CHEM, V267, P14477; ORSTAVIK KH, 1975, THROMB RES, V7, P373, DOI 10.1016/0049-3848(75)90031-6; PRENDERGAST FG, 1977, J BIOL CHEM, V252, P840; PRICE PA, 1987, P NATL ACAD SCI USA, V84, P8335, DOI 10.1073/pnas.84.23.8335; PRZYSIECKI CT, 1987, P NATL ACAD SCI USA, V84, P7856, DOI 10.1073/pnas.84.22.7856; RABIET MJ, 1987, J BIOL CHEM, V262, P14895; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SMITH KJ, 1984, THROMB RES, V33, P211, DOI 10.1016/0049-3848(84)90182-8; SUGIMOTO M, 1988, BRIT J HAEMATOL, V72, P216; ULRICH MMW, 1988, J BIOL CHEM, V263, P9697; VANDIEIJEN G, 1985, THROMB HAEMOSTASIS, V53, P396; WALLMARK A, 1991, BLOOD S1, V78, pA60; WARE J, 1989, J BIOL CHEM, V264, P11401; WATZKE HH, 1990, J BIOL CHEM, V265, P11982; WU SM, 1990, J BIOL CHEM, V265, P13124; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049; ZHANG L, 1992, BLOOD, V80, P942	46	35	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3869	3876						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632006				2022-12-25	WOS:A1996TV72400080
J	Liu, YS; Guyton, KZ; Gorospe, M; Xu, QB; Kokkonen, GC; Mock, YD; Roth, GS; Holbrook, NJ				Liu, YS; Guyton, KZ; Gorospe, M; Xu, QB; Kokkonen, GC; Mock, YD; Roth, GS; Holbrook, NJ			Age-related decline in mitogen-activated protein kinase activity in epidermal growth factor-stimulated rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; DNA-SYNTHESIS; PHOSPHATASE; COMPLEX; JUN; FOS	A number of studies have demonstrated that the proliferative capacity of cells declines with aging. In particular, epidermal growth factor (EGF)-stimulated DNA synthesis is reduced in hepatocytes from aged rats relative to young rats. Growth factor stimulation activates a genetic program in large part regulated by a family of mitogen-activated protein kinases (MAPK) that phosphorylate and thereby activate transcription factors involved in controlling the expression of proliferation-associated genes. In the present study, we compared the activation of the extracellular signal-regulated kinase 2 (ERK2) and c-Jun N-terminal kinase 1 (JNK1) MAPK in EGF-stimulated hepatocytes derived from young (6-month) and aged (24-month) rats. JNK activity was not appreciably altered by EGF treatment of cells from either age group, In contrast, ERK2 was highly activated by EGF treatment, but the magnitude of activation was significantly lower in hepatocytes of aged animals compared to those of young animals (7-fold versus 20-fold, respectively). The reduced ERK2 activity in response to EGF was associated with decreased c-fos and c-jun mRNA expression and lower levels of AP-1 transcription factor DNA binding activity in the aged hepatocytes. Finally, the basal expression of MAPK phosphatase 1, a MAPK-regulated gene involved in regulating MAPK activity, was higher in aged hepatocytes. Taken together, these findings suggest that an alteration in the balance between MAP kinase-phosphatase activities could con tribute to the age-related decline in proliferative capacity.	NIA,GERONTOL RES CTR,GENE EXPRESS & AGING SECT,BALTIMORE,MD 21224; NIA,MOLEC PHYSIOL & GENET SECT,CELLULAR & MOLEC BIOL LAB,BALTIMORE,MD 21224	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)			Liu, Yusen/E-3527-2011	Liu, Yusen/0000-0002-0994-0109				ABDELHAFIZ HAM, 1992, MOL ENDOCRINOL, V16, P2079; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ATADJA PW, 1994, MOL CELL BIOL, V14, P4991, DOI 10.1128/MCB.14.7.4991; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BUCHER NLR, 1964, CANCER RES, V24, P509; CHARLES CH, 1992, ONCOGENE, V7, P187; COSCO OA, 1995, CELL, V81, P1137; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HENSLER PJ, 1995, AM J PATHOL, V147, P1; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; ISHIGAMI A, 1993, BIOCHEM BIOPH RES CO, V196, P181, DOI 10.1006/bbrc.1993.2232; ISHIGAMI A, 1994, J CELL PHYSIOL, V158, P231, DOI 10.1002/jcp.1041580204; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; PEACOCKE M, 1991, J CELL BIOCHEM, V45, P147, DOI 10.1002/jcb.240450205; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; YAN MH, 1994, NATURE, V372, P798	36	86	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3604	3607						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631968				2022-12-25	WOS:A1996TV72400042
J	Gollahon, LS; Shay, JW				Gollahon, LS; Shay, JW			Immortalization of human mammary epithelial cells transfected with mutant p53 (273(his))	ONCOGENE			English	Article						telomerase; telomeres; senescence; life span	HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN-DIPLOID FIBROBLASTS; LARGE TUMOR-ANTIGEN; LARGE T-ANTIGEN; BREAST-CANCER; CELLULAR SENESCENCE; PROTEIN; TRANSFORMATION; GENE; DNA	Normal human breast epithelial cells were transfected with expression vectors containing the p53 gene mutated at either codon 143, 175, 248 or 273, or by infection with a recombinant retroviral vector containing the p53 gene mutated at codons 143, 175, 248, or 273. The breast epithelial cells were monitored for extension of in vitro lifespan and immortalization. Expression of some, but not all, p53 mutants resulted in an extension of in vitro lifespan. Experiments with the p53 temperature sensitive mutant 143(ala) revealed that at 32 degrees C, the nonpermissive temperature, the growth of breast epithelial cells was inhibited. At 37 degrees C, the mutant conformation, there was increased proliferation of cells, resulting in extension of in vitro lifespan. Breast epithelial cells expressing p53 mutant 273(his) maintained DNA binding and transcriptional activities and one clone immortalized after a period of growth arrest (crisis). The progression of this immortalization event was characterized by the reactivation of telomerase using the telomeric repeat amplification protocol (TRAP), and terminal restriction fragment analysis (TRF). This is the first reported immortalization of human mammary epithelial cells transfected with a mutant 53.	UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Shay, Jerry W/F-7878-2011					ALDAZ CM, 1989, MOL CARCINOGEN, V2, P22, DOI 10.1002/mc.2940020104; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BOND JA, 1994, ONCOGENE, V9, P1885; CALLAHAN R, 1989, J NATL CANCER I, V81, P780; CHEN JY, 1993, ONCOGENE, V8, P2159; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; EYFJORD JE, 1995, CANCER RES, V55, P646; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FORRESTER K, 1995, ONCOGENE, V10, P2103; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GILLESPIE P, 1991, P NATL ACAD SCI USA, V88, P2593; GOTZ C, 1995, INT J ONCOL, V6, P1129; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HIYAMA K, 1995, ONCOGENE, V10, P937; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUANGE HJS, 1988, SCIENCE, V292, P1563; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSLER LG, 1992, CANCER-AM CANCER SOC, V69, P1896, DOI 10.1002/1097-0142(19920401)69:7+<1896::AID-CNCR2820691704>3.0.CO;2-1; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KULJU KS, 1995, EXP CELL RES, V217, P336, DOI 10.1006/excr.1995.1095; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LI FP, 1988, CANCER RES, V48, P5358; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIU ZJ, 1995, VIROLOGY, V207, P260, DOI 10.1006/viro.1995.1075; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1993, CANCER GENET CYTOGEN, V66, P83, DOI 10.1016/0165-4608(93)90233-C; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MUNGER K, 1989, J VIROL, V63, P4417; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PEREIRASMITH OM, 1987, MOL CELL BIOL, V7, P1541, DOI 10.1128/MCB.7.4.1541; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; Pollock Raphael E., 1992, Cancer Bulletin (Houston), V44, P268; REW DA, 1994, BRIT J SURG, V81, P1416, DOI 10.1002/bjs.1800811005; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; SHAY JW, 1992, MUTAT RES, V277, P163, DOI 10.1016/0165-1110(92)90003-R; SHAY JW, 1993, ONCOGENE, V8, P1407; SHAY JW, 1993, INT J ONCOL, V3, P559; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; SHAY JW, 1993, BREAST CANCER RES TR, V25, P83, DOI 10.1007/BF00662404; SMITH JK, 1992, AM J OBSTET GYNECOL, V167, P1883, DOI 10.1016/0002-9378(92)91791-8; SMITH ML, 1995, ONCOGENE, V10, P1053; TSUTSUI T, 1995, CARCINOGENESIS, V16, P25, DOI 10.1093/carcin/16.1.25; VANDERHAEGEN BA, 1993, IN VITRO CELL DEV-AN, V29A, P180, DOI 10.1007/BF02634177; WATANABE S, 1989, SCIENCE, V248, P76; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILLIAMS AC, 1995, ONCOGENE, V11, P141; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; WYLLIE FS, 1993, MOL CARCINOGEN, V7, P83, DOI 10.1002/mc.2940070205; WYLLIE FS, 1995, ONCOGENE, V10, P49; WYNFORDTHOMAS D, 1995, MOL CARCINOGEN, V12, P119; ZHANG W, 1992, ONCOGENE, V7, P1644	78	74	76	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					715	725						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632893				2022-12-25	WOS:A1996TW68600002
J	vanGrunsven, LA; Thomas, A; Urdiales, JL; Machenaud, S; Choler, P; Durand, I; Rudkin, BB				vanGrunsven, LA; Thomas, A; Urdiales, JL; Machenaud, S; Choler, P; Durand, I; Rudkin, BB			Nerve growth factor-induced accumulation of PC12 cells expressing cyclin D1: Evidence for a G1 phase block	ONCOGENE			English	Article						NGF; PC12; cyclin D1; flow cytometry; cell cycle; differentiation	PHEOCHROMOCYTOMA CELLS; DIFFERENTIATION; DNA; OVEREXPRESSION; PROGRESSION; FIBROBLASTS; METABOLISM; PROTEIN; G(1); LINE	The anti-proliferative effect of nerve growth factor (NGF) on the rat pheochromocytoma cell line PC12 has been previously shown to be accompanied by the accumulation of cells in either the G1 phase with a 2c DNA content, or with a 4c DNA content characteristic for G2/M, as evidenced by flow cytometric analysis of DNA distribution using propidium iodide. Herein, these apparently conflicting results are clarified. The present studies indicate that a simple DNA distribution profile obtained by this technique can confound interpretation of the biological effects of NGF on cell-cycle distribution due to the presence of tetraploid cells. Using cyclin D1 and incorporation of bromodeoxyuridine as markers of respectively, G1 and S phase, we show that PC12 cultures can have a considerable amount of tetraploid cells which, when in the G1 phase, have a 49 DNA content and express cyclin D1. During exposure to NGF, this population increases, reflecting the accumulation of cells in the G1 phase of the cell cycle. The data presented, support the possibility that events affecting the expression or action of G1 regulatory proteins may be involved in the molecular mechanism of the antimitogenic effect of NGF.	ECOLE NORMALE SUPER LYON,BIOL CELLULAIRE & MOLEC LAB,UMR CNRS 49,F-69364 LYON 07,FRANCE; SCHERING PLOUGH CORP,LAB RECH IMMUNOL,F-69570 DARDILLY,FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON); Merck & Company; Schering Plough Corporation			van Grunsven, Leo/E-5839-2010; Urdiales, José Luis/K-1125-2014; Choler, Philippe/A-7270-2008	van Grunsven, Leo/0000-0002-0990-7034; Urdiales, José Luis/0000-0002-2519-9293; Choler, Philippe/0000-0002-9062-2721; RUDKIN, Brian B./0000-0003-3700-1982				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Barde Y A, 1994, Prog Clin Biol Res, V390, P45; BOCCHINI V, 1969, P NATL ACAD SCI USA, V64, P787, DOI 10.1073/pnas.64.2.787; BUCHKOVICH KJ, 1994, MOL BIOL CELL, V5, P1225, DOI 10.1091/mbc.5.11.1225; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; DAHMER MK, 1988, ENDOCRINOLOGY, V122, P2109, DOI 10.1210/endo-122-5-2109; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; FUJITA K, 1989, ENVIRON HEALTH PERSP, V80, P127, DOI 10.2307/3430738; GRECO A, 1993, CELL GROWTH DIFFER, V4, P539; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUNNING PW, 1981, J NEUROSCI, V1, P368; IGNATIUS MJ, 1985, J NEUROSCI, V5, P343; JIANG W, 1993, ONCOGENE, V8, P3447; KATO J, 1993, GENE DEV, V7, P331; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1994, ONCOGENE, V9, P2159; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MILANI D, 1993, J GEN VIROL, V74, P2587, DOI 10.1099/0022-1317-74-12-2587; MUNOZ A, 1993, J CELL BIOL, V121, P423, DOI 10.1083/jcb.121.2.423; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAUSCH DM, 1989, J NEUROSCI RES, V24, P49, DOI 10.1002/jnr.490240108; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P2579, DOI 10.1073/pnas.74.6.2579; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; TAMARU T, 1994, NEUROSCI LETT, V168, P229, DOI 10.1016/0304-3940(94)90457-X; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103	34	48	48	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					855	862						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632908				2022-12-25	WOS:A1996TW68600017
J	Katagiri, K; Yokoyama, KK; Yamamoto, T; Omura, S; Irie, S; Katagiri, T				Katagiri, K; Yokoyama, KK; Yamamoto, T; Omura, S; Irie, S; Katagiri, T			Lyn and Fgr protein-tyrosine kinases prevent apoptosis during retinoic acid-induced granulocytic differentiation of HL-80 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; HL-60 CELLS; MONOCYTIC DIFFERENTIATION; EXPRESSION; GENE; NEUTROPHILS; INDUCTION; LINE; VAV; PHOSPHORYLATION	The human promyelocytic leukemia cell line HL-60 can be induced to differentiate toward neutrophils and subsequently die via apoptosis in vitro. In this paper, we investigated the roles of protein-tyrosine kinases (PTKs) in retinoic acid (RA)-induced granulocytic differentiation of HL-60 cells. Accompanying the RA-induced differentiation, activities of src family PTKs Lyn and Fgr became detected and reached a plateau 2 days after the stimulation. The immunoblotting using anti-phosphotyrosine antibody (PY-20) showed that the proteins of 56 and 53 kDa were predominantly tyrosine-phosphorylated at day 2. Adsorption and immunoprecipitation of the cell lysate by specific antibodies evidenced that these phosphotyrosine-containing proteins are Lyn and Fgr PTKs. The degree of both activities and tyrosine phosphorylation of these PTKs was reduced to be minimal at day 5 when the HL-60 cells start to die by apoptosis. The inhibitors of PTKs, herbimycin A and genistein, were demonstrated to cause premature cell death of HL-60 cells in the presence of RA. The death was the consequence of an apoptotic process. The RA-treated HL-60 cells, when incubated with specific c-lyn or c-fgr antisense oligodeoxynucleotide, also underwent premature death at day 2. These data implicate that Lyn and Fgr PTKs prevent programmed cell death to promote granulocytic differentiation of HL-60 cells.	NIPPI INC,INST BIOMATRIX,ADACHI KU,TOKYO 120,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,TSUKUBA,IBARAKI 305,JAPAN; UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN; KITASATO INST,BIOL FUNCT RES CTR,MINATO KU,TOKYO 108,JAPAN	RIKEN; University of Tokyo	Katagiri, K (corresponding author), KITASATO INST,CTR BASIC RES,DEPT MOLEC IMMUNOL,MINATO KU,5-9-1 SHIROKANE,TOKYO 108,JAPAN.							AFFORD SC, 1992, J BIOL CHEM, V267, P21612; BERTON G, 1994, J CELL BIOL, V126, P1111, DOI 10.1083/jcb.126.4.1111; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CASTAIGNE S, 1990, BLOOD, V76, P1704; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GRIGG JM, 1991, LANCET, V338, P720, DOI 10.1016/0140-6736(91)91443-X; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HAMADA F, 1993, P NATL ACAD SCI USA, V90, P6305, DOI 10.1073/pnas.90.13.6305; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; KATAGIRI K, 1992, CELL IMMUNOL, V140, P282, DOI 10.1016/0008-8749(92)90196-V; KATAGIRI K, 1994, BLOOD, V84, P1780; KATAGIRI K, 1991, J IMMUNOL, V146, P701; KATAGIRI K, 1993, J IMMUNOL, V150, P585; KATAGIRI T, 1989, P NATL ACAD SCI USA, V86, P10064, DOI 10.1073/pnas.86.24.10064; MANFREDINI R, 1993, J EXP MED, V178, P381, DOI 10.1084/jem.178.2.381; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; NAUMOVSKI L, 1994, BLOOD, V83, P2261; NISHIZAWA M, 1986, MOL CELL BIOL, V6, P511, DOI 10.1128/MCB.6.2.511; NUNEZ G, 1994, IMMUNOL TODAY, V15, P582, DOI 10.1016/0167-5699(94)90221-6; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; ORITANI K, 1992, BLOOD, V80, P2298; PORFIRI E, 1991, BLOOD, V78, P1069; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868	36	70	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11557	11562		10.1074/jbc.271.19.11557	http://dx.doi.org/10.1074/jbc.271.19.11557			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626717				2022-12-25	WOS:A1996UJ94400077
J	Krebs, J; Means, RL; Honegger, P				Krebs, J; Means, RL; Honegger, P			Induction of calmodulin kinase IV by the thyroid hormone during the development of rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CEREBELLAR GRANULE CELLS; BINDING PROTEIN; GENE-EXPRESSION; STIMULATION; GR; PHOSPHORYLATION; DIFFERENTIATION; GROWTH; FETAL	This communication reports the specific induction of calmodulin kinase IV by the thyroid hormone 3,3',5-triiodo-L-thyronine (T-3) in a time and concentration-dependent manner at a very early stage of brain differentiation using a fetal rat telencephalon primary cell culture system, which can grow and differentiate under chemically defined conditions. The induction of the enzyme that can be observed both on the mRNA and on the protein level is T-3-specific, i.e. it cannot be induced by retinoic acid or reverse T-3, and can be inhibited on both the transcriptional and the translational level by adding to the culture medium actinomycin D or cycloheximide, respectively. The earliest detection of calmodulin kinase IV in the fetal brain tissue of the rat is at days E16/E17, both on the mRNA as well as on the protein level. This is the first report in which a second messenger-dependent kinase involved in the control of cell regulatory processes is itself controlled by a primary messenger, the thyroid hormone.	DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710; UNIV LAUSANNE,INST PHYSIOL,CH-1005 LAUSANNE,SWITZERLAND	Duke University; University of Lausanne	Krebs, J (corresponding author), ETH ZURICH,INST BIOCHEM,CH-8092 ZURICH,SWITZERLAND.		krebs, joachim/B-3023-2013; Krebs, Joachim/CAF-0460-2022		NICHD NIH HHS [HD-07503] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALMAZAN G, 1985, DEV NEUROSCI-BASEL, V7, P45, DOI 10.1159/000112275; BALAZS R, 1971, BRAIN RES, V25, P555, DOI 10.1016/0006-8993(71)90460-4; BLAND MM, 1994, GENE, V142, P191, DOI 10.1016/0378-1119(94)90260-7; CORTHESYTHEULAZ I, 1991, AM J PHYSIOL, V261, pC124, DOI 10.1152/ajpcell.1991.261.1.C124; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISHER CL, 1991, J IMMUNOL, V146, P1743; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P17592; GUERINI D, 1984, J BIOL CHEM, V259, P5172; HANISSIAN SH, 1993, J BIOL CHEM, V268, P20055; HANSONPL, 1992, ANN REV BIOCH, V61, P559; HONEGGER P, 1979, NATURE, V282, P305, DOI 10.1038/282305a0; HONEGGER P, 1982, DEV BRAIN RES, V3, P229, DOI 10.1016/0165-3806(82)90023-2; HONEGGER P, 1983, DEV BRAIN RES, V11, P245, DOI 10.1016/0165-3806(83)90222-5; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; JORGENSEN OS, 1986, INT J DEV NEUROSCI, V4, P519, DOI 10.1016/0736-5748(86)90004-3; KAWAOI A, 1985, ACTA ENDOCRINOL-COP, V108, P518, DOI 10.1530/acta.0.1080518; KREBS J, 1995, P 9 INT S CALC BIND, pGS8; KREBS J, 1992, P 8 INT S CALC BIND, pB35; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON CA, 1995, P 77 M END SOC WASH, P48; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MEANS AR, 1994, FEBS LETT, V347, P1, DOI 10.1016/0014-5793(94)00492-7; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; OHMSTEDE CA, 1991, P NATL ACAD SCI USA, V88, P5784, DOI 10.1073/pnas.88.13.5784; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OKUNO S, 1993, J BIOCHEM-TOKYO, V114, P167, DOI 10.1093/oxfordjournals.jbchem.a124149; OKUNO S, 1994, J BIOCHEM, V116, P923, DOI 10.1093/oxfordjournals.jbchem.a124617; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; SAHYOUN N, 1991, P NATL ACAD SCI USA, V88, P2643, DOI 10.1073/pnas.88.7.2643; SAKAGAMI H, 1992, MOL BRAIN RES, V16, P20, DOI 10.1016/0169-328X(92)90189-I; SAKAGAMI H, 1993, MOL BRAIN RES, V19, P215, DOI 10.1016/0169-328X(93)90029-O; SCHMITT CA, 1988, J BIOL CHEM, V263, P17643; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SLAUGHTER GR, 1987, BIOL REPROD, V37, P1259, DOI 10.1095/biolreprod37.5.1259; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; TOKUMITSU H, 1994, J BIOL CHEM, V269, P15520; ZURINI M, 1984, J BIOL CHEM, V259, P618	44	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11055	11058		10.1074/jbc.271.19.11055	http://dx.doi.org/10.1074/jbc.271.19.11055			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626646				2022-12-25	WOS:A1996UJ94400006
J	Silvagno, F; Xia, HH; Bredt, DS				Silvagno, F; Xia, HH; Bredt, DS			Neuronal nitric-oxide synthase-mu, an alternatively spliced isoform expressed in differentiated skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEM; CELL; GENE	Nitric oxide (NO) functions as a molecular mediator in numerous processes in cellular development and physiology. Differential expression and regulation of a family of three NO synthase (NOS) gene products help achieve this diversity of action. Previous studies identify post- translational modification and interaction of NOS with specific protein targets as tissue-specific modes of regulation, Here, we show that alternative splicing specifically regulates neuronal NOS (nNOS, type I) in striated muscle. nNOS in skeletal muscle is slightly more massive than nNOS from brain owing to a 102-base pair (34-amino acid) alternatively spliced segment between exons 16 and 17. Following purification, this novel nNOS mu isoform has similar catalytic activity to that of nNOS expressed in cerebellum. nNOS mu appears to function exclusively in differentiated muscle as its expression occurs coincidentally with myotube fusion in culture. An isoform-specific antibody detects nNOS mu protein only in skeletal muscle and heart, This study identifies alternative splicing as a means for tissue-specific regulation of nNOS and reports the first additional protein sequence for a mammalian NOS since the original cloning of the gene family.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								BALLIGAND JL, 1993, P NATL ACAD SCI USA, V90, P347, DOI 10.1073/pnas.90.1.347; BALLIGAND JL, 1995, J BIOL CHEM, V270, P14582, DOI 10.1074/jbc.270.24.14582; BALON TW, 1994, J APPL PHYSIOL, V77, P2519, DOI 10.1152/jappl.1994.77.6.2519; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BREITBART RE, 1985, CELL, V41, P67, DOI 10.1016/0092-8674(85)90062-5; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; COOPER TA, 1985, J BIOL CHEM, V260, P1140; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HALL AV, 1994, J BIOL CHEM, V269, P33082; HAN X, 1994, J PHYSIOL-LONDON, V476, P309, DOI 10.1113/jphysiol.1994.sp020132; HARE JM, 1995, J CLIN INVEST, V95, P360, DOI 10.1172/JCI117664; HOFFMAN EP, 1988, NEURON, V1, P411, DOI 10.1016/0896-6273(88)90191-2; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; LEE KH, 1994, J BIOL CHEM, V269, P14371; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NATHAN C, 1994, J BIOL CHEM, V269, P13725; OGURA T, 1993, BIOCHEM BIOPH RES CO, V193, P1014, DOI 10.1006/bbrc.1993.1726; RANDO TA, 1994, J CELL BIOL, V125, P1275, DOI 10.1083/jcb.125.6.1275; STERN MD, 1992, FASEB J, V6, P3092, DOI 10.1096/fasebj.6.12.1325933; WANG T, 1995, NATURE, V374, P262, DOI 10.1038/374262a0; WHALEN RG, 1981, NATURE, V292, P805, DOI 10.1038/292805a0; XIE JL, 1995, P NATL ACAD SCI USA, V92, P1242, DOI 10.1073/pnas.92.4.1242	28	288	295	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11204	11208		10.1074/jbc.271.19.11204	http://dx.doi.org/10.1074/jbc.271.19.11204			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626668				2022-12-25	WOS:A1996UJ94400028
J	Zhang, L; Yu, YK; Mackin, S; Weight, FF; Uhl, GR; Wang, JB				Zhang, L; Yu, YK; Mackin, S; Weight, FF; Uhl, GR; Wang, JB			Differential mu opiate receptor phosphorylation and desensitization induced by agonists and phorbol esters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPIOID RECEPTOR; RAT-BRAIN; EXPRESSION; CLONING	mu opiate receptors, the principal sites for opiate analgesia and reward, can display compensatory responses to opiate agonist drug administration. Agonist-induced K+ channel responses mediated by these receptors desensitize when examined in Xenopus oocyte expression systems. Mechanisms underlying such processes could include phosphorylation events similar to those re ported to desensitize other G protein-linked receptors. We used C-terminally directed anti-mu receptor antibodies to immunoprecipitate a phosphoprotein with size appropriate for the mu receptor from stably expressing Chinese hamster ovary cells. Phosphorylation of this mu opiate receptor protein was enhanced approximately 5-fold by treatment with the mu agonist morphine. The time course and dose-response relationships between mu receptor phosphorylation and agonist-induced desensitization display interesting parallels. Phosphorylation of mu opiate receptor protein is also enhanced similar to 5-fold by treatment with the protein kinase C activator phorbol 12-myristate 13-acetate. The protein kinase inhibitor staurosporine blocked the effect of phorbol 12-myristate 13-acetate on mu receptor phosphorylation. However, staurosporine failed to block morphine-induced phosphorylation. These observations suggest that several biochemical pathways can lead to mu receptor phosphorylation events that may include mechanisms involved in mu receptor desensitization.	UNIV MARYLAND,SCH PHARM,DEPT PHARMACEUT SCI,BALTIMORE,MD 21201; NIAAA,MOLEC & CELLULAR NEUROBIOL LAB,BETHESDA,MD 20892; NATL INST DRUG ABUSE,MOL NEUROBIOL BRANCH,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21224	University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); Johns Hopkins University; Johns Hopkins University			Zhang, Li/W-2104-2019					ARDEN JR, 1995, J NEUROCHEM, V65, P1636; CHEN Y, 1994, J BIOL CHEM, V269, P7839; CHEN Y, 1993, MOL PHARMACOL, V44, P8; CHENG PY, 1995, ANALGESIA, V1, P363; CHILDERS SR, 1991, LIFE SCI, V48, P1191; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P6596, DOI 10.1073/pnas.90.14.6596; EPPLER CM, 1993, J BIOL CHEM, V268, P26447; FUKUDA K, 1993, FEBS LETT, V327, P311, DOI 10.1016/0014-5793(93)81011-N; HERZ A, 1993, OPIOIDS HDB EXPT PHA, V104; JOHNSON PS, 1994, REGUL PEPTIDES, V54, P139, DOI 10.1016/0167-0115(94)90429-4; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOVOOR A, 1995, J BIOL CHEM, V270, P589, DOI 10.1074/jbc.270.2.589; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; NORTH RA, 1987, P NATL ACAD SCI USA, V84, P5487, DOI 10.1073/pnas.84.15.5487; PEI G, 1995, MOL PHARMACOL, V48, P173; ROTHMAN RB, 1995, SYNAPSE, V21, P60, DOI 10.1002/syn.890210109; SMART D, 1994, J NEUROCHEM, V62, P1009; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; THOMPSON RC, 1993, NEURON, V11, P903, DOI 10.1016/0896-6273(93)90120-G; TOBIN AB, 1993, J BIOL CHEM, V268, P9817; WALAAS SI, 1991, PHARMACOL REV, V43, P299; WANG JB, 1993, P NATL ACAD SCI USA, V90, P10230, DOI 10.1073/pnas.90.21.10230; WANG JB, 1994, FEBS LETT, V338, P217, DOI 10.1016/0014-5793(94)80368-4	23	145	145	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11449	11454		10.1074/jbc.271.19.11449	http://dx.doi.org/10.1074/jbc.271.19.11449			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626702	hybrid			2022-12-25	WOS:A1996UJ94400062
J	Galan, JM; Moreau, V; Andre, B; Volland, C; HaguenauerTsapis, R				Galan, JM; Moreau, V; Andre, B; Volland, C; HaguenauerTsapis, R			Ubiquitination mediated by the Npi1p/Rsp5p ubiquitin-protein ligase is required for endocytosis of the yeast uracil permease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; HALF-LIFE; GENE; INVIVO; PATHWAY; ACTIN; CELLS	Uracil uptake by Saccharomyces cerevisiae is mediated by the FUR4-encoded uracil permease. This permease undergoes endocytosis and subsequent degradation in cells subjected to adverse conditions. The data presented here show that uracil permease also undergoes basal turnover under normal growth conditions. Both basal and induced turnover depend on the essential Npi1p/Rsp5p ubiquitin-protein ligase. Epitope-tagged ubiquitin variants have been used to show that uracil permease is ubiquitinated in vivo. The ubiquitin-permease conjugates that are readily demonstrated in wild type cells were barely detectable in npi1 mutant cells, indicating that uracil permease may be a physiological substrate of the Npi1p ubiquitin ligase. The lack of ubiquitination of the permease in npi1 cells resulted in an increase in active, i.e. plasma membrane-located, permease, suggesting that there is a direct relationship between ubiquitination and removal of the permease from the plasma membrane. The accumulation of ubiquitin-permease conjugates in thermosensitive act1 mutant cells, deficient in the internalization step of endocytosis is consistent with this idea. On the other hand, the degradation of uracil permease does not require a functional proteasome since the permease was not stabilized in either pre1 pre2 or cim3 and cim5 mutant cells that have impaired catalytic (pre) or regulatory (cim) proteasome subunits. In contrast, both basal and stress-stimulated turnover rates were greatly reduced in pep4 mutant cells having defective vacuolar protease activities. We therefore propose that ubiquitination of uracil permease acts as a signal for endocytosis of the protein that is subsequently degraded in the vacuole.	UNIV PARIS 07, INST JACQUES MONOD, CNRS, F-75251 PARIS 05, FRANCE; CNRS, INST BIOL MOLEC & CELLULAIRE, F-67084 STRASBOURG, FRANCE; FREE UNIV BRUSSELS, LAB PHYSIOL CELLULAIRE & GENET LEVURES, B-1050 BRUSSELS, BELGIUM	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Universite Libre de Bruxelles; Vrije Universiteit Brussel			André, Bruno/D-1725-2010; Haguenauer-Tsapis, Rosine/C-5446-2012	Moreau, Violaine/0000-0002-4513-7022				ANDRE B, 1994, BIOCHEM BIOPH RES CO, V205, P1201, DOI 10.1006/bbrc.1994.2793; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BECHET J, 1970, EUR J BIOCHEM, V12, P31, DOI 10.1111/j.1432-1033.1970.tb00817.x; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; BENITO B, 1991, BIOCHIM BIOPHYS ACTA, V1063, P265, DOI 10.1016/0005-2736(91)90381-H; BISSON LF, 1993, CRIT REV BIOCHEM MOL, V28, P259, DOI 10.3109/10409239309078437; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; EGNER R, 1995, MOL CELL BIOL, V15, P5879; Egner R, 1996, FEBS LETT, V378, P177, DOI 10.1016/0014-5793(95)01450-0; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FINLEY D, 1992, MOL CELLULAR BIOL YE, V2, P539; GALAN JM, 1994, BIOCHEM BIOPH RES CO, V201, P769, DOI 10.1006/bbrc.1994.1767; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GRENSON M, 1983, EUR J BIOCHEM, V133, P141, DOI 10.1111/j.1432-1033.1983.tb07439.x; GRENSON M, 1983, EUR J BIOCHEM, V133, P135, DOI 10.1111/j.1432-1033.1983.tb07438.x; HARE JF, 1990, BIOCHIM BIOPHYS ACTA, V1031, P71, DOI 10.1016/0304-4157(90)90003-U; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JUND R, 1988, EUR J BIOCHEM, V171, P417, DOI 10.1111/j.1432-1033.1988.tb13806.x; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; KUBLER E, 1993, EMBO J, V12, P2855, DOI 10.1002/j.1460-2075.1993.tb05947.x; LAI K, 1995, J BIOL CHEM, V270, P2525, DOI 10.1074/jbc.270.6.2525; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; MCGRAW P, 1995, YEAST S, V11, pS405; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; RIBALLO E, 1995, J BACTERIOL, V177, P5622, DOI 10.1128/jb.177.19.5622-5627.1995; RICHTERRUOFF B, 1994, FEBS LETT, V354, P50, DOI 10.1016/0014-5793(94)01085-4; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHORK SM, 1995, J BIOL CHEM, V270, P26446, DOI 10.1074/jbc.270.44.26446; SHORTLE D, 1984, P NATL ACAD SCI-BIOL, V81, P4889, DOI 10.1073/pnas.81.15.4889; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; URBANGRIMAL D, 1995, BIOCHEM J, V308, P847, DOI 10.1042/bj3080847; VOLLAND C, 1994, J BIOL CHEM, V269, P9833; VOLLAND C, 1994, FOLIA MICROBIOL, V39, P554, DOI 10.1007/BF02814106; VOLLAND C, 1992, J BIOL CHEM, V267, P23767; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; ZOLADEK T, 1995, MOL CELL BIOL, V15, P6884; [No title captured]	56	260	263	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10946	10952		10.1074/jbc.271.18.10946	http://dx.doi.org/10.1074/jbc.271.18.10946			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631913	hybrid			2022-12-25	WOS:A1996UJ34200081
J	Bayewitch, M; Rhee, RH; AvidorReiss, T; Breuer, A; Mechoulam, R; Vogel, Z				Bayewitch, M; Rhee, RH; AvidorReiss, T; Breuer, A; Mechoulam, R; Vogel, Z			(-)-Delta(9)-Tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; TETRAHYDROCANNABINOL; ANANDAMIDE; MODULATION; INVITRO; BRAIN	(-)-Delta(9)-Tetrahydrocannabinol ((-)-Delta(9)-THC) is the major active psychotropic component of the marijuana plant, Cannabis sativa. The membrane proteins that have been found to bind this material or its derivatives have been called the cannabinoid receptors. Two GTP-binding protein-coupled cannabinoid receptors have been cloned. CB1 or the neuronal cannabinoid receptor is found mostly in neuronal cells and tissues while CB2 or the peripheral cannabinoid receptor has been detected in spleen and in several cells of the immune system. It has previously been shown that activation of CB1 or CB2 receptors by cannabinoid agonists inhibits adenylyl cyclase activity. Utilizing Chinese hamster ovary cells and COS cells transfected with the cannabinoid receptors we report that (-)-Delta(9)-THC binds to both receptors with similar affinity. However, in contrast to its capacity to serve as an agonist for the CB1 receptor, (-)-Delta(9)-THC was only able to induce a very slight inhibition of adenylyl cyclase at the CB2 receptor. Morever, (-)-Delta(9)-THC antagonizes the agonist-induced inhibition of adenylyl cyclase mediated by CB2. Therefore, we conclude that (-)-Delta(9)-THC constitutes a weak antagonist for the CB2 receptor.	WEIZMANN INST SCI, DEPT NEUROBIOL, IL-76100 REHOVOT, ISRAEL; HEBREW UNIV JERUSALEM, FAC MED, DEPT NAT PROD, IL-91120 JERUSALEM, ISRAEL	Weizmann Institute of Science; Hebrew University of Jerusalem			Rhee, Man Hee/O-5705-2016; Avidor-Reiss, Tomer/AAK-6153-2020	Rhee, Man Hee/0000-0002-3088-1318; Avidor-Reiss, Tomer/0000-0003-0918-526X	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006265, R01DA006481] Funding Source: NIH RePORTER; NIDA NIH HHS [DA6481, DA6265] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BAYEWITCH M, 1995, FEBS LETT, V375, P143, DOI 10.1016/0014-5793(95)01207-U; BIDAUTRUSSELL M, 1990, J NEUROCHEM, V55, P21, DOI 10.1111/j.1471-4159.1990.tb08815.x; BUFORD NT, 1995, J PHARMACOL EXP THER, V274, P134; COMPTON DR, 1993, J PHARMACOL EXP THER, V265, P218; DELEAN A, 1988, USERS GUIDE ALLFIT, P97; DEROCQ JM, 1995, FEBS LETT, V369, P177, DOI 10.1016/0014-5793(95)00746-V; DEVANE WA, 1992, J MED CHEM, V35, P2065, DOI 10.1021/jm00089a018; DILL JA, 1988, J PHARMACOL EXP THER, V244, P1157; FACCI L, 1995, P NATL ACAD SCI USA, V92, P3376, DOI 10.1073/pnas.92.8.3376; FELDER CC, 1995, MOL PHARMACOL, V48, P443; FELDER CC, 1992, MOL PHARMACOL, V42, P313; FRIDE E, 1995, J PHARMACOL EXP THER, V272, P699; GERARD CM, 1991, BIOCHEM J, V279, P129, DOI 10.1042/bj2790129; HELDMAN E, 1996, IN PRESS EUR J PHARM; HOWLETT AC, 1988, MOL PHARMACOL, V33, P297; HOWLETT AC, 1984, MOL PHARMACOL, V26, P532; HOWLETT AC, 1986, MOL PHARM, V29, P161; KAMINSKI NE, 1992, MOL PHARMACOL, V42, P736; KAMINSKI NE, 1994, BIOCHEM PHARMACOL, V48, P1899, DOI 10.1016/0006-2952(94)90588-6; KEOWN WA, 1990, METHOD ENZYMOL, V185, P527, DOI 10.1016/0076-6879(90)85043-N; LEE M, 1995, J PHARMACOL EXP THER, V275, P529; LEVITZKI A, 1984, RECEPTORS QUANTITATI, P19; LOPEZCEPERO M, 1986, J LEUKOCYTE BIOL, V39, P679, DOI 10.1002/jlb.39.6.679; LYNN AB, 1994, J PHARMACOL EXP THER, V268, P1612; MACKIE K, 1992, P NATL ACAD SCI USA, V89, P3825, DOI 10.1073/pnas.89.9.3825; MACKIE K, 1993, MOL PHARMACOL, V44, P498; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1990, TETRAHEDRON-ASYMMETR, V1, P315, DOI 10.1016/S0957-4166(00)86322-3; MECHOULAM R, 1972, J AM CHEM SOC, V94, P6159, DOI 10.1021/ja00772a038; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SAVARESE TM, 1992, BIOCHEM J, V283, P1; SLIPETZ DM, 1995, MOL PHARMACOL, V48, P352; VOGEL Z, 1993, J NEUROCHEM, V61, P352, DOI 10.1111/j.1471-4159.1993.tb03576.x; WALLACH J, 1994, FEBS LETT, V338, P257, DOI 10.1016/0014-5793(94)80279-3	36	121	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9902	9905		10.1074/jbc.271.17.9902	http://dx.doi.org/10.1074/jbc.271.17.9902			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626625				2022-12-25	WOS:A1996UG25700009
J	Fu, MX; Requena, JR; Jenkins, AJ; Lyons, TJ; Baynes, JW; Thorpe, SR				Fu, MX; Requena, JR; Jenkins, AJ; Lyons, TJ; Baynes, JW; Thorpe, SR			The advanced glycation end product, N-(epsilon)(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; ATHEROGENESIS; PROTEIN	N-epsilon-(Carboxymethyl)lysine (CML) is an advanced glycation end product formed on protein by combined nonenzymatic glycation and oxidation (glycoxidation) reactions, We now report that CML is also formed during metal-catalyzed oxidation of polyunsaturated fatty acids in the presence of protein. During copper-catalyzed oxidation in vitro, the CML content of low density lipoprotein increased in concert with conjugated dienes but was independent of the presence of the Amadori compound, fructoselysine, on the protein, CML was also formed in a time-dependent manner in RNase incubated under aerobic conditions in phosphate buffer containing arachidonate or linoleate; only trace amounts of CML were formed from oleate. After 6 days of incubation the yield of CML in RNase from arachidonate was similar to 0.7 mmol/mol lysine compared with only 0.03 mmol/mol lysine for protein incubated under the same conditions with glucose. Glyoxal, a known precursor of CML, was also formed during incubation of RNase with arachidonate. These results suggest that lipid peroxidation, as well as glycoxidation, may be an important source of CML in tissue proteins in vivo and that CML may be a general marker of oxidative stress and long term damage to protein in aging, atherosclerosis, and diabetes.	UNIV S CAROLINA,DEPT CHEM & BIOCHEM,COLUMBIA,SC 29208; UNIV S CAROLINA,SCH MED,COLUMBIA,SC 29208; MED UNIV S CAROLINA,DEPT MED,CHARLESTON,SC 29245	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Medical University of South Carolina				Lyons, Timothy/0000-0003-2106-1622; Jenkins, Alicia/0000-0003-0583-3717	NEI NIH HHS [5R29 EY 10697] Funding Source: Medline; NIA NIH HHS [AG-11471] Funding Source: Medline; NATIONAL EYE INSTITUTE [R29EY010697] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; BROWNLEE M, 1994, DIABETES, V43, P836, DOI 10.2337/diab.43.6.836; CHUNG BH, 1986, METHOD ENZYMOL, V128, P181; CURCIO F, 1992, IN VITRO CELL DEV-AN, V28A, P787; CURTISS LK, 1985, DIABETES, V34, P452, DOI 10.2337/diabetes.34.5.452; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; FOLCH J, 1957, J BIOL CHEM, V226, P497; FU MX, 1994, DIABETES, V43, P676, DOI 10.2337/diabetes.43.5.676; GIARDINO I, 1994, J CLIN INVEST, V94, P110, DOI 10.1172/JCI117296; GLOMB MA, 1995, J BIOL CHEM, V270, P10017, DOI 10.1074/jbc.270.17.10017; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; KAWAMURA M, 1994, J CLIN INVEST, V94, P771, DOI 10.1172/JCI117396; KNECHT KJ, 1991, DIABETES, V40, P190, DOI 10.2337/diabetes.40.2.190; LOIDLSTAHLHOFEN A, 1994, BBA-LIPID LIPID MET, V1211, P156, DOI 10.1016/0005-2760(94)90264-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MLAKAR A, 1994, BBA-LIPID LIPID MET, V1214, P209; MULLARKEY CJ, 1990, BIOCHEM BIOPH RES CO, V173, P932, DOI 10.1016/S0006-291X(05)80875-7; NIYATISHIRKHODAEE F, 1993, J AGR FOOD CHEM, V41, P227, DOI 10.1021/jf00026a016; OSBORNE JC, 1986, METHOD ENZYMOL, V128, P213; PALINSKI W, 1995, ARTERIOSCL THROM VAS, V15, P571, DOI 10.1161/01.ATV.15.5.571; PHILISTSIMIKAS A, 1995, ARTERIOSCL THROM VAS, V15, P367, DOI 10.1161/01.ATV.15.3.367; PICARD S, 1992, P NATL ACAD SCI USA, V89, P6876, DOI 10.1073/pnas.89.15.6876; REDDY S, 1995, BIOCHEMISTRY-US, V34, P10872, DOI 10.1021/bi00034a021; REQUENA JR, 1993, DIABETES RES, V20, P43; TSAI EC, 1994, DIABETES, V43, P1010, DOI 10.2337/diabetes.43.8.1010; VLASSARA H, 1994, LAB INVEST, V70, P138; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027; WELLSKNECHT MC, 1995, BIOCHEMISTRY-US, V34, P15134, DOI 10.1021/bi00046a020; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499	30	680	706	0	58	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9982	9986		10.1074/jbc.271.17.9982	http://dx.doi.org/10.1074/jbc.271.17.9982			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626637	hybrid			2022-12-25	WOS:A1996UG25700021
J	Kanety, H; Hemi, P; Papa, MZ; Karasik, A				Kanety, H; Hemi, P; Papa, MZ; Karasik, A			Sphingomyelinase and ceramide suppress insulin-induced tyrosine phosphorylation of the insulin receptor substrate-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; CELLS	The sphingomyelin pathway is a newly described signal transduction pathway mediating the action of several cytokines including tumor necrosis factor-alpha (TNF), TNF was recently shown to interfere with insulin-induced tyrosine phosphorylation of the insulin receptor substrate-1 (IRS-1). In this work we examined the possible effect of direct activation of the sphingomyelin pathway on insulin-induced tyrosine phosphorylation of IRS-1. Incubation of the insulin-sensitive rat hepatoma Fao cells with bacterial sphingomyelinase (SMase) that causes membrane hydrolysis of sphingomyelin led to a time- and dose-dependent decrease in insulin-induced tyrosine phosphorylation of IRS-1, The effect was apparent after 10 min of incubation and with a dose of 10 milliunits/ml SMase, It was not associated with a decrease in insulin receptor autophosphorylation, In addition, SMase treatment interrupted the association of the 85-kDa catalytic subunit of phosphatidylinositol 3-kinase with IRS-1. A similar impact on IRS-1 tyrosine phosphorylation was observed after addition of cell-permeable ceramide analogs (C2 and C6). Comparable changes in IRS-1 tyrosine phosphorylation and electrophoretic mobility were found after exposure of cells to either TNF, SMase, or ceramide. Our findings suggest that TNF may utilize the sphingomyelin pathway in its effect on the insulin-stimulated tyrosine phosphorylation of IRS-1.	CHAIM SHEBA MED CTR,DEPT SURG,IL-52621 TEL HASHOMER,ISRAEL; CHAIM SHEBA MED CTR,INST ENDOCRINOL,IL-52621 TEL HASHOMER,ISRAEL	Chaim Sheba Medical Center; Chaim Sheba Medical Center								BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KANETY H, 1994, P NATL ACAD SCI USA, V91, P1853, DOI 10.1073/pnas.91.5.1853; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIU J, 1994, J BIOL CHEM, V269, P3047; MIRALPEIX M, 1992, BIOCHEMISTRY-US, V31, P9031, DOI 10.1021/bi00152a046; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; RAINES MA, 1993, J BIOL CHEM, V268, P14572; SALEEM A, 1995, J IMMUNOL, V154, P4150; SANTANA P, 1995, ENDOCRINOLOGY, V136, P2345, DOI 10.1210/en.136.5.2345; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; WHITE MF, 1994, J BIOL CHEM, V269, P1; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; ZHANG YH, 1995, ENDOCRINOLOGY, V136, P4157, DOI 10.1210/en.136.10.4157	24	142	145	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9895	9897		10.1074/jbc.271.17.9895	http://dx.doi.org/10.1074/jbc.271.17.9895			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626623	hybrid			2022-12-25	WOS:A1996UG25700007
J	Khurana, S; Nath, SK; Levine, SA; Bowser, JM; Tse, CM; Cohen, ME; Donowitz, M				Khurana, S; Nath, SK; Levine, SA; Bowser, JM; Tse, CM; Cohen, ME; Donowitz, M			Brush border phosphatidylinositol 3-kinase mediates epidermal growth factor stimulation of intestinal NaCl absorption and Na+/H+ exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOINOSITIDE 3-KINASE; GLUCOSE-TRANSPORT; FACTOR RECEPTORS; SKELETAL-MUSCLE; F-ACTIN; MEMBRANE; CELL; PHOSPHORYLATION; TRANSLOCATION	In terminally differentiated ileal villus Na+-absorptive cells, epidermal growth factor (EGF) stimulates NaCl absorption and its component brush border Na+/H+ exchanger, acting via basolateral membrane receptors, and as we confirm here, a brush border tyrosine kinase, In the present study we show that brush border phosphatidylinositol 3-kinase (PI 3-kinase) is involved in EGF stimulation of NaCl absorption and brush border Na+/H+ exchange, In rabbit ileum studied with the Ussing chamber-voltage clamp technique, EGF stimulation of active NaCl absorption is inhibited by the selective PI 3-kinase inhibitor wortmannin, PI 3-kinase, a largely cytosolic enzyme, translocates specifically to the brush border of ileal absorptive cells following EGF treatment, This translocation occurs as early as 1 min after EGF treatment and remains increased at the brush border for at least 15 min, EGF also causes a rapid (1 min) and large (4-5-fold) increase in brush border PI 3-kinase activity, Involvement of PI S-kinase activity in intestinal Na+ absorption is established further by studies done in the human colon cancer cell line, Caco-2, stably transfected with the intestinal brush border isoform of the Na+/H+ exchanger, NHE3 (Caco-2/NHE3 cells), Brush border Na+/H+ exchange activity was measured using the pH-sensitive fluorescent dye 2'7'-bis(carboxyethyl)5-(6)-carboxyfluorescein EGF added to the basolateral surface but not apical surface of Caco-2n/NHE3 cells increased brush border Na+/H+ exchange activity, The EGF-induced increase in brush border Na+/H+ exchange activity was completely abolished in cells pretreated with wortmannin, EGF treatment caused increased tyrosine phosphorylation of PI 3-kinase in both ileal brush border membranes and Caco-2/NHE3 cells, suggesting that a tyrosine kinase upstream of the PI 3-kinase is involved in the EGF effects on Na+ absorption. In conclusion, the present study provides evidence in two separate intestinal models, the ileum and a human colon cancer cell line, that PI 3-kinase is an intermediate in EGF stimulation of intestinal Na+ absorption.	JOHNS HOPKINS UNIV HOSP,SCH MED,DIV GASTROINTESTINAL,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV HOSP,SCH MED,DIV GASTROINTESTINAL,DEPT PHYSIOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine				Khurana, Seema/0000-0002-6884-810X	NIDDK NIH HHS [R01 DK 266523, P01DK44484] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044484] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNARD RJ, 1992, FASEB J, V6, P3238, DOI 10.1096/fasebj.6.14.1426762; BISHOP WP, 1994, AM J PHYSIOL-GASTR L, V267, pG892, DOI 10.1152/ajpgi.1994.267.5.G892; CANNON C, 1985, NATURE, V314, P443, DOI 10.1038/314443a0; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARTEE GD, 1991, J APPL PHYSIOL, V70, P1593, DOI 10.1152/jappl.1991.70.4.1593; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; COHEN B, 1990, P NATL ACAD SCI USA, V87, P4458, DOI 10.1073/pnas.87.12.4458; COHEN ME, 1991, J CLIN INVEST, V88, P855, DOI 10.1172/JCI115387; COHEN ME, 1990, P NATL ACAD SCI USA, V87, P8990, DOI 10.1073/pnas.87.22.8990; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DONOWITZ M, 1987, AM J PHYSIOL, V252, pG723, DOI 10.1152/ajpgi.1987.252.6.G723; DONOWITZ M, 1994, AM J PHYSIOL, V266, pG647, DOI 10.1152/ajpgi.1994.266.4.G647; DOWNES CP, 1991, CELL SIGNAL, V3, P501, DOI 10.1016/0898-6568(91)90027-R; EBERLE M, 1990, J BIOL CHEM, V265, P16725; EMMER E, 1989, J MEMBRANE BIOL, V108, P207, DOI 10.1007/BF01871735; GROSS DAE, 1994, BIOCHEM J, V303, P21; HIRST BH, 1985, BIOCHEM J, V231, P641, DOI 10.1042/bj2310641; HOLMGREN K, 1992, AM J PHYSIOL, V262, pC672, DOI 10.1152/ajpcell.1992.262.3.C672; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KELLY KL, 1992, J BIOL CHEM, V267, P3423; Khurana S, 1996, BIOCHEM J, V313, P509, DOI 10.1042/bj3130509; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; MA YH, 1994, J BIOL CHEM, V269, P30734; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; OKADA T, 1994, J BIOL CHEM, V269, P3568; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; POWIS G, 1994, CANCER RES, V54, P2419; SCHEVING LA, 1989, J BIOL CHEM, V264, P1735; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; THOMPSON JF, 1993, AM J PHYSIOL, V265, pG63, DOI 10.1152/ajpgi.1993.265.1.G63; THOMPSON JF, 1994, GASTROENTEROLOGY, V107, P1278, DOI 10.1016/0016-5085(94)90528-2; TSE CM, 1993, P NATL ACAD SCI USA, V90, P9110, DOI 10.1073/pnas.90.19.9110; WANG Z, 1993, J BIOL CHEM, V268, P11925; WEISER MM, 1973, J BIOL CHEM, V248, P2536; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1; ZHANG J, 1992, J BIOL CHEM, V267, P4686	39	93	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9919	9927		10.1074/jbc.271.17.9919	http://dx.doi.org/10.1074/jbc.271.17.9919			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626628	hybrid			2022-12-25	WOS:A1996UG25700012
J	ChavesOlarte, E; Florin, I; Boquet, P; Popoff, M; vonEichelStreiber, C; Thelestam, M				ChavesOlarte, E; Florin, I; Boquet, P; Popoff, M; vonEichelStreiber, C; Thelestam, M			UDP-glucose deficiency in a mutant cell line protects against glucosyltransferase toxins from Clostridium difficile and Clostridium sordellii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTO-TOXIN; METABOLISM; INVIVO; GRP78	We have previously isolated a fibroblast mutant cell with high resistance to the two Rho-modifying glucosyltransferase toxins A and B of Clostridium difficile. We demonstrate here a low level of UDP-glucose in the mutant, which explains its toxin resistance since: (i) to obtain a detectable toxin B-mediated Rho modification in lysates of mutant cells, addition of UDP-glucose was required, and it promoted the Rho modification dose-dependently; (ii) high pressure liquid chromatography analysis of nucleotide extracts of cells indicated that the level of UDP-glucose in the mutant (0.8 nmol/10(6) cells) was lower than in the wild type (3.7 nmol/10(6) cells); and (iii) sensitivity to toxin B was pestered upon microinjection of UDP-glucose, Using the mutant as indicator cell we also found that the related Clostridium sordellii lethal toxin is a glucosyltransferase which requires UDP-glucose as a cofactor. Like toxin B it glucosylated 21-23-kDa proteins in cell lysates, but Rho was not a substrate for lethal toxin.	KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN; UNIV COSTA RICA,FAC MICROBIOL,INST CLODOMIRO PICADO,SAN JOSE,COSTA RICA; FAC MED NICE,INSERM,F-06107 NICE 2,FRANCE; INST PASTEUR,UNITE TOXINES MICROBIENNES,F-75724 PARIS 15,FRANCE; UNIV MAINZ,VERFUGUNGSGEBAUDE FORSCH & ENTWICKLUNG,INST MED MIKROBIOL & HYG,D-55101 MAINZ,GERMANY	Karolinska Institutet; Universidad Costa Rica; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Johannes Gutenberg University of Mainz								CHANG SC, 1987, P NATL ACAD SCI USA, V84, P680, DOI 10.1073/pnas.84.3.680; FLORIN I, 1983, BIOCHIM BIOPHYS ACTA, V763, P383, DOI 10.1016/0167-4889(83)90100-3; FLORIN I, 1991, MICROB PATHOGENESIS, V11, P337, DOI 10.1016/0882-4010(91)90019-7; FLORIN I, 1994, ZBL BAKT S, V24, P406; GREEN GA, 1995, GENE, V161, P57, DOI 10.1016/0378-1119(95)00263-6; GRUBB MF, 1994, BIOCHEM MOL BIOL INT, V30, P819; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; JETHMALANI SM, 1994, J BIOL CHEM, V269, P23603; JUST I, 1995, J CLIN INVEST, V95, P1026, DOI 10.1172/JCI117747; JUST I, 1994, J BIOL CHEM, V269, P10706; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; KEPPLER D, 1965, METHOD ENZYMAT AN, P2225; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUGHLIN MR, 1988, J BIOL CHEM, V263, P2285; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1; LYERLY D M, 1988, Clinical Microbiology Reviews, V1, P1; MCCAULIFFE DP, 1992, J BIOL CHEM, V267, P2557; MITCHELL MJ, 1987, INFECT IMMUN, V55, P1610, DOI 10.1128/IAI.55.7.1610-1615.1987; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; PAOPFF MR, 1996, IN PRESS J BIOL CHEM, V271; POPOFF MR, 1987, INFECT IMMUN, V55, P35, DOI 10.1128/IAI.55.1.35-43.1987; Selzer J., 1994, Naunyn-Schmiedeberg's Archives of Pharmacology, V349, pR15; SHOSHAN MC, 1990, EUR J CELL BIOL, V53, P357; SWEENEY C, 1993, BIOCHEM J, V290, P563, DOI 10.1042/bj2900563; THELESTAM M, 1980, SCAND J INFECT DIS S, V22, P16; VONEICHELSTREIB.C, 1996, MOL MICROBIOL, V17, P313; VONEICHELSTREIBER C, 1994, ZBL BAKT S, V24, P51; WEHRLI SL, 1992, ANAL BIOCHEM, V202, P105, DOI 10.1016/0003-2697(92)90214-R	30	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6925	6932		10.1074/jbc.271.12.6925	http://dx.doi.org/10.1074/jbc.271.12.6925			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636120	hybrid			2022-12-25	WOS:A1996UB15700055
J	Gu, HH; Wall, S; Rudnick, G				Gu, HH; Wall, S; Rudnick, G			Ion coupling stoichiometry for the norepinephrine transporter in membrane vesicles from stably transfected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRIC-ACID; SENSITIVE DOPAMINE TRANSPORTER; BRAIN GABA TRANSPORTER; RAT-BRAIN; SEROTONIN TRANSPORTER; PLASMA-MEMBRANE; PLATELET 5-HYDROXYTRYPTAMINE; ACTIVE-TRANSPORT; CLONING; EXPRESSION	We prepared membrane vesicles from stable LLC-PK1 cells expressing serotonin (5-HT) gamma-aminobutyric acid (GABA) and norepinephrine (NE) transporters (SERT, GAT-1, and NET), These vesicles accumulate transport substrates when the appropriate transmembrane ion gradients are imposed, For NET, accumulation of [H-3]dopamine (DA) was stimulated by imposition of Na+ and Cl- gradients (out > in) and of a K+ gradient (in > out), The presence of Na+ or Cl-, even in the absence of a gradient, stimulated DA accumulation by NET, but K+ had little or no effect in the absence of a K+ gradient, Stimulation by a K+ gradient was markedly enhanced by increasing the K+ permeability with valinomycin, suggesting that net positive charge is transported together with DA. Cationic DA is likely to be the major substrate for NET, since varying pH did not affect K-m. We estimated the Na+:DA stoichiometry by measuring the effect of the transmembrane Na+ gradient on peak DA accumulation, The results suggest a 1:1 cotransport of Na+ with DA. Taken together, the results suggest that NET catalyzes cotransport of one cationic substrate molecule with one Na+ ion, and one Cl- ion, and that K+ does not participate directly in the transport process.	YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510	Yale University								AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BORDEN LA, 1992, J BIOL CHEM, V267, P21098; BROWN CDA, 1984, BIOCHIM BIOPHYS ACTA, V769, P471, DOI 10.1016/0005-2736(84)90332-8; CAMMACK JN, 1994, NEURON, V13, P949, DOI 10.1016/0896-6273(94)90260-7; CAMMACK JN, 1993, J PHYSIOL-LONDON, V472, P81, DOI 10.1113/jphysiol.1993.sp019938; CLARK JA, 1992, NEURON, V9, P337, DOI 10.1016/0896-6273(92)90172-A; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; GALLI A, 1995, J EXP BIOL, V198, P2197; GIROS B, 1991, FEBS LETT, V295, P149, DOI 10.1016/0014-5793(91)81406-X; GIROS B, 1992, MOL PHARMACOL, V42, P383; GU H, 1994, J BIOL CHEM, V269, P7124; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HARDER R, 1985, J NEUROCHEM, V45, P1154, DOI 10.1111/j.1471-4159.1985.tb05536.x; HEDIGER M, 1995, J PHYSL P, V452, pS7; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; HUMPHREYS CJ, 1991, BIOCHEM SOC T, V19, P95, DOI 10.1042/bst0190095; Iversen L., 1967, UPTAKE STORAGE NORAD; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P1207, DOI 10.1021/bi00600a011; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KANNER BI, 1994, J EXP BIOL, V196, P237; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KNOTH J, 1981, J BIOL CHEM, V256, P6541; KOBOLD G, 1985, N-S ARCH PHARMACOL, V331, P209, DOI 10.1007/BF00634240; KUHAR MJ, 1978, J NEUROCHEM, V31, P251, DOI 10.1111/j.1471-4159.1978.tb12456.x; LEE CM, 1982, J NEUROSCI, V2, P1515; LESCH KP, 1993, J NEUROCHEM, V60, P2319, DOI 10.1111/j.1471-4159.1993.tb03522.x; LESCH KP, 1993, J NEURAL TRANSM-GEN, V91, P67, DOI 10.1007/BF01244919; Lin Fan, 1995, Society for Neuroscience Abstracts, V21, P781; LINGJAERDE O, 1969, FEBS LETT, V3, P103, DOI 10.1016/0014-5793(69)80108-0; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; MCELVAIN JS, 1992, BIOCHEM PHARMACOL, V43, P2189, DOI 10.1016/0006-2952(92)90178-L; NELSON H, 1990, FEBS LETT, V269, P181, DOI 10.1016/0014-5793(90)81149-I; NELSON N, 1994, J EXP BIOL, V196, P213; NELSON PJ, 1979, J BIOL CHEM, V254, P84; NELSON PJ, 1982, J BIOL CHEM, V257, P6151; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PIETRINI G, 1994, J BIOL CHEM, V269, P4668; RADIAN R, 1983, BIOCHEMISTRY-US, V22, P1236, DOI 10.1021/bi00274a038; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; RAMAMOORTHY S, 1992, AM J PHYSIOL, V262, pC1189, DOI 10.1152/ajpcell.1992.262.5.C1189; RAMAMOORTHY S, 1993, BIOCHEMISTRY-US, V32, P1346, DOI 10.1021/bi00056a021; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; RUDNICK G, 1978, BIOCHEMISTRY-US, V17, P4739, DOI 10.1021/bi00615a021; RUDNICK G, 1986, PLATELET FUNCTION ME, V2, P119; SCHERMAN D, 1981, EUR J BIOCHEM, V116, P535, DOI 10.1111/j.1432-1033.1981.tb05369.x; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; SNEDDON JM, 1969, BRIT J PHARMACOL, V37, P680, DOI 10.1111/j.1476-5381.1969.tb08506.x; TALVENHEIMO J, 1983, J BIOL CHEM, V258, P6115; UHL GR, 1994, J EXP BIOL, V196, P229; USDIN TB, 1991, P NATL ACAD SCI USA, V88, P11168, DOI 10.1073/pnas.88.24.11168; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649	53	54	57	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6911	6916		10.1074/jbc.271.12.6911	http://dx.doi.org/10.1074/jbc.271.12.6911			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636118	hybrid			2022-12-25	WOS:A1996UB15700053
J	Matera, KM; Takahashi, S; Fujii, H; Zhou, H; Ishikawa, K; Yoshimura, T; Rousseau, DL; Yoshida, T; IkedaSaito, M				Matera, KM; Takahashi, S; Fujii, H; Zhou, H; Ishikawa, K; Yoshimura, T; Rousseau, DL; Yoshida, T; IkedaSaito, M			Oxygen and one reducing equivalent are both required for the conversion of alpha-hydroxyhemin to verdoheme in heme oxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEGRADATION; SYSTEM; PURIFICATION; MICROSOMES; FEATURES; IRON; FORM	Heme oxygenase is a central enzyme of heme degradation and associated carbon monoxide biosynthesis. We have prepared the alpha-hydroxyheme-heme oxygenase complex, which is the first intermediate in the catalytic reaction. The active site structure of the complex was examined by optical absorption, EPR, and resonance Raman spectroscopies. In the ferric form of the enzyme complex, the heme iron is five coordinate high spin and the alpha-hydroxyheme group in the complex assumes a structure of an oxophlorin where the alpha-meso hydroxy group is deprotonated. In the ferrous form, the alpha-hydroxy group is protonated and consequently the prosthetic group assumes a porphyrin structure. The alpha-hydroxyheme group undergoes a redox-linked conversion between a keto and an enol form. The ferric alpha-hydroxyheme reacts with molecular oxygen to form a radical species. Reaction of the radical species with a reducing equivalent yields the verdoheme-heme oxygenase complex. Reaction of the ferrous alpha-hydroxyheme-heme oxygenase complex with oxygen also yields the verdoheme-enzyme complex. We conclude that the catalytic conversion of ferric alpha-hydroxyheme to verdoheme by heme oxygenase requires molecular oxygen and one reducing equivalent.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106; AT&T BELL LABS,MURRAY HILL,NJ 07974; YAMAGATA TECHNOPOLIS FDN,INST LIFE SUPPORT TECHNOL,YAMAGATA 990,JAPAN; YAMAGATA UNIV,SCH MED,DEPT BIOCHEM,YAMAGATA 99023,JAPAN	Case Western Reserve University; AT&T; Nokia Corporation; Nokia Bell Labs; Yamagata University			Ikeda-Saito, Masao/K-2703-2015; Ikeda-Saito, Masao/A-5992-2008		NIGMS NIH HHS [GM39492, GM48714, GM51588] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051588, R01GM048714, R01GM039492] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCH AL, 1993, J AM CHEM SOC, V115, P1422, DOI 10.1021/ja00057a027; BOGUMIL R, 1995, BIOCHEMISTRY-US, V34, P10483, DOI 10.1021/bi00033a021; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; FUJII H, 1990, THESIS KYOTO U; HERNANDEZ G, 1994, BIOCHEMISTRY-US, V33, P6631, DOI 10.1021/bi00187a033; IKEDASAITO M, 1992, J BIOL CHEM, V267, P22843; ISHIKAWA K, 1992, BIOCHEM BIOPH RES CO, V182, P981, DOI 10.1016/0006-291X(92)91828-E; ISOGAI Y, 1995, J BIOL CHEM, V270, P7853, DOI 10.1074/jbc.270.14.7853; ITOMAKI M, 1995, ARCH BIOCHEM BIOPHYS, V317, P253, DOI 10.1006/abbi.1995.1160; KIKUCHI G, 1980, TRENDS BIOCHEM SCI, V5, P323, DOI 10.1016/0968-0004(80)90141-3; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MASUOKA N, 1987, BIOCHEMISTRY-US, V26, P3672, DOI 10.1021/bi00386a062; MEFFERT MK, 1994, NEURON, V13, P1225, DOI 10.1016/0896-6273(94)90060-4; MORISHIMA I, 1995, INORG CHEM, V34, P1528, DOI 10.1021/ic00110a035; NOGUCHI M, 1983, J BIOCHEM, V93, P1027, DOI 10.1093/oxfordjournals.jbchem.a134226; SAITO S, 1986, J CHEM SOC PERK T 1, P1, DOI 10.1039/p19860000001; SANO S, 1986, P NATL ACAD SCI USA, V83, P531, DOI 10.1073/pnas.83.3.531; SHRAGALEVINE Z, 1994, BIOCHEMISTRY-US, V33, P14656, DOI 10.1021/bi00253a002; SUEMATSU M, 1995, J CLIN INVEST, V96, P2431, DOI 10.1172/JCI118300; SUN J, 1993, BIOCHEMISTRY-US, V32, P14151, DOI 10.1021/bi00214a012; SUN J, 1994, BIOCHEMISTRY-US, V33, P13734, DOI 10.1021/bi00250a026; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; TAKAHASHI S, 1995, J AM CHEM SOC, V117, P6002, DOI 10.1021/ja00127a013; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; VARADARAJAN R, 1989, BIOCHEMISTRY-US, V28, P3771, DOI 10.1021/bi00435a022; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WILKS A, 1993, J BIOL CHEM, V268, P22357; YOSHIDA T, 1981, J BIOCHEM-TOKYO, V90, P125, DOI 10.1093/oxfordjournals.jbchem.a133441; YOSHIDA T, 1984, J BIOCHEM-TOKYO, V96, P563, DOI 10.1093/oxfordjournals.jbchem.a134868; YOSHIDA T, 1978, J BIOL CHEM, V253, P4230; YOSHIDA T, 1980, J BIOL CHEM, V255, P4418; YOSHIDA T, 1978, J BIOL CHEM, V253, P4224; YOSHIDA T, 1979, J BIOL CHEM, V254, P4487; YOSHIDA T, 1982, J BIOL CHEM, V257, P9345; YOSHIDA T, 1980, J BIOCHEM-TOKYO, V88, P557, DOI 10.1093/oxfordjournals.jbchem.a133003	38	98	101	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6618	6624		10.1074/jbc.271.12.6618	http://dx.doi.org/10.1074/jbc.271.12.6618			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636077	hybrid			2022-12-25	WOS:A1996UB15700012
J	Hammell, RL; HitchcockDeGregori, SE				Hammell, RL; HitchcockDeGregori, SE			Mapping the functional domains within the carboxyl terminus of alpha-tropomyosin encoded by the alternatively spliced ninth exon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTOMYOSIN SUBFRAGMENT-1 ATPASE; MUSCLE THIN-FILAMENTS; TROPONIN-T; SKELETAL-MUSCLE; F-ACTIN; NONPOLYMERIZABLE TROPOMYOSIN; LABELED TROPOMYOSIN; ESCHERICHIA-COLI; AMINO TERMINUS; BINDING-SITES	Tropomyosins are highly conserved, coiled-coil actin binding proteins found in most eukaryotic cells, Striated and smooth muscle alpha-tropomyosins differ by the regions encoded by exons 2 and 9, Unacetylated smooth tropomyosin expressed in Escherichia coli binds actin with high affinity, whereas unacetylated striated tropomyosin requires troponin, found only in striated muscle, for strong actin binding, The residues encoded by exon 9 cause these differences (Cho, Y.-J., and Hitchcock-DeGregori, S, E. (1991) Proc. Natl, Acad, Sci, U, S. A, 88, 10153-10157), We mapped the functional domains encoded by the alpha-tropomyosin exon 9a (striated muscle-specific) and 9d (constitutively expressed), by measuring actin binding and regulation of the actomyosin MgATPase by tropomyosin exon 9 chimeras and truncation mutants expressed in E. coli, We have shown that: 1) the carboxyl-terminal nine residues define the actin affinity of unacetylated tropomyosin; 2) in the presence of Ca2+, the entire exon 9a is required for troponin to promote fully high affinity actin binding; 3) the first 18 residues encoded by exon 9a are critical for the interaction of troponin with tropomyosin on the thin filament, even in the absence of Ca2+. The results give new insight into the structural requirements of tropomyosin for thin filament assembly and regulatory function.			Hammell, RL (corresponding author), ROBERT WOOD JOHNSON MED SCH, DEPT NEUROSCI & CELL BIOL, 675 HOES LANE, PISCATAWAY, NJ 08854 USA.				NHLBI NIH HHS [HL35726] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILEY K, 1948, BIOCHEM J, V43, P2791; BARTEGI A, 1990, EUR J BIOCHEM, V194, P845, DOI 10.1111/j.1432-1033.1990.tb19478.x; BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; CHO YJ, 1990, J BIOL CHEM, V265, P538; CHO YJ, 1991, P NATL ACAD SCI USA, V88, P10153, DOI 10.1073/pnas.88.22.10153; CHO YJ, 1991, THESIS RUTGERS; CHONG PCS, 1982, J BIOL CHEM, V257, P9152; DAHIYA R, 1994, J BIOL CHEM, V269, P29457; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FANNING AS, 1994, CELL MOTIL CYTOSKEL, V29, P29, DOI 10.1002/cm.970290104; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; FLICKER PF, 1982, J MOL BIOL, V162, P495, DOI 10.1016/0022-2836(82)90540-X; GOA J, 1953, SCAND J CLIN LAB INV, V5, P218, DOI 10.3109/00365515309094189; Greenfield NJ, 1995, BIOCHEMISTRY-US, V34, P16797, DOI 10.1021/bi00051a030; Hammell R. L., 1994, Molecular Biology of the Cell, V5, p401A; HEALD RW, 1988, J BIOL CHEM, V263, P5254; HEELEY DH, 1987, J BIOL CHEM, V262, P9971; HITCHCOCK SE, 1975, EUR J BIOCHEM, V52, P255, DOI 10.1111/j.1432-1033.1975.tb03993.x; HITCHCOCK SE, 1973, J MOL BIOL, V80, P825, DOI 10.1016/0022-2836(73)90212-X; HITCHCOCKDEGREGORI SE, 1982, J BIOL CHEM, V257, P2573; HITCHCOCKDEGREGORI SE, 1990, J MOL BIOL, V214, P885, DOI 10.1016/0022-2836(90)90343-K; HITCHCOCKDEGREGORI SE, 1994, ADV EXP MED BIOL, V358, P85; HITCHCOCKDEGREGORI SE, 1987, J BIOL CHEM, V262, P9730; ISHII Y, 1991, J BIOL CHEM, V266, P6894; ISHII Y, 1990, BIOCHEMISTRY-US, V29, P1160, DOI 10.1021/bi00457a010; KLUWE L, 1995, J MUSCLE RES CELL M, V16, P103, DOI 10.1007/BF00122528; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LEESMILLER JP, 1990, MOL CELL BIOL, V10, P1729, DOI 10.1128/MCB.10.4.1729; LEHRER SS, 1994, J MUSCLE RES CELL M, V15, P232; LEHRER SS, 1984, J BIOL CHEM, V259, P2070; LEHRER SS, 1982, J BIOL CHEM, V257, P8073; LEHRER SS, 1975, P NATL ACAD SCI USA, V72, P3377, DOI 10.1073/pnas.72.9.3377; LIN JJC, 1988, J CELL BIOL, V107, P563, DOI 10.1083/jcb.107.2.563; MAK AS, 1983, J BIOL CHEM, V258, P4330; MAK AS, 1981, J MOL BIOL, V149, P541, DOI 10.1016/0022-2836(81)90486-1; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; NOVY RE, 1993, BIOCHIM BIOPHYS ACTA, V1162, P255, DOI 10.1016/0167-4838(93)90289-4; NOVY RE, 1993, CELL MOTIL CYTOSKEL, V26, P248, DOI 10.1002/cm.970260308; OBRIEN EJ, 1971, PHILOS T ROY SOC B, V261, P201, DOI 10.1098/rstb.1971.0051; PATO MD, 1981, J BIOL CHEM, V256, P602; PEARLSTONE JR, 1982, J BIOL CHEM, V257, P587; PEARLSTONE JR, 1983, J BIOL CHEM, V258, P2534; PITTENGER MF, 1995, J CELL SCI, V108, P3253; PITTENGER MF, 1992, J CELL BIOL, V118, P841, DOI 10.1083/jcb.118.4.841; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; POTTER JD, 1974, BIOCHEMISTRY-US, V13, P2697, DOI 10.1021/bi00710a007; RUIZOPAZO N, 1987, J BIOL CHEM, V262, P4755; Sambrook J., 2002, MOL CLONING LAB MANU; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; TAO T, 1986, BIOCHEMISTRY-US, V25, P7633, DOI 10.1021/bi00371a054; URBANCIKOVA M, 1994, J BIOL CHEM, V269, P24310; WEGNER A, 1981, BIOCHEMISTRY-US, V20, P5633, DOI 10.1021/bi00522a043; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; WIECZOREK DF, 1988, MOL CELL BIOL, V8, P679, DOI 10.1128/MCB.8.2.679; YANG YZ, 1979, J BIOL CHEM, V254, P7137; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535; [No title captured]	62	77	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4236	4242						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626768				2022-12-25	WOS:A1996TW96000046
J	Jezewska, MJ; Bujalowski, W				Jezewska, MJ; Bujalowski, W			Global conformational transitions in Escherichia coli primary replicative helicase DnaB protein induced by ATP, ADP, and single-stranded DNA binding - Multiple conformational, states of the helicase hexamer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMENSIONAL HOMOGENEOUS LATTICE; COOPERATIVE BINDING; THEORETICAL ASPECTS; LARGE LIGANDS; MECHANISM	The direct evidence of dramatic conformational changes of the DnaB hexamer, induced by nucleotide binding, and the presence of multiple conformational states of the enzyme have been obtained by using analytical sedimentation equilibrium, sedimentation velocity studies, and the rigorous fluorescence titration technique. Equilibrium sedimentation measurements show that in the presence of the ATP nonhydrolyzable analog, AMP-PNP, the DnaB helicase fully preserves its hexameric structure. However, in the presence of the saturating concentration of AMP-PNP, the sedimentation coefficient of the hexamer is s(20,w) = 11.9 +/- 0.2 compared to the sedimentation coefficient s(20,w) = 10.5 +/- 0.2 of the free DnaB helicase hexamer. This large sedimentation coefficient change indicates dramatic global conformational transitions of the hexamer, encompassing all six subunits, upon binding the ATP analog, In the presence of ADP, the sedimentation coefficient is s(20,w) = 11.4 +/- 0.2, indicating that the conformation of the ADP form of the hexamer is different from the ATP form. The sedimentation coefficient of the ternary complex DnaB-(AMP-PNP)-d epsilon G(p epsilon A)(19), s(20,w) = 12.4, suggests that the DnaB helicase undergoes further conformational changes upon binding single-stranded DNA (ssDNA). The large global structural changes correlate with the functional activities of the enzyme, In the absence of the ATP analog, the hexamer exists in a ''closed'' conformation which has extremely low affinity toward ssDNA. Upon binding the ATP analog, the DnaB hexamer transforms into a ''tense'' state which binds ssDNA with an affinity of similar to 4 orders of magnitude higher than in the absence of the nucleotide, In the presence of ADP, the DnaB hexamer assumes a ''relaxed'' conformation. The functional difference between these two conformations is reflected in the much weaker allosteric effect of ADP on the ssDNA binding with the affinity constant similar to 3 orders of magnitude weaker than in the presence of the ATP analog (tense state).	UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston					NIGMS NIH HHS [GM-46679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046679] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI K, 1981, J BIOL CHEM, V256, P5260; ARAI K, 1981, J BIOL CHEM, V256, P5253; BAKER TA, 1987, J BIOL CHEM, V262, P6877; BUJALOWSKI W, 1994, BIOCHEMISTRY-US, V33, P4682, DOI 10.1021/bi00181a028; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31359; BUJALOWSKI W, 1993, BIOCHEMISTRY-US, V32, P5888, DOI 10.1021/bi00073a023; BUJALOWSKI W, 1995, BIOCHEMISTRY-US, V34, P8513, DOI 10.1021/bi00027a001; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; BUJALOWSKI W, 1989, BIOPOLYMERS, V28, P1637, DOI 10.1002/bip.360280912; Cantor C. R, 1980, BIOPHYSICAL CHEM 2, P591; HILL TL, 1981, P NATL ACAD SCI-BIOL, V78, P4796, DOI 10.1073/pnas.78.8.4796; HOWLETT GJ, 1977, BIOCHEMISTRY-US, V16, P5077, DOI 10.1021/bi00642a021; KORNBERG A, 1992, DNA REPLICATION, P355; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MCMACKEN R, 1977, J BIOL CHEM, V253, P3313; PEARCE TC, 1978, J MOL BIOL, V105, P383; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4051; WICKNER S, 1973, P NATL ACAD SCI USA, V71, P783; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350	23	66	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4261	4265						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626772				2022-12-25	WOS:A1996TW96000050
J	Mohr, S; Stamler, JS; Brune, B				Mohr, S; Stamler, JS; Brune, B			Posttranslational modification of glyceraldehyde-3-phosphate dehydrogenase by S-nitrosylation and subsequent NADH attachment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDE-GENERATING AGENTS; NITRIC-OXIDE; ADP-RIBOSYLATION; PROTEIN; BINDING	Nitric oxide (NO)-related activity has been associated with an NAD(+)-dependent modification of the glycolytic enzyme, glyceraldehyde-3-phosphate dehydrogenase (GAPDH). However, the mechanism by which NO effects covalent attachment of nucleotide and its role in regulation of enzyme activity are controversial. Recent studies have shown that S-nitrosylation of GAPDH (Cys(149)) initiates subsequent modification by the pyridinium cofactor. Here we show that NADH rather than NAD(+) is the preferred substrate. Transnitrosation from active site S-nitrosothiol to the reduced nicotinamide ring system appears to facilitate protein thiolate attack on the enzyme-bound cofactor. This results in attachment of the intact NADH molecule. Moreover, we find that S-nitrosylation of GAPDH is responsible for reversible enzyme inhibition, whereas attachment of NADH accounts for irreversible enzyme inactivation. S-Nitrosylation may serve to protect GAPDH from oxidant inactivation in settings of cytokine overproduction and to regulate glycolysis. NADH attachment is more likely to be a pathophysiological event associated with inhibition of gluconeogenesis.	UNIV ERLANGEN NURNBERG,FAC MED,DEPT 4,EXPT DIV,D-91054 ERLANGEN,GERMANY; UNIV KONSTANZ,FAC BIOL,D-78434 CONSTANCE,GERMANY; DUKE UNIV,MED CTR,DIV PULM,DURHAM,NC 27710; DUKE UNIV,MED CTR,DIV CARDIOVASC,DURHAM,NC 27710	University of Erlangen Nuremberg; University of Konstanz; Duke University; Duke University				Stamler, Jonathan/0000-0002-6866-1572	NHLBI NIH HHS [HLS2529, HLO2582] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002582] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; BARRIO JR, 1972, P NATL ACAD SCI USA, V69, P2039, DOI 10.1073/pnas.69.8.2039; BRUNE B, 1989, J BIOL CHEM, V264, P8455; BRUNE B, 1990, P NATL ACAD SCI USA, V87, P3304, DOI 10.1073/pnas.87.9.3304; BRUNE B, 1994, LIFE SCI, V54, P61, DOI 10.1016/0024-3205(94)00775-6; DEGROOTE MA, 1995, P NATL ACAD SCI USA, V92, P6399, DOI 10.1073/pnas.92.14.6399; DIMMELER S, 1992, J BIOL CHEM, V267, P16771; DIMMELER S, 1992, EUR J BIOCHEM, V210, P305, DOI 10.1111/j.1432-1033.1992.tb17422.x; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; HENDERSON SA, 1994, J BIOL CHEM, V269, P25239; HENRY Y, 1993, FASEB J, V7, P1124, DOI 10.1096/fasebj.7.12.8397130; HORTON RA, 1994, BIOCHEM J, V299, P735, DOI 10.1042/bj2990735; KLEPP J, 1989, J AM CHEM SOC, V111, P4440, DOI 10.1021/ja00194a045; KOTS AY, 1992, FEBS LETT, V300, P9, DOI 10.1016/0014-5793(92)80153-8; LIPTON SA, 1994, NEUROPHARMACOLOGY, V33, P1229, DOI 10.1016/0028-3908(94)90021-3; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; MEYER DJ, 1994, FEBS LETT, V345, P177, DOI 10.1016/0014-5793(94)00429-3; MOHR S, 1994, FEBS LETT, V348, P223, DOI 10.1016/0014-5793(94)00596-6; MORRIS SL, 1981, J BACTERIOL, V148, P465, DOI 10.1128/JB.148.2.465-471.1981; OAE S, 1983, ORG PREP PROCED INT, V15, P165, DOI 10.1080/00304948309355444; Oppenheimer N. J., 1987, PYRIDINE NUCLEOTIDE, P323; PANCHOLI V, 1993, P NATL ACAD SCI USA, V90, P8154, DOI 10.1073/pnas.90.17.8154; RACKER E, 1952, J BIOL CHEM, V198, P731; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; TABUCHI A, 1994, FEBS LETT, V351, P123, DOI 10.1016/0014-5793(94)00839-6; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; ZHANG J, 1992, P NATL ACAD SCI USA, V89, P9382, DOI 10.1073/pnas.89.20.9382	31	199	205	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4209	4214						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626764				2022-12-25	WOS:A1996TW96000042
J	Sattler, M; Salgia, R; Okuda, K; Uemura, N; Durstin, MA; Pisick, E; Xu, G; Li, JL; Prasad, KV; Griffin, JD				Sattler, M; Salgia, R; Okuda, K; Uemura, N; Durstin, MA; Pisick, E; Xu, G; Li, JL; Prasad, KV; Griffin, JD			The proto-oncogene product p120(CBL) and the adaptor proteins CRKL and c-CRK link c-ABL, p190(BCR/ABL) and p210(BCR/ABL) to the phosphatidylinositol-3' kinase pathway	ONCOGENE			English	Article						BCR/ABL; c-CBL; c-CRK; CRKL; phosphatidylinositol-3' kinase	ACUTE LYMPHOBLASTIC-LEUKEMIA; V-CBL; FUSED TRANSCRIPT; 3-KINASE; BINDING; DOMAIN; TRANSFORMATION; FIBROBLASTS; TRUNCATION; CELLS	Chronic myelogenous leukemia (CML) and some acute lymphoblastic leukemias (ALL) are caused by the t(9;22) chromosome translocation, which produces the constitutively activated BCR/ABL tyrosine kinase. When introduced into factor dependent hematopoietic cell lines, BCR/ABL induces the tyrosine phosphorylation of many cellular proteins. One prominent BCR/ABL substrate is p120(CBL), the cellular homolog of the v-Cbl oncoprotein. In an effort to understand the possible contribution of p120(CBL) to transformation by BCR/ABL, we looked for cellular proteins which associate with p120(CBL) in hematopoietic cell lines transformed by BCR/ABL. In addition to p210(BCR/ABL) and c-ABL, p120(CBL) coprecipitated with an 85 kDa phosphoprotein, which was identified as the p85 subunit of PI3K. Anti-p120(CBL) immunoprecipitates from BCR/ABL-transformed, but not from untransformed, cell lines contained PI3K lipid kinase activity. Interestingly, the adaptor proteins CRKL and c-CRK were also found in these complexes. In vitro binding studies indicated that the SH2 domains of CRKL and c-CRK bound directly to p120(CBL), while the SH3 domains of c-CRK and CRKL bound to BCR/ABL and c-ABL. The N-terminal and the C-terminal SH2 and the SH3 domain of p85(PI3K) bound directly in vitro to p120(CBL). The ABL-SH2, but not ABL-SH3, could also bind to p120(CBL). These data suggest that BCR/ABL may induce the formation of multimeric complexes of signaling proteins which include p120(CBL), PI3K, c-CRK or CRKL, c-ABL and BCR/ABL itself.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR IMMUNOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Li, Jian-Liang/AAE-9315-2019	Li, Jian-Liang/0000-0002-6487-081X	NCI NIH HHS [CA36167, CA60821] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA036167, R01CA036167, K08CA060821] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BEDI A, 1994, BLOOD, V83, P2038; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; ERNST TJ, 1994, J BIOL CHEM, V269, P5764; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FREDERICKSON TN, 1994, J NATL CANCER I, V72, P447; Langdon W Y, 1992, Curr Top Microbiol Immunol, V182, P467; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MUSHINSKI JF, 1994, ONCOGENE, V9, P2489; NICHOLS GL, 1994, BLOOD, V84, P2912; ODA T, 1994, J BIOL CHEM, V269, P22925; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SATTLER M, 1995, EXP HEMATOL, V23, P1040; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; WALKER LC, 1987, NATURE, V329, P851, DOI 10.1038/329851a0; XIAO HY, 1995, INT J ONCOL, V6, P405; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	48	259	264	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	1996	12	4					839	846						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632906				2022-12-25	WOS:A1996TW68600015
J	Welsh, GI; Miyamoto, S; Price, NT; Safer, B; Proud, CG				Welsh, GI; Miyamoto, S; Price, NT; Safer, B; Proud, CG			T-cell activation leads to rapid stimulation of translation initiation factor eIF2B and inactivation of glycogen synthase kinase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; POLYPEPTIDE-CHAIN INITIATION; RABBIT RETICULOCYTE LYSATE; PROTEIN-SYNTHESIS; LYMPHOCYTE STIMULATION; FACTOR-II; PHOSPHORYLATION; PHYTOHEMAGGLUTININ; MECHANISM; INSULIN	Mitogenic stimulation of T-lymphocytes causes a rapid activation of protein synthesis, which reflects in part increased expression of many translation components. Their levels, however, rise more slowly than the rate of protein synthesis, indicating an enhancement of the efficiency of their utilization. Initiation factor eIF2B catalyzes a hey regulatory step in the initiation of translation, and we have therefore studied its activity following T-cell activation. eIF2B activity rises quickly, increasing as early as 5 min after cell stimulation. This initial phase is followed by an additional slow but substantial increase in eLF2B activity. The level of eIF2B subunits did not change over the initial rapid phase but did increase at later time points. Northern analysis revealed that levels of eIF2B mRNA only rose during the later phase. The rapid activation of eIF2B following mitogenic stimulation of T-cells is therefore mediated by factors other than its own concentration. The largest (epsilon) subunit of elF2B is a substrate for glycogen synthase kinase 3 (GSK-3), the activity of which rapidly decreases following T-cell activation. Since phosphorylation of eIF2B by GSK-3 appears to inhibit nucleotide exchange in vitro, this provides a potential mechanism by which eIF2B may be activated.	UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND; NHLBI,MOLEC HEMATOL BRANCH,NIH,BETHESDA,MD 20892	University of Bristol; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)				Welsh, Gavin Iain/0000-0002-2148-6658; Proud, Christopher/0000-0003-0704-6442	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHERN T, 1973, BIOCHIM BIOPHYS ACTA, V331, P91, DOI 10.1016/0005-2787(73)90422-X; AHERN T, 1974, NATURE, V248, P519, DOI 10.1038/248519a0; AHERN T, 1975, EXP CELL RES, V92, P513, DOI 10.1016/0014-4827(75)90410-3; ASHMAN RF, 1984, FUNDAMENTAL IMMUNOLO, P267; BOAL TR, 1993, BIOCHIM BIOPHYS ACTA, V1176, P257, DOI 10.1016/0167-4889(93)90053-R; CARTER CS, 1987, TRANSFUSION, V27, P362, DOI 10.1046/j.1537-2995.1987.27487264750.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN RB, 1990, EMBO J, V9, P3831, DOI 10.1002/j.1460-2075.1990.tb07601.x; COOPER HL, 1977, J CELL PHYSIOL, V93, P213, DOI 10.1002/jcp.1040930207; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DHOLAKIA JN, 1988, P NATL ACAD SCI USA, V85, P51, DOI 10.1073/pnas.85.1.51; DHOLAKIA JN, 1986, P NATL ACAD SCI USA, V83, P6746, DOI 10.1073/pnas.83.18.6746; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; GROSS M, 1988, J BIOL CHEM, V263, P12486; GROSS M, 1989, J BIOL CHEM, V264, P21879; HERSHEY JWB, 1990, ENZYME, V44, P17, DOI 10.1159/000468744; HERSHEY WB, 1991, ANNU REV BIOCHEM, V60, P717; HUGHES K, 1992, BIOCHEM J, V288, P309, DOI 10.1042/bj2880309; JEDLICKA P, 1991, J BIOL CHEM, V266, P15663; KAY JE, 1975, BIOCHIM BIOPHYS ACTA, V378, P241, DOI 10.1016/0005-2787(75)90112-4; KAY JE, 1971, BIOCHIM BIOPHYS ACTA, V247, P322, DOI 10.1016/0005-2787(71)90680-0; KIMBALL SR, 1995, BIOCHEM BIOPH RES CO, V212, P1074, DOI 10.1006/bbrc.1995.2079; MEHTA HB, 1983, J BIOL CHEM, V258, P3438; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MOULE SK, 1995, BIOCHEM J, V311, P595, DOI 10.1042/bj3110595; OLDFIELD S, 1992, EUR J BIOCHEM, V208, P73, DOI 10.1111/j.1432-1033.1992.tb17160.x; PRICE N, 1994, BIOCHIMIE, V76, P748, DOI 10.1016/0300-9084(94)90079-5; PRICE NT, 1989, BIOCHIM BIOPHYS ACTA, V1008, P177, DOI 10.1016/0167-4781(80)90005-6; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; REDPATH NT, 1992, ANAL BIOCHEM, V202, P340, DOI 10.1016/0003-2697(92)90115-N; REDPATH NT, 1994, BBA-MOL CELL RES, V1220, P147, DOI 10.1016/0167-4889(94)90130-9; SAITO Y, 1994, BIOCHEM J, V303, P27, DOI 10.1042/bj3030027; SINGH LP, 1994, BIOCHEMISTRY-US, V33, P9152, DOI 10.1021/bi00197a018; SINGH LP, 1995, BIOCHEM BIOPH RES CO, V212, P1007, DOI 10.1006/bbrc.1995.2070; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; VANLINT J, 1993, ANAL BIOCHEM, V208, P132, DOI 10.1006/abio.1993.1018; WELSH GI, 1992, BIOCHEM J, V284, P19, DOI 10.1042/bj2840019; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; WETTENHALL RE, 1974, BIOCHIM BIOPHYS ACTA, V349, P214, DOI 10.1016/0005-2787(74)90082-3	42	91	92	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11410	11413		10.1074/jbc.271.19.11410	http://dx.doi.org/10.1074/jbc.271.19.11410			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626696	hybrid			2022-12-25	WOS:A1996UJ94400056
J	Hutson, RA; Zhou, YT; Collins, MD; Johnson, EA; Hatheway, CL; Sugiyama, H				Hutson, RA; Zhou, YT; Collins, MD; Johnson, EA; Hatheway, CL; Sugiyama, H			Genetic characterization of Clostridium botulinum type A containing silent type B neurotoxin gene sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; PROGENITOR TOXIN; COMPONENT; CLONING	A recent study detected genes encoding type B botulinum neurotoxin in some type A strains of Clostridium botulinum that exhibit no type B toxin activity, In this study, we investigated the presence, structure, linkage, and organization of genes encoding botulinum neurotoxin (BoNT) and other components of the progenitor complex. Sequence analysis showed that the silent BoNT/B gene is highly related to that from authentic proteolytic type B C. botulinum, However, a stop signal and deletions were found within the sequence, A non-toxin nonhemagglutinin gene (NTNH) was mapped immediately upstream of both the BoNT/A and silent BoNT/B genes. Significantly the NTNH gene adjacent to the defective BoNT/B gene was ''chimeric,'' the 5'- and 3'-regions of the gene had high homology with corresponding regions of the type B NTNH gene, while the 471-amino acid sequence in the central region was identical to NTNH of type A. Hemagglutinin genes HA-33 and HA-II were not found adjacent to the NTNH/A gene, but instead there was an unidentified open reading frame previously reported in strains of C. botulinum types E and F. By contrast HA-II, HA-33, and NTNH genes were located immediately upstream of the silent BoNT/B gene, Pulsed field gel electrophoretic analysis of chromosomal DNA digests indicated the distance between type A and B gene clusters to be less than 40 kilobases.	CTR DIS CONTROL & PREVENT,NCID,DBMD,ATLANTA,GA 30333; BIOL & BIOTECH SCI RES COUNCIL,INST FOOD RES,READING LAB,READING RG6 6BZ,BERKS,ENGLAND; UNIV WISCONSIN,DEPT FOOD MICROBIOL & TOXICOL,MADISON,WI 53706; UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706	Centers for Disease Control & Prevention - USA; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								CORDOBA JJ, 1995, SYST APPL MICROBIOL, V18, P13, DOI 10.1016/S0723-2020(11)80443-1; EAST AK, 1994, SYST APPL MICROBIOL, V17, P306, DOI 10.1016/S0723-2020(11)80045-7; EAST AK, 1994, CURR MICROBIOL, V29, P69, DOI 10.1007/BF01575751; EAST AK, 1992, FEMS MICROBIOL LETT, V96, P225, DOI 10.1016/0378-1097(92)90408-G; FRANCIOSA G, 1994, J CLIN MICROBIOL, V32, P1911, DOI 10.1128/JCM.32.8.1911-1917.1994; FUJII N, 1993, J GEN MICROBIOL, V139, P79, DOI 10.1099/00221287-139-1-79; GIMENEZ DF, 1970, ZENTBL BAKTERIOLOG P, V215, P212; Hatheway C.L., 1993, CLOSTRIDIUM BOTULINU, P3; LIN WJ, 1995, APPL ENVIRON MICROB, V61, P4441, DOI 10.1128/AEM.61.12.4441-4447.1995; SOMERS E, 1991, J PROTEIN CHEM, V10, P415, DOI 10.1007/BF01025256; THOMPSON DE, 1990, EUR J BIOCHEM, V189, P73, DOI 10.1111/j.1432-1033.1990.tb15461.x; TSUZUKI K, 1992, BIOCHEM BIOPH RES CO, V183, P1273, DOI 10.1016/S0006-291X(05)80328-6; TSUZUKI K, 1990, INFECT IMMUN, V58, P3173, DOI 10.1128/IAI.58.10.3173-3177.1990; WHELAN SM, 1992, APPL ENVIRON MICROB, V58, P2345, DOI 10.1128/AEM.58.8.2345-2354.1992; ZHOU YT, 1995, INFECT IMMUN, V63, P2087, DOI 10.1128/IAI.63.5.2087-2091.1995	15	69	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10786	10792		10.1074/jbc.271.18.10786	http://dx.doi.org/10.1074/jbc.271.18.10786			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631890	hybrid			2022-12-25	WOS:A1996UJ34200058
J	Johnson, MC; Kajikawa, O; Goodman, RB; Wong, VA; Mongovin, SM; Wong, WB; FoxDewhurst, R; Martin, TR				Johnson, MC; Kajikawa, O; Goodman, RB; Wong, VA; Mongovin, SM; Wong, WB; FoxDewhurst, R; Martin, TR			Molecular expression of the alpha-chemokine rabbit GRO in Escherichia coli and characterization of its production by lung cells in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE INFLAMMATORY PROTEIN-1; MESSENGER-RNA EXPRESSION; ALVEOLAR MACROPHAGES; STIMULATORY ACTIVITY; HUMAN NEUTROPHIL; INTERLEUKIN-8; IL-8; FIBROBLASTS; ACTIVATION; CYTOKINES	GRO proteins are alpha-chemokine cytokines that attract neutrophils and stimulate the growth of a variety of cells, Previously, we observed that rabbit alveolar macrophages transcribe the genes for at least two GRO homologues. In order to study the role of GRO cytokines in lung inflammation, we cloned the predominant rabbit GRO cDNA (RabGRO) from alveolar macrophages, expressed bioactive recombinant protein (rRabGRO) in Escherichia coli, and developed a sensitive and specific enzyme-linked immunosorbent assay for RabGRO protein. We found that rabbit AM express and secrete GRO in vitro in response to both exogenous (e.g. lipopolysaccharide, heat-killed Staphylococcus aureus, and crystalline silica) and endogenous inflammatory stimuli (e.g. tumor necrosis factor-alpha) as determined by both radioimmunoprecipitation and enzyme-linked immunosorbent assay. Biologically significant amounts of GRO are present in vivo in the bronchoalveolar lavage fluid of rabbits with E. coli pneumonia; by in situ hybridization, GRO mRNA is detectable in infiltrating pulmonary leukocytes and bronchial epithelial cells. These results indicate that GRO chemokines are likely to be important mediators of the inflammatory response that accompanies acute infectious processes in the lungs.	VET AFFAIRS MED CTR, MED RES SERV, SEATTLE, WA 98108 USA; UNIV WASHINGTON, SCH MED, DEPT MED, DIV PULM & CRIT CARE MED, SEATTLE, WA 98108 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL030542, F32HL009042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029103] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30542, HL09042-01] Funding Source: Medline; NIAID NIH HHS [AI29103] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; BECKER S, 1994, AM J PHYSIOL, V266, pL278, DOI 10.1152/ajplung.1994.266.3.L278; BECKER S, 1991, J IMMUNOL, V147, P4307; BROXMEYER HE, 1989, J EXP MED, V170, P1583, DOI 10.1084/jem.170.5.1583; CAO Y, J EXP MED, V182, P2069; DERYNCK R, 1990, BIOCHEMISTRY-US, V29, P10225, DOI 10.1021/bi00496a011; DRISCOLL KE, 1993, AM J RESP CELL MOL, V8, P311, DOI 10.1165/ajrcmb/8.3.311; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FOLKESSON HG, 1995, J CLIN INVEST, V96, P107, DOI 10.1172/JCI118009; FREVERT CW, 1995, J IMMUNOL, V154, P335; GEISER T, 1993, J BIOL CHEM, V268, P15419; GOODMAN RB, 1994, CHEST, V105, pS99; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; HASKILL S, 1988, J IMMUNOL, V140, P1690; HUANG SL, 1992, BIOCHEM BIOPH RES CO, V184, P922, DOI 10.1016/0006-291X(92)90679-F; JOHNSON MC, 1994, GENE, V151, P337, DOI 10.1016/0378-1119(94)90684-X; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; JOSE PJ, 1991, BIOCHEM J, V278, P493, DOI 10.1042/bj2780493; KAJIKAWA O, 1993, AM REV RESPIR DIS, V147, pA751; KRIEGER M, 1992, J IMMUNOL, V149, P2662; KUNKEL SL, 1991, EXP LUNG RES, V17, P17, DOI 10.3109/01902149109063278; KURDOWSKA A, 1994, CYTOKINE, V6, P124, DOI 10.1016/1043-4666(94)90033-7; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; MARTIN TR, 1992, J CLIN INVEST, V90, P2209, DOI 10.1172/JCI116106; MILLER EJ, 1992, AM REV RESPIR DIS, V146, P427, DOI 10.1164/ajrccm/146.2.427; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; NAKAGAWA H, 1994, BIOCHEM J, V301, P545, DOI 10.1042/bj3010545; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; OHMORI Y, 1994, J IMMUNOL, V153, P2204; OQUENDO P, 1989, J BIOL CHEM, V264, P4133; RICHMOND A, 1985, CANCER RES, V45, P6390; ROGIVUE C, 1995, LAB INVEST, V72, P689; ROT A, 1991, CYTOKINE, V3, P21, DOI 10.1016/1043-4666(91)90006-Y; SCHWARTZ D, 1994, J CLIN INVEST, V94, P1968, DOI 10.1172/JCI117548; SEBOK K, 1993, J IMMUNOL, V150, P1524; SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0; SHOBERG DS, 1995, AM J RESP CRIT CARE, V151, pA454; STRIETER RM, 1995, J LEUKOCYTE BIOL, V57, P752, DOI 10.1002/jlb.57.5.752; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; SYLVESTER I, 1990, AM REV RESPIR DIS, V141, P683, DOI 10.1164/ajrccm/141.3.683; TEKAMPOLSON P, 1990, J EXP MED, V172, P911, DOI 10.1084/jem.172.3.911; THOMAS KM, 1994, J IMMUNOL, V152, P2496; UNEMORI EN, 1993, J BIOL CHEM, V268, P1338; WALZ A, 1991, J LEUKOCYTE BIOL, V50, P279, DOI 10.1002/jlb.50.3.279; WATANABE K, 1989, J BIOL CHEM, V264, P19559; XING Z, 1994, AM J RESP CELL MOL, V10, P148, DOI 10.1165/ajrcmb.10.2.8110470; YOSHIMURA T, 1991, J IMMUNOL, V146	47	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10853	10858		10.1074/jbc.271.18.10853	http://dx.doi.org/10.1074/jbc.271.18.10853			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631900	hybrid			2022-12-25	WOS:A1996UJ34200068
J	Lin, JX; Mietz, J; Modi, WS; John, S; Leonard, WJ				Lin, JX; Mietz, J; Modi, WS; John, S; Leonard, WJ			Cloning of human Stat5B - Reconstitution of interleukin-2-induced Stat5A and Stat5B DNA binding activity in COS-7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR GAMMA-CHAIN; IL-2 RECEPTOR; FUNCTIONAL COMPONENT; LINE; GENE	We have isolated a second human Stat5 cDNA, Stat5B, and demonstrated that the genes encoding both Stat5A and Stat5B are located at chromosome 17q11.2, Both genes were constitutively transcribed in peripheral blood lymphocytes. By using specific antisera, we demonstrated that both Stat5A and Stat5B are activated by interleukin-2 (IL-2) in peripheral blood lymphocytes, natural killer-like YT leukemia cells, and human T cell lymphotropic virus type I-transformed MT-2 T cells. In COS-7 cells, which constitutively express the Janus family tyrosine kinase Jak1, reconstitution of IL-2-induced Stat5A and Stat5B DNA binding activities was dependent on the coexpression of Jak3 along with the IL-2 receptor beta chain and the common cytokine receptor gamma-chain. This IL-2-induced Stat5 activation was dependent on the presence of either of two tyrosines (Tyr-392 or Tyr-510) in the IL-2 receptor beta chain, indicating that either of these two tyrosines can serve as a docking site, Moreover, we demonstrated that human Stat5 activation is also dependent on Tyr-694 in Stat5A and Tyr-699 in Stat5B, indicating that these tyrosines are required for dimerization. The COS-7 reconstitution system described herein provides a valuable assay for further elucidation of the IL-2-activated JAK-STAT pathway.	NHLBI,LAB MOL IMMUNOL,NIH,BETHESDA,MD 20892; NCI,FREDERICK CANC RES & DEV CTR,SCI APPLICAT INT CORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Leonard, Warren/AAA-1397-2022	John, Susan/0000-0002-5620-1982				AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; GAFFEN SL, 1995, P NATL ACAD SCI USA, V92, P7192, DOI 10.1073/pnas.92.16.7192; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GNARRA JR, 1990, P NATL ACAD SCI USA, V87, P3440, DOI 10.1073/pnas.87.9.3440; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IZQUIERDO M, 1993, EUR J IMMUNOL, V23, P131, DOI 10.1002/eji.1830230121; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KIMURA Y, 1995, INT IMMUNOL, V7, P115, DOI 10.1093/intimm/7.1.115; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; Leonard WJ, 1996, ANNU REV MED, V47, P229; LEONARD WJ, 1994, IMMUNOL REV, V138, P61, DOI 10.1111/j.1600-065X.1994.tb00847.x; LEONARD WJ, 1994, CURR OPIN IMMUNOL, V6, P631, DOI 10.1016/0952-7915(94)90152-X; LIN JX, 1993, MOL CELL BIOL, V13, P6201, DOI 10.1128/MCB.13.10.6201; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; RUI H, 1994, J BIOL CHEM, V269, P5364; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TORY K, 1992, GENOMICS, V13, P275, DOI 10.1016/0888-7543(92)90243-L; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; YODOI J, 1985, J IMMUNOL, V134, P1623; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	51	185	191	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10738	10744		10.1074/jbc.271.18.10738	http://dx.doi.org/10.1074/jbc.271.18.10738			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631883	hybrid			2022-12-25	WOS:A1996UJ34200051
J	Martys, JL; Wjasow, C; Gangi, DM; Kielian, MC; McGraw, TE; Backer, JM				Martys, JL; Wjasow, C; Gangi, DM; Kielian, MC; McGraw, TE; Backer, JM			Wortmannin-sensitive trafficking pathways in Chinese hamster ovary cells - Differential effects on endocytosis and lysosomal sorting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEMLIKI FOREST VIRUS; RECEPTOR TYROSINE KINASES; PHOSPHATIDYLINOSITOL 3-KINASE; INSULIN-RECEPTOR; JUXTAMEMBRANE REGION; TRANSFERRIN RECEPTOR; BINDING-SITE; SH2 DOMAINS; PROTEIN; ACTIVATION	Phosphatidylinositol (PI) 3'-kinases are a family of lipid kinases implicated in the regulation of cell growth by oncogene products and tyrosine kinase growth factor receptors. The catalytic subunit of the p85/p110 PI 3'kinase is homologous to VPS-34, a phosphatidylinositol-specific lipid kinase involved in the sorting of newly synthesized hydrolases to the yeast vacuole. This suggests that PI 3'-kinases may play analogous roles in mammalian cells. We have measured a number of secretory and endocytic trafficking events in Chinese hamster ovary cells in the presence of wortmannin, a potent inhibitor of PI S'-kinase. Wortmannin caused a 40-50% down-regulation of surface transferrin receptors, with a dose dependence identical to that required for maximal inhibition of the p85/p110 PI 3'-kinase in intact cells. The redistribution of transferrin receptors reflected a 60% increase in the internalization rate and a 35% decrease in the recycling rate. Experiments with fluorescent transferrin showed that entry of transferrin receptors into the recycling compartment and efflux of receptors out of the compartment were slowed by wortmannin. Wortmannin altered the morphology of the recycling compartment, which was more vesiculated than in untreated cells. Using Semliki Forest virus as a probe, we also found that delivery of the endocytosed virus to its lysosomal site of degradation was slowed by wortmannin, whereas endosomal acidification was unaffected. In contrast to these effects on endocytosis and recycling, wortmannin did not affect intracellular processing of newly synthesized viral spike proteins. Wortmannin did induce missorting of the lysosomal enzyme cathepsin D to the secretory pathway, but only at a dose 20-fold greater than that required to inhibit p85/p110 PI 3'kinase activity or to redistribute transferrin receptors. Our data demonstrate the presence of wortmannin-sensitive enzymes at three distinct steps of the endocytic cycle in Chinese hamster ovary cells: internalization, transit from early endosomes to the recycling and degradative compartments, and transit from the recycling compartment back to the cell surface. The wortmannin-sensitive enzymes critical for endocytosis and recycling are distinct from those involved in sorting newly synthesized lysosomal enzymes.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOLEC PHARMACOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT CELL BIOL, BRONX, NY 10461 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY 10032 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Columbia University				Kielian, Margaret/0000-0002-7395-4791	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052929] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-44541] Funding Source: Medline; NIGMS NIH HHS [GM-52929] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1991, J CELL BIOL, V115, P1535, DOI 10.1083/jcb.115.6.1535; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; BECK KA, 1991, J BIOL CHEM, V266, P4442; BRAULKE T, 1987, EUR J CELL BIOL, V43, P316; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARPENTIER JL, 1992, P NATL ACAD SCI USA, V89, P162, DOI 10.1073/pnas.89.1.162; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DECURTIS I, 1988, P NATL ACAD SCI USA, V85, P8052, DOI 10.1073/pnas.85.21.8052; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DONG JM, 1989, J BIOL CHEM, V264, P7377; DUFFUS WA, 1995, J VIROL, V69, P2471, DOI 10.1128/JVI.69.4.2471-2479.1995; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GONCALVES E, 1993, P NATL ACAD SCI USA, V90, P5762, DOI 10.1073/pnas.90.12.5762; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; JOHNSON LS, 1993, MOL BIOL CELL, V4, P1251, DOI 10.1091/mbc.4.12.1251; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; KAPELLER R, 1991, MOL ENDOCRINOL, V5, P769, DOI 10.1210/mend-5-6-769; KIELIAN M, 1990, J VIROL, V64, P4614, DOI 10.1128/JVI.64.10.4614-4624.1990; KIELIAN MC, 1984, J VIROL, V52, P281, DOI 10.1128/JVI.52.1.281-283.1984; KODAKI T, 1994, EUR J BIOCHEM, V219, P775, DOI 10.1111/j.1432-1033.1994.tb18557.x; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE AD, 1995, FEBS LETT, V361, P51, DOI 10.1016/0014-5793(95)00147-2; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; MARSH EW, 1995, J CELL BIOL, V129, P1509, DOI 10.1083/jcb.129.6.1509; MARSH M, 1989, ADV VIRUS RES, V36, P107, DOI 10.1016/S0065-3527(08)60583-7; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PHALEN T, 1991, J CELL BIOL, V112, P615, DOI 10.1083/jcb.112.4.615; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; POWIS G, 1994, CANCER RES, V54, P2419; PRESLEY JF, 1993, J CELL BIOL, V122, P1231, DOI 10.1083/jcb.122.6.1231; RICHO GR, 1994, J BIOL CHEM, V269, P14806; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROSENWALD AG, 1992, BIOCHEMISTRY-US, V31, P3581, DOI 10.1021/bi00129a005; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SHEPHERD PR, 1995, BIOCHEM BIOPH RES CO, V211, P535, DOI 10.1006/bbrc.1995.1846; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STACK JH, 1994, J BIOL CHEM, V269, P31552; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STOCKERT RJ, 1995, J BIOL CHEM, V270, P16107, DOI 10.1074/jbc.270.27.16107; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; STROUS JAM, 1980, CELL, V22, P709, DOI 10.1016/0092-8674(80)90547-4; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; TOKER A, 1994, J BIOL CHEM, V269, P32358; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WATTS C, 1985, J CELL BIOL, V100, P633, DOI 10.1083/jcb.100.2.633; WEIGEL PH, 1992, GLYCOCONJUGATES COMP, P421; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WILEY HS, 1982, J BIOL CHEM, V257, P4222; WOSCHOLSKI R, 1994, FEBS LETT, V342, P109, DOI 10.1016/0014-5793(94)80482-6; YANO H, 1993, J BIOL CHEM, V268, P25846; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107; ZHANG J, 1993, J BIOL CHEM, V268, P22251	74	115	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10953	10962		10.1074/jbc.271.18.10953	http://dx.doi.org/10.1074/jbc.271.18.10953			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631914				2022-12-25	WOS:A1996UJ34200082
J	Itano, N; Kimata, K				Itano, N; Kimata, K			Expression cloning and molecular characterization of HAS protein, a eukaryotic hyaluronan synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERICELLULAR MATRIX; CELLS; SEQUENCES; GENE	We developed a mammalian transient expression system to isolate cDNA clones that determine hyaluronan expression. HAS(-), a mouse mammary carcinoma mutant cell line, which is defective in hyaluronan synthase activity, was first established and used as a recipient for the expression cloning, One cloned cDNA that overcame the deficiency was isolated, The cDNA termed HAS contains an open reading frame of 1749 base pairs encoding a new protein of 583 amino acids, Homology analysis of the amino acid sequence suggests that HAS protein is related to streptococcal hyaluronan synthase and also to Xenopus laevis DG42 protein that was found to be homologous to bacterial hyaluronan synthase. Expression of HAS cDNA in HAS(-) cells complemented not only their mutant phenotypes such as deficient hyaluronan-matrix deposition but also hyaluronan synthase activity itself, Therefore, HAS cDNA is responsible for the activity of the hyaluronan synthase, a key enzyme of hyaluronan synthesis in eukaryotic cells.	AICHI MED UNIV, INST MOLEC SCI MED, NAGAKUTE, AICHI 48011, JAPAN	Aichi Medical University								ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEANGELIS PL, 1994, BIOCHEM BIOPH RES CO, V199, P1, DOI 10.1006/bbrc.1994.1184; DOUGHERTY BA, 1994, J BIOL CHEM, V269, P169; HEFFERNAN M, 1991, NUCLEIC ACIDS RES, V19, P85, DOI 10.1093/nar/19.1.85; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HUANG L, 1993, J BIOL CHEM, V268, P26725; KIMATA K, 1983, CANCER RES, V43, P1347; KLEWES L, 1993, BIOCHEM J, V290, P791, DOI 10.1042/bj2900791; KNUDSON W, 1989, CIBA F SYMP, V143, P150; KNUDSON W, 1991, J CELL SCI, V99, P227; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; MIAN N, 1986, BIOCHEM J, V237, P343, DOI 10.1042/bj2370343; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NG KF, 1989, J BIOL CHEM, V264, P11776; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; SEMINO CE, 1995, P NATL ACAD SCI USA, V92, P3498, DOI 10.1073/pnas.92.8.3498; TENGBLAD A, 1979, BIOCHIM BIOPHYS ACTA, V578, P281, DOI 10.1016/0005-2795(79)90158-2; TENGBLAD A, 1980, BIOCHEM J, V185, P101, DOI 10.1042/bj1850101; Toole B.P., 1981, CELL BIOL EXTRACELLU, P259, DOI DOI 10.1007/978-1-4613-0881-2_10; TURLEY EA, 1989, CIBA F SYMP, V143, P121; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; YAMAGATA M, 1993, J CELL SCI, V106, P55; YASUDA H, 1991, CELL STRUCT FUNCT, V16, P105, DOI 10.1247/csf.16.105; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657	27	140	157	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9875	9878		10.1074/jbc.271.17.9875	http://dx.doi.org/10.1074/jbc.271.17.9875			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626618	hybrid			2022-12-25	WOS:A1996UG25700002
J	Shainskaya, A; Karlish, SJD				Shainskaya, A; Karlish, SJD			Chymotryptic digestion of the cytoplasmic domain of the beta subunit of Na/K-ATPase alters kinetics of occlusion of Rb+ ions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA,K-ATPASE ALPHA-SUBUNIT; CATION OCCLUSION; OUABAIN BINDING; INTRACELLULAR-TRANSPORT; EXTRACELLULAR DOMAIN; NA+,K+-ATPASE; ECTODOMAIN; EXPRESSION; NA,K-PUMP; DELETIONS	This paper demonstrates that specific chymotryptic digestion of the cytoplasmic domain of the beta subunit of Na/K-ATPase leads to changes in the kinetics of occlusion of Rb+ ions. The experiments utilize extensively trypsinized Na/K-ATPase, ''19-kDa membranes,'' which lack cytoplasmic loops of the alpha subunit, whereas membrane-embedded fragments (a COOH-terminal 19 kDa and three fragments of 8.1-11.7 kDa) containing transmembrane segments and extracellular loops are intact. The beta subunit is partially split into NH2- and COOH-terminal fragments of 16 and approximate to 50 kDa, respectively. Cation occlusion and ouabain binding are preserved. The 19-kDa membranes were incubated, at 37 degrees C, with a selection of proteases, in the presence of Rb+ ions. In these conditions, only alpha-chymotrypsin destroyed the ability to occlude Rb+ ions. This process was associated with truncation of the 16-kDa fragment of the beta subunit in two stages. In the first stage, chymotrypsin removed 10 residues from the 16-kDa fragment to form a 15-kDa fragment (NH2-terminal Ile(15)) and 4 or 6 residues from the NH2 terminus of the alpha subunit fragment beginning at Asp(68). In these membranes Rb+ occlusion was still intact at 37 degrees C. Strikingly, however, deocclusion of two Rb+ ions, which is characteristically biphasic in 10-kDa membranes, displayed deocclusion kinetic with mainly one fast phase. These membranes also showed a much lower affinity for Rb+ ions compared with 19-kDa membranes; and, consistent with the lower Rb+ affinity, Rb+ ions, at nonsaturating concentrations, protected less well against thermal inactivation of Rb+ occlusion. In the second stage, the 15-kDa fragment was truncated further to a 14-kDa fragment (NH2-terminal Leu(24)), followed by thermal destabilization of Rb+ occlusion even at high concentrations of Rb+ ions. Eventually, the thermally inactivated complex of fragments of alpha and beta subunits was digested to the limit peptides. The results suggest that the cytoplasmic domain of the beta subunit interacts with that of the alpha subunit, possibly with residues leading into the first transmembrane segment, and controls access of Rb+ ions into or out of the occlusion sites.	WEIZMANN INST SCI, DEPT BIOCHEM, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								ANTOLOVIC R, 1995, EUR J BIOCHEM, V227, P61, DOI 10.1111/j.1432-1033.1995.tb20359.x; ARYSTARKHOVA E, 1992, J BIOL CHEM, V267, P13694; BEGGAH AT, 1993, BIOCHEMISTRY-US, V32, P14117, DOI 10.1021/bi00214a007; BLANCO G, 1995, BIOCHEMISTRY-US, V34, P319, DOI 10.1021/bi00001a039; BLANCO G, 1994, J BIOL CHEM, V269, P23420; BLOSTEIN R, 1993, J BIOL CHEM, V268, P10654; CANESSA CM, 1993, J BIOL CHEM, V268, P17722; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CHOW DC, 1993, AM J PHYSIOL, V265, pC1562, DOI 10.1152/ajpcell.1993.265.6.C1562; CHOW DC, 1995, J EXP BIOL, V198, P1; EAKLE KA, 1994, J BIOL CHEM, V269, P6550; EAKLE KA, 1992, P NATL ACAD SCI USA, V89, P2834, DOI 10.1073/pnas.89.7.2834; EAKLE KA, 1995, J BIOL CHEM, V270, P13937, DOI 10.1074/jbc.270.23.13937; FAMBROUGH DM, 1994, AM J PHYSIOL, V266, pC579, DOI 10.1152/ajpcell.1994.266.3.C579; FORBUSH B, 1987, J BIOL CHEM, V262, P11116; FORBUSH B, 1983, CURR TOP MEMBR TRANS, V19, P167; GEERING K, 1991, FEBS LETT, V285, P189, DOI 10.1016/0014-5793(91)80801-9; GEERING K, 1993, AM J PHYSIOL, V265, pC1169, DOI 10.1152/ajpcell.1993.265.4.C1169; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GLYNN IM, 1985, J PHYSIOL-LONDON, V368, P453, DOI 10.1113/jphysiol.1985.sp015868; GOLDSHLEGER R, 1995, BIOCHEMISTRY-US, V34, P8668, DOI 10.1021/bi00027a016; HAMRICK M, 1993, J BIOL CHEM, V268, P24367; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JAISSER F, 1996, IN PRESS AM J PHYSL; JAN LY, 1992, ANNU REV PHYSIOL, V54, P535, DOI 10.1146/annurev.physiol.54.1.535; JAUNIN P, 1993, J CELL BIOL, V123, P1751, DOI 10.1083/jcb.123.6.1751; Jorgensen P L, 1974, Methods Enzymol, V32, P277; Karlish S J, 1991, Soc Gen Physiol Ser, V46, P129; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KIRLEY TL, 1990, J BIOL CHEM, V265, P4227; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LEMAS MV, 1992, J BIOL CHEM, V267, P20987; LINGREL JB, 1991, SOC GEN PHY, V46, P1; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; MCDONOUGH AA, 1990, FASEB J, V4, P1598, DOI 10.1096/fasebj.4.6.2156741; NOGUCHI S, 1994, FEBS LETT, V341, P233, DOI 10.1016/0014-5793(94)80463-X; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; OR E, 1993, J BIOL CHEM, V268, P16929; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; RENAUD KJ, 1991, J BIOL CHEM, V266, P20491; SACHS G, 1995, ANNU REV PHARMACOL, V35, P277, DOI 10.1146/annurev.pa.35.040195.001425; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHULTHEIS PJ, 1993, J BIOL CHEM, V268, P22686; SCHWAPPACH B, 1994, J BIOL CHEM, V269, P21620; SHAINSKAYA A, 1994, J BIOL CHEM, V269, P10780; SHANI M, 1987, BIOCHIM BIOPHYS ACTA, V904, P13, DOI 10.1016/0005-2736(87)90081-2; SHIN JM, 1994, J BIOL CHEM, V269, P8642	52	24	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10309	10316		10.1074/jbc.271.17.10309	http://dx.doi.org/10.1074/jbc.271.17.10309			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626600	hybrid			2022-12-25	WOS:A1996UG25700072
J	Suehiro, K; Smith, JW; Plow, EF				Suehiro, K; Smith, JW; Plow, EF			The ligand recognition specificity of beta 3 integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; ARG-GLY-ASP; DIVALENT-CATION REGULATION; VITRONECTIN RECEPTOR; GPIIB-IIIA; BINDING-SITES; CROSS-LINKING; MONOCLONAL-ANTIBODY; FIBRINOGEN BINDING; ADHESION RECEPTOR	alpha(IIb)beta(3) (platelet membrane glycoprotein IIb-IIa) and alpha(v) beta(3) are members of the beta(3) subfamily of integrin adhesion receptors. A cyclic peptide, KYGC(s-s)HarGDW-PC(s-s) (cHarGD), originally described by Scarborough et al. (Scarborough, R. M., Naughton, M. A., Teng, W., Rose, J. W., Phillips, D. R., Nannizzi, L., Arsten, A., Campbell, A. M., and Charo, I. F. (1993) J. Biol Chem. 268, 1066-1073) has been employed as a high affinity ligand for alpha(IIb)beta(3) to examine the specificity of the beta(3) integrins. cHarGD interacted with high affinity with purified alpha(IIb)beta(3) (K-d = 10 nm) or with platelets (K-d = 120 nM). While cHarGD was specific for alpha(IIb)beta(3)-specific, even in the presence of Mn2+. cHarGD became cross-linked to a site in beta(3) of alpha(IIb)beta(3), which is distinct from that of RGD peptides. These results allow identification of at lease four classes of beta(3) ligands: Class, I represented by RGD peptides and vitronectin, react similarly with alpha(IIb)beta(3) and alpha(v) beta(3); Class II, represented by cHarGD, gamma-chain peptides and fibrinogen, react with both receptors in the presence of Mn2+ but only with alpha(IIb)beta(3) in the presence of Ca2+; Class III, represented by barbourin, are alpha(IIb)beta(3)-specific under all cation conditions; Class IV, represented by osteopontin, bind primarily to alpha(v) beta(3).	CLEVELAND CLIN FDN, JOSEPH J JACOBS CTR THROMBOSIS & VASC RES FF20, DEPT MOL CARDIOL, CLEVELAND, OH 44195 USA; BURNHAM INST, LA JOLLA, CA 92037 USA	Cleveland Clinic Foundation; Sanford Burnham Prebys Medical Discovery Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038292, R01HL054924] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-54924, HL-38292] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1991, J IMMUNOL, V147, P1891; BAJT ML, 1992, J BIOL CHEM, V267, P3789; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BARUTHIO F, 1988, CLIN CHEM, V34, P227; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; Brandt M, 1986, MANGANESE METABOLISM, P3; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CALVETE JJ, 1994, THROMB HAEMOSTASIS, V72, P1; CALVETE JJ, 1992, EUR J BIOCHEM, V206, P759, DOI 10.1111/j.1432-1033.1992.tb16982.x; CALVETE JJ, 1994, BIOCHEM BIOPH RES CO, V202, P135, DOI 10.1006/bbrc.1994.1903; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; CHARO IF, 1991, J BIOL CHEM, V266, P1415; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; DOBRINA A, 1991, J CLIN INVEST, V88, P20, DOI 10.1172/JCI115278; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DSOUZA SE, 1988, J BIOL CHEM, V263, P3943; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1; GINSBERG MH, 1986, J CLIN INVEST, V78, P1103, DOI 10.1172/JCI112667; HAAS TA, 1994, CURR OPIN CELL BIOL, V6, P656, DOI 10.1016/0955-0674(94)90091-4; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; HU DD, 1995, J BIOL CHEM, V270, P9917, DOI 10.1074/jbc.270.17.9917; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P18525; LANZA F, 1992, J CLIN INVEST, V89, P1995, DOI 10.1172/JCI115808; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LEFKOVITS J, 1995, NEW ENGL J MED, V332, P1553, DOI 10.1056/NEJM199506083322306; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; LU XJ, 1994, BIOCHEM J, V304, P929, DOI 10.1042/bj3040929; LUSCINSKAS FW, 1994, FASEB J, V8, P929, DOI 10.1096/fasebj.8.12.7522194; MARCINKIEWICZ C, 1995, THROMB HAEMOSTASIS, V73, pA1123; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MASUMOTO A, 1993, J CELL BIOL, V123, P245, DOI 10.1083/jcb.123.1.245; MCLANE MA, 1994, BIOCHEM J, V301, P429, DOI 10.1042/bj3010429; PFAFF M, 1994, J BIOL CHEM, V269, P20233; PLOW EF, 1984, J BIOL CHEM, V259, P5388; PLOW EF, 1985, BLOOD, V66, P724; PLOW EF, 1992, J LAB CLIN MED, V120, P198; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RAMSAMOOJ P, 1991, BIOCHEM J, V276, P725, DOI 10.1042/bj2760725; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1058; SHADLE PJ, 1984, J CELL BIOL, V99, P2056, DOI 10.1083/jcb.99.6.2056; SHATTIL SJ, 1995, THROMB HAEMOSTASIS, V74, P149; SMITH JW, 1990, J BIOL CHEM, V265, P2168; SMITH JW, 1990, J BIOL CHEM, V265, P12267; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SMITH JW, 1991, J BIOL CHEM, V266, P11429; SMITH JW, 1994, J BIOL CHEM, V269, P960; SMYTH SS, 1993, BLOOD, V81, P2827; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; THIAGARAJAN P, 1988, J BIOL CHEM, V263, P3035; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	65	70	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10365	10371		10.1074/jbc.271.17.10365	http://dx.doi.org/10.1074/jbc.271.17.10365			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626608	hybrid			2022-12-25	WOS:A1996UG25700080
J	VanNhieu, GT; Krukonis, ES; Reszka, AA; Horwitz, AF; Isberg, RR				VanNhieu, GT; Krukonis, ES; Reszka, AA; Horwitz, AF; Isberg, RR			Mutations in the cytoplasmic domain of the integrin beta(1) chain indicate a role for endocytosis factors in bacterial internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; COATED PIT FORMATION; DENSITY-LIPOPROTEIN RECEPTOR; LYSOSOMAL ACID-PHOSPHATASE; CULTURED ANIMAL-CELLS; FIBRONECTIN RECEPTOR; TYROSINE PHOSPHORYLATION; YERSINIA-ENTEROCOLITICA; TRANSMEMBRANE LINKAGE; TRANSFERRIN RECEPTOR	Mutations that result in defective beta(1)-integrin focal adhesion formation were analyzed for effects on bacterial internalization. Mutations in the cytoplasmic domain of the beta(1) chain that disrupt the sequence NPIY resulted in integrins deficient in bacterial uptake, Other mutations in the beta(1) chain that reduced cytoskeletal association showed enhanced bacterial uptake, Replacement of the NPIY sequence of the beta(1) subunit by the endocytosis internalization sequence PPGY resulted in integrin receptors highly proficient in bacterial internalization, yet severely defective in focal contact localization, Electron microscopy indicated that coated structures associated specifically with bacteria-binding beta(1)-integrins, with an apparent recruitment of coated pits from ventral cell surfaces to apical surfaces corresponding to nascent bacterial phagosomes. Clathrin inhibition studies indicated a role for the adaptor molecule AP2 as well as clathrin in integrin-mediated bacterial internalization. These results indicate that association of beta(1)-integrins with the cytoskeleton at focal contacts interferes with integrin-mediated bacterial internalization. Also, although actin polymerization is required for bacterial uptake, clathrin is probably involved in bacterial uptake promoted by beta(1)-integrins.	TUFTS UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MOLEC BIOL & MICROBIOL, BOSTON, MA 02111 USA; UNIV ILLINOIS, DEPT CELL & STRUCT BIOL, URBANA, IL 61801 USA	Howard Hughes Medical Institute; Tufts University; University of Illinois System; University of Illinois Urbana-Champaign			Van Nhieu, Guy Tran/Y-6359-2018	Van Nhieu, Guy Tran/0000-0002-3901-2186	NIAID NIH HHS [R01-AI23538] Funding Source: Medline; NIDDK NIH HHS [P30 DK34928] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023538] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGGELER J, 1982, J CELL BIOL, V94, P613, DOI 10.1083/jcb.94.3.613; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; AVNUR Z, 1981, CELL, V25, P121, DOI 10.1016/0092-8674(81)90236-1; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BRASAEMLE DL, 1988, BIOTECHNIQUES, V6, P418; BRETSCHER MS, 1989, EMBO J, V8, P1341, DOI 10.1002/j.1460-2075.1989.tb03514.x; BRODSKY FM, 1985, J CELL BIOL, V101, P2047, DOI 10.1083/jcb.101.6.2047; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CHIN DJ, 1989, P NATL ACAD SCI USA, V86, P9289, DOI 10.1073/pnas.86.23.9289; CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; CLARKE MSF, 1992, J CELL SCI, V102, P533; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; FINLAY BB, 1988, BIOCHIMIE, V70, P1089, DOI 10.1016/0300-9084(88)90271-4; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GREENBERG S, 1993, J EXP MED, V177, P529, DOI 10.1084/jem.177.2.529; GRINNELL F, 1986, J CELL BIOL, V103, P2697, DOI 10.1083/jcb.103.6.2697; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HAYASHI Y, 1990, J CELL BIOL, V110, P175, DOI 10.1083/jcb.110.1.175; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; ISBERG RR, 1985, NATURE, V317, P262, DOI 10.1038/317262a0; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LEE CA, 1992, P NATL ACAD SCI USA, V89, P1847, DOI 10.1073/pnas.89.5.1847; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; OKA JA, 1989, J BIOL CHEM, V264, P12016; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; PITT A, 1992, J CLIN INVEST, V90, P1978, DOI 10.1172/JCI116077; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; RAUB TJ, 1989, EXP CELL RES, V184, P407, DOI 10.1016/0014-4827(89)90340-6; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; ROSENSHINE I, 1992, INFECT IMMUN, V60, P2211, DOI 10.1128/IAI.60.6.2211-2217.1992; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Shattil SJ, 1991, CURR OPIN CELL BIOL, V3, P869, DOI 10.1016/0955-0674(91)90062-4; SMYTHE E, 1992, J CELL BIOL, V119, P1163, DOI 10.1083/jcb.119.5.1163; SOLOWSKA J, 1989, J CELL BIOL, V109, P853, DOI 10.1083/jcb.109.2.853; SUZUKI T, 1991, FASEB J, V5, P187, DOI 10.1096/fasebj.5.2.1706281; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; TAPLEY P, 1989, ONCOGENE, V4, P325; VANNHIEU GT, 1993, EMBO J, V12, P1887, DOI 10.1002/j.1460-2075.1993.tb05837.x; VANNHIEU GT, 1993, IMMUNOMETHODS, V2, P71; VIGNOUD L, 1994, BIOCHEM BIOPH RES CO, V199, P603, DOI 10.1006/bbrc.1994.1271; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; WRIGHT SD, 1985, J LEUKOCYTE BIOL, V38, P327, DOI 10.1002/jlb.38.2.327; WRIGHT SD, 1983, J EXP MED, V158, P2016, DOI 10.1084/jem.158.6.2016; YOKOTA A, 1992, P NATL ACAD SCI USA, V89, P5030, DOI 10.1073/pnas.89.11.5030; YOUNG VB, 1992, J CELL BIOL, V116, P197, DOI 10.1083/jcb.116.1.197	62	61	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7665	7672		10.1074/jbc.271.13.7665	http://dx.doi.org/10.1074/jbc.271.13.7665			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631804				2022-12-25	WOS:A1996UC77400072
J	Ancsin, JB; Kisilevsky, R				Ancsin, JB; Kisilevsky, R			Laminin interactions important for basement membrane assembly are promoted by zinc and implicate laminin zinc finger-like sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; HEPARAN-SULFATE PROTEOGLYCAN; AMINO-ACID SEQUENCE; DENSITY-LIPOPROTEIN-RECEPTOR; COLLAGEN TYPE-IV; NUCLEOTIDE-SEQUENCE; A-CHAIN; MULTIDOMAIN PROTEIN; BINDING-SITES; CELL-ADHESION	Laminin is an abundant basement membrane (BM) glycoprotein which regulates specific cellular functions and participates in the assembly and maintenance of the BM superstructure. The assembly of BM is believed to involve the independent polymerization of collagen type IV and laminin, as well as high affinity interactions between laminin, entactin/nidogen, perlecan, and collagen type IV. We report here that Zn2+ can influence laminin binding activity, in vitro. Laminin contains 42 cysteine-rich repeats of which 12 contained nested zinc finger consensus sequences. Recently, the entactin binding site was mapped to one of these zinc finger-containing repeats on the laminin gamma chain (Mayer, U., Nischt, R., Poschl, E., Mann, K., Fukuda, K., Gerl, M., Yamada, Y., and Timpl, R. (1993) EMBO J. 12, 1879-1885), Based on these observations, the effect of a series of essential ions (Ca2+, Cd2+, CU2+, Mg2+, Mn2+, and Zn2+) on laminin binding activity was evaluated, Zn2+ was found to be the most effective at enhancing laminin-entactin and laminin collagen type IV binding. Laminin-bound Zn2+ was detected by flame atomic absorption spectroscopy at a maximum of 8 mol/mol of laminin, Furthermore, Ca2+ dependent laminin polymerization was unaffected by Zn2+. an observation consistent with the lack of zinc finger-containing repeats in the terminal globular domains required fbr polymerization, We conclude that Zn2+-laminin complexes may generate high affinity binding sites which contribute to BM cross-linking important for its assembly and homeostasis. Zinc is likely a cofactor for 2 kinds of cross-linking interactions; one involving direct binding between laminin and collagen type IV and the other a ternary complex of lamininentactin-collagen type IV.	QUEENS UNIV,DEPT PATHOL,KINGSTON,ON K7L 3N6,CANADA	Queens University - Canada								APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; ARNOLD FH, 1991, SCIENCE, V252, P1796, DOI 10.1126/science.1648261; AUMAILLEY M, 1989, EUR J BIOCHEM, V184, P241, DOI 10.1111/j.1432-1033.1989.tb15013.x; BATTAGLIA C, 1992, EUR J BIOCHEM, V208, P359, DOI 10.1111/j.1432-1033.1992.tb17195.x; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; CHARONIS AS, 1985, J CELL BIOL, V100, P1848, DOI 10.1083/jcb.100.6.1848; CHI HC, 1989, J BIOL CHEM, V264, P1543; COLOGNATOPYKE H, 1995, J BIOL CHEM, V270, P9398, DOI 10.1074/jbc.270.16.9398; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; DOOLITTLE RF, 1984, NATURE, V307, P558, DOI 10.1038/307558a0; ENGEL J, 1989, FEBS LETT, V251, P1, DOI 10.1016/0014-5793(89)81417-6; FOSTER DC, 1985, P NATL ACAD SCI USA, V82, P4673, DOI 10.1073/pnas.82.14.4673; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; GRAF J, 1987, BIOCHEMISTRY-US, V26, P6896, DOI 10.1021/bi00396a004; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GRANT D, 1992, BIOCHEM J, V287, P849, DOI 10.1042/bj2870849; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; HUDSON BG, 1989, LAB INVEST, V61, P256; KALB E, 1991, J BIOL CHEM, V266, P19047; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; KASHTAN C, 1986, J CLIN INVEST, V78, P1035, DOI 10.1172/JCI112658; KUSCHEGULLBERG M, 1992, EMBO J, V11, P4519, DOI 10.1002/j.1460-2075.1992.tb05553.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE GW, 1986, J MOL BIOL, V189, P205, DOI 10.1016/0022-2836(86)90391-8; LYON AW, 1991, LAB INVEST, V64, P785; MANN K, 1989, EMBO J, V8, P65, DOI 10.1002/j.1460-2075.1989.tb03349.x; MASON IJ, 1986, EMBO J, V5, P1465, DOI 10.1002/j.1460-2075.1986.tb04383.x; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; MONTELL DJ, 1988, CELL, V53, P463, DOI 10.1016/0092-8674(88)90166-3; NARINDRASORASAK S, 1992, LAB INVEST, V67, P643; NARINDRASORASAK S, 1995, LAB INVEST, V72, P272; NISSINEN M, 1991, BIOCHEM J, V276, P369, DOI 10.1042/bj2760369; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; NOONAN DM, 1988, J BIOL CHEM, V263, P16379; NY T, 1984, P NATL ACAD SCI-BIOL, V81, P5355, DOI 10.1073/pnas.81.17.5355; PALM SL, 1983, J CELL BIOL, V96, P1218, DOI 10.1083/jcb.96.5.1218; PAN TC, 1993, EUR J BIOCHEM, V215, P733, DOI 10.1111/j.1432-1033.1993.tb18086.x; PANAYOTOU G, 1989, CELL, V56, P93, DOI 10.1016/0092-8674(89)90987-2; PAULSSON M, 1988, J BIOL CHEM, V263, P5425; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; PAULSSON M, 1992, CRIT REV BIOCHEM MOL, V27, P93; PERLMUTTER LS, 1990, BRAIN RES BULL, V24, P677, DOI 10.1016/0361-9230(90)90007-M; PIKKARAINEN T, 1987, J BIOL CHEM, V262, P10454; PIKKARAINEN T, 1988, J BIOL CHEM, V263, P6751; REINHARDT D, 1993, J BIOL CHEM, V268, P10881; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SCHITTNY JC, 1990, J CELL BIOL, V110, P825, DOI 10.1083/jcb.110.3.825; SIPERSTEIN MD, 1988, AM J MED, V85, P119, DOI 10.1016/0002-9343(88)90404-4; TIMPL R, 1981, EUR J BIOCHEM, V120, P203, DOI 10.1111/j.1432-1033.1981.tb05690.x; TSILIBARY EC, 1988, J BIOL CHEM, V263, P19112; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; YAMAMOTO T, 1985, BIOCHEM BIOPH RES CO, V132, P605, DOI 10.1016/0006-291X(85)91176-3; YURCHENCO PD, 1988, AM J PATHOL, V132, P278; YURCHENCO PD, 1984, BIOCHEMISTRY-US, V23, P1839, DOI 10.1021/bi00303a040; YURCHENCO PD, 1993, J BIOL CHEM, V268, P17286; YURCHENCO PD, 1987, J CELL BIOL, V105, P2559, DOI 10.1083/jcb.105.6.2559; YURCHENCO PD, 1994, CURR OPIN CELL BIOL, V6, P674, DOI 10.1016/0955-0674(94)90093-0; YURCHENCO PD, 1990, J BIOL CHEM, V265, P3981; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	66	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6845	6851		10.1074/jbc.271.12.6845	http://dx.doi.org/10.1074/jbc.271.12.6845			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636109	hybrid			2022-12-25	WOS:A1996UB15700044
J	Kordula, T; Ripperger, J; Morella, KK; Travis, J; Baumann, H				Kordula, T; Ripperger, J; Morella, KK; Travis, J; Baumann, H			Two separate signal transducer and activator of transcription proteins regulate transcription of the serine proteinase inhibitor-3 gene in hepatic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE-PHASE RESPONSE; ALPHA-1-ACID GLYCOPROTEIN GENE; 3 C/EBP ISOFORMS; STIMULATING FACTOR; PROTEASE INHIBITORS; MOLECULAR-CLONING; BINDING-PROTEIN; GM-CSF; EXPRESSION; RECEPTOR	The serine proteinase inhibitor (SPI-3) gene expression is transcriptionally regulated by interleukin (IL)-6 and glucocorticoids in hepatic cells. To identify the transcription factors involved in regulation of the SPI-3 promoter-chloramphenicol acetyltransferase constructs we overexpressed Signal Transducer and Activator of Transcription (STAT) proteins (STAT1, STAT3, STAT5B, and STAT6) and CAAT enhancer-binding protein beta. Specific: signaling pathways were activated by cointroduced receptors for growth hormone, IL-3, IL-4, or chimeric receptors containing the cytoplasmic domain of gp130. STAT3 and STAT5B induced transcription via the SPI-3 promoter. The STAT5B response was substantially enhanced by truncation of the 5'-flanking region from -1021 to -148. The responsiveness to STAT3 and STAT5B required the STAT binding element at -132 to -124. This element was sufficient to confer regulation onto a heterologous promoter gene construct. In contrast, overexpression of CAAT enhancer-binding protein beta reduced the transcriptional activity of the SPI-3 promoter, presumably by interfering with STAT protein binding to the promoter element. The SPI-3 gene is the first example of an acute phase gene that is responsive to both STAT3 and STAT5B.	ROSWELL PK CANC INST, DEPT MOLEC & CELLULAR BIOL, BUFFALO, NY 14263 USA; UNIV GEORGIA, DEPT BIOCHEM & MOLEC BIOL, ATHENS, GA 30602 USA; JAGIELLONIAN UNIV, INST MOLEC BIOL, PL-31120 KRAKOW, POLAND; UNIV ERLANGEN NURNBERG, D-91068 ERLANGEN, GERMANY	Roswell Park Cancer Institute; University System of Georgia; University of Georgia; Jagiellonian University; University of Erlangen Nuremberg					NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033886] Funding Source: NIH RePORTER; NCI NIH HHS [CA26122] Funding Source: Medline; NHLBI NIH HHS [HL26148] Funding Source: Medline; NIDDK NIH HHS [DK33886] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAM T, 1993, J BIOL CHEM, V268, P15681; ALAM T, 1992, J BIOL CHEM, V267, P5021; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1994, J BIOL CHEM, V269, P16297; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HILL RE, 1987, NATURE, V326, P96, DOI 10.1038/326096a0; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KORDULA T, 1994, BIOCHEM BIOPH RES CO, V201, P222, DOI 10.1006/bbrc.1994.1692; Kordula T, 1996, BIOCHEM J, V313, P1019, DOI 10.1042/bj3131019; KORDULA T, 1995, BIOCHEM J, V309, P63, DOI 10.1042/bj3090063; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; LECAM A, 1994, J BIOL CHEM, V269, P21532; LECAM A, 1987, EMBO J, V6, P1225, DOI 10.1002/j.1460-2075.1987.tb02358.x; LECAM G, 1987, FEBS LETT, V210, P1, DOI 10.1016/0014-5793(87)81286-3; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MORELLA KK, 1995, BLOOD, V86, P557, DOI 10.1182/blood.V86.2.557.bloodjournal862557; MORELLA KK, 1995, J BIOL CHEM, V270, P8298, DOI 10.1074/jbc.270.14.8298; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; PAGES G, 1990, GENE, V94, P273, DOI 10.1016/0378-1119(90)90398-B; PAQUEREAU L, 1992, EUR J BIOCHEM, V209, P1053, DOI 10.1111/j.1432-1033.1992.tb17381.x; PROWSE KR, 1988, MOL CELL BIOL, V8, P42, DOI 10.1128/MCB.8.1.42; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; ROSSI V, 1992, NUCLEIC ACIDS RES, V20, P1061, DOI 10.1093/nar/20.5.1061; THOMAS MJ, 1995, MOL CELL BIOL, V15, P12, DOI 10.1128/MCB.15.1.12; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; WARD LD, 1994, J BIOL CHEM, V269, P23286; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; YOON JB, 1990, J BIOL CHEM, V265, P19947; ZIEGLER SF, 1995, EUR J IMMUNOL, V25, P399, DOI 10.1002/eji.1830250214; ZIEGLER SF, 1993, MOL CELL BIOL, V13, P2384, DOI 10.1128/MCB.13.4.2384	41	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6752	6757		10.1074/jbc.271.12.6752	http://dx.doi.org/10.1074/jbc.271.12.6752			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636096	hybrid			2022-12-25	WOS:A1996UB15700031
J	Isakoff, SJ; Yu, YP; Su, YC; Blaikie, P; Yajnik, V; Rose, E; Weidner, KM; Sachs, M; Margolis, B; Skolnik, EY				Isakoff, SJ; Yu, YP; Su, YC; Blaikie, P; Yajnik, V; Rose, E; Weidner, KM; Sachs, M; Margolis, B; Skolnik, EY			Interaction between the phosphotyrosine binding domain of Shc and the insulin receptor is required for Shc phosphorylation by insulin in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; GRB2	Stimulation of the insulin receptor (IR) results in tyrosine phosphorylation of the intermediate molecules insulin receptor substrate-1 (IRS-1), IRS-2, and Shc, which then couple the IR to downstream signaling pathways by serving as binding sites for signaling molecules with SH2 domains. It has been proposed that direct binding of IRS-1, IRS-2, and Shc to an NPX-Tyr(P) motif in the juxtamembrane region of the IR is required for tyrosine phosphorylation of these molecules by the LR. In this regard, Shc and IRS-1 contain domains that are distinct from SH2 domains, referred to as the phosphotyrosine binding (PTB) or phosphotyrosine interaction (PI) domains, which bind phosphotyrosine in the context of an NPX-Tyr(P) motif. To further clarify the role of the Shc PTB/PI domain, we identified a mutation in this domain that abrogated binding of Shc to the IR in vitro. Interestingly, this mutation completely abolished Shc phosphorylation by the IR in vivo whereas mutation of the arginine in the FLVRES motif of the Shc SH2 domain did not affect Shc phosphorylation by insulin. In addition, we identified specific amino acids on the IR that are required for the IR to stimulate Shc but not IRS-1 phosphorylation in vivo. As with the PTB/PI domain Shc mutant, the ability of these mutant receptors to phosphorylate Shc correlates with the binding of the PTB/PI domain of Shc to similar sequences in vitro. These findings support a model in which binding of the PTB/PI domain of Shc directly to the NPX-Tyr(P) motif on the LR mediates Shc phosphorylation by insulin.	NYU,MED CTR,DEPT PHARMACOL,SKIRBALL INST BIOMOL MED,NEW YORK,NY 10016; MAX DELBRUCK CTR MOLEC MED,D-13125 BERLIN,GERMANY; UNIV MICHIGAN,SCH MED,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109	New York University; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Howard Hughes Medical Institute; University of Michigan System; University of Michigan			Isakoff, Steven/ABE-3566-2020					BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FERNANDEZ R, 1995, EMBO J, V14, P3373, DOI 10.1002/j.1460-2075.1995.tb07343.x; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P12; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LI NX, 1994, ONCOGENE, V9, P3457; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PRIGENT SA, 1995, J BIOL CHEM, V270, P22097, DOI 10.1074/jbc.270.38.22097; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TRUB T, 1995, J BIOL CHEM, V270, P18205; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VOYJTEK AB, 1993, CELL, V74, P205; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; Yajnik V, 1996, J BIOL CHEM, V271, P1813, DOI 10.1074/jbc.271.4.1813; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	38	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					3959	3962						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626723				2022-12-25	WOS:A1996TW96000001
J	Nitsch, RM; Deng, MH; Growdon, JH; Wurtman, RJ				Nitsch, RM; Deng, MH; Growdon, JH; Wurtman, RJ			Serotonin 5-HT2a and 5-HT2e receptors stimulate amyloid precursor protein ectodomain secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PROTEIN; ALZHEIMERS-DISEASE; GROWTH-FACTOR; KINASE-C; PEPTIDE; ACTIVATION; RELEASE; CLEAVAGE; ALPHA; IDENTIFICATION	Alzheimer's disease amyloid consists of amyloid beta-peptides (A beta) derived from the larger precursor amyloid precursor protein (APP). Non-amyloidogenic APP processing involves regulated cleavage within the A beta domain followed by secretion of the ectodomain (APPs). APPs secretion can be stimulated by muscarinic acetylcholine receptors coupled to phospholipases and kinases. To determine whether other receptor classes can regulate APP processing, we examined the relation between serotonin receptors and APPs secretion. Serotonin increased APPs release 3-4 fold in 3T3 cells stably overexpressing 5-HT2aR or 5 HT2cR. The increase was dose-dependent and was blocked by serotoninergic antagonists. Phorbol esters also increased APPs secretion, but neither kinase inhibitors nor down-regulation of PKC blocked the serotonin-induced increase in APPs secretion. Thus PKC is not necessary to stimulate APPs secretion. Phospholipase A(2) (PLA(2)) inhibitors blocked the 5-HT2aR-mediated increase in APPs secretion, suggesting a role of PLA(2) in coupling 5-HT2aR to APP processing. In contrast, coupling of 5-HT2cR to APPs secretion involved both PKC and PLA(2). Serotonin also stimulated the release of the APLP2 ectodomain, suggesting that additional members of the APP multigene family are processed via similar regulated pathways. Inasmuch as generation of APPs precludes the formation of amyloidogenic derivatives, serotonin receptors provide a novel pharmacological target to reduce these derivatives in Alzheimer's disease.	MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT NEUROL,BOSTON,MA 02114	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Massachusetts General Hospital								ALLINQUANT B, 1995, J CELL BIOL, V128, P919, DOI 10.1083/jcb.128.5.919; BARGER SW, 1995, J NEUROCHEM, V64, P2087; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BUXBAUM JD, 1994, P NATL ACAD SCI USA, V91, P4489, DOI 10.1073/pnas.91.10.4489; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DYRKS T, 1994, FEBS LETT, V349, P210, DOI 10.1016/0014-5793(94)00671-7; EMMERLING MR, 1993, BIOCHEM BIOPH RES CO, V197, P292, DOI 10.1006/bbrc.1993.2474; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FARBER SA, 1995, J NEUROSCI, V15, P7442; GABUZDA D, 1993, J NEUROCHEM, V61, P2326, DOI 10.1111/j.1471-4159.1993.tb07479.x; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GREENBERG SM, 1994, P NATL ACAD SCI USA, V91, P7104, DOI 10.1073/pnas.91.15.7104; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1993, J BIOL CHEM, V268, P3021; HUNG AY, 1993, J BIOL CHEM, V268, P22959; JULIUS D, 1988, SCIENCE, V241, P558, DOI 10.1126/science.3399891; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; LEE RKK, 1995, P NATL ACAD SCI USA, V92, P8083, DOI 10.1073/pnas.92.17.8083; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; MUCKE L, 1995, J EXP MED, V181, P1551, DOI 10.1084/jem.181.4.1551; MUCKE L, 1994, BRAIN RES, V666, P151, DOI 10.1016/0006-8993(94)90767-6; MUCKE L, 1996, IN PRESS ANN NY ACAD; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; NITSCH RM, 1993, P NATL ACAD SCI USA, V90, P5191, DOI 10.1073/pnas.90.11.5191; NITSCH RM, 1994, BIOCHEM PHARMACOL, V47, P1275, DOI 10.1016/0006-2952(94)90325-5; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; ROCH JM, 1994, P NATL ACAD SCI USA, V91, P7450, DOI 10.1073/pnas.91.16.7450; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SANDMANN J, 1991, J BIOL CHEM, V266, P6031; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SLACK BE, 1993, J BIOL CHEM, V268, P21097; SLACK BE, 1995, J BIOL CHEM, V270, P8337, DOI 10.1074/jbc.270.14.8337; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; STAM NJ, 1992, EUR J PHARM-MOLEC PH, V227, P153, DOI 10.1016/0922-4106(92)90123-D; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; VONDERKAMMER H, 1994, DNA CELL BIOL, V13, P1137, DOI 10.1089/dna.1994.13.1137; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WOLF BA, 1995, J BIOL CHEM, V270, P4916, DOI 10.1074/jbc.270.9.4916; XU HX, 1995, J BIOL CHEM, V270, P23243, DOI 10.1074/jbc.270.40.23243	52	179	190	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4188	4194						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626761				2022-12-25	WOS:A1996TW96000039
J	Hensold, JO; Stratton, CA; Barth, D; Galson, DL				Hensold, JO; Stratton, CA; Barth, D; Galson, DL			Expression of the transcription factor, Spi-1 (PU.1), in differentiating murine erythroleukemia cells is regulated post-transcriptionally - Evidence for differential stability of transcription factor mRNAs following inducer exposure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; PUTATIVE ONCOGENE SPI-1; DNA-BINDING PROTEIN; C-FOS; GENE; ACTIVATION; GLOBIN; CLONING; VIRUS; DEADENYLATION	Increased expression of the transcription factor Spi-1 (PU.1) results from retroviral insertion in nearly all Friend spleen focus-forming virus-transformed murine erythroleukemia cell lines and exposure of these cells to Me(2)SO, induces their differentiation and decreases Spi-1 mRNA level by 4-5-fold. While these results suggest that alterations in Spi-1 expression have significant effects on erythroblast growth and differentiation, neither the cause nor the effect of the decrease in Spi-1 expression that follows Me(2)SO exposure has been established. The experiments described here demonstrate that the effect of inducers on Spi-1 expression is regulated post-transcriptionally. Nuclear run-off transcriptions demonstrated that Spi-1 transcription was not decreased following Me(2)SO exposure. Additionally, expression of a recombinant Spi-1 mRNA under transcriptional control of a constitutively active Rous sarcoma virus promoter was regulated identically to endogenous Spi-1 mRNA. The ability of Me(2)SO to destabilize Spi-1 mRNA was selective, as the stability of the erythroid transcription factors GATA-1 and NF-E2 were not similarly effected. The effect of Me(2)SO on the stability of Spi-1 mRNA provides a novel means of altering gene expression in these cells and is likely to have significance for the differentiation of these cells.	CASE WESTERN RESERVE UNIV,IRELAND CANC CTR,DEPT MED,CLEVELAND,OH 44106; DEPT VET AFFAIRS MED CTR,CLEVELAND,OH 44106; MASSACHUSETTS GEN HOSP,ARTHRIT UNIT,BOSTON,MA 02129	Case Western Reserve University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Harvard University; Massachusetts General Hospital			Galson, Deborah L./E-9370-2010	Galson, Deborah L./0000-0002-2045-8807	NIDDK NIH HHS [DK43414] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIRD WC, 1994, J BIOL CHEM, V269, P883; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; EBERT PS, 1976, CANCER RES, V36, P1809; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GALSON DL, 1988, MOL CELL BIOL, V8, P381, DOI 10.1128/MCB.8.1.381; GIEBEL LB, 1988, DEV BIOL, V125, P200, DOI 10.1016/0012-1606(88)90073-5; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; HENSOLD JO, 1990, MOL CELL BIOL, V10, P1600, DOI 10.1128/MCB.10.4.1600; HENSOLD JO, 1991, BLOOD, V77, P1362; KABNICK KS, 1988, MOL CELL BIOL, V8, P3244, DOI 10.1128/MCB.8.8.3244; KINDY MS, 1987, MOL CELL BIOL, V7, P2857, DOI 10.1128/MCB.7.8.2857; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOMINATO Y, 1995, MOL CELL BIOL, V15, P59; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAIRDOFFRINGA IA, 1990, MOL CELL BIOL, V10, P6132, DOI 10.1128/MCB.10.12.6132; LAUB O, 1980, P NATL ACAD SCI-BIOL, V77, P3297, DOI 10.1073/pnas.77.6.3297; LAVIGEUR A, 1990, NEW BIOL, V2, P1015; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PEACOCK J, 1990, MOL CELL BIOL, V10, P3307; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHOJI W, 1994, J BIOL CHEM, V269, P5078; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; STOECKLE MY, 1993, BIOTECHNIQUES, V15, P227; TILGHMAN SM, 1977, P NATL ACAD SCI USA, V74, P4406, DOI 10.1073/pnas.74.10.4406; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; WILSON GN, 1978, P NATL ACAD SCI USA, V75, P5367, DOI 10.1073/pnas.75.11.5367; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WOYCHIK RP, 1984, P NATL ACAD SCI-BIOL, V81, P3944, DOI 10.1073/pnas.81.13.3944; YEN TJ, 1988, MOL CELL BIOL, V8, P1224, DOI 10.1128/MCB.8.3.1224; ZHENG DE, 1994, MOL CELL BIOL, V14, P373	49	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3385	3391						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631937				2022-12-25	WOS:A1996TV72400011
J	Hill, A; Nantel, A; Rock, CD; Quatrano, RS				Hill, A; Nantel, A; Rock, CD; Quatrano, RS			A conserved domain of the viviparous-1 gene product enhances the DNA binding activity of the bZIP protein EmBP-1 and other transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABSCISIC-ACID; ZIPPER PROTEIN; TAX PROTEIN; MAIZE; ACTIVATOR; EMBRYOGENESIS; EXPRESSION; RECOGNIZES; SEQUENCE; PROMOTER	The maize VP1 protein is a seed-specific regulator of gene expression that effects the expression of a subset of abscisic acid (ABA)-regulated genes that are expressed during the maturation program of the seed. In addition, VP1 has pleiotropic effects on seed development that are not related to ABA. In transient expression assays, VP1 has been shown to transactivate gene expression through at least two distinct promoter elements: the G boxes from the ABA-inducible wheat Em gene and the SphI box from the maize C1 gene. We have investigated how VP1 can transactivate gene expression through diverse promoter elements by analyzing its association in vitro with EmBP-1, a factor that binds the Em promoter. We demonstrate that VP1 can greatly enhance the DNA binding activity of EmBP-1 in a gel retardation assay. This enhancing activity has also been observed on transcription factors as diverse as Opaque-2, Max, Sp1, and NF-kappa B. Deletion of a small but highly conserved region (BR2) in VP1 eliminates the enhancement in vitro as well as the ability of VP1 to transactivate Em gene expression in a transient expression assay. A 40-amino acid fragment from VP1 sandwiched between the maltose-binding protein and LacZ can confer the enhancement function to this fusion protein in vitro. A weak and relatively nonspecific interaction between BR2 and DNA is demonstrated by UV cross-linking. The in vitro properties we observe for VP1 might explain the regulatory effects of VP1 on a diverse set of genes and why mutations in the vp1 locus have pleiotropic effects.	UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill				, Christopher/0000-0002-2090-0650	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013588] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44288, GM14752, GM13588-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; BANNISTER AJ, 1992, NUCLEIC ACIDS RES, V20, P3523, DOI 10.1093/nar/20.13.3523; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHANDLER PM, 1994, ANNU REV PLANT PHYS, V45, P113, DOI 10.1146/annurev.pp.45.060194.000553; DOONER HK, 1985, PLANT PHYSIOL, V77, P486, DOI 10.1104/pp.77.2.486; EDGERTON MD, 1992, PLANT CELL, V4, P161, DOI 10.1105/tpc.4.2.161; FOSTER R, 1994, FASEB J, V8, P192, DOI 10.1096/fasebj.8.2.8119490; Fujisawa J, 1993, Hum Cell, V6, P266; GALAU GA, 1991, PHYSIOL PLANTARUM, V81, P280; GIRAUDAT J, 1992, PLANT CELL, V4, P1251, DOI 10.1105/tpc.4.10.1251; GUILTINAN MJ, 1990, SCIENCE, V250, P267, DOI 10.1126/science.2145628; HATTORI T, 1995, PLANT J, V7, P913, DOI 10.1046/j.1365-313X.1995.07060913.x; HATTORI T, 1994, PLANT MOL BIOL, V24, P805, DOI 10.1007/BF00029862; HATTORI T, 1992, GENE DEV, V6, P609, DOI 10.1101/gad.6.4.609; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KIDOU SI, 1994, DNA SEQUENCE, V5, P125, DOI 10.3109/10425179409039714; Litts J C, 1991, DNA Seq, V1, P263, DOI 10.3109/10425179109020781; LITTS JC, 1992, PLANT MOL BIOL, V19, P335, DOI 10.1007/BF00027357; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LU GH, 1992, P NATL ACAD SCI USA, V89, P11490, DOI 10.1073/pnas.89.23.11490; MARCOTTE WR, 1988, NATURE, V335, P454, DOI 10.1038/335454a0; MARCOTTE WR, 1989, PLANT CELL, V1, P969, DOI 10.2307/3868997; MCCARTY DR, 1989, DEV GENET, V10, P473, DOI 10.1002/dvg.1020100608; MCCARTY DR, 1991, CELL, V66, P895, DOI 10.1016/0092-8674(91)90436-3; MCCARTY DR, 1989, PLANT CELL, V1, P523, DOI 10.1105/tpc.1.5.523; MEINKE DW, 1994, PLANT CELL, V6, P1049, DOI 10.1105/tpc.6.8.1049; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; PAIVA R, 1994, PLANTA, V192, P332, DOI 10.1007/BF00198568; PAOLELLA DN, 1994, SCIENCE, V264, P1130, DOI 10.1126/science.8178171; PARCY F, 1994, PLANT CELL, V6, P1567, DOI 10.1105/tpc.6.11.1567; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PIETRZAK M, 1986, NUCLEIC ACIDS RES, V14, P5857, DOI 10.1093/nar/14.14.5857; PLA M, 1991, MOL GEN GENET, V230, P394, DOI 10.1007/BF00280296; RIVIN CJ, 1991, PLANT PHYSIOL, V95, P358, DOI 10.1104/pp.95.2.358; ROCK CD, 1994, CURR BIOL, V4, P1013, DOI 10.1016/S0960-9822(00)00229-3; Rock Christopher D., 1995, P671; Scandalios J G, 1990, Adv Genet, V28, P1; SCHMIDT RJ, 1992, PLANT CELL, V4, P689, DOI 10.1105/tpc.4.6.689; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STRAUSS JK, 1994, SCIENCE, V266, P1829, DOI 10.1126/science.7997878; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WATT F, 1988, NUCLEIC ACIDS RES, V16, P1471, DOI 10.1093/nar/16.4.1471; WILLIAMS B, 1991, PLANT MOL BIOL, V16, P919, DOI 10.1007/BF00015086; WILLIAMS BA, 1994, DEV GENET, V15, P415, DOI 10.1002/dvg.1020150504; WILLIAMSON JD, 1992, P NATL ACAD SCI USA, V89, P8842, DOI 10.1073/pnas.89.18.8842	46	102	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3366	3374						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631935	hybrid, Green Published			2022-12-25	WOS:A1996TV72400009
J	Sabourin, JC; Kern, AS; Gregori, C; Porteu, A; Cywiner, C; Chatelet, FP; Kahn, A; Pichard, AL				Sabourin, JC; Kern, AS; Gregori, C; Porteu, A; Cywiner, C; Chatelet, FP; Kahn, A; Pichard, AL			An intronic enhancer essential for tissue-specific expression of the aldolase B transgenes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE GENE-EXPRESSION; PYRUVATE-KINASE; RAT-LIVER; METABOLIC ZONATION; MESSENGER-RNAS; PROMOTER; POSITION; MICE; TRANSCRIPTION; CELLS	Expression in mice of transgenes directed by regulatory regions of the rat aldolase B gene requires the presence of a B element located in the first intron, while constructs devoid of this intronic enhancer are silent. Histo- and immunochemical staining of transgenic tissue sections showed that the longer transgene was expressed in the proximal tubular cells of the kidney, enterocytes located in small intestine villi and liver parenchymal cells. In the liver, a maximal expression was observed in perivenous hepatocytes, while the transgene was weakly active in periportal hepatocytes, which reproduced the pattern of functional zonation already reported for other glycolytic and gluconeogenic genes in the liver. We also established that the transgene retained the necessary elements for a correct chronological expression during development but was lacking elements necessary for activation by high carbohydrate diet. Instead, transgene expression was paradoxically stimulated in fasted animals, suggesting that the endogenous gene, which must be active under both glycolytic and gluconeogenic conditions, could possess distinct elements activating it in fasted as well as in carbohydrate-fed animals; the former element might be conserved in the transgene and the latter one might be lost.	INSERM, U129, INST COCHIN GENET MOLEC, F-75014 PARIS, FRANCE; CHU ST ANTOINE, LAB BIOL MOLEC MORPHOL, F-75012 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite								BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BODE J, 1988, BIOCHEMISTRY-US, V27, P4706, DOI 10.1021/bi00413a019; BROOKS AR, 1994, MOL CELL BIOL, V14, P2243, DOI 10.1128/MCB.14.4.2243; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONCORDET JP, 1993, MOL CELL BIOL, V13, P9, DOI 10.1128/MCB.13.1.9; CUIF MH, 1992, MOL CELL BIOL, V12, P4852, DOI 10.1128/MCB.12.11.4852; DONOGHUE MJ, 1991, J CELL BIOL, V115, P423, DOI 10.1083/jcb.115.2.423; DONOGHUE MJ, 1992, CELL, V69, P67, DOI 10.1016/0092-8674(92)90119-W; FRASER P, 1990, NUCLEIC ACIDS RES, V18, P3503, DOI 10.1093/nar/18.12.3503; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREGORI C, 1993, NUCLEIC ACIDS RES, V21, P897, DOI 10.1093/nar/21.4.897; GREGORI C, 1994, NUCLEIC ACIDS RES, V22, P1242, DOI 10.1093/nar/22.7.1242; GREGORI C, 1991, BIOCHEM BIOPH RES CO, V176, P722, DOI 10.1016/S0006-291X(05)80244-X; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GUDER WG, 1984, KIDNEY INT, V26, P101, DOI 10.1038/ki.1984.143; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; Hildebrand R, 1980, Adv Anat Embryol Cell Biol, V60, P1; JUNGERMANN K, 1988, SEMIN LIVER DIS, V8, P329, DOI 10.1055/s-2008-1040554; KALOS M, 1995, MOL CELL BIOL, V15, P198, DOI 10.1128/MCB.15.1.198; KATZ N, 1977, FEBS LETT, V83, P272, DOI 10.1016/0014-5793(77)81021-1; KIM SH, 1993, J CELL BIOL, V123, P877, DOI 10.1083/jcb.123.4.877; KUO FC, 1991, MOL CELL BIOL, V11, P6050, DOI 10.1128/MCB.11.12.6050; MIETHKE H, 1985, BIOL CHEM H-S, V366, P493, DOI 10.1515/bchm3.1985.366.1.493; MISKIMINS R, 1992, DEV BRAIN RES, V65, P217, DOI 10.1016/0165-3806(92)90182-V; MUNNICH A, 1985, J CLIN INVEST, V75, P1045, DOI 10.1172/JCI111766; NUMAZAKI M, 1984, EUR J BIOCHEM, V142, P165, DOI 10.1111/j.1432-1033.1984.tb08265.x; PHIVAN L, 1990, MOL CELL BIOL, V10, P2302, DOI 10.1128/MCB.10.5.2302; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; RAYMONDJEAN M, 1991, NUCLEIC ACIDS RES, V19, P6145, DOI 10.1093/nar/19.22.6145; SCHAPIRA F, 1975, ISOZYMES, V3, P987; SHIH HM, 1994, J BIOL CHEM, V269, P9380; TRUS M, 1980, J HISTOCHEM CYTOCHEM, V28, P579, DOI 10.1177/28.6.7391551; VAULONT S, 1986, J BIOL CHEM, V261, P7621; WEBER A, 1984, J BIOL CHEM, V259, P1798; WELSH FA, 1972, J HISTOCHEM CYTOCHEM, V20, P107, DOI 10.1177/20.2.107	37	21	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3469	3473						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631949	hybrid			2022-12-25	WOS:A1996TV72400023
J	Pocard, M; Chevillard, S; Villaudy, J; Poupon, MF; Dutrillaux, B; Remvikos, Y				Pocard, M; Chevillard, S; Villaudy, J; Poupon, MF; Dutrillaux, B; Remvikos, Y			Different p53 mutations produce distinct effects on the ability of colon carcinoma cells to become blocked at the G1/S boundary after irradiation	ONCOGENE			English	Article						p53 mutations; colon carcinoma; cell cycle arrest; transfection	WILD-TYPE P53; COLORECTAL TUMORIGENESIS; TUMOR SUPPRESSION; BREAST-CANCER; GROWTH ARREST; MUTANT P53; PROTEIN; DNA; GENE; INSTABILITY	The LoVo colon carcinoma cell line that presents two wild type p53 alleles was used as the recipient for a series of transfections with p53 expression vectors coding for wild-type or three different mutants (143ala, 175his or 273his). The parental cell line as well as all clones that had rearranged the plasmid with consequent loss of p53 c-DNA were readily blocked at the G1/S boundary following 10 Gy of irradiation. For each mutation two clones with different levels of mutant protein expression were selected. Confirmation of the integration of the exogenous sequence was obtained by the expression of the mutant m-RNA, established by reverse transcription and DGGE or Southern blot. Flow cytometric measurements of 5-bromodeoxyuridine incorporation revealed a total G(1)/S block of the 143ala transfectants, similarly to the parental and control transfectant cells, but little or no cell cycle block for the 175his and 273his clones. Although it has been shown in vitro that all three mutations interfere with transcriptional activation by the wild-type protein, not only did we observe p53 protein induction and nuclear accumulation following irradiation, but WAF-1/CIP-1 m-RNA was increased in some of the clones for which the G1/S block was abolished. Our results show that mutant p53 proteins are to some extent submitted to the control of the cellular environment in cancer cells with wild type p53 alleles, but with an efficacy that depends on the mutation.	INST CURIE,UMR CYTOGENET MOLEC & ONCOL 147,F-75231 PARIS 05,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie				Chevillard, Sylvie/0000-0001-5889-4041				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DEAN SW, 1989, EXP CELL RES, V183, P473, DOI 10.1016/0014-4827(89)90406-0; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; HALL PA, 1993, ONCOGENE, V8, P203; HANN, 1995, NAT GENET, V9, P221; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLSTEIN M, 1991, SCIENCE, V253, P49; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1994, INT J CANCER, V57, P623, DOI 10.1002/ijc.2910570502; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHIELI P, 1994, CANCER RES, V54, P3391; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MULERIS M, 1988, CANCER GENET CYTOGEN, V32, P43, DOI 10.1016/0165-4608(88)90310-X; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TOMINAGA O, 1993, ONCOGENE, V8, P2653; TOMINAGA O, 1992, Critical Reviews in Oncogenesis, V3, P257; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VSOJTESEK B, 1993, J CELL SCI, V105, P607; WILLIAMS AC, 1995, ONCOGENE, V11, P141; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	38	62	62	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					875	882						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632910				2022-12-25	WOS:A1996TW68600019
J	deVitry, C; Breyton, C; Pierre, Y; Popot, JL				deVitry, C; Breyton, C; Pierre, Y; Popot, JL			The 4-kDa nuclear-encoded PetM polypeptide of the chloroplast cytochrome b(6)f - Complex nucleic acid and protein sequences, targeting signals, transmembrane topology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDOMONAS-REINHARDTII; MEMBRANE-PROTEINS; MOLECULAR-WEIGHT; TRANSIT PEPTIDES; GENES; SUBUNITS; MITOCHONDRIAL; EXPRESSION; SPINACH	The 4-kDa subunit of cytochrome b(6)f complex encoded by the nuclear PetM gene in Chlamydomonas reinhardtii has been characterized, 38 of the 39 residues of the mature protein have been established by Edman degradation, a cDNA clone encoding the complete precursor has been isolated and sequenced, and a 0.6-kb transcript detected, The deduced amino acid sequence of the precursor includes an N-terminal transit peptide of 60 amino acids with stromal targeting features. Examination of the sequence suggests that PetM spans the membrane as a single transmembrane alpha-helix, which is supported by its non-extractability following dissociating treatments, When PetM and PetG, another small subunit of the b(6)f complex, are folded into alpha-helices, an array of identical residues becomes apparent, Proteolysis data, charge distribution, and homology with PetG are consistent with a lumenal localization of the N terminus of PetM.			deVitry, C (corresponding author), INST BIOL PHYSICOCHIM,CNRS URA 1187,SERV PHOTOSYNTHESE,13 RUE PIERRE & MARIE CURIE,F-75005 PARIS,FRANCE.							ATTEIA A, 1992, J BIOL CHEM, V267, P226; BALD D, 1992, P 9 INT C PHOT, P629; BERTHOLD DA, 1995, J BIOL CHEM, V270, P29293, DOI 10.1074/jbc.270.49.29293; BREYTON C, 1994, J BIOL CHEM, V269, P7597; BUSCHLEN S, 1991, FEBS LETT, V284, P257, DOI 10.1016/0014-5793(91)80698-3; DALBEY RE, 1995, TRENDS CELL BIOL, V5, P380, DOI 10.1016/S0962-8924(00)89079-0; DELEPELAIRE P, 1979, P NATL ACAD SCI USA, V76, P111, DOI 10.1073/pnas.76.1.111; DEVITRY C, 1989, CR ACAD SCI III-VIE, V309, P709; DEVITRY C, 1994, J BIOL CHEM, V269, P7603; DEVITRY C, 1991, J BIOL CHEM, V266, P16614; DEVITRY C, 1989, J CELL BIOL, V109, P991, DOI 10.1083/jcb.109.3.991; deVitry C, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P595; DRAPIER D, 1992, PLANT CELL, V4, P283, DOI 10.2307/3869540; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FONG SE, 1992, CURR GENET, V21, P527, DOI 10.1007/BF00351664; FRANZEN LG, 1990, FEBS LETT, V260, P165, DOI 10.1016/0014-5793(90)80094-Y; GAVEL Y, 1991, FEBS LETT, V282, P41, DOI 10.1016/0014-5793(91)80440-E; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; GOLDSCHMIDTCLERMONT M, 1986, J MOL BIOL, V191, P421, DOI 10.1016/0022-2836(86)90137-3; HALEY J, 1989, P NATL ACAD SCI USA, V86, P1534, DOI 10.1073/pnas.86.5.1534; HERRMANN RG, 1993, FEBS LETT, V326, P192, DOI 10.1016/0014-5793(93)81789-3; HUANG D, 1994, BIOCHEMISTRY-US, V33, P4401, DOI 10.1021/bi00180a038; Joliot A, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P615; LEMAIRE C, 1986, BIOCHIM BIOPHYS ACTA, V851, P229, DOI 10.1016/0005-2728(86)90130-1; PIERRE Y, 1995, J BIOL CHEM, V270, P29342, DOI 10.1074/jbc.270.49.29342; PIERRE Y, 1993, CR ACAD SCI III-VIE, V316, P1404; POPOT JL, 1990, ANNU REV BIOPHYS BIO, V19, P369; Popot JL, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P507; SCHMIDT CL, 1993, PHOTOSYNTH RES, V38, P73, DOI 10.1007/BF00015063; TAKAHASHI Y, 1996, IN PRESS EMBO J; Theg Steven M., 1993, Trends in Cell Biology, V3, P186, DOI 10.1016/0962-8924(93)90212-J; WYNN RM, 1988, BIOCHIM BIOPHYS ACTA, V935, P115, DOI 10.1016/0005-2728(88)90208-3	32	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10667	10671		10.1074/jbc.271.18.10667	http://dx.doi.org/10.1074/jbc.271.18.10667			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631873	hybrid			2022-12-25	WOS:A1996UJ34200041
J	LopezBeltran, EA; Mate, MJ; Cerdan, S				LopezBeltran, EA; Mate, MJ; Cerdan, S			Dynamics and environment of mitochondrial water as detected by H-1 NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; RED-BLOOD-CELLS; HUMAN-ERYTHROCYTES; DIFFUSION PERMEABILITY; TRANSPORT; GRADIENT; O-17	The dynamics and environment of water in suspensions of isolated rat liver mitochondria have been investigated by H-1 NMR, NMR longitudinal and transversal relaxation times (T-1 and T-2) were measured in the resuspension medium (2.65 s and 44.57 ms) and in mitochondrial suspensions (1.74 s and 23.14 ms), respectively, Results showed monoexponential relaxation in both cases, suggesting a fast water exchange across the inner mitochondrial membrane. Ferromagnetically induced shift of the extramitochondrial water with nonpermeant ferromagnetic particles revealed no detectable water signal from the intramitochondrial compartment, confirming the fast exchange case, Simulations on a two-compartment model indicated that the intramitochondrial water residence time has an upper limit of approximately 100 mu s. Calculated intramitochondrial relaxation times revealed that the intramitochondrial environment has an apparent viscosity 30 times larger than the resuspension medium and 15 times larger than the cytosol of erythrocytes. The higher apparent viscosity of the mitochondrial matrix could account for reductions of more than one order of magnitude in the diffusion coefficient of water and other substrates, limitations in the rate of enzymatic reactions which are diffusion controlled and a more favorable formation of multienzyme complexes.	CSIC, INST INVEST BIOMED, E-28029 MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)				Cerdan, Sebastian/0000-0001-9965-0270				ANDRASKO J, 1976, BIOCHIM BIOPHYS ACTA, V428, P304, DOI 10.1016/0304-4165(76)90038-6; BENGA G, 1990, J BIOCHEM BIOPH METH, V21, P87, DOI 10.1016/0165-022X(90)90057-J; BENGA G, 1992, EUR J CELL BIOL, V59, P219; BENGA G, 1989, INT REV CYTOL, V114, P273; CHIEN DY, 1977, BIOCHIM BIOPHYS ACTA, V464, P45, DOI 10.1016/0005-2736(77)90369-8; CLEVELAND GG, 1976, BIOPHYS J, V16, P1043, DOI 10.1016/S0006-3495(76)85754-2; CONLON T, 1972, BIOCHIM BIOPHYS ACTA, V288, P354, DOI 10.1016/0005-2736(72)90256-8; COOKE R, 1974, ANNU REV BIOPHYS BIO, V3, P95, DOI 10.1146/annurev.bb.03.060174.000523; Darley-Usmar V.M., 1987, MITOCHONDRIA PRACTIC, P4; Dawson A., 1987, MITOCHONDRIA PRACTIC, P35; FEHRST A, 1977, ENZYME STRUCTURE MEC, P126; FOSTER MA, 1984, MAGNETIC RESONANCE M, P137; GADIAN DG, 1982, NUCL MAGNETIC RESONA, P125; GARLID KD, 1979, CELL ASS WATER, P293; GUNTER TE, 1972, BIOPHYS J, V12, P625, DOI 10.1016/S0006-3495(72)86108-3; HAINES TH, 1994, FEBS LETT, V346, P115, DOI 10.1016/0014-5793(94)00470-6; HERBST MD, 1989, AM J PHYSIOL, V256, pC1097, DOI 10.1152/ajpcell.1989.256.5.C1097; HUTSON SM, 1992, BIOCHEMISTRY-US, V31, P1322, DOI 10.1021/bi00120a007; Israelachvili J, 1996, NATURE, V379, P219, DOI 10.1038/379219a0; KOENIG SH, 1969, J BIOL CHEM, V244, P3283; KOENIG SH, 1975, P NATL ACAD SCI USA, V72, P2667, DOI 10.1073/pnas.72.7.2667; LANG RDA, 1987, MITOCHONDRIA PRACTIC, P17; LANOUE KF, 1984, J BIOL CHEM, V259, P4116; LATOUR LL, 1994, P NATL ACAD SCI USA, V91, P1229, DOI 10.1073/pnas.91.4.1229; MCCONNELL HM, 1958, J CHEM PHYS, V28, P430, DOI 10.1063/1.1744152; MOLDAY RS, 1982, J IMMUNOL METHODS, V52, P353, DOI 10.1016/0022-1759(82)90007-2; MOLDES M, 1994, NMR BIOMED, V7, P249, DOI 10.1002/nbm.1940070602; NEVILLE MC, 1974, SCIENCE, V184, P1072, DOI 10.1126/science.184.4141.1072; NIETO R, 1992, BIOCHIMIE, V74, P903, DOI 10.1016/0300-9084(92)90074-O; OVADI J, 1992, TRENDS BIOCHEM SCI, V17, P445, DOI 10.1016/0968-0004(92)90485-R; POXLEITNER M, 1993, Z NATURFORSCH C, V48, P654; PRICE WS, 1989, BIOPHYS CHEM, V33, P205, DOI 10.1016/0301-4622(89)80022-5; RENSHAW P F, 1986, Magnetic Resonance Imaging, V4, P351, DOI 10.1016/0730-725X(86)91045-3; SCARPA A, 1979, MEMBRANE TRANSPORT B, V2, P263; SHPORER M, 1975, BIOCHIM BIOPHYS ACTA, V385, P81, DOI 10.1016/0304-4165(75)90076-8; SOLOMON AK, 1989, METHOD ENZYMOL, V173, P192; Srere P A, 1987, Biochem Soc Symp, V54, P173; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; STRAUME M, 1992, METHOD ENZYMOL, V210, P87; WANG JH, 1951, J AM CHEM SOC, V73, P510, DOI 10.1021/ja01146a002; WELCH GR, 1994, TRENDS BIOCHEM SCI, V19, P193; WELCH GR, 1986, S BIOL HUNG, V30, P217	42	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10648	10653		10.1074/jbc.271.18.10648	http://dx.doi.org/10.1074/jbc.271.18.10648			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631870	hybrid			2022-12-25	WOS:A1996UJ34200038
J	Pandey, A; Liu, X; Dixon, JE; DiFiore, PP; Dixit, VM				Pandey, A; Liu, X; Dixon, JE; DiFiore, PP; Dixit, VM			Direct association between the Ret receptor tyrosine kinase and the Src homology 2-containing adapter protein Grb7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; BINDING; DOMAINS; LINE	Adapter proteins containing Src homology 2 (SH2) domains link transmembrane receptor protein-tyrosine kinases to downstream signal transducing molecules, A family of SH2 containing adapter proteins including Grb7 and Grb10 has been recently identified, We had previously shown that Grb10 associates with Ret via its SH2 domain in an activation-dependent manner (Pandey, A., Duan, H., Di Fiore, P.P., and Dixit, V.M, (1995) J. Biol, Chem, 270, 21461-21463), We now demonstrate that the related adapter molecule Grb7 also associates with Ret in vitro and in vivo, and that the binding of the SH2 domain of Grb7 to Ret is direct, This binding is depend ent upon Ret autophosphorylation since Grb7 is incapable of binding a kinase-defective mutant of Ret, Thus two members of the Grb family, Grb7 and Grb10, likely relay signals emanating from Ret to other, as yet, unidentified targets within the cell.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT BIOCHEM,ANN ARBOR,MI 48109; EUROPEAN INST ONCOL,MILAN,ITALY	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; IRCCS European Institute of Oncology (IEO)			Pandey, Akhilesh/B-4127-2009; dixit, vishva m/A-4496-2012; Di Fiore, Pier Paolo/K-2130-2012	Pandey, Akhilesh/0000-0001-9943-6127; dixit, vishva m/0000-0001-6983-0326; Di Fiore, Pier Paolo/0000-0002-2252-0950	NIDDK NIH HHS [DK 39255] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039255] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASAI N, 1995, MOL CELL BIOL, V15, P1613; BORRELLO MG, 1994, ONCOGENE, V9, P1661; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HU HM, 1994, J BIOL CHEM, V269, P30069; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; MARGOLIS B, 1994, PROG BIOPHYS MOL BIO, V62, P223, DOI 10.1016/0079-6107(94)90013-2; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; OOI J, 1995, ONCOGENE, V10, P1621; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; ROMANO A, 1994, ONCOGENE, V9, P2923; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; ZHU GC, 1992, P NATL ACAD SCI USA, V89, P9559, DOI 10.1073/pnas.89.20.9559	21	71	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10607	10610		10.1074/jbc.271.18.10607	http://dx.doi.org/10.1074/jbc.271.18.10607			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631863	hybrid			2022-12-25	WOS:A1996UJ34200031
J	Tsuda, H; Yamada, SH; Yamane, Y; Yoshida, K; Hopwood, JJ; Sugahara, K				Tsuda, H; Yamada, SH; Yamane, Y; Yoshida, K; Hopwood, JJ; Sugahara, K			Structures of five sulfated hexasaccharides prepared from porcine intestinal heparin using bacterial heparinase - Structural variants with apparent biosynthetic precursor-product relationships for the antithrombin III-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; HUMAN-ENDOTHELIAL CELLS; 2 SERIES; OLIGOSACCHARIDES; DEPOLYMERIZATION; TETRASACCHARIDES; PURIFICATION; AFFINITY; SEQUENCE; IDENTIFICATION	Porcine intestinal heparin was extensively digested with Flavobacterium heparinase and size-fractionated by gel chromatography. Subfractionation of the hexasaccharide fraction by anion exchange high pressure liquid chromatography yielded 10 fractions. Six contained oligosaccharides derived from the repeating disaccharide region, whereas four contained glycoserines from the glycosaminoglycan-protein linkage region. The latter structures were reported recently (Sugahara, K., Tsuda, H., Yoshida, K., Yamada, S., de Beer, T., and Vliegenthart, J. F. G. (1995) J. Biol. Chem. 270, 22914-22923). In this study, the structures of one tetra- and five hexasaccharides from the repeat region were determined by chemical and enzymatic analyses as well as 500-MHz H-1 NMR spectroscopy. The tetrasaccharide has the hexasulfated structure typical of heparin. The five hexa- or heptasulfated hexasaccharides share the common core pentasulfated structure Delta HexA(2S)alpha 1-4GlcN(NS,6S)alpha 1-4IdoA alpha/GlcA beta 1-4GlcN(6S)alpha 1-4GlcA beta 1-4GlcN(NS) with one or two additional sulfate groups (Delta HexA, GlcN, IdoA, and GlcA represent 4-deoxy-alpha-L-threo-hex-4-enepyranosyluronic acid, D-glucosamine, L-iduronic acid, and D-glucuronic acid, whereas 2S, 6S, and NS stand for 2-O-, 6-O-, and 2-N-sulfate, respectively). Three components have the following hitherto unreported structures: Delta HexeA(2S)alpha 1-4GlcN(NS,6S)alpha 1-4GlcA beta 1-4GlcN(NS,GS)alpha 1-4GlcA beta 1-4GlcN(NS,6S), Delta HexA(2S)alpha 1-4GlcN(NS,6S)alpha 1-4IdoA alpha 1-4GlcNAc(6S)alpha 1-4GlcA beta 1-4GlcN(NS,3S), and Delta HexA(2S)alpha 1-4GlcN(NS,6S)alpha 1-41doA(2S) alpha 1-4GlcNAc(6S)alpha 1-4GlcA beta 1-4GlcN(NS,6S). Two of the five hexasaccharides are structural variants derived from the antithrombin III-binding sites containing 3-O-sulfated GlcN at the reducing termini with or without a 6-O-sulfate group on the reducing N,3-disulfated GlcN residue. Another contains the structure identical to that of the above heptasulfated antithrombin III binding site fragment but lacks the 3-O-sulfate group and therefore is a pro-form for the binding site. Another has an extra sulfate group on the internal IdoA residue of this pro-form and therefore can be considered to have diverged from the binding site in the biosynthetic pathway. Thus, the isolated hexasaccharides in this study include the three overlapping pairs of structural variants with an apparent biosynthetic precursor-product relationship, which may reflect biosynthetic regulatory mechanisms of the binding site.	KOBE PHARMACEUT UNIV,DEPT BIOCHEM,HIGASHINADA KU,KOBE 658,JAPAN; SEIKAGAKU CORP,TOKYO RES INST,HIGASHIYAMATO,TOKYO 207,JAPAN; ADELAIDE CHILDRENS HOSP INC,DEPT CHEM PATHOL,LYSOSOMAL DIS RES UNIT,ADELAIDE,SA 5006,AUSTRALIA	Kobe Pharmaceutical University; Seikagaku Corporation								BARZU T, 1989, J CELL PHYSIOL, V140, P538, DOI 10.1002/jcp.1041400320; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; FOLKMAN J, 1989, HEPARIN, P317; FREEMAN C, 1992, BIOCHEM J, V282, P899, DOI 10.1042/bj2820899; GALLAGHER JT, 1989, HEPARIN, P135; GILAT D, 1995, J EXP MED, V181, P1929, DOI 10.1084/jem.181.5.1929; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; HOOGEWERF AJ, 1995, J BIOL CHEM, V270, P3268, DOI 10.1074/jbc.270.7.3268; HORNE A, 1992, CARBOHYD RES, V225, P43, DOI 10.1016/0008-6215(92)80038-3; ISHIHARA M, 1994, GLYCOBIOLOGY, V4, P817, DOI 10.1093/glycob/4.6.817; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KLAGSBRUN M, 1985, P NATL ACAD SCI USA, V82, P805, DOI 10.1073/pnas.82.3.805; KUSCHE M, 1988, J BIOL CHEM, V263, P15474; KUSCHE M, 1990, J BIOL CHEM, V265, P7292; LINDAHL U, 1983, J BIOL CHEM, V258, P9826; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LINDAHL U, 1965, J BIOL CHEM, V240, P2821; Lindahl U., 1989, HEPARIN, P159; LINHARDT RJ, 1992, J BIOL CHEM, V267, P2380; LINKER A, 1984, CARBOHYD RES, V127, P75, DOI 10.1016/0008-6215(84)85107-1; LYON M, 1994, J BIOL CHEM, V269, P11216; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MACIAG T, 1984, SCIENCE, V225, P932, DOI 10.1126/science.6382607; MARCUM JA, 1989, HEPARIN, P275; MCLEAN MW, 1984, EUR J BIOCHEM, V145, P607, DOI 10.1111/j.1432-1033.1984.tb08600.x; MERCHANT ZM, 1985, BIOCHEM J, V229, P369, DOI 10.1042/bj2290369; MORITA T, 1977, J BIOCHEM-TOKYO, V82, P1495, DOI 10.1093/oxfordjournals.jbchem.a131840; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; RAZI N, 1995, J BIOL CHEM, V270, P11267, DOI 10.1074/jbc.270.19.11267; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; SUGAHARA K, 1995, J BIOL CHEM, V270, P22914, DOI 10.1074/jbc.270.39.22914; SUGAHARA K, 1992, J BIOL CHEM, V267, P1528; SUGAHARA K, 1987, ARCH BIOCHEM BIOPHYS, V258, P391, DOI 10.1016/0003-9861(87)90360-2; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; TSUKADA T, 1987, COMP BIOCHEM PHYS B, V86, P565, DOI 10.1016/0305-0491(87)90449-4; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; YAMADA S, 1992, J BIOCHEM-TOKYO, V112, P440, DOI 10.1093/oxfordjournals.jbchem.a123919; YAMADA S, 1995, J BIOL CHEM, V270, P8696; YAMADA S, 1994, GLYCOBIOLOGY, V4, P69, DOI 10.1093/glycob/4.1.69; YAMADA SH, 1993, J BIOL CHEM, V268, P4780; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YOSHIDA K, 1989, 10TH P INT S GLYC JE, P330	51	24	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10495	10502		10.1074/jbc.271.18.10495	http://dx.doi.org/10.1074/jbc.271.18.10495			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631846	hybrid			2022-12-25	WOS:A1996UJ34200014
J	Zhou, J; Mulshine, JL; Unsworth, EJ; Scott, FR; Avis, IM; Vos, MD; Treston, AM				Zhou, J; Mulshine, JL; Unsworth, EJ; Scott, FR; Avis, IM; Vos, MD; Treston, AM			Purification and characterization of a protein that permits early detection of lung cancer - Identification of heterogeneous nuclear ribonucleoprotein-A2/B1 as the antigen for monoclonal antibody 703D4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING-PROTEINS; GENE-EXPRESSION; SEQUENCE; SENSITIVITY; CELLS	We have reported that a mouse monoclonal antibody, 703D4, detects lung cancer 2 years earlier than routine chest x-ray or cytomorphology, We purified the 703D4 antigen to elucidate its role in early lung cancer biology, using Western blot detection after SDS-polyacrylamide gel electrophoresis. Purification steps included anion exchange chromatography, preparative isoelectric focusing, polymer-based C-18-like, and analytical C-4 reverse phase high performance liquid chromatography. After 25-50,000-fold purification, the principal immunostaining protein was >95% pure by Coomassie staining, The NH2 terminus was blocked, so CNBr digestion was used to generate internal peptides, Three sequences, including one across a site of alternate exon splicing, all identified a single protein, heterogeneous nuclear ribonucleoprotein-A2 (hnRNP-A2), A minor co-purifying immunoreactive protein resolved at the final C-4 high performance liquid chromatography step is the splice variant hnRNP-B1, Northern analysis of RNA from primary normal bronchial epithelial cells demonstrated a low level of hnRNP-A2/B1 expression, consistent with immunohistochemical staining of clinical samples, and increased hnRNP-A2/B1 expression was found in lung cancer cells, hnRNP-A2/B1 expression is under proliferation-dependent control in normal bronchial epithelial cell primary cultures, but not in SV40-transformed bronchial epithelial cells or tumor cell lines, With our clinical data, this information suggests that hnRNP-A2/B1 is an early marker of lung epithelial transformation and carcinogenesis.	NCI, BIOMARKERS & PREVENT RES BRANCH, DCS, ROCKVILLE, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BEVERLEY PCL, 1991, BRIT J CANCER, V63, P10; BIAMONTI G, 1993, J MOL BIOL, V230, P77, DOI 10.1006/jmbi.1993.1127; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BOSSER R, 1995, MOL CELL BIOL, V15, P661; BRODER CC, 1994, P NATL ACAD SCI USA, V91, P11699, DOI 10.1073/pnas.91.24.11699; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; DAVIS LG, 1986, BASIC METHODS MOL BI, P129; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FROST JK, 1984, AM REV RESPIR DIS, V130, P549; GANJU RK, 1994, J CLIN INVEST, V94, P1784, DOI 10.1172/JCI117526; GROSS E, 1974, BIOCHEM BIOPH RES CO, V59, P1145, DOI 10.1016/S0006-291X(74)80098-7; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; KATZ DA, 1994, NUCLEIC ACIDS RES, V22, P238, DOI 10.1093/nar/22.2.238; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KUMAR A, 1986, J BIOL CHEM, V261, P1266; KYOGASHIMA M, 1989, ARCH BIOCHEM BIOPHYS, V275, P309, DOI 10.1016/0003-9861(89)90378-0; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P6461, DOI 10.1093/nar/20.24.6461; MERRILL BM, 1988, J BIOL CHEM, V263, P3307; MULSHINE JL, 1983, J IMMUNOL, V131, P497; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; PERTON FG, 1995, BIOL CHEM H-S, V376, P243; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; PLANCK SR, 1988, NUCLEIC ACIDS RES, V16, P11663, DOI 10.1093/nar/16.24.11663; PRASAD S, 1994, BIOCHEM BIOPH RES CO, V204, P772, DOI 10.1006/bbrc.1994.2526; RAJPUROHIT R, 1994, J BIOL CHEM, V269, P1075; RISIO M, 1992, J CELL BIOCHEM, P79; SACCOMANNO G, 1970, ACTA CYTOL, V14, P377; SOULARD M, 1993, NUCLEIC ACIDS RES, V21, P4210, DOI 10.1093/nar/21.18.4210; TOCKMAN MS, 1988, J CLIN ONCOL, V6, P1685, DOI 10.1200/JCO.1988.6.11.1685; WILLIAMS KR, 1985, P NATL ACAD SCI USA, V82, P5666, DOI 10.1073/pnas.82.17.5666; ZEITLIN PL, 1991, AM J RESP CELL MOL, V4, P313, DOI 10.1165/ajrcmb/4.4.313; ZHOU J, 1996, IN PRESS LUNG CANC	32	113	126	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10760	10766		10.1074/jbc.271.18.10760	http://dx.doi.org/10.1074/jbc.271.18.10760			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631886				2022-12-25	WOS:A1996UJ34200054
J	DeSmedt, F; Boom, A; Pesesse, X; Schiffmann, SN; Erneux, C				DeSmedt, F; Boom, A; Pesesse, X; Schiffmann, SN; Erneux, C			Post-translational modification of human brain type I inositol-1,4,5-trisphosphate 5-phosphatase by farnesylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; INOSITOL 1,4,5-TRISPHOSPHATE 3-KINASE; RAT-BRAIN; HUMAN-PLATELETS; TRISPHOSPHATE; MEMBRANE; PURIFICATION; EXPRESSION; POLYPHOSPHATE-5-PHOSPHATASE; TETRAKISPHOSPHATE	In brain, type I inositol-1,4,5-trisphosphate 5-phosphatase (InsP(3) 5-phosphatase) is the major isoenzyme hydrolyzing the calcium-mobilizing second messenger InsP. Activity of this enzyme could be measured in both soluble and particulate fractions of tissue homogenates. The protein sequence showed a putative C-terminal isoprenylation site (CVVQ). In this study, two mutants have been generated. The first mutant (C409S) has a serine replacing a cysteine at position 409 of the wild-type enzyme. The second mutant (K407D1) is a deletion mutant that lacks the last five C-terminal amino acids. These constructs were individually expressed by transfection in COS-7 cells. Western blot analysis of wild-type transfected cells indicated that both soluble and particulate fractions had a 43-kDa immunoreactive band, with a higher proportion of the original homogenate associated with the particulate part. On the contrary, when the two mutated constructs were transfected in COS-7 cells, the phosphatase was predominantly soluble. Confocal immunofluorescence studies showed the wild-type enzyme to be present on the cell surface of transfected COS-7 cells and in subcellular compartments around the nucleus. This was not observed for the two mutants, where uniform immunofluorescence labeling was observed throughout the cytosol. Recombinant type I InsP(3) 5-phosphatase expressed in Escherichia coli was a substrate of purified farnesyltransferase. Altogether, the data therefore suggest a direct participation of Cys-409 in a C-terminally anchored InsP(3) 5-phosphatase by farnesylation.	FREE UNIV BRUSSELS, INTERDISCIPLINARY RES INST, B-1070 BRUSSELS, BELGIUM; FREE UNIV BRUSSELS, NEUROPATHOL & NEUROPEPTIDE RES LAB, BRAIN RES INST, B-1070 BRUSSELS, BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel				Schiffmann, Serge/0000-0002-0118-9816				ADAMSON P, 1992, J BIOL CHEM, V267, P20033; ARMSTRONG SA, 1995, J BIOL CHEM, V270, P7864, DOI 10.1074/jbc.270.14.7864; ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; CONNOLLY TM, 1987, J BIOL CHEM, V262, P2146; CONNOLLY TM, 1986, CELL, V46, P951, DOI 10.1016/0092-8674(86)90077-2; COX AD, 1995, METHOD ENZYMOL, V250, P105; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DESMEDT F, 1994, FEBS LETT, V347, P69, DOI 10.1016/0014-5793(94)00509-5; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; ERNEUX C, 1989, EUR J BIOCHEM, V181, P317, DOI 10.1111/j.1432-1033.1989.tb14726.x; ERNEUX C, 1986, BIOCHEM BIOPH RES CO, V134, P351, DOI 10.1016/0006-291X(86)90570-X; ERNEUX C, 1995, EUR J BIOCHEM, V234, P598, DOI 10.1111/j.1432-1033.1995.598_b.x; Gottesman M M, 1987, Methods Enzymol, V151, P3, DOI 10.1016/S0076-6879(87)51004-7; HANSBRO PM, 1994, ARCH BIOCHEM BIOPHYS, V311, P47, DOI 10.1006/abbi.1994.1207; HANSEN CA, 1987, J BIOL CHEM, V262, P17319; IRVINE RF, 1986, NATURE, V320, P631, DOI 10.1038/320631a0; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; JEFFERSON AB, 1995, J BIOL CHEM, V270, P9370, DOI 10.1074/jbc.270.16.9370; JOLY C, 1995, J NEUROSCI, V15, P3970; KING WG, 1989, J BIOL CHEM, V264, P6070; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAXMINARAYAN KM, 1993, J BIOL CHEM, V268, P4968; LAXMINARAYAN KM, 1994, J BIOL CHEM, V269, P17305; LU CY, 1989, J MEMBRANE BIOL, V109, P85, DOI 10.1007/BF01870793; MATZARIS M, 1994, J BIOL CHEM, V269, P3397; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MITCHELL CA, 1989, J BIOL CHEM, V264, P8873; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; NIINOBE M, 1994, BIOCHEM BIOPH RES CO, V205, P1036, DOI 10.1006/bbrc.1994.2770; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHGURO H, 1991, EMBO J, V10, P3669, DOI 10.1002/j.1460-2075.1991.tb04934.x; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RUBIERA C, 1990, BIOCHEM J, V269, P353, DOI 10.1042/bj2690353; SHEARS SB, 1988, BIOCHEM J, V256, P363, DOI 10.1042/bj2560363; TAKAZAWA K, 1990, BIOCHEM J, V272, P107, DOI 10.1042/bj2720107; TAKAZAWA K, 1991, BIOCHEM J, V278, P883, DOI 10.1042/bj2780883; TAKIMOTO K, 1989, J BIOCHEM-TOKYO, V106, P684, DOI 10.1093/oxfordjournals.jbchem.a122917; VERJANS B, 1994, BIOCHEM J, V300, P85, DOI 10.1042/bj3000085; WALTON PD, 1991, J CELL BIOL, V113, P1145, DOI 10.1083/jcb.113.5.1145; WILCOX RA, 1994, SIGNAL ACTIVATED PHO, P190; ZHANG FL, 1994, J BIOL CHEM, V269, P23465; ZHANG FL, 1996, IN PRESS ANN REV BIO, V65; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853	48	66	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10419	10424		10.1074/jbc.271.17.10419	http://dx.doi.org/10.1074/jbc.271.17.10419			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626616	hybrid			2022-12-25	WOS:A1996UG25700088
J	Smith, AN; Barth, ML; McDowell, TL; Moulin, S; Nuthall, HN; Hollingsworth, MA; Harris, A				Smith, AN; Barth, ML; McDowell, TL; Moulin, S; Nuthall, HN; Hollingsworth, MA; Harris, A			A regulatory element in intron 1 of the cystic fibrosis transmembrane conductance regulator gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINE; EPITHELIAL-CELLS; PROMOTER REGION; CFTR EXPRESSION; IDENTIFICATION; CHROMATIN; DIFFERENTIATION; LOCALIZATION; SEQUENCES; INDUCTION	The cystic fibrosis transmembrane conductance regulator (CFTR) gene exhibits a tightly regulated pattern of expression in human epithelial cells. The mechanism of this regulation is complex and is likely to involve a number of genetic elements that effect temporal and spatial expression, To date none of the elements that have been identified in the CFTR promoter regulate tissue-specific expression. We have identified a putative regulatory element within the first intron of the CFTR gene at 181 + 10kb, The region containing this element was first identified as a DNase I hypersensitive site that was present in cells that express the CFTR gene but absent from cells not transcribing CFTR, In vitro analysis of binding of proteins to this region of DNA sequence by gel mobility shift assays and DNase I footprinting revealed that some proteins that are only present in CFTR-expressing cells bound to specific elements, and other proteins that bound to adjacent elements were present in all epithelial cells irrespective of their CFTR expression status. When assayed in transient expression systems in a cell line expressing CFTR endogenously, this DNA sequence augmented reporter gene expression through activation of the CFTR promoter but had no effect in nonexpressing cells.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND; UNIV NEBRASKA,MED CTR,EPPLEY INST,OMAHA,NE 68198	University of Oxford; University of Nebraska System; University of Nebraska Medical Center			Saraiva-Pereira, Maria Luiza/H-6302-2013	Saraiva-Pereira, Maria Luiza/0000-0003-3905-9563	NIDDK NIH HHS [DK46589] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046589] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHOU JL, 1991, J BIOL CHEM, V266, P24471; COLEMAN L, 1991, J CELL SCI, V98, P85; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; FOGH J, 1977, J NATL CANCER I, V58, P209, DOI 10.1093/jnci/58.2.209; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; GRIESENBACH U, 1994, PAED PULMONOL S, V10, P199; HARRIS A, 1989, J CELL SCI, V92, P687; HARRIS A, 1991, DEVELOPMENT, V113, P305; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; HINES RN, 1988, CARCINOGENESIS, V9, P1599, DOI 10.1093/carcin/9.9.1599; HOLLINGSWORTH MA, 1994, NUCLEIC ACIDS RES, V22, P1138, DOI 10.1093/nar/22.7.1138; HUET C, 1987, J CELL BIOL, V105, P345, DOI 10.1083/jcb.105.1.345; JENUWEIN T, 1993, GENE DEV, V7, P2016, DOI 10.1101/gad.7.10.2016; KIM YW, 1989, PANCREAS, V4, P353, DOI 10.1097/00006676-198906000-00013; KOH J, 1993, J BIOL CHEM, V268, P15912; KOZENS AL, 1994, AM J RESPIR CELL MOL, V10, P38; MA YG, 1992, DEV BIOL, V154, P45, DOI 10.1016/0012-1606(92)90046-J; MCDONALD CD, 1994, GENE, V150, P267, DOI 10.1016/0378-1119(94)90436-7; MCDONALD RA, 1995, P NATL ACAD SCI USA, V92, P7560, DOI 10.1073/pnas.92.16.7560; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROCHWERGER L, 1994, J CELL SCI, V107, P2439; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SIDDIQUI AH, 1988, MOL CELL BIOL, V8, P4634, DOI 10.1128/MCB.8.11.4634; SMITH AN, 1995, BIOCHEM BIOPH RES CO, V211, P274, DOI 10.1006/bbrc.1995.1807; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; TRAPNELL BC, 1991, J BIOL CHEM, V266, P10319; TREZISE AEO, 1993, HUM MOL GENET, V2, P213, DOI 10.1093/hmg/2.3.213; VYAS P, 1992, CELL, V69, P781, DOI 10.1016/0092-8674(92)90290-S; YOSHIMURA K, 1991, NUCLEIC ACIDS RES, V19, P5417, DOI 10.1093/nar/19.19.5417; YOSHIMURA K, 1991, J BIOL CHEM, V266, P9140	34	76	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9947	9954		10.1074/jbc.271.17.9947	http://dx.doi.org/10.1074/jbc.271.17.9947			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626632	hybrid			2022-12-25	WOS:A1996UG25700016
J	Zhao, WN; McAlisterHenn, L				Zhao, WN; McAlisterHenn, L			Assembly and function of a cytosolic form of NADH-specific isocitrate dehydrogenase in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL MALATE-DEHYDROGENASE; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; GENE; DISRUPTION; BINDING; PHOSPHORYLATION; EXPRESSION; PROTEINS; CLONING	Mitochondrial NAD-dependent isocitrate dehydrogenase catalyzes a rate-limiting step in the tricarboxylic acid cycle. Yeast isocitrate dehydrogenase is an octomer composed of two subunits (IDH1 and IDH2) encoded by different genes and possessing independent mitochondrial targeting presequences. Oligonucleotide-directed mutagenesis was used to remove the presequences from each gene and from both genes carried on centromere-based expression plasmids. Effects on cellular localization were examined in a yeast strain containing chromosomal disruptions of IDH1 and IDH2 loci. Each subunit was found to be dependent upon its prese quence for mitochondrial localization, and the subunits are independently imported into mitochondria under most growth conditions. Furthermore, an active holoenzyme can be assembled in the cytosol and this ''cytosolic'' form of isocitrate dehydrogenase can reverse the acetate(-) growth phenotype characteristic of the Delta IDH1/Delta IDH2 disruption strain, indicating functional replacement of the mitochondrial enzyme. However, transformants containing plasmids lacking either the IDH1 or IDH2 presequence coding regions were unexpectedly found to be capable of growth on acetate medium. Further investigation demonstrated that cellular localization of the IDH1 subunit can be biased by this stringent growth pressure.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NIGMS NIH HHS [GM51265] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051265] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNES LD, 1971, BIOCHEMISTRY-US, V10, P3939, DOI 10.1021/bi00797a022; BEDWELL DM, 1987, MOL CELL BIOL, V7, P294; BOTSTEIN D, 1979, GENE, V8, P12; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CUPP JR, 1992, J BIOL CHEM, V267, P16417; CUPP JR, 1993, BIOCHEMISTRY-US, V32, P9323, DOI 10.1021/bi00087a010; CUPP JR, 1991, J BIOL CHEM, V266, P22199; DAUM G, 1982, J BIOL CHEM, V257, P3028; DOUGLAS MG, 1986, MICROBIOL REV, V50, P166, DOI 10.1128/MMBR.50.2.166-178.1986; ELZINGA SDJ, 1993, NUCLEIC ACIDS RES, V21, P5328, DOI 10.1093/nar/21.23.5328; HASELBECK RJ, 1993, J BIOL CHEM, V268, P12116; HASELBECK RJ, 1991, J BIOL CHEM, V266, P2339; HATHAWAY JA, 1963, J BIOL CHEM, V238, P2875; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KEYS DA, 1990, J BACTERIOL, V172, P4200; KIM KS, 1986, MOL CELL BIOL, V6, P1936, DOI 10.1128/MCB.6.6.1936; LOFTUS TM, 1994, BIOCHEMISTRY-US, V33, P9661, DOI 10.1021/bi00198a035; MCALISTERHENN L, 1987, J BACTERIOL, V169, P5157, DOI 10.1128/jb.169.11.5157-5166.1987; MINARD KI, 1991, MOL CELL BIOL, V11, P370, DOI 10.1128/MCB.11.1.370; OHNISHI T, 1966, J BIOL CHEM, V241, P1797; RALEIGH EA, 1988, NUCLEIC ACIDS RES, V16, P1563, DOI 10.1093/nar/16.4.1563; ROISE D, 1988, J BIOL CHEM, V263, P4509; Sambrook J., 2002, MOL CLONING LAB MANU; SIKORSKI RS, 1989, GENETICS, V122, P19; STEIN I, 1994, MOL CELL BIOL, V14, P4770, DOI 10.1128/MCB.14.7.4770; THOMPSON LM, 1989, J BIOL CHEM, V264, P12091; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K	30	17	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10347	10352		10.1074/jbc.271.17.10347	http://dx.doi.org/10.1074/jbc.271.17.10347			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626605	hybrid			2022-12-25	WOS:A1996UG25700077
J	Dick, LR; Cruikshank, AA; Grenier, L; Melandri, FD; Nunes, SL; Stein, RL				Dick, LR; Cruikshank, AA; Grenier, L; Melandri, FD; Nunes, SL; Stein, RL			Mechanistic studies on the inactivation of the proteasome by lactacystin A central role for clasto-lactacystin beta-lactone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Lactacystin is a Streptomyces metabolite that inhibits cell cycle progression and induces differentiation in a murine neuroblastoma cell line, The cellular target of lactacystin is the 20 S proteasome, also known as the multicatalytic proteinase complex, an essential component of the ubiquitin-proteasome pathway for intracellular protein degradation, In aqueous solution at pH 8, lactacystin undergoes spontaneous hydrolysis to yield N-acetyl-L-cysteine and the inactive lactacystin analog, clasto-lactacystin dihydroxy acid, We have studied the mechanism of lactacystin hydrolysis under these conditions and found that it proceeds exclusively through the intermediacy of the active lactacystin analog, clasto-lactacystin beta-lactone, Conditions that stabilize lactacystin (and thus prevent the transient accumulation of the intermediate beta-lactone) negate the ability of lactacystin to inactivate the proteasome. Together these findings suggest that lactacystin acts as a precursor for clasto-lactacystin beta-lactone and that the latter is the sole species that interacts with the proteasome.			Dick, LR (corresponding author), PROSCRIPT INC,38 SIDNEY ST,CAMBRIDGE,MA 02139, USA.		Dick, Lawrence/ABA-8831-2021	Dick, Larry/0000-0002-6880-0405				CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COREY EJ, 1992, J AM CHEM SOC, V114, P10677, DOI 10.1021/ja00052a096; COREY EJ, 1993, TETRAHEDRON LETT, V34, P6977, DOI 10.1016/S0040-4039(00)61575-7; FENTEANY G, 1994, P NATL ACAD SCI USA, V91, P3358, DOI 10.1073/pnas.91.8.3358; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GANOTH D, 1988, J BIOL CHEM, V263, P12412; GOLDBERG AL, 1995, CHEM BIOL, V2, P503, DOI 10.1016/1074-5521(95)90182-5; HOUGH R, 1987, J BIOL CHEM, V262, P8303; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; RIVETT AJ, 1993, BIOCHEM J, V291, P1; RUBIN D, 1995, CURR BIOL, V3, P854; TANAKA K, 1995, MOL BIOL REP, V21, P21, DOI 10.1007/BF00990966; WILK S, 1993, ENZYME PROTEIN, V47, P187, DOI 10.1159/000468677	15	338	349	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7273	7276		10.1074/jbc.271.13.7273	http://dx.doi.org/10.1074/jbc.271.13.7273			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631740				2022-12-25	WOS:A1996UC77400008
J	Chatterjee, R; Allen, RM; Ludden, PW; Shah, VK				Chatterjee, R; Allen, RM; Ludden, PW; Shah, VK			Purification and characterization of the vnf-encoded apodinitrogenase from Azotobacter vinelandii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-MOLYBDENUM COFACTOR; 2ND ALTERNATIVE NITROGENASE; DINITROGENASE REDUCTASE; VANADIUM NITROGENASE; NUCLEOTIDE-SEQUENCE; MUTATIONAL ANALYSIS; INVITRO SYNTHESIS; STRUCTURAL GENES; FEMO-COFACTOR; PROTEIN	The unf-encoded apodinitrogenase (apodinitrogenase 2) has been purified from Azotobacter vinelandii strain CA117.30 (Delta nifKDB), and is an alpha(2) beta(2) delta(2) hexamer. Apodinitrogenase 2 can be activated in vitro by the addition of the iron-vanadium cofactor (FeV-co) to form holodinitrogenase 2, which functions in C2H2, H+, and N-2 reduction. Under certain conditions, the alpha(2) beta(2) delta(2) hexamer dissociates to yield the free delta subunit (the VNFG protein) and a form of apodinitrogenase 2 that exhibits no C2H2, H+, or N-2 reduction activities in the in vitro FeV-co activation assay; however, these activities can be restored upon addition of VNFG to the FeV-co activation assay system. No other vnf-, nif-, or non-nif-encoded proteins were able to replace the function of VNFG in the in vitro processing of alpha(2) beta(2) apodinitrogenase 2 (in the presence of FeV-co) to a form capable of substrate reduction, Apodinitrogenase 2 is also activable in vitro by the iron-molybdenum cofactor to form a hybrid enzyme with unique properties, most notably the inability to reduce N-2 and insensitivity to CO inhibition of C2H2 reduction.	UNIV WISCONSIN, COLL AGR & LIFE SCI, DEPT BIOCHEM, MADISON, WI 53706 USA; UNIV WISCONSIN, COLL AGR & LIFE SCI, CTR STUDY NITROGEN FIXAT, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								ALLEN RM, 1993, J BIOL CHEM, V268, P23670; ALLEN RM, 1996, IN PRESS J BIOL CHEM, V271; BISHOP PE, 1986, SCIENCE, V232, P92, DOI 10.1126/science.232.4746.92; Bishop PE, 1992, BIOL NITROGEN FIXATI, P736; BULEN WA, 1966, P NATL ACAD SCI USA, V56, P979, DOI 10.1073/pnas.56.3.979; BURRIS RH, 1957, METHOD ENZYMOL, V4, P355, DOI 10.1016/0076-6879(57)04064-1; CHISNELL JR, 1988, J BACTERIOL, V170, P27, DOI 10.1128/jb.170.1.27-33.1988; DAVIS R, 1996, IN PRESS J BACTERIOL, V178; DILWORTH MJ, 1987, NATURE, V327, P167, DOI 10.1038/327167a0; EADY RR, 1991, ADV INORG CHEM RAD, V36, P77; GOLLAN U, 1993, EUR J BIOCHEM, V215, P25, DOI 10.1111/j.1432-1033.1993.tb18003.x; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; HALES BJ, 1986, BIOCHEMISTRY-US, V25, P7253, DOI 10.1021/bi00371a001; HOMER MJ, 1995, J BIOL CHEM, V270, P24745, DOI 10.1074/jbc.270.42.24745; HOOVER TR, 1988, BIOCHEMISTRY-US, V27, P3647, DOI 10.1021/bi00410a019; IMPERIAL J, 1987, J BACTERIOL, V169, P1784, DOI 10.1128/jb.169.4.1784-1786.1987; JACOBSON MR, 1989, J BACTERIOL, V171, P1017, DOI 10.1128/jb.171.2.1017-1027.1989; JOERGER RD, 1986, J BACTERIOL, V168, P673, DOI 10.1128/jb.168.2.673-682.1986; JOERGER RD, 1990, J BACTERIOL, V172, P3400, DOI 10.1128/jb.172.6.3400-3408.1990; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; JOERGER RD, 1989, J BACTERIOL, V171, P1075, DOI 10.1128/jb.171.2.1075-1086.1989; KENNEDY C, 1986, MOL GEN GENET, V205, P318, DOI 10.1007/BF00430445; KIM CH, 1995, BIOCHEMISTRY-US, V34, P2798, DOI 10.1021/bi00009a008; MADDEN MS, 1990, P NATL ACAD SCI USA, V87, P6517, DOI 10.1073/pnas.87.17.6517; MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003-2697(90)90134-U; MOORE VG, 1994, J AM CHEM SOC, V116, P12101, DOI 10.1021/ja00105a080; PAU RN, 1993, BIOCHEM J, V293, P101, DOI 10.1042/bj2930101; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; ROBSON RL, 1986, NATURE, V322, P388, DOI 10.1038/322388a0; SCOTT DJ, 1990, NATURE, V343, P188, DOI 10.1038/343188a0; SHAH VK, 1986, P NATL ACAD SCI USA, V83, P1636, DOI 10.1073/pnas.83.6.1636; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SMITH BE, 1988, BIOCHEM J, V250, P299, DOI 10.1042/bj2500299; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; UGALDE RA, 1984, J BACTERIOL, V159, P888, DOI 10.1128/JB.159.3.888-893.1984; WAUGH SI, 1995, J BACTERIOL, V177, P1505, DOI 10.1128/jb.177.6.1505-1510.1995	36	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6819	6826		10.1074/jbc.271.12.6819	http://dx.doi.org/10.1074/jbc.271.12.6819			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636105	hybrid			2022-12-25	WOS:A1996UB15700040
J	Liu, MY; Qin, Y; Liu, J; Tanswell, AK; Post, M				Liu, MY; Qin, Y; Liu, J; Tanswell, AK; Post, M			Mechanical strain induces pp60(src) activation and translocation to cytoskeleton in fetal rat lung cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; INSOLUBLE CELLULAR MATRIX; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SRC-FAMILY; STABLE ASSOCIATION; FOCAL ADHESIONS; 2ND MESSENGERS; PHOSPHORYLATION; SUBSTRATE	We have previously shown that mechanical strain-induced fetal rat lung cell proliferation is transduced via the phospholipase C-gamma-protein kinase C pathway. In the present study, we found that protein-tyrosine kinase activity of fetal lung cells increased after a short period of strain, which was accompanied by tyrosine phosphorylation of proteins of similar to 110-130 kDa. Several components of this complex were identified as pp60(src) substrates. Strain increased pp60(src) activity in the cytoskeletal fraction, which coincided with a shift in subcellular distribution of pp60(src) hom the Triton-soluble to the cytoskeletal fraction. Strain-induced pp60(src) translocation did not appear to be mediated via the focal adhesion kinase-paxillin pathway. In contrast, strain increased the association between pp60(src) and the actin filament-associated protein of 110 kDa. Preincubation of cells with herbimycin A, a tyrosine kinase inhibitor, abolished strain-induced phospholipase C-gamma 1 tyrosine phosphorylation and its coimmunoprecipitation with pp60(src). It also inhibited strain-induced DNA synthesis. These results suggest that activation of pp60(src) is an upstream event of the phospholipase C-gamma-protein kinase C pathway that may represent an important mechanism by which mechanical perturbations are converted to biological reactions in fetal lung cells.	UNIV TORONTO,HOSP SICK CHILDREN,RES INST,DEPT PEDIAT,MED RES COUNCIL,GRP LUNG DEV,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,HOSP SICK CHILDREN,RES INST,DEPT PEDIAT,NEONATAL RES DIV,TORONTO,ON M5G 1X8,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)				Liu, Mingyao/0000-0002-9188-8417				BANES AJ, 1990, AM BIOTECHNOL LAB, V8, P12; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; BRIGHTON CT, 1992, J ORTHOPAED RES, V10, P385, DOI 10.1002/jor.1100100311; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHENG HC, 1992, J BIOL CHEM, V267, P9248; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DHAR A, 1994, J BIOL CHEM, V269, P9123; DOWNING JR, 1991, ONCOGENE, V6, P607; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; FRANGOS JA, 1993, PHYSICAL FORCES MAMM; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; Harding R., 1991, LUNG SCI F, P1655; HISHIKAWA K, 1994, J CLIN INVEST, V93, P1975, DOI 10.1172/JCI117189; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KITTERMAN JA, 1988, CAN J PHYSIOL PHARM, V66, P1122, DOI 10.1139/y88-184; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIAO F, 1993, BIOCHEM BIOPH RES CO, V191, P1028, DOI 10.1006/bbrc.1993.1320; LIU M, 1992, AM J PHYSIOL, V263, pL376; LIU MY, 1995, AM J PHYSIOL-LUNG C, V268, pL729, DOI 10.1152/ajplung.1995.268.5.L729; LIU MY, 1995, AM J PHYSIOL-LUNG C, V269, pL178, DOI 10.1152/ajplung.1995.269.2.L178; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; NOLLERT MU, 1990, BIOCHEM BIOPH RES CO, V170, P281, DOI 10.1016/0006-291X(90)91271-S; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PIKE LJ, 1982, P NATL ACAD SCI-BIOL, V79, P1443, DOI 10.1073/pnas.79.5.1443; RANKIN S, 1994, J BIOL CHEM, V269, P704; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; RILEY DJ, 1990, AM REV RESPIR DIS, V142, P910, DOI 10.1164/ajrccm/142.4.910; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SIMPSON LL, 1985, AM J ANAT, V172, P31, DOI 10.1002/aja.1001720103; SKINNER SJM, 1989, RES PERINATAL MED, V8, P133; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDENBURGH HH, 1993, J CELL PHYSIOL, V155, P63, DOI 10.1002/jcp.1041550109; VANDENBURGH HH, 1992, AM J PHYSIOL, V262, pR350, DOI 10.1152/ajpregu.1992.262.3.R350; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417	48	105	108	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7066	7071		10.1074/jbc.271.12.7066	http://dx.doi.org/10.1074/jbc.271.12.7066			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636139	hybrid			2022-12-25	WOS:A1996UB15700074
J	Vaandrager, AB; Ehlert, EME; Jarchau, T; Lohmann, SM; deJonge, HR				Vaandrager, AB; Ehlert, EME; Jarchau, T; Lohmann, SM; deJonge, HR			N-terminal myristoylation is required for membrane localization of cGMP-dependent protein kinase type II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; GUANYLYL CYCLASE; MECHANISM; STABILITY; RECEPTOR	The apical membrane of intestinal epithelial cells harbors a unique isozyme of cGMP-dependent protein kinase (cGK type II) which acts as a key regulator of ion transport systems, including the cystic fibrosis transmembrane conductance regulator (CFTR)-chloride channel. To explore the mechanism of cGK II membrane-anchoring, recombinant cGK II was expressed stably in HEK 293 cells or transiently in COS-1 cells, In both cell lines, cGK II was found predominantly in the particulate fraction, Immunoprecipitation of solubilized cGK II did not reveal any other tightly associated proteins, suggesting a membrane binding motif within cGK II itself. The primary structure of cGK II is devoid of hydrophobic transmembrane domains; cGK II does, however, contain a penultimate glycine, a potential acceptor for a myristoyl moiety, Metabolic labeling showed that cGK II was indeed able to incorporate [H-3]myristate. Moreover, incubation of cGK II expressing 293 cells with the myristoylation inhibitor 2-hydroxymyristic acid (1 mM) significantly increased the proportion of cGK II in the cytosol from 10 +/- 5 to 35 +/- 4%. Furthermore, a nonmyristoylated cGK II Gly(2) --> Ala mutant was localized predominantly in the cytosol after transient expression in COS-1 cells, The absence of the myristoyl group did not affect the specific enzyme activity or the K-alpha for cGMP and only slightly enhanced the thermal stability of cGK II. These results indicate that N-terminal myristoylation fulfills a crucial role in directing cGK II to the membrane.	ERASMUS UNIV ROTTERDAM,FAC MED & HLTH SCI,DEPT BIOCHEM,CARDIOVASC RES INST COEUR,3000 DR ROTTERDAM,NETHERLANDS; UNIV WURZBURG,MED CLIN,LAB CLIN BIOCHEM,D-97080 WURZBURG,GERMANY	Erasmus University Rotterdam; University of Wurzburg			Ehlert, Erich M/A-4054-2012	Vaandrager, Arie/0000-0001-9394-9239				BERGER HA, 1993, J BIOL CHEM, V268, P2037; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; DEJONGE HR, 1984, BIOCHEM SOC T, V12, P180, DOI 10.1042/bst0120180; DEJONGE HR, 1981, ADV CYCLIC NUCL PROT, V14, P315; ELHUSSEINI AED, 1995, J NEUROCHEM, V64, P2814; FIELD M, 1989, NEW ENGL J MED, V321, P800; FRENCH PJ, 1995, J BIOL CHEM, V270, P26626, DOI 10.1074/jbc.270.44.26626; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; MACMILLANCROW LA, 1994, BIOCHEMISTRY-US, V33, P8035, DOI 10.1021/bi00192a007; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; MEINECKE M, 1994, MOL PHARMACOL, V46, P283; NADLER MJS, 1993, BIOCHEMISTRY-US, V32, P9250, DOI 10.1021/bi00086a034; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; TAKIO K, 1984, BIOCHEMISTRY-US, V23, P4207, DOI 10.1021/bi00313a030; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; UHLER MD, 1993, J BIOL CHEM, V268, P13586; Vaandrager A B, 1994, Adv Pharmacol, V26, P253, DOI 10.1016/S1054-3589(08)60057-5; VAANDRAGER AB, 1993, J BIOL CHEM, V268, P2174; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	27	75	81	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7025	7029		10.1074/jbc.271.12.7025	http://dx.doi.org/10.1074/jbc.271.12.7025			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636133	hybrid, Green Published			2022-12-25	WOS:A1996UB15700068
J	Potterf, SB; Muller, J; Bernardini, I; Tietze, F; Kobayashi, T; Hearing, VJ; Gahl, WA				Potterf, SB; Muller, J; Bernardini, I; Tietze, F; Kobayashi, T; Hearing, VJ; Gahl, WA			Characterization of a melanosomal transport system in murine melanocytes mediating entry of the melanogenic substrate tyrosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE GRANULAR FRACTIONS; LYSOSOMAL MEMBRANE-TRANSPORT; HUMAN FIBROBLAST LYSOSOMES; RAT-THYROID CELLS; CYSTINE TRANSPORT; AMINO-ACIDS; STIMULATION; NUTRITION; MELANOMA; DISEASE	In this study, we identify a transport system for tyrosine, the initial precursor of melanin synthesis, in the melanosomes of murine melanocytes. Melanosomes preloaded with tyrosine demonstrated countertransport of 10 mu M [H-3]tyrosine, indicating carrier-mediated transport. Melanosomal tyrosine transport was saturable, with an apparent K-m for tyrosine transport of 54 mu M and a maximal velocity of 15 pmol of tyrosine/unit of hexosaminidase/min. Transport was temperature-dependent (E(alpha) = 7.5 kcal/mol) and showed stereospecificity for the L-isomer of tyrosine. Aromatic, neutral hydrophobic compounds (such as tryptophan and phenylalanine), as well as the small, bulky neutral amino acids (such as leucine, isoleucine, and methionine) competed for tyrosine transport. Tyrosine transport was inhibited by the classical system L analogue, 2-aminobicyclo[2.2.1]heptane-2-carboxylic acid and by monoiodotyrosine, but not by cystine, lysine, glutamic acid, or 2-(methylamino)isobutyric acid. Tyrosine transport showed no dependence on Na+ or K+, and did not require an acidic environment or the availability of free thiols. These results demonstrate the existence of a neutral amino acid carrier in murine melanocyte melanosomes which resembles the rat thyroid FRTL-5 lysosomal system h. This transport system is critical to the function of the melanosome since tyrosine is the essential substrate required for the synthesis of the pigment melanin.	NICHHD,SECT HUMAN BIOCHEM GENET,HERITABLE DISORDERS BRANCH,BETHESDA,MD 20892; NCI,CELL BIOL LAB,BETHESDA,MD 20892; US FDA,DIV VIRAL PROD,CTR BIOL EVALUAT & RES,ROCKVILLE,MD 20852; NIDDK,MOL & CELLULAR BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Kobayashi, Takeshi/0000-0002-4372-5285				ANDERSSON HC, 1990, J BIOL CHEM, V265, P10950; AROCA P, 1993, J BIOL CHEM, V268, P25650; BENNETT DC, 1989, DEVELOPMENT, V105, P379; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BERNAR J, 1986, J BIOL CHEM, V261, P7107; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; COLLARINI EJ, 1989, BIOCHIM BIOPHYS ACTA, V987, P139, DOI 10.1016/0005-2736(89)90536-1; DIMENT S, 1995, J BIOL CHEM, V270, P4213, DOI 10.1074/jbc.270.9.4213; GAHL WA, 1989, ANNU REV NUTR, V9, P39, DOI 10.1146/annurev.nu.09.070189.000351; GAHL WA, 1983, BIOCHEM J, V216, P393, DOI 10.1042/bj2160393; GAHL WA, 1985, BIOCHEM J, V228, P263, DOI 10.1042/bj2280263; GAHL WA, 1996, IN PRESS PIGMENT CEL; GREENE AA, 1990, J BIOL CHEM, V265, P9888; HARPER GS, 1988, J BIOL CHEM, V263, P9320; HATTA S, 1988, J INVEST DERMATOL, V91, P181, DOI 10.1111/1523-1747.ep12464454; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; ITO S, 1993, PIGMENTATION PIGMENT; JIMENEZ M, 1991, J BIOL CHEM, V266, P1147; KOBAYASHI T, 1994, J BIOL CHEM, V269, P29198; MENON IA, 1976, UNIQUE PROPERTIES ME; NAKAGAWA H, 1984, J INVEST DERMATOL, V83, P140, DOI 10.1111/1523-1747.ep12263344; OETTING WS, 1994, J INVEST DERMATOL, V103, pS131, DOI 10.1111/1523-1747.ep12399447; OHKURA T, 1984, ARCH BIOCHEM BIOPHYS, V235, P63, DOI 10.1016/0003-9861(84)90255-8; ORLOW SJ, 1995, J INVEST DERMATOL, V105, P3, DOI 10.1111/1523-1747.ep12312291; ORLOW SJ, 1993, J INVEST DERMATOL, V100, P55, DOI 10.1111/1523-1747.ep12354138; PISONI RL, 1991, BIOCHIM BIOPHYS ACTA, V1071, P351, DOI 10.1016/0304-4157(91)90002-E; PISONI RL, 1990, J CELL BIOL, V110, P327, DOI 10.1083/jcb.110.2.327; PISONI RL, 1995, J BIOL CHEM, V270, P1179, DOI 10.1074/jbc.270.3.1179; RENLUND M, 1986, SCIENCE, V232, P759, DOI 10.1126/science.3961501; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; SMIT NPM, 1993, BIOCHIM BIOPHYS ACTA, V1181, P1, DOI 10.1016/0925-4439(93)90082-C; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TIETZE F, 1989, J BIOL CHEM, V264, P15316; WILBRANDT W, 1961, PHARMACOL REV, V13, P109; ZHOU BK, 1994, P NATL ACAD SCI USA, V91, P7076, DOI 10.1073/pnas.91.15.7076	35	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4002	4008						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626732				2022-12-25	WOS:A1996TW96000010
J	Best, A; Ahmed, S; Kozma, R; Lim, L				Best, A; Ahmed, S; Kozma, R; Lim, L			The Ras-related GTPase Rac1 binds tubulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING PROTEIN; KINASE; RAF-1; RHO	The Ras-related Rho family are involved in controlling actin-based changes in cell morphology. Microinjection of Rac1, RhoA, and Cdc42Hs into Swiss 3T3 cells induces pinocytosis and membrane ruffling, stress fiber formation, and filopodia formation, respectively. To identify target proteins involved in these signaling pathways cell extracts immobilized on nitrocellulose have been probed with [gamma-P-32]GTP-labeled Rac1, RhoA, and Gdc42Hs. We have identified two 55-kDa brain proteins which bind Rac1 but not RhoA or Cdc42Hs. These 55-kDa proteins were abundant, had pI values of around 5.5, and could be purified by Q-Sepharose chromatography. The characteristics on two dimensional gel analysis suggested the proteins comprised alpha- and P-tubulin. Indeed, beta-tubulin specific antibodies detected one of the purified 55-kDa proteins. Rad bound pure tubulin (purified by cycles of polymerization and depolymerization) only in the GTP-bound state. The GTPase negative Rac1 point mutants, G12V and Q61L, did not significantly affect the ability of Rac1 to interact with tubulin while the ''effector-site'' mutant D38A prevented interaction. These results suggest that the Rac1-tubulin interaction may play a role in Rac1 function.	NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, GLAXO IMCB GRP, SINGAPORE 0411, SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Best, A (corresponding author), INST NEUROL, DEPT NEUROCHEM, 1 WAKEFIELD ST, LONDON WC1N 1PJ, ENGLAND.		Kozma, Robert/C-6365-2013	Kozma, Robert/0000-0001-7011-5768				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AHMED S, 1994, J BIOL CHEM, V269, P17642; AHMED S, 1993, J BIOL CHEM, V268, P10709; AHMED S, 1995, METHOD ENZYMOL, V256, P114; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; GLOUSHANKOVA NA, 1994, P NATL ACAD SCI USA, V91, P8597, DOI 10.1073/pnas.91.18.8597; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; MANSER E, 1992, J BIOL CHEM, V267, P16025; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SERRANO L, 1986, METHOD ENZYMOL, V134, P179; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; TANAKA E, 1995, J CELL BIOL, V128, P139, DOI 10.1083/jcb.128.1.139; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOTJEK AB, 1993, CELL, V74, P205; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; XU XM, 1994, J BIOL CHEM, V269, P23569; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	31	108	110	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3756	3762						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631991				2022-12-25	WOS:A1996TV72400065
J	Buccione, R; Bannykh, S; Santone, I; Baldassarre, M; Facchiano, F; Bozzi, Y; DiTullio, G; Mironov, A; Luini, A; DeMatteis, MA				Buccione, R; Bannykh, S; Santone, I; Baldassarre, M; Facchiano, F; Bozzi, Y; DiTullio, G; Mironov, A; Luini, A; DeMatteis, MA			Regulation of constitutive exocytic transport by membrane receptors - A biochemical and morphometric study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BASOPHILIC LEUKEMIA-CELLS; IMMATURE SECRETORY GRANULES; HETEROTRIMERIC G-PROTEIN; ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEINS; GOLGI MEMBRANES; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; PHORBOL ESTERS	Biochemical and morphometric approaches were combined to examine whether constitutive secretory transport might be controlled by plasma membrane receptors, as this possibility would have significant physiological implications. Indeed, IgE receptor stimulation in rat basophilic leukemia cells potently increased the rate of transport of soluble pulse-labeled S-35-sulfated glycosaminoglycans from distal Golgi compartments to the cell surface. This effect was largely protein kinase C (PKC)-dependent. Direct activation of PKC also stimulated constitutive transport of glycosaminoglycans, as indicated by the use of agonistic and antagonistic PKC Ligands. PKC ligands also had potent, but different, effects on the exocytic transport from distal Golgi compartments to the plasma membrane of a membrane-bound protein (vesicular stomatitis virus glycoprotein), which was slightly stimulated by activators and profoundly suppressed by inhibitors of PKC, Morphological analysis showed impressive changes of the organelles of the secretory pathway in response to IgE receptor stimulation and to direct PKC activation (enhanced number of buds and vesicles originating from the endoplasmic reticulum and Golgi and increase in surface and volume of Golgi compartments), suggestive of an overall activation of exocytic movements. These results show that rapid and large changes in constitutive transport fluxes and in the morphology of the exocytic apparatus can be induced by membrane receptors (as well as by direct PHC stimulation).	IST RIC FARMACOL MARIO NEGRI, CONSORZIO MARIO NEGRI SUD, PHYSIOPATHOL SECRET UNIT, I-66030 SANTA MARIA IMBARO, CHIETI, ITALY	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Buccione, R (corresponding author), IST RIC FARMACOL MARIO NEGRI, CONSORZIO MARIO NEGRI SUD, MOLEC NEUROBIOL LAB, I-66030 SANTA MARIA IMBARO, CHIETI, ITALY.		Baldassarre, Massimiliano/E-6236-2011; Baldassarre, Massimiliano/AAI-6581-2021; Facchiano, Francesco/K-8716-2016; Luini, Alberto/L-1372-2013	Baldassarre, Massimiliano/0000-0002-2498-4767; Baldassarre, Massimiliano/0000-0002-2498-4767; Facchiano, Francesco/0000-0003-4313-0617; Luini, Alberto/0000-0002-8729-2549; Buccione, Roberto/0000-0001-9210-5261; De Matteis, Maria Antonietta/0000-0003-0053-3061				AHMED S, 1990, BIOCHEM J, V272, P767, DOI 10.1042/bj2720767; AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; AKITA Y, 1994, J BIOL CHEM, V269, P4653; Arvan Peter, 1992, Trends in Cell Biology, V2, P327; BADDELEY AJ, 1986, J MICROSC-OXFORD, V142, P259, DOI 10.1111/j.1365-2818.1986.tb04282.x; BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; BARR FA, 1991, FEBS LETT, V294, P239, DOI 10.1016/0014-5793(91)81438-E; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BEAVEN MA, 1987, J CELL BIOL, V105, P1129, DOI 10.1083/jcb.105.3.1129; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BERGMANN JE, 1989, METHOD CELL BIOL, V32, P85; BOMSEL M, 1993, J BIOL CHEM, V268, P25824; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BRANDLI AW, 1988, J BIOL CHEM, V263, P16283; BRION C, 1992, J BIOL CHEM, V267, P1477; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BUCCIONE R, 1994, BIOCHEM J, V298, P149, DOI 10.1042/bj2980149; CARDONE MH, 1994, J CELL BIOL, V124, P717, DOI 10.1083/jcb.124.5.717; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; DAVIDSON HW, 1992, J CELL BIOL, V116, P1343, DOI 10.1083/jcb.116.6.1343; DEMATTEIS MA, 1991, J BIOL CHEM, V266, P10452; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DVORAK AM, 1992, AM J PATHOL, V141, P1309; EKER P, 1994, J BIOL CHEM, V269, P18607; FABBRI M, 1994, J BIOL CHEM, V269, P26848; GRAHAM JM, 1988, BIOCHEM J, V252, P437, DOI 10.1042/bj2520437; GRIFFITHS G, 1989, J CELL BIOL, V108, P277, DOI 10.1083/jcb.108.2.277; HANSEN SH, 1994, J CELL BIOL, V126, P677, DOI 10.1083/jcb.126.3.677; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBIVIC A, 1990, J CELL BIOL, V110, P1533, DOI 10.1083/jcb.110.5.1533; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; LOTTI LV, 1992, J CELL BIOL, V118, P43, DOI 10.1083/jcb.118.1.43; Luini Alberto, 1993, Trends in Cell Biology, V3, P290, DOI 10.1016/0962-8924(93)90002-I; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; MORI K, 1993, CELL, V74, P743; NARULA N, 1992, J CELL BIOL, V117, P27, DOI 10.1083/jcb.117.1.27; NICKEL W, 1994, J CELL BIOL, V125, P721, DOI 10.1083/jcb.125.4.721; OHASHI M, 1994, J BIOL CHEM, V269, P24897; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PAGANO RE, 1988, TRENDS BIOCHEM SCI, V13, P202, DOI 10.1016/0968-0004(88)90082-5; PARK DJ, 1991, J BIOL CHEM, V266, P24237; PFEIFFER JR, 1985, J CELL BIOL, V101, P2145, DOI 10.1083/jcb.101.6.2145; PIMPLIKAR SW, 1994, J BIOL CHEM, V269, P19054; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; ROSA P, 1992, EUR J CELL BIOL, V59, P265; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; RYVES WJ, 1991, FEBS LETT, V288, P5, DOI 10.1016/0014-5793(91)80989-G; SAUCAN L, 1994, J CELL BIOL, V125, P733, DOI 10.1083/jcb.125.4.733; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SLACK BE, 1993, J BIOL CHEM, V268, P21097; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; SWANSON JA, 1985, J CELL BIOL, V100, P851, DOI 10.1083/jcb.100.3.851; TOOZE SA, 1992, METHOD ENZYMOL, V219, P81; TUOMIKOSKI T, 1989, NATURE, V342, P942, DOI 10.1038/342942a0; TURNER MD, 1992, BIOCHEM J, V286, P13, DOI 10.1042/bj2860013; TWOMEY B, 1990, BIOCHEM BIOPH RES CO, V171, P1087, DOI 10.1016/0006-291X(90)90795-O; WHATMORE J, 1994, FEBS LETT, V352, P113, DOI 10.1016/0014-5793(94)00930-9; WILSON BS, 1994, ENDOCRINOLOGY, V134, P233, DOI 10.1210/en.134.1.233; WOODMAN PG, 1992, J CELL BIOL, V116, P331, DOI 10.1083/jcb.116.2.331; YU KT, 1991, J BIOL CHEM, V266, P22564	72	57	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3523	3533						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631957				2022-12-25	WOS:A1996TV72400031
J	Na, SQ; Chuang, TH; Cunningham, A; Turi, TG; Hanke, JH; Bokoch, GM; Danley, DE				Na, SQ; Chuang, TH; Cunningham, A; Turi, TG; Hanke, JH; Bokoch, GM; Danley, DE			D4-GDI, a substrate of CPP32, is proteolyzed during Fas-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-DISSOCIATION INHIBITOR; GTP-BINDING PROTEIN; DEATH GENE CED-3; LYMPHOCYTES; INDUCTION; ENZYME; CELLS	Apoptosis (programmed cell death) is a fundamental process for normal development of multicellular organisms, and is involved in the regulation of the immune system, normal morphogenesis, and maintenance of homeostasis. ICE/CED-3 family cysteine proteases have been implicated directly in apoptosis, but relatively few of the substrates through which their action is mediated have been identified. Here we report that D4-GDI, an abundant hematopoietic cell GDP dissociation inhibitor for the Ras-related Rho family GTPases, is a substrate of the apoptosis protease CPP32/Yama/Apopain. D4-GDI was rapidly truncated to a 23-kDa fragment in Jurkat cells with kinetics that parallel the onset of apoptosis following Fas cross-linking with agonistic antibody or treatment with staurosporine. Fas- and staurosporine-induced apoptosis as well as cleavage of D4-GDI were inhibited by the ICE inhibitor, YVAD-cmk. D4-GDI was cleaved in vitro by recombinant CPP32 expressed in Escherichia coli to form a 23-kDa fragment. The CPP32-mediated cleavage of D4-GDI was completely inhibited by 1 mu M DEVD-CHO, a reported selective inhibitor of CPP32. In contrast, the ICE-selective inhibitors, YVAD-CHO or YVAD-cmk, did not inhibit CPP32-mediated D4-GDI cleavage at concentrations up to 50 mu M. N-terminal sequencing of the 23-kDa D4-GDI fragment demonstrated that D4-GDI was cleaved between Asp(19) and Ser(20) of the poly(ADP-ribose) polymerase-like cleavage sequence DELD(19)S. These data suggest that regulation by D4-GDI of Rho family GTPases may be disrupted during apoptosis by CPP32-mediated cleavage of the GDI protein.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; PFIZER INC, DIV CENT RES, DEPT MOLEC SCI, GROTON, CT 06340 USA	Scripps Research Institute; Scripps Research Institute; Pfizer			Chuang, Tsung-Hsien/F-9679-2010		NIGMS NIH HHS [GM44428, GM39434] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434, R01GM044428] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANEL A, 1994, EUR J IMMUNOL, V24, P2469, DOI 10.1002/eji.1830241032; BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; CHUANG TH, 1993, J BIOL CHEM, V268, P775; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CRITCHFIELD JM, 1994, SCIENCE, V263, P1139, DOI 10.1126/science.7509084; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GILLETTEFERGUSON I, 1994, EUR J IMMUNOL, V24, P1181, DOI 10.1002/eji.1830240526; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LARRICK JW, 1992, TRENDS BIOTECHNOL, V10, P146, DOI 10.1016/0167-7799(92)90202-7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LELIAS JM, 1993, P NATL ACAD SCI USA, V90, P1479, DOI 10.1073/pnas.90.4.1479; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; RUSSELL JH, 1991, P NATL ACAD SCI USA, V88, P2151, DOI 10.1073/pnas.88.6.2151; SCHERLE P, 1993, P NATL ACAD SCI USA, V90, P7568, DOI 10.1073/pnas.90.16.7568; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VIGNAUX F, 1995, J EXP MED, V181, P781, DOI 10.1084/jem.181.2.781; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	43	197	203	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11209	11213		10.1074/jbc.271.19.11209	http://dx.doi.org/10.1074/jbc.271.19.11209			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626669	hybrid			2022-12-25	WOS:A1996UJ94400029
J	Bhunia, AK; Han, H; Snowden, A; Chatterjee, S				Bhunia, AK; Han, H; Snowden, A; Chatterjee, S			Lactosylceramide stimulates Ras-GTP loading, kinases (MEK, Raf), p44 mitogen-activated protein kinase, and c-fos expression in human aortic smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; PROLIFERATION; MODULATION; COMPLEX; DOMAIN; MYC; JUN	Previously, our laboratory has shown that lactosylceramide (LacCer) can serve as a mitogenic agent in the proliferation of aortic smooth muscle cells ''a hallmark in the pathogenesis of atherosclerosis'' (Chatterjee, S. (1991) Biochem. Biophys. Res. Commun. 181, 554-561). Here we report a novel aspect of LacCer-mediated signal transduction. We demonstrate that LacCer (10 mu M) can stimulate the phosphorylation of mitogen-activated protein (MAP) kinase p44(MAPK) to phosphorylated p44(MAPK) in aortic smooth muscle cells from rabbit or human origin. Western immunoblot assays and direct measurement of activity in immunoprecipitated MAP kinase revealed that within 5 min of incubation of cells with LacCer there was a 3.5-fold increase in the activity of p44(MAPK). This continued up to 10 min of incubation; thereafter, the MAP kinase activity decreased in these cells. Phosphoamino acid analysis revealed that the tyrosine and threonine moieties of p44(MAPK) was phosphorylated by LacCer. Incubation of cells with ceramide and glucosylceramide did not significantly stimulate p44(MAPK) activity. Preincubation with tyrphostin (20 mu M; a potent and specific inhibitor of tyrosine kinase) markedly inhibited the LacCer mediated stimulation in p44(MAPK) activity. Next we investigated the upstream and downstream parameters in MAP kinase signaling pathways. We found that lactosylceramide stimulated (7-fold) the loading of GTP on Ras. Concomitantly, Lac-Cer stimulated the phosphorylation of MAP kinase kinases (MEK) and Raf within 2.5 min. Lactosylceramide specifically induced c-fos mRNA expression (3-fold) in these cells as compared to control. In summary, one of the biochemical mechanisms in LacCer mediated induction in the proliferation of aortic smooth muscle cells may involve Ras-GTP loading activation of the kinase cascade (MEK, Raf, p44(MAPK)), and c-fos expression.	JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, LIPID RES UNIT, BALTIMORE, MD 21287 USA	Johns Hopkins University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL047212] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031722] Funding Source: NIH RePORTER; NHLBI NIH HHS [1-P50 HL47212] Funding Source: Medline; NIDDK NIH HHS [R01-DK31722] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BREMER EG, 1986, J BIOL CHEM, V261, P2434; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHATTERJEE S, 1991, BIOCHEM BIOPH RES CO, V181, P554, DOI 10.1016/0006-291X(91)91225-2; CHATTERJEE S, 1989, J BIOL CHEM, V264, P12554; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DEUG T, 1994, NATURE, V371, P171; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAIRD AD, 1995, J BIOL CHEM, V270, P26742, DOI 10.1074/jbc.270.45.26742; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; NISHIDA E, 1992, INT REV CYTOL, V138, P211, DOI 10.1016/S0074-7696(08)61589-2; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; RAO GN, 1994, J BIOL CHEM, V269, P32586; RAO GN, 1995, J CLIN INVEST, V96, P842, DOI 10.1172/JCI118130; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; SENGUPTA A, 1988, P NATL ACAD SCI USA, V85, P8062, DOI 10.1073/pnas.85.21.8062; SETH A, 1991, J BIOL CHEM, V266, P23521; SETH A, 1992, J BIOL CHEM, V267, P24796; SHAYMAN JA, 1991, J BIOL CHEM, V266, P22968; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEINSTEIN SL, 1992, J BIOL CHEM, V267, P14955; WINSTON BW, 1995, J BIOL CHEM, V270, P27391, DOI 10.1074/jbc.270.46.27391	50	67	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10660	10666		10.1074/jbc.271.18.10660	http://dx.doi.org/10.1074/jbc.271.18.10660			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631872	hybrid			2022-12-25	WOS:A1996UJ34200040
J	Kawasaki, T; Fujimura, Y; Usami, Y; Suzuki, M; Miura, S; Sakurai, Y; Makita, K; Taniuchi, Y; Hirano, K; Titani, K				Kawasaki, T; Fujimura, Y; Usami, Y; Suzuki, M; Miura, S; Sakurai, Y; Makita, K; Taniuchi, Y; Hirano, K; Titani, K			Complete amino acid sequence and identification of the platelet glycoprotein Ib-binding site of jararaca GPIb-BP, a snake venom protein isolated from Bothrops jararaca	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; VONWILLEBRAND-FACTOR; ALBOAGGREGIN-B; BOTROCETIN; PEPTIDE	Jararaca GPIb-BP, a snake venom protein composed of alpha and beta subunits purified from Bothrops jararaca, binds to platelet glycoprotein (GP)Ib and functions as a receptor blocker for von Willebrand factor binding to GPIb (Fujimura, Y., Ikeda, Y., Miura, S., Yoshida, E., Shima, H., Nishida, S., Suzuki, M., Titani, K., Taniuchi, Y., and Kawasaki, T. (1995) Thromb. Haemostasis 74, 743-750). We present here the entire 142- and 123-residue amino acid sequences of the respective alpha and beta subunits and also demonstrate that the platelet GPIb-binding site resides on the beta and not on the alpha subunit based on an enzyme-linked immunosorbent assay using biotin-labeled jararaca GPIb-BP and competing ligands. Sequences of the alpha and beta subunits were determined by analysis of the intact S-pyridylethylated proteins and their peptides generated by digestion with Achromobacter protease I, Staphyloccocus aureus V8 protease, pepsin, endoproteinase Asp-N, or L-1-tosylamino-2-phenylethyl chloromethyl ketone-trypsin. A 38-39% identity of amino acid sequence between the alpha and beta subunits of jararaca GPIb-BP was observed, as well as a high degree of sequence identities (38-64%) with the respective subunits of botrocetin (Usami, Y., Fujimura, Y., Suzuki, M., Ozeki, Y., Nishio, K., Fukui, H., and Titani, K (1993) Pr oc. Natl. Acad. Sci. U.S. A. 90, 928-932) and the beta-chain of echicetin (Peng, M., Holt, J. C., and Niewiarowski, S. (1994) Biochem. Biophys. Res. Commun. 205, 68-72).	NARA MED UNIV,DEPT BLOOD TRANSFUS,KASHIHARA,NARA 634,JAPAN; GIFU PHARMACEUT UNIV,DEPT PHARMACEUT,GIFU 502,JAPAN; FUJITA HLTH UNIV,SCH MED,INST COMPREHENS MED SCI,DIV BIOMED POLYMER SCI,TOYOAKE,AICHI 40711,JAPAN	Nara Medical University; Gifu Pharmaceutical University; Fujita Health University	Kawasaki, T (corresponding author), YAMANOUCHI PHARMACEUT CO LTD,INST DRUG DISCOVERY RES,CARDIOVASC & ATHEROSCLEROSIS RES LABS,TSUKUBA,IBARAKI 305,JAPAN.		Sakurai, Yoshihiko/C-5622-2011	Sakurai, Yoshihiko/0000-0002-1773-5535				BRUINS AP, 1987, ANAL CHEM, V59, P2642, DOI 10.1021/ac00149a003; CHEN YL, 1995, BIOCHEM BIOPH RES CO, V210, P472, DOI 10.1006/bbrc.1995.1684; FUJIMURA Y, 1991, BIOCHEMISTRY-US, V30, P1957, DOI 10.1021/bi00221a032; FUJIMURA Y, 1995, THROMB HAEMOSTASIS, V74, P743; HERMODSON MA, 1973, BIOCHEMISTRY-US, V12, P3136; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HIGGINS RC, 1979, ANAL BIOCHEM, V93, P257, DOI 10.1016/S0003-2697(79)80077-9; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P486; KAWASAKI T, 1995, BIOCHEM J, V308, P947, DOI 10.1042/bj3080947; KNECHT R, 1986, ANAL CHEM, V58, P2375, DOI 10.1021/ac00125a006; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAHONEY WC, 1980, J BIOL CHEM, V255, P1199; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P44, DOI 10.1016/0005-2744(81)90106-6; OZEKI Y, 1994, ARCH BIOCHEM BIOPHYS, V308, P306, DOI 10.1006/abbi.1994.1043; PENG ML, 1991, BIOCHEMISTRY-US, V30, P11529, DOI 10.1021/bi00113a007; PENG ML, 1994, BIOCHEM BIOPH RES CO, V205, P68, DOI 10.1006/bbrc.1994.2630; PENG ML, 1993, BLOOD, V81, P2321; Ruegg U T, 1977, Methods Enzymol, V47, P111; SAKARIASSEN KS, 1979, NATURE, V279, P636, DOI 10.1038/279636a0; TANIUCHI Y, 1995, BBA-GEN SUBJECTS, V1244, P331, DOI 10.1016/0304-4165(95)00052-D; USAMI Y, 1993, P NATL ACAD SCI USA, V90, P928, DOI 10.1073/pnas.90.3.928; YOSHIDA E, 1995, BRIT J HAEMATOL, V89, P861; YOSHIDA E, 1993, BIOCHEM BIOPH RES CO, V191, P1386, DOI 10.1006/bbrc.1993.1371	23	68	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10635	10639		10.1074/jbc.271.18.10635	http://dx.doi.org/10.1074/jbc.271.18.10635			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631868				2022-12-25	WOS:A1996UJ34200036
J	Otto, JC; Smith, WL				Otto, JC; Smith, WL			Photolabeling of prostaglandin endoperoxide H synthase-1 with 3-trifluoro-3-(m-[I-125]iodophenyl)diazirine as a probe of membrane association and the cyclooxygenase active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; SUBCELLULAR-LOCALIZATION; MESSENGER-RNA; SYNTHETASE; SHEEP; PURIFICATION; CELLS; DRUGS; ACID	Previous studies of the crystal structure of the ovine prostaglandin endoperoxide ET synthase-1 (PGHS-1)/S-flurbiprofen complex (Picot, D., Loll, P. J,, and Garavito, R. M. (1994) Nature 367, 243-249) suggest that the enzyme is associated with membranes through a series of four amphipathic helices located between residues 70 and 117. We have used the photoactivatable, hydrophobic reagent 3-trifluoro-3-(m-[I-125]iodophenyl)diazirine ([I-125]TID) which partitions into membranes and other hydrophobic domains to determine which domains of microsomal PGHS-1 are subject to photolabeling. After incubation of ovine vesicular gland microsomes with [I-125]TID, ovine PGHS-1 was one of the major photolabeled proteins. Proteolytic cleavage of labeled PGHS-1 at Arg(277) with trypsin established that [I-125]TID was incorporated into both the 33-kDa tryptic peptide containing the amino terminus and the 38-kDa tryptic peptide containing the carboxyl terminus. This pattern of photolabeling was not affected by the presence of 20 mM glutathione, indicating that the photolabeling observed for PGHS-1 was not due to the presence of [I-125]TID in the aqueous phase, However, nonradioactive TID as well as two inhibitors, ibuprofen and sulindac sulfide, which bind the cyclooxygenase active site of PGHS-1, prevented the labeling of the 38-kDa carboxyl-terminal tryptic peptide. These results suggest that [I-125]TID can label both the cyclooxygenase active site in the tryptic 38-kDa fragment and a membrane binding domain located in the 33-kDa fragment. Cleavage of photolabeled PGHS-1 with endoproteinase Lys-C yielded a peptide containing residues 25-166 which was labeled with [I-125]TID. This peptide contains the putative membrane binding domain of ovine PGHS-1. Our results provide biochemical support for the concept developed from the crystal structure that PGHS-1 binds to membranes via four amphipathic helices located near the NH2 terminus of the protein.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007404] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042509, R01DK022042, R37DK022042] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07404] Funding Source: Medline; NIDDK NIH HHS [DK42509, DK22042] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BHATTACHARYYA DK, 1995, ARCH BIOCHEM BIOPHYS, V317, P19, DOI 10.1006/abbi.1995.1130; BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNNER J, 1981, BIOCHEMISTRY-US, V20, P7174, DOI 10.1021/bi00528a019; CHEN YNP, 1987, J BIOL CHEM, V262, P16892; DEWITT DL, 1981, J BIOL CHEM, V256, P375; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1212; FUTAKI N, 1993, GEN PHARMACOL, V24, P105, DOI 10.1016/0306-3623(93)90018-S; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P502, DOI 10.1016/0003-9861(89)90317-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; MIZUNO K, 1982, PROSTAGLANDINS, V23, P743; MUTSAERS JHGM, 1985, EUR J BIOCHEM, V147, P569; OTTO JC, 1994, J BIOL CHEM, V269, P19868; PICOT D, 1994, FEBS LETT, V346, P21, DOI 10.1016/0014-5793(94)00314-9; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; REGIER MK, 1993, ARCH BIOCHEM BIOPHYS, V301, P439, DOI 10.1006/abbi.1993.1168; ROLLINS TE, 1980, J BIOL CHEM, V255, P4872; SILVIA WJ, 1994, MOL ANDROL, V6, P197; SIROIS J, 1992, J BIOL CHEM, V267, P6382; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; SMITH WL, 1994, EICOSANOIDS THEIR IN, P1; STRITTMATTER P, 1982, J BIOL CHEM, V257, P1883; VANDEROUDERAA FJ, 1980, EUR J BIOCHEM, V109, P1; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; WHITE BH, 1988, BIOCHEMISTRY-US, V27, P8741, DOI 10.1021/bi00424a009; WHITE BH, 1992, J BIOL CHEM, V267, P15770; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0	35	30	30	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9906	9910		10.1074/jbc.271.17.9906	http://dx.doi.org/10.1074/jbc.271.17.9906			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626626				2022-12-25	WOS:A1996UG25700010
J	Poppleton, H; Sun, H; Fulgham, D; Bertics, P; Patel, TB				Poppleton, H; Sun, H; Fulgham, D; Bertics, P; Patel, TB			Activation of G(s alpha) by the epidermal growth factor receptor involves phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC ADENYLATE-CYCLASE; REGULATORY PROTEIN; TYROSINE KINASE; EGF RECEPTOR; GS-ALPHA; BINDING; IDENTIFICATION; SITE; RECONSTITUTION; PURIFICATION	Previous studies from our laboratory have shown that epidermal growth factor (EGF) stimulates cAMP accumulation in the heart via a process involving G(s alpha) and the EGF receptor (EGFR) protein tyrosine kinase activity (Nair, B. G., Parikh, B., Milligan, G., and Patel, T. B. (1990) J. Biol. Chem. 265, 21317-21322; Nair, B. G., and Patel, T. B. (1993) Biochem. Pharmacol. 46, 1239-1245). Therefore, studies were performed to investigate the hypothesis that the EGFR protein tyrosine kinase phosphorylates G(s alpha) and activates this protein. Employing purified EGFR and G(s alpha), we have demonstrated that the EGFR kinase phosphorylates G(s alpha) in a time-dependent manner with a stoichiometry of 2 mol of phosphate incorporated/mol of G(s alpha). As determined by phosphoamino acid analysis, the phosphorylation of G(s alpha) by the EGFR kinase was exclusively on tyrosine residues. Interestingly, GDP and guanosine 5'-3-O-(thio)triphosphate (GTP gamma S) inhibited the phosphorylation of G(s alpha) without altering EGFR autophosphorylation, However, G protein beta gamma subunits protected against GDP- and GTP gamma S-mediated inhibition of phosphorylation of G(s alpha). In functional studies, phospho-G(s alpha) demonstrated a greater GTPase activity and also a greater capacity to bind GTP gamma S as compared to the nonphosphorylated G(s alpha). Moreover, the phospho-G(s alpha) augmented adenylyl cyclase activity in S49 cyc(-) cell membranes to a greater extent than its nonphosphorylated counterpart. Therefore, we conclude that phosphorylation of G(s alpha) on tyrosine residues by the EGFR kinase activates this G protein and increases its ability to stimulate adenylyl cyclase.	UNIV TENNESSEE, CTR HLTH SCI, DEPT PHARMACOL, MEMPHIS, TN 38163 USA; UNIV WISCONSIN, DEPT BIOMOLEC CHEM, MADISON, WI 53706 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Wisconsin System; University of Wisconsin Madison					NHLBI NIH HHS [HL 48308] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048308] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRANDT DR, 1983, BIOCHEMISTRY-US, V22, P4357, DOI 10.1021/bi00288a002; BUSHFIELD M, 1991, EUR J BIOCHEM, V192, P537; CADENA DL, 1994, J BIOL CHEM, V269, P260; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1990, HDB EXPT PHARM, V95, P69; COLEMAN DE, 1994, J MOL BIOL, V238, P630, DOI 10.1006/jmbi.1994.1320; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; GRAZIANO MP, 1991, METHOD ENZYMOL, V195, P192; HART MJ, 1990, J BIOL CHEM, V265, P5990; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; HERNANDEZSOTOMAYOR SMT, 1992, J MEMBRANE BIOL, V128, P81; HUBLER L, 1992, BIOCHEM J, V281, P107, DOI 10.1042/bj2810107; KRUPINSKI J, 1988, J BIOL CHEM, V263, P12333; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTENSEN TM, 1984, METHOD ENZYMOL, V107, P3; MOYERS JS, 1995, BIOCHEM J, V305, P411, DOI 10.1042/bj3050411; MUMBY S, 1988, J BIOL CHEM, V263, P2020; NAIR BG, 1990, J BIOL CHEM, V265, P21317; NAIR BG, 1993, BIOCHEM PHARMACOL, V46, P1239, DOI 10.1016/0006-2952(93)90473-A; NAIR BG, 1993, GROWTH FACTORS, V8, P41, DOI 10.3109/08977199309029133; NAIR BG, 1989, BIOCHEM J, V264, P563, DOI 10.1042/bj2640563; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; PYNE NJ, 1989, FEBS LETT, V243, P77, DOI 10.1016/0014-5793(89)81221-9; STERNWEIS PC, 1979, J BIOL CHEM, V254, P3333; STRASSHEIM D, 1994, J BIOL CHEM, V269, P14307; SUN H, 1995, P NATL ACAD SCI USA, V92, P2229, DOI 10.1073/pnas.92.6.2229; ZICK Y, 1986, P NATL ACAD SCI USA, V83, P9294, DOI 10.1073/pnas.83.24.9294	32	69	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6947	6951		10.1074/jbc.271.12.6947	http://dx.doi.org/10.1074/jbc.271.12.6947			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636123	hybrid			2022-12-25	WOS:A1996UB15700058
J	Streicher, R; Kotzka, J; MullerWieland, D; Siemeister, G; Munck, M; Avci, H; Krone, W				Streicher, R; Kotzka, J; MullerWieland, D; Siemeister, G; Munck, M; Avci, H; Krone, W			SREBP-1 mediates activation of the low density lipoprotein receptor promoter by insulin and insulin-like growth factor-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL REGULATORY ELEMENT; LEUCINE ZIPPER PROTEIN; MESSENGER-RNA; LDL-RECEPTOR; HUMAN-LIVER; GENE; IDENTIFICATION; TRANSCRIPTION; EXPRESSION; SEQUENCE	Transcription of the low density lipoprotein (LDL) receptor gene is regulated by intracellular cholesterol concentration, hormones, and growth factors. We studied the mechanisms by which insulin and estradiol stimulate promoter activity of the LDL receptor gene. Hormonal effects were analyzed in HepG2 cells after transient transfection with promotor reporter gene constructs. Successive 5' deletions of the LDL receptor promoter fragment from -537 to +88 revealed the sterol regulatory element 1 (SRE-1) between -65 and -56 as an insulin- and estradiol-sensitive cis-element. If the SRE-1 is point mutated at position -59 (C to G), which abolishes the binding of the SRE binding proteins (SREBP-1 and SREBP-2), no insulin or estradiol stimulatory effect on reporter gene expression was observed, indicating a role of SRE binding proteins in this regulatory mechanism, The concentration of the 125-kDa membrane-integrated SREBP-1 precursor protein in LDL repressed HepG2 cells is not altered by hormone treatment. Concentrations of SREBP-1 mRNA and precursor protein are reduced significantly by high and stable expression of an SREBP-1 antisense cDNA fragment in HepG2 cells (SREBP1(-) cells). Transfection of SREBP1(-) cells with promoter construct phLDL4 (-105 to +88) reduces induction of reporter gene activity by insulin and insulin-like growth factor-I to 35 and 17%, respectively, compared with HepG2 cells. The stimulatory effect of estradiol remains unchanged, and the inductions by pravastatin are enlarged. We conclude that different regulatory effects converge at SRE-1, but that SREBP-1 is selectively involved in the signal transduction pathway of insulin and insulin-like growth factor-I leading to LDL receptor gene activation.	UNIV COLOGNE,KLIN 2,D-50924 COLOGNE,GERMANY; UNIV COLOGNE,POLIKLIN INNERE MED,D-50924 COLOGNE,GERMANY	University of Cologne; University of Cologne				Kotzka, Jorg/0000-0003-1173-9372; , Gerhard/0000-0002-4712-0531				ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECKERANDRE M, 1989, NUCLEIC ACIDS RES, V17, P9437, DOI 10.1093/nar/17.22.9437; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; KRONE W, 1988, DIABETES, V37, P1386, DOI 10.2337/diabetes.37.10.1386; LLOYD DB, 1995, J BIOL CHEM, V270, P25812, DOI 10.1074/jbc.270.43.25812; MAURER RA, 1987, MOL CELL BIOL, V7, P4247, DOI 10.1128/MCB.7.12.4247; MAZZONE T, 1989, J BIOL CHEM, V264, P1787; NANJEE MN, 1990, BIOCHIM BIOPHYS ACTA, V1046, P151, DOI 10.1016/0005-2760(90)90182-W; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; Sambrook J., 2002, MOL CLONING LAB MANU; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; SMITH JR, 1990, J BIOL CHEM, V265, P2306; STAELS B, 1990, J LIPID RES, V31, P1211; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; WADE DP, 1989, EUR J BIOCHEM, V181, P727, DOI 10.1111/j.1432-1033.1989.tb14784.x; WANG XD, 1993, J BIOL CHEM, V268, P14497; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WINDLER EET, 1980, J BIOL CHEM, V255, P464; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	27	132	138	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7128	7133		10.1074/jbc.271.12.7128	http://dx.doi.org/10.1074/jbc.271.12.7128			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636148	hybrid			2022-12-25	WOS:A1996UB15700083
J	Girard, JP; Springer, TA				Girard, JP; Springer, TA			Modulation of endothelial cell adhesion by hevin, an acidic protein associated with high endothelial venules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; L-SELECTIN; VASCULAR ADDRESSIN; HUMAN TENASCIN; BINDING; THROMBOSPONDIN; SPARC; DIFFERENTIATION; MOLECULE; PEPTIDES	High endothelial venules (HEV) are specialized plump postcapillary venules in lymphoid tissues that support high levels of lymphocyte extravasation from the blood. We have recently identified a novel human transcript, expressed to high levels in HEV, that encodes a secreted, acidic protein closely related to the anti-adhesive extracellular matrix protein known as BM-40, osteonectin, and SPARC (secreted protein acidic and rich in cysteine). Here, we show that this protein, designated hevin, is associated with basal, lateral, and apical surfaces of HEV cells, and unlike MECA-79 antigen, is not expressed on the underlying basement membrane. In contrast to fibronectin or other adhesive extracellular matrix proteins, purified hevin does not support endothelial cell adhesion in vitro. Moreover, addition of soluble exogenous hevin inhibits attachment and spreading of endothelial cells on fibronectin substrates. Hevin-treated cells do not form focal adhesions and exhibit a rounded morphology. Together, these results suggest that hevin is an abundant extracellular protein that modulates high endothelial cell adhesion to the basement membrane.	HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; CNRS,LAB BIOL MOLEC EUCARYOTE,F-31062 TOULOUSE,FRANCE	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)			GIRARD, Jean-Philippe/F-5229-2010	GIRARD, Jean-Philippe/0000-0002-9154-1691	NCI NIH HHS [CA 31798] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA031798, R01CA031798] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDERUCCIO F, 1991, J EXP MED, V173, P941, DOI 10.1084/jem.173.4.941; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; Bebbington CR, 1987, DNA CLONING PRACTICA, VIII, P163; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; CARLEY WW, 1988, EXP CELL RES, V178, P426, DOI 10.1016/0014-4827(88)90411-9; DEJANA E, 1988, J CELL BIOL, V107, P1215, DOI 10.1083/jcb.107.3.1215; GASTINEL LN, 1992, P NATL ACAD SCI USA, V89, P638, DOI 10.1073/pnas.89.2.638; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; GIRARD JP, 1995, IMMUNOL TODAY, V16, P449, DOI 10.1016/0167-5699(95)80023-9; GIRARD JP, 1995, IMMUNITY, V2, P113, DOI 10.1016/1074-7613(95)90083-7; GOLDBLUM SE, 1994, P NATL ACAD SCI USA, V91, P3448, DOI 10.1073/pnas.91.8.3448; HARLOW E, 1988, ANTIBODIES LABORATOR; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; IMAI Y, 1993, NATURE, V361, P555; JOSHI P, 1993, J CELL SCI, V106, P389; LAHAV J, 1988, EXP CELL RES, V177, P199, DOI 10.1016/0014-4827(88)90037-7; LANE TF, 1990, J CELL BIOL, V111, P3065, DOI 10.1083/jcb.111.6.3065; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; MICHIE SA, 1993, AM J PATHOL, V143, P1688; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; MURPHYULLRICH JE, 1995, J CELL BIOCHEM, V57, P341, DOI 10.1002/jcb.240570218; MURPHYULLRICH JE, 1991, J CELL BIOL, V115, P1127, DOI 10.1083/jcb.115.4.1127; MURPHYULLRICH JE, 1993, J BIOL CHEM, V268, P26784; NORDGARDSUMNICH.KE, 1993, SCIENCE, V261, P480; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; POTTGIESSER J, 1994, J MOL BIOL, V238, P563, DOI 10.1006/jmbi.1994.1315; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SAGE H, 1989, J CELL BIOL, V109, P341, DOI 10.1083/jcb.109.1.341; SRIRAMARAO P, 1993, J CELL SCI, V105, P1001; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; TAKAHASHI K, 1990, IN VITRO CELL DEV, V25, P265; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; WATT FM, 1986, TRENDS BIOCHEM SCI, V11, P482, DOI 10.1016/0968-0004(86)90252-5; ZHU DZ, 1991, P NATL ACAD SCI USA, V88, P9568, DOI 10.1073/pnas.88.21.9568	37	109	111	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4511	4517						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626806				2022-12-25	WOS:A1996TW96000084
J	Taipale, J; KeskiOja, J				Taipale, J; KeskiOja, J			Hepatocyte growth factor releases epithelial and endothelial cells from growth arrest induced by transforming growth factor-beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX GENE-EXPRESSION; TGF-BETA; EXTRACELLULAR-MATRIX; SCATTER FACTOR; II RECEPTOR; PERICELLULAR MATRIX; NEGATIVE REGULATION; DEPENDENT KINASE; INHIBITION; ACTIVATION	Human lung fibroblasts and Mv1Lu mink lung epithelial cells were used as a model to study the role of extracellular matrix in epithelial-mesenchymal interactions. Extracellular matrices of fibroblasts were found to contain growth promoting activity that reduced the sensitivity of Mv1Lu cells to the growth inhibitory effects of transforming growth factor-beta (TGF-beta). The majority of the activity was identified as hepatocyte growth factor/scatter factor (HGF) by inhibition with specific antibodies and by reconstitution of the effect by recombinant HGF. HGF induced cell proliferation when contact-inhibited Mv1Lu cells were trypsinized and plated in the presence of TGF-beta 1. The effect was valid also in assays where Madin-Darby canine kidney epithelial cells or bovine capillary endothelial cells were used. The multiplication of chronically TGF-beta 1 inhibited Mv1Lu cells was also induced by HGF. In addition, HGF induced anchorage independent growth of Mv1Lu cells that was refractory to TGF-beta 1 growth inhibition. Immunoprecipitation analysis indicated that HGF prevented the suppression of Cdk4 and Cdk2, but not the induction of p21, by TGF-beta 1. Since both TGF-beta 1 and HGF require proteolysis for activation, the results imply that proteolytic activity of epithelial and endothelial cells directs their responses to signals from mesenchymal-type extracellular matrices, and that during development, matrix-bound growth and invasion promoting and suppressing factors are activated in a coordinated manner.	HELSINKI UNIV, HAARTMAN INST, DEPT VIROL, SF-00014 HELSINKI, FINLAND; HELSINKI UNIV, DEPT DERMATOL, SF-00014 HELSINKI, FINLAND; HELSINKI UNIV, DEPT VENEREOL, SF-00014 HELSINKI, FINLAND	University of Helsinki; University of Helsinki; University of Helsinki								ASSOIAN RK, 1986, J CELL BIOL, V102, P1217, DOI 10.1083/jcb.102.4.1217; BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; Brownh PD, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037500; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CZAJA MJ, 1989, J CELL BIOL, V108, P2477, DOI 10.1083/jcb.108.6.2477; DROZDOFF V, 1994, P NATL ACAD SCI USA, V91, P5528, DOI 10.1073/pnas.91.12.5528; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FALCONE DJ, 1993, J BIOL CHEM, V268, P11951; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; HAN EKH, 1993, J CELL BIOL, V122, P461, DOI 10.1083/jcb.122.2.461; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HEDMAN K, 1979, J CELL BIOL, V81, P83, DOI 10.1083/jcb.81.1.83; HEINE UI, 1990, DEVELOPMENT, V109, P29; HOWE PH, 1990, J CELL PHYSIOL, V142, P39, DOI 10.1002/jcp.1041420106; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; KAMALATI T, 1992, J CELL SCI, V101, P323; KATO J, 1993, GENE DEV, V7, P331; KAWAIDA K, 1994, P NATL ACAD SCI USA, V91, P4357, DOI 10.1073/pnas.91.10.4357; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAIHO M, 1987, J BIOL CHEM, V262, P17467; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIU YH, 1994, MOL CELL BIOL, V14, P7046, DOI 10.1128/MCB.14.11.7046; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATSUMOTO K, 1992, J BIOL CHEM, V267, P24917; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MIYAZAWA K, 1994, J BIOL CHEM, V269, P8966; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; MIZOI T, 1993, CANCER RES, V53, P183; MIZUNO K, 1994, J BIOL CHEM, V269, P1131; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MOSES HL, 1985, CANCER CELL, V3, P65; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NEVINS JR, 1992, SCIENCE, V258, P424; PELTON RW, 1991, J CELL BIOL, V115, P1091, DOI 10.1083/jcb.115.4.1091; PELTON RW, 1990, DEV BIOL, V141, P456, DOI 10.1016/0012-1606(90)90401-4; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; ROBERTS AB, 1980, P NATL ACAD SCI-BIOL, V77, P3494, DOI 10.1073/pnas.77.6.3494; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; SANTOS OFP, 1993, DEV BIOL, V160, P293, DOI 10.1006/dbio.1993.1308; SANTOS OFP, 1994, DEV BIOL, V163, P525, DOI 10.1006/dbio.1994.1169; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SERRA R, 1994, DEVELOPMENT, V120, P2153; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SILBERSTEIN GB, 1992, DEV BIOL, V152, P354, DOI 10.1016/0012-1606(92)90142-4; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SUN LZ, 1994, J BIOL CHEM, V269, P26449; SUN LZ, 1994, EXP CELL RES, V214, P215, DOI 10.1006/excr.1994.1251; TAIPALE J, 1995, J BIOL CHEM, V270, P4689, DOI 10.1074/jbc.270.9.4689; TAIPALE J, 1994, CELL GROWTH DIFFER, V5, P1309; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; TAIPALE J, 1992, J BIOL CHEM, V267, P25378; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; YAN H, 1995, J CELL BIOL, V129, P1, DOI 10.1083/jcb.129.1.1; YANAGITA K, 1993, J BIOL CHEM, V268, P21212	81	54	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4342	4348						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626783				2022-12-25	WOS:A1996TW96000061
J	Witteveen, CFB; Giovanelli, J; Kaufman, S				Witteveen, CFB; Giovanelli, J; Kaufman, S			Reduction of quinonoid dihydrobiopterin to tetrahydrobiopterin by nitric oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; L-ARGININE; METHYLENETETRAHYDROFOLATE REDUCTASE; BIOCHEMICAL-CHARACTERIZATION; DIHYDROPTERIDINE REDUCTASE; MURINE MACROPHAGES; LIVER; PURIFICATION; COFACTOR; INHIBITION	Rat cerebellar nitric oxide synthase (NOS) purified from transfected human kidney cells catalyzes an NADPH-dependent reduction of quinonoid dihydrobiopterin (qBH(2)) to tetrahydrobiopterin (BH4). Reduction of qBH(2) at 25 mu M proceeds at a rate that is comparable with that of the overall reaction (citrulline synthesis) and requires calcium ions and calmodulin for optimal activity; NADH has only 10% of the activity of NADPH. The reduction rate with the quinonoid form of 6-methyldihydropterin is approximately twice that with qBH(2). 7,8-Dihydrobiopterin had negligible activity. Neither 7,8-dihydrobiopterin nor BH4 affected the rate of qBH(2) reduction. Reduction is inhibited by the flavoprotein inhibitor diphenyleneiodonium, whereas inhibitors of electron transfer through heme (7-nitroindazole and N-nitroarginine) stimulated the rate to a small extent, Methotrexate, which inhibits a variety of enzymes catalyzing dihydrobiopterin reduction, did not inhibit. These studies provide the first demonstration of the reduction of qBH(2) to BH4 by NOS and indicate that the reduction is catalyzed by the flavoprotein ''diaphorase'' activity of NOS. This activity is located on the reductase (C-terminal) domain, whereas the high affinity BH4 site involved in NOS activation is located on the oxygenase (N-terminal) domain. The possible significance of this reduction of qBH(2) to the essential role of BH4 in NOS is discussed.	NIMH,NEUROCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)								ABUSOUD HM, 1994, J BIOL CHEM, V269, P32318; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; ARCHER MC, 1970, CAN J BIOCHEM CELL B, V48, P278, DOI 10.1139/o70-049; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CAMPOS KL, 1995, J BIOL CHEM, V270, P1721, DOI 10.1074/jbc.270.4.1721; CAMPOS KL, 1992, BIOL NITRIC OXIDE, V2, P47; CHEN PF, 1994, J BIOL CHEM, V269, P25062; CITRON BA, 1992, PROTEIN EXPRES PURIF, V3, P93, DOI 10.1016/S1046-5928(05)80024-5; CRAINE JE, 1972, J BIOL CHEM, V247, P6082; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GRISCAVAGE JM, 1994, J BIOL CHEM, V269, P21644; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; HAAVIK J, 1983, J CHROMATOGR, V257, P361, DOI 10.1016/S0021-9673(01)88192-9; HEALES S, 1989, J CHROMATOGR-BIOMED, V494, P77, DOI 10.1016/S0378-4347(00)82658-4; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; KAUFMAN S, 1971, ADV ENZYMOL RAMB, V35, P245; KAUFMAN S, 1967, J BIOL CHEM, V242, P3934; KAUFMAN S, 1959, J BIOL CHEM, V234, P2683; KAUFMAN S, 1961, J BIOL CHEM, V236, P804; KLATT P, 1994, J BIOL CHEM, V269, P13861; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; KLATT P, 1993, J BIOL CHEM, V268, P14781; KLATT P, 1992, J BIOL CHEM, V267, P11374; KOWLESSUR D, 1995, P NATL ACAD SCI USA, V92, P4743, DOI 10.1073/pnas.92.11.4743; KUTZBACH C, 1971, BIOCHIM BIOPHYS ACTA, V250, P459, DOI 10.1016/0005-2744(71)90247-6; KWON NS, 1989, J BIOL CHEM, V264, P20496; MANGUM JH, 1979, CHEM BIOL PTERIDINES, P453; MATSUURA S, 1986, P81; MATTHEWS RG, 1980, J BIOL CHEM, V255, P6014; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; NAKANISHI N, 1977, J BIOCHEM-TOKYO, V81, P681, DOI 10.1093/oxfordjournals.jbchem.a131504; NISHIMURA JS, 1995, BIOCHEM BIOPH RES CO, V210, P288, DOI 10.1006/bbrc.1995.1659; OSBORN MJ, 1958, P SOC EXP BIOL MED, V97, P429; PUFAHL RA, 1992, BIOCHEMISTRY-US, V31, P6822, DOI 10.1021/bi00144a024; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SHETA EA, 1994, J BIOL CHEM, V269, P15147; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; TEW DG, 1993, BIOCHEMISTRY-US, V32, P10209, DOI 10.1021/bi00089a042; TURNER AJ, 1979, CHEM BIOL PTERIDINES, P501; UMANS JG, 1995, ANNU REV PHYSIOL, V57, P771, DOI 10.1146/annurev.ph.57.030195.004011; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020; WOLFF DJ, 1994, ARCH BIOCHEM BIOPHYS, V311, P300, DOI 10.1006/abbi.1994.1241; ZHANG J, 1995, ANNU REV PHARMACOL, V35, P213	52	39	39	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4143	4147						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626754				2022-12-25	WOS:A1996TW96000032
J	Ye, XH; Robinson, MB; Batshaw, ML; Furth, EE; Smith, I; Wilson, JM				Ye, XH; Robinson, MB; Batshaw, ML; Furth, EE; Smith, I; Wilson, JM			Prolonged metabolic correction in adult ornithine transcarbamylase-deficient mice with adenoviral vectors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-TRANSPLANTATION; GENE; MOUSE; EXPRESSION; MUTATION; HEPATOCYTES; TOXICITY	A murine model of ornithine transcarbamylase (OTC) deficiency was used in this study to evaluate the efficacy of recombinant adenoviruses for correcting the metabolic defect in liver. Recombinant adenoviruses deleted in E1 and containing a human OTC cDNA expressed little functional OTC enzyme in vivo and had no observable impact on the underlying metabolic abnormalities of the OTC-deficient mouse (i.e. elevated urinary orotate and serum glutamine). E1-deleted vectors were improved through the use of the strong constitutive promoter from cytomegalovirus driving the normal murine homolog of OTC cDNA and the ablation of E2a with a temperature-sensitive mutation. Infusion of this improved vector into the mouse model was associated with a complete normalization of liver OTC enzyme activity that persisted for at least 2 months with complete but transient correction in serum glutamine and urine erotic acid. These studies illustrate the utility of improved adenoviral vectors in the treatment of liver metabolic disease.	UNIV PENN,DEPT MOLEC & CELLULAR ENGN,PHILADELPHIA,PA 19104; UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN HLTH SYST,DEPT PEDIAT,PHILADELPHIA,PA 19104; UNIV PENN HLTH SYST,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV PENN HLTH SYST,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; CHILDRENS SEASHORE HOUSE,PHILADELPHIA,PA 19104; CHILDRENS HOSP,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Ye, XH (corresponding author), UNIV PENN,MED CTR,WISTAR INST,INST HUMAN GENE THERAPY,RM 204,3601 SPRUCE ST,PHILADELPHIA,PA 19104, USA.		Wilson, James M/F-9220-2011	Wilson, James M/0000-0002-9630-3131	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD032649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009031, P30DK047757] Funding Source: NIH RePORTER; NICHD NIH HHS [HD32649] Funding Source: Medline; NIDDK NIH HHS [DK09031, DK47757] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Batshaw ML, 1995, GENE THER, V2, P743; BATSHAW ML, 1982, NEW ENGL J MED, V306, P1387, DOI 10.1056/NEJM198206103062303; BROELSCH CE, 1990, ANN SURG, V212, P368, DOI 10.1097/00000658-199009000-00015; BRUSILOW SW, 1989, J CHROMATOGR-BIOMED, V493, P388, DOI 10.1016/S0378-4347(00)82746-2; BRUSILOW SW, 1995, METABOLIC BASIS INHE, V1, P1187; CAVARD C, 1988, NUCLEIC ACIDS RES, V16, P2099, DOI 10.1093/nar/16.5.2099; CROMBLEHOLME TM, 1994, SEMIN PERINATOL, V18, P376; DOOLITTLE DP, 1974, J HERED, V65, P194, DOI 10.1093/oxfordjournals.jhered.a108500; ENGELHARDT JF, 1994, HUM GENE THER, V5, P1217, DOI 10.1089/hum.1994.5.10-1217; ENGELHARDT JF, 1994, P NATL ACAD SCI USA, V91, P6196, DOI 10.1073/pnas.91.13.6196; ENSINGER MJ, 1972, J VIROL, V10, P328, DOI 10.1128/JVI.10.3.328-339.1972; GOLDMAN MJ, 1995, HUM GENE THER, V6, P839, DOI 10.1089/hum.1995.6.7-839; GROSSMAN M, 1992, HUM GENE THER, V3, P501, DOI 10.1089/hum.1992.3.5-501; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HODGES PE, 1989, P NATL ACAD SCI USA, V86, P4142, DOI 10.1073/pnas.86.11.4142; HORWICH AL, 1984, SCIENCE, V224, P1068, DOI 10.1126/science.6372096; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; JONES SN, 1990, J BIOL CHEM, V265, P14684; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; LARGILLIERE C, 1989, J PEDIATR-US, V115, P415, DOI 10.1016/S0022-3476(89)80843-1; LEE JT, 1989, J CLIN INVEST, V84, P1762, DOI 10.1172/JCI114360; LI QT, 1993, HUM GENE THER, V4, P403, DOI 10.1089/hum.1993.4.4-403; LOGAN J, 1984, P NATL ACAD SCI-BIOL, V81, P3655, DOI 10.1073/pnas.81.12.3655; MIZUTANI A, 1968, J HISTOCHEM CYTOCHEM, V16, P172, DOI 10.1177/16.3.172; MORSY MA, 1993, J CLIN INVEST, V92, P1580, DOI 10.1172/JCI116739; NAGATA N, 1991, AM J MED GENET, V39, P228, DOI 10.1002/ajmg.1320390226; QURESHI IA, 1979, PEDIATR RES, V13, P807, DOI 10.1203/00006450-197907000-00003; ROBINSON MB, 1993, J NEUROCHEM, V61, P2099, DOI 10.1111/j.1471-4159.1993.tb07447.x; STRATFORDPERRICAUDET LD, 1990, HUM GENE THER, V1, P241, DOI 10.1089/hum.1990.1.3-241; TODO S, 1992, HEPATOLOGY, V15, P419, DOI 10.1002/hep.1840150311; TUCHMAN M, 1989, NEW ENGL J MED, V320, P1498; VERES G, 1987, SCIENCE, V237, P415, DOI 10.1126/science.3603027; YANG Y, 1996, IN PRESS GENE THER; YANG YP, 1994, NAT GENET, V7, P362, DOI 10.1038/ng0794-362; YANG YP, 1995, P NATL ACAD SCI USA, V92, P7257, DOI 10.1073/pnas.92.16.7257; YANG YP, 1995, NAT MED, V1, P890, DOI 10.1038/nm0995-890; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; YANG YP, 1994, IMMUNITY, V1, P433, DOI 10.1016/1074-7613(94)90074-4	39	131	164	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3639	3646						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631974				2022-12-25	WOS:A1996TV72400048
J	Hwang, ES; Naeger, LK; DiMaio, D				Hwang, ES; Naeger, LK; DiMaio, D			Activation of the endogenous p53 growth inhibitory pathway in HeLa cervical carcinoma cells by expression of the bovine papillomavirus E2 gene	ONCOGENE			English	Article						tumour suppressor protein; growth arrest; human papillomavirus	WILD-TYPE P53; MOUSE B-MYB; CELLULAR-RESPONSE; DNA DAMAGE; PROTEIN; E6; TRANSCRIPTION; PRODUCT; RB; KERATINOCYTES	We previously showed that expression of the bovine papillomavirus (BPV) E2 gene results in a dramatic inhibition of the proliferation of several human cervical carcinoma cell lines, including HeLa cells which contain human papillomavirus (HPV) type 18 DNA. We have assessed the status of endogenous G1 cell cycle regulatory proteins, including the tumor suppressor proteins, p53 and p105Rb, in order to investigate growth regulatory pathways in HeLa expression. The p53 tumor suppressor stabilized following the introduction of the E2 gene into HeLa cells. This results in the induction of the p53-responsive gene encoding the cyclin dependent kinase (cdk) inhibitor, p21/WAF1, complex formation between p21/WAF1 and cdk2 and reduction of in vitro cdk2/cyclin E kinase activity. The reduced cdk kinase activity is accompanied by the accumulation of the growth inhibitory hypophosphorylated form of the tumor suppressor protein, p105Rb. The level of the p105Rb-regulated transcription factor, E2F1, is reduced, as is transcription of a variety of E2F1-regulated genes, including B-myb. Thus, the p53 growth inhibitory pathway has evidently not accumulated mutations in HeLa cells but rather appears intact. However, this pathway remains dormant, until it is mobilized by appropriate manipulations, such as the expression of the BPV E2 protein.	YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA	Yale University					NATIONAL CANCER INSTITUTE [P01CA016038] Funding Source: NIH RePORTER; NCI NIH HHS [CA16038] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUTZ K, 1995, ONCOGENE, V10, P927; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; CROOK T, 1991, ONCOGENE, V6, P873; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUJITA M, 1992, CANCER RES, V52, P5323; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HASHIDA T, 1991, J GEN VIROL, V72, P1569, DOI 10.1099/0022-1317-72-7-1569; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAVRE PA, 1995, CANCER RES, V55, P4420; HICKMAN ES, 1994, ONCOGENE, V9, P2177; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; HWANG ES, 1993, J VIROL, V67, P3720, DOI 10.1128/JVI.67.7.3720-3729.1993; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; PECORARO G, 1991, AM J PATHOL, V138, P1; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THIERRY F, 1987, EMBO J, V6, P3391, DOI 10.1002/j.1460-2075.1987.tb02662.x; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	52	83	84	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	1996	12	4					795	803						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632901				2022-12-25	WOS:A1996TW68600010
J	Chung, SM; Jiang, L; Cheng, S; Furneaux, H				Chung, SM; Jiang, L; Cheng, S; Furneaux, H			Purification and properties of HuD, a neuronal RNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; DROSOPHILA-MELANOGASTER; UNTRANSLATED REGIONS; RICH DOMAINS; HELA-CELLS; IDENTIFICATION; RECOGNITION; SEQUENCE; ELAV; SPECIFICITY	HuD is a human neuronal specific RNA-binding protein. In this study we have purified HuD and examined its RNA binding properties in detail. HuD binds to mRNAs that contain an AU-rich element with high affinity. In the case of the c-fos AU-rich element, HuD binds to a 27-nucleotide core element comprising AUUUA, AUUUUA and AUUUUUA motifs. Mutation in any two of these motifs abrogates binding. HuD contains two tandem RNA recognition motifs (RRM), a basic domain, and a third RRM. Deletion analysis has shown that only the first and second RRMs are essential for RNA binding. Thus, these specific RNA binding properties support the idea that the HuD regulates gene expression at the post-transcriptional level.	MEM SLOAN KETTERING CANC CTR,MOLEC NEUROONCOL LAB,PROGRAM MOL PHARMACOL & THERAPEUT,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,PROGRAM CELLULAR BIOCHEM & BIOPHYS,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center				furneaux, henry/0000-0003-2212-1017	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029682] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA08748] Funding Source: Medline; NINDS NIH HHS [NS29682] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abe R, 1994, DNA Res, V1, P175, DOI 10.1093/dnares/1.4.175; ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; [Anonymous], 1995, NEUROSCIENTIST, DOI DOI 10.1177/107385849500100203; BARAMI K, 1995, J NEUROBIOL, V28, P82, DOI 10.1002/neu.480280108; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CAMPOS AR, 1985, J NEUROGENET, V2, P197, DOI 10.3109/01677068509100150; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2601, DOI 10.1021/bi00280a002; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416; FURNEAUX HM, 1985, P NATL ACAD SCI USA, V82, P4351, DOI 10.1073/pnas.82.13.4351; GAO FB, 1994, P NATL ACAD SCI USA, V91, P11207, DOI 10.1073/pnas.91.23.11207; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; HOMYK T, 1985, J NEUROGENET, V2, P309, DOI 10.3109/01677068509102326; HUANG LY, 1993, J BIOL CHEM, V268, P25769; JIMMINEZ F, 1979, NATURE, V282, P310; KATZ DA, 1994, NUCLEIC ACIDS RES, V22, P238, DOI 10.1093/nar/22.2.238; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KIM YJ, 1993, J NEUROSCI, V13, P1045; KING PH, 1994, J NEUROSCI, V14, P1943; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; LIU J, 1995, NEUROLOGY, V45, P544, DOI 10.1212/WNL.45.3.544; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MARUSICH MF, 1994, J NEUROBIOL, V25, P143, DOI 10.1002/neu.480250206; NAKAGAWA J, 1995, P NATL ACAD SCI USA, V92, P2051, DOI 10.1073/pnas.92.6.2051; PERRON M, 1995, MECH DEVELOP, V51, P235, DOI 10.1016/0925-4773(95)00368-1; PRUZAN R, 1990, J BIOL CHEM, V265, P2804; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHAW J, 1988, J IMMUNOL, V140, P2243; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	43	152	153	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11518	11524		10.1074/jbc.271.19.11518	http://dx.doi.org/10.1074/jbc.271.19.11518			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626712	hybrid			2022-12-25	WOS:A1996UJ94400072
J	Mothe, I; VanObberghen, E				Mothe, I; VanObberghen, E			Phosphorylation of insulin receptor substrate-1 on multiple serine residues, 612, 632, 662, and 731, modulates insulin action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; OKADAIC ACID; TYROSINE PHOSPHORYLATION; PROTEIN IRS-1; CELLS; SIGNAL; ADIPOCYTES; PLASMID	Okadaic acid has been described previously as being a negative regulator of insulin signaling, as it inhibits insulin stimulation of glucose transport. In addition, this drug induces on insulin receptor substrate-1 (IRS-1) a decrease in tyrosine phosphorylation, concomitantly with an increase in serine/threonine phosphorylation. The present work was aimed at the identification of the serine/threonine residues that, upon phosphorylation, might be involved in modulating insulin signaling. To this end, we studied double-point mutants of IRS-1, in which serines 612/632 and 662/731 were replaced with alanine. These are four plausible sites of phosphorylation by mitogen-activated protein kinases and are in the immediate proximity of tyrosine residues, which are potential sites of interaction with the phosphatidylinositol 3-kinase Src homology 2 domains. Using transient expression in 293 EBNA cells, we demonstrate that serines 612, 632, 662, and 731 and mitogen-activated protein kinases are not involved in the okadaic acid effect on IRS-1. Rather, these serines appear to play a role in modulating basal and insulin-stimulated IRS-1 tyrosine phosphorylation, association of IRS-1 with p85, and phosphatidylinositol 3-kinase activity in the IRS-1 . p85 immune complex, since mutation of these sites enhances these events. Our findings suggest the existence of an IRS-1 desensitization mechanism resulting from serine/threonine phosphorylation, occurring at least on serines 612, 632, 662, and 731.			Mothe, I (corresponding author), FAC MED NICE,INSERM,U145,AVE VALLOMBROSE,F-06107 NICE 2,FRANCE.		MOTHE-SATNEY, ISABELLE/Q-6377-2016	MOTHE-SATNEY, ISABELLE/0000-0002-2693-8385				CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; FREYCHET P, 1971, BIOCHEM BIOPH RES CO, V43, P400, DOI 10.1016/0006-291X(71)90767-4; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; HAYSTEAD TAJ, 1990, J BIOL CHEM, V265, P16571; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; JULLIEN D, 1993, J BIOL CHEM, V268, P15246; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1996, IN PRESS MOL CELL BI; PONS S, 1995, MOL CELL BIOL, V15, P4453; ROCCHI S, 1995, ENDOCRINOLOGY, V136, P5291, DOI 10.1210/en.136.12.5291; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TANASIJEVIC MJ, 1993, J BIOL CHEM, V268, P18157; TANTI JF, 1994, J BIOL CHEM, V269, P6051; TANTI JF, 1993, AM J PHYSIOL, V264, pE868, DOI 10.1152/ajpendo.1993.264.6.E868; VANOBBERGHEN E, 1994, DIABETOLOGIA, V87, P125; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0	29	213	225	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11222	11227		10.1074/jbc.271.19.11222	http://dx.doi.org/10.1074/jbc.271.19.11222			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626671	hybrid			2022-12-25	WOS:A1996UJ94400031
J	Thomas, JG; Baneyx, F				Thomas, JG; Baneyx, F			Protein misfolding and inclusion body formation in recombinant Escherichia coli cells overexpressing heat-shock proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNAK; GROEL; CHAPERONINS; MUTATION	PreS2-S'-beta-galactosidase, a three-domain fusion protein that aggregates extensively in the cytoplasm of Escherichia coli, was used to systematically investigate the effects of heat-shock protein (hsp) overproduction on protein misfolding and inclusion body formation. While the co-overexpression of the DnaK and DnaJ molecular chaperones led to a 3-6-fold increase in the recovery of enzymatically active preS2-S'-beta-galactosidase over a wide range of growth temperatures (30-42 degrees C), an increase in the concentration of the GroEL and GroES chaperonins had a significant effect at 30 degrees C only, Coimmunoprecipitation experiments confirmed that preS2-S'-beta-galactosidase formed a stable complex with DnaK, but not with GroEL, at 42 degrees C, When the intracellular concentration of chromosomal heat-shock proteins was increased by overproduction of the heat-shock transcription factor sigma(32), or by addition of 3% ethanol (v/v) to the growth medium, a 2-3-fold higher recovery of active enzyme was observed at 30 and 42 degrees C, but not at 37 degrees C, The overexpression of all heat-shock proteins or specific chaperone operons did not significantly affect the synthesis rates or stability of preS2-S'-beta-galactosidase and did not lead to the disaggregation of preformed inclusion bodies. Rather, the improvements in the recovery of soluble and active fusion protein resulted primarily from facilitated folding and assembly. Our findings suggest that titration of the DnaK-DnaJ early folding factors leads to the formation of preS2-S'-beta-galactosidase inclusion bodies.	UNIV WASHINGTON,DEPT CHEM ENGN,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NIGMS NIH HHS [GM088437] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMREIN KE, 1995, P NATL ACAD SCI USA, V92, P1048, DOI 10.1073/pnas.92.4.1048; Ayling A, 1996, PROTEIN SCI, V5, P478; BANEYX F, 1992, J BIOL CHEM, V267, P11637; BANEYX F, 1994, ANN NY ACAD SCI, V745, P383; BLUM P, 1992, BIO-TECHNOL, V10, P301, DOI 10.1038/nbt0392-301; BROSS P, 1993, BIOCHIM BIOPHYS ACTA, V1182, P264, DOI 10.1016/0925-4439(93)90068-C; CASPERS P, 1994, CELL MOL BIOL, V40, P635; DALE GE, 1994, PROTEIN ENG, V7, P925, DOI 10.1093/protein/7.7.925; DUENAS M, 1994, BIOTECHNIQUES, V16, P476; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; GATENBY AA, 1994, ANNU REV PLANT PHYS, V45, P469; GATENBY AA, 1992, PLANT MOL BIOL, V19, P677, DOI 10.1007/BF00026793; Georgiou G., 1990, RECOMBINANT DNA TECH, P333; GOLUBINOFF P, 1989, NATURE, V337, P44; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; GROSSMAN AD, 1987, GENE DEV, V1, P179, DOI 10.1101/gad.1.2.179; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HERMAN C, 1995, P NATL ACAD SCI USA, V92, P3516, DOI 10.1073/pnas.92.8.3516; HWANG DS, 1990, J BIOL CHEM, V265, P19244; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEE SC, 1992, J BIOL CHEM, V267, P2849; LEE SC, 1990, EUR J BIOCHEM, V187, P417, DOI 10.1111/j.1432-1033.1990.tb15320.x; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Miller JH., 1972, EXPT MOL GENETICS; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; NEIDHARDT FC, 1987, ESCHERICHIA COLI SAL, P1334; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PEREZPEREZ J, 1995, BIOCHEM BIOPH RES CO, V210, P524, DOI 10.1006/bbrc.1995.1691; PHILLIPS GJ, 1990, NATURE, V344, P882, DOI 10.1038/344882a0; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; Steczko J, 1991, Protein Expr Purif, V2, P221, DOI 10.1016/1046-5928(91)90075-T; THOMAS JG, 1996, IN PRESS ANN N Y ACA; TILLY K, 1989, J BACTERIOL, V171, P1585, DOI 10.1128/jb.171.3.1585-1589.1989; VANBOGELEN RA, 1987, J BACTERIOL, V169, P26, DOI 10.1128/jb.169.1.26-32.1987; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WYNN RM, 1992, J BIOL CHEM, V267, P12400; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YURA T, 1993, ANNU REV MICROBIOL, V47, P321, DOI 10.1146/annurev.mi.47.100193.001541	41	170	182	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11141	11147		10.1074/jbc.271.19.11141	http://dx.doi.org/10.1074/jbc.271.19.11141			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626659	hybrid			2022-12-25	WOS:A1996UJ94400019
J	Yang, WL; Bruno, MEC; Carman, GM				Yang, WL; Bruno, MEC; Carman, GM			Regulation of yeast CTP synthetase activity by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTIDINE 5'-TRIPHOSPHATE SYNTHETASE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; TRIPHOSPHATE SYNTHETASE; MUTATOR GENE; CELL-CYCLE; MUTANTS; PURIFICATION; PHOSPHORYLATION; BIOSYNTHESIS	CTP synthetase (EC 6.3.4.2, UTP:ammonia ligase (ADP-forming)) is an allosterically regulated enzyme in the yeast Saccharomyces cerevisiae. In this work we examined the regulation of CTP synthetase activity by S. cerevisiae protein kinase C (Pkc1p) phosphorylation. The results of labeling experiments with S. cerevisiae mutants expressing different levels of the PKC1 gene indicated that phosphorylation of CTP synthetase was mediated by Pkc1p in vivo. In vitro, Pkc1p phosphorylated purified CTP synthetase on serine and threonine residues, which resulted in the activation (3-fold) of enzyme activity. The mechanism of this activation involved an increase in the apparent V-max of the reaction and an increase in the enzyme's affinity for ATP. In vitro phosphorylated CTP synthetase also exhibited a decrease in its positive cooperative kinetic behavior with respect to UTP and ATP. Phosphorylation of CTP synthetase did not have a significant effect on the kinetic properties of the enzyme with respect to glutamine and GTP, Phosphorylation of CTP synthetase resulted in a decrease in the enzyme's sensitivity to product inhibition by CTP. Phosphorylation did not affect the mechanism by which CTP inhibits CTP synthetase activity.	RUTGERS STATE UNIV, COOK COLL, NEW JERSEY AGR EXPT STN, DEPT FOOD SCI, NEW BRUNSWICK, NJ 08903 USA	Rutgers State University New Brunswick					NIGMS NIH HHS [GM-50679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON PM, 1983, BIOCHEMISTRY-US, V22, P3285, DOI 10.1021/bi00282a038; ANTONSSON B, 1994, J BIOL CHEM, V269, P16821; ARONOW B, 1984, J BIOL CHEM, V259, P9035; BELL RM, 1991, J BIOL CHEM, V266, P4661; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNER MF, 1992, TRENDS BIOCHEM SCI, V17, P66, DOI 10.1016/0968-0004(92)90504-3; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CHOCK PB, 1980, ANNU REV BIOCHEM, V49, P813, DOI 10.1146/annurev.bi.49.070180.004121; CHU EHY, 1984, BIOCHEM GENET, V22, P701, DOI 10.1007/BF00485854; CULBERTSON MR, 1975, GENETICS, V80, P23; DESAINTVINCENT BR, 1980, BIOCHIM BIOPHYS ACTA, V610, P352; EXTON JH, 1990, J BIOL CHEM, V265, P1; FISCHL AS, 1983, J BACTERIOL, V154, P304, DOI 10.1128/JB.154.1.304-311.1983; HAID A, 1983, METHOD ENZYMOL, V96, P192; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; KAIBUCHI K, 1985, J BIOL CHEM, V260, P1366; KAMEMOTO ES, 1986, J BIOL CHEM, V261, P4346; KAUFMAN ER, 1986, MUTAT RES, V161, P19, DOI 10.1016/0027-5107(86)90096-5; KIZAKI H, 1980, CANCER RES, V40, P3921; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; LEVITZKI A, 1969, P NATL ACAD SCI USA, V62, P1121, DOI 10.1073/pnas.62.4.1121; LEVITZKI A, 1971, BIOCHEMISTRY-US, V10, P3365, DOI 10.1021/bi00794a008; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P247, DOI 10.1021/bi00752a016; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P241, DOI 10.1021/bi00752a015; LEWIS DA, 1989, BIOCHEMISTRY-US, V28, P8454, DOI 10.1021/bi00447a027; LIEBERMAN I, 1956, J BIOL CHEM, V222, P765; LIN K, 1995, J BIOL CHEM, V270, P26833, DOI 10.1074/jbc.270.45.26833; LONG CW, 1967, J BIOL CHEM, V242, P4715; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; MEUTH M, 1979, P NATL ACAD SCI USA, V76, P6505, DOI 10.1073/pnas.76.12.6505; MEUTH M, 1982, SOMAT CELL GENET, V8, P423, DOI 10.1007/BF01538705; NADKARNI AK, 1995, J BIOL CHEM, V270, P24982, DOI 10.1074/jbc.270.42.24982; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OZIERKALOGEROPOULOS O, 1991, MOL GEN GENET, V231, P7, DOI 10.1007/BF00293815; OZIERKALOGEROPOULOS O, 1994, MOL GEN GENET, V242, P431, DOI 10.1007/BF00281793; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; THOMAS PE, 1988, BIOCHIM BIOPHYS ACTA, V953, P334, DOI 10.1016/0167-4838(88)90042-8; TIPPLES G, 1995, J BIOL CHEM, V270, P7908, DOI 10.1074/jbc.270.14.7908; TRACH K, 1988, J BACTERIOL, V170, P4194, DOI 10.1128/jb.170.9.4194-4208.1988; TRUDEL M, 1984, J BIOL CHEM, V259, P2355; VANDENBERG AA, 1993, EUR J BIOCHEM, V216, P161; VONDERSAAL W, 1985, J BIOL CHEM, V260, P4993; WARNER JR, 1991, METHOD ENZYMOL, V194, P423; WATANABE M, 1994, J BIOL CHEM, V269, P16829; WEBER G, 1980, LIFE SCI, V27, P793, DOI 10.1016/0024-3205(80)90333-1; Weber G, 1978, Adv Enzyme Regul, V17, P1; WENG M, 1986, J BIOL CHEM, V261, P5568; WU WI, 1994, J BIOL CHEM, V269, P29495; YAMAUCHI M, 1990, EMBO J, V9, P2095, DOI 10.1002/j.1460-2075.1990.tb07377.x; YANG WL, 1994, BIOCHEMISTRY-US, V33, P10785, DOI 10.1021/bi00201a028; YANG WL, 1995, J BIOL CHEM, V270, P14983, DOI 10.1074/jbc.270.25.14983	60	42	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11113	11119		10.1074/jbc.271.19.11113	http://dx.doi.org/10.1074/jbc.271.19.11113			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626655	hybrid			2022-12-25	WOS:A1996UJ94400015
J	Bruck, I; Woodgate, R; McEntee, K; Goodman, MF				Bruck, I; Woodgate, R; McEntee, K; Goodman, MF			Purification of a soluble UmuD'C complex from Escherichia coli - Cooperative binding of UmuD'C to single-stranded DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECA PROTEIN; SOS MUTAGENESIS; POLYMERASE-III; CLEAVAGE; REPAIR; UMUC; GENE; UV; LEXA; OVERPRODUCTION	The Escherichia coli UmuD' and UmuC proteins play essential roles in SOS-induced mutagenesis, Previous studies investigating the molecular mechanisms of mutagenesis have been hindered by the lack of availability of a soluble UmuC protein, We report the extensive purification of a soluble UmuD'C complex and its interactions with DNA, The molecular mass of the complex is estimated to be 70 kDa, suggesting that the complex consists of one UmuC (46 kDa) and two UmuD' (12 kDa) molecules, In contrast to its inability to bind to double-stranded DNA, UmuD'C binds cooperatively to single-stranded DNA as measured by agarose gel electrophoresis and confirmed by steady-state fluorescence depolarization, A Hill coefficient, n = 3, characterizes the binding of UmuD'C to M13 DNA and to a 600 nucleotide DNA oligomer, suggesting that at least three protein complexes may interact cooperatively when binding to DNA, The apparent equilibrium binding constant of UmuD'C to single-stranded DNA is approximately 300 nM. Binding of the complex to a short, 80 nucleotide, DNA oligonucleotide was detectable by fluorescence depolarization, but it did not appear to be cooperative, Binding of UmuD'C to single stranded M13 DNA causes an acceleration of the protein-DNA complex, suggesting that the longer DNA may undergo compaction, The UmuD'C complex associates with RecA-coated DNA, and the UmuD'C complex remains bound to DNA in the presence of RecA.	NIH, SECT DNA REPLIACT REPAIR & MUTAGENESIS, BETHESDA, MD 20892 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	National Institutes of Health (NIH) - USA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Bruck, I (corresponding author), UNIV SO CALIF, DEPT BIOL SCI, HEDCO MOL BIOL LABS, LOS ANGELES, CA 90089 USA.			Woodgate, Roger/0000-0001-5581-4616	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021422, R01GM042554, R01GM021422] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011398] Funding Source: NIH RePORTER; NIA NIH HHS [AG11398] Funding Source: Medline; NIGMS NIH HHS [GM42554, GM21422] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILONE A, 1991, BIOCHIMIE, V73, P479, DOI 10.1016/0300-9084(91)90115-H; BONNER CA, 1988, J BIOL CHEM, V263, P18946; BRIDGES BA, 1985, P NATL ACAD SCI USA, V82, P4193, DOI 10.1073/pnas.82.12.4193; BRIDGES BA, 1984, MOL GEN GENET, V196, P364, DOI 10.1007/BF00328073; BRIDGES BA, 1976, MOL GEN GENET, V144, P53, DOI 10.1007/BF00277304; BURCKHARDT SE, 1988, P NATL ACAD SCI USA, V85, P1811, DOI 10.1073/pnas.85.6.1811; CHABBERT M, 1987, BIOCHEMISTRY-US, V26, P2218, DOI 10.1021/bi00382a022; CHABBERT M, 1991, J BIOL CHEM, V266, P5395; ECHOLS H, 1990, MUTAT RES, V236, P301, DOI 10.1016/0921-8777(90)90013-U; FRANK EG, 1993, P NATL ACAD SCI USA, V90, P8169, DOI 10.1073/pnas.90.17.8169; FREITAG N, 1989, P NATL ACAD SCI USA, V86, P8363, DOI 10.1073/pnas.86.21.8363; FRIEDBERG EC, 1995, DNA REPAIR; HAGENSEE ME, 1987, P NATL ACAD SCI USA, V84, P4195, DOI 10.1073/pnas.84.12.4195; IWASAKI H, 1990, J BACTERIOL, V172, P6268, DOI 10.1128/jb.172.11.6268-6273.1990; KITAGAWA Y, 1985, P NATL ACAD SCI USA, V82, P4336, DOI 10.1073/pnas.82.13.4336; KOHWISHIGEMATSU T, 1978, P NATL ACAD SCI USA, V75, P4689, DOI 10.1073/pnas.75.10.4689; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE, P145; LAWRENCE CW, 1996, IN PRESS MOL GEN GEN; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; MARSH L, 1985, J BACTERIOL, V162, P155, DOI 10.1128/JB.162.1.155-161.1985; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MURLI S, 1993, CURR OPIN GENET DEV, V3, P719, DOI 10.1016/S0959-437X(05)80089-9; NEWPORT JW, 1981, J MOL BIOL, V145, P105, DOI 10.1016/0022-2836(81)90336-3; NOHMI T, 1988, P NATL ACAD SCI USA, V85, P1816, DOI 10.1073/pnas.85.6.1816; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; PERRY KL, 1985, P NATL ACAD SCI USA, V82, P4331, DOI 10.1073/pnas.82.13.4331; PETIT MA, 1994, J BIOL CHEM, V269, P23824; Radman M., 1975, MOL MECHANISMS REPAI, P355; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; ROSENBERG M, 1990, J BIOL CHEM, V265, P20641; SASSANFAR M, 1990, J MOL BIOL, V212, P79, DOI 10.1016/0022-2836(90)90306-7; SHINAGAWA H, 1988, P NATL ACAD SCI USA, V85, P1806, DOI 10.1073/pnas.85.6.1806; SILVER MS, 1982, BIOCHEMISTRY-US, V21, P6066, DOI 10.1021/bi00267a007; SOMMER S, 1993, MOL MICROBIOL, V10, P963, DOI 10.1111/j.1365-2958.1993.tb00968.x; SWEASY JB, 1990, J BACTERIOL, V172, P3030, DOI 10.1128/jb.172.6.3030-3036.1990; TESSMAN I, 1994, GENETICS, V136, P439; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WITKIN EM, 1976, BACTERIOL REV, V40, P869, DOI 10.1128/MMBR.40.4.869-907.1976; WOODGATE R, 1994, J BACTERIOL, V176, P5011, DOI 10.1128/jb.176.16.5011-5021.1994; WOODGATE R, 1991, MOL GEN GENET, V229, P10, DOI 10.1007/BF00264207; WOODGATE R, 1992, MOL MICROBIOL, V6, P2213, DOI 10.1111/j.1365-2958.1992.tb01397.x; WOODGATE R, 1989, P NATL ACAD SCI USA, V86, P7301, DOI 10.1073/pnas.86.19.7301; WOODGATE R, 1992, MUTAT RES, V281, P221, DOI 10.1016/0165-7992(92)90012-7; YUEN SW, 1989, BIOTECHNIQUES, V7, P74	47	95	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10767	10774		10.1074/jbc.271.18.10767	http://dx.doi.org/10.1074/jbc.271.18.10767			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631887				2022-12-25	WOS:A1996UJ34200055
J	Fleming, I; Fisslthaler, B; Busse, R				Fleming, I; Fisslthaler, B; Busse, R			Interdependence of calcium signaling and protein tyrosine phosphorylation in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-P-450 INHIBITORS; KINASE INHIBITORS; HUMAN PLATELETS; T-CELLS; INFLUX; ENTRY; MOBILIZATION; BRADYKININ; INCREASE	The signal transduction cascade which initiates trans membraneous influx of Ca2+ into endothelial cells in response to the discharge of intracellular Ca2+ stores is thought to involve a step sensitive to tyrosine kinase inhibition. We investigated the interrelationship between Ca2+ signaling and protein tyrosine phosphorylation following cell stimulation with either the receptor-dependent agonist, bradykinin, or the protein-tyrosine phosphatase inhibitor, phenylarsine oxide. In cultured human endothelial cells phenylarsine oxide instigated a concentration-dependent increase in the intracellular concentration of free Ca2+ ([Ca2+](i)). This increase in [Ca2+](i) was not associated with the tyrosine phosphorylation of phospholipase C gamma, enhanced formation of inositol 1,4,5-trisphosphate, or the rapid depletion of intracellularly stored Ca2+ but was coincident with the enhanced and prolonged tyrosine phosphorylation of a number of cytoskeletal proteins. In bradykinin-stimulated cells the tyrosine phosphorylation of the same cytoskeletal proteins (most notably 85- and 100-kDa proteins) was transient when cells were stimulated in the presence of extracellular Ca2+, was maintained under Ca2+-free conditions, and was reversed following readdition of extracellular Ca2+. These data suggest that the tyrosine phosphorylation of 2 cytoskeletal proteins is determined by the level of Ca2+ present in intracellular stores thus indicating a critical role for tyrosine phosphorylation in the control of capacitative Ca2+ entry in endothelial cells.			Fleming, I (corresponding author), UNIV FRANKFURT KLINIKUM,ZENTRUM PHYSIOL,THEODOR STERN KAI 7,D-60590 FRANKFURT,GERMANY.		Fleming, Ingrid/L-1225-2014; Fleming, Ingrid/AAB-6123-2022	Fleming, Ingrid/0000-0003-1881-3635; Fleming, Ingrid/0000-0003-1881-3635				ALVAREZ J, 1992, J BIOL CHEM, V267, P11789; ALVAREZ J, 1991, BIOCHEM J, P274; ASAHI M, 1992, FEBS LETT, V309, P10, DOI 10.1016/0014-5793(92)80728-Y; BERVEN LA, 1994, FEBS LETT, V346, P235, DOI 10.1016/0014-5793(94)00481-1; BIRD GS, 1995, NATURE, V373, P481, DOI 10.1038/373481b0; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BUSSE R, 1991, N-S ARCH PHARMACOL, V344, P126; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; FLEMING I, 1995, CIRC RES, V76, P522, DOI 10.1161/01.RES.76.4.522; FLEMING I, 1994, CIRC RES, V74, P1220, DOI 10.1161/01.RES.74.6.1220; FLETCHER MC, 1993, J BIOL CHEM, V268, P23697; GRAIER WF, 1995, J PHYSIOL-LONDON, V482, P259, DOI 10.1113/jphysiol.1995.sp020515; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; JENNER S, 1994, BIOCHEM J, V303, P337, DOI 10.1042/bj3030337; LEE KM, 1993, J BIOL CHEM, V268, P9945; NIKLINSKA BB, 1992, J BIOL CHEM, V267, P7154; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SARGEANT P, 1992, CELL CALCIUM, V13, P553, DOI 10.1016/0143-4160(92)90035-Q; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; YATOMI Y, 1992, BIOCHEM BIOPH RES CO, V186, P1480, DOI 10.1016/S0006-291X(05)81573-6; YULE DI, 1994, BIOCHEM BIOPH RES CO, V202, P1697, DOI 10.1006/bbrc.1994.2130	24	67	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					11009	11015		10.1074/jbc.271.18.11009	http://dx.doi.org/10.1074/jbc.271.18.11009			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631922	hybrid			2022-12-25	WOS:A1996UJ34200090
J	Stephens, JM; Morrison, RF; Pilch, PF				Stephens, JM; Morrison, RF; Pilch, PF			The expression and regulation of STATs during 3T3-L1 adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; TRANSCRIPTIONAL REPRESSION; GENE-EXPRESSION; PREADIPOCYTES; COORDINATE; CELLS; GLUT4	STATs (Signal Transducers and Activators of Transcription) comprise a family of transcription factors that reside in the cytoplasm of resting cells, In response to a variety of stimuli, STATs become tyrosine-phosphorylated and translocate to the nucleus where they mediate transcriptional regulation, We have used the 3T3-L1 murine cell line to examine the expression of STAT proteins as a function of their differentiation into adipocytes, The expression of STATs 1, 3, and 5, but not of STAT 6, is markedly elevated in adipocytes as compared with their fibroblast precursors, Exposure of 3T3-L1 preadipocytes to tumor necrosis factor alpha (TNF alpha) blocks their differentiation into adipocytes, Therefore, we examined STAT expression as a function of differentiation in the presence of this cytokine, The expression of STATs 1 and 5 is markedly attenuated in the presence of TNF alpha, whereas STAT 3 expression is unaffected by this treatment, Only STAT 1 is down-regulated by TNF alpha in fully differentiated cells, Thus, although the expression of STATs 1, 3, and 5 is markedly enhanced upon differentiation, only STAT 5 expression is tightly correlated with the adipocyte phenotype, These data suggest that STAT 5, and possibly STAT 1, could be potential inducers of tissue-specific genes, which contribute to the development and maintenance of the adipocyte phenotype.	BOSTON UNIV,MED CTR,DEPT BIOCHEM,BOSTON,MA 02118	Boston University			Stephens, Jacqueline M/R-5217-2018	Pilch, Paul/0000-0003-1997-0499	NIDDK NIH HHS [DK44269, DK46200, DK30425] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200, R01DK030425, P01DK044269] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARAHMANDPOUR F, 1995, FEBS LETT, V360, P29, DOI 10.1016/0014-5793(95)00072-H; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; CORNELIUS P, 1994, ANNU REV NUTR, V14, P99, DOI 10.1146/annurev.nu.14.070194.000531; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; RODBELL M, 1964, J BIOL CHEM, V239, P375; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SMAS CM, 1995, BIOCHEM J, V309, P697, DOI 10.1042/bj3090697; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; STEPHENS JM, 1992, J BIOL CHEM, V267, P13580; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TORTI FM, 1989, J CELL BIOL, V108, P1105, DOI 10.1083/jcb.108.3.1105	21	98	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10441	10444		10.1074/jbc.271.18.10441	http://dx.doi.org/10.1074/jbc.271.18.10441			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631837	Green Published, hybrid			2022-12-25	WOS:A1996UJ34200005
J	EllisDavies, GCR; Kleyman, TR; Kaplan, JH				EllisDavies, GCR; Kleyman, TR; Kaplan, JH			Photolabile amiloride derivatives as cation site probes of the Na,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNIT; OCCLUDED STATE; CDNA SEQUENCE; SODIUM-PUMP; BINDING; KIDNEY; OCCLUSION; CELLS; (NA+; (NA+,K+)-ATPASE	Treatment of purified canine renal Na,K-ATPase with a range of photoactivatable amiloride derivatives results in inhibition of ATPase activity prior to illumination. Inhibition by amiloride derivatives substituted on a guanidium N could not be prevented by the presence of either K or Na; however, these cations could protect the enzyme against inhibition by derivatives substituted on the 5-position of the pyrazine ring. In the case of 5-(N-ethyl-[2'-methoxy-4'-nitrobenzyl])amiloride (NENMBA), the presence of monovalent cations (Na, K, and Rb) protected the enzyme effectively against inhibition, with concentrations in the millimolar range. ATP did not prevent inhibition; furthermore, native and NENMBA-treated enzyme exhibited normal levels of high affinity [H-3]ADP (and hence ATP) binding. The rate of inhibition increased with increasing concentrations of NENMBA. Extensive washing of NENMBA-inhibited enzyme did not restore ATPase activity, showing that NENMBA has an extremely slow off-rate for dissociation from its inhibitory site. Partially inhibited enzyme could be rapidly pelleted and resuspended in NENMBA-free buffer and inhibition was observed to continue, albeit at a somewhat diminished rate, suggesting that NENMBA gains access to its inhibitory site after partitioning into the lipid phase rather than directly from the aqueous solution. Photolysis of NENMBA inhibited enzyme resulted in covalent incorporation of the reagent into the ar-subunit of the Na,K-ATPase, as observed by separation of labeled protein on a Laemmli gel and Western analysis using a polyclonal amiloride antibody. Almost all of the covalent labeling could be prevented by the presence of Rb in the incubation and labeling medium. These results suggest that NENMBA inhibits the Na,K-ATPase by disruption of the cation transport domain rather than the catalytic domain of the enzyme and that it promises to be a useful tool for cation site localization.	OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA; UNIV PENN, DEPT MED, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT PHYSIOL, PHILADELPHIA, PA 19104 USA; VET ADM MED CTR, PHILADELPHIA, PA 19104 USA	Oregon Health & Science University; University of Pennsylvania; University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Kaplan, Jack/0000-0002-7048-6574	NIGMS NIH HHS [GM39500] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039500] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMLER E, 1988, BIOCHIM BIOPHYS ACTA, V945, P367, DOI 10.1016/0005-2736(88)90499-3; ARGUELLO JM, 1991, J BIOL CHEM, V266, P14627; ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; BAXTERLOWE LA, 1989, FEBS LETT, V257, P181, DOI 10.1016/0014-5793(89)81816-2; BROTHERUS JR, 1981, BIOCHEM BIOPH RES CO, V100, P146, DOI 10.1016/S0006-291X(81)80075-7; DAVID P, 1993, BIOCHIM BIOPHYS ACTA, V1146, P59, DOI 10.1016/0005-2736(93)90338-Z; ELLISDAVIES GCR, 1990, J BIOL CHEM, V265, P20570; ELLISDAVIES GCR, 1993, BIOPHYS J, V64, pA332; FORBUSH B, 1987, J BIOL CHEM, V262, P11104; FORBUSH B, 1988, J BIOL CHEM, V263, P7979; GARVIN JL, 1985, J MEMBRANE BIOL, V87, P45, DOI 10.1007/BF01870698; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GLYNN IM, 1985, J PHYSIOL-LONDON, V368, P453, DOI 10.1113/jphysiol.1985.sp015868; GLYNN IM, 1982, J PHYSIOL-LONDON, V330, P17, DOI 10.1113/jphysiol.1982.sp014326; JELENC PC, 1978, P NATL ACAD SCI USA, V75, P3564, DOI 10.1073/pnas.75.8.3564; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; KAPLAN JH, 1985, ANNU REV PHYSIOL, V47, P535, DOI 10.1146/annurev.ph.47.030185.002535; KAPLAN JH, 1989, RED BLOOD CELL MEMBR, P455; KAWAKAMI K, 1986, J BIOCHEM-TOKYO, V100, P389, DOI 10.1093/oxfordjournals.jbchem.a121726; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; KLEYMAN TR, 1989, AM J PHYSIOL, V257, pC1135, DOI 10.1152/ajpcell.1989.257.6.C1135; KLEYMAN TR, 1989, J BIOL CHEM, V264, P11995; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; KRONENBERG ME, 1966, RECL TRAV CHIM PAY-B, V85, P56; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBOVITZ RM, 1989, EMBO J, V8, P193, DOI 10.1002/j.1460-2075.1989.tb03364.x; LIANG SM, 1976, BIOCHIM BIOPHYS ACTA, V452, P552, DOI 10.1016/0005-2744(76)90207-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERCER RW, 1986, MOL CELL BIOL, V6, P3884, DOI 10.1128/MCB.6.11.3884; OR E, 1993, J BIOL CHEM, V268, P16929; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; PEDEMONTE CH, 1986, J BIOL CHEM, V261, P3632; PEDEMONTE CH, 1990, AM J PHYSIOL, V258, pC1, DOI 10.1152/ajpcell.1990.258.1.C1; PEDEMONTE CH, 1986, J BIOL CHEM, V261, P6660; ROBINSON JD, 1985, FEBS LETT, V24, P6783; SCHONER W, 1969, FEBS LETT, V5, P285, DOI 10.1016/0014-5793(69)80369-8; SHANISEKLER M, 1988, J BIOL CHEM, V263, P19331; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SOLTOFF SP, 1983, SCIENCE, V220, P957, DOI 10.1126/science.6302840; TAKEYASU K, 1988, J BIOL CHEM, V263, P4347; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040; VERREY F, 1989, AM J PHYSIOL, V256, pF1034, DOI 10.1152/ajprenal.1989.256.6.F1034; YAMAGUCHI M, 1983, CURR TOP MEMBR TRANS, V19, P203; ZHUANG YX, 1984, BIOCHEMISTRY-US, V23, P4481, DOI 10.1021/bi00314a038	44	7	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10353	10358		10.1074/jbc.271.17.10353	http://dx.doi.org/10.1074/jbc.271.17.10353			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626606	hybrid			2022-12-25	WOS:A1996UG25700078
J	Orita, S; Sasaki, T; Komuro, R; Sakaguchi, G; Maeda, M; Igarashi, H; Takai, Y				Orita, S; Sasaki, T; Komuro, R; Sakaguchi, G; Maeda, M; Igarashi, H; Takai, Y			Doc2 enhances Ca2+-dependent exocytosis from PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; NEUROTRANSMITTER RELEASE; SYNAPTOTAGMIN P65; EXPRESSION; KINASE; TISSUE; DIACYLGLYCEROL; RABPHILIN-3A; ACTIVATION; MESSENGER	We previously isolated a new protein having two C2-like domains which interacted with Ca2+ and phospholipid and named Doc2 (Double C2). Because Doc2 was abundantly expressed in brain where it was highly concentrated on the synaptic vesicle fraction, we have examined here whether Doc2 is involved in Ca2+-dependent exocytosis from cultured PC12 cells. For this purpose, we took advantage of the growth hormone (GH) co-expression assay system of PC12 cells in which GH is stored in dense core vesicles and released in response to high K+ in an extracellular Ca2+-dependent manner. Northern and Western blot analyses indicated that Doc2 is present in PC12 cells. Overexpression of hemagglutinin-tagged Doc2 stimulated the Ca2+-dependent, high K+-induced release of co-expressed GH without affecting the basal release. in the PC12 cells transfected with a plasmid with the coding sequence of Doc2 in the antisense orientation, the high K+-induced release of co-expressed GH was inversely inhibited. The Doc2 mutant expressing an N-terminal fragment or a C-terminal fragment containing two C2-like domains inhibited the high K+-induced release of co-expressed GH. These results indicate that Doc2 enhances Ca2+-dependent exocytosis of dense core vesicles from PC12 cells.	OSAKA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,SUITA,OSAKA 565,JAPAN; SHIONOGI INST MED SCI,SETTSU 566,JAPAN; NATL INST PHYSIOL SCI,DEPT CELL PHYSIOL,OKAZAKI,AICHI 444,JAPAN	Osaka University; Shionogi & Company Limited; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)								AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BORSE N, 1992, SCIENCE, V256, P1021; CHUNG SH, 1995, J BIOL CHEM, V270, P16714, DOI 10.1074/jbc.270.28.16714; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DEBELLO WM, 1993, CELL, V74, P947, DOI 10.1016/0092-8674(93)90716-4; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GODA Y, 1994, P NATL ACAD SCI USA, V91, P12942, DOI 10.1073/pnas.91.26.12942; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LITTLETON JT, 1995, TRENDS NEUROSCI, V18, P177; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MIZOGUCHI A, 1989, BIOCHEM BIOPH RES CO, V162, P1438, DOI 10.1016/0006-291X(89)90835-8; MIZOGUCHI A, 1994, BIOCHEM BIOPH RES CO, V202, P1236; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; ORITA S, 1995, BIOCHEM BIOPH RES CO, V206, P439, DOI 10.1006/bbrc.1995.1062; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P360; Sambrook J., 2002, MOL CLONING LAB MANU; SANO K, 1989, BIOCHEM BIOPH RES CO, V158, P377, DOI 10.1016/S0006-291X(89)80058-0; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; SCHWEITZER ES, 1985, J CELL BIOL, V101, P667, DOI 10.1083/jcb.101.2.667; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1994, J BIOL CHEM, V269, P32717; SHIRATAKI H, 1992, J BIOL CHEM, V267, P12096; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; TAKAI Y, 1979, BIOCHEM BIOPH RES CO, V91, P1218, DOI 10.1016/0006-291X(79)91197-5; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WICK PF, 1993, J BIOL CHEM, V268, P10983; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	39	76	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7257	7260		10.1074/jbc.271.13.7257	http://dx.doi.org/10.1074/jbc.271.13.7257			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631736	hybrid			2022-12-25	WOS:A1996UC77400004
J	Miano, JM; Olson, EN				Miano, JM; Olson, EN			Expression of the smooth muscle cell calponin gene marks the early cardiac and smooth muscle cell lineages during mouse embryogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ACTIN GENE; TATA-LESS PROMOTERS; HUMAN ELASTIN GENE; 5'-FLANKING REGION; VASCULAR INJURY; Z-DNA; TRANSCRIPTION; PROTEIN; BINDING; ACTIVATION	Although several genes are considered markers for vascular smooth muscle cell (SMC) differentiation, few have been rigorously tested for SMC specificity in mammals, particularly during development where considerable overlap exists between different muscle gene programs. Here we describe the temporospatial expression pattern of the SMC calponin gene (formerly hi or basic calponin) during mouse embryogenesis and in adult mouse tissues and cell lines. Whereas SMC calponin mRNA expression is restricted exclusively to SMCs in adult tissues, during early embryogenesis, SMC calponin transcripts are expressed throughout the developing cardiac tube as well as in differentiating SMCs. Transcription of the SMC calponin gene initiates at two closely juxtaposed sites in the absence of a consensus TATAA or initiator element. Transient transfection assays in cultured SMC demonstrated that high level SMC calponin promoter activity required no more than 549 nucleotides of 5' sequence. In contrast to the strict cell type-specificity of SMC calponin mRNA expression, the SMC calponin promoter showed activity in several cell lines that do not express the endogenous SMC calponin gene. These results demonstrate that SMC calponin responds to cardiac and smooth muscle gene regulatory programs and suggest that the cardiac and smooth muscle cell lineages may share a common gene regulatory program early in embryogenesis, which diverges as the heart matures. The finding that the isolated SMC calponin promoter is active in a wider range of cells than the endogenous SMC calponin gene also suggests that long-range repression or higher order regulatory mechanism(s) are involved in cell-specific regulation of SMC calponin expression.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Miano, Joseph/L-5634-2018	Miano, Joseph/0000-0001-7522-3207	NCI NIH HHS [CA-16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPLEGATE D, 1994, J BIOL CHEM, V269, P10683; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BASHIR MM, 1989, J BIOL CHEM, V264, P8887; BIRUKOV KG, 1991, CELL TISSUE RES, V266, P579, DOI 10.1007/BF00318599; BLACK FM, 1991, J CLIN INVEST, V88, P1581, DOI 10.1172/JCI115470; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLANK RS, 1995, CIRC RES, V76, P742, DOI 10.1161/01.RES.76.5.742; BLANK RS, 1992, J BIOL CHEM, V267, P984; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK EB, 1995, DEV MECHANISMS HEART; COOPER TA, 1988, NUCLEIC ACIDS RES, V16, P8553; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DUBAND JL, 1993, DIFFERENTIATION, V55, P1, DOI 10.1111/j.1432-0436.1993.tb00027.x; FOSTER DN, 1992, J BIOL CHEM, V267, P11995; GENG YP, 1993, MOL CELL BIOL, V13, P4894, DOI 10.1128/MCB.13.8.4894; GIMONA M, 1990, FEBS LETT, V274, P159, DOI 10.1016/0014-5793(90)81353-P; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI DH, 1993, TRENDS CARDIOVAS MED, V3, P184, DOI 10.1016/1050-1738(93)90004-P; GRABCZYK E, 1995, J BIOL CHEM, V270, P1791, DOI 10.1074/jbc.270.4.1791; KAHARI VM, 1990, J BIOL CHEM, V265, P9485; KATOH Y, 1994, J BIOL CHEM, V269, P30538; LAWRENCE R, 1994, J BIOL CHEM, V269, P28913; LECAIN E, 1991, J NEUROSCI RES, V28, P601, DOI 10.1002/jnr.490280417; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; LI L, 1995, IN PRESS J CELL BIOL; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MEZGUELDI M, 1992, J BIOL CHEM, V267, P15943; MIANO JM, 1993, AM J PATHOL, V142, P715; MIANO JM, 1993, ARTERIOSCLER THROMB, V13, P211, DOI 10.1161/01.ATV.13.2.211; MIANO JM, 1994, CIRC RES, V75, P803, DOI 10.1161/01.RES.75.5.803; MIN BH, 1988, NUCLEIC ACIDS RES, V16, P10374, DOI 10.1093/nar/16.21.10374; MIWA T, 1991, MOL CELL BIOL, V11, P3296, DOI 10.1128/MCB.11.6.3296; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; NADALGINARD B, 1989, J CLIN INVEST, V84, P1693, DOI 10.1172/JCI114351; NISHIDA W, 1993, GENE, V130, P297, DOI 10.1016/0378-1119(93)90435-6; NORDHEIM A, 1983, NATURE, V303, P674, DOI 10.1038/303674a0; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; REILLY CF, 1989, J BIOL CHEM, V264, P6990; RUZICKA DL, 1988, J CELL BIOL, V107, P2575, DOI 10.1083/jcb.107.6.2575; Sambrook J, 1989, MOL CLONING LABORATO; SCHUBERT D, 1974, J CELL BIOL, V61, P398, DOI 10.1083/jcb.61.2.398; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; STRASSER P, 1993, FEBS LETT, V330, P13, DOI 10.1016/0014-5793(93)80909-E; TAKAHASHI K, 1987, LIFE SCI, V41, P291, DOI 10.1016/0024-3205(87)90151-2; TAKAHASHI K, 1991, J BIOL CHEM, V266, P13284; TAKAHASHI K, 1993, CIRCULATION, V88, P174; TAKEUCHI K, 1991, J BIOCHEM, V109, P311; TAUBMAN MB, 1989, J CELL BIOL, V108, P1799, DOI 10.1083/jcb.108.5.1799; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; WINDER SJ, 1993, CELL SIGNAL, V5, P677, DOI 10.1016/0898-6568(93)90029-L; WITTIG B, 1992, EMBO J, V11, P4653, DOI 10.1002/j.1460-2075.1992.tb05567.x; WOODCOCKMITCHELL J, 1988, DIFFERENTIATION, V39, P161, DOI 10.1111/j.1432-0436.1988.tb00091.x	57	109	112	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7095	7103		10.1074/jbc.271.12.7095	http://dx.doi.org/10.1074/jbc.271.12.7095			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636144	hybrid			2022-12-25	WOS:A1996UB15700079
J	Yano, M; Marinelli, RA; Roberts, SK; Balan, V; Pham, L; Tarara, JE; deGroen, PC; LaRusso, NF				Yano, M; Marinelli, RA; Roberts, SK; Balan, V; Pham, L; Tarara, JE; deGroen, PC; LaRusso, NF			Rat hepatocytes transport water mainly via a non-channel-mediated pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL CHIP28 PROTEIN; XENOPUS OOCYTES; MESSENGER-RNA; GLUCOSE TRANSPORTERS; EPITHELIAL-CELLS; PLASMA-MEMBRANES; BILE FORMATION; EXPRESSION; PERMEABILITY; KIDNEY	During bile formation by the liver, large volumes of water are transported across two epithelial barriers consisting of hepatocytes and cholangiocytes (i.e. intrahepatic bile duct epithelial cells), Tire recently reported that a water channel, aquaporin-channel-forming integral protein of 28 kDa, is present in cholangiocytes and suggested that it plays a major role in water transport by these cells, Since the mechanisms of water transport across hepatocytes remain obscure, we performed physiological, molecular, and biochemical studies on hepatocytes to determine if they also contain water channels. Water permeability was studied by exposing isolated rat hepatocytes to buffers of different osmolarity and measuring cell volume by quantitative phase contrast, fluorescence and laser scanning confocal microscopy, Using this method, hepatocytes exposed to hypotonic buffers at 23 degrees C increased their cell volume in a time and osmolarity-dependent manner with an osmotic water permeability coefficient of 66.4 x 10(-4) cm/s, In studies done at 10 degrees C, the osmotic water permeability coefficient decreased by 55% (p < 0.001, at 23 degrees C; t test), The derived activation energy from these studies was 12.8 kcal/mol. After incubation of hepatocytes with amphotericin B at 10 degrees C, the osmotic water permeability coefficient increased by 198% (p < 0.001) and the activation energy value decreased to 3.6 kcal/mol, consistent with the insertion of artificial water channels into the hepatocyte plasma membrane, Reverse transcriptase polymerase chain reaction with hepatocyte RNA as template did not produce cDNAs for three of the known mater channels. Both the cholesterol content and the cholesterol/phospholipid ratio of hepatocyte plasma membranes were significantly (p < 0.005) less than those of cholangiocytes; membrane fluidity of hepatocytes estimated by measuring steady-state anisotropy was higher than that of cholangiocytes. Our data suggests that the osmotic flow of water across hepatocyte membranes occurs mainly by diffusion via the lipid bilayer (not by permeation through water channels as in cholangiocytes).	MAYO CLIN & MAYO FDN,MAYO MED SCH,CTR BASIC RES DIGEST DIS,DEPT INTERNAL MED,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,MAYO MED SCH,CTR BASIC RES DIGEST DIS,DEPT BIOCHEM & MOLEC BIOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK024031, R01DK024031] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 24031] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRE P, 1993, AM J PHYSIOL, V265, pF463; ALPINI G, 1986, AM J PHYSIOL, V251, pC872, DOI 10.1152/ajpcell.1986.251.6.C872; BOYER JL, 1979, YALE J BIOL MED, V52, P61; BROOKER G, 1990, P NATL ACAD SCI USA, V87, P2813, DOI 10.1073/pnas.87.7.2813; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORASANTI JG, 1990, AM J PHYSIOL, V258, pG290, DOI 10.1152/ajpgi.1990.258.2.G290; DEEN PMT, 1992, BIOCHEM BIOPH RES CO, V188, P1267, DOI 10.1016/0006-291X(92)91368-Z; ECHEVARRIA M, 1992, J GEN PHYSIOL, V99, P573, DOI 10.1085/jgp.99.4.573; ECKLOFF BW, 1994, INT J SYST BACTERIOL, V44, P320, DOI 10.1099/00207713-44-2-320; Erlinger Serge, 1994, P769; Finkelstein A., 1987, WATER MOVEMENT LIPID; FISCHBARG J, 1990, P NATL ACAD SCI USA, V87, P3244, DOI 10.1073/pnas.87.8.3244; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; GRAF J, 1984, P NATL ACAD SCI-BIOL, V81, P6516, DOI 10.1073/pnas.81.20.6516; HADDAD P, 1991, AM J PHYSIOL, V261, pG340, DOI 10.1152/ajpgi.1991.261.2.G340; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; ISHII M, 1989, GASTROENTEROLOGY, V97, P1236, DOI 10.1016/0016-5085(89)91695-8; LAYDEN TJ, 1978, J CLIN INVEST, V62, P1375, DOI 10.1172/JCI109258; Lenzen Romana, 1993, P539; MEIER PJ, 1984, J CELL BIOL, V98, P991, DOI 10.1083/jcb.98.3.991; MYERS BM, 1991, J CLIN INVEST, V88, P1207, DOI 10.1172/JCI115423; PFALLER W, 1993, J CELL PHYSIOL, V154, P248, DOI 10.1002/jcp.1041540206; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; ROBERTS SK, 1994, P NATL ACAD SCI USA, V91, P13009, DOI 10.1073/pnas.91.26.13009; SCHACHTER D, 1984, HEPATOLOGY, V4, P140, DOI 10.1002/hep.1840040124; SCHARSCHMIDT BF, 1990, HEPATOLOGY TXB LIVER, P303; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; TIETZ P, 1994, GASTROENTEROLOGY, V106, pA998; TRIPATHI S, 1989, Q J EXP PHYSIOL CMS, V74, P385, DOI 10.1113/expphysiol.1989.sp003288; VERKMAN AS, 1989, AM J PHYSIOL, V257, pC837, DOI 10.1152/ajpcell.1989.257.5.C837; ZAHREBELSKI G, 1995, HEPATOLOGY, V21, P1361, DOI 10.1002/hep.1840210521; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZHANG R, 1991, AM J PHYSIOL, V260, pC26, DOI 10.1152/ajpcell.1991.260.1.C26; ZHANG R, 1990, J BIOL CHEM, V265, P15375	36	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6702	6707		10.1074/jbc.271.12.6702	http://dx.doi.org/10.1074/jbc.271.12.6702			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636089	hybrid			2022-12-25	WOS:A1996UB15700024
J	Endo, T; Mitsui, S; Nakai, M; Roise, D				Endo, T; Mitsui, S; Nakai, M; Roise, D			Binding of mitochondrial presequences to yeast cytosolic heat shock protein 70 depends on the amphiphilicity of the presequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEINS; PEPTIDE-BINDING; IMPORT; TRANSLOCATION; SPECIFICITY; POLYPEPTIDE; KINETICS; GROEL; BIP	The interactions between a yeast cytosolic hsp70, Ssa1p, and various synthetic peptides, including mitochondrial presequences, have been studied, The interactions were monitored both indirectly, by measuring the effects of the presequences on the ATPase activity and oligomeric state of the enzyme, and directly, by measuring the increased steady-state fluorescence polarization of fluorescent derivatives of the presequences as they bind to Ssa1p, The presequences are all able to convert Ssa1p from an oligomeric to a monomeric form in a concentration-dependent manner. The presequences are also able to stimulate the ATPase activity of the enzyme at similar concentrations, Quantification of the binding by fluorescence polarization showed that the affinity for Ssa1p is directly related to the physical properties of the presequences. The most amphiphilic presequences, as measured by retention times on reversed-phase high pressure liquid chromatography or surface activity in lipid monolayers, had the highest affinity for Ssa1p, The least amphiphilic presequences, which had previously been shown to be ineffective as mitochondrial targeting sequences, had relatively low affinity for Ssa1p, The results show that Ssa1p interacts with a broad range of amino acid sequences and that the strength of these interactions is related to the physical properties of the sequence, That the physical properties recognized by Ssa1p are identical to those necessary for the targeting function of mitochondrial presequences suggests that Ssa1p may interact with mitochondrial precursor proteins in the cytosol, The interactions may serve a variety of purposes: the maintenance of precursors in translocation-competent forms, the prevention of improper association of precursors with non-mitochondrial membranes, and the delivery of precursors to the mitochondrial surface.	NAGOYA UNIV,FAC SCI,DEPT CHEM,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN; UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093	Nagoya University; University of California System; University of California San Diego								ALLISON DS, 1986, P NATL ACAD SCI USA, V83, P9011, DOI 10.1073/pnas.83.23.9011; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; ENDO T, 1995, FEBS LETT, V359, P93, DOI 10.1016/0014-5793(95)00015-2; FISHER WR, 1973, J BIOL CHEM, V248, P3188; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; HACHIYA N, 1994, EMBO J, V13, P5146, DOI 10.1002/j.1460-2075.1994.tb06844.x; HACHIYA N, 1993, EMBO J, V12, P1579, DOI 10.1002/j.1460-2075.1993.tb05802.x; HAMADA D, 1993, BIOCHEMISTRY-US, V32, P10351, DOI 10.1021/bi00090a010; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P125; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; MURAKAMI K, 1990, EMBO J, V9, P3201, DOI 10.1002/j.1460-2075.1990.tb07518.x; MURAKAMI K, 1992, J BIOL CHEM, V267, P13119; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; ROISE D, 1992, P NATL ACAD SCI USA, V89, P608, DOI 10.1073/pnas.89.2.608; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SWANSON ST, 1992, BIOCHEMISTRY-US, V31, P5746, DOI 10.1021/bi00140a009	26	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4161	4167						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626757				2022-12-25	WOS:A1996TW96000035
J	Lyczak, JB; Zhang, K; Saxon, A; Morrison, SL				Lyczak, JB; Zhang, K; Saxon, A; Morrison, SL			Expression of novel secreted isoforms of human immunoglobulin E proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 MESSENGER-RNAS; IGE; CHAIN; FORMS	Four human IgE isoforms produced by alternative splicing of the epsilon primary transcript were expressed as chimeric mouse/human anti 5-dimethylamino-1-naphthalenesulfonyl antibodies in the murine myeloma cell line Sp2/0, The four isoforms include the classic secreted form and three novel isoforms with altered carboxyl termini, All of these isoforms lack the transmembrane region encoded by the M1/M1' exon and are therefore predicted to be secreted proteins, When expressed in Sp2/0 cells, three of the IgE isoforms are assembled into complete molecules of two Ig heavy chains and two Ig light chains, whereas the fourth isoform is predominately assembled into half-molecules of one Ig heavy chain and one Ig light chain. All four isoforms are secreted with similar kinetics. In contrast, when the isoform containing the C epsilon 4 domain joined directly to the M2' exon (IgE grande) is expressed in the J558L cell line, it is degraded intracellularly, suggesting a cell line-dependent regulation of secretion. These data show that these novel isoforms of human IgE, predicted to occur from in vivo and in vitro mRNA analysis, can be produced and secreted by mammalian cells. The differ ent forms of IgE may have physiologically relevant but distinct roles in human IgE-mediated immune inflammation. The availability of purified recombinant human IgE isoforms makes it possible to analyze the functional differences among them.	UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, SCH MED, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED, INST MOLEC BIOL, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED, DIV CLIN IMMUNOL, HART & LOUISE LYON LAB, LOS ANGELES, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NCI NIH HHS [CA 16858] Funding Source: Medline; NIAID NIH HHS [AI-15251, AI-34567] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA016858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015251, U01AI034567, U19AI034567, R21AI015251] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATISTA FD, 1995, J IMMUNOL, V154, P209; DIAZSANCHEZ D, 1995, J IMMUNOL, V155, P1930; EARLY P, 1980, CELL, V20, P313, DOI 10.1016/0092-8674(80)90617-0; HELLMAN L, 1993, EUR J IMMUNOL, V23, P159, DOI 10.1002/eji.1830230126; MACDONALD SM, 1991, INT ARCH ALLER A IMM, V94, P144, DOI 10.1159/000235347; MACY E, 1988, FASEB J, V2, P3003, DOI 10.1096/fasebj.2.14.3263291; MEGUR KE, 1994, J IMMUNOL, V153, P5549; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; OI VT, 1986, BIOTECHNIQUES, V4, P214; PENG C, 1992, J IMMUNOL, V148, P129; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; ROGERS J, 1980, CELL, V20, P303, DOI 10.1016/0092-8674(80)90616-9; SARFATI M, 1992, IMMUNOLOGY, V76, P662; SHIN SU, 1989, METHOD ENZYMOL, V178, P459; SHIN SU, 1990, P NATL ACAD SCI USA, V87, P5322, DOI 10.1073/pnas.87.14.5322; YU LM, 1990, J IMMUNOL, V145, P3932; ZHANG K, 1992, J EXP MED, V176, P233, DOI 10.1084/jem.176.1.233; ZHANG K, 1994, J BIOL CHEM, V269, P456	18	25	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3428	3436						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631944				2022-12-25	WOS:A1996TV72400018
J	Miyazawa, K; Shimomura, T; Kitamura, N				Miyazawa, K; Shimomura, T; Kitamura, N			Activation of hepatocyte growth factor in the injured tissues is mediated by hepatocyte growth factor activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE CHAIN FORM; SCATTER FACTOR; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; SERINE-PROTEASE; LIVER; PURIFICATION; IDENTIFICATION; REGENERATION; PRECURSOR	Hepatocyte growth factor (HGF) is a potent mitogen, motogen, and morphogen for epithelial cells in vitro. It appears likely that HGF participates in tissue regeneration following hepatic and renal injury in vivo. The activity of HGF is localized to the injured tissues by a proteolytic activation system; HGF remains as an inactive single-chain form in the normal state and is converted to an active heterodimeric form in response to tissue injury. A protease responsible for this conversion is induced in the injured liver, but it has not yet been identified. We have previously purified and characterized HGF activator (HGFA), a serum-derived serine protease that efficiently activates single-chain HGF in vitro. In this study, we found that the HGF-converting activity in the injured liver was inhibited by an anti-HGFA antibody. We also found that the active form of HGFA was generated exclusively in the injured tissues. Thus, it appears likely that HGFA is the key enzyme that regulates the activity of HGF in the injured tissues. We also analyzed the heparin binding properties of the precursor and mature forms of HGFA. HGFA had a weak affinity for heparin near the physiological salt concentration in its precursor form but acquired a strong affinity for heparin upon activation that is linked to blood coagulation. This property may ensure the local action of this enzyme at the site of tissue injury.	KANSAI MED UNIV, INST LIVER RES, MORIGUCHI, OSAKA 570, JAPAN; MITSUBISHI KASEI CORP, RES CTR, AOBA KU, YOKOHAMA, KANAGAWA 227, JAPAN; TOKYO INST TECHNOL, FAC BIOSCI & BIOTECHNOL, DEPT LIFE SCI, MIDORI KU, YOKOHAMA, KANAGAWA 226, JAPAN	Kansai Medical University; Tokyo Institute of Technology			MIYAZAWA, KEIJI/I-9713-2014					ASTRUP T, 1952, ARCH BIOCHEM BIOPHYS, V40, P346, DOI 10.1016/0003-9861(52)90121-5; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; IGAWA T, 1993, AM J PHYSIOL, V265, pF61, DOI 10.1152/ajprenal.1993.265.1.F61; KAPLAN AP, 1988, METHOD ENZYMOL, V163, P3; LIU KX, 1992, AM J PHYSIOL, V263, pG642, DOI 10.1152/ajpgi.1992.263.5.G642; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; MARS WM, 1993, AM J PATHOL, V143, P949; MASUMOTO A, 1991, BIOCHEM BIOPH RES CO, V174, P90, DOI 10.1016/0006-291X(91)90489-T; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MIYAZAWA K, 1994, J BIOL CHEM, V269, P8966; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MIZUNO K, 1992, BIOCHEM BIOPH RES CO, V189, P1631, DOI 10.1016/0006-291X(92)90264-L; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKA D, 1992, J BIOL CHEM, V267, P20114; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; OKAJIMA A, 1990, EUR J BIOCHEM, V193, P375, DOI 10.1111/j.1432-1033.1990.tb19349.x; OKIGAKI M, 1992, BIOCHEMISTRY-US, V31, P9555, DOI 10.1021/bi00155a007; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SHIMOMURA T, 1995, EUR J BIOCHEM, V229, P257, DOI 10.1111/j.1432-1033.1995.0257l.x; SHIMOMURA T, 1992, CYTOTECHNOLOGY, V8, P219, DOI 10.1007/BF02522039; SHIMOMURA T, 1993, J BIOL CHEM, V268, P22927; TSUBOUCHI H, 1991, HEPATOLOGY, V13, P1; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; ZARNEGAR R, 1989, CANCER RES, V49, P3314	34	188	202	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3615	3618						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631970				2022-12-25	WOS:A1996TV72400044
J	Tsytsykova, AV; Tsitsikov, EN; Geha, RS				Tsytsykova, AV; Tsitsikov, EN; Geha, RS			The CD40L promoter contains nuclear factor of activated T cells-binding motifs which require AP-1 binding for activation of transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; IDENTIFICATION; CALCINEURIN; ELEMENTS; ENHANCER; PROTEIN; FOS; JUN	Four nuclear factor of activated T cells (NF-AT) binding motifs were found in the murine CD40 ligand promoter. Electrophoretic mobility shift assays using 18-base pair (bp) long oligonucleotides corresponding to the proximal site and nuclear extracts from activated T cells revealed two complexes which were inhibited by cyclosporin A and contained NF-ATc and NF-ATp. Neither complex contained AP-1 proteins. Multimers of the 18-bp oligonncleotides were not active in transient transfection assays using luciferase reporter gene constructs. In contrast, a 30-bp long oligonucleotide bound AP-1 proteins in addition to NP-AT proteins and its multimers strongly induced luciferase gene expression. These results suggested that NF-AT proteins play an important role in the expression of the CD40L gene and that their transcriptional activity requires AP-1 binding.	CHILDRENS HOSP,DIV IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School					NIAID NIH HHS [AI-31541, AI-28046] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI028046, U01AI031541, U19AI031541] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BRUGNONI D, 1994, EUR J IMMUNOL, V24, P1919, DOI 10.1002/eji.1830240831; CASTIGLI E, 1994, P NATL ACAD SCI USA, V91, P12135, DOI 10.1073/pnas.91.25.12135; CASTIGLI E, 1993, J IMMUNOL, V150, P3284; CHOI MSK, 1994, IMMUNITY, V1, P179, DOI 10.1016/1074-7613(94)90096-5; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FULEIHAN R, 1994, J CLIN INVEST, V93, P1315, DOI 10.1172/JCI117089; FULEIHAN R, 1994, EUR J IMMUNOL, V24, P1925, DOI 10.1002/eji.1830240832; FULEIHAN R, 1995, CLIN IMMUNOL IMMUNOP, V76, P52, DOI 10.1006/clin.1995.1087; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; ISRAEL A, 1994, NATURE, V369, P443, DOI 10.1038/369443a0; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KUBO M, 1994, J BIOL CHEM, V269, P19441; KUBO M, 1994, INT IMMUNOL, V6, P179, DOI 10.1093/intimm/6.2.179; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; RAMESH N, 1994, IMMUNOL REV, V138, P87, DOI 10.1111/j.1600-065X.1994.tb00848.x; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; ROONEY JW, 1994, EMBO J, V13, P625, DOI 10.1002/j.1460-2075.1994.tb06300.x; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; TSITSIKOV EN, 1994, MOL IMMUNOL, V31, P895, DOI 10.1016/0161-5890(94)90009-4; VENKATARAMAN L, 1994, IMMUNITY, V1, P189, DOI 10.1016/1074-7613(94)90097-3; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6	33	98	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3763	3770						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631992				2022-12-25	WOS:A1996TV72400066
J	Jones, MD; Narhi, LO; Chang, WC; Lu, HS				Jones, MD; Narhi, LO; Chang, WC; Lu, HS			Refolding and oxidation of recombinant human stem cell factor produced in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; CONDITIONED MEDIUM; RAT; IDENTIFICATION; PURIFICATION; PROTEINS; BPTI	Oxidative folding of recombinant human stem cell factor (rhSCF) produced in Escherichia coli was investigated in vitro. Folding of denatured and reduced rhSCF involves at least five intermediate forms, I-1 to I-5, detectable by their differences in hydrophobicity using reverse-phase high performance liquid chromatography. Both I-1 and I-2 contain a native-like disulfide bond, Cys(4)-Cys(89) and Cys(43)-Cys(138), respectively, and I-3 forms a mispaired disulfide, Cys(43)-Cys89. These forms appear to reach steady state equilibrium and are important folding intermediates. I-1 was found to be the prominent intermediate that directly folds into native rhSCF (N); and the thermodynamically less stable I-2 favors rearrangment into I-1. I-3 may serve as an intermediate for disulfide rearrangement between I-1 and I-2, I-4 and I-5, which are disulfide-linked dimers, are in equilibrium with reduced rhSCF and other intermediates and may not play an important role in rhSCF folding. Both trifluoroacetic acid-trapped I-1 and I-2, after isolation by high performance liquid chromatography, proceed with the remaining oxidative folding process after reconstitution. Iodoacetate-trapped I-1 and I-2 contain low alpha-helical content and some tertiary structure, while I-3 and reduced rhSCF have little ordered structure. Gel filtration/light-scattering experiments indicate that reduced rhSCF and iodoacetate-trapped I-1, I-2, and I-3 exist as dimeric forms, indicating that rhSCF dimerization precedes formation of disulfide bonds. I-I, I-2, I-3, and the C43,138A analog lacking Cys(43)-Cys(138) bond are not biologically active or exhibit significantly lower activity. The two disulfide bonds in rhSCF seem to be essential for the molecule to maintain an active conformation required for its receptor binding and biological activities.	AMGEN INC,AMGEN CTR,THOUSAND OAKS,CA 91320	Amgen				Jones, Michael/0000-0001-7541-7634				ARAKAWA T, 1991, J BIOL CHEM, V266, P18942; CHANG JY, 1993, J BIOL CHEM, V268, P4043; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; CREIGHTON TE, 1993, J MOL BIOL, V232, P1176, DOI 10.1006/jmbi.1993.1470; CREIGHTON TE, 1991, SCIENCE, V156, P111; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; JONES MD, 1994, ANAL BIOCHEM, V216, P135, DOI 10.1006/abio.1994.1017; KATO A, 1992, BIOCHIM BIOPHYS ACTA, V1159, P22, DOI 10.1016/0167-4838(92)90070-T; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGLEY KE, 1994, ARCH BIOCHEM BIOPHYS, V311, P55, DOI 10.1006/abbi.1994.1208; LANGLEY KE, 1992, ARCH BIOCHEM BIOPHYS, V295, P21, DOI 10.1016/0003-9861(92)90482-C; LU HS, 1995, BIOCHEM J, V305, P563, DOI 10.1042/bj3050563; Lu HS, 1996, J BIOL CHEM, V271, P11309, DOI 10.1074/jbc.271.19.11309; LU HS, 1992, ARCH BIOCHEM BIOPHYS, V298, P150, DOI 10.1016/0003-9861(92)90106-7; LU HS, 1991, J BIOL CHEM, V266, P8102; LU HS, 1992, J BIOL CHEM, V267, P8770; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MUI PW, 1985, BIOCHEMISTRY-US, V24, P4481, DOI 10.1021/bi00337a033; SMITH KA, 1992, CURRENT PROTOCOLS IM; TAKAGI T, 1990, J CHROMATOGR, V280, P409; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; ZHANG JX, 1993, BIOCHEMISTRY-US, V32, P14075, DOI 10.1021/bi00214a001; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	25	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11301	11308		10.1074/jbc.271.19.11301	http://dx.doi.org/10.1074/jbc.271.19.11301			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626682	Green Published, hybrid			2022-12-25	WOS:A1996UJ94400042
J	Kobayashi, H; Gotoh, J; Hirashima, Y; Terao, T				Kobayashi, H; Gotoh, J; Hirashima, Y; Terao, T			Inter-alpha-trypsin inhibitor bound to tumor cells is cleaved into the heavy chains and the light chain on the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE DERMAL FIBROBLASTS; HYALURONIC-ACID; AFFINITY-CHROMATOGRAPHY; EXTRACELLULAR-MATRIX; LIMITED PROTEOLYSIS; SERUM; PROTEIN; PROLIFERATION; COMPLEX; FAMILY	Inter-alpha-trypsin inhibitor (ITI), a human serum protease inhibitor of molecular mass 240 kDa which may release physiological derivatives, has been shown to interact with hyaluronic acid (HA), resulting in pericellular matrix stabilization (Chen, L., Mao, S. J. T., McLean, L. R., Powers, R. W., and Larsen, W. J. (1994) J. Biol. Chem. 269, 28282-28287). The purpose of this study is to determine whether ITI binding to tumor cell surface is mediated by urinary trypsin inhibitor (UTI) receptor or cell-associated hyaluronic acid (HA). We demonstrated specific complex formation of the heavy (H) chains of ITI with HA. Binding of the H-chains of ITI to immobilized HA was detected and quantified using colorimetric immunoassays, Binding was time-, temperature-, and concentration-dependent. However, UTI and HI-8 (the carboxyl terminus of UTI) failed to bind to immobilized HA. ITI bound to RA remained functional protease inhibiting activity. After incubation of SMT-cc1 cells with purified biotinylated ITI, biotinylated ITI is bound to the cells, dissociated, and gives rise to the H-chains and UTl on the cell surface. The cell surface receptor-bound UTI derived from ITI may be the result of the limited proteolysis on the cell surface. In the cells treated with hyaluronidase, bound H-chains disappeared from the surface of the cells, while most of the cell surface ITI derivatives was present in deglycosylated UTI (28 kDa). It is suggested that the binding of ITI to the cell surface Is mediated by HA on the cells. This was confirmed by the fact that the hyaluronidase-treated cells can abolish the ITI binding. The cell surface UTI formation was inhibited by diisopropyl fluorophosphate, phenylmethylsulfonyl fluoride, and eglin C, suggesting that elastase-like enzyme(s) may be responsible for the UTI formation. Preincubation of the cells with UTI did not decrease in exogenously added ITI on the cell surface. A model for cell surface UTI formation is proposed in which ITI binding to cells hom serum used for the culture is followed by the limited proteolysis by trace amounts of active serine proteases, to form cell-surface receptor-bound UTI and the H-chains intercalated into cell surface HA. This process is subject to regulation of cell-associated UTI and of stabilization of pericellular matrix.			Kobayashi, H (corresponding author), HAMAMATSU UNIV SCH MED, DEPT OBSTET & GYNECOL, HANDACHO 3600, HAMAMATSU, SHIZUOKA 43131, JAPAN.							AUBRY M, 1976, BIOCHIM BIOPHYS ACTA, V438, P221, DOI 10.1016/0005-2744(76)90238-2; BALDUYCK M, 1993, BIOL CHEM H-S, V374, P895, DOI 10.1515/bchm3.1993.374.7-12.895; BOURGUIGNON J, 1989, BIOCHEM J, V261, P305, DOI 10.1042/bj2610305; CAMAIONI A, 1993, J BIOL CHEM, V268, P20473; CHAPMAN HA, 1990, AM J PHYSIOL, V259, pL432, DOI 10.1152/ajplung.1990.259.6.L432; CHEN L, 1992, J BIOL CHEM, V267, P12380; CHEN L, 1994, J BIOL CHEM, V269, P28282; FENDERSON BA, 1993, DIFFERENTIATION, V54, P85; GUESDON JL, 1979, J HISTOCHEM CYTOCHEM, V27, P1131, DOI 10.1177/27.8.90074; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HOCHSTRASSER K, 1981, H-S Z PHYSIOL CHEM, V362, P1357, DOI 10.1515/bchm2.1981.362.2.1357; HOCHSTRASSER K, 1989, HOPPESEYLERS Z PHYSL, V370, P1689; HUANG L, 1993, J BIOL CHEM, V268, P26725; ITOH H, 1994, J BIOL CHEM, V269, P3818; KOBAYASHI H, 1995, CANCER RES, V55, P1847; KOBAYASHI H, 1994, J BIOL CHEM, V269, P20642; KOBAYASHI H, 1994, CLIN EXP METASTAS, V12, P117, DOI 10.1007/BF01753978; KOBAYASHI H, 1994, CANCER RES, V54, P844; KOBAYASHI H, 1994, INT J CANCER, V57, P378, DOI 10.1002/ijc.2910570315; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; MAEDA M, 1987, Acta Obstetrica et Gynaecologica Japonica (Japanese Edition), V39, P256; MAEHARA K, 1995, BIOCHEM BIOPH RES CO, V206, P927, DOI 10.1006/bbrc.1995.1131; PERKINS SJ, 1992, BIOCHEM J, V285, P263, DOI 10.1042/bj2850263; PRATT CW, 1987, BIOCHEMISTRY-US, V26, P2855, DOI 10.1021/bi00384a029; SALIER JP, 1980, ANAL BIOCHEM, V109, P273, DOI 10.1016/0003-2697(80)90649-1; SALIER JP, 1990, TRENDS BIOCHEM SCI, V15, P435, DOI 10.1016/0968-0004(90)90282-G; SJOBERG EM, 1992, ARCH BIOCHEM BIOPHYS, V295, P217, DOI 10.1016/0003-9861(92)90509-U; TENGBLAD A, 1979, BIOCHIM BIOPHYS ACTA, V578, P281, DOI 10.1016/0005-2795(79)90158-2; VETR H, 1990, BIOL CHEM H-S, V371, P1185, DOI 10.1515/bchm3.1990.371.2.1185; WACHTER E, 1981, H-S Z PHYSIOL CHEM, V362, P1351, DOI 10.1515/bchm2.1981.362.2.1351; YONEDA M, 1988, J CELL SCI, V90, P265; YONEDA M, 1990, J BIOL CHEM, V265, P5247; YONEDA M, 1988, J CELL SCI, V90, P275; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657	34	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11362	11367		10.1074/jbc.271.19.11362	http://dx.doi.org/10.1074/jbc.271.19.11362			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626690	hybrid			2022-12-25	WOS:A1996UJ94400050
J	Kandasamy, RA; Orlowski, J				Kandasamy, RA; Orlowski, J			Genomic organization and glucocorticoid transcriptional activation of the rat Na+/H+ exchanger Nhe3 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL EPITHELIAL-CELLS; PROTEIN-KINASE-C; NA/H ANTIPORTER ACTIVITY; PROXIMAL TUBULE CELLS; BRUSH-BORDER MEMBRANE; DNA-BINDING; MOLECULAR-CLONING; RESPONSE ELEMENTS; H+ EXCHANGE; METABOLIC-ACIDOSIS	The activity of the apical membrane Na+/H+ exchanger NHE3 isoform of renal or intestinal epithelial cells is chronically regulated by a wide variety of stimuli, including acidosis, cAMP, glucocorticoids, and thyroid hormone, To understand the molecular mechanisms responsible for long term regulation of this cation transporter, we have isolated and determined the structure of this gene from a rat genomic library. The Nhe3 gene spans >40 kilobases and contains 17 exons that are flanked by typical splice donor and acceptor sequences at the exon-intron boundaries. The transcription initiation site was mapped by S1 nuclease protection analyses of mRNA from rat kidney and intestine, Multiple start sites were clustered between nucleotides -100 and -96 relative to the translation initiation codon, An atypical TATA-box and CCAAT-box are centered 30 and 147 nucleotides, respectively, upstream of the predominant transcription initiation site, Sequence analysis of approximately 1.4 kilobases of the 5'-flanking promoter region also revealed the presence of other putative cis-acting elements recognized by various transcription factors (e.g. AP-1, AP-2, C/EBP, NF-I, OCT-1/OTF-1, PEA3, Spl, glucocorticoid, and thyroid hormone receptors), some of which may participate in the chronic regulation of this gene, The glucocorticoid responsiveness of the Nhe3 gene was assessed by fusing its 5' regulatory region to the firefly luciferase reporter gene and then by measuring the expression of the chimeric gene in transiently transfected renal epithelial OK and LLC-PK1 cells, Glucocorticoid treatment significantly increased the luciferase activity of the chimeric gene in both cell lines, thereby indicating that glucocorticoid regulation of Nhe3 is mediated primarily by a transcriptional mechanism.	MCGILL UNIV,DEPT PHYSIOL,MONTREAL,PQ H3G 1Y6,CANADA	McGill University				Orlowski, John/0000-0001-7371-175X				AMEMIYA M, 1995, AM J PHYSIOL-CELL PH, V269, pC126, DOI 10.1152/ajpcell.1995.269.1.C126; AZARANI A, 1995, J BIOL CHEM, V270, P20004, DOI 10.1074/jbc.270.34.20004; BAUM M, 1994, AM J PHYSIOL, V267, pF437, DOI 10.1152/ajprenal.1994.267.3.F437; BAUM M, 1993, AM J PHYSIOL, V264, pF1027, DOI 10.1152/ajprenal.1993.264.6.F1027; BOOTH IW, 1985, LANCET, V1, P1066; BRANT SR, 1993, GENOMICS, V15, P668, DOI 10.1006/geno.1993.1122; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CANO A, 1993, J CLIN INVEST, V92, P1632, DOI 10.1172/JCI116748; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DYCK JRB, 1995, J BIOL CHEM, V270, P1375, DOI 10.1074/jbc.270.3.1375; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GRINSTEIN S, 1986, J MEMBRANE BIOL, V90, P1, DOI 10.1007/BF01869680; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GUILLERY EN, 1995, AM J PHYSIOL-RENAL, V268, pF710, DOI 10.1152/ajprenal.1995.268.4.F710; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HORIE S, 1990, P NATL ACAD SCI USA, V87, P4742, DOI 10.1073/pnas.87.12.4742; HORIE S, 1992, P NATL ACAD SCI USA, V89, P5236, DOI 10.1073/pnas.89.12.5236; HORIE S, 1992, J CLIN INVEST, V89, P365, DOI 10.1172/JCI115594; IGARASHI P, 1992, AM J PHYSIOL, V263, pF83, DOI 10.1152/ajprenal.1992.263.1.F83; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; JUANG HH, 1995, J BIOL CHEM, V270, P12629, DOI 10.1074/jbc.270.21.12629; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KANDASAMY RK, 1995, J BIOL CHEM, V270, P29209, DOI 10.1074/jbc.270.49.29209; KAPUS A, 1994, J BIOL CHEM, V269, P23544; KINSELLA J, 1985, P NATL ACAD SCI USA, V82, P3606, DOI 10.1073/pnas.82.11.3606; KINSELLA J, 1984, J BIOL CHEM, V259, P3224; KLANKE CA, 1995, GENOMICS, V25, P615, DOI 10.1016/0888-7543(95)80002-4; KOLYADA AY, 1994, BBA-GENE STRUCT EXPR, V1217, P54; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEVINE SA, 1995, J BIOL CHEM, V270, P13716, DOI 10.1074/jbc.270.23.13716; LEVINE SA, 1993, J BIOL CHEM, V268, P25527; LIFTON RP, 1990, GENOMICS, V7, P131, DOI 10.1016/0888-7543(90)90530-8; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; MAHNENSMITH RL, 1985, CIRC RES, V56, P773, DOI 10.1161/01.RES.56.6.773; MILLER RT, 1991, J BIOL CHEM, V266, P10813; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; MOE OW, 1991, J CLIN INVEST, V88, P1703, DOI 10.1172/JCI115487; MOE OW, 1995, J CLIN INVEST, V96, P2187, DOI 10.1172/JCI118273; MORDUCHOWICZ GA, 1989, KIDNEY INT, V36, P576, DOI 10.1038/ki.1989.233; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; OVCHINNIKOV YA, 1988, FEBS LETT, V233, P87, DOI 10.1016/0014-5793(88)81361-9; PATHAK BG, 1990, GENOMICS, V8, P641, DOI 10.1016/0888-7543(90)90250-X; PITTMAN N, 1995, J BIOL CHEM, V270, P28848, DOI 10.1074/jbc.270.48.28848; PRESTRIDGE DS, 1991, COMPUT APPL BIOSCI, V7, P203; RAHMSDORF HJ, 1990, PHARMACOL THERAPEUT, V48, P157, DOI 10.1016/0163-7258(90)90079-H; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; REILLY RF, 1991, AM J PHYSIOL, V261, pF1088, DOI 10.1152/ajprenal.1991.261.6.F1088; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SHULL MM, 1989, J BIOL CHEM, V264, P17532; SOLEIMANI M, 1994, J BIOL CHEM, V269, P15613; SOLEIMANI M, 1994, J BIOL CHEM, V269, P27973; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SZPIRER C, 1994, MAMM GENOME, V5, P153, DOI 10.1007/BF00352346; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSE CM, 1991, EMBO J, V10, P1957, DOI 10.1002/j.1460-2075.1991.tb07725.x; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE CM, 1993, J BIOL CHEM, V268, P11917; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; WANG Z, 1993, J BIOL CHEM, V268, P11925; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; YAMAJI Y, 1995, P NATL ACAD SCI USA, V92, P6274, DOI 10.1073/pnas.92.14.6274; YUN CHC, 1993, J BIOL CHEM, V268, P206; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	84	70	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10551	10559		10.1074/jbc.271.18.10551	http://dx.doi.org/10.1074/jbc.271.18.10551			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631855	hybrid			2022-12-25	WOS:A1996UJ34200023
J	Maveyraud, L; Saves, I; BurletSchiltz, O; Swaren, P; Masson, JM; Delaire, M; Mourey, L; Prome, JC; Samama, JP				Maveyraud, L; Saves, I; BurletSchiltz, O; Swaren, P; Masson, JM; Delaire, M; Mourey, L; Prome, JC; Samama, JP			Structural basis of extended spectrum TEM beta-lactamases - Crystallographic, kinetic, and mass spectrometric investigations of enzyme mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS; INTERMEDIATE; MECHANISM; CEPHALOSPORINS; INHIBITION; RESOLUTION; HYDROLYSIS; CATALYSIS; PC1	The E166Y and the E166Y/R164S TEM-1 beta-lactamase mutant enzymes display extended spectrum substrate specificities, Electrospray mass spectrometry demonstrates that, with penicillin G as substrate, the rate-limiting step in catalysis is the hydrolysis of the E166Y acyl-enzyme complex, Comparison of the 1.8-Angstrom resolution x-ray structures of the wild-type and of the E166Y mutant enzymes shows that the binding of cephalosporin substrates is improved, in the mutant enzyme, by the enlargement of the substrate binding site. This enlargement is due to the rigid body displacement of 60 residues driven by the movement of the R-loop. These structural observations strongly suggest that the link between the position of the Omega-loop and that of helix H5, plays a central role in the structural events leading to extended spectrum TEM-related enzymes, The increased Omega-loop flexibility caused by the R164S mutation, which is found in several natural mutant TEM enzymes, may lead to similar structural effects. Comparison of the kinetic data of the E166Y, E166Y/R164S, and R164S mutant enzymes supports this hypothesis.	PHARMACOL & TOXICOL FONDAMENTALES LAB,GRP CRISTALLOG BIOL,F-31077 TOULOUSE,FRANCE; PHARMACOL & TOXICOL FONDAMENTALES LAB,GRP INGN PROT,F-31077 TOULOUSE,FRANCE; PHARMACOL & TOXICOL FONDAMENTALES LAB,GRP SPECTROMETRIE MASSE,F-31077 TOULOUSE,FRANCE				Mourey, Lionel/B-5662-2009; Maveyraud, Laurent/C-6066-2011	Mourey, Lionel/0000-0002-8259-1259; Maveyraud, Laurent/0000-0003-4610-8319; Schiltz, Odile/0000-0002-3606-2356				ADACHI H, 1991, J BIOL CHEM, V266, P3186; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; APLIN RT, 1990, FEBS LETT, V277, P212, DOI 10.1016/0014-5793(90)80847-C; BLAZQUEZ J, 1995, ANTIMICROB AGENTS CH, V39, P145, DOI 10.1128/AAC.39.1.145; BRUNGER AT, X PLOR MANUAL BERSIO; CHRISTENSEN H, 1990, BIOCHEM J, V266, P853; DELAIRE M, 1991, PROTEIN ENG, V4, P805, DOI 10.1093/protein/4.7.805; FARACI WS, 1986, BIOCHEMISTRY-US, V25, P2934, DOI 10.1021/bi00358a030; FARACI WS, 1985, BIOCHEMISTRY-US, V24, P903, DOI 10.1021/bi00325a014; HENDRICKSON WA, 1980, BIOMOLECULAR STRUCTU, V1, P43; HERZBERG O, 1991, BIOCHEMISTRY-US, V30, P9503, DOI 10.1021/bi00103a017; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JACOBY GA, 1991, ANTIMICROB AGENTS CH, V35, P1697, DOI 10.1128/AAC.35.9.1697; JELSCH C, 1993, PROTEINS, V16, P364, DOI 10.1002/prot.340160406; JONES TA, 1985, METHOD ENZYMOL, V115, P157; MOROSINI MI, 1995, ANTIMICROB AGENTS CH, V39, P458, DOI 10.1128/AAC.39.2.458; NAUMOVSKI L, 1992, ANTIMICROB AGENTS CH, V36, P1991, DOI 10.1128/AAC.36.9.1991; PALZKILL T, 1995, ANTIMICROB AGENTS CH, V39, P1199, DOI 10.1128/AAC.39.5.1199; PETIT A, 1995, BIOCHEM J, V305, P33, DOI 10.1042/bj3050033; RAQUET X, 1994, J MOL BIOL, V244, P625, DOI 10.1006/jmbi.1994.1756; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SAVES I, 1995, BIOCHEMISTRY-US, V34, P11660, DOI 10.1021/bi00037a003; SAVES I, 1995, J BIOL CHEM, V270, P18240, DOI 10.1074/jbc.270.31.18240; SOWEK JA, 1991, BIOCHEMISTRY-US, V30, P3179, DOI 10.1021/bi00227a004; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; SWAREN P, 1995, STRUCTURE, V3, P603, DOI 10.1016/S0969-2126(01)00194-0; VENKATACHALAM KV, 1994, J BIOL CHEM, V269, P23444; VIADIU H, 1995, J BIOL CHEM, V270, P781, DOI 10.1074/jbc.270.2.781	28	30	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10482	10489		10.1074/jbc.271.18.10482	http://dx.doi.org/10.1074/jbc.271.18.10482			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631844	Green Published, hybrid			2022-12-25	WOS:A1996UJ34200012
J	Noonberg, SB; Scott, GK; Benz, CC				Noonberg, SB; Scott, GK; Benz, CC			Evidence of post-transcriptional regulation of U6 small nuclear RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III; CAP STRUCTURE; SPLICEOSOME; GENES; U1; U2; ANTIBODIES; ELEMENTS; INVITRO; SNRNAS	Mechanisms regulating the intracellular level of endogenous U6 small nuclear RNA were studied by transient transfection of ectopic U6 gene constructs into immortalized normal and malignant human cell lines, Transfection and expression of a modified U6 gene containing native promoter, capping, and termination sequences but lacking all highly conserved internal spliceosome sequences produced dose-dependent effects on endogenous U6 gene expression, At low transfection doses, no significant changes in endogenous U6 RNA levels or half-life were noted, However, as the dose of the transfected gene and its expression increased, native U6 RNA levels dramatically decreased in association with an apparent decrease in U6 RNA half-life, Down-regulation of native U6 RNA levels was transient, with recovery noted within 48-96 h in conjunction with declining expression of the ectopic gene. These modulatory effects appeared specific to endogenous U6 transcripts, because no changes were noted in 7sk, U1, U3, or 5S RNA levels or half-lives. Transfection with an unmodified U6 gene did not alter total U6 transcript levels but did produce a similar dose-dependent decrease in U6 RNA half-life, These studies suggest a hitherto unrecognized U6-specific intracellular regulatory mechanism, through which over-accumulation of U6 small nuclear RNA is prevented.	UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NCI NIH HHS [CA 36773] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA036773] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGET SM, 1986, CELL, V46, P691, DOI 10.1016/0092-8674(86)90344-2; BROW DA, 1989, NATURE, V337, P14, DOI 10.1038/337014a0; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; GUPTA S, 1990, J BIOL CHEM, V265, P9491; GUPTA S, 1990, J BIOL CHEM, V265, P19137; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; Hernandez N, 1992, TRANSCRIPTIONAL REGU, P281; KUNKEL GR, 1986, P NATL ACAD SCI USA, V83, P8575, DOI 10.1073/pnas.83.22.8575; KUNKEL GR, 1989, NUCLEIC ACIDS RES, V17, P7371, DOI 10.1093/nar/17.18.7371; KUNKEL GR, 1988, GENE DEV, V2, P196, DOI 10.1101/gad.2.2.196; LOBO SM, 1989, CELL, V58, P55, DOI 10.1016/0092-8674(89)90402-9; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MANGIN M, 1985, SCIENCE, V229, P272, DOI 10.1126/science.2409601; NOONBERG SB, 1994, NUCLEIC ACIDS RES, V22, P2830, DOI 10.1093/nar/22.14.2830; NOONBERG SB, 1994, THESIS U CALIFORNIA; RAY R, 1994, MOL CELL BIOCHEM, V131, P67, DOI 10.1007/BF01075726; REDDY R, 1987, J BIOL CHEM, V262, P75; Reddy R., 1988, STRUCTURE FUNCTION M, P1, DOI 10.1007/978-3-642-73020-7_1; RINKE J, 1982, CELL, V29, P149, DOI 10.1016/0092-8674(82)90099-X; Sambrook J., 2002, MOL CLONING LAB MANU; SAUTERER RA, 1988, EXP CELL RES, V176, P344, DOI 10.1016/0014-4827(88)90336-9; SHIMBA S, 1994, J BIOL CHEM, V269, P12419; SHUMYATSKY G, 1993, NUCLEIC ACIDS RES, V21, P4756, DOI 10.1093/nar/21.20.4756; SINGH R, 1989, P NATL ACAD SCI USA, V86, P8280, DOI 10.1073/pnas.86.21.8280; Stefanovic Branko, 1994, Gene Expression, V4, P1; TERNS MP, 1993, GENE DEV, V7, P1898, DOI 10.1101/gad.7.10.1898; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; WOLFF T, 1993, GENE DEV, V7, P1377, DOI 10.1101/gad.7.7b.1377	30	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10477	10481		10.1074/jbc.271.18.10477	http://dx.doi.org/10.1074/jbc.271.18.10477			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631843	hybrid			2022-12-25	WOS:A1996UJ34200011
J	Sorby, M; Ostman, A				Sorby, M; Ostman, A			Protein-tyrosine phosphatase-mediated decrease of epidermal growth factor and platelet-derived growth factor receptor tyrosine phosphorylation in high cell density cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE PHOSPHOTYROSINE PHOSPHATASE; FACTOR-I	Contact-induced growth inhibition is a characteristic feature of normal cells grown in monolayer. The importance of reversible tyrosine phosphorylation in mitogenic signaling, together with earlier reports of increased levels of protein-tyrosine phosphatases (PTPs) in densely cultured cells, has led to the proposal that PTPs may be involved in mediating contact inhibition of cell growth. We have compared net levels of ligand-induced tyrosine phosphorylation of the epidermal growth factor (EGF) receptor in mink lung epithelial cells cultured under sparse or dense conditions. The levels of net tyrosine phosphorylation of the stimulated EGF receptor was found to be more than 4-fold higher in sparse cultures. This difference was greatly reduced when cells were pretreated with the PTP inhibitor phenyl arsine oxide. Monitoring of dephosphorylation rates in vivo of the stimulated EGF receptors revealed increased EGF receptor-directed PTP activity in dense cultures. The platelet-derived growth factor beta-receptor, expressed in stably transfected porcine aortic endothelial cells, also displayed lower levels of ligand induced net tyrosine phosphorylation in cells from dense cultures. This density-dependent difference in tyrosine phosphorylation was reduced by pretreatment of cultures with the PTP inhibitor orthovanadate. A PTP-mediated decrease of the in vivo net levels of ligand induced tyrosine phosphorylation of EGF and platelet-derived growth factor receptors in cells at high density have thus been demonstrated. Loss of this previously unnoticed regulatory pathway may be involved in cellular transformation.	LUDWIG INST CANC RES,S-75124 UPPSALA,SWEDEN	Ludwig Institute for Cancer Research								BRADYKALNAY SM, 1995, CURR OPIN CELL BIOL, V7, P650, DOI 10.1016/0955-0674(95)80106-5; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; CELLER JW, 1995, BIOCHEM BIOPH RES CO, V209, P614, DOI 10.1006/bbrc.1995.1544; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; MANSBRIDGE JN, 1992, J CELL PHYSIOL, V151, P433, DOI 10.1002/jcp.1041510302; MOONEY RA, 1992, J BIOL CHEM, V267, P23443; MORI S, 1991, J BIOL CHEM, V266, P21158; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; PALLEN CJ, 1991, P NATL ACAD SCI USA, V88, P6996, DOI 10.1073/pnas.88.16.6996; SAP J, 1994, MOL CELL BIOL, V14, P1; SOUTHEY MC, 1995, BIOCHEM J, V305, P485, DOI 10.1042/bj3050485; WAY BA, 1993, J BIOL CHEM, V268, P26409	17	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10963	10966						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631915				2022-12-25	WOS:A1996UJ34200083
J	Hirano, K; Young, SG; Farese, RV; Ng, J; Sande, E; Warburton, C; PowellBraxton, LM; Davidson, NO				Hirano, K; Young, SG; Farese, RV; Ng, J; Sande, E; Warburton, C; PowellBraxton, LM; Davidson, NO			Targeted disruption of the mouse apobec-1 gene abolishes apolipoprotein B mRNA editing and eliminates apolipoprotein B48	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; INTESTINE; PROTEINS	A site-specific C to U editing reaction modifies nuclear apolipoprotein B100 (apoB100) mRNA, producing apolipoprotein B48 in the mammalian small intestine, This reaction is mediated by a multicomponent enzyme complex, which contains a catalytic subunit, Apobec-1. We have used gene targeting to disrupt mouse apobec-1 in order to establish its requisite importance in apoB mRNA editing and also, in view of its widespread tissue distribution in rodents, as a preliminary indication of other potential roles. Both heterozygous (apobec-1(+/-)) and homozygous (apobec-1(-/-)) gene-targeted mice appear healthy and fertile with no alterations in serum cholesterol or triglyceride concentrations. The apobec-1(+/-) mice demonstrated reduced levels of hepatic apoB mRNA editing. By contrast, levels of small intestinal apoB mRNA editing were indistinguishable in wild-type and apobec-1(+/-) animals, suggesting that Apobec-1 is expressed in limited quantities in the liver but not in the small intestine. The apobec-1(-/-) mice lacked detectable levels of Apobec-1 mRNA, expressed only unedited apoB mRNA in all tissues, and contained no apoB48 in their serum, demonstrating that there is no functional duplication of this gene.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,CARDIOVASC RES INST,SAN FRANCISCO,CA 94141; GENENTECH INC,CARDIOVASC RES,SAN FRANCISCO,CA 94080; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637	University of California System; University of California San Francisco; The J David Gladstone Institutes; Roche Holding; Genentech; University of Chicago				Young, Stephen/0000-0001-7270-3176	NHLBI NIH HHS [HL-38180, HL-18577] Funding Source: Medline; NIDDK NIH HHS [DK-42086] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038180, R37HL038180, P01HL018577] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK042086] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANT S, 1995, J BIOL CHEM, V270, P14762, DOI 10.1074/jbc.270.24.14762; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; CALLOW MJ, 1995, J BIOL CHEM, V270, P23914, DOI 10.1074/jbc.270.41.23914; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; Davidson Nicholas O., 1995, Current Opinion in Lipidology, V6, P70, DOI 10.1097/00041433-199504000-00002; FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774; FUNAHASHI T, 1995, J LIPID RES, V36, P414; GIANNONI F, 1994, J BIOL CHEM, V269, P5932; GIANNONI F, 1995, J LIPID RES, V36, P1664; GREEVE J, 1993, J LIPID RES, V34, P1367; HADJIAGAPIOU C, 1994, NUCLEIC ACIDS RES, V22, P1874, DOI 10.1093/nar/22.10.1874; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; HIGUCHI K, 1992, J LIPID RES, V33, P1753; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; MCCORMICK PA, 1995, P NATL ACAD SCI USA, V92, P10147; NAKAMUTA M, 1995, J BIOL CHEM, V270, P13042, DOI 10.1074/jbc.270.22.13042; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; PURCELLHUYNH DA, 1995, J CLIN INVEST, V95, P2246, DOI 10.1172/JCI117915; TENG BB, 1990, J BIOL CHEM, V265, P20616; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; TENG BB, 1992, J BIOL CHEM, V267, P21265; TENG BB, 1990, BIOCHEM BIOPH RES CO, V173, P74, DOI 10.1016/S0006-291X(05)81023-X; WU JH, 1990, J BIOL CHEM, V265, P12312; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; YAMANAKA S, 1995, P NATL ACAD SCI USA, V92, P8483, DOI 10.1073/pnas.92.18.8483; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	30	120	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9887	9890		10.1074/jbc.271.17.9887	http://dx.doi.org/10.1074/jbc.271.17.9887			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626621	hybrid			2022-12-25	WOS:A1996UG25700005
J	Smit, MJ; Roovers, E; Timmerman, H; vandeVrede, Y; Alewijnse, AE; Leurs, R				Smit, MJ; Roovers, E; Timmerman, H; vandeVrede, Y; Alewijnse, AE; Leurs, R			Two distinct pathways for histamine H-2 receptor down-regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; DEPENDENT PROTEIN-KINASE; MESSENGER-RNA; BETA-2-ADRENERGIC RECEPTOR; AGONIST REGULATION; MOLECULAR-CLONING; CAMP; HISTAMINE-H2-RECEPTOR; DESENSITIZATION; EXPRESSION	Pretreatment of Chinese hamster ovary cells expressing the histamine H-2 receptor (CHOrH(2) cells) with histamine resulted in a time-dependent (t(1/2) approximate to 7 h) and dose-dependent (EC(50) = 18 nM) H-2 receptor down-regulation measured as [I-125]iodoaminopotentidine binding (44 +/- 10% down-regulation). Pretreatment of CHOrH(2) cells with cholera toxin or forskolin also led to H-2 receptor down-regulation. Forskolin time-dependently (t(1/2) approximate to 7 h) and dose-dependently (EC(50) = 0.3 mu M) induced H-2 receptor down-regulation. Both histamine and forskolin induced rapid down-regulation of H-2 receptor mRNA levels, probably caused by mRNA destabilization. Recently, Moro et al. (Moro, O., Lameh, J., Hogger, P., and Sadee, W. (1993) J. Biol. Chem. 268, 22273-22276) showed that hydrophobic amino acids in a conserved G-protein-coupled receptor motif in the second intracellular loop are implicated in G-protein coupling, To uncouple the H-2 receptor from the G(s)-protein, we introduced the Leu(124) --> Ala mutation in the second intracellular loop of the H-2 receptor. The H-2 Leu(124) --> Ala mutant showed altered agonist-binding parameters, attenuated histamine-induced cAMP production, and was down-regulated by concentrations of histamine that did not give rise to cAMP production, Taken together, in CHOrH(2) cells, H-2 receptor down-regulation appears to be induced by two distinct pathways, a cAMP-dependent and cAMP-independent pathway.	VRIJE UNIV AMSTERDAM, LEIDEN AMSTERDAM CTR DRUG RES, DEPT PHARMACOCHEM, 1081 HV AMSTERDAM, NETHERLANDS	Leiden University; Leiden University - Excl LUMC; Vrije Universiteit Amsterdam			Leurs, Rob/AAC-8508-2022; Leurs, Rob/ABB-4299-2021	Leurs, Rob/0000-0003-1354-2848; Smit, Martine/0000-0003-2713-0238				ALLEN JM, 1989, MOL PHARMACOL, V36, P248; ARIMA N, 1993, AM J PHYSIOL, V265, pG987, DOI 10.1152/ajpgi.1993.265.5.G987; BOUVIER M, 1989, J BIOL CHEM, V264, P16786; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL PT, 1991, MOL PHARMACOL, V39, P192; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS S, 1991, ANNU REV PHYSIOL, V53, P497, DOI 10.1146/annurev.physiol.53.1.497; COLLINS S, 1993, TRENDS BIOMED RES, V6, P480; DIAZ J, 1994, BIOCHEM BIOPH RES CO, V198, P1195, DOI 10.1006/bbrc.1994.1169; ERIKS JC, 1992, J MED CHEM, V35, P3239, DOI 10.1021/jm00095a021; FELIX SB, 1991, AGENT ACTION SUPPL, V33, P257; FUKUSHIMA Y, 1993, BIOCHEM BIOPH RES CO, V190, P1149, DOI 10.1006/bbrc.1993.1170; GANTZ I, 1991, BIOCHEM BIOPH RES CO, V178, P1386, DOI 10.1016/0006-291X(91)91047-G; GANTZ I, 1991, P NATL ACAD SCI USA, V88, P429, DOI 10.1073/pnas.88.2.429; GREEN SA, 1994, J BIOL CHEM, V269, P26215; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HADCOCK JR, 1989, J BIOL CHEM, V264, P13956; HADCOCK JR, 1993, J NEUROCHEM, V60, P1, DOI 10.1111/j.1471-4159.1993.tb05816.x; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; HOLDEN CA, 1987, AGENTS ACTIONS, V22, P36, DOI 10.1007/BF01968814; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; LEE NH, 1994, J BIOL CHEM, V269, P4291; LEURS R, 1994, BRIT J PHARMACOL, V112, P847, DOI 10.1111/j.1476-5381.1994.tb13157.x; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; MAHAN LC, 1985, P NATL ACAD SCI USA, V82, P129, DOI 10.1073/pnas.82.1.129; MORO O, 1993, J BIOL CHEM, V268, P22273; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NORDSTEDT C, 1990, ANAL BIOCHEM, V189, P231, DOI 10.1016/0003-2697(90)90113-N; PORT JD, 1992, J BIOL CHEM, V267, P24103; RODGERS JR, 1985, METHOD ENZYMOL, V109, P572; RUAT M, 1991, BIOCHEM BIOPH RES CO, V179, P1470, DOI 10.1016/0006-291X(91)91738-X; SAKURAI T, 1992, BIOCHEM BIOPH RES CO, V186, P342, DOI 10.1016/S0006-291X(05)80813-7; SHEAR M, 1976, J BIOL CHEM, V251, P7572; SMIT MJ, 1995, BIOCHEM BIOPH RES CO, V214, P1138, DOI 10.1006/bbrc.1995.2404; SMIT MJ, 1994, EUR J PHARM-MOLEC PH, V288, P17, DOI 10.1016/0922-4106(94)90005-1; STERK GJ, 1987, EUR J MED CHEM, V22, P427, DOI 10.1016/0223-5234(87)90031-6; SU YF, 1980, J BIOL CHEM, V255, P7410; THOLANIKUNNEL BG, 1995, J BIOL CHEM, V270, P12787, DOI 10.1074/jbc.270.21.12787; TRAIFFORT E, 1992, P NATL ACAD SCI USA, V89, P2649, DOI 10.1073/pnas.89.7.2649; VANDERGOOT H, 1994, BIOORG MED CHEM LETT, V4, P1913, DOI 10.1016/S0960-894X(01)80533-3; ZHANG LJ, 1994, MOL PHARMACOL, V45, P878	42	33	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7574	7582		10.1074/jbc.271.13.7574	http://dx.doi.org/10.1074/jbc.271.13.7574			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631790	Green Published, Green Submitted, hybrid			2022-12-25	WOS:A1996UC77400058
J	Balsinde, J; Dennis, EA				Balsinde, J; Dennis, EA			Distinct roles in signal transduction for each of the phospholipase A(2) enzymes present in P388D(1) macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-II PHOSPHOLIPASE-A(2); RAT MESANGIAL CELLS; CALCIUM-INDEPENDENT PHOSPHOLIPASE-A2; ARACHIDONIC-ACID RELEASE; SWISS 3T3 CELLS; TRANSFORMING GROWTH-FACTOR-BETA-2; ACTIVATION; INHIBITION; SECRETION; PROSTAGLANDIN-E(2)	Receptor-stimulated arachidonic acid (AA) mobilization in P388D(1) macrophages consists of a transient phase in which AA accumulates in the cell and a sustained phase in which AA accumulates in the incubation medium. We have shown previously that a secretory group II phospholipase A(2) (sPLA(2)) is the enzyme responsible for most of the AA released to the incubation medium. By using selective inhibitors for each of the PLA(2)s present in P388D(1) macrophages, we demonstrate herein that the cytosolic group IV PLA(2) (cPLA(2)) mediates accumulation of cell-associated AA during the early steps of P388D(1) cell activation. The contribution of both cPLA(2) and sPLA(2) to AA release can be distinguished on the basis of the different spatial and temporal characteristics of activation and substrate preferences of the two phospholipase A(2)s (PLA(2)s). Furthermore, the results suggest the possibility that a functionally active cPLA, may be necessary for sPLA(2) to act. cPLA(2) action precedes that of sPLA(2), and overcoming cPLA(2) inhibition by artificially increasing intracellular free AA levels restores extracellular AA release. Although this suggests cross-talk between cPLA(2) and sPLA(2), selective inhibition of one other PLA(2) present in these cells, namely the Ca2+-independent PLA(2), does not block, but instead enhances receptor-coupled AA release. These data indicate that Ca2+-independent PLA(2), does not mediate AA mobilization in P388D(1) macrophages. Collectively, the results of this work suggest that each of the PLA(2) present in P388D(1) macrophages serves a distinct role in cell activation and signal transduction.	UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093	University of California System; University of California San Diego			Balsinde, Jesús/C-7833-2018; Dennis, Edward A./M-5554-2019	Balsinde, Jesús/0000-0002-4157-6714; Dennis, Edward A./0000-0003-3738-3140	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026171] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 26171] Funding Source: Medline; NIGMS NIH HHS [GM 20501] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; AMIS R, 1994, BIOCHEM J, V298, P543; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BARTOLI F, 1994, J BIOL CHEM, V269, P15625; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CURRIE S, 1992, J BIOL CHEM, V267, P6056; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DIEZ E, 1994, BIOCHEM J, V301, P721, DOI 10.1042/bj3010721; DOMIN J, 1993, J BIOL CHEM, V268, P8927; FERNANDEZ B, 1994, J BIOL CHEM, V269, P26711; FONTEH AN, 1994, J IMMUNOL, V152, P5438; FONTEH AN, 1993, J IMMUNOL, V150, P563; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; GLASER KB, 1990, J BIOL CHEM, V265, P8658; HANEL AM, 1993, BIOCHEMISTRY-US, V32, P5949, DOI 10.1021/bi00074a005; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; Huang Z., 1994, MEDIAT INFLAMM, V3, P307; JOO F, 1993, BIOCHIM BIOPHYS ACTA, V1149, P231, DOI 10.1016/0005-2736(93)90206-F; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; PLESNIAK LA, 1993, BIOCHEMISTRY-US, V32, P5009, DOI 10.1021/bi00070a006; QIU ZH, 1993, J BIOL CHEM, V268, P24506; RAMANADHAM S, 1993, BIOCHEMISTRY-US, V32, P337, DOI 10.1021/bi00052a042; SCHALKWIJK C, 1992, J BIOL CHEM, V267, P8846; SCHALKWIJK CG, 1992, EUR J BIOCHEM, V210, P169, DOI 10.1111/j.1432-1033.1992.tb17405.x; SCHEVITZ RW, 1995, NAT STRUCT BIOL, V2, P458, DOI 10.1038/nsb0695-458; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S	35	332	337	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6758	6765		10.1074/jbc.271.12.6758	http://dx.doi.org/10.1074/jbc.271.12.6758			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636097	hybrid, Green Published			2022-12-25	WOS:A1996UB15700032
J	Buton, X; Morrot, G; Fellmann, P; Seigneuret, M				Buton, X; Morrot, G; Fellmann, P; Seigneuret, M			Ultrafast glycerophospholipid-selective transbilayer motion mediated by a protein in the endoplasmic reticulum membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL-MEMBRANES; RAT-LIVER; PHOSPHOLIPID-BILAYER; ERYTHROCYTE-MEMBRANE; ISOTROPIC MOTION; PHOSPHATIDYLCHOLINE; VESICLES; MOVEMENT; LIPIDS; PHOSPHATIDYLETHANOLAMINE	A relatively rapid transbilayer motion of phospholipids in the microsomal membrane seems to be required due to their asymmetric synthesis in the cytoplasmic leaflet, Marked discrepancies exist with regard to the rate and specificity of this flip-flop process, To reinvestigate this problem, we have used both spin-labeled and radioactively labeled long chain phospholipids with a new fast translocation assay, Identical results were obtained with both types of probes, Transbilayer motion of glycerophospholipids was found to be much more rapid than previously reported (half-time less than 25 s) and to occur identically for phosphatidylcholine, phosphatidylserine, and phosphatidylethanolamine. Such transport is nonvectorial and leads to a symmetric transbilayer distribution of phospholipids, In contrast, transverse diffusion of sphingomyelin was 1 order of magnitude slower, Phospholipid flip-flop appears to occur by a protein-mediated transport process displaying saturable and competitive behavior, Proteolysis, chemical modification, and competition experiments suggest that this transport process may be related to that previously described in the endoplasmic reticulum for short-chain phosphatidylcholine (Bishop, W. R,, and Bell, R, M, (1985) Cell 42, 51-60), The relationship between phospholipid flip-flop and nonbilayer structures occurring in the endoplasmic reticulum was also investigated by P-31-NMR. Several conditions were found under which the (31)p isotropic NMR signal previously attributed to nonbilayer structures is decreased or abolished, whereas transbilayer diffusion is unaffected, suggesting that the flip-flop process is independent of such structures, It is concluded that flip-flop in the endoplasmic reticulum is mediated by a bidirectional protein transporter with a high efficiency for glycerophospholipids and a low efficiency for sphingomyelin. lie vivo, the activity of this transporter would be able to redistribute all changes in phospholipid composition due to biosynthetic processes between the two leaflets of the endoplasmic reticulum membranes within a time scale of seconds.	INST BIOL PHYSICOCHIM,F-75005 PARIS,FRANCE; UNIV DENIS DIDEROT,F-75251 PARIS 05,FRANCE	UDICE-French Research Universities; Universite Paris Cite	Buton, X (corresponding author), LAB BIOPHYS CELLULAIRE,URA 526,13 RUE PIERRE & MARIE CURIE,F-75005 PARIS,FRANCE.							BAKER JM, 1981, NATURE, V327, P341; BALLAS LM, 1981, BIOCHIM BIOPHYS ACTA, V665, P586, DOI 10.1016/0005-2760(81)90274-5; BELLEAU B, 1968, J AM CHEM SOC, V90, P1651, DOI 10.1021/ja01008a045; BISHOP WR, 1985, CELL, V42, P51, DOI 10.1016/S0092-8674(85)80100-8; BOLLEN IC, 1980, BIOCHEM J, V189, P475, DOI 10.1042/bj1890475; CLASSEN J, 1987, BIOCHEMISTRY-US, V26, P6604, DOI 10.1021/bi00395a007; COLEMAN R, 1978, J CELL BIOL, V76, P245, DOI 10.1083/jcb.76.1.245; DEKRUIJFF B, 1980, BIOCHIM BIOPHYS ACTA, V600, P343, DOI 10.1016/0005-2736(80)90438-1; DEKRUIJFF B, 1978, BIOCHIM BIOPHYS ACTA, V507, P38, DOI 10.1016/0005-2736(78)90372-3; DEKRUIJFF B, 1978, BIOCHIM BIOPHYS ACTA, V514, P1, DOI 10.1016/0005-2736(78)90072-X; FELLMANN P, 1994, METHODS MOL BIOL 2, V27; GERRITSEN WJ, 1980, BIOCHIM BIOPHYS ACTA, V598, P554, DOI 10.1016/0005-2736(80)90035-8; HERRMANN A, 1990, BIOCHEMISTRY-US, V29, P2023, DOI 10.1021/bi00460a010; HIGGINS JA, 1981, BIOCHIM BIOPHYS ACTA, V640, P1, DOI 10.1016/0005-2736(81)90527-7; HIGGINS JA, 1987, J LIPID RES, V28, P268; HIGGINS JA, 1977, BIOCHIM BIOPHYS ACTA, V470, P342, DOI 10.1016/0005-2736(77)90126-2; HIGGINS JA, 1979, BIOCHIM BIOPHYS ACTA, V558, P48, DOI 10.1016/0005-2736(79)90314-6; HIGGINS JA, 1987, BIOL MEMBRANES PRACT, V2, P125; HUSTON JL, 1982, BIOCHIM BIOPHYS ACTA, V687, P247; KAWASHIMA Y, 1987, J BIOL CHEM, V262, P16495; MORROT G, 1989, BIOCHEMISTRY-US, V28, P3456, DOI 10.1021/bi00434a046; PRITCHARD PH, 1981, BIOCHEM J, V196, P261, DOI 10.1042/bj1960261; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SAMUEL NKP, 1985, J AM CHEM SOC, V107, P42, DOI 10.1021/ja00287a008; SEIGNEURET M, 1984, BIOCHEMISTRY-US, V23, P4271, DOI 10.1021/bi00314a002; STIER A, 1978, FEBS LETT, V91, P109, DOI 10.1016/0014-5793(78)80028-3; VANDENBESSELAAR AMHP, 1978, BIOCHIM BIOPHYS ACTA, V510, P242, DOI 10.1016/0005-2736(78)90024-X; VANDUIJN G, 1986, BIOCHIM BIOPHYS ACTA, V863, P193, DOI 10.1016/0005-2736(86)90259-2; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1; ZILVERSMIT DB, 1977, BIOCHIM BIOPHYS ACTA, V469, P99, DOI 10.1016/0005-2736(77)90329-7	30	93	94	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6651	6657		10.1074/jbc.271.12.6651	http://dx.doi.org/10.1074/jbc.271.12.6651			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636082				2022-12-25	WOS:A1996UB15700017
J	Kim, JH; Ryan, MG; Knaut, H; Hille, R				Kim, JH; Ryan, MG; Knaut, H; Hille, R			The reductive half-reaction of xanthine oxidase - The involvement of prototropic equilibria in the course of the catalytic sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN-ATOM TRANSFER; ELECTRON-PARAMAGNETIC-RESONANCE; RELEVANT ANALOG COMPLEXES; DIFFERENT REDUCED FORMS; MOLYBDENUM CENTER; REACTION SYSTEM; ACTIVE-SITES; MOLYBDOENZYMES; MECHANISM; KINETICS	The pH dependence and solvent isotope sensitivity of three discrete steps in the reductive half-reaction of xanthine oxidase have been investigated, The pH dependence of both K-cat/K-m from steady-state experiments and k(red)/K-d from rapid reaction experiments with xanthine as substrate indicate that enzyme reacts preferentially with the neutral form of substrate and that an ionizable group in the active site having a pK(alpha) of similar to 6.6 must be unprotonated for reaction to take place. The solvent kinetic isotope effect on k(red)/K-d is 2.4, once a uniform shift on going to D2O of similar to 1 unit for both pK(alpha) values is taken into account. The pH dependence of the formation and decay of E(red)-P formed in the course the reaction of xanthine oxidase with lumazine has also been examined, Formation of this complex exhibits bell-shaped pH dependence, with pK(alpha) values of 6.5 and 7.8, consistent with the results obtained with xanthine. Decay of the E(red)-P complex is base-catalyzed with a pK(alpha) > 11 and exhibits a small solvent kinetic isotope effect of 1.7 at pH/D 8.5. By contrast, the catalytic intermediate giving rise to the ''very rapid'' EPR signal that is transiently observed in the course of the reaction of enzyme with the substrate 2-hydroxy-6-methylpurine is found to undergo acid-catalyzed breakdown with an associated pK(alpha) < 6. Formation and decay of this species exhibit solvent kinetic isotope effects of 2.0 and 3.5 at pH 10. The results are discussed in the context of a specific reaction mechanism for the reductive half-reaction of xanthine oxidase, in which discrete ionizations associated with the molybdenum center of the active site play critical roles in determining the magnitude of the rate constants by which the Mo(IV)-P and Mo(V)-P intermediates form and decay.	OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210	Ohio State University				Knaut, Holger/0000-0002-8399-8720	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038917] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 38917] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBERT A, 1954, J CHEM SOC, P2060, DOI 10.1039/jr9540002060; BAZELYANSKY M, 1986, BIOCHEMISTRY-US, V25, P125, DOI 10.1021/bi00349a019; BERG JM, 1985, J AM CHEM SOC, V107, P917, DOI 10.1021/ja00290a029; BERG JM, 1984, J AM CHEM SOC, V106, P3035, DOI 10.1021/ja00322a050; BRAY RC, 1964, J BIOL CHEM, V239, P2667; BRAY RC, 1988, Q REV BIOPHYS, V21, P299, DOI 10.1017/S0033583500004479; BRAY RC, 1982, BIOCHEMISTRY-US, V21, P5992, DOI 10.1021/bi00266a041; BRAY RC, 1969, BIOCHEM J, V114, P725, DOI 10.1042/bj1140725; BRAY RC, 1985, BIOCHEM SOC T, V13, P560, DOI 10.1042/bst0130560; CARADONNA JP, 1988, J AM CHEM SOC, V110, P2139, DOI 10.1021/ja00215a022; CRAMER SP, 1981, J AM CHEM SOC, V103, P7721, DOI 10.1021/ja00416a005; CRAMER SP, 1985, J AM CHEM SOC, V107, P8164, DOI 10.1021/ja00312a059; DAVIS MD, 1982, J BIOL CHEM, V257, P4730; DAVIS MD, 1984, J BIOL CHEM, V259, P3526; DOWERAH D, 1987, J AM CHEM SOC, V109, P5655, DOI 10.1021/ja00253a016; EDMONDSON D, 1973, J BIOL CHEM, V248, P6135; GHELLER SF, 1992, J AM CHEM SOC, V114, P6934, DOI 10.1021/ja00043a059; GREENWOOD RJ, 1993, J AM CHEM SOC, V115, P5385, DOI 10.1021/ja00066a005; GUTFREUND H, 1977, ENZYMES PHYSICAL PRI, P173; GUTTERIDGE S, 1978, BIOCHEM J, V175, P887, DOI 10.1042/bj1750887; GUTTERIDGE S, 1980, BIOCHEM J, V189, P615, DOI 10.1042/bj1890615; GUTTERIDGE S, 1978, BIOCHEM J, V175, P869, DOI 10.1042/bj1750869; Hille R., 1985, Metal Ions in Biology, V7, P443; HILLE R, 1987, J BIOL CHEM, V262, P10914; HILLE R, 1989, INORG CHEM, V28, P4018, DOI 10.1021/ic00320a016; HOLM RH, 1990, COORDIN CHEM REV, V100, P183, DOI 10.1016/0010-8545(90)85010-P; JANCSO G, 1974, CHEM REV, V74, P689, DOI 10.1021/cr60292a004; KARSTEN WE, 1995, J AM CHEM SOC, V117, P5914, DOI 10.1021/ja00127a002; KIM JH, 1993, J BIOL CHEM, V268, P44; KURZ LC, 1983, BIOCHEMISTRY-US, V22, P382, DOI 10.1021/bi00271a023; LORIGAN GA, 1994, BBA-BIOENERGETICS, V1185, P284, DOI 10.1016/0005-2728(94)90243-7; MALTHOUSE JPG, 1981, BIOCHEM J, V199, P629, DOI 10.1042/bj1990629; MASSEY V, 1970, J BIOL CHEM, V245, P6595; MASSEY V, 1969, J BIOL CHEM, V244, P1682; MASSEY V, 1973, IRON SULFUR PROTEINS, P301; MCWHIRTER RB, 1991, J BIOL CHEM, V266, P23724; MOORE JW, 1981, KINETICS MECHANISM, P290; MORRISON M, 1963, J BIOL CHEM, V238, P2847; OERTLING WA, 1990, J BIOL CHEM, V265, P17446; OLSON JS, 1974, J BIOL CHEM, V249, P4350; OLSON JS, 1974, J BIOL CHEM, V249, P4363; PALMER G, 1964, J BIOL CHEM, V239, P2657; ROBERTS SA, 1990, INORG CHEM, V29, P3650, DOI 10.1021/ic00344a007; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; SCHULTZ BE, 1993, INORG CHEM, V32, P4244, DOI 10.1021/ic00072a016; SKIBO EB, 1986, BIOCHEMISTRY-US, V26, P3032; Stiefel E. I., 1977, PROG INORG CHEM, V21, P1; STIEFEL EI, 1973, P NATL ACAD SCI USA, V70, P988, DOI 10.1073/pnas.70.4.988; Tanner SJ, 1978, BIOCHEM SOC T, V6, P1328, DOI 10.1042/bst0061328; TURNER NA, 1989, BIOCHEM J, V260, P563, DOI 10.1042/bj2600563; WILSON GL, 1991, J AM CHEM SOC, V113, P6803, DOI 10.1021/ja00018a014; XIAO ZG, 1992, J AM CHEM SOC, V114, P9194, DOI 10.1021/ja00049a065	52	66	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6771	6780		10.1074/jbc.271.12.6771	http://dx.doi.org/10.1074/jbc.271.12.6771			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636099	hybrid			2022-12-25	WOS:A1996UB15700034
J	Wang, JA; Morris, AJ; Tolan, DR; Pagliaro, L				Wang, JA; Morris, AJ; Tolan, DR; Pagliaro, L			The molecular nature of the F-actin binding activity of aldolase revealed with site-directed mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT MUSCLE ALDOLASE; GLYCOLYTIC-ENZYMES; CONTAINING-FILAMENTS; SKELETAL-MUSCLE; 3T3 CELLS; PROTEINS; CYTOPLASM; DEHYDROGENASE; ORGANIZATION; METABOLISM	We used site-directed mutagenesis of rabbit muscle aldolase, falling ball viscometry, co sedimentation binding assays, and negative stain electron microscopy, to identify specific residues involved in the aldolase-actin interaction, Three mutants, R42A (Arg --> Ala), K107A (Lys --> Ala), and R148A (Arg --> Ala), had minimal actin binding activity relative to wild type (wt) aldolase, and one mutant, K229A (Lys --> Ala), had intermediate actin binding activity, A mutant with similar to 4,000-fold reduced catalytic activity, D33S (Asp --> Ser), had normal actin binding activity, The aldolase substrates and product, fructose 1,6-bisphosphate, fructose 1-phosphate, and dihydroxyacetone phosphate, reversed the gelling of wt aldolase and F-actin, consistent with at least partial overlap of catalytic and actin-binding sites on aldolase, Molecular modeling reveals that the actin-binding residues we have identified are clustered in or around the catalytic pocket of the molecule. These data confirm that the aldolase-actin interaction is due to specific binding, and they suggest that electrostatic interactions between specific residues, rather than net charge, mediate this interaction. Low concentration of wt and D33S aldolase caused formation of high viscosity actin gel networks, while high concentrations of wt and D33S aldolase resulted in solation of the gel by bundling actin filaments, consistent with a potential role for this enzyme in the regulation of cytoplasmic structure.	UNIV WASHINGTON,CTR BIOENGN,SEATTLE,WA 98195; BOSTON UNIV,DEPT BIOL,BOSTON,MA 02215	University of Washington; University of Washington Seattle; Boston University				Tolan, Dean/0000-0002-0598-7241	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043521] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK17017, DK43521] Funding Source: Medline; NIGMS NIH HHS [GM08291] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD H, 1970, EUR J BIOCHEM, V15, P360, DOI 10.1111/j.1432-1033.1970.tb01016.x; ARNOLD H, 1971, EUR J BIOCHEM, V22, P121, DOI 10.1111/j.1432-1033.1971.tb01522.x; ARNOLD H, 1968, EUR J BIOCHEM, V6, P163, DOI 10.1111/j.1432-1033.1968.tb00434.x; BARANOWSKI T, 1949, J BIOL CHEM, V180, P543; BAUER AC, 1964, FED PROC, V23, P310; BEERNINK PT, 1994, PROTEIN SCI, V3, P1383, DOI 10.1002/pro.5560030904; BRONSTEIN WW, 1981, CAN J BIOCHEM CELL B, V59, P494, DOI 10.1139/o81-069; CLARK DL, 1986, ADV TEACHER ED, V2, P1; CLARKE FM, 1985, CELL MOTILITY MECHAN, P235; CLEGG JS, 1984, AM J PHYSIOL, V246, pR133, DOI 10.1152/ajpregu.1984.246.2.R133; DEDUVE C, 1984, GUIDED TOUR LIVING C, P17; DON M, 1988, MOL CELL BIOCHEM, V81, P145; GAMBLIN SJ, 1991, J MOL BIOL, V219, P573, DOI 10.1016/0022-2836(91)90650-U; GAMBLIN SJ, 1990, FEBS LETT, V262, P282, DOI 10.1016/0014-5793(90)80211-Z; HARRIS SJ, 1987, BIOCHIM BIOPHYS ACTA, V911, P121, DOI 10.1016/0167-4838(87)90279-2; HARTMAN FC, 1976, J BIOL CHEM, V251, P3057; Horecker B. L, 1972, ENZYMES, P213, DOI DOI 10.1016/S1874-6047(08)60450-3; HUMPHREYS L, 1986, INT J BIOCHEM, V18, P7, DOI 10.1016/0020-711X(86)90003-0; KELETI T, 1977, ADV ENZYME REGUL, V15, P233, DOI 10.1016/0065-2571(77)90019-X; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAI CY, 1975, ARCH BIOCHEM BIOPHYS, V166, P358, DOI 10.1016/0003-9861(75)90398-7; LAI CY, 1974, SCIENCE, V183, P1204, DOI 10.1126/science.183.4130.1204; MASTERS C, 1984, J CELL BIOL, V99, pS222, DOI 10.1083/jcb.99.1.222s; MEJEAN C, 1989, BIOCHEM J, V264, P671, DOI 10.1042/bj2640671; MORRIS AJ, 1994, BIOCHEMISTRY-US, V33, P12291, DOI 10.1021/bi00206a036; MORRIS AJ, 1993, J BIOL CHEM, V268, P1095; OREILLY G, 1993, FEBS LETT, V321, P69, DOI 10.1016/0014-5793(93)80623-3; OVADI J, 1991, J THEOR BIOL, V152, P1, DOI 10.1016/S0022-5193(05)80500-4; PAGLIARO L, 1988, J CELL BIOL, V107, P981, DOI 10.1083/jcb.107.3.981; PAGLIARO L, 1989, J CELL SCI, V94, P333; PAGLIARO L, 1992, J CELL BIOL, V118, P859, DOI 10.1083/jcb.118.4.859; Pagliaro L., 1995, ADV MOL CELL BIOL, V11, P93, DOI [10.1016/S1569-2558(08)60249-0, DOI 10.1016/S1569-2558(08)60249-0]; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PENHOET EE, 1971, J BIOL CHEM, V246, P318; PETERS RA, 1930, T FARADAY SOC, V26, P767; PETTE D, 1962, BIOCHEM BIOPH RES CO, V9, P367, DOI 10.1016/0006-291X(62)90056-6; RACKER E, 1952, J BIOL CHEM, V196, P347; ROBINSON JB, 1985, J BIOL CHEM, V260, P800; RYAZANOV AG, 1988, FEBS LETT, V237, P1, DOI 10.1016/0014-5793(88)80159-5; SRIVASTAVA DK, 1986, SCIENCE, V234, P1081, DOI 10.1126/science.3775377; STRYER L, 1995, BIOCHEMISTRY-US, P181; TAKASAKI Y, 1990, PROG CLIN BIOL RES, V344, P935; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TELLAM RL, 1989, TRENDS BIOCHEM SCI, V14, P130, DOI 10.1016/0968-0004(89)90142-4; WALSH TP, 1977, BIOCHEM J, V165, P165, DOI 10.1042/bj1650165; WALSH TP, 1980, BIOCHEM J, V186, P89, DOI 10.1042/bj1860089; WALTER H, 1995, FEBS LETT, V361, P135, DOI 10.1016/0014-5793(95)00159-7; WANG J, 1994, J BIOCHEM BIOPH METH, V28, P251, DOI 10.1016/0165-022X(94)90001-9; WELCH GR, 1977, PROG BIOPHYS MOL BIO, V32, P103; Wilson EB., 1925, CELL DEV HEREDITY, V3rd edition; WILSON JE, 1978, TRENDS BIOCHEM SCI, V3, P124, DOI 10.1016/S0968-0004(78)80029-2	51	107	111	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6861	6865		10.1074/jbc.271.12.6861	http://dx.doi.org/10.1074/jbc.271.12.6861			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636111	hybrid			2022-12-25	WOS:A1996UB15700046
J	Rye, KA; Hime, NJ; Barter, PJ				Rye, KA; Hime, NJ; Barter, PJ			The influence of sphingomyelin on the structure and function of reconstituted high density lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; HUMAN-PLASMA-LIPOPROTEINS; CHOLESTEROL ACYLTRANSFERASE; EGG PHOSPHATIDYLCHOLINE; CELLULAR CHOLESTEROL; COMPLEXES; BILAYERS; PROTEIN; MEMBRANES; VESICLES	The effect of sphingomyelin (SPM) on the structure and function of discoidal and spherical reconstituted high density lipoproteins (rHDL) has been studied. Three preparations of discoidal rHDL with 1-palmitoyl-2-oleoyl phosphatidylcholine (POPC)/SPM/unesterified cholesterol (UC)/apolipoprotein (apo)A-I molar ratios of 99.6/0.0/10.2/1.0, 86.0/13.6/10.8/1.0, and 72.5/26.3/11.4/1.0 were prepared by cholate dialysis. SPM did not affect discoidal rHDL size or surface charge. Esterification of cholesterol by lecithin:cholesterol acyltransferase (LCAT) was inhibited in the SPM-containing discoidal rHDL, When the discoidal rHDL of POPC/SPM/UC/ apoA-I molar ratio 99.6/0.0/10.2/1.0 were incubated with low density lipoproteins (LDL) and LCAT, SPM transferred spontaneously from the LDL to the rHDL (t(1/2) = 0.8 h) and spherical particles with a POPC/SPR4/UC/CE/ apoA-I molar ratio of 24.6/4.9/3.6/24.9/1.0 were formed. Depleting the spherical rHDL of SPM head groups by incubation with sphingomyelinase increased the negative charge on the surface, but did not change their size, Cholesteryl ester transfer protein (CETP)-mediated transfers of cholesteryl esters and triglyceride between spherical rHDL and Intralipid were not affected by SPM head group depletion, The effect of SPM on rHDL structure was assessed spectroscopically. SPM increased POPC acyl chain and head group packing in the discoidal rHDL. When the spherical rHDL were depleted of SPM head groups, POPC acyl chain packing order decreased, but head group packing order was not affected. SPM inhibited the lipid-water interfacial hydration of discoidal rHDL, This parameter was not affected when the spherical rHDL were depleted of SPM head groups. The SPM molecule and the SPM head group, respectively, inhibited the unfolding of apoA-I in discoidal and spherical rHDL. It is concluded that (i) SPM influences the structure of discoidal and spherical rHDL, (ii) SPM inhibits the LCAT reaction in discoidal rHDL, and (iii) the SPM head group does not affect CETP-mediated lipid transfers into or out of spherical rHDL.	UNIV ADELAIDE,ROYAL ADELAIDE HOSP,DEPT MED,ADELAIDE,SA 5000,AUSTRALIA	Royal Adelaide Hospital; University of Adelaide	Rye, KA (corresponding author), ROYAL ADELAIDE HOSP,DIV CARDIOVASC SCI,LIPID RES LAB,LEVEL 1,HANSON CTR,FROME RD,ADELAIDE,SA 5000,AUSTRALIA.							BARENHOLZ Y, 1980, BIOCHIM BIOPHYS ACTA, V604, P129, DOI 10.1016/0005-2736(80)90572-6; BARENHOLZ Y, 1982, PHOSPHOLIPIDS, P129; BENYASHAR V, 1991, CHEM PHYS LIPIDS, V60, P1, DOI 10.1016/0009-3084(91)90009-Z; BRADLEY CA, 1987, CLIN CHEM, V33, P81; BURSTEIN M, 1970, J LIPID RES, V11, P583; DAVIDSON WS, 1995, J BIOL CHEM, V270, P5882, DOI 10.1074/jbc.270.11.5882; EISENBERG S, 1984, J LIPID RES, V25, P1017; GUPTA AK, 1992, J LIPID RES, V33, P1741; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HOPKINS GJ, 1989, ATHEROSCLEROSIS, V75, P73, DOI 10.1016/0021-9150(89)90209-8; JONAS A, 1988, J LIPID RES, V29, P1349; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1989, J BIOL CHEM, V264, P4818; KAN CC, 1991, BIOCHEMISTRY-US, V30, P7759, DOI 10.1021/bi00245a013; KAWANO M, 1993, BIOCHEMISTRY-US, V32, P5025, DOI 10.1021/bi00070a008; KUKSIS A, 1992, BIOCHIM BIOPHYS ACTA, V1124, P205, DOI 10.1016/0005-2760(92)90132-F; LENTZ BR, 1976, BIOCHEMISTRY-US, V15, P4521, DOI 10.1021/bi00665a029; LENTZ BR, 1989, CHEM PHYS LIPIDS, V50, P171, DOI 10.1016/0009-3084(89)90049-2; MAHADEVAN V, 1983, BIOCHIM BIOPHYS ACTA, V752, P89, DOI 10.1016/0005-2760(83)90236-9; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MCINTOSH TJ, 1992, BIOCHEMISTRY-US, V31, P2012, DOI 10.1021/bi00122a017; OSBORNE JC, 1986, METHOD ENZYMOL, V128, P213; Pace C N, 1986, Methods Enzymol, V131, P266; PATTNAIK NM, 1979, J BIOL CHEM, V254, P2782; PIRAN U, 1979, J LIPID RES, V20, P1040; PORN MI, 1993, J LIPID RES, V34, P1385; PRENDERGAST FG, 1981, BIOCHEMISTRY-US, V20, P7333, DOI 10.1021/bi00529a002; REICHL D, 1992, BIOCHIM BIOPHYS ACTA, V1127, P28, DOI 10.1016/0005-2760(92)90197-4; RYE KA, 1990, BIOCHIM BIOPHYS ACTA, V1042, P227, DOI 10.1016/0005-2760(90)90013-N; RYE KA, 1989, J LIPID RES, V30, P335; RYE KA, 1994, J BIOL CHEM, V269, P10298; RYE KA, 1993, BIOCHIM BIOPHYS ACTA, V1167, P316, DOI 10.1016/0005-2760(93)90235-2; RYE KA, 1995, J BIOL CHEM, V270, P189, DOI 10.1074/jbc.270.1.189; RYE KA, 1992, J LIPID RES, V33, P215; Scanu A M., 1979, BIOCH ATHEROSCLEROSI, P3; SCHERER PG, 1989, BIOCHEMISTRY-US, V28, P7720, DOI 10.1021/bi00445a030; SLATER SJ, 1993, BIOCHEMISTRY-US, V32, P3714, DOI 10.1021/bi00065a025; SPARKS DL, 1992, J LIPID RES, V33, P123; SPARKS DL, 1993, J BIOL CHEM, V268, P23250; STRAUME M, 1987, BIOCHEMISTRY-US, V26, P5113, DOI 10.1021/bi00390a033; SUBBAIAH PV, 1993, J BIOL CHEM, V268, P20156; SWANEY JB, 1983, J BIOL CHEM, V258, P1254; TOLLEFSON JH, 1988, AM J PHYSIOL, V255, pE894, DOI 10.1152/ajpendo.1988.255.6.E894; WEBER G, 1979, BIOCHEMISTRY-US, V18, P3075, DOI 10.1021/bi00581a025; WEISWEILER P, 1987, CLIN CHIM ACTA, V169, P249, DOI 10.1016/0009-8981(87)90325-1; WETTERAU JR, 1983, J BIOL CHEM, V258, P2637; WINKLER KE, 1989, J LIPID RES, V30, P979; XU XX, 1991, J BIOL CHEM, V266, P24849	50	87	91	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4243	4250						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626769				2022-12-25	WOS:A1996TW96000047
J	Hirose, F; Yamaguchi, M; Kuroda, K; Omori, A; Hachiya, T; Ikeda, M; Nishimoto, Y; Matsukage, A				Hirose, F; Yamaguchi, M; Kuroda, K; Omori, A; Hachiya, T; Ikeda, M; Nishimoto, Y; Matsukage, A			Isolation and characterization of cDNA for DREF, a promoter-activating factor for Drosophila DNA replication-related genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; POLYMERASE-ALPHA; ESCHERICHIA-COLI; GROWTH-REGULATION; BUDDING YEAST; EXPRESSION; CYCLE; TRANSCRIPTION; PROTEIN; BINDING	DREF, a transcription regulatory factor which specifically binds to the promoter-activating element DRE (DNA replication related element) of DNA replication-related genes, was purified to homogeneity from nuclear extracts of Drosophila Kc cells, cDNA for DREF was isolated with the reverse-transcriptase polymerase chain reaction method using primers synthesized on the basis of partial amino acid sequences and following screening of cDNA libraries, Deduced from the nucleotide sequences of cDNA, DREF is a polypeptide of 701 amino acid residues with a molecular weight of 80,096, which contains three characteristic regions, rich in basic amino acids, proline, and acidic amino acids, respectively, Deletion analysis of bacterially expressed DREF fused with glutathione S-transferase (GST-DREF) indicated that a part of the N-terminal basic amino acid region (16-115 amino acids) is responsible for the specific binding to DRE, A polyclonal and four monoclonal antibodies were raised against the GST-DREF fusion protein, The antibodies inhibited specifically the transcription of DNA polymerase alpha promoter in vitro. Cotransfection experiments using Kc cells demonstrated that overproduction of DREF protein overcomes the re repression of the proliferating cell nuclear antigen gene promoter by the zerknullt gene product. These results confirmed that DREF is a trans activating factor for DNA replication-related genes. Immunocytochemical analysis demonstrated the presence of DREF polypeptide in nuclei after the eighth nuclear division cycle, suggesting that nuclear accumulation of DREF is important for the coordinate zygotic expression of DNA replication-related genes carrying DRE sequences.	AICHI CANC CTR,RES INST,CELL BIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; MITSUBISHI KAGAKU INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN; MED BIOL LAB,INA,NAGANO 396,JAPAN	Aichi Cancer Center; Mitsubishi Kagaku Institute of Life Sciences (MITILS)				Yamaguchi, Masamitsu/0000-0002-6321-9750				Ashburner M., 1989, DROSOPHILA LAB MANUA, P214; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHANG CD, 1990, MOL CELL BIOL, V10, P3289, DOI 10.1128/MCB.10.7.3289; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROSS DP, 1978, J EMBRYOL EXP MORPH, V45, P161; DATE T, 1988, BIOCHEMISTRY-US, V27, P2983, DOI 10.1021/bi00408a048; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; EDGAR BA, 1986, CELL, V44, P871, DOI 10.1016/0092-8674(86)90009-7; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOE VE, 1989, DEVELOPMENT, V107, P1; HIROSE F, 1991, NUCLEIC ACIDS RES, V19, P4991, DOI 10.1093/nar/19.18.4991; HIROSE F, 1994, J BIOL CHEM, V269, P2937; HIROSE F, 1993, J BIOL CHEM, V268, P2092; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KADONAGA JT, 1990, J BIOL CHEM, V265, P2624; KIM YK, 1991, MOL CELL BIOL, V11, P2296, DOI 10.1128/MCB.11.4.2296; KNIPPLE DC, 1985, NATURE, V317, P40, DOI 10.1038/317040a0; Kornberg A, 1992, DNA REPLICATION, P471; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LI R, 1993, P NATL ACAD SCI USA, V90, P3554; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; MATSUKAGE A, 1986, DEV BIOL, V117, P226, DOI 10.1016/0012-1606(86)90365-9; MATSUKAGE A, 1995, GENE AMST, V116, P233; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MIYAZAWA H, 1993, J BIOL CHEM, V268, P8111; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; RUSHLOW C, 1987, NATURE, V330, P583, DOI 10.1038/330583a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VERMA R, 1992, P NATL ACAD SCI USA, V89, P9479, DOI 10.1073/pnas.89.20.9479; WAHL AF, 1988, MOL CELL BIOL, V8, P5016, DOI 10.1128/MCB.8.11.5016; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WHITE RAH, 1986, CELL, V47, P311, DOI 10.1016/0092-8674(86)90453-8; YAMAGUCHI M, 1990, MOL CELL BIOL, V10, P872, DOI 10.1128/MCB.10.3.872; YAMAGUCHI M, 1991, MOL CELL BIOL, V11, P4909, DOI 10.1128/MCB.11.10.4909; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P15808, DOI 10.1074/jbc.270.26.15808; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P25159, DOI 10.1074/jbc.270.42.25159; YAMAGUCHI M, 1991, J CELL SCI, V100, P729	47	118	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3930	3937						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632015				2022-12-25	WOS:A1996TV72400089
J	Tiberi, M; Nash, SR; Bertrand, L; Lefkowitz, RJ; Caron, MG				Tiberi, M; Nash, SR; Bertrand, L; Lefkowitz, RJ; Caron, MG			Differential regulation of dopamine D1A receptor responsiveness by various G protein-coupled receptor kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED DESENSITIZATION; HETEROLOGOUS DESENSITIZATION; ADENYLYL CYCLASE; CELLS; STRIATUM; ARRESTIN; RETINA	The role of G protein-coupled receptor kinases (GRKs) in the regulation of dopamine D1A receptor responsiveness is poorly understood, To explore the potential role played by the GRKs in the regulation of the rat dopamine D1A receptor, we performed whole cell phosphorylation experiments and cAMP assays in 293 cells cotransfected with the receptor alone or with various GRKs (GRK2, GRK3, and GRK5). The agonist-dependent phosphorylation of the rat D1A receptor was substantially increased in cells overexpressing GRK2, GRK3, or GRK5. Moreover, we report that cAMP formation upon receptor activation was differentially regulated in cells overexpressing either GRK2, GRK3, and GRK5 under conditions that elicited similar levels of GRK-mediated receptor phosphorylation, Cells expressing the rat D1A receptor with GRK2 and GRK3 displayed a rightward shift of the dopamine dose-response curve with little effect on the maximal activation when compared with cells expressing the receptor alone, In contrast, cells expressing GRK5 displayed a rightward shift in the EC(50) value with an additional 40% reduction in the maximal activation when compared with cells expressing the receptor alone, Thus, we show that the dopamine D1A receptor can serve as a substrate for various GRKs and that GRK-phosphorylated D1A receptors display a differential reduction of functional coupling to adenylyl cyclase, These results suggest that the cellular complement of G protein-coupled receptor kinases may determine the properties and extent of agonist-mediated responsiveness and desensitization.	DUKE UNIV, MED CTR, DEPT CELL BIOL, HOWARD HUGHES MED INST LABS, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, HOWARD HUGHES MED INST LABS, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, HOWARD HUGHES MED INST LABS, DURHAM, NC 27710 USA	Duke University; Duke University; Duke University			Lefkowitz, Robert/AAW-2649-2021		NINDS NIH HHS [NS-15976] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMLAIKY N, 1987, MOL PHARMACOL, V31, P129; AMLAIKY N, 1985, J BIOL CHEM, V260, P1983; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BALMFORTH AJ, 1990, J NEUROCHEM, V55, P2111, DOI 10.1111/j.1471-4159.1990.tb05803.x; BARTON AC, 1990, MOL PHARMACOL, V38, P531; BATES MD, 1991, AM J PHYSIOL, V260, pF937, DOI 10.1152/ajprenal.1991.260.6.F937; BENOVIC JL, 1987, J BIOL CHEM, V262, P9026; BENOVIC JL, 1986, NATURE, V321, P869, DOI 10.1038/321869a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; CHNEIWEISS H, 1990, EUR J PHARM-MOLEC PH, V189, P287, DOI 10.1016/0922-4106(90)90121-D; CLARK D, 1987, SYNAPSE, V1, P347, DOI 10.1002/syn.890010408; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; DJAMGOZ MBA, 1992, NEUROCHEM INT, V20, P139, DOI 10.1016/0197-0186(92)90166-O; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; DRAGO J, 1994, P NATL ACAD SCI USA, V91, P12564, DOI 10.1073/pnas.91.26.12564; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; GINGRICH JA, 1988, BIOCHEMISTRY-US, V27, P3907, DOI 10.1021/bi00411a003; GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503; HAGA T, 1994, J NEUROCHEM, V63, P400; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; INGLESE J, 1993, J BIOL CHEM, V268, P23735; JARVIE KR, 1994, DOPAMINE RECEPTORS T, P133; KOCH WJ, 1995, SCIENCE, V268, P1350, DOI 10.1126/science.7761854; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NESTLER EJ, 1994, CELL, V79, P923, DOI 10.1016/0092-8674(94)90022-1; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; OFORI S, 1993, J PHARMACOL EXP THER, V266, P350; OLSON MF, 1992, MOL ENDOCRINOL, V6, P1095, DOI 10.1210/me.6.7.1095; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PEI G, 1994, P NATL ACAD SCI USA, V91, P3633, DOI 10.1073/pnas.91.9.3633; PING PP, 1995, J CLIN INVEST, V95, P1271, DOI 10.1172/JCI117777; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; Sokal R. R, 1981, BIOMETRY; STOFFEL RH, 1994, J BIOL CHEM, V269, P27791; TIBERI M, 1994, J BIOL CHEM, V269, P27925; UNGERER M, 1994, CIRC RES, V74, P206, DOI 10.1161/01.RES.74.2.206; XU M, 1994, CELL, V79, P945, DOI 10.1016/0092-8674(94)90026-4; XU M, 1994, CELL, V79, P729, DOI 10.1016/0092-8674(94)90557-6; ZHOU X-M, 1991, Molecular and Cellular Neuroscience, V2, P464	49	144	147	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3771	3778						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631993				2022-12-25	WOS:A1996TV72400067
J	Ren, ZP; Hedrum, A; Ponten, F; Nister, M; Ahmadian, A; Lundeberg, J; Uhlen, M; Ponten, J				Ren, ZP; Hedrum, A; Ponten, F; Nister, M; Ahmadian, A; Lundeberg, J; Uhlen, M; Ponten, J			Human epidermal cancer and accompanying precursors have identical p53 mutations different from p53 mutations in adjacent areas of clonally expanded non-neoplastic keratinocytes	ONCOGENE			English	Article						p53; skin; cancer; mutation; immunohistochemistry; LOH	XERODERMA-PIGMENTOSUM PATIENTS; SQUAMOUS-CELL CARCINOMA; SKIN CANCERS; HUMAN TUMORS; GENE; DNA; POLYMORPHISM; POPULATIONS; SUNLIGHT	Microdissection of biopsies with sequencing of exons 4-8 of the p53 gene permitted precise morphological identification of correlation between mutations and/or loss of heterozygosity, immunoreactivity of p53 and type of squamous neoplasia, Seventy-two specimens from ten lesions of sun-exposed sites including normal epidermis were analysed. Irrespective of p53 immunoreactivity and morphological grade dysplasia, in situ or invasive cancer, in each case, carried the identical mutation indicating that invasive skin cancer and its precursors derive from the same original neoplastic clone. Additionally, morphologically normal epidermis showed some sharply demarcated immunoreactive areas. These never had the same p53 mutation as that of the adjacent tumor, indicating that their mutations were separate events and ruling them out as common precursors of cancer, Nonimmunoreactive normal epidermis did not show p53 mutations, Our findings indicate that a large fraction of keratinocytes in sun-exposed human skin carry mutations of p53 and suggest that at least two options exist for such cells (i) innocuous clonal expansion with preserved morphology and normal differentiation or (ii) malignant transformation with the p53 mutation as an early event. Suggestive evidence existed that the p53 mutations were qualitatively different in the two respective groups of lesions.	ROYAL INST TECHNOL,DEPT BIOCHEM & BIOTECHNOL,S-10044 STOCKHOLM,SWEDEN	Royal Institute of Technology	Ren, ZP (corresponding author), UNIV UPPSALA HOSP,DEPT PATHOL,S-75185 UPPSALA,SWEDEN.		Uhlen, Mathias/AAV-8746-2021; Uhlen, Mathias/B-3262-2016	Uhlen, Mathias/0000-0002-4858-8056				BERG C, 1995, CLIN CHEM, V41, P1461; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CAMPBELL C, 1993, J INVEST DERMATOL, V100, P746, DOI 10.1111/1523-1747.ep12475717; CAMPBELL C, 1993, BRIT J DERMATOL, V129, P235, DOI 10.1111/j.1365-2133.1993.tb11840.x; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DUMAZ N, 1993, P NATL ACAD SCI USA, V90, P10529, DOI 10.1073/pnas.90.22.10529; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIALKOW PJ, 1976, BIOCHIM BIOPHYS ACTA, V458, P283, DOI 10.1016/0304-419X(76)90003-2; FUTREAL PA, 1991, NUCLEIC ACIDS RES, V19, P6977, DOI 10.1093/nar/19.24.6977; HEDRUM A, 1994, BIOTECHNIQUES, V17, P118; HULTMAN T, 1991, BIOTECHNIQUES, V10, P84; JIN YS, 1993, CANCER RES, V53, P2140; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KRICKER A, 1994, CANCER CAUSE CONTROL, V5, P367, DOI 10.1007/BF01804988; KUBO Y, 1994, J INVEST DERMATOL, V102, P440, DOI 10.1111/1523-1747.ep12373002; LEITNER T, 1993, BIOTECHNIQUES, V15, P120; Lever W. F., 1990, HISTOPATHOLOGY SKIN; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; MOLES JP, 1993, ONCOGENE, V8, P583; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; NELSON MA, 1994, CANCER LETT, V85, P23, DOI 10.1016/0304-3835(94)90234-8; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; PONTEN F, 1995, J INVEST DERMATOL, V105, P402, DOI 10.1111/1523-1747.ep12321071; Potten C S, 1981, Int Rev Cytol, V69, P271; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; SATO M, 1993, CANCER RES, V53, P2944; STEPHENSON TJ, 1992, BRIT J DERMATOL, V127, P566, DOI 10.1111/j.1365-2133.1992.tb14866.x; TAGUCHI M, 1994, J INVEST DERMATOL, V103, P500, DOI 10.1111/1523-1747.ep12395643; WAINSCOAT JS, 1990, CANCER RES, V50, P1355; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	31	136	140	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					765	773						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632898				2022-12-25	WOS:A1996TW68600007
J	Carrero, J; Mallender, WD; Voss, EW				Carrero, J; Mallender, WD; Voss, EW			Anti-metatype antibody stabilization of Fv 4-4-20 variable domain dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; FLUORESCYL ANTIBODIES; CONFORMATIONAL DRIFT; ESCHERICHIA-COLI; CONTACT RESIDUES; IDIOTYPE FAMILY; LIGAND-BINDING; DISSOCIATION; AFFINITY	Anti-metatype (anti-Met) antibodies are immunoglobulins that specifically recognize and stabilize antibodies in their liganded or metatypic state, but lack specificity for either the hapten or the unliganded antibody. Autologous anti-Met antibodies were previously observed in vivo, suggesting that a metatypic autoantibody response could play a physiological role in the immune network, e.g. controlling the clearance of immune complexes from circulation. The first elicited anti-Met antibodies were against the fluorescein-liganded high affinity murine anti-fluorescein monoclonal antibody 4-4-20. The fluorescein-hapten system has proved to be an invaluable tool for both the recognition and characterization of the metatypic response by utilization of its spectral properties. In this investigation, hydrostatic pressure measurements, in conjunction with fluorescence spectroscopy, were performed on the recombinant Fv derivative (Fv 4-4-20) of the high affinity anti-fluorescein monoclonal antibody 4-4-20 complexed to anti-Met antibodies to study the influence of anti-Met antibodies on Fv 4-4-20 intervariable domain interactions. Anti-Met antibodies bound to liganded Fv 4-4-20 were observed to cause a change in the fluorescence properties of fluorescein that was not observed when anti-Met antibodies were bound to the liganded parent immunoglobulin. The variation of these spectral properties upon addition of anti-Met antibodies was shown to be correlated with dissociation of the variable domains in Fv 4-4-20 in response to its interaction with the anti-Met antibody. The ability to cause variable domain dissociation was dependent on whether monoclonal or polyclonal anti-Met antibodies were bound to the metatype. A model was proposed that elucidated the interaction of anti-Met antibodies, polyclonal and monoclonal, with variable domains of the primary anti-antigen antibody.	UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign					NCRR NIH HHS [RR03155-01] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BALDWIN RW, 1990, MONOCLONAL ANTIBODIE; BEDZYK WD, 1989, J BIOL CHEM, V264, P1565; BEDZYK WD, 1990, J BIOL CHEM, V265, P133; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; COELHOSAMPAIO T, 1994, J BIOL CHEM, V269, P8146; COELHOSAMPAIO T, 1993, BIOCHEMISTRY-US, V32, P10929, DOI 10.1021/bi00092a001; CUMBER AJ, 1992, J IMMUNOL, V149, P120; DENNISON G, 1995, FASEB J, V9, P127; DENZIN LK, 1993, MOL IMMUNOL, V30, P1331, DOI 10.1016/0161-5890(93)90094-R; DENZIN LK, 1992, J BIOL CHEM, V267, P8925; DENZIN LK, 1991, J BIOL CHEM, V266, P14095; GULLIVER GA, 1995, BIOCHEMISTRY-US, V34, P5158, DOI 10.1021/bi00015a029; HERRON JN, 1986, BIOCHEMISTRY-US, V25, P4602, DOI 10.1021/bi00364a022; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; HERRON JN, 1994, BIOPHYS J, V67, P2167, DOI 10.1016/S0006-3495(94)80738-6; HERRON JN, 1984, FLUORESCEIN HAPTEN I, P49; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; KIM ML, 1994, J BIOL CHEM, V269, P8695; KING L, 1986, BIOCHEMISTRY-US, V25, P3637, DOI 10.1021/bi00360a024; KRANZ DM, 1981, MOL IMMUNOL, V18, P889, DOI 10.1016/0161-5890(81)90012-2; KRANZ DM, 1984, FLUORESCEIN HAPTEN I, P121; MALLENDER WD, 1996, J BIOL CHEM, V270, P5338; MIKLASZ SD, 1995, J MOL RECOGNIT, V8, P258, DOI 10.1002/jmr.300080404; MULLER JD, 1994, BIOCHEMISTRY-US, V33, P6221; PALADINI AA, 1981, BIOCHEMISTRY-US, V20, P2587, DOI 10.1021/bi00512a034; PANTOLIANO MW, 1991, BIOCHEMISTRY-US, V30, P10117, DOI 10.1021/bi00106a007; REINITZ DM, 1984, J IMMUNOL, V135, P3365; REITER Y, 1994, BIOCHEMISTRY-US, V33, P5451, DOI 10.1021/bi00184a014; SELF CH, 1994, CLIN CHEM, V40, P2035; SILVA JL, 1986, BIOCHEMISTRY-US, V25, P5780, DOI 10.1021/bi00367a065; TETIN SY, 1992, BIOCHEMISTRY-US, V31, P12029, DOI 10.1021/bi00163a010; TOWBIN H, 1995, J IMMUNOL METHODS, V181, P167, DOI 10.1016/0022-1759(94)00343-U; VOSS EW, 1988, MOL IMMUNOL, V25, P751, DOI 10.1016/0161-5890(88)90111-3; VOSS EW, 1992, MOL IMMUNOL, V29, P241, DOI 10.1016/0161-5890(92)90105-7; WATT RM, 1977, IMMUNOCHEMISTRY, V14, P533, DOI 10.1016/0019-2791(77)90308-1; Weber G, 1987, HIGH PRESSURE CHEM B, P401; WEIDNER KM, 1992, J BIOL CHEM, V267, P10281; WEIDNER KM, 1993, MOL IMMUNOL, V30, P1003, DOI 10.1016/0161-5890(93)90125-U; WEIDNER KM, 1991, J BIOL CHEM, V266, P2513	39	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11247	11252		10.1074/jbc.271.19.11247	http://dx.doi.org/10.1074/jbc.271.19.11247			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626674	hybrid			2022-12-25	WOS:A1996UJ94400034
J	Trainer, VL; Brown, GB; Catterall, WA				Trainer, VL; Brown, GB; Catterall, WA			Site of covalent labeling by a photoreactive batrachotoxin derivative near transmembrane segment IS6 of the sodium channel alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCORPION TOXIN BINDING; A BENZOATE BINDING; RAT-BRAIN; RECEPTOR-SITE; NEUROTOXIN BINDING; LOCAL-ANESTHETICS; CA2+ CHANNELS; INHIBITION; 20-ALPHA-BENZOATE; IDENTIFICATION	The binding site for batrachotoxin, a lipid soluble neurotoxin acting at Na+ channel receptor site 2, was localized using a photoreactive, radiolabeled batrachotoxin derivative to covalently label purified and reconstituted rat brain Na+ channels. In the presence of the brevetoxin 1 from Ptychodiscus brevis and the pyrethroid RU51049, positive allosteric enhancers of batrachotoxin binding, a protein with an apparent molecular mass of 240 kDa corresponding to the Na+ channel alpha subunit was specifically covalently labeled. The region of the alpha subunit specifically photolabeled by the photoreactive batrachotoxin derivative was identified by antibody mapping of proteolytic fragments. Even after extensive trypsinization, an anti-peptide antibody recognizing an amino acid sequence adjacent to Na+ channel transmembrane segment IS6 was able to immunoprecipitate up to 70% of the labeled peptides. Analysis of a more complete digestion with trypsin or V8 protease indicated that the batrachotoxin receptor site is formed in part by a portion of domain I. The identification of a specifically immunoprecipitated photolabeled 7,3-kDa peptide containing transmembrane segment S6 from domain I restricted the site of labeling to residues Asn-388 to Glu-429 if V8 protease digestion was complete or Leu-380 to Glu-429 if digestion was incomplete. These results implicate the S6 transmembrane region of domain I of the Na+ channel alpha subunit as an important component of the batrachotoxin receptor site.	UNIV ALABAMA,DEPT PSYCHIAT & BEHAV NEUROBIOL,BIRMINGHAM,AL 35924	University of Alabama System; University of Alabama Birmingham	Trainer, VL (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195, USA.		Trainer, Vera/AAE-9306-2022		NIDA NIH HHS [DA07237] Funding Source: Medline; NIEHS NIH HHS [F32 ES 05586] Funding Source: Medline; NINDS NIH HHS [NS15751] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES005586] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015751] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BROWN GB, 1988, MOL PHARMACOL, V34, P54; BROWN GB, 1986, J NEUROSCI, V6, P2064; BROWN GB, 1988, INT REV NEUROBIOL, V29, P76; CASEBOLT TL, 1993, TOXICON, V31, P1113, DOI 10.1016/0041-0101(93)90126-4; CATTERALL WA, 1980, ANNU REV PHARMACOL, V20, P15, DOI 10.1146/annurev.pa.20.040180.000311; CATTERALL WA, 1981, J BIOL CHEM, V256, P8922; CATTERALL WA, 1979, J BIOL CHEM, V254, P1379; CREVELING CR, 1983, MOL PHARMACOL, V23, P350; DOUCET JP, 1990, ANAL BIOCHEM, V190, P209, DOI 10.1016/0003-2697(90)90182-9; FELLER DJ, 1985, J BIOL CHEM, V260, P1542; GORDON D, 1988, BIOCHEMISTRY-US, V27, P7032, DOI 10.1021/bi00418a054; GORDON D, 1987, P NATL ACAD SCI USA, V84, P8682, DOI 10.1073/pnas.84.23.8682; HARTSHORNE RP, 1984, J BIOL CHEM, V259, P1667; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; KHODOROV BI, 1979, NEUROSCIENCE, V4, P1315, DOI 10.1016/0306-4522(79)90159-3; LOMBET A, 1988, BRAIN RES, V459, P44, DOI 10.1016/0006-8993(88)90284-3; NAKAYAMA H, 1991, P NATL ACAD SCI USA, V88, P9203, DOI 10.1073/pnas.88.20.9203; NARAHASHI T, 1971, J GEN PHYSIOL, V58, P54, DOI 10.1085/jgp.58.1.54; NODA M, 1989, FEBS LETT, V259, P213, DOI 10.1016/0014-5793(89)81531-5; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; Orth DN, 1979, METHOD HORM RADIOIMM, P245; Peterson BZ, 1996, J BIOL CHEM, V271, P5293, DOI 10.1074/jbc.271.10.5293; POSTMA SW, 1984, MOL PHARMACOL, V25, P219; Rogers J. C., 1996, Biophysical Journal, V70, pA319; SATIN J, 1992, SCIENCE, V256, P1202, DOI 10.1126/science.256.5060.1202; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEUER T, 1990, SCIENCE, V247, P854, DOI 10.1126/science.2154850; SHARKEY RG, 1984, BIOCHEMISTRY-US, V23, P6078, DOI 10.1021/bi00320a027; SHARKEY TG, 1986, MOL PHARMACOL, V31, P273; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; STRIESSNIG J, 1990, P NATL ACAD SCI USA, V87, P9108, DOI 10.1073/pnas.87.23.9108; TAMKUN MM, 1984, J BIOL CHEM, V259, P1676; TEJEDOR FJ, 1988, P NATL ACAD SCI USA, V85, P8742, DOI 10.1073/pnas.85.22.8742; TEJEDOR FJ, 1990, CELL MOL NEUROBIOL, V10, P257, DOI 10.1007/BF00734578; TERLAU H, 1991, FEBS LETT, V293, P93, DOI 10.1016/0014-5793(91)81159-6; THOMSEN WJ, 1989, P NATL ACAD SCI USA, V86, P10161, DOI 10.1073/pnas.86.24.10161; TRAINER VL, 1994, J BIOL CHEM, V269, P19904; TRAINER VL, 1993, J BIOL CHEM, V268, P17114; WANG GK, 1994, PFLUG ARCH EUR J PHY, V427, P309, DOI 10.1007/BF00374539; WILLOW M, 1982, MOL PHARMACOL, V22, P627; [No title captured]	42	48	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11261	11267		10.1074/jbc.271.19.11261	http://dx.doi.org/10.1074/jbc.271.19.11261			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626676	hybrid			2022-12-25	WOS:A1996UJ94400036
J	Broustas, CG; Larkins, LK; Uhler, MD; Hajra, AK				Broustas, CG; Larkins, LK; Uhler, MD; Hajra, AK			Molecular cloning and expression of cDNA encoding rat brain cytosolic acyl-coenzyme A thioester hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHASE; COA HYDROLASE; ESCHERICHIA-COLI; CLOFIBRIC ACID; PURIFICATION; LIVER; ENZYME; PROLIFERATORS; MITOCHONDRIA; MICROSOMES	The cDNA encoding rat brain cytosolic acyl-CoA thioester hydrolase (ACT) has been cloned and sequenced, and the primary structure of the enzyme has been deduced. A partial amino acid sequence (38 amino acids) of the enzyme was determined using the peptides generated after CNBr digestion of the purified enzyme. Primers synthesized on the basis of this information were used to isolate two cDNA clones, each encoding the full length of the enzyme. The nucleotide sequences of these clones contained an open reading frame encoding a 358-amino acid polypeptide with a calculated molecular mass of 39.7 kDa, similar to that determined for the purified enzyme (40.9 kDa). The deduced ACT sequence showed no homology to the known sequences of any other thioesterases nor to any other known protein sequence. However, there was a strong homology to a number of expressed sequence tag human brain cDNA clones. The identity of the ACT cDNA was confirmed by the expression of ACT activity in Escherichia coli. There was a 10-15-fold increase in ACT-specific activity in the bacterial extracts after induction with isopropyl thio-galactoside, and the properties of the expressed enzyme (fusion protein) were the same as those of the purified rat brain ACT. Northern blot analysis showed that a 1.65-kilobase ACT transcript was present in rat brain and testis but not in any other rat tissues examined. However, the ACT mRNA was induced in the liver of rats that were fed Wy-14,643, a peroxisome proliferator and inducer of rodent liver cytosolic acyl-CoA thioesterase. These results indicate that the induced rat liver ACT is homologous to the constitutive rat brain ACT.	UNIV MICHIGAN, DEPT BIOL CHEM, NEUROSCI LAB, ANN ARBOR, MI 48104 USA; UNIV MICHIGAN, MENTAL HLTH RES INST, ANN ARBOR, MI 48104 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan				Broustas, Constantinos/0000-0001-7169-807X	NINDS NIH HHS [NS 15747] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015747] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ANDERSON AD, 1971, J NEUROCHEM, V18, P1179, DOI 10.1111/j.1471-4159.1971.tb00216.x; BERGE RK, 1979, EUR J BIOCHEM, V96, P393, DOI 10.1111/j.1432-1033.1979.tb13051.x; BERGE RK, 1979, BIOCHIM BIOPHYS ACTA, V574, P321, DOI 10.1016/0005-2760(79)90013-4; BERGE RK, 1984, EUR J BIOCHEM, V141, P637, DOI 10.1111/j.1432-1033.1984.tb08239.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROUSTAS CG, 1995, J NEUROCHEM, V64, P2345; BROUSTAS CG, 1995, THESIS U MICHIGAN; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHO HS, 1993, J BIOL CHEM, V268, P9238; DORMANN P, 1994, BBA-LIPID LIPID MET, V1212, P134, DOI 10.1016/0005-2760(94)90199-6; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; GROSS RW, 1983, BIOCHEMISTRY-US, V22, P5641, DOI 10.1021/bi00293a028; HWANG CS, 1993, J BIOL CHEM, V268, P14278; KATOH H, 1987, BIOCHIM BIOPHYS ACTA, V920, P171; KAWASHIMA Y, 1981, J PHARMACOBIO-DYNAM, V4, P711, DOI 10.1248/bpb1978.4.711; KUROOKA S, 1972, J BIOCHEM, V71, P625; LEHNER R, 1993, J BIOL CHEM, V268, P24726; LIN AY, 1984, NEUROCHEM RES, V9, P1571, DOI 10.1007/BF00964592; LOADER NM, 1993, PLANT MOL BIOL, V23, P769, DOI 10.1007/BF00021532; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MIYAZAWA S, 1981, EUR J BIOCHEM, V117, P425, DOI 10.1111/j.1432-1033.1981.tb06356.x; NAGGERT J, 1991, BIOCHEM J, V273, P787, DOI 10.1042/bj2730787; NAGGERT J, 1991, J BIOL CHEM, V266, P11044; POULOSE AJ, 1985, J BIOL CHEM, V260, P5953; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SMITH RE, 1981, DEV NEUROSCI-BASEL, V4, P337, DOI 10.1159/000112773; SRERE PA, 1959, BIOCHIM BIOPHYS ACTA, V33, P313, DOI 10.1016/0006-3002(59)90118-0; SVENSSON LT, 1995, J BIOL CHEM, V270, P12177, DOI 10.1074/jbc.270.20.12177; SVENSSON LT, 1995, EUR J BIOCHEM, V230, P813; TAI MH, 1993, P NATL ACAD SCI USA, V90, P1852, DOI 10.1073/pnas.90.5.1852; UHLER MD, 1993, J BIOL CHEM, V268, P13586; WAKU K, 1992, BIOCHIM BIOPHYS ACTA, V1124, P101, DOI 10.1016/0005-2760(92)90085-A; WILCKE M, 1994, EUR J BIOCHEM, V222, P803, DOI 10.1111/j.1432-1033.1994.tb18927.x; WITKOWSKI A, 1991, J BIOL CHEM, V266, P18514; YAMADA J, 1994, ARCH BIOCHEM BIOPHYS, V308, P118, DOI 10.1006/abbi.1994.1017	39	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10470	10476		10.1074/jbc.271.18.10470	http://dx.doi.org/10.1074/jbc.271.18.10470			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631842	hybrid			2022-12-25	WOS:A1996UJ34200010
J	Das, KP; Petrash, JM; Surewicz, WK				Das, KP; Petrash, JM; Surewicz, WK			Conformational properties of substrate proteins bound to a molecular chaperone alpha-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; B-CRYSTALLIN; A-CRYSTALLIN; EXPRESSION; TISSUES; FLUORESCENCE; DISEASE; GROEL	alpha-Crystallin, the major protein of the ocular lens, acts as a molecular chaperone by suppressing the nonspecific aggregation of damaged proteins. To investigate the mechanism of the interaction between alpha-crystallin and substrate proteins, we prepared a tryptophan-free mutant of human alpha A-crystallin and assessed the conformation of thermally destabilized proteins captured by this chaperone using fluorescence spectroscopy. The fluorescence emission characteristics of bound substrates (rhodanese and gamma-crystallin) and the results of fluorescence quenching experiments indicate that the proteins captured by alpha-crystallin are characterized by a very low degree of unfolding. In particular, the structure of rhodanese bound to alpha A-crystallin appears to be considerably more native-like compared to that of the enzyme bound to the chaperonin GroEL. We postulate that alpha-crystallin (and likely other small heat shock proteins) recognize preferentially the aggregation-prone conformers that occur very early on the denaturation pathway. With its ability to capture and stabilize these early non-native structures, alpha-crystallin appears to be uniquely well suited to chaperone the transparency properties of the ocular lens.	UNIV MISSOURI,MASON EYE INST,COLUMBIA,MO 65212; UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65212; WASHINGTON UNIV,DEPT OPHTHALMOL & VISUAL SCI,ST LOUIS,MO 63110	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; Washington University (WUSTL)				Das, Kali/0000-0001-7686-9077	NEI NIH HHS [P30 EY02687, EY05856] Funding Source: Medline; NIDDK NIH HHS [P60 DK20579] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY005856, P30EY002687, R55EY005856, R23EY005856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AYOAMA A, 1993, MOL CELL BIOL, V13, P1824; CARVER JA, 1995, BBA-PROTEIN STRUCT M, V1252, P251, DOI 10.1016/0167-4838(95)00146-L; DAS KP, 1995, BIOCHEM J, V311, P367, DOI 10.1042/bj3110367; DAS KP, 1995, FEBS LETT, V369, P321, DOI 10.1016/0014-5793(95)00775-5; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; HAYERHARTL MK, 1994, EMBO J, V13, P3192, DOI 10.1002/j.1460-2075.1994.tb06618.x; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOROWITZ PM, 1995, J BIOL CHEM, V270, P1536; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HORWITZ J, 1993, INVEST OPHTH VIS SCI, V34, P10; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAKOB U, 1993, J BIOL CHEM, V268, P1517; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LANDRY SJ, 1994, ANNU REV BIOPH BIOM, V23, P645, DOI 10.1146/annurev.bb.23.060194.003241; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LOWE J, 1992, J PATHOL, V166, P61, DOI 10.1002/path.1711660110; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1992, J BIOL CHEM, V267, P24648; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; MERCK KB, 1993, J BIOL CHEM, V268, P1046; PETRASH JM, 1992, J BIOL CHEM, V267, P24833; RAMAN B, 1994, J BIOL CHEM, V269, P27264; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; SIEZEN RJ, 1983, BIOCHIM BIOPHYS ACTA, V748, P56, DOI 10.1016/0167-4838(83)90027-4; SRINIVASAN AN, 1992, J BIOL CHEM, V267, P23337; SUREWICZ WK, 1995, BIOCHEMISTRY-US, V34, P9655, DOI 10.1021/bi00030a001; VANDENIJSSEL PRLA, 1994, FEBS LETT, V355, P54, DOI 10.1016/0014-5793(94)01175-3; WANG KY, 1994, J BIOL CHEM, V269, P13601	34	112	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10449	10452		10.1074/jbc.271.18.10449	http://dx.doi.org/10.1074/jbc.271.18.10449			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631839	hybrid			2022-12-25	WOS:A1996UJ34200007
J	MartinezCosta, OH; Arias, P; Romero, NM; Parro, V; Mellado, RP; Malpartida, F				MartinezCosta, OH; Arias, P; Romero, NM; Parro, V; Mellado, RP; Malpartida, F			A relA/spoT homologous gene from Streptomyces coelicolor A3(2) controls antibiotic biosynthetic genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							PROBE PLASMID VECTORS; ESCHERICHIA-COLI; STRINGENT RESPONSE; SECONDARY METABOLISM; NUCLEOTIDE-SEQUENCE; RIBOSOMAL-RNA; GUANOSINE TETRAPHOSPHATE; CLONING VECTORS; PHYSIOLOGICAL DIFFERENTIATION; TRANSCRIPTIONAL REGULATION	A 0.972-kilobase pair DNA fragment from Streptomyces lividans that induces the production of the blue-pigmented antibiotic actinorhodine in S, lividans when cloned on a multicopy plasmid has led to the isolation of a 4-kilobase pair DNA fragment from Streptomyces coelicolor containing homologous sequence, Computer-assisted analysis of the DNA sequence revealed three putative open reading frames (ORFs), ORF1, ORF2, and ORF3, ORF2 extends beyond the sequenced DNA fragment, and its deduced product shares no similarities with any other known proteins in the data bases, ORF3 is also truncated, and its 41-amino acid C-terminal product is identical 60 the S. coelicolor adenine phosphoribosyltransferase. The 847-amino acid ORF1 protein, with a predicted molecular mass of 94.2 kDa, strongly resembled the relA and spoT gene products from Escherichia coli and the homologs from Vibrio sp, strain S14, Haemophilus influenzae, Streptococcus equisimilis H46A, and Mycoplasma genitalium, Unlike these proteins, the ORF1 amino acid sequence analysis revealed the presence of a putative ATP/GTP-binding domain, A mutant was generated by deleting most of the ORF1 gene that showed an actinorhodine-nonproducing phenotype, while undecylprodigiosin and the calcium-dependent antibiotic were unaffected, The mutant strain grew at a much lower rate than the wild-type strain, and spore formation was delayed, When the gene was propagated on a low copy number vector, not only was actinorhodine production restored, but actinorhodine and undecylprodigiosin production was enhanced in both the mutant and wild-type strains and morphological differentiation returned to wild-type characteristics. (p)ppGpp synthetase activity was not detected in purified ribosomes from the ORF1-deleted mutant, while it was restored by complementation of this strain.	CSIC,CTR NACL BIOTECNOL,E-28049 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)			Parro, Victor/K-3788-2014; Mellado, Rafael P/D-2680-2009; Martinez-Costa, Oscar/B-7275-2014; Malpartida, Francisco/D-2563-2009	Martinez-Costa, Oscar/0000-0003-4893-2205; Parro, Victor/0000-0003-3738-0724				ADAMIDIS T, 1992, J BACTERIOL, V174, P4622, DOI 10.1128/JB.174.14.4622-4628.1992; ADAMIDIS T, 1990, J BACTERIOL, V172, P2962, DOI 10.1128/jb.172.6.2962-2969.1990; ANZAI H, 1987, J BACTERIOL, V169, P3482, DOI 10.1128/jb.169.8.3482-3488.1987; BARACCHINI E, 1988, J BIOL CHEM, V263, P2597; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; BASCARAN V, 1991, J GEN MICROBIOL, V137, P1625, DOI 10.1099/00221287-137-7-1625; BIBB MJ, 1982, MOL GEN GENET, V187, P265, DOI 10.1007/BF00331128; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASHEL M, 1969, J BIOL CHEM, V244, P3133; Cashel M, 1987, ESCHERICHIA COLI SAL, P1410; CHAMPNESS W, 1992, GENE, V115, P55, DOI 10.1016/0378-1119(92)90540-6; CHAMPNESS W, 1990, J CELL BIOCHEM, V14, P88; CHAMPNESS WC, 1988, J BACTERIOL, V170, P1168, DOI 10.1128/jb.170.3.1168-1174.1988; CHAMPNESS WC, 1994, REGULATION OF BACTERIAL DIFFERENTIATION, P61; CHATER KF, 1985, EMBO J, V4, P1893, DOI 10.1002/j.1460-2075.1985.tb03866.x; CHATER KF, 1982, GENE, V19, P21, DOI 10.1016/0378-1119(82)90185-8; CHATER KF, 1983, GENE, V26, P67, DOI 10.1016/0378-1119(83)90037-9; CHATER KF, 1989, TRENDS GENET, V5, P372, DOI 10.1016/0168-9525(89)90172-8; COVARRUBIAS L, 1982, GENE, V17, P79, DOI 10.1016/0378-1119(82)90103-2; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DISTLER J, 1987, NUCLEIC ACIDS RES, V15, P8041, DOI 10.1093/nar/15.19.8041; FEHR S, 1981, J BACTERIOL, V145, P68, DOI 10.1128/JB.145.1.68-73.1981; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FERNANDEZMORENO MA, 1992, J BIOL CHEM, V267, P19278; FERNANDEZMORENO MA, 1992, J BACTERIOL, V174, P2958; FERNANDEZMORENO MA, 1991, CELL, V66, P769, DOI 10.1016/0092-8674(91)90120-N; FERNANDEZMORENO MA, 1994, J BIOL CHEM, V269, P24854; FLARDH K, 1994, J BACTERIOL, V176, P5949; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GALLANT JA, 1979, ANNU REV GENET, V13, P393, DOI 10.1146/annurev.ge.13.120179.002141; HARA A, 1983, J BIOL CHEM, V258, P1678; HARA O, 1983, J GEN MICROBIOL, V129, P2939; HODGSON DA, 1981, J GEN MICROBIOL, V124, P339; Hopwood D. A., 1985, GENETIC MANIPULATION; HOPWOOD DA, 1983, J GEN MICROBIOL, V129, P2257; HOPWOOD DA, 1983, J GEN MICROBIOL, V129, P3575; HOPWOOD DA, 1988, PROC R SOC SER B-BIO, V235, P121, DOI 10.1098/rspb.1988.0067; HORINOUCHI S, 1990, GENE, V95, P49, DOI 10.1016/0378-1119(90)90412-K; ISHIZUKA H, 1992, J BACTERIOL, V174, P7585, DOI 10.1128/JB.174.23.7585-7594.1992; JANSSEN GR, 1993, GENE, V124, P133, DOI 10.1016/0378-1119(93)90774-W; JONES GH, 1994, J BACTERIOL, V176, P1475, DOI 10.1128/jb.176.5.1475-1481.1994; JONES GH, 1994, J BACTERIOL, V176, P1482, DOI 10.1128/jb.176.5.1482-1487.1994; KELLY KS, 1991, J BACTERIOL, V173, P2297, DOI 10.1128/JB.173.7.2297-2300.1991; KROHN M, 1995, ANAL BIOCHEM, V225, P188, DOI 10.1006/abio.1995.1138; LAKEY JH, 1983, J GEN MICROBIOL, V129, P3565; LAWLOR EJ, 1987, GENE DEV, V1, P1305, DOI 10.1101/gad.1.10.1305; LAZZARINI RA, 1971, J BIOL CHEM, V246, P4381; LESKIW BK, 1991, P NATL ACAD SCI USA, V88, P2461, DOI 10.1073/pnas.88.6.2461; LESKIW BK, 1993, J BACTERIOL, V175, P1995, DOI 10.1128/JB.175.7.1995-2005.1993; LYDIATE DJ, 1985, GENE, V35, P223, DOI 10.1016/0378-1119(85)90001-0; MALPARTIDA F, 1986, MOL GEN GENET, V205, P66, DOI 10.1007/BF02428033; MALPARTIDA F, 1990, GENE, V93, P91, DOI 10.1016/0378-1119(90)90141-D; Maniatis T., 1982, MOL CLONING; MCCORMICK F, 1985, SCIENCE, V230, P78, DOI 10.1126/science.3898366; MECHOLD U, 1993, MOL GEN GENET, V241, P129, DOI 10.1007/BF00280210; MERRICK MJ, 1976, J GEN MICROBIOL, V96, P299, DOI 10.1099/00221287-96-2-299; METZGER S, 1989, J BIOL CHEM, V264, P21146; METZGER S, 1988, J BIOL CHEM, V263, P15699; MURRAY MG, 1986, ANAL BIOCHEM, V158, P165, DOI 10.1016/0003-2697(86)90605-6; NARVA KE, 1990, J BACTERIOL, V172, P326, DOI 10.1128/JB.172.1.326-333.1990; OCHI K, 1987, AGR BIOL CHEM TOKYO, V51, P829, DOI 10.1080/00021369.1987.10868121; OCHI K, 1984, J GEN MICROBIOL, V130, P2473; OCHI K, 1986, J GEN MICROBIOL, V132, P299; OCHI K, 1987, J GEN MICROBIOL, V133, P2787; OCHI K, 1986, J GEN MICROBIOL, V132, P2621, DOI 10.1099/00221287-132-9-2621; OCHI K, 1987, J BACTERIOL, V169, P3608, DOI 10.1128/jb.169.8.3608-3616.1987; OCHI K, 1990, J GEN MICROBIOL, V136, P2405, DOI 10.1099/00221287-136-12-2405; OCHI K, 1990, J BACTERIOL, V172, P4008, DOI 10.1128/jb.172.7.4008-4016.1990; OHNUKI T, 1985, J BACTERIOL, V164, P85, DOI 10.1128/JB.164.1.85-94.1985; PARKER J, 1976, MOL GEN GENET, V144, P111, DOI 10.1007/BF00277313; PETERSON SN, 1995, J BACTERIOL, V177, P3199, DOI 10.1128/jb.177.11.3199-3204.1995; RAMAGOPAL S, 1974, P NATL ACAD SCI USA, V71, P820, DOI 10.1073/pnas.71.3.820; RICE P, 1995, EMBNET NEWS, V2, P5; RIESENBERG D, 1984, J GEN MICROBIOL, V130, P2549; RUDD BAM, 1980, J GEN MICROBIOL, V119, P333; RYALS J, 1982, J BACTERIOL, V151, P1261, DOI 10.1128/JB.151.3.1261-1268.1982; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SARMIENTOS P, 1983, P NATL ACAD SCI-BIOL, V80, P7010, DOI 10.1073/pnas.80.22.7010; SARUBBI E, 1988, MOL GEN GENET, V213, P214, DOI 10.1007/BF00339584; SARUBBI E, 1989, J BIOL CHEM, V264, P15074; SCHREIBER G, 1991, J BIOL CHEM, V266, P3760; SHAND RF, 1989, J BACTERIOL, V171, P737, DOI 10.1128/jb.171.2.737-743.1989; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEIN D, 1989, J BACTERIOL, V171, P2258, DOI 10.1128/jb.171.4.2258-2261.1989; STEPHENS JC, 1975, P NATL ACAD SCI USA, V72, P4389, DOI 10.1073/pnas.72.11.4389; STRAUCH E, 1991, MOL MICROBIOL, V5, P289, DOI 10.1111/j.1365-2958.1991.tb02109.x; STUTZMANENGWALL KJ, 1992, J BACTERIOL, V174, P144, DOI 10.1128/jb.174.1.144-154.1992; SVITIL AL, 1993, J BIOL CHEM, V268, P2307; SY J, 1976, BIOCHEMISTRY-US, V15, P606, DOI 10.1021/bi00648a024; TAKANO E, 1992, MOL MICROBIOL, V6, P2797, DOI 10.1111/j.1365-2958.1992.tb01459.x; VOGTLI M, 1994, MOL MICROBIOL, V14, P643, DOI 10.1111/j.1365-2958.1994.tb01303.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARD JM, 1986, MOL GEN GENET, V203, P468, DOI 10.1007/BF00422072; WRIGHT F, 1992, GENE, V113, P55, DOI 10.1016/0378-1119(92)90669-G; WRIGHT LF, 1976, J GEN MICROBIOL, V95, P96, DOI 10.1099/00221287-95-1-96; WRIGHT LF, 1976, J GEN MICROBIOL, V96, P289, DOI 10.1099/00221287-96-2-289; XIAO H, 1991, J BIOL CHEM, V266, P5980; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	101	66	69	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10627	10634		10.1074/jbc.271.18.10627	http://dx.doi.org/10.1074/jbc.271.18.10627			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631867	hybrid			2022-12-25	WOS:A1996UJ34200035
J	Yen, PM; Liu, Y; Sugawara, A; Chin, WW				Yen, PM; Liu, Y; Sugawara, A; Chin, WW			Vitamin D receptors repress basal transcription and exert dominant negative activity on triiodothyronine-mediated transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; RETINOIC-ACID RECEPTOR; DNA-BINDING; RESPONSE ELEMENTS; V-ERBA; GENE; 1,25-DIHYDROXYVITAMIN-D3; RESISTANCE; EXPRESSION; DOMAIN	We have examined vitamin D receptor (VDR), thyroid hormone receptor (TR), and retinoid X receptor beta (RXR beta) binding to vitamin D (VDREs), two thyroid hormone (TREs) (DR4 and F2), and a retinoic acid response element (DR5). VDR/RXR bound well to the VDREs and to DR4 and DR5 using the electrophoretic mobility shift assay. Surprisingly, VDR/RXR also bound well to F2, which contains half-sites arranged as an inverted palindrome. In co-transfection experiments using CV-1 cells, we observed that VDR repressed basal transcription in the absence of ligand on DR3 and osteopontin VDREs and F2, but had no effect on DR4 or DR5, VDR selectively mediated ligand-dependent transcription on only VDREs. VDR also exhibited dominant negative activity as it blocked triiodothyronine (T-3)-mediated transcriptional activity on DR4 and F2. These results demonstrate that VDR/RXR heterodimers can bind promiscuously to a wide range of hormone response elements, including inverted palindromes. Moreover, they show that unliganded VDRs, similar to TRs and retinoic acid receptors, can repress basal transcription. Last, they also suggest a novel repressor function of VDR on T-3 mediated transcription which may be significant in tissues where VDR and TR are co-expressed.	TOHOKU UNIV,DEPT INTERNAL MED 2,SENDAI,MIYAGI 980,JAPAN	Tohoku University	Yen, PM (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV GENET,GW THORN RES BLDG,RM 907,20 SHATTUCK ST,BOSTON,MA 02115, USA.		Yen, Paul M/V-9857-2019	Sugawara, Akira/0000-0003-4511-8101; Yen, Paul/0000-0002-3790-8114	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002186] Funding Source: NIH RePORTER; NIDDK NIH HHS [K08DK-02186] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; BENDIK I, 1995, J BIOL CHEM, V270, P3107, DOI 10.1074/jbc.270.7.3107; BRENT G A, 1989, New Biologist, V1, P329; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CHEN DJ, 1995, NATURE, V377, P454; CHESKIS B, 1994, MOL CELL BIOL, V14, P3329, DOI 10.1128/MCB.14.5.3329; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FREEDMAN LP, 1994, MOL ENDOCRINOL, V8, P265, DOI 10.1210/me.8.3.265; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; IKEDA M, 1995, END SOC M WASH JUN; JUGEAUBRY CE, 1995, J BIOL CHEM, V270, P18117, DOI 10.1074/jbc.270.30.18117; KAJI H, 1989, ENDOCRINOLOGY, V124, P930, DOI 10.1210/endo-124-2-930; KATZ D, 1993, J BIOL CHEM, V268, P20905; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KRISTJANSSON K, 1993, J CLIN INVEST, V92, P12, DOI 10.1172/JCI116539; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LENG XK, 1994, J BIOL CHEM, V50, P31435; LIU RT, 1995, MOL ENDOCRINOL, V9, P86, DOI 10.1210/me.9.1.86; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGAYA T, 1992, J BIOL CHEM, V267, P13014; NAGAYA T, 1993, J BIOL CHEM, V268, P24278; NELSON CC, 1993, MOL ENDOCRINOL, V7, P1185, DOI 10.1210/me.7.9.1185; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; Sambrook J., 2002, MOL CLONING LAB MANU; SCHRADER M, 1994, DNA CELL BIOL, V13, P333, DOI 10.1089/dna.1994.13.333; SCHRADER M, 1995, MOL CELL BIOL, V15, P1154; SCHRADER M, 1994, NATURE, V370, P382, DOI 10.1038/370382a0; SEGARS JH, 1993, MOL CELL BIOL, V13, P2258, DOI 10.1128/MCB.13.4.2258; SONE T, 1989, J BIOL CHEM, V264, P20230; SUGAWARA A, 1993, ENDOCRINOLOGY, V133, P965, DOI 10.1210/en.133.3.965; SUGAWARA A, 1994, ENDOCRINOLOGY, V135, P1956, DOI 10.1210/en.135.5.1956; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WILLIAMS GR, 1992, MOL ENDOCRINOL, V6, P1527, DOI 10.1210/me.6.10.1527; WILLIAMS GR, 1994, ENDOCRINOLOGY, V134, P1888, DOI 10.1210/en.134.4.1888; YANG YZ, 1995, 11 INT THYR C TOR; YEN PM, 1994, J BIOL CHEM, V269, P12704; YEN PM, 1992, J BIOL CHEM, V267, P3565; YEN PM, 1995, ENDOCRINOLOGY, V136, P2845, DOI 10.1210/en.136.7.2845; YEN PM, 1994, TRENDS ENDOCRIN MET, V5, P65, DOI 10.1016/1043-2760(94)90004-3; YEN PM, 1994, J BIOL CHEM, V269, P903; YEN PM, 1994, ENDOCRINOLOGY, V134, P1075, DOI 10.1210/en.134.3.1075; YEN PM, 1992, J BIOL CHEM, V267, P23248; YEN PM, 1993, ENDOCR J, V1, P461; ZHANG XK, 1991, NEW BIOL, V3, P169	57	53	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10910	10916		10.1074/jbc.271.18.10910	http://dx.doi.org/10.1074/jbc.271.18.10910			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631908	hybrid			2022-12-25	WOS:A1996UJ34200076
J	Sackett, DL; KoskKosicka, D				Sackett, DL; KoskKosicka, D			The active species of plasma membrane Ca2+-ATPase are a dimer and a monomer-calmodulin complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE CA-2+-ATPASE; MOLECULAR-CLONING; OLIGOMERIZATION; FLUORESCENCE; ASSOCIATION; ACTIVATION; ISOFORMS; BINDING; ATPASE; STATES	The purified plasma membrane Ca2+-ATPase is fully activated through the enzyme concentration-dependent self-association at physiologically relevant Ca2+ concentrations (Kosk-Kosicka, D., and Bzdega, T. (1988) J. Biol. Chem. 263, 18184-18189; Kosk-Kosicka, D., Bzdega, T., and Wawrzynow, A. (1989) J. Biol. Chem. 264, 19495-19499). We have previously shown that the Ca2+-ATPase activity of the oligomeric enzyme is independent of calmodulin, in contrast to another active enzyme species, a presumable monomer, that is activated by calmodulin binding, Presently, we have succeeded in determining the molecular mass of the two active enzyme species by equilibrium ultracentrifugation. For the calmodulin dependent species, the molecular mass is 170 +/- 30 kDa, which is consistent with predominantly monomeric Ca2+-ATPase with bound calmodulin, The molecular mass of calmodulin-independent oligomers is 260 +/- 34 kDa, indicating that they are dimers, Results of experiments performed under different calcium and potassium concentrations and in the presence of dextran that causes molecular crowding verify a strict Ca2+ requirement of the dimerization process, We conclude that the active species of the Ca2+-ATPase are a monomer-calmodulin complex and a dimer.	JOHNS HOPKINS UNIV,SCH MED,DEPT ANESTHESIOL & CRIT CARE MED,BALTIMORE,MD 21287; NIDDK,NIH,BIOCHEM PHARMACOL LAB,BETHESDA,MD 20892	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)					NIGMS NIH HHS [GM 447130] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GRAF E, 1981, ARCH BIOCHEM BIOPHYS, V210, P257, DOI 10.1016/0003-9861(81)90187-9; Harding S. E., 1992, ANAL ULTRACENTRIFUGA; KOSKKOSICKA D, 1990, ADV EXP MED BIOL, V269, P169; KOSKKOSICKA D, 1988, J BIOL CHEM, V263, P18184; KOSKKOSICKA D, 1989, J BIOL CHEM, V264, P19495; KOSKKOSICKA D, 1995, FEBS LETT, V371, P57, DOI 10.1016/0014-5793(95)00870-F; KOSKKOSICKA D, 1990, BIOCHEMISTRY-US, V29, P1875, DOI 10.1021/bi00459a030; KOSKKOSICKA D, 1990, BIOCHEMISTRY-US, V29, P3771; KOSKOSICKA D, 1986, J BIOL CHEM, V261, P3333; Laue T. M., 1994, MODERN ANAL ULTRACEN; MCCASLIN DR, 1981, BIOCHEMISTRY-US, V20, P5212, DOI 10.1021/bi00521a018; REYNOLDS JA, 1985, METHOD ENZYMOL, V117, P41; SACKETT DL, 1989, ANAL BIOCHEM, V180, P319, DOI 10.1016/0003-2697(89)90439-9; SACKETT DL, 1991, BIOCHEMISTRY-US, V30, P3511, DOI 10.1021/bi00228a023; SACKETT DL, 1993, BIOPHYS J, V64, pA334; SCHWARZENBACH G, 1957, HELV CHIM ACTA, V40, P1886, DOI 10.1002/hlca.19570400640; SHULL GE, 1988, J BIOL CHEM, V263, P8646; STAUFFER TP, 1995, J BIOL CHEM, V270, P12184, DOI 10.1074/jbc.270.20.12184; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; TANFORD C, 1977, J PHYS CHEM-US, V81, P1555, DOI 10.1021/j100531a007; VERMA AK, 1988, J BIOL CHEM, V263, P14152	24	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9987	9991		10.1074/jbc.271.17.9987	http://dx.doi.org/10.1074/jbc.271.17.9987			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626638	hybrid			2022-12-25	WOS:A1996UG25700022
J	Su, L; Zhao, Z; Bouchard, P; Banville, D; Fischer, EH; Krebs, EG; Shen, SH				Su, L; Zhao, Z; Bouchard, P; Banville, D; Fischer, EH; Krebs, EG; Shen, SH			Positive effect of overexpressed protein-tyrosine phosphatase PTP1C on mitogen-activated signaling in 293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SH3 DOMAINS; CORKSCREW; PHOSPHORYLATION; TRANSDUCTION; EXPRESSION; KINASES; HOMOLOG; SH-PTP2	PTP1C, an SH2 domain-containing protein-tyrosine phosphatase, is predominantly expressed in hematopoietic cells, in which it negatively regulates cellular signaling. However, this enzyme is also expressed in many non-hematopoietic cells. We demonstrate here that in non-hematopoietic 293 cells, overexpression of a catalytically inactive mutant of PTP1C strongly suppressed the stimulatory effects of the epidermal growth factor or serum on cell proliferation, early gene transcription, and DNA synthesis. Similarly, the phosphorylation of the mitogen-activated protein kinase and mitogen-activated protein kinase kinase activity was markedly inhibited by overexpression of mutant PTP1C. The inhibitory effect of mutant PTP1C was overcome by cotransfection with wild-type PTP1C, but not with the structurally related PTP2C. Furthermore, expression of the mutant phosphatase resulted in hyperphosphorylation on tyrosine of a 95-kDa protein that was co-immunoprecipitated with the mutant, but not with the wildtype protein. These results suggest that, unlike in hematopoietic cells, PTP1C in 293 cells plays a positive role in epidermal growth factor- or serum-activated mitogenesis. Thus, PTP1C participates in multiple signaling pathways, where the enzyme, depending on its target molecules, may function as either a positive or negative mediator.	NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,PHARMACEUT SECTOR,MONTREAL,PQ H4P 2R2,CANADA; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3G 1A4,CANADA	National Research Council Canada; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; McGill University								AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BANVILLE D, 1995, GENOMICS, V27, P165, DOI 10.1006/geno.1995.1020; BOUCHARD P, 1994, J BIOL CHEM, V269, P19585; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COSSETTE LJ, IN PRESS EXP CELL RE; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI RY, 1995, EMBO J, V14, P2519, DOI 10.1002/j.1460-2075.1995.tb07249.x; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MATOZAKI T, 1994, BIOCHEM BIOPH RES CO, V204, P874, DOI 10.1006/bbrc.1994.2541; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; REEVES SA, 1995, EUR J BIOCHEM, V233, P55, DOI 10.1111/j.1432-1033.1995.055_1.x; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; Treisman R, 1990, Semin Cancer Biol, V1, P47; UCHIDA T, 1993, J BIOL CHEM, V268, P11845; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	38	62	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10385	10390		10.1074/jbc.271.17.10385	http://dx.doi.org/10.1074/jbc.271.17.10385			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626611	hybrid			2022-12-25	WOS:A1996UG25700083
J	Chen, W; Steenbergen, C; Levy, LA; Vance, J; London, RE; Murphy, E				Chen, W; Steenbergen, C; Levy, LA; Vance, J; London, RE; Murphy, E			Measurement of free Ca2+ in sarcoplasmic reticulum in perfused rabbit heart loaded with 1,2-bis(2-amino-5,6-difluorophenoxy)ethane-N,N,N',N'-tetraacetic acid by F-19 NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-CONCENTRATION; INTRACELLULAR CA2+; SKELETAL-MUSCLE; ATP-HYDROLYSIS; ELECTRON-PROBE; FREE-ENERGY; CALSEQUESTRIN; RELEASE; CA-2+; MYOCYTES	Measurements of free calcium ion concentration in the sarcoplasmic reticulum ([Ca2+](SR)) and an evaluation of its relationship to changes in cytosolic free calcium and energy state of the cell, as well as heterogeneity of the SR calcium pool, were performed using F-19 NMR in Langendorff perfused rabbit hearts loaded with acetoxymethyl ester of 1,2-bis(2-amino-5,6-difiuorophenoxy)ethane-N,N,N',N'-tetraacetic acid. We report a base-line time-average [Ca2+](SR) value of 1.5 mM (n = 13) in the beating heart, similar to the value measured at diastole. We further report that [Ca2+](SR) decreases by similar to 30% at the start of systole and that there is no evidence of spacial heterogeneity in [Ca2+](SR) during the contraction cycle. However, there appears to be a heterogeneous response to SR calcium channel release activator (caffeine) and SR calcium-ATPase inhibitor (cyclopiazonic acid), consistent with studies suggesting that there are subpopulations of SR. Raising cytosolic free calcium by depolarizing the cell with 30 mM extracellular KCl, resulted in an increase in [Ca2+](SR); however, the calcium gradient was unchanged. Lowering cell phosphorylation potential, which would reduce the free energy available for the SR Ca2+-ATPase, leads to a decrease in the calcium gradient across the SR, but this reduced gradient was primarily due to an increase in cytosolic free calcium and not a net release of SR calcium.	DUKE UNIV, MED CTR, DEPT PATHOL, DURHAM, NC 27710 USA	Duke University	Chen, W (corresponding author), NIEHS, LAB MOLEC BIOPHYS, MD 4A-01, POB 12233, RES TRIANGLE PK, NC 27709 USA.		London, Robert E/F-7990-2019	London, Robert E/0000-0001-9108-8463	NHLBI NIH HHS [R01-HL39752, R01 HL039752] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039752] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN DG, 1983, J PHYSIOL-LONDON, V339, P107, DOI 10.1113/jphysiol.1983.sp014706; BARO I, 1993, J PHYSIOL-LONDON, V465, P21, DOI 10.1113/jphysiol.1993.sp019664; BASSANI JWM, 1994, J PHYSIOL-LONDON, V476, P279, DOI 10.1113/jphysiol.1994.sp020130; BASSANI JWM, 1993, AM J PHYSIOL, V265, pC533, DOI 10.1152/ajpcell.1993.265.2.C533; BASSANI JWM, 1995, AM J PHYSIOL-CELL PH, V268, pC1313, DOI 10.1152/ajpcell.1995.268.5.C1313; BAUDET S, 1993, CIRC RES, V73, P813, DOI 10.1161/01.RES.73.5.813; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; GRIESE M, 1988, J MOL CELL CARDIOL, V20, P1189, DOI 10.1016/0022-2828(88)90598-6; HASSELBACH W, 1983, ANNU REV PHYSIOL, V45, P325, DOI 10.1146/annurev.ph.45.030183.001545; HOERTER JA, 1988, AM J PHYSIOL, V255, pC192, DOI 10.1152/ajpcell.1988.255.2.C192; ISENBERG G, 1993, CARDIOVASC RES, V27, P1800, DOI 10.1093/cvr/27.10.1800; JORGENSEN AO, 1988, CIRC RES, V63, P1060, DOI 10.1161/01.RES.63.6.1060; KAMMERMEIER H, 1982, J MOL CELL CARDIOL, V14, P267, DOI 10.1016/0022-2828(82)90205-X; KIJIMA Y, 1993, J BIOL CHEM, V268, P3499; KODAMA T, 1985, PHYSIOL REV, V65, P467, DOI 10.1152/physrev.1985.65.2.467; KRAUSE KH, 1991, J BIOL CHEM, V266, P9453; KUPRIYANOV VV, 1993, J MOL CELL CARDIOL, V25, P1235, DOI 10.1006/jmcc.1993.1135; LONDON RE, 1994, AM J PHYSIOL, V266, pC1313, DOI 10.1152/ajpcell.1994.266.5.C1313; MARBAN E, 1988, CIRC RES, V63, P673, DOI 10.1161/01.RES.63.3.673; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; MURPHY E, 1994, AM J PHYSIOL, V266, pC1323, DOI 10.1152/ajpcell.1994.266.5.C1323; NIH, 1985, NIH PUBLICATION, V85-23; REIMER KA, 1981, CIRC RES, V49, P901, DOI 10.1161/01.RES.49.4.901; SMITH GL, 1992, J PHYSIOL-LONDON, V458, P457, DOI 10.1113/jphysiol.1992.sp019427; SOMLYO AV, 1985, J BIOL CHEM, V260, P6801; SOMLYO AV, 1981, J CELL BIOL, V90, P577, DOI 10.1083/jcb.90.3.577; STEENBERGEN C, 1990, CIRC RES, V66, P135, DOI 10.1161/01.RES.66.1.135; TANFORD C, 1983, ANNU REV BIOCHEM, V52, P379, DOI 10.1146/annurev.bi.52.070183.002115; VOLPE P, 1991, FEBS LETT, V278, P274, DOI 10.1016/0014-5793(91)80134-O; WATABE S, 1991, COMP BIOCHEM PHYS B, V99, P545, DOI 10.1016/0305-0491(91)90336-C; WATKINS MW, 1992, AM J PHYSIOL, V263, pH1811, DOI 10.1152/ajpheart.1992.263.6.H1811; WEBER A, 1968, J GEN PHYSIOL, V52, P750, DOI 10.1085/jgp.52.5.750; YOSHIOKA T, 1984, J CELL BIOL, V99, P558, DOI 10.1083/jcb.99.2.558	35	84	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7398	7403		10.1074/jbc.271.13.7398	http://dx.doi.org/10.1074/jbc.271.13.7398			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631764	hybrid			2022-12-25	WOS:A1996UC77400032
J	Ghosh, P; Sica, A; Cippitelli, M; Subleski, J; Lahesmaa, R; Young, HA; Rice, NR				Ghosh, P; Sica, A; Cippitelli, M; Subleski, J; Lahesmaa, R; Young, HA; Rice, NR			Activation of nuclear factor of activated T cells in a cyclosporin A-resistant pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERSUS-HOST DISEASE; REGULATORY ELEMENTS; ANTIGEN RECEPTOR; IDENTIFICATION; CALCINEURIN; EXPRESSION; PROMOTER; BINDING	The mechanism of action of the immunosuppressive drug cyclosporin A (CsA) is the inactivation of the Ca2+/calmodulin-dependent serine-threonine phosphatase calcineurin by the drug-immunophilin complex, Inactive calcineurin is unable to activate the nuclear factor of activated T cells (NFAT), a transcription factor required for expression of the interleukin 2 (IL-2) gene. IL-2 production by CsA-treated cells is therefore dramatically reduced, We demonstrate here, however, that NFAT can be activated, and significant levels of IL-2 can be produced by the CsA-resistant CD28-signaling pathway. In transient transfection assays, both multicopy NFAT- and IL-2 promoter-beta-galactosidase reporter gene constructs could be activated by phorbol 12-myristate 13-acetate (PMA)/alpha CD28 stimulation, and this activation was resistant to CsA. Electrophoretic mobility shift assay showed the induction of a CsA-resistant NFAT complex in the nuclear extracts of peripheral blood T cells stimulated with PMA plus alpha CD28. Peripheral blood T cells stimulated with PMA/alpha CD28 produced IL-2 in the presence of CsA. Collectively, these data suggest that NFAT can be activated and IL-2 can be produced in a calcineurin independent manner.	SAIC,EXPTL IMMUNOL LAB,DIV BASIC SCI,FREDERICK,MD 21702; SAIC,BIOL CARCINOGENESIS DEV PROGRAM,FREDERICK,MD 21702; SYNTEX RES,DEPT LEUKOCYTE BIOL,PALO ALTO,CA 94304; NCI,MOLEC BASIS CARCINOGENESIS LAB,ABL BASIC RES PROGRAM,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702	Science Applications International Corporation (SAIC); SAIC-Frederick; Science Applications International Corporation (SAIC); SAIC-Frederick; Syntex Corporation; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Cippitelli, Marco/AAF-4857-2021; Sica, Antonio/AAB-9546-2020; Young, Howard/A-6350-2008	Cippitelli, Marco/0000-0002-9620-538X; Young, Howard/0000-0002-3118-5111				BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; CHAN G, 1995, EUR J IMMUNOL, V25, P1999, DOI 10.1002/eji.1830250730; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GHOSH P, 1994, CANCER RES, V54, P2969; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; PAI SY, 1994, BLOOD, V84, P3974, DOI 10.1182/blood.V84.11.3974.bloodjournal84113974; PENIX L, 1993, J EXP MED, V178, P1483, DOI 10.1084/jem.178.5.1483; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; STORB R, 1985, IMMUNOL REV, V88, P215, DOI 10.1111/j.1600-065X.1985.tb01160.x; STORB R, 1986, BLOOD, V68, P119; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; VANLIER RAW, 1991, EUR J IMMUNOL, V21, P1775, DOI 10.1002/eji.1830210731; WOLFF RA, 1994, J BIOL CHEM, V269, P19605	27	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7700	7704		10.1074/jbc.271.13.7700	http://dx.doi.org/10.1074/jbc.271.13.7700			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631809	hybrid			2022-12-25	WOS:A1996UC77400077
J	Cole, JL; Carroll, SS; Kuo, LC				Cole, JL; Carroll, SS; Kuo, LC			Stoichiometry of 2',5' oligoadenylate-induced dimerization of ribonuclease L - A sedimentation equilibrium study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON ACTION	Ribonuclease L is an endoribonuclease that is activated by binding of 2',5'-linked oligoadenylates. Activation of ribonuclease L also induces dimerization. Here, we demonstrate using equilibrium sedimentation that dimerization requires the binding of one 5'-monophosphate 2',5'-(adenosine)(3) molecule per ribonuclease L monomer. No dimerization was observed in the absence of activator up to a protein concentration of 18 mu M, indicating that unliganded enzyme is unable to dimerize or the association is very weak. In parallel with dimerization, enzymatic activity is also maximized at a 1:1 activator: ribonuclease L stoichiometry. The same stoichiometry for dimerization is observed using a nonphosphorylated activator 2'-5'-(adenosine)(3). Adenosine triphosphate or RNA oligonucleotide substrates do not induce dimerization. The observed stoichiometry supports a model for ribonuclease L dimerization in which activator binds to monomer, which subsequently dimerizes.			Cole, JL (corresponding author), MERCK SHARP & DOHME RES LABS,DEPT BIOL CHEM,W POINT,PA 19486, USA.		Cole, James/G-2586-2011					Cohn E., 1943, PROTEINS AMINO ACIDS, P157; DONG BH, 1995, J BIOL CHEM, V270, P4133, DOI 10.1074/jbc.270.8.4133; DONG BH, 1994, J BIOL CHEM, V269, P14153; DURCHSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; FLOYDSMITH G, 1981, SCIENCE, V212, P1030, DOI 10.1126/science.6165080; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KERR IM, 1978, P NATL ACAD SCI USA, V75, P256, DOI 10.1073/pnas.75.1.256; WRESCHNER DH, 1981, NATURE, V289, P414, DOI 10.1038/289414a0; Wyman J., 1990, BINDING LINKAGE FUNC, P203; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	10	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					3979	3981						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626728				2022-12-25	WOS:A1996TW96000006
J	Derman, MP; Chen, JY; Spokes, KC; Zhou, SY; Cantley, LG				Derman, MP; Chen, JY; Spokes, KC; Zhou, SY; Cantley, LG			An 11-amino acid sequence from c-met initiates epithelial chemotaxis via phosphatidylinositol 3-kinase and phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR; CELLS; MOTILITY	Interaction of hepatocyte growth factor with its high affinity receptor c-met initiates a cascade of intracellular events leading to epithelial motility. An 11-amino acid sequence from the c-met receptor has been found to cause cell transformation in transfected fibroblasts (Ponzetto, C., Bardelli, A, Zhen, Z., Maina, F., Dalla, Z. P., Giordano, S., Graziani, A, Panayotou, G., and Comoglio, P. M. (1994) Cell 77, 261-271). We inserted this sequence into a mutant platelet-derived growth factor receptor (F5) to determine if this region of c-met can initiate cell motility and which signaling pathways it activates. The platelet-derived growth factor (PDGF) receptor/c-met hybrid (F5 met) initiated PDGF-dependent chemotaxis in renal epithelial cells (8.0 +/- 2.3 versus 70.5 +/- 4.8 cells/mm(2)), while the parental construct, F5, did not. Addition of PDGF to cells expressing F5 met caused activation of the phosphatidylinositol (PI) 3-kinase (control 2.0 +/- 0.8, +PDGF 17.1 +/- 5.1, n = 3, p < 0.05) and phospholipase C (control 478.5 +/- 67 dpm/well, +PDGF 1049.3 +/- 93, n = 4, p = 0.003), while neither pathway was activated in cells expressing F5. The chemotactic response of F5 met was inhibited by both the PI 3-kinase inhibitor wortmannin and the phospholipase C inhibitor U-71322. Selective activation of the PI 3-kinase utilizing a PDGF receptor mutant (F3) containing the native high affinity PI 3-kinase binding site also resulted in PDGF stimulated chemotaxis, although less than that generated by the c-met sequence. These findings demonstrate that the 11-amino acid sequence from c-met initiates epithelial motility via coincident activation of the PI 3-kinase and phospholipase C and that selective activation of the PI 3-kinase can initiate a partial chemotactic response.			Derman, MP (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DIV NEPHROL,DANA 517,330 BROOKLINE AVE,BOSTON,MA 02215, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044503, R01DK018078] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 18078, DK 44503] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BLEASDALE JE, 1993, NEUROPROTOCOLS, V3, P125; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CANTLEY LG, 1995, J AM SOC NEPHROL, V5, P1872; CANTLEY LG, 1994, AM J PHYSIOL, V267, pF271, DOI 10.1152/ajprenal.1994.267.2.F271; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; DERMAN MP, 1995, AM J PHYSIOL-RENAL, V268, pF1211, DOI 10.1152/ajprenal.1995.268.6.F1211; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; KUNDRA V, 1994, NATURE, V367, P464; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RAUCHMAN M, 1993, AM J PHYSIOL, V34, pF416; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; STOKER M, 1989, J CELL PHYSIOL, V139, P565, DOI 10.1002/jcp.1041390316; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WENNSTROM S, 1994, ONCOGENE, V9, P651	20	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4251	4255						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626770				2022-12-25	WOS:A1996TW96000048
J	Krebsbach, PH; Lee, SK; Matsuki, Y; Kozak, CA; Yamada, RM; Yamada, Y				Krebsbach, PH; Lee, SK; Matsuki, Y; Kozak, CA; Yamada, RM; Yamada, Y			Full-length sequence, localization, and chromosomal mapping of ameloblastin - A novel tooth-specific gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; ENAMEL; BONE; PHOSPHOPROTEIN; PURIFICATION; SIALOPROTEIN	We report the full-length sequencing, cell type-specific expression, and immunolocalization of a novel gene expressed in rat incisors, which we have designated ameloblastin. Northern blot analysis of RNA from multiple rat and mouse tissues demonstrated high levels of expression of two distinct transcripts of approximately 2.0 and 1.6 kilobase pairs that were expressed only in teeth. In situ hybridization using a digoxigenin-labeled RNA probe showed that the tissue distribution of ameloblastin was limited to the ameloblast in rat incisors. Immunohistochemical staining of rat incisors using a polyclonal antibody raised against a fusion protein revealed a unique localization pattern. Ameloblastin was found to be expressed during the differentiation of inner enamel epithelium into ameloblasts, with intense localization in the Tomes' processes of secretory ameloblasts. In contrast to amelogenin, only modest amounts of ameloblastin were detected in enamel matrix. The ameloblastin gene encodes an open reading frame of 422 amino acids corresponding to a putative protein of 45 kDa. The predicted protein is acidic (pI = 5.54) and the most abundant amino acids are Pro (15.2%), Gly (9.9%), and Leu (9.9%). We have also mapped the ameloblastin gene, Ambn, to a locus on mouse chromosome 5 near other genes associated with mineralized tissues. Thus, ameloblastin represents a unique ameloblast-specific gene product that may be important in enamel matrix formation and mineralization.	NIDR,DEV BIOL LAB,NIH,BETHESDA,MD 20892; NIAID,MOLEC MICROBIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Krebsbach, Paul H./AAC-4765-2021	Yamada, Kenneth/0000-0003-1512-6805				ADAMSON MC, 1991, VIROLOGY, V183, P778, DOI 10.1016/0042-6822(91)91010-E; BROOKES SJ, 1995, ARCH ORAL BIOL, V40, P1, DOI 10.1016/0003-9969(94)00135-X; Carter J., 1984, TOOTH ENAMEL, P229; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crall M G, 1992, Proc Finn Dent Soc, V88 Suppl 1, P285; CROSBY AH, 1995, GENOMICS, V27, P155, DOI 10.1006/geno.1995.1018; CROSBY AH, 1996, IN PRESS MAMMAL GENO; DEUTSCH D, 1991, J BIOL CHEM, V266, P16021; DEUTSCH D, 1989, ANAT RECORD, V224, P189, DOI 10.1002/ar.1092240209; FISHER LW, 1983, J BIOL CHEM, V258, P2723; FISHER LW, 1987, J BIOL CHEM, V262, P9702; FORSMAN K, 1994, HUM MOL GENET, V3, P1621, DOI 10.1093/hmg/3.9.1621; FUKAE M, 1987, CALCIFIED TISSUE INT, V40, P286, DOI 10.1007/BF02555263; GEORGE A, 1993, J BIOL CHEM, V268, P12624; GORSKI JP, 1988, J BIOL CHEM, V263, P15938; Green E., 1981, GENETICS PROBABILITY, DOI 10.1007/978-1-349-04904-2; JOWETT AK, 1993, DEVELOPMENT, V117, P461; KOLLAR EJ, 1991, J CRAN GENET DEV BIO, V11, P223; Kollar EJ, 1983, EPITHELIAL MESENCHYM, P27; KOZAK CA, 1990, GENOMICS, V8, P519, DOI 10.1016/0888-7543(90)90039-W; KOZAK CA, 1994, MAMM GENOME, V5, pS65; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEDOUARIN NM, 1993, DEV BIOL, V159, P24, DOI 10.1006/dbio.1993.1219; LUMSDEN AGS, 1984, C INSERM, V125, P29; LUMSDEN AGS, 1988, DEVELOPMENT S, V103, P55; LYU MS, 1995, MAMM GENOME, V6, P487, DOI 10.1007/BF00360663; MATSUKI Y, 1995, J DENT RES, V74, P307, DOI 10.1177/00220345950740010401; MATSUKI Y, 1995, ARCH ORAL BIOL, V40, P161, DOI 10.1016/0003-9969(94)00150-A; OSUMIYAMASHITA N, 1994, DEV BIOL, V164, P409, DOI 10.1006/dbio.1994.1211; Sambrook J, 1989, MOL CLONING LABORATO; SIMMER JP, 1994, CALCIFIED TISSUE INT, V55, P302, DOI 10.1007/BF00310410; TERMINE JD, 1980, J BIOL CHEM, V255, P9769; THESLEFF I, 1981, DIFFERENTIATION, V18, P75, DOI 10.1111/j.1432-0436.1981.tb01107.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WARSHAWSKY H, 1974, ANAT RECORD, V179, P423, DOI 10.1002/ar.1091790403	35	260	275	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4431	4435						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626794				2022-12-25	WOS:A1996TW96000072
J	Street, JC; Mahmood, U; Ballon, D; Alfieri, AA; Koutcher, JA				Street, JC; Mahmood, U; Ballon, D; Alfieri, AA; Koutcher, JA			C-13 and P-31 NMR investigation of effect of 6-aminonicotinamide on metabolism of RIF-1 tumor cells in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; TRICARBOXYLIC-ACID CYCLE; GLYCOGEN-METABOLISM; INVITRO; INVIVO; ENERGY; LIVER	The effect of 6-aminonicotinamide on the metabolism of RIF-1 tumor cells was investigated using C-13 and P-31 NMR spectroscopy, 6-Aminonicotinamide can be metabolized to 6-amino-NAD(P), a competitive inhibitor of NAD(P)-requiring processes. 40 mu M 6-aminonicotinamide led to an inhibition of 6-phosphogluconate dehydrogenase and an accumulation of 6-phosphogluconate. A subsequent accumulation of the 6-phosphogluconate precursor 6-phosphoglucono-delta-lactone was observed in the C-13 NMR spectrum, These metabolites were shown to be intracellular, although a small amount of leakage of 6-phosphoglucono-delta-lactone occurred. The intracellular concentrations of 6-phosphogluconate and 6-phosphoglucono-delta-lactone were 1.9 +/- 0.8 mu mol/10(8) cells (+/- 1 standard deviation) and 0.8 +/- 0.4 mu mol/10(8) cells, respectively, after 15 h. Glucose utilization and lactate production were significantly inhibited by 6-aminonicotinamide (both p < 0.05), indicating inhibition of glycolysis, P-31 NMR data showed that phosphocreatine was significantly depleted in cells exposed to 6-aminonicotinamide (p < 0.05), Exposure of RLF-1 cells to 6-aminonicotinamide prior to 3- or 6-Gy x-irradiation induced a supra-additive cell kill, indicating that 6-aminonicotinamide is acting as a radiosensitizer. There was no effect of 6-aminonicotinamide alone or when the drug was given postradiation, suggesting that its mechanism of action may be by inhibition of radiation-induced repair.	MEM SLOAN KETTERING CANC CTR,DEPT RADIOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT MED,NEW YORK,NY 10021; BETH ISRAEL MED CTR,NEW YORK,NY 10003	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Harvard University; Beth Israel Deaconess Medical Center	Street, JC (corresponding author), MEM SLOAN KETTERING CANC CTR,DEPT MED PHYS,1275 YORK AVE,NEW YORK,NY 10021, USA.			Mahmood, Umar/0000-0001-7414-6123; Ballon, Douglas/0000-0002-7162-9020	NCI NIH HHS [P0 1 CA 25842] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA025842] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLON D, 1993, MAGNET RESON MED, V30, P754, DOI 10.1002/mrm.1910300615; BAUER HP, 1983, EUR J BIOCHEM, V133, P163, DOI 10.1111/j.1432-1033.1983.tb07442.x; BELL JD, 1993, BIOCHIM BIOPHYS ACTA, V1225, P71, DOI 10.1016/0925-4439(93)90124-J; BENHORIN H, 1995, CANCER RES, V55, P2814; BERGER NA, 1982, CANCER RES, V42, P4382; BHUJWALLA ZM, 1994, MAGNET RESON MED, V32, P303, DOI 10.1002/mrm.1910320305; BLAZER RM, 1980, J AM CHEM SOC, V102, P5082, DOI 10.1021/ja00535a045; BRODIE AF, 1955, J BIOL CHEM, V212, P677; COHEN SM, 1987, BIOCHEMISTRY-US, V26, P581, DOI 10.1021/bi00376a033; COPER H, 1964, BIOCHIM BIOPHYS ACTA, V82, P167, DOI 10.1016/0304-4165(64)90023-6; DIETRICH LS, 1958, J BIOL CHEM, V233, P964; DIETRICH LS, 1958, CANCER RES, V18, P1272; GALONS JP, 1990, INT J CANCER, V45, P168, DOI 10.1002/ijc.2910450130; HERTER FP, 1960, CANCER RES, V21, P31; HUNTING D, 1985, BIOCHEM PHARMACOL, V34, P3999, DOI 10.1016/0006-2952(85)90379-X; KAHANA SE, 1960, J BIOL CHEM, V235, P2178; KAUFFMAN FC, 1974, J NEUROBIOL, V5, P379, DOI 10.1002/neu.480050502; KENIRY MA, 1989, BIOCHEM BIOPH RES CO, V164, P947, DOI 10.1016/0006-291X(89)91550-7; KOHLER E, 1970, FEBS LETT, V6, P225, DOI 10.1016/0014-5793(70)80063-1; KUNNECKE B, 1993, NMR BIOMED, V6, P264, DOI 10.1002/nbm.1940060406; KUNNECKE B, 1991, BIOCHIM BIOPHYS ACTA, V1095, P103, DOI 10.1016/0167-4889(91)90071-5; LANGE K, 1970, N-S ARCH PHARMAKOL, V267, P177, DOI 10.1007/BF00999399; LEVINTOW L, 1961, ANNU REV BIOCHEM, V30, P605, DOI 10.1146/annurev.bi.30.070161.003133; LOWRY OH, 1964, J BIOL CHEM, V239, P18; MAHMOOD U, 1995, CANCER RES, V55, P1248; MALLOY CR, 1990, AM J PHYSIOL, V259, pH987, DOI 10.1152/ajpheart.1990.259.3.H987; MCCOMB RB, 1964, CANCER RES, V24, P198; MILLER WM, 1989, BIOTECHNOL BIOENG, V33, P477, DOI 10.1002/bit.260330413; NAVON G, 1989, FEBS LETT, V247, P86, DOI 10.1016/0014-5793(89)81246-3; NAVON G, 1977, P NATL ACAD SCI USA, V74, P87, DOI 10.1073/pnas.74.1.87; OFORINKANSAH N, 1972, N-S ARCH PHARMAKOL, V272, P156, DOI 10.1007/BF00508766; RADDA GK, 1986, SCIENCE, V233, P640, DOI 10.1126/science.3726553; REITZER LJ, 1980, J BIOL CHEM, V255, P5616; RHEINWALD JG, 1964, CELL, V2, P287; ROTHMAN DL, 1991, SCIENCE, V254, P573, DOI 10.1126/science.1948033; SHINKARENKO L, 1994, NMR BIOMED, V7, P209, DOI 10.1002/nbm.1940070503; SINGER S, 1993, CANCER RES, V53, P5808; SINGER S, 1993, SURG ONCOL, V2, P7, DOI 10.1016/0960-7404(93)90039-2; STOLFI RL, 1992, CANCER RES, V52, P4074; STREET JC, 1993, BIOCHEM J, V291, P485, DOI 10.1042/bj2910485; Varnes M E, 1988, NCI Monogr, P199; WARBURG O, 1930, METABOLISM TUMORS; [No title captured]	43	33	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4113	4119						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626749				2022-12-25	WOS:A1996TW96000027
J	Kurokawa, M; Tanaka, T; Tanaka, K; Ogawa, S; Mitani, K; Yazaki, Y; Hirai, H				Kurokawa, M; Tanaka, T; Tanaka, K; Ogawa, S; Mitani, K; Yazaki, Y; Hirai, H			Overexpression of the AML1 proto-oncoprotein in NIH3T3 cells leads to neoplastic transformation depending on the DNA-binding and transactivational potencies	ONCOGENE			English	Article						AML1; transformation; fibroblasts; DNA-binding; transactivational potencies	ACUTE MYELOID-LEUKEMIA; DROSOPHILA SEGMENTATION GENE; FUSION TRANSCRIPT; POLYOMAVIRUS ENHANCER; HEMATOPOIETIC-CELLS; ONCOGENIC ACTIVITY; NUCLEAR FACTOR; RUNT; EXPRESSION; RECEPTOR	The AML1 gene encodes DNA-binding proteins that contain the runt homology domain and is found at the breakpoints of t(8;21) and t(3;21) translocations associated with myelogenous leukemias. From the AML1 gene, two representative forms of proteins, AML1a and AML1b, are generated by alternative splicing. Both forms have the runt homology domain that possesses the DNA-binding ability but, unlike AML1b, AML1a lacks a putative transcriptional activation domain downstream of the runt homology domain. By using retroviral infection, we demonstrated that AML1b causes neoplastic transformation of NIH3T3 cells, AML1b-expressing cells form macroscopic colonies in soft agar and induce tumors in nude mice, indicating that AML1 can be a transforming gene when overexpressed in fibroblasts. Both the runt homology domain and the transactivational domain were required to transform NIH3T3 cells. By analysis of deletion mutants, it was shown that an element determining the transactivational potency exists between amino acids 288 and 396 within the region downstream of the runt homology domain. Furthermore, we demonstrated that this region was also required for fibroblast transformation, indicating that the transforming activity of AML1 is correlated with the transactivational potencies. These results suggest a role of AML1 in the regulation of cellular proliferation, as well as myeloid cell differentiation.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo			Tanaka, Tomoyuki U/A-4775-2008; Tanaka, Kozo/Y-6566-2018	Tanaka, Kozo/0000-0001-6086-2858				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DUFFY JB, 1991, GENE DEV, V5, P2176, DOI 10.1101/gad.5.12a.2176; DUFFY JB, 1991, DEVELOPMENT, V113, P1223; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; ERICKSON P, 1992, BLOOD, V80, P1825; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FURUKAWA K, 1990, CELL GROWTH DIFFER, V1, P135; GERGEN JP, 1988, GENE DEV, V2, P1179, DOI 10.1101/gad.2.9.1179; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P2090; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KOZU T, 1993, BLOOD, V82, P1270; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LU J, 1995, MOL CELL BIOL, V15, P1651; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1993, BLOOD, V81, P2728; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; PIERCE JH, 1990, P NATL ACAD SCI USA, V87, P5613, DOI 10.1073/pnas.87.15.5613; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SATAKE M, 1992, JPN J CANCER RES, V83, P714, DOI 10.1111/j.1349-7006.1992.tb01971.x; SATAKE M, 1988, ONCOGENE, V3, P69; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA K, 1995, BIOCHEM BIOPH RES CO, V211, P1023, DOI 10.1006/bbrc.1995.1913; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; TANAKA T, 1994, J BIOL CHEM, V269, P24020; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; ZHU XJ, 1994, MOL CELL BIOL, V14, P8051, DOI 10.1128/MCB.14.12.8051	54	59	60	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					883	892						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632911				2022-12-25	WOS:A1996TW68600020
J	Sakano, S; Takemura, H; Yamada, K; Imoto, K; Kaneko, M; Ohshika, H				Sakano, S; Takemura, H; Yamada, K; Imoto, K; Kaneko, M; Ohshika, H			Ca2+ mobilizing action of sphingosine in Jurkat human leukemia T cells - Evidence that sphingosine releases Ca2+ from inositol trisphosphate- and phosphatidic acid-sensitive intracellular stores through a mechanism independent of inositol trisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PAROTID ACINAR-CELLS; DIACYLGLYCEROL KINASE; CALCIUM RELEASE; SIGNAL-TRANSDUCTION; HUMAN NEUTROPHILS; ANTIGEN RECEPTOR; PLASMA-MEMBRANE; PHOSPHOLIPASE-D; CA-2+ POOL	Effects of sphingosine on Ca2+ mobilization in the human Jurkat T cell line mere examined. Sphingosine increased the cytoplasmic Ca2+ concentration ([Ca2+](i)) in a dose-dependent manner with an ED(50) of around 8 mu M. Sphingosine and OKT3, a CD3 monoclonal antibody, transiently increased [Ca2+](i), which declined to the resting level in the absence of extracellular Ca2+, Under the same conditions, pretreatment with sphingosine inhibited but did not abolish an increase in [Ca2+](i) induced by the subsequent addition of OKT3 and vice versa, However, pretreatment with sphingosine did not affect an increase in [Ca2+](i) induced by OKT3 in the presence of Ca2+. OKT3 increased IP3 formation, but sphingosine did not affect the level of IP3 by itself nor did it cause IP3 formation induced by OKT3, In permeabilized Jurkat cells, the addition of IP3 released Ca2+ from nonmitochondrial intracellular stores, but the addition of sphingosine did not. Sphingosine, stearylamine, and psychosine increased [Ca2+](i) and diacylglycerol (DG) kinase activation; however, ceramide did not, whereas sphingosine 1-phosphate slightly activated DG kinase without elevation of [Ca2+](i). Pretreatment with R59022, a DG kinase inhibitor, abolished the peak but did not affect the sustained response of [Ca2+](i) to sphingosine. Phosphatidic acid (PA) elevated [Ca2+](i), after which it declined to a resting level even in the presence of extracellular Ca2+. In accordance with this, PA did not stimulate Ca-45(2+) uptake into cells, but sphingosine and OKT3 did, Pretreatment with PA partially inhibited a rise in [Ca2+](i) induced by the subsequent addition of sphingosine and vice versa in the absence of extracellular Ca2+. Under similar conditions, pretreatment with PA affected an elevation of [Ca2+](i) induced by OKT3 less, after which the subsequent addition of sphingosine did not increase [Ca2+](i). In permeabilized Jurkat cells, the addition of IP3 did not release Ca2+, but PA did in the presence of heparin. Pretreatment with thapsigargin, a microsomal Ca2+-ATPase inhibitor, abolished the rises of [Ca2+](i) induced by the subsequent addition of sphingosine, OKT3, and PA in the absence of extracellular Ca2+. The present results suggest that at least two binds of intracellular Ca2+ stores exist in Jurkat cells, both of which are IP3- and PA-sensitive, and that sphingosine mobilizes Ca2+ from both stores in an IP3-independent manner, Furthermore, the IP3- but not the PA-sensitive intracellular Ca2+ store seems to regulate Ca2+ entry induced by sphingosine.	HOKKAIDO UNIV,SCH MED,DEPT PHARMACOL,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO UNIV,SCH MED,DEPT EMERGENCY & CRIT CARE MED,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO UNIV,SCH HLTH SCI,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University; Hokkaido University; Hokkaido University				Sakano, Shoji/0000-0003-2509-1917				ARNOLD RS, 1991, BIOCHEMISTRY-US, V30, P7747, DOI 10.1021/bi00245a011; AVIRAM A, 1990, CELL CALCIUM, V11, P269, DOI 10.1016/0143-4160(90)90003-D; BREITTMAYER JP, 1994, J BIOL CHEM, V269, P5054; BREITTMAYER JP, 1991, IMMUNOLOGY, V73, P134; CHAO CP, 1994, J BIOL CHEM, V269, P5849; CHOW SC, 1990, CELL CALCIUM, V11, P641, DOI 10.1016/0143-4160(90)90018-P; CHOW SC, 1990, J BIOL CHEM, V265, P902; CLEMENTI E, 1994, EUR J IMMUNOL, V24, P1365, DOI 10.1002/eji.1830240619; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DESAI NN, 1992, J BIOL CHEM, V267, P23122; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; GILLO B, 1993, BLOOD, V81, P783; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUSE AH, 1993, BIOCHEM J, V291, P447, DOI 10.1042/bj2910447; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; HANNUN YA, 1989, CLIN CHIM ACTA, V185, P333, DOI 10.1016/0009-8981(89)90224-6; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HASHIZUME T, 1992, BIOCHEM J, V282, P243, DOI 10.1042/bj2820243; HOYT DB, 1994, SHOCK, V2, P23, DOI 10.1097/00024382-199407000-00005; IMBODEN JB, 1985, J IMMUNOL, V134, P663; IMBODEN JB, 1987, BIOCHEM J, V247, P695, DOI 10.1042/bj2470695; JEFFERSON AB, 1988, J BIOL CHEM, V263, P15241; KIM MY, 1991, J BIOL CHEM, V266, P484; KIM S, 1995, J BIOL CHEM, V270, P5266, DOI 10.1074/jbc.270.10.5266; KISS Z, 1992, BIOCHEM J, V288, P853, DOI 10.1042/bj2880853; LAVIE Y, 1990, FEBS LETT, V277, P7, DOI 10.1016/0014-5793(90)80796-L; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LEMAITRE RN, 1990, BIOCHEM J, V266, P291, DOI 10.1042/bj2660291; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MCDONALD OB, 1991, J BIOL CHEM, V266, P21773; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; MULLMANN TJ, 1991, J BIOL CHEM, V266, P2013; NAARALA J, 1993, FEBS LETT, V330, P222, DOI 10.1016/0014-5793(93)80278-3; NATARAJAN V, 1994, AM J RESP CELL MOL, V11, P221, DOI 10.1165/ajrcmb.11.2.8049083; NG J, 1990, BIOCHIM BIOPHYS ACTA, V1053, P97, DOI 10.1016/0167-4889(90)90031-8; OISHI K, 1990, J BIOL CHEM, V265, P70; PARTISETI M, 1994, J BIOL CHEM, V269, P32327; PAWELCZYK T, 1992, ARCH BIOCHEM BIOPHYS, V297, P328, DOI 10.1016/0003-9861(92)90680-U; PREMACK BA, 1992, AM J PHYSIOL, V263, pC1119, DOI 10.1152/ajpcell.1992.263.6.C1119; PUSHKAREVA MY, 1992, J BIOL CHEM, V267, P15246; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RITCHIE T, 1992, BIOCHEM BIOPH RES CO, V186, P790, DOI 10.1016/0006-291X(92)90815-3; SABBADINI R, 1993, BIOCHEM BIOPH RES CO, V193, P752, DOI 10.1006/bbrc.1993.1689; SABBADINI RA, 1992, J BIOL CHEM, V267, P15475; SAKANE F, 1991, J BIOL CHEM, V266, P7096; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; SUGIYA H, 1991, FEBS LETT, V286, P113, DOI 10.1016/0014-5793(91)80953-Z; SUGIYA H, 1990, CELL CALCIUM, V11, P469, DOI 10.1016/0143-4160(90)90079-A; TAKEMURA H, 1995, LIFE SCI, V56, P1443, DOI 10.1016/0024-3205(95)00107-H; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TENG CM, 1994, THROMB HAEMOSTASIS, V71, P517; TORNQUIST K, 1994, BIOCHEM J, V299, P213, DOI 10.1042/bj2990213; WONG K, 1993, CELL CALCIUM, V14, P493, DOI 10.1016/0143-4160(93)90008-T; YAMADA K, 1993, BIOCHIM BIOPHYS ACTA, V1169, P217; YULE DI, 1993, J BIOL CHEM, V268, P12353; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	62	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11148	11155		10.1074/jbc.271.19.11148	http://dx.doi.org/10.1074/jbc.271.19.11148			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626660	hybrid			2022-12-25	WOS:A1996UJ94400020
J	Fominaya, J; Wels, W				Fominaya, J; Wels, W			Target cell-specific DNA transfer mediated by a chimeric multidomain protein - Novel non-viral gene delivery system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS EXOTOXIN; ERBB-2 RECEPTOR; ADENOVIRUS ENHANCEMENT; EXPRESSION; INVIVO; ENDOCYTOSIS; COMPLEXES; HEPATOCYTES; FRAGMENT; CARRIER	Based on the multidomain structure of the bacterial Pseudomonas exotoxin A, a recombinant fusion protein was constructed which serves as a target cell-specific carrier for the transfer of DNA via receptor-mediated endocytosis. The protein consists of three functional do mains: 1) an ErbB-2-specific single chain antibody confers target cell specificity, 2) the exotoxin A translocation domain facilitates endosome escape, and 3) a DNA binding domain derived from the yeast GAL4 protein enables sequence-specific high affinity binding to DNA. Carrier protein purified from bacterial lysates displayed both ErbB-2-specific and DNA sequence-specific binding in vitro., Complexes which formed spontaneously by the interaction of the fusion protein with a luciferase reporter gene construct carrying a GAL4-specific recognition sequence, after condensation of the DNA and compensation of excess negative charge with poly L-lysine were able to transfect ErbB-2-expressing cells in vitro in a cell specific manner. Transient expression of the luciferase gene driven by the SV40 early promoter was observed and correlates with the amount of carrier protein in the complex, Truncated forms of the carrier protein lacking either the cell recognition domain or the translocation domain failed to facilitate efficient DNA transfer.	INST EXPTL CANC RES,TUMOR BIOL CTR,D-79106 FREIBURG,GERMANY					Wels, Winfried/0000-0001-9858-3643				BAEZA I, 1987, BIOCHEMISTRY-US, V26, P6387, DOI 10.1021/bi00394a012; BLOOMFIELD VA, 1991, BIOPOLYMERS, V31, P1471, DOI 10.1002/bip.360311305; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSCHLE M, 1995, HUM GENE THER, V6, P753, DOI 10.1089/hum.1995.6.6-753; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CHEN J, 1994, HUM GENE THER, V5, P429, DOI 10.1089/hum.1994.5.4-429; CHEN JB, 1994, FEBS LETT, V338, P167, DOI 10.1016/0014-5793(94)80357-9; CHEN SY, 1995, GENE THER, V2, P116; CHOWDHURY NR, 1993, J BIOL CHEM, V268, P11265; COTTEN M, 1990, P NATL ACAD SCI USA, V87, P4033, DOI 10.1073/pnas.87.11.4033; COTTEN M, 1992, P NATL ACAD SCI USA, V89, P6094, DOI 10.1073/pnas.89.13.6094; Cotten Matt, 1993, Current Opinion in Biotechnology, V4, P705, DOI 10.1016/0958-1669(93)90053-Y; CRISTIANO RJ, 1993, P NATL ACAD SCI USA, V90, P2122, DOI 10.1073/pnas.90.6.2122; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; DONNELLY JJ, 1993, P NATL ACAD SCI USA, V90, P3530, DOI 10.1073/pnas.90.8.3530; FISHER KJ, 1994, BIOCHEM J, V299, P49, DOI 10.1042/bj2990049; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOUILLEUX F, 1991, NUCLEIC ACIDS RES, V19, P1563, DOI 10.1093/nar/19.7.1563; HARWERTH IM, 1992, J BIOL CHEM, V267, P15160; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; LEDLEY FD, 1995, HUM GENE THER, V6, P1129, DOI 10.1089/hum.1995.6.9-1129; MCKEE TD, 1994, BIOCONJUGATE CHEM, V5, P306, DOI 10.1021/bc00028a004; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MERWIN JR, 1994, BIOCONJUGATE CHEM, V5, P612, DOI 10.1021/bc00030a017; MICHAEL SI, 1994, GENE THER, V1, P223; MIDOUX P, 1993, NUCLEIC ACIDS RES, V21, P871, DOI 10.1093/nar/21.4.871; OGATA M, 1992, J BIOL CHEM, V267, P25396; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; PERALES JC, 1994, EUR J BIOCHEM, V226, P255, DOI 10.1111/j.1432-1033.1994.tb20049.x; PLANK C, 1994, J BIOL CHEM, V269, P12918; PLANK C, 1992, BIOCONJUGATE CHEM, V3, P533, DOI 10.1021/bc00018a012; PRIOR TI, 1991, CELL, V64, P1017, DOI 10.1016/0092-8674(91)90325-S; READ RJ, 1993, CURR OPIN STRUC BIOL, V3, P853, DOI 10.1016/0959-440X(93)90148-E; REMY JS, 1995, P NATL ACAD SCI USA, V92, P1744, DOI 10.1073/pnas.92.5.1744; ROSS GF, 1995, HUM GENE THER, V6, P31, DOI 10.1089/hum.1995.6.1-31; SEETHARAM S, 1991, J BIOL CHEM, V266, P17376; STANKOVICS J, 1994, HUM GENE THER, V5, P1095, DOI 10.1089/hum.1994.5.9-1095; TRUBETSKOY VS, 1992, BIOCONJUGATE CHEM, V3, P323, DOI 10.1021/bc00016a011; WAGNER E, 1991, P NATL ACAD SCI USA, V88, P4255, DOI 10.1073/pnas.88.10.4255; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P7934, DOI 10.1073/pnas.89.17.7934; WAGNER E, 1992, P NATL ACAD SCI USA, V89, P6099, DOI 10.1073/pnas.89.13.6099; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; WELS W, 1995, INT J CANCER, V60, P137, DOI 10.1002/ijc.2910600120; WELS W, 1992, BIO-TECHNOL, V10, P1128, DOI 10.1038/nbt1092-1128; WELS W, 1992, CANCER RES, V52, P6310; WILSON JM, 1992, J BIOL CHEM, V267, P963; WU GY, 1987, J BIOL CHEM, V262, P4429; WU GY, 1988, J BIOL CHEM, V263, P14621; WU GY, 1994, J BIOL CHEM, V269, P11542; WU GY, 1991, J BIOL CHEM, V266, P14338; YANG J, 1991, EMBO J, V10, P2291, DOI 10.1002/j.1460-2075.1991.tb07765.x; YIN WN, 1994, BIOCHEM BIOPH RES CO, V205, P826, DOI 10.1006/bbrc.1994.2739; ZENKE M, 1990, P NATL ACAD SCI USA, V87, P3655, DOI 10.1073/pnas.87.10.3655	56	118	150	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10560	10568		10.1074/jbc.271.18.10560	http://dx.doi.org/10.1074/jbc.271.18.10560			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631856	hybrid			2022-12-25	WOS:A1996UJ34200024
J	Xie, XQ; Melvin, LS; Makriyannis, A				Xie, XQ; Melvin, LS; Makriyannis, A			The conformational properties of the highly selective cannabinoid receptor ligand CP-55,940	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBIT ADENYLATE-CYCLASE; NUCLEIC-ACIDS; FORCE-FIELD; PROTEINS; SPECTROSCOPY; RESOLUTION; COSY	During a search for novel drugs possessing analgesic properties but devoid of the psychotropic effects of marijuana, a group of molecules designated as nonclassical cannabinoids was synthesized by Pfizer. Of these non classical cannabinoids CP-55,940 has received the most attention principally because it was used as the high affinity radioligand during the discovery and characterization of the G-protein-coupled cannabinoid receptor. In an effort to obtain information on the stereoelectronic requirements at the cannabinoid receptor active site, me have studied the conformational properties of CP-55,940 using a combination of solution NMR and computer modeling methods. Our data show that for the most energetically favored conformation, (i) the aromatic phenol ring is perpendicular to the cyclohexane ring, and the phenolic O-H bond is coplanar with the aromatic ring and points away from the cyclohexyl ring; ii) the dimethylheptyl chain adopts one of four preferred conformations in all of which the chain is almost perpendicular to the phenol ring; and iii) an intramolecular H-bond between the phenolic and hydroxypropyl groups allows all three hydroxyl groups of CP-55,940 to be oriented toward the upper face of the molecule. Such an orientation by the OH groups may be a characteristic requirement for cannabimimetic activity.	UNIV CONNECTICUT,SCH PHARM,DEPT PHARMACEUT SCI,STORRS,CT 06269; UNIV CONNECTICUT,INST SCI MAT,STORRS,CT 06269; MIT,FRANCIS BITTER NATL MAGNET LAB,CAMBRIDGE,MA 02139; PFIZER INC,CENT RES,GROTON,CT 06340	University of Connecticut; University of Connecticut; Massachusetts Institute of Technology (MIT); Pfizer			Makriyannis, Alexandros/GRF-1518-2022	Makriyannis, Alexandros/0000-0003-3272-3687	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007215, R01DA003801, R37DA003801] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-3801, DA-00152, DA-07215] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BAX A, 1986, J MAGN RESON, V67, P565, DOI 10.1016/0022-2364(86)90395-1; *BIOS INC, BIOS INS DISC VERS 2; BODENHAUSEN G, 1984, J MAGN RESON, V58, P370, DOI 10.1016/0022-2364(84)90142-2; Booth H., 1969, PROGR NMR SPECTROSCO, V5, P149; BOUABOULA M, 1993, EUR J BIOCHEM, V214, P173, DOI 10.1111/j.1432-1033.1993.tb17910.x; DEWEY WL, 1986, PHARMACOL REV, V38, P151; DIEHL P, 1972, NMR BASIC PRINCIPLES, P1; FESIK SW, 1989, COMPUTER AIDED DRUG, P56; HAGLER AT, 1985, SCIENCE, V227, P1309, DOI 10.1126/science.3975616; HERBETTE LG, 1994, DRUG DEVELOP RES, V33, P214, DOI 10.1002/ddr.430330305; HOWLETT AC, 1988, MOL PHARMACOL, V33, P297; HOWLETT AC, 1990, TRENDS NEUROSCI, V13, P420, DOI 10.1016/0166-2236(90)90124-S; HOWLETT AC, 1990, NEUROPHARMACOLOGY, V29, P161, DOI 10.1016/0028-3908(90)90056-W; Jeffrey G.A., 1991, HYDROGEN BONDING BIO, DOI [10.1007/ 978- 3- 642- 85135- 3, DOI 10.1007/978-3-642-85135-3, 10.1007/978-3-642-85135-3]; Johnson M.R., 1986, CANNABINOIDS THERAPE, P121; JOHNSON MR, 1981, J CLIN PHARMACOL, V21, P271; KAMINSKI NE, 1992, MOL PHARMACOL, V42, P736; KESSLER H, 1987, METHODS STEREOCHEMIC, V9, P153; KRIWACKI RW, 1989, MOL PHARMACOL, V35, P495; MAKRIYANNIS A, 1990, LIFE SCI, V47, P2173, DOI 10.1016/0024-3205(90)90147-J; MAKRIYANNIS A, 1995, CANNABINOID RECEPTOR, P87; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; Mechoulam R., 1986, CANNABINOIDS THERAPE, DOI [10.1201/9780429260667, DOI 10.1201/9780429260667]; MELVIN LS, 1984, J MED CHEM, V27, P67, DOI 10.1021/jm00367a013; MELVIN LS, 1996, IN PRESS MOL NEUROPH; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; ONDA M, 1988, B CHEM SOC JPN, V16, P4015; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; REGGIO PH, 1989, J MED CHEM, V32, P1630, DOI 10.1021/jm00127a038; REGGIO PH, 1987, J MOL STRUCT, V149, P331; RHODES DG, 1985, MOL PHARMACOL, V27, P612; ROSENQVIST E, 1975, ACTA CHEM SCAND B, VB 29, P379, DOI 10.3891/acta.chem.scand.29b-0379; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; XIE XQ, 1994, J MED CHEM, V37, P1418, DOI 10.1021/jm00036a006	35	49	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10640	10647		10.1074/jbc.271.18.10640	http://dx.doi.org/10.1074/jbc.271.18.10640			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631869	hybrid			2022-12-25	WOS:A1996UJ34200037
J	Boudreaux, JM; Towler, DA				Boudreaux, JM; Towler, DA			Synergistic induction of osteocalcin gene expression - Identification of a bipartite element conferring fibroblast growth factor 2 and cyclic AMP responsiveness in the rat osteocalcin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLAST PHENOTYPE; MC3T3-E1 CELLS; DIFFERENTIATION; PROLIFERATION; TRANSCRIPTION	Fibroblast growth factors (FGFs) are important regulators of calvarial osteoblast growth and differentiation. We have studied the regulation of the osteoblast-specific gene osteocalcin (OC) by FGF2 in phenotypically immature MC3T3-E1 calvarial osteoblastic cells. FGF2 markedly induces OC mRNA accumulation in MC3T3-E1 cells in She presence of forskolin (FSK). Similarly, OC promoter activity (luciferase reporter) is up-regulated 6-10-fold by FGF2/FSK or by FGF2/8-bromo cyclic AMP. Half-maximal induction of OC promoter activity occurs at 1 nM FGF2, By 5' deletion analysis and dinucleotide point mutations, we map one component of this FGF2/FSK response to a GCAGTCA motif in the region -144 to -138 relative to the OC transcription initiation site. The OC promoter region -154 to -90 confers FGF2/FSK responsiveness on the Rous sarcoma virus minimal promoter. By 3' and internal deletion analyses, the region between -90 to -99 is also found to be necessary for FGF2/FSK synergy (encodes a PuGGTCA motif previously identified as a component of FSK induction). A DNA binding activity that recognizes the region -148 to -125 of the rat OC promoter is induced in crude nuclear extracts from MC3T3-E1 cells treated with FGF2 or FGF2/FSK. This binding activity is sequence-specific and does not recognize the TCAGTCA DNA cognate of AP1. Members of the ATF, Fos, and Jun family are not immunologically detected in this inducible DNA binding activity. However, transient co-expression of ATF3 but not ATF2 selectively attenuates the FGF2 component of induction. Thus, a novel FGF2-regulated DNA-protein interaction in the OC promoter participates in the transcriptional control of OC expression by FGF and cyclic AMP in MC3T3-E1 calvarial osteoblasts.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)				Towler, Dwight/0000-0003-2107-7923				CHEN BPC, 1994, J BIOL CHEM, V269, P15819; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN MM, 1993, AM J MED GENET, V47, P581, DOI 10.1002/ajmg.1320470507; DEMAY MB, 1989, J BIOL CHEM, V264, P2279; DESBOIS C, 1994, J BIOL CHEM, V269, P1183; DUCY P, 1995, MOL CELL BIOL, V15, P1858; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235; FRANCESCHI RT, 1994, J BONE MINER RES, V9, P843; FRENKEL B, 1994, P NATL ACAD SCI USA, V91, P10923, DOI 10.1073/pnas.91.23.10923; GLOBUS RK, 1988, ENDOCRINOLOGY, V123, P98, DOI 10.1210/endo-123-1-98; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HOFFMANN HM, 1994, P NATL ACAD SCI USA, V91, P12887, DOI 10.1073/pnas.91.26.12887; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; HURLEY MM, 1993, J BIOL CHEM, V268, P5588; JABS EW, 1994, NAT GENET, V8, P275, DOI 10.1038/ng1194-275; KUDLA AJ, 1995, MOL CELL BIOL, V15, P3238; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LONG MW, 1995, J CLIN INVEST, V95, P881, DOI 10.1172/JCI117738; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; NAGAI H, 1993, GROWTH FACTORS, V9, P73; NAKAMURA T, 1995, ENDOCRINOLOGY, V136, P1276, DOI 10.1210/en.136.3.1276; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PITARU S, 1993, J BONE MINER RES, V8, P919; REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994-98; ROBEY PG, 1993, J BONE MINER RES, V8, P483; RODAN G A, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P85; RODAN SB, 1989, J BIOL CHEM, V264, P19934; SCHEDLICH LJ, 1994, J BONE MINER RES, V9, P143; STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; TAMURA M, 1994, J CELL BIOL, V126, P773, DOI 10.1083/jcb.126.3.773; TAN Y, 1994, MOL CELL BIOL, V14, P7546, DOI 10.1128/MCB.14.11.7546; TONG HS, 1994, J BONE MINER RES, V9, P577; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P1484, DOI 10.1210/me.8.11.1484; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; TOWLER DA, 1995, ENDOCRINOLOGY, V136, P1089, DOI 10.1210/en.136.3.1089; VERHEIJEN MHG, 1995, ENDOCRINOLOGY, V136, P3331, DOI 10.1210/en.136.8.3331	41	90	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7508	7515		10.1074/jbc.271.13.7508	http://dx.doi.org/10.1074/jbc.271.13.7508			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631781	hybrid			2022-12-25	WOS:A1996UC77400049
J	Krook, A; Moller, DE; Dib, K; ORahilly, S				Krook, A; Moller, DE; Dib, K; ORahilly, S			Two naturally occurring mutant insulin receptors phosphorylate insulin receptor substrate-1 (IRS-1) but fail to mediate the biological effects of insulin - Evidence that IRS-1 phosphorylation is not sufficient for normal insulin action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION; PROTEIN; ACTIVATION; MUTATIONS; CELLS; ASSOCIATION; RESISTANCE; 3'-KINASE	Two naturally occurring mutant insulin receptors, Arg-1174 --> Gln and Leu-1178 --> Pro, found in patients with dominantly inherited Type A insulin resistance, showed unusual signaling properties when stably expressed in Chinese hamster ovary (CHO) cells. Both mutant receptors were expressed on the cell surface and bound insulin normally, but showed markedly impaired autophosphorylation in response to insulin. In addition, the in vitro tyrosine kinase activity of both mutant receptors toward an artificial substrate was also severely impaired. Despite these defects of kinase activity, antiphosphotyrosine immunoblotting of whole cell lysates and anti-phosphotyrosine immunoprecipitation of P-32-labeled cells showed insulin-stimulated tyrosine phosphorylation of a protein of similar to 185 kDa to an extent comparable to that seen in CHO cells expressing wild-type human insulin receptors. Anti-insulin receptor substrate-1 (IRS-1) immunoprecipitation followed by antiphosphotyrosine immunoblotting confirmed that this tyrosine-phosphorylated protein was IRS-1. In contrast, CHO cells expressing an insulin receptor mutated at the ATP binding site (Lys-1030 --> Arg) showed no insulin-stimulated autophosphorylation or phosphorylation of IRS-1. Despite exhibiting apparently normal insulin stimulation of IRS-1 tyrosine-phosphorylation, cells expressing the Arg-1174 --> Gln or Pro-1178 --> Leu receptors showed marked impairment in insulin stimulation of glycogen synthesis, thymidine incorporation, and activation of MAP kinase. The inability of these mutant receptors to signal normally to metabolic and mitogenic responses suggests that insulin-stimulated tyrosine phosphorylation of IRS-1 alone is insufficient to fully mediate insulin action.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND; BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Krook, A (corresponding author), UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT MED,HILLS RD,CAMBRIDGE CB2 2QR,ENGLAND.		O'Rahilly, Stephen/ABF-6509-2020; Krook, Anna/K-1192-2015	O'Rahilly, Stephen/0000-0003-2199-4449; Krook, Anna/0000-0002-0891-0258	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045874] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45874] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission)		ACCILI D, 1995, 77 ANN M END SOC WAS; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BACKER JM, 1990, BIOCHEMISTRY-US, V30, P6366; CAMA A, 1992, J BIOL CHEM, V267, P8383; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; GUSTAFSON TA, 1995, DIABETES, V44, pA49; ISAKOFF SJ, 1995, DIABETES, V44, pA19; KAPELLER R, 1991, MOL ENDOCRINOL, V5, P769, DOI 10.1210/mend-5-6-769; KIM H, 1992, DIABETOLOGIA, V35, P261, DOI 10.1007/BF00400927; KROOK A, 1994, DIABETES, V43, P357, DOI 10.2337/diabetes.43.3.357; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MOLLER DE, 1990, J BIOL CHEM, V265, P14979; MOLLER DE, 1994, DIABETES, V43, P247, DOI 10.2337/diabetes.43.2.247; MORITZ W, 1994, FEBS LETT, V351, P276, DOI 10.1016/0014-5793(94)00876-0; MURKAMI MS, 1991, J BIOL CHEM, V266, P22653; OUWENS DM, 1994, J BIOL CHEM, V269, P33116; PATTI ME, 1995, DIABETES, V44, pA31; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SHOELSON SE, 1992, P NATL ACAD SCI USA, V89, P2027, DOI 10.1073/pnas.89.6.2027; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1995, DIABETES, V44, pA49; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TAYLOR SI, 1992, ENDOCR REV, V13, P566, DOI 10.1210/er.13.3.566; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1988, CELL, V54, P642; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAMOTOHONDA R, 1993, J BIOL CHEM, V268, P16859; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664	46	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7134	7140		10.1074/jbc.271.12.7134	http://dx.doi.org/10.1074/jbc.271.12.7134			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636149	hybrid			2022-12-25	WOS:A1996UB15700084
J	Maruyama, S; Kurosaki, T; Sada, K; Yamanashi, Y; Yamamoto, T; Yamamura, H				Maruyama, S; Kurosaki, T; Sada, K; Yamanashi, Y; Yamamoto, T; Yamamura, H			Physical and functional association of cortactin with Syk in human leukemic cell line K562	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ERYTHROID-DIFFERENTIATION; TYROSINE-PHOSPHORYLATION; GENE-EXPRESSION; HUMAN CARCINOMAS; SUBSTRATE; IDENTIFICATION; INDUCTION; ACTIVATION; GLOBIN	Human leukemic cell line K562 is induced to differentiate into the megakaryocytic lineage by stimulation with 12-O-tetradecanoylphorbol-18-acetate (TPA). We demonstrate here that TPA stimulation increases tyro sine phosphorylation of an 80-kDa protein at an early stage of megakaryocytic differentiation and that this 80-kDa protein is identical with cortactin. Since tyrosine kinase Syk, was activated by TPA stimulation, we examined the possibility that cortactin is a potential substrate of Syk in K562 cells. TPA-induced tyrosine phosphorylation of cortactin was decreased profoundly by overexpression of dominant-negative Syk. Furthermore, cortactin was associated with Syk even before TPA stimulation. Since cortactin was previously referred as an 80/85-kilodalton pp60(src) substrate, we examined the association between Src and cortactin, whereas its association could not be detected. These data suggest that Syk phosphorylates cortactin in K562 cells upon TPA treatment.	KOBE UNIV,SCH MED,DEPT BIOCHEM,CHUO KU,KOBE 650,JAPAN; FUKUI MED SCH,DEPT BIOCHEM,FUKUI 91011,JAPAN; UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN; AMER CYANAMID CO,LEDERLE LABS,DEPT CARDIOVASC MOLEC BIOL,PEARL RIVER,NY 10965; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510	Kobe University; University of Fukui; University of Tokyo; Yale University			Sada, Kiyonao/H-7373-2015; Kurosaki, Tomohiro/D-1306-2009	Sada, Kiyonao/0000-0001-6124-3100; Kurosaki, Tomohiro/0000-0002-6352-304X				ALITALO R, 1990, LEUKEMIA RES, V14, P501, DOI 10.1016/0145-2126(90)90002-Q; BARNEKOW A, 1986, EMBO J, V5, P701, DOI 10.1002/j.1460-2075.1986.tb04270.x; BENHAMOU LE, 1994, EUR J IMMUNOL, V24, P1993, DOI 10.1002/eji.1830240909; BINSPAHR KJ, 1990, J IMMUNOL, V145, P971; CHARNAY P, 1983, SCIENCE, V220, P1281, DOI 10.1126/science.6574602; COOPER JA, 1984, MOL CELL BIOL, V4, P30, DOI 10.1128/MCB.4.1.30; DEAN A, 1983, P NATL ACAD SCI-BIOL, V80, P5515, DOI 10.1073/pnas.80.18.5515; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; FILVAROFF E, 1990, MOL CELL BIOL, V10, P1164, DOI 10.1128/MCB.10.3.1164; FORCE T, 1991, J BIOL CHEM, V266, P6650; GILMORE T, 1983, NATURE, V306, P487, DOI 10.1038/306487a0; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; HOFFMAN R, 1991, CANCER CHEMOTH PHARM, V28, P102, DOI 10.1007/BF00689696; HONMA Y, 1989, CANCER RES, V49, P331; KATAGIRI K, 1993, J IMMUNOL, V150, P585; KATAYAMA N, 1989, BLOOD, V73, P123; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; Leary J F, 1987, J Biol Regul Homeost Agents, V1, P73; LI WQ, 1994, J BIOL CHEM, V269, P2349; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUISIDELUCA C, 1984, J CLIN INVEST, V74, P821, DOI 10.1172/JCI111498; MAA MC, 1992, ONCOGENE, V7, P2429; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; NAKAJIMA M, 1989, BIOCHEM BIOPH RES CO, V158, P958, DOI 10.1016/0006-291X(89)92815-5; ROWLEY PT, 1981, EXP HEMATOL, V9, P32; RUTHERFORD T, 1981, P NATL ACAD SCI-BIOL, V78, P348, DOI 10.1073/pnas.78.1.348; RUTHERFORD TR, 1979, NATURE, V280, P164, DOI 10.1038/280164a0; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1992, ONCOGENE, V7, P355; Siebert P D, 1985, Prog Clin Biol Res, V191, P233; SUTHERLAND JA, 1986, J BIOL RESP MODIF, V5, P250; TABILIO A, 1983, CANCER RES, V43, P4569; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TANIUCHI I, 1995, EMBO J, V14, P3664, DOI 10.1002/j.1460-2075.1995.tb00036.x; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7; TONKONOW BL, 1982, BLOOD, V59, P738; VAINCHENKER W, 1981, BLOOD CELLS, V7, P357; VILLEVAL JL, 1983, EXP CELL RES, V146, P428, DOI 10.1016/0014-4827(83)90145-3; WONG S, 1992, ONCOGENE, V7, P2407; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; YANAGI S, 1995, CELL SIGNAL, V7, P185, DOI 10.1016/0898-6568(94)00088-S; YEN A, 1993, CANCER RES, V53, P3085; YU G, 1989, J BIOL CHEM, V264, P10276; ZHAN X, 1994, J BIOL CHEM, V269, P20221	47	41	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6631	6635		10.1074/jbc.271.12.6631	http://dx.doi.org/10.1074/jbc.271.12.6631			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636079	hybrid			2022-12-25	WOS:A1996UB15700014
J	Coso, OA; Teramoto, H; Simonds, WF; Gutkind, JS				Coso, OA; Teramoto, H; Simonds, WF; Gutkind, JS			Signaling from G protein-coupled receptors to c-Jun kinase involves beta gamma subunits of heterotrimeric G proteins acting on a Ras and Rac1-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Stimulation of a variety of cell surface receptors enhances the enzymatic activity of mitogen-activated protein kinases (MAPKs). MAPKs have been classified in three subfamilies: extracellular signal-regulated kinases (ERKs), Stress-activated protein kinases or c-Jun NH2-terminal kinases (SAPKs/JNKs), and p38 kinase. Whereas the pathway linking cell surface receptors to ERKs has been partially elucidated, the mechanism of activation of JNKs is still poorly understood. Recently, we have shown that stimulation of G protein-coupled receptors can effectively induce JNK in NIH 3T3 cells (Coso, O. A., Chiariello, M., Kalinec, G., Kyriakis, J. M., Woodgett, J., and Gutkind, J. S. (1995) J. Biol. Chem. 270, 5620-5624). In the present study, we have used the transient expression in COS-7 cells of m1 and m2 muscarinic receptors (mAChRs) as a model system to study the signaling pathway linking G protein-coupled receptors to JNK. We show that stimulation of either muscarinic receptor subtype leads to JNK activation; however, this effect was not mimicked by expression of activated forms of alpha(s), alpha(i2), alpha(q), or alpha(13) G protein alpha subunits. In contrast, overexpression of G beta gamma subunits potently induced JNK activity. Furthermore, we show that signaling from mi and m2 mAChRs to JNK involves beta gamma subunits of heterotrimeric G proteins, acting on a Ras and Rac1-dependent pathway.	NIDR,CELLULAR DEV & ONCOL LAB,MOL SIGNALING UNIT,BETHESDA,MD 20892; NIDDK,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; 				ASHKENAZI A, 1989, TRENDS PHARMACOL SCI, P16; BARDWELL L, 1994, DEV BIOL, V166, P363, DOI 10.1006/dbio.1994.1323; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626	21	192	196	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					3963	3966						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626724				2022-12-25	WOS:A1996TW96000002
J	Margot, JB; Williams, DL				Margot, JB; Williams, DL			Estrogen induces the assembly of a multiprotein messenger ribonucleoprotein complex on the 3'-untranslated region of chicken apolipoprotein II mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERRIN RECEPTOR EXPRESSION; RNA-BINDING-PROTEIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; POLYPEPTIDE-CHAIN ELONGATION; 3' UNTRANSLATED REGION; YOLK PRECURSOR PROTEIN; AVIAN LIVER; TRANSLATIONAL CONTROL; NUCLEOTIDE-SEQUENCE; TISSUE DISTRIBUTION	UV cross-linking was used to identify estrogen-induced hepatocyte proteins that bind to apoII mRNA. Probes spanning the entire message revealed the pres ence of eight estrogen-induced proteins cross-linked to the 3'-untranslated region (UTR), but not to the coding region or the 5'-UTR. Two estrogen-induced proteins of 132 and 50 kDa were either absent or barely detectable in control animals, whereas six additional proteins of 93, 83, 74, 65, 58, and 45 kDa were clearly present in control animals and increased 2-5-fold by estrogen. A similar profile of estrogen-induced proteins was seen with the 3'-UTRs of the estrogen-regulated mRNAs for apoB and vitellogenin II, but not with the 3'-UTRs of the non-estrogen regulated mRNAs for apoA-I and glyceraldehyde-phosphate dehydrogenase. These findings indicate that the estrogen-induced proteins discriminate among mRNAs and suggest that they interact selectively with the family of estrogen-regulated mRNAs. The estrogen-induced proteins are found in the cytoplasmic fraction of liver extracts, and a subset of them are also found in adrenal glands, testes, heart, brain, and kidneys, but they are estrogen induced only in the liver. Deletion analysis defined a 150-nucleotide region of the apoII 3'-UTR that is necessary for maximal binding of the estrogen-induced proteins. An internal deletion of endonucleolytic cleavage sites previously identified within the apoII 3'-UTR selectively reduced the binding of the 58-kDa protein. These findings reveal remarkable complexity in estrogen-stimulated protein-RNA interactions within the 3'-UTRs of estrogen-regulated mRNAs. These proteins may participate in the mRNA degradation process or in other aspects of cytoplasmic mRNA metabolism that accompany estrogen-stimulated vitellogenesis.	SUNY STONY BROOK, HLTH SCI CTR, DEPT PHARMACOL SCI, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NIDDK NIH HHS [DK 18171] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018171, R37DK018171] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALNAVE D, 1974, J ENDOCRINOL, V61, P29, DOI 10.1677/joe.0.0610029; BAST RE, 1977, P NATL ACAD SCI USA, V74, P3133, DOI 10.1073/pnas.74.8.3133; BERGINK EW, 1974, AM ZOOL, V14, P1177; BETTANY AJE, 1992, J BIOL CHEM, V267, P16531; BICKEL M, 1992, P NATL ACAD SCI USA, V89, P10001, DOI 10.1073/pnas.89.21.10001; BINDER R, 1989, J BIOL CHEM, V264, P16910; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BRAWERMAN G, 1993, CONTROL MESSENGER RN; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BROCK ML, 1983, CELL, V34, P207, DOI 10.1016/0092-8674(83)90151-4; COCHRANE AW, 1984, J BIOL CHEM, V259, P5408; COOK JS, 1986, P NATL ACAD SCI USA, V83, P7583, DOI 10.1073/pnas.83.20.7583; DASHTI N, 1983, J LIPID RES, V24, P368; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DODSON RE, 1994, MOL CELL BIOL, V14, P3130, DOI 10.1128/MCB.14.5.3130; DOMPENCIEL RE, 1995, J BIOL CHEM, V270, P6108, DOI 10.1074/jbc.270.11.6108; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GAVIS ER, 1994, NATURE, V369, P315, DOI 10.1038/369315a0; GEHRKE L, 1981, J BIOL CHEM, V256, P2514; GEHRKE L, 1981, J BIOL CHEM, V256, P2522; GORDON DA, 1988, J BIOL CHEM, V263, P2625; GOTTLIEB E, 1992, P NATL ACAD SCI USA, V89, P7164, DOI 10.1073/pnas.89.15.7164; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; HARFORD JB, 1990, ENZYME, V44, P28, DOI 10.1159/000468745; HUARTE J, 1987, GENE DEV, V1, P1201, DOI 10.1101/gad.1.10.1201; HWANG SPL, 1989, J BIOL CHEM, V264, P8410; KIRCHGESSNER TG, 1987, GENE, V59, P241, DOI 10.1016/0378-1119(87)90332-5; KISLAUSKIS EH, 1994, J CELL BIOL, V127, P441, DOI 10.1083/jcb.127.2.441; KUDZMA DJ, 1975, J LIPID RES, V16, P123; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; LIANG HM, 1991, NUCLEIC ACIDS RES, V19, P2289, DOI 10.1093/nar/19.9.2289; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MANNING R, 1989, INT J BIOCHEM, V21, P517, DOI 10.1016/0020-711X(89)90131-6; MARGOT JB, 1989, MOL ENDOCRINOL, V3, P1053, DOI 10.1210/mend-3-7-1053; NACHALIEL N, 1993, J BIOL CHEM, V268, P24203; NIELSEN DA, 1990, MOL ENDOCRINOL, V4, P953, DOI 10.1210/mend-4-7-953; PALMITER RD, 1974, P NATL ACAD SCI USA, V71, P2357, DOI 10.1073/pnas.71.6.2357; PANDEY NB, 1991, NUCLEIC ACIDS RES, V19, P5653, DOI 10.1093/nar/19.20.5653; PARIS J, 1990, MOL CELL BIOL, V10, P5634, DOI 10.1128/MCB.10.11.5634; RAJAVASHISTH TB, 1987, J BIOL CHEM, V262, P7058; RATNASABAPATHY R, 1990, J BIOL CHEM, V265, P14050; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; Sambrook J, 1989, MOL CLONING LABORATO; SCHJEIDE OA, 1963, AM ZOOL, V3, P167; SCHJEIDE OA, 1970, CELL DIFFER, P447; SHEETS MD, 1994, GENE DEV, V8, P926, DOI 10.1101/gad.8.8.926; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; VANHETSCHIP FD, 1987, J MOL BIOL, V196, P245, DOI 10.1016/0022-2836(87)90688-7; WANG XM, 1995, MOL CELL BIOL, V15, P1769; WILLIAMS DL, 1993, CONTROL MESSENGER RN, P161; WISKOCIL R, 1980, P NATL ACAD SCI-BIOL, V77, P4474, DOI 10.1073/pnas.77.8.4474; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; ZUKER M, 1989, METHOD ENZYMOL, V180, P262	55	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4452	4460						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626798				2022-12-25	WOS:A1996TW96000076
J	Zhang, Y; Wang, ZG; Ravid, K				Zhang, Y; Wang, ZG; Ravid, K			The cell cycle in polyploid megakaryocytes is associated with reduced activity of cyclin B1-dependent Cdc2 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET FACTOR-IV; PROTEIN-KINASE; HEMATOPOIETIC-CELLS; G1-SPECIFIC CYCLINS; HUMAN FIBROBLASTS; MESSENGER-RNA; G1 PHASE; EXPRESSION; LINE; LEUKEMIA	The platelet precursor, the megakaryocyte, matures to a polyploid cell as a result of DNA replication in the absence of mitosis (endomitosis). The factors controlling endomitosis are accessible to analysis in our megakaryocytic cell line, MegT, generated by targeted expression of temperature-sensitive simian virus 40 large T antigen to megakaryocytes of transgenic mice. We aimed to define whether endomitosis consists of a continuous phase of DNA synthesis (S) or of S phases interrupted by gaps. Analysis of the cell cycle in MegT cells revealed that, upon inactivation of large T antigen, the cells shifted from a mitotic cell cycle to an endomitotic cell cycle consisting of S/Gap phases. The level of the G(1)/S cyclin, cyclin A, as well as of the G, phase cyclin, cyclin D3, were elevated at the onset of DNA synthesis, either in MegT cells undergoing a mitotic cell cycle or during endomitosis. In contrast, the level of the mitotic cyclin, cyclin B1, cycled in cells displaying a mitotic cell cycle while not detectable during endomitosis. Comparable levels of the mitotic kinase protein, Cdc2, were detected during the mitotic cell cycle or during endomitosis; however, cyclin B1-dependent Cdc2 kinase activity was largely abolished in the polyploid cells. Fibroblasts immortalized with the same heat-labile oncogene do not display reduced levels of cyclin B1 upon shifting to high temperature nor do they become polyploid, indicating that reduced levels of cyclin B1 is a property of megakaryocytes and not of the T-antigen mutant. We conclude that cellular programming during endoreduplication in megakaryocytes is associated with reduced levels of cyclin B1.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Boston University				Ravid, Katya/0000-0002-9918-3024	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053080] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53080-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI M, 1991, EXP HEMATOL, V19, P923; AKIYAMA N, 1993, BIOCHEM BIOPH RES CO, V195, P1041, DOI 10.1006/bbrc.1993.2149; BARTLETT R, 1990, BIOESSAYS, V10, P457; CHANG MS, 1995, J BIOL CHEM, V270, P511, DOI 10.1074/jbc.270.2.511; CHAPMAN DL, 1993, DEVELOPMENT, V118, P229; CHAPMAN DL, 1992, MOL REPROD DEV, V33, P259, DOI 10.1002/mrd.1080330305; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; GREENBERG SM, 1988, BLOOD, V72, P1968; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HUBBARDSMITH K, 1992, MOL CELL BIOL, V12, P2273, DOI 10.1128/MCB.12.5.2273; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KUBIAK JZ, 1993, EMBO J, V12, P3773, DOI 10.1002/j.1460-2075.1993.tb06055.x; KUTER DJ, 1994, P NATL ACAD SCI USA, V91, P11104, DOI 10.1073/pnas.91.23.11104; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; NASMYTH KA, 1990, CELL, V63, P1117, DOI 10.1016/0092-8674(90)90404-3; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; ODELL TT, 1968, EXP CELL RES, V53, P321, DOI 10.1016/0014-4827(68)90302-9; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RAVID K, 1993, BLOOD, V81, P2885; RAVID K, 1993, J CELL BIOL, V123, P1545, DOI 10.1083/jcb.123.6.1545; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; ROBINSON MO, 1994, P NATL ACAD SCI USA, V91, P12798, DOI 10.1073/pnas.91.26.12798; ROVOLIC Z, 1974, PLATELETS PRODUCTION, P143; SAMEJIMA I, 1994, MOL CELL BIOL, V14, P6361, DOI 10.1128/MCB.14.9.6361; SCHULTZ SJ, 1993, CELL GROWTH DIFFER, V4, P821; SLEDGE GW, 1986, CANCER RES, V46, P2155; SMITH AV, 1991, DEVELOPMENT, V112, P997; SUDA T, 1983, P NATL ACAD SCI-BIOL, V80, P6689, DOI 10.1073/pnas.80.21.6689; TABILIO A, 1983, CANCER RES, V43, P4569; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; WENDLING F, 1994, NATURE, V369, P571, DOI 10.1038/369571a0; WESTENDORF JM, 1989, J CELL BIOL, V108, P1431, DOI 10.1083/jcb.108.4.1431; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	46	96	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4266	4272						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626773				2022-12-25	WOS:A1996TW96000051
J	Martire, G; Mottola, G; Pascale, MC; Malagolini, N; Turrini, I; SerafiniCessi, F; Jackson, MR; Bonatti, S				Martire, G; Mottola, G; Pascale, MC; Malagolini, N; Turrini, I; SerafiniCessi, F; Jackson, MR; Bonatti, S			Different fate of a single reporter protein containing KDEL or KKXX targeting signals stably expressed in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUMINAL ER PROTEINS; HUMAN CD8 GLYCOPROTEIN; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE PROTEINS; INTERMEDIATE COMPARTMENT; DISULFIDE-ISOMERASE; MEMBRANE-PROTEINS; SECRETORY PATHWAY; PLASMA-MEMBRANE; GOLGI-COMPLEX	In mammalian cells, resident luminal and type I transmembrane proteins of the endoplasmic reticulum usually contain KDEL and KKXX at the carboxyl terminus. These sequences induce retrieval hom compartments located downstream in the secretory pathway. It has been suggested that the retrieval may occur from multiple sites, ranging from the intermediate compartment to the trans-Golgi network. To compare the retrieval of luminal and type I membrane proteins, we have used different forms of a single reporter, the human CD8 glycoprotein, stably expressed in FRT cells. Metabolic labeling and oligosaccharide analysis show that the mechanism based on the KDEL signal is leaky. With time, the KDEL-containing CD8 form reaches the trans/trans-Golgi network compartments, where the protein is terminally glycosylated. At this stage, the retrieval mechanism stops being effective and the protein is consequently secreted. Conversely, the mechanism based on the KKXX signal guarantees that most of the KKXX-containing CD8 form resides in the endoplasmic reticulum, little in the Golgi complex and undetectable levels at the plasma membrane. The O-glycosylation of this protein comprises for the vast majority the sole addition of peptide-bound GalNAc that occurs in an early Golgi compartment.	UNIV NAPLES FEDERICO II, DIPARTIMENTO BIOCHIM & BIOTECNOL MED, I-80131 NAPLES, ITALY; UNIV BOLOGNA, DIPARTIMENTO PATOL SPERIMENTALE, I-40126 BOLOGNA, ITALY; RW JOHNSON PHARMACEUT RES INST, SAN DIEGO, CA 92121 USA	University of Naples Federico II; University of Bologna; Johnson & Johnson; Johnson & Johnson USA			Pascale, Maria/B-4273-2012; Mottola, Giovanna/Y-7540-2019	Mottola, Giovanna/0000-0002-7541-0472				BONATTI S, 1989, J BIOL CHEM, V264, P12590; BROCKHAUSEN I, 1985, BIOCHEMISTRY-US, V24, P1866, DOI 10.1021/bi00329a010; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DAHLLOF B, 1991, J BIOL CHEM, V266, P1804; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; GRIFFITHS G, 1994, J CELL BIOL, V127, P1557, DOI 10.1083/jcb.127.6.1557; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; LEAHY DJ, 1992, CELL, V68, P1145, DOI 10.1016/0092-8674(92)90085-Q; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; LOTTI LV, 1992, J CELL BIOL, V118, P43, DOI 10.1083/jcb.118.1.43; MALAGOLINI N, 1994, GLYCOCONJUGATE J, V11, P89, DOI 10.1007/BF00731148; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MIESENBOCK G, 1995, J CELL BIOL, V129, P309, DOI 10.1083/jcb.129.2.309; MIGLIACCIO G, 1989, EXP CELL RES, V185, P203, DOI 10.1016/0014-4827(89)90049-9; MIGLIACCIO G, 1990, EUR J CELL BIOL, V52, P291; MIGLIACCIO G, 1992, J CELL BIOL, V117, P15, DOI 10.1083/jcb.117.1.15; MOREMEN KW, 1985, J BIOL CHEM, V260, P6654; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NITSCH L, 1985, EUR J CELL BIOL, V38, P57; PASCALE MC, 1992, J BIOL CHEM, V267, P9940; PASCALE MC, 1992, J BIOL CHEM, V267, P25196; PELHAM H R B, 1991, Current Opinion in Cell Biology, V3, P585, DOI 10.1016/0955-0674(91)90027-V; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; PELHAM HRB, 1988, EMBO J, V7, P1757, DOI 10.1002/j.1460-2075.1988.tb03005.x; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PEREZVILAR J, 1991, J BIOL CHEM, V266, P23967; PETER F, 1992, J BIOL CHEM, V267, P10631; PILLER V, 1990, J BIOL CHEM, V265, P9264; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; SARASTE J, 1991, J CELL SCI, V100, P415; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SCHWEIZER A, 1993, J CELL SCI, V104, P671; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SERAFINICESSI F, 1995, ADV EXP MED BIOL, V376, P135; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; TAKEMOTO H, 1992, ARCH BIOCHEM BIOPHYS, V296, P129, DOI 10.1016/0003-9861(92)90554-A; TANG BL, 1994, EUR J CELL BIOL, V65, P298; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; TOWNSLEY FM, 1994, EUR J CELL BIOL, V64, P211; TOWNSLEY FM, 1993, EMBO J, V12, P2821, DOI 10.1002/j.1460-2075.1993.tb05943.x; VASSARD C, 1995, GLYCOCONJ J, V12, P447; VERDE V, 1995, EUR J CELL BIOL, V67, P267; ZAGOURAS P, 1989, J CELL BIOL, V109, P2633, DOI 10.1083/jcb.109.6.2633	56	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3541	3547						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8631959				2022-12-25	WOS:A1996TV72400033
J	Matsuda, S; Nakanishi, H; Sasaki, T; Takai, Y				Matsuda, S; Nakanishi, H; Sasaki, T; Takai, Y			A membrane-associated GDP/GTP exchange protein specific for Rho small GTP-binding protein - Partial purification and characterization from rat brain	ONCOGENE			English	Article						small G protein; Rho; mRho GEP; Rho GDI; dbl	SWISS 3T3 CELLS; ADP-RIBOSYLATION; CLOSTRIDIUM-BOTULINUM; REGULATORY PROTEIN; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; ONCOGENE PRODUCT; DBL ONCOGENE; SMG P21S; GDP	The Rho subfamily, consisting of three members (RhoA, -B and -C), belongs to the small GTP-binding protein superfamily. The Rho subfamily is implicated in regulation of various actin filament-dependent cell functions, such as cell aggregation, cell motility and cytokinesis. The Rho subfamily receives an upstream signal and is converted from the GDP-bound inactive form to the GTP-bound active form which transduces a signal to a downstream pathway. This conversion is regulated by GDP/GTP exchange proteins (GEPs) and several GEPs for the Rho subfamily have been identified. The GEPs thus far reported are mainly isolated from the cytosol fraction of various tissues and are not specific for the Rho subfamily. Here we have partially purified a membrane-associated GEP specific for the Rho subfamily (mRho GEP). mRho GEP was extracted from the crude synaptic membrane fraction of rat brain by a combination of detergent and NaCl, and partially purified by several column chromatographies. The partially purified mRho GEP was active on RhoA but was inactive on other small GTP-binding proteins including at least Rad, Ki-Ras and Rab3A. RhoA undergoes post-translational lipid modifications and mRho GEP required these lipid modifications for its GEP activity. mRho GEP was not active in the presence of Rho GDI, an inhibitory Rho GEP. These results indicate that there is a membrane-associated GEP specific for Rho and suggest that Rho is activated by this GEP on the membranes.	OSAKA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,SUITA,OSAKA 565,JAPAN; NATL INST PHYSIOL SCI,DEPT CELL PHYSIOL,OKAZAKI,AICHI 444,JAPAN	Osaka University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)				Nakanishi, Hiroyuki/0000-0002-9765-0266				BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GRAZIANI G, 1989, ONCOGENE, V4, P823; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HARIHARAN IK, 1995, EMBO J, V14, P292, DOI 10.1002/j.1460-2075.1995.tb07003.x; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HORI Y, 1991, ONCOGENE, V6, P515; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; ISOMURA M, 1990, BIOCHEM BIOPH RES CO, V169, P652, DOI 10.1016/0006-291X(90)90380-6; ISOMURA M, 1991, ONCOGENE, V6, P119; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KATAYAMA M, 1991, J BIOL CHEM, V266, P12639; KIKUCHI A, 1992, ONCOGENE, V7, P289; KIKUCHI A, 1995, METHOD ENZYMOL, V257, P57; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LANG P, 1992, J BIOL CHEM, V267, P11677; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIURA Y, 1993, J BIOL CHEM, V268, P510; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MORII N, 1992, J BIOL CHEM, V267, P20921; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NONAKA H, 1995, IN PRESS EMBO J; NORMAN JC, 1994, J CELL BIOL, V126, P1005, DOI 10.1083/jcb.126.4.1005; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SELF AJ, 1993, ONCOGENE, V8, P655; SHIMIZU K, 1991, BIOCHEM BIOPH RES CO, V175, P199, DOI 10.1016/S0006-291X(05)81220-3; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; STASIA MJ, 1991, BIOCHEM BIOPH RES CO, V180, P615, DOI 10.1016/S0006-291X(05)81110-6; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; TAKAISHI K, 1995, ONCOGENE, V11, P39; TANAKA K, 1995, METHOD ENZYMOL, V256, P41; TOKSOZ D, 1994, ONCOGENE, V9, P621; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; UEDA T, 1990, J BIOL CHEM, V265, P9373; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	60	3	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					915	920						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632914				2022-12-25	WOS:A1996TW68600023
J	Beck, G; Cardinale, S; Wang, L; Reiner, M; Sugumaran, M				Beck, G; Cardinale, S; Wang, L; Reiner, M; Sugumaran, M			Characterization of a defense complex consisting of interleukin 1 and phenol oxidase from the hemolymph of the tobacco hornworm, Manduca sexta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPHENOLOXIDASE ACTIVATION; QUINONE METHIDE; PURIFICATION; ALPHA-2-MACROGLOBULIN; MACROGLOBULIN; RECOGNITION; CYTOKINES; IMMUNITY; INSECTS; PROTEIN	Hemolymph of fifth instar Manduca sexta larvae collected under non-sterile conditions exhibited the presence of a novel high molecular weight protein complex, which was absent from the hemolymph collected aseptically. The high molecular weight complex consisted of, at least, prophenol oxidase, phenol oxidase, and an interleukin 1-like molecule, thereby demonstrating the generation of this complex as a consequence of a host defense response. While the native phenol oxidase and the interleukin 1-like molecule possessed molecular weights of about 80,000 and 17,000, respectively, the complex had a molecular weight of about 400,000. Apart from prophenol oxidase, phenol oxidase, and interleukin 1, dopachrome isomerase and other, as of yet unidentified, proteins may be part of the complex as judged by the presence of additional bands observed during SDS-polyacrylamide gel electrophoresis. The significance of the assembly of this defense complex for insect host defense strategies is discussed.			Beck, G (corresponding author), UNIV MASSACHUSETTS,DEPT BIOL,100 MORRISSEY BLVD,BOSTON,MA 02125, USA.		Beck, Gregory/Q-2772-2019	Beck, Gregory/0000-0003-4076-1077	NIAID NIH HHS [R01 AI 14753] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI014753] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ashida M., 1990, P239; BECK G, 1991, MOL IMMUNOL, V28, P577, DOI 10.1016/0161-5890(91)90126-5; BECK G, 1991, IMMUNOL TODAY, V12, P180, DOI 10.1016/0167-5699(91)90049-Y; BELL RA, 1976, ANN ENTOMOL SOC AM, V69, P365, DOI 10.1093/aesa/69.2.365; BORTH W, 1989, J BIOL CHEM, V264, P5818; COCIANCICH S, 1994, PARASITOL TODAY, V10, P132, DOI 10.1016/0169-4758(94)90260-7; DINARELLO CA, 1985, J CLIN IMMUNOL, V5, P287, DOI 10.1007/BF00918247; DUNN PE, 1990, BIOSCIENCE, V40, P738, DOI 10.2307/1311506; GUPTA AP, 1988, HEMOCYTIC HUMORAL IM; HALL M, 1995, P NATL ACAD SCI USA, V92, P7764, DOI 10.1073/pnas.92.17.7764; JAMES K, 1990, IMMUNOL TODAY, V11, P163, DOI 10.1016/0167-5699(90)90067-J; JAMES K, 1980, TRENDS BIOCHEM SCI, V5, P43, DOI 10.1016/S0968-0004(80)80094-6; KATONA LI, 1992, INFECT IMMUN, V60, P4995, DOI 10.1128/IAI.60.12.4995-5003.1992; NAPPI AJ, 1993, INSECT IMMUNITY, P131; NELLAIAPPAN K, 1994, ANAL BIOCHEM, V220, P122, DOI 10.1006/abio.1994.1307; NELLAIAPPAN K, 1986, STAIN TECHNOL, V61, P269, DOI 10.3109/10520298609109952; OBRIEN PJ, 1991, CHEM-BIOL INTERACT, V80, P1, DOI 10.1016/0009-2797(91)90029-7; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; RAMESH N, 1988, J BIOL CHEM, V263, P11523; RATCLIFFE NA, 1984, SCIENCE, V226, P557, DOI 10.1126/science.226.4674.557; SAUL SJ, 1989, FEBS LETT, V249, P155, DOI 10.1016/0014-5793(89)80614-3; SAUL SJ, 1987, ARCH INSECT BIOCHEM, V5, P1, DOI 10.1002/arch.940050102; SODERHALL K, 1982, DEV COMP IMMUNOL, V6, P601; Sottrup-Jensen L., 1987, PLASMA PROTEINS, V5, P191; SUGUMARAN M, 1990, UCLA SYM BI, V121, P47; SUGUMARAN M, 1991, J BIOL CHEM, V266, P6073; SUGUMARAN M, 1991, BIOCHEM BIOPH RES CO, V176, P1371, DOI 10.1016/0006-291X(91)90438-D; SUGUMARAN M, 1987, ARCH INSECT BIOCHEM, V6, P9, DOI 10.1002/arch.940060103; SUGUMARAN M, 1993, PARASITES PATHOGENS, V1, P317; SUN S, 1990, SCIENCE, V259, P1729	30	41	44	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11035	11038		10.1074/jbc.271.19.11035	http://dx.doi.org/10.1074/jbc.271.19.11035			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626641	hybrid			2022-12-25	WOS:A1996UJ94400001
J	Dodd, IB; Egan, JB				Dodd, IB; Egan, JB			DNA binding by the coliphage 186 repressor protein CI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LATE CONTROL GENE; TEMPERATE COLIPHAGE-186; EXPRESSION; TRANSCRIPTION; SEQUENCE; REPLICATION; LYSOGENY; SWITCH; REGION	The cI gene of coliphage 186 maintains lysogeny and confers immunity to 186 infection by repressing the major early promoter, p(R), and the promoter for the late transcription activator gene, p(B). Gel mobility shift and DNase I footprinting show that CI protein binds to the DNA at p(R) and p(B) and also to sites similar to 300 base pairs upstream and downstream of p(R), called FL and FR. Mutations which cause virulence reduce CI binding to p(R). The biochemical and genetic data identify three CI operators at p(R), two at p(B), and single operators at FL and FR. The operators at the p(B), FL, FR, and central p(R) sites are inverted repeat sequences, separated by 5 base pairs (Type A) or, in the case of p(R), by 4 base pairs (Type A'). A different inverted repeat operator sequence (Type B) is proposed for the binding sites on each side of the central site at p(R). Thus, CI appears to recognize two distinct DNA sequences. CI binds cooperatively to adjacent operators, and binding at p(R) is strongly dependent on these cooperative interactions. A high order CI multimer appears to be the active DNA binding species, even at single operators.	UNIV ADELAIDE,DEPT BIOCHEM,ADELAIDE,SA 5005,AUSTRALIA	University of Adelaide				Dodd, Ian/0000-0003-2969-6841				Bertani LE, 1988, BACTERIOPHAGES, V2, P73; CARLSON NG, 1993, J MOL BIOL, V230, P1108, DOI 10.1006/jmbi.1993.1229; DEVARGAS LM, 1988, CELL, V54, P923, DOI 10.1016/0092-8674(88)90107-9; DIBBENS JA, 1992, MOL MICROBIOL, V6, P2629, DOI 10.1111/j.1365-2958.1992.tb01440.x; DIBBENS JA, 1992, MOL MICROBIOL, V6, P2643, DOI 10.1111/j.1365-2958.1992.tb01441.x; DODD IB, 1993, MOL MICROBIOL, V10, P1139, DOI 10.1111/j.1365-2958.1993.tb00983.x; DODD IB, 1990, J MOL BIOL, V214, P27, DOI 10.1016/0022-2836(90)90144-B; DODD IB, 1993, CONTROL LYSIS LYSOGE; DREW HR, 1984, J MOL BIOL, V176, P535, DOI 10.1016/0022-2836(84)90176-1; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; EUSTANCE RJ, 1994, J MOL BIOL, V242, P330; JOHNSON AD, 1981, NATURE, V294, P217, DOI 10.1038/294217a0; KALIONIS B, 1986, J MOL BIOL, V191, P211, DOI 10.1016/0022-2836(86)90258-5; KALIONIS B, 1986, J MOL BIOL, V191, P199, DOI 10.1016/0022-2836(86)90257-3; LAMONT I, 1989, P NATL ACAD SCI USA, V86, P5492, DOI 10.1073/pnas.86.14.5492; LAMONT I, 1993, J BACTERIOL, V175, P5286, DOI 10.1128/JB.175.16.5286-5288.1993; LAMONT I, 1988, J MOL BIOL, V199, P3279; LIU B, 1993, NATURE, V366, P33, DOI 10.1038/366033a0; MAO CH, 1994, J MOL BIOL, V235, P532, DOI 10.1006/jmbi.1994.1011; Miller J.H., 1972, EXPT MOL GENETICS; Ptashne M., 1986, A GENETIC SWITCH; RICHARDSON H, 1989, J MOL BIOL, V206, P251, DOI 10.1016/0022-2836(89)90539-1; RICHARDSON H, 1989, J MOL BIOL, V206, P59, DOI 10.1016/0022-2836(89)90523-8; Sambrook J., 2002, MOL CLONING LAB MANU; SENEAR DF, 1993, BIOCHEMISTRY-US, V32, P6179, DOI 10.1021/bi00075a010; Shearwin KE, 1996, J BIOL CHEM, V271, P11525, DOI 10.1074/jbc.271.19.11525; SMITHMUNGO L, 1994, J BIOL CHEM, V269, P20798; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	29	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11532	11540		10.1074/jbc.271.19.11532	http://dx.doi.org/10.1074/jbc.271.19.11532			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626714	hybrid			2022-12-25	WOS:A1996UJ94400074
J	Dudler, T; Gelb, MH				Dudler, T; Gelb, MH			Palmitoylation of Ha-Ras facilitates membrane binding, activation of downstream effectors, and meiotic maturation in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; ONCOGENIC RAS-P21; FATTY ACYLATION; IDENTIFICATION; STIMULATION; REQUIREMENT; CONTAINS; INSULIN; P21RAS; SYSTEM	Ras proteins serve as critical relays in signal transduction pathways that control growth and differentiation and must undergo posttranslational modifications before they become functional. While it is established that farnesylation is necessary for membrane binding and cellular functions of all Ras proteins, the significance of palmitoylation is unclear. We have studied the contribution of Ha-Ras palmitoylation for biological activity in Xenopus oocytes. In contrast to wild-type Ha-Ras, which binds to membranes and induces meiosis when microinjected into oocytes, a nonpalmitoylated but farnesylated and methylated mutant mislocalizes to the cytosol and fails to promote maturation. This lack of responsiveness correlates with the inability of the mutant to induce phosphorylation and activation of mitogen-activated protein kinase and maturation promoting factor, which are both strongly activated by wild-type Ha-Ras. Costimulation of oocytes with insulin increases their responsiveness to Ras and partially rescues the biological activity of the palmitoylation-resistant mutant. However, 25-50 times higher doses of mutant were required to elicit responses equivalent to wild-type Ha-Ras. These results suggest that palmitoylation and membrane association of Ha-Ras is necessary for efficient activation of the mitogen-activated protein kinase cascade in vivo and are consistent with a biochemical function for Ras as a membrane targeting signal for downstream effectors in this pathway.	UNIV WASHINGTON,DEPT CHEM,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle				gelb, michael/0000-0001-7000-5219	NCI NIH HHS [CA52874] Funding Source: Medline; NIGMS NIH HHS [GM562] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052874] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN NG, 1990, J BIOL CHEM, V265, P11487; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BHATTACHARYA S, 1995, P NATL ACAD SCI USA, V92, P2984, DOI 10.1073/pnas.92.7.2984; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; CARNERO A, 1994, J CELL BIOCHEM, V55, P465, DOI 10.1002/jcb.240550406; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CELIS JE, 1994, CELL BIOL LAB MANUAL; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; CHUANG LM, 1994, J BIOL CHEM, V269, P27645; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DESCHENES RJ, 1987, MOL CELL BIOL, V7, P2344, DOI 10.1128/MCB.7.7.2344; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FUKOTO M, 1994, J BIOL CHEM, V269, P33097; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GROTOH Y, 1995, J BIOL CHEM, V270, P25898; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HATTORI S, 1992, J BIOL CHEM, V267, P20346; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; ITOH T, 1993, J BIOL CHEM, V268, P3025; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P11270; KIM R, 1990, MOL CELL BIOL, V10, P5945, DOI 10.1128/MCB.10.11.5945; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; KURODA S, 1995, J BIOL CHEM, V270, P2460, DOI 10.1074/jbc.270.6.2460; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVERS SJ, 1994, NATURE, V369, P411; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; MAGEE AI, 1995, METHOD ENZYMOL, V250, P330; MALLER JL, 1981, DEV BIOL, V85, P309, DOI 10.1016/0012-1606(81)90262-1; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MCGEADY P, 1995, J BIOL CHEM, V270, P26347, DOI 10.1074/jbc.270.44.26347; NEBREDA AR, 1993, ONCOGENE, V8, P467; POMERANCE M, 1992, J BIOL CHEM, V267, P16155; PORFIRI E, 1995, METHOD ENZYMOL, V255, P13; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SCHAFER WR, 1992, ANNU REV GENET, V30, P206; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6	51	85	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11541	11547		10.1074/jbc.271.19.11541	http://dx.doi.org/10.1074/jbc.271.19.11541			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626715	hybrid			2022-12-25	WOS:A1996UJ94400075
J	Quinn, KA; Treston, AM; Unsworth, EJ; Miller, MJ; Vos, M; Grimley, C; Battey, J; Mulshine, JL; Cuttitta, F				Quinn, KA; Treston, AM; Unsworth, EJ; Miller, MJ; Vos, M; Grimley, C; Battey, J; Mulshine, JL; Cuttitta, F			Insulin-like growth factor expression in human cancer cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I IGF-I; BINDING-PROTEINS; MESSENGER-RNA; BREAST-CANCER; LUNG-TUMORS; RECEPTORS; LIVER	The insulin-like growth factors (IGFs), IGF-I and IGF-II, are potent mitogens for human lung and other epithelial cancer cell lines. Previous studies in defined medium lacking added IGF or insulin suggest that an IGF-related ligand can act as an autocrine growth factor for many cancer cell lines through action via the type I IGF receptor (IGF-R). Analysis of RNA isolated from human lung and breast cancer cell lines by reverse transcription of mRNA and polymerase chain reaction reveal that IGF-I and IGF-II mRNAs were co-expressed with IGF-R in the majority of cell lines. IGF-I mRNA was detected in 11/12 small cell lung cancer cell lines (SCLC), 13/14 non-small cell lung cancer (NSCLC) cell lines, and 1/2 breast cancer cell lines. IGF-II mRNA was detected in 8/10 SCLC, 11/12 NSCLC cell lines, and 2/2 breast lines. All cell lines expressed IGF-R. For analysis of IGF peptide secretion, cell lines were adapted to growth in serum/hormone-free culture medium (R(0)), and to avoid interference by IGF-binding proteins, secreted IGF peptides were isolated under acidic conditions and analyzed by Western blotting. Based upon measurement of the sensitivity of the anti-IGF antibodies for detection of recombinant human IGFs, IGF peptides accumulated in conditioned medium at greater than picomolar concentrations should have been readily detected. In three cell lines (two lung and one breast) secreted IGF immunoreactivity was detected as three molecular mass species of 23, 14, and 6 kDa. Isolation and NH4-terminal sequencing of each of these species definitively identified them as differentially processed forms of the IGF-II prohormone. Despite the high frequency of IGF-I gene expression detected by reverse transcription-polymerase chain reaction analysis, only one lung cancer cell line, NCI-N417d, was found that unequivocally secreted IGF-I peptide. This direct sequence determination unambiguously identifies IGF-II as the predominant IGF involved in the autocrine growth stimulation of human lung and breast epithelial tumor cell lines and supports a growing body of literature that implicates IGF-II/IGF-R autocrine loops as a common growth mechanism in epithelial carcinogenesis.	NCI,NIH,BIOMARKERS & PREVENT RES BRANCH,ROCKVILLE,MD 20850; PERKIN ELMER CORP,DIV APPL BIOSYST,FOSTER CITY,CA 94404; NIDCD,NIH,GAITHERSBURG,MD 20850	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Thermo Fisher Scientific; Applied Biosystems; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)				Mulshine, James/0000-0002-4648-9177				ADAMO ML, 1992, ENDOCRINOLOGY, V131, P1858, DOI 10.1210/en.131.4.1858; ANGELLOZNICAUD P, 1995, P NATL ACAD SCI USA, V92, P11970; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; Battey, 1986, BASIC METHODS MOL BI; Blum W F, 1994, Growth Regul, V4 Suppl 1, P11; CHEW SL, 1995, ENDOCRINOLOGY, V136, P1939, DOI 10.1210/en.136.5.1939; DAUGHADAY WH, 1993, P NATL ACAD SCI USA, V90, P5823, DOI 10.1073/pnas.90.12.5823; GOWAN LK, 1987, ENDOCRINOLOGY, V121, P449, DOI 10.1210/endo-121-2-449; HAN VKM, 1987, SCIENCE, V236, P193, DOI 10.1126/science.3563497; HUDGINS WR, 1992, J BIOL CHEM, V267, P8153; JAQUES G, 1989, EXP CELL RES, V184, P396, DOI 10.1016/0014-4827(89)90339-X; NAKANISHI Y, 1988, J CLIN INVEST, V82, P354, DOI 10.1172/JCI113594; Nielsen Finn Cilius, 1992, Progress in Growth Factor Research, V4, P257, DOI 10.1016/0955-2235(92)90023-B; PERDUE JF, 1991, ENDOCRINOLOGY, V129, P3101, DOI 10.1210/endo-129-6-3101; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; REEVE JG, 1990, BRIT J CANCER, V61, P727, DOI 10.1038/bjc.1990.163; REEVE JG, 1993, CANCER RES, V53, P4680; REEVE JG, 1992, J NATL CANCER I, V84, P628, DOI 10.1093/jnci/84.8.628; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1995, CANCER RES, V55, P2463; ROHLIK QT, 1987, BIOCHEM BIOPH RES CO, V149, P276, DOI 10.1016/0006-291X(87)91635-4; ROHLIK QT, 1993, BIOCHEM BIOPH RES CO, V204, P22; ROTSCH M, 1992, J CANCER RES CLIN, V118, P502, DOI 10.1007/BF01225264; ROTWEIN P, 1986, P NATL ACAD SCI USA, V83, P77, DOI 10.1073/pnas.83.1.77; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHARDT C, 1993, EXP CELL RES, V204, P22, DOI 10.1006/excr.1993.1004; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SIEGFRIED JM, 1994, J BIOL CHEM, V269, P8596; Steller MA, 1995, P NATL ACAD SCI USA, V92, P11970, DOI 10.1073/pnas.92.26.11970; STILES AD, 1989, AM J RESP CELL MOL, V1, P21, DOI 10.1165/ajrcmb/1.1.21; YANG YWH, 1985, J BIOL CHEM, V260, P2570; YEE D, 1988, CANCER RES, V48, P6691; ZIA F, 1996, IN PRESS J CELL BIOC	33	166	180	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11477	11483		10.1074/jbc.271.19.11477	http://dx.doi.org/10.1074/jbc.271.19.11477			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626706	hybrid			2022-12-25	WOS:A1996UJ94400066
J	Yamanaka, S; Poksay, KS; Driscoll, DM; Innerarity, TL				Yamanaka, S; Poksay, KS; Driscoll, DM; Innerarity, TL			Hyperediting of multiple cytidines of apolipoprotein B mRNA by APOBEC-1 requires auxiliary protein(s) but not a mooring sequence motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; TRANSGENIC MICE; EXPRESSION; SITES; B100	An RNA-binding cytidine deaminase (APOBEC-1) and unidentified auxiliary protein(s) are required for apolipoprotein (apo) B mRNA editing. A sequence motif on apoB mRNA (''mooring sequence,'' nucleotides 6671-6681) is obligatory for the editing of cytidine 6666 (C-6666), the only cytidine on apoB mRNA converted to uridine in normal animals. Transgenic animals with hepatic overexpression of APOBEC-1 develop liver tumors, and other non-apoB mRNAs are edited, suggesting a loss of the normally precise specificity. In this study, we examined apoB mRNA from these transgenic animals to determine if cytidines aside from C-6666 are edited. Multiple cytidines downstream from C-6666 in apoB mRNA were edited extensively by the overexpressed APOBEC-1. This pathophysiological ''hyperediting'' could be mimicked in vitro by incubating a synthetic apoB RNA substrate with the transgenic mouse liver extracts. Multiple cytidines in the synthetic apoB RNA were edited by recombinant APOBEC-1 but only with supplementation of the auxiliary protein(s). Mutations in the mooring sequence markedly decreased the normal editing of C-6666 but, surprisingly, increased the hyperediting of downstream cytidines. Furthermore, cytidines in an apoB RNA substrate lacking the mooring sequence were also edited in vitro. These results indicate that the hyperediting of apoB mRNA by overexpressed APOBEC-1 depends upon auxiliary protein(s) but is independent of the mooring sequence motif. These results suggest that hyperediting may represent the first step in a two-step recognition model for normal apoB mRNA editing.	UNIV CALIF SAN FRANCISCO, INST CARDIOVASC RES, SAN FRANCISCO, CA 94141 USA; UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94141 USA; CLEVELAND CLIN FDN, DEPT CELL BIOL, CLEVELAND, OH 44195 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Cleveland Clinic Foundation	Yamanaka, S (corresponding author), UNIV CALIF SAN FRANCISCO, GLADSTONE INST CARDIOVASC DIS, POB 419100, SAN FRANCISCO, CA 94141 USA.				NHLBI NIH HHS [HL47660] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL047660] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANANT S, 1995, J BIOL CHEM, V270, P14762, DOI 10.1074/jbc.270.24.14762; BACKUS JW, 1994, BBA-GENE STRUCT EXPR, V1217, P65; BACKUS JW, 1991, NUCLEIC ACIDS RES, V19, P6781, DOI 10.1093/nar/19.24.6781; BACKUS JW, 1994, BBA-GENE STRUCT EXPR, V1219, P1, DOI 10.1016/0167-4781(94)90240-2; BENNE R, 1993, RNA EDITING, P13; BOSTROM K, 1989, J BIOL CHEM, V264, P15701; CHEN SH, 1990, J BIOL CHEM, V265, P6811; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CHIESA GL, 1993, J BIOL CHEM, V268, P23747; DAVIDSON NO, 1995, RNA, V1, P3; DRISCOLL DM, 1994, J BIOL CHEM, V269, P19843; DRISCOLL DM, 1993, MOL CELL BIOL, V13, P7288, DOI 10.1128/MCB.13.12.7288; GREEVE J, 1993, J LIPID RES, V34, P1367; HODGES P, 1992, TRENDS BIOCHEM SCI, V17, P77, DOI 10.1016/0968-0004(92)90506-5; JOHNSON DF, 1993, BIOCHEM BIOPH RES CO, V195, P1204, DOI 10.1006/bbrc.1993.2172; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; MANO H, 1990, ONCOGENE, V5, P1781; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; PAULAUSKIS JD, 1989, BIOCHEM BIOPH RES CO, V158, P690, DOI 10.1016/0006-291X(89)92776-9; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; SHAH RR, 1991, J BIOL CHEM, V266, P16301; Smith H C, 1993, Semin Cell Biol, V4, P267, DOI 10.1006/scel.1993.1032; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; THOMMES P, 1992, NUCLEIC ACIDS RES, V20, P1069, DOI 10.1093/nar/20.5.1069; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; YAMANAKA S, 1995, P NATL ACAD SCI USA, V92, P8483, DOI 10.1073/pnas.92.18.8483; YAMANAKA S, 1995, CIRCULATION, V92, P788	28	56	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11506	11510		10.1074/jbc.271.19.11506	http://dx.doi.org/10.1074/jbc.271.19.11506			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626710	hybrid			2022-12-25	WOS:A1996UJ94400070
J	Collins, JF; Ghishan, FK				Collins, JF; Ghishan, FK			The molecular defect in the renal sodium-phosphate transporter expression pathway of Gyro (Gy) mice is distinct from that of hypophosphatemic (Hyp) mice	FASEB JOURNAL			English	Article						Na+/P-i transporter; Hyp mouse model; Gy mouse model; X-linked hypophosphatemic vitamin D-resistant rickets	D-RESISTANT RICKETS; MOUSE MODEL; MEMBRANES; HYP	Two animal models of the human disorder hypophosphatemic vitamin D-resistant rickets exist, the Hyp and Gy mice, Affected mice and humans both manifest an X-linked phenotype, and show decreased Na+/P-i transport activity in the renal proximal tubules, which is characterized by a decreased maximal velocity (V-max). The defect in Hyp mice is most likely due to a decreased transcription rate of the renal Na+/P-i transporter gene, The current studies were designed to define the molecular defect in the Gy mice, Sodium-dependent uptake of phosphate (P-i) in renal BBMV showed uptake levels of 170.58 +/- 25 and 66.00 +/- 11 pmol . mg protein(-1). 6 s(-1) in normal and Gy mice, respectively (n=3; P=0.0102). Glucose uptake levels in the BBWV were 1.94 +/- 0.81 and 1.91 +/- 0.35 pmol . mg protein .(1)6 s(-1) in normal and Gy mice, respectively (n=3), Northern blot analysis of kidney cortex in both mice revealed nearly equivalent message levels (normal/Gy=1.01 +/- 0.12, n=3), Iu situ hybridization localized the mRNA to the renal cortex in both mice and confirmed equal message levels, Western blot analysis of renal BBM proteins, using a polyclonal antiserum, showed one predominant band at 87 kDa in both mouse samples, with intensities being decreased in the Gy mice (normal/Gy=4.129 +/- 0.70, n=4, P < 0.04), Immunohistochemical analysis localized the protein to the apical membrane of proximal tubules in both mice, These results suggest that the molecular defect in the Gy mice is distinct from that in the Hyp mice, and furthermore, that the manifestation of the diseased phenotype in Gy mice is related to a different defect in the renal Na+/P-i transporter expression pathway, The molecular mechanism of the defect likely relates to protein processing, metabolic turnover rate, or translocation to the brush-border membrane, These results further suggest that two distinct X-linked factors modulate different steps in the expression pathway of the Na+/P-i transporter gene.	UNIV ARIZONA, ARIZONA HLTH SCI CTR, STEELE MEM CHILDRENS RES CTR, DEPT PEDIAT, TUCSON, AZ 85724 USA; UNIV ARIZONA, ARIZONA HLTH SCI CTR, STEELE MEM CHILDRENS RES CTR, DEPT PHYSIOL, TUCSON, AZ 85724 USA	University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona Health Sciences					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033209] Funding Source: NIH RePORTER; NIDDK NIH HHS [2R01 DK33209] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albright F, 1937, AM J DIS CHILD, V54, P529; COLLINS JF, 1995, AM J PHYSIOL-GASTR L, V268, pG917, DOI 10.1152/ajpgi.1995.268.6.G917; COLLINS JF, 1994, FASEB J, V8, P862, DOI 10.1096/fasebj.8.11.8070635; COLLINS JF, 1995, AM J PHYSIOL-RENAL, V269, pF439, DOI 10.1152/ajprenal.1995.269.3.F439; COWGILL LD, 1979, J CLIN INVEST, V63, P1203, DOI 10.1172/JCI109415; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; EICHER EM, 1976, P NATL ACAD SCI USA, V73, P4667, DOI 10.1073/pnas.73.12.4667; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; Ghishan Fayez K., 1994, Pediatric Research, V35, P510, DOI 10.1203/00006450-199404000-00026; GIASSON SD, 1977, PFLUG ARCH EUR J PHY, V371, P33, DOI 10.1007/BF00580769; HAMMERMAN MR, 1983, AM J PHYSIOL, V245, pF701, DOI 10.1152/ajprenal.1983.245.6.F701; LYON MF, 1986, P NATL ACAD SCI USA, V83, P4899, DOI 10.1073/pnas.83.13.4899; MEYER RA, 1980, ENDOCRINOLOGY, V107, P1577, DOI 10.1210/endo-107-5-1577; NAKAGAWA N, 1991, J BIOL CHEM, V266, P13616; NAKAGAWA N, 1994, P SOC EXP BIOL MED, V205, P162, DOI 10.3181/00379727-205-43692; NAKAGAWA N, 1993, P SOC EXP BIOL MED, V203, P328; OHNO S, 1973, NATURE, V244, P259, DOI 10.1038/244259a0; Rasmussen H., 1983, METABOLIC BASIS INHE, V5th, P1743; Sambrook J., 2002, MOL CLONING LAB MANU; SELA J, 1982, METAB BONE DIS RELAT, V4, P129, DOI 10.1016/0221-8747(82)90026-1; SHETTY NS, 1991, TERATOLOGY, V44, P463, DOI 10.1002/tera.1420440412; TENENHOUSE HS, 1994, J CLIN INVEST, V93, P671, DOI 10.1172/JCI117019; VAUGHN LK, 1987, PHYSIOL BEHAV, V40, P131, DOI 10.1016/0031-9384(87)90195-8; WINTERS RW, 1958, MEDICINE, V37, P97, DOI 10.1097/00005792-195805000-00001	24	14	14	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	1996	10	7					751	759		10.1096/fasebj.10.7.8635692	http://dx.doi.org/10.1096/fasebj.10.7.8635692			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UN798	8635692				2022-12-25	WOS:A1996UN79800009
J	Clarke, JL; Watkins, WM				Clarke, JL; Watkins, WM			alpha 1,3-L-Fucosyltransferase expression in developing human myeloid cells Antigenic, enzymatic, and mRNA analyses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; LINE HL-60; SIALYL-LEX; TERMINAL DIFFERENTIATION; NEURAMINIDASE TREATMENT; DETERMINES EXPRESSION; ACCEPTOR SPECIFICITY; CARBOHYDRATE UNITS	In an attempt to correlate the cell surface expression of Le(x) and sialyl-Le(x) structures in immature and mature myeloid cells with the genes expressing alpha 1,3-fucosyltransferase(s) we have examined: 1) the properties of the cellular alpha 1,3-fucosyltransferases and the mRNA transcripts corresponding to the five cloned genes, Fuc-TIII, Fuc-TIV, Fuc-TV, Fuc-TVI, and Fuc-TVII, in mature granulocytes and in the myeloid cell line HL-60, before and after dimethyl sulfoxide-induced differentiation and 2) the properties of the alpha 1,3-fucosyltransferases expressed in COS 7 cells transfected with plasmids containing Fuc-TIV and Fuc-TVII cDNAs. The previously shown increase in cell surface expression of sialyl-Le(x) on differentiation of HL-60 cells (Skacel P. O., Edwards A. J., Harrison C. T., and Watkins W. M. (1991) Blood 78, 1452-1460) is accompanied by a sharp fall in expression of Fuc-TIV mRNA and a persistence of expression of Fuc-TVII mRNA. The properties of the alpha 1,3-fucosyltransferase expressed in COS-7 cells transfected with Fuc-TIV are consistent with this being the major gene responsible for the expression of Le(x) in the immature myeloid cells. In Northern blot analyses, no transcripts of Fuc-TIII, Fuc-TV, or Fuc-TVI were detected in total RNA from mature granulocytes or mRNA from HL-60 cells before or after differentiation. In total RNA from mature granulocytes, Fuc-TIV transcripts were only faintly visible, whereas Fuc-TVII transcripts were quite definitely expressed. The specificity properties of Fuc-TVII expressed in COS-7 cells are consistent with this gene being the major candidate alpha 1,3-fucosyltransferase controlling the expression of sialyl-Le(x) on mature cells. However, Le(x) continues to be expressed on the surface of mature granulocytes and cell extracts retain the capacity to transfer fucose to non-sialylated acceptor substrates. The question therefore remains as to whether these properties result from the weakly expressed Fuc-TIV gene or whether another alpha 1,3-fucosyltransferase gene remains to be identified.	HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, DEPT HAEMATOL, LONDON W12 0NN, ENGLAND	Imperial College London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BETTELHEIM P, 1989, LEUKOCYTE TYPING, V4, P798; BOYER PD, 1959, ENZYMES, V1, P511; CARTRON JP, 1980, REV FR TRANSFUS IMMU, V23, P271, DOI 10.1016/S0338-4535(80)80131-0; CHOU TH, 1977, BIOCHEM BIOPH RES CO, V74, P1001, DOI 10.1016/0006-291X(77)91617-5; CIVIN CI, 1984, J IMMUNOL, V133, P157; CIVIN CI, 1981, BLOOD, V57, P842; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1978, P NATL ACAD SCI USA, V75, P2458, DOI 10.1073/pnas.75.5.2458; COUILLIN P, 1991, CYTOGENET CELL GENET, V56, P108, DOI 10.1159/000133061; DEVRIES T, 1992, HISTOCHEM J, V24, P761, DOI 10.1007/BF01046347; DONALD ASR, 1988, CARBOHYD RES, V178, P79, DOI 10.1016/0008-6215(88)80103-4; DYSON NJ, 1991, ESSENTIAL MOL BIOL, V2, P111; ELMAGHRABI MR, 1984, J BIOL CHEM, V259, P3104; FUKUDA M, 1991, Glycobiology, V1, P347, DOI 10.1093/glycob/1.4.347; FUKUDA M, 1981, P NATL ACAD SCI-BIOL, V78, P6299, DOI 10.1073/pnas.78.10.6299; FUKUSHI Y, 1984, J BIOL CHEM, V259, P511; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GAHMBERG CG, 1979, P NATL ACAD SCI USA, V76, P4087, DOI 10.1073/pnas.76.8.4087; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GREENWELL P, 1983, FEBS LETT, V164, P314, DOI 10.1016/0014-5793(83)80308-1; JOHNSON PH, 1992, GLYCOCONJUGATE J, V9, P251, DOI 10.1007/BF00731137; JOHNSON PH, 1987, BIOCHEM SOC T, V15, P396, DOI 10.1042/bst0150396; KOSZDIN KL, 1992, BIOCHEM BIOPH RES CO, V187, P152, DOI 10.1016/S0006-291X(05)81472-X; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LUBBERT M, 1991, BLOOD, V77, P909; LUNDJOHANSEN F, 1993, J LEUKOCYTE BIOL, V54, P47, DOI 10.1002/jlb.54.1.47; MACHER B A, 1991, Glycobiology, V1, P577, DOI 10.1093/glycob/1.6.577; MACHER BA, 1988, J BIOL CHEM, V263, P10186; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; MORGAN WTJ, 1967, METHOD IMMUNOL IMMUN, V1, P75; NAKAMURA M, 1992, J BIOL CHEM, V267, P23507; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NILSSON B, 1979, J BIOL CHEM, V254, P4545; NORIJI H, 1984, BLOOD, V64, P534; OLSSON I, 1981, EXP CELL RES, V131, P225, DOI 10.1016/0014-4827(81)90422-5; PANTAZIS P, 1981, J CELL BIOL, V90, P396, DOI 10.1083/jcb.90.2.396; PASQUALETTO V, 1995, GLYCOBIOLOGY, V5, P59, DOI 10.1093/glycob/5.1.59; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SCHENKELBRUNNER H, 1972, EUR J BIOCHEM, V30, P269, DOI 10.1111/j.1432-1033.1972.tb02095.x; SCHMID K, 1979, BIOCHIM BIOPHYS ACTA, V581, P356, DOI 10.1016/0005-2795(79)90255-1; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHAHREDDY I, 1982, AM J HEMATOL, V12, P29, DOI 10.1002/ajh.2830120105; SKACEL PO, 1991, BLOOD, V78, P1452; SKACEL PO, 1988, BIOCHEM SOC T, V16, P1034, DOI 10.1042/bst0161034; SKACEL PO, 1987, GLYCOCONJUGATE J, V4, P267, DOI 10.1007/BF01048432; SKACEL PO, 1992, THESIS U LONDON; SPIRO RG, 1974, J BIOL CHEM, V249, P5704; STRAUSS LC, 1983, BLOOD, V61, P1222; TABILIO A, 1984, BRIT J HAEMATOL, V58, P697, DOI 10.1111/j.1365-2141.1984.tb06117.x; TAMM I, 1950, P SOC EXP BIOL MED, V74, P108, DOI 10.3181/00379727-74-17825; TETTEROO PAT, 1984, INT J CANCER, V33, P355, DOI 10.1002/ijc.2910330312; TETTEROO PAT, 1987, J BIOL CHEM, V262, P15984; TIEMEYER M, 1991, P NATL ACAD SCI USA, V88, P1138, DOI 10.1073/pnas.88.4.1138; URDAL DL, 1983, BLOOD, V62, P1022; VANBEEK WP, 1982, CANCER RES, V42, P5222; WALTZ G, 1990, SCIENCE, V250, P1132; Watkins W. M, 1972, GLYCOPROTEINS, V5, P830; WATKINS WM, 1993, ACS SYM SER, V519, P324; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; WILKINSON M, 1991, ESSENTIAL MOL BIOL, V1, P69; WILLIAMS J, 1984, CARBOHYD RES, V134, P141, DOI 10.1016/0008-6215(84)85029-6; [No title captured]	67	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10317	10328		10.1074/jbc.271.17.10317	http://dx.doi.org/10.1074/jbc.271.17.10317			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626601	hybrid			2022-12-25	WOS:A1996UG25700073
J	Matsumine, A; Senda, T; Baeg, GH; Roy, BC; Nakamura, Y; Noda, M; Toyoshima, K; Akiyama, T				Matsumine, A; Senda, T; Baeg, GH; Roy, BC; Nakamura, Y; Noda, M; Toyoshima, K; Akiyama, T			MCC, a cytoplasmic protein that blocks cell cycle progression from the G(0)/G(1) to S phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; TUMOR SUPPRESSOR GENES; APC GENE; PHOSPHORYLATION; IDENTIFICATION; MUTATIONS; CANCER; CHROMOSOME-5Q21; ASSOCIATION; GROWTH	The MCC gene was isolated from the human chromosome 5q21 by positional cloning and was found to be mutated in several colorectal tumors. In this study, we prepared specific antibodies and detected the MCC gene product as a cytoplasmic 100-kDa phosphoprotein in mouse NIH3T3 cells. Immunoelectron microscopic analysis showed that the MCC protein is associated with the plasma membrane and membrane organelles in mouse intestinal epithelial cells and neuronal cells. The amount of the MCC protein remained constant during the cell cycle progression of NIH3T3 cells, while its phosphorylation state changed markedly in a cell cycle-dependent manner, being weakly phosphorylated in the G(0)/G(1) and highly phosphorylated during the G(1) to S transition. Overexpression of the MCC protein blocked the serum-induced cell cycle transition from the G(1) to S phase, whereas a mutant MCC, initially identified in a colorectal tumor, did not exhibit this activity. These results suggest that the MCC protein may play a role in the signaling pathway negatively regulating cell cycle progression.	OSAKA UNIV, SCH MED, DEPT ANAT, OSAKA 565, JAPAN; OSAKA UNIV, INST MICROBIAL DIS, DEPT ONCOGENE RES, OSAKA 565, JAPAN; UNIV TOKYO, INST MED SCI, MOLEC MED LAB, TOKYO 108, JAPAN; KYOTO UNIV, FAC MED, DEPT MOLEC ONCOL, KYOTO 606, JAPAN	Osaka University; Osaka University; University of Tokyo; Kyoto University			Baeg, Gyeong-Hun/A-2951-2008					AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; AKIYAMA T, 1990, ONCOGENE, V5, P179; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DAMICO D, 1992, CANCER RES, V52, P1996; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG Y, 1992, CANCER RES, V52, P6525; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; NODA A, 1994, EXP CELL RES, V211; NUELL MJ, 1991, MOL CELL BIOL, V11, P1372, DOI 10.1128/MCB.11.3.1372; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Sal G.D., 1992, CELL, V70, P595; SENDA T, 1991, HISTOCHEMISTRY, V96, P25, DOI 10.1007/BF00266757; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1993, CANCER RES, V53, P2728; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1989, J CELL BIOL, V109, P2905, DOI 10.1083/jcb.109.6.2905; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	46	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10341	10346		10.1074/jbc.271.17.10341	http://dx.doi.org/10.1074/jbc.271.17.10341			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626604	Green Submitted, hybrid			2022-12-25	WOS:A1996UG25700076
J	Hsu, HY; Nicholson, AC; Hajjar, DP				Hsu, HY; Nicholson, AC; Hajjar, DP			Inhibition of macrophage scavenger receptor activity by tumor necrosis factor-alpha is transcriptionally and post-transcriptionally regulated	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MONOCYTE-DERIVED MACROPHAGES; SMOOTH-MUSCLE CELLS; LINE THP-1; ATHEROSCLEROTIC LESIONS; LIPID-ACCUMULATION; INTERFERON-GAMMA; EXPRESSION; GENE; ESTER	Regulation of expression of the scavenger receptor is thought to play a critical role in the accumulation of lipid by macrophages in atherosclerosis. Tumor necrosis factor-alpha (TNF-alpha) has been shown to suppress macrophage scavenger receptor function (van Lenten, B. J., and Fogelman, A. M. (1992) J. Immunol. 148, 112-116). However the mechanism by which it does so is unknown. We evaluated the mechanism by which TNF-alpha inhibited macrophage scavenger receptor surface expression and binding of acetylated low density lipoprotein (aLDL). Binding of aLDL to phorbol 12-myristate 13-acetate (PMA)-differentiated THP-1 macrophages was suppressed by TNF-alpha in a dose-dependent manner. Inhibition of aLDL binding was paralleled by a reduction of macrophage scavenger receptor protein as detected by the Western blot. TNF-alpha partially decreased macrophage scavenger receptor mRNA steady state levels in PMA-differentiated THP-1 macrophages, a result that was confirmed by reverse transcription-polymerase chain reaction. PMA increased the luciferase activity driven by the macrophage scavenger receptor promoter in the transfected cells, whereas TNF-alpha partially reduced luciferase activity. However, macrophage scavenger receptor mRNA half-life was dramatically reduced in cells treated with TNF-alpha relative to untreated cells. Reduction in macrophage scavenger receptor message in response to TNF-alpha was dependent on new protein synthesis because it was blocked by cycloheximide. These results indicate that TNF-alpha regulates macrophage scavenger receptor expression in PMA-differentiated THP-1 macrophages by transcriptional and post-transcriptional mechanisms but principally by destabilization of macrophage scavenger receptor mRNA.	CORNELL UNIV,COLL MED,DEPT BIOCHEM,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT MED,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT PATHOL,NEW YORK,NY 10021	Cornell University; Cornell University; Cornell University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049666, K14HL003158, P01HL046403] Funding Source: NIH RePORTER; NHLBI NIH HHS [K14 HL-03158, HL-46403, HL-49666] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKESON AL, 1991, J LIPID RES, V32, P1699; AVIRAM M, 1990, ARTERIOSCLEROSIS, V10, P559, DOI 10.1161/01.ATV.10.4.559; AVIRAM M, 1989, METABOLISM, V38, P425, DOI 10.1016/0026-0495(89)90192-3; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BOTTALICO LA, 1991, J BIOL CHEM, V266, P22866; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5894; CONWAY EM, 1988, MOL CELL BIOL, V8, P5588, DOI 10.1128/MCB.8.12.5588; CORTON JM, 1992, EUR J BIOCHEM, V204, P203, DOI 10.1111/j.1432-1033.1992.tb16625.x; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; DORSETT DL, 1983, J VIROL, V48, P218, DOI 10.1128/JVI.48.1.218-228.1983; EMI M, 1993, J BIOL CHEM, V268, P2120; FOGELMAN AM, 1982, P NATL ACAD SCI-BIOL, V79, P922, DOI 10.1073/pnas.79.3.922; FONG LG, 1990, J BIOL CHEM, V265, P11751; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; GENG YJ, 1994, ARTERIOSCLER THROMB, V14, P798, DOI 10.1161/01.ATV.14.5.798; GENG YJ, 1992, J CLIN INVEST, V89, P1322, DOI 10.1172/JCI115718; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GONG QQ, 1995, J BIOL CHEM, V270, P21672, DOI 10.1074/jbc.270.37.21672; HAJJAR DP, 1980, AM J PATHOL, V100, P683; HAJJAR DP, 1982, J CLIN INVEST, V70, P479, DOI 10.1172/JCI110639; HAJJAR DP, 1983, J LIPID RES, V24, P1176; HAJJAR DP, 1985, J BIOL CHEM, V260, P6124; HALEY NJ, 1980, J LIPID RES, V21, P961; HARA H, 1987, BIOCHEM BIOPH RES CO, V146, P802, DOI 10.1016/0006-291X(87)90601-2; HSU HY, 1994, J BIOL CHEM, V269, P9213; ISHIBASHI S, 1990, J BIOL CHEM, V265, P14109; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI HM, 1995, J CLIN INVEST, V95, P122, DOI 10.1172/JCI117628; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARSHALL PJ, 1985, ANAL BIOCHEM, V145, P192, DOI 10.1016/0003-2697(85)90347-1; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; MOHAMED F, 1995, ARTERIOSCL THROM VAS, V15, P52, DOI 10.1161/01.ATV.15.1.52; MOHAMED F, 1995, FASEB J, V9, P326; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; MOULTON KS, 1992, P NATL ACAD SCI USA, V89, P8102, DOI 10.1073/pnas.89.17.8102; NAITO M, 1992, AM J PATHOL, V141, P591; PAPE ME, 1989, MOL CELL BIOL, V9, P974, DOI 10.1128/MCB.9.3.974; PHILLIPS DR, 1985, NATURE, V316, P746, DOI 10.1038/316746a0; RUS HG, 1991, ATHEROSCLEROSIS, V89, P247; SCHUTZE S, 1992, SEMIN ONCOL, V19, P16; SOLISHERRUZO JA, 1988, J BIOL CHEM, V263, P5841; STOPECK AT, 1993, J BIOL CHEM, V268, P17489; TIPPING PG, 1993, AM J PATHOL, V142, P1721; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; TSUCHIYA S, 1982, CANCER RES, V42, P1530; VANLENTEN BJ, 1985, J IMMUNOL, V134, P3718; VANLENTEN BJ, 1992, J IMMUNOL, V148, P112; VIA DP, 1989, J LIPID RES, V30, P1515; VILLIERS WJS, 1994, J EXP MED, V180, P705; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205	55	92	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7767	7773		10.1074/jbc.271.13.7767	http://dx.doi.org/10.1074/jbc.271.13.7767			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631819	hybrid			2022-12-25	WOS:A1996UC77400087
J	Petruzzelli, L; Takami, M; Herrera, R				Petruzzelli, L; Takami, M; Herrera, R			Adhesion through the interaction of lymphocyte function-associated antigen-1 with intracellular adhesion molecule-1 induces tyrosine phosphorylation of p130(cas) and its association with c-CrkII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-CONTAINING PROTEINS; CELL-ADHESION; SH3 DOMAINS; TRANSENDOTHELIAL MIGRATION; EXTRACELLULAR-MATRIX; COUNTER-RECEPTOR; T-CELLS; V-CRK; LFA-1; ACTIVATION	The B-lymphoblastoid cell line JY undergoes homotypic aggregation in a lymphocyte function-associated antigen-1 (LFA-1)-mediated, intracellular adhesion molecule-1 (ICAM-1)-dependent manner when stimulated with phorbol 12-myristate 13-acetate or anti-LFA-1 antibodies. Under conditions that lead to cell aggregation, we observed rapid tyrosine phosphorylation of p130(cas), a protein previously identified to be phosphorylated on tyrosine in both v-src- and v-crk-transformed cells. Phosphorylation of p130(cas) was dependent on binding of LFA-1 to its ligand, ICAM-1, as demonstrated by the use of anti-ICAM-1 antibodies. Several observations suggest that this event may be an important step in the signaling pathway initiated by LFA-1. p130(cas) phosphorylation was rapidly reversible upon disengagement of the LFA-1 . ICAM-1 complex and required cell adhesion since binding of phorbol 12-myristate 13-acetate-stimulated JY cells to purified ICAM-1 or cross-linking of either LFA-1 or ICAM-1 was not sufficient to induce phosphorylation of p130(cas). The integrin-stimulated phosphorylation of p130(cas) created binding sites that were recognized in vitro by the SH2 domain of c-CrkII, a key adaptor protein involved in cell differentiation and transformation. Moreover, we also showed that the LFA-1-stimulated tyrosine phosphorylation of p130(cas) induces the formation of a p130(cas). CrkII and p130(cas). CrkL complex in intact cells. This observation suggests that adhesion mediated by the interaction of LFA-1 and ICAM-1 initiates a signaling cascade that involves the activation of protein tyrosine kinases and leads to the regulation of protein-protein interaction via SH2 domains, a key process shared with growth factor signaling pathways.	WARNER LAMBERT PARKE DAVIS, PHARMACEUT RES DIV, DEPT SIGNAL TRANSDUCT, ANN ARBOR, MI 48105 USA; UNIV MICHIGAN, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; DEPT VET AFFAIRS MED CTR, ANN ARBOR, MI 48109 USA	Pfizer; University of Michigan System; University of Michigan								ARROYO AG, 1994, J CELL BIOL, V126, P1277, DOI 10.1083/jcb.126.5.1277; BERTON G, 1994, J CELL BIOL, V126, P1111, DOI 10.1083/jcb.126.4.1111; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; GRAHAM IL, 1994, J CELL BIOL, V127, P1139, DOI 10.1083/jcb.127.4.1139; HELLBERG C, 1995, EXP CELL RES, V217, P140, DOI 10.1006/excr.1995.1073; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KANNER SB, 1993, P NATL ACAD SCI USA, V90, P7099, DOI 10.1073/pnas.90.15.7099; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KEIZER GD, 1985, EUR J IMMUNOL, V15, P1142, DOI 10.1002/eji.1830151114; KLICKSTEIN LB, 1995, LEUCOCYTE TYPING 5, P1542; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LOLLO BA, 1993, J BIOL CHEM, V268, P21693; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; PATCH LA, 1995, J CELL SCI, V108, P1371; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PETRUZZELLI L, 1995, J IMMUNOL, V155, P854; REILLY PL, 1995, J IMMUNOL, V155, P529; Ribon V, 1996, MOL CELL BIOL, V16, P45; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SCHLAEPFER DD, 1994, NATURE, V372, P786; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SMITH CW, 1988, J CLIN INVEST, V82, P1746, DOI 10.1172/JCI113788; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SUGIE K, 1995, J IMMUNOL, V154, P1691; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; VANSEVENTER GA, 1992, J IMMUNOL, V149, P3872; VAZEUX R, 1992, NATURE, V360, P485, DOI 10.1038/360485a0; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WANG SCT, 1995, J LEUKOCYTE BIOL, V57, P343, DOI 10.1002/jlb.57.2.343; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	58	72	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7796	7801		10.1074/jbc.271.13.7796	http://dx.doi.org/10.1074/jbc.271.13.7796			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631823	hybrid			2022-12-25	WOS:A1996UC77400091
J	Gorman, C; Skinner, RH; Skelly, JV; Neidle, S; Lowe, PN				Gorman, C; Skinner, RH; Skelly, JV; Neidle, S; Lowe, PN			Equilibrium and kinetic measurements reveal rapidly reversible binding of ras to raf	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; ONCOGENIC P21(RAS); GROWTH-FACTORS; KINASE-KINASE; HA-RAS; P21; IDENTIFICATION; EXPRESSION; SEQUENCE; C-RAF-1	Raf is a serine/threonine kinase that binds through its amino-terminal regulatory domain to the GTP form of Ras and thereby activates the mitogen activated protein kinase pathway, In this study, we have characterized the interaction of the Ras-binding domain of Raf with Ras using equilibrium binding methods (scintillation proximity assay and fluorescence anisotropy), rather than with more widely used nonequilibrium procedures (such as enzyme-linked immunosorbent assay and affinity precipitation). Initial studies using glutathione S-transferase fusion proteins with either residues 1-257 or 1-190 of Raf showed that although it was possible to detect Ras binding using an enzyme-linked immunosorbent assay or affinity precipitation, it was substoichiometric; under equilibrium conditions with only a small excess of Raf almost no binding was detected, This difference was probably due to the presence of a high percentage of inactive Raf protein, Further studies used protein containing residues 51-131 of Raf, which expressed in Escherichia coli as a stable glutathione S-transferase fusion, With this protein, binding with Ras could readily be measured under equilibrium conditions. The catalytic domain of neurofibromin inhibited binding of Ras to Raf, and Raf inhibited the binding of Ras to neurofibromin showing that Raf and neurofibromin cannot be bound simultaneously to Ras, The affinities of interaction of neurofibromin and Raf with Barvey-Ras(Leu-61) were similar, The rate constant for dissociation of Raf from Ras was estimated to be >1 min-l, suggesting that Ras, Raf, and neurofibromin may be in rapid equilibrium in the cell. In contrast to previous reports, under equilibrium conditions there was no evidence for a difference in affinity between the minimal Ras binding domain of Raf (residues 51-131) and a region containing an additional 16 carboxyl-terminal amino acids, suggesting that residues 132-147 do not form a critical binding determinant.	WELLCOME RES LABS, BECKENHAM BR3 3BS, KENT, ENGLAND; INST CANC RES, CANC RES CAMPAIGN, BIOMOLEC STRUCT UNIT, SUTTON SM2 5NG, SURREY, ENGLAND	GlaxoSmithKline; Wellcome Research Laboratories; University of London; Institute of Cancer Research - UK								BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1989, CANCER RES, V49, P4682; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; ECCLESTON JF, 1993, J BIOL CHEM, V268, P27012; EMERSON SD, 1994, BIOCHEMISTRY-US, V33, P7745, DOI 10.1021/bi00191a001; FRIDMAN M, 1994, J BIOL CHEM, V269, P30105; GHOSH S, 1994, J BIOL CHEM, V269, P30785; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; ISHIKAWA F, 1988, ONCOGENE, V3, P653; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; LOWE PN, 1991, J BIOL CHEM, V266, P1672; LOWE PN, 1994, CELL SIGNAL, V6, P109, DOI 10.1016/0898-6568(94)90067-1; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; PAGE MJ, 1989, J BIOL CHEM, V264, P19147; RAPP UR, 1988, HDB ONCOGENES, P213; REY I, 1994, ONCOGENE, V9, P685; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SCHEFFLER JE, 1994, J BIOL CHEM, V269, P22340; SKINNER RH, 1994, ANAL BIOCHEM, V223, P259, DOI 10.1006/abio.1994.1582; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	37	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6713	6719		10.1074/jbc.271.12.6713	http://dx.doi.org/10.1074/jbc.271.12.6713			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636091	hybrid			2022-12-25	WOS:A1996UB15700026
J	Kramer, A; Carstens, CP; Fahl, WE				Kramer, A; Carstens, CP; Fahl, WE			A novel CCAAT-binding protein necessary for adhesion-dependent cyclin A transcription at the G(1)/S boundary is sequestered by a retinoblastoma-like protein in G(0)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCT; CELL-CYCLE; COMPLETE TRANSFORMATION; FOCUS FORMATION; 3T3 CELLS; EXPRESSION; KINASE; FIBROBLASTS; ONCOGENE; PROMOTER	Loss of adhesion leads to cell cycle arrest at the G(1)/S boundary in normal, adhesion-dependent, mesenchymal cells. This arrest is accompanied by the inability to produce cyclin A. Using deletional and mutational analysis of the cyclin A promoter, we have identified a CCAAT element that mediates the adhesion; dependent transcriptional activation of cyclin A in late G, phase of the cell cycle, Specific binding of a novel 40/115-kDa heterodimeric protein complex, which we have named CBP/cycA, to this CCAAT element was detectable in growing but not in G(0)-arrested or nonadherent normal rat kidney fibroblasts, During G(0) CBP/cycA appears to be present but sequestered by a retinoblastoma family member. These results suggest that expression of cyclin A, which controls cell cycle progression by adhesion at the G(1)/S boundary, is regulated by CBP/cycA and the phosphorylation status of the retinoblastoma protein dr a retino blastoma-related protein.	UNIV WISCONSIN, MCARDLE LAB CANC RES, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison					NATIONAL CANCER INSTITUTE [R37CA042024] Funding Source: NIH RePORTER; NCI NIH HHS [R37-CA42024] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRETT JC, 1979, CANCER RES, V39, P1504; Berger LC, 1996, J VIROL, V70, P1203, DOI 10.1128/JVI.70.2.1203-1212.1996; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHESTERS PM, 1990, J GEN VIROL, V71, P449, DOI 10.1099/0022-1317-71-2-449; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COSTA RH, 1988, MOL CELL BIOL, V8, P81, DOI 10.1128/MCB.8.1.81; DAGNINO L, 1995, CELL GROWTH DIFFER, V6, P191; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; GOOD L, 1995, J CELL PHYSIOL, V163, P636, DOI 10.1002/jcp.1041630326; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUADAGNO TM, 1991, J CELL BIOL, V115, P1419, DOI 10.1083/jcb.115.5.1419; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HAYHURST GP, 1995, J VIROL, V69, P182, DOI 10.1128/JVI.69.1.182-188.1995; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HURLIN PJ, 1987, CANCER RES, V47, P5752; JIN HM, 1993, P NATL ACAD SCI USA, V90, P7563, DOI 10.1073/pnas.90.16.7563; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KATO J, 1993, GENE DEV, V7, P331; KNIGHT GB, 1987, P NATL ACAD SCI USA, V84, P8350, DOI 10.1073/pnas.84.23.8350; LUM LSY, 1992, MOL CELL BIOL, V12, P2599, DOI 10.1128/MCB.12.6.2599; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MARTINELLI R, 1994, MOL CELL BIOL, V14, P8322, DOI 10.1128/MCB.14.12.8322; MCCLURE DB, 1983, CELL, V32, P999, DOI 10.1016/0092-8674(83)90084-3; MONTELL C, 1984, CELL, V36, P951, DOI 10.1016/0092-8674(84)90045-X; NAKAMURA T, 1995, EXP CELL RES, V216, P422, DOI 10.1006/excr.1995.1053; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; ORCHARD K, 1993, NUCLEIC ACIDS RES, V21, P3335, DOI 10.1093/nar/21.14.3335; SCHLAEPFER DD, 1994, NATURE, V372, P786; STEELE C, 1992, CANCER RES, V52, P4706; STEVENS CW, 1988, MOL CELL BIOL, V8, P2089, DOI 10.1128/MCB.8.5.2089; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266	45	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6579	6582						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636070				2022-12-25	WOS:A1996UB15700005
J	McCarthy, TL; Casinghino, S; Mittanck, DW; Ji, CH; Centrella, M; Rotwein, P				McCarthy, TL; Casinghino, S; Mittanck, DW; Ji, CH; Centrella, M; Rotwein, P			Promoter-dependent and -independent activation of insulin-like growth factor binding protein-5 gene expression by prostaglandin E(2) in primary rat osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; BONE-FORMATION; FACTOR-BETA; CELLS; IDENTIFICATION; STIMULATION; SERUM; ACID; MITOGENESIS; FIBROBLASTS	Insulin-like growth factor (IGF) action is mediated by high affinity cell surface IGF receptors and modulated by a family of secreted IGF binding proteins (IGFBPs), IGFBP-5, the most conserved of six IGFBPs characterized to date, uniquely potentiates the anabolic actions of IGF-I for skeletal cells, In osteoblasts, IGFBP-5 production is stimulated by prostaglandin E(2) (PGE(2)), a local factor that mediates certain effects induced by parathyroid hormone, cytokines such as interleukin-1 and transforming growth factor-beta, and mechanical strain, In this study, we show that transcriptional and post-transcriptional events initiated by PGE(2) collaborate to enhance IGFBP-5 gene expression in primary fetal rat osteoblast cultures, PGE(2) treatment stimulated up to a 7-fold rise in steady-state levels of IGFBP-5 mRNA throughout 32 h of incubation, Analysis of nascent IGFBP-5 mRNA suggested that PGE(2) had only a modest stimulatory effect on IGFBP-5 gene transcription, and transient transfection studies with IGFBP-5 promoter-reporter genes confirmed that PGE, enhanced promoter activity by similar to 2-fold. Similar stimulatory effects were seen with forskolin. A DNA fragment with only 51 base pairs of the 5'-flanking sequence retained hormonal responsiveness, which may be mediated by a binding site for transcription factor AP-2 located at positions -44 to -36 in the proximal LGFBP-5 promoter, Incubation of osteoblasts with the mRNA transcriptional inhibitor 5,6-dichforo-1-beta-D-ribofilranosylbenzimidazole demonstrated that PGE(2) enhanced IGFBP-5 mRNA stability by 2-fold, increasing the t(1/2) from 9 to 18 h. The effects of PGE(2) on steady-state IGFBP-5 transcripts were abrogated by preincubating cells with cycloheximide, indicating that the effects of PGE(2) on both gene transcription and mRNA stability required ongoing protein synthesis, Therefore, both promoter-dependent and -independent pathways converge to enhance IGFBP-5 gene expression in response to PGE(2) in osteoblasts.	WASHINGTON UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOPHYS, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT INTERNAL MED, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	McCarthy, TL (corresponding author), YALE UNIV, SCH MED, SECT PLAST SURG, POB 208041, NEW HAVEN, CT 06520 USA.		Rotwein, Peter/R-5783-2019	Rotwein, Peter/0000-0002-9505-1817	NIDDK NIH HHS [DK47421, R01 DK042748, DK42748] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047421, R01DK042748] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; ANDRESS DL, 1992, J BIOL CHEM, V267, P22467; ANDRESS DL, 1991, BIOCHEM BIOPH RES CO, V176, P213, DOI 10.1016/0006-291X(91)90911-P; ARAI T, 1994, J BIOL CHEM, V269, P20388; BAUTISTA CM, 1991, BIOCHEM BIOPH RES CO, V176, P756, DOI 10.1016/S0006-291X(05)80249-9; BICHELL DP, 1993, ENDOCRINOLOGY, V133, P1020, DOI 10.1210/en.133.3.1020; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; CANALIS E, 1995, J BIOL CHEM, V270, P10771, DOI 10.1074/jbc.270.18.10771; CENTRELLA M, 1994, ENDOCRINOLOGY, V135, P1611, DOI 10.1210/en.135.4.1611; CENTRELLA M, 1989, ENDOCRINOLOGY, V125, P199, DOI 10.1210/endo-125-1-199; CENTRELLA M, 1995, MOL CELL BIOL, V15, P3273; CENTRELLA M, 1996, IN PRESS ANN NY ACAD; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOW JWM, 1994, AM J PHYSIOL, V267, pE287, DOI 10.1152/ajpendo.1994.267.2.E287; CHYUN YS, 1984, PROSTAGLANDINS, V27, P97, DOI 10.1016/0090-6980(84)90223-5; CLAUSSEN M, 1994, ENDOCRINOLOGY, V134, P1964, DOI 10.1210/en.134.4.1964; CLEMMONS DR, 1991, INSULIN LIKE GROWTH, V1; CONOVER CA, 1993, ENDOCRINOLOGY, V132, P2525, DOI 10.1210/en.132.6.2525; CONOVER CA, 1993, J CLIN ENDOCR METAB, V76, P1153, DOI 10.1210/jc.76.5.1153; DUAN CM, 1995, J BIOL CHEM, V270, P24844, DOI 10.1074/jbc.270.42.24844; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GABBITAS B, 1995, ENDOCRINOLOGY, V136, P2397, DOI 10.1210/en.136.6.2397; JEE WSS, 1990, BONE MINER, V15, P175; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; KANZAKI S, 1994, ENDOCRINOLOGY, V134, P383, DOI 10.1210/en.134.1.383; KIEFER MC, 1991, J BIOL CHEM, V266, P9043; KIEFER MC, 1992, J BIOL CHEM, V267, P12692; KLEINNULEND J, 1990, ENDOCRINOLOGY, V126, P1070, DOI 10.1210/endo-126-2-1070; KOU K, 1995, DNA CELL BIOL, V14, P241, DOI 10.1089/dna.1995.14.241; MARUSIC A, 1991, J IMMUNOL, V146, P2633; MCCARTHY TL, 1995, ENDOCRINOLOGY, V136, P3901, DOI 10.1210/en.136.9.3901; MCCARTHY TL, 1994, J CELL PHYSIOL, V160, P163, DOI 10.1002/jcp.1041600119; MCCARTHY TL, 1988, J BONE MINER RES, V3, P401; MCCARTHY TL, 1993, ADV EXP MED BIOL, V343, P407; NAM TJ, 1994, ENDOCRINOLOGY, V135, P1385, DOI 10.1210/en.135.4.1385; NGAN P, 1990, ARCH ORAL BIOL, V35, P717, DOI 10.1016/0003-9969(90)90094-Q; NICOLETTI VG, 1993, BIOTECHNIQUES, V14, P532; PEAD MJ, 1989, CALCIFIED TISSUE INT, V45, P34, DOI 10.1007/BF02556658; RAWLINSON SCF, 1991, J BONE MINER RES, V6, P1345; ROTWEIN P, 1995, MOL ENDOCRINOL, V9, P913, DOI 10.1210/me.9.7.913; Sambrook J., 2002, MOL CLONING LAB MANU; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; THRAILKILL KM, 1995, ENDOCRINOLOGY, V136, P3527, DOI 10.1210/en.136.8.3527	44	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6666	6671		10.1074/jbc.271.12.6666	http://dx.doi.org/10.1074/jbc.271.12.6666			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636084	hybrid			2022-12-25	WOS:A1996UB15700019
J	Qi, XY; Qin, W; Sun, Y; Kondoh, K; Grabowski, GA				Qi, XY; Qin, W; Sun, Y; Kondoh, K; Grabowski, GA			Functional organization of saposin C - Definition of the neurotrophic and acid beta-glucosidase activation regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAUCHER DISEASE; AMINO-ACID; PROTEIN-2 SAP-2; INVESTIGATE; SEQUENCE; PATIENT; VARIANT; SPLEEN; GLUCOCEREBROSIDASE; BIOSYNTHESIS	Saposin C is an essential co-factor for the hydrolysis of glucosylceramide by acid beta-glucosidase in mammals, In addition, prosaposin promotes neurite outgrowth in vitro via sequences in saposin C. The regional organization of these neurotrophic and activation properties of saposin C was elucidated using recombinant or chemically synthesized saposin Cs from various regions of the molecule. Unreduced and reduced proteins were analyzed by electrospray-mass spectrometry to establish the complement of disulfide bonds in selected saposin Cs. Using saposin B as a unreactive backbone, chimeric saposins containing various length segments of saposin B and C localized the neurotrophic and acid beta-glucosidase activation properties to the carboxyl- and NH2-terminal 50% of saposin C, respectively. The peptide spanning residues 22-31 had neurotrophic effects. Molecular modeling and site-directed mutagenesis localized the activation properties of saposin C to the region spanning residues 47-62. Secondary structure was needed for retention of this property. Single substitutions of R and S at the conserved cysteines at 47 or 78 diminished but did not obliterate the activation properties. These results indicate the segregation of neurotrophic and activation properties of saposin C to two different faces of the molecule and suggest a topographic sequestration of the activation region of prosaposin for protection of the cell from adverse hydrolytic activity of acid beta-glucosidase.	CHILDRENS HOSP,MED CTR,RES FDN,DIV HUMAN GENET,CINCINNATI,OH 45229; UNIV CINCINNATI,COLL MED,DEPT PEDIAT,CINCINNATI,OH 45229; EHIME UNIV,SCH MED,DEPT NEUROPSYCHIAT,MATSUYAMA,EHIME 79001,JAPAN	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Ehime University					NIDDK NIH HHS [DK 36729] Funding Source: Medline; NINDS NIH HHS [NS 34071] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034071] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERENT SL, 1981, BIOCHIM BIOPHYS ACTA, V664, P572, DOI 10.1016/0005-2760(81)90134-X; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; CHRISTOMANOU H, 1989, KLIN WOCHENSCHR, V67, P999, DOI 10.1007/BF01716064; CHRISTOMANOU H, 1986, BIOL CHEM H-S, V367, P879, DOI 10.1515/bchm3.1986.367.2.879; COLLARD MW, 1988, BIOCHEMISTRY-US, V27, P4557, DOI 10.1021/bi00412a050; FABBRO D, 1991, J BIOL CHEM, V266, P15021; FUJIBAYASHI S, 1985, AM J HUM GENET, V37, P741; FUJIBAYASHI S, 1986, BIOCHIM BIOPHYS ACTA, V875, P554; FUJIBAYASHI S, 1986, J BIOL CHEM, V261, P5339; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; GARRETT KO, 1985, ARCH BIOCHEM BIOPHYS, V238, P344, DOI 10.1016/0003-9861(85)90173-0; GAVRIELIRORMAN E, 1989, GENOMICS, V5, P486; GRABOWSKI GA, 1990, CRIT REV BIOCHEM MOL, V25, P385, DOI 10.3109/10409239009090616; GREENBERG P, 1990, BIOCHIM BIOPHYS ACTA, V1039, P12, DOI 10.1016/0167-4838(90)90220-A; HIRAIWA M, 1992, P NATL ACAD SCI USA, V89, P11254, DOI 10.1073/pnas.89.23.11254; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HO MW, 1971, P NATL ACAD SCI USA, V68, P2810, DOI 10.1073/pnas.68.11.2810; IYER SS, 1983, BIOCHIM BIOPHYS ACTA, V748, P1, DOI 10.1016/0167-4838(83)90020-1; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; KLEIN A, 1994, BIOCHEM BIOPH RES CO, V200, P1440, DOI 10.1006/bbrc.1994.1612; KONDOH K, 1993, J COMP NEUROL, V334, P590, DOI 10.1002/cne.903340407; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORIMOTO S, 1990, J BIOL CHEM, V265, P1933; NAKANO T, 1989, J BIOCHEM-TOKYO, V105, P152, DOI 10.1093/oxfordjournals.jbchem.a122629; OBRIEN JS, 1995, FASEB J, V9, P681, DOI 10.1096/fasebj.9.8.7768361; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; OBRIEN JS, 1994, P NATL ACAD SCI USA, V91, P9593, DOI 10.1073/pnas.91.20.9593; OSIECKINEWMAN K, 1987, BIOCHIM BIOPHYS ACTA, V915, P87, DOI 10.1016/0167-4838(87)90128-2; PRENCE E, 1985, ARCH BIOCHEM BIOPHYS, V236, P98, DOI 10.1016/0003-9861(85)90609-5; QI XY, 1994, J BIOL CHEM, V269, P16746; RAFI MA, 1993, SOMAT CELL MOLEC GEN, V19, P1, DOI 10.1007/BF01233949; REINER O, 1989, J MOL NEUROSCI, V1, P225; SANO A, 1988, J BIOL CHEM, V263, P19597; SANO A, 1992, BIOCHIM BIOPHYS ACTA, V1120, P75, DOI 10.1016/0167-4838(92)90426-E; SCHNABEL D, 1991, FEBS LETT, V284, P57, DOI 10.1016/0014-5793(91)80760-Z; SUN Y, 1994, AM J PATHOL, V145, P1390; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; UEMURA KL, 1991, J BIOCHEM-TOKYO, V1100, P96; VACCARO AM, 1995, J BIOL CHEM, V270, P9953, DOI 10.1074/jbc.270.17.9953; WEILER S, 1995, PROTEIN SCI, V4, P756	40	73	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6874	6880		10.1074/jbc.271.12.6874	http://dx.doi.org/10.1074/jbc.271.12.6874			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636113	hybrid			2022-12-25	WOS:A1996UB15700048
J	Wolfe, PC; Chang, EY; Rivera, J; Fewtrell, C				Wolfe, PC; Chang, EY; Rivera, J; Fewtrell, C			Differential effects of the protein kinase C activator phorbol 12-myristate 13-acetate on calcium responses and secretion in adherent and suspended RBL-2H3 mucosal mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; HISTAMINE-RELEASE; IMMUNOGLOBULIN-E; 2H3 CELLS; TYROSINE PHOSPHORYLATION; CROSS-LINKING; RECEPTOR; INFLUX; EXOCYTOSIS; SIGNALS	Adhesion of RBL-2H3 mucosal mast cells to fibronectin-coated surfaces has been linked to changes in secretion and tyrosine kinase activity, me now show that adhesion affects the sensitivity of RBL cells to the protein kinase C activator phorbol 12-myristate 13-acetate (PMA). In suspended cells, PMA inhibited antigen-induced calcium influx (as measured by manganese influx) and changes in intracellular free calcium and had complex effects on antigen-stimulated secretion, However, in adherent cells PMA had little effect on these responses, Suspended cells only secreted in response to thapsigargin if they were co-treated with PMA, while adherent cells secreted in response to thapsigargin alone, The thapsigargin-induced secretion in adherent cells was inhibited by protein kinase C down-regulation and by the protein kinase C inhibitor GF 109203X, but not by calphostin C, We suggest that protein kinase C is constitutively activated in adherent cells, possibly due to modification of the regulatory domain of the enzyme.	NIAMS,NIH,SECT CHEM IMMUNOL,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Wolfe, PC (corresponding author), CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853, USA.		Wan, Daniel/F-4689-2010		NIAID NIH HHS [AI 19910] Funding Source: Medline; NIGMS NIH HHS [GM 08210] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008210] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI H, 1994, BIOCHEM J, V304, P431, DOI 10.1042/bj3040431; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BEAVEN MA, 1987, J CELL BIOL, V105, P1129, DOI 10.1083/jcb.105.3.1129; BEAVEN MA, 1984, J BIOL CHEM, V259, P7129; BEAVEN MA, 1984, J BIOL CHEM, V259, P7137; BEAVEN MA, 1988, PROG ALLERGY, V42, P123; BENHAMOU M, 1992, J BIOL CHEM, V267, P7310; CLEVELAND PL, 1993, CELL CALCIUM, V14, P1, DOI 10.1016/0143-4160(93)90013-V; CREWS FT, 1981, ARCH BIOCHEM BIOPHYS, V212, P561, DOI 10.1016/0003-9861(81)90399-4; CUNHAMELO JR, 1989, J IMMUNOL, V143, P2617; EISEN HN, 1959, J EXP MED, V110, P187, DOI 10.1084/jem.110.2.187; FALCONE D, 1995, J CELL PHYSIOL, V164, P205, DOI 10.1002/jcp.1041640125; FASOLATO C, 1993, P NATL ACAD SCI USA, V90, P3068, DOI 10.1073/pnas.90.7.3068; FEWTRELL C, 1987, BIOCHEMISTRY-US, V26, P6995, DOI 10.1021/bi00396a021; FEWTRELL C, 1981, BIOCH ACUTE ALLERGIC, P295; GERMANO P, 1994, J BIOL CHEM, V269, P23102; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; HAMAWY MM, 1992, J IMMUNOL, V149, P615; HAMAWY MM, 1994, IMMUNOL TODAY, V15, P62, DOI 10.1016/0167-5699(94)90135-X; HAMAWY MM, 1994, J IMMUNOL, V153, P4655; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HOGG N, 1993, CURR OPIN IMMUNOL, V5, P383, DOI 10.1016/0952-7915(93)90057-Y; KANNER BI, 1984, J BIOL CHEM, V259, P188; KILEY SC, 1992, CARCINOGENESIS, V13, P1997, DOI 10.1093/carcin/13.11.1997; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LIU FT, 1980, J IMMUNOL, V124, P2728; MELLONI E, 1987, P NATL ACAD SCI USA, V84, P5282, DOI 10.1073/pnas.84.15.5282; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MILLARD PJ, 1989, J BIOL CHEM, V264, P19730; MOHR FC, 1987, J CELL BIOL, V104, P783, DOI 10.1083/jcb.104.3.783; MOHR FC, 1991, FASEB J, V5, pA1044; OZAWA K, 1993, J BIOL CHEM, V268, P2280; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; SAGIEISENBERG R, 1985, NATURE, V313, P59, DOI 10.1038/313059a0; SAGIEISENBERG R, 1984, IMMUNOL LETT, V8, P237, DOI 10.1016/0165-2478(84)90002-6; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1995, BIOCHEM BIOPH RES CO, V214, P888, DOI 10.1006/bbrc.1995.2370; TAUROG JD, 1979, J IMMUNOL, V122, P2150; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WHITE KN, 1988, J IMMUNOL, V141, P942; YAMADA K, 1992, J IMMUNOL, V149, P1031	44	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6658	6665		10.1074/jbc.271.12.6658	http://dx.doi.org/10.1074/jbc.271.12.6658			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636083	hybrid			2022-12-25	WOS:A1996UB15700018
J	Wood, SJ; MacKenzie, L; Maleeff, B; Hurle, MR; Wetzel, R				Wood, SJ; MacKenzie, L; Maleeff, B; Hurle, MR; Wetzel, R			Selective inhibition of A beta fibril formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; CIRCULAR-DICHROISM; AMYLOID PROTEIN; PEPTIDES; BINDING; TRANSTHYRETIN; CONFORMATION; INVITRO	We describe here an inhibitor of in vitro fibril formation, hexadecyl-N-methylpiperidinium (HMP) bromide, which is selective for the Alzheimer's disease peptide A beta. At 10 mu M, its IC50 for inhibiting A beta aggregation at pH 5.8, HMP bromide does not inhibit fibril formation by other amyloidogenic polypeptides nor does it affect the folding stability of the beta-sheet-rich immunoglobulin V-L domain REI, In addition, small structural modifications of HMP bromide reduce or eliminate its ability to inhibit pH 5.8 aggregation of A beta, These indications of specificity, plus the ability of the molecule to inhibit A beta aggregation at concentrations almost an order of magnitude below its critical micelle concentration, suggest a mechanism of inhibition other than micellar solubilization of A beta. HMP bromide is required in approximately a 1:1 stoichiometry for effective inhibition at pH 5.8. Although stoichiometric amounts of HMP bromide with respect to total A beta inhibit A beta fibril formation at pH 7.4, the molecule is incapable, at lower concentrations, of blocking the seeding of fibril formation by small amounts of added A beta fibrils, The results suggest the existence of a binding surface on A beta capable of binding amphipathic molecules such as HMP bromide and which, when occupied, precludes assembly of A beta into amyloid fibrils. Molecules that bind to this site with high specificity may prove to be useful therapeutic agents for preventing or retarding the cerebral amyloid plaque formation implicated in Alzheimer's disease pathology.	SMITHKLINE BEECHAM PHARMACEUT,DEPT TOXICOL,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT BIOMOL CHEM,KING OF PRUSSIA,PA 19406; SMITHKLINE BEECHAM PHARMACEUT,DEPT MACROMOLEC SCI,KING OF PRUSSIA,PA 19406	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline			Wetzel, Ronald/G-7453-2011					BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; Budavari S., 1989, MERCK INDEX; CLARKE S, 1975, J BIOL CHEM, V250, P5459; CLELAND JL, 1992, J BIOL CHEM, V267, P13327; COLON W, 1992, BIOCHEMISTRY-US, V31, P8654, DOI 10.1021/bi00151a036; EPP O, 1974, EUR J BIOCHEM, V45, P513, DOI 10.1111/j.1432-1033.1974.tb03576.x; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; FINN BE, 1992, PROTEIN ENG PRACTICA, P167; FRASER PE, 1994, J MOL BIOL, V244, P64, DOI 10.1006/jmbi.1994.1704; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1971, SCIENCE, V174, P712, DOI 10.1126/science.174.4010.712; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; HERRMANN KW, 1966, J COLLOID INTERF SCI, V22, P352, DOI 10.1016/0021-9797(66)90015-4; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; HOWLETT DR, 1995, NEURODEGENERATION, V4, P23, DOI 10.1006/neur.1995.0003; HURLE MR, 1994, P NATL ACAD SCI USA, V91, P5446, DOI 10.1073/pnas.91.12.5446; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; LEE JP, 1995, BIOCHEMISTRY-US, V34, P5191, DOI 10.1021/bi00015a033; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; Moeller J.V., 1993, J BIOL CHEM, V268, P18659; MULLAN M, 1993, TRENDS NEUROSCI, V16, P398, DOI 10.1016/0166-2236(93)90007-9; MULTHAUP G, 1993, BIOL CHEM H-S, V374, P1; PIKE CJ, 1993, J NEUROSCI, V13, P1676; ROBINSON NC, 1975, BIOCHEMISTRY-US, V14, P369, DOI 10.1021/bi00673a025; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SELKOE DJ, 1995, NATURE, V375, P734, DOI 10.1038/375734a0; SHIRAHAMA T, 1975, AM J PATHOL, V81, P101; Sisodia S S, 1992, Curr Opin Neurobiol, V2, P648, DOI 10.1016/0959-4388(92)90033-H; SNYDER SW, 1994, BIOPHYS J, V67, P1216, DOI 10.1016/S0006-3495(94)80591-0; SOREGHAN B, 1994, J BIOL CHEM, V269, P28551; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P2843, DOI 10.1073/pnas.87.7.2843; WESTERMARK P, 1990, P NATL ACAD SCI USA, V87, P5036, DOI 10.1073/pnas.87.13.5036; WESTERMARK P, 1994, AMYLOID, V1, P47, DOI 10.3109/13506129409148624; WETLAUFER DB, 1995, PROTEIN SCI, V4, P1535, DOI 10.1002/pro.5560040811; WOOD SJ, 1995, BIOCHEMISTRY-US, V34, P724, DOI 10.1021/bi00003a003; WOOD SJ, 1996, IN PRESS J MOL BIOL, V255; YANG JT, 1986, METHOD ENZYMOL, V130, P208	42	156	164	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4086	4092						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626745				2022-12-25	WOS:A1996TW96000023
J	Yu, B; Wright, SD				Yu, B; Wright, SD			Catalytic properties of lipopolysaccharide (LPS) binding protein - Transfer of LPS to soluble CD14	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS	Lipopolysaccharide (LPS) binding protein (LBP) is a lipid transfer protein that catalyzes transfer of LPS monomers from micelles to a binding site on soluble CD14 (sCD14) and transfer of LPS from LPS sCD14 complexes to HDL particles, To characterize the first of these two reactions, LPS covalently derivatized with the fluorophore, boron dipyrromethene difluoride (BODIPY), was used to monitor LBP-catalyzed movement of LPS in real time. The fluorescence efficiency of micelles of BODIPY-LPS was low but was strongly increased upon dissolution in detergent or upon binding to sCD14. Spontaneous binding of BODIPY-LPS to sCD14 was very slow but was accelerated by substoichiometric concentration of LBP, and the rate of binding was measured under a variety of conditions. LBP catalyzed transfer was first order with respect to both sCD14 and LPS concentration, and the apparent K-m values were 1 similar to 2 mu g/ml for sCD14 and 100 ng/ml for LPS. The maximum turnover number for LBP was approximately 150 molecules of LPS min(-1) LBP(-1). LBP alone caused a small but measurable increase in the fluorescence of BODIPY-LPS, suggesting that it bound LPS aggregates but did not readily remove LPS monomers. The subsequent addition of sCD14 caused a large fluorescence increase, suggesting transfer of BODIPY-LPS to sCD14. These and other observations suggest that LPS is transferred by an ordered ternary complex reaction mechanism in which LBP transfers LPS monomer from LPS aggregates to sCD14 without dissociating from the LPS aggregate.	ROCKEFELLER UNIV,CELLULAR PHYSIOL & IMMUNOL LAB,NEW YORK,NY 10021	Rockefeller University					NIAID NIH HHS [AI 30556] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030556] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		GAZZANOSANTORO H, 1994, INFECT IMMUN, V62, P1185, DOI 10.1128/IAI.62.4.1185-1191.1994; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; JUAN TSC, 1995, J BIOL CHEM, V270, P5219, DOI 10.1074/jbc.270.10.5219; KIRKLAND TN, 1993, J BIOL CHEM, V268, P24818; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; SHUMANN RR, 1990, SCIENCE, V249, P1429; TOBIAS PS, 1989, J BIOL CHEM, V264, P10867; TOBIAS PS, 1995, J BIOL CHEM, V270, P10482, DOI 10.1074/jbc.270.18.10482; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; VANVOORHIS WC, 1983, J EXP MED, V158, P126, DOI 10.1084/jem.158.1.126; WALSH C, 1979, ENZYMATIC REACTION M, P216; WRIGHT SD, 1995, J IMMUNOL, V155, P6; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; WRIGHT SD, 1989, J EXP MED, V170, P1241; WURFEL MM, 1995, J EXP MED, V181, P1743, DOI 10.1084/jem.181.5.1743; WURFEL MM, 1994, J EXP MED, V180, P1025, DOI 10.1084/jem.180.3.1025; YU B, 1995, J INFLAMM, V45, P115	18	171	181	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4100	4105						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626747				2022-12-25	WOS:A1996TW96000025
J	Bittner, MA; Bennett, MK; Holz, RW				Bittner, MA; Bennett, MK; Holz, RW			Evidence that syntaxin 1A is involved in storage in the secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; BOTULINUM NEUROTOXIN-A; MOTOR-NERVE TERMINALS; HUMAN GROWTH-HORMONE; TETANUS-TOXIN; NEUROTRANSMITTER RELEASE; CLOSTRIDIAL NEUROTOXINS; SYNAPTIC VESICLES; STREPTOLYSIN-O; LIGHT-CHAINS	Syntaxin 1A is a nervous system-specific protein thought to function during the late steps of the regulated secretory pathway by mediating the docking of secretory vesicles with the plasma membrane. We have examined the effects of transiently overexpressing syntaxin 1A on protein secretion in constitutively secreting cell lines that do not normally express the protein. Syntaxin 1A slowed the constitutive release of marker proteins human growth hormone (hGH) and vesicular stomatitis virus glycoprotein from COS-1 cells, increasing the intracellular half-life of human growth hormone from 90 min to 18 h. A similar effect was observed in HEK 293 cells. Immunofluorescence microscopy revealed that these secretory proteins were concentrated in the periphery of the cell. The effect was specific for the full-length neuronal protein. Neither a syntaxin 1A variant which lacks a membrane attachment domain nor syntaxin 2 caused the cells to retain human growth hormone. The effect of syntaxin 1A was partially reversed by incubating the cells with botulinum type C-1 neurotoxin, which specifically cleaves syntaxin Ik Release of human growth hormone from syntaxin 1A-expressing cells was maintained during a blockade of protein synthesis, suggesting that the hormone was being released from a pool of stored vesicles which accumulated before the addition of cycloheximide. The existence of a post-Golgi storage compartment in syntaxin 1A-expressing cells was confirmed using brefeldin A to collapse the Golgi stacks in both HEK 293 and COS-1 cells. Brefeldin A rapidly blocked growth hormone release in control cultures while having no effect on release in cells expressing syntaxin 1A. Reducing the temperature to 19 degrees C, which inhibits transport from the trans-Golgi network, also inhibited hGH secretion from cells without syntaxin 1A but had little effect on hGH secretion hom cells with syntaxin 1A. The present experiments indicate that syntaxin 1A enables the storage of vesicles which would otherwise be immediately released.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	Bittner, MA (corresponding author), UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,M 1301 MSRB III,ANN ARBOR,MI 48109, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027959] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK27959] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHNERTHILGER G, 1993, NEUROSCIENCE, V53, P547, DOI 10.1016/0306-4522(93)90219-6; AHNERTHILGER G, 1989, J NEUROCHEM, V52, P1751, DOI 10.1111/j.1471-4159.1989.tb07253.x; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BINZ T, 1994, J BIOL CHEM, V269, P1617; BITTNER MA, 1989, J BIOL CHEM, V264, P10354; BITTNER MA, 1988, J NEUROCHEM, V51, P451, DOI 10.1111/j.1471-4159.1988.tb01059.x; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; DREYER F, 1987, N-S ARCH PHARMACOL, V335, P1, DOI 10.1007/BF00165027; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GANSEL M, 1987, PFLUG ARCH EUR J PHY, V409, P533, DOI 10.1007/BF00583812; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GREEN R, 1984, J CELL BIOL, V99, P97, DOI 10.1083/jcb.99.1.97; HALPERN JL, 1990, J NEUROCHEM, V55, P2072, DOI 10.1111/j.1471-4159.1990.tb05797.x; HUANG XF, 1994, J BIOL CHEM, V269, P20838; INOUE A, 1992, J BIOL CHEM, V267, P10613; LEE SA, 1986, J BIOL CHEM, V261, P7089; LEVEQUE C, 1994, J BIOL CHEM, V269, P6306; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MOORE HPH, 1985, J CELL BIOL, V101, P1773, DOI 10.1083/jcb.101.5.1773; PENNER R, 1986, NATURE, V324, P76, DOI 10.1038/324076a0; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PFEFFER SR, 1994, P NATL ACAD SCI USA, V91, P1987, DOI 10.1073/pnas.91.6.1987; POULAIN B, 1991, J BIOL CHEM, V266, P9580; SANDERS D, 1992, N-S ARCH PHARMACOL, V346, P358; SCHIAVO G, 1995, J BIOL CHEM, V270, P10566, DOI 10.1074/jbc.270.18.10566; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1993, J BIOL CHEM, V268, P23784; SCHIAVO G, 1993, J BIOL CHEM, V268, P11516; SCHULZE KL, 1995, CELL, V80, P311, DOI 10.1016/0092-8674(95)90414-X; SCHWEITZER ES, 1985, J CELL BIOL, V101, P667, DOI 10.1083/jcb.101.2.667; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHENG ZH, 1994, NEURON, V13, P1303, DOI 10.1016/0896-6273(94)90417-0; SIMPSON LL, 1988, J PHARMACOL EXP THER, V245, P867; SIMPSON LL, 1989, BOTULINUM NEUROTOXIN, P153; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STROUS GJ, 1993, J BIOL CHEM, V268, P2341; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; WICK PW, 1993, J BIOL CHEM, V28, P10983; YAMASAKI S, 1994, J BIOL CHEM, V269, P12764	48	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11214	11221		10.1074/jbc.271.19.11214	http://dx.doi.org/10.1074/jbc.271.19.11214			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626670				2022-12-25	WOS:A1996UJ94400030
J	Li, M; Makkinje, A; Damuni, Z				Li, M; Makkinje, A; Damuni, Z			The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE KIDNEY CORTEX; CATALYTIC SUBUNIT; PROTAMINE-KINASE; REGULATORY SUBUNIT; OKADAIC ACID; PHOSPHORYLATION; TYPE-2A; FORMS; PURIFICATION; SEQUENCE	Two potent heat-stable protein phosphatase 2A (PP2A) inhibitor proteins designated I-1(PP2A) and I-2(PP2A) have been purified to apparent homogeneity from extracts of bovine kidney (Li, M., Guo, H., and Damuni, Z. (1995) Biochemistry 34, 1988-1996). N-terminal and internal amino acid sequencing indicated that I-2(PP2A) was a truncated form of SET, a largely nuclear protein that is fused to nucleoporin Nup214 in acute non-lymphocytic myeloid leukemia. Experiments using purified preparations of recombinant human SET confirmed that this protein inhibited PP2A. Half-maximal inhibition of the phosphatase occurred at about 2 nM SET. By contrast, SET (up to 20 nM) did not affect the activities of purified preparations of protein phosphatases 1, 2B, and 2C. The results indicate that SET is a potent and specific inhibitor of PP2A and suggest that impaired regulation of PP2A may contribute to acute myeloid leukemogenesis.	PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT CELLULAR & MOLEC PHYSIOL, COLL MED, HERSHEY, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health								ADACHI Y, 1994, J BIOL CHEM, V269, P2258; AMICK GD, 1992, BIOCHEM J, V287, P1019, DOI 10.1042/bj2871019; ARINO J, 1988, P NATL ACAD SCI USA, V85, P4252, DOI 10.1073/pnas.85.12.4252; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; DAMUNI Z, 1989, J BIOL CHEM, V264, P6412; Deibler G E, 1984, Prog Clin Biol Res, V146, P249; FAVRE B, 1994, J BIOL CHEM, V269, P16311; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; FORNEROD M, 1995, ONCOGENE, V10, P1739; GUO H, 1993, J BIOL CHEM, V268, P11193; GUO H, 1993, P NATL ACAD SCI USA, V90, P2500, DOI 10.1073/pnas.90.6.2500; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; MAKKINJE A, 1995, J BIOL CHEM, V270, P14824, DOI 10.1074/jbc.270.24.14824; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MITELMAN F, 1990, CYTOGENET CELL GENET, V55, P358, DOI 10.1159/000133022; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; REDDY SAG, 1990, J BIOL CHEM, V265, P7748; REDDY SAG, 1993, J BIOL CHEM, V268, P15298; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SILVA OBD, 1987, FEBS LETT, V221, P415, DOI 10.1016/0014-5793(87)80966-3; SILVA OBDC, 1987, FEBS LETT, V226, P176; SNEDDON AA, 1990, EMBO J, V9, P4339, DOI 10.1002/j.1460-2075.1990.tb07883.x; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; VAESEN M, 1994, BIOL CHEM H-S, V375, P113, DOI 10.1515/bchm3.1994.375.2.113; VONLINDERN M, 1992, BAILLIERE CLIN HAEM, V5, P857, DOI 10.1016/S0950-3536(11)80049-1; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; ZOLNIEROWICZ S, 1994, BIOCHEMISTRY-US, V33, P11858, DOI 10.1021/bi00205a023	42	400	421	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	1996	271	19					11059	11062		10.1074/jbc.271.19.11059	http://dx.doi.org/10.1074/jbc.271.19.11059			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ944	8626647	hybrid			2022-12-25	WOS:A1996UJ94400007
J	Lawrie, AM; Rizzuto, R; Pozzan, T; Simpson, AWM				Lawrie, AM; Rizzuto, R; Pozzan, T; Simpson, AWM			A role for calcium influx in the regulation of mitochondrial calcium in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-TISSUES; CA2+; INACTIVATION; CA-2+; AEQUORIN; CHANNELS; CURRENTS; EXCHANGE; HEART	By using an endothelial cell line (ECV304), derived from human umbilical vein and transfected with recombinant aequorin targeted to the mitochondrial matrix, we find that stimulation with ATP evokes long lasting increases in mitochondrial Ca2+ ([Ca2+](m)) that largely depend on Ca2+ influx. In these cells, the release of stored Ca2+ is inefficient at elevating [Ca2+](m), Consequently it appears that in ECV304 cells, bulk cytosolic Ca2+ ([Ca2+](c)) is the main determinant of [Ca2+](m) changes. In ECV304 cells <4% of mitochondria are within 700 nm of the endoplasmic reticulum as opposed to 65% in HeLa cells, whereas 14% are within 700 nm of the inner surface of the plasma membrane, compared with <6% in HeLa cells, Following Ca2+ depletion, readdition of extracellular Ca2+ evokes an increase in [Ca2+](m) but not in [Ca2+](c). Under these conditions, microdomains of high [Ca2+](c) may occur beneath the plasma membrane of ECV304 cells resulting in the preferential elevation of Ca2+ in mitochondria located in this region. A model is discussed in which the localization of mitochondria with respect to Ca2+ sources is the main determinant of their in situ Ca2+ uptake kinetics, Thus, in any given cell type mitochondria may be localized to suit the energy and metabolic demands of their physiological actions.	UNIV LIVERPOOL, DEPT HUMAN ANAT & CELL BIOL, LIVERPOOL L69 3BX, MERSEYSIDE, ENGLAND; UNIV PADUA, DEPT BIOMED SCI, I-35121 PADUA, ITALY	University of Liverpool; University of Padua			Rizzuto, Rosario/B-6312-2008	Rizzuto, Rosario/0000-0001-7044-5097	Telethon [495] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Telethon(Fondazione Telethon); Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLAUSTEIN MP, 1977, BIOPHYS J, V20, P79, DOI 10.1016/S0006-3495(77)85538-0; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; COBBOLD PH, 1990, CELLULAR CALCIUM PRA, P55; DENTON RM, 1990, ANNU REV PHYSIOL, V52, P451, DOI 10.1146/annurev.ph.52.030190.002315; GIANNATTASIO B, 1991, J GEN PHYSIOL, V98, P987, DOI 10.1085/jgp.98.5.987; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; KASS GEN, 1989, J BIOL CHEM, V264, P15192; KOHR G, 1991, J GEN PHYSIOL, V98, P941, DOI 10.1085/jgp.98.5.941; MCCORMACK JG, 1993, BIOCHEM SOC T, V21, P793, DOI 10.1042/bst0210793; MCCORMACK JG, 1992, BIOCHEM SOC T, V20, P153, DOI 10.1042/bst0200153; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MIYATA H, 1991, AM J PHYSIOL, V261, pH1123, DOI 10.1152/ajpheart.1991.261.4.H1123; MONCADA S, 1991, PHARMACOL REV, V43, P109; NEWBY AC, 1990, ANNU REV PHYSIOL, V52, P661; RASGADOFLORES H, 1987, AM J PHYSIOL, V252, pC499, DOI 10.1152/ajpcell.1987.252.5.C499; RIZZUTO R, 1987, BIOCHEM J, V246, P271, DOI 10.1042/bj2460271; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; RIZZUTO R, 1994, METHOD CELL BIOL, V40, P339; SHIMOMURA O, 1988, BIOCHEM J, V251, P405, DOI 10.1042/bj2510405; TAKAHASHI K, 1990, IN VITRO CELL DEV, V25, P265; YUE DT, 1990, SCIENCE, V250, P1735, DOI 10.1126/science.2176745	26	163	163	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10753	10759		10.1074/jbc.271.18.10753	http://dx.doi.org/10.1074/jbc.271.18.10753			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631885	hybrid			2022-12-25	WOS:A1996UJ34200053
J	Wu, YY; Sonnino, S; Li, YT; Li, SC				Wu, YY; Sonnino, S; Li, YT; Li, SC			Characterization of an alternatively spliced G(M2) activator protein, G(M2A) protein - An activator protein which stimulates the enzymatic hydrolysis of N-acetylneuraminic acid, but not N-acetylgalactosamine, from G(M2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-HEXOSAMINIDASE-A; GM2 GANGLIOSIDOSIS; SULFATIDE ACTIVATOR; ENZYMIC-HYDROLYSIS; MOLECULAR-GENETICS; DEGRADATION; VARIANT; DEFICIENCY; EXPRESSION	G(M2) activator protein is a protein cofactor which stimulates the enzymatic hydrolysis of both GalNAc and NeuAc from G(M2). We have previously isolated two cDNA clones, G(M2) activator cDNA and G(M2A) cDNA, for human G(M2) activator protein (Nagarajan, S., Chen, H.-C., Li, S.-C., Li, Y.-T., and Lockyer, J. M. (1992) Biochem. J. 282, 807-813). G(M2A) mRNA is an RNA alternative splicing product that contains exons 1, 2, 3, and intron 3 of the genomic DNA sequence of G(M2) activator protein (Klima, H., Tanaka, A., Schnabel, D., Nakano, T., Schroder, M., Suzuki, K., and Sandhoff, K. (1991) FEES Left. 289, 260-264). G(M2A) cDNA encodes a protein (G(M2A) protein) containing 1-109 of the 160 amino acids of human G(M2) activator protein, plus a tripeptide (VST) encoded by intron 3 at the COOH terminus. Thus, G(M2A) protein can be regarded as a form (truncated version) of G(M2) activator protein. We have expressed G(M2A) cDNA in Escherichia coli using pT7-7 as the vector. The recombinant G(M2A) protein was purified to an electrophoretically homogeneous form and was found to stimulate the hydrolysis of NeuAc from G(M2) by clostridial sialidase, but not the hydrolysis of GalNAc from G(M2) by beta-hexosaminidase A. Like G(M2) activator protein, G(M2A) protein also specifically recognized the terminal G(M2) epitope in GalNAc-GD1a and stimulated the hydrolysis of only the external NeuAc from this ganglioside by clostridial sialidase. These results enabled us to discern the enzymatic hydrolyses of GalNAc and NeuAc from the G(M2) epitope and established that the NeuAc recognition domain of G(M2) activator protein is located within amino acids 1-109. The presence of G(M2A) mRNA in human tissues and the selective stimulation of NeuAc hydrolysis by G(M2A) protein indicate that this activator protein may be involved in the catabolism of G(M2) through the asialo-G(M2) pathway.	TULANE UNIV,SCH MED,DEPT BIOCHEM,NEW ORLEANS,LA 70112; UNIV MILAN,SCH MED,DEPT MED CHEM & BIOCHEM,I-20133 MILAN,ITALY	Tulane University; University of Milan			Sonnino, Sandro/R-4154-2017	Sonnino, Sandro/0000-0001-8180-5908	NINDS NIH HHS [NS 09626] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009626] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACQUOTTI D, 1994, EUR J BIOCHEM, V225, P271, DOI 10.1111/j.1432-1033.1994.00271.x; BURG J, 1985, ANN HUM GENET, V49, P41, DOI 10.1111/j.1469-1809.1985.tb01674.x; CONZELMANN E, 1978, P NATL ACAD SCI USA, V75, P3979, DOI 10.1073/pnas.75.8.3979; CONZELMANN E, 1979, H-S Z PHYSIOL CHEM, V360, P1837, DOI 10.1515/bchm2.1979.360.2.1837; FINGERHUT R, 1992, EUR J BIOCHEM, V208, P623, DOI 10.1111/j.1432-1033.1992.tb17227.x; FURST W, 1990, EUR J BIOCHEM, V192, P709, DOI 10.1111/j.1432-1033.1990.tb19280.x; FURST W, 1988, BIOL CHEM H-S, V369, P317, DOI 10.1515/bchm3.1988.369.1.317; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; HARRIS G, 1954, CHEM IND-LONDON, P249; HECHTMAN P, 1982, PEDIATR RES, V16, P217, DOI 10.1203/00006450-198203000-00011; HIRABAYASHI Y, 1983, J NEUROCHEM, V40, P168, DOI 10.1111/j.1471-4159.1983.tb12667.x; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; KLIMA H, 1991, FEBS LETT, V289, P260, DOI 10.1016/0014-5793(91)81084-L; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SC, 1995, J BIOL CHEM, V270, P24246, DOI 10.1074/jbc.270.41.24246; LI SC, 1988, J BIOL CHEM, V263, P6588; LI SC, 1981, J BIOL CHEM, V256, P6234; LI YT, 1973, J BIOL CHEM, V248, P7512; LI YT, 1984, LYSOSOM BIOL PATHOL, P99; MEIER EM, 1991, J BIOL CHEM, V266, P1879; NAGARAJAN S, 1992, BIOCHEM J, V282, P807, DOI 10.1042/bj2820807; NAKANO T, 1989, J BIOCHEM-TOKYO, V105, P152, DOI 10.1093/oxfordjournals.jbchem.a122629; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; RADIN NS, 1972, METHOD ENZYMOL, V28, P300; RIBONI L, 1995, J NEUROCHEM, V64, P451; SCHRODER M, 1993, HUM GENET, V92, P437, DOI 10.1007/BF00216446; SCHRODER M, 1989, FEBS LETT, V251, P197, DOI 10.1016/0014-5793(89)81454-1; SVENNERHOLM L, 1972, METHODS CARBOHYD CHE, V6, P464; UDA Y, 1977, J BIOL CHEM, V252, P5194; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; WU YY, 1994, J BIOL CHEM, V269, P16276; XIE B, 1991, BIOCHEM BIOPH RES CO, V177, P1217, DOI 10.1016/0006-291X(91)90671-S	32	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	1996	271	18					10611	10615		10.1074/jbc.271.18.10611	http://dx.doi.org/10.1074/jbc.271.18.10611			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UJ342	8631864				2022-12-25	WOS:A1996UJ34200032
J	Dong, ZG; Xu, RH; Kim, JB; Zhan, SN; Ma, WY; Colburn, NH; Kung, HF				Dong, ZG; Xu, RH; Kim, JB; Zhan, SN; Ma, WY; Colburn, NH; Kung, HF			AP-1/jun is required for early Xenopus development and mediates mesoderm induction by fibroblast growth factor but not by activin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; JUN; RECEPTOR; FOS; EXPRESSION; EMBRYOS; FGF; ONCOGENE; ENHANCER; KINASE	In Xenopus, normal mesoderm formation depends on signaling through the fibroblast growth factor (FGF) tyrosine kinase receptor. An important signaling pathway from receptor tyrosine kinases involves Ras/Raf/MAP kinase, However, the downstream pathway that occurs in the nucleus to finally trigger gene expression for mesoderm formation remains unknown, We report here that a high level of activator protein-1 (AP-1)-dependent transcriptional activity is detected during the early development of Xenopus embryos. Injection of a dominant negative mutant jun (DNM-jun or TAM67) RNA into the two-cell stage embryos inhibited endogenous AP-1 activity and blocked normal embryonic development with severe posterior truncation in tadpoles. The inhibition of AP-1 activity and the phenotypic change induced by TAM67 was rescued by co-injection of wild-type c-jun RNA, but not by the control beta-galactosidase RNA. The FGF-stimulated mesoderm induction was markedly inhibited in animal cap explants from the embryos injected with TAM67. Activin induction of mesoderm, on the other hand, was normal in the embryos injected with TAM67 RNA. These findings suggest that AP-1 mediates FGF, but not activin, receptor signaling during mesoderm induction and the AP-1/Jun is a key signaling molecule in the development of posterior structure.	SAIC,LAB BIOCHEM PHYSIOL,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD; NCI,FREDERICK CANC RES & DEV CTR,VIRAL CARCINOGENESIS LAB,NIH,CELL BIOL SECT,DIV BASIC SCI,FREDERICK,MD 21702	Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Dong, ZG (corresponding author), UNIV MINNESOTA,HORMEL INST,801 16TH AVE NE,AUSTIN,MN 55912, USA.		Xu, Ren-He/M-3125-2016; Xu, Ren-He/AAK-7392-2021; Kim, Jaebong/AAV-1986-2021	Kim, Jaebong/0000-0003-1609-338X				ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; HARLAND RM, 1994, P NATL ACAD SCI USA, V91, P10243, DOI 10.1073/pnas.91.22.10243; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KINDY MS, 1989, CELL GROWTH DIFFER, V31, P27; LABONNE C, 1995, DEVELOPMENT, V121, P1475; LAZARUS P, 1994, CANC LETT, V82, P201; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MAENO M, 1994, P NATL ACAD SCI USA, V91, P10260, DOI 10.1073/pnas.91.22.10260; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; Moon R. T., 1989, TECHNIQUE, V1, P76; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; UENO H, 1992, J BIOL CHEM, V267, P1470; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; VOGT PK, 1992, CANCER, V69, P2610, DOI 10.1002/1097-0142(19920515)69:10<2610::AID-CNCR2820691035>3.0.CO;2-J; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; XU RH, 1995, BIOCHEM BIOPH RES CO, V212, P212, DOI 10.1006/bbrc.1995.1958; XU RH, 1995, IN PRESS P NATL ACAD	38	44	46	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9942	9946		10.1074/jbc.271.17.9942	http://dx.doi.org/10.1074/jbc.271.17.9942			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626631	hybrid			2022-12-25	WOS:A1996UG25700015
J	Flores, I; Casaseca, T; MartinezA, C; Kanoh, H; Merida, I				Flores, I; Casaseca, T; MartinezA, C; Kanoh, H; Merida, I			Phosphatidic acid generation through interleukin 2 (IL-2)-induced alpha-diacylglycerol kinase activation is an essential step in IL-2-mediated lymphocyte proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PHOSPHOLIPASE-C; INDUCED TRANSLOCATION; SIGNAL TRANSDUCTION; IL-2 RECEPTOR; HAND MOTIFS; CELLS; RESPONSES; CLONING; ENZYME	Proliferation of T lymphocytes is triggered by the interaction of interleukin 2 (IL-2) with its high affinity specific receptor that is expressed on the cell surface following T lymphocyte activation. Significant advances have recently been made in identifying the multiple signals that follow IL-2 receptor occupancy, although the exact mechanism responsible for IL-2-induced proliferation remains an enigma. It has been shown previously that unique species of phosphatidic acid are rapidly produced in vivo following IL-2 binding. It was then suggested that, in contrast to other eukaryotic growth factor systems, phosphatidic acid was at least in part generated through IL-2-induced diacylglycerol (DG) kinase activation. In the present study me demonstrate IL-2-dependent activation of the alpha isoform of DG kinase. Confocal microscopy studies reveal that the enzyme is located in the cytosol and nuclei of resting T cells. Interleukin 2 stimulation induces translocation of the enzyme to the perinuclear region. Furthermore, our results indicate that inhibition of the alpha isoform of DG kinase has a profound effect on IL-2-induced T cell growth. Studies on cell cycle distribution demonstrate that the inhibition of IL-2-induced phosphatidic acid production induces arrest in late G1 phase of IL-2 dependent cells. Altogether, these results link previous observations of interleukin 2 and phosphatidic acid production to activation of an specific isoform of DG kinase and suggest that activation of this enzyme is part of a novel signaling cascade that utilizes phosphatidic acid as an effector molecule.	CTR NACL BIOTECNOL,DEPT IMMUNOL & ONCOL,E-28049 MADRID,SPAIN; SAPPORO MED COLL,DEPT BIOCHEM,SAPPORO,HOKKAIDO 060,JAPAN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Sapporo Medical University			Flores, Ignacio/E-8304-2016; Merida, Isabel/A-9713-2014	Flores, Ignacio/0000-0001-8789-6396; Merida, Isabel/0000-0003-2762-6241				BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P9378, DOI 10.1073/pnas.83.24.9378; BISHOP WR, 1986, J BIOL CHEM, V261, P6993; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BORCHARDT RA, 1994, BBA-LIPID LIPID MET, V1212, P327, DOI 10.1016/0005-2760(94)90207-0; CANO E, 1992, EUR J IMMUNOL, V22, P1883, DOI 10.1002/eji.1830220731; DECURCELLES DD, 1989, J BIOL CHEM, V264, P3274; EARDLEY DD, 1991, SCIENCE, V251, P78, DOI 10.1126/science.1824727; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GOMEZ J, 1995, EXP CELL RES, V218, P105, DOI 10.1006/excr.1995.1136; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; GOTO K, 1994, P NATL ACAD SCI USA, V91, P13042, DOI 10.1073/pnas.91.26.13042; GRAVES JD, 1992, J IMMUNOL, V148, P2417; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HA KS, 1993, J CELL BIOL, V123, P1789, DOI 10.1083/jcb.123.6.1789; HAKATEYAMA M, 1989, SCIENCE, V244, P551; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; KAI M, 1994, J BIOL CHEM, V269, P18492; KANOH H, 1986, J BIOL CHEM, V261, P5597; KANOH H, 1990, TRENDS BIOCHEM SCI, V15, P47, DOI 10.1016/0968-0004(90)90172-8; KNAUSS TC, 1990, J BIOL CHEM, V265, P14457; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; MACDONALD ML, 1988, J BIOL CHEM, V263, P1584; MARONEY AC, 1989, J BIOL CHEM, V264, P2537; MARTIN A, 1993, J BIOL CHEM, V268, P23924; MERIDA I, 1991, J IMMUNOL, V147, P2202; MERIDA I, 1993, DNA CELL BIOL, V12, P473, DOI 10.1089/dna.1993.12.473; MERIDA I, 1990, P NATL ACAD SCI USA, V87, P9421, DOI 10.1073/pnas.87.23.9421; MILLS GB, 1988, CELL, V55, P91, DOI 10.1016/0092-8674(88)90012-8; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MITCHELL RH, 1994, CURR BIOL, V4, P370; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; SAKANE F, 1991, J BIOL CHEM, V266, P7096; SAKANE F, 1991, BIOCHEM BIOPH RES CO, V181, P1015, DOI 10.1016/0006-291X(91)92038-L; SAKANE F, 1989, FEBS LETT, V255, P409, DOI 10.1016/0014-5793(89)81134-2; SAKANE F, 1990, NATURE, V344, P345, DOI 10.1038/344345a0; SCHAAP D, 1993, BIOCHEM J, V289, P875, DOI 10.1042/bj2890875; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; VALGE VE, 1988, CELL, V55, P101, DOI 10.1016/0092-8674(88)90013-X; YAMADA K, 1989, FEBS LETT, V244, P402, DOI 10.1016/0014-5793(89)80572-1; YOUNES A, 1992, J BIOL CHEM, V287, P842; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	53	108	113	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10334	10340		10.1074/jbc.271.17.10334	http://dx.doi.org/10.1074/jbc.271.17.10334			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626603	hybrid			2022-12-25	WOS:A1996UG25700075
J	Hua, XX; Sakai, J; Brown, MS; Goldstein, JL				Hua, XX; Sakai, J; Brown, MS; Goldstein, JL			Regulated cleavage of sterol regulatory element binding proteins requires sequences on both sides of the endoplasmic reticulum membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER PROTEIN; HERPES-SIMPLEX VIRUS; SITE; TRANSCRIPTION; GENE	Sterol regulatory element binding proteins (SREBP-1 and SREBP-2) are attached to the endoplasmic reticulum (ER) and nuclear envelope by a hairpin domain consisting of two transmembrane regions connected by a short lumenal loop of similar to 30 hydrophilic amino acids. In sterol-depleted cells, a protease cleaves the protein in the region of the first transmembrane domain, releasing an NH2-terminal fragment of similar to 500 amino acids that activates transcription of genes encoding the low density lipoprotein receptor and enzymes of cholesterol synthesis. In sterol-overloaded cells, proteolysis does not occur, and transcription is repressed. Through mutational analysis in transfected cells, we identify two segments of SREBPs that are required for proteolysis, one on either side of the ER membrane. An arginine in the lumenal loop is essential. A tetrapeptide sequence (DRSR) on the cytosolic face adjacent to the first transmembrane domain is also required for maximal cleavage. Both of these elements are conserved in the human and hamster versions of SREBP-1 and SREBP-2. Sterol-mediated suppression of cleavage of SREBP-1 was found to be dependent on the extreme COOH-terminal region (residue 1034 to the COOH terminus), which exists in two forms as a result of alternative splicing. The form encoded by the ''a'' class exons (exons 18a and 19a) undergoes sterol-regulated cleavage. The form encoded by the ''c'' class exons (18c and 19c) is cleaved less efficiently and is not suppressed by sterols. These studies were made possible through use of a vector that achieves low level expression of epitope-tagged SREBPs under control of the relatively weak thymidine kinase promoter from herpes simplex virus. In contrast to SREBPs overproduced by high level expression vectors, the SREBPs produced at low levels were subject to the same regulated cleavage pattern as the endogenous SREBPs. These results indicate that sterol-regulated proteolysis of SREBPs is a complex process, requiring sequences on both sides of the ER membrane.			Hua, XX (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.			Sakai, Juro/0000-0003-4043-1035	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bollag D.M., 1991, PROTEIN METHODS; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; HUA XX, 1995, GENOMICS, V25, P667, DOI 10.1016/0888-7543(95)80009-B; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; ISOLA VJ, 1989, J VIROL, V63, P2325, DOI 10.1128/JVI.63.5.2325-2334.1989; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; MCKNIGHT SL, 1982, CELL, V31, P355, DOI 10.1016/0092-8674(82)90129-5; SATO R, 1994, J BIOL CHEM, V269, P17267; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	17	167	173	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					10379	10384		10.1074/jbc.271.17.10379	http://dx.doi.org/10.1074/jbc.271.17.10379			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626610	hybrid			2022-12-25	WOS:A1996UG25700082
J	Trapp, T; Holsboer, F				Trapp, T; Holsboer, F			Nuclear orphan receptor as a repressor of glucocorticoid receptor transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; MINERALOCORTICOID RECEPTOR; MAMMALIAN-CELLS; EXPRESSION; DNA; SUPERFAMILY; ACTIVATION; MULTIPLE; JUN	Nuclear orphan receptors belong to the superfamily of ligand activated transcription factors that show a close structural relationship and sequence homology. Ligands and functions of most of the orphan receptors have not yet been identified. The first nuclear orphan receptors that were cloned displayed a high degree of amino acid identity with the human estrogen receptor and were termed estrogen receptor-related (ERR) 1 and 2. In the present study, we show that ERR2 functions as a potent repressor of transcriptional activity mediated by the glucocorticoid receptor (GR). Transient transfection of different cell lines with a steroid-responsive reporter plasmid and receptor expression plasmids revealed that transcriptional activity mediated by GR in response to agonists was strongly suppressed by coexpression of ERR2. The orphan receptor displayed no promoter activity when expressed without GR. The inhibitory activity of ERR2 is cell-specific and also receptor-specific because transactivation mediated by the progesterone receptor is unaffected by ERR2. Our observations provide evidence that the nuclear orphan receptor ERR2 acts as an endogenous modulator of GR transcriptional activity.			Trapp, T (corresponding author), MAX PLANCK INST PSYCHIAT,INST CLIN,DEPT NEUROENDOCRINOL,KRAEPELINSTR 10,D-80804 MUNICH,GERMANY.							ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; ARRIZA JL, 1988, NEURON, V1, P887, DOI 10.1016/0896-6273(88)90136-5; BAMBERGER CM, 1995, J CLIN INVEST, V95, P2435, DOI 10.1172/JCI117943; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CIDLOWSKI JA, 1990, MOL ENDOCRINOL, V4, P1427, DOI 10.1210/mend-4-10-1427; DASILVA SL, 1995, ENDOCRINOLOGY, V136, P2276; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KASTNER P, 1990, J BIOL CHEM, V265, P12163; MCDONNELL DP, 1994, J STEROID BIOCHEM, V48, P425, DOI 10.1016/0960-0760(94)90190-2; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; POWER RF, 1992, TRENDS PHARMACOL SCI, V13, P318, DOI 10.1016/0165-6147(92)90099-R; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; RUPPRECHT R, 1993, NEURON, V11, P523, DOI 10.1016/0896-6273(93)90156-L; RUPPRECHT R, 1993, MOL ENDOCRINOL, V7, P597, DOI 10.1210/me.7.4.597; STRAHLE U, 1987, P NATL ACAD SCI USA, V88, P6092; TRAPP T, 1994, NEURON, V13, P1457, DOI 10.1016/0896-6273(94)90431-6; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	28	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	1996	271	17					9879	9882		10.1074/jbc.271.17.9879	http://dx.doi.org/10.1074/jbc.271.17.9879			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UG257	8626619	hybrid			2022-12-25	WOS:A1996UG25700003
J	Williamson, LC; Halpern, JL; Montecucco, C; Brown, JE; Neale, EA				Williamson, LC; Halpern, JL; Montecucco, C; Brown, JE; Neale, EA			Clostridial neurotoxins and substrate proteolysis in intact neurons - Botulinum neurotoxin C acts on synaptosomal-associated protein of 25 kDa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL-CORD NEURONS; TETANUS-TOXIN; NEUROTRANSMITTER RELEASE; SYNAPTIC TRANSMISSION; MEMBRANE-PROTEIN; CULTURE; SNAP-25; FUSION; IDENTIFICATION; SYNAPTOBREVIN	Clostridial neurotoxins are zinc endopeptidases that block neurotransmission and have been shown to cleave, in vitro, specific proteins involved in synaptic vesicle docking and/or fusion. We have used immunohistochemistry and immunoblotting to demonstrate alterations in toxin substrates in intact neurons under conditions of toxin-induced blockade of neurotransmitter release. Vesicle-associated membrane protein, which colocalizes with synaptophysin, is not detectable in tetanus toxin-blocked cultures. Syntaxin, also concentrated in synaptic sites, is cleaved by botulinum neurotoxin C. Similarly, the carboxyl terminus of the synaptosomal-associated protein of 25 kDa (SNAP-25) is not detectable in botulinum neurotoxin A-treated cultures. Unexpectedly, tetanus toxin exposure causes an increase in SNAP-25 immunofluorescence, reflecting increased accessibility of antibodies to antigenic sites rather than increased expression of the protein. Furthermore, botulinum neurotoxin C causes a marked loss of the carboxyl terminus of SNAP-25 when the toxin is added to living cultures, whereas it has no action on SNAP-25 in in vitro preparations, This study is the first to demonstrate in functioning neurons that the physiologic response to these toxins is correlated with the proteolysis of their respective substrates, Furthermore, the data demonstrate that botulinum neurotoxin C, in addition to cleaving syntaxin, exerts a secondary effect on SNAP-25.	US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892; UNIV PADUA,CTR CNR BIOMEMBRANE,I-35121 PADUA,ITALY; UNIV PADUA,DIPARTIMENTO SCI BIOMED SPERIMENTALI,I-35121 PADUA,ITALY; USA,INST INFECT DIS,FT DETRICK,MD 21701	US Food & Drug Administration (FDA); University of Padua; University of Padua	Williamson, LC (corresponding author), NICHHD,DEV NEUROBIOL LAB,NIH,BLDG 49,RM 5A38,BETHESDA,MD 20892, USA.				Telethon [473] Funding Source: Medline	Telethon(Fondazione Telethon)		BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BERGEY GK, 1987, J NEUROPHYSIOL, V57, P121, DOI 10.1152/jn.1987.57.1.121; BIGALKE H, 1985, BRAIN RES, V360, P318, DOI 10.1016/0006-8993(85)91248-X; BINZ T, 1994, J BIOL CHEM, V269, P1617; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CALAKOS N, 1994, J BIOL CHEM, V269, P24534; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; DasGupta BR, 1989, BOTULINUM NEUROTOXIN, P53; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; FACCHIANO F, 1993, TRENDS BIOCHEM SCI, V18, P327, DOI 10.1016/0968-0004(93)90066-V; FITZGERALD SC, 1989, DISSECTION TISSUE CU; GILOH H, 1982, SCIENCE, V217, P1252, DOI 10.1126/science.7112126; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HESS DT, 1992, J NEUROSCI, V12, P4634; INOUE A, 1992, J BIOL CHEM, V267, P10613; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; MARXEN P, 1991, NEUROREPORT, V2, P33, DOI 10.1097/00001756-199101000-00008; MATSUDA M, 1989, BOTULINUM NEUROTOXIN, P69; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MONTECUCCO C, 1994, MOL MICROBIOL, V13, P1, DOI 10.1111/j.1365-2958.1994.tb00396.x; OSENSAND A, 1993, NATURE, V364, P445, DOI 10.1038/364445a0; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PRESEK P, 1992, J NEUROCHEM, V59, P1336, DOI 10.1111/j.1471-4159.1992.tb08445.x; RANSOM BR, 1977, J NEUROPHYSIOL, V40, P1132, DOI 10.1152/jn.1977.40.5.1132; SCHIAVO G, 1995, J BIOL CHEM, V270, P10566, DOI 10.1074/jbc.270.18.10566; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SCHIAVO G, 1992, J BIOL CHEM, V267, P23479; SCHIAVO G, 1993, J BIOL CHEM, V268, P23784; SCHIAVO G, 1993, J BIOL CHEM, V268, P11516; SCHIAVO G, 1993, FEBS LETT, V335, P99, DOI 10.1016/0014-5793(93)80448-4; SCHIAVO G, 1994, J BIOL CHEM, V269, P20213; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; TRIMBLE WS, 1990, J NEUROSCI, V10, P1380; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; WASHBOURNE P, 1995, BIOCHEM J, V305, P721, DOI 10.1042/bj3050721; WILLIAMSON LC, 1992, J NEUROCHEM, V59, P2148; YAMASAKI S, 1994, BIOCHEM BIOPH RES CO, V200, P829, DOI 10.1006/bbrc.1994.1526; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925	43	169	181	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	1996	271	13					7694	7699		10.1074/jbc.271.13.7694	http://dx.doi.org/10.1074/jbc.271.13.7694			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UC774	8631808	hybrid			2022-12-25	WOS:A1996UC77400076
J	Kitagawa, H; Ujikawa, M; Sugahara, K				Kitagawa, H; Ujikawa, M; Sugahara, K			Developmental changes in serum UDP-GlcA:chondroitin glucuronyltransferase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGE-RELATED-CHANGES; HEPARAN-SULFATE; PROTEOGLYCANS; BIOSYNTHESIS; CARTILAGE	Bovine, rat, and chicken UDP-GlcA:chondroitin glucuronyltransferase activities in sera during prenatal and postnatal development were systematically measured with polymeric chondroitin as an exogenous acceptor and with UDP-[C-14]GlcA as a donor. The results indicated that the activity changed markedly with develop ment in all species examined. Specifically, the activity was the highest at the middle prenatal stage in the bovine and chicken sera and at the late prenatal stage in the rat serum, and it decreased sharply thereafter in all three species. Although the origin of the serum enzyme has not yet been determined, these changes may reflect developmentally regulated biosynthesis of chondroitin sulfate and also suggest that the glucuronyltransferase could be a regulatory enzyme controlling the expression of chondroitin sulfate.	KOBE PHARMACEUT UNIV,DEPT BIOCHEM,HIGASHINADA KU,KOBE 658,JAPAN	Kobe Pharmaceutical University			Kitagawa, Hiroshi/AAJ-1344-2020	Kitagawa, Hiroshi/0000-0002-9307-7079				FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; Hascall V.C., 1981, CELL BIOL EXTRACELLU, P39; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; INEROT S, 1983, COLLAGEN REL RES, V3, P245; JOHNSTONE A, 1982, IMMUNOCHEMISTRY PRAC, P31; KIMATA K, 1973, MOL CELL BIOCHEM, V1, P211, DOI 10.1007/BF01659331; KITAGAWA H, 1995, J BIOCHEM-TOKYO, V117, P1083, DOI 10.1093/oxfordjournals.jbchem.a124810; LIND T, 1993, J BIOL CHEM, V268, P20705; POOLE AR, 1986, BIOCHEM J, V236, P1; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; RODEN L, 1980, BIOCH GLYCOPROTEINS, P491; ROUGHLEY PJ, 1980, J BIOL CHEM, V255, P217; SUGAHARA K, 1989, BIOCHEM BIOPH RES CO, V162, P189, DOI 10.1016/0006-291X(89)91980-3; SUGAHARA K, 1987, ANAL BIOCHEM, V166, P404, DOI 10.1016/0003-2697(87)90591-4; SUGAHARA K, 1987, ARCH BIOCHEM BIOPHYS, V258, P391, DOI 10.1016/0003-9861(87)90360-2; SWEET MBE, 1979, ARCH BIOCHEM BIOPHYS, V198, P439, DOI 10.1016/0003-9861(79)90518-6; YOSHIDA K, 1989, ANAL BIOCHEM, V177, P327, DOI 10.1016/0003-2697(89)90061-4	18	19	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6583	6585		10.1074/jbc.271.12.6583	http://dx.doi.org/10.1074/jbc.271.12.6583			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636071	hybrid			2022-12-25	WOS:A1996UB15700006
J	Nakatani, Y; Bagby, S; Ikura, M				Nakatani, Y; Bagby, S; Ikura, M			The histone folds in transcription factor TFIID	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; TATA BOX-BINDING; PREINITIATION COMPLEX; PROMOTER INTERACTIONS; INITIATION; PURIFICATION; DOWNSTREAM; PROTEIN; DNA	The transcription factor TFIID is a multimeric protein complex containing the TATA box-binding polypeptide (TBP) and TBP-associated factors. We have previously reported that the N-terminal regions of dTAF(II)62 and dTAF(II)42 have sequence similarities with histones H4 and H3. Here, we demonstrate that the histone-homologous regions of dTAF(II)62 and dTAF(II)42 form a heteromeric complex both in vitro and in a yeast two-hybrid system. Neither dTAF(II)62 nor dTAF(II)42 forms a homomeric complex, in agreement with a nucleosomal histone character. Moreover, circular dichroism measurements show that the heteromeric complex is dominated by cy-helical secondary structure. These results strongly suggest the existence of a histone-like surface on TFIID.	UNIV TORONTO,ONTARIO CANC INST,DIV MOLEC & STRUCT BIOL,TORONTO,ON M5G 2M9,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5G 2M9,CANADA; UNIV TSUKUBA,CTR TSUKUBA ADV RES ALLIANCE,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Tsukuba; University of Tsukuba	Nakatani, Y (corresponding author), NICHHD,NIH,LAB MOLEC GROWTH REGULAT,BLDG 6,RM 416,6 CTR DR,MSC 2753,BETHESDA,MD 20892, USA.			Ikura, Mitsuhiko/0000-0002-9524-1303; Bagby, Stefan/0000-0003-2302-9511				ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; ARENTS G, 1995, P NATL ACAD SCI USA, V92, P11170, DOI 10.1073/pnas.92.24.11170; BAGBY S, 1995, CELL, V82, P857, DOI 10.1016/0092-8674(95)90483-2; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BURLEY SK, 1996, IN PRESS ANN REV BIO; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HISATAKE K, 1995, P NATL ACAD SCI USA, V92, P8195, DOI 10.1073/pnas.92.18.8195; HORIKOSHI M, 1989, P NATL ACAD SCI USA, V86, P4843, DOI 10.1073/pnas.86.13.4843; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NAKATANI Y, 1990, P NATL ACAD SCI USA, V87, P4289, DOI 10.1073/pnas.87.11.4289; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; RAMAKRISHNAN V, 1994, CURR OPIN STRUC BIOL, V4, P44, DOI 10.1016/S0959-440X(94)90058-2; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; TJIAN R, 1995, SCI AM, V272, P54, DOI 10.1038/scientificamerican0295-54; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; WEINZIERL ROJ, 1993, EMBO J, V12, P5303, DOI 10.1002/j.1460-2075.1993.tb06226.x; YAMASHITA S, 1992, P NATL ACAD SCI USA, V89, P2839, DOI 10.1073/pnas.89.7.2839	27	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6575	6578		10.1074/jbc.271.12.6575	http://dx.doi.org/10.1074/jbc.271.12.6575			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636069	hybrid			2022-12-25	WOS:A1996UB15700004
J	Shire, D; Calandra, B; Delpech, M; Dumont, X; Kaghad, M; LeFur, G; Caput, D; Ferrara, P				Shire, D; Calandra, B; Delpech, M; Dumont, X; Kaghad, M; LeFur, G; Caput, D; Ferrara, P			Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; CELLS; INHIBITION; RHODOPSIN	The antagonist SR 141716A has a high specificity for the central CB1 cannabinoid receptor and negligeable affinity for the peripheral CB2 receptor, making it an excellent tool for probing receptor structure-activity relationships. From binding experiments with mutated CB1 and with chimeric CB1/CB2 receptors we have begun to identify the domains of CB1 implicated in the recognition of SR 141716A, Receptors were transiently expressed in COS-3 cells, and their binding characteristics were studied with SR 141716A and with CP 55,940, an agonist recognized equally well by the two receptors. The region delineated by the fourth and fifth transmembrane helices of CB1 proved to be crucial for high affinity binding of SR 141716A. The CB1 and CB2 second extracellular loops, e2, were exchanged, modifications that had no effect on SR 141716A binding in the CB1 variant but that eliminated CP 55,940 binding in both mutants, The replacement of the conserved cysteine residues in e2 of CB2 by serine also eliminated CP 55,940 binding, but replacement of those in CB1 resulted in the sequestration of the mutated receptors in the cell cytoplasm, The e2 domain thus plays some role in CP 55,940 binding but none in SR 141716A recognition, binding of the latter clearly implicating residues in the adjoining transmembrane helices.			Shire, D (corresponding author), SANOFI RECH,LABEGE INNOPOLE BP 137,F-31676 LABEGE,FRANCE.							BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMBLETT RD, 1995, LIFE SCI, V56, P1971, DOI 10.1016/0024-3205(95)00178-9; BRAMBLETT RD, 1995, 1995 ICRS S CANN CAN; DAVIDSON FF, 1994, P NATL ACAD SCI USA, V91, P4029, DOI 10.1073/pnas.91.9.4029; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FELDER CC, 1995, MOL PHARMACOL, V48, P443; FELDER CC, 1992, MOL PHARMACOL, V42, P838; FONG TM, 1994, J BIOL CHEM, V269, P2728; GAONI Y, 1964, J AM CHEM SOC, V86, P1646, DOI 10.1021/ja01062a046; GERARD CM, 1991, BIOCHEM J, V279, P129, DOI 10.1042/bj2790129; HILLARD CJ, 1995, J NEUROCHEM, V64, P677; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HOWLETT AC, 1985, MOL PHARMACOL, V27, P429; HOWLETT AC, 1986, MOL PHARMACOL, V29, P307; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOZELL LB, 1994, J BIOL CHEM, V269, P30299; LU RS, 1993, MOL CELL BIOCHEM, V121, P119, DOI 10.1007/BF00925970; LUPKER JH, 1983, GENE, V24, P281, DOI 10.1016/0378-1119(83)90088-4; MACKIE K, 1992, P NATL ACAD SCI USA, V89, P3825, DOI 10.1073/pnas.89.9.3825; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; MILOUX B, 1994, GENE, V149, P341, DOI 10.1016/0378-1119(94)90173-2; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; OLAH ME, 1994, J BIOL CHEM, V269, P24692; PAN Y, 1994, J BIOL CHEM, V269, P31933; PITTEL Z, 1994, MOL PHARMACOL, V45, P61; RINALDICARMONA M, 1995, LIFE SCI, V56, P1941, DOI 10.1016/0024-3205(95)00174-5; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; RINALDICARMONA M, 1995, 1995 ICRS S CANN CAN; SACHAIS BS, 1994, MOL PHARMACOL, V46, P122; SACHAIS BS, 1993, J BIOL CHEM, V268, P2319; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; SHIRE D, 1995, J BIOL CHEM, V270, P3726, DOI 10.1074/jbc.270.8.3726; SLIPETZ DM, 1995, MOL PHARMACOL, V48, P352; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SURYANARAYANA S, 1992, J BIOL CHEM, V267, P21991; XUE JC, 1994, J BIOL CHEM, V269, P30195; ZHOU W, 1994, MOL PHARMACOL, V45, P165	45	92	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					6941	6946		10.1074/jbc.271.12.6941	http://dx.doi.org/10.1074/jbc.271.12.6941			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636122	hybrid			2022-12-25	WOS:A1996UB15700057
J	Therien, AG; Nestor, NB; Ball, WJ; Blostein, R				Therien, AG; Nestor, NB; Ball, WJ; Blostein, R			Tissue-specific versus isoform-specific differences in cation activation kinetics of the Na,K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELL; SODIUM-PUMP; ENZYMATIC-PROPERTIES; MOLECULAR-CLONING; NA+/K+-ATPASE; CROSS-LINKING; ALPHA-SUBUNIT; ION-TRANSPORT; BETA-SUBUNIT; POTASSIUM	The experiments described in this report reconcile some of the apparent differences in isoform-specific kinetics of the Na,K-ATPase reported in earlier studies. Thus, tissue-specific differences in Na+ and K+ activation kinetics of Na,K-ATPase activity of the same species (rat) were observed when the same isoform was assayed in different tissues or cells. In the case of alpha 1, alpha 1-transfected HeLa cell, rat kidney, and axolemma membranes were compared. For alpha 3, the ouabain-insensitive alpha 3*-transfected HeLa cell (cf.Jewell, E. A., and Lingrel, J.B. (1991) J. Biol. Chem. 266, 16925-16930), pineal gland, and axolemma (mainly alpha 3) membranes were compared. The order of apparent affinities for Na+ of alpha 1 pumps was axolemma approximate to rat alpha 1-transfected HeLa > kidney, and for K+, kidney approximate to HeLa > axolemma. For alpha 3, the order of apparent affinities for Na+ was pineal gland approximate to axolemma > alpha 3*-transfected HeLa, and for K+, alpha 3*-transfected HeLa > axolemma approximate to pineal gland. In addition, the differences in apparent affinities for Na+ of either kidney alpha 1 or HeLa alpha 3* as compared to the same isoform in other tissues were even greater when the K+ concentration was increased. A kinetic analysis of the apparent affinities for Na+ as a function of K+ concentration indicates that isoform-specific as well as tissue-specific differences are related to the apparent affinities for both Na+ and K+, the latter acting as a competitive inhibitor at cytoplasmic Na+ activation sites. Although the nature of the tissue-specific modulation of K+/Na+ antagonism remains unknown, an analysis of the nature of the beta isoform associated with alpha 1 or alpha 3 using isoform-specific immunoprecipitation indicates that the presence of distinct beta subunits does not account for differences of alpha 1 of kidney, axolemma, and HeLa, and of alpha 3 of axolemma and HeLa; in both instances beta 1 is the predominant beta isoform present or associated with either alpha 1 or alpha 3. However, a kinetic difference in K+/Na+ antagonism due to distinct beta s may apply to alpha 3 of axolemma (alpha 3 beta 1) and pineal gland (alpha 3 beta 2).	MCGILL UNIV, DEPT BIOCHEM, MONTREAL, PQ, CANADA; UNIV CINCINNATI, COLL MED, DEPT PHARMACOL, CINCINNATI, OH 45267 USA	McGill University; University System of Ohio; University of Cincinnati			Therien, Alex/AAS-8437-2021					ABBOTT A, 1993, BIOCHEMISTRY-US, V32, P3511, DOI 10.1021/bi00064a040; AKERA T, 1985, EUR J PHARMACOL, V111, P147, DOI 10.1016/0014-2999(85)90751-4; BERREBIBERTRAND I, 1994, FEBS LETT, V348, P55, DOI 10.1016/0014-5793(94)00550-8; BLANCO G, 1994, P NATL ACAD SCI USA, V91, P8542, DOI 10.1073/pnas.91.18.8542; BLANCO G, 1995, BIOCHEMISTRY-US, V34, P319, DOI 10.1021/bi00001a039; BLANCO G, 1995, BIOCHEMISTRY-US, V34, P9897, DOI 10.1021/bi00031a011; Blostein R, 1989, CURR OPIN CELL BIOL, V1, P746, DOI 10.1016/0955-0674(89)90044-6; CANTLEY LC, 1977, J BIOL CHEM, V252, P7421; CENA V, 1987, J BIOL CHEM, V262, P14467; CHOW DC, 1995, J EXP BIOL, V198, P1; DUNHAM PB, 1992, COMP BIOCHEM PHYS A, V102, P625, DOI 10.1016/0300-9629(92)90715-3; FORBUSH B, 1983, ANAL BIOCHEM, V128, P159, DOI 10.1016/0003-2697(83)90356-1; FOUSSARDGUILBERT F, 1982, BIOCHIM BIOPHYS ACTA, V692, P296, DOI 10.1016/0005-2736(82)90534-X; GARAY RP, 1973, J PHYSIOL-LONDON, V231, P297, DOI 10.1113/jphysiol.1973.sp010234; GEERING K, 1990, J MEMBRANE BIOL, V115, P109, DOI 10.1007/BF01869450; GLYNN IM, 1993, J PHYSIOL-LONDON, V462, P1; JAISSER F, 1992, J BIOL CHEM, V267, P16895; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JORGENSEN PL, 1971, BIOCHIM BIOPHYS ACTA, V233, P366, DOI 10.1016/0005-2736(71)90334-8; JORGENSEN PL, 1980, PHYSIOL REV, V60, P864; JOSEPHSON L, 1977, BIOCHEMISTRY-US, V16, P4572, DOI 10.1021/bi00640a006; KAWAKAMI K, 1986, NUCLEIC ACIDS RES, V14, P2833, DOI 10.1093/nar/14.7.2833; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE LK, 1993, J BIOL CHEM, V268, P17930; LYTTON J, 1985, J BIOL CHEM, V260, P1177; Markwell M A, 1981, Methods Enzymol, V72, P296; MARTIN DW, 1992, J BIOL CHEM, V267, P23922; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; MERCER RW, 1986, MOL CELL BIOL, V6, P3884, DOI 10.1128/MCB.6.11.3884; MUNZER JS, 1994, J BIOL CHEM, V269, P16668; MUNZER JS, 1994, SODIUM PUMP, P464; PERIYASAMY SM, 1983, J BIOL CHEM, V258, P9878; PERIYASAMY SM, 1983, J BIOL CHEM, V267, P23922; SACHS JR, 1977, J PHYSIOL-LONDON, V273, P489, DOI 10.1113/jphysiol.1977.sp012106; SACHS JR, 1986, J PHYSIOL-LONDON, V374, P221, DOI 10.1113/jphysiol.1986.sp016076; SACHS JR, 1994, BBA-BIOMEMBRANES, V1193, P199, DOI 10.1016/0005-2736(94)90349-2; SCHMALZING G, 1992, J BIOL CHEM, V267, P20212; SHYJAN AW, 1990, P NATL ACAD SCI USA, V87, P1178, DOI 10.1073/pnas.87.3.1178; SUN Y, 1992, AM J PHYSIOL, V262, pC1491, DOI 10.1152/ajpcell.1992.262.6.C1491; SWEADNER KJ, 1985, J BIOL CHEM, V260, P9016; SWEADNER KJ, 1992, CAN J PHYSIOL PHARM, V70, pS255, DOI 10.1139/y92-269; SWEADNER KJ, 1985, J BIOL CHEM, V260, P1508; SWEADNER KJ, 1988, METHOD ENZYMOL, V156, P65; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; VASILETS LA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P201, DOI 10.1016/0304-4157(93)90012-D; WIERZBICKI W, 1993, P NATL ACAD SCI USA, V90, P70, DOI 10.1073/pnas.90.1.70; XU ZC, 1992, AM J PHYSIOL, V263, pC1007	48	80	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	1996	271	12					7104	7112		10.1074/jbc.271.12.7104	http://dx.doi.org/10.1074/jbc.271.12.7104			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UB157	8636145	hybrid			2022-12-25	WOS:A1996UB15700080
J	Allen, RM; Chatterjee, R; Ludden, PW; Shah, VK				Allen, RM; Chatterjee, R; Ludden, PW; Shah, VK			The requirement of reductant for in vitro biosynthesis of the iron-molybdenum cofactor of nitrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOTOBACTER-VINELANDII; KLEBSIELLA-PNEUMONIAE; DINITROGENASE REDUCTASE; INVITRO SYNTHESIS; PROTEIN; APODINITROGENASE; HOMOCITRATE; ACTIVATION; COMPONENT	A source of reductant is routinely added to the in vitro iron-molybdenum cofactor (FeMo-co) synthesis assay, although a requirement for reductant has not been established, This report demonstrates that the addition of reductant to the in vitro FeMo-co synthesis system is not required when Azotobacter vinelandii cell-free extract is prepared in buffer that lacks added reductant, The addition of reductant is required, however, if the A. vinelandii cell-free extract is chemically oxidized prior to addition to the assay, These results might suggest that extracts of A. vinelandii contain a physiological source of reductant that functions in the in vitro synthesis of FeMo-co, It is possible that the proteins required for FeMo-co biosynthesis (e,g, NIFNE and dinitrogenase reductase) are at the appropriate redox state to function in the in vitro reaction in the extract that is free of added reductant but not in the chemically oxidized extract, It is also possible that dinitrogenase reductase and/or NIFNE (both Fe-S proteins required for FeMo-co synthesis) might catalyze the reductant-dependent reaction for FeMo-co synthesis, Dithionite, Ti(III) citrate, and NADH are able to serve as the source of reductant for in vitro FeMo-co biosynthesis.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,COLL AGR & LIFE SCI,CTR STUDY NITROGEN FIXAT,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NIGMS NIH HHS [GM35332] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035332, R01GM035332] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RM, 1993, J BIOL CHEM, V268, P23670; ALLEN RM, 1995, J BIOL CHEM, V270, P26890, DOI 10.1074/jbc.270.45.26890; BENEMANN JR, 1971, BIOCHIM BIOPHYS ACTA, V226, P205, DOI 10.1016/0005-2728(71)90087-9; BOLIN JT, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P117; BULEN WA, 1965, P NATL ACAD SCI USA, V53, P532, DOI 10.1073/pnas.53.3.532; BULEN WA, 1966, P NATL ACAD SCI USA, V56, P979, DOI 10.1073/pnas.56.3.979; ENSIGN SA, 1990, BIOCHEMISTRY-US, V29, P2162, DOI 10.1021/bi00460a029; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HEDMAN B, 1988, J AM CHEM SOC, V110, P3798, DOI 10.1021/ja00220a013; HOLLIGER C, 1993, J AM CHEM SOC, V115, P5651, DOI 10.1021/ja00066a034; HOMER MJ, 1995, J BIOL CHEM, V270, P24745, DOI 10.1074/jbc.270.42.24745; HOOVER TR, 1988, BIOCHEMISTRY-US, V27, P3647, DOI 10.1021/bi00410a019; HOOVER TR, 1989, BIOCHEMISTRY-US, V28, P2768, DOI 10.1021/bi00433a004; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; LOACH PA, 1968, HDB BIOCH, P27; MARTIN AE, 1989, J BACTERIOL, V171, P3162, DOI 10.1128/jb.171.6.3162-3167.1989; MAYHEW SG, 1978, EUR J BIOCHEM, V85, P535, DOI 10.1111/j.1432-1033.1978.tb12269.x; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; PIENKOS PT, 1981, J BACTERIOL, V145, P743, DOI 10.1128/JB.145.2.743-751.1981; PIERIK AJ, 1993, EUR J BIOCHEM, V212, P51, DOI 10.1111/j.1432-1033.1993.tb17632.x; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; SEEFELDT LC, 1994, ANAL BIOCHEM, V221, P379, DOI 10.1006/abio.1994.1429; SHAH VK, 1972, BIOCHIM BIOPHYS ACTA, V256, P498, DOI 10.1016/0005-2728(72)90078-3; SHAH VK, 1994, J BIOL CHEM, V269, P1154; SHAH VK, 1986, P NATL ACAD SCI USA, V83, P1636, DOI 10.1073/pnas.83.6.1636; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SHAH VK, 1985, J BIOL CHEM, V260, P3891; YATES MG, 1970, BIOCHIM BIOPHYS ACTA, V197, P161, DOI 10.1016/0005-2728(70)90027-7	31	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4256	4260						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626771				2022-12-25	WOS:A1996TW96000049
J	Jilling, T; Kirk, KL				Jilling, T; Kirk, KL			Cyclic AMP and chloride-dependent regulation of the apical constitutive secretory pathway in colonic epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTIC-FIBROSIS; PROTEIN-KINASE; INTRACELLULAR ORGANELLES; GOLGI-COMPLEX; BREFELDIN-A; LINE; CONDUCTANCE; EXPRESSION; CURRENTS; BINDING	Epithelial cells of the colonic crypt engage in cAMP-mediated fluid and electrolyte secretion. In addition to participating in electrolyte transport, colonic crypt cells also synthesize and secrete a number of proteins and peptides that play a crucial role in mucosal homeostasis. In the present study me show that cAMP regulates not only electrolyte secretion but also polarized protein secretion in a tissue culture model of colonic crypt cells. We found that apical but not basolateral protein secretion was stimulated by a physiological activator of the cAMP pathway, vasoactive intestinal peptide, as well as by a cell-permeant analogue of cAMP (8-(4-chlorophenylthio)cAMP) at concentrations as low as 12.5 mu M. Based on several criteria, we determined that the regulation of protein secretion by cAMP in HT29-CL19A cells occurs via stimulation of constitutive membrane traffic from the trans-Golgi network (TGN) to the apical cell surface, In addition, the regulation of apical protein secretion by cAMP was Cl--dependent with cAMP inhibiting rather than stimulating secretion in Cl--depleted cells. The locus of cAMP action on the secretory pathway is at least in part at the level of the TGN, where it stimulates the sialylation of alpha 1-antitrypsin (i.e. one of the identified secretory proteins) in addition to the traffic of secretory proteins from the TGN to the apical cell surface. We propose that a cyclic AMP and Cl--dependent regulation of TGN acidification could modulate both sialylation and secretory vesicle budding at the TGN.			Jilling, T (corresponding author), UNIV ALABAMA, DEPT PHYSIOL & BIOPHYS, GREGORY FLEMING JAMES CYST FIBROSIS RES CTR, 1918 UNIV BLVD, BIRMINGHAM, AL 35294 USA.			Jilling, Tamas/0000-0002-6200-3851	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050830] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK50830] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALAWQATI Q, 1995, CURR OPIN CELL BIOL, V7, P504, DOI 10.1016/0955-0674(95)80006-9; ALAWQATI Q, 1992, J EXP BIOL, V172, P245; APPEL RD, 1994, NUCLEIC ACIDS RES, V22, P3581; AUGERON C, 1984, CANCER RES, V44, P3961; BAE HR, 1990, NATURE, V348, P637, DOI 10.1038/348637a0; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BARASCH J, 1993, J CELL SCI, P229; Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; BELL CL, 1992, AM J PHYSIOL, V262, pC555, DOI 10.1152/ajpcell.1992.262.3.C555; BOS CR, 1995, J BIOL CHEM, V270, P665, DOI 10.1074/jbc.270.2.665; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; BRADBURY NA, 1994, J BIOL CHEM, V269, P8296; BRADBURY NA, 1992, AM J PHYSIOL, V262, pC752, DOI 10.1152/ajpcell.1992.262.3.C752; CUNNINGHAM SA, 1992, AM J PHYSIOL, V262, pC783, DOI 10.1152/ajpcell.1992.262.3.C783; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; ECKMANN L, 1993, GASTROENTEROLOGY, V105, P1689, DOI 10.1016/0016-5085(93)91064-O; GREEN SA, 1990, J BIOL CHEM, V265, P21269; GRIFFITHS G, 1990, J CELL SCI, V96, P691; HANSEN SH, 1994, J CELL BIOL, V126, P677, DOI 10.1083/jcb.126.3.677; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HUANG KM, 1993, J BIOL CHEM, V268, P9302; KUBO M, 1992, J PHYSIOL-LONDON, V456, P351, DOI 10.1113/jphysiol.1992.sp019340; LADINSKY MS, 1994, J CELL BIOL, V127, P29, DOI 10.1083/jcb.127.1.29; LAFONT F, 1994, NATURE, V372, P801; LETHEM MI, 1993, AM J RESP CELL MOL, V9, P315, DOI 10.1165/ajrcmb/9.3.315; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MCCOOL DJ, 1990, BIOCHEM J, V267, P491, DOI 10.1042/bj2670491; MOLMENTI EP, 1993, J CLIN INVEST, V92, P2022, DOI 10.1172/JCI116797; MORRIS AP, 1994, AM J PHYSIOL, V266, pC254, DOI 10.1152/ajpcell.1994.266.1.C254; MOSTOV KE, 1995, BIOESSAYS, V17, P129, DOI 10.1002/bies.950170208; NILIUS B, 1994, BRIT J PHARMACOL, V112, P1049, DOI 10.1111/j.1476-5381.1994.tb13189.x; OGUCHI S, 1993, BIOCHEM BIOPH RES CO, V196, P789, DOI 10.1006/bbrc.1993.2318; PIMPLIKAR SW, 1994, J BIOL CHEM, V269, P19054; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; PRINCE LS, 1994, P NATL ACAD SCI USA, V91, P5192, DOI 10.1073/pnas.91.11.5192; ROSA P, 1992, EUR J CELL BIOL, V59, P265; SALLENAVE JM, 1994, AM J RESP CELL MOL, V11, P733, DOI 10.1165/ajrcmb.11.6.7946401; SOLIS ROL, 1983, BIOCHIM BIOPHYS ACTA, V729, P237, DOI 10.1016/0005-2736(83)90490-X; STRONG TV, 1994, J CLIN INVEST, V93, P347, DOI 10.1172/JCI116966; VENEMBRE P, 1994, FEBS LETT, V346, P171, DOI 10.1016/0014-5793(94)80695-0; WANG XD, 1993, CAN J PHYSIOL PHARM, V71, P662, DOI 10.1139/y93-097; WELSH MJ, 1982, SCIENCE, V218, P1219, DOI 10.1126/science.6293054; YILLA M, 1993, J BIOL CHEM, V268, P19092; ZEUZEM S, 1992, P NATL ACAD SCI USA, V89, P6619, DOI 10.1073/pnas.89.14.6619	45	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	1996	271	8					4381	4387						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TW960	8626788				2022-12-25	WOS:A1996TW96000066
J	Baumgart, E; Fahimi, HD; Stich, A; Volkl, A				Baumgart, E; Fahimi, HD; Stich, A; Volkl, A			L-lactate dehydrogenase A(4)- and A(3)B isoforms are bona fide peroxisomal enzymes in rat liver - Evidence for involvement in intraperoxisomal NADH reoxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-OXIDATION; MALATE-DEHYDROGENASE; HYPOLIPIDEMIC DRUG; PROTEINS; LOCALIZATION; OXIDASE; BEZAFIBRATE; ASSOCIATION; CLOFIBRATE; BIOGENESIS	The subcellular localization of L-lactate dehydrogenase (LDH) in rat hepatocytes has been studied by analytical subcellular fractionation combined with the immunodetection of LDH in isolated subcellular fractions and liver sections by immunoblotting and immunoelectron microscopy. The results clearly demonstrate the presence of LDH in the matrix of peroxisomes in addition to the cytosol, Both cytosolic and peroxisomal LDH subunits have the same molecular mass (35.0 kDa) and show comparable cross-reactivity with an anti-cytosolic LDH antibody. As revealed by activity staining or immunoblotting after isoelectric focussing, both intracellular compartments contain the same liver-specific LDH-isoforms (LDH-A(4) > LDH-A(3)B) with the peroxisomes comprising relatively more LDH-A(3)B than the cytosol. Selective KCl extraction as well as resistance to proteinase K and immunoelectron microscopy revealed that at least 80% of the LDH activity measured in highly purified peroxisomal fractions is due to LDH as a bona fide peroxisomal matrix enzyme. In combination with the data of cell fractionation, this implies that at least 0.5% of the total LDH activity in hepatocytes is present in peroxisomes, Since no other enzymes of the glycolytic pathway (such as phosphoglucomutase, phosphoglucoisomerase, and glyceraldehyde-3-phosphate dehydrogenase) were found in highly purified peroxisomal fractions, it does not seem that LDH in peroxisomes participates in glycolysis, Instead, the marked elevation of LDH in peroxisomes of rats treated with the hypolipidemic drug bezafibrate, concomitantly to the induction of the peroxisomal beta-oxidation enzymes, strongly suggests that intraperoxisomal LDH may be involved in the reoxidation of NADH generated by the beta-oxidation pathway. The interaction of LDH and the peroxisomal palmitoyl-CoA beta-oxidation system could be verified in a modified beta-oxidation assay by adding increasing amounts of pyruvate to the standard assay mixture and recording the change of NADH production rates, A dose dependent decrease of NADH produced was simulated with the lowest NADH value found at maximal LDH activity. The addition of oxamic acid, a specific inhibitor of LDH, to the system or inhibition of LDH by high pyruvate levels (up to 20 mM) restored the NADH values to control levels. A direct effect of pyruvate on palmitoyl-CoA oxidase and enoyl-CoA hydratase was excluded by measuring those enzymes individually in separate assays. An LDH-based shuttle across the peroxisomal membrane should pro vide an efficient system to regulate intraperoxisomal NAD(+)/NADH levels and maintain the flux of fatty acids through the peroxisomal beta-oxidation spiral.	UNIV HEIDELBERG,INST ANAT & CELL BIOL 2,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg			Baumgart-Vogt, Eveline/I-5945-2013	Baumgart-Vogt, Eveline/0000-0002-8265-3763				AGOSTINI A, 1966, NATURE, V200, P1024; BAUDHUIN P, 1964, BIOCHEM J, V92, P179, DOI 10.1042/bj0920179; BAUMGART E, 1989, J CELL BIOL, V108, P2221, DOI 10.1083/jcb.108.6.2221; BAUMGART E, 1994, PEROXISOMES, P37; BEAUFAY H, 1964, BIOCHEM J, V92, P184, DOI 10.1042/bj0920184; BEIER K, 1988, EUR J CELL BIOL, V46, P383; Bergmeyer HU, 1983, METHOD ENZYMAT AN, V2, P211; BRDICZKA D, 1973, BIOCHIM BIOPHYS ACTA, V297, P203, DOI 10.1016/0304-4165(73)90066-4; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CATTANEO A, 1985, EXP CELL RES, V161, P130, DOI 10.1016/0014-4827(85)90497-5; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; DANSCHER G, 1983, J HISTOCHEM CYTOCHEM, V31, P1394, DOI 10.1177/31.12.6631001; DEHOOP MJ, 1992, BIOCHEM J, V286, P657, DOI 10.1042/bj2860657; EVERS J, 1973, ADV ENZYMOL, V28, P61; FAHIMI HD, 1982, ANN NY ACAD SCI, V386, P111, DOI 10.1111/j.1749-6632.1982.tb21410.x; FINE IH, 1963, BIOCHEMISTRY-US, V2, P116, DOI 10.1021/bi00901a020; FRNACO R, 1988, BIOCH INT, V16, P689; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; FUKASAWA KM, 1986, MOL BIOL EVOL, V3, P330; GEE R, 1974, ARCH BIOCHEM BIOPHYS, V161, P187, DOI 10.1016/0003-9861(74)90250-1; GIETL C, 1992, BIOCHIM BIOPHYS ACTA, V1100, P217, DOI 10.1016/0167-4838(92)90476-T; GLOVER JR, 1994, P NATL ACAD SCI USA, V91, P10541, DOI 10.1073/pnas.91.22.10541; KLINE ES, 1986, ARCH BIOCHEM BIOPHYS, V246, P673, DOI 10.1016/0003-9861(86)90323-1; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LI SSL, 1989, BIOCHEM SOC T, V17, P304, DOI 10.1042/bst0170304; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUERS G, 1993, J CELL BIOL, V121, P1271, DOI 10.1083/jcb.121.6.1271; MANN VM, 1992, COMP BIOCHEM PHYS B, V102, P561, DOI 10.1016/0305-0491(92)90048-V; MARKERT CL, 1975, SCIENCE, V189, P102, DOI 10.1126/science.1138367; MAYER RJ, 1980, IMMUNOCHEMICAL METHO, P126; MCGROARTY E, 1974, ARCH BIOCHEM BIOPHYS, V161, P194, DOI 10.1016/0003-9861(74)90251-3; MCNEW JA, 1994, J CELL BIOL, V127, P1245, DOI 10.1083/jcb.127.5.1245; MIDDELKOOP E, 1993, BIOCHIM BIOPHYS ACTA, V1220, P15, DOI 10.1016/0167-4889(93)90091-3; NOVIKOV DK, 1994, J BIOL CHEM, V269, P27125; OSMUNDSEN H, 1982, INT J BIOCHEM, V14, P905, DOI 10.1016/0020-711X(82)90074-X; OSMUNDSEN H, 1994, BIOCHEM SOC T, V22, P436, DOI 10.1042/bst0220436; OSUMI T, 1979, BIOCHEM BIOPH RES CO, V89, P580, DOI 10.1016/0006-291X(79)90669-7; REHFELD DW, 1972, J BIOL CHEM, V247, P4803; SAKURABA H, 1995, J BIOL CHEM, V270, P37, DOI 10.1074/jbc.270.1.37; SCHRADER M, 1994, EUR J CELL BIOL, V64, P281; Sies H., 1982, METABOLIC COMPARTMEN, P205; SMALL GM, 1985, BIOCHEM J, V227, P205, DOI 10.1042/bj2270205; THOMPSON ST, 1975, P NATL ACAD SCI USA, V72, P669, DOI 10.1073/pnas.72.2.669; TSUJI S, 1994, P NATL ACAD SCI USA, V91, P9392, DOI 10.1073/pnas.91.20.9392; VANROERMUND CWT, 1995, EMBO J, V14, P3480, DOI 10.1002/j.1460-2075.1995.tb07354.x; VANVELDHOVEN PP, 1987, J BIOL CHEM, V262, P4310; VOLKL A, 1988, J HISTOCHEM CYTOCHEM, V36, P329, DOI 10.1177/36.4.3346536; VOLKL A, 1985, EUR J BIOCHEM, V149, P257, DOI 10.1111/j.1432-1033.1985.tb08920.x; WALTON PA, 1995, MOL BIOL CELL, V6, P675, DOI 10.1091/mbc.6.6.675; WILCKE M, 1995, J BIOL CHEM, V270, P6949, DOI 10.1074/jbc.270.12.6949; WILLIAMS KR, 1985, P NATL ACAD SCI USA, V82, P5260, DOI 10.1073/pnas.82.16.5260; ZHONG XH, 1990, MOL CELL BIOL, V10, P770, DOI 10.1128/MCB.10.2.770; SIGMA TECHNICAL B, V340; SIGMA TECHNICAL B, V104	54	76	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3846	3855						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632003				2022-12-25	WOS:A1996TV72400077
J	Saxena, S; Allon, M				Saxena, S; Allon, M			The role of cytosolic calcium in chronic adaptation to phosphate depletion in opossum kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLULAR MECHANISMS; REABSORPTION; INHIBITION; EXPRESSION; EVOLUTION; TRANSPORT; GENE; CDNA; RNA; RAT	Chronic dietary phosphate restriction is associated with up-regulation of sodium-dependent phosphate (Na/P-i) cotransport by renal proximal tubular epithelial cells in association with increases in Na/P-i cotransporter mRNA and protein. We investigated whether changes in cytosolic calcium mediate this adaptive response in opossum kidney cells, a continuous line of renal epithelial cells, After 24 h of phosphate depletion, steady-state cytosolic calcium levels were increased; this increase was observed at physiologic levels of phosphate restriction and was prevented by the calcium channel blocker verapamil, Chronic phosphate depletion was also associated with parallel increases in Na/P-i cotransport activity, Na/P-i cotransporter mRNA, and Na/P-i cotransporter protein, all of which were blocked in verapamil-treated cells, Actinomycin D, at a dose that prevented the increase in NaPi-4 mRNA during phosphate depletion, also prevented the increase in Na/P-i cotransport activity, Incubation with the calcium ionophore ionomycin or A23187 reproduced the increase in Na/P-i cotransporter mRNA in phosphate-replete cells, Conversely, chelation of cytosolic calcium by quin-2/AM prevented the increase in Na/P-i cotransporter mRNA in phosphate-depleted cells, The effect of an increase in cytosolic calcium was specific for the Na/P-i cotransporter as mRNA levels for the sodium-dependent glucose transporter were not affected. Our observations suggest that chronic phosphate restriction increases steady-state cytosolic calcium, which, in turn, increases transcription of Na/P-i cotransporter mRNA, thereby stimulating Na/P-i cotransport activity.	UNIV ALABAMA,CTR NEPHROL RES & TRAINING,BIRMINGHAM,AL; VET ADM MED CTR,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)								ALLON M, 1993, AM J PHYSIOL, V264, pF404, DOI 10.1152/ajprenal.1993.264.3.F404; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; HAYES G, 1994, J BIOL CHEM, V269, P24143; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; KAUFFMAN RF, 1980, J BIOL CHEM, V255, P2735; KIERSZTEJN M, 1992, J AM SOC NEPHROL, V2, P1484; LEVI E, 1992, ENDOCRINOLOGY, V131, P2182, DOI 10.1210/en.131.5.2182; LEVI M, 1994, AM J PHYSIOL-RENAL, V267, pF900, DOI 10.1152/ajprenal.1994.267.5.F900; MASSRY SG, 1991, AM J PHYSIOL, V260, pF12, DOI 10.1152/ajprenal.1991.260.1.F12; MIYAUCHI A, 1990, AM J PHYSIOL, V259, pF485, DOI 10.1152/ajprenal.1990.259.3.F485; MURER H, 1991, AM J PHYSIOL, V260, pC885, DOI 10.1152/ajpcell.1991.260.5.C885; MURER H, 1992, J AM SOC NEPHROL, V2, P1649; SAXENA S, 1995, BIOCHEM BIOPH RES CO, V216, P141, DOI 10.1006/bbrc.1995.2602; SMOGORZEWSKI M, 1995, KIDNEY INT, V47, P1182, DOI 10.1038/ki.1995.168; SORRIBAS V, 1994, J BIOL CHEM, V269, P6615; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WEINSTOCK RS, 1993, AM J PHYSIOL, V264, pE519, DOI 10.1152/ajpendo.1993.264.4.E519; WEIR MR, 1992, TRANSPLANTATION, V54, P681, DOI 10.1097/00007890-199210000-00023; WERNER A, 1994, J BIOL CHEM, V269, P6637; YANG JP, 1993, MOL ENDOCRINOL, V7, P753, DOI 10.1210/me.7.6.753	21	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	1996	271	7					3902	3906						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TV724	8632011				2022-12-25	WOS:A1996TV72400085
